10-K405

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

(Mark One)
	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2001

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission file number 033-76414

ARIAD Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	22-3106987
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

26 Landsdowne Street, Cambridge, Massachusetts 02139-4234

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (617) 494-0400

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $.001 Par Value

Rights to Purchase Series A Preferred Stock

     Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES    No 

     Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. 

     The number of shares of the registrant’s Common Stock outstanding as of March 18, 2002: 32,418,371.

     The aggregate market value of the voting stock held by nonaffiliates of the registrant was approximately $143 million as of March 18, 2002, based on the last reported sales price of the registrant’s Common Stock on the Nasdaq National Market on such date.

TABLE OF CONTENTS

PART I
	ITEM 1: BUSINESS
	ITEM 2: PROPERTIES
	ITEM 3: LEGAL PROCEEDINGS
	ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
PART II
	ITEM 5: MARKET FOR REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
	ITEM 6: SELECTED FINANCIAL DATA
	ITEM 7: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
	ITEM 7A: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
	ITEM 8: FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
	ITEM 9: CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
PART III
	ITEM 10: DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
	ITEM 11: EXECUTIVE COMPENSATION
PART IV
	ITEM 14: EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
SIGNATURES
EXHIBIT INDEX
EX-10.49 AMENDMENT TO LOAN & SECURITY AGREEMENT
EX-10.50 MASTER SECURITY AGREEMENT DEC-27-2001
EX-10.51 ADDENDUM TO MASTER LEASE AGREEMENT
EX-10.52 PROMISSORY NOTE DEC-28-2001
EX-10.53 RESEARCH & DEVELOPMENT AGREEMENT
EX-10.54 RESEARCH & DEVELOPMENT AGREEMENT
EX-10.55 CONSULTING AGREEMENT WITH BRIAN LAJOIE
EX-10.56 EXECUTIVE EMPLOYMENT AGREEMENT W/L. ALLEN
EX-10.57 STOCK TRANSFER AGREEMENT
EX-10.58 NOTICE OF EXTENSION OF LEASE
EX-23.1 CONSENT OF DELOITTE & TOUCHE LLP

TABLE OF CONTENTS

PART I
	Item 1:	Business	1
	Item 2:	Properties	21
	Item 3:	Legal Proceedings	21
	Item 4:	Submission of Matters to a Vote of Security Holders	22
PART II
	Item 5:	Market for Registrant’s Common Equity and Related Stockholder Matters	23
	Item 6:	Selected Financial Data	24
	Item 7:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	26
	Item 7A:	Quantitative and Qualitative Disclosures About Market Risk	31
	Item 8:	Financial Statements and Supplementary Data	33
	Item 9:	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	52
PART III
	Item 10:	Directors and Executive Officers of The Registrant	53
	Item 11:	Executive Compensation	56
	Item 12:	Security Ownership of Certain Beneficial Owners and Management	60
	Item 13:	Certain Relationships and Related Transactions	61
PART IV
	Item 14:	Exhibits, Financial Statement Schedules and Reports on Form 8-K	62

PART I

ITEM 1: BUSINESS

The following Business section contains forward-looking statements, which involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors (see “Certain Factors That May Affect Future Results of Operations”). In this Annual Report on Form 10-K, we incorporate by reference certain information from parts of other documents filed with the Securities and Exchange Commission, or the SEC. The SEC allows us to disclose important information by referring to it in that manner. Please refer to such information when reading this Annual Report.

Corporate Overview

We are engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. Breakthrough medicines are products, created de novo, that may be used to treat diseases in innovative ways. We currently have five lead product candidates in our development pipeline, including: (1) our drug candidate, AP23573, that controls cell proliferation and nutrient uptake to tumors to treat cancer; (2) our bone-targeted drug candidate, AP23451, to treat the complications of cancer that has spread to bone, or bone metastases; (3) our regulated protein therapy product candidate to treat anemia in which the production of erythropoietin is precisely controlled in vivo using an orally administered drug, AP22594; (4) our T cell immunotherapy product candidate in which a non-immunosuppressive drug, AP1903, may be used to treat graft-vs-host disease, or GvHD, following donor bone marrow transplantation – a therapy for cancer and other immune and blood diseases; and (5) our dual-action drug candidates, AP23485 and its analogs, that block bone resorption and stimulate bone formation to treat osteoporosis. Our product candidate for GvHD is in phase 2 development. Our product candidates for cancer, bone metastases and anemia are at the pre-investigational new drug, or pre-IND, stage of development, and our drug candidates for osteoporosis are in preclinical development.

With respect to the development and commercialization of our current lead product candidates, we intend to: (1) develop our current lead product candidates at least through phase 2 clinical trials; (2) establish the commercial infrastructure to market our portfolio of hematology and oncology product candidates in the United States; and (3) pursue a worldwide partner for our osteoporosis product candidate and partners for our hematology and oncology products outside the United States, generally after we are able to obtain phase 2 clinical data.

The NF-kB pathway has emerged as an important drug target in pharmaceutical research. This cellular protein and its associated cell-signaling pathways regulate genes involved in many major diseases, including atherosclerosis, asthma, arthritis, cancer, diabetes, infectious disease, inflammatory bowel disease, rheumatoid arthritis, sepsis, and stroke. We have an exclusive license to pioneering technology related to the discovery, development, and use of drugs that modulate the NF-kB pathway.

Our RegTech cell-signaling regulation technologies already are being used by over 500 academic investigators worldwide for scientific research and are the subject of over 120 published papers in the scientific literature. In return for providing these technologies for academic research, we receive certain intellectual property and commercialization rights to discoveries made resulting from their use. In effect, these researchers provide a robust source of potential new technologies, drug targets and product candidates that we may develop.

Our business plan aims to balance potential near-term revenues from licensing with longer-term product development. We are marketing licenses to our RegTech technologies and our NF-kB intellectual property portfolio to pharmaceutical and biotechnology companies to accelerate their genomics, proteomics and drug

discovery efforts. Commercial licenses have not been entered into as of yet. In addition, we may partner our cell-signaling regulation technologies for joint development of novel products, especially with companies that have proprietary therapeutic genes, cellular systems (e.g., stem cells) or gene delivery vectors.

ARIAD was organized as a Delaware corporation in April 1991. Our principal executive offices are located at 26 Landsdowne Street, Cambridge, Massachusetts 02139-4234, and our telephone number is (617) 494-0400. We maintain a web site at www.ariad.com.

Our Lead Product Candidates

We currently have five lead product candidates in our development pipeline, all of which are small-molecule drugs that regulate cell signaling. Many of the critical functions of cells, such as cell growth, differentiation, gene transcription, metabolism, motility and survival, take place through the processes of cell signaling. Disruption or over-stimulation of cell-signaling pathways has been implicated in many disease states. Our cell-signaling inhibitor programs are focused on discovering and optimizing small-molecule drugs that interfere with specific cellular proteins or pathways that have been well-characterized and validated as targets.

All of our lead product candidates were developed in-house through the integration of our major areas of scientific expertise: structure-based drug design and chemo-informatics, or computational chemistry, functional genomics and proteomics, and protein engineering. We believe that our lead product candidates will serve large, unmet medical needs.

The first four lead product candidates in our pipeline constitute our growing portfolio of hematology and oncology product candidates that we intend to commercialize in the United States. For those product candidates for which we are able to obtain phase 2 clinical data demonstrating initial evidence of efficacy and safety, we plan to pursue partnerships with major pharmaceutical or biotechnology companies (e.g., a worldwide partner for our product candidate for osteoporosis and partners for our hematology and oncology product candidates outside the United States market). Our lead product candidates are as follows:

Product
Candidate	Target	Initial Clinical Indications	Status
AP23573	mTOR	Cancer (PTEN-deficient tumors)	Pre-IND
AP23451	Src	Bone metastases, Bone pain, Hypercalcemia	Pre-IND
AP22594 - ARGENT	EPO	Anemia (Multiple myeloma, Chronic renal failure)	Pre-IND
AP1903 - ARGENT	Fas	Graft-vs-host disease (T cell immunotherapy)	Phase 2 Development
AP23485	Src	Osteoporosis, Paget’s disease	Preclinical Development

Preclinical development means that in vivo and in vitro studies are underway to designate a compound for clinical development. Examples of these studies include comparative safety and efficacy studies of lead compound analogs in disease models and formulation optimization. After clinical candidate designation, pre-IND development is initiated and consists of studies required by the U.S. Food and Drug

2

Administration, or FDA, or other regulatory authorities for inclusion in an IND or other regulatory filings to initiate clinical studies. Examples of these studies include toxicology, pharmacology, and metabolism studies conducted under the current Good Laboratory Practices, or cGLP, requirements. Clinical development requires manufacturing of clinical-grade material (e.g., small-molecule drugs and gene-transfer vectors) produced under the current Good Manufacturing Practices, or cGMP, requirements. Phase 2 development includes obtaining regulatory and institutional review board, or IRB, approvals for administering product candidates to patients with disease and conducting clinical trials that are designed to provide safety data and initial indications of a product’s clinical efficacy in its proposed use. With respect to our GvHD product candidate, this may include patients with various types of blood cancers, various degrees of human leukocyte antigen, or HLA, mismatch, and various types of malignant and non-malignant diseases.

Cancer

The Disease: Cancer, the second leading cause of death in the Western world, is a complex collection of hundreds of separate diseases characterized by uncontrolled cell growth. Great strides have been made in the past few decades in understanding the molecular basis for this transformation by searching for genetic differences between normal cells and cancer cells. These studies have revealed that cancer cells often harbor genetic mutations that alter the controlling mechanisms in cell signaling that constrain cell growth in healthy cells. Two major classes of such genetic alteration have been identified. Genes that turn on cell growth and division are often over-activated or over-expressed in tumors. These genes are called oncogenes, and they represent key targets for anti-cancer drug design, since drugs that inhibit their activity should re-establish normal growth control. A second class of genes, called tumor suppressors, plays an opposite role by preventing unwanted cell growth. These genes are often inactivated or deleted in tumors, again leading to uncontrolled proliferation and potentially enhancing the effects of oncogenes.

Current Therapies: Several forms of medical therapy have evolved as adjuncts or alternatives to surgery, including the introduction of cytotoxic chemotherapy and radiation therapy over 50 years ago. Although they continue to be the mainstay of cancer treatment, especially after the cancer has spread from its site of origin, these therapies are limited by lack of specificity and toxicity. Healthy cells, along with malignant cells, are killed by these agents. Recently, a number of alternative therapies have been introduced, including endocrine therapy to treat cancers of certain hormone-sensitive organs, recombinant biologics, and small molecules and monoclonal antibodies that target the molecular determinants of the transformation of normal cells to cancer cells. Several growth factor inhibitors and protein kinase inhibitors have been developed to block molecular pathways implicated in cancer.

Our Approach: Using our expertise in structure-based design of drugs that regulate cell-signaling pathways, our scientists are engaged in several anti-cancer drug development programs. The most advanced program has led to the discovery of one of our lead product candidates, AP23573 – a potent small-molecule inhibitor of the protein kinase, mTOR, that plays a key role in orchestrating the progression of the cell cycle and controlling nutrient uptake to tumors. Genetic and other studies have demonstrated that blocking mTOR arrests tumor growth. This effect is even more pronounced in tumor cells with a deleted or mutated form of a tumor suppressor gene known as PTEN. Tumors with abnormalities in PTEN represent several of the major difficult-to-treat cancers, including prostate, uterine, pancreatic, and ovarian cancer, as well as melanoma, leukemia and gliomas.

Since cancer patients with PTEN-deficient tumor cells can be identified using genetic tests, it should be possible to select those who may benefit most from AP23573, which is currently in pre-IND development.

3

Bone Metastases

The Disease: The spread of malignant cells from the primary tumor to the skeleton and the subsequent destruction of bone is a frequent and debilitating complication of many cancers, especially breast, prostate, and lung cancer and multiple myeloma. Bone metastases are a common cause of cancer-associated morbidity.

Like osteoporosis, bone metastases result in severe bone loss but also are associated with local pain, fractures, vertebral instability and compression, and elevations in blood calcium often to life-threatening levels. These clinical findings can be devastating to a cancer patient. Bone metastases are a major problem in cancer management, both in terms of cost and human suffering.

Current Therapies: There is no known cure for bone metastases. However, several therapies are used to treat bone metastases and skeletal-related events, including chemotherapy, hormonal therapy, radiotherapy, analgesics for pain and anti-resorptive drugs. Most recently, newer-generation bisphosphonates have been advanced for the treatment of bone metastases and have already achieved substantial worldwide sales for this indication. However, the efficacy of this class of agents in treating certain of these complications of cancer appears to decline during treatment.

Our Approach: Recent research demonstrates that most skeletal destruction due to bone metastases is mediated by osteoclasts – bone cells responsible for bone resorption. In fact, there appears to be a close relationship between metastatic cancer cells and osteoclasts. Cancer cells stimulate osteoclasts to increase their bone-resorbing activity, which, in turn, release bone-derived growth factors that both attract cancer cells to the bone surface and facilitate their growth and proliferation.

Advances in our understanding of the co-dependent relationship between osteoclasts and cancer cells have led us to a new preventive and therapeutic strategy – designing a potent inhibitor of bone resorption by down-regulating the cell signaling pathway that controls the activity of osteoclasts. We believe that inhibiting bone resorption through this mechanism will not only prevent the skeletal-related clinical events directly attributable to bone loss but also result in a less favorable local environment for tumor growth.

AP23451 is a small-molecule drug that potently inhibits a well-validated protein tyrosine kinase believed to be implicated in the activation of osteoclasts. AP23451 is highly specific in targeting this kinase in bone. Its anti-resorptive activity has been repeatedly demonstrated in in vivo studies conducted by our researchers and corroborated by academic scientific teams. AP23451 is in pre-IND development.

Anemia

The Disease: Red blood cells, produced in the bone marrow, transport oxygen from the lungs to the cells of the body and carbon dioxide to the lungs. Erythropoietin, or Epo, is a naturally occurring protein made primarily in the kidney that stimulates the manufacture of more red blood cells, when needed, by a process known as erythropoiesis. The role of Epo, therefore, is to maintain the number of red blood cells at an optimal level to provide sufficient oxygen transport to cells and tissues. If the amount of oxygen available to the cells is too low, a feedback mechanism stimulates the production of Epo and the manufacture of red blood cells. In addition, Epo stimulates the growth of stem cells in the bone marrow to become mature red blood cells. If the body loses its ability to manufacture sufficient quantities of Epo, the optimal number of red blood cells in the circulation no longer can be maintained. This is the case for many individuals who suffer from severe renal disease and results in a steady decrease in the number of red blood cells, which eventually leads to a decrease in the required transport of oxygen to tissues. A clinically significant reduction in the number of red blood cells (and their oxygen carrying component, hemoglobin) is known as anemia.

4

Current Therapies: Recombinant Epo (including a newer-generation version) is presently being used for the treatment of anemia caused by chronic renal failure (including end-stage renal disease), cancer chemotherapy and zidovudine treatment of HIV-infected individuals. Epo also has a role in the treatment of anemic patients undergoing elective noncardiac or orthopedic surgery, reducing the need for these patients to undergo pre-operative blood collections and post-surgical blood infusion. Today’s standard treatment generally requires recombinant Epo to be injected on a recurring schedule into a vein or under the skin.

Our Approach: We are developing an alternative approach to deliver and regulate therapeutic proteins such as Epo based on our ARGENT cell-signaling regulation technology. We have selected Epo as our initial product candidate to demonstrate the clinical utility of this platform for orally regulated protein therapy. Rather than relying on repetitive injections of Epo to provide the therapeutic benefit, our approach provides a form of protein therapy regulated by small-molecule drugs. Our orally regulated protein therapy candidate is designed to involve a single, or infrequent, injection(s) of the Epo gene using a gene-transfer vector into the patient’s muscle or other tissue in an inactive form. The patient then will take our orally administered drug, AP22594, which we believe will activate the Epo gene to manufacture the patient’s own Epo. The production of Epo would only occur in response to the patient taking the drug, and the amount of Epo manufactured in vivo would depend on the amount of AP22594 the patient takes. The Epo produced by the genes in the body appears to work in the same way and have the same beneficial effects as Epo naturally produced by healthy kidneys. The ARGENT cell-signaling regulation technology may offer a means of precisely controlling the amounts of Epo to be delivered by adjusting the dose of the drug.

Worldwide sales for recombinant human Epo reached approximately $6 billion in 2001, and substantial growth in the market is anticipated over the next five years as new products and more convenient dosing regimens are developed. This provides opportunities for new technologies that have potential benefits over the current products. We believe that the potential competitive advantages of our product candidate for anemia include:

• Replacement of an injectable recombinant product largely by an orally active drug administered infrequently;

• Protein production precisely controlled within a therapeutic window as opposed to the oscillating blood levels that frequently occur by injectable routes of administration;

• Sustained high levels of protein achievable, if desired, greater than those routinely obtained with the recombinant protein;

• Manufacturing costs minimized.

Our scientists have demonstrated regulated production of Epo in animals, including mice and non-human primates, for a duration of over three and one-half years. In addition to potentially providing improved medical care for patients with anemia, we believe this program will serve as an excellent model to demonstrate the clinical utility of our ARGENT system for the delivery of many different therapeutic proteins. Our AP22594 product candidate for anemia is currently in pre-IND development.

Graft-vs-Host Disease

The Disease: Bone marrow transplantation, or BMT, followed by T cell immunotherapy, has become a well-established medical procedure to treat diseases that until recently were considered incurable. Such procedures are an important therapy today for numerous cancers, in particular hematologic malignancies such as leukemias. In addition, patients with solid tumors, such as breast and colon cancer, and non-malignant diseases, such as hemoglobinopathies and autoimmune diseases, have been shown to benefit from bone marrow transplants. In principle, the procedure permits patients to receive high doses of cytotoxic

5

chemotherapy and/or radiation therapy to kill abnormal cells within the bone marrow itself or abnormal cells at a site other than in the bone marrow. In either case, the aggressive treatment not only eliminates the unwanted (cancerous) cells but also destroys healthy cells within the bone marrow. Therefore, the patient’s bone marrow must be replaced by infusion of bone marrow or peripheral stem cells from a donor, generally followed by T cell immunotherapy to help reconstitute the recipient’s immune system.

There are approximately 40,000 bone marrow transplants performed annually. Over 35% of these are allogeneic (i.e., the bone marrow and T cells are obtained from a donor rather than from the patient’s body). In approximately half of the recipients of donor bone marrow and T cells, the T cells attack the patients’ own tissues, causing a disease known as graft-vs-host disease, or GvHD. If there is not a good genetic match between the donor and patient, the recipient has an even higher risk (as high as 90% depending on the degree of mismatch) of developing GvHD. This life-threatening complication is mediated by the ability of T cells to recognize an inherited set of genetic markers known as HLA that are found on the surface of human cells. If the donor’s T cells recognize that the patient’s HLA are sufficiently different from the donor’s HLA, the donor’s T cells quickly activate the immune system to destroy the recipient’s cells, which are recognized as foreign. The major organs attacked in this process are the patient’s skin, mucosa, liver and gastrointestinal tract. BMT patients also have an increased susceptibility to viral and bacterial infection until their immune system has reconstituted.

Current Therapies: The incidence and severity of GvHD can be reduced by withholding or limiting T cell immunotherapy following BMT. Unfortunately, this also eliminates the beneficial effects of those T cells, which include: (1) anti-tumor activity; (2) improved engraftment of donor bone marrow in the patient and immune reconstitution; and (3) prevention of early infectious complications by providing a functional cellular immune system. To recapture the beneficial effects of T cells, T cell depleted bone marrow often is supplemented with delayed infusion of donor T cells, referred to as a donor lymphocyte infusion or T cell immunotherapy. However, for these patients, GvHD represents a common and potentially lethal complication of the procedure.

Highly effective treatments for GvHD are currently unavailable. In fact, clinical experience indicates that approximately 50% of GvHD patients fail to respond fully to the current standard treatment which generally consists of immunosuppressive agents. Such drugs also put the patient at greater risk of infection, since they compromise an already weakened immune system. Although there are several alternate therapies under clinical investigation, including T cell directed monoclonal antibodies, and cytokine antagonists, we believe that they are limited by their inability to distinguish the T cells that are causing GvHD from those T cells providing beneficial effects. Consequently, these treatments may eliminate the beneficial effects of the immune cells that are being produced by the transplanted bone marrow.

Our Approach: We are developing a non-immunosuppressive treatment for GvHD that we believe will target and eliminate the T cells that cause the disease (i.e., the donor’s T cells), if those T cells attack the patient’s own tissues, while preserving the immune cells that are being produced by the BMT. In our GvHD product candidate, donor T cells are modified using a gene transfer vector to make them susceptible to our drug candidate, AP1903. This drug candidate may be administered if GvHD occurs, potentially killing the disease-causing donor T cells. Our product candidate uses the ARGENT cell-signaling regulation technology, our proprietary system for controlling cellular events with small molecules.

We believe that our AP1903 T cell immunotherapy product candidate can be integrated into routine BMT procedures, as follows:

• T cells would be isolated from a donor using standard procedures and be genetically engineered to introduce an inactive form of the apoptosis, or cell death, gene, known as Fas;

6

• The engineered donor lymphocytes would then be infused into the patient at the time of BMT or at predefined times after BMT;

• If GvHD occurs, the patient would receive our small-molecule drug, AP1903;

• AP1903 activates Fas cell signaling and would rapidly cause the donor’s T cells to die, leaving the underlying bone marrow and immune system unaffected and thus potentially treating the primary cause of GvHD.

We believe that our AP1903 T cell immunotherapy product candidate will have a favorable impact on patient outcome and increase the number of patients who could benefit from allogeneic BMT by improving the risk-to-benefit ratio of the treatment. AP1903 was found to be safe and well tolerated in a Phase 1 clinical study. In addition, this study showed that AP1903 reached blood levels that are expected to be clinically effective. Our product candidate for GvHD is in phase 2 development.

Osteoporosis

The Disease: Osteoporosis, or porous bone, is characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and increased susceptibility to fractures, most commonly of the hip, spine and wrist. Bone is a living substance in which the tissue is constantly being broken down (resorption), while new bone is being formed. This process is called bone turnover. A full cycle of normal bone remodeling takes about two to three months. Bone resorption is accomplished by specialized cells in bone, known as osteoclasts, and new bone is generated by another group of special cells, known as osteoblasts. The balance or imbalance between the activity of the osteoclasts and osteoblasts determines whether bone mass increases, remains the same or decreases over time.

During the first 20 to 30 years of life, bone regeneration is greater than bone resorption which results in a net increase in bone mass. Beginning at about 35 years of age, a slow phase of bone resorption begins in which bone breakdown is slightly greater than bone regeneration. This slow phase continues well into old age in both men and women resulting in a net decrease in bone mass. Superimposed onto this slow phase of bone loss, women experience an accelerated postmenopausal phase of bone resorption and can cause the loss of up to 20% of their bone mass within five to seven years following menopause. According to the National Osteoporosis Foundation, osteoporosis is a major public health threat for more than 28 million Americans, 80% of whom are women. In the United States alone, ten million individuals (eight million women and two million men) are believed to already have the disease, and 18 million more have low bone mass, or osteopenia), placing them at risk for osteoporosis.

Osteoporosis is often called a “silent disease,” because bone loss occurs without symptoms. People may not know that they have osteoporosis until their bones become so weak that a sudden strain, bump or fall causes a fracture or a vertebra to collapse. One in two women and one in eight men over the age of 50 are expected to have osteoporosis-related fractures. Vertebral fractures, which occur in 27% of women 65 years of age or older, may initially be felt or seen in the form of severe back pain, loss of height or spinal deformities such as a stooped posture. According to the National Osteoporosis Foundation, the cost of osteoporosis-related hip fractures alone is approaching $14 billion annually in the U.S.

Current Therapies: There is no known cure for osteoporosis today. However, several medications are marketed for the prevention or treatment of osteoporosis. The major activity of these products is to reduce the bone resorbing activity of the osteoclasts, thereby reducing or preventing further bone loss. In addition, decreasing osteoclast activity provides an opportunity to indirectly shift the balance of activity to the osteoblasts which further assists in prevention of further bone breakdown along with a potential for some increase in bone mass.

7

Marketed treatments for osteoporosis include estrogen replacement therapy, or ERT, and Selective Estrogen Receptor Modulators, or SERMs. ERT has been available for several years and provides a beneficial effect through hormonal mechanisms. The major risk-to-benefit issue that needs to be considered in using this therapy is the association of ERT with the risk of developing cancer of the uterine lining, or endometrial cancer. The more recent availability of SERMs holds the promise of reduced risk of cancer. Additional experience, however, will be needed to clarify their comparative risks. Other reported side effects with SERMs include hot flashes and the occurrence of blood clots in deep veins.

Another marketed treatment for osteoporosis is the oral administration of a non-hormonal class of drugs known as bisphosphonates. They inhibit osteoclast-mediated bone resorption and, as such, have been widely used. These drugs are associated with side effects that can be disturbing to some patients. In particular, they are irritating to the lining of the upper gastrointestinal tract causing some patients to experience nausea, heartburn and irritation of the esophagus. Although the incidence of these side effects can be reduced by carefully controlling the administration of drug in relation to food intake, as well as controlling the physical activity of the patient for a time period following each administration, we believe that patient compliance would be greatly enhanced if more palatable, effective drugs become available.

Calcitonin, a naturally occurring non-sex hormone involved in bone metabolism, is also approved for treatment of osteoporosis. This drug is not available in an orally administered form and must be taken by nasal inhalation. Other drugs, such as parathyroid hormone administered under the skin, have undergone clinical trials and are awaiting regulatory approval.

Our Approach: While each of the above therapies provides beneficial effects to patients with osteoporosis, there is an opportunity to develop better-tolerated and more-effective drugs. One major advance would be the introduction of a novel class of drugs that not only inhibits osteoclast-mediated bone resorption but also directly stimulates the growth of new bone. Our scientists are developing such a class of small-molecule drug candidates for the treatment of osteoporosis and related bone diseases, including Paget’s disease and periodontal disease. The drugs that are being developed are designed to interact with a specific protein in bone cells that is critically involved in bone breakdown and bone formation. Src, a protein tyrosine kinase enzyme, has been shown to be a validated target for osteoporosis through genomics experiments. In a special strain of mice that was genetically manipulated to delete this gene, several groups of researchers found that the deletion prevented bone resorption, increased bone mass and enhanced bone formation. Based on these observations, we anticipate that a drug capable of inhibiting the activity of this tyrosine kinase should provide the same effects as observed in the specific gene-depleted mice.

In vitro and in vivo animal studies have demonstrated that our lead product candidates for the treatment of osteoporosis, AP23485 and its analogs, are potent Src inhibitors that have beneficial effects on both stages of bone remodeling as predicted in the validation models. We anticipate that the dual action of these compounds will provide an extremely important advancement in treatment, prevention and potential reversal of osteoporosis. AP23485 and its analogs are in preclinical development. Further studies aimed at selecting one of the AP23485 analogs as a clinical candidate and at optimizing the formulations of these analogs for convenient dosing are underway.

Additional Drug Discovery Programs

Overview: The regulation of cell signaling is a part of normal cellular function, and defects play critical roles in many major diseases. As a result, our technologies have a broad range of potential therapeutic applications, and we have several research programs aimed at developing additional product candidates. These programs leverage the knowledge and expertise we have gained in the development of our current lead product candidates and our focus on the hematology and oncology area.

8

Cell-signaling Inhibitors that Target Cancer: We are developing a series of highly potent small-molecule compounds that are designed to selectively inhibit oncogenic cell-signaling protein tyrosine kinases that have been implicated convincingly in human cancer and are well validated cell-signaling targets for treating cancer. Protein tyrosine kinases, such as c-Src, c-Abl, and Her2/neu, are known to play important roles in regulating tumor growth and proliferation, apoptosis (cell death), angiogenesis (blood supply), and metastasis (spread to distant sites). Using structure-based drug design and chemo-informatics, our scientists have discovered proprietary compounds that target these protein kinases and block the growth of breast, prostate, colon, lung, bone and kidney tumors and leukemia in various models. Further studies aimed at optimizing these compounds for therapeutic use are ongoing.

Cellular Therapy: Stem cells are “master” cells that retain the ability to specialize, or “differentiate,” into many different types of specialized cells. Recent research has emphasized the broad potential of stem cells, both embryonic and adult forms, to treat disease by providing a source of cells that can be used to replace defective cells, tissues or even whole organs. We have demonstrated, both in vitro and in vivo, that our cell-signaling regulation technologies can potentially overcome the two key limitations to the widespread use of stem-cell based therapies: (1) the inability to transfer therapeutic or corrective genes into stem cells efficiently; and (2) the subsequent difficulty in reliably deriving large numbers of specialized cells of the correct type and purity to patients.

We have also demonstrated regulated growth of other potentially useful cell types, using ARGENT cell-growth switches customized for the desired cell therapy product. These include liver cells (for the treatment of hepatic disease), muscle cells (for the treatment of heart failure), and pancreatic islet cells (for the treatment of diabetes). At present, we are evaluating these opportunities for potential product development.

Orally Regulated Protein Therapy: Our cell-signaling regulation technologies are a promising general platform for the delivery of secreted therapeutic proteins, because they have the potential to control the level of gene expression using an orally administered drug. Protein levels can be optimized within a therapeutic window. Allowing therapy to be terminated, if necessary, enhances safety. We believe that information obtained from the development of our Epo product candidate for anemia could be used to accelerate the development of additional protein therapy product candidates.

Our Core Competencies

Our research programs are built around key areas of competency in structure-based drug design and chemo-informatics, functional genomics and proteomics, and protein engineering. The integration of these strengths provides us with unique opportunities in the era of post-genomic drug discovery.

Functional genomics and proteomics are the study of gene and protein function, or more specifically the study of how particular genes regulate cellular function. A further aspect of functional genomics is the study of how the protein products are linked in cell-signaling pathways and how these pathways are regulated. Functional genomics has particular relevance to the process of identifying specific disease-related molecular targets for drug discovery, a process termed target validation.

Protein engineering is the design and modification of proteins based on the knowledge of their atomic level structure, obtained through the use of protein X-ray crystallography or nuclear magnetic resonance spectroscopy. Usually, the design process utilizes the three-dimensional structure of the protein to incorporate non-native amino acids into the protein’s structure. This process generates new surface characteristics, thereby altering the small molecule or protein binding properties of the protein.

Structure-based drug design is a computational approach used to design small organic drug molecules that bind specifically to a particular protein in a cell-signaling pathway, for example, the critical molecular target in that pathway known to be linked to a disease. Using the target protein’s three-dimensional atomic

9

structure, drugs can be designed and optimized to bind both tightly and selectively to the target, which should lead to more potent drugs with fewer side effects. Structure-based drug design integrates structural biology and computer-assisted molecular modeling methods and has been applied directly to validated molecular targets in our cell-signaling programs to discover and optimize lead compounds. Chemo-informatic techniques and virtual screening further expand the utility of structural methods in drug discovery.

Our Enabling Platform Technologies

NF-kB Cell-signaling Technology

Dr. David Baltimore, a founding member of our Board of Scientific and Medical Advisors, and his colleagues discovered NF-kB, a cellular protein that plays a critical role in cell-signaling pathways that regulate the transcription of key genes involved in many major diseases, including atherosclerosis, asthma, arthritis, cancer, diabetes, infectious disease, inflammatory bowel disease, rheumatoid arthritis, sepsis and stroke.

Recognizing the importance of NF-kB as a validated drug target, the pharmaceutical industry has developed and is developing a number of drugs designed to regulate the activity of this protein and other targets in its pathway. We have established what we believe to be a dominant NF-kB intellectual property position based on an exclusive license to the pioneering work of the Baltimore laboratory from Massachusetts Institute of Technology, The Whitehead Institute for Biomedical Research and Harvard University.

Regulation Technologies to Accelerate Drug Discovery

Overview: Our proprietary portfolio of cell-signaling regulation technologies includes the ARGENT Signaling, ARGENT Transcription, and RPD Secretion Technologies (collectively known as our RegTech technologies). Intracellular processes can be controlled with small molecules providing versatile tools for use in cell biology, functional genomics, proteomics, and drug-discovery research. To maximize their use by the scientific community, we distribute our technologies free of charge to academic investigators in the form of our Regulation Kits. Over 500 investigators worldwide already are using our Regulation Kits in diverse areas of research, and over 120 scientific papers describing their use have been published. For researchers in pharmaceutical and biotechnology companies, we have established an alternative licensing program to provide them with access to our cell-signaling regulation technologies on commercial terms.

Target Validation – Cell Signaling: As analysis of the human genome sequence uncovers a wealth of new uncharacterized genes, a key challenge will be validating those genes that are good drug targets. Many of these are likely to be signaling proteins. Our ARGENT Signaling Technology allows single signaling proteins to be activated in isolation, allowing their precise functional role to be assessed in vitro and then in vivo. ARGENT tools are effective for early analysis of newly identified “orphan” signaling proteins, because no knowledge of natural ligands or binding partners is required. In addition, identification of new pathway components and gene expression changes that occur with activation can be used to identify and further validate new drug targets.

Once a cell-signaling pathway has been validated, the same ARGENT technology can provide useful tools for the next stages of drug development. The inducible gene can be engineered into experimental animals to provide an ARGENT model of the associated disease. ARGENT cell lines in which the validated signaling complex can be inducibly activated also can provide the basis for highly targeted cell-based screening for small-molecule drug candidates.

Target Validation – Gene Transcription: Varying the expression level of a gene is an effective way to study its function. The tight, dose-dependent control of expression afforded by our ARGENT Transcription

10

Technology allows precise correlation of gene expression levels with their physiological consequences. Our technology also can be used to inducibly express inhibitors of supposed targets, such as dominant-negative mutants or gene-specific DNA binding proteins, for validation purposes.

A major application of our ARGENT Transcription Technology, based on its tight regulation of genes, is the creation of inducible knockout mice. Knockout mice in which both copies of a gene of interest have been eliminated are extremely useful for assessing the role of the deleted gene in disease. Unfortunately, many knockout mice are not viable, because expression of the gene is required during embryonic development. In addition, complete knockouts often suffer from changes in the expression of other genes that may compromise interpretation of the resulting physical, biochemical, and physiological makeup of the animal, or its phenotype. We believe that both of these problems can be solved using our ARGENT Transcription Technology by generating inducible knockouts in which genes are eliminated in the adult mouse by administering a small molecule.

Product Validation: The human genome sequence provides a rich source of potential proteins that are themselves drug candidates. In addition, advances in protein and antibody engineering are increasingly yielding large numbers of novel proteins that have therapeutic potential. Validating these molecules as products required extensive efforts in protein manufacturing, purification, scale-up and formulation. Inducible expression in animals can be used to validate therapeutic protein product candidates, in particular, secreted proteins and monoclonal antibodies, without the need to express and purify large amounts of recombinant protein. Since the level of protein delivered can be precisely controlled, this approach offers an effective way to characterize both the therapeutic and safety profiles of protein product candidates.

Our ARGENT Transcription and RPD Secretion Technologies provide complementary alternatives to this approach to product validation. The use of our ARGENT Transcription Technology allows a protein to be delivered over the course of several days, whereas the alternative approach based on our RPD Secretion Technology is particularly useful for generating rapid bursts of protein expression. The use of our ARGENT and RPD technologies to validate protein therapeutic candidates has particular value when a large number of related proteins need to be evaluated, as studies can be done on a high-throughput basis.

Drug Screening: The ability to induce a specific cell signaling, gene activation or protein secretion event in a cell allows the configuration of “targeted” cell-based screens in which the unique cell context of interest for drug design can be chemically induced. These screens very specifically search for drugs affecting cells in which a particular cell signaling or gene activation event has occurred. The tight regulation afforded by our ARGENT and RPD technologies means that highly specific screens can be set up, using the uninduced cell line as a stringent counter-screen. Because the cellular event of interest can be induced chemically, the induction step can be configured into high-throughput screens.

Our Business Strategy

Our business strategy balances near-term revenues from licensing with longer-term product development. To achieve this goal, we plan to:

• Develop our current lead product candidates at least through phase 2 clinical trials;

• Establish the commercial infrastructure to market our hematology and oncology lead products in the United States;

• Pursue a worldwide partner for our osteoporosis product candidate and partners for our hematology and oncology lead products outside the United States, generally after we are able to obtain phase 2 clinical data;

11

• License our cell-signaling regulation technologies and our NF-kB intellectual property portfolio to biotechnology and pharmaceutical companies to accelerate their genomics, proteomics and drug discovery programs; and

• Partner our cell-signaling regulation technologies for joint development of novel products, especially with companies that have proprietary therapeutic genes, cellular systems (e.g., stem cells) or gene delivery vectors.

Research and Development Spending

During each of the three years ended December 31, 2001, 2000 and 1999, respectively, we spent approximately $16.6 million, $12.5 million, and $28.8 million, respectively, on our research and development activities.

Manufacturing

When advantageous, we intend to rely on strategic partners or third-party contractors for manufacturing cGMP material to be used in our product candidates. We believe that our small-molecule drugs can be produced in commercial quantities through conventional synthetic and natural-product fermentation techniques. We expect to access manufacturing methods for viral vectors from potential partners and third-party manufacturers. Thus far, we have contracted with various commercial and academic entities to develop and optimize our manufacturing methods, but we have not entered into any formal manufacturing agreements adequate to produce our product candidates for large-scale clinical trials or commercial use.

Intellectual Property

Patents and other intellectual property rights are essential to our business. We file patent applications to protect our technology, inventions and improvements to our inventions that are considered important to the development of our business.

As of March 18, 2002, we have 116 patents and pending patent applications in the United States, of which 54 are owned, co-owned or exclusively licensed by us and 62 are owned, co-owned or exclusively licensed by our subsidiary, ARIAD Gene Therapeutics, Inc., or AGTI. In addition, we have filed foreign counterparts, as appropriate. We also have several nonexclusive technology licenses from certain institutions in support of our research programs. We anticipate that we will continue to seek licenses from universities and others where applicable technology complements our research and development efforts.

Many of the patents and patent applications in our portfolio cover our cell-signaling regulation technologies. These patents and pending applications cover regulatory technologies, specialized variants of the technologies, critical nucleic acid components, small-molecule drugs, the identification and use of dimerizer hormone mimetics, and various uses of the technologies in health care and drug discovery. Patents issued to date include 24 patents covering our cell-signaling regulation technologies. These patents issued in the United States beginning in November 1998 and should provide proprietary protection for our protein and cell therapy product candidates until at least 2015. We hope to obtain additional patents in the ensuing years based on pending applications.

Our patent portfolio also covers research tools and methods used in our drug discovery programs, as well as multiple classes of small-molecule compounds discovered in those programs. We also have a number of issued patents and pending applications relating to the cell-signaling proteins, NF-kB and NF-AT, and their use in drug discovery.

12

We also rely on unpatented trade secrets and proprietary know-how. However, trade secrets are difficult to protect. We enter into confidentiality agreements with our employees, consultants and collaborators. In addition, we believe that certain technologies utilized in our research and development programs are in the public domain. Accordingly, we do not believe that patent or other protection is available for these technologies. If a third party were to obtain patent or other proprietary protection for any of these technologies, we may be required to challenge such protections, obtain a license for such technologies or terminate or modify our programs that rely on such technologies.

Our Board of Scientific and Medical Advisors

We have assembled a Board of Scientific and Medical Advisors that currently consist of experts in the fields of molecular and cellular biology, biochemistry, immunology, and organic, physical, and computational chemistry, and molecular medicine. Each advisor is engaged under a consulting agreement that requires the advisor to provide consulting services to us in our field of interest and not to disclose any of our confidential information. Our Board of Scientific and Medical Advisors is chaired by Dr. Stuart L. Schreiber, Morris Loeb Professor and Chair, Chemistry and Chemical Biology; Co-Director, Institute of Chemistry and Cell Biology; and Scientific Co-Director, Bauer Center of Genomics Research at Harvard University and an Investigator of the Howard Hughes Medical Institute.

Our Licenses

We and our subsidiary, AGTI, have entered into license agreements with various research institutions and universities pursuant to which we and/or AGTI are the licensee of certain technologies upon which some of our product candidates are based.

We have agreed to pay royalties to our licensors on sales of certain products based on the licensed technologies, as well as, in some instances, milestone payments and patent filing and prosecution costs. The licenses also impose various milestones, commercialization, sublicensing, royalty as well as insurance and other obligations. Failure by us to comply with these requirements could result in the termination of the applicable agreement, which could have a material adverse effect on our business, financial condition, and results of operations.

Competition

In the area of cell-signaling regulation, companies such as Amgen, Inc., AstraZeneca plc, Biogen, Inc., Eli Lilly and Co., Imclone Systems, Inc., Ligand Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Novartis Pharma AG, OSI Pharmaceuticals, Inc., Tularik, Inc., and Vertex Pharmaceuticals, Inc. are developing drugs to treat human disease by inhibiting cell-signaling pathways. Companies developing gene-delivery technologies related to our programs include Avigen, Inc., Biogen, Inc., Cell Genesys, Inc., Genzyme Corp., MediGene, GmbH, and Targeted Genetics Corp. Several companies are developing products to treat GvHD, including Abgenix, Inc., AVAX, Inc., BioTransplant, Inc., Protein Design Labs, Inc., and Repligen Corp. Other companies have products on the market or in development against which our products may have to compete. In the area of oncology, such companies include Wyeth Corp., Bristol-Myers Squibb Co., Glaxo Smith Kline plc., and Pharmacia, Inc. In the field of bone diseases, such companies include Merck & Co., Inc., NPS Pharmaceuticals, Inc., and Proctor and Gamble, Inc. We may also experience competition from companies that have acquired or may acquire technology from companies, universities, and other research institutions. As these companies develop their technologies, they may develop proprietary positions that may materially and adversely affect us.

13

Government Regulation

Our ongoing research and development activities, our clinical trials, the manufacturing and testing procedures and the marketing of our product candidates, if they are approved, all are subject to extensive regulation by numerous governmental authorities in the United States and other countries. Any drug developed by us must undergo rigorous preclinical studies and clinical testing and an extensive regulatory approval process administered by the FDA under the federal Food, Drug and Cosmetic Act prior to marketing in the United States. Satisfaction of such regulatory requirements, which includes demonstrating that a product is both safe and effective for its intended indications for use, typically takes several years or more depending upon the type, complexity and novelty of the product and requires the expenditure of substantial resources. Preclinical studies must be conducted in conformance with the FDA’s good laboratory practice regulations. Before commencing clinical trials in the United States, we must submit to and receive clearance from the FDA of an IND. There can be no assurance that submission of an IND will result in FDA clearance to commence clinical trials. Clinical testing must meet requirements for IRB oversight, informed consent and good clinical practice and is subject to continuing FDA oversight. In addition, certain clinical studies involving gene transfer conducted in the United States require the review and approval of the National Institutes of Health Recombinant DNA Advisory Committee, or the RAC. There can be no assurance that submission to the RAC will result in clearance to commence clinical trials. We have a limited history of conducting preclinical studies and the clinical trials necessary to obtain regulatory approval. Furthermore, we or the FDA may suspend clinical trials at any time if either party believes that the subjects participating in such trials are being exposed to unacceptable risks or if the FDA finds deficiencies in the conduct of the trials or other problems with our product under development.

Before receiving FDA approval to market a product, we will have to demonstrate that the product is safe and effective in the patient population that will be treated. Data obtained from preclinical studies and clinical trials are susceptible to varying interpretations that could delay, limit or prevent regulatory clearances. In addition, delays or rejections may be encountered based upon additional government regulation from future legislation or administrative action or changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. Similar delays also may be encountered in foreign countries. There can be no assurance that even after such time and expenditures, regulatory approval will be obtained for any product candidates developed by us, or, even if approval is obtained, that the labeling for such products will not limit the product’s condition of use, which could materially impact the marketability and profitability of the product. If regulatory approval of a product is granted, such approval will be limited to those disease states and conditions for which the product has been shown useful, as demonstrated by clinical trials. Furthermore, approval may entail ongoing requirements for post-market studies. Even if such regulatory approval is obtained, a marketed product, its manufacturer and its manufacturing facilities and procedures are subject to continual review and periodic inspections by the FDA. Discovery of previously unknown problems with a product, manufacturer, manufacturing procedures or facility may result in restrictions on such product or manufacturer, including costly recalls, an injunction against continued marketing and manufacturing until the problems have been adequately addressed to the FDA’s satisfaction or even withdrawal of the product from the market. There can be no assurance that any compound developed by us alone or in conjunction with others will prove to be safe and efficacious in clinical trials and will meet all of the applicable regulatory requirements needed to receive and maintain marketing approval. Additionally, the marketing, labeling and advertising for an approved product is subject to ongoing FDA scrutiny and the failure to adhere to applicable requirements can result in regulatory action that could have a material adverse impact on the profitability of the product.

Outside the United States, our ability to market a product will be contingent upon receiving a marketing authorization from the appropriate regulatory authorities. The requirements governing the conduct of clinical trials, marketing authorization, pricing and reimbursement vary widely from country to country. At present, foreign marketing authorizations are applied for at a national level, although within the European Community certain registration procedures are available to companies wishing to market a product in more

14

than one member state. If the regulatory authority is satisfied that adequate evidence of safety, quality and efficacy has been presented, a marketing authorization will be granted. This foreign regulatory approval process includes all of the risks associated with FDA clearance set forth above.

Our Employees

As of March 18, 2002, we had 69 employees, 34 of whom hold post-graduate degrees, including 18 with a Ph.D. or M.D. Most of our employees are engaged directly in research and development. We have entered into confidentiality and noncompetition agreements with all of our employees. None of our employees are covered by a collective bargaining agreement, and we consider relations with our employees to be good.

RISK FACTORS

THE RISKS AND UNCERTAINTIES DESCRIBED BELOW ARE THOSE THAT WE CURRENTLY BELIEVE MAY MATERIALLY AFFECT OUR COMPANY. ADDITIONAL RISKS AND UNCERTAINTIES THAT WE ARE UNAWARE OF OR THAT WE CURRENTLY DEEM IMMATERIAL ALSO MAY BECOME IMPORTANT FACTORS THAT AFFECT OUR COMPANY.

Risks Relating to Our Business

We may never succeed in developing marketable drugs or generating product revenues.

We are an early-stage company with no product revenues, and we may not succeed in producing pharmaceutical products for commercialization. We do not expect to have any products on the market for several years, if at all. Our main focus is research and product development. We are exploring human diseases at the cellular level. We seek to discover which genes within cells malfunction to cause disease, which signals are triggered within cells during the disease process to cause these cells to respond abnormally and which drugs can halt or reverse those activities within cells. As with all science, we face much trial and error, and we may fail at numerous stages along the way. If we are not successful in developing marketable products, we will not be profitable.

We have incurred significant losses to date and may never be profitable.

We have incurred significant operating losses in each year since our formation in 1991 as a Delaware corporation through 2001 and have an accumulated deficit of approximately $108.5 million from our operations through December 31, 2001. It is likely that we will incur significant operating losses for the foreseeable future. We currently have no product revenues or commitments for future research revenues, may never be able to earn such revenues and may never have profitable operations, even if we are able to commercialize any of our product candidates or enter into additional research agreements. If our losses continue and we are unable to successfully develop, commercialize, manufacture and market product candidates, we may never have product revenues or achieve profitability. Losses have resulted principally from costs incurred in research and development of product candidates and from general and administrative costs associated with our operations.

Insufficient funding may jeopardize our research and development programs and may prevent commercialization of our products and technologies.

All of our operating revenue to date has been generated through collaborative research agreements that have expired or been terminated. Accordingly, we may not be able to secure the significant funding which is required to maintain and continue each of our research and development programs at the current levels or at levels that may be required in the future. We do not have any committed strategic alliance funding for the advancement of any of our programs. Although we intend to seek additional funding from product-based

15

collaborations, technology licensing, and public and private financings, additional funding may not be available on terms acceptable to us, or at all. If we cannot secure adequate financing, we may be required to delay, scale back or eliminate one or more of our research and development programs or to enter into license arrangements with third parties to commercialize products or technologies that we would otherwise seek to develop ourselves.

Because we do not own all of the outstanding stock of our subsidiary, ARIAD Gene Therapeutics, Inc., or AGTI, we may not realize all of the potential future economic benefit from products developed based on technology licensed to or owned by our subsidiary.

Our subsidiary, AGTI, holds licenses from Harvard University, Stanford University and other universities relating to our ARGENT cell-signaling regulation technology, a key component of our small-molecule regulated anemia and graft-vs-host disease product candidates. Minority stockholders of AGTI, including Harvard University, Stanford University, some of our scientific advisors, and some current and former members of our management, own 20% of the issued and outstanding capital stock of AGTI. We own the remaining 80% of the issued and outstanding capital stock of AGTI. We do not currently have a license agreement with AGTI that provides us with rights to commercialize products based on our ARGENT cell-signaling regulation technology or products based on technology or compounds derived from our ARGENT programs. In order to commercialize any product based on these technologies or compounds, we will either license them on terms to be determined or commercialize these products through AGTI. The economic benefit to our stockholders from products that we commercialize will be diminished by any royalties paid under a future license agreement, if any, with AGTI. The economic benefit to our stockholders from products, if any, that AGTI may commercialize would be reduced in an amount related to the percentage owned by the minority stockholders of AGTI.

Alternatively, we may acquire all of the interests of the minority stockholders in AGTI for cash, shares of our common stock or other securities of ours, if any. AGTI has a right of first refusal on the sale to third parties of 73% of the minority stockholders’ AGTI shares. AGTI does not have a call option, or a right to require the minority stockholders to sell their shares to us, for any of these shares. If we acquire these minority interests for either form of consideration, it will result in dilution to our stockholders. The economic value of the minority stockholders’ interests is difficult to quantify in the absence of a public market, and the market price of our publicly traded common stock may not accurately reflect its value. Accordingly, the market could change its perception of the value of these minority interests in our subsidiary at any time in reaction to our increased emphasis on these product candidates, announcements regarding these product candidates or for other reasons, any of which could result in a decline in our stock price. In addition, if we acquire the minority interests at a cost greater than the value attributed to them by the market, this also could result in a decline in our stock price. If we choose to acquire these minority interests through a short-form merger in which we do not solicit the consent of the minority stockholders of AGTI, we could become subject to an appraisal procedure, which would result in additional expense and diversion of management resources.

Because members of our management team and/or board of directors beneficially own a material percentage of the capital stock of our subsidiary, AGTI, and we have agreements with AGTI, there may be conflicts of interest present in dealings between ARIAD and AGTI.

Four members of our management team and/or board of directors own or have the right to acquire up to approximately 6.1% of the outstanding capital stock of AGTI. Harvey J. Berger, M.D., our Chairman, Chief Executive Officer and President, owns 3.4%; David L. Berstein, Esq., our Senior Vice President and Chief Patent Counsel, owns 0.3%; John D. Iuliucci, Ph.D., our Senior Vice President, Drug Development, owns 0.7%; and Jay R. LaMarche, one of our Directors and a part-time employee, owns 1.7%. These same individuals beneficially own approximately 7.1% of our outstanding common stock. In addition, as part of the formation of AGTI, we entered into agreements with AGTI to provide for the operations of AGTI. As a result, the market may perceive conflicts of interest to exist in

16

dealings between AGTI and us. AGTI is the exclusive licensee of the ARGENT intellectual property from Harvard University and Stanford University and of related technologies from other universities. In the event that we commercialize products based on or derived from our ARGENT cell-signaling regulation technology or related technologies or compounds, we will have to negotiate the terms of a license agreement with AGTI or acquire all of the capital stock of AGTI that we do not currently own. Because of the apparent conflicts of interest, the market may be more inclined to perceive the terms of any transaction between us and AGTI as being unfair to us.

The loss of key members of our scientific and management staff could delay and may prevent the achievement of our research, development and business objectives.

Our Chairman, Chief Executive Officer and President, Harvey J. Berger, M.D.; our Senior Vice President and Chief Patent Counsel, David L. Berstein, Esq.; our Senior Vice President, Drug Development, John D. Iuliucci, Ph.D.; our Senior Vice President and Chief Business Officer, Fritz Casselman; and other key officers and members of our scientific staff responsible for areas such as drug development, regulatory affairs, drug discovery, and manufacturing are important to our specialized scientific business. We also are dependent upon a few of our scientific advisors to assist in formulating our research and development strategy. The loss of, and failure to promptly replace, any member of our management team could significantly delay and may prevent the achievement of our research, development and business objectives. While we have entered into employment agreements with all of our officers, these officers may not remain with us.

We may be unable to develop or commercialize our product candidates, if we are unable to obtain or maintain certain licenses.

We have entered into license agreements for some of our technologies, either directly or through AGTI. We are currently attempting to obtain additional licenses for technology useful to our programs. Our inability to obtain any one or more of these licenses, on commercially reasonable terms, or at all, or to circumvent the need for any such license, could cause significant delays and cost increases and materially affect our ability to develop and commercialize our product candidates. We also use gene sequences or proteins encoded by those sequences and other biological materials in each of our research programs which are, or may become, patented by others and to which we would be required to obtain licenses in order to develop or market our product candidates. Some of our programs, including, for example, our regulated protein therapy program, may require the use of multiple proprietary technologies, especially gene-transfer vectors and therapeutic genes. Obtaining licenses for these technologies may require us to make cumulative royalty payments or other payments to several third parties, potentially reducing amounts paid to us or making the cost of our products commercially prohibitive.

Some of our licenses obligate us to exercise diligence in pursuing the development of product candidates, to make specified milestone payments and to pay royalties. In some instances, we are responsible for the costs of filing and prosecuting patent applications. These licenses generally expire upon the earlier of a fixed term of years after the date of the license or the expiration of the applicable patents, but each license is also terminable by the other party upon default by us of our obligations. Our inability or failure to meet our diligence requirements or make any payments required under these licenses would result in a reversion to the licensor of the rights granted which, with respect to the licenses pursuant to which we have obtained exclusive rights, would materially and adversely affect our ability to develop and market products based on our licensed technologies.

We may be unable to access vectors or other gene transfer technologies that we will need to develop and commercialize our regulated protein and cellular therapy product candidates.

We may not be able to access the gene transfer technologies required to develop, manufacture, and commercialize our regulated protein and cellular therapy product candidates. We are reliant on our ability

17

to enter into license agreements with appropriate academic institutions and/or gene therapy companies that can provide us with rights to the necessary technology, production methods, and components of gene delivery systems. The inability to reach an appropriate agreement with such an entity on reasonable commercial terms could delay or prevent the preclinical evaluation, clinical testing and/or commercialization of our product candidates. Our inability to access gene transfer technology, including suitable manufacturing methods, would have significant adverse effects on some of our product candidates. If we do not market our product candidates, we will never become profitable. In addition, the intellectual property landscape covering gene transfer technologies is currently uncertain and fragmented. Accordingly, if we select one partner as a source for selected intellectual property rights, we may find that we have not licensed sufficient rights to be able to commercialize our products or we may be forced to acquire additional rights or discontinue marketing our product candidates unexpectedly.

We have no experience in manufacturing any of our product candidates, which raises uncertainty as to our ability to develop and commercialize our product candidates.

We have no experience in, and currently lack the resources and capability to, manufacture any of our product candidates on a large scale. Our ability to conduct clinical trials and commercialize our product candidates will depend, in part, on our ability to manufacture our products on a large scale, either directly or through third parties, at a competitive cost and in accordance with cGMP and other regulatory requirements. We currently do not have the capacity to manufacture our product candidates in large quantities. We depend on third-party manufacturers or collaborative partners for the production of our product candidates for preclinical research and clinical trials and intend to use third-party manufacturers to produce any products we may eventually commercialize. If we are not able to obtain contract manufacturing on commercially reasonable terms, we may not be able to conduct or complete clinical trials or commercialize our product candidates, and we do not know whether we will be able to develop such capabilities. If we are not able to develop cell processing methods that comply with recently adopted regulatory guidelines known as current Good Tissue Practices, or cGTP, we may not be able to commercialize our regulated cellular therapy products.

Competing technologies may render some or all of our programs or future products noncompetitive or obsolete.

Many well-known pharmaceutical, healthcare and biotechnology companies, academic and research institutions and government agencies, which have substantially greater capital, research and development capabilities and experience than us, are presently engaged in:

• Developing products based on cell signaling, genomics, proteomics, computational chemistry and protein and cellular therapies; and

• Conducting research and development programs for the treatment of all the disease areas in which we are focused.

Some of these entities already have product candidates in clinical trials or in more advanced preclinical studies than we do. These entities may succeed in commercializing competitive products before us, which would give them a competitive advantage. Competing technologies may render some or all of our programs or future products noncompetitive or obsolete, and we may not be able to make the enhancements to our technology necessary to compete successfully with newly emerging technologies. If we are unable to compete in our chosen markets, we will not become profitable.

18

We may not be able to protect our intellectual proprietary rights.

We and our licensors have pending patent applications covering biochemical and cellular tests useful in drug discovery, new chemical compounds discovered in our drug discovery programs, certain components, configurations and uses of our cell-signaling regulation technologies, and methods and materials for conducting pharmaceutical research. These patent applications may not issue as patents and may not issue in all countries in which we develop, manufacture or sell our products. In addition, patents issued to us or our licensors may be challenged and subsequently narrowed, invalidated or circumvented. In that event, such patents may not afford meaningful protection for our technologies or product candidates, which would materially impact our ability to develop and market our product candidates. Certain technologies utilized in our research and development programs are already in the public domain. Moreover, a number of our competitors have developed technologies, filed patent applications or obtained patents on technologies and compositions that are related to our business and may cover or conflict with our patent applications. Such conflicts could limit the scope of the patents that we may be able to obtain or may result in the denial of our patent applications. If a third party were to obtain intellectual proprietary protection for any of these technologies, we may be required to challenge such protections, terminate or modify our programs that rely on such technologies or obtain licenses for use of these technologies.

If our product candidates are not accepted by physicians and insurers, we will not be successful.

Our success is dependent on the acceptance of our product candidates. Our product candidates may not achieve significant market acceptance among patients, physicians or third-party payors, even if we obtain necessary regulatory and reimbursement approvals. Failure to achieve significant market acceptance of our product candidates will harm our business. We believe that recommendations by physicians and health care payors will be essential for market acceptance of any product candidates. In the past, there has been concern regarding the potential safety and effectiveness of gene therapy products. Physicians and health care payors may conclude that any of our product candidates are not safe.

If we are unable to establish sales, marketing and distribution capabilities or to enter into agreements with third parties to do so, we may be unable to successfully market and sell any products.

We currently have no sales, marketing or distribution capabilities. If we are unable to establish sales, marketing or distribution capabilities either by developing our own sales, marketing and distribution organization or by entering into agreements with others, we may be unable to successfully sell any products that we are able to begin to commercialize. If we are unable to effectively sell our products, our ability to generate revenues will be harmed. We may not be able to hire, in a timely manner, the qualified sales and marketing personnel we need, if at all. In addition, we may not be able to enter into any marketing or distribution agreements on acceptable terms, if at all. If we cannot establish sales, marketing and distribution capabilities as we intend, either by developing our own capabilities or entering into agreements with third parties, sales of future products, if any, may be harmed.

If we develop a product for commercial use, a subsequent product liability-related claim or recall could have an adverse effect on our business.

Our business exposes us to potential product liability risks inherent in the testing, manufacturing and marketing of pharmaceutical products, and we may not be able to avoid significant product liability exposure. A product liability-related claim or recall could be detrimental to our business. In addition, except for insurance covering product use in our clinical trials, we do not currently have any product liability insurance, and we may not be able to obtain or maintain such insurance on acceptable terms, or we may not be able to obtain any insurance to provide adequate coverage against potential liabilities. Our inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or limit the commercialization of any products that we develop.

19

Risks Relating to Governmental Approvals

We have limited experience in conducting clinical trials, which may cause delays in commencing and completing clinical trials of our product candidates.

Clinical trials must meet FDA and foreign regulatory requirements. We have limited experience in conducting the preclinical studies and clinical trials necessary to obtain regulatory approval. Consequently, we may encounter problems in clinical trials that may cause us or the FDA or foreign regulatory agencies to delay, suspend or terminate these trials. If the clinical trials of our product candidates fail, we will not be able to market our product candidates. Problems we may encounter include the possibility that we may not be able to manufacture sufficient quantities of cGMP materials for use in clinical trials, conduct clinical trials at preferred sites, enroll sufficient test subjects or begin or successfully complete clinical trials in a timely fashion, if at all. Furthermore, we, the FDA or foreign regulatory agencies may suspend clinical trials at any time if we or they believe the subjects participating in the trials are being exposed to unacceptable health risks or if we or they find deficiencies in the clinical trial process or conduct of the investigation. The FDA and foreign regulatory agencies could also require additional clinical trials, which would result in increased costs and significant development delays. Our failure to adequately demonstrate the safety and effectiveness of a therapeutic product candidate under development could delay or prevent regulatory approval of the product candidate and could have a material adverse effect on our business.

We may not be able to obtain government regulatory approval for our product candidates prior to marketing.

To date, we have not submitted a marketing application for any product candidate to the FDA or any foreign regulatory agency, and none of our product candidates have been approved for commercialization in the United States or elsewhere. Prior to commercialization, each product candidate would be subject to an extensive and lengthy governmental regulatory approval process in the United States and in other countries. We may not be able to obtain regulatory approval for any product candidate we develop or even if approval is obtained, the labeling for such products may be required to bear limitations that could materially impact the marketability and profitability of the product involved. We have no history of conducting and managing the clinical testing necessary to obtain such regulatory approval. Satisfaction of these regulatory requirements, which includes satisfying the FDA and foreign regulatory authorities that the product is both safe and effective under its intended indications of use, typically takes several years or more depending upon the type, complexity and novelty of the product and requires the expenditure of substantial resources.

Furthermore, the regulatory requirements governing our potential products are uncertain. This uncertainty may result in excessive costs or extensive delays in the regulatory approval process, adding to the already lengthy review process. If regulatory approval of a product is granted, such approval will be limited to those disease states and conditions for which the product is proven safe and effective, as demonstrated by clinical trials, and our products will be subject to ongoing regulatory reviews. Although we have been granted orphan drug designation by the FDA for AP1903, the small-molecule drug used in our GvHD product candidate, this designation may be challenged by others or may prove to be of no practical benefit.

We will not be able to sell our product candidates, if we or our third-party manufacturers fail to comply with FDA manufacturing regulations.

Before we can begin to commercially manufacture our product candidates, we must either secure manufacturing in an approved manufacturing facility or obtain regulatory approval of our own manufacturing facility and processes. In addition, the manufacturing of our product candidates must comply with the FDA’s cGMP and/or cGTP requirements. These requirements govern, among other things, quality control and documentation procedures. We, or any third-party manufacturer of our product candidates, may not be able to comply with these requirements, which would prevent us from selling such

20

products. Material changes to the manufacturing processes of our products after approvals have been granted are also subject to review and approval by the FDA or other regulatory agencies.

Even if we bring products to market, we may be unable to effectively price our products or obtain adequate reimbursement for sales of our products, which would prevent our products from becoming profitable.

If we succeed in bringing our product candidates to the market, they may not be considered cost-effective, and reimbursement to the patient may not be available or may not be sufficient to allow us to sell our products on a competitive basis. In both the United States and elsewhere, sales of medical products and treatments are dependent, in part, on the availability of reimbursement to the patient from third-party payors, such as government and private insurance plans. Third-party payors are increasingly challenging the prices charged for pharmaceutical products and services. Our business is affected by the efforts of government and third-party payors to contain or reduce the cost of health care through various means. In the United States, there have been and will continue to be a number of federal and state proposals to implement government controls on pricing. In addition, the emphasis on managed care in the United States has increased and will continue to increase the pressure on the pricing of pharmaceutical products. We cannot predict whether any legislative or regulatory proposals will be adopted or the effect these proposals or managed care efforts may have on our business.

Risks Relating to Our Common Stock

Results of our operations and general market conditions for biotechnology stocks could result in the sudden change in the value of our stock.

As a biopharmaceutical company, we have experienced significant volatility in our common stock. Fluctuations in our operating results and general market conditions for biotechnology stocks could have a significant impact on the volatility of our common stock price. During 2001, our stock price ranged from a high of $8.38 to a low of $1.66. Factors contributing to such volatility include: results and timing of preclinical studies and clinical trials; evidence of the safety or effectiveness of pharmaceutical products; announcements of new collaborations; failure to enter into collaborations; our funding requirements; announcements of technological innovations or new therapeutic products; governmental regulation; policies regarding recombinant DNA and gene therapy; healthcare or cost-containment legislation; developments in patent or other proprietary rights, including litigation; general market trends for the biotechnology industry and related high-technology industries; the impact of changing interest rates and policies of the Federal Reserve; and public policy pronouncements.

ITEM 2: PROPERTIES

We have leased approximately 100,000 square feet (approximately 37,000 square feet currently under sublease to third parties) of laboratory and office space at 26 Landsdowne Street, located at University Park at M.I.T., in Cambridge, Massachusetts. The lease is for a ten-year term ending in July of 2002, with two consecutive five-year renewal options. We have extended the lease for the first five-year option. We believe that our currently leased facility will, in large part, be adequate for our research and development activities at least through the year 2004.

ITEM 3: LEGAL PROCEEDINGS

We were named as a defendant in a purported class action lawsuit commenced in June 1995 in the U.S. District Court for the Southern District of New York. The action named as defendants ARIAD Pharmaceuticals, Inc.; the underwriter of our initial public offering and a market maker in our stock, D. Blech & Co.; the managing director and sole shareholder of D. Blech & Co. and one of our former directors, David

21

Blech; certain other of our directors, and the qualified independent underwriter for the initial public offering, Shoenberg Hieber, Inc., or SHI.

Counsel for the plaintiff class, counsel for the Company and the named director defendants, excluding David Blech, or the Company Defendants, and counsel for SHI have executed a stipulation of settlement in the action, or the Proposed Settlement. The Proposed Settlement, in substance, contemplates a payment of $620,000 as consideration for plaintiffs’ consent to entry of judgment dismissing the action with prejudice and barring “contribution-type” claims against the Company Defendants by non-settling parties. The Proposed Settlement further is subject to the Court’s approval of that stipulation as fair, adequate and reasonable, and to entry of an appropriate judgment of dismissal in the action and in a related action entitled In re: Blech Securities Litigation, 94 Civ. 7696 (RWS), from which the Court previously ordered us dismissed as a defendant. The amount we have contributed to a legal escrow account was not material, and accordingly, no liability is recorded on the 2001 balance sheet.

On May 19, 1999, we filed suit in the Massachusetts Superior Court against Michael Z. Gilman, Ph.D., or Dr. Gilman, our former Chief Scientific Officer, seeking equitable relief for breach of his employment agreements in accepting a position as the research director of molecular biology at Biogen, Inc., or Biogen. The Superior Court issued a temporary injunction on May 19, 1999 restraining Dr. Gilman from using any of our confidential information in his new employment. On June 21, 1999, Dr. Gilman filed counterclaims against us seeking an order awarding damages for breach of contract and barring us from enforcing any provisions of our employment agreements with Dr. Gilman. On May 26, 1999 Biogen filed a motion to intervene as a defendant in the action which the Superior Court granted on August 2, 1999. Discovery in the case has been completed, and Summary Judgment Motions have been filed, heard and ruled upon. Our claim against Dr. Gilman and Dr. Gilman’s counterclaims will now proceed to trial. No trial date has been set. The ultimate outcome of the litigation with Dr. Gilman is not determinable or estimatable at this time, and accordingly, no liability is recorded on the balance sheets.

ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to a vote of security holders during the quarter ended December 31, 2001.

22

PART II

ITEM 5: MARKET FOR REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

Market Information

         Our common stock has been traded on the Nasdaq National Market under the symbol “ARIA” since September 19, 1994. The following table sets forth the high and low sales prices of our common stock as quoted on the Nasdaq National Market for the periods indicated.

	High		Low
2001:
First Quarter	$	8.38	$	2.78
Second Quarter		6.84		3.80
Third Quarter		5.40		1.66
Fourth Quarter		6.40		2.41
2000:
First Quarter	$	48.50	$	2.50
Second Quarter		17.50		5.69
Third Quarter		15.88		8.31
Fourth Quarter		13.00		4.50

Holders

The approximate number of holders of record of our common stock as of March 18, 2002 was 461, and the approximate total number of beneficial holders of our common stock as of March 18, 2002 was 29,000.

Dividends

We have not declared or paid dividends on our common stock in the past and do not intend to declare or pay such dividends in the foreseeable future. Our long-term debt agreement prohibits the payment of cash dividends. (See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources” and Note 5 of “Notes to Consolidated Financial Statements.”)

23

ITEM 6: SELECTED FINANCIAL DATA

The selected financial data set forth below as of December 31, 2001, 2000, 1999, 1998 and 1997 and for the years then ended have been derived from the audited consolidated financial statements of the Company, of which the financial statements as of December 31, 2001 and 2000 and for the years ended December 31, 2001, 2000, and 1999 are included elsewhere in this Annual Report on Form 10-K and are qualified by reference to such financial statements. The information set forth below should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the audited consolidated financial statements, and the notes thereto, and other financial information included herein.

				Years Ended December 31,
In thousands, except share and per share data				2001			2000			1999			1998			1997
Consolidated Statements of Operations Data:
Research revenue (principally related parties prior to 2000)				$	4		$	128		$	12,468		$	12,143		$	9,234
Operating expenses:
	Research and development				16,587			12,467			28,844			35,515			20,287
	General and administrative				4,469			3,318			3,938			2,634			2,925
			Total operating expenses		21,056			15,785			32,782			38,149			23,212
Loss from operations					(21,052	)		(15,657	)		(20,314	)		(26,006	)		(13,978	)
Other income (expense):
	Interest income				1,578			2,050			445			999			1,757
	Interest expense				(285	)		(225	)		(522	)		(481	)		(410	)
	Gain on sale of Genomics Center										46,440
	Equity in net loss of Genomics Center										(1,493	)		(660	)
		Total other income (expense)			1,293			1,825			44,870			(142	)		1,347
Income (loss) before cumulative effect of change in accounting principle					(19,759	)		(13,832	)		24,556			(26,148	)		(12,631	)
Cumulative effect of change in accounting principle											(364	)
Net income (loss)					(19,759	)		(13,832	)		24,192			(26,148	)		(12,631	)
Repurchase and accretion costs attributable to redeemable convertible preferred stock											(6,435	)		(36	)
Net income (loss) attributable to common stockholders				$	(19,759	)	$	(13,832	)	$	17,757		$	(26,184	)	$	(12,631	)
Earnings (loss) per share:
Per common share (basic):
Income (loss) attributable to common stockholders before cumulative effect of change in accounting principle				$	(.68	)	$	(.53	)	$	.82		$	(1.25	)	$	(.66	)
Cumulative effect of change in accounting principle											(.02	)
Net income (loss) – basic				$	(.68	)	$	(.53	)	$	.80		$	(1.25	)	$	(.66	)
Weighted average number of shares of common stock outstanding – basic					29,256,767			25,875,663			22,004,646			20,966,586			19,252,885
Per common share (diluted):
Income (loss) before cumulative effect of change in accounting principle				$	(.68	)	$	(.53	)	$	.71		$	(1.25	)	$	(.66	)
Cumulative effect of change in accounting principle											(.01	)
Net income (loss) – diluted				$	(.68	)	$	(.53	)	$	.70		$	(1.25	)	$	(.66	)
Weighted average number of shares of common stock outstanding – diluted					29,256,767			25,875,663			34,448,015			20,966,586			19,252,885

24

	Years Ended December 31,
In thousands	2001			2000			1999			1998			1997
Consolidated Balance Sheet Data:
Cash, cash equivalents and marketable securities	$	47,186		$	39,781		$	28,320		$	14,176		$	29,359
Working capital		42,775			36,866			22,731			5,806			16,539
Total assets		55,361			48,813			44,236			30,786			47,409
Long-term debt		6,847			3,700			1,900			3,295			5,156
Redeemable convertible preferred stock								8,070			5,036
Accumulated deficit		(108,474	)		(88,715	)		(74,883	)		(92,640	)		(66,457	)
Stockholders’ equity		43,093			40,851			27,068			11,733			28,374

25

'

ITEM 7: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS

You should read the following discussion and analysis in conjunction with “Selected Consolidated Financial Data” and our consolidated financial statements and the related notes included elsewhere in this report.

Overview

We are engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. Breakthrough medicines are products, created de novo, that may be used to treat diseases in innovative ways. Our lead product candidates – treatments for cancer, cancer that has spread to bone, or bone metastases, anemia, graft-vs-host disease following T cell immunotherapy and osteoporosis – all were developed through the integration of genomics, proteomics and structure-based drug design. We have an exclusive license to pioneering technology related to the discovery, development, and use of drugs that modulate the cellular protein, NF-kB, and other targets in its pathway, which regulate key genes involved in many major diseases.

Aventis Relationship

From November 1995 through December 1999, substantially all of our research revenue and the majority of our research expenses were incurred in collaboration with Aventis Pharmaceuticals Inc., or Aventis (formerly known as Hoechst Marion Roussel, Inc.) and its affiliates.

In November 1995, we entered into an agreement with Hoechst Marion Roussel, S.A. to collaborate on the discovery and development of drugs to treat osteoporosis and related bone diseases, or the Osteoporosis Agreement, one of our cell-signaling inhibitor programs. In March 1997, we entered into an agreement, which established a 50%/50% joint venture, called the Hoechst-ARIAD Genomics Center, LLC, or the Genomics Center, with Aventis to pursue functional genomics with the goal of identifying genes that encode novel therapeutic proteins and small-molecule drug targets. We recognized aggregate revenue under these agreements of $12.5 million in 1999, $11.7 million in 1998 and $8.7 million in 1997.

On December 31, 1999, we completed the sale of our 50% interest in the Genomics Center to Aventis, and as a result: (1) we received $40.0 million in cash; (2) 3,004,436 shares of our series B preferred stock were returned to us; (3) Aventis forgave $1.9 million of long-term debt we owed to them; (4) we received drug candidates and related technologies resulting from the Osteoporosis Agreement; and (5) we received the right to use certain genomics and bioinformatics technologies developed by the Genomics Center. We recorded a net gain on the sale of $46.4 million. As a result of this sale, we did not receive any revenue from our relationship with Aventis after 1999, and we realized a reduction of revenue in fiscal 2000 of $12.4 million from 1999, which was more than offset by a reduction in research and development expenses of approximately $16.3 million, primarily associated with the Genomics Center.

General

Since our inception in 1991, we have devoted substantially all of our resources to our research and development programs. We receive no revenue from the sale of pharmaceutical products, and substantially all revenue to date has been received in connection with our past relationship with Aventis. Except for the gain on the sale of the Genomics Center in December 1999, which resulted in net income for fiscal 1999, we have not been profitable since inception. We expect to incur substantial and increasing operating losses for the foreseeable future, primarily due to the expansion of our pharmaceutical product development programs, clinical trials, and product manufacturing. We expect that losses will fluctuate from quarter to quarter and that these fluctuations may be substantial. As of December 31, 2001, we had an accumulated deficit of $108.5 million.

26

Our business plan aims to balance near-term revenues from licensing with longer-term product development. To achieve this goal, we plan to develop our lead product candidates at least through phase 2 clinical trials, establish the commercial infrastructure to market our hematology and oncology lead products in the United States, pursue a worldwide partner for our osteoporosis product candidate and partners for our hematology and oncology lead products outside the United States, generally after we are able to obtain phase 2 clinical data, license our cell-signaling regulation technologies and our NF-kB intellectual property portfolio to biotechnology and pharmaceutical companies to accelerate their genomics, proteomics and drug discovery programs, and partner our cell-signaling regulation technologies for joint development of novel products, especially with companies that have proprietary therapeutic genes, cellular systems (e.g., stem cells) or gene delivery vectors. However, there can be no assurance that we will be successful in achieving our strategies and generating future revenue streams. As of January 1, 2002, we had no collaborative agreements that would generate revenue in 2002.

Critical Accounting Policies

Our financial position and results of operations are affected by subjective and complex judgments, particularly in the areas of stock-based compensation to consultants and the carrying value of intangible assets. In determining stock-based compensation expense, we utilize a financial model that takes into account, among other things, the price and volatility of our common stock, an interest-free discount rate, and an estimate of the life of the option contract. Fluctuations in those factors result in uneven expense charges to our statement of operations.

At December 31, 2001, we reported $5.3 million of intangible assets consisting of costs related primarily to purchased patents, patent applications and licenses. These costs are being amortized over the estimated useful lives of the underlying intangible assets. Changes in these lives or a decision to discontinue using the technologies could result in material changes to our balance sheet and statements of operations.

Results of Operations

Years Ended December 31, 2001 and 2000

Revenue

We recognized research revenue of $4,000 for the year ended December 31, 2001 compared to $128,000 for the year ended December 31, 2000. The decrease in research revenue was due to the termination of our services agreements with the Genomics Center as a result of the sale of our 50% ownership interest in the Genomics Center to Aventis on December 31, 1999. Research revenue for the year ended December 31, 2000 was comprised principally of transitional research revenue for services provided to Aventis following the December 31, 1999 sale of our interest in the Genomics Center. As of January 1, 2002, we had no collaborative agreements that would generate revenue in 2002.

Operating expenses

Research and development expenses increased 33% to $16.6 million in 2001 from $12.5 million in 2000. This $4.1 million increase in 2001 expenses as compared to those incurred in 2000 was primarily due to a higher level of spending on product development of $867,000, product manufacturing and external activities in support of clinical trials of $1.7 million, costs associated with the launch of our initiatives to promote the commercialization and licensing of our cell-signaling regulation technologies by both corporate and academic researchers of $325,000, increased personnel expenses of $567,000 and overhead expenses of $471,000. We expect our research and development expenses to increase over the next year as a result of our continued expansion of our product development programs, clinical trials and product manufacturing. However, the amount of such increase in research and development spending will be determined, in part, by

27

our ability to attract additional capital or to realize revenues through partnerships, licensing, joint ventures, or similar arrangements.

General and administrative expenses increased 35% to $4.5 million in 2001 from $3.3 million in 2000. This $1.2 million increase in 2001 expenses as compared to those incurred in 2000 was primarily due to increased professional expenses of $419,000 and personnel expenses of $825,000.

Other income/expense

Interest income decreased 23% to $1.6 million in 2001 from $2.1 million in 2000 primarily as a result of declining interest rates during the year. Interest expense increased 27% to $285,000 in 2001 from $225,000 in 2000. This increase was primarily due to a higher level of long-term debt outstanding in 2001.

Operating Results

We reported a loss from operations of $21.1 million in 2001 compared to a loss from operations of $15.7 million in 2000, an increase in loss of $5.4 million or 34%. We expect that operating losses will increase and be substantial for several more years as our product development activities expand, and these losses are expected to fluctuate as a result of differences in the timing and composition of revenue earned and expenses incurred.

We reported a net loss attributable to common stockholders of $19.8 million in 2001 or $.68 per share (basic and diluted). We reported a net loss attributable to common stockholders of $13.8 million in 2000 or $.53 per share (basic and diluted).

Years Ended December 31, 2000 and 1999

Revenue

We recognized research revenue under our services agreements and collaborative research arrangements of $128,000 for the year ended December 31, 2000 compared to $12.5 million for the year ended December 31, 1999. This decrease of $12.4 million was due to the reduction in revenues associated with the termination of our services agreements with the Genomics Center of $6.4 million as a result of the sale of our 50% ownership interest in the Genomics Center and the termination of the Osteoporosis Agreement of $6.0 million.

Operating Expenses

Research and development expenses decreased 57% to $12.5 million in 2000 from $28.8 million in 1999. This decrease of $16.3 million in 2000 expenses as compared to those incurred in 1999 was primarily due to the termination of research services provided to the Genomics Center.

General and administrative expenses decreased 16% to $3.3 million in 2000 from $3.9 million in 1999. This $620,000 decrease in 2000 expenses as compared to those incurred in 1999 was primarily due to lower professional and legal expenses.

Other income/expense

Interest income increased 361% to $2.1 million in 2000 from $445,000 in 1999 as a result of a higher level of invested funds. Interest expense decreased 57% to $225,000 in 2000 from $522,000 in 1999. This decrease was primarily due to a lower level of debt outstanding in 2000 as a result of repayments on our borrowings.

28

Accounting Change

We adopted Statement of Position, or SOP 98-5, Reporting the Cost of Start-Up Activities, effective January 1, 1999 and recorded a charge of $364,000 as a cumulative effect of change in accounting principle.

Operating Results

We reported a loss from operations of $15.7 million in 2000 compared to a loss from operations of $20.3 million in 1999, a decrease in loss of $4.6 million or 23%. We reported a loss of $13.8 million in 2000 and reported income before cumulative effect of change in accounting principle of $24.6 million in 1999. After such cumulative effect, we reported net income of $24.2 million for 1999. Our results for 1999 included the gain on the sale of our 50% interest in the Genomics Center of $46.4 million. Although we earned taxable income in 1999 due to the gain on the sale of the Genomics Center, we were able to utilize net operating loss carryforwards to eliminate substantially all taxes due.

On December 31, 1999 and January 14, 2000, we repurchased and retired all of our series C preferred stock and recorded a charge of $6.2 million in 1999 representing the premium paid on the repurchase, which has been deducted from net income in determining net income attributable to common stockholders. Accretion costs attributable to the series C preferred stock of $250,000 were also recognized in 1999. We reported a net loss attributable to common stockholders of $13.8 million in 2000 or $.53 per share (basic and diluted). We reported net income attributable to common stockholders of $17.8 million in 1999 or $.80 per share (basic) and $.70 per share (diluted).

Selected Quarterly Financial Data

Summarized quarterly financial data are as follows:

         In thousands, except per share amounts

	2001 Quarters
	First			Second			Third			Fourth
Total research revenues	$	1		$	1		$	1		$	1
Net loss		(4,157	)		(4,716	)		(4,745	)		(6,141	)
Net loss per share — diluted		(.15	)		(.17	)		(.16	)		(.20	)

	2000 Quarters
	First			Second			Third			Fourth
Total research revenues	$	108		$	18		$	1		$	1
Net loss		(3,522	)		(3,190	)		(3,287	)		(3,833	)
Net loss per share — diluted		(.15	)		(.12	)		(.12	)		(.14	)

Liquidity and Capital Resources

We have financed our operations and investments primarily through the private placement and public offering of our equity securities, and research revenue and other transactions with Aventis, including the sale of our 50% interest in the Genomics Center in December 1999. In addition, we have financed our operations through the issuance of long-term debt, operating and capital-lease transactions, interest income, and government sponsored research grants.

29

At December 31, 2001, we had cash, cash equivalents and marketable securities totaling $47.2 million and working capital of $42.8 million compared to cash, cash equivalents and marketable securities totaling $39.8 million and working capital of $36.9 million at December 31, 2000.

The primary uses of cash during the year ended December 31, 2001 were $16.5 million to finance our operations and working capital requirements, $7.6 million to acquire marketable securities, $614,000 to purchase laboratory equipment, $1.0 million to acquire intellectual property and $1.2 million to repay long-term debt.

The primary sources of funds during the year ended December 31, 2001 were $34.4 million from the sales and maturities of marketable securities, $4.6 million of new borrowings as a result of increasing our existing bank term loan ($3.8 million) and entering into a new term loan with an equipment financing company ($790,000), $21.6 million from the sale of common stock and $489,000 from the sale of common stock from the exercise of stock options and purchases under the terms of the employee stock purchase plan.

On June 22, 2001, we filed a shelf registration statement with the SEC for the issuance of up to 4.5 million registered shares of our common stock, which was declared effective by the SEC on August 1, 2001. The registered shares are available for sale at our discretion. On October 31, 2001, we sold 1,927,712 registered shares of our common stock to institutional investors at a price of $4.15 per share and received gross proceeds of $8.0 million before commissions and expenses of $464,000. This net amount of $7.5 million was included in the 2001 primary sources of funds mentioned in the preceding paragraph. At December 31, 2001, we had 2,572,288 registered shares remaining available for sale under this shelf registration. On January 9, 2002, we filed an additional shelf registration statement with the SEC for the issuance of up to 3.0 million registered shares of our common stock, which was declared effective on February 13, 2002. The registered shares are available for sale at our discretion.

We have substantial fixed contractual obligations under various research and licensing agreements, consulting and employment agreements, lease agreements and long-term debt instruments. These contractual obligations were comprised of the following as of December 31, 2001:

In thousands Payments Due By Period

					1 – 3		4 – 5		6th
Contractual Obligations	Total		Less than 1 year		years		years		year
Long-term debt	$	8,290	$	1,443	$	6,847	$	—	$	—
Operating leases		5,196		1,520		2,431		1,245
Other long-term obligations *		5,490		3,087		1,917		324		162
Total fixed contractual obligations	$	18,976	$	6,050	$	11,195	$	1,569	$	162

* Other long-term obligations are comprised primarily of employment agreements and licensing agreements.

We will require substantial additional funding for our research and development programs, including preclinical development and clinical trials, for operating expenses, for the pursuit of regulatory approvals and for establishing manufacturing, marketing and sales capabilities. Adequate funds for these purposes, whether obtained through financial markets or other arrangements with collaborative partners, or from other sources, may not be available when needed or on terms acceptable to us.

Based on the historical spending levels to support our operations, our available funds will be adequate to satisfy our capital and operating requirements for the next two years. However, there can be no assurance

30

that changes in our research and development plans or other future events affecting our revenues or operating expenses will not result in the earlier depletion of our funds.

At December 31, 2001, we had available for federal tax reporting purposes net operating loss carryforwards of approximately $110.1 million that expire commencing in 2009 and for state tax reporting purposes, net operating loss carryforwards of approximately $85.2 million that expire commencing in 2002. We also had federal research and development tax credit carryovers of approximately $6.0 million that expire commencing in 2006. The utilization of both the net operating loss carryforwards and tax credits is subject to certain limitations under federal tax laws.

New Accounting Pronouncements

In June 1998, the Financial Accounting Standards Board issued SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities. The new standard, which was adopted on January 1, 2001, requires that all companies record derivatives on the balance sheet as assets or liabilities, measured at fair value. Gains or losses resulting from changes in the values of those derivatives are accounted for depending on the use of the derivative and whether it qualifies for hedge accounting. The adoption of this standard on January 1, 2001 had no impact on our financial position or results of operations.

In June 2001, the Financial Accounting Standards Board issued SFAS No. 141, Business Combinations, and SFAS No. 142, Goodwill and Other Intangible Assets. SFAS No. 141 supersedes APB No. 16, Business Combinations, and SFAS No. 38, Accounting for Preacquisition Contingencies of Purchased Enterprises, and requires that all business combinations be accounted for by a single method – the purchase method. SFAS No. 141 also provides guidance on the recognition of intangible assets identified in a business combination and requires enhanced financial statement disclosures. SFAS No. 142 adopts a more aggregate view of goodwill and bases the accounting for goodwill on the units of the combined entity into which an acquired entity is integrated. In addition, SFAS No. 142 concludes that goodwill and intangible assets that have indefinite useful lives will not be amortized but rather will be tested at least annually for impairment. Intangible assets that have finite lives will continue to be amortized over their useful lives. SFAS No. 141 is effective for all business combinations initiated after June 30, 2001. The adoption of SFAS No. 142 is required for fiscal years beginning after December 15, 2001 (the year 2002 for the Company), except for the nonamortization and amortization provisions which are required for goodwill and intangible assets acquired after June 30, 2001. We believe that the adoption of SFAS No. 141 and SFAS No. 142 will not have a material impact on our financial position or results of operation.

In October 2001, the Financial Accounting Standards Board issued SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets.” SFAS No. 144 supersedes previous guidelines for financial accounting and reporting for the impairment or disposal of long-lived assets and for segments of a business to be disposed of. We believe that the adoption of SFAS No. 144 will not have a material impact on our financial position or results of operations.

ITEM 7A: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We maintain an investment portfolio in accordance with our investment policy to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment.

We invest cash balances in excess of operating requirements in short-term securities, generally with maturities of 90 days or less. Our marketable securities generally consist of corporate debt and U.S. Government securities primarily with maturities of one year or less, but generally less than six months. These securities are classified as available-for-sale. Available-for-sale securities are recorded on the balance sheet at fair market value with unrealized gains or losses reported as a separate component of stockholders’

31

equity (accumulated other comprehensive loss). Gains and losses on marketable security transactions are reported on the specific-identification method. Interest income is recognized when earned. A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. These investments are sensitive to interest rate risk. We believe that the effect, if any, of reasonable possible near-term changes in the interest rates on our financial position, results of operations and cash flows would not be material due to the short-term nature of these investments.

We have an executive compensation plan which provides a deferred compensation benefit for certain executives and key employees. Under the plan, benefits are deferred and generally vest over four years. The benefits obligation is recorded as compensation and a liability based on the underlying fair market value of the obligation as it vests. As of December 31, 2001, in the event of a hypothetical 10% increase in the underlying fair market value of the obligation, we would incur approximately $47,000 of additional compensation expense in 2002.

At December 31, 2001, we have a bank term note which bears interest at prime plus 1%. This note is sensitive to interest rate risk. In the event of a hypothetical 10% increase in the prime rate (47.5 basis points), we would incur approximately $33,000 of additional interest expense per year.

Certain Factors That May Affect Future Results of Operations

The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Annual Report contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be made directly in this Annual Report, and they may also be made a part of this Annual Report by reference to other documents filed with the SEC, which is known as “incorporation by reference.”

Words such as “may,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “believes” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding the Company’s preclinical studies, the Company’s ability to conduct clinical trials of its product candidates and the results of such trials, as well as risks and uncertainties relating to economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on the Company’s collaborators and other factors. Please also see the discussion of risks and uncertainties under “Risk Factors” in Item 1 of this Report.

In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Annual Report or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only of the date of this Annual Report or the date of the document incorporated by reference in this Annual Report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to the Company or to any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

32

ITEM 8: FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Independent Auditors’ Report

The Board of Directors and Stockholders of
ARIAD Pharmaceuticals, Inc.:

We have audited the accompanying consolidated balance sheets of ARIAD Pharmaceuticals, Inc. and its subsidiaries (the “Company”) as of December 31, 2001 and 2000, and the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2001. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of ARIAD Pharmaceuticals, Inc. and its subsidiaries as of December 31, 2001 and 2000, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2001, in conformity with accounting principles generally accepted in the United States of America.

As discussed in Note 1 to the financial statements, in 1999 the Company changed its method of accounting for start-up activities.

/s/DELOITTE & TOUCHE LLP

Boston, Massachusetts
January 18, 2002

33

ARIAD PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

				December 31,
In thousands, except share and per share data				2001			2000
ASSETS
Current assets:
	Cash and cash equivalents			$	46,742		$	12,543
	Marketable securities				444			27,238
	Inventory and other current assets				1,010			1,347
		Total current assets			48,196			41,128
Property and equipment:
	Leasehold improvements				12,624			12,606
	Equipment and furniture				5,417			4,821
		Total			18,041			17,427
	Less accumulated depreciation and amortization				(16,190	)		(14,914	)
		Property and equipment, net			1,851			2,513
Intangible and other assets, net					5,314			5,172
			Total assets	$	55,361		$	48,813
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
	Accounts payable			$	1,505		$	1,434
	Current portion of long-term debt				1,443			1,200
	Accrued compensation and benefits				822			540
	Accrued product developments expenses				1,073			460
	Accrued expenses				578			628
		Total current liabilities			5,421			4,262
Long-term debt					6,847			3,700
Commitments, contingent liabilities and minority interest (Notes 1, 6, 10) Stockholders’ equity:
	Preferred stock, authorized, 10,000,000 shares, none issued and outstanding Common stock, $.001 par value, authorized, 60,000,000 shares, issued and outstanding, 32,146,774 shares in 2001 and 27,292,138 shares in 2000				32			27
	Additional paid-in capital				151,638			129,761
	Deferred compensation				(106	)		(217	)
	Accumulated other comprehensive income (loss)				3			(5	)
	Accumulated deficit				(108,474	)		(88,715	)
		Total stockholders’ equity			43,093			40,851
			Total liabilities and stockholders’ equity	$	55,361		$	48,813

See notes to consolidated financial statements.

34

ARIAD PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

				Years Ended December 31,
In thousands, except share and per share data				2001			2000			1999
Research revenue (principally related parties in 1999)				$	4		$	128		$	12,468
Operating expenses:
	Research and development *				16,587			12,467			28,844
	General and administrative *				4,469			3,318			3,938
			Total operating expenses		21,056			15,785			32,782
Loss from operations					(21,052	)		(15,657	)		(20,314	)
Other income (expense):
	Interest income				1,578			2,050			445
	Interest expense				(285	)		(225	)		(522	)
	Gain on sale of Genomics Center										46,440
	Equity in net loss of Genomics Center										(1,493	)
		Total other income			1,293			1,825			44,870
Income (loss) before cumulative effect of change in accounting principle					(19,759	)		(13,832	)		24,556
Cumulative effect of change in accounting principle											(364	)
Net income (loss)					(19,759	)		(13,832	)		24,192
Repurchase and accretion costs attributable to redeemable convertible preferred stock											(6,435	)
Net income (loss) attributable to common stockholders				$	(19,759	)	$	(13,832	)	$	17,757
Earnings (loss) per share:
Per common share (basic):
Income (loss) attributable to common stockholders before cumulative effect of change in accounting principle				$	(.68	)	$	(.53	)	$	.82
Cumulative effect of change in accounting principle											(.02	)
Net income (loss) – basic				$	(.68	)	$	(.53	)	$	.80
Weighted average number of shares of common stock outstanding – basic					29,256,767			25,875,663			22,004,646
Per common share (diluted):
Income (loss) before cumulative effect of change in accounting principle				$	(.68	)	$	(.53	)	$	.71
Cumulative effect of change in accounting principle											(.01	)
Net income (loss) – diluted				$	(.68	)	$	(.53	)	$	.70
Weighted average number of shares of common stock outstanding – diluted					29,256,767			25,875,663			34,448,015
*Includes non-cash stock-based compensation expense - - Research and development expense				$	146		$	142		$	86
	- General and administrative expense			$	57

See notes to consolidated financial statements.

35

ARIAD PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
For the Years Ended December 31, 1999, 2000 and 2001

		Series B																Accumulated
		Convertible										Additional						Other
		Preferred Stock						Common Stock				Paid-in			Deferred			Comprehensive			Accumulated			Stockholders'
In thousands, except share data		Shares			Amount			Shares		Amount		Capital			Compensation			Income (Loss)			Deficit			Equity
Balance, January 1, 1999			2,526,316		$	25			21,938,754	$	22	$	104,361		$	0		$	(34	)	$	(92,640	)	$	11,734
Additional issuance of Series B Convertible Preferred Stock			478,120			5							5,742												5,747
Issuance of shares pursuant to ARIAD and AGTI stock option plans and an ARIAD stock purchase plan									93,134				159												159
Stock-based compensation to consultants													86												86
Repurchase and accretion costs attributable to series C preferred stock																						(6,435	)		(6,435	)
Redemption on sale of Genomics Center			(3,004,436	)		(30	)						(8,420	)											(8,450	)
Comprehensive income:
	Net income																					24,192			24,192
	Other comprehensive income - Unrealized gains on marketable securities																		34						34
Comprehensive income																									24,226
Balance, December 31, 1999			0			0			22,031,888		22		101,928			0			0			(74,883	)		27,067
Issuance of common stock, series C settlement									1,078,038		1		1,144												1,145
Issuance of common stock, net of issuance costs									857,024		1		9,742												9,743
Exercise of warrants									1,389,498		1		11,636												11,637
Issuance of shares pursuant to ARIAD and AGTI stock option plans and an ARIAD stock purchase plan									1,935,690		2		4,952												4,954
Stock-based compensation to consultants													359			(359	)
Amortization of stock-based compensation																142									142
Comprehensive loss:
	Net loss																					(13,832	)		(13,832	)
	Other comprehensive loss- Unrealized loss on marketable securities																		(5	)					(5	)
Comprehensive loss																									(13,837	)
Balance, December 31, 2000			0			0			27,292,138		27		129,761			(217	)		(5	)		(88,715	)		40,851
Issuance of common stock, net of issuance costs									4,551,541		5		21,296												21,301
Issuance of shares pursuant to ARIAD stock option and purchase plans									303,095				489												489
Stock-based compensation to consultants													92			(92	)
Amortization of stock-based compensation																203									203
Comprehensive loss:
	Net loss																					(19,759	)		(19,759	)
	Other comprehensive income - Unrealized gains on marketable securities																		8						8
Comprehensive loss																									(19,751	)
Balance, December 31, 2001			0		$	0			32,146,774	$	32	$	151,638		$	(106	)	$	3		$	(108,474	)	$	43,093

See notes to consolidated financial statements

36

ARIAD PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

				Years Ended December 31,
In thousands				2001			2000			1999
Cash flows from operating activities:
	Net income (loss)			$	(19,759	)	$	(13,832	)	$	24,192
	Adjustments to reconcile net income (loss) to net cash used in operating activities:
	Depreciation and amortization				1,889			1,675			3,682
	Deferred compensation				175			163			102
	Stock-based compensation to consultants				203			142			86
	Gain on sale of the Genomics Center										(46,440	)
	Increase (decrease) from:
		Inventory and other current assets			337			262			584
		Due from Genomics Center									333
		Other assets			(53	)		(408	)		72
		Accounts payable			70			(842	)		(1,046	)
		Accrued compensation and benefits			282			58			(91	)
		Accrued product development expenses			438			103			(680	)
		Accrued expenses			(50	)		(2,393	)		619
		Advance from Genomics Center						(26	)		(3,137	)
			Net cash used in operating activities		(16,468	)		(15,098	)		(21,724	)
Cash flows from investing activities:
	Acquisitions of marketable securities				(7,585	)		(42,965	)		(211	)
	Proceeds from sales and maturities of marketable securities				34,356			15,805			7,806
	Investment in property and equipment, net				(614	)		(447	)		(677	)
	Acquisition of intangible and other assets				(1,002	)		(1,205	)		(710	)
	Proceeds from disposition of investment in Genomics Center										40,000
	Investment in Genomics Center										(6,261	)
	Return of investment in Genomics Center										7,960
			Net cash provided by (used in) investing activities		25,155			(28,812	)		47,907

See notes to consolidated financial statements.

(Continued)

37

ARIAD PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

			Years Ended December 31,
In thousands			2001			2000			1999
Cash flows from financing activities:
	Proceeds from long-term debt borrowings		$	4,590		$	3,000
	Repayment of long-term debt borrowings			(1,200	)		(1,200	)	$	(2,056	)
	Proceeds from exercise of warrants, net						11,637
	Proceeds from sale/leaseback of equipment, net									309
	Proceeds from issuance of common stock, net of issuance costs			21,633			9,743
	Proceeds from issuance of common stock pursuant to stock option and purchase plans			489			4,953			159
	Proceeds from issuance of series B convertible preferred stock									5,747
	Proceeds from related party long-term debt									1,801
	Repurchase of redeemable convertible preferred stock									(10,325	)
		Net cash provided by (used in) financing activities		25,512			28,133			(4,365	)
Net increase (decrease) in cash and equivalents				34,199			(15,777	)		21,818
Cash and equivalents, beginning of year				12,543			28,320			6,502
Cash and equivalents, end of year			$	46,742		$	12,543		$	28,320

See notes to consolidated financial statements.

(Concluded)

38

ARIAD PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of Business and Summary of Significant Accounting Policies

Nature of Business

The Company is engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. Breakthrough medicines are products, created de novo, that may be used to treat diseases in innovative ways. The Company’s lead product candidates – treatment of cancer, cancer that has spread to the bone, or bone metastases, anemia, graft-vs-host disease following T cell immunotherapy and osteoporosis – all were developed through the integration of genomics, proteomics and structure-based drug design. The Company has an exclusive license to pioneering technology related to the discovery, development and use of drugs that modulate the cellular protein, NF-kB, and other targets in its pathway, which regulate key genes involved in many major diseases.

Principles of Consolidation

The consolidated financial statements include the accounts of ARIAD Pharmaceuticals, Inc., its wholly owned subsidiary, ARIAD Corporation, and its 80% owned subsidiary (79% on a fully diluted basis with respect to AGTI), ARIAD Gene Therapeutics, Inc. (“AGTI”) (Note 8). The Company’s research and development relating to product candidates based on its ARGENT cell-signaling regulation technology and product candidates based on technology or compounds derived from its ARGENT programs are conducted by AGTI. Intercompany accounts and transactions have been eliminated. There is no minority interest for AGTI recorded in the consolidated balance sheet, because AGTI currently has a deficiency in its stockholders’ equity. The Company accounts for any gain from the exercise of AGTI options as an adjustment to additional paid-in capital. Because AGTI is a research and development company, the Company believes that the gain realization from the exercise of AGTI options cannot be assured and therefore should be accounted for as a capital transaction in the Company’s consolidated financial statements.

Fair Value of Financial Instruments

The carrying amounts of cash, cash equivalents, accounts payable and accrued liabilities approximate fair value because of their short-term nature. Marketable securities are recorded in the consolidated financial statements at aggregate fair value (Note 2). The carrying amount of the Company’s bank term note approximate fair value due to the variable interest rate (Note 5). The fair value of the General Electric Capital Corporation term note was $790,000 as of December 31, 2001.

Accounting Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts and disclosure of assets and liabilities at the date of the consolidated financial statements and the reported amounts and disclosure of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash Equivalents

Cash equivalents include short-term, highly liquid investments, which consist principally of United States Treasury and Agency securities, high-grade domestic corporate securities, purchased with remaining maturities of 90 days or less and money market accounts.

39

Marketable Securities

The Company has classified its marketable securities as “available-for-sale” and, accordingly, carries such securities at aggregate fair value. The difference between fair value and original cost is reflected as a component of accumulated other comprehensive income (loss). Fair value has been determined based on quoted market prices, in a dealer market, at the closing bid for each individual security held.

Inventory

Inventories are carried at cost using the first-in, first-out method and are charged to research and development expense when consumed. Inventory consists of bulk pharmaceutical material to be used for multiple preclinical and clinical development programs and amounted to $682,000 and $898,000 at December 31, 2001 and 2000, respectively.

Property and Equipment

Property and equipment are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (3 to 10 years). Assets acquired under capital lease obligations are stated at the lower of the present value of the minimum lease payments or the fair market value at the inception of the lease. Assets recorded under capital leases and leasehold improvements are amortized over the shorter of their useful lives or lease term using the straight-line method (4 to 10 years).

Investment in Genomics Center

The Company accounted for its investment in the Genomics Center using the equity method through December 31, 1999. Intercompany transactions were eliminated to the extent of the Company’s interest (50%) in the Genomics Center (Note 4).

Intangible and Other Assets

Intangible and other assets consist primarily of purchased patents, patent applications, licenses, and deposits. The cost of purchased patents and patent applications and costs incurred in filing patents are capitalized. Capitalized costs related to patent applications are expensed, when it becomes determinable that such applications will not be pursued. Capitalized costs related to issued patents are amortized over a period not to exceed seventeen years or the remaining life of the patent, whichever is shorter, using the straight-line method. Amortization expense for intangible and other assets amounted to $502,000, $431,000, and $501,000 for 2001, 2000 and 1999, respectively. Accumulated amortization of intangible and other assets at December 31, 2001 and 2000 was $2.9 million and $2.0 million, respectively.

Impairment of Long-Lived Assets

The Company reviews its long-lived assets for impairment when events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.

Revenue Recognition

Under collaborative research and development agreements, research revenue is recognized as the research is performed under the terms of the applicable agreement. Amounts received in advance under the 1995 Osteoporosis Agreement (Note 3) were recorded as deferred revenue and were amortized over the minimum term of the Agreement using the straight-line method. Revenue earned upon the attainment of research or product development milestones was recognized when achieved. Research revenue associated with the

40

Services Agreements with the Genomics Center (Note 4) was billed on a cost reimbursement basis, which includes direct costs incurred in connection with research activities and an allocation of certain other costs incurred by the Company and was recognized as services were provided.

Segment Reporting

The Company organizes itself into one segment reporting to the chief executive officer. No significant revenues from product sales or services occurred in 2001 or 2000. In years prior to 2000, revenues were primarily derived from research and development activities with collaborative and strategic partners in the pharmaceutical industry.

Stock-Based Compensation

SFAS No. 123, Accounting for Stock-Based Compensation, addresses the financial accounting and reporting standards for stock or other equity-based compensation arrangements. The Company has elected to continue to use the intrinsic value-based method to account for employee stock option awards under the provisions of Accounting Principles Board Opinion No. 25 and provides disclosures based on the fair value method in the notes to the financial statements as permitted by SFAS No. 123. Stock or other equity-based compensation for non-employees must be accounted for under the fair value-based method as required by SFAS No. 123 and Emerging Issues Task Force (“EITF”) No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services” and other related interpretations. Under this method, the equity-based instrument is valued at either the fair value of the consideration received or the equity instrument issued on the date of grant. The resulting compensation cost is recognized and charged to operations over the service period, which is usually the vesting period.

Earnings Per Share

Basic earnings per common share are computed using the weighted average number of common shares outstanding during each year. Diluted earnings per common share reflect the effect of the Company’s outstanding options, warrants and convertible securities, except where such items would be anti-dilutive. In years in which a net loss is reported, basic and diluted per share amounts are the same. In 2001 and 2000, options amounting to 4,639,782, and 3,480,360 shares of common stock, respectively, were not included in the computation of dilutive earnings per share, because this effect would be anti-dilutive. In 1999, options and warrants amounting to 3,504,188 shares of common stock were not included in the computation of dilutive earnings because this effect would be anti-dilutive.

The following is a reconciliation of the shares used in the calculation of basic and diluted net income per share for the year ended December 31, 1999. Potentially dilutive shares were calculated using the treasury stock method:

	1999
Weighted average shares for basic shares outstanding		22,004,646
Incremental shares from assumed conversion of preferred stock		11,846,541
Incremental shares from assumed exercise of potentially dilutive stock options		596,828
Weighted average shares for dilutive shares outstanding		34,448,015
In thousands
Net income attributable to common stockholders	$	17,757
Effect of repurchase and accretion costs attributable to redeemable convertible preferred stock		6,435
Net income	$	24,192

41

Accounting Change

In April 1998, the American Institute of Certified Public Accountants issued Statement of Position (“SOP”) 98-5, Reporting on the Cost of Start-Up Activities, which required that all organizational costs be expensed as incurred. The Company adopted this SOP effective January 1, 1999 and recorded a charge of $364,000 as a cumulative effect of change in accounting principle.

Recently Issued Accounting Pronouncements

In June 1998, the Financial Accounting Standards Board issued SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities. The new standard, which was adopted on January 1, 2001, requires that all companies record derivatives on the balance sheet as assets or liabilities, measured at fair value. Gains or losses resulting from changes in the values of those derivatives are accounted for depending on the use of the derivative and whether it qualifies for hedge accounting. The adoption of this standard on January 1, 2001 had no impact on the Company’s financial position or results of operations.

In June 2001, the Financial Accounting Standards Board issued SFAS No. 141, Business Combinations, and SFAS No. 142, Goodwill and Other Intangible Assets. SFAS No. 141 supersedes APB No. 16, Business Combinations, and SFAS No. 38, Accounting for Preacquisition Contingencies of Purchased Enterprises and requires that all business combinations be accounted for by a single method – the purchase method. SFAS No. 141 also provides guidance on the recognition of intangible assets identified in a business combination and requires enhanced financial statement disclosures. SFAS No. 142 adopts a more aggregate view of goodwill and bases the accounting for goodwill on the units of the combined entity into which an acquired entity is integrated. In addition, SFAS No. 142 concludes that goodwill and intangible assets that have indefinite useful lives will not be amortized but rather will be tested at least annually for impairment. Intangible assets that have finite lives will continue to be amortized over their useful lives. SFAS No. 141 is effective for all business combinations initiated after June 30, 2001. The adoption of SFAS No. 142 is required for fiscal years beginning after December 15, 2001 (the year 2002 for the Company), except for the nonamortization and amortization provisions which are required for goodwill and intangible assets acquired after June 30, 2001. The Company believes that the adoption of SFAS No. 141 and SFAS No. 142 will not have a material impact on the Company’s financial position or results of operation.

In October 2001, the Financial Accounting Standards Board issued SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets.” SFAS No. 144 supersedes previous guidelines for financial accounting and reporting for the impairment or disposal of long-lived assets and for segments of a business to be disposed of. The Company believes that the adoption of SFAS No. 144 will not have a material impact on the Company’s financial position or results of operations.

Reclassifications

Certain reclassifications have been made to prior year financial statements to conform to the 2001 presentation.

2. Marketable Securities

The Company has classified its marketable securities as available-for-sale and, accordingly, carries such securities at aggregate fair value. At December 31, 2001 and 2000, all of the Company’s marketable securities consisted of corporate debt securities. At December 31, 2001, all marketable securities had contractual maturities of one year or less.

42

At December 31, 2001, the aggregate fair value and amortized cost of the Company’s marketable securities were $444,000 and $441,000, respectively. Gross unrealized gains and losses were $3,000 and $0, respectively, at December 31, 2001. At December 31, 2000, the aggregate fair value and amortized cost of the Company’s marketable securities were $27.2 million. Gross unrealized gains and losses were $11,000 and $16,000, respectively, at December 31, 2000.

Gains and losses on investment security transactions are reported on the specific-identification method. Realized gains and losses on sales of marketable securities were not material during the years ended December 31, 2001, 2000 and 1999. Changes in market values resulted in an increase (decrease) in net unrealized gains (losses) of $8,000, ($5,000) and $34,000 for the years ended December 31, 2001, 2000 and 1999, respectively.

3. Collaborative Research and Development Agreements

In November 1995, the Company entered into an agreement with Hoechst Marion Roussel, S.A. (“HMR”) (the “1995 Osteoporosis Agreement”) to collaborate on the discovery and development of drugs to treat osteoporosis and related bone diseases, one of the Company’s cell-signaling inhibitor programs. Under the 1995 Osteoporosis Agreement, the Company granted to HMR exclusive rights to develop and commercialize these drugs worldwide. Under the terms of this Agreement, HMR made an initial cash payment to the Company of $10.0 million, agreed to provide research funding in equal quarterly amounts of $1.0 million up to an aggregate of $20.0 million over a five-year period and agreed to provide an aggregate of up to $10.0 million upon the attainment of certain research milestones. This Agreement further provided for the payment of royalties to the Company based on product sales. Revenue recognized under the 1995 Osteoporosis Agreement amounted to $6.0 million in 1999 including $2.0 million for the achievement of the second research milestone.

Subsequently, in connection with the sale of the Company’s 50% interest in the Genomics Center in 1999 (Note 4), all drug candidates and related technologies resulting from the 1995 Osteoporosis Agreement were assigned to the Company, and any further obligations of HMR to fund the Company’s research were terminated.

4. Hoechst-ARIAD Genomics Center, LLC

Formation of the Genomics Center

In March 1997, the Company entered into an agreement which established a 50%/50% joint venture with Aventis Pharmaceuticals, Inc. (formerly known as Hoechst Marion Roussel, Inc.) (“Aventis”) to pursue functional genomics with the goal of identifying genes that encode novel therapeutic proteins and small-molecule drug targets (the “1997 Genomics Agreement”). The joint venture, named the Hoechst-ARIAD Genomics Center, LLC (the “Genomics Center”), was located at the Company’s facility in Cambridge, Massachusetts. Under the terms of the 1997 Genomics Agreement, the Company and Aventis agreed to commit $85.0 million to the establishment of the Genomics Center and its first five years of operation. The Company and Aventis agreed to jointly fund $78.5 million of operating and related costs, and the Company agreed to invest up to $6.5 million in leasehold improvements and equipment for use by the Company in conducting research on behalf of the Genomics Center. Through December 31, 1999, the Company had invested $6.5 million in leasehold improvements and equipment and funded $15.0 million in operating and related costs. Aventis committed to provide the Company with capital adequate to fund ARIAD’s share of such costs through the purchase of up to $49.0 million of the Company’s series B convertible preferred stock over the five-year period, including an initial investment of $24.0 million, which was completed in March 1997 and $5.7 million which was completed in January 1999 (Note 7). Using a loan facility made available by Aventis, the Company borrowed $1.8 million during 1999 to fund a portion of its investment obligations relating to the Genomics Center.

43

Services Agreements

The Company also entered into agreements with the Genomics Center to provide research and administrative services (the “Services Agreements”) to the Genomics Center on a cost reimbursement basis. The Company’s costs of providing the research and administrative services to the Genomics Center were charged to research and development expense and general and administrative expense in the consolidated financial statements. Under the Services Agreements, the Company billed the Genomics Center for 100% of its cost of providing the research and administrative services; however, because the Company was providing 50% of the funding of the Genomics Center, the Company recognized as revenue only 50% of the billings to the Genomics Center. The remaining 50% was accounted for as a return of the Company’s investment in the Genomics Center. Revenue recognized pursuant to the Services Agreements amounted to $6.4 million and $5.0 million for the years ended December 31, 1999 and 1998, respectively.

Sale of the Company’s 50% Interest in the Genomics Center

On December 31, 1999, the Company completed the sale of its 50% interest in the Genomics Center to Aventis and received: (1) $40.0 million in cash, (2) 3,004,436 shares of the Company’s previously issued series B convertible preferred stock (which was immediately retired), (3) the forgiveness of $1.9 million of long-term debt including accrued interest owed by the Company to Aventis, (4) drug candidates and related technologies resulting from the 1995 Osteoporosis Agreement (Note 3) and (5) the right to use certain genomics and bioinformatics technologies developed by the Genomics Center. In addition, the Company agreed to (1) sublease to Aventis approximately 35,000 square feet of laboratory and office space, for an amount equal to the Company’s cost, for a period through July 2002, after which time the sublease rate shall be negotiated between the two parties for a period of up to five years, (2) assign equipment leases with aggregate rental payments of $1.8 million to Aventis (Note 6), and (3) provide certain transitional laboratory support services.

The Company recorded a net gain on the sale of $46.4 million recognizing proceeds of (1) $40.0 million in cash, (2) $8.5 million equivalent to the fair market value of the common stock underlying the series B convertible preferred stock, and (3) $1.9 million of long-term debt and interest forgiven; offset by (1) $2.3 million of unamortized leasehold improvements associated with laboratory space under sublease, and (2) $1.6 million representing the Company’s investment account and other costs of completing the sale.

The major components of the Genomics Center’s results of operations for the year ending December 31, 1999 were as follows:

In thousands
Revenues		$	—
Operating expenses:
	ARIAD		12,936
	Other		2,958
Net loss		$	(15,894	)
ARIAD’s 50% share of net loss		$	(7,947	)
Elimination of intercompany transactions			6,454
ARIAD’s equity in the net loss on the Genomics Center		$	(1,493	)

44

5.  Long-Term Debt

Long-term debt was comprised of the following at December 31:

	2001			2000
	In thousands
Bank term note at prime plus 1% (5.75%, at December 31, 2001) payable in monthly installments of $100,000 plus interest, through January 1, 2005	$	7,500		$	4,900
General Electric Capital Corporation term note at 9.51% payable in monthly installments of $25,104, which includes interest, through December 2004		790
Less current portion		(1,443	)		(1,200	)
Long-term debt	$	6,847		$	3,700

The bank term note is collateralized by all assets of the Company with the exception of the assets to collateralize the General Electric Capital Corporation (“G.E.”) term note. The Company may, at its option, pledge marketable securities under the bank term note, and, in such event, the interest rate would be adjusted to the equivalent of 90-day LIBOR plus 1.25%. No securities were pledged at December 31, 2001.

The bank term note agreement contains certain covenants that would require consent from the bank to change the Company’s Chief Executive Officer, increase indebtedness, limit capital spending and stock redemption, prohibit dividend distributions, and require the Company to pledge its marketable securities or maintain minimum levels of tangible net worth of $15.0 million, working capital of $7.0 million and liquid assets of $15.0 million plus the outstanding principal balance of the G.E. term note, all as defined.

The G.E. term note, which provides for borrowings up to $1.2 million, is collateralized by certain assets of the Company. As of December 31, 2001, the Company has drawn down $790,000 and has available $410,000 remaining to be drawn down on the note. The G.E. term note contains a covenant that requires the Company to maintain a minimum unrestricted cash balance of $10.0 million.

The annual aggregate future principal payments of the above debt agreements are $1.4 million for 2002, $1.5 million for 2003 and 2004 and $3.9 million in 2005. Interest payments during 2001, 2000, and 1999 were $255,000, $204,000 and $376,000 respectively.

6.  Leases, Licensed Technology and Other Commitments

Facility Lease

The Company conducts its operations in a 100,000 square foot office and laboratory facility under a ten-year non-cancelable operating lease. The lease expires in July 2002 and has two five-year options to extend. The Company has extended the lease for the first five-year extension period. The Company has sublet approximately 37,000 square feet of space to Aventis (Note 4) and another tenant. Rent expense, net of sublease income of $950,000, $1.2 million and $264,000 for the years ended December 31, 2001, 2000, and 1999, respectively, amounted to $654,000, $477,000, and $1.2 million, respectively. Future minimum annual rental payments, net of sublease income, for the next five years are approximately $778,000 for 2002, $710,000 for 2003 and $747,000 for 2004, 2005 and 2006, respectively.

Equipment Leases

The Company utilizes lease credit facilities from various equipment leasing companies to acquire equipment, which is resold to a lessor at cost, with no resulting gain or loss recognized. The lease agreements, which are classified as operating leases for financial reporting purposes, have terms ranging from three to five years with

45

various lease renewal or purchase options at the end of the initial term. The Company did not enter into any new equipment lease agreements in 2001 and 2000. During the year ended December 31, 1999, the Company entered into sales leaseback transactions amounting to $309,000. Equipment rental expense for the years ended December 31, 2001, 2000 and 1999 amounted to $897,000, $933,000 and $1.8 million, respectively. Some of the agreements contain covenants requiring the Company to maintain certain minimum levels of net worth, working capital and liquid assets. Minimum future rental payments under the initial terms of the leases are approximately $741,000 for 2002, $196,000 for 2003, and $33,000 for 2004.

Licensed Technology

The Company and AGTI have entered into agreements with several universities under the terms of which the Company and AGTI have received exclusive licenses or options to technology and intellectual property. The agreements, which are generally cancelable by the Company and AGTI, provide for the payment of license fees and/or minimum payments, which are generally creditable against future royalties. Fees aggregated $127,000, $127,000 and $105,000 for 2001, 2000 and 1999, respectively, and were charged to research and development expense and are expected to amount to approximately $232,000 for 2002, and $162,000 annually for 2003, 2004, 2005 and 2006. In addition, the agreements provide for payments upon the achievement of certain milestones in drug development. The agreements also require the Company to fund certain costs associated with the filing and prosecution of patent applications.

Executive Compensation Plan

The Company has an executive compensation plan which provides a deferred compensation benefit for certain executives and key employees. Under the plan, benefits are deferred and generally vest over four years. The benefits obligation is recorded as compensation and a liability based on the underlying fair market value of the obligation as it vests. The fair market value of the vested portion of this liability was $474,000, $299,000 and $144,000 for December 31, 2001, 2000 and 1999, respectively.

Other Commitments

The Company has entered into various employment agreements with its senior officers. The agreements provide for aggregate annual base salaries of $2.2 million and remaining terms of employment of up to two years.

7.  Stockholders’ Equity

Preferred Stock

The Company has authorized 10.0 million shares of preferred stock which the Board of Directors is empowered to designate and issue in different series. At December 31, 2001, the Board of Directors had designated 500,000 shares as series A preferred stock, and 9.5 million shares remained undesignated.

Series B Convertible Preferred Stock (“Series B Preferred Stock”)

In connection with the 1997 Genomics Agreement, on March 18, 1997, Aventis purchased 2,526,316 shares of the Company’s Series B Preferred Stock for $24.0 million, and on January 5, 1999, Aventis purchased an additional 478,120 shares of Series B Preferred Stock for $5.7 million. In connection with the sale of the Company’s interest in the Genomics Center, all shares of Series B Preferred Stock were redeemed by the Company and retired.

Series C Redeemable Convertible Preferred Stock (“Series C Preferred Stock”)

On November 9, 1998, the Company issued 5,000 shares of the Company’s Series C Preferred Stock to two institutional investors (the “Investors”) and received proceeds of approximately $5 million. Each share of

46

Series C Preferred Stock had a liquidation value of $1,000, plus an additional amount equal to a 5% per annum accretion amount, accrued from the date of issue, and was convertible into common stock of the Company, at a conversion price equal to the lower of a variable conversion price or $2.09 per share.

On December 31, 1999, the Company repurchased 2,000 shares of Series C Preferred Stock from one of the Investors for an aggregate cash payment of $3.4 million. On January 14, 2000, the Company completed the repurchase of the remaining 3,000 shares of its Series C Preferred Stock for an aggregate consideration of $6.9 million plus 1,078,038 shares of common stock. The aggregate premium of $6.2 million paid on both transactions has been included in the 1999 consolidated statements of operations as repurchase and accretion costs attributable to redeemable convertible preferred stock. Redeemable convertible preferred stock was carried at redemption cost at December 31, 1999.

Common Stock – Sales

In 2001, the Company sold an aggregate of approximately 2.6 million shares of common stock and received net proceeds of $13.8 million in addition to the sale of registered shares mentioned below. In 2000, the Company sold an aggregate of 857,000 shares of common stock and received net proceeds of $9.7 million. All of the approximately 3.5 million shares sold were publicly registered.

Common Stock – Shelf Registration

On June 22, 2001, the Company filed a shelf registration statement with the Securities and Exchange Commission (the “SEC”) for the issuance of up to 4.5 million registered shares of its common stock, which was declared effective by the SEC on August 1, 2001. The registered shares are available for sale at the Company’s discretion. On October 31, 2001, the Company sold 1,927,712 registered shares of its common stock to institutional investors at a price of $4.15 per share and received gross proceeds of $8.0 million before commissions and expenses of $464,000. At December 31, 2001 the Company had 2,572,287 registered shares remaining available for sale.

Redemption of Warrants

The Company received funds aggregating approximately $11.6 million from the exercise of approximately 1.4 million of its publicly traded warrants during the first and second quarters of 2000. Each warrant was exercisable for one share of common stock at an exercise price of $8.40 per share. The warrants had been called for redemption effective April 27, 2000. At December 31, 2001 and 2000, there were no warrants outstanding.

Stockholder Rights Plan

The Board of Directors of the Company adopted a new Rights Agreement, dated as of June 8, 2000 (the “2000 Rights Agreement”), between the Company and State Street Bank and Trust Company, as Rights Agent, and approved the declaration of a dividend distribution of one Preferred Share Purchase Right (a “Right”) on each outstanding share of its Common Stock. In general, the Rights become exercisable if a person or group hereafter acquires 15% or more of the Common Stock of the Company or announces a tender offer for 15% or more of the Common Stock. The Board of Directors will, in general, be entitled to redeem the Rights at one cent per Right at any time before any such person hereafter acquires 15% or more of the outstanding Common Stock. The plan is designed to protect the Company’s stockholders in the event that an attempt is made to acquire the Company without an offer of fair value.

If a person hereafter acquires 15% or more of the outstanding Common Stock of the Company (the “Acquiring Person”), each Right will entitle its holder to purchase, for an initial exercise price of $65, a number of shares of Common Stock having a market value at that time of twice the Right’s exercise price. Rights held by the Acquiring Person will become void. If the Company is acquired in a merger or other business combination

47

transaction after a person acquires 15% or more of the Company’s Common Stock, each Right will entitle its holder to purchase, at the Right’s then-current exercise price, a number of the acquiring company’s common shares having a market value at that time of twice the Right’s exercise price.

The dividend distribution of Rights was payable on July 19, 2000 to shareholders of record on June 19, 2000. The Rights will expire in ten years. The Rights distribution is not taxable to the Company’s stockholders.

The Board of Directors also adopted two amendments to the Rights Agreement dated December 15, 1994, (the “1994 Rights Agreement”), between the Company and State Street Bank and Trust Company, as Rights Agent. As a result of these amendments, the adoption of the 2000 Rights Agreement and the setting of a record date to distribute new Rights, the 1994 Rights Agreement is no longer in effect.

Minority Interest in Subsidiary

The 20% minority interest in AGTI includes shares owned by Stanford University and Harvard University (which together own 2%) issued in 1995 in connection with a license agreement and shares issued to option holders (18%), including members of the Company’s management, Board of Directors, and certain consultants. Additional stock options are outstanding and, if exercised, would increase the minority interest to 21% (Note 8).

8.  Stock Option and Stock Purchase Plans

ARIAD Stock Option and Stock Plans

The Company’s 1991, 1994 and 2001 Stock Option and Stock Plans (the “Plans”) provide for the granting of nonqualified and incentive stock options to purchase up to a maximum of 7,615,714 shares of common stock to officers, directors, employees and consultants of the Company. Options become exercisable as specified in the related option agreement, typically over a four-year period, and expire ten years from the date of grant.

48

Transactions under the Plans for the years ended December 31, 1999, 2000 and 2001 are as follows:

						Weighted Average
			Number			Exercise Price
			of Shares			Per Share
Options outstanding, January 1, 1999				4,538,737		$	3.34
	Granted			2,128,095			1.03
	Forfeited			(1,555,588	)		3.09
	Exercised			(41,875	)		1.59
Options outstanding, December 31, 1999				5,069,369			2.48
	Granted			553,300			10.99
	Forfeited			(226,668	)		4.04
	Exercised			(1,915,641	)		2.40
Options outstanding, December 31, 2000				3,480,360			3.77
	Granted			1,554,220			5.61
	Forfeited			(120,688	)		5.75
	Exercised			(274,110	)		1.51
Options outstanding, December 31, 2001				4,639,782		$	4.47
Options exercisable,
		December 31, 1999		3,536,268		$	2.47
		December 31, 2000		2,268,950		$	2.64
		December 31, 2001		2,650,830		$	3.31

The following table sets forth information regarding options outstanding at December 31, 2001:

										Weighted Average
				Weighted		Weighted Average		Number of Option		Exercise Price for
Range of		Number of		Average		Remaining Life		Shares Currently		Currently
Exercise Prices		Shares		Exercise Price		(years)		Exercisable		Exercisable
	$.75 - 1.25		552,239	$	.77		7.8		530,639	$	.76
	1.34 - 2.31		1,196,575		1.76		4.5		941,287		1.84
	2.68 - 4.88		1,005,066		4.30		6.5		705,937		4.21
	4.89 - 8.00		1,544,902		6.05		9.0		376,469		6.33
	12.56 - 14.63		341,000		13.41		8.5		96,498		13.31
	$.75 - 14.63		4,639,782	$	4.47		7.1		2,650,830	$	3.31

49

As described in Note 1, the Company uses the intrinsic value method to measure compensation expense associated with grants of stock options to employees. The Company has also issued options to consultants, which are included in the table above. The unearned portion of these awards is classified as a component of stockholder equity and is listed as “deferred compensation” on the consolidated balance sheet. On a proforma basis, had the Company used the fair value method to measure compensation, the net income (loss) and net income (loss) per share would have been reported as follows:

	Years ended December 31,
In thousands (except per share data)	2001			2000			1999
Basic:
Proforma net income (loss) attributable to common stockholders	$	(23,376	)	$	(16,667	)	$	16,311
Proforma net income (loss) per share	$	(.80	)	$	(.64	)	$	.74
Diluted:
Proforma net income (loss) attributable to common stockholders plus repurchase and accretion costs attributable to redeemable convertible preferred stock	$	(23,376	)	$	(16,667	)	$	22,746
Proforma net income (loss) per share	$	(.80	)	$	(.64	)	$	.66

At December 31, 2001, the Company has 449,759 options available to be issued at future dates under the Plans.

The above disclosure, required by SFAS No. 123, includes only the effect of grants made subsequent to January 1, 1996. For purposes of calculating the above disclosure, the fair value of options on their grant date was measured using the Black-Scholes option pricing model. Key assumptions used to apply this pricing model included a risk-free interest rate of 4.2% for 2001, 5.9% for 2000 and 5.5% for 1999, expected lives of the option grants ranging from one to six years and expected rates of volatility for the underlying stock of 108% for 2001, 109% for 2000 and 100% for 1999. Using this model, the weighted average fair value per option for all options granted to employees in 2001, 2000 and 1999 was $4.71, $9.35 and $1.09, respectively.

ARIAD Gene Therapeutics, Inc. Stock Option Plan

The Company’s subsidiary, AGTI, adopted a stock option plan in 1993 substantially similar to the Plans and reserved 1,785,714 shares of AGTI’s common stock for issuance pursuant to such plan. At December 31, 2001, options with respect to 87,428 shares of AGTI’s common stock (all granted in 1994) were outstanding at an exercise price of $.42 per share, and all option shares were exercisable. During 2001, no options were exercised or forfeited. During 2000, 758,282 options were exercised with aggregate proceeds of $318,000, and 25,000 option shares were forfeited. During 1999, 89,285 options were exercised with aggregate proceeds of $37,000, and 207,142 option shares were forfeited. As of December 31, 2001, AGTI had 5,195,779 shares of its common stock outstanding.

Employee Stock Purchase Plan

In 1997, the Company adopted the 1997 Employee Stock Purchase Plan and reserved 500,000 shares of common stock for issuance under this plan. Under this plan, substantially all of its employees may, through payroll withholdings, purchase shares of the Company’s stock at a price of 85% of the lesser of the fair market value at the beginning or end of each three-month withholding period. In 2001, 2000 and 1999, 28,985, 20,049, and 51,259 shares of common stock were issued under the plan, respectively.

50

9.  Income Taxes

At December 31, 2001, the Company had available for federal tax reporting purposes, net operating loss carryforwards of approximately $110.1 million, which expire commencing in 2009 and for state tax reporting purposes, net operating loss carryforwards of approximately $85.2 million, which expire commencing in 2002. The Company also had federal research and development credit carryovers of approximately $6.0 million, which expire commencing in 2006. Both the net operating loss carryforwards and credits are subject to certain limitations under federal tax law.

The components of deferred income taxes were as follows at December 31:

In thousands		2001			2000
Deferred tax liabilities:
	Intangible and other assets	$	2,091		$	1,882
	Organizational costs					2
Total deferred tax liabilities			2,091			1,884
Deferred tax assets:
	Net operating loss carryforwards		42,590			34,707
	Federal and State tax credit carryovers		10,808			9,860
	Depreciation		3,612			3,416
	Other		408			255
Total deferred tax assets			57,418			48,238
Deferred tax assets, net			55,327			46,354
Valuation allowance			(55,327	)		(46,354	)
Total deferred taxes		$	0		$	0

Although the Company earned taxable income in 1999 due to the gain on sale of the Genomics Center, it was able to utilize net operating loss carryforwards to eliminate substantially all taxes due. Since the Company has not yet achieved sustained profitable operations, management believes the tax benefits as of December 31, 2001 and 2000 do not satisfy the realization criteria set forth in SFAS No. 109 and has recorded a valuation allowance for the entire net deferred tax asset. The increase in the valuation allowance of $8.9 million in 2001 and $11.6 million in 2000 resulted primarily from net operating loss carryforwards and tax credit carryovers that resulted from operations in those years. The decrease in the valuation allowance of $8.4 million in 1999 resulted from the utilization of net operating loss carryforwards.

10. Litigation

The Company was named as a defendant in a purported class action lawsuit commenced in June 1995 in the U.S. District Court for the Southern District of New York. The action named as defendants the Company; the underwriter of the Company’s initial public offering and a market maker in the Company’s stock, D. Blech & Co.; the managing director and sole shareholder of D. Blech & Co. and a former director of the Company, David Blech; certain other directors of the Company, and the qualified independent underwriter for the initial public offering, Shoenberg Hieber, Inc. (“SHI”).

Counsel for the plaintiff class, counsel for the Company and the named director defendants, excluding David Blech, (the “Company Defendants”) and counsel for SHI have executed a stipulation of settlement in the action (the “Proposed Settlement”). The Proposed Settlement, in substance, contemplates a payment of $620,000 as consideration for plaintiffs’ consent to entry of judgment dismissing the action with prejudice and barring “contribution-type” claims against the Company Defendants by non-settling parties. The

51

Proposed Settlement further is subject to the Court’s approval of that stipulation as fair, adequate and reasonable, and to entry of an appropriate judgment of dismissal in the action and in a related action entitled In re: Blech Securities Litigation, 94 Civ. 7696 (RWS), from which the Court previously ordered the Company dismissed as a defendant. The amount the Company has contributed to a legal escrow account was not material, and accordingly, no liability is recorded on the 2001 balance sheet.

On May 19, 1999, the Company filed suit in the Massachusetts Superior Court against Michael Z. Gilman, Ph.D. (“Dr. Gilman”), the Company’s former Chief Scientific Officer, seeking equitable relief for breach of his employment agreements in accepting a position as the research director of molecular biology at Biogen, Inc. (“Biogen”). The Superior Court issued a temporary injunction on May 19, 1999 restraining Dr. Gilman from using any of the Company’s confidential information in his new employment. On June 21, 1999, Dr. Gilman filed counterclaims against the Company seeking an order awarding damages for breach of contract and barring the Company from enforcing any provisions of its employment agreements with Dr. Gilman. On May 26, 1999 Biogen filed a motion to intervene as a defendant in the action which the Superior Court granted on August 2, 1999. Discovery in the case has been completed, and Summary Judgment Motions have been filed, heard and ruled upon. The Company’s claim against Dr. Gilman and Dr. Gilman’s counterclaims will now proceed to trial. No trial date has been set. The ultimate outcome of the litigation with Dr. Gilman is not determinable or estimatable at this time, and accordingly, no liability is recorded on the balance sheets.

ITEM 9:  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not Applicable.

52

PART III

ITEM 10:  DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

The directors, officers and key employees of the Company are as follows:

Name	Age		Position
Harvey J. Berger, M.D.		51	Chairman of the Board of Directors, Chief Executive Officer and President
Sandford D. Smith		54	Vice Chairman of the Board of Directors
Laurie A. Allen, Esq		41	Senior Vice President, Chief Legal Officer, and Secretary
David L. Berstein, Esq		49	Senior Vice President and Chief Patent Counsel
Fritz Casselman		52	Senior Vice President and Chief Business Officer
John D. Iuliucci, Ph.D.		59	Senior Vice President, Drug Development
Timothy P. Clackson, Ph.D.		36	Vice President, Gene Therapy and Genomics
David C. Dalgarno, Ph.D.		44	Vice President, Physical and Chemical Sciences
Maryann G. Krane		42	Vice President, Regulatory Affairs
Tomi K. Sawyer, Ph.D.		47	Vice President, Drug Discovery
Thomas A. Pearson		60	Senior Advisor, Corporate Communications and Planning
Brian A. Lajoie		55	Interim Chief Financial Officer
Joseph Bratica		38	Director, Finance and Controller
Vaughn D. Bryson		63	Director
John M. Deutch, Ph.D.		63	Director
Jay R. LaMarche		55	Director
Ralph Snyderman, M.D.		62	Director
Raymond S. Troubh		75	Director

Harvey J. Berger, M.D. is our principal founder and has served as our Chairman of the Board, Chief Executive Officer and President since April 1991. From 1986 to 1991, Dr. Berger held a series of senior management positions at Centocor, Inc., a biotechnology company, including Executive Vice President and President, Research and Development Division. He also has held senior academic and administrative appointments at Emory University, Yale University and the University of Pennsylvania and was an Established Investigator of the American Heart Association. Dr. Berger is a director of PTC Therapeutics, Inc., a closely held biotechnology company. Dr. Berger received his A.B. degree in Biology from Colgate University and his M.D. degree from Yale University School of Medicine and did further medical and research training at the Massachusetts General Hospital and Yale-New Haven Hospital.

Sandford D. Smith, one of our Directors since October 1991 and our Vice Chairman since January 1999, is Corporate Vice President and President, Genzyme Europe and International, Genzyme Corporation. From October 1997 to December 2000, he was President, Therapeutics International, Genzyme Corporation, and from May 1996 to September 1996, Vice President and General Manager, Specialty Therapeutics and International Group, Genzyme Corporation, a biotechnology company. Mr. Smith was President and Chief Executive Officer and a Director of Repligen Corporation, a biotechnology company, from 1986 to March 1996. Mr. Smith previously held a number of positions with Bristol-Myers Squibb and Company from 1977 to 1986, including, most recently, Vice President of Corporate Development and Planning for the United States Pharmaceutical and Nutritional Group. Mr. Smith is a Director of CSPI, a software company. Mr. Smith earned his B.A. degree from the University of Denver.

53

Laurie A. Allen, Esq. has served as our Senior Vice President and Chief Legal Officer since March 2002 and has served continuously as our Secretary since January 1999. Previously, from January 1999 to December 1999, she served as our Senior Vice President, Corporate Development and Legal Affairs and General Counsel. From January 2000 to February 2002, Ms. Allen was Senior Vice President, Business Development and Legal Affairs at Alexandria Real Estate Equities, Inc., a real estate investment trust. Previously, she was a partner with Brobeck, Phleger and Harrison, LLP, a leading technology law firm, from January 1996 to December 1998. She also was an associate with Brobeck, Phleger & Harrison, LLP from February 1991 to December 1995. Ms. Allen received her A.B. degree in History from the University of California, Los Angeles, her L.L.M. degree in taxation from New York University and her J.D. degree from Emory University School of Law.

David L. Berstein, Esq. has served as our Senior Vice President and Chief Patent Counsel since June 2000. Previously, he served as our Vice President and Chief Patent Counsel from September 1993 to June 2000. Prior to joining us, from 1990 through 1993, Mr. Berstein was Patent Counsel at BASF Bioresearch Corporation, a biotechnology company, where he was responsible for intellectual property matters, including patents and licensing. From 1985 to 1990, Mr. Berstein was a patent attorney at Genetics Institute, Inc., a biotechnology company, where he was involved in various aspects of the patent process from patent procurement through litigation. Mr. Berstein joined Genetics Institute from the law firm of Cooper & Dunham. Mr. Berstein received his B.S. degree from the University of Michigan and his J.D. degree from Fordham University School of Law.

Fritz Casselman has served as our Senior Vice President and Chief Business Officer since February 2001. From February 2000 to January 2001, Mr. Casselman was Senior Vice President, Strategy and Corporate Development at Avant Immunotherapeutics Inc., a biotechnology company. From 1997 to 2001, Mr. Casselman was Director of Worldwide Business Development at SmithKline Beecham, plc, a pharmaceutical company; from 1988 to 1996, Vice President and consultant to Cambridge Biotech Corporation, a biotechnology company; and from 1982 to 1988 an associate and then a partner at the law firm of Bromberg, Sunstein and Casselman. Mr. Casselman received his B.A. degree from the University of Wisconsin (Madison) and his J.D. degree from Boston University School of Law.

John D. Iuliucci, Ph.D. has served as our Senior Vice President, Drug Development since January 1999. Previously, he also served as our Vice President, Drug Development from October 1996 to December 1998 and our Vice President, Preclinical Development from June 1992 to September 1996. Prior to joining us, Dr. Iuliucci was Director of Preclinical Pharmacology and Toxicology at Centocor, Inc., a biotechnology company, from 1984 to 1992. From 1975 to 1984, Dr. Iuliucci headed the Drug Safety Evaluation Department at Adria Laboratories, a pharmaceutical company. He was a Senior Toxicologist at the Warner-Lambert Pharmaceutical Research Institute from 1972 to 1975. Dr. Iuliucci received his B.S. degree in Pharmacy and M.S. and Ph.D. degrees in Pharmacology from Temple University.

Timothy P. Clackson, Ph.D. has served as our Vice President, Gene Therapy and Genomics since June 2000. Previously he served as our Director, Gene Therapy from August 1999 to June 2000 and as our Department Head, Gene Therapy Biology from March 1999 to August 1999. Prior to joining us in December 1994, Dr. Clackson was a postdoctoral fellow at Genentech, Inc., a biotechnology company, from 1991 to 1994, where he studied the molecular basis for human growth hormone function. Dr. Clackson received his B.A. degree in Biochemistry from the University of Oxford. Dr. Clackson received his Ph.D. in Biology from the University of Cambridge, for research conducted at the MRC Laboratory of Molecular Biology into antibody engineering and the development of phage display technology.

David C. Dalgarno, Ph.D. has served as our Vice President, Physical and Chemical Sciences since November 1999. Previously, he served as our Director, Physical and Chemical Sciences from September 1998 to November 1999 and as our Director, Spectroscopy from October 1996 to August 1998. Prior to joining us in March 1992, Dr. Dalgarno was a scientist at Schering-Plough Corp. focusing on protein structure determination by nuclear magnetic resonance. Dr. Dalgarno received his B.A. and Ph.D. degrees in

54

Chemistry from the University of Oxford. He received his postdoctoral training in Molecular Biophysics and Biochemistry at Yale University.

Maryann G. Krane has served as our Vice President, Regulatory Affairs since May 2001. From September 2000 to May 2001, she served as Senior Director, Regulatory Affairs and Quality Assurance at Avant Immunotherapeutics, Inc., a biotechnology company. From 1986 to 1992 and from 1993 to 2000, Ms. Krane held various positions in regulatory affairs and research at Genetics Institute, Inc., currently a unit of American Home Products Corporation, a diversified healthcare company. Most recently, she was Head, Regulatory Affairs, Global Development of Hemophilia and Oncology Products at Genetics Institute. From August 1992 to April 1993, she was Manager, Regulatory Affairs at Genzyme Corporation, a biotechnology company. Ms. Krane received her B.S. degree in Microbiology from the University of Massachusetts at Amherst, MA.

Tomi K. Sawyer, Ph.D. has served as our Vice President, Drug Discovery since January 1999. Previously, he served as our Director, Drug Discovery – Signal Transduction from October 1997 to December 1998. From July 1993 to September 1997, he was Head and Associate Research Fellow, Structure-Based Design and Chemistry at Parke-Davis Pharmaceutical Research a Division of Warner-Lambert Company, a pharmaceutical company, and Section Director, Peptide and Peptidomimetic Chemistry at Parke-Davis from July 1991 to July 1993. Dr. Sawyer received his B.S. degree in Chemistry from Moorhead State University and his Ph.D. degree in Organic Chemistry from the University of Arizona.

Thomas A. Pearson has served as our Senior Advisor, Corporate Communications and Planning since January 2001. Previously, he served as our corporate communications consultant since 1992. Mr. Pearson was an independent business consultant since 1983, specializing in biotechnology and high-technology companies. Previously, Mr. Pearson held various management positions in the television stations division of CBS, an entertainment and broadcasting company. Mr. Pearson received his B.A. degree in liberal arts from Wheaton College.

Brian A. Lajoie has served as our Interim Chief Financial Officer since October 2001 and also served in this position from October 2000 to February 2001. Mr. Lajoie has been a financial management consultant for more than two years. From August 1989 to October 1999, he was Vice President, Finance at Biopure Corporation, a biopharmaceutical company. Mr. Lajoie received his B.A. degree in Economics from the University of Massachusetts at Amherst, MA.

Joseph Bratica has served as our Director of Finance and Controller since January 1999. Previously, he served as our Assistant Controller from January 1997 to December 1998 and as our Accounting Manager from August 1994 to December 1996. Prior to joining us, he was Accounting Manager at Creative BioMolecules, Inc., a biotechnology company, from 1992 to 1994. Mr. Bratica received his B.A. degree in Accounting from Suffolk University.

Vaughn D. Bryson, one of our Directors since February 1995, is President of Life Science Advisors, Inc., a healthcare consulting company. Mr. Bryson was a thirty-two year employee of Eli Lilly & Co., a pharmaceutical company, from 1961 to 1993 and served as President and Chief Executive Officer of Eli Lilly from 1991 to 1993. He served as Executive Vice President of Eli Lilly from 1986 until 1991. He also served as a member of Eli Lilly’s Board of Directors from 1984 until his retirement in 1993. Mr. Bryson was Vice Chairman of Vector Securities International Inc., an investment-banking firm, from April 1994 to December 1996. He also is a Director of Chiron Corporation, a biotechnology company, AtheroGenics, Inc., a biotechnology company, Amylin Pharmaceuticals, Inc., a biotechnology company, and Quintiles Transnational Corporation, a pharmaceutical services company. He received his B.S. degree in Pharmacy from the University of North Carolina and completed the Sloan Program at the Stanford University Graduate School of Business.

55

John M. Deutch, Ph.D., one of our Directors since March 1997, is an Institute Professor at the Massachusetts Institute of Technology. From 1992 to 1997, he previously served as Director of Central Intelligence, Deputy Secretary of Defense, and Undersecretary of Defense (Acquisition and Technology). Prior to this, he was Provost of the Massachusetts Institute of Technology, Dean of the School of Science, Chairman of the Department of Chemistry and the Karl Taylor Compton Professor of Chemistry. Mr. Deutch is a Director of Citicorp, a financial services company, CMS Energy Corporation, an energy company, Cummins Engine Company, Inc., a manufacturer of engines and engine components, Raytheon, Inc., a defense and commercial electronics company, and Schlumberger Ltd., an oil and gas equipment services company. Mr. Deutch received his B.A. degree from Amherst College and his D.Sc. degree from the Massachusetts Institute of Technology and was a postdoctoral fellow at the National Institutes of Health.

Jay R. LaMarche, one of our Directors since January 1992, has served as a financial advisor since November 2000. Previously, he served as our Chief Financial Officer and Treasurer from January 1992 to November 2000 and as our Executive Vice President from March 1997 to November 2000. Mr. LaMarche was our Senior Vice President, Finance from January 1992 to February 1997. Prior to joining us, he was Chief Financial Officer and a Director of ChemDesign Corporation, a fine chemicals manufacturer. Previously, Mr. LaMarche was a partner with Deloitte Haskins & Sells, a public accounting firm. Mr. LaMarche received his B.B.A. degree in Public Accountancy from the University of Notre Dame and served as an officer in the United States Navy.

Ralph Snyderman, M.D., one of our Directors since June 1998, has been Chancellor for Health Affairs and Dean, School of Medicine at Duke University since March 1989, and President and Chief Executive Officer of Duke University Health System since July 1998. He was formerly Senior Vice President of Medical Research and Development at Genentech, Inc., a biotechnology company, from January 1987 to May 1989. Dr. Snyderman is a Director of Proctor and Gamble, Inc., a consumer products and healthcare company. Dr. Snyderman received his B.S. degree from Washington College, Chestertown, Maryland and his M.D. degree from the State University of New York.

Raymond S. Troubh, one of our Directors since October 1991, has been a financial consultant for more than five years. Prior to this, he was a general partner of Lazard Freres & Co., an investment banking firm, and a governor of the American Stock Exchange. Mr. Troubh is a Director of Diamond Offshore Drilling, Inc., a contract drilling company, Enron Corporation, an energy trading company, General American Investors Company, Inc., an investment trust company, Gentiva Health Services, Inc., a healthcare provider, Health Net, Inc., a managed healthcare company, Petrie Stores Corporation, a liquidating trust, Starwood Hotels & Resorts, Inc., a hotel operating company, Hercules Incorporated, a specialty chemicals company, Triarc Companies, Inc., a holding company, and WHX Corporation, a steel products company. He received his A.B. degree from Bowdoin College and his L.L.B. degree from Yale Law School.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Exchange Act requires our directors, executive officers and beneficial owners of more than 10% of our Common Stock to file reports of ownership and changes of ownership with the Commission on Forms 3, 4 and 5. We believe that during the fiscal year ended December 31, 2001, our directors, executive officers and beneficial owners of more than 10% of our Common Stock complied with all applicable filing requirements. In making these disclosures, we have relied solely on copies of such reports furnished to us.

ITEM 11:  EXECUTIVE COMPENSATION

The following table sets forth aggregate amounts of compensation paid or accrued by us for the years ended December 31, 2001, 2000 and 1999 for services rendered in all capacities, by our Chief Executive Officer and our four next most highly compensated executive officers (as of December 31, 2001).

56

Summary Compensation Table

							Long-Term
			Annual Compensation				Compensation
			Base		Other		Number of Shares		All Other
Name and Principal Position	Year		Salary		Compensation(1)		Underlying Options		Compensation (2)
Harvey J. Berger, M.D.		2001	$	395,000	$	-0-		115,000	$	3,318
Chairman, Chief Executive		2000		363,000		-0-		100,000		3,400
Officer and President		1999		330,000		-0-		250,000		3,200
David L. Berstein, Esq		2001		221,000		60,000		60,000		3,951
Senior Vice President and		2000		200,000		47,000		35,000		3,082
Chief Patent Counsel		1999		190,000		25,000		67,000		2,889
Fritz Casselman		2001		180,923		-0-		200,000		3,896
Senior Vice President and		2000		-0-		-0-		-0-		-0-
Chief Business Officer (3)		1999		-0-		-0-		-0-		-0-
John D. Iuliucci, Ph.D.		2001		221,000		60,000		55,000		5,016
Senior Vice President,		2000		207,500		37,000		-0-		16,485
Drug Development		1999		200,000		30,000		90,000		4,281
Lee C. Steele		2001		183,346		-0-		-0-		3,858
Senior Vice President (3)		2000		-0-		-0-		27,500		-0-
		1999		-0-		-0-		-0-		-0-

(1)	The amounts listed are for deferred compensation awarded under our 1997 Executive Compensation Plan, a non-qualified, unfunded, deferred compensation plan. The amounts awarded vest over a four-year period commencing on the first anniversary of the date of the award.
(2)	The amounts listed for each year consist of our matching contributions of up to $3,400 per year under our 401(k) Plan and, in the case of Mr. Berstein, Mr. Casselman, Dr. Iuliucci and Mr. Steele, include the aggregate difference between the fair market value and the purchase cost of common stock purchased during fiscal year 2001 under our 1997 Employee Stock Purchase Plan. Dr. Berger is not eligible to participate in our Employee Stock Purchase Plan.
(3)	Mr. Casselman’s employment was effective February 6, 2001. Mr. Steele’s employment was effective February 1, 2001, and he resigned as senior vice president on March 18, 2002.

Stock Options

The following table sets forth information regarding each stock option granted during the fiscal year ended December 31, 2001 to each of the named executive officers.

Stock Option Grants in Last Fiscal Year

	Individual Grants										Potential Realizable
											Value at Assumed Annual
	Number of			Percent of							Rates of Stock Price
	Shares			Total Options							Appreciation for Option
	Underlying			Granted to			Exercise				Term (2)
	Options			Employees in			Price		Expiration
Name	Granted(1)			Fiscal Year			(per share)		Date		5%		10%
Harvey J. Berger, M.D.		115,000	(3)(4)		7.4	%	$	4.80		07/26/11	$	347,150	$	879,746
David L. Berstein, Esq		60,000	(3)(4)		3.9	%		5.65		06/07/11		240,805		540,279
Fritz Casselman		200,000	(3)(4)		12.9	%		7.38		01/24/11		1,047,751		2,350,770
John D. Iuliucci, Ph.D.		55,000	(3)(4)		3.5	%		5.65		06/07/11		220,738		495,255
Lee C. Steele		-0-

(1)	Options to purchase shares of our common stock.
(2)	These amounts, based on assumed appreciation rates of 5% and 10% as prescribed by the rules of the SEC, are for illustration purposes only and are not intended to forecast possible future appreciation, if any, of our stock price.
(3)	Vest annually over four years commencing on the first anniversary of the award.
(4)	Dr. Berger’s and Mr. Berstein’s options were granted under the 2001 Stock Plan. Mr. Casselman’s and Dr. Iuliucci’s options were granted under the 1991 Stock Option Plan for Employees.

57

Aggregated Option Exercises in Last Fiscal Year and Fiscal Year-End Option Values

The following table provides information regarding the exercise of options by each of the named executive officers during the fiscal year ended December 31, 2001. In addition, this table includes the number of shares covered by both exercisable and unexercisable stock options as of December 31, 2001 and the values of “in-the-money” options, which values represent the positive spread between the exercise price of any such option and either the actual or estimated fair market value of the underlying security, as applicable.

Aggregated Option Exercises in Last Fiscal Year and Fiscal Year-End Option Values

					No. of Shares Underlying
	Shares				Unexercised Options at Fiscal			Value of Unexercised
	Acquired on		Value		Year-End			In-the-Money Options at
Name	Exercise(#)		Realized		Exercisable/Unexercisable			Fiscal Year-End
Harvey J. Berger, M.D.		0	$	0		589,714/250,000	(1)(2)	$	1,884,138/235,750	(4)
		0		0		1,402/0	(3)		0/0	(5)
David L. Berstein, Esq		0		0		122,964/102,750	(1)		440,491/51,823	(4)
		0		0		112/0	(3)		0/0	(5)
Fritz Casselman		0		0		0/200,000	(1)		0/0	(5)
John D. Iuliucci, Ph.D.		0		0		209,178/78,750	(1)		731,354/69,821	(4)
		0		0		280/0	(3)		0/0	(5)
Lee C. Steele		0		0		27,500/0	(1)		0/0	(4)

(1)	Options to purchase shares of our common stock.
(2)	Includes options to purchase 235,714 shares of our common stock held by The Berger Family Trust, all of which are exercisable.
(3)	Options to purchase common stock of our subsidiary, AGTI.
(4)	Based upon a fair market value of $5.33 per share of common stock, which was the closing price of a share of our common stock on the NASDAQ National Market on December 31, 2001.
(5)	Based upon an estimated value of the common stock of AGTI, for which there was no public market on December 31, 2001.

Director Compensation

Effective as of 2001, non-employee directors receive an annual award of options to purchase 15,000 shares of our common stock, which are exercisable on the date of grant. On December 3, 2001, each non-employee director was awarded options to purchase 15,000 shares of our common stock at $4.09 per share, pursuant to our stock options plans. Such options were exercisable on the grant date. On July 1, 2001, each non-employee director was also awarded a one-time grant of 8,500 options for each year of service on the Board of Directors, up to a maximum of three years of service and a total of 25,500 options to purchase shares of our common stock at $5.00 per share. Such options were exercisable on the date of grant. Mr. Smith receives $4,000 per month for his services as Vice Chairman of the Board of Directors. No other non-employee director receives any cash compensation for service on the Board of Directors or its committees. Directors are reimbursed for their expenses for each meeting they attend.

Executive Employment Agreements

Dr. Berger, our Chairman of the Board of Directors, Chief Executive Officer and President, has an employment agreement with us which commenced in January 1992 and terminates in December 2004. Dr. Berger’s employment agreement is automatically renewable for successive three-year terms unless terminated by either party. The agreement provides that he shall be employed as our Chief Executive Officer and President, shall be nominated for election to our Board of Directors, serve as Chairman of the

58

Board and receive an annual base salary during 2002 of $433,000, increasing each year by at least 10% of the preceding year’s base salary. Dr. Berger is eligible each year to receive a discretionary bonus, determined by the Board of Directors, of up to 50% of his annual base salary. If we fail to renew the employment agreement, we are obligated to pay Dr. Berger, in addition to his compensation for the remainder of the term, a lump sum payment equal to two times Dr. Berger’s annual salary for the final year of the term and to provide for the immediate exercisability of all stock options and other equity rights.

Dr. Berger’s employment agreement provides that, if the agreement is terminated by either party upon the occurrence of certain events, including (i) our sale or merger (or stockholder approval of a merger agreement) or an acquisition of a substantial equity interest in us by a person or group of persons, (ii) if Dr. Berger is not elected to membership on our Board of Directors, named as Chairman or designated as Chief Executive Officer or ceases to be our highest ranking executive officer or ceases to control personnel decisions with respect to our employees, (iii) if we are in material breach of the terms of his employment agreement, (iv) if we are bankrupt or insolvent or (v) if we terminate Dr. Berger’s employment agreement without cause, (1) we will pay Dr. Berger the greater of (x) any remaining salary payable during the term of the agreement plus the maximum possible bonus for each year remaining in the term (taking into account, in both cases, obligated 10% increases in salary) and (y) an amount equal to twice his current annual salary and maximum bonus for the current year of employment (the “Severance Payment”) and (2) all of his stock options, stock awards and similar equity rights will immediately vest and become exercisable. We are not obligated to make the Severance Payment if we discharge Dr. Berger for cause. If the vesting of certain benefits and the payment of certain amounts by us to Dr. Berger are treated as payments in the nature of compensation that are contingent on a “change in control” (within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”)), the deductibility of such payments could, depending upon the aggregate amount of such payments, be disallowed pursuant to Section 280G of the Code and an excise tax could be imposed on Dr. Berger pursuant to Section 4999 of the Code for which he would, pursuant to the employment agreement, be indemnified by us on a net after-tax basis. The employment agreement contains a non-competition provision that is effective during the term of the agreement and, if Dr. Berger is terminated for cause, for a period of one year following the date of termination.

We also entered into employment agreements with Mr. Berstein, Mr. Casselman, and Dr.  Iuliucci. The agreements provide for employment through December 31, 2003 for Mr. Berstein and Dr. Iuliucci, and through February 28, 2004 for Mr. Casselman, at annual base salaries during 2002 of $242,000, $242,000 and $227,000, respectively, increasing each year by an amount to be determined by the Board of Directors. In addition, each executive is eligible each year to receive a performance bonus, to be determined by the Board of Directors, of up to 30% of his annual base salary, which may be paid in the form of deferred compensation under the 1997 Executive Compensation Plan, awards of our stock options, or cash. The agreements are renewable for successive one-year terms with the mutual consent of the parties. Effective March 18, 2002, Mr. Steele resigned as Senior Vice President but has been retained under an agreement which provides for his part-time employment through no later than June 28, 2002.

Our agreements with Mr. Berstein, Mr. Casselman and Dr. Iuliucci also provide that (i) upon a change of control, such officers will be entitled to receive, upon termination by the officer within 90 days after the change in control, any remaining salary payable during the term or six months’ salary, whichever is less, and all stock options held by such officers will immediately vest and become exercisable; and (ii) upon termination by us, without cause, such officer will be entitled to receive his current salary for the remaining period of the applicable term and all outstanding options that would have vested during such term shall vest immediately.

59

Compensation Committee Interlocks and Insider Participation

During the fiscal year ended December 31, 2001, the Compensation Committee was comprised of Messrs. Smith, Snyderman and Troubh. Pursuant to our stock option plans, each member of the Compensation Committee was awarded options to purchase 15,000 shares of our common stock at $4.09 per share and 25,500 shares of our common stock at $5.00 per share.

ITEM 12: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth, as of March 20, 2002, certain information with respect to (i) each person (including any “group” as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), known to us to own beneficially more than 5% of our Common Stock, (ii) each of our directors, (iii) each executive officer named in the Summary Compensation Table under “Executive Compensation” and (iv) all directors and executive officers as a group. In accordance with the rules promulgated by the SEC, such ownership includes shares currently owned, as well as shares that the named person has the right to acquire within 60 days of March 20, 2002, including, but not limited to, shares that the named person has the right to acquire through the exercise of any option. Except as otherwise indicated, we believe that the stockholders listed in the table have sole voting and investment powers with respect to the Common Stock shown as beneficially owned by them based on information provided to us by these stockholders. Percentage ownership is based on 32,418,371 shares of our common stock outstanding as of March 20, 2002.

Stock Ownership by Management, Directors and 5% Beneficial Owners

	Number and Nature of
Beneficial Owner	Shares Beneficially Owned			Percent of Class
Ironwood Capital Management, LLC		2,195,800	(1)		6.8	%
Laurie A. Allen, Esq		135,000	(2)		*
Harvey J. Berger, M.D.		1,787,747	(3)		5.4	%
David L. Berstein, Esq		134,415	(4)		*
Fritz Casselman		52,329	(5)		*
John D. Iuliucci, Ph.D.		251,286	(6)		*
Brian A. Lajoie		2,000	(7)		*
Vaughn D. Bryson		140,500	(8)		*
John M. Deutch, Ph.D.		140,053	(9)		*
Jay R. LaMarche		449,356	(10)		1.4	%
Sandford D. Smith		156,705	(11)		*
Ralph Snyderman, M.D.		173,000	(12)		*
Raymond S. Troubh		166,749	(13)		*
All directors and executive officers as a group (12 persons)		3,589,140	(14)		10.5	%

*	Indicates less than one percent of the outstanding shares of common stock.
(1)	Such shares are held of record by Ironwood Capital Management, LLC, located at 21 Custom House Street, Suite 240, Boston, Massachusetts 02109. This information is based solely on review of schedule 13G, which was filed with the SEC on February 14, 2002.
(2)	Consists of 135,000 shares issuable upon the exercise of stock options.
(3)	Includes 416,500 shares issuable upon the exercise of stock options. Includes 771,428 shares of common stock held of record by the Berger Family Trust and 8,928 shares of common stock held of record by the Wolk Family Trust. Wendy S. Berger and Harvey J. Berger, as co-trustees of such trusts, have the right to vote and dispose of the shares held by such

60

	trusts; however, in certain circumstances, Wendy S. Berger as co-trustee will have sole voting power with respect to the shares held by each such trust. Includes 120,000 shares held by Edith Berger, Dr. Berger’s mother, 40,892 shares held by Wendy S. Berger, Dr. Berger’s spouse, and 13,928 shares held by Dr. Berger’s children. Dr. Berger’s address is c/o ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139. Dr. Berger disclaims beneficial ownership of any of the 955,176 shares held by the Berger Family Trust, the Wolk Family Trust, Edith Berger, Wendy S. Berger and Dr. Berger’s children.
(4)	Includes 131,964 shares issuable upon the exercise of stock options.
(5)	Includes 50,000 shares issuable upon exercise of stock options.
(6)	Includes 240,428 shares issuable upon the exercise of stock options.
(7)	Consists of 2,000 shares issuable upon exercise of stock options.
(8)	Includes 98,000 shares issuable upon the exercise of stock options.
(9)	Includes 105,500 shares issuable upon the exercise of stock options.
(10)	Includes 145,607 shares issuable upon the exercise of stock options and 6,696 shares held by Carol B. LaMarche, Mr. LaMarche’s spouse.
(11)	Includes 128,357 shares issuable upon the exercise of stock options.
(12)	Includes 63,000 shares issuable upon the exercise of stock options.
(13)	Includes 110,500 shares issuable upon the exercise of stock options.
(14)	Includes 1,626,856 shares issuable upon the exercise of stock options held by all directors and executive officers as a group.

ITEM 13: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Our subsidiary, AGTI, holds licenses from Harvard University, Stanford University and other universities relating to our ARGENT cell-signaling regulation technology. Minority stockholders of AGTI, including Harvard University, Stanford University, some of our scientific advisors, and some current and former members of our management, own 20% of the issued and outstanding capital stock of AGTI. We own the remaining 80% of the issued and outstanding capital stock of AGTI. Four members of our management team and/or Board of Directors own or have the right to acquire up to approximately 6.1% of the outstanding capital stock of AGTI. Harvey J. Berger, M.D. owns 3.4%; David L. Berstein, Esq. owns 0.3%; John D. Iuliucci, Ph.D. owns 0.7%; and Jay R. LaMarche owns 1.7%. AGTI has a right of first refusal on the sale to third parties of 73% of the minority stockholders’ AGTI shares. AGTI does not have a call option, or a right to require the minority stockholders to sell their shares to us, for any of these shares. As part of the formation of AGTI, we entered into agreements with AGTI to provide for the operations of AGTI.

61

PART IV

ITEM 14:  EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K

         (a)(1)  The following Consolidated Financial Statements, Notes thereto and Independent Auditors’ Report have been presented in Item 8:

                     Independent Auditors’ Report

                     Consolidated Balance Sheets

                     Consolidated Statements of Operations

                     Consolidated Statements of Stockholders’ Equity

                     Consolidated Statements of Cash Flows

                     Notes to Consolidated Financial Statements

         (a)(2)  Financial Statement Schedules:

Schedules have been omitted because of the absence of conditions under which they are required or because the required information is included in the financial statements or notes thereto.

The Exhibits listed in the Exhibit Index are filed herewith in the manner set forth therein.

(b) Reports on Form 8-K

We filed a Current Report on Form 8-K on October 9, 2001 announcing that we will present an update of our product development portfolio and business development initiatives at the UBS Warburg Global Life Sciences Conference on October 11, 2001.

We filed a Current Report on Form 8-K on October 11, 2001 announcing that results of recent studies on our new small-molecule drug candidates to treat bone metastases and solid tumors and the status of their development are being presented at the UBS Warburg Global Life Sciences Conference.

We filed a Current Report on Form 8-K on October 12, 2001 announcing that new data of our lead product candidates to treat bone metastases and osteoporosis are being reported at the annual meeting of The American Society for Bone and Mineral Research.

We filed a Current Report on Form 8-K on December 7, 2001 announcing that results of preclinical studies comparing the safety profile of our regulated erythropoietin (Epo) product candidate with that of an uncontrolled version of Epo therapy in animal models are being presented at the annual meeting of the American Society of Hematology.

62

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge and Commonwealth of Massachusetts on the 22nd of March, 2002.

ARIAD PHARMACEUTICALS, INC.
By:	/s/ Harvey J. Berger, M.D.
Name:	Harvey J. Berger, M.D.
Title:	Chairman, Chief Executive Officer, and President

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Harvey J. Berger Harvey J. Berger, M.D.	Chairman of the Board of Directors, Chief Executive Officer, President (Principal Executive Officer)	March 22, 2002
/s/ Sandford D. Smith Sandford D. Smith	Vice Chairman of the Board of Directors	March 22, 2002
/s/ Brian A. Lajoie Brian A. Lajoie	Interim Chief Financial Officer (Principal Financial and Accounting Officer)	March 22, 2002
/s/ Vaughn D. Bryson Vaughn D. Bryson	Director	March 22, 2002
/s/ John M. Deutch John M. Deutch, Ph.D.	Director	March 22, 2002
/s/ Jay R. LaMarche Jay R. LaMarche	Director	March 22, 2002
/s/ Ralph Snyderman Ralph Snyderman, M.D.	Director	March 22, 2002
/s/ Raymond S. Troubh Raymond S. Troubh	Director	March 22, 2002

63

EXHIBIT INDEX

Exhibit No.	Title
3.1	Certificate of Incorporation of the Company, as amended. (1)
3.2	Restated By-laws of the Company, as amended. (6)
3.3	Amendment of Certificate of Incorporation of the Company, dated April 8, 1994. (2)
3.4	Amendment of Certificate of Incorporation of the Company, dated October 4, 1994. (5)
3.5	Certificate of Designations in respect of Series B Preferred Stock of the Company. (8)
3.6	Certificate of Designations, Preferences and Rights of Series C Convertible Preferred Stock of the Company. (10)
4.1	Principal Stockholders’ Agreement, dated as of January 5, 1992, among ARIAD Pharmaceuticals, Inc., David Blech, David Blech as trustee of The Blech Family Trust, Mark S. Germain, Harvey J. Berger, Harvey J. Berger and Wendy S. Berger as Trustees of the Berger Family Trust, Avalon Ventures and Avalon Ventures IV. (1)
4.2	Rights Agreement, dated as of June 8, 2000, between the Company and State Street Bank and Trust Company, which includes the Form of Certificate of Designations in respect of the Series A Preferred Stock, as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Series A Preferred Stock as Exhibit C. Pursuant to the Rights Agreement, Right Certificates will not be mailed until after the Separation Date (as defined therein). (4)
4.3	Stock Purchase Agreement, dated as of April 24, 1995, between ARIAD Pharmaceuticals, Inc. and Biotech Target S.A. (7)
10.1	Lease Agreement, dated January 8, 1992, between ARIAD Pharmaceuticals, Inc. and Forest City Cambridge, Inc. (1)
10.2+	Executive Employment Agreement, dated as of January 1, 1992, between ARIAD Pharmaceuticals, Inc. and Harvey J. Berger, M.D. (1)
10.3+	Executive Employment Agreement, dated as of January 3, 1992, between ARIAD Pharmaceuticals, Inc. and Joan S. Brugge, Ph.D. (1)
10.4+	Executive Employment Agreement, dated as of January 1, 1992, between ARIAD Pharmaceuticals, Inc. and Jay R. LaMarche. (1)
10.5+	Executive Employment Agreement, dated as of October 14, 1991, between ARIAD Pharmaceuticals, Inc. and Manfred Weigele, Ph.D. (1)
10.6	Loan and Security Agreement, dated September 23, 1992, by and between ARIAD Pharmaceuticals, Inc., ARIAD Corporation and BayBank Boston, N.A. and related instruments and documents. (1)
10.7	Loan Agreement, dated October 28, 1992, among ARIAD Corporation, ARIAD Pharmaceuticals, Inc. and the Massachusetts Business Development Corporation and related instruments and documents. (1)
10.8	Equipment Lease Agreement, dated December 10, 1992, by and between ARIAD Corporation and General Electric Capital Corporation. (1)
10.9	Master Lease Agreement, dated December 21, 1992, by and between ARIAD Corporation and Comdisco, Inc. (1)
10.10+	ARIAD Pharmaceuticals, Inc. 1991 Stock Option Plan for Employees, as amended. (5)
10.11+	ARIAD Pharmaceuticals, Inc. 1991 Stock Option Plan for Directors. (1)
10.12+	ARIAD Retirement Savings Plan. (1)
10.13	Amended and Restated Agreement, dated as of December 12, 1997, between The Board of Trustees of The Leland Stanford Junior University and ARIAD Gene Therapeutics, Inc. (9)

10.14+	Amendment, dated April 19, 1994, to Executive Employment Agreement between ARIAD Pharmaceuticals, Inc. and Harvey J. Berger, M.D. (3)
10.15+	Amendment, dated March 2, 1994, to Executive Employment Agreement between ARIAD Pharmaceuticals, Inc. and Joan S. Brugge, Ph.D. (3)
10.16+	Amendment, dated March 2, 1994, to Executive Employment Agreement between ARIAD Pharmaceuticals, Inc. and Jay R. LaMarche. (3)
10.17+	Amendment, dated March 2, 1994, to Executive Employment Agreement between ARIAD Pharmaceuticals, Inc. and Manfred Weigele, Ph.D. (3)
10.18	Unit Purchase and Technology Right of First Negotiation Agreement, dated May 5, 1994, among Genentech, Inc., ARIAD Pharmaceuticals, Inc. and ARIAD Gene Therapeutics, Inc. (3)
10.19+	Amendment No. 2, dated June 30, 1994, to Executive Employment Agreement between ARIAD Pharmaceuticals, Inc. and Harvey J. Berger, M.D. (5)
10.20+	ARIAD Pharmaceuticals, Inc. 1994 Stock Option Plan for Non-Employee Directors. (5)
10.21	Collaborative Research and License Agreement, dated November 5, 1995, between Roussel Uclaf and ARIAD Pharmaceuticals, Inc. (7)
10.22	License Agreement, dated as of September 12, 1996, between Mochida Pharmaceuticals Co., Ltd. and ARIAD Pharmaceuticals, Inc. (8)
10.23	Joint Venture Agreement, dated as of February 14, 1997, between Genovo, Inc. and ARIAD Gene Therapeutics, Inc. (8)
10.24	Collaborative Agreement, dated as of March 4, 1997, between Incyte Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. (8)
10.25+	Amendment, dated January 1, 1997, to Executive Employment Agreement between ARIAD Pharmaceuticals, Inc. and Harvey J. Berger, M.D. (8)
10.26+	Amendment, dated January, 1, 1997, to Executive Employment Agreement between ARIAD Pharmaceuticals, Inc. and Jay R. LaMarche (8)
10.27+	Amendment, dated January 1, 1997, to Executive Employment Agreement between ARIAD Pharmaceuticals, Inc. and Manfred Weigele, Ph.D. (8)
10.28+	Consulting Agreement, dated July 1, 1997, between ARIAD Pharmaceuticals, Inc. and Joan S. Brugge, Ph.D. (8)
10.29+	ARIAD Pharmaceuticals, Inc. 1997 Employee Stock Purchase Plan. (8)
10.30+	Amendment to the 1991 Stock Option Plan for Employees and Consultants. (8)
10.31+	Amendment to the 1994 Stock Option Plan for Non-Employee Directors. (8)
10.32	Fourth Amendment to Loan and Security Agreement, dated June 27, 1997, with BankBoston, N.A. as successor in interest to BayBank, N.A. (8)
10.33	License Agreement, dated July 17, 1997, between ARIAD Pharmaceuticals, Inc. and Mitotix Inc. (8)
10.34	Technology Purchase and Sale Agreement and related agreements, dated July 17, 1997, between ARIAD Pharmaceuticals, Inc. and Mitotix, Inc. (8)
10.35	ARIAD Pharmaceuticals, Inc. 1997 Executive Compensation Plan. (9)
10.36+	Amendment, dated November 10, 2000, to Executive Employment Agreement between ARIAD Pharmaceuticals, Inc. and Jay R. LaMarche. (15)
10.37+	Executive Employment Agreement, dated December 15, 2000, between ARIAD Pharmaceuticals, Inc. and Lee C. Steele. (15)
10.38+	Executive Employment Agreement, dated January 24, 2001, between ARIAD Pharmaceuticals, Inc. and Fritz Casselman. (15)
10.39	Common Stock Purchase Agreement, dated as of June 27, 2000, by and between ARIAD Pharmaceuticals, Inc. and Acqua Wellington North American Equities Fund, Ltd. (11)

10.40	Common Stock Purchase Agreement, dated as of June 27, 2000, by and between ARIAD Pharmaceuticals, Inc. and the Purchaser named therein. (11)
10.41+	Executive Employment Agreement, dated May 1, 1992, Fourth Amendment to Employment Agreement dated June 8, 2000, Third Amendment to Employment Agreement dated January 1, 1999, and Amendments to Employment Agreements dated January 1, 1997 and March 2, 1994 between ARIAD Pharmaceuticals, Inc. and John Iuliucci, Ph.D. (12)
10.42+	Executive Employment Agreement, dated August 1, 1993, Third Amendment to Employment Agreement dated June 8, 2000, and Amendments to Employment Agreements dated January 1, 1997 and March 2, 1994 between ARIAD Pharmaceuticals, Inc. and David L. Berstein, J.D. (12)
10.43	Restructuring Agreement, dated December 31, 1999, by and between Hoechst Marion Roussel (France) and ARIAD Pharmaceuticals, Inc. (**)(13)
10.44	Restructuring Agreement, dated December 31, 1999, by and among Aventis Pharmaceuticals, Inc., the Hoechst-Ariad Genomics Center, LLC and ARIAD Pharmaceuticals, Inc. (**)(13)
10.45	Settlement and Repurchase Agreement by and among ARIAD Pharmaceuticals, Inc., Promethean Investment Group LLC and HFTP Investments, LLC, dated as of January 14, 2000. (14)
10.46+	Amendment, dated as of January 1, 2001, to Executive Employment Agreement with John Iuliucci, Ph.D. (16)
10.47+	Amendment, dated as of January 1, 2001, to Executive Employment Agreement with David Berstein, Esq. (16)
10.48+	ARIAD Pharmaceuticals, Inc. 2001 Stock Plan. (17)
10.49	December 2001 Amendment to Loan and Security Agreement, dated December 26, 2001, by and among ARIAD Pharmaceuticals, Inc., ARIAD Corporation, ARIAD Gene Therapeutics, Inc. and Fleet National Bank, which includes as Exhibit A, the Second Amended and Restated Secured Term Note dated as of December 26, 2001 (18)
10.50	Master Security Agreement, dated as of December 27, 2001, by and between ARIAD Pharmaceuticals, Inc. and General Electric Capital Corporation. (18)
10.51	Financial Covenants Addendum No. 001 to Master Lease Agreement between ARIAD Pharmaceuticals, Inc. and General Electric Capital Corporation. (18)
10.52	Promissory Note dated as of December 28, 2001. (18)
10.53	Research and Development Agreement, dated as of March 15, 2002, by and between ARIAD Pharmaceuticals, Inc. and ARIAD Corporation. (18)
10.54	Research and Development Agreement, dated as of March 15, 2002, by and between ARIAD Gene Therapeutics, Inc. and ARIAD Corporation. (18)
10.55+	Consulting Agreement, dated as of October 5, 2001, between ARIAD Pharmaceuticals, Inc. and Brian A. Lajoie. (18)
10.56+	Executive Employment Agreement, dated as of March 4, 2002, between ARIAD Pharmaceuticals, Inc. and Laurie Allen, Esq. (18)
10.57	Stock Transfer Agreement between ARIAD Gene Therapeutics, Inc. and the individuals listed on Exhibit A thereto. (18)
10.58	Notice of Extension of Lease, dated October 2, 2001, from ARIAD Corporation to Forest City Commercial Group. (18)
21.1	Subsidiaries of the Company. (3)
23.1	Consent of Deloitte & Touche LLP. (18)

Notes to Exhibits:
(+)	Management Contract or Compensatory Plan or Arrangement

(**)	Confidential treatment has been requested from the Securities and Exchange Commission.
(1)	Incorporated by reference to Registration Statement on Form 10 of the Company filed with the Securities and Exchange Commission on June 25, 1993.
(2)	Incorporated by reference to Form 10-K of the Company for the fiscal year ended December 31, 1993 filed with the Securities and Exchange Commission on April 15, 1994.
(3)	Incorporated by reference to Registration Statement on Form S-1 of the Company (No. 33-76414) filed with the Securities and Exchange Commission on March 11, 1994.
(4)	Incorporated by reference to Form 8-A of the Company filed with the Securities and Exchange Commission on June 19, 2000.
(5)	Incorporated by reference to Form 10-K of the Company for the fiscal year ended December 31, 1994 filed with the Securities and Exchange Commission on March 30, 1995.
(6)	Incorporated by reference to Registration Statement on Form S-3 of the Company (No. 333-38664) filed with the Securities and Exchange Commission on June 23, 2000.
(7)	Incorporated by reference to Form 10-K of the Company for the fiscal year ended December 31, 1995 filed with the Securities and Exchange Commission on March 15, 1996.
(8)	Incorporated by reference to Forms 10-Q of the Company filed with the Securities and Exchange Commission on May 12, 1997, August 12, 1997 and November 12, 1997.
(9)	Incorporated by reference to Form 10-K of the Company for the fiscal year ended December 31, 1997 filed with the Securities and Exchange Commission on March 5, 1998.
(10)	Incorporated by reference to Form 8-K of the Company filed with the Securities and Exchange Commission on November 12, 1998.
(11)	Incorporated by reference to Form 8-K of the Company filed with the Securities and Exchange Commission on July 7, 2000.
(12)	Incorporated by reference to Form 10-Q of the Company filed with the Securities and Exchange Commission on August 10, 2000.
(13)	Incorporated by reference to Form 8-K of the Company, dated December 31, 1999 and filed with the Securities and Exchange Commission on January 18, 2000.
(14)	Incorporated by reference to Form 8-K of the Company, dated January 14, 2000 and filed with the Securities and Exchange Commission on January 18, 2000.
(15)	Incorporated by reference to Form 10-K of the Company for the fiscal year ended December 31, 2000 filed with the Securities and Exchange Commission on March 29, 2001.
(16)	Incorporated herein by reference to Form 10-Q of the Company filed with the Securities and Exchange Commission on May 14, 2001.
(17)	Incorporated herein by reference to Form S-8 of the Company filed with the Securities and Exchange Commission on June 22, 2001.
(18)	Filed herewith.

10-K405 3 b41666are10-kpdf.pdf ARIAD PHARACEUTICALS, INC begin 644 b41666are10-kpdf.pdf M)5!$1BTQ+C0-)>+CS],-"C$@,"!O8FH-/#P@#2]4>7!E("]086=E(`TO4&%R M96YT(#,V,2`P(%(@#2]297-O=7)C97,@,B`P(%(@#2]#;VYT96YT"!;(#`@,"`V,3(@-SDR(%T@ M#2]#R4"G$A".9-OJ1UFS2)Q:O)"U(^'+ZM4Q` MDY(B^:?Z8Y8J/W>E]R(U.79 MJWQNM2H$',G:W(]ZK)^.KCPKNAI@OY7A#LXBU$N1I"8S3I[MZ?!]4L@:[&C9 M)!`8&1+TL>]!3!>9TE+%@S^R5UHUG=NBO7RN7&G8G+@:P%0^+^#$.4Q+#2:U M,D:^ZUJ8]_(^=$,=>H@/N97JS!DO=314_<)AL&-`M(N*DY3TH7YA8`"[7V)* M2`GY]#IL5[RP$V!M'<*F;C`Y6F[!7CG/R1[\@V.QH.+/L6T?G2J4?N14],>. M_BSW'^_JJ+:OVX9U*,B941;@-H:H8!WMC7BS&H;0]6)H!9W3XG$`B+G\T`Y! M@`2`Q<(PH%]6KO==/3R(WT$H@V&;X-IN`RK0JL/=A;$>)C6KTZ/6B)58`>EX M*$!=`<[CT0@C1HU1=BK"+DD1+0N,FI77E;BZ>HJ\C$#@U01>8P[U8IXF"\ZL M$7P.,B_R"7YO5MTG`F!@"7'3@D@I.W&=E.!_)K>PK`";$%R0\)+ENE7#/[[R M+!:?4A":%*79S!T.M&2%#0!<7((0XOK?I`2I/2H=$']>/G`)KU!L,]G>@0!D MR$2C.+7A,(#S"OAC*H!(*MCJ)?#B>EQA1>*"2&:%[N62]<%`V5ARR$P2R.)Q MF=D#;-1SV.1@"`Z.01/%(]@@35DV[@`C#L5XP,)Q@&)X$%3S%3'M`48.E5TD MR#LU8L3%N76"+(*$:.-,7Y,_+5L3T>I&+*+Y'2T_D'G>P1NB#80;)-F#UIL$ M2QYR,Y7NX<;(_7'PX.NR0LOSMMF@YZ6L M![*5R[HE*O&R00+R8+!)%!PRRHGK@&$IP`VLEQ)"`E8+N1OZZ-(-"D)!O27> M\L(9P&T=?Z+J`3AQ5(3;;58Z9"A<<_PYAO144Q,N]`E8>+K*,##%XB71 M>6[D>TAJ01D$R&)$G639FAF1!QCR:5!31CX'$>4WXDC)CA,6-QYM86X,A*0\ M3L(]BH2=8)1W+:64IUA=%W@D%A_Y/F(17F3E@B@1@1HBW\?YZT1E$3M@YQ.6 M@BTR:8XOS)^G`3]5T]-RSY^5N_I6O2]CC1^I#KR/Y_J$+M:1!7AI(Y;[^_M( M/G%3O`*9;R;J0![I'KB1^#ZYE$6AI/D6/2HWU@G?[U;8+X$2*B0V\"H7RA5=K@`*,6:E8K-]NM=5-4FR`;]OL.4-^`Z8%N(ZP';DH[(BI%O49! MR49&N/POK/?XP@#"$XHPBZ(VFQ(ED)<`FFL M$`U>MF0<@4>9*^$!(G-W1"/*3.52/&<1K%F+C:?2D_UEH#8UP>O0XLV`KL8B M:*A5Q83>UO>T@$TNV=/P_O)E<>B3,:'1076,*+E00@-Q1G.S9MZ6B,>S=U@*$9._W\N'E[@Z?.^2:#LHS? M;>#O7?PV0T0$1=.8>*\9F?'G=%;-X8V6^1-,73(S`KD)\2LUSWF4 M:$AZ-?:BW!O@;5I$@:G%H_?:D@VOCNR'V&/Q=EX2RS4?)&SVO#?TAQ<,(WY, MFZ7L6'G?4L?;'1U7M"S__*[Y_JOF%3VJ6NJ8NCMJ8N+[Q:=_4J=?>B^!U$GO M935[/_M_`!YA["!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A M=&4@,"`-/CX@#65N9&]B:@TU(#`@;V)J#3P\(`TO4')O8U-E="!;("]01$8@ M+U1E>'0@72`-+T9O;G0@/#P@+T8Q(#$Y-2`P(%(@+U14-B`Q.3,@,"!2("]4 M5#@@,3DT(#`@4B`O5%0Q,"`Q.38@,"!2(#X^(`TO17AT1U-T871E(#P\("]' M4S,@,S@S(#`@4B`^/B`-/CX@#65N9&]B:@TV(#`@;V)J#3P\("],96YG=&@@ M-38P,R`O1FEL=&5R("]&;&%T941E8V]D92`^/B`-X! M*=G9E*I$S*7OW:=[_G'SYHMKRK%^=+==T_7UR8U]79F^-C?OMS=OMMO,A&:[ MO]FL-IE9TQ]_1)ML%68F#_-5D9CMZ69M#C=O?KF/S6&X6:_6ZZ@PVXJ_UI'9 M/MW\S7Y^]V4;Y*O0FH]!MHJM"?Z^_=/-,HI6Z3HSRVB51&%NMC\S49R#?,GT MN=!_).+(;H/"WOUFPI^"94BL@F6:%_8];?XE(!:1O9=K?PY2>W=_+S+(B$*, M6+.<)"T@A[F'B="TD%0=3=5.S,[MZ#U%TBWX3^G&].2G= MZ/K:LVB>S;[O3L;3'\D5N>T&9X*"/NA:6*S@KIA<-]95?2[%PM'M3,TN]:=F M/#JBVW<(1D+;3P'BJ/=[R:_=TH>"_'$0#W,4F"?%SYVCI0.PRZU?7 M#DSC2S[.Z2CN$^>8;@\JHM9H9/1=MT9W=:,:NWXP7ZUL#I0(E!2.8T^4_Y)+ MM[`CLR_8?'C!8'O4)=**"'_#JO!"GL7F=[*I"N@/R8J9C?DPC5/OS!=HSY'Q MW(:+*9_.[*B4=/$"J6:&?\OWUT"NK82G,1];"E"PW$#EP:C\5C;:23DT+]P: M;7Q>AAOO5^0J'/O%G8,$J1)`A7X4LZAF/P1+9$P7I-@_T4]B3;A>_LK7%Y+# MYLEQ+67T7>G5<]>7HS,/=*^PS_R?M=6C@/'ND7)*DR+D)#4QSR:BP:) M`.5*Z)"AU.&SED3MQ3[.37R<]`JYC),8U;N&8GH1"(+[)W/6FSUEHMBH5TQ' M"2].[@W7?<%H)(6:$4N``&0AAW(H,@Z>?]THJ1)Z-%?C7L%".**+[%Z11@L3-E)V+^>-9QC$"IP.?'6_=TMH=WVR-$G]>YN M3=DTW=-@ID%TCS2'"+.&JF&1J24@J4]G;@7QG&-ERUQ&[RQ5X@(!#*%S1XHR MT82BKYB44-PYXA#12GD^/$N6]<"C41%--6(+ZI'R9SX1^]$.HJ+X/?O+D0"W M;5U/YG]N7#FXH)"41FL@[B33C)T9INH()"U8)6:>K#9I'EV8?]\5R"!8`O>E MK&Q"6:[M2JQS+4DJ=VR4;J'L6[5]*K74ES'Q+3+-N+FF4A'I:YW4LV=D[@8Y M$5&CZ+$U`EP*PA@=$[+K,2&.YW$DNXPCL5IP2T,,_+SAWL"N/7._Z'0%+/A$ M@\DC7W&Z*ZN:^JI["GS9O!Y0BG`&KDM#B+1R_NJDA>32DI"4KCWHUH%!`*T- M:.DX)3ECZY\]*1(QII+:N4?7=&>^@MF!,A*S@P<*P^CW0(&08O\V'OMN M4D`_<#\[\ETB.[D=M==6NA^`'F%#4BCMJ,C9N\/4^#W@8M.8H3X("K15HQ#JLJ.DX[>D%SVT8M\RY[W93A:&K4FX%CQ@^ON%:`DS9NEG'V:4VDGA. MK5#1?^=8MFD#R5>X^;%;O$J5>!4GFRL$6\\M+M(61Q%@35(,)IBT3KI\-@^. MX(O4H_H=5=]TQJ4X80>_QO!\GN@U$RFY``L#.F$*A1D%0BLK[HXA]U$J`GYA MF*?R&?6[H>$D)H7(]Y3-A/?4(IEF;&2\X'Z`C1)M+,2E7(5C/($,.E=NZYV*DW-C4A^'4[ M"7D\;9EF9]J).P;-ZWT-UTSGL?SF7G>8T=\Z871\W7[89]Z2"T(SCFXN+SS- MIY&H\!1"KKI25G!.@/Y>L7JN?TM^C&@X##FCNP!SR<0V]^9!EB`@#OP26`J; MDE$I5N8'SBVY(.?RO>-X2"Y[N3ONLG4`U)1OU8RCQ=M1G*3A(@CY-2.'HHCY MH47R.;UP^?(I:Q\WQO./8_Y&WD0;#``HD0!)0]=JV<+^<'$]<#YAD$;A:3[ MK/E)5Z-R&N:/8,TQX5-9O%5"O&Y@0RPW\4I@DU#27C'I+S@>=0+#A`/;Z_@[`N_C69F>^?C"H&=@H+&FJQT/NAL%1J94-GC44M:S*%=10VB$C?$J*1/0 M"&L&)4IRH6^8XP\:9419'1?7C?("&/X1@3J)+0"65'B4U6/WJD]21877.+I. M9Q^FVB>G02:-D"8-G000%,Y?=DF"3`8`^ODBQM'3C`[R5/";('F?%W^FYI_3MQL3E/+ M<"(D(R(0,P306-V7YV>&%R0UG^_DE3E5#-X9(V+ND225X]P*_QUW9\5`P)=L MRTWS1-)3%20'GJ?LF=)XQ9:)@EEFEQ#@"4XRGXH=D^],5S0#1UG<<"8LDO4@ MU#0B*(+G=O$]I+'?BXO?BRN_%S:DP6QA(#D3;(RH)/#`PJP48"#%P!2(6QGI M4X;V@J&=K#O0;=DH]]A8/@K9\LB=I)NA&S[F]R++5=Z$%T2HBX61V\).X/(7 M?DR@0?P1?@GMSYSX"[.7NPUSD__LK-@B((4TD(C=B(F63-IU[95*C-$;3R,G MHLY+;_2]W!>N5_:7K:A]%N':.7%>(K81IZ`5:U7R=7!TR%SZV56J,]4I]C\H M.$SD>-`@._#>(DTCJ_MG%"+!E]F+G1VWVQX(!'OT5JO+ERP\[Y;MV.&,&D5W MD02<"V'\B7O_B9L&RA"*;AT9IN\YOZ:]G.BB]D@_P5N)5U-7;WQ.! M=@B;4SE$.\22VZ'>4565O)&`+.6>;JIK:&@D&.M:3ZD^FA3)Z6UI7SO5VZ._ MNHW6^LJ*A5KQPYI,L@NT9W--9C):%6D0`H`PF18\I-7_9;Q:EAPWCF#XNE^! M(QDQLR((/NV;PUZ'+KMA:Q2Z^((!FB2T(,'`8\:CKW=F5C5`SJX4NLRP&_VH MKD=6IC[UXFF=("=^RVM]:C"@/MV,"QY,`-F>DR%W;B.&:=I42&U]U5;R&1T; M;#?!9B,DXLK6&->U-YU3^2%Z+;?M:%69V!:[RM88U1N,U=G=;DH@@]T)&&^N M/8SWI;S0MN>W)\9;_7VVW@<3^=1C[=NM479+U M._;5L7*7^TF!F:LGUI0J9SA7^7^?IF)!TK"(Q5?0?W>XZE\ORKZ4F)>F`CTB M8%)UJLS%U*JO)S^ILQ?J_1_-_-IO@R-M^/3TK7"M1*TC/N*T#Z(/"?GT/MD9XS+-H]S M2_JHF\2HK'W7X&2Q&9M?!-5EXC^"X7F5)WD;$HA&R$?-XT7AL;)%+Z'KJZ/` M6T(4R+Y>W/AD.0K1Q_J7"A%;"XJN M`:GGO-PH=1QQ18ANXX>KR2VC;!=\[>DSL#FJ3]'SLW%$7](655Y7O^6*J['W M-;6"U$*1?3(:?>@>DE=Z5"$@)K#<&6PGUP#J39:^BW$ZIFCJ'*]O_HIFF8)'>PAN MK(6==)P:+YM[M-F-A0.VFUL!,270[EMS655XMD,1*ZQM!L>NH^KWE"C^$I[[ MV0A:RSO0&I,GW4DEI5*1;>7+ZX[:P!?C42A9__)<5]V)5"D6@9M_#Q(WF>71 M0R8X_]Z*YS#%+1'@_$.;=[TA,F4DG`5:``3QG[8U.>?M5RS",_I$@,`NE[*I M4!\*^#**E_[0N'(!^)(,95C3&,F%(+4L0V4L5FOS^N.]R2LOAI/='HRFG'/+ MU;ZIY6Z:19\>I=@LBY_LPS1OL[7 M4D#H[IWE*-!JF=T4U&(WYJB7U`"\3UZ;MBY?JQ)XG[?]);0D%RM%R-PQ$.WH M`F!$$$Z)O[:-W[/[N-_N]C=1F1IDY@T2G3DV_JV)2F)*[/\;[_];[__;F4_W MXM=JTH:H6JN$\86PV69IN:UK.^,+&Z56%JG)8P;QPNJ^.7ST2H-,A"0C/-Y/,`Q, MC9^=!7`W.%'E,2"R>5W#[$./&`,_ MU>Z?:US8),USG[-#Z1'L%7DWYJ??^:YC?I-,2YJ&1K)5`+;T>K,SO^[,F@MLNF-DC7TZI-O%M:3#[LDG$-[1`W&"7N?CR[: MFU1G`W-KM&U_][4'&U&*I#.0DO@-9_9)#`#RA59DD>)Q/0F.#XLP]%7DB>I2 MID-"7%Z<0,R?3BBZ(M3U4,=Y#RBNWM_5@3RS?-_`D*]]@$D>LHN@OG2&G:DV MH:3B9SIB/7.8:(3>116CKJ5P&LUY[,`C)Y+NC!B94EU,*!X](MAW>O5?;[[# M;L%CXQ%ZG-AZ4(H+9_=B!*R`%W&5_:Q^P>UX"UV(YH?/;XFYBC'B4<>=+P7/A-\;T?YNO!4IMQ"8+DKP"/(C`8#,OBU M1&:J<*ZGSV/+FE95^FZ_'[0JR6V$]-WZZ4;HC!EM.I^F$/ M:&=%=[R9:'VVV5?3*CK7#OC=RVX"=4-ZWK',]A2&\YBWEF1-5=*)I[;J*Z," MEH>0)N':C5-JAK!YL=W^4=.E-BDA:MKF:T"=_A(20YAX,<9T]C*GWT(4=&\/47FL7;`)S^;2 M.=)J:]'WH:/.6YO.$TVB1-;R:=95&Q[DQ!2Z$0M.R+^8R0 MR>H8[`@\A[W)5C<\;^V;$OMB)A0GFV2MB9M3PMG@R$'F)P@6D(BYG=Y"XKU9 M,9)D/(?W5N'#8%N0<<^^U,Y]46D%)Y_KQ2+)`4:D6'D9SEBR\CL)4>O9]ZMZ M.9*ZA4L9=)<-"JR3F.W9,_82&7O8L[)8DBSUC6QI;9W9\*J^[1_J4I(SSI*O M'9HVL?6%$*<*O,O(5W6H"O9F?0XY6O.<3)8+2OFFYT3P_0/>OI\]_VH]HG#` MZQ.[6S61SGST8DVU3=+E(KD.E'@Z0^]@'UKD!K/"?&SNY1D/7(;'@N2V MH0A$T2*T9+B6IM_-F9M6L(\YTX.PA)&S#W.6B6-EK0$?"A?W;XE/1S50N,7. M_\^@C*&4^/$\31IA"49=H1H*,?M^40/C$U)_ M0NE2JY)973&7>'U!@P!5,C"%`^F]H;;FME*X4*;)H=4;$)*S-YRE@H=$KEIB MM04_'`YPT<.D9F73O5I(L[%5:'\7IH!IHI5`?%&_6*FJ\J1MGH>N1VEX*K"U M#6V!%G%PGISY;(\<=0.KO$Y$S3)4@9R$;-OO;YSD;?C5.N-*B?>X5>:M#.2F M`3(/%+"TOBD:OD(6:,'1FF>?D[K'WI]N;F_Z5IQU4Z]S.4C&558E15KL'%L> M\SXY]V-RIM&5:(=(\'/^9LW5:JVYWFHK;SV/]\FQ\B.^0.C"Q97CS"68;.PT M1G]1"TBN9`=;E3'1*?%1):P[R^WC6F8FD^K9%XU;"S\[N4)4V$^%C`'SI4F\ MWR=:(O*2S4Y@,U_,_+M_B%R.,][HP)%$9ME]#3^M=%%:"BR)VMJ:$OKL*Y5.`&P="> M\R(,?57D7E,B[,^5%3G8Z1:D?H(3A[8F$NW4"Z71;J@'LFV85#26U^=K?O&& M!B<26?XM.]I(Y MFQO^^?3AWQ_^/P"F'OBS"F5N9'-T>^O?3NU]L5[GV:C^,W3BUO7536YNI-4]_VC^]V^\+ M$YO]X:F,RMQL\,#N/DYLB8 M#^$Z3J-M,(99E`5]N-Y%._QD41K8J6ZKSG1M;8?9S@8[D^!4A?_<__4I+J(\ M3NY/4+[5T8AN5P9D31CE**982U!'QRJ(B0,2QTYPGUEP$8W.IW;PR=B:)P=DBHR2F M"+KNQ=Q$3Q&XDZG9H#+HS[J!="=!:U72+-';<-BR.%ZJ;,E[HGEW)Y7@C']" M*9RG\3RUUND*:M"Q\AS1R:#(3OKE;"\.#7*TPZ)Z92@5'&0^:^87\AJG9B>; MJ')3_)_-E\!&QVAE\*7G8U)?\Y?0C!/%&&6TR"X#A+9KN26NMG;CA):0*F'? M8H,JS,K,.YONR%GYIMZ^_R5$DP8_O/\84JV9&WX*JA(V#_6((I84A=194TCQ M/H:42=TTX$.!E)-K7]$8E9ZJC(BT?*3C[WKDE9+)4O)8^/E12>5"5)*LB`[J M.?Y]CU2P/)%JXK*,T68_0VR)=LDXR'Z/G*GEY5SI$?N;K2^L@=^O84*F&E%W M.,AJ;;TO,%(.RH::C1//FL?*DH:D`&?Q$FNJ-HHU#G'.DMS\&,:)=&/"K4DF M-B&5TPPGMOI,RG)$:[U=-MDPIC1]$E&3M?*P,A^J/J0.?&:W=Y"PIA:45-F5 M^:D2R?)?%=FR//Y-'H7UH1'1MXNI#,-U'BD`6+>9)M-1)&&-O,/X&Q([K'O.TZ\1#5CC[?_[0.JF(HU91_2X-F023$!')6V M')-/II(WK88HWFQEZ"4T]*C'M[M"YHT4Q7:9@Y^#V^T65=+=$R%A%K3ZVE#R MMT$DJ_78J^_W>0J7"C@LDXQD8C/&*D9S+J-YG6"18T&@C'H;FK:IPIBV.JOX>B<$&U97),N`77!6 M5"$=]66:,`*`Y#J:@;,'H)GI2"40MY%9G8%+;++[K,:SEY6+,#*H%H/(E%9G M]7B9Z($Z0$;0N1?@C)%>9-V<6]&01_FFB$7#9T!XQ]A.>8YQ=D#[5%UG>,0D M`<^J&%!Y:NL30\/<5_Y$A\8M@W6O>SN@3&<5DU/4:U%LWP"%GSO-=#G.1J?/ M%K7%C4[3&:)CFKD0S44JGS<,6#0B#`_YDHLVNV_A&4]==00V_D1K._]I>#'C M`;IP?@(CJ?T)DD(E3!$[7(::R4JADQS]2*=D*#&EP&2;+S4/](Q9`@RN!*UF MJB'@+-MWG)A($901/7"GE6G:P\%2]EOO4"O*QV$EX=K_89EBGM@HCM+\,XX& M;LX>Q\$,-\X\4\M`;4:*5Z;G@9T#5S81C3!>9^N#=N[QG70FS%I*)3\(FWLQ M#[(;P^0#VRXAFN+:7OECMV(&$,-S]B`/_@66T.DS!87SXT[3>#DJ'SIQR)7= M`-YKY4)V)GZJL25U)4]4QN]!)79*-]KAZ#M-^SO#7(K+]`$!A%U[&-"&7/M] M=]AR&I=R;)L4FX@W*B MD\KSS"M6FOPN*SU[.2=9N0D/TM67F6.0(#!)OGU`AMV"#.H+"+NM?]_1)Q$HX/4<0FG MEL[..Y[# M(@>-ESC7V@M7+&#>HJB6DJ>!+LFGEM`.:<,D^$H;Z`&;.5YS+YT@;8/F`.P1 MX/%'H)XBFI+T$W<3GZ"`)L'O,/*W@Z*E"Q=A!?B^4Y0],=_$A?*\0@"4#%XZY!'K6_C[`TY_3;\ M<]W2]*/JM;^=[>0+$\#S1]S^)HJ_K%QXU$^*QY;?UL_+G"5L0+50LR'F`!B@ M61Q+!V0,-%S32;3-\_AQ2$1+-3>F/@GJV'Y>NG%J8_ M6DJ0!"!T%I[BM[T^,RYCS/CCDD[;>W5S2+=!-[VL?-FKR:_ITK<0OQ"5'X`NM*2ING.B]_P M7:T\X$X>IV_CM;1IHFUZ:XEDV(F(-F>E).A8&0'04FD/J)-.1:',H-#*$TLD M$5XV;[%FT;BT8J*MN#\1L9]F9PX*-U(,=V=84ZW+2J1T)M4K?*[(4QX M-)_'B?$^4])S&+MV7(C-R?8/W"=A6ID(J68I\G84;KE(;7RQJ]UOAN&=G/EK MPCC4&HA.?R%2PJB-=2\-I9V6KQ4.L.R+#]?`A_O4M^#$+(21TJ+BG7"[$5,, MUYY:?D$,B$:EC.VI7%S)S;K%`/MJ*6%$=O\^\*!MA;Y1.@M"JT].Z=2?`2'N M-,I%919(N%<%A\;;^[_J^GOE`Q3C^YK''L3"Z![/QI>%9QH%&1$8-YKQV>DR M'!):M.6ALM!^P2UK$GDU-9$Y+46R]SMPP@U%K=7!<82VT5>GO\#S?AQFONKP M.J.(KWD8D1!A?'QMG>*-%VSLM6WL4%N:4/9P6%36_R&\2K;;-H+@75^!(^8] MD<9.(#?;DA4?(BLV<],%)D$)#K<`(!7F,_+%Z:J>`4B*<@Y\Q`"SUE1W5QT& MYF&;I_5JJ.TN\9F4!;PM%U4G*?J%9D??"DZ&1]_N&E*?]@\E>R>]RJ;3;A0! MHC#:9S9KEM*M]0DM"[]*O(+ZC#.O3$I#:TM8$1='-?\U!7[(-3,>M\_#[2+, M7`F;53MG=R%<(P@*&?.]MA3O*E3"":L?_Z`#XN-0<]&WVCJZD0QU96G4>H]^ M-7X:7SLZ#=6,NS]E<=CGRM#FRA=@*2@MYY:K+W)_/8JIH@C=L;`=/?W?\3#N M^(V^G*ONLN6"X^1O[J9I6 M9PC=NJKD(">OXEO9S+;-XC(=94TC/N#U(_ MX>QL:!I4FFHJ8D8$Y=SI<_=%DV.!S*`C@%[N=RWN%I\E]I]5M".#X:'N^K2E MG.#-"Y^UUR\*\KOI-/,$XL55#/F1LF[G8>%`CRE"1DYE`?6' MQJ@:!L+,R+^RA"6U*_&QRZ$TJ@;J3JN=]%#D2]J]FY1(M MS_:#>H)*A5,3`7*V25V9FPRC<"P8_62;21(R,U_8*K;F@Z6[UDQ_'*\@@WH8 M\G%RAH-0(U=JG-U`,!D7A0`8B#N(BW-84J`2CXM)[$SE@T'BB.)T$ANJ20D3 MI,NIQ,+$__)5\D21!*"(0=6:5<@+J7WXV,SOUCTITG M3_F>!TZW2/)]F-[>C^:55#HQ6(9JS3,3Z>-W.\WR*V8>F_K:1W-9QB;9<.59 M?SH$:!0G:8C386.CN)AD_K=F)H]9&F3^AXW)F:ER!CV2+3'(;*,S-$GQN M:20K_;OV+HW?EO5:7,HH2>+$UTTT*J5&G^_I7V^(\N5D&EN8)D7J8/KU0&3$ M=X*F@&-6K0PD+Y[+4T3ZB9)H@"0Z@B3UHR@M$D`B-7P$^YD2&BEX_JWV^"+M M-,\F_ONU@=:K5LPLMR"E&W(;=:;#WV MM9\WK[FL]JYT#M>`C0AY]#3+;*#J3*Z+%UU`N/==]F"JA[ZR;-[=$MB8`ND4 MVD=_ZLTJ\:CU"B9#>NQ,H(HLIX^"4A1OT5@CM3T\&D.7H$ADH7]3[84:*M=C MN!38BG7WQAVDPQVDPQT@S/-4N'PIR+_(Z17^G%1%H9.4L@4=F<3\C7X45&VW M:^_!1KXHHIGC#0 MVB8<$?EQY'R38MBR+2$UR\):)]UK:[]Q,]DB*?L-BR-K=R$Q>G9[\U>[B%0X M#3:F]P"1]0!B-??6=!K4B:XYWT`L=3R/ACGB>)!N[C);\K*C`MS-:R;\RL#: MZA?JR-V:^7%>-2_,>>6!^5/@I,C=,-G*G>@0G>2)771@J?.+(!5GM"*OMSIH MYWP4YX=0G=!J]*XSS$5EGE7TP7?:;#A;UFM(*:4%=/*&]6Z[HN&"(?`[4=RW M?YJX5HD')VD+5U51VPD!`&.9=5.7=@V.5/ MP;@03S.-"PV+K:*!%SLN:0DG5SSIZ5?:4'IBV>CK11B=Q.'%[,^P=V,JJ^-T MMGFUM%/U+%_HET:[\?)#7T/:AJ,N(04SH6[FNC;.C2M#-6@?V@/J@'_>'C[F M1CWOO2UVNO'&^]],0Z\U@*4?]=FN5I'S6?]1\5L?IY=:-Z_OKG4K%_57T+,Z MLJS>-I0F-M:TNU5N84B"4`[`MQ&:@7,#FH_F)(;7MM8E[";+-N M^]%=JQ>]62C'0RT#`\>3GN.92QE@*LHL[2H$9BMBYB^-Y[J1!;\?-+(R1!;C MX(_QM['W:;/!3@KUJP5X,?=NFMV3YYS.[U?_#0`UPBOT"F5N9'-T7!E("]086=E(`TO4&%R96YT(#,V,2`P M(%(@#2]297-O=7)C97,@,3$@,"!2(`TO0V]N=&5N=',@,3(@,"!2(`TO5&AU M;6(@,C,T(#`@4B`-+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R;W!" M;W@@6R`P(#`@-C$R(#'1'4W1A=&4@/#P@+T=3,R`S.#,@,"!2(#X^(`T^/B`-96YD;V)J#3$R(#`@ M;V)J#3P\("],96YG=&@@-38U,R`O1FEL=&5R("]&;&%T941E8V]D92`^/B`- MBZ:FXO[MNA&\;VY.:Q MKGHJ3&B>]@_EMLS,#O_X1[P+MUEAXF);%.;I]+`SAX>OWO\[ M-H<)OY]J^N_EP<;!TZ\/FRC>[K)=9+)B&R9)9I[>/>RVN]VNX(7X%46T^F?[ M=7-J^S;8E-O"3G,0;Q,[5O*WQ?^1'8)-OBUM'R3X>#3#:/X1;(IM;M]A.K1? MTU"P"6/L-X-L/+K1C.[`OQ<\%-.[;8:3$FP8KQB/K:D674SG%Q9N\.M:-YG@ M/T__?(B2;0E+X0"8OR&KP\C;GZC]^V"3TO8@HK--V]?=@G,B>DX[T+O(]A"V M&[PR##'>8RT^JV"3W;Z^_]<[0_LLOR:5U^A#\`99._/)F;_M:O3VMEO//O`C M9!7;/PS-K`BC==0Q&LHB#]3>#B!P]WDS.2'EB8HV<\4>8YM:-EQI6W$ M]>DVS,M07,_FLN=_M@[O^MS6`QL7PA,4^`,AHK17=LNC.1\KF84K:>3$[L,- M`Y\-"^*HR._.3E979.**3@ZD^-G#]9%B56R]H8U!PO"+2_L\Z-*6[Y[D7O)# M:=7]<;I-=WG![D_"\(]389K9H:;VD&^6>G:-6=AIA:9``TS,"EH$:1E'U\_F M?9`"R[IQ:,R'ZGE`'@U!ABUCL,/D5?#U<633,UO/;>TFSJCZ_8>/CT`:%B28 M^;2TZ^\33N?[$XM0?]NU/=V16L5$!E=%F).W[@1C4?G'GFWC(G/IQF-X5=8'YI]SI4S\O8]@<"&"$4EH4WB(8P)\3BS6'4 M[\8934>E$/=S/>S;-[*IS$?CWQ1)&]$=&K;H>>=$3`WNDLK9D;V)2#PFN=!9YG30`.R'\3XWD_`UH;*#"G&0PA.`H)=0668ZRS@?>O'*@0!'O&3J M&YJ+VZZVT6&J$"`H+D-G/]8*F="3)_/2^M]'T_BK'+TN\:9,<%:(4//GS:7U MP-1X\^R&_AS`!Z^=S:00%O@F5@`Z9\WKF#PS'_7WS/SB+V'_$KZ`A5:J::3G M(;U\4=W])=PH#"W89Z)8V+V;KZ;AGXPH"1>S'R#2J_9`)>?A#D,-6Y^Q(R/+ M#P/&R-)^4J6PET-\2/ZWNG8MH=DNT\SUYL5B'5PEG,DPX5@9!S5!%4;_M#SJ MU]17V"14"JS.$UUZ9MT%Z$]$/).#%/A)D7T$AJM5$S#B6":D- MW>\8G[Q3DRX34&/@AE((17/1=6,[2.9F)+.N9[<&A#R'@#QW@VC4@;6F7G2S MO'8C"N_]<9/QUD@>'4;G)L7$[Q&W4?Y5*:INVXL(,\?E)+C/67E"ZW9N^4V5 MUU!?9R==/K5A70NL0(O1` M\GUJZ^.C0A`N*O/B3D!'J]5IN+).SN*&H-N(JA)W7G1*_$-^QC#)X"G8H9CL M11-SA&G9JH$/_7JF.'`V7[RD'_H-^XFU@9YQT,"N9\P>OOJ6UWF?K(T/"DS+ M17<*Z'074%&H]$/^;.4H-%B9-%B(*0(0QX4_+HY%Y7Y;$4:";(T^]J#WN-M4 MA.67*[)]0L%_UTZNFMS?J!>[]7,0HGD1WTIYN*JS4-69,7(SDH>E[I&%+$C, M$><"1U4C`C!$P:<%A&G6U`!MG$1_IJE!$"3:&E?-1^*260'D[_C)C\^)&6C::'5O=SPP5PQU'771QYMFY7JDVMJ_7<=GP M0HWM_*O*28KUK-W%-)N]>P%H?+M!"@TG+LS0*2G<:=8IE$QH,]^M')GFG3G1 MPD*9F+1ZI\M'B>=S-;4BDU`O%#N3EPO:./8,T6F_XM%WE'=H8P3*0@K8Y'2) M]J#U>KBL.?"52K88=%#-7Q9J4;IV`:DGFCUZ!X=$GODB).P^R.05:@ MA;EO8O&\U$HG>ZR`#8A95W6DG7CFR(&HF,JI8%";(*<3>6>A5@M(E#N+0!RS MQ)-4^9K6QVI\]OIV$^=([3AY6R9W:Q,5*Q%1-\;>IB-.BRC\TL>RM`,$EJ`^ M9VNUNI5B]$`A`H)UDNR\AJ0"DG1@[0)J%5>,BKHJ6J1N9'5!61N8I4=23;Z50S) MPB]KN2CVGA9T-;4=X*2CRJ:"88LNX^C\]>N=U]>X78$;KL`-%;@KNEZH%4RU MSI^J7QEL,H:(=RB;K+\F;L=H="]]@6R8EEIZ0FTAB:`2>U%AYS@QF,/$*LAV^36W^]8UQ(A!*ED6ZEE,;R'AF1H) MN:."V%U&/4-Z7?W`NX6N.DX!\3))/TG565]3R?+FE>"+RAN4UTH?1\H$>`D7 M&ZBE=O*A&GII9B"=G!%1"C2`H36V]'"J,N-&IG1Q+<-S>]&!F4N&)1DX7-;5 M[O,9VG[2.<_N$4@M+^ZI(5^CKS6(V"E&SYL(VG.F301<^89HT$$CD+"(V+U4 M`WM`H,(SZHHJF!GZ6JHP&J<#G\?45[*GPW47U'4E(XV1:X]\K;ORAR](:O-; MW"9O26UT]&0G()K-;^YJYFH\N)EREAJNO<52B6KF=3,S0/0)"QA+G]4 M)&B/7B3/F].G&Q2EN3.5C2T21`-H=)_^&@WJ9%QQ)L9;DX.H;2#BSWZ*-NFM M#=/Y5M2YR4?5_5VH]L/8W?>;O$@3G!T%YRB"4U,^`28LPBJG^R];5O`R:Q$L M/TAX%IE1J2:SJ(9:G^ZZL:V(!(+H*34DQ6M9KJ)TJ0ZYM5$ITF@C$C3GC;1D M#-G#HE+3?.&&]._HDV0-TMKIRY;SJJO>^>0L(-R09HI[=V9Q"KJ8:9@;3;E: MT!4'KOQ[ZT9XD`>66DZSM=-!#ZJA:!D64A*XUOO?Q$H+(B MEC<4>-D7JU;E]R>+8%J0^7-CZP2.VKY98!_5/VE()=9J,33X(?V MZIB5R%@QD/6UT>5M\T>X'S1V_9A3[WJZ05H(IN&4_ZM:?+#[-G8]R^KK$YVM*I+J= MJ7UEILI_8'.XSQ(-2@NT90L4DH@>**K6H1+>P$%+AT-VN2YU#/F_"I'BL(1(;DP.:90P1Z%! M[B;''NA8>5`GJL=QO/+A[LLE9O3##QMS^Q>GHYXW4XT38PI"L2F7N_G",925 M=J.4K^9+&Y[Y]G3>W,37#O3`#=_1J#-(@3J"_`J:]IJQLW=Q`'):GI>)3UQ' M.&7IOGW-RBMOK_2W:$!M;]@CQ=';8^R4(=+,B+C*2\&DZ>+K4&GE%.FQG[AI M(8XH5J1_L=D6D<91=I)/D+,8QSN%:G=4$*Q]O5L>YG];=4]1U/^A[J MP,C-KL[`H&?>`0B'WVZ#FZW4MG_Y.S2)Z&G([/G+\@Y57:5@_>&0&KM/LW=V M"^0(Z\GQTNI1??/UKW^Y><1:HJ?E@`!?]RVPQN!H=^Z`>_C5B3&`HB[<_+.O MK1#$]FIF7$]PR[HWW"'\P92Q9OLP;)E=5CZ)7VY:A'IH$,:E:3 MU)7>!??M)^)0?[@ZW4<*]RW$_`636201P+$R\^XLJXVIZ;`UGXEL^:V#(#TR M2((N$;3X?EAN#J.V'&E)W-L(!-V(#LJ+M_6DGO)5T4G)N&T\?5=0@G@Y_'E2 M*@NUMB]TD[--=AM);Z#I[S.,;E]ZEJTI:C>TOIX-,5O-(>ES>V)DXSIEDH&, MVBNBZD/=2EK#Z;U-:%IO7:A]2QY7[).\X5K9)G7S*=V5__;:+?)62:W M+"-P76:S]2&N>@:6ZWBVU#,S+IJANVF3?3ZD56PTIJ7`@_=V>S+K@3MZ2<;$ MO]M5<:$3[K/H9;_'Z5,;& M0D6Q]O9+N:ATF0J8>]?"0A4#+450>V"XO&;::.Y((()M<5"U>$4HD)UL4D^& M)'2@3H.=Y7)V6N1RIAXT+_VL='/[+\?78[[>W!(*.PN%R=M.]K(3%6`)VS&U ML2Q@`N9)SQI9]I!Q=7G;#A?/=T)K0^H0<.W%]OB88(N.88C+O[5#*CK,-;H" MN-#:?8QZJQ=[C.=/^W6U8`MZ41V]+]=\'YO2OO3/+H? M6!PNEY&U:*CJ\R._@]1`G-_MM!9\_X]V!I+@QRQ5;;G,DQM4GH"2V>C\;Q>H M;N#%*!R(YDFY&N8:+3@HQWX*)R%.UXSS:4KJ<:1Z0/1'?U(W MT:\YL\LSS)^G8$.JYS:OU5[WB+U=DBES_1'E7G-CLUN`V\[_P'*W9BDWX![@ MS:D.GM8!3&&*Q@>0UA%=1W^J3M;*"D!A3RC%DS8^D/,8GNN*.2H'5;U#%);' M59>;+S&>6P)JI#2>L6IL)W(M(!8EE23`2S"!O!ZK3K+^JXF/U-*]:.R@/#Y% M-$`?L@OF*Q^,G#7*P MR!![VI'A`MA=[&V@TO=>=_3D?O@WGO?9=K1,[$X%GW^*;_S+Q.'A>(3+251-'N M!HDD'$^17?K")*^'3$LZ8L$_N>ZK2=9/$K+[[&=&U5-*P8,U=.[2VO,5NSQD M1A(8^(;N1A7_0'00SI`S2!E.EPAU8!&6`H2^<8IC4CD>606\E*:5NZ8U1,YI M]-.D+5#`+G;)4L\'9Z<4&4"/FJ2W98?J71).;JE9`Y,65`WF8W)=88)>#XJ[ M!X:NJ%;+7D.X.'%^/RL(H.1Y^Q1@/U]BI:GTS>NH?HV:$F=F(V1^L(E2&W,T MG?J=^^=BQZ;&4#NSUC-'&M4ND=I7"B.CZ:Q29I/,MIOB;!P4;&1B%2Q9_^TC M,VB/G57>@?6JGTR8TSEMLJUJ<]*6XOE^V+$H/CJM^_J3A=_/O)+O(VQ^ZQ3L M0JH140`TBW.GDCYL")+",*I[GQOI30!K$KDB?6>5NC!IN#C__N[KZ,+D(*$J MFZ*'-.-O^JDC^GYF#!ZE[C8JTTCKHMRN2N02.EOK9J7>\:8%&7'3"X>A;W2? MP2[N#!51.6E\ZZ7,X\MNCI7\?!_&;FEA39!MX14*+NEN'I+MB\3.LN@T7Y@) MNTS^\XB:1`?&\UX\YWLTF-RH0OQ!,VN???;.K$V,.O?OK__X45RJ/40AQYI2 MLYMP/7\Y%NH7LB(3#\(EP0#SAH-[85UMFV2T#=%:!A0/<1P6LE;R1YG(HG_! MUM'B6OVTB2GM%U#F\@^<]KK)JN^->92:7!O,)^Z[;N9&;E>!!`5:RU0YSDBM]-(@-M=FL[]NY]'-0,,(N$)6[9/;G/S8'^ M*=E'_F\@0Y+!30.(W0H0(8A)"LFEP"H!ZI<\34C%8P*N^2'M$[##@$4*L/C0 M]?1S`;>?%,"M9[`"B*L*(,43Q#'83(.F3-<0KD`N`%[]`T`*96YD"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TQ M-"`P(&]B:@T\/"`-+U!R;V-3970@6R`O4$1&("]497AT(%T@#2]&;VYT(#P\ M("]45#8@,3DS(#`@4B`O5%0X(#$Y-"`P(%(@+U14,3`@,3DV(#`@4B`O5%0Q M,B`Q.3<@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S,@,S@S(#`@4B`^/B`- M/CX@#65N9&]B:@TQ-2`P(&]B:@T\/"`O3&5N9W1H(#4S,#<@+T9I;'1E=7\"@!:;>URWWK MZ@)FP30&Z,E;80ZR3-OLDB672-O('YGOG1<+95=VH5&%M$21P5C?B_CV\M/O M=NB"N]E?IV&:W=F&V?5F=N;ET]O+3V]OKWGO[<7Y(R??N#9-0B8Y47ZTV]R4W=KK.Z;K,IMG1D18^;+1W\DGQ*FW6;3&FUWB:C-;_9T'G\M]ZD_WW[)\G,F``!EQF[ M2NQRYS1K89$*P'*.GW<3KMBPP>-YFDW@YQ+&E^M"!/BO5B4,-JC\T:B4$?M* M:,8;KSMLA#\2;[_1YRJY6NC&3ENQP:599>N\*LCJ+\G>^C!?^^`@M<5U8[J! MW\G*75RQQGFY"^8<9OL-$NE3GH2X/,+6%BKL[Z-@SO M9JA#O,B^BE,V[(XR(W=(!K8Q"XI6LJ"CLV1"3D:F*W*W&:[C MD;7@3]#"_'`;[-SB%_$E+PS!73B0&0)ISN]VP!NN3Z:SGE[3.?C9?!(!$QS2 M4`PHK`F*LV.M<]RQW6XE=T7M)>V+7-1F6VLDB"<=VL1R%&EAMO$)\3B?.224 M4+VN7KV%YTF!.ED6R<:5K$6Y?F*?TW-(*7TMS*8X:[Y%+1\)M]2X(L07ROB= MVW,5(5O"^WH)"^*\+6-M4H`4(K),3O[+I77R-:UQSJ8921[(,[RJ( M7+`2GZD<-\GS?J1IK8^O9L>'%7OX&,N7"/`>$2R7P`'Y=[=V\F+EQ\SZ<(6V M0UKK)L,WCBF`,#%Z`)?B48P%'\3"G5G?>LE=E=0THE;CKY MZN6SZ2C`LL>KV;3>.][5!0I9A6"9.Y>?+(NH$]]I!CVA@LVEDTVBTH?2R6*0 ML@4_)4*'N>O#%0YX-3<[![N;N\&X$8E),$%9"7>\FV[<4QY>6"CRH-D^8?)# MIC+#+%!8P0L"+E4RC:\LQ`[VQOD([''3Z"5D;C2[06%HFO::T"C&WEVU_,Y& M8>D@Y1?L:,)D!G>PJW!B**EE68#/,4KJRY&3@Q->E'^D.UM0+Q:48@&TM(-? M,[F@TGIQ1EB4BIXB"/A`L=!K!EX\1KL?-;($X95@G(^F"B.'?4A%T?[\P*D>)OYZG3EGF2B#>1-R/*&LLR2NSZ#'+.DN MCCYBV?\7XVGGXX# M!VZGOF2&99I#X)8]U98R!+8T5?V4)TA8U%L@^--7RF@':7]U?*KD@E33*?I9#UB(CMR#]R4([, MW=[)?JJ^Y+MOZC/6O_H`,V7]($CM7CM!:\7P(_Z6RB;""@+IO9+)02`?=/VBKNTW"F7M] M@3ZIH$?;R#O\\@!%M]H22I]#3>D>ZMXXOZGO6.4<>=J`.D90D<-67_?O\4,O M97)RJ+H]#2!Z!S(\,#(CT:(,BL2124>JQ`GVFN-/1RPOW^G"8-E]4/G MA88]];[$DD?)/J#])O]+`(37O=!@RV5-8Q^!F!LE]D>!+5!<0!\%EU0RV@1I MS%'C"3<"K'"6G"]#M(6'0.;6!B'+=313'%#%/C9A2_YF5>38D0&E)Y(#!&!4 MN5QL-WO@,(,8.@HT(;()Y7F=]?DH9I"6T,J.$98V5+#FQPRH/3N74KZ$K5)H M_?=U-K]0_)/+1;OPKC]])#L0/MCNX?&B7;!MTT:VX\S^G1L9BW8,YD'!AA4D MEVG?74FO3C`X`\#I.ZP],[I,*7.];)-3,X];G;RH`"-O)<6K M2G7J";5'+M(7R27U^,=!;<'90BGE;/?2_B"-<;J322+PS?&3V:&J?+!:YA,J M2[;YH*'PYG\8L@1F"#%+ZCYZ.PR>HT9@VR2721A^]"[N'="RT!WDUMZN*I5K=+,6@&T@W3?`G<%%'-LJP(@&CN0(7F'Z,Y8'1Y-;(-H(&J M8>('+%QXI_REM80K29LL$@7;2IT^J=?NAPG%K36K"GX8$7XPY+#3>(PA'?W) M7<`?08GHSDSR@/8Z\3K@A#23F;361]?+P",=MCCY`^9KL#C+",W+9%CH@AJ[ M7Q^LHQ)2#J/1@.*2LTQ2.)E2*\X'2LX+`ENZ0-*@8L*7P<]S&R@36J_$@J_V M^^&2?;2D801_ZV+L03-V)5/;3$D/OR.^2MG@AJ/1X:V7D@CNYA9?$7^_ISD& MVOO)L>E$Y=0U&LRM_$[T0BTF.C-TF2K+LY665%"**,KVN4%96LI<\4J4C#R. M0>)F^1E4<9RG>PPL91KGN(2P#Q/GUN/C4V1I$CH960BS["<;T3P]AWPA"U;Q M0^(UBY[J6DD0!$8NK9DP/>FPBQ%Y9<[>W%QO.C'$=2 MQ`PHJ>_^JS8RPJ#6-`'B25*QDIZ2T-V&1VW_"40S/A2\44F4F96,LF"!/JX^ M"OVD2S?[2`/6\ZFVR&?EXCW%^0&MW)7SH$-'?4/;_C%?+'#QD(8_ MXN]U568U"$HS&WN1V.A7=3VR,J=1X&:09!RKDSY1JTN+Q_V/[2S0^6VRRY:^ MFJ.7&:.2'NE/+?6K#S4L!UPZ^V?@JQX8I7E/@#=(ZQ]Z`JXO9)0-B;.;B-0!7 M>```CM=9)=R!_PWW[0"%__^HM\>Z;L\A(@ MCU8A4<,9)V,":S"!-&+`<+U8)(U:8[5#K-2H5!:>H2_[;L)X`[_+UW?SPNFM M0Q;G?1LN'1I^??/U#-W;9+N`[@\2K'9M%U156UOTKVCN*`M)Q-'L/0,4!"%? MI%<$??EYDRU:PZW56R\36KB1YSUJRQ^E[)2)"_VO'8X>@F#,GU;K]9^FI^^K M8JQ-EVVU)_C#--KHH$"=*X,*P-ZA^]]P7?]MJ?JD8(6S#.[`KBYGA4-5!4K[ MZS1&8;*.T4P%:&-%6P;@TF\>F:S M$.&6U*ZI[(/X&9)WLE`VG?:/L-I:Z!HQR**?-8IL=Y,2QK6^_!/PGF:K=1(K M,P%!SD&0]3F./QJ\#B1>_,B.0$'%&>7E:YM0*HYN#(NF>$77E_UTH@88(4// MH/)[#@3;<`)'E?&I%DOXC6=?(2WH;6G/M/7`?U`2Z6W:HEN;PHQ`D MB574H9(`YA:7-+K4&/!3`6B0E^*>4KVH&.KXX8R!P&4Q MFCFZYW4?1H]KU`U()_=Q<(3_!$KC'+22CTB0%#I?$/QHB/9Q9-=M+7\_88=S MR,<5\]'%2H^QCXL<;31;3A!^_%1?,7!<=P$UJ`KNI8%+%[Q[N1G5\\!J^?Q6 M:6JXZLY1=W8!'U^P*.S;\K6?YQ=6',QW2WNFQ_%R:37?EO[X@0[X`7[N`QUY M-&'G2?1>]:Z,P5QTO/->8$T8EFQ:*7N[5`JZ@IIEU72$P'8`FTZ4<(RQ-A0F M"G;`IK\]/R>?G5AR_)1NGCYG>7+#]]4-8!(#&,UJS1@PF%>.7KMPTM8.6I"B M>_Z8&G\48C657AAM@8:I:E-505L2$!/@C>:4F"NT1DFON(2Z*HGZ0BA:Z":I M--3U>O6NEK+LAHW9[%VUNE2VH:'M>_X_V/"&&0?#I7VQ%U=:R:V!@@G3;8YXB9NB[ZTE:-W\?/OR-; MTN6.;3+OF)E2@DW/0AU_]1*SH?J[;;7T$!&PV=YQYIFS9RO+#_?O"EI`*ZON MNO`[<-$4E',;#0\*\#8[%?,>3X:EN@?,!8IQLV`N-V--U`HQC#-X$.QJF2[@1I$H)F^" MLL'BLOIKR'KI?;/OO1P-2.5[<^H;HKTOV^KJ9O,QO0]#@2O?3$:!:N"H0.UP MV][LVTF((5BXUI%4!7+MOU$A[S)1(&L3[5T2+.%[J@U*36[U\PH4-M<`:#P? MA.U`,IW!IZM6A&M55N6#@B$2BO68(Q@\V:T9@?U\=.4ESJ@>WO(]A&./<+)/J M-2Z@W<63Z+4X21?-WQ=/7U[F]-M.V*Y$0:)+7BK[JOZ=Q3T*(`WOD8#&N3V1 M"_FW)+L&?JV-_LZF[T62T+2?B-"/^-B!&T#6HA"@.VIM`UJ:EUE)O&JQ#M/1 M*,!14T?"5GA5>JAHS;KK23(,1"%':3QN@6@"9D1129(.Z$0O$W*8[-)@=DGV M9Y+3U)867";^&?U@")!&4Z6H\>V(.K)U@KJ[J)O:H%*/#BBZ`VU3LBVFVE+0 MHFVXP-=!'M;`)RL+,_!6%O1H/GLTOP$B'^:MZ`=KUAT!MW.U_9(6`%<)+AQ9 M0E5H/`>M\%UDT\6+:ZKB;*,V3L$*[/1&0,7(CF\(2E-M2X$M-GF6;1O)R&6? M&\,I71O<1$/<5RZYJ#"1SVYQ-[)P19Y\?W035DUV3+!?L*MR\]G]W%[OTO0& MNC/-2XSF*;J1EE":/2IRLHDKNM625)L(.="R:O=EZ4??!8T%+!!4T#>")*)> M!GW^%OQF1:^9OW9XTQIO.O5VRALY]7+6=8&:03X,[+/*CW=1U=S2@.*((C>< M>S#?=<;&\%7!((M"*^CGJS5YUA2%A7UKU-WPJ\+_!QTX0W4QX[`5"`9FCX0KV_S%A@X)NIJ#KC;>-ROJEJA7JX>`'0C'LGV$M MW"\\S[63&=<<%'Z//P/).?LRRS[+UVQ!(;/(H@L;%RPQ!>H7OB^FP##-@#&6 M`I4Z:YE!'6K&A46=!$+8XDDL*\*#)=HNF!^>P^(?P]UO9WO/QQR\3\'4E!^Z2"9' MV[]*JV'VL#;5?))'M M4_$WU9*XO@WS@@+5GC>75WNZ"*&BKPR\Q%D:7\DJ2Z`L))`E@M&O;N9F25#&B3#JV3[-)/6NB(E'8Q%;E&!N\!R:=O-JI[D^(_)JR'L MOO+J!)`8:Q.'?%4P4CQ$[@X6*WX<&!+_:(^$K<5M4W0F[X( M`1%S0Q08DY.NVX1UQWDE/XP_J[G-7'.;=S6G32IT)ZNS=*XS1"2]E323FHM_ M4+6K4+6_15P9LCZLO#O=*T>3UV31=TVPA/0FU%#?7[WA"6ORY`I;WESL!TNH MLHH?']RY:FSJ5-N/0ZSO^BTVT[V5U4N`B;=0CBX4+XO[A]5&?F=\J8WE$0WX MH"=5304FL._K\Z=_??K_`&C%<3@*96YD"!;(#`@,"`V,3(@ M-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TQ-R`P(&]B:@T\/"`-+U!R M;V-3970@6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]45#8@,3DS(#`@4B`O M5%0X(#$Y-"`P(%(@+U14,3`@,3DV(#`@4B`O5%0Q,B`Q.3<@,"!2(#X^(`TO M17AT1U-T871E(#P\("]'4S,@,S@S(#`@4B`^/B`-/CX@#65N9&]B:@TQ."`P M(&]B:@T\/"`O3&5N9W1H(#4V,S4@+T9I;'1ETFLPM6]'4,PG5H_?P0Q!B5YX86,3W^.?CW[A]W2F_7 M49:&4-K?L\G]/7$N]QCSQ54DS_9!;$_XVD#4"W[7N6VZ,EAEZX(T^'3&7+S> MVMY\Q4+5SC4F,FQNNH/1?:83W0K[YH85:Q/FZSA/(E&"=4B\#E$F.AQ"&R)X'-[IN:J_FA:Y,L$YZ M\-H\NMKL^\%,1Y*566=8E564KK.XB`P>%Z7QHE"Q*!2)0M/@2!T[G7"%Z?>& M1UV0JO$3&(I,T?"\J?B';WVYFNHX\!-"VQ&07,>KK=GS;]/.`4RIO%]UMQL#F*]N1C)>1&I'EN?' M(,)N]S5X5L6[R@UBH`U;)B$TBFG"Q32AXK(Z!N0F=^K)X[&=@!J=(LP`E.7Y M:LJ.IVKSGZ;N\9G;"U9#[)]%G9I>F_ M_[8"%K9L$=JX=]4$HT,*:1]EZS3+XAO2$'9>>T5[W5R:>BY;$E+8<6T`:]QA M3=F._'LL1U.:H6\=I`(_BV8,_HSO32QA@G&>68\LOEN1%15>@VC18+,5#6"9 MC-QQ`KP+"X"<\<&>B3&>,(CA](2`ULEH#&C%S!UOK-W`EBS@;UKM&\(:(E2& MQK6PB4BY.-/UR%!T5)?F>OA87([QP(>M<14L`09U=# MXY&LE\.3(<'XX(;K,T!7SQ7\`%U2>S`3\P@A@^P,/=P2D0A;*EI7VY[?O:5+T. M6AQ"R%13HXO=:/1DQS:L#;%>Q/+)CN.T&KWM\FTN08;H/RGT7"0@TD3UBNW?L-0 M&^4JLB&SU6)&UN_&=/#.`?WG0:9G1N0*885*[$%N7$.4*-TWB*4`WIU M;:H&`?L:<7MNOTDT]IT197-+,I''B)C'BOT-*`$IK3^T)3)%LB2[:(%SJN3URSR8CYSLSF<*HXWMR^KX MF#4S(#!+;ZZ-V;4K[V7)FK\[4X+":W=Q+7-1C[C.[9EXC5)BD'&(@B!*^0;% M*+FEH$IZWR`+)U1D_%#ZP,FASDCQ,6:UN:OV< M@HA.I$\2WT MD7-&":WSTLYD?;;:[D\::HNU8F7\+^Q48/+H*%OFPK&(@8E\%FZ9M;E"&G1# M>VWTNHY?=!"0;1_WG?5W:J@1D&\CB"):DXEJ\L)Z7Y31\L@E.=N3F-E\DDQ. M>8/2AI$42O&J>2-*P[NV8DJBL[?`ZQ*Q00FPO?0L:T1-F]-.'UCU3HD/^'T3=Q'YGNIT# M2JTN"+GIDN8%KFRZ;X(>A$J8WU<=2WT9:7WIBYF"VB6KS1B5_(5%]P2W$9:( MR`Z>VCIGYE'/=!R5!\]RADJ&U>2#M!OWOE-8>57NP+)ZC^9 M(LGXB`NS;?[_^L\;=W(**2MB`<8Y56-'K5>IMF)_Z&[N+1&+G7EK&(I4XTWJ M[%?'\:=@39@M,ZO;B"US>XLZZ)<]Y(JXN-4?C(TO39<>A"$)I90M* M'%V1<=ORCRDKN5=F+Z5J8>17+F&LL=F,J"7"17N]B,H1@H5LDT>6RA^R<9:X MV?L;9RZ"A\>KSN6]0J[C:9GZB?6G"B9=6DNZ[DU82+;>\\&ME`GCQRX23V)@ ML#1<"[2EE(R8\"FA!]38<*>*B8Z7]=(]Q]Y;+YEL;FNCGQT+:Z]\5#=7%9<7 MX+?QO&21F&L`S@<%5P5,RG+E$?^31:.2,A+A5;3AI;LV-M45/:N[7^]U%]4/ M?AM?Z%_-0*.%9RHV4VYH;EK0CO+$A.O?&D3VEC=%Q)53#-"`8[WR80 M7'"1?9'1I7_H%%!;A45\URDDMZA5K3ER,D9;*F5XPF5X!G/5[LP@Q3=ENN"DL,XZ5Q*[YF\$NLB2<4ZY2^$-5GRM*[)(%K\(/PF]$X5F8W`75ZGV# M$&MS1DF!\HW2_[O$3:!WYJ6OK[Y;/)]]HM<)+@;1I%#^?>L'77P-0L*]^;'R M-*-FM1/831I6U+&:,Q`)>:J.%76S1=WLKI\10+/_*'BX>:#9BY3EHPYQA99G ME.HEW22V:G2YE9[(K^L/EYW8-8U&]U&F2[C"I,NXPHP1")TN`_%>('A$RBJ? M9/1!#PW)#X6.-"12HAW=NQZ"S<>N(#.]4O6H69MK4+8WN3ZTHV;-I8WC5NSS MIUL#)T9&E!99<6_D[6)DK68.'=6M&MCH\:2[(WQP-B4KZN+$0&UZ*R\P" MR>E1Z$("J"VK*O,MQ]%W`3;RXCJ)#+4=1WOJ^Y0(V)9*FT+.5XK=$D=`FBN??D7:_#H(_XZ]X,_F'/1?KA15 M]&#H7D@R)HA:9=H`H::CD1O=L%_K8!4.+<&IL)?XD&AX9ZJ""+$7?&XM?[6G MH5Q-A]AVNUFLT%6T1T6^.ON$!&YX_ZZ=!91;[]2#?IIX)$E MD>-N`]!TK#@>TX MG)-Q5?1UP>#SH*^X<5YTG&"^=N%HK='&BB?% ML0UO]F%4-K]9[V`/GZ)[34!25-4MCKSC%NIYB>?BS2*,:DRG9!G416#R,YE- MP@!?=\ER6+.LAP_U8G7CPLK%-:/M`.6V2MR66AFJM(*"M1L.*B7DUPL@:==@ M7[B>RD&:3-&KFV$R.;(U`2LH5%9$[OQ/01V0&?;>W.2D!+I,>A5U"WW?#T>_ M$=C&A3&_GYC@;P'6U@W'HP`N--<83P:EAZ"^K9(I99,H0\+:*&>H%X-)RGIY M8[WFBRFL\A-,YX!I=5_]L%4O&J2\$$!45LUQ'+R*5,(RREIPO<6L/L=WZ*S,A=YJJ:6[FG#>5VZ:$3)YQ3$67X75_EMJ2+.#38;!=<&'9\H_CXB4U"A4$#23C:,$@KBR7B:555#0GF;"#9+BD,GBH8.4/VM\BU+RU19YG(NZ-Q!9#Y\[!>.Q@JF?@\LOLK#31LFPADP3> M#4`IE@:1B-4FCXP&M`'QN);I2VNWP;J6 MK#%[L0+*['FQ^!+XWC%&3THPX%T(:Q.*W>MH:2&B)4IQETCH0AB[`U1:&W4E M:D>P\:,)-DE$L.!JM;@AA'I>NC3(BUJ)F*D4](24C/XJ>SD-!,-J5=S,TLRS M2/IE+(YP"%,_!Y#_N?E2DM=W_1$SR)]YJBL6W*#AG5659)1Z/Y4^7N4APB"ITP39Q>!!MWJI*T;>P MM]<^[?31E("\G23PC4XXS[-U>]DA/[&]\_>36G]W$'##@3QI9+N3X`044NJ> M$M/V]X5V*>?*L1LZCA+O0HB=H7B$^ZHFA-@S.FMU0C2YX`!8,HT!NLS0-#L7 MUMZ8`*]J%JM;;S(71UEH"-XK255"?$NU0("?X>"?A(*K;&<=^E=>)^K9;$RE M-@:X!#WZW2'-8^[%)@JB*21233YE3YPF);.D9I4EY5QE"@/7_XLP*G,)=B#- MJ$T:[]:E]SW>JXP]?=J$U:X=PY_QSMYO0B='"SGMTM-(90J]:J\P'@?H^;/) MX;ASUL!P5K,`+;)'=X9$5U@N!&C12B-(FQ(5O.M,_,Y6+[3.]A02*Z9QW[O) MCV_>60N1,\_2&\4N"L-_DOP#J'MH$=B$/4=+ZF#)C>]=M+S6+S-RW*7E>^&_ M\?M!#!L!B7=%)J.Y$`"%*^F#DB_C0+`=/(5A.<64-/4A7LA"XB$J2=P:^?S/ MG_\C6/QOS9P?7MQTX0!P0X2L%FTAYTV4QPX"\EGF89WDM:VY2K2_L=5>7Z$W MM27.<8[MT9^HEVZV?;W_U,-7-8JN\^3K!9R_(E`]!QGY+I86A*QT)T*Y7Y2W\S35?)I9Q M_R*HE4)U*"POB4;-/H[#V<2_,^(KA`]6V73LTWNT!\!WEBR&3?7HD,8V^_>* M;B^"[@OI(P`-AE_4=Q&NY@BM&/L^J7N?)#OT[8MCS;M@1+TG$Q4D^2%1_(XM M"U:!$O/Q\CCS_01@ZH:]03\2XXS)GF;NJDH(FR^X:XZK2,0Q42LC+26`'92: MXF?/8N@8JXC/$_"3[@+2,*)<)V_P./E9X>/TW"G9,X6=&'JHBLZ;S*?_.J/" M:<+8094DD&=#FRDD`C@,!(`F0X50Q*-@?SEU._FD.?7RM[_<2XW\INY-&Y-( M_`9!3Z[%>JA(J:NP/VJ7D1<.5B0.L470A@]$FPOQEEBF?3?MA;4MPYQVUVU" M,/C1I,.@=WJ:5!B1JI;Y56W/UM9.G8C2^9&J1K.">P8L'-L12`<5-NI><2?+ MIOF*:L^3OC*3ZHDO.11,')($'X3)M@#.?=N'+=;)#E@UT`=)BI2XL^6B,4"= M$35?S@=K:GCB!7#_KIU@4DXJGWXSII3(0YO4PV838B)+DMJ`"CKBJ28&LFN4 M<=KHY?@JN86EM4PB`$BAMP'DUEVA8_7CH?AD(K/@KH6 MW],]15=F5%5Q0J?P?O(<%Z3O$`&B5BN1LJM,ZDV)G$!.?3D9S)^8[476[=S< M11O<#OROO+KM[6%-?#OH]0Q'&T#0VXF_(`1.:1X%20LC?;35XI#R?+FJBUO@ MJ[\$OF"N8R_21X"N$0%?$J8%"QN1EZ7NK"W%V]ZJ.*'JQBZ$O859-P M].,^0+$>VQB\Z44%#7R,IIT'78"0"\7E=E+UF'@G8L=MV+X0S#:[X;I+'+0N M?E])?@6LC>4:PA7(!0#D#=';"F5N9'-T7!E("]086=E(`TO4&%R96YT(#,V,2`P(%(@#2]297-O=7)C97,@ M,C`@,"!2(`TO0V]N=&5N=',@,C$@,"!2(`TO5&AU;6(@,C0P(#`@4B`-+TUE M9&EA0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R;W!";W@@6R`P(#`@-C$R(#B&T9]<&'UC1F_N?MS>?=QN:V/-]G"W66[69H5__"5? MV>6Z-GF]K&NS/=VMS/'NX^?_Y.8XX?NVH3_7NV2=;G^[6V3Y969=+VU1 MK,WVT]UJN5KA"2W$MZRFU?]+FM:=AG11+]=)2.VR2EHW[M)%N2R3\[/1;WV: MX_T^7=@2GQ_QJTR&T<2%>Y\N-OC4GV+'#[T)V+%:YDG+^V\-A\$\TJ8\\5T7 MCWE(%[2Z)W>*9,"F(AEAHL"[$W[E\80NK7"":5S73>9*RW%>FF%!:--%A;-\ M/+S$X07L./,P],[@609;V+$18U4RCL/5^#"Y[F!P*7W*OM#-V=P`&UDRGO1E M9])?M_]`P!=VF95YC*ZU,;IVH]%E#W?![,SD@S-DIT*`,O:J3ERZR,BP.*L/ M=SU_&(YJENBOVQ5T&;;4WUJ)ERO@,#N:T=UXW75IS,]JR/EHRA:<%=G7["9W M;T++ZYW9'8^CFR9@U(31[0+'+$M<'TP_4%!L$LQ`X4FZ9^,ZTXM08J=S1`96Y0H/3B[ M>.UMKMXR]CR#K`;NXC=R$+F@>P-#-F?TY.1Y1!\.7F,AX6[)IUD@-\O74P8[8H3'<81DZ2,V?P!Y+Q04IWDA@O\O5RD]=6<)EM7KS?S-XK,KD: MQ!4N`;)3)U=S(M!MD@O!OTJF8!Z<&=VYPTI+9=8XT$"!%>;AV?C^0#^JY#+) M]2OHK_X81%5*^"N\`R5F02-6BNW$(+< M*$&V=!FR<48&&JJU&@GQ`;FQEJMC19L8#EC@SP0();T/DSA0L0,V4AXYD!,2 M)['\C$(I851WN=-R+M9L66R*>.N<\3-#B:Z];=.*LP"NH/_G,_)5(;I_@-T\ M9^B4$KAV(:4ZPV5*/G&-'Z98W<,4T5C%-<.FWLD'6F+,;#V)NU!#*6<@;C)$;-2)$X-Z)K4Z\ M!7G^ZPD\F9??&=E_H/*PT1^-A)PBX7B_/\P<8I5#`+QAAB+*QC%C('X-*,\O MW1+%CM#$C@P/#+."XD(]S`N/,P8SNKF4([JJ MM>5+.69S*XOYGBNIY\X?N,UH;^7^13V;*K.@S-"'%-^K-XX*691"SHJ#C'@Q M(IMT^0?^,=&-M?WFK#^8POG9UQ1IT5)5[Z54_[X;_]RSB`!6^5/^$A1@=/C# M"P6>*%;!(?4D/TP;=0>%EA3"@6ZTX;LS=VKM\3+/EX`*X;T3+0;S+`BZ%+4' M1MW<#WB+D^,U#4AM652W;:>8B;N02PAGYR);]'O/K8V)&2YK^N]9,EC&9\ZB M8<:%[`I!OS2/VE+TN7>L]*+=,'U0.K^*9./NG,]$J4Z_QOIJ/?.D.A[\-%W( M,B(#VJF3>]/LT#B8UXX$+3\YB!#SV`_"QE<4=6]VVMS@T6:UV=RTC#DV=BU' M',?=(2R>IH7()-8I.4YCK(E]G+\&\*>49!UZ*=+R&1E_XJKZPCR8)9_X%VFF MPUQ_-5.=GXR63I1R)*7@_)%+=!CVYE4]RWO/^QOT6[+6B,QM-7[Q7J_C-PMU MJ_W:A:L#O-9".RQY6_[E"&-K2DK)764-.;F3A7N6"=)N=&]@C2?[M&E0;@FA M\CXEWXPLX3*E-JKVC'MZO5K7>6Y?1SJHCEZ!)/ST"!I#_EKQ[9UEE-W-ZCL( MM;,ZN!?B]_+KJ,CC"[YW]_>UY5SZF41O[Z!F'=7CR4^L5",CUBPRD906:I+J MU3WQ#>M8F=UP5F;HC^9S?/GETY(DF2@Y@*+S![=`8%7;9)6]T3;?3EVC2VW^ M>EYRO<L+RG4YL MX9GNO.5#JQOEP_[?B,CWNY>P2>#9:&#\LU"1Z>#(CWE`0-Z3/QV!J(2S/80L MSPG,HQ)G('5R8H@]ZC&Z>9,HNLR&\ILYXI4Z/]J#S8(XJD M4'%LD5S[R(,38@7'OOPB_/D#/2U)P4<^U&8?B=>9`T4SAZ4,X;_T,JT"<&BA=Q]XC.4$4:LL:!@-K:%7-R*#!/W3-!V8^Q=R77WY@G3%= M#@??T$K23P$SX=X?#J!,VDKL>V`Y7R8G.4I4_#I13TO1YF4R0KG"YOW["NJF ML+6GRUV9DY%:VKV5*8"@!73^3N&M6/B2K'J4W@WWV'LNBYJR82/N7S3Z7XI'@0A/G=ROKZU0 MHV]:HY/`2#C9R&9D2M__*2^C>EN]43XOHB'3QLC6I.^2+L,4Z8\],Y@,@;;" M\]_0"P?QOTB.NJ6?C'YCN4!?FD<<['N]7\;W6Q,)GN/FH7'32WU6>7'3M;\5 M!@2?VY%VDNDD0]WFHE@1>>`*@N%T$8*TB4J$2:0!V+&L;J7!2_M4#MC=@Z-) MQ.]ZM.@=$C5X(8*>W0_(W:L'HA0*GB37L1IS:(<-2/P-*K^9"<,88T7(`L\B MUC_^DQZMDRT++8XH77>.;\=L,F'NBPEYG[`XL^.+SB2@"+<85<^B#FNI2: M;^O\:.3!228)KHYO83ASL`1D>I:B*6F'7$;H-5,6$DG9XW0>Y[T5$0B//M+0ZT\[KEZHM!$3FTEB@,S=">#`)0$VQY- MITZ<9(N^4(JD%[)#X:V7?=-KOH6W/YUD3+MPOGHQ)9,I("+@SY+S,ZA&$HLY M5[Y<8VI[E792%D6R18G\]P7M=0*6"I=>3=%`QLJ5J]YST5CQ7R5746]N)5YT`Z3>QFN9JV$ M@_,WA&!GCK/*<=>6.[!O5#^V/-^B[/AQ?-KQ2'C9N^\-A+.%(MWI0.D7X7)* M2R8^P>WB_W17RY+;QA7=ZRMZDS)8-<,0!)_62HD<:1/'L:?*"VL#`1BR,R"` MX#%C?DC^-^>>>QL$26DS0S2Z&]WW<1Y"+2[-0%K,+5!&+.LZ>H^E2RSU.K]I M=<4KA;U0AGPKCHS3:9E.%X(G']F4F@S]+!0$FLOUL5*1H@_PM/2WJT@W*.0! M&T"BB3UE\:WYCH+*,)X0'H9%J0(-4GWZ!J,]7A-_$D]J4.2(U*#HQ``CE'E@ MAD"_OA\4(<4[>!VZMU!A1M^',7R)U.XF^_3+31[`:+`%9!E=;))N)U(S' MSEA9E0'0!3I5U8EA2E4-MU`3-O M:J'67NN``Q*_/=(=R^GJ5Y^KAO251N3@;`-GQQ@$21"CK!\WJVQ*2;P/5M1N M>%/-8^SC_45K#F7:4B")\#H-IG9%*1G42XIALW`N$1HL*1'?H@\D56G3#T;\ M7XO0=>@WA3.P$?L:IU_LIGT]ZMXE=6]DS3FVI?X0/UG".3S]YQVNFRS6VUL! M\@?-45T56JN**V_8JB\J([B.6;DP_RI>Q3=*ZSXTW="0WO1OR8Z\C@8ELM1] MH@T3L^S?M%74Z.F[(Q?C*F5ZYFYA'U%?ST-G'DZM8D7S2N^%'@7R!Z$O4P)< M`:T0P=TD%OLQG'%PIA#M8!S7\^LU)9A+`;@BLX51SF9-F=%-=*RSLXIJB&:> M2VX"JJE5K%:\M!M/=`%.'N6[2FIY134[*OB5]NR&991%OFB+^7B$45?QPV-"]`"?_>&H.2AE\28Z&T=" M7+L>ZI1DP@ED$S$=S!\S\(FL\?KY(SUC)@*MZDLMG[,;;&'ZFOK2(O-5"Q=R M>!-/FCBT6UF(Y:W<U&.^RC&'Y&\N M[$CUE?:A0.V3MV+HV]XJB1H@\9_^9$_":O@>DKW6@87^^XN02I!]5BM:=TO6 M'9BP"5NH.P@W\^5XTEHGHCJ;6G48/,T,3#U(=?4&Q=(%2V5=#;1"=>\Z-7); M:\WA@JM. M$^X[7(];(1K>6NHT5'HE[2";*AR_D1`7-M!)N:4'B9!R\W:^V,>;";+=Y0F% M\MN`P^?M8`$_S!*XC[3LU#_5KAEZ4RERK5VD6F4E*-:[,$8<<@>+$09@*EO? MO4A."<)A6:\H"*WQX#HO==<;1ATYI3@'YK7S7_?_BMTWVAL#`!+N;$N2 M66+OUL!D^L:;MV*_%50.(K&V_%\2#7"!_(RJ07HW`@Z9@Q'CI#-^[.,ZD;_5@_4\*+Z?1D!0+_03\I[XY<60\'_>$N8P4@06!A M>FA`N!TW'%OWEW>M'B+ER-4^XN?6X_ET/S=()I9V\AQ)^W;!7@`OB)T+G.P! MU"8E)<4QCG>1F0>;PISO).-(.#U%J>IH3V,V*A0/$01KZTS&HEV#(I6?6:GX M1Z&VH5`31''V5`587.Z3Y??ET1\XS55#;PJEO1 M=%?S`WP<`L/[+BSO*+T?W)N(NM*#@2]HRI->U_<].O3'5"NW%W&+7CP[&VB5 MRPI:6M8[/*UH.$6\F'()*0]O(4XK6_K5EU[G8&Z-R%O#RS>\F=?#$!;*'="? MH(R5DAA+^:CV=32`K@_<+8"PBX(0X#%7F)?9`'1:-8MEBAG>3RJ\!?T%_#^Z MY[8^Z2OUM^CDB]'\=I7>ZT[U`5XOABJ[TM3TL'-"&:#+_;U6S(0$6^^GXOHN M'56G`)A$_V5##46E<>AI&\KS@P9_KN&'GNTN*D!#WD%@0R,@:^:AEBC2RR>W MXR?-09U"U8&K_388Q#J&K&U4<*_AM9]H'5LJ.\649UFQQ_#3CO= M:#/?+#?3R-\!G7._%]IM"W!8[>?!@+3L0"B'5#3$4 M%2ZEJY9'AEB_G*;"B2W-,^\EJ,),Q)')%%`9FP1\%<>3QK1$`U.&CA)"Y=B& M>`@X*U(,?XF\5OB\F#]PVX3;QC*G5DDBS-+^('$"7>,\8T_NT7Z7SXW:*3;M M1"CZ,@.E/;M@3K')^@JI4GVC?U/)VCK*7O@D9][S/*3VT+((Q2+93+#M\1J& M$C,=34HQ_$.0BV\&$:[WUFY*/(-PF[T4/!+5'-##T%!MN5S/<-DH8,(V-_1Z1W[*U;U1D8;^`2?VT^!(J3B@;5! MVU6S9%KWQ+.#TBRM.I]8*+D[U;E_]K@4F$TAL6()'\+,8`]"\.+%;EK+=]15 M$4.K[AF:[!7`#I_86X_6W!E`^6+T*X=84QB<7#<$U9$5#71.6=RN8_A4?]@Q M;FAT3(#%'][@@&!5U+.Y(A\BUB-,'WZ)4:QS-9(.06*A'&<"=KYSX\J-K(NE MV;B0[/<5N)J?O+STZ,!.65X:92FJ-Y>V^D30>)T)EWZ6"3L@&ZY:8U&6#5KF M+>J[D9&^J&8JDX@%8$4XL!AV' M%L`N'C,^B:HY"$4(>!";Y6N0O?JS#:"`,A9ZFM:A5*&MNRU&E%31L0.$SP1* M?YV)AOKTT\_<3\NMG(G">NS\P=2.,HYM5] MN!JAQU"_R(YZKY*+$$UHGII7(N763>N+GM?2@?-L(8ZHZ\ECTBQ<&UZ/ZB-7SA1&F(F?E>SS3$S:\$X M@EP%56D9U9]>^S0:T&9TL+E.S4C7_&9FKC77S'%;_6V^+TR0)M/7^GSQB8=6 MI^9W[_5$KM7_9A#EQ70BX?@[,GP$W/@"N%B>H0:*?&AIM3I4`,9**:!M]-;] M>)V:"<=;Y^E._],6!IAB4A0X]HV;#&7.ZW9F'4NR+:PG[D@W8<^*[9NYM.4: M>2-B2\F@]&QM/Q.,L_DP*I*PG(](="Z-F^E-G`T*-HK>P?8+J4`>?@T:G4>KRFP<1*TDN?*$@$P9Z9--U2%P+.S-VA MWGM1D%2)6^L%=B*>3E0%)AIL!N'%EC;*:743!($N[\RKX!YKR)/%Y:1CDA(C M#"18=V^9($%$*BZACKVVZI[H!NWSP(`]"$SO&4B9*7`0O;&Q*V?S!6J1O'^$ MQ_<:O9^>WOW[W?\'`+,FW(H*96YD"!;(#`@,"`V,3(@-SDR M(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TR,R`P(&]B:@T\/"`-+U!R;V-3 M970@6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]45#8@,3DS(#`@4B`O5%0X M(#$Y-"`P(%(@+U14,3(@,3DW(#`@4B`^/B`-+T5X=$=3=&%T92`\/"`O1U,S M(#,X,R`P(%(@/CX@#3X^(`UE;F1O8FH-,C0@,"!O8FH-/#P@+TQE;F=T:"`U M-S$V("]&:6QT97(@+T9L871E1&5C;V1E(#X^(`US=')E86T-"DB)?%?+KN/& M$=W?K^A=R.!*P[?(9.7)(+8#R`5G865!D2V2&(A4V*5GYC_QO3CU(29.) M<8$K=G=U=55UU:G3_WK[\%?;E5-[M7\:NF%LSW8:V\J,K7G[N'_[L-_G)C3[ MXUNQ+3(3X(\_XB#<9KF)\VV>F_WY+3"GMP_?_BTV)X?O?47_;F_>SM__\VT3 MQ=L@"R*3Y=LP23*S__06;(,@S%B0OA*2_MG[C[_9;6//^)ND2+Q]XZ?;G6>- M[?GCU/J;',LRLG:TM:D'##),;3*LR&`TW9TD(^],^E+OX@?;W!-M(E*IP&2= MNFQIH+0FG]31AM"S8T M]"933KQ$L]Z$`)OA:#[^L#?#2$O^/_9_>0NW<1:F9A-NHS1>`Y2O`8HD0!?X M;(\M*2X\G$_:G"F/DQU)XQ]%V8:U)683;1''15L6+SX.^\JII'A_G">T>`$L@VV!%Z[#&/6_:6?`_9=UJ= M*+:(WLW/,"(]<\=BM1EM967+%0&91R/:SY`LO+(3LW8W>;@;?N$N[\EXC_'A7UE-F,CA08;I:RDCZS!,//-G M_.1>";\PTKG*=BPK_XW,(C]2_)Q8GOS/X`<+M#*2%5/*J#8W.(?TG$4((2DO M8D+MP^Y%^UUV\4U4Y2QG62-&-JS*4AV0JEY^QM_QM!J[)W-%E\[(7I$5Q;4< M;-^-"%H_)/.O,OUB_NO!C^Q-.'N3<,DW%+QF;Y1+_.>^MF-W1YS"`#I#[V0. M7"ID2T!)8\T9@48)CYA/O.%F*.X4S03Q:<]4;"CK&8*.M&!PYY1U$R5>BO2) MR<:Y9S7'HZU($6=B%"!A4#,E75.J98P2:F9G+@/5=@8\H((.2;)5N:Z[FVFT MK";U=')J^Y.4^Z@+[5F7,!'AYVXJG0!02)2"+\H[7G'R9_A/:7^$,H]+,4(I M4AE]![M0B53NV]\J[G`-=JC!_KL%9G6M175-#6!FH%),O!EJ=X#(;WZB]/>Y M.B5!$%[%2Y'I:4#%GU!@&HOLO(N_.0,>HV;--D7)-M]Q>X`YN.=J@O>X,UQ% M3>%`;=3E9,VMQ3&<;PTO8 M1FL<`HW#!:D#K9(#]+_%Q1>"ZX5.`7\$\V584?F1YV@JU$2D"Y6R@T"_&BWE M)6&:@[8=EV/"/8-UFU[UG0\\#70&Y/]?2V0DFL0[=,PL0"EQ0%?(KE8<)\=N M=$2&(PF7!E-Q"A/`(N1)" M2`G1J5)Z"U;P453_0**YMS>'.UV1U`#T7;FT&3!B0L+EJM0;P8<5(.+\T9#T MLB;N`0VGI04'X=`[G\KH,\/.ACL*MQ(LM9H];S.06'?=F,@+I6-^YV6Y] MRB5CON^EZY1UW;(!(M921J4$99.Z&`9:E1;593F!8F`6UN&GNO+L8 M*Q(-:QIN/502RKC0PM>W.UW;-1:LZK M]G($?P7)P-2O',V+K61I-4=44Q94HD]T.@IG,"VD>1&]&7:.W*9/J[3T*' M5]A23@J0`_]C[EQ0BC%CMB8R-1I1)YHNYP5\M:7AD9')(R/@MI85Q8I[VMC$ MEQ_=1/V!628G_X6&X.[CX%I9<810D;Y!P'=Y+$C\]5<+Q35FG"+0FYB!6*&+,)!6!D)(6F0S<^:1-'S7:7H)J"3^ M@T,,?,_<1!994*68B1(72@^FUCI3-9P*Y4@4EL\=VW];:2%`J3S;/;>09&TA M:GDM[8!@O`/7.C#RIRL-X[,%T!TGH-'97IQ8MKMI1/K,HZYVG.=&5[E]("RP M;%@D)LXA:18("N1QZ-(LD!G9\TM(;`]7VS6O!^YE]#(;8.\DRG`);B82:YE( M`$#;?NEF`3/?02EGRI0S(E]5$3=%X.*I[=J)7S$@EP^/A2TNO9]C@PKF3N)F M5]G+U![X.B/O10%./(K?,1$+(D,(E77OLO<\..VS$U-@]'%FN41E^8?,1$/M ME);>B4FLK\FFO;R_XH`P,'=IX=@7MM^D3X.,.52>^4AQ6^[@]7Y-UUZ)X:IW M!S$P#I]M3RD5IEHEB1"@AU]PS9CZX5%%PI6+3J<([U2N@A"D#UCSIK]82%&5N@%2_H=5N1(R+J)A[,` M"6>DQ`BQN-J1N(HYSN#AU9T#5W56A2BS^F$\EQV[3!U@5:JUJ89]P;G%I-&> MAQHO#KJXG$^,4'6Q=$92P]PW!Y&C.0;(W'.F/#"D%?SJB#P1U1TWT37HD*P) MN<\*\:67PF@!5JJA%['&+=D]BFLX!BDAH47Z9%'R"&V0KJ_4=.&@$?-%'((` M]$:_G-QP657R(CI?M-J[UDDB-D07>#.]24'`G9R)2.YBG/.XSA6(0V5,MFK+ M#LA=\TO,&>T2O33Z_T%^N8T8M*$`$7L4_N8U61*%RL\]]A:(9H3P]5+D!1QB MO!$N["8[4*7BO;LL3X`H_>XY\+5T6,.E60BP0ZL`L-3,JO6$M\>HNR>[[#S< M'QI9QS`MMQ+MPO7]B+>F.8UQTE.IY:#WO^L>\YL> M\Y)\PVL![=VSWTB?M1>Q75\THS!?(ZSO%M`'26YS*(F:Y*R.?OMJ62$2P!_M M^5DH+%ZD#OHQW?1#?WJX`EHSK0>IBDIN`02/<82Z*K6UZ:X7>Z30Y\\;R7T) M!MR7N:%:S"6"%1(PN>4`.1@WB$2D-&&$PY;#5[:PU.*`_JK79Q_OW7[9[ M!(PKI6`Q&86[1\%&J_Y@T8_*3.0M2/2-Z=JHH]K*L4[GK]S!D=-3>Z85%]FD?J,8D\_"@2#8,0R$L[.IDQ4:!K!%"`JC@P=WEI MB&'EZ`CBN_:X0`CN(@G3]!4-Z;R#/D_I#,;1D[PHJ:CE<=G*8X?PT9D3'PNG M]>$YZONVX>/QJLC^RW>U[+AN'-%?:1BY``7H3H:D2%'9)0&,>!,'\'56WE!2 M:T0/11(D-8K^/G5.5;<><^W%8,1^=W75>9#5;5';6:JGO%>GZ\C#:ST$-R9R MJVR9*0X:V9*I?3FJ1&AV1XP[FZQKJ2;GR04%H-SG3&L(H\\!/R7HF:3.KNS@K^0CE+!^!Q$VP M`,,Q5+72O\.Z9/B M/]6:Y1.8_Q>MVC/3=A#7"A^6(/XX]P0MDYN*J(*0D3.+1CTVNK,HQ82/AP][ M.YST2$D<]I)!WH2-$1V7\[M;PGFNP81/VKLAFHD"S(X^64^)3/LHXU?)>:I)YBM!7,OWLLK6 M?V9:N'C&.*2)$"38:$LW("=?W_!^9EMC$G&1JX)+53<"244FUYW\G2>U.[FM MZ5W+E2827GNL)3_)X.*M%D9ES3U87(OWB].+-*56P,PL:>S_#L\M?O6HD"+> M3A!M/H[A4+4P?"(7NQ7K=3YW:!'[]BA6$ZDGX3=`A"H,V9F];"V16HVI:S`:4U=PB?;=PB(5)XN:;;,VARJ(_&3G`."T_NMT3#8< M;UQ`U,8LJX7%VO"K[^YB@O5/<>\ZX#M.'FXZQ]&?:X&E$&$EL\="!FB^:$H7 MN);O?ENX6I-A5+4B&L:WC>#!WLQ)9B`D_S5"`)FH0J5VQ4(#PDMI'FRQ;\!:%=5T(@VMU M!Z>XHXQ8V\92LN-C2D?HC2'2"/6D&75A-"]\OT'X5XX/Z)'ZK'];+,D>N<2! M++J#'\*W0EE)L!5*/2U4+=!FSBH>QF9ZU[$$UE0@P'81D$P>=Q^8&6L""XB_ MF5[B-:))^_KXUGG^!'LKA;TLP-Z*4HVB3M$@MP83`'((#SY3,=FV$!ED$V=- M[H>I:7TWJW>2!"V*>Z:-`)Q6QK1(!F'8Y0\DV'@]I4QMZDF9'5^V8N`1FLF0 MN=_MSL)$8<.B+*H["14W-(?$LH#43X1*Y(+B7&8W,9197,IL` M.@(Y_T&]):%Y0"U(?;*1>54E5SU/UT?;)H'+Q*0]R]$HC596>N^=2<$+=;+B M-'B`9JM0O`&]'YDF7F7P=<&^,/;#FET?Q!T..EMK/P1?9#R4L@`PQ)T[3.:KJEVYY/@^7&Z)"VM"&2K9JX(@C]=--< M/.DC.&:K<-S74L];N\-8[^:S($V_`,".5-VN=A]^G/UV7#"!:O68D$U$X9W^ M;]MZF"!P?@Y6`YP+$\`?"'H%\41@L*D7#*WLZ[0H61BOY+F"'DC_[ZG_2FOU MJ-HU;)X.\F"5-95L$=))UCY%19C=QNHZ'S1FH6O$A-QD%Y:OW[P-/)@"*5Y= M+5&1^R%#RZ$$N/O)(,=DT\JPC6W-]!7@+9'W MK4V9F;Z>+DNB>+!^S0X;0Z$D>DA>#I[IO_I:UMG>YH!!OS-E*2*EV;%T)(B. M6..T?/`2?5OO#KZ=7:\(0H)'H7D/]6+T MOI+D69'W15*>8%=@!D:_@/K6,MMR95&E[VZPGZC#EL1$3N&Z,O7(C-Q`Y(0" MG8:FLTFMVWO9Q,)]HGN0R MG9`;7AG.0P6*^`^Q'@9,'8%)'$C/2*2T;AMZ#Q/9-\$<5/@"]($RW^`]%_`+ MT0.DB6TZ:H))=`B64HN;Z@XK(V5EQI%"QC^J8A%-DZAMVE`F9?0AD('J0]B8 MBJ2!S-JQ9>+S5JA7XFP_V8&@-6-]I5I?N2IQZ$96&5O#' MC$PWD>$M]`$XQ>R(2RP)?@1O7((>:!A&=-2Z_^YH@EB178>_N;^D*[`F@LX8D=;O>O:O^$C^U2N[70`/ M2Z`$UY496;FY6_93AOBQ;L5J[,5ESLS?AH76=Y-2BXJI$FE6/4OT*BYFH3LQ M"I9+X[L''T%,2V!F4]YN&.6(*M@M*QKNB\`DVNXXQ9)T%C,SZ\)^H1S\554[ MV1%##RH(^7M20PJ)722#:U+UZ*2& MQ$7.F@M7I\T'=62H]@FWLH=1!7W>S13Q4!83L0*R!`/S@3F?*N;57/Z_:J_!_<(^K]Y.: M66VE%Q#4V[7U-*NK$T9^F#'ZK2TX$F378=+^'-"U6F_*N_2+(@3YC?N90:N2 M2$GP;T*'EB0E3U,EC1JD,/AP'NTYCGYD6"IJV2(Z%:T4.3.4QT_$V2+1%5V] MWS=A6501`QIZES>$Y>&?#,2-(7)+>H(SKPY6W(TJ+.3=Y6I.6;A"/N[:T#$[ M^[73<$EV,7YEHJ0FE[XBHSZ:L/849G3W#S@,_4AVE-O"1U2D;+-"PIQ-!WF6 M-*,H0PX3_4'I?%4#P'<4N4!W*61H6) M8DG\'\K0"$#YQD03.%$3;ZMHION#/4U[1!DHBSL[[)D7&6>\OXQ/@?%1N4;^&&R.8/DI@ MJLAMW_GPT]KLNU:(>M_CFGG27X*D==;3JE7HHQ;*A(,U$LU\_/]@JL#M*+"" M$JC!>>!FI@6L<6T&-@-4','RTV$%B+%X&H86LN[AG`%<@$`##3SK0IE;F1S=')E M86T-96YD;V)J#3(U(#`@;V)J#3P\(`TO5'EP92`O4&%G92`-+U!A"!;(#`@,"`V,3(@-SDR(%T@#2]# M'0@72`-+T9O;G0@ M/#P@+U14-B`Q.3,@,"!2("]45#@@,3DT(#`@4B`O5%0Q,"`Q.38@,"!2("]4 M5#$R(#$Y-R`P(%(@/CX@#2]%>'1'4W1A=&4@/#P@+T=3,R`S.#,@,"!2(#X^ M(`T^/B`-96YD;V)J#3(W(#`@;V)J#3P\("],96YG=&@@-38T.2`O1FEL=&5R M("]&;&%T941E8V]D92`^/B`-55%RNZ>1M!`6Q+)8K'XZM6K M_SY]^FZ&9NIOYC<[6->?S>3Z5KE>/?UC]_1IM]NJ3.T.3_6RKM0*?_Q0K+)E MM57%=KG=JMWY::6.3Y_^^:-01X_G74O_7I[T-MG]?$KS8KFJ5KFJMLNL+"NU M^_UIM5RM,IZ'A[R@R7_JKTFZ7N:ZP8]VSV8RG9J]6-"-MHA2>&;OG9&&3\Y>S284^#+F*05?I0SEZ%I M#>SR@DE-)WXPKKF\+A0V^D)6E[7^GE3XOENH1J9VZH<93$LA4U_(-EFL]3%8 M4LE_=O_&^=-LF:^+>-A\/NVJEM-^3S;P@]PB?\UELEB^T3C+BJQ\E=>.W2[T M-[8W$(M":H]_KV>^U^+T?#.X!,361U-9IF8I$.L]2U9+2O==P8VX"0Y5VESZ-L>&YC#`2&7V*9% MM5RMBYI#7)*1WY]2=K&(EHL`J>GD[!6GS>B"$,)PZR?@(Z;YSRGDTWW)NP5 M+!B)=;GF\FBP"I%J!?8*+ M]+Q?1M%S2)M^5%2*!#.ZP7C-ZWA+J\W[])Q.G!MPDDVM<&4G M7'NAC6J\M[BFJ:>DW,`E0MH8$9H2#`])6F"(4$GPV*F7_JT5)*!!X+R$Z%G9 M@^I"H`#](GL`Y:JH/KNCA[IC"O@0)#(0)FKBUP@_`_\]Y(9GR6HQ3Q*)^) M0=:ZZ_JIMV,8FR,37'E+>ZM[KF_%'_/7!5=A8')!IV`N?R$660`1PZ#VC%(F MQES@3F7`JE8B!-+I#Z]TI[U3+:]'ZEWB6/AE;J;#($,3@I/Z)BB M[`2`JD&4)SI'(5Q MQLH>)DK05K$,25?''\`:^=4.<(6FP$]RDFHAY2G2S%S4S?0C18LO,VZ>`@AU M.?-K'CT(I>`SF2]A9D5A))11;*6*.T6$N*6GY_"))NCPW-$/XH("/U=]FCQQ MTFVX.!$,)G6@\DHG(NY"0ON`SRDLM!=.V@SW.(^1$!#8PZ$DP(F+,]-^==]O M")4SO`:WSB`'5/;H4Y(QZ>?LQ@IN1&H+OL75:K1CBA%Z1H$Y,Y212>.\&06* M>)L(+VP=QJ+K7LU6@S-."O?UZ'^5%FG$H-Q+&=#X/%JYX1>N&B,YN('?/B$: M4/L^E`)_.=&\BHH(^7#A.E7I4U@^AG44:Z(.O^3H@<:)U^3;:T(<3L*++9WZ M/0J9A,?3.IYO.7W9A2D53J.ZRW#@"1T9V^K^W8;AL]K;,7Q1+OIBW67BH('& MX$.AH],)Q3$>6=Z"G46P\38<_MJ>XL@I#-WB=OOP$'Z"<;Z(W=]F%?.6BNR]PSR1YDVLC[,\2P(X-V_@MDWG/=AD2/" MK0B;4]]>A_BR(%Y^5?$U(?H`I_7.]5/X.`GH>XB`MIPYCFOY!15$OAQ#U205/L_F:`-`1$U^"CG8CV'JH"87'DD_$=94+-E1 M,U5WSRAP6T(K!4YF4?@FKZ)ET@IO8_:@HK*9M+/\;?U+J)"#O>4AB/.K-\V" M]?K<&31NVE^EICB9*WT(%0X)+(HQQ;9B.8],I"LO26]19@AJUIK:(#F)#%^" M]S+:2&4_7DG1?AZP)JT">$IN/3!&JXLP7]`5WXQT76O=`JZL:]9:U'M+MUU1 M6?O0)V1!<*I/:-$#V#^`X(?"3ZZ.&'EO9AFS?U7QNS.'ZX!<;.W(G1J)@&$( M.G4\_JID95E'GM9W,$#4[+ZYIDJQB::RI M?8)&M:33IS#UF8D:FBB\>^Y*U(L9Q,3P;N#C2G"OT$6`&Y\[=!]`:CQ[?3][ M;`@`\--K.&S?QB8H;MN2'(OGN9%$#=EXF<]Z;W)(@:!P0U*'095DN<0C-)E% M7CXTA'./F05A<9:+XA2HM+HP.L*;ZQ&X@V6F&@8K?/?22\*.//.8D+16IFD# M7)M.*CI_=XW\AB56UD!^&I905=QHD/%>V!N",@A=\?Z=()QQ&7LET+0P[<1] M6LY%MB1M<1F$=GO.*VI3U(NH<<8G:&CH",U'9YH)T`57L,PZT=0N=D2;JMX^ MA/`=SZ`>'Z3MN#1#,S7[`="2W$IV/Y^(XZI\\[#^%T%+"EI*U-[,.AOY<6O0 MJ\!I^+Y6_,;4G^FA[2?+Q`HY-2Y4^*S&\(`R%F<.L0,B-4Q$ M!6GO>D`V++#E(3"NW/"S4_)QGC2B8-K$V]C>\7-%BTP4&$GA78_9JS M'U,:)'$3!/.9X(-$LT*^/B$8388E;R&2]W&D)_KF`^Q.T+],2/R*EU$B0KY0 MR0L[W$*1D;?0A>8:]XN494$AJFYDZ,;F-;S96$CIOL)C)YTJMY?;AT)>I%P$^%_"J//9B1&CY(+HM0W`RX/4@U01MW*ZH$*I_,H+X001-OCSS@%RP/>38T&JBHE'H9 MF837L>57'G(QV?N.^EMNY>IEF17KAVR;?*O9QS?I)V$O8 M*'`8!_(Z=G"82[$4E_A%=-CZ-($OTK>5M8M5NVP=C>6Z]&*\UI6YJ1]K`G"K(PTQ@0 M8-?6_/J-]R(2<'WT7*H,F61&1D:\CUG=\FXORG8N?Q(0>7PWY'WM1^/#N=+N MA$@I\%+&`H61)K9?SR"I[2(0CC,X'S6RUC^;]8J!!$6=JU-H^.C"J/WSVMZT M(YWK;>X4`N`W5,<\TF)DS`I"MG:]8;7\-+U]`IY*E5I!'K\>#MOL#4Z^SZFH M#ZD?@;:\=5VO@O9,DI7JFVB^4/]1/2FHO"+DDEOOR?%"`DW7"]1,`DR;J=.2 M:B3+<&%2I3N43TD>W2AYSJQ(Y#"#"<3T[IK_$6Y]/J%4`T(H%(?%>JOKH5D&9R_M-*D&+H9%Y7_K?= MW59H=$;1V-`XNGFV+3CH3-#_9&5VB='#]LFDPEX6544H+-5JE@-U"S[KBSJ& MX7NJ0U%8*3#\)81IHP%H,V-UD0R'X`#*-42\_*KTU-B5R.P'+DH(18(:\)-84#;%&GE6NH5N87UBG[F`7GBC61:26W4NK09^8>:D&K9KG MF>ZN<1+9#%1[2EPZ`I?D-GX#9ITU54*PBST2,2,';MWT&BQ.H$T&\&/^;1^, M;SAE][DR]E#!^^C/5S6F'CH1"@)/W@;U8L9+]Z)C\_W1=Z2!`3/!Y,9H/R\S MEFNPL<(/P=+6,RV[:UUX*S^XWGA'ZF'YARMTE6^]52,6LBN6L@3Z[EA[=6]L MLU.V`7:PL4K?^`D[A+Q@,;$QTK"\T6$.KQJZ&ZUD1&@?/`&"MU.(N!H_$2?+ M%05"I'K8D49%-+2E^MYWAYQ,H^&*H(=L'D4EA)>)F!U$3#\HA>[@4<'.'G6_O>UW MU9=DE8SSP["']HDNO)JH+1X_0VZ8&3:W.(DKLZ3H0\&L\F1'&+`ZL[#?X/W< MP'MKX'\:ATBD(L!`F^A^UMG3Z(>[#<\JI6N5L87"7KRST9;T+=56]V&^#RR0 M,L2@!@3Z9OK&M?;V_TD(7^I')%_]%.!HHJ2:)08IW:87JD.TQ\YT#>?H7D^O MCAY(WT*%R-@XOWB-I72[<.5U^X%T#F;5Z-O(]D?=@DU'1()U=Z@8I6Q1+24` M]B[6R4V*!?!D4I-A?HZ[/`HX.G4`Z38(Y`;6G13^AZ=:S(%,+'RK%NUFINPJUK7^=@)>W)N3VS^:TN@=9+9(3ZR M-1YM:_)U>\[2)?YT/Z^QVYMO%0L#ABK?!2(WN$U7LBD]+Q\'E<-,(HHCHN#3 M_6T0T@N[\RJ)R;+.]KP.(N-ZF;3/$;32\$%N28N4;J74&3Z&-]$1=^&G.4I. MJ!P2Y-K)*Z$`#HPHR++=2_-I:`Z,H,J")`<-G>C@,40,'.C'$D!C/I],;Q/C@1A$_9+.> M6I0;^[OK]?V@3SI<:_'R]Q?W[3L?]TEZ.JS*`E8O5DESL+EAE']<*$BW]3A6@=Z3#!"^6=3'9J0U5I#P"UC?FJ`)RJ\:4_Q@CJ'-(5HQP7#&"_.9^94!0>]M(>$D45@"3XIIJ826` M^D6]W/&=.IVQ<^:VG7%;T1$PKK.QX^.-PKEE;Y>FJT?W4C=ZN$98@TG2V?<8 MK`=PEY)DHXO.DT:Z>E7X)^()N+K7#X8I3!3W4R*G)T!8(5_0^20P#"U[4;J0 MJBMANB0M7V!1@+/^'EQ12YB8:A.C^HA84H6"SI3;P894P4HUKI.T:N>EFS5' M@VBZ`4!WT&8[:NEE6GI)>-(9$]TJP/$8Z?M>;:P^H/6/:'W,K;F8_I;2^&91 M?N=KA0!T/AO]&,$3N=?;.C;^H)R_2#7]?4K74MW%R%C_UVA<\*VI_EW04]D2PAEZ5A) M9(+-X^X^;,4\T!7J;GV<*%;/1]*LZ>\_;3L[W^-)GME"B84]Z'ILBSK:5+?,?-]A[!9=K<^>-L%A"K'E6`!U<,0.3-C!4]#U. M*$#0+JDU=0T[B6]=&2PK5QAK%>.MKLQ^$._DAY?\E6\6]9>I5MI2]67G\T_$ MTK>RK`$X.'(K%T?#Y7YAYE`[D^%OK)G7^]6J[A56=^UP]U M1@6$#VOE.O$Z+OIPOXXU/9QF4:3&2Z/\M^`6,/$DNM^__..-)I2L';;92D^] M,S[._7X!:U:W)I^"Y1"N":*H\$WCQKI2>= MMF&GW/7Y,('%VFX0#XCR:6(A&>PAVP_N^28:%Y2GOD>V$-J-Z;:XB2!#*G>V M;#);E'!I7]!!!PJJTJO+Z)O\U16#W&4A=$`^$[;VENA-(L0'B%&DF:%F?YR7 M3DR$MXI,U[Q]A2"ZYG]T[)O!E?7HQ1F-`'BQ-9+.,02[V\00H($A:7%0G_LZ@^Z).][57PF``F^5(SZPG3? M2#_Q1;GL)+?S0JSR*F,O?+EHRQ%L')0DDDDSD@^%3J0JP;*5-F-^I5C4:4(K M^N@51!>>"\'T&AG@4F:7Y2*$+62-,>P?-BMIAFX4M01P'H0O]3O]S3TM9*F' M!\GZSLU([XF.DQTJW,0ND],(`C0\?@6EJ*WMW0\61?0B_;>3XBTK4$4I&JSW MPU1#"PJ6[*(7[U1<)DAC93_KUM2MM?>%2.R9&`(I:JV_AM^FPM"HE%LIM2+J MO+@-`QW31^1LL(3390]>+7WGU5)XM4=U+>4=AG3/DEWQW!6WT07EK:H/HEE; MP5_G-53%=\W_!VGQYZ=7(HR#-!%1S$B&\G*@-$)Y$:1_"W,YM.9P#>$*Y`(` M1EA#<@IE;F1S=')E86T-96YD;V)J#3(X(#`@;V)J#3P\(`TO5'EP92`O4&%G M92`-+U!A"!;(#`@,"`V M,3(@-SDR(%T@#2]#'0@72`-+T9O;G0@/#P@+U14-B`Q.3,@,"!2("]45#@@,3DT(#`@4B`O5%0Q M,"`Q.38@,"!2("]45#$R(#$Y-R`P(%(@/CX@#2]%>'1'4W1A=&4@/#P@+T=3 M,R`S.#,@,"!2(#X^(`T^/B`-96YD;V)J#3,P(#`@;V)J#3P\("],96YG=&@@ M-34V-R`O1FEL=&5R("]&;&%T941E8V]D92`^/B`-&8H4,'CP\@6"2AP2:@P`[J-Z0/]LNET.S6 MV(J.:**VK*Q<7K[\Z>G#1]M6KKG9[X9VF)K.NJFIS=28IS\>GCX<#J6)S>'\ MM-_N"Q/ACS_2*-X6I4G+;5F:0_<4F8RX_M0T[^7IV`?'GXD&7$B M0C9)NHV**#%%N8VSK#"'/SUMHFT411D?PE>:T=/X:;'`LZ-MN.GI+&0QAMDV#UM8+/PI+UK#F&Z\P-$GR]-7J\6KU6-2NAV[DER>0 M1B*6_H0Q&0\FNU9DGS1P6-H'1D=X8((?>N#<7'K2!:.3<0->!FTHMEK6*`WN M.%D&IM%=U^;8Z(K*''K6&'&RR_-8+`RUZ*E[J!3C_\7V9)T]W)D$M:DM+("+ MQ30];!"3:2APDH"EZ^3%C--`]\:X#(8(K*X:=_<+,Q;*H.FM^2+RZ(Z>QW=O%DV5PH#RH=.)?;&RZ:@-OY;DN(DXU+< M6<*=+S"LN>ELVYSTB_3*6*\'PQ=L)-G(WBEA;N6+"^S,$1\YA1#EA&]EJ9'@/ M?2)2)@XA1>V,.8Z/'>,&[2:GYP(FKY,5F:/0[99ODN]G_C8R6$2S*T1CKI)) M4V\^3?4S?KX]MN0- M9FRK.V]%`&$F"4:%,UF?G-[GS-O'MU8U;%3L@P\T;O\'0$SVLK3LPYWXL"0? MA@F!E).`VP4=7'VA&S,,AA>G<7A%7*:!T=,]CTZ4E&USIB!$M$^KZ$$PK7_V M^T>QT#!Z<4"#"&^8)8MG\SF@B#0G$D6NVJ2/&7K]'+(H,BM2IADN9'*$/T"+ MSL)#,<5].PPJ@="6;UC".!C']OY&@M_T&+WIFO#%FO!:SE!6^1V`F/4#5ML% M?/D\:F+$`>/FB3/Y82\9&EZ<&V?GSR$B_U\TGWH9O'PQLYN6VBV3W1PK@=&, M_/E:I^+4ZQ7O1*\9B7R:EHN`MP27YD[5(\>OMI-T'C:-0#.`*-L7F0C=O(6W M-!&IR/4.G*+F$("+GLVP3&:N&[8YO<<)[@OBPM^S(F@*3$AWF4;B:L_=:L_4 M`RB@\]3,]7"SD^4H&E%%734I5-Z!FTB-+.""EE#.+)H<*&G\$"1Y"9^MUO&^ MXDKG`%\$7(KYS!3VA#NSIS%8FX+RJ*!UY0KGHG7C:9]=@. M@GZP$&'W%]QHD3(Z^X+40-*N%],SB!X<$26S>_:F2K;1/MZ_"[UD=7&D+AYQ M/B?THWH^S(X!`W%%14(&]IF,Q<`@T"=,HN>#SW+0M`M%1Z&S%S[X;(ZJY.,) MJR?8/(Q`.<):,*WAQYQTHX*7:*'R.V(5I4>PV:P"6NNI09;E^P3% MWM%?N)K;KJDD6P!W6M`@N1%_#LLLBG;#R;8R-S.>(.77KD M;%1$P\G7V9.?<,Q/7KD`Z_D0R6N:B)J`,L&NKOG9IS"N0X!)XL0P0@J!&L%[ MB6`%`\4?K:M0LAKM@I0S"\Y3#5%&PVBGWTU_V1K/93TG!W;AM5'AS9ER`$EB MIRL7;QDL(61VL8I-MV9PPJI&FD5%]<^F-KF9_E`]L`%O\C@1'F5!15YA2 M4+@".>;7*:JZ##O0LL(CF,D)?!7;79$GGG3#@$B!C[9^>].$`%647051'(#6 M7[T[)$U0.C*Q7,P5F#=5,U_I+TSS-'N(AY7T)*?D.%E"]TCH:'3MJ40IJN)87!;OZ>AO(_4XN*L1 M3,@X$+/@.-T9P5%BD(CL^HPQ<:77F00(P*YUYLS%4+`3<=U!!Z>40Z;`ET/N M1STKHHKG!Q3P;),[ZA&[`USKUIQ68LW]FV=/9D8%KBW%@CZ91%`2\&9_04C$ M2ML$4#0T)X0GS$DF.WKB5]NO$,:O-SKT7'8(O'.FI^_]B/M"R5.\NYEG3;H% M?1;RR=X4]-`=O5R5@Z"A'>2M:`,K:0I[BM(?K+GJ&$+9UX\W=X,V)3,CM)MT MKY-6@GT24S4CGZX`&0EH(2)2HB0^2N,X7Q&RS.69,#KG@[EI6P$%'*/B%*J/ MB<^9=WB((U&R:$[Q7"$_*X?"!@(`&B!;=`5"_A\)N,;L.[ M.Y/?P6"8@>D/,39N\<+#CT^;#$U?M"\>R,;F;<*FJ@-89,^5(",R$5.OB+*# MZ+GP*`VX?>"F!`%:4K/%FX:0J9EQ5HH?M0L)TPV$*BTS"K?#13DDM6'<@-4J MKC5YADX*M(3OHW+@7@9E=O9N6J]?USBO]ZIR MKW2!TH,(')]Z:4"EA<\76^T3D%-4EH>S8,#;[%D=D;^'F-G9;L--S5$#EG/Q M:GW\CDI*]FR,??`->HE8ECZ'K%+3Z];C6M=V4M?6)""``@]'23%^`U'.)'B] M1I@%LK(>ILG6CKD3I]K%*X`^R@CT(*U0-9U?Z*1L2$'^:K<4KRPY5I9LS^<& MS0(U(N"H[?T/Q`)SAM'/0<)/XZ$U\W*^V0^H7X^ZCY0YC7+C:3HVO*.QS M(9)IH+7(P<1NWJY>><,#H[612+216$$V)\_K5\M<>4;/2IUB244(H0@4FJ7& M:)CEC+5(KQ-!P=+Z28S1]KQ(=@-\\?I!>A`7DKF)?;.M*+E[>,ZGT5.5A7C#"$FD$"B![G,^8 M+\Y::^^#D=S=55UM<3F'??9E75ZIZF#/!F_)W^,0V`1D>\I&7D%W^8VFO0[ZEE]W*A%F)UQ7^@I_(LZ5NBQJQK:>;N,)E;<* M?QODY]9/$PV2%NE`28)X#!*HNY(E_9. MH%B^0(IMU8)7*Q1S?ZA?Z[8/.Q/ZD9%N>O0UG\SG.@0/[,F*[$-79+.N<"[\ MQU"V5@O_\R[M!G]R--]YU;4_+)W(B"^_6C,,*SNL/]!5W7BE.1E#>0G\^-=[ MH88D/.V>-@O-]2&;TIU'.`NF-36@Z5G-%(?$5='&5=%&JDB0$_"0#Z>F-ZSJ M9&>IADY\@AM]JPVWPM0/A3W3@O=W`)SW554D?AI7?+W:E\U:4S6VCFF2I2485XBOQ7 M.;=TT^"_!*]1R[8-.6"'!YW\ MYC'R0G?D2D!G/X2V`)7YSP/]ZUD+822AI$@%A^%Z!";HU+_.B4'G*G;02BFW MYK/'3A(=;SV`-!;+N",BRKTUTRD\ZXS-,4XSV:1!]5E6G/CN&F.>@<2G]*VA M^LIY!)/9TF)O*$H>$]&HQO?8V^\W=F5KCLH0H8KBZZ1[;`8J%[W.\R$9YYM5 M)4;\(6I>(KNLC;^K>K33CVKZRY=Z>C=#J50_ M0_S5ZC'_6N0G?-$)PTF&N262,FKA%IZ'ZY]*8:V"1[J@(VSJ$Y((T89CG& MP<0V\G$V,UMR;OCDRM)@9H2=!Y;C*D-B3Z.R`ORA8I.G*PMDN`[1+934^G:L M4E<'!V)885V:QR(3)_A<(Y2*X%D\I$F-FH')&+,TQ0 M:H@Z46,BNRFR&OQ5M)TEBGLZPU$\5/Z\"Y_SOWY[DHVM@Z@&@^R,022OLUU1 MA`(923MUK"A3"1SX,ZPH2Z._]<9K=JF$%+K+FIPO4`E=1?"_8RK[SGX3/O/1 M=/.G:$.PUQ!17)1#=9("YG'E&8[R@\Q#0HUM7<OC"J!,FG"RC+J(J$+J8=@'AI'EZ:YU$!=(9&\DZSE,E5[:? MKZ&R!?2BR0%]S#`V,03=^KFT9PZ:%-.Z!CEAX='7SX:R5A&8Y% M@4GSW6;!I,GL-Q.OLDY74,MZF:AWDKCNPXX;K^B#N46?A=J%F^7F.&?<$29% M__[0Y=9#X];@:&[CUFM,]1'HT`C4(#]D=9T>3WJ!PO3#^#X5^P4-KV^E;>I) M'Z&CNZ,-<:XAAM_#@8091=R_-J@_<,J&'J07WK0;UZYQ3_G?ZXP7C_U)HD@? M81\4_OH#I%!T[H$OXZ6V6`&N+TWEFU(?+9W6YM9I+1SGK%8W16@1#_*TS,B; M?![UUC`I.63S68@/028C1>B?&XUN=M0;=[%")_P0@E1KPC@`RC9?^#/2?S5+ M`D;X,]8.E%Y1.5X$O_QX7,G,6N)XXF:5$24TC4C@/D\6AB291R/ST2B9WP0- MP?:VEK-6)%):0YA1H>>!L?6.+I!?\@-+?*52(/^\A[G,'_,LVR]ROKY->IK, M^OC4&WZ\F4(?_')2/(0;GU)HIL/5^IK#NR(;FQ9.K>5`?U';=%^!Z%A5U:W+ M5M)Y'J_'YAA$MJ]J#8;H=BX^C=/IS7^]SX;)'-'!K83/J*+U8>:L\.,_VD01 MTG5]],B6OC.4_VFI>FXQ;)/?CO5W1B-,@)[88-/0]F&FB4XW-^!QG!>+=U""9#,-^O9,I MPD0MS`RE2&,/.]=3;I>/>9%F"XJ=-<;&9_K<'P2*QN>-;0_3&4S M@[O.^4TW1L_ZJ<1CPI`:+G%63[:[!3;-S9EX<^H(J8[`+O\J%=59F_=OYK): M^R/SA8$ZZIW:^#UU6L;C!O@V2=;N)(O2&'PH_QK0!>C#BGRPOBO76YTQ3M+J ME'T0?&".9W,&0>IGL@$(J5!!-I2"]M#TP>!CTU,+'_DB]<#R#3F;R/)IQ$=< M[.V5.K!3%_U[#;87R*.5TGSW39#WTKT+V*-J<*JU:Y-ADWXK=`"VTHD"!B4. M2B#GA1VLU@,<;P;YS4B"IFNM6TLP:6F+.[L#$*#:[XVJN+#D?U606R'\.RK] MA%2<_&GH1YMY:-8+Q$OT&^/>:^A!B.JRG4Y!MXCI),*8XF'_S[B_BVU:KX9] M4.AM\S];3%^3;$TAWU#^[?50U^M#,C&86`/\*H71V/A?C^)JH MK)K#&,TW.6^VI%?;&9AD\R1>M$RMN;/6W!&HO!O39+/_$9!TXO@_71>/MC7L M5)@JZ?>5)HF<(L.HJFV\:ACRN/8[MEFX&GA2+FUG)RIE&(Q%GIFL,0BR9NEEONL-FUQ<%06"JD"63I('(K5$TH3 M4T1)?*$;1(K`U?4X0_FR1[GJ,:3,8S#V2K[O1_\U>2W7SR4QG]PIU'4>PISD M#I#DJC)B2PN8B]BZ>A]?)S=L_B)R1$!IH_*"V,KJ%"3N-GU*?N0-":@'3AF_ M;<@`)!B9@'ULXU`B\[VA(QZ673!+9]<[BIWU\%END:SI5$XA+Q[$G9RX$]OQ M

4_/^'4FR3/?L2(C<'MCMI_B$*E\0\9K!5+\?BT MWR_WF+-A.[0M16LG7;)7$7@TBM7I9&5Y*X&;%#SU'^7Y8E2-KMD7BTWG&>$9 MM2VX<*;K3"!1#7"M.*8E,5<2,VMJQ.X"R14=SRB%A&]=I6M"() MC%1"PYQYM:5\T1=_^?+3/W_Z_P#HVT#3"F5N9'-T7!E("]086=E(`TO4&%R96YT(#,V,R`P(%(@#2]297-O M=7)C97,@,S(@,"!2(`TO0V]N=&5N=',@,S,@,"!2(`TO5&AU;6(@,C0X(#`@ M4B`-+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R;W!";W@@6R`P(#`@ M-C$R(#[*%_F11I#L^G(=#XRER.[L^>MF^#D_H6] MOC,[3*R7>=#2)P[J<)'@9+/K_-&0<+3"[.'H\2L*FG"U7`=/?.=@&UO)-&R& M;PK!YHG.E-ECF$#8&E_V!^OOS>4H5[CJ*`HO)HT7T3+.DEGM8E8[44L#*ZVQN[W>,JP-.9+N*"#?$@B:O[%CB\L@@$6H\/8`X=63G>MMX>^ MI'V;P-M!9B??Z7PC#U[Q2],HFI^:S$\MY*D[US5D]*`[P,SA@AR3XJF5/JJ# M4>&]\\@F)CWCP/8+EAP&-ZC#=*$VIPY>&M5Y4G"`B MLT(#:-),?7`BLV8PM3]V]<"J8=!"G0+J\:./.CD@2FT[B9S/C;,U;T9>75#`,[TN<_!M@@'[8%'?B17C M91:MQ8B+YYF=;$1;4TM8.'@)YN)+-@%<#&@(ND>$)=NC8/,F@4H;R5Y6".DK M$I;RM0@D*VAB$JXZ4FZ-4.G(+C&=IFL4Z&^.XD]Z!&G?+=3DHOUMG,XAJMJ[ M=M_UFN\GOA7Q!J3TMM(,;]WO-!T%H]5(B?DI:XT4K#RZWH^ZU)BAZA$Q$]K` MV/NQ5Q"!,>P?YU),FRU7.8QX1;AX5FXMR@&8_-&:T3OQ71(X_Z3.WIN;M(P( M-AH#E%>E*:J=[A%E)=G5+GKU$`F6.%#ON$@S8!'$?:].&:XNNGMMPUB,20+&O^@5JUYX6. M)T3H9+9A02E$L10%U;&5U89.FD3E!$=8I9I%\8UJ>1[/52G+;E[X\1W.3@.) ME%?O=`]LT$/B/?[_`L]\,W`A*N+%1"OSP7S];67J.V1E'&]N@"7X"]7"9S?3 M*9L<5G@^!B87(^H!M3.5R\NF[?A0D" MSLB>?4A1&NAHY%CNS8,,RYY1$F7QA?272NZP=..MAGOY5*CZHHOY8%6?2I]C M7M?ZQ`%_\^DU,KB_;CSRUTG:RRH!52Y0RU@@.I3TT-&JJBIYK:')"G&CGHAF M#(@8`R01`:(H(Q_?+3C.WD7B2SPL3=+;`L<[IF!4CR,,4U"/*\I$+R'PX=YP M"<#+43Z:L=%1CRH!`H+RXC6^CB`F6HN$5J`&GB?QI^%Z3.^`H81+!86VZ5'0 MJ$Q-U2GCZI1Q=1+R)S4*\XZI6Q:@1.F40%H67'2,>_QQ6@NI1)K>ZC&J.Q8L M(Z?`7;%,UEG^DJZD^1STD3)*A`D.Z?$W#N#FM7@+M2QC3*)IQW_/(9,'%G?R MZ(Z%6EY6B.:9?4A5P'SG'9:7G_BW.=Q,R3[+UN&X"XR>*VH\\EER8L.R,B.[ MZ^?"R*F,O!31S%-(7.1VZEO'Z"KO`8<)4<.`.;8<.':M?.YQ)L5WRQ!<-3P8 M:R?C0PBSEYZQ]Z@@'>%OSR\@30M^!YU4A3$#7/ZG4G*;WLU21A7R]+:-7G/" MWT)>$E$R]KI+(].A17[BSH+VS0$IEVS#J( MJ@Q8(TM97N)H$^($]L!TCV>$L':]PB]H2+Q*TYL<_)$I,Y-(F?HGP46Z&*Y[ M.?*'[Z3G@!;CYOYHQY..)36GC:XV.M_+7DJ>@M@_$A+/&>QYH$Q!*1DF25!R M"-1$)Y@'Y7K6=[LT,XUB_7$BE[2YH,U@E<3RC,^VHM+#*=X*J\L#-U6G`^?D M-#P!RBF3%E$"Z8[)8>]+V=-R':R4I*HA#$@/@:!4;$5!T+Y\%?\O,`B8;9C^._]845\@?'Z;"Z(E+,:DQ,L65$>K+I)7)>UT\ M2EJ9\U%K%I4\G%;9T9.C*6"9&E5ZJ9%;6Q:O1U%*SNJ?I$1)BW*MRDF@JM?V MT82#NQ/X.HT9],U=5L),6Z+:`^-,- MC=ZID*\C[C\``N[QAC+KQ?Z(=V@'!.!F;D[IYEKS\M4HO`L\[+^>' MFWH>KS?7>C[;-=(H.Y?(27"SZTT9D';2&$([PG43##O8PM0Q.>F)[>YT,/"/TC[F5`-&* M;/-_4XP?X.W!2%U'S03#`***\U+A$BDWN&O<\M MV>F.88[H)*(F+WK1S%P#.E;#8W/9HOVJFE$1BEI=8";LU;C*NA3+G3T.ZXY^I+CU(B-^+R>+6^WG@EJXHE!W'PHAZ&L MCN-@/8+T9PUE>B1JR?0^YT=OY[Y2S1HOB[3(7K(F7#[=J%=2_]'JI8U^#T_W M9HNG_'PN69M_4C84*HB`Z`>@QO(_=Y1I3$FMYL^?TW6J M@`>04,\9YTBQ@@)/>C1BL6C1N@-UJR+2R:QY78$;VYXY'>\&M3-O93P>S%OI M`I@DQ(%,/Y%Q-M=&XEE'MTIO6MU/>!`)`ZZ=O?SM14N(LK)*\C]K$,RGD7L! MA4P"&L9+K[G(")Z20A%SW7/7^WW7N(F:4*!39[$8IJE#.R=^-#.$E&$7P6.F M>ZP^S#N`&788#QK4^'H^(;8LRUOK*@G+1JW]Z$/CG4)O6^!JR-! M@RNA'*U/TQNQ]BN%6]^U@I",'5]!Y@VY>')]$!8+0D72>S)9+W MH*BY=<^=.Q9?ZJ/<^YIJ)8M^HVJK>R?G?[D&\D$1IMO\CGSN2%WZ=RAKWXJ$ MB=F"VVA7EU((LA*TVG(UD_TSP%[I"L?CN:W5P8V+%"`64[J_ZA`5%T*O:G8" M/%+](OPDI<\:[AJ=V+$ET%>D^*E%%L)?N][CBX74X$Y;U`&VS!EF\0Q[T^W- ME1CX%C05XA_$`4@SKFE1RJ+R1_Q?T:/D$+Q"94X?6NY[\6(*5I%^2),!,*6! M*/1AOF2ODT6IR<>VW8$/0L@Z:6H>V3GXP^U3FBSG"NR3K;G3;9P^G:DZ>O#V MUL1L/`6D[YJ@39-YV#G][9JPS]#^69MLE0D:-C#C)]JABS8%M'JV7,[2L;Y+ MA[R9LI%\)1NO]JB15:9G7A=J;'5L27%8Z)3>%Y69M`)B[JSKS*]%]V0)A4PL MI^$_S0/Z);$ENI`"'C;D@1/"_Y\T.) M[JGE[5ZK']_'R?96_LF$',N`'*.TUY;^!\;0<()PHD/T,;'8IA?O6PZYTUEJ M((Y@H@;[4-H8,:-*_MXQS_WM8)S0BYM;Y%-)6V@W!GM\*_!3$_BG`QD$]WZT M/Z6VN#^/=6E#C;,_+3&O#%6EF0+>D:-[V0"UKC4%2G"-!%8.Q(>MRR) MD4@LU$U4BB1PX5VWD,I@GZGZI*01BDB"`-U$/`#0`-F7,T%[^KT.G8/84)[= MBH[7VQ+939Z-3+J(FC(NEN=6@Z(6`;]XE;/0%+6M"+LKVK4_#E_S&-EZ$VYR ME4Z<$%M:GHM%3A\@S+.7-O4C_[N/!9NSJ2O^ZCQ])Y)03MQRS/WA_BI2X[]\ MJO?M;'Y3Z]/^>_?.*T`<+M=`C>74$3>](&TBP7U0F3I0_LK-*'"+1;.'AI5^ M'6H@S4Z=&(6X%NA9&BG>3ATAHD:2*V9)X/`(QO?4J5GTZSG\TPU*`"ZUTS0@ M@F4(4:!;IA"65$4R%X)5_>043.M?K43#@6=*]D]5Q+DM#T5?E+C4^C=T$F*6 M[BS<9Q4$(JFY(OXOLVSUK4;%2A"MK:JDO4>U6Y[\U&IJ^M4DZ@#R9G=Z@U/7 MU)]]!02!DK<6S/>'0[P%8=7 M4WEC8YHL_=\:@@MJ$VFN;HI*QQLS"*_#+?1V#^`/.T>O\'M%;%^1\T^]5C+#I@%#?>PD7-S;8NZ& M1"`19'/R%N20LI#XN%L",AZ-*#^(B:RT,VY8O#2X@XI8;=-9AUB%(D477:9F MAL1MOD5*M'F:SXS'*KFA>&('+42D;2$'QD5&H;TU49Q$^N8N("0D3?-[^&6W MXKK1G(\KP.%VF;XSG$2L3]&E1H^"_=^'BZ2FJ^VW4`F=(OV![A`?(\V!?'9* MALT0&%BH3HRF\[N=QYU)+ MFTU]J=B/G&1S"SKYLG(R:Y*9MG.?K61;UERGV/S:2&&)?MO3#'HC&(C,=FHH M]4!G\4DXSJ07FWIO2T[*45:V]:RAD5C(Z8H,N-'C!3$:%FXI;"VUO?_U7/'8KVW@B!^%D@:(E0.+;/6?0.^1"FUSCP%W`C'JVL@1Q\*^(4DIQ M2+U\D\]`8Y)(2ZN8@X-2H,@&_(X*Z#6)6R*)E$==6;3NA;.\E`?@X$RHBBEK M]7O0?<3NX">V)E?:&0]/=FUW[FVK@_@U5>`6Z[ND3SH@-AMFHL,[Z=J-I@3@ M'D2!28!P@ZB6[>K6,-/Q4U.(/[6E\E!DPKPVR53F5C^.K!!5>TRF?P?9,:21ZDAJP-EG%#H>(/\O*#EKD@769( MYTLK'2$EX61^U9&AFJ!.Y8$G`60MA%U=:8NV+C@97.'NW!C'I?818509*\/! M)GF>LV,I??-.= MCF&.?C\"&)ZAQFM]K(QYSQ3C9?W2A"I?;O.9CHW3]YWJJ8*EC!?B?H1[?;LG M32>1CGD/.)*=J`U@!]-TK@TVTVFMZ MY#5!-#$B%75IZ`O\$^F&?%=N,&9)B)?K*,SD\A,E\M4^5*)%/Z-"GB&;SI`% M;#Z>&O]%D1'5&Z1"R-R1D]'$A^H"9>J/8AL[:)I^US4T3LE.\>PDR M#N0F37!0#(&.@L1@4D:;(>"$/8@TTU>2B+('@-2MKKCG*G,.DHNQ@YIX&H[6 MSECIJ%!J".#+LZEUR$PVV-3Y5:UQ52JX;7ADNGT`39%XB2JQ@)\SQ3&YS=0J M]%D`*L-:DLU^KS?H1_=1@DHYOI4L9^J"6+6X_TU$WZCR*=0`B>4/7<+]0WXS M=8HB'ISMU.-FMF#$(929#MAB)^YWO[2,?O]>:&Z>XC3)9IUP5T7N(Y,$ZW<5 M33-:9@]*A0(`@;37IB,1>2-8)@UIWRKV6.X'1(LYX4H(X3.%^FHOKH(5PWBN MS"1>@Q!DS'?`,0G!V-"I'E&+YY8H`7[GUJHM-I&./M%`"K[R$74M9;LFK\C` M^."JC@)[4,XC\Z^CQ\J??&OPH[\CQ8DK=7JK"D8'>QUK3*+P84=Q-D]>SCX7 M]>V*W:XCYO05&N/EZO3IO!!7U`L*+O+H!^&55010>NX+_1`M5*L.BU4MSM9D MZGYX_NX_W_U_`$AGPR\*96YD"!;(#`@,"`V,3(@-SDR(%T@ M#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TS-2`P(&]B:@T\/"`-+U!R;V-3970@ M6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]45#8@,3DS(#`@4B`O5%0X(#$Y M-"`P(%(@+U14,3`@,3DV(#`@4B`O5%0Q,B`Q.3<@,"!2(#X^(`TO17AT1U-T M871E(#P\("]'4S,@,S@S(#`@4B`^/B`-/CX@#65N9&]B:@TS-B`P(&]B:@T\ M/"`O3&5N9W1H(#4P.#$@+T9I;'1EOX)$*VAY+LFPYMTDV6&P"9(-99W-8Y."6:)O;^O!( ME"?.K\^K#\KM;F30AY8ELEBL>O7JU=>G3U]<E2;DL2[-OGU;F]/3IQU]RK>T[T[CDW_N_/F6;99YN<4GT@[F`*LJ(;HZ6O20%/)]=5\8W86AKS\S08]GJA;B_295;DN.[>HJ)>&EN M&N318"5BH4>>XP*?;+`O](,N0&K&Z7)A7W`]5YO``4GM<')A?)95XU2=C;ZG M$.#D6K>TOL.'%+BR75AT[J3+`I:ER`5%.[77A.)CG<1LQ=%:I^D]U9LYU1N) M5SN)([@ZIY@B8_H!0.)4X+5;)`N*!3F4V0O0>)07!("UK

MFOP=5]7'RZ51E,XG<53)O93PBOH2 MD&A*"9KTH#:_H`C7]L>_D,N(QM[LAQA9"E!AQVKPE_#>Z#X&A`E!"W15KK,W M%9K-_$'0IWL0JE/*_.GV#*<0;IQ56@)N0:BE4C,(E&=$JK7J6%#3"U\0)>DEF\.,)YX84<>;^TH!_M1.`&/&F=>I3R[)+=]Q:E.[>N]9$$7N$)6$#I:X1./ MLM[9RH$U_@9##+H4FU^U@J9@6E\Y$VNEDV`C:66QEF#?2^0W<-Z9`N%1D2\< MBGAP.)OHD+RX>#?2)0Y2-#C:\9VZX)2&D0%S/EP=R,5U,4QZL)1H/#V=,YUJ MIW"-;YE5GE&1\O*64&0U2.KU.RAM9RAI M-;QVC!'*_VLOP2B9&==6UY$[.3=5 M7)_;+.*R@4GNL8#]X+[*687U`X)23X-'.*5W%(`E[7\9;FP/+`#!4;NK7)FZ M$]'%I8W+I8<'!.JG[I&^OT-G3#!<\(0,_4>\7%`%=\_<;*DAM1=*'%45_*7B MH"4<-.+?5UTUA5%)#OL)J=*4](W^&`-S\8PB*AA?G)`^:([/4G!H5[R#[76H MQKNY0Y!;M(<;OXO5IY[>D;5XU!.*K*IO+P-'"1*J%>H`]25$($Y*'*`)K!ZV MW#8*&U?U3*C=O9B(*(&:<6JDU6(I\'+1IG?F)GC37I'0%E^I89(LN054/6&) M*/'L6HGA?.+=6BS-Y8XRB6Z!TG2;=GJT)FW&39#/=&>GIUT\6HUP^6 M55*V'/-W'G)X]W_X/X4*4O+`V.4I$DAN-IMWO+YA\;3H[]H2ML1RH\UW\@^(#A75/(45;-P MP,GHQXE[]F`^?P$1Y.CUTN4[<7_N[ZRW$0].?H0;>_5!CWV0WG$PD$3)?TC7 MEYLV%W+*#1%OL[3B>C81>92FAU;*)-4EJ^7<34MERG2&[?BP/=<&2#").\X\ M7HP1#*B+C%D1>=*=HE+9-83QT1VF4;(WHXG5-3IY@\X\.R-8=73C-RQ8D+Z/ M02OGH)4S#2K[L5#V(]M"UW4#16B'#/(2,[;\OP'(Y_F$N@8#`A)L:IQJ2::9F9IBJ8'X]-`0+UN;T#U_(3U9CZ?UUW_TQ MGC?/H.FF?)C//HAVLZ<"XLF$+6I@)TZP2%M$/6IX/"J0VKAKU(>O(E!EH[Z3 M;%5QZ9W^KIX35L:%(]_#Z'%F(*DT=[E99[#K'6D0-<)`R;EBDNN7EZ'4M M"7^4P&.]B=IZUPUOWC7U?9QK#C(/880UW:2*JGUQ;X9>72L#'K2/Y#G.0'.* MU_<4%SQ^D25(9OG)Y.\$ASM9`]4M,XV;`G05@:H3CF9,T8(&6?HU/FLR=VQ: M.YA(/-Q?!A@V3I@FH=M2Q8`6B!&4\.+'C^+L49MEJ00+-P4#!]*)VN&_)B36 M)H83*T8H>->-4IO^RCJ!Z-$=222S+HKAVFFO+"P+9=PT&CH>I.\!(CFFA[O` MG^$>I7X52*!"T6-J?#:7:5#)[+F/'R$D",'\_=F,E8P-((954=[-9C,9K:*B M:]QBHCML[<7`MPUKCV.?T`PZM!@H:9C<,#;IVY(2AU+56LW7RS3?OI/X'YW_ M"8[-'4V4NHQ]JM>S.'Q0%5&`K,XDK0Q-#7=ZV*!F#[5?F]";ZT'G#\`CQ'&0 MU! M:]&-SYQ\?3G@B*F)/Y[O`R2[^FXX^H##T:'FJ1TKR:A8(=XXB+ZI&>X\\^C_ MJNF[0R,'@6:RK'P#@;1X/Z.R'68H01,3E!?89SP";@"I;YX7G'5"HT9(JD`T M_CDI&/N=_.?\)#1DQ+&,G*5/M2*7@T<00`G<0$5$0H=6]DQ)QO6RH'$M,&-B ML$ETB,E(C.A\J7?[H,ON'6!HBH<1ZE#(_(=>.<7(2[0 MK?2TPK**;FC\TZC"M;3,OS5F^^:P64)E61QTE%7"T#`0=?`::4]W'ZI]QFRJT08#NBK@LN9;HIP/FD"S(\!0(NG" M!!E\&@X5Z;S_0C+*EW`64.4,JB(6K)8J8*1\F1;%]GMS0FU&80>E_Z,+-\K( MT5-/T.S,++E%).\E,MO2^W![`6`[P0L%FA5"P5H1S$1R([B1N^`R4B.((=N6 M*C^_`\Z?)\PDY&1AOPA+_(_Q:MERG%B"^_F*6LJ<:6[K95FPNIR9PPZ&'K-B M)=NRK8LL&3VZZ>\`_I?(R*RRV]TSYZZL1UDJ949$1OAH8F*S2'T^,4Y.&@8S MAH+"W)1?N',/GTS+/BB4,S58T#%(2?BK8UA1&>Y)C^2IE M_189:3U`<0B(8@QXN2[0#,N;DWNT)6UC]^Q<:8Y!"9JO6$ M[[4IL:CM`X'XX\C2>;SD M/#;DVEC&-=%:,;W``!&`+;7.CM3^#@ADG3D'("R8X(/SU\X^8>FC-K/B!4-J MF917ZA)&16RC8A@G10ZM'+6)L%"+A^RFMR5B8)SZ6YQ7H])QU$)AS*"^J22< M]9%''M7.[L_D)*#]L)#&_L@'?V3#R^@G/GI-?GJG?.?W?V-47LT[B*![@$6, MHT]X1XP63H2\Z'BFT48,/C`6M>K?Y9!*,[&6!2^0N7%AKG^JO>\)B_1IEXF@ M[Z@`H.02^\2=8-%H(0189ON9IKP=XXE[M*-VQK2R(*%N=!7Y`.;"1PM)$P3^"U_G-L1AN#_UFOX\2!L7OX-=NF3,2\*+]LTC_H!PZ< M2O-![9C[#$6HNT9)V=$DVJWO_*M6^B8$BGAY1;F+3"16#?"CUCKFT4:XA%39 M-BH^T[/Z#^E)TR&UA)5N/,.9[05U==MJP\;FH,LUX-G*MC%#=C##C[F:ID5Z MW:*`FM0H)`*CM8\E_4>P%/J'!!<98 MD;+)[?O!^SZ,,O3V1B]??=ANF`_(!`:?G'O(-`AD/@ALC_4I?)K=:#&J%)4[ MRGP]U@9$5L7RH<.@?@YPO?JK6KJQKI3/,F(D,1[Q`;@%091]T7/(;37RF'%2 MA-$URG39:L".,?@J@[W-.&N2J.LQP.]L!T&4>:+L8F7B>W5*<60W6]E-+\.8 MT8R*=:%,?$,9`B^A,0/HP03_IP4W,EW-AW[K(3S#(Z(2@R^PFQK5.#P1@G[` M1B^0=M4>K=\!E9MGFL8KHZ+MOS*QA)_U_[^:;Q\X:6CXN6O=+(.A6'IMK1GZ MQ`_5)=.1KNY;N]?3_7.@\D^G^L4#S7C3?I:1W9H@^5#Y@P2^(Y>U>N-99@O@ MPWHEJD9@R)[O0A+:!A)N_5L$L&,]N?G\WGNIIM/Z'R@1.C#\?H!AG)-J@+() MZJW)>]O%BKC2:@*G;IP&:JVHYT(-/K:NO929)C">N0!\O3.2Y&*1?JBWE;@C M6M=8###V("BTA+DL5]?2%"9J8E9S,&D-8L!WHM*,A"B'3Y>KO+A2(F^8G%8@ MI_D%>J4(Y#L$5E7E^3WK9K*"Z9*_LOBO9R>U8:*6+656J#9,5.KZK#O3$^DI MU!O2MK?E!]Y0WXI/N<_+^*L%P);QY?+?%>%GE@&>@-GN2#][9PN\9;C`O`6(^C M^SSI+1$X(`+1X,8[W//QJ^15QHACCS\\WFWFD5P0(-?^<*0+%4CZF"`OV-B) MZ%LLF:[;@J-=[;.''UAI'I?7_B`)[S57>:?95#-L/9P@1H^U!4D1K5PC9!MLOG3^?5&P*;BN-IF_MU"WB^Y6?-BGR M$'AY&W3#=(U-7=?](J=59N*$'2(Z42YA.X<#$N%!)IXNK%KD682-MNJX'MZ/ MU[\+F@10E-F7:?>/*AUJB671![RI[<]:69D*VQGS!%K1>E%F,3#OSR94@_J] MWJY+O8*RVK7&?J^T6[3>N^Q[Q6\"SQ)G^4N]V8;01D\E^Z#+J4;^3+=%H7M`$M=8[3: M#W9)K"YJ/J`Q\U!+-#C9G>%W##TK!@V`V#7,V=HOF.Q-;4^KE\EPE6W:;67A MSMDJ/=W:6%^2'6DD.J7/]==-ONTA.R45&8!Q:]>2 M,&/O3>-^[19D";PW-+.:ZM%WPS\!\B*`NE%)'*17WA.VC+`3;JFT`CYI M"@V]H#D@Q[`LK(L1&@/M"O&(.WEQ0MIE.C'DLJAO+-6G!_9K,Q&H8Q7V+#]3/.];\HC@Z55/?:H[2^X"!"!308G((;Q1T92Y[UF\DN`].F+))@ M5%16*BKR45BP]2\D6U][<>)38ZT4)MI54_7]8OV_=Q_7[WYY]^\`C>3THPIE M;F1S=')E86T-96YD;V)J#3,W(#`@;V)J#3P\(`TO5'EP92`O4&%G92`-+U!A M"!;(#`@,"`V,3(@-SDR M(%T@#2]#'0@72`- M+T9O;G0@/#P@+T8Q(#$Y-2`P(%(@+U14-B`Q.3,@,"!2("]45#@@,3DT(#`@ M4B`^/B`-+T5X=$=3=&%T92`\/"`O1U,S(#,X,R`P(%(@/CX@#3X^(`UE;F1O M8FH-,SD@,"!O8FH-/#P@+TQE;F=T:"`T-C4V("]&:6QT97(@+T9L871E1&5C M;V1E(#X^(`US=')E86T-"DB)G%?+LN.V$:UL[U=@X068DC0$7R(KJS@NNY+* MI*8\2GDQSH*7@B2Z^-#PH3O7_Y'_S>D'*NGH:[,4)NG;P]/;PZ'W#AS.#T5NR(S(?YX$!7%SF4FSG=Y M;@[M4VC.3V]^>!^;\_@4[L(P,X<*'P\O3]9%P>&7IVT4[?)P'YDLWX5%EIC# M=T];L@P=FV(4.[+_8/\;;/-=9DVP38K$_K.N?#=ZT\^#J7P3;%V(R29PN\1N MQ_K,'Q+;E<$VI8FZH^6I/9L!4PD^^6`;X=]Y;M1FJGNRV=LNB&%I)E]=9%&G M$TV_[%OS07XTNI:6)/8(YUQDR:=_?;\-_G/XQ].;[YT$*BIVN&>,2.&*X3T. M?Z(PW.,9[M)DL9)`1&L@(@G$MZ;N)KUR8AM?33.\R&ALKD-_Q42\BZT?IE=S M[8?IU"^V=6\F#-T./LH=V<=ME.^B-#9;3"3.L8,X#V[HR>%>3GY&A-)=;BZ*AM3R3;ME=?4 M".-$`<9._%V\BMQNGR=[#1B\<,GB#R#&_I054N^'/@&0TH?1B-GDVY$^QS-<9C/2ZC4*XH50K:X MI@$ZUF/5W_SPNISG;'\>RG;\"VV6X(9'WC!3S"0-X?\=\ MK)A/5LQ'C/D]8?[4![SS8'ZA77+$+Z'Y;C)'?R-D%C"4CX+&S+8"&9CT)ZF2 M#H%J9`C4'N=J0IK\>/55S46UM[I1\VI>:AE.%PD?1R]5P*Y)2%=\I!*]BGP0 MG#'(+IR" M&=^,/PVVHZ#B6N(])0N1'\SX.DY>4]+"%H@S/UN_.^\V!C.M,%K!28QHAY\# MTS.P/2+<@)0'+?+7!4[JX.>P?.3;&WBB'\:=TDTF=/.(PZPHEH5<:4P_>KL? M_>C+(0!/V.H"+!_-=X%0J+T%&94V#9N>Q]?6`R"`%)BFL)-Y?_7=$3#D27'X M@?#X[#Q:CHZ+]>Q0BP!'(2TSIVNHF7)X,V>-+X'7/3Z8'O]R>PJP$M\G6#ED M.W)+!0NP&[\TKK_7,A`Y<-3)7&:2-+(Z>+\?T$.)WY5O\VMMG0?!@8K"=1$8I\H,*C1%F2)@OH&M)R9MFZ: M6LJ]%P7I^+0-YL&#,B_K=2(@P"@S[G'/;R`=.5^<;(6W4T!JGSWP]EHK3M%4 M\VF1%?G@37&G@8N?6H[F=:-*RGH@9D87S509#N0S,":KB\R68G44"I*%`&)' MBQQ`J/2MSCTPQUHB'VPIQJI6\*2>P!N[%;+9(V3W*V(Y[!_LV[*;3X!0#%V: MYH%'-85=X1I_#?NN^`.U_^GB.Z-L?0RV)$PW_=E-.C@'C@%#-!"SM&=V!NV\ M>%.K"G#[@SNA$F43,_6((*`@@>Y`/,,B"LM.9["9Y!1JZ?;)8UOBY-+74K)" MDD0;8S025W&?@9J+X5@]\)FQW1+71@]K7JD58((%K!*(WIU@5[&/5.P[^,<4 M1OI#VPRFI?YB3QW;?.*84Y>WIZ9.TQV#VK,P_K).5IEURC#5#\!+8M^^,U0? M0XT>92*898Q`8//9FWD$,7"U""(C0B1-SD'$WDBI.G:D$R^DQ]8BS-JH,W' MF0DSL_I%6MZ)2T3;RH03GMBA7VP)F:F]F(K5CIH"XH_N)@B[;Z+]>]])D[\< MRETVY+);]_>DL`\>I':Y1*=?`8-E.>,ML]R+<4>X7GTR)YGS`SAB6I;J*=+= M/[P&DL\8]Z%'_FW'1AU4MU3=QWDII3&@QE*R[S\1SU$!:L&AC1U'1C.7] M;I6F]0:?UVTZC+/R52)\*@?0*-M[;2W6MI$.N'''N$QIORFGBE(39X$WF`9>N`&J M`REX)BIJ2E#YMW*0S]3%.'8X@A^X3L4I+W2B;:GK0E6R<4G'YK81,BH[WNMH MRJH\4L^B)U4!JRMW-^!V;)VL/MS'T@WE;X_8%BHJ>+('A9!`*7$:,]O:,](;0#Z/INO01."YDK&B+W M/"^@=WL4YN\I2**E28(HC)M0P\]BD?!#!0,^ M]4.KGZ@]!YC;U8(7S@%QV4D_WG4I675IG^)Z*/N[_P*Z0*"/GI9""(* M&NUJ;J':[^2-HN\0MO'R:9(6^P];L"\8?2\'OF/W@/>>(=1;.IV$6= M!D7/_NX:W3BWNJRA7%P]=3Y#?58AOTSCH@3,LFCU#03!=\+M$S\$:K5H2#>H M?IXU\(0V/!%7;?V MV^(7]DU7"DC7MF(B32/',&"U+YC<(VD]94='3T3\*NP9+7ZM9W5L=N/[,,\2 MH"$H:MII=!9#$G&[+H82T>G:4>"WUV8!Y"`<@WC='R91_,`0\9>I)O=Y8\HO M**);PO$[$8(.V(<82F0I?U0I?3=JW<4L?;Z4"!>;B4R0LS`I>E/AF^3DN"%+/[/\[BR[6(^+@\? M*9$B66OR+L-.'RE_'0/JGPQ)QIZ4EFYNWO+KC,K#N'S#K\0H#`/J+Z,-OW)) M.DEUC)B5\O`"-3N7L1V@"QU5JRZ04DNM'E?*EZ.Y>AUQ+=3Z:D0H'#K0[&N[ MF!*%P+:RHF)68M-:;B*V>EHMOPS-B[]>`/9OFE@VX8..YCW]EU-E^>:+X,CU M+P\K*ZU@#5F:/%;?@TJLNN8TZ>4`PG_I_'$#X&U[J17Z34SL/Y&/<*!JD&0@ M0KK:5P,*((;)B#Q@^ORJ50(BR__'>)7L-FY$0>3JK^"1!$8>2Y1DZ>@@F<"' M3!8XIYQDDI8ZH4B!RPR4%'N`7,:C[F8O;ZEE<^'$WKJEL6?D9_<( M_'J!E"TIY'9=IGI_O=/[:]!SJ`[IP MQ6[J=J=JA/&`VGATIV(+B]L/B1W;^2@$L5]KY;8>'$X-B065#057?:=0.NN.O? M+YP+010+Q\@`C-2%"RBKC#\T`II/^U:J:BJ^SZ:1I&Z14=P6Z.XX` MS%D)]$)65$"C%FT_C M8EI6\$(!-WCK MMGY^+%!_W(5"_B:Y=%5?20I`EA4'BH$]`SFG0CD:;RN4"U>="Z$V4"44X>0C M0Y41A0Y1EDAZ4-KJG5]#7:L\CPK+0>6KUA<"94A3YYK M+R")H,8IJVZC:GHUYBC:XTFOA32JCO:.I>3AFHI9)\^WMXO%%:9-)T?HD%J% MCJ0QM"PQ/[NF3-S>F%T1A5)'52^0RT-_ZX7OI1`/.A/F[/JEN6/5SY8[!0TE M^DI2'@Y5I*R8/<;W#O4WM$ M=3_6OF*(DZVW)S/=V)7LM#HNT*]]L,SBQ(P&`IWR?DU-%FKA%NKI@&1>Q>PB MH$L+:.5/;TI3[VL:-=[JW>A26H;6%_:R6*A"1H@I59$<-*K!E,[:&$+L!GC82. MO8$A0H\0E0$FU$))+G>D^[_BZM!V1TLUB,[B<0Q,*]Y1#0+G@'^A!4B])@N8 MKDZ]L_3)%III=(7=JP$K2Q^?!0=HLB.Q_5B.C+"--JU$2&UGVH^]<,BVKOP@ MVW:R.O-EM#JS:SK*"-NO5$J]HU%_]ZR'6Q99$V_>>:/$L9%#<-MJU67S$!:].;W"WX[X6 MM`U165;)@K^7_.?"\_;L3@8)R0_-/G$K![!/'K MCR?>93)#:YW<.%=1SC=M;5^UV=V$7)N4]"XT\M\.2AN_I$+]?\?K)B=ZXR_C"70DLAEZ/0RHY07?I`GQ&$DV<\CYFQQ4W\TG/-'S8_ M69_/K?S*E^JH>#P#\^;;[>9LQ&QC[3ZG3C`[]S/\586CCOVT+VV!7_]%K1*_ZI++&W;3N4.4 MY3K!8V,;3.^\@EQFX\\4E92M1%S\%_DCN3`2"QF(5]D$/V1.IYJ.!/A(RS-;84+@\T)!2CV-34JD]WO2&=<1J@HN5]<;SS@QI+[#!.QMP?R/@F;M< MV0KD(#@27QNY?ZU$W4VZ1N(:NNIV.GW2?#I\,[&O:\Q?U,BC%'G'Z%2-1H;, M6D*]09B@?'5_%L/G."T\3I=<15-EB.0)K<&MO(G&5`F.EM9&$[?9R M^_MI>X=MT,+9^=S+^+4*N.B%)N(4X8I.ZM2!_LTRP'C!N/+<1S^7& M>-'L-*0BG7<3;XS)XJ0$=*C#`H M`/X\C6PMGJ:"C`847'TR98;G)D?7X7W2`? MG'Z7/?UU\_'I:6,KH$B7:-LID?GB3+/>S=^+"_#^SY]$%[.'IP]Q:`".I;C# M"ETRU3)K^$+)O&-"J5K19MY75H"3BM(^/S[=_';S[P`)0:7!E("]086=E(`TO4&%R96YT(#,V M,R`P(%(@#2]297-O=7)C97,@-#$@,"!2(`TO0V]N=&5N=',@-#(@,"!2(`TO M5&AU;6(@,C4T(#`@4B`-+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R M;W!";W@@6R`P(#`@-C$R(#^OX",%M#76U1+R-)=@9H)=;+#301X6>9`EVF(BB[V4W!WGZW.J MBI+MN6P0--"6*+*NITX5?W]X\ZL9FMF^F/=N<-Z>S.QMJ[Q5#^^>'MX\/54J M44^'ASJN2[7%'S^D=1TGIMC&VVVIGEHL/KT^ MZ"2+GO[YL$G3N-KN4E56<9+G^/Z!-R8[WDE/&6W_3?_=J&:87%3$.ZV\&2[* M19LRSO2(I4JK<[2IXS2\/3>SD:C-/JI$MG7KV M(OJ?1&=?9PL.UYF-4L!U3TCZ>_("R;)$Z+;`E!"!:>TD)"`#-GT\[0AV"8 M<39>V3':[,A-IUI'C[4>#]!+?MD.>VPSV!D+V[C4%]4#5@.K/"2@]1"O?F M9IQ9SOL!-=]Q7@M]0CP0][?1AJ2UK?.= M%9?&8_#M@@+::8YOYQ3'C7(&=_1,$;<HG'LD:XEC'M=5N;O%W>;>W"P`#XYM_X-&E-LS`%#3O`6YE[VB M&>&BH&B)&:F=(\Z`2*&X/7LQ1#Z(GFB3@3,86X5VP0DLTGED/DFT&T4P&RR. M>;%[C.BL$T_F_L9)L?G[E+=",*V7R''4P#$4L$H"-C'`6/$)RHC8]@9E]/O9 M>M06<6&HNQX5LB-O2F82(CZ4K3X",37J83K?;PP`@G.,PS(NTMV"P]6R5"QS M(\Q@J,&X_2-75Q4^H$ZL MR@/JELAE2[C\R8ZP@%N?H2*1,#DT'3Q1([LPZ7!6BAE>@``TCC/J$[$#]`XXLQE ME(1`_Q*5^LS(\5%%2MZYJ"3KY+53\GJ0CU]:2UU/WD!>:"?,!IWZV72V;0:T MO%2_[5[XD(VV>I+S(FUB9*QF5K=F5LF5*ZN5*]E*FD[Z!MS63),Y@2PZU<#. MQL.ZPVJ3I8D'S)(GVYOVFJ2KK$H\;KD3+/;"5CLYS\FI.3JL7V5(@!W5R@UD0]4Y+H=ON>YF/OEVQ&TIM>C3)TMF M$%]22V2HJH?,D":0YJ-"(+@*WU#CAQ\NM.@ M3)@>4"M@%WULC@#PF42A<-!7&QG&*&7@MH2/[9#16?)CP_+Q.E]R1(`A?@!6 MO:A(].]1A6JF!(&K&=,5TP?M6_9\ISFLX`J3G"CL*.>IYOH@V@^DAK[T8L,W M(Z"ON++)9H9+:&#T,!XQG/L7D/5"?S73+UTI)K7NBA`FAF/*9$1][D!=.4'* MN9D,0:%:ANA=7M52CIO[,L_7`B&`H%/8D7LK#;;A%X5)791O-\3^/`#`@E$N M.=1I2XJO4^$+MV,ZV'*YYJ#=*;`+TMG"CY_U=._&=[LB&88QI53RM+RAS:\H M^#=A^Z]Y,P(>D"SB>871K@U>]!'-=30M+-*+>A?84^\OZH./U9?YW/A9_82G MMO?&[NE6][/S'G)^T5L=]#MYD4_N*!WD\B?UWFT^(+SMS+@4%V'M(VYMT[)FYS.-*`=2 MG1"A,/ONB/]`[>$6=A'2Y8$2@.O4>W0+]J!+V^BN"#%WYTKD[47)J$7 M,I]2\UE[<\LV"Q39#:E-MFI9W4Q\U+ MFT`C[]WR@`CS[XMA"]#K9WML9JEP8O&,0).04?(&7VC;4L3!J/OQT M2D8A?RHT1K!7Z>Y6&G\OK5SZ52I'3:-[3)6[9S`TWM)TWH]WM!P@H7H9Y_C]*`C.'!!U,;#6#\ MY:*\NU`2*Q[4],!`P6>.$E4PNIWBC`C?\O5&XC)*1E-<,JK\CVXS:@J-@P9!-"(ER(U]\@DPYQL#IEDP%RVZ' M^:]2!2CUHW@:KC`I8^91-14TG% MU4Q^MB3Y9`-$!S/-"QC_RWBY-;>-'%'XW;\"3RDR):E(D""I1UF[\;KBW2B1 M:C>5/('@B)PR;L;%-O?7YYSN'A`DM5MYD0A@,#/HZ3[]'ZL:+_TOG%VBTFJG+X0GN)!]_D.#K+5DUV+ZT"F M2L"X;RE9M&`K`F7%90@X/QBP:("]>64P>4]T/A<&MY:?(8?3`>3CD:7WR,Y<4BIIA%8WO-R.E'7Q5;*D$.2C3,N/6LLIZ#KL_O8'Q+LHC50`..KE8P:\ER25'ALW/ MEU;J/%94"LN*THW\0!.HI9A<$\SA1CSH@C+R)C9NYB=LU,ZODS]6PE=%[8"> M7B_*2UA\^>N[\Q**#3<_:B^P-&HT59U=9_ M=+2SV/+RD\_S8Y!P[H"H^5AAJH]2$&N3\2RO5/C0L)Z/;6=XZ8HV+/U)U$N1 M)WHR>3G(C$'WU<04=IDY>A&TIRP^Y6H;D8BT*5(XC"GY]B92G_.L6/51E>(I#+/5 M:2XFLC;N<_F7`$Z+%4SN[-SZ`-USN(C/-^H.[^6-E*_NHE^!2>Y[]'20!UP" M"Q)&(%OL![;>:2TAR(&&9+DQ#;V9G#OWU>55[8$3NZ;?MY$X%'(#BR'J&@>+ M>^B+M(QV7K,TN=LL$;81U`\9MC#2@O6!]&VMP;+N8$#]5FTF2LM3Z9.!84[U M*DZD%$:15K?4JB4U[0V%Z+^^V:^CO4$\6[)!/E9%&&6OL7;M(ZWFO-@AKBVA M"M]SP3Y77(N*<[<[E]-I'6E+)!>Q3J6JDMM_<2%F`7D'G0EXOQ/,5J^P)T8( MS!1M`"<5'^VN;*368E;)?#[*F0'(YJ;2_G-F0Z&(8N^GA*!1L7$' MYQF$Z@O;,*MK)L=JC(B6A`JCPBQ`%B3CGQ2*?Y@NQ7`PFS?0XGX7?N^CAVTX M<3^E%GV_/K2'7Q_^/:5:F+2H&+V79IM,7O3CFU0?M_"JMC=SEY=:Q:0 M\>XG3XW.T#EO;D;&1C^XUF[L[SW")R!J"D$-*/ MQF&0Q54<;RX;5I`A[J$3[N97H+A8)"GAJRJSBDV0\9(JV7.1>]3_4K*Q[3/M M:+8+8B!2'3EGRR[6F\VXNUQ9*)ZE+]7H(%O[';L)N$0_^[>C@\%YE*>Q;`&@ M0+%YK\,:E2/?JNO$!+=\$$]^#CV%O-\:[`1JGJN<7$#$H#0S4YKG+]/-I/?; MK6Q@+C%`?YGAP".B(FB=TO3\]C6!KQ&$+17A*6!;/1Z;)._S?\*`1N&"`S?Q`A39DF\TD! MDRF3W0IS1;]1*X#3>6MGZK[7\(O.5OL#*SL;T#XV9J)FNB?51.4@H*$%JT2ED@> MX7B^]!AFJ$/]*BL]ZKS:*R6B5B@PLD,EN2"\R8B_;J(^7*"_MO@V5?.$IV(0 M9M]SP:O7%#9,SF:`+^BH^O"JSAXTL&;>?)^,:3NCS@5MASZI5)3A6J,''NI: ME'DAPA]V)C?L\.:;NWAS+DI7R)N9FAA_QM:I!#^%VU>L&*JO<`27\@UC:PL> M+$343E&>:B^AZZ2(8I%93'&4QB0Z%1J1CJY#)&VOHW0;MCI@2(W\[$+$6-P) MIJOM='E`,BL"99L"LAQL>(?/6D].>9/(N^%7A\RWGX/'3(96;I<[QF$]^2HJ M2Q!RIZ&OKR[KHAY'(Y_SX\N[?[[[WP`F3QD="F5N9'-T7!E("]086=E(`TO4&%R96YT(#,V,R`P(%(@#2]2 M97-O=7)C97,@-#0@,"!2(`TO0V]N=&5N=',@-#4@,"!2(`TO5&AU;6(@,C4V M(#`@4B`-+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R;W!";W@@6R`P M(#`@-C$R(#__(I,8?A9K5LBIX#9YB2PM_BW[I7MSB=K-<1WU[TJ?6+VX3 M_)LG'3B,C8R4\J[?:_GK%M@L:LWB]^V_9H=9F=MXNC):).[-S+Z[ISN2S74_CWNB2 M"L,PA)C7\-;:91+5;GAGNK'G!3A=U=1M7>F1F@5--[B7,(#)LC*.CK"=1T11S)E(.1 M]?L%KB..*-XI^TZ7UIM@?D>?U]%8>5,%XS)4[TK$H8@H>O5>-K21NYBR=Z8\ MLX'HQ>W>F;)I>'`8G_]8(%ZPY>FC<=\\75.\+-@I&PT(3A$A'^916%N*PBU# M)9Z@LI8P]`X@1&CI2ADD%J9PB<\70Q&ENXA.CNYV`T"2]7$P!XI\'NG\%T<0 MY]F>+36&_VBI/W:RMO:`B4$$[4HV(`RL8.[(GL:`FD5>K290;\C3WW`!G]O: MNYWYY$O/%[0SG:P%?APOQG.&5)[6VBDAK"9$;ZIN;#VYDA!8W+`TYJZ]F%T_ M*F)ND\TR66WB5\!YFUR:('`),4(P!"#CX,W(;N5T/B!A1^?&`1U=-R!QZ$!, M!\%LUW=A\@"H.$J9Q6T&O&CBY`CB(,=$('<4.QU7XR8LR>=+$"%":3'-.VA^ M7]=]9X81U`X$&`!!?&,XT!1*++"0Y'4>7;['U`Q44VXEF80(!K*($/S"3PUE M0X4XK*.!S\%IL<8%G@@00%P]*",PGE.@DB;K)(JS/_*(>7RXHSS#X,AQ!QN$ M:3RAGV8*K`#8I)A!8Y8`N?BZI]665B?XV]%?$MYZPC'^&_/8=?KIG7D@S.B7 MEE-"/YE[#I7E1,'-\O4ET4E8SJ,RW5%D$^(=8]T[J"/C#X3-G=$S_5@GMFICN_+'\V@4_8N3&[YAG;&[?=@84J;/>ZO M]F"VUDO%I$DK=CP0`+[M-$/_6!@^4T=?%4!DH"?#J6%$9P)5Z71V;4Z4"N2Z.!4 M7,I.Y\9]4R51+^BKOTCN!)NZ$5<;8L8% MX0`,.UD#V"A%240<'=^6K&#\K2FDD@#JO=M_"T4";80<4_NL> M;^KFCUD#I7CP<]5"XHWP.LD7,5XX),EJRTTMM)E"GFW2^R41"B<;#!6;>1'^Q(MF@L!UX'Y20G6&)@2V? MNUZ?O`@#/!&PBT![2;8$Z]G757@Z53S)MTD>UA57+ZU;ZY!BD*[$;Q_>8`UIXV89(&GS[2C5593&\2M MI"?-)WS4-UVNG\!^7YWL8%`RK.*X]G2(HU\]5:742=PHDK M-PF][3]$[DSW8C6YJ\:5?4EWN^^[$PRN.6&E+#R*Y'A@BW=$ZJQ0P8D??V5Y M\(#X;86B'<6P;$&19,&1:$:I:KNISL9T73^ILZ7*]6$4?SP+Y2,G0!E.3U7Q MM-`>B#-D&,(3&$?HF=U,*$_@9DP'`'!U4L-Y-X;\\G11CX+VAP6A\NY:7MGC M5XG^IH^[!M!W!"(*60$?63/0L&(GP\5PLH#&XRR=12*93&I"`EX-8ZHA?-Y+ MMT3:3>L'2SC6MU)N#C.)*4_.>:(WV3!?KM:)G6WXY@RCDK@0,-5B$@O4;8H` MW7.^0.Z8CT^+-/I@T+OV%/FJ^KIUD=%ME(C"]IU^*-;8]W0HJ"ZWNLD MXO%&MZQ;#4S"@:V,WFC(P4NEF?4.L4(17=L]0CEM1!*2#;(Y MT*PMLIFYB6UL'MK:E]I]U:BB92RE&VF(Y"8SMPDVRU9O-/:UY1-CO[(F8?XE MZ2ST1(CJ6EC\R"CBU.#D#?253SI[E#$W3`3V3U>2P"E8HS/C/CG"%8'U]#RW M(%:5E\6.6'D0K^[,W6X*<0X5?`W*1#Q6B>>%VJR<`4]ULK\(B]YW(I].)VU! MO0A@:5L@X[A%H9H?%LR MI)X/5#)4:A$/'T.=9\'U_U6.(*@Z/@%#X(GS,HWNM16II7;(K8R--V&Y%AM4 M`M4/NC^<*H)/6AN(%T[7LC`C<4Y02X31B-N^7Z04;#9&R@(\\%]GCOK^HCT' MA%%3G[A]^QM!/Z$UT50ZUL.UHZ2]^J"AP9C"7C&KPK6(0IU+#=5YTJ96XQA: M7"48R^X7)%%'M5`+KT/#&)TB*_0SQSI$XSMKEA*[6=#-J<3:T,!@6D@;)DKJ MBB(=[ZDUR=$.(-:=W'@:>?T(,A2EGTL+`ZI2.9A'W(7J,UA`IX$,=#]V`,'_ ML?)_(SP?QQXGZKGP%"K5(#!9TG&B2`4[BD*`+*:R>6=.Y05(']OZAT?79- MC;Z1&J(R2,QIJM9&=A(9-H2455=>J?)T\D=K(^U35_6Y](0FSBM'"%``#M2?=0.@CCOFSV-;5E6@M[Q8Y==@A/MP9U\^-^@`ZN$+ M][WUGE!(&::U]LA:ECL4LV>L9MQXH53O!K-S>WB,G%4I4:M&9XG_RL+$7^S* MZT2<^#9))M%#A3&POI1SS@>!>TJ"-12%WG2!I(YT8WV'4XG"@\-).F_R[%5> M*1!.0V"QT,&A]S1G:;%@/62[,B4I)*JVYG^$5\N6FT@6_!66:([L4P@]ES[C M[NTLVK/JE0Q(PD8@\R@?S6?,%T]$W)NI1Y4]FRJ10))Y,VX\IL`#%?\M8`$? MKU^KIKNH93)@/4/+52T"*;G!;4F<2/WDR>FU>@Q4974F&2(FCGT, M:)D=-&LXGAY&=7"WCS);P$KZ(X?J/I_!:S[2B?@$6#T3ROXVW&*"F8A[;SHVZCDK`[P^-OZ50*O"[:H$R7T.5_X?5!I^ MUBT:3RG156"GR+`PJ[N)%X4_WR3!-?I`JVA8AD04!NKX@EY_*V,"S8J@^3L- M.J#&"#I+1E^*FX8"[5ZSW4=75ZM5\AJ>O=X1SUCUV,H8[<*+VEL6M9NQK[6O M'"KS8J;@T5@4W=240$GCZ[_.)<6V-Z]VQR8#F[;LW^-JX M2?:CRF2K:-56;GW*4C9L*Z>YAH61EYIK.5?=&.[,();15\PTM7D0.;I5:B\- M%!^](D?F+8)7*[K*#9N"AU^Y!]S2SY7^ZMY(;*B"0N798G7G.2,Q MT>%S(V4R76148<+"IJ*YU:[@K!L&/Z*62\C0J'U[=NY;?-RLM_GODD,KI1W5 M=JC"43^X"P`.7LUNU%VP)OQK,#_`EVL9$_*?!%V5">$IW\"F0G*?:#ZZU*7O ML*FL\8_U0*1L1!A*91X,@+6T#>=DSR;^(,@6OIL&8$=7-*,2@XWLH3!9_2H" MWJ75X\LX-_%!F\1I"T(XVXF&2)Y'?T7)SE.*2-6.#S#?8D-W:7?UG'8AFLX4 MVL"E:^KB:B)!K+P0\A(9"ZIH^F,TVR?S_\FEZFM3H#!-%$/RJ<\%H?2?%=5I M&;6'$#F+.P!82XGS(,6^@R?3=@MP?D8T6>9@R4+!;O+"7*;Z72-`$S#KNS9` M430S$?#:S*2%2S3U7WR(3IG9`T<(G-EC_3UM1((T`AS7=I"UV(6ZQ6MPQRQVO+F,IUE:*+R>+9]HL/XU< MI@N/6=GVEK*,YE`%,IP]=1#H8%!@ZD[)*%N/R!.*)R]9TL=5+9I]0J":)\:) MW"T9Q2Q5I[9$,5Z M3(HP7M9EB`4S4F<3,)`86&7$J$U,+#MM*^]0\?'@,)[+AY;MOC1'.$)"!U['Q02-K1KW+S7G/P5/@3+0)? M0O:`A(R>GHP>_?M/]/@F1HXGFDKPX((JDY3U4.T'^*UQ/U8>`:&3V3K_G=+O M:1F4:#L_&4"H-E+K=$CM$/,7A9YIX^>)SZ*I22;<$,/62A[A_\'L^!C5_"Q8.@_IQZ@,DBMTC,(?9[X?1ZK6>XK74J0;"L`.G58_C/L(0@^`)SFM1V:*)8B^*-!Q:)-U;)*U;Y:+>#7]O;$G M=(?,/K<'$U\A5H!&<\N;L^/UZH1 MF->&208>:L(4[U)+%HDXRR.US,CG!5F%[$_U2_8]@\O7;S.V1%5(!K9RA2L+ M&6R`A?SV3GX[TVG2IDXPQN8UDKW=+^6EK((V0!C8`E$@8(68&^M!J9?*#7LNFF3PB>].0^,_KX%\_/,W MG/P-<_/=6*LE#-*?;6*`2!'IY*"`3E";L?$F/5F3[-(;`LX^TIH'G@"%+#WX M8*'3MX`..9R.]"NT`8U^CVIU5N94DAV^W[$$9HXGHR5/PH1/@6N;8Q7EDXK1DA#BV MV2Z#MIAHY@'>G('(6*9>DKH-4S1H.U2J$!U4I8%9A)DNK'Y,/C%5SC3=+X&&0S0?90;#9;W\Z M[#_#>R"H`O&\+KMDJ$N0AW\K<"X%NS^+[0`SRTM(;_IZ2"E&*W^5FLFX$EA!5!DW%%3UC@W(^D2[Y_M:\6G:GC MF\N-`69+.?U0]R-!SI<]$<^_%C10T2-W(+#T0CM$CC8PRQN!,,#@:&YUDC_VN)3SXA MUG3AT+@EEG,%+[(W^](TP8G[P.72^!J6B@,+?KJZ,^-+\QE]Y?SR@P[(?\,( MC5[!88;5MU55FE$&VU7UJ^57*H8.+W"&23$,5+R*-\0X#F1[Z1CF"$:=OQO1 M'V'];CQY(\B?+#Z4M,Y=&R>Q[S37^4V7'Q;B`#O.%2HYK%!Y?-Z67Z+3V=00 M\K$>O!GXM*@M3VD6/9LZ5=P'WYL?HWG36NAOW-HHX79F%#O3:)OCZ%'OMB]6Y1`.J8'B^5)V2A[;]&'C"W:6>B,>F$%+=:/\ M[@Q9/Z:@3;VQ?H;4FK$;`IS6$/`BE(HN(?H#*]TBO0,H^`N_'14 M41SSH1[]YM<0..F,I`[WVE$E'F/0_T#&Q[@B)E`[U0^/B,]=DOXUC8/CNRXK M????_&*F`F:6:/\B4&C[\S2HH2XJ&!0S4%,?I%4GB&4VT49>>=;!.*)?/%7: M%,\6$SS<^'L-R1.<;3Z`-D&J89'V*`\!("33Q8Q/Y];!.26VWRI-'GQ*,!N2 MU^/#V9$&?J7=^VD\=7W]G[T4_\!R\Q#/1I*7BSAQ`W&6)*/NB\W:].$7E>\N M0,98/2$TXT[,&*G1\%5N:ZO!E0[$46PQ\(IA MBVLN.DM"K"L< M@-^Q9D=:595MS&^-LJK^6F MLSCCZX2^5-'""&'VN@=A_&3)N!3NMJ2A//3*95C7V:F"[F*T$US0U,M?_N(6 M#O#3&`3;E_FH48M8]Q>O^\78:_:"]H.7)&N.6N4<$\/C=8JJ?54?C1"LC\WF M:3,\``[SS:.QI+'99/.<]()CG8]VHGF;9W!"[PEZC=C?I@[Q8;'\^'+O1F]9 M;.%9+`I$J:<.PJ2]_-C-R0=+0^LV3.,A>>W2R[C(G/7\\F77+=59X M]&3UAX5X]K]_3#TLI4]LQC6E>XKJA*".@0Q+$GS?QOP&X,C%\&JJL,->"5+:S> MS$F%)3-0#H?7*7G@'@.PJ%"`=AC+02T.4%\I(Q-:S`++2:!.J#2LV@+E4UAU MA6AOY,&5Y0/C'QQ(KB%<@5P`G+^(A0IE;F1S=')E86T-96YD;V)J#30V(#`@ M;V)J#3P\(`TO5'EP92`O4&%G92`-+U!A"!;(#`@,"`V,3(@-SDR(%T@#2]#'0@72`-+T9O;G0@/#P@+U14-B`Q.3,@,"!2 M("]45#@@,3DT(#`@4B`O5%0Q,B`Q.3<@,"!2(#X^(`TO17AT1U-T871E(#P\ M("]'4S,@,S@S(#`@4B`^/B`-/CX@#65N9&]B:@TT."`P(&]B:@T\/"`O3&5N M9W1H(#0W,CD@+T9I;'1EOZ,>ARB("(0D>=6QEDXTO*5O>5&IK'S",)#8(=`#91^?7[]?= M`Y*=I+9<)3,S/7V?K[O_O/CP8,NT*U[L55W63;&S75-DU!1T\C,/3C\3RD6>P'483S:R$<3X427V'`Y/\VW3:MJ/9&L:F\R`^,I9WU M1D'D)V;W;!MJN[2S/M'G-75;2XW='*!_W8!F`IHCI8=NZXWF^*Z]R#1%=Z3" M&T%MTWHA?JGE56A2[S^K?UZ$D3^+DAB&]1K-!XTF3J.B71"'T\F@:#0H.E-%[7I=9.`PA7;9D;;NLZ5G:RO:-[:U56>A M;S"%L$MRY[1S'\T/VQ75IM\_>*R3.C,RR(V_==\=LQ=B4]1\/(7&0D5\-C>O M15E"*FT:(4Y<+"$O&NN!L*A=+O:`NF6L,C^1V]_NF?G'?I7IG M+&Z)@J#W2Q#V?@EB]0LN9;9M)0V@R=1DY2&W+:50$F)"4[M^JP;+]YHS/2^6H,'-],'![M"/YHE26^7A'LD=JE9]]X,,<).:!HOQB\M M=_NR]F;X/,JOA9$]V_B<;32->[:39.`[3I3QHO6F""E>X1P:KE5#NDV;;(L= M*!_$E^3!;^%X["78""_I%0+GQGH<,U(RQ"F4+)XE9'<>9\F^]*825&9\]#B, MT%&D7=(D>B=1>2JS6AD(ZQ@,\$PBH]QRR5/:ZV7EUDG,1AQ=<-J(I";-#ZD> M6"?TG:-.*A@!T2X%_6E4!+)2'&"XFYK%+=Q27[8DM6 M*#`J>^^-C4I4T`N,DG8>6P(KOEE2)H)N@7D9U.AL8_.W[YA]I5D^`'$T5V<5 M55=3)O`UA>PQP\Z:38Q,D3,H3$4#7E<(*+"K2!66%&)#]@6Y+:5PUZ@2N(DX ML0+AF_5?.X_W]T#&#D\_8.2OJY[)!H>(F>W%[@"P3E`+J.BV:EL(O)U$X:G( M!),!HYQMYUA4'QI^,)SA>Y?!I>"+P]JCQY4%$85O[_#-#VK"2MM?LV`*B1A4 M'^Y*-KCZXM1[5U^&9`U=LF;U"\<+]8[?SK.X[JZ6#ZN%TMPQLH1FI:NE([MV'U<>X\4#NR4V2O*'%YNEXM8UG2UN'+C< MH^1^H\7#DE:?^%L9\6JQHF]%C>K6Z^G]B$YL8I\B_>.@>+<72R M.CQ9':K5MT#GV"Q@:FB^T_EJM13U$U$_<)LW$+KXZ'$2ZN_2/>2K%=U+T7C2 M>O9`5[J^_>IQ&[.X^XYWN+B^5FXK_:/E MF?NOEQ[R&X&Y]5#/69D)'#J:&EXOY)9XD:N_GNKF#2UN'IEW;%0>G2YP4)U1 M7&NNY`GU=$SF#GX38BZ9;_'H\RWCX=Q\O8?C[E9X+NX57ZWXQ:S$O7/S27MJ MF+CX^'')X7R2&$JCAB".1'V.XO]KP<*A)/5/ZZ'@5E%&*$^@C?MG0,0]4&3& MKE63T:8%IBTJ[D+?/^0W'=GH;6>/EDC$H(+NTB-5UF7,"P]"ARRS_4:.JDWY MZ;BL]]!$R[_T]\%8VGM]MJG4SF>N?3-4!FE`*6\.^8::`POR0B7S,0(#;%^L6E;MR`(2B0+?^+SO2)/H]%L)Z+E;2 M@<"E:$K*XPASX,8"Y26?=Y)#>PG_S#C"H^)Z`JE;O5DI-536#QZ%N'G*!H6Y MRE9:)[BE0M_47JK@"#Y^=6%0@EJ8=J=`3+2A8)8<#DB!2PHM,LIB\^N^,!@R MVPTLV[392;.$N4/&RT.'R:YT+&5,Z61Z4G[`J7@63\^&V-G`,>IK]VYGFZR0 MX0G]1/%WVA5UI=U9/O144O=TAJNX],$\^]<>M=T)`FA,YF=]S#O%D?G;](5# M=92\0`)H8D!;:5[ZT9:&P'"+8DFMG4N.GNP:A8D?C[G&O>U,3DC@Y+:(GHZ: MR&#46?G=$K"NNVU!8.;S:5-'Q3J,;` MTY);-@QF`"+JFD+;.`R(,H=PPZY8II:5CE-+^0'ATJ.->#;OI4#KUO71XSVJT+NYZO1H)ZY+8,?(NPP8OO@?#2[E/'>;#2/18=-* MW'!!\V$KB[*C6F="H1(X;=C`;8U?(%YT/:T%0`AKG1RF]]XR>=Z>S,@*4\H6]ES M$Z`J\D:T+\41]/1Y+8J&*A*UBC&)67)R,1-7TMIV+'C-"NQU_OS*QJQ,QXO)<9T33= MU=55^:`%NT:?-IR:R<'MB;ODJS9\?D=F[\,CRK92;285^L.[L3!N;6N!8,&%`>%7PC)JI0;J>$.]W M1%&>S?XFRQ[1ID3LRJ""@:V6$O,:5CA@+MT)D/G>YI[,8-A# M#0PON)RZQZ9-*DXT=XE7UY2\!J:UT<:FV*I)JS4&=AM[E=O:WX"^+?UWHF]* MBKCZHJ_M3I^UALVLQCGJQ7$46_!`[L++$52MQ]%AO$N53X]N&8_ONES1-LX. MAXQ\MZH\P"KY.2UT7XS%#N49_I86CX1QOY.R59-YW$*SY4,^=0UC]DZ_WG M5&I[E]AK]&=CK^W;7FE,3ECJ$\6ES?*M&`NUB%+XQX\?7A+3QB%VN+JJ*T$; MLW[D3:/W+J/[._(?3G=V19G\'.K@KSIK8\$""G%,MK9:9O\^\BI1%KS_C0VM MXS^FWJ=]]FG)KQ/U8-M\">!8:`41\BR[6(,X(`!+6-4X%BCKZ$84-0;8>)QV M[NU:A2BV`F?"61F1EG(S"CIN0,'8^DO!#W5RW/:B;<([`C*;4YMY:D_F@*AM M`P$H.=VG^QA,%@H[^HE"PB@>]=0/WDM2A(K"QCM>[$1DB1VY4[8FW20.U\E&>W-;QJ$VBC_5%M)98'53-WNU\4\3C>*T4`>ZQB[WF;;+][H)$[;R?=V:"2-;V MTTW"VZ6=D8,E$NV]62_EXYS(C0OA:^105[S7C*W3!%;IE3+Y'1!C(Y6 MZ%N(9L$=TOS\6`B']=1Y8-^5D;"8)D"[E.WB;I,:`6[3?I@4_)RIUJ%,DN'D M@E-U38R2"/)2(PVQTNKXU=%<*$!FM]\O4K5[K;2;8V6H,PG&67EC8E8,8[C3 MQOC9W"C.ZC!S/#:3OQIZ'Z,.E:1UAP+BJ2_Q@W-*%!VE$K!/Z-`WD*P460-Z MOO6U!%%H6L>EF^N3L3+IX^2# MM3ISGI&+I>(7U(:)B[QW-.$;]V0X"<8[^NWFNEWTD\G$S@?19D$N-MH3#GYU M:,39-NNY=N82?J$ZK8WOS!DQ4K43[8,M`ONQSHI%`6[G8$M;ZM*$ETVZ7STU MK3/`](P*^4W9/0C*97^\NZD166SWED1]A?&LFZN_\04>#@]9S=;Y:UB;Y73F MP`;9+RBC"E:A#%>T+_M\ MNPIN$>S])!9"5R9(UQXITJ]20<_KGB?#T4*;ZQBZ MUK,F&7(B_'6Y6U+0W#^9]T\/4&SM$`76J8Y=TS<&X+=)MH^:=BMV=OUD"=ZB M0?/-[E5MYMN'&M_.(H\M8")RDIJ-@M*UL$VH&Q.1-B70,_+9!;J-NC`F?@C. M;=0^M%5,P=K"[UF=+!,OFJ!*B`G?2.[3$>;345]+TW-[:@X^)GPZF MROD\]$Y-\C[$R5+PMB4W^?.H$B=B:/U)A6JOCLD4T#KVT`^^UW"V77R/ MZWLKVWZ"L!Q.B])8L(*1T2&J$("+S(,P7I+#X)\]97V#JCKLERCV!G(!23?( MG]#+?"3GP$::C$S82!#A@QC4U#=DZ$P:;5L]#9`BV@FG+O?Y_W7HU!CJH3)6 M4@L1$F M6PVS@3-FC_2R@8")']]2JH4'H2C&EWCWX).HZ/\2`-V5P6D0K+K*37U+GZ7B?3$3*B=4*H62;4XDTED1G17"1)%QFT:?-@4UIKZA%S`2>[.U@#&U!-.>`9?:2FMND; MSYJ#&[LY!T).2_.L9T)X[)Y[B[&+2WH2M&VFJV<%7?0TW%T,G2^VV[?@'-"( M>1"G#\")?++J8'R7/S[\_N'?`0`>`KX$ M"F5N9'-T7!E("]086=E(`TO M4&%R96YT(#,V,R`P(%(@#2]297-O=7)C97,@-3`@,"!2(`TO0V]N=&5N=',@ M-3$@,"!2(`TO5&AU;6(@,C8P(#`@4B`-+TUE9&EA0F]X(%L@,"`P(#8Q,B`W M.3(@72`-+T-R;W!";W@@6R`P(#`@-C$R(#@N]J>N[GK7V+%WI>F=>?IQ M]_1EM\M,:':'IWR5;\P:?_P1Y?DJW)@X6V69V35/:W-\^O+Z:VR.P]-ZM5YO MS*[$YN[]*0@WB]U_GY91M,K6V\ALLE68)#C_F2^N([Z)KRBCZ[\'95?7Q6*9 MKC;!ONOU:W2+98[?KETLM_@=GLUHRY.NND6RBH-:K_#B>#6Z=HMHE02E;0>E MT>)"$AR?C=*6=67.T]X_*3^=]>Z"+0ABS<&U_-F6#ORSX#@PJ4U056YT';96 M(3T,>!,DPW5@#E-;N?9HL(J"AD^NAI]WBWB5!Z/96[/XS^[OL-HR7$5I["T4 M9MY"8206*BZ%JXL].-1XFP76=*T9L;1]`WEA'5.4I3T+81)D#[9A4%N^10RW M@9D@=M/K.U^>7&^K>U69_S*.5GF<;MB\21C."-S,"$Q$C,H*`+/@ M^FR&4K]KX`BZF+VNRV\PG[&U:QA7&6,E"O1T7(0`#GG&TC5Q>P?K=`?3$6HA MYH*$[R']8(N^/)FBK4QE+[;NS@UIE+`1$J(&`/*KF.P1]'K(O$!W(!9C9^21 M2!(#JKUQ[4CXH[`PM2L?+PR/B(ORV23A;))<(4>`[7O!_=$VMAT'4>K="8)%'HS.#B08X)`CL$7O!N;"OQAP+9TWKOM#/BQI6H%B2A8J1U$- MH4YOMT&K-&K]/3(#5?'$6CTXP+P3EC)""O(/EMU45R)X-YYLK_9X7Q!Z'`PR M6/MM)DBI)`SNC?07N&'?F6YBNL&P()ZVOMAA)4203H%USJ>@A[R4;C.BMV2" M6T\PW@K!'VU93.0E-K0U54TA6!Z M>QS&0C^1EN1&>X3+Z.8PDLW`@A!^8+FC1)+VG\6N&!6JIW""&:;]X"IR+[E- M-J_LGV?S\I5Y;X,WWGZ!Z''PLWFUB)4=.245-]++,[^QT\B;CMP()"%UO9&T M6T5RN>)\\&_T"24#^&72!T@4G%8I?75MU^A3 MVJ*$MB<)4LE_L($]/,@W`LTWRCVO.B7<2%B<>_(Q$F2E^Y/GAHAC',OC[FQU MO_),"Y9T0(;U-%O>N0^3=7('ZY@L_GO`];JC@Q5%9Y4$9%(W\^\;(G`,KY0$;*//V*CW4A,9`&_77EPS.[C\X\ MF?$^PR;4C/BO27F$%'@#A`19`+Y'S0"D/*).DK4IDZ1!77&^25&@*1E#4S8N M90K6X=!WC?E;T5\*I-!_MS[TDC3-[T)OSCNAYAWT;OW@1C#^=2RH:FZ"0[<@ M7PD9&#KQEZA4162SF&)%;\.5E`S-1*=)()OR0&`R=2NN$.#MW/R.:2N@SVR!;F1:+OJ]QZ_>6?.\-EBD2HZ^7@CNJDEDVL MU&INO?!Q1/D\3C3&]Z%$IK;EI$K7]K&2S(5DSJ51Y*TF M*J4(FHI;4?))8!LNE\%MIS)'[I!)%A3\Y658GKIA-)33<\0HGVD9XL**BHKF MS0-KG27Q#5B?JSYJ0\7E5#(8B*"0F7](7#F.^A8C@T]R5RX='`^H';P;!2>U M5ET!3M3]O,CS5VYL*$1<6WK'3)7X%6W.#6DLY6-/',T-ZEJGAKNH22F;?`R) M+84$/.1CXO'2X.<("IIF00K#Z221EC4^.%#UX51#JTFL"%#&J->WUCF>1=,J MKMW?4#HK+>WH#C1A5!?'?!,FCR))9&M5%-PQ\G1K@);VRE5XK?$F/`(#*-S#3R.-%RDDR M#$9_2U\Y1IR\PE1'Z.;SL_,W:X$ED>A*;?B^W61ZH5LY\$CANGL#P'^S]RJ1 MS/^_`_RR+N*NC6> MF]`)K[/[WFM&6*@(HW:.^[B,>WN:"<@09(+:,#R8(PV#8H5O6E,/4JJ@-QLH M1T=&U14V$-9H`:*'MN^3QK]15\HD3*L!)L5"42J+FGN0JQPPP$[%!?V3E$$& MK!]&EC%R[D$=AE7#F68$'.*K0*#V*?"VJ?I)R>JGC*+R5UQSZQSRH,OHZ`5K=';6- MQO@F$UU*XQP'*_5DL,]>Z0^63Z&9SZC;T)M&VHI\;BNT,&DCP<%#S2EUEL*_ MUE^P!^=25US,N9^=*&^$S-9H!K$]"H'/00?I#'NABW9L[E%RZE%H)'G]1>[" M_'.*98D?:U0X2QWJI(%9A@B3_=#^$D;ZHJ&*^M9Z6Z%(0C83$.CA"Q6&>::6\C.)334)@0D'$TFBKPM-Q/<69#?YC0@73:\AVHP^+Y, M>.!N$M[GHYE'E/E<;WR3=>*LVG>^P9122G8_\:UCFDND8#F!X).L*`:DY(O3C" M2II!EI-GGC.?]41;@`L+9=JX*@LH&R")OVN9B)#JPQFR0W'HWMNG"Q;Q\DWEQ$"716FSJO1]RT/,5?3=U=/ M<72666\!HK-NNLI#545^A&HXAUJHAD80`-Z%.4PC5Y:)HMIJJ>1"66CV8(P" MQ.QI/I07S]@/C#M0>MAP1!1P`T3E"-62$HT"!N\$,QTC."*T M[/D-,54$)((`3?PI0V#B*&7W)WX0V+(%$^]WN)R26AB(X/?=U0U^G^N]SB_( M#*09&1W]1O^8F=$9E&4!M-[Z1:+K%=F9&3$)Y$` M!-O)7ERL.:-`1T3$`1$Q$*$\"8+*I!5NG;4_@4 M'X6Z1=:HO#9(54+2@!L\J<%03JXUQTK'+3(;IJAUP4`3:/Z%;W2=1MO2D:N, M#D^01!R%Q(HRWQCB[RKUXU%X5W6(I$OZ\/%"XA^SE3%;]J-4`_:'$EX\\U(6 M]DHZ1)#7M2Q9L6XSL"6&;PA3[NX#%6HB10YDR?J]1+:F_@1K<[0\@;=ZB=G+ M0?%MV/;*%[6V7JKK6&*A["YG3M:3?:*18Z,@;';H'0;'[D!GFEN[&F$MM\.M MH$R,P"77T2JY9Y9D7#TS7@P&=]*33+2K"%?2SC77L`K(-5Q@ZT9QCTP?A*"Z M*GPTS*'I6J]SO0:91]3F.K16L[K)A6LNH4"$?31&N3F03!P(VK.1?+),TU7^ M7L`.12=4"2TN/I<)CFE`U-WL?-O94UOMA@YV2/N])@3`3#=3J3FR3KR^D9HQ MUQ;!Z;I"(W&LM&0U0;[=JG(D[^-]*\V@"PF2NDWR]5W=CF7[8)>1$Z]C]8F2 MFU&D*%YA91OE#:^O+_P+B*SI[>+@<",XW,D*3=#Y>`!,_V*-JC?J`C^G$L!" ML+5TQI@F#>/--XR*H6K;<"NY;&VBQQR@>;RR0'&>F?4`$:V^FF,+P"OD,*=" ML"1:\\\IAIE#4I`P`"<.J/_>)FEECZ*0A[X3A>/)5Y9;QG7-]=E/1XMW"?4- MIM,*ST.%W[F\3CM^#@;J+6&^151-K*X85&!EL!XBND8NC4HO:GX`JT3^W5WE M^)2.OFJ%IAR[JP%-0^J>=N#/HOQ#\INQ--,922E5:P`(Z^R3#==-:[_ZB].( MR$]P:-]-5?8]?.\%XJ[A95I*]9C@0S4*580W)PV9EN!.Y?]*FX\H)NHS+S$N M>M_4"T>4K,DXDGM*M)P234XV'*VL[:.:@1?E=AR,I_6]#Y8RS=-4(_I?;5HY MYR2*L)0(6YF"S1FV.&C8--!A3CI,%:&9X4'5$M6]7HQ".U9FQ5JJ.T4^O1;' MH1HO?Q.BJY'D.16WT965QE#'T02Y.5&(!12YX-,)]"\$B]#5\_6* MW&RFF?:=A&^W\^5PM,]Z@);G_8-]8Q!J%HJH>S\'1';R*F-'M!AO4FDY#]_V M8%!"Z-#%M&Z)G8BC>$J#U>7-^2L51. M-OGBF)&(&1'X.1NG9HEG8<*@^;*7O>@==*9C5?;.2Q)>[84@!32,?I_,RK)I MM[[>F\2%1$(\)AII-0F*"6E<_5OT4390M.6AL-+;5]RC"[MX^L@*WK/HY.BOH)/#9.GO8O.=J@R`+M!.HR3KYT`:N&R@/GCNO29*] M*(J$W,R7I53]]VK#<6V--]'1> M<5O30I6R<"?*F\9L,SL'JR6Y*SH%B11;$")7$P4FQWR$]QP""L-`WZ,,5UK+ MV%)\^FW1A^I+TFP2XM557%B(JVZA_28QYFO,74X(M)0CI_`;Y+LU[Z->,15' MVU9[ZS1;KVFO=6`B5Y+Q](F>7K"QM4:JETC#)1)>0L9QBU$JA9O\OY*6[KD# M'\0L."$QU_20I4PJ'$'7**1JW%N'5&]<`@?K=/=V\%J=HA^EY(.Y.!)&6^LV MQIUAC;"BVT(%(XY'7\-[C)(7O4/;?5.^.!(0NG.-F9%XI:T7T"D8T.MPF!D[ MMRRLI!&)T:'".533RIX(FJ\8UNI1XB8?0,)( M@NM)Q1=]WQHE/+/XAGY4*?DJ>T^KCXS9AL!:YKPZ>:H*0E>2U!OS.3"J:W2B9?ZNJ2&/19%%?`2 ML(.'INT_B%(UI7!2E72JVGW5ZAF"F@A.1Z1P%J43I'ZXQ49B4!VK3L0[XDC[ MA,.NL`/34#>]ZNAQ_#C.\?VU!XK@HJ!(R5CHMKU#=>.92%N1G%;FI5C?:\K> M\/(RIQ?MPG,3MGDY-`%OX`0[)&S`N,%',,%F]HE]YLO3@J"PZ7IJ"BJ2B4YW MSZ(1I1MUP[,5QO](Q1`!BJ!LO,E-3W^'#DT&G,]!6D@/AM4(>D(@W)25*9RA MK197VD,5"K@DZF_0!?J):PU^"EX)0*#`%1.>S]RM:K)_NJU16VR?AD,H^)/E M0SH5`^EXE]1T8O7GN9*4*@Q5J.L^,\>_GF%]E31XS0[B+#SJS$"!O]-D-=DC MMSVBQ,I+E>9Z%E2"_=]7IZH62A14&5FJMD',2O@KKO_]ER_1RDD.=@)XJ>\H MCIT0=I*N-]>*SL:*SG3+'ZJR&$;E5)V>%4`!3,`+_`>+.!B0D_60PL;K8H]8 M"F/*.8/3<7T5WI]D'@BPWMK`]](G;:.P=M$J7VVOVZ*?XT%CCP#$ISH(_SOSK]9->QXZ@@(R`PF-)VG[A M;^L,-^OJT\"_+>>1KR)Z)0Q2IR:J4J\?7?A[X3Y^^O+$`0B4A"4OF`32N:'P M")UF/-.WKWI^GLDF[+7H=-E*,&&[UWRK5^ETPILGUR2S:3`F1R#SWP<>GPA,>G&=FP&1=:U0\LY\VT@8W]2P_[3VB$4^@ZIV=4\2@KN1L_"%Q.T4>G17[1@LU9L&"N M6\[?:BE\;_0C!=S8^Q;Y7H3I18B.C&MEM/2L;3(-,YK.WH'1: M=RA>1;BP>Q%NF>2[]7L;@%O5E_9-HQ*@*!G>7!0..PJTS7!6)="KRU)_<95B M/..=@AU)LO)$!J).`"WWUY$I7WKZ)]K2[NYZ7[@4)GX7Z= MP]TMU8T]+A<21I0X4M>Z'P_T3(5OU>\5I+0-Q6@DM6WO?;6S6(23W_9T1*`< MHX+C__1G50Z]E_3\>P[,[W:B0EN8.+BRK?LL)>(U97124JEFV'!`7.<-M\_, MQG6:#TG1=_]PC[(BB.4#O-.KW[I?K+>)_]HD#^\Z28E*UU=>S>["_01/*SA` MOU_JSI$$!S!IW7\J_%R/^1M`96XE)C M(,-9;P,9C8&,+)"?BYYE3H)(*4JRF0ZY'R65%#G$+'(&)7]<&-[>$-\PI6,Y M.'$%$L&?FP,']95[7+HG6^3HA[+T"_=9'P],WO*1,H(!8E*&,=R;]7J"XM'4 M1::4-8@)(#1/4+&_,UYXN,8,Y,X\1W(QO`:A6_$AR*MDP@]?.Z#'=K"6NY]# M`+O'ZK4Z-F?S.]#]$=!%S01XO4%#"&%U5]V?K00JM_4=LS%_F()']I#@26IS M2>S/$%H"0C&H3*W[;8XRDX/_4OQ:M.5ACM;_()>)("%8A9A9V>^=O+.?TG`E M4DS:X_SOOJM@-V$8AM[YBER06FF3"%"J'CGLL.,D?J"#`!6T5&V9QM_O^=DI M:&([-4W=V$[BY_=6I"0K\AE*0K41&>-QBAGIJX90NK;LU.A5'_)C;8TOZ*`] MZP(:90C<@)RAV&IT#(X_!7YL&+9^`,OGDTG:JJE_0NO_D$F5,#G"!XI41U>L ME2=GRX65]!G(RS*AW\FV,@-O1C<,D6%!SIE+J,V!"DCLA9D726U]O*8ZL$`:7BH579R. M_YRPA^\6H.4<-P$Y05LT+_K1LF_YT@TQMH>]O5_%^=@=8@L?CH3%X/8*EEW- MTRT'PU2=5>R,[$]F]D8]V#)6*OE2XQ^SD9-$*`:EV;G*7J1HEK:,*P]=".J3 MQEG\;D"MBUHPPU'O&9T6<.IH[+D8?.(<.?A*16@"$#0KE$`TE&QS5HY,MSR) MT)64:N*HX7?Q3>XF1LQT\>`4![/N43)/1>EOU@%@NIZ!%6/SKLON%`:0HAM9 M/OEHE@1I<-M+H_Q1[TFON(62R[/YOU(1Y*`B+!6)LR=,(CMX@BU&A;A8DV:"6;/#+!+LB!U$V;/L[=^UE?VR6 MGN9L&3@>[H&X>]M,/B8_7+)M\PIE;F1S=')E86T-96YD;V)J#34R(#`@;V)J M#3P\(`TO5'EP92`O4&%G92`-+U!A"!;(#`@,"`V,3(@-SDR(%T@#2]#'0@72`-+T9O;G0@/#P@+U14."`Q.30@,"!2("]4 M5#$R(#$Y-R`P(%(@/CX@#2]%>'1'4W1A=&4@/#P@+T=3,R`S.#,@,"!2(#X^ M(`T^/B`-96YD;V)J#34T(#`@;V)J#3P\("],96YG=&@@-3(T."`O1FEL=&5R M("]&;&%T941E8V]D92`^/B`-3EY,O/K MS8N/KLZ'ZL&][NK.5XT;?%60K^CFU?[FQ7Z_I83VAYO=?+>F!?[)0[K;S9,U M9=OY=DO[YF9!QYL7;S]E=.QO%O/%8DW[`HO[QYLHV<3[SS>W:3K?+C8IK;?S M9+G$_IT<7&SD))[2C(__-W)_%O780Q^JJ\+%M\EROHK:F/_VSE%WH`&+BWD6 MG631TJC6\W6!A<7;MB&/.:SAY',ZQU9^>'2_R__6\WZ7*^W"UA MB&F0;(,&2:H:T,%W\6J^CAKZ-?L+9-()Q#75098>MD_,TMI5^ MI,:)V,J)XS91/R=ZUP;'+7:;[97GLLES&_._)USO5OW0>\2I)?31Z>AG?KJ#L1^@7,<@$CFE$ M!3!VVU?'%M>NHYH!&57M$1$ZLGG;:*QE9ZAD"QH-ZM%=5`1G;M)TI"#8Q"B`;EPQQ"I,9"PX`P)&M(@#9L04$^)XDG:?K M;/44M,S2[%@%0$!DT35ZPYE]O(ZZ$;^,J[;L9QPA]6.VGN^V:P4LNRQH/ODQ M2U3X8U77*OR4LP>WP!8-';7JGK7@,X%W;'>(.;+.,GLMV,GXW?FF!_(YMH". MG19B:'L7WH_B!N^4++91X]I!;W^LAA/',-E@^:T@;O^.?2A?KA$+R9ZO[,Y5 M-%;>A1WHCX13.)^`4%L^5T,X0/W0%98E7_CP2]5FND9\MO@1=,EJ2IJ5.FLX M"65H*I1P$FL#G&,59$;%Z+VSM:&^6,Q4XT>YJY7OYYH>1*]2_N('"RX7N'36!HY82-@@J:J6C0.&`M&6NJ?S$D?!71V#SPG&)X-@P2!3\ M#)400*7-B\JEP8?E?@H]:SQ48AR`#L6&1^>,.L;^28X87W)XE]?AM?T>X`,A MW#M._]'PJY^" M#5`*82LNV47(#5'@"^_!I@ULAL&-:^Z=CW%=`,QJ.LK/(_[S-O5%A7@#:'BI M#JC\>;P2HZ-2Y.1L?\(8BW@'^0[Z<9E8X=`UUD M=HP0NXOZJG6]^`(UBN.`3.WLQ&=T*P!S/V%B>PV)W7+BCG0JN`LKN.^1WPFN MR*#IZQ-'H/*:?=*-Y/$"9JVC&7YUOW('>O.G*V#@3BIRRAT*J9P#XH^&(.=/ M2OH`TZO2\0MR7*3^FL]%]CI@0S:2411$MG MQN`F_58WK2MY;LW2>!F^N_/C41UX%_88-O+]N7EV_#?=.:G&NDQW\Y\4E,5N M(G$#]KNQKL:BJ&;T0;H/S@N-T*A&(-L0$.F/6*EKU26K.`)(1G%A)I^S"*%"7HT/H+5,F[:N>^/D\(]*6`2)25)CDK+JBPX3P&6F$GFVR62VX1*0,-6UX\&VN'@"JJ.OK/*C]MF69W+C MWJUJSIT7]3/I[W;1=W('KHD:%0[)V=G10MFA,FO0_^L#6@(I58,4J7MM4%?" MJ^:C'K.*"*0_7/!*#?=BIPOOHAU7B=*=75L*7U]GU=0ERU"HA<.`-9Z[6+R` MOXA83@?W&*^%QV7]P(HC4<4<;*0PA3U1Q1QG)QTN?\M5ZY9%Z(9]IB^%N',# MZ>6#KJ@DO<'K"]JMI;30O$:Y+O;7Q_4`^BJY#F#5SYNQ9DKA5E,.Z"=ZZ*@L MP\J#"$2*RSVF"I&0ZZ'2(+H2]F.99]8>@QM>4BO/Z\E*4>):(V\7N^,EM*SB M,MKK/>XG2?X,K'773RD]N^[X6,>I[:I'+U/'V5N39VWB65L_]-+>G>O0#[H? M!%VH"2S!%$(F0XABJ9YJ;`!IPR#BFC"#`%B#LV5P7V0S[@Z#(8!9UZX.L`0(29H&?I-61GB>3CD=Y$)F0H,=Z(L+MI$.J.I`T1:.-IY:X&3_V MT@H)=CX#+HD@"1O<%@GG;B-T1T1_G"IP[Z,+HR4:%R=#R#0NF!9/^+G]ODID MI@MFEXZF>1'Q.=>F5W?1T$@OEQ\Q53[%5.&#$0ASI>D+(M=1D5UEG7:8M7;I MW[G#JMN,A[3;C9CHIII''+!6U[D6)(B'=TTNU6H;V0[)?#MY%&98DW`U5]R: M)CI=[)Y\,B559H4*K,FWWFL26`B(&R\DB+X_7J-2+?]S]O^GW>\B)2!7SHGS8#*7A@AB8`&S"IW,%A2GCK8 MG6(WUPV%=@LTHL*X\1!WR+BZ[V(-`&K0SUATGG1"_?RKRP?\?I_A?UX(=9[H>N3\H[L$O% MZ#ULJR^!TX?!-6=-6JZ\4HR/%!8ZB8D8C=_N/K2`B)(]E4S[P%LU5(:,KLT# MH!B2XNK05<:9C!IPK:3%VBY0_[5:"."Z2+H]?3Q>2'L:S(K2+;G#6(<>B94R M?N&BZ[NCE\MW4<.\^/[_C%?+EMI8$MSW5V@I^I2G2X"@^(!9S').USF]\`J$ M@'LL)%D/V_CK)R(RKQ!EESTKT-75?61&1D0:,6%&J'W\$'SML"!=#S>G_:TV ML[B^_FG4-*%XZ2AF`'AU$AXDIZDC'B!Y37<'QW`A9T4WUA]XCN4T/8'>`6;)`M2;O8=F%B`5]Z6`[@W&?!*4F*4)76-@R MM1C;-$K<;J9POQ#)CVAF4#PL@8?.X4:7[@>Y:.1>2QND]@G7HY07_M6(0/3> M2YQK5W21BJTW2,1OO>T211;?-[W?*M2%AR03=-Y,E'=9I3Z**`7_6T609Y`4 ME)DXU`<.2GZH`O+_?_9/Y'-B?46F6.%K=JHM%]S<3V,3E.$7-7)M%]AC@U[K^=$CBAKY)8T_ M;3_3V/=%3]6"+I(3[LXCBBIOLEX[E+@HS6ZA# M0;.YKWKI-!*Y(YOGNK/G>Q'U MNM[,ZGKM=;WQNMZD/CPH%'+U?Y.K<@4NGUD/.C'OLZ+@92_,-8V>EV:>5F-< M7URS5K)`P4\QIJL,0+XC;@)U%D%]:M3/=DGY;7^546NU1*7S$'U"^]GSJ@IR M^YC+?_(QL6\Z-K2XBL]!*J1$!#2O6';[]J:);^:?[Y_\=:5]= MA:BJG\?`MM?#8=I5B@A1N9;HL8JO0PO)17C;+I31]+B)NM&L/"B@BU\C2J+G MRXC>LQ&FG%_?ED;^4J6S@T6"/I8.$3..L+E*KQ$A,;'^DF;%I;CH/W M-*'X4;QG\/N8DMQE@;PL,@="E*K'IW-T:5+6NT$SBG]ACBF20"%W8/"7*,>F:F\O7![=M MXJGT9GW?%9R/JJEC>*1:OQ!V6#E&58O0%% M[C@MTPTR^BW44F':I?40XG?N.QD)=&X!+MMQ=;62!$_M=MDO:4Y=P9(IP@G; MF-?C1+V(K3N/SCR*QS9+/P5W]<\S^Q=M"IR6BY=7EQ_E=]5%8@.E];80WVS+S2TF.F1^X08BC#E_)?4[ZF)N^=*/QM83/T7$MC[L2(,3=B M-(.5JZ')T\+G`-B">*Y.`OK2'!XGGHU+\W2(JQ*M3>)/WT@`Z]2?1`=8//1Q MLO="MM:;E>,1"DLVX)I#C9]_(1ME$KP'K!=&I6/7C]-8;-(RI1.D^J!A*],P M!7TI`VH=;CXM-WC$$(8H4/E,H%82*`4K^$L?IT+M1&N#\!.[I@_Q4F^MWKTI MW=Y9F2NAX$6,IX!.XQIO5I5]O%FS8$,)EQHOXA_>KE;JG.-N)%Y+Q3"5-7A# MK5I$XA"L"$6-_ZF3WH"+4->]$^+@?F^%6]P+JRV*MW^]1([JK6"G?M7T2>QU9SW4JC+%(I8W7XUK_M,Q&F4'OHN.5!X=Y" MHY;L*'@@1=[2.E>Q#K(XMI:6Y%B>?!BNA@9^[*<^90&-E99D,GB@P7#6Y.@_ MHVED`;K*KU4*ZY2>`@SK1URGASBW"E:22Y0=:FPAV[V4:%==;]N_"^6(3<+]SYUS_P(WJYZ214X\&(PQN"]-B MXC184$*$7TQ$+',>3_(@)(P(I,G'>LG=&/<=DC=+/+:(:VL1+SX=1J\YB.>, MASD6ZNG4"MCKG^]09_FMJ,8^?%$HK.>\L%(]6V.$Z3&Y3ECGT)+"2%WO@H^3 M[/PO`;NS=VP7T!_"1!4=BATEC[-O'<\ MS](:3#=5^I3,C)@=_'T/B`)&#Z5S)]&)2;*7Z!:[B)LMBX8="S[52L]Z"O MEW;)HKE>K3Z0SR(P<1F.Q@JH[,''OO/L&0J7:>K*LSV.\YE[]^M#7)`VH)D& M?2$TCR";6HW3,2E*_]A_WBS(!^GEB_H`[-_%75ISZ7Q!!/J6](.USSCJ<]_6 M'O;:EK#*:*HB*E[FH#`S__.B%2:@=Y4QDPF@7[4H&@B]0NF3D^U.G&6;IU`KDZG=?CR?\5`X3M M*=(\B2)/CS\W.'=.CQ88,+%07Z=&:0L%_6Y_)E",[O,JGP$&)P20^WJN=BM+ MO`Y.1?)7$K$8$*57U)*8,:3##T?_2S/AMO@?B\K*%6QE?GM=L"JQSL=5C7M)/.4@*ZV7NDO8)V,]0VW,1OTB558 M*`W^0;_8L#=+]N<%R[PKR^O#4O8>6J>O;.RB]_1WG2W:+I9F\"45-G7O1P%- M[0%Z=8#7Q79Z7RS8!B;V4%.JUKZ9?1@W!`R7Z3@?:TS7YN=G(?/I*-7-[6%[?=XPJ^\?Q;O[(E\-^O?_SW MC_\-`+N2OAX*96YD"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A M=&4@,"`-/CX@#65N9&]B:@TU-B`P(&]B:@T\/"`-+U!R;V-3970@6R`O4$1& M("]497AT(%T@#2]&;VYT(#P\("]&,2`Q.34@,"!2("]45#@@,3DT(#`@4B`O M5%0Q,B`Q.3<@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S,@,S@S(#`@4B`^ M/B`-/CX@#65N9&]B:@TU-R`P(&]B:@T\/"`O3&5N9W1H(#0U-3<@+T9I;'1E MJT7R]7RQ)4=T]A0:ZR%0R,Y87+UY\ M??KT']O5LWNS?Q^Z8707.X^N,:,S3W][>?KT\E*:V+PE>;D\1>;T].GG_Z;F-#U%^RC*S4N#Q9?WIR`NPY??GG9)LB^C(C%Y MN8^S#+__]+2CG;H53VE.^W\-FCK0]W M<81G%\;[,IC/,!8K,59.YQE/23#AESPP\C*$R;[`R]F:WC9VXJ\SW:-WC7+Z MS[BJX?PO^]_.,)=B=)#+^]P7'L##/332*$ M$W%N'-C+M#?FA6]-86<*.ZQQ/=L7!Z_L0!6XSLTWCGB$MP';RL",5GJ;&48`P+Z1];.&]8R=!SB(]<9#+(Z2 M:H,QNEBSHR9TKG<-GUM1H`Z(0<>Q,?;-OR_Z,(>$;S?TSZ;IG$:,XHZ2:1X_ MGNTT,WKSP/44G#(X&=TB7[2?X,**(;:3082_/T`11ZJD2'&0Z"#$P?TA#_I. M]A6!XV0@;X"M&1;$B=W+J!:I(H86]6(:_:9O7?OPN254_@N?B8.4=(YENL\/ M4?[C6&J],O9R1B[%:04NO1%P4X5G'C2@B\E74T[5-(_Z$T4')'+TO['5Q#D@ MD'Z0('3#28V[,=D\HVR:3OEAX2RU$G9".NWSD58O-K@47XK5ET)\F18W*U.P M/XBV-1>LQ&1`OQR).(I`MS1D)`"RC')M@6OI&R6B^(&(,N&A=V*L@@.3$+Z5 MB;BTSGKNFS63.ZV)H!`ZO9D1)\;P^BPN)H=]6L&)R-=<5*U%Y]/4@H\F:^SQ M:!MBM]Y0`1&P`'K@`#51F?A MP.=>/M2?X"#:B)N9%H2*"J:BA-E\MAU=6.';9E[TF^Z1'U?WN67_&A!WVQ'% MT]72=_IV:O3Q2I;D.+KAE)5DLNN%18G4,VY2G+QLCY3']^0ERB6^VKCRF%U1 M;:-VZ((6!SF/RZP"\AP?;+5!3F%.I>S`T7,<=9U<*@-J4K9%[/]*V"?Z&$84^$D$17=[ M]N5=[:,"E/F(JGA50K&:Y!A5DZ6K_4XZS/A&4W2U).IJ40H M_LO86'.4YU&/L"V194G:AC]$SFE9ZA'QK;+#IA[3%>-*-0MZWIKRT9V$%PA" M,<3'LZ#MG=E'B[+,DVV@5=_=S-'U+?18/9-[2B2@$*X=*3MX>D!!/^)NS91K M;#_!FVDY'EWCK-9N+Z9L;`-K>*@/)`^X5Z?!JS7?%HR9!Z/-J]HTK\(W+S0< MHTA>F"%'%G8+$9.>BCXIWO/V&PK4'%6QG2$E+]^B.1GCHZ^)&Z]=:JE`E MW-Y;L*U"@T=]$?^BK MR)!(VD1Y9VOEE)KHVI\=DNB?K?1(;GUHGFAX&$AJ77`3!X!IQ;&V!TMZ88IZ M!1H&W;IP)QZWR8ZRT@<\Y6BL@1$9I*ZYM&I^TM:+Z8=?K@+19CA4P4"=/M)$4<\_C1:H/'B*-_ M7U5H#L];@1"31M,G-%[/!'+(S4OC'X\I0M';TE/A[B5%R9("'7$2[A**3`*O M\+5QE\%X0IMY'`VLRFM=?)5^OIWR9.81C'`?YO9^8*5!'8@LXK%%>S@FIE'+ MR/DEC9DT^`-%;?"3%@\C%U:=*QWGGHY)68BH(M=Y<"B\M(P^'%#\&"HQRAE< M/.9.&"\AMEI[%4E/>TBP2[:NNGFG$A6Z&'-"KUT3';VV5@WGRG2-AM`Y_!D\-GI"5>I\ M'HGH*M9@I'S/E,J*B8L$J!M;UA6..`W=N::6>+6S5U?416;W)J*.2G7"GIX_ M;2E2M1]GBS+*-FI\G5IBGP4<0/H@&%O^'E()BA>.\3.S+;6GGUFF_//?1C>U M3#4T`;*@.I,1HO=H;$0YGI:NGF7/2&FA$AHM=]B+U?%2CIK!)?)N[M,MF_V- MU/\1H]RIP8\-6@F]EMDLC^`X\TFZU M1>>'38=>Q8%V"VW&R%(GPE:5*X'LZU)3_:&"W*R]E:1T'O`D!(=5E:'1I/GA M&U46'[Z%&940!!X0/7N-R(P^MCM"UPT^];X9)%P4X@&&WC@O/IKBV/^1I4TS ML,5=5[]*_?#K6#,^61S3QJ,N0VWZ*%5QLI6YW^77;DD%J70K=;+Z>Z!D4%25 M?""+'E219B!\^0VAK$CL?`>V;/UHM<(I M/_IL'MVZ@.2@AL-[0_!?TSPH4KAO5S);)B#Z+%D4#I9>QK2/Y9PE)7K* M`;Z7,-A'LK_]>+J\R]JX>I"6TV;"N!G[1A,=(WGA)E=W'9F-I-)]!V$S6<>O6I4&X@JH,FD?I4I@7`1#*_S.N5@>-U,K_$* M@5B5,<]<,?-.I8*J%*U#O2>EIH+"IJ+0"G_XX"3,,D@7T$/6>HRJ_#L0W2M? MX\?AJ$#2?JZAF[N.J%%?O(SI?4\C5WT;'"^D<&6RH1]5O5),9)#:=,'.DQY1 M8DKE$M*YS=!S&4BECO=)Z]K9V9),$*(@8*`--8*I@C%;>4O$I1R#8KRX2.)JN9JV>4D4/U$^4E8&SS?91FI%$2C M'61>)8^^$#<$PSO-`639F80R@[,*J%>_4W,+8^J3G?C=<=XU?AD/HC12",): M8+L;KF:B$V*&-\3AF$'KKLSJ# M\)EZ'-$U,W2=5CG/X#[KE-1!I-%)NQI82VM$`YM+=(:VT_II@"5'7#U%%!:< MO1L2?X"*$%U1VP+'DQ3AU3@G%S4B2`=>5;WQJC$W02EJ\R06TDA>7\3^;,78 M7-I=L'EM)RC[K!7?S3E3@>$ZAZCHWJC$L6W2D8%38V"Q9TKTJCD2J)%RQD9< MT=,4.)FHAEGRV`[8HA0PS6772TB^T0+":=:QK5%`.H-)$?M9ZVJ/5#KE[!N/ MYFUF*DKXP-CP;S3=FO<17,M)=JM9-,'),K*\&?0MK=?-G\D3AQ+N-U_7&S<&7F5?,E=;0\FEDL0C6R&CX_CQ,!^P613$[SA(*C1 M^;_IU>WH_OW"M-D1$)5IU::KS1A117O#M"W0;^@/BE6`06G`&.X],>MI7C:% MI[A@[2^F"OT/D6A@T-6$$'_M;/!7H\!P!B<*_#]$]RTL:I.5;[D#)TQW#$8;\2/,?EA-(Z9&T=3D*Y`C0*'J;(4 M6$["/Z=P;N7N04\<]Y,!TM\79_25(O**LE_.;.PC*I)Y24+7N,!M^"1`'?]D M4/=;.FFH90&`=*#+QKZ<_?`C-/^D_>XW@#^5C",>FO!,?M'8M):&KB'.,M&K M&67PME+C.VCZ<5_Q6J3HP:UN M7,3SO/,&8T$H3DFXL,+(8\I,4@\_\SF]UIBDA<5=4Y7__U1]V,I)\E7%;6MP M+0D;K=GR9LV6C/W2K=G8`;R[)R8BKDH:C;(UYQ;@&A)-05DMRWI9"^F?@PV* MUD_RRYBLH/X6U/4&1H2276N5D_F+8:XMX!T+62.^R=]*Q2?7_0@:U_!QNV:C MR'[(/#C`ZZ=^#LE4BX'[)L8T2S[T`IF)@-?PCN?(""R,X,` M#<;(F=W%B40!2[C,TC@BM3X5YRG;^2$=?HY?5]A>U'P=K\P9;QSW-@WHTD8QZPPI@R;8^J4W,<2,T:F2`,;/:O53F//BL M:L(]L&:<9S-T3*-]KP?/)-AC42O$C9V9&YA33_?86RC"OIN6PED5`>2SJXL= MNE#U\RC!H84$O:P,ELNE.Q7J:EU#\(:Q!QAA(9'59T4X;D>UEJ.0EG.H)$L1S/TNLZ6W2I<+/]/00<47#"ON_T"Q$J6<&9&ERJ MDFN@9UQIC^#]JYPW2LF^G65[^-IHW#0C-P#LQLG/X_N]EJ;_M^]N[Z>H[ER.+`N@2G75A.^E#;N@J;X*L(U'$T\EU+G M=A148*'>4A]T_4'3UL\A=!J%&6F+>YN:)+\_`1?]F$@$`/'2V9/M(>#D4W[, M-I^KA[K72U$\$,]2C6]MB+OG#7LE;!_`'J5P+6;/Q*\0(?&#W)X+2>-U2.V& MT=[,4$):[RE85!47VQ(8R=6V,&!KJ2ECZ%\?O_SYY;\!`-ZX^JX*96YD"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B M:@TU.2`P(&]B:@T\/"`-+U!R;V-3970@6R`O4$1&("]497AT(%T@#2]&;VYT M(#P\("]45#@@,3DT(#`@4B`O5%0Q,B`Q.3<@,"!2(#X^(`TO17AT1U-T871E M(#P\("]'4S,@,S@S(#`@4B`^/B`-/CX@#65N9&]B:@TV,"`P(&]B:@T\/"`O M3&5N9W1H(#4R-C<@+T9I;'1E^OX*,4M#W6U=)K-DBP`8(%L@;V8;`/LD1;3&3)HTLWG*_/ MJ0MENWMF$S30EBBRR*HZ=>KPV\N7?]JNFMV;_6GHAM%=[#RZVHS.O/SY\/+E M<"A,9`ZGEW);YF:'/WZ(RW(;Y28IMD5A#I>7G3F_?/G;KXDY3R^[[6Z7FT.- MP%?9"B*Q=(FCK?%;A^;O-A&>#"'O[QL:)&NPE.2T]*OP6_67*J; MZ<--M-MFP1!&^#^;8[C)MGE@PPTL!:;2]R[S;",QLDRO\ELU8XW5\]+I<\?#:ZO:L.JZ6J\&3]V#C:%ALD\#4PYL=Q0J<,4ELZXWG!8 M$(QH&V?)&HS]&HQ$@M&,RSG$N1HW\='8\3BX8>R5,A\'P$N,XUEY>S=U&Z;R MSC,OR%T>L+-Q0+[@F%4'/T-*U^7*BP?R-PD6((YW"#K&3`1T+(>G"'H'63T2N?E08);F=" M5Q*,U65Z15S'N<*F-($.GVU3N,99NB(1.;F0XZ?(J(=_X M(U/DT^A>CO%:CK$ZK,.D?>"'Q"G`B9.!ZUJ>C]1&.67TZ:ML`O#S0S>9TS#^ M`*7)BM+]&BK&"^)4SWQP^-2?F4"(G5HN9*T\SF\97/2UMLN\5F4G18D`3/9Y M>MUNC3FT&/]8VHS#!`?,%8>``DY]`95-0V:0`Q_=L4I(CLD16%8MZ;,%B].,`@S#8 MZ3CHJ'87-=6C>]G)5Z1YETIM`8("1,7%E02M>?=D8!K[9KOA^FHN:JY?3OH$ MXA^M00!MH4'QLK@LTK!^BZQ,'?J9_=9FZY=&"\:JN8Q>#_HR=*M\WIN4XR?BW M<$_@U$DSP8Q)A^AS1=`^RJ,')BM7)HOD'..(EDQ)?;?-*S@\S(.WJG,-W$6/ M"IGQ":SH"K4;:\9^'##Q12`KXMLW9B:";L,QY!?#?10=AM^JV=AUVNL=*'RZ MCZ2UGC'1YCDM=`2/CVCD]Q-2+_\&)OV1:8,Q#"RGSSR:RX$J,\HJQXJ-3/0H@2[NF-J9T2U2FO MR)M2'#%PR!$?!*3$0D6@4"V@GNI*%$FOGYS^ZC"Q*L01F/*]=7Y5*Y7D]UHZ M7>.3H2Y\P.TG(7/Q+4-)E=B\NQE/]A=655?]HO),WXZ"(]?I7"=QCI!!U)%6 M\J4!;N5Q1@!1[E34/U&7E5$7$GC7-D-6!F9G M-)#S2CJ@[L[]1U:@")Q,$#'T6-[IRFU)1F&2Q&>:[C"GG''K&HGZ0\JKK49( MF9SJ`P5-OXTXSI4A:UB1D@Z@?@M`[!A^-'?&+*`";O/$,_Y'+"78MJE`=958 M&FW5W/@SCB^J,Y>B)`MR`O2:;)E2*2DD14Y M4CO4]CF]`YO&2!'E#UKN\XJ*/JK,QW7I#;TLUT_YN5V5M&`U5F[W1NIZOEXG!7BG3$ M[RGQK])$UH3=JRYG3Q]N#:S<3C()P1+QAO8)M#SS<-G2P[W-8(S*SX MGSI)]&/LW^]$G7I,K>J5$[TVQX!%XVB_+6X475JK/&Z9:9DM(_*L5QM"=I"3 MSQ.]!'("HGR;Q?OXC^ASZ'&666^])0L`U&&_UAMK8CXGW]$R;BFT]^GF53@Y M1^=!6'7993+^RO5TS9(R)7:Z>0SI">\8VGAYJU>ER)]S]96,+E*'O)."6,\/X"BW5T*=`+PH>-]H\GWV$*E5`<9Z6YNLW#^72E:X)(^XTE(XR\/JI9/5$OU5(ZHX;CTRTQM\><::JKNV5*X68O3%'E$![ MFUQ-A4X]"PVEZJ&:^HGGY"!1NG.-=KQC%BO?'6YA9/?(&*SM-)V6;NO=*\2[ M';M5WLGVHOBQ?\ M4?[_+E,V+L``7-H%-VNSGIA7[^H@\S50L3-$#6>="4J$QH'>Y7K5=T47 M9P[,4?52D+P56+7(-"'@2:ZG@NHI<&.SN59$^]+_F0#1L`8"(=U$C3L1&%FN M4=N<*^IO'+`$711^Z4JP9[BU!M1IO(*'S0B)IP_IHP`CA?K1*,>YR7,;) MOUV8Q:Q>.A"Z*_+\5G64];\*!7$:L:Y;2'&E@;0K;9\4`,QI'25FXBM)%IQ[ MS@IKRTP5HF_!:Y.63*D5SI<\]Q_@??B3I"M=TY5[3#_>LM+[+L*1D+M*(*I_VFMZ[-8%F*VUJP(@Y7NG M:Y8+M1<"]OM7PEVYQE$;T+4B^)EW)]2`4('Z@"6KG;.?7?5?NJMER5$D"=[G M*SB"6?5:2T(2=9S#'O8TNV;[`Q(@%38(:GATK^;KU]TC,D%2UZ5*F21!9F2$ M/UH01+9/`V-ZFX7&^I[OEK[:Q+[:>%^%;B08V.7Z('3!AI?"PX4+U55.@IY_ M82G5O?;V(?RCZARG-P(C3@E[P(2QC)'52^Q"G9;/J M:A7DRLCE2WD=5%XY/4NPE$,=K:%Z;LV:JA;&^M30POM> MF[;Q]RA?5SM\.J+OM%M]J:M(/:%7`DD>\JJ70KB;5&N]CCIJ M@=743]_;AX5;@>?F^'4;PM8-E04`K_NV>#Q0)%4KACTJ%P''7C+S9MUXDB^: MN].Y%:FD6!_D)E46WIM;F(D;@_(*(7VFC$Y`^I?IKI*Q!EB?.L'HNY(IPV?/ M*YL3(GRA7K_V=B"^,8"#*O')G[(IG:<\]U,8#=L,MZB@@/?NFOAL)[]1<;_: MW$%Z!$728+]AN7^C6Z=EY587L[9S5],/5W>97?.W_?#Q)(%C$5&=3-795O^I'SFXV.S)L>P;C,_!`B MGTG`N0#^[ILV6MBECQVW,4]TA0@R`0.XK*&?H8KFH->WTNMG2CN<+V@$.\QH...+MX7"R%?+YSGWXMDOJV=1]4X"QM^0`[9Q#EC@?'79!-] MEQ7B^"N&[\*'K#`RY_QD$9*XC(Y#*QGT=,YPRB@(I#:._G.P./;^FSUM7*I] M5ZC)!#F>'/L"2G_0,?_&41R2NC:4[@[01ZY;?3(Y+Q1OK&Q0ST M@7B-"R!5:WB!M;OUCJ`,I'<1CW1AQ?C*_3(JT11LG/I!,C"5_.3$+T%":$2A M!XW';+SAH@@!=K*,S7`QB9MX!M/9YCW;#B^/SN-U]LUW#=Q\6G[/(FW"*C$R M.;7)/`(X3V#(\UC_-=LSP,#D@79+(+1OTC8GW>"=UY:GWX:Z/;D&F^K*?R5E M>VIN1(FA+D^`^;*?VRI(3(C+M>X^1!C=Q`-N_(`GP%W%7120I$-&^!]K)S*- M@`8FH:"!D73PATW#P&AR;#KP_:^E\?[XOC1Z'AO=-?\?*.7S/#;>M0CC+`UY M][_/?@R%,N)J:PI6T3T9FO'/ M,8E?1L.93CKR5EPO\*4/M1B0'7`3OMI='R`%K\P7_T4!`2*>AQC9(>8HB'FB MM[5NCO>RVRST%D3I0F_])?G\"$_8$GE<6-:+'"V=[(+4-=VXB(\G:1ME'EG) M);E_LL^LNHWNN$+IW+JZ\KD?[E\;,'OC5';U""#\\N%[T]-UY;JN0_H8WZ]K M(WGRHJJ?3.31:BT#O-V`P%D^=[8S,U512M&Q>M3%Q5@R`(H(`"PI MM2_;Q"4,^G-TF1($BC/6#AO,B_?G-$5N,)#&5LB_?E$2&.?1$HJV[#4,@.SL8497(Y4Q%TXS3<6K$B9E0$P M.EC&TU).0\#,M@:9=T38=S)J.L>;]F9VS_^))Q>P=V+(H^,:=6& M?%AMS(,_1V[>DO`[HTA0TZPT;RY9:+)B$8>YBF,F>!;]%&1="R:G4PXT69-`A?JFW M'U5VX:<[ZN[#Z0H[W>'I=$4:2T$R^$'?WUT/%[YQ/2F#=#YXY?%"?S05-G-KVH`/1\<' M3%&NJ>&.*?OMCWGX"KM?%&S3A?S$NJ)M""2V2E2\UPM0L@G4!JRVGESR8_+` M#*PZTY]=XUU,2<`>YKHX( M+;%C4[>1^.O=T^HYU*1\K\[5AG7-Y#4%/82:@L?!BP&;-H?BN&!3'@U5X-X; MZ@ZT#_66[8U&*7Q;#6SJ;QB:7-6UEVC^ELO8'6E5^HRZ[6(O$:0X>S>W_P\`-S`/ M;@IE;F1S=')E86T-96YD;V)J#38Q(#`@;V)J#3P\(`TO5'EP92`O4&%G92`- M+U!A"!;(#`@,"`V,3(@ M-SDR(%T@#2]#'0@ M72`-+T9O;G0@/#P@+U14-B`Q.3,@,"!2("]45#@@,3DT(#`@4B`O5%0Q,B`Q M.3<@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S,@,S@S(#`@4B`^/B`-/CX@ M#65N9&]B:@TV,R`P(&]B:@T\/"`O3&5N9W1H(#4T-C<@+T9I;'1E-U@@%&9+,OU56G3IWZ_O3N%]>4 M8WUU'[JFZ^NS&_MZ;_K://UU^_1NN\U-:+:'IV)5I&:-/WZ(BF(5IF:3K_+< M;,]/:W-\>O?YUXTY#D_KU7J=FNT>@]O7)QNM@^U7VBB5C5ZB:)6OL\BD.;;( M,[/]R$LV":UYH<=U0BM_M[_4P[?!L'U!N%X5MFZ/0;H*K1D[^?TLOU?^[X*7 M"#]]D.%_&[R$T6ICSZX=R\:\#XI59B\7^;A<5,%%H8; MV-'K#-?N_9#1H3:(5HDU^ZZMIKU^&_VWH^QC]H^GTIKYA19A3:E3S.@/\R/# MLWD]/4X^F7-Y,_ZXS/+MA*GPI/A M*EK'[$D)<3;[,Q.'8K\+'YE+(`N]=L[73O&KU\ZM'[\[.Z>;T)I2I_AKY_/( M8#I8NX9=!YW23;T!(%YRC'7B[9B.-?NRU:G5\@AY*?4313>V;EAYV.0+U"24 M`8+K=>)O&BFL/S1U6^]+Z*(VB!&!RARZWM7'UO3N*/.F1F>,P1K6=T&.=.C96J1@$:64SVID&'HC MPT*,O!E*(-N[[\B2S$YU[S3<0!'3T1X4LQ6;T(."TF#$N1R']FC\\XF]X!!`MZ?#.2;>K2E<29XS M`UF5LP=2.U6U&XQ.:#E\E5DLYI'%#G3,')V4&8)C"?W!O'**OA&6`\X:&K3$4:`$-CI=]B+$7)1!$K'9>[=$8)5(`.!%'PJ M%A?P?$1GI#D"CJ2H601CF(:+`]V1X8ZC;,\,+-ORE-'1A7`Y\1.A"==/*-!_ M._!=U;]$:YJB8,8Y0=?Q?'@JAVL`$C`(P]('(*$`=(>9W1#-A.F->$TFM%5= M,912JR,CHPX^..A`W:!*./-:-XUI*:<),(2+T>S&0%/22%ND3!% M,V7HB8*O7+#>$8H+H)SP+8F>,X!Q7#-53NDD9:1&1"?=,/AYN[KQCR/2_*0; MCT(,;/.<6W0>IU+.>`NMW]C[2@P72,U!C=[F*GRK*`6C$'B]]Y3KIX,^[<%H M"-O4.T#O@(H6IDQ>8%IQ)TSX/LTE@H3(6&L]&8D&@1"?`)\#JF[_D/3Z$HC5 MLH4_>'1`:VJ7.8X<-)2M"U9@9?+P_I8E'I!*VSPOE4ZBI8IV86?&_Y-FZ"#O MX/4;'/Y8=7E9P=';6"H;!]?W*%!##<0]`RQ]!ZS#F9P9!:F$#4E.<2GFC%)- MP%%LY.ZKX\*T9HX47MJY8RV4Q>9'/#A,>RH8AZF13PV4%G!96.@=-SI6-721 M>EF]HA]J3RVS6LY"7\7,",&NZV]+3RQ`QEK\=WM0G`ZGFK.PL.VSJ0_F$=7Z MUC3(P4]3#V+JJ1)8$"X1PK/0\D?B8HVFTG%])$+>6"8+7/S.Q!'5/67?B-FW MF-D7E1)8/.LWU1P/;A9:55A%?/WB7'DGN0X<3IG#H%TP2LOR'23>VN[NT'!)MPP7>#"8.YL`5H2D8`R;^0KT,K MZ1ARIA3V:`*D<&'G(A"3%R5?3FZ^83[?,+=$[E3)8`PI(R@MSMK,=H-C?J<^ MR4RM3@<*+Z,^$RN?G-]Q5`5T$N=L__(SC=YS0P9_L%TU"VFP"!N2=@M=`-?&A>#]5Z*`314D6DU MX`2GBMKP=J+_>8T?IVI#B4BV2F%`-JEI9S]H#?NF-PL*"QC;&P>%;^T M"IEM=,H]XS+.N-B*KO.+V=/[3LKKU%3F@66'#GNJ#OQ.RM]_KJIZ%/9(M`EX M9&?A[>S_\#:(1#+\Q%O4GOQ/YE7W)HMZ-TR-UC(6U'-AX<:U=[H?L/XS*9P+ M\^V[8=2DH6Q+X#JF&.S*%',DFX%FM1ES1E,AN9E70]L)HUW.CL<;G723D!+Y MLU[_)_360;_5#17FD=87K)MRZ\^O"/M0&EJ<008.!:%R9]'A,ID-DIW'?B8- M*LCSKJ>`NI]!/Q[<>'N\X4,MF#$5IG.?ISAVAP/J6'UUM(RS`R4!X*:WOKRX M:91[UOM9K4&HT1$!^ER0`"DVD$SE9H&6A9N%<,W>HEC9@SW<7 M3CJ$NT'ZIFNOKH?JA59*\JT"+#PR,['>1Z MZ6M_ENXY]Y>2E>MXX6^A>M_`])+BWP+D.Y65E-,C!),C#T*[\@',E_$KXC^K M'*IFMIVI9BG/G=U)7X'`ME-IFRIF=F>ICLJXX^CF`C&W(M3.D>K0U\NEF2E? MY`2H`5@44@`MAN&3-B-74J*N];T)4ZNK ME`.XG4JYOFULK]HCL^>SZ_=SEU/_QZ]0U'_TD/ND!CD]`T2YG&6 M),2!]'H^!X1YO@7L+TD?J0/S*([N#HPB;PGI$K($_9\9(0A)';\QV[QPVHC?6$W.6!9*8 M1:`68+=^8[]X,_.]`NQV=^S%%E#UJNI5OGR9Q]'BW,C2\+NM4/@<1EP;,#71 MEXK<&:6.)GBG\:Q#AV4N(F<"]GF<$N2YI0]F;[&8O^B5<9PY&I3_:F,18\X2N2X&Y\\D07DWY9((4'63/B<=?< M1N[=WF_FB5R.%>&N;J;K`N+*2:.11U":[45E`N$555"(MJXKY(GRM-3K"KP? M<;]PW%>='S,S&9"[L>/-W:FB:__X5-;A^Y&'$XQ0@MVP/[DF>`^ MF5GW+QG\BZ4!;+'`@7^2!OB<@E?P)&=!EL?)ZNI<::O"UD+;%8GEDTAG8SDE M*:]@UP?[F-ZOYZN-\$V]XYD<]$TOI/HT%3G<9HL?[S/>U?`+U?FRHV5]_.O# MQQ6:?[I'L5$8=%*8R*T?BT0RM,F5F MCK'56XQ=86Q12&=K#ANE?HGJO-,^<:274V6GV^)T51-^UT/A>J[403M9V[5O M^&9WM.$=A;.?%+F,/OWVP'WF[I/"D@7YHDRH,:JCF%0AH/7K$-CY9(/[8,`P M?]`&0C;::]6'U=W/=$A5B&'N97**.H(PWM$O_]G])'X,+0'*YA2'0K_>HAOZ"W0OBO!X0+4&A86P@(8@[N$N]F+4"#-+G7Y M+51W/U7*C!),E()8GLLZ!`L$M@KWJA.NXM9'\W9?APH>9WD_H_S9O3KE!]WN M-=+9]K5YN(FH_&9YD2;O!]^-T@0E2C`D!8*'[PS2_N(69V MA-LSI_B3)O%IN.+4XBE4`2_,6G(HH#04T-(+*)-!\C.%::5M#*.[Z(CDAH&- MW?>25I95YFB$1U&E7MK>0J#A]W:HS)1AX7R"Y'>1?U!JLIC5L"^OO;^M&G#> MX\D@@"I\_=%)H%'%]S<'Q_?T]KY*M&Z=ZKS=4(=.%B0BKI!,'UZB3O=M%S1E MEY!")**^Z92R,^IF,4NZ*(UPM_&-51WUWN=.R4KWKTQ-O+P=72-_FYYF,WIF M8O/8W]?6:4Q::REL([X+TXJB(J.VWRWV:OJU#,-OWW?(UVU@L;9$U67P#1O% MM)0]5\86>?P2U#[NZO?#V[/EL[/EP2N\.EFNK:7TN6%8E!!7H\0`[DA&*6$% MBH2PE&B<&J7(&?P^]LOHI9*>Y4\H2"@_8B@WIX@T<#0U]54.`H0,$DH.#U8%,J.S_L M8=S,%HD.PA@_;.%>7_3I1'K)??H^6?@V>?]K7157`^>) MDGHU%)3`6BMNS<4:!AKBC/ M6&\;6]#&WMI0;,U2M:#;>[K9*=[IKV]:&D6;][&U($22OU;C"ZN"3K#W*IE4 M,&EJI**M4=%+T+*U0`-N5JI6\5]VCX`BH2.6(_7%Q]:UWG%R=[&5RE9*(:>[ M4ZV\T&NP0A[,(V"_X\B3N=/X>!K-FC0)2>>IA$E['ZW9A%:GM&-B39IGP,5L MI.TI'$J]PJGQ+O,!EY,&^+BHN`XDG94'P87QCM"]$J;M:*-V%L[>M>QAI%_- MQ[UIGHVPV'Z83_KR6T+2?H"4LTU$#U\4)O66G-\O[][,MAT0.#`G=6+7RK\? M63GAB\6S#W;0O1]E_NZ[`PX676K+D*%SV/4JY)#0^5RCSW@29=&\_L/.\2-[ ML1U!NK4[,9"1B4EEA"LXS-]4_E\O*3\7++15?,<_Z-258,%FPPJRL1K0N:"H M4#K'9C;=9K0)R;69/!)D,9"DJ/N3GNM:CPUA>4S2$)CU0+K`=48MI`+?78/. MO$8AEE@\9ULD#5C@4!J^#B5.1C6&P9JU)UV!YRK+0>T;:O17@WF:_A?-MO3^ M^OB8+B)D]\!,HQ*SS3;`?S%F.FAM^$NP?ATUNK96?\FJ!">[(,'Z9#*CAKS4 M%QL%N8MY]MLOW>9=B)C,G^Q[8:]L&"B/VLD&ZUPJ"*Y4Z"_O8YJTF^VIA(VJ M#BSX=KYB.P_O[_J3Q;)'C_51#Q=]V%O=K"`@)4`/@M]L'=[&SW,`Y3V MKXM\3%6_3M:^M3HZ7_1!;FX4C?/76K%YM0W?F^WQBVT!".Z"VGY?'_ZMI.GD!>U=,C7`T7&FYEJ)(<]''E-BX`\HY;JO@NBJ;U,5*L9P\%_[ MA,V_'["&]+*$,X<&V1-:6U-4A?_LD]2A$QK%>0A]KH_*BFH?8-XKZ+LR>#$> MO^`A=\8E6PT*ESVAF3D\^V\WH>_KY-44OV@EM^R#W-G M[^F+=XW>66XC];.89"(?CTE*F:3QFQTFS)$$*,9KI4B6F\N9Q^AWSVQ&[=X' M.],V=V8F)3R7,D4S"&6Q:L3+GL_&]]8O>N]R1VZ0"T&IPN\U=@-A99.OLQUD; MP-APJ\+K?3"?$FLR#K8@W^VM:1:0AE M6:(@=7'`QL_D['7-5/CWL4X)#NGG(L&;=V/&S?L^YP]7EQ=$N'?B/V>21+67 MQ?,=W*A3KC[_(]OX15^O*`,B-LT-L-:E8F-UBOZ/2Q,.^A7DPB3+M9W]_X^_ MG8#`Q@SC0#Z#;>4,=+BZP%'+9WF, M+8'+T3UT:72XAI8B9>+1;<#1C$XGXS%(N>U/EJ6_/W[XUX?_#0`Y0U&-"F5N M9'-T7!E("]086=E(`TO4&%R M96YT(#,V-"`P(%(@#2]297-O=7)C97,@-C4@,"!2(`TO0V]N=&5N=',@-C8@ M,"!2(`TO5&AU;6(@,C'1'4W1A=&4@/#P@+T=3,R`S.#,@,"!2(#X^(`T^/B`-96YD M;V)J#38V(#`@;V)J#3P\("],96YG=&@@-3$W.2`O1FEL=&5R("]&;&%T941E M8V]D92`^/B`-!`P0& M[#&\,+*@R!;5OA0ILTE-]/I4]1\OGW^R?3V[F_UV M[,?)7>P\N<9,SKS\]?7E\^MK:1+S>GJIMM7![/#''VE5;9.#R[>3JWC3G>+\]1/7`/YWU\:;$AYE',Y^MN=3Q M)BFV^VA83G4S+Y,;X@V-NSC=%I&Y3O&_7O_QDF;;I"@KV`#A&Y*Y6Z5GB4@? M&UR5X9#UWGHSGN(-B33C,M$UFX1&8QMOLFT9D9H&LG/,Z48H;+`KC73Z"G-N M^MU[<];/FS5':P?#>FV"8IMDF^99<$V:!^5VN2C7P?PTFN+=-B%?'/`SV];4 MDS5U[[%816,,9>5SB7%M=/P]AC'-+%K-O$YV)-AA^::;LV]QC@^C=^)&4AL[ M;^*WW38-;F/%JE4Q]1I"=+QS;,Q,H5R4RVX]L6(%/6P\D-;;CSI:;N[,#'&@=$Y-BU%8<"M4DJL-VH\IMT MN\^+*IBP2X,):2DF_.V&<#@*8BZQA(9OB!)]DF#"A"X/C*J.(ID3N`@.%:0S M'%9]&7F7>I+Q%Q[;^1-=RJ&XU/=PN\4$^6X9Y*):YWN19^.2H@.PV],)H42N M]G?(=8T%+G&6HBCP+"-)'A$Q3F8\DIH)NQF8I*B[P=2M_8-3)HD6Y)AX;N2W:8S4GVCJQB`15]W0N7+WIS*Z9?)XN`ZMH,6&51 M\%41?(6O)TE!7U5"5\0EQ79I%0ZYE@.*F]#2A5 M;MTQ/*O]BLYB16%2.RZ/.$6B`R@X9A9D#AR-G(QD, MIJD%JD/K6OV;)*B_>$?\=!J@D_GT4X<>_TA6`-'KX; MPC0[:AAG$)PA,B7*Q%K< M.O#-+1C#78Z+0'"/^0OA3XP[L'A*H+.FWE4/SXYV773TK+I.WHAQRB#-]?IQ M[)%ZDQX%(9EAE)+$9_UR.CF0TD!S<#8KDK"7,_*RGNI[/?1F%D_IS?*][7NC M"\B,A]3<)VO57`&29&O5C$DQX#D-5#02-&$0%@#0&@[G+9>KY1I'I$#_';E? M\5U[1X7W!SUSE!,,9V[M)\R-`P.COM6([M'UXGDGF4!5(S\\9,)7=6.^ M,Y,E9.('%!:/*"PY^)6@D`!X(/@Q81)33N-EW8AF)W)3NY%=$R1H:J@V@H45 M#+NU3TBU3PCXOH\3Z!.LP?&F`%+_$*#M8WQWX\U.O"RYA+H44HCYI62JV*^' M9$]+U><6LH@W6+"27Z:P#:7IVDM;1H=28@%"UNLY6):OG0`,#!/0F*7O2;M5 M+!?^5(4TB*Y,>J'`+.I0#L7&G&TL(MW1]S9L6??&Y.(G**5K6Y"NX=V5*]$Q MXTNY]=2)TKB>.F#^-#*RP;1AEOD./F0,UT3Y:=3897[`=D'8)H\!VTB9R$O? M]`QR8L$RW;\#[P'EA6BF($/EOY%F\.V/S.%+3`DUF>/BG92@@7LC;C(0!$D! MSZEO'%*$&1C6'.^2VMA*C0;IBF:3>82^.%.+Z(&F2<$/6'RG:>U8"5[:C',R M:&"DD6\5\FDD_?U':!RBL'Z7J#W`Q*]GB=W1AS6CRIEU$ZKD2*UD*V5_CY9A MQR5+/`R;TN?'P!K\+`W!MUREE+!.YDS0(\KKN9.:SUQ;:0(\0S61&K5I7#KB M0N2;N85E-R[*>Y=P!WP0"=D&GZI*'TK?5^E-:OVB[0>7/R%@FI%LS`7_A0ZL MY_(,%<\Z?].Z;#6F_!;1M5!1WQSJ4*/4,,;DZ6'F7@-[%GBQDN[]J7W@(F)# M@3/#Y]I(0E'T93A/:.E*/B1K'W"/XH9'T]B'VC1POH?.BM7L)%1U MV[J0HKN\U-J`H.AFU5W.L-^-O5S9C7N&.8*#(KO*X=*119?@??WM0@EIM7TK M"&).:M7_%_SWC&5]GSL)`?UO47B8^@>&Q8A>E_(Y<(0)%F0G'K,]]1.P%3K/ MFF".*?A-&K/$A_X*4M&9H)#ZM`'W><:]9A#6QNR[RI*9E(- M@L^R*.S56YAM9:7G-CH.X09H#"^4'8 M*#>\G:U9WG;.][I&(0+MA?:+Z:I;UE4MA@>T?)KSE+?Y+GZK,(3%KW2&VO[OUI9[JN'NF/`6>F_*0NF MM2PE7)80?KH71)9DX;6R>2I">[GPSKQ'"L'1DG+P]1)*9$)*#H1,?N]Y?F5N M37BC'>2-M@ERJ!$I@O89RUI=3])^EB_].$I2@]: M;\(+U8R+&@MNODH3.M6S/ES#PW=@1WA"BHQ;HX]=?L0.X'.]WUQX2X6XTQ$\ M"/G*6;B5#[>\XA[U^2C.FU.82:2#T4>7SLX6S9?N'57RJ!K=44.DV1F;+YZE M0WBPGYZ''YQA7.!0DB60(.KQ2_NDL1T>.2(Y5/^-),XU@LW<:^5^<6(N3?]- MTZ_FJ5[6%R%I#4VQA@8!,5Z+[\P,`L.V`0?E(PRJK%S[UQ7ZNTIT^@;Q,T>5X:2]JC2GD[:J:Y/:<&M`%1V.S;23E8/:HM[1MWRB9A+0?8NI[%@=L1?E M=:C7(^'LOZ]VF]40>PA]V] MO?4&P0%YH:6Q12SUD2%IQ_\^U=4])"4[>1'%X4Q/3T]W=16']NK%T;;50]GF M")RN!HD9',,CR6Y&*?>QXY221?ZH+_1BH<<&7_D7\F+M&M;Y,9JJN$!?GWFJ MRU7I!.YC?+G$P7^)B#,3%3:T%4ALY)19HM%=\#*7B8GVJNI:3Z_%@HINJ/!C?%6RH(Q=OMZ6O M+\D[)BM[/]BS7]B$,OZOKYU_*K?^L)&^)+I6N`AZH\)OFCSX2#_3J1&O6.1& MY=:F5%^$38*U^4T#E@N2)23$G=AC9I1#J,FP[]M/3]6GI.K2^:Y[`BG[79+U M5PW$R!ZX>LN-%M:%-WY/8B(#351@#U&J^F?#.TELR9&J,FYH]NX5.X[!W@7W M`1Q"<43X*6^\=F;0)I55&ZB)8@-$4:R6LW\,VDB:/@0$[RCCY2UM],B`6),6 ML2ETO*J*^\%7,#F^V7+Q3_(-MRH0]M#:^U8J84E^2MH?_!]M&?P^TFY*JN'> M-9M1=QEVD(M>><2T\>"VA'8G(?/+AL/<'G8$4AH3CWU9+K&+8"C--6B6T M<"&Q5/NVVY'$M%+F4'+51FJX2WX>8-!BN[Q7_[%OH8PYD'9L2_(*H"KN.P?J M3)/[\B`UO,*<0^-N/AM3>L_XVV*Y\IEQ#N&MH5!*>WJY=CMO+Q5E7K-3SKVQ M463Z49IDW5R1^Y7.7V<2\A M<$WPAVA2@`0]0(A;YR*3QPN11Y40I1;)[F!96)EQL+?HPH$+MFW=!,[&6>C4 MVT1-,LAJH8=0TI.1<#.13Y6--&`6.\3C2IGDBF),GFN22'D^*AZ^D`@C6O!" M1L#1$6&@D&@A8M,*.0G&S9LABVFD.6P(/4LVAX4Z(@!N19ROLD$1QS[X&*'R M\0(T/7ITXS2%Y>JM(\;O1FA/QZI$J5FD:FUZWOWBMSXNK?HRI`M]DO4Y1H\L M@%]][<.3O];]U\17P3`!;%ANN2-(MN0A0^[,6]-^\4Z9-3B4XZ)1+>S;&HA[)S2%?BM/)N.B? M3$+EK'M2V\(DAE)[C4U MTL`7-9D!+Y?ICM`$I$@1&A3*[R,GC3$5[N70X<$[FF-X$4XI,[?X^E"R,8.F MU:?(+M;YL,ME\UZ"69LHF%@ILM$A)@MYHHP^CIB/O,H4Y\$&!"XALBO[+[%= MD^_GG.%QFXC0G5H)$C+Y,W:5SMR8?9VW[;;[51:7U"E/;/4^Z#8ZIK->,(*Y M7SAD;H7O.M@Q$![V',OFBSY1%W9B9=_NT^3#Y-MD?$;KW<_%GES]WJ3&5E)G M27&*+!B[3\4H9^<7%-#?*&146K0ZZ*G_9AW_ES%(GV\ZR9MD\NQJA2TQ3_2- M@%^84M!YZN*5BH*7KK9@()S-"WH$YTUN#`^H!Q':Q.,2[_[3JC=J\D)[0(K. MQDY573F0-":D]$4_1]'UIEIY36S!"6J_:8W;-R.Y4J@"]X"?JQ>/0Z'2_+,2 M-J1C/I\-U`68?\18R^3*'4^-"1D%SJ4@I!-@*F#7_TE+P(]LE?XCXT;S!4X) MYFM5LO?NQ+.`]J%5F)&3+9/HJ^S-CK>P9J([W_NJ]$^$=[GA`5G.UY=M=]F= MR-ARLS,2UB@'$,)N`,16VU0OXJ'.J>'R@_W?E.`?1E>>RZH::Q^,;,Y5D1D^ M>G>*_YLQO!V18&B;FDGV"PF%%+"!1H,ACJ"5>AL-FYU#!A`OLD%W(U:O&^U[\6/5^ MK+K>K"5J`.&=UK]!E^*%?@,N&P`5N+^'B"&%/@TZSR"S`(L))RW^,$J[6='> M1M&E&&*F*S8,Q<+FJD&U,80F6ZINZA'40*NJ=8A(4!IZD'@<:6N9F=O`,;*/ M,]<-_O1-_75IGB_.9PT!S[M?)W>3MWESVO-FB_M-6:O0"R1U,V;GC'U&Q6(; M]#NJBN_D^$)8=\J6W)W-B\,0E_SB>M-&D$TBDC1_IH+TBIRH^]DT4\#3&HIN M6BT]:QS^?PQ$MCSYCF#-M5UY5VB!P'_0LO)XT,D'&][[K6!`FL1Y-66;DU&Y M`BG[!RUW>SO8`ILOT@2X4KOW\IXF7XD1'^SMQA`S'N(BX!U@ZD&^[(B\1=B# MU;1-N2DJ%1^0:1\4E3<351RMI=^!L@)4[3F4D`?"L1BT]62:9X,F\8JRN:,V M^)90$=!1"6-=(X.D.\7>1HX/?N:#Z,/B@!J#W@-]X5;`K!529_I:?LTLC:`( M&?1]\=W+3LX4'E"X;HZJD!;)][&[F;B?*A\'=A:\.=)WB:CUH'IUGJZ9==`? M)>A,SHE<699PI4DO+[%'N/&,B*L;HBDW#Q)\E0F=L+4O` M9KOZ6$7C-6V)UIMIU(A>\BJZ36K\Q M%Y[*&"7>Y.VW'_[WPU\#`(`M#Q<*96YD"!;(#`@,"`V,3(@ M-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TV."`P(&]B:@T\/"`-+U!R M;V-3970@6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]45#8@,3DS(#`@4B`O M5%0X(#$Y-"`P(%(@/CX@#2]%>'1'4W1A=&4@/#P@+T=3,B`S.#(@,"!2("]' M4S,@,S@S(#`@4B`^/B`-/CX@#65N9&]B:@TV.2`P(&]B:@T\/"`O3&5N9W1H M(#,W-38@+T9I;'1E=7S$,>!BD2)BX$@>1-5LKV5EQVK5B5JNSF800.*#C@Q0-06OW&)A^< MTQ>`I-8IER5AIF_3TWWZS/?9NY]]YX;VV;\_=L?0[OT0VMJ$ULSN-K-WFTUI M$K-I9E5<%6:)?_Q'6E5Q4IBLC,O2;/:SI=G-WGUXR,RNGRWCY;(PFQJ+FY>9 M3=-H\VVV2-.X7*Y34Y1QDN?8OY\M2#(14?Q%BR^S7^Q=M,CCRG;1,LZLIX^U MK:-%%I?VZ:_R:?1;=\/@HL4:?[2LJMU?U1(?K7YJ=9FL75 M>E4AET@"G7Q9CCE(4\E!>]CZD\>/`QE$/.:,C_`2X(?B:Z,L3NW@@VF.`6&P M7>Q4N(Z+V7PRJZGUIF6#N6V'UE&(N>W,Z?S(Z4H1=XU$-3Z,8KMH4>&\<^0H MU^@7V1H5D%5FD<3I*AN=)>GH+"G%V$6AN?=CA=Z9I^MCZ1Q_FYM.A MCN?FJ-?Q\/%3+!Z69I'&>95/IJ?T))J>]\=HA7#/B+)`=GO?(0^\Q,F@8WES MZEP;+4J^-%H9(JJ(MFE,W>'L"6OV^\6I"35$9 M6X3H?ZN[\[;EXZ9V-Z4)EO(DF?)437E*)$_W[KG=FKO.UT^>L'\=RV@H'J46?\S=J]IX+-;&< M1BYZ)*],UU*=W/G+J6(RO=9@'J@F,_L1.2WM)_/DY,3/'BGP]7GPW$@YMR-M MF'YH3^=.OX;V2!<.!(@2Z'//YRSE!THEPO%[BHSN]3"@&;2DQ^#>E'0VY7,M M`>)BJ9N]<37[6J,L#KPDZ1VWOTJ?YO9X4JE>^F!K'A`*12%J0VS,9M3B-O@: MCB>^EPSWDI,FE"2#>;S,BN32WQ?H3')MN^/,R;U.CB1TJH/"(N> M-*8G7N,2O4G*)8-R6R]1,9F^436GX#7.K6S7:*<5%>@%=BY=DD]7J:#CR`M& MGGET(;1<(+*B;$H%N2GG*V]R=S)A3%)M"E*8B#FOQE, MY%PW(V)B!!-B*.(2VAQECO57X(38P*1;QA<5&Y(7,(H M53`5XEQF"ER%A>;OVDD]E[AQIU,8A\$J*]87*$LSB>?X[#K`-JRY`=C.ZBA2 M@G@"7-*M`-7%%7FZ\`XQ<9";XU)HBV,8:!\<.RH5/<@T[1XE1#GD).Y,\-U5E-M;G2E+8R868QPBQ*G3 M6]C\>6(M]<1D*.F?,%\L_/Q%.(ST[P.(0`!_Q13Z>RLE0CY31D)T72J$*R(*LJH2=,DB_I"8-++N!AUM!SY\TCA]A1`7EP;7[E7+]P M_@![

^>.3A?H?K[?L[1PO+GVB3PSN$NIUI;-KI;/\BL%M MQHI17&1[AM,C0]8YHH?-@63,BQ8YL4`CTE2PP@1KD;^8#$I/6JYL&B0KU=WR M4%0'"*D37LY[.ZI=,2K+QDOH=1!Y"0)578\!@DNE5WXU3#6BY^96%!G&^TQ$ MY:0J>@DP2,Q.(F`D63.I_N&H7:XF^%YIMA%/$)N2D4?7N4/M3?_D_1"3WB(!IE5`5WGK3265)Y?&TL[Z,MTW\OO9*;%* MJCG^5Q%/"/S]HJ,Y8=8GQ$4HGZQM31_!9Z[L:R0^S+>N.>%;'O7945OD5G[2 M`PF_:MD]RZ)7RB?6Y*?LF(>SOA)]N"9B0<)\+U_GH'$X&?2N':EN,5DUGT3FC^B0E1@`2PU0_X&'E?)QS3B<&Y^2J*\3W#1#PW-_'(JGS$_X=" ME%-%*(?XT'*)%?S`9?"59!($P_XY@(-+E8TB/ICW3ZUOZ+F'YZ8^0,!V_&%H MF[8V7QK\]!C>O??_;L7Z@5]#.R-DI+#?QT=1LBRSJ_J;>B31'CFW`R:UIW%% M/AMYI@3SB)&.>^27T>W3Y4DX:,O/G=[@`=3).TK$7@4(IM8*314^O(-++'T(-K*U\BV5.YECPJ MJ%B#[[T+-7T`Z`-XF@@'([_IA``C^>@\716&#=@5TH%!0ATCP$&>7PU(V%TK M'W)Q!YX0:)(M+'Y(,(=_Y0C.2X\B=8T06+9&TF#>!H]+++1 MJA,?&JOH@$#2B8Z:YC].HL4U0ZM):(9CGA:XX.A83/X'< M0M-'>C+`Q5;8"[:QYL5\I;=3:K:?>$W,](S]1K:]4L(73AFZE\V=J$T2]2Y6 MT<(H[R/70G`_&O<@\`L48)?-1+$29/=NK7#"JP;UF0# M=G0P"4"11KH*>C41 M"M]@#HVG`T1,V,2RJGY$^ M\G1M#U2I>=2>38^*.-[B%+32HR).3!'7R,,'%K7CJ$,<&R:GX%')Z8,JQEC1 M!`D*0L.YC'4K1`,G$W#0\3O+W/UFH7-NQW84L8D@DA!$!.02`X720(2[:0GP MUQ'()O-SM#,#,'O/M72=GID[S.X(4+R((C%/J4U!GX#I)7(?BP.YA7.N1RTE MIB&4-\]VFC02=O/LW[IY>J22L8F"V)S,K3GYGQ1,K0M3E5 MXP0(M3Q;0M&9P./YM,LEEC,[]EF02PJZ.5`4O::*\XS+/=TW.:KZ*3K@-M[' MX`SIO2^52:_4XJ/D-;K12M9/!+#5,=4HVI2,@M^>LVY32:551R/^!1Y(@1^@ M[('8.M:.4HP?,4O+N-O>E/44+06/#:AW?9KK;2?N!:T_4-1 MJE,[Q%1DU_;H7],IL'=/<2^(;266F;XN_&I<7F9V))W3\E975?ZSX[A`HJH>[??!-G"IMGZ)JK02*LN2O?4W-_-L]-76T]Q*54#M50:)\FB*C MQ"HE-E]J-Y@0>N&OX%6.*W7;1(L7$`8+4);>=:6^'.'PN.C?S4O/-).%@7,7 MQ*W#=%*+`:>N;"+EJWV M3Y*NH:C\^"^$K/3*.Y>'\U,'_)%W:A].XKBS0_BU&FT*BAMVD7W)R M7^E%5%,H=%U072FCBIN>(=G8PM+^[W/OVIWWH;6,?[M>SYV\Y(.Z(3`S7RY? MP?=;L,8:?'-SY])WID#DL-GE8K3Z_AZ?[FBW6MU^!>9](?)]51^GHX^0P.[N M:KV^N5\Y[D9#=^5^\)>=H?0^>[ER=?-!@Y^,OM]'ARZT#'YBC?N$#;C-9R#3 M;'2-D6UWOXI77PROODCZJX\7_1-8ER1U5&5!LBE6I&\DDMT&^R?(<(?7TFP?E2(,VZCC+M/E=*#C^GXV*CFW M[1J@F;8<8(5`Q-MASKM?7=:(KQ1JTY$FR#4DFQ*+Y*6O-O)U*D)[,AX+BXD` ML7RX6;_Y]N;O`.R+-!D*96YD"!;(#`@,"`V,3(@-SDR(%T@ M#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TW,2`P(&]B:@T\/"`-+U!R;V-3970@ M6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]45#8@,3DS(#`@4B`O5%0X(#$Y M-"`P(%(@/CX@#2]%>'1'4W1A=&4@/#P@+T=3,B`S.#(@,"!2("]'4S,@,S@S M(#`@4B`^/B`-/CX@#65N9&]B:@TW,B`P(&]B:@T\/"`O3&5N9W1H(#(Q.3D@ M+T9I;'1E=7 M]$,>!BD3Q@"#6]X<28ZU:TEK"ENI5))R0<1(PIHD9`!45K\1N_9[MR\S($73 MKJ18K=%?3O5_5OX)Y%AKU*I@7N"PJ.#^'X/?J M'[-Y'(>)3A*8QZ&)=4$RZ&(TB8A+$7%>G5U`2G*T^B&8ZQ17".9I7J@+E)N& MB5K\4]:S"EY?+6!QQL<2]=/YM?M5!28LU0*?8ES=M7/A? MEW#V[M]RY#R8YWBAHD6K7U@*^.NGJ.FM>ZB\SE.XKKR@$Z?/F??FZNWIV4+\ M-V&J"PUS'<:1V2&H\PGT7]F]G&23\#2,U>):L/.7$;HT+Z?+L?'8I<9)J`GX M7/4?2$"IK#R.A&:NX'PCV[==OZZ?O6IEZ0(4G"IW3"S?T2EB"XK8QTYG7K]V M^J^"!.]M\6^A>EAV)#51ZS7Y952W@4&(,0:)ZI8?^#00:.J^'N`F,,K:39#B M;1CQH0\(+U4WM@&\3%OW+-O")=]%)PP>&)KZ8Y!/%B/5\K2,D??>T'(RU/'T M,J![>)VDH%RTLL6_&FVL5W!1(X!TP,HKV`9S3"'$A4C9V!YD_YZO6!B>R,%" MK6]XNUO!IU>+\U>?86@W2[M+`+:*7$H3;UK"IG$X(Y<`U_9A#(CU=AU04&Y0 MGRY?X/^`C"A-"`$B!M4]^VSAM@M(^RJ@H,G?3H#Y`P64Z!EM;>[8>A#9Z'J, MRXT<1Q=PS9$O$>-!)V3'"^^9**42G4Z(-T`BR`^BZ\X=JS=!H1HX8I-3Z,QP M5K!VI_>A%U'+0%/`W2YK$HMNB:OHCSQM.569B]0/@DCM MA5.,E$N8?G(L=TR+SI)$*0QDIG)*3P9B=X90D&T)Y+2+K.L$)(6 M=.K9-C')4/Z164[.CH)&*&@X#F2L4,\P]4C%@ZR$!0;)BVDHSQ2T(JYIE[7< M:<$IM5^`1C2B7XIR5I2=GR@4F#[,R80566CDPB!>(-HQF@]I>E= MD+-A\SQ+:/=MA^!3M(MCE413.YA*B4FG--"I4T6"RE*]1@D9JLBP,/4#(SM* MO-YM<4U5W:% M6'A644>,J2,F6-%CP')+K3-#SPR@>5AR>SN[G:'[(6+B7R?TSA3R#EOP\\9; M1I"F*(&:[G[#-7KGM'[N]+5E(N=8P5_N)W&-D2\S@@*UZ%^0NT01S MS?K+@@)LL*BI-#0HWF"=PYU,FQ27%)4H'6;9OEXI@*S7I1=(G,EKS#(I-X:+ M"EGOU6.PMLQD,2!C`W0:9=Z"[&L6(+.U:P\ZU"F:L[,C#I%U>J\3`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`X?=9J\_:)$ M^YG'?94Y$!_J)QBVRWMH"`C++B8*`T':2_J)!247!VYILJ&/+=PB-8.U](#QW MO;5K*XI'_"I!M0FKG>=N#,=.>],*$OC5A,;Q'D'\Y,-"L^8DPY=`U].=;0?E MH=B5!S=$+%W*4!-!0C0MI\2C+$A7WI9!40Z&PASX#:=)"Y\N:CE2W_$4:259 MW3UJNW]*DW+9=4_LX699>EWN*DT9_D$4M[X&:*YY_%UQTNW[W9(;SB26?V@70[_@NB'5 M3ZS9DN=>)LDX9N07')8..9$X<4RZ>K`]49]J=,MI:]`.JJ`#_`_>MJX*?D2E M6E.]:=KQ"=R-#292[@T]<9L/[>A^K6!A!R=SVR_M\%GV#Z]?NC.CA=2=0,)] MDI^75&RQ"!;(#`@ M,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TW-"`P(&]B:@T\ M/"`-+U!R;V-3970@6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]45#8@,3DS M(#`@4B`O5%0X(#$Y-"`P(%(@+U14,30@,3DY(#`@4B`O5%0Q-B`R,#`@,"!2 M("]45#$X(#(P,2`P(%(@/CX@#2]%>'1'4W1A=&4@/#P@+T=3,B`S.#(@,"!2 M("]'4S,@,S@S(#`@4B`^/B`-/CX@#65N9&]B:@TW-2`P(&]B:@T\/"`O3&5N M9W1H(#8R,C0@+T9I;'1ER#2=RT4>*$)-W`WYC= M'[S?N=AQ!UI"+77*=2YUZISO7.KSU9,WW:8]]??=\]UF=^BWW>G0K\RA-U=_ M6UX]62Z3L69Y<]44330E_GCARU18_*0B);/<7I7FX]63W]YZ\_%X519E&M/4)_G MCHFD2;=_-R2F'Z1,ER;_S_+OLRN7!MLAV68T,;C)1.O$Q.4M-#=99XXPHLZZ MO,37!NM&UZL3/FS6K:Q!(IVT:WFJNC96%&"F[22UNY9)KL`M3?=X:33=SVSOS#699 M-:L]Y-;C5^U_P"AJ)&Z(EBUH@2+^5.V1C!NH2:)4UUV/_DTP7%Y MS#KE-.ONT#/G/?\7%IA]V+'(%O\CV03,W;)$9]J[M8B<2)$*K.B>=38<64"$ M-_DB:M#!0@$)&05[PDH"/,1*NI]#I+ROD8&XX(3!U01,NN"PZENR96..)UZ< MEHL';9#A!`[IQN\P5Y_/ENNV>)@;Z_71NE?V%ZO[JE2P(= M"??TX&=J/XC(="H;NA@MI7@$.R7/.;^MYK>$5/&M>;)E1VED3^2B*?0_`^$) MNR-8+:,8@*,PN%)WC6[,\&?K1P&HYZI1!)^+0]GF#[DG&1P/3P4LK23`]73L M14J5U[/(?/@%V)%9-I)6X6NU5-A'Z(BJ$I$;]]X]6J.U'20VY;Z>W%YI( M_(7_529&"[!>@#?"*4"F5\(*;7LT2';DOS(]L$=/7IMGI`U,:HE<_QO;H])Z MJHC?P#$UC0^10\**512*I@\Q1>ZL!-'\(!'=-"78"7T"BN>[8=V?QA:/J)%C M!K(Z0.\:B0=82]08^B?4$1@\EFGSFJ@^VU.]0^D]8%C;#G$I`[SA3I M@98*-KGO1"=3K`(7OE9VR<3`$`UT`S,0/&MN@Z@T3.KH=@CU0\Y#IPIW,UU3 MD^%+S))RH4Z7JU1ZD]-M1Z%U*/(W8\==4"BH>3E>K&AT]!EUL83O#6HE6"VM M=X>M[IYZ]@*V!@E-/\IM[M9T0LCT(/TRT\'Z.RH8N'P5LCD-G3;(U)F*,O"@ MS0L?FZ)V)I;0R(,V#==A*CQ."\^_.QJ2$@U+A'5+_6DKN36^L7 M.IB-/*22`X%Q%E$MVP\J0MK0LJK,6Z%<3]:.T[Q'OPHP%&JBB\T4!QF_:%4K MIEX-Z#Z[NR,E`#K.L-;5-?TX.:>3K:^,W)5\Z-X^M\"*]50I>>.6&DTM!6!M M]LIV^(Z%5S1'MY>N=K#=EM5LI*HKLAI%QXZ>=7!017,$L&-]0%S'G1([57+4 MYO%-K9M^S?B)\;>"9^#&<:?F\U\NZ:7DZ*7D$,E88FI`@$.!SD@S8$*9OL+C MHW`&;S#O$A&4*]![9,[E:]3V.))M$XL0YG0\X1[B*:#0F*IN"$OS!UOPWTW+ MSW-;\K":J%X=Y7>34V7I^?\ZIW:*EM8P]JV=]LS;4^Z"S+,SXI9`!%@-LGO, MJ:`947R3.SK-O$:<*=V`/=Y0#7+B:`MCY05(SLG00&J?3N$]O]]L454T9VAX M)TPV&MTW5%X88I3(QZ[5]G_@UB#OLC#VN$-W+Z58V0?ILG=:F,W[;'_H=7,4 M[5G1?M2[V=!$LQD_3Z3/COK6TAK,/N=J.]FB7'UW-#A@QU4D\,S*^^,&.\6I M$,.35^_SL>B[F&H"1^GH^BC][`UR1/9+OOP$V`/@GCD"``2.+-"^*^K&FO,N MNY+'.+C7-D%<^0NBD#P`*'BG1*$7(#($=P'1U9%&&R'"T&L>]:HLQ*1;AKB: MBI;?<=F`J=HA6469+YN2'YK$AD[C=.'#CW*L2DV1OD\QS2VA/I9:0OWIS*H` M_WEN22V<9O-:!U+NZ0$UK>0RVS):*L(#];A^^&AHAL;.5VGE^VXX=L>G"I#S MW%'%VDT/WGJ*YSL>K'SMLS==+D-5PSBC-7H$SV2K6\HTS_,3+]9X[E+2^>Q> M.#>4MC1L+2B&^SQQ#L=)D\J==-3'$1$O4;JR#=,X5''2OG/PO,WSO9E]:Y@\<"NJ(I#ZK":A0^,\?2"`RZ$8D M$4E@5N@Q]L>8Q&-2I5U>9HPYX+)&-`C15DM^FF@I!"GVGG^JB5#9"D+(";A% M^\1$"*%+_DIO=$;:<2[#6G?D/8:(*383=R%Y='A:71KZ7*$RA, M]&5:^17&=5Z--:&5]58+Z8Q)/XXY%Q`:O=*%;ME3OGLYG;!514Q`X9H`$.$J MH2,=:SEU@42H,Z]TFAZ(3HE>!F5`HD\,C5<&V!L:)J,24?8S.2HYS.6]/3,T M3AC@_-0PG1^&1:PQI]!D$NRY%B7R2*8]S]:M,J7N>G_"B0ZYJ3J!>H>O0N?YBR"CG\X6=4()\$IS(^F1QA^\(@!]RI)LM^7\Y"3; M[:E84F5LA-B>I1+W;.@XK MU7+AM!5SQI&SIKC,6=&L1Z4ELWIBQ(U'I0'GD,-#:45/^D$YGE`75(BV\G[]/_M5T]PX;D3O^14\Y$!N60[Q M#59R=[:_)']O>G7W8!(6TQF[KF((KK1`('N M]UZ3&"8W.KG(+:[!K-^_"I`?3D-J/G2`$]\XID-;0WOYS` MU&*EI9&`.S'+O"T^QW!J&W"+SN*\)GKKS94(^9!D%OJA'/$A%M22^BM1#Z.\ M!7CQ&R`^"<1;.!#7LBD@$XDOK]%+R1!!%A00_3.+F&D1,\WT4FYRR;IZ(CZV M$WF9Z'L-G8/()<_UFFC/+]*KR#G03<+^._H.Z*+(9P;G@WC+BUR%H\6PQ$P6 M22]B9BQPPX#K>T)R82[J2UWW9D;0YC2ZJ'=X,W0RDZB0.2!A2%C@!FP(@]@) M_%.*;`;\WS"9DA(SYVG`_3IN^"(LCXMHH3WE8/@0I7V0-B`WZ+1^)CUS)O&R M04Z#+R-=!CJCC`1%OP)14=^9:4[5;3]!Y*:SVSU..:F;QIRX=#1`=7R"K5"2 M;HSV;H+:)%ZI>'[D#B'U&A[ZA_LOUMTZ>)2IO%0R@6MN0W`Z\2*(4'=6`#&%]DDAZ2%FFBHR??M![3*T-]4NU_I-\WJ\B<*VE.?'$Z4"F&C\N!L:):XLAY1O_8 MFJBT]53H=CSE.O"*:OE<'DVEE:K2L,'0VEU\>N'L0I>[[Y;CCSA)*\?D^B.? M'P:VU>T)EE`=J(P@XLABJ9XWEJ<6SA.>=IIJ(5BZ96ISN)QM:5W.0M,)EULF M2:$A6$'DWGD)`MZ^R-C>T<'8-<:NUA7&KN85QJ[F%<8^!_\FQJ:\ M?4?8+M2\&:TF!X#H!G.C$PV%Z$V_-IR"SV\$O'!E-W)Z[W M@W7,=13BB'(Q-<;VE:E"XLI_C7<+W"+BV,DK]4Z6";U&S.U71K8OW;.NTVT? MA5QO#P_,M;J8ACH,[-0M:*VUD=`PRO1!L^IV2R>0!`-0\Z\#HQ8P,#'#`S6- M:T,/^,1ZKO!W%8^&XU3=UVZ^TO)77QP$2KP9G@,[]`^": M<'RG[Y3SS.VY(G[N7]6TV,Y!UG\`YA/%?3W6`+J8>'W=U_W2HX0PY\0HK9G3 M_42O?V9F*"KR\=)PSH/-F,^R8ZRKFO_5 MF;I,.L"OE6*UKM1B-:\48S6O5.,Y^#>5([5_^5TUAMP$DE;C/Y$OJGE(QKP> MMY)`JH5$*D'+<''55U4XGP<0!)<-YNCC.*"$)I1,OWM6UTY+RO4G-IP6\7CH M94@Z=W?WRB/5?$=U3B*_X\$:YQ*724_15&`H2ZE\9$J<`#6E_SQ-3[?8<4%\ M@,5^;B;D*%BKT,<:<">!$$EH"4$$C<>=SB`(D#_W:E\NU)U>.!"=3^R_@!-B M+CANEKK8P)5W0?[A6,9KJWJX6,AK!@JH[\A?'")`@#-H])0%*+!6F4C>3__Z MTZ8Y49E39]<.)U6I8XQMB-'`M0C0)<%$$!Q?&RM?Z6Z+B*`]?Q!#AH!JFZF/ MHWS[[@[73V#_@@"IO]7W/4,W?:ZZ/P]&4Z2MI0]8#K*WQ8W'Y,ZZ7]5+MO7" M3]R25,!C9.;G%]QTI.Q&HE;C_K-T@=/QA$Q)=%[]G]\AH=&C_E8DW*2P0))` MZLJ9[ASI%UJ$5+@K_0P"RQP"91JU.G:Q`RRN]TR0$`E,SL;9)9MK;[Q>,E8B M"*7S1!]&4AY=J.E32/R*K`L&1PS':)":T*V6K9%_KP;?F\Q_05>FB%PA+YYD M@]=)LH)MDZ+COQ@>/:3018WC/+5DJR*G6M>05Q!;9-6X_O>!FEMEK M]]\VOF*N._\6XK7%X?];YO6MQ@T,-!RJ)OA@\`V2(8@H4CW4F4GL$PU)D;3:"XIS`69)M?X M0K;]4>F7^<$)/U#Y`*[!59/2O0I+SG<6ELKV5MC>U-\C&$+YH3GPT+Z&PE1Q M)BY@37]>$TV@KOR\W!@H(+;!K3Z_`*`>N>*J">B?SSMGXB+!T_$F=/"^KGAL MF\)Q$9786'!F(`DE!\)XO6GP$HYL^\IT\\2B0/[O<:WCH`'%P&W^B8>NOT)=)FS`;VXX'$Y#&VNOXX9:8>!03>],=$F M]DPNS#P#Z&%\XZI!O:6J2_VU-(=95K5R:'`+5+FR>AP-*R56I'0?<(W$Q!S: M(S1+50B,T;5=M!G7$4K,S3UQP9OS#2\%Q_^[VDM=K0B':UXN]:/NRWY'B__S:>"= MZ8.NFB7W'U3K5E$6\*IF760KB4;-I60Y'#6L9'D232/J?9[E?N8I6?[&]9SE M4&;7#.19:&"4K32P;FD;2CF'Y42'>[@0_9SH\XUPHMNYYP418$,`S36BMWY. MY=5:J;Q9A:NKN7)U-2L95W,EXVI6MCT'7YI7V-:-;Q28M("I8C",2)V?I]W# MX\OTN1$1X`$M'3VF8QUX&-`=3&CX2"0=7I_NB*1;_5%Q$OUZL'*=P*J,N./4 M+3VV7)DZ!FI7`,Y2IP`U$!3'T.&M=$9?+C`QTTICE;1L:I\)T/N7TX`:?;D= M(!X^`ZP!W#UPG;+H#PQ3EA-E6":=7OS9;RLKTM5ZDXKT$J5!79EI251R1&MC M>O0/!,4A\M!5XD>LN?0K95'!)5DJS402*G;4_5G"[MK:V@G*ED/=LNUS"K)EV3F:$S]R M08BK/;L2!LU=O3PZ\1O/?B7J*4CD3&_.!Q**W//,#LS2@>,K9O,]$IS:,F?G MH$`M$M&]6;9%UF47N14*%HK.,1[3.P'G*,\4%L*XI%86/C8][Q9ZOLSTO%GJ M^5SUO+V@YTF%QGZWAQ!F`N/WN9XWQ43_76K^TP^"'*WU&)5'/QX@";$U4:6E MGUB;2F-JA"X-Z#)S@X%?%F<`$7$EG'-P08BC]"@:XS_LUTM.PS`0!N`]I^B" M1;L`96([L8_!&5J$$!)L@/,S_SR&S7<3R?1;MD[>IO:X__ M=$#Z?M;+ST?-NCMO,==/+3F^@[S2STZ]2^;=T3NSIF!4PC-M'V(B)H#N0QYL M5]CI_"=LNM#>453[9IOZQZL\!!;PZQ//+S99:,CJ/C.!9.^%?FZE1TY"@7B: MT5GDM5G[G5)#A+-TQ%+ M7'3!H1>#JXA8(OBDA. M7%O@C?V@S+1&X;^\KY4W721OVR;B6+WM4[OU=E!O1_7VV/)V_N;M(MPN?KH3 M;9^L.:OU(0Y]U[Y.(M>-MG/5=E:ZYIZV\Z+MLZKK,Z5K>]8A#-B96MJ>AM4` M1-ODVCYK?:/M7+4=UC4;^9Y/%\A7'6W[W8ZV_79'VWZ[H^VE\4NT3>/$GQML MYXKMU,9VX>7RJ1E0K(UK4#LJM<C1JH[Y(>ZS2KA6.DC"L3*3M%^+L M[,ZNQ>+LLG\YT`2I]W+&=J.IX$:2E_VEZ'N,%7Z'-&17C'#)2=+="<.GO;_2 M3UC_5B3)/LO;LZ[ZBQPG7K[,\`LY3G25Q8D?99+@`$`6D?70PIE;F1S=')E86T-96YD;V)J#3"!; M(#`@,"`V,3(@-SDR(%T@#2]#'0@72`-+T9O;G0@/#P@+U14."`Q.30@,"!2("]45#$T(#$Y.2`P M(%(@+U14,38@,C`P(#`@4B`O5%0Q."`R,#$@,"!2(#X^(`TO17AT1U-T871E M(#P\("]'4S(@,S@R(#`@4B`O1U,S(#,X,R`P(%(@/CX@#3X^(`UE;F1O8FH- M-S@@,"!O8FH-/#P@+TQE;F=T:"`Q-#4T("]&:6QT97(@+T9L871E1&5C;V1E M(#X^(`US=')E86T-"DB)C%9+;R,W#+[[5^C0@U1X)I*H9V_=S:)HT[E??AX^/Z\?M MZF'8;U=78KL2LP^+V+NL5XB:4\1),HYW%SO1F95>9M[ZR$)$C20[2JOZ$>+G4N+$GNIM5&=]SF.>XU[ M\$D:WN><5>G\$`@L].J]23;84+1,ZQM2Q_YWO MT8XAACZB0N3_:1SY%@8FV&*;C\IH=.JC2OB[V=&:Y%IE=.V*?Z\5]%XN][Q! M;]OQ3'Q8KI5)N%^JSJ*#-A@3%#Z#.+LC@I?#4.Z)4V1@+4.9PT]B]&1-"#`] M.`#4`^V)[@9K)BX40I$G,++(8;1$D(7'*X.'%/OPVM[5T(7ZCIT+\?^;.=B: M9,W()?A,#62C4[-R9QP:>%G7'666D7=H;8,9TK$/Q-5(OE,=I9H8T'I&/N$Q MI=+SZKOJTH3-6A$73$A/SF-F>T+$]H!HR$*\1J(4#\CTP&-[7^_O5:`DJ\>7 M)$&4ZTH4N_IQA70CGXD]WEW5YU:5NA.X&I/E#P2+)*NK#&-3TZ1`7T!<,6Z\ MCHQVV>`)5'1NZ)C,%&U#GJ!M1:>&!JLG:!.U(70&4MA4L!L%B>%=L'TI!WBL M#BDQEJ).4_G*R7/ZG\NO9*Z$:42>(J.N-N7DMGDUR6]D+2J2[6!-&AG4!5WC MJH^MHI([K[L8?1&18KYS+@-;B/;A")A"F`*M=ZS"&QS!3(`0;)2^DN;*(3#5 MG>9K4ZY@P+$57S_OH5@G'5DG:C@49*"<@-XX[TI.+,A`EDWF.'`Q=]DTG@S# MCY7=CF(OE,BF5L7MATR'+4.S]!Y_-0MC)`16T+%/J5@X!J01D`P<`!2K!>!& M@(50`5`:Q4B)J5'*G3A2G"8#Y!?J6^X-8SO"$F/!%.U_1W4I7C0G9Y2WRABT M0H?EL9H"8T@U+JB2KLPQS[,,R.<72%8F*&8`I M42O6J%%(?\.4/*44L,V*39+JQ"75#?0OEYH!E<;2M]. M>%SSQ+';5QY8HRB][JOJ;)X(MJ1&=(%BG*29T\O`.N,N,D/<9!Z%#LGQ&@H, M#0>HS]Z_&_HADV5L[R+4N>9GJI:>:RGT;ER?*;0!_8WB^[9;EVH!DHL'5?O2 ME5$0"F'K`K0=%V&0-ZO&<(76B>TB62.@G^1%+86H3JH?J%&BPQL8?[I1!H$76!<4@WW!'-U-[%U[=O,`9JT#MT970)-1O7`D5 M&HZN.-_F@Z<9]0L<#WW"\,-Q&\D6)V_\P?;^56Q>-WB/8PH.!!@]-'CQ2#Z. MX&W.^_S6-1Q=[-O74&"\UWF,(&W\M$1TAQF=*F1+H#,N>8%+I"V]EWK3/8T- M,)[B#,9#.L[(/)Q3Z&]W_Q)5UCHZE!0K'L`5D MF)3_L9B6[C#!81>=[?08G2)08 M7DZ-,1C.$PI]7'D\X17<88+\//MO`$_KT#X*96YD"!;(#`@ M,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TX,"`P(&]B:@T\ M/"`-+U!R;V-3970@6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]&,2`Q.34@ M,"!2("]45#8@,3DS(#`@4B`O5%0X(#$Y-"`P(%(@+U14,3`@,3DV(#`@4B`^ M/B`-+T5X=$=3=&%T92`\/"`O1U,S(#,X,R`P(%(@/CX@#3X^(`UE;F1O8FH- M.#$@,"!O8FH-/#P@+TQE;F=T:"`U,S$Y("]&:6QT97(@+T9L871E1&5C;V1E M(#X^(`US=')E86T-"DB)=%=9;]M($L:^^E.9SR8Q`-; M@\4@LP\4U98ZH=A>'M;Z;^S#_-ZMJRDI!PR+9!]5U75\]?5_KMX\F+8>[8MY MYUK7VX,9>]NHWJJKM^NK-^MUJ6*U?KJJPBI7$?S12U)589RKM`S+4JT/5Y': M7;WYZ3%5N^$J"J,H5^L&!M?'*YWDP?HS"LI9T#))PC(J$I47886[;ZZ6N"6. M:0^\93%N_*3OUN^#91:6^D,`*W*MBF"9P_.?P3+&IPJ6JP)FKW&XU!_E^9/? M)<^/L#R&Y>L@#3/]OT<>53QPF^BY>.W]P]XN`Q>>=5=4(2IOD=U%9P7USR22@AM'$ELO?HDS"`T7GV4 M^=`F.6O_PTUJV$/\PI5V4[OE-]4'2U1B@BPL=.U'1UEHU)-K6W>TW0XL*W!* MEM@@AFU#,PV#=>307'?!,L4E=;>%_[I]'2PY;:4'\&&EE>U4X\3[W>>I:T80 M@[YT0:0[=:35!HM>)?$IV#QB!&/P<0R_,J6>Q*Q6#3)?CY3:L/`@0>ED9B#+ M>)\,[?G3J-Z@!RK=UK.:Y$Q-Y_SPH*S8V`7H@Z:=9)'QBTT[L#"6+`W M&,!+_7;`##IM>>9A##)F=B^K0RPQ[]<3,$64MH5/VA.$?8*L+_4+5`%$O`_B M")[\90,8.<+D+*L\EU7&U5P",[HE%8:`27>3H="$PTE.+5F M")5Z*^>+^7P\/0%L59K,PD/RZ;A,.\A"VE!B"&)X&/7V$56[M,,W+PI9_C67PLXB&W3#U@178! M'AM77!(3DN8:7'\/>5B!KQ/TI6I-O45/TIXM MYPLX534URY0AA$?(L0RQ!G$73/@+/`86X%G&@^'5D'`5I.$3B^MG*0VB9XH5 MB0F1Z,6W,YB[.%"/2EZP]!.0-CSW:.3(0L\A%MD'NRI!3WW2FP#KP%&E=6:A M7*\VH!(+U`]"6HVTBC`6B@:!!RW'#_3M0I%I&:(I0I&M%VH'.U:8>C4$=*Y(T@*#I@3F'T#%3M" M]!.W%TA'*":$Q@@JK6/8W*DU%[(]T`FARB;R;J4)NF/$J3UU#M.+Y&<"(WSK M/-9C"2HWC(:`%W0]N]Z_2A=&B["OJK\D6?UIOD*%U5P,*SX1Y7B*.'`TT`,$ M^+`$]CVE4TI1R?5$-9]P;T@UP:CM1K/KJ;5%1!L26D[!8BA5`)8[T[D#)G@E M*SST#NQW("=QGIXJ-IZA*Q;H6F#VC\8=;$/=$KHJ9VE)-9+H9IR@5:(TA.`2 MCAG]J$#UR"M7J9YF%9Y*9D[IVY4S'Z33-C74+AU M1\Q*F?]"OQVPE%O;&'$;SPU&C1)[<@P@_;-UG3$]H:9?MB-FH4;3B'\[6=W* M<_<*'0+[0T+TB3&*_0<]NW);R M&L+:SC,1454\`I82.JTX3?><&;9;*,_O;R$C5E#XU!9N8^X*0&_CO"SD5*?; MU-_D,N5Y1KA*S\\N!W[+YW4^T?<(A76_,R.BO+)L%!]B4,\UMG@*^1%+68.W MF6U!`31[1;6+O"O5W/*IX7\QKU`I-(6-E#T)9N=XJ;L$TF_)C^U>''."]H59 M#L6%&QO0AU?J<<`_,_T9\!9R@1NX07@48I%!/>(']O[O4KF\FNE76ITN0&+" M]0NQ:V!)0!L?3!N`?F;@<(7`F6[8V^,.WX4]V8YNNUU4(-TV88J95@^!"7@;.W@,#" MBT3-$[H)P8QE!@EE7F^@'?2-*.B]^!?#\B:C1/+6&V4X#(`Q^C/X)!?QO<6> M#"YZ59?ZSMKH&8;/+DK$14[80GQA%,+2,]I"<2TUX9*\$]C3-[$4W4Q]3WF# MVQK'/+]MZPV+!HBWPE\=42;)+Z*4UR^,>`E!&6`3Q)]F?]O7_:%NS#3:1GQ3 MMX.ZZYJ0NCYL[$;+767XEC(L+S$CEH)H/\R#\'E8.IEW0*?X, MV`8OGV@YT#%EQ\&//5U8:ULKX^-<9EP"U:F\TQ/U]0!TUP74.CZZH*`4$ZP[ M!$@F-T2%I0``:V`0RIBN/'`'HIU,=7B,(DULZ'R.)6/*DJ9Z%R#W[8UA'5[C M^1;19-%EN8SM>3OY[&>6"3X>B*7)K@]U;X6,4:<[V_$0E$S2L"=.O(M_V?26 M]BWX:(^AV'0=JHLS-/SDQ?Q;,P_<\`Q2%O*'*#,WO*A#UM MV5)+!@V-P\"@H)YY*U&Y@KR&/4E6*WG*6K^GE=,XXDC/!T-(@7LAK?$6XI[X M_N?WBQ+LNWQ?83FB$M9S6T)B"+Z76;K4(I(*A"'WIBHI3%0D-NL:< MKGQ.0_B[@*\5*THI@$7'(Y`7\"RP:E&'?$V0(W@=(QJ")&4Y$%I;^F#9O+]N MK5SVBGF&$]R/T[5I3],\M+'^.X%U?T8=Q!.B8&1,/ MONS3>J78BR(4#N]-NH`@2"(,@A0`[FCU]:[,K`8YHYG#[A!`=W5U/;(RM>X+ M0^">=%H;"8DU!41/;NLKGWF???B/=?\8?O[Y\Z-/=,I2JJ;H!$+V]>\?,.PO M9I2]DG&H8%29%R>?HVFN;,,A.@6+9VD/FQ&;U>9.;2VGI!>Z"C7;"Y*; M,E8;CH&4+FX`O!R_1U*'VLX@33ZSU>Q,4Q;-KG9BP7VRL?_N#[0+VG+@BZ`_ MM<<)3'HZ89&48W!;E4[8>2*>XD5>$^UT8A^I*Y;.YPR0R/23:[N,_F,$EQ?2 M';8NRV,4][(RI8P;I!D-0\-PLKI\.@E:SVU=7=L:,LKA#]&V%$MFQ&!OYJOB M+M@%W/LU&21@^[HZ'WB.9>U/J_CR<.CK0SGBTS=>?`U6>NUVM0,N&T:E?Q<) MGO*ZF;/%VV8N#\`%L[K$+5G^*7L#E&"/?C$J^6!]O@BGIFT;?>@PPA9DG6`5 M3L--*UA3/)B!F?U+DU4X28MN1(RB:J/4H:TG&2-^.`3`UAKA71(S'F:`DS5F MY"IY7D4G!'@$Y%OQX`F8R>,W211??KKHV12)*1#RYY<91E[W1F44!@_@'5L" MI(4[3Q]QQ`S)MAN_U+@TRA#AT-J+K5TE;30PWF/64+9UT.*]-)L_7?G1?,[R&,@XGDN(EVL[_C/\EJ2_S1`C*^FZ@:)](#$L MQ'CF?'@&I-I#.)$@,KT=\ZO,9HD_5>5PY*]_F>',#.>/L+!.YL4C$KY.BGP9 M?$UI/C"T*P4Z2_SIRD;NPU#WC2WYM[5XO:\IFX912RHF\'\45Q_,Q+\`2E^/ MU[Y#JL_A.L##'"V2)>;G)^7RFV8'Q-(0]F1M&2'(.,*AU.IO8BJU!8K/J?X\ MZPH;/<4>>"+M!K:V\>$P(UX^T7I*U#(4[4]A5V]'9.(L7'DA^LI=UM($W2=9 MP@T*')IK>V7V6K+WG%[H!RYOF'[4 M-@L-R+3/$0Z&W`HYSH6,:H_#1_6&8EF!2&"S5H<]\!LSOICP(#.,6A7K&_QF MQ53!2SD^,BD^"T0(?IF)[L*J/M-;<"V2^!/[-XX)Z/T^'U:HMV7?')R3$97X6[E?D`E975V' MVEAQ/Y86Q'P2<]I&Z@2`S*7L`#BG1C&O!@%%84YON1IX8T/$OVL3^]!PJ3^5 M?JQ650XMF45PM;R;B]E$0N;Y+3$;!2]'G9P9J99!5X5L6"&6G<%*WB:[JEGK M+IR8OEWE88L'[77*:./VC/#?1*87R61JY`7,N+L15.O;<"@;'VBO9MV-!)%F#2+;)0`F37RTK!5I(U$/Q=)& M(7JJF#!CZ8"Z`:C@K!`^6?J\A]X8F(Y;HI8QO#CR=LU.(9(A[1GURFM5!6'A M=*#PP0+5^)+]O5O5#`CBAX7,^N*-B0<=#56F M7^^/KWPQA7F^<'KO$4)R6O^?M:)7[+"I;$A8#Y*>6E&Z=9:3O^[TVU5@5MM^M#F]!7;SK6^/M`GQ"46M_ MV5?NAY^R(SR0[&9^81UY.7EJ]4FK>7S]QZ7NW)[?Q;U$(V7)!P0IG42ATZ.+ MB8H_&@/!NOUNS-IHKIHS0C&%1$=I\FCLQ%;VC:TL!X'I<*Z:$J228@Q!R*A/ M(#=R(MB"^E0SXHL8(IGA`G*/UBGF/D]ON79DM@!IO,<_OGY=!O-]CQM9/2TW M&]R(19.M>2?7N#4 MYO0*>R`Z6@2_;8.&I$\Q?P*;S(E+0V0J?-U74;%.P]5GYMT.5>6">!/'Y_MT MW`3U?3[7MQ8T1M`^78VE#OJJO8U.5;;B0^N28=RG(PTZB MT'[GZ=VXGT_:-'-0LBZG!F&F)NV"2UB^QL:`T'RU!,V@6+_[&,XM#2N+W>L0 MWK6AA[!4X5AB8Q2,"^^0\CQ^&ZUV_.<0MJ1P"P:;_MN5BI7[_^L45K=@`!YL MS$N_='6E_C1DC._"2\-7=LHQG*]]N,231G)CG6'3?6&B9CZUWBU(N0=IE!TC M5IT#Q#&^0>`!4R_-R!HPI(480?E_$YVK5>(=B9CIDF<]A_`3?FR2/U`SZ#2] MOXP0+@7596ZWZ,-DF!9\6:*(6&H=BMTMBHK9]F:UYY91(>)JMJ">PNY)%DCH! M)F#FSH\?:5=;$8QT3BH/"R"\JT@4'LD,%GZD&[>*+?P-@0)'7>7V&.$9]G:: M^K9*?W201>A=@P*^].UPML.X3HL2( MTN\,6H`UR1D%D#0COV_A^!I=/[#FDJX"=2$P\_G0]<9)MUVH`^L7M;].$,0&W_9ANDK*G.G>H8EWN-6 M^[YLF`$CF^X0SI>Z]Y=NTMM)E@ZAC0U'YX9!N&`FWC:'ZP*_[VNJ.Y_$31;O M?$12,1?JQHL[/]?J*(Q]$W_KJUT(O%OO,.4R:Q,X!H].\?UU M[[\J"UFCG=W!2@]Q*));`8Z*`49E>QX<@`>;U2]2.L;#PK[5"+03KG$U1^1) MX?P]ONU-`"(3[TJ9?'7CV-Y3O\\PK21ERGX2&).HN!O1,GM7%,KE## M4;!0<&$FWRV_(S>T@]2[0,$#([X+5[:`4Z:8N[>X>^9'R)*OEY=^E*S[%[GQ M/*/@,#6IPUXKDQ\=@^:<)G)DRS*S".3IHZD9B\XRF=O/F04Y"BS:])#HM%T, M6"BKZBI+\KV]=\K#2P,?T:K-1*O22*OV3=6,02)U[X3I(9VOGV>$GH6H^EG: M2++V&7,H4MR?OO[PGQ_^/P!@!PCZ"F5N9'-T7!E("]086=E(`TO4&%R96YT(#,V-"`P(%(@#2]297-O=7)C M97,@.#,@,"!2(`TO0V]N=&5N=',@.#0@,"!2(`TO5&AU;6(@,C@R(#`@4B`- M+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R;W!";W@@6R`P(#`@-C$R M(#'1'4W1A=&4@/#P@+T=3,R`S.#,@,"!2(#X^(`T^/B`-96YD;V)J#3@T(#`@ M;V)J#3P\("],96YG=&@@-3`U-B`O1FEL=&5R("]&;&%T941E8V]D92`^/B`- M;A^Z>'#T]/CDKQ.GSX]K/)\W6SJW%3-.BM+S/_XL**5FX:7XJEH M:/V_DY\79P[+W*>K;+/>):--5P5^9[QGZPR_-&JNPSY=532?%NL\,?K6I[3F MPM_&M7XR&,B3@RZ*G[9JVX1-=,*EJQP_JW15XL?#2I'H"IVZ&*<#S_H[+E\X M:D[RN7XQ7O8<9XG"FY'YSQOTI,)U_L99]'\R)? MX`P-Y9/?]K*'V-`=[GU;;7%@=<[(_`(`-(DSPYVY_9&BP--'6EQ0,."W:74# M'17_]&7/PFXN2H4Y54_MB:_STR9 M9;=ZR&(]9)*:=NC'OF5D9LE@4)[A.:(\P]:/QLY>9PY#/_-DD9R-/UN!?SNA M+G88NUC71B.F'T].7V;O*$X"O,5Q*CGS$V*,\UYX79FXS]8C^CCK%LO,V8:) MM^L'7=*]4GEF#190M5;)T4QCR]'>8NGF[=+!JC'.X5$<(J-TSC)Y`^E\%S"= M[4+<,HT;:HO`@O/SKS7_&LENG?3>'LTO?N_M_&BNBYNI^='Q<"**M69T\29=!0&^?S>ZN25D:-?"-AT M1A;V,X[*/A2ZZDC[2`E3ZK,*,^1!'6;Z(_PW>_'J&#VLHX?SS<5O0:V(4"LD M9!,G$P:V"+?D%.4P"=`DJ[5FLV(^*'AS1E?(:,$9K36CQ5U&\UM&9_UF\8)3 M.H^E3)&G>;DNBUV.7A-R&QW-:G&4DTDQD5P2&Q8`7YY(4CL[6K'P5)GF`Y^WX\2HU78FD*XR?+@P"U2N3IP/>^)BY!`U+(\ MF5BH]#8`#^"/H[YZ_7WD)C#.5(A,K#E]27%O[3"LYKZC&0EMG;RQU=-,J3,= M^D^W#,&Z)DB73*/Q%K2\XHK3RHH5UMO9Z'>Q&F,I_UU1^#&E>EAQ5#Y\S$0# M%*"P$LU#$G-K\7^B#G^3"JB;XI:\]['[WE#;J[E`AL&V?F%WX")3@90"4\/5 M.O^JJ2GJ=5$76T5QM%Y%Z]K)KI/SIVG@4,`$I?B@A^IQ*`PA-AB@DY_5CXF" M4V,`8&5@JD-C2FX`M6<=(,_P<]'7UBY>,[[E+%&'45.7JV`O6*&P`ED2$$2_[?E*@,K`CXI\?^&N0GV@A,;!07A_T'I6U/=,MY5MI6D1 MG0D>]8UXKH'[1MP2@^#ZWO+)29L1G^P=.59&*P#9E9%J.AZW4.!G? M3@Q]:X[$AK60(LI)*YAA^FQ5EJ"[N!GJ\Z^3!!`(*NKZCFVB#,A5!KP`&NZ1 M2@RDWRKH1G.P9IR,OL[SXL),*ZI'-)ON45<@GLT?:#3N;P7K<=PFT&%4R1?) M,.C=PYIY0<7/\TFZU0+EI6NDCQHUTDI3./?V.2[H`@GB8D'M\%TK+Z-'Y:V5 M0\ZQ3:A5OB-45$+ET]:B_T8KX4Y$_?(H*LH<0[:$5 M0ZQV]3:[R\>[W(,(GBTN2V86?O"L7IU5%KUP+2'%'#7S'6U3PUMB%!2R0N8G M^0TT'1H(D)+)TZ.`2'KS-ME`+-!_?LG?+D&VSFE6W_0MA"N3$RY96][YCI>:LO;"(`5-Q-TSEJ*):A?3/*?62O4R! M:"I6S!)ZNI50=^JB[J/>1,I'EEL)-=M&O/M46EK-<4%"UN(X&G>EC=L0\NKH M>7'S7)/W@TM)3?74]0;S7=L*NRVC[\>.'\T_9`CZ.2-*S)(6F-OA6%P:8L8,@9*(P(4/R`R2[LGYO`* M1CA\"LQ6<4_/B=WU$^J&RD%&EP!U!^$,21P8]\SZ1=UB#41U$PIVIO8Z^ZG]O#J$(>Y*$.8W M+615:;W,260.P2#'#F)6:/AS,-NU&(`E0!(8W^[6KX?[I)QMH_$9HOR-)13 M_[M<,ZU`%I$]:0V5L8:PS+"JK+B$$%'((W_6.<]75^/U]3,D6+`N@DV.D^NW M[Q4H!R_&KHRA(Z$+_@!U/-+Q,ZY0&KQP0YCB/0@QD\KT=#6EE<[(ICM`DW47 MGC-9RJX)V]1),!P_A&["[>OM=O09TP&XZWD:=-0'JT/O7V_,0)I+A"\)<4;L M.W=#AG?(\.?']YN9>X>])`]G4K=FOY)M=#='O)$E.AM\5X=[)M69HVA<<%T7 M?67K<,ZOBM^;ALBK-P`7!0_5Z_M+0"'7DE<@G'F!Q=7V).-G821F4:UTPFH; MGKQ3.ZU'X7P<%KX#[AC>9'++7%C(14B($,Q.UT:F6W!OD>W^2/3I38L<:\)U MBC1$!2]/^]9#1!JF?4F;#Z8A2+95M0 M)*K7T-Z;IOZ"AF,UY&+3<^E0`>6"KIG*<<=J'JJ$)#8G7Q+AM=`$DXBP:'IT M?;V!3..\CBE&>]V5WSZ.ZBL18>9'V]K+`7>[0GCQ6V+J3E-E[\242XE@5<5? M)X=^9_XLJ[;RLY8YW<1<^F&([8`Y>KSC?.[M'3,S@R9/6#BB#8-V&5(-*63M M^[FFV8=72%58%*HM.,;(E:?L#VJ._`,OZ/H+WQ!UBEL=R@S]D&M:O_]*BWB3 MUDR#>UT9\J=LEU^O0M_HL)8,SA4FYJ1U18*WC&1(/)<&3`8+Z^2Z$9O$R6*%&7)X!X;"8/% MAR>37__JG*K&=CPWR0IHNJNKJZO..65=HA\E"WN`$.2U9&(ACTJTRHL7D>:J MDRH)N1C+E[_$P5Z:)!*I5CEB4\^E=I9EI1PHN&HJF9.!>8 M;^]%5I!]"V/R`ZJ.##<%I#G8!!';Y"^[\RO)?G_4S"@H9`7PP4?=#1)A*T0` M[A@(C>@PS8Y0=-V,MDM_7:CBT>V;L0[4.MTY*^IA9N*5$:)XNR&@C\'Z[;L' M]3?Y^MA=R55T,6R"-OJK.0"0" M>AJ4*%HFG[(BR6\PK5AN\*975/$A(=?BLJ^NEC[MZ/WDPD",B.Z%XVQ@TKY/ M!,TNNP7.H#23C2E-;S)U:W`^43C&2!=5VCQ@LT!^:FW@?8ORG(FPS?/-WSJ5 M[;53L>U^-5'?QP7)%!3H?I8"D5)#1DV2A#+)=2=#]V>RD;8"A;15$R`J7\Y[)D)>A91BB?JMNC_<+7QPU8L5NJ M3?$ZG.A"8T!6:7G]Q[W4C;/9[AH5J]7?T1-*A@,`#GKJ)BZ(`))Y,;H..4]] M%.>L>2R1^;K@-5Y'[FFS$G.\MU<=AAH#[F"1=^^TZF,)[."XGD&)(5`Q6K/G M+:7"D:*@&H1&PB%TG4A!$-S4L$X$O<&86-%]]*=[2M)RI>O6;G'E8V1^O+;I M&$,+O'OULHC"U9T8A)@U56"(2+7A`X`SX+!*-0"`1LU>$4(7H'@ MO56CV\MSZIE]*%(`@)I"O\`=@<415C`?GWDU,*2+7G'G]CZ+D!L>=78@'J,@ M*^W1#QX MY-FAKKN>:7@BC3:\@7J1&L`L1@`2"G+=LSK&V3F?@+^NC MM`T)'PD;(6SYPORW5$QV.U%7NV@GR?AK7&I-I6QX8%(-:`XBU30+M\C"5]U- MBQ5287M3K+I*R9L+0LU>??K`&50MG%E_I>E;.&"=&1N^L8N$E$=_*^HJR9%* MHRJPKB9!;"1,4$9GF]RV[U=9,=@@.*^,QH8Z#QJM[\)TK4/]&`(%INLR_8"= MUJGA07U$L&@+!<*`B0X/U4-?43O]I4%LIMY]5FEV`9E@BLKBY:4--?N4W*3+"F96$?S`^./VRAY&UNJI.P^,C9Z")'71GHR(MJ& MS[U0Y,6W@)P,ZJH)FA%A1]02]SKT;$]Q:^+74PP=+1>0PP0PAT8**EK,4QMY M^!(;@>_ELQG_:Q(]"4&Y$V_/=J#%Q.SO[$L/2-F`?_0X!`7T`&H%9[._+:*3 MR59H$A5"&-5<@9#YA,;TN0@+U6X:U?.`R7<[\V24)%!P`KIJNQK0XU*E:/?# M#2IWI*&&O'N`'3!TH11P)[7^08FW5CC(%4F*:Z7G6NER/2-OZ1PK^!(]]HT^ M#RPT(X!8KPCC`LGZN6=AB=*">Y([$B5I*#45F(7<4.>>3[QR)=B-6;*Y]QX] ME<5V17XKHO4JY@XW6V+.7-M*-4KP$9OS:V4_9H+#T-"!ZVFV$5L`_Z?.TL`, M^K^R\`03NO;2&`I?A[R&S%F4_C,#C_/YW`_30JAUJTVF)'E-SLSEOA!!H=HF M#&BGAA5/.I+HXU/\G,ECJU_NQ)3O5DA:]JVC:$RS(8!#$@`4;-F?RE6%#::8 MH]H?[G"CR#>1I].1M)DP[:@\7%MIZ<^J%J*C^*9,3*W8<(<=]0'U%K\F[M[8 M4L#Z"&`Q5A>M=E)!V0L<+W+QH8NX$:Z[P!E"_JX*Z1['N7=M0\.7+T*A>)Q`-4,"Z3LY6^[9]'IL#?MO7@GYIZZ:)$Y>/X3UE*LLG1=O)M M)4D?&.(LL_JN\ZTS>E5V\[HTUQI&@:Q9<_U%J@::X^BKO;N=^R&8I>7B91KP M?9L(&@`\@CM"$[][VJHGIXPW,[T'-U"<;ZA]4A;Z)OI7KKRA2@NZSIO$:`'Z M9D$(EBT42N.C-3O(EDVDUI0(C$^ML=(_EQA'T&8%\]4E[SK#1WCZYR3]P<:@ M&XX[,Z(]'E_G-ISY%8UB$?TM`E^!I26N61D*B?HY2:B0D*VS)PQD%"P5LE+^ M*'YL6$PHNX[%3Y^D^%E%*6':U@I$.WOUP*H4!-2?61?HKQ!="))S6"MISX9! M"J@H-]HP/-_7?F:"?##P.HTKHN@C?G*;/+J!47OK>)5[>+155B%_]2S"MXD[885M:N<_*BT MXJJ3_ITQO*%)ZE`*96YD"!;(#`@,"`V M,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TX-B`P(&]B:@T\/"`- M+U!R;V-3970@6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]45#8@,3DS(#`@ M4B`O5%0X(#$Y-"`P(%(@+U14,3(@,3DW(#`@4B`^/B`-+T5X=$=3=&%T92`\ M/"`O1U,S(#,X,R`P(%(@/CX@#3X^(`UE;F1O8FH-.#<@,"!O8FH-/#P@+TQE M;F=T:"`S-#4W("]&:6QT97(@+T9L871E1&5C;V1E(#X^(`US=')E86T-"DB) MC%=-C^/&$;W/K^B#%B"#$9??;!X3VU@X%P..@"!8YT!1+8DV12I-:C;K7Y]7 M5=VD-#MC!P.,V%_5W56O7KW^S]/'GTW?S-V+^6[L1]M=S&R[5ME./?UM]_1Q MM],J4;OC4QW5I8KQQQ]I74=)J3(=::UVEZ=8G9X^?OI'ID[34QS%<:EV+3IW M7YZ"5(>[7Y^V:1KIN$I5J:,DSS'^/4^,$YZ)K[2FZ9^#\695$VZ+J`KVX3:. MBJ#KNSG<)O3Y5:8>K";0WC0TBCIV>%T33X=?3=L\)N_LXW M:[`N_/?N[_`H+IH6F?=>4GOO)8GS7EA@B27'Y8&:N@N=IH0+&WC5VF;`>!F< MS`6_>6!DGG3.M'D:3-&R5QKE=>[W2G._%T67]OH4EMB+;=!52ES%-6S3JT9Z M#JHY7+I!G-EQ,"8$C@!'ET:G,O^]&ID\83P)X.5.VBWB,9F#RHH/%!WVTB:/ M"G4)Z4X]@DR^ELFJ\Q&OZ>XI8>MH1[[;A=VB-AF"6051)L=1U%TY0_!3RIZH MV9(6NX'B'6`LCI3:G?G*W70?CIQ\[WR4+C[2XJ,-)BC97;:ATPR\K>R2N99< ME2[.8WQZ<0RUR3$%.::95'M_I2L0I(/&PDGS&`(O22!NFL]\<+H75A-6C7@U M"=J;I?GLKCJ0/MHP5E]@'DT=7$$$L$^6N_ZK.MP,`1_9S@`C#Y%O?'B^P>9G M&!B/9B*<8\D`.,A=W&$T764\JDV>U,]Q'.H@)KPD!,:#NB)QQF$PZR)T3P)8 M6:;3XCGF4%)8>'LP52E,)<`MZ]I')6?D;CE-<@G+3R'A/0[.QL),2O=I"4MI M<#$?L6L(9,)C`R+BK>M[ZSI9K*?%$O-"C/\XL*79(''G1S>W'(\+^]"$'*V# M\6Y,0P(=L$G1(L`3_`"@4LD"!_A`S-\;3A>XT\$IZGX3M4'[;KVL\5:2-ZS$ M"L$/$QJ490(!(*,!/4ZW?E:T_$B<"_L/B;!XO%@][IR":_8A4Q'_'W!7?,O/ MB3&G7&MFX)D0%P?M3B%%7_H4>$,&I1>XY%2PCW9DSIF[C/K*G6*NL4CB'P=& MSJMM9@&;&$:JW)V2XR/]"%+UP6TP8I`X)=7%.LZ@US-9VR%Q-*E@`#*;5Z:0ZR_!32S"W@+SL! MX?O9K;@QYV?!/,U'EF1??=_9'BRXBU9,US(T:4X2LYP$I3_ MS#">WDGM]/V*]T^#%+@*!5K0QPQ`-'+].I@F+C=;GSE:W%0'5R<9#)4]Z9+D M(U;7CJ^EGSQ*L$A+4R1]:`OC#JBP+3P.M3KI.70](: M=\2MKZI_<,8$\7D'I$L53%P5O.`64C[$>,WA9=J57T+QLVIM1%*([J_SBX,UN5Y1^0]H@=97@[JYF0#?\P M*!DDJ5Q\D+.=V%>X.0R1`[@43.H+([,.^EZYKX'MN%,VTG+5<.O/]TB,B#JB,-)*UD0G'$#=E+N"V=&7"&D M488/-USY8/A4*>177F7B-)\M[2(EZ3POIA^O%Y_O`^L.".L6@JV;Q;4=G`%7 MXL(T*#=8X][W9K9O*I,-'CD4ZM#=SRB!CLF)%7Y0"VSD"4(T/4[F19F+&>W MI"E/+%8DMGA7K-IK6R[B2[HF<4;GC3TH/6DP78)HK7$L^.+.!A(VC95O8A2_ MV[?Z3S9YN^C&]?KH0NZPR`-UXO'EI?P?Z-25V30Q&\`MW#8XJ;(E=IB%1"B0 M?,>)7:4:O,2<8MXSB]SF9M^[P@+OM4Y:ZH351J?N:1 M]E33F2<22'\)]LW4M6_S7)J]1FDCG'D`]/H;'/A+*,3#KBW9LQ1J^XJT5Y^DWN?>:[\LJ>2%&$J#AN]Q>ITFN1%G=-7JBMOI:: MQ^?GD\&CFOT9TN%+"(B"E5M*RBU@!_LJCK)S5\:+2K\?IW\AW?@2D_IA."`> MWYM6DA*E>V]D3&7),VEREF;$9DE=HU6_K4:J18LL6?@Y^-F\L"E#)7.XO?N8 MT'^2F/0V`1?%#.DMQ^=WG!JDAXNT\M)#B_B$/K'1S2$1<.;`WY"JJ!8H)/:E M(RYL3M88R4@C60A!U,C70?D;.$[<2E M^,P8F58=H84.DU=DME!4EBUHH:))KM@DJ7XF7-&S+PYKRMSCR)K9*G[O$INC M'%K%C@"%NM!>0J+KO51R*X%U%F+5B@F90S)(+]))1#J5-G5A3A!JH>X!_TO> MGUK8GW(C`Y@K]^I@EG-GH;[[LV1\ELJ?Y6UV62JSW![HJR-Y7]P+??]\7$H? M(4H.+9-SSNC<9;0F:<0S!ZY)_#3@5P#5]M2-26VD>UA1`M#I*+=P6.$4G%11 M[12<]NACGK\1O*9IW0S5MVN(]KYT;)C?:)`P\HV]Y:E`+X^M9HQ3?S.[II@8 M5K5:R373]PIA\EIDD11:D4_Y<`I35D^&I0YY(Z<$8'B2T$L@[L^D7Z3KDQE& MJ7"7CG(C9V%(4%'?F0'G5_`-BMI1IF]$09?R$X5;2KY<6B)2(4\;:9,9*J)N MU`D9R9,C!8*WA4IT,U`0T$\W*J0CEI\/M$OVSKO1:0-RB8/3^$6><@-JP9DU M,[V7,@I^!Q%*X@_:R0FWF<+,8R)/!<:8!F#:5=']:,=)6L=5I%.?Q5:I`WD%@FO))=ORBAVJM4?=G4R$U5: MW'&_O'F2C!.&"^,0_>D[MEQ+9/GXCJT?W[$5H?\'TH?`3RX/E'>*RV(]+9?B MDKOZQ!8-%Y:EE&1<=>D7==?0>X!+R=6)$O`7NZ9@7(A$+=F')%`7/CJHHOH` M#A7Z#&M&_B(MN":]5A4YY0&K"GJAE@@(+N'0M4)LDI`-B.Y>[WTC7[K[!-T"9"KQ\KYU0 M9EJ4)X0.+EZ7KW%E>78VT)'?T`X#GW-.>J[88V\@!PZ^!792OXY8"PQ MCI`']J(J=((>HN5(/%N:P2+H>S6'JW``B4&Q'[+8#^HP?J.OJ!\8232_;DVT M]/7NJ.8T0SK$E^$BC@B-'IH!::V<-T-:2#,X!A$-"0A.9UW`J*H8P;$+Q.BC M@-0%B5NNLF1=!26)"\$3AI7T<]H%^5T7I#^[XT5A-\_BY=EGL?R,-J/1K&'E M`1W3RU`E`N';:@1[S"MLK6RT5H6`/0=`5T68%4XO\37N-D,X5IO`'(L!*2V6 MNK(V!1CTG+_;M![AB,@)<"=Z4 MM?'SZX2[V(&8\T0&K9?,?<:\RMPPA__L9^L0>!1U9R]CY:D/O2:_5$IDBV<8L!*@^/7K8+JA:>?ZWU%TA/P-UYJXR435(]O] MT?6]JD]WA0,M85XLA8I5A=MRB5+!K_>GMZ?_`@P`)+8:+@IE;F1S=')E86T- M96YD;V)J#3@X(#`@;V)J#3P\(`TO5'EP92`O4&%G92`-+U!A"!;(#`@,"`V,3(@-SDR(%T@#2]#'0@72`-+T9O;G0@/#P@ M+U14-B`Q.3,@,"!2("]45#@@,3DT(#`@4B`O5%0Q-"`Q.3D@,"!2("]45#$V M(#(P,"`P(%(@+U14,3@@,C`Q(#`@4B`^/B`-+T5X=$=3=&%T92`\/"`O1U,R M(#,X,B`P(%(@+T=3,R`S.#,@,"!2(#X^(`T^/B`-96YD;V)J#3DP(#`@;V)J M#3P\("],96YG=&@@,S@X.2`O1FEL=&5R("]&;&%T941E8V]D92`^/B`-7[U8KVMCS7I[U21-:5+\R3^N:1);FJQ.ZMJL]U>IN;]Z\?HV,_?C59JD M:6G6'3;7GZXBU\3K_Y%1J8Q6SB5U6CE3UF!15V;]BUQ)"[F#_US!B^^BE_&J M2%S4==3SYQ"OLL1&]^;50PN"9>VY,/%_U[]=:)V:E4ORO&AF*5E- M*2L16*N8_WC3;HYQE5318^R2)IKB(O)QFM31QMQRT78H7]>*5==%3'=6<@;^K?S^:EUUL,QQSK=P_ MSHK/&UX9WAB_W?KN@M";WUJUZ=0.GZF.O5'WP^DV<;FES]]%MFD:$T,34-.C M@^^.8@)<$&W\QK2F>\!).\`FZ.BADKJV@=II9*ZS,H]M&MVD*3^I:4=U%RZ> M&!1H$.?1#BH@(1QU!YL>2^@X:TWC+WBJ1"JT"(T,KW#+M%U0D7DW,SL3F\>A MYZKC]B/E^F1)O/)IXM5SXM$=(?&LU<1[P^L29C\@YO#0U!\H`KJ\]>-I-XW/ MYW-MEWQV^5PUK+F0SH-'WA3!Q9.X>*<;XVBVPS%>4<9>O:@'CTB6%%\_0`G= M.H@F8YR3*N12(0Z$D\VU+9+**(]^MSO?H1]7=;BM]QRT,YU2Z(W'V.*T':#; MI/O?Z'@F7E3DG:"@6/!_-'1IDGV;D>*UC%Y[)_PMU4:,W9E*8P`P9R:\1S2S5YQZ4LKABKO.D-(O@KT0J MZV91)8Y9:;&S)H750>Y-RSE7]_!T+H5YN=OUCSMO])ITP)I9 MH?[/U4TDS",55D9AQ8##\0QU&;W<3G[X3AK9Q5>-^FH\P8Y"[(']#2QA2`K8 M[[#YQ/X;\\EKTH9R+<7!E3CX($S$K_`X_I"5_S:GWD7W M;5#?2-FJ5*PF]90W8RM1(G-6+B,0*&<5BO2GV0<(AA\G$\RX9"7BZ877,A/$ M,0(7RL7>X`4D8RG.M-@+P^05Z%%#3EAR`&9H-:)5I5JQH^1@):XLEYY7A0L) MG0X:\W*'L=Q$#SKU*3T3.S`]=(]Q]^V@U^B[]J_V;N>?IMB28UEY!BRAP_=B M!6=O+B58<8"9\VZA&6PV)P^(@'07$)!%8?$@%[U!7"X8&:4)"R(+?&?24?H* MIRON[^06\5NJ@/F%?(9/E@@<2)\?NO9:(2CYR3S&6 M"[_/=]%TZ0PN=(:NU8X\#)^WQ^'3O*)N5;09,0:-9W$V[)G](9Q/P8OCZ6Z< MVKFGR[":8F9O'S9WN\]F^=?,I'_YD5G`W*3>BZZHL2;_08:]B2D&%WX)I41H MT'FI&"LMO8KNXDS&L M'-@J@&/N-*"!5I%`O(K5$?@-?M*1J;B&!SOY5W^ER=?:^>R\XM`!;?!@Z*@4 M-"@7KWOF%>:&W_J!7'5+92D70&3\?@APYKE@$XUIL&=DUQY$0`"[K',9Z?:, M=WD,Q*M]K]8.`_[7I>#.!`T[3/$RM*1&<96@'EE)B<-C:(=>MZ9>O_<*.R:5 MXFF=]#9&CFG0RVC"RCRV_29H<`@/BCIA[Q)XY9>`B+;,?:`MCZ#I3J_SR$6Z M-$_IGA^9:;T4AE-?W7E_`+3:G#H./B"_O3EX:?"-J)5SD(N@!A$AZ[U_>HK; MF`K[)WO]08'`_8^844',R,KE%1ZVLX;EHF&N&D)>.TU#?W=B`2`Y:+.T;!0M MXBM1V?/C\,FT[6NDT*;&Z=@%]W]X(#(^[C9^&#%F7W;`DP)FA5@=MIH5>IIC MSQ2IO%%*2>Q"^ED3_C>MKO17044O>7VG@3_IB?93+8I*FW<3*5-MKE9:>14& M0!$(A]X'.5\7SJR&\F#AE"B<`.$K12:I(I."#:#BFRZ5-C]K@38O;T753)D& ME<+#L41^RV/V(+JI85\(2L,TYNZ,9(B=P6]A_Z@5_C(`"B*T].D'9(\NZ?521J)51RM.D+'=,3Y%6.WW,GV/ MP2)E?4D>J#](FWI@V67A1"4PS50?W=TJ(EK>"I5@H5)&NOX*5.HOK`JR^_"5 M]X.>J%7F.BEBR]F?F4?,`I6G6=."))/!^SZZ:_5$>773Y8)/%M0-/LH@((&T73;&]=@,R*I)OY7&M='W!W ML17T)EUQDC=,J'MV2Y;^?'FO]<)]Y8ZZUP<0M[HX19AD;#_(J=S<23=CE+YZ MRJ%QQ6P)1GDK:J^DL!;V82>L9!C$P1PU'*&I4PV*RFP'B02#`C/&OGL??P=S MYO:)5B-2UTDE/&/+SB8Q>L"!LF88&40XK)``TN=6PR>"7JS7I0'#;<`@ M)92>1>9GD:'MWOH=GDDT"L4)V7\(YU0&9\Q>BZ8OW]UGB:_Y53X]B`_MH>NU MCQ#""'*-IG;1HK[4HG;?1VVWQ%%\OJ+![UL&;>B_\(.L^O.D&\+;#P!@6P3% M4CKWH8%\=V8CWTE^S?F.U_]'P1=X7>UVQT_C/Q8=X091TC5):?/"$,+5MEGR M_CP0,M55BO./F+B''%E^;),38T4/AO4HJ(B@R-JT#LT.A<^NQG=C713+T)&@ M8'(59>AXO\:*JU<6["KA9J4T5A7:^JVB';3F#;J1K5)4^3KF0^Z!M85F/6C% M@]P)'ETYUPA315M`BX-\@%VHUC_75R]>WSIS/UZY"N*,*U!EI:GP]JL-NUF- ML7"%2.*L-U=9`;!>SU09(&9Y294U.,[G8YL5EX<_K\7K(37D:HH_^<>F+L$$ M=EF65/#[GEIEHA6@0!;PGWK(H`R+/$>D\46"R[>R,W;\UJ(\(^L"BCQ1%4_- MY3!ODOS):6[KB],G9N2UVOC<&4Q\WBZ'J>PN[9(:6%"M6K;6Y^Z$FB+F;!48 MUAS,'[V^9D]X;R"G7=U$U_$JRW+TE0A9AGA+A2+>2#,YLQ51E.74[EN]EE1AM16.*7>>S,;.E&%U) M8[%^,TO5;>EI]$OC!L'B/B^_M(JWR[[D(;[J8&](.^889@1TA*\J9NZN9N^-% M_-Y\N3:'9F#7\8GB:GLP/]^?V7*(',B0/\'(J+N=S+FR[/ED7_>O="`[]<%T MHAD7RSJX1V^X2)YKM)@V/K1[7'!WO8`=1.F<66+1F"[1#F'1]F:0:,/[TP46\VS_'5 M`4_'^']?8Y7!Q*=6)A_,^?H@>BPDQV9_F_!X;_&;9/I-NL]0'4W[:+K/>OQ< MFA[V9>HO2I&-PO'PK^GK_96YP?4:(<\!"F9K>&EC(=,:=A6?HERAV^NH^AHD\G41(/N!-Y034;\\E\ MC._>'PZZBGK5_[J\SMB:K\@/U1OZ421)%F>-P_J@FI2)L_H^MS%X[H"NC'%W M7J:7YEV[8?#VN#H-,NZ//>WZJ!'X))<:$Z_O-6^*9)&8`:G!2#YV,0D?)4IW M@,J3.=0/P]9@X>C\0E7A$T7*#0L^\T")<\,8W=P=:\7,6N,V1BUC M=B?ZB.>@V&@9E\.P-:MF@[W)06 M[7+M_<`&XC?-@Y(.3_44_Z1S*G/L3R1EO MMG%PZ+]%]CPV2'P@:4BO(HD!M%OE=%K#'X\H8T[. MMO"GH?WDCF8 M$"3L@Q#]`F`A(JQ_P>6`3]9UEV>W8%Q/D.4D_)#QX<4)PF3VY1K6@Y,CC=:" M,+TTXWS>+5ZV^1M4CK@OC?<@G/"2RNT4T-8MN+Q:$YH)81 MGNUD6^^0/!(SJ@+[BT"+Y%&BYDK]H7&"!;(#`@,"`V M,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TY,B`P(&]B:@T\/"`- M+U!R;V-3970@6R`O4$1&("]497AT(%T@#2]&;VYT(#P\("]45#8@,3DS(#`@ M4B`O5%0X(#$Y-"`P(%(@+U14,3(@,3DW(#`@4B`^/B`-+T5X=$=3=&%T92`\ M/"`O1U,R(#,X,B`P(%(@+T=3,R`S.#,@,"!2(#X^(`T^/B`-96YD;V)J#3DS M(#`@;V)J#3P\("],96YG=&@@-3(Q,2`O1FEL=&5R("]&;&%T941E8V]D92`^ M/B`-?_FV[>FJ?[6]]UP_M MR4Y#VYBA-7=_W]Y]VFY+$YGMX:X*JMR$]";Q[M._ M_DS,XW@7!F&8FVU#D]N7.R\)_>U_[S9Q')1A$9N\#*(TI?4O(AB+('U$+/S5 M^SR9+[:Q)S\+4F_GAT'IV<$DT8.)P]`O@MRCSQ=KCB20>[6_24EN;YIZY)G" M>U@_C?U.&PIO;I_KSI[]34ZBTVCJLRC?&SXD9AT)J1J>[%3O.FM&V\Q#._F; MBH1:.QK][$DZ\72@F[H6NA[-?5H$L6ILNZ[M^;C"P_)ZI/^?[>_DETT4Q%GB M?!#EBQ-2>.&%#XO()G]3DA8Y):93FOK23G5G_$T4>Y`Y^!ORK$<&T`\;X+5^ MQ-+.B,K#;M/HD&4NY-G$JP>[)U7L9#.QNLQS[LOA23X_]S"Q^I-G4P]>Y17G MU)QOR*:=R#_%.TY=W!F)];2S[D1;(D86WJ.?D(7F/JGH,E?.2J-H\5;!WOKJ MG.V)?&DM\W`B>Z1THVOI\:Q9(:"?S52R8Q?G-R M/!4N"7XN8L,FWI3-ZPJH5N1<.F10G.JUS0`8$5MY;F4((5YE#X0='@Q M9#4WT&=G;`0]2[5,8GCC,@_-L49I&ZWI]'/7#_HU]8.$//5>!2^4Q(PO=CG5 M";K512Z?8ZAZ7IV/N7SX^:7H.9-=CB9O=U-E,O4P:Y3F=-6ZI7F M+F7M"&BAK%%4*&^7*IVCNG`&S%)^$F\_FCV%7ZN>*XI.*:4N)ZV,)',9QBGC M)J*]U!YW2U.4DDS=4U*32]!]D@8^A:?P4A@1J).9W)DCE?/Q M;19^`+P:U^`P%=Q*=3RY*H^['Y8%20%\[K2&WK0%15WBI?@1U"5<8WATA;J$ M4>>TGRWJ\(LAQ`]2&*FSO$`RHE"S6RMO!"XC*@^2`SHBC(QS-W%];<_-8)T0 MMXB2@M+/%(0?3AGV3JON=_H3G!6A0>T$?P2X)R-0ZE`2&)^1Y]90K[X!XJ67 MX"=`4R\Q6DI-R:7FFV]N-N\)**1?C!8L4::)C;D>Y<0)'2Q_MB]:ERL&%$NP M<;W>_NQ3DHM_7]KI:*YGK3KXNY\+"1`_7$YN6KPV:9&738WS9"/&$R^X7.E[ MO0%;7+E$3%+V'UR9`6WDGZ+R.4-"+I/R\[C*.`6&'E4E7U6CY(@ MA9BQCDF&.L\`ZM1^B+%Q8G*JD(4G]A*S(Y9UF\<)8HW2I"Q*:5>P=/]*_9I'Z5D]&.Q M7$UVTLPHQ)B:;@C[H("L9KL^X&9)L>*N@)_^\$'BF1R8WV=\6.$>)H[E31(] M^.(VHAKYNGAHI=QV\A]S>\HEID5D?"8L371!XD"EZ%'J,/9!9")KF;YRFZXQ M:#GZF;-(TO1:5J7L2">`>Y40.:+*L*TH6`8F'KMK@ZM"5,]H.0N_%[C M3G+46W8A+E:*47R]3)Q/3J0FBCF^0\DO'PS%P@(6QIYKV>"E"6^4RL#WE"1- M=?$L6HP[9E/H?"--XLEG.BW/JA>4\RUV6"$G]7&-C)_]K/+)V&%G@BYV,+;JL MJZ*>WEURF('D+._#P>ROS6&G$!*S!]^H5/RB8#$>B$< ML5*K,/*9/3Q(H!:#<"9D8>F>M2?LWBHN'@K91#7W5SSW+J#7_A>A#(V2(T>) MK/A7F/AM;F&$-"30RL4R3;33R2^$KHL&@_V:[I!P\D\"L-LL;94Y;E)YE.9+ M*6D7]).>^4V!TGBFFM;$2R2)G^T[YP]Z)\D_K6*F9G(M>QL_EK9P>^7[5`IJ M$&6&W@[,;G)WN<57Z-1,40?;6&A[)L<_RD516Z$5&YT=')?MWR0<:_?4-]?0 MNVQF[%A+7!XS!^#7W)=!>/4^C(5V$W1V]@!!LJO!UPD$EML=%?\17'V\W3?B M/5LQU?MQL6?'9:49OCD[S>DI*1`/P\`8>:A4I-J<-:T(;!'QM/J$C3.>'EB= MP!A_4EEPG79/B/^`>2;DV524?#D_2(H"-F1\YK<+SMM=P&BXX M`([IN068HO4H\OG))>.UB*]0.6COWLM;4.6@;>V2Q=(1'8K9JBMK?S+MPI#: MWZ0'8&4N]5`KPNH+Q"D4GQ777PACF;(">LN)%3N?"?]:>@39"[=X4R:^>C=T M`T=HNNU-_)`5L>Z-RQ*T`PRC?(=A0(DKY(Z::"%/>:?Z_=H7+3R+@5Y;J[UK MY&K/SK$@^'DE%5!_4R3T/BY:]I9Y7)M^37[><"D]ZJ,+#XY-X0[7G(K"](?C M>S4^Y@5OUK]OM4VDG+-+ MI\E=0>W$:9G6-PLUAYO8%AY$H&,00E*KPFM=JP.=K$I)M#.-5^*0C36]S+65 M1Y>U5,@B9]C*'G-EC]6RY(S*2Q,ZZ^+, M61=FL.Z*$+9$!.G8?VH2BY=V&G49"'*EY$0)5Q6?'TUAO/(_`::@1])A5``L MS&3C#/J)&^8KX'-'490"_M\$,/]E`IC_*@',!"2._ZWL[]UGW]K?-?Y_67.L MF>PGS+3'>3=..CQSJ)DMLF&M3G:4TS_(84U_G@:=:Z2,3;,30>[WO)U+O9C3 MM8^Z/$FF19R>(G`>J0`*-/@Z@UK__#_2JV6Y=>.([O45L]`"=)$T9C!X99>; MFTI2Y2K;%55YX15%021B$.`%0,GZD7QOSND>@*2HF_A6%A+`&?1,/T^?WFC? M[^ON-"!F0S4M;/Q)U"@UO"R;^@9>+*PD@ MG'S,9@>5H(LB-#1IJLU0A67*(KNG3:5";'*-<*0\TM\H60#!:EQ8>AYLD)>H M*JBRQY'L8I5)QH08\NK^I)]487,<)L:$PA^J*QI(^A>`HIP](1'/KB.>?11Q M.T<\^SCBKZ(SX8_<\`#&,[`*!6X`.SA[SW)I&L()D.U5GS2+X"8Q5EP5U(', M9["3@TPSNF/U(;@$W9S^C*<']0J?_"E\(N9___"`80;&/X?2R9D;.IX4DTM\ MX';_:,VX#Q@Y;.2E?1JF%N#9 M+:+_.5#66(#K$P"MB/B!^0GN"PV=W$^9WF0"FX"SN5EA0BBR?(:Q\J9O_Z43 M_H^X*N-AX,#T$=<&`V.*LQ\7H7CEP\U8!PD0X)6/':4>%H4JP8R%H.A@RS6, M3HQ35285Q'2W+FT:RLO\4`V!3",&:2GU:+-R=M;%=.@I@L38M'#LXN%?^,#[ M5-%:0J(B@M:Q'O\FNE6;?B&#KUXD;LFN5"M+2?=?B9HKY[)T_C1/_(U2YWX0 M,-2:?TN/24(`X+/2W2BFMLR:94$S:AA<@/:399=.L^NT0.[,JD&92;/_J90/ M2J7_IU*(:U:6YBP694AZN)_)AR[YD?N_XOF_/MQ]_[=_.K,;[C+.<*S"2%\53%BAU0_1?34OEKE6>!2>UX=GIT3U?B])]OQ1*<:B^M%2O/ M96Q#&=NE]T`]YW-+(^[QFL7L/AD+VD7+PN?L$$5V&8G9'`BO4W9XW//*+\S)U%(B.%OM6:U$@L2ET>K18R_CS,G3JG#AYESFR]YS+=W^9). M+2XDRX\+,HCCP@L/!A&CN^H%>VXI=(($V#0+3C(NV@R2/)4^D#!YF4H&V<2E M4;JT);SOLZ1$>%*040D/]Y.XQ)RZ](G5F(B,1S9*TJ$)V*7SZ04_*7PRTS=_ M+G.;7:JMVN[EG>KU9`PA]V?E5V2\%]E/KF'TLT=E'D1Z?K+1+^MPQF"^DWHF M.B:Q6P=#$^)_NO2H$9CJXRA9QD5^82J"NJ9!I=4$U#D,Z!9&6O@,;PGB"2&T MPVDYX;+-W-D)I=#PSU_A)@^=DM:4_)13$*]L<6RS(G- MV5>AQ<)OWX(L\*C-OAU9SF)K&;FVL^74-%O&:7R-*S8N\6HMTIO`7D3I5^$D MF/"'T>0;34#G7Q?%>Q/R@"9QZ2=L3-$C[YEUA9M3Z@).D,_0TWG02\`)`I5= MHHDK2U%NW@:%N=@.)B=9SHWP50KH+2Z_\AYI,^TF=,O%9LK^."N0)'\$SN*8 M2EW`&7,O=9>M'&S!*5LHTISX9!-T?SX=*DE^HWQO^W)PAP9O\@;N5&^$S4P" M<+,;?#7)JJMN=B?AZ^W)A2(\>_!F5X1OMH.#17;R[_L]D7R_.3E?)2??W^RJ M[/OMCT)CBR*DXQ0:)=Q^0JPDY.5W1#SPS!\QZ`"K!4L\6#3QJ-VM1L%HHN#! M=!RHV,ZGB0H`MF#MU==21*<$$Q&73/@0IR1X7`Y9>`2Y`^>'/-KH9-GK&%0W M;SK(%9$@*7*D.AR;[DV$4DRT[6B"R&X!@AIA;A5=<]F362\%>=Q,`VL"K3#` MUMNJ'?1JKE*!74!>HGLN\)LF$W#:2QZ_V>$2G`Z6ELG8.E%::0LZK\QPDH'M<6#KR"+17+PJ/QO1/WIZJC'SM+JT M0%-[/K5/^)!JIU>L\X%KG#LJVU3 MM_56^E\)DWB=JK-8(8FCH)1GUY=.78"#JCZL MCVP5&=*5,9>SF#J2IM7O1V1%%03'D&-[D(\$27L\]<.IIF)T3O>,`.Y.C9R* MA:Y_,^']>.RE1A"*E[#4#-=M7?KZKY'L6FCA80[OK(8QK*'%#WMD/A2U:C2G M!K'Q,(F=GD/PP\)6"G$\]4B&Y?Q9_UNEII1($CG&7-T[A%]:]B1L1'S4S%82 M[2C_'^L&N5N*^@Z<%)QW5'*V`(1G!#5 MY566N'ER)/$.:1(:_^N>^M/K>^07V3!!B'4\RO\-@:$D_A3B*&',3T8W5:3G MY=%IITM2)ZF().(%VA%.:;?UIM&<.6SZWT2@&@<#H^2,$>KKJ62N<"2-<+C2 M@R7',US,16\#S^K[3;N3\J@.FD^2>JG8D,,KO`BX0".F1=X"/KCM^"4JOMD\ MRCH+'&"Z$:^`^[W`P5C*U`9`X-A6/1P,G9_[[A#@:5+R(@$5H)(9H))`+Z4+ M#"'].SGZU&\9LT/`@3=U4=N-YK%B.EFB_0LGO"0*W]1->'EL@'C[J@W,%`:6 MB/+L+#<3Z#@0Z+:JGA!!^KPUH[JKI]M*(OEV6QUE'M"=#8_7UP[I9DXS($\W MG1'Y8QSZ)`6`9L4[<>&^,GLEUZ3M",X8*J/K`]PD`C=H1L-1\6D&4ZDP2+)4 MP7<:8ME@Y@/$EP#[XS%TT:X'E)P6T@%[.0HFS&B%W@J\9_A1CTM!]+#^HD4: M?M5->*$OM`Q?F1S<:4*$N"TUFX6:E>.KH)NC\]Y-'XK=JRDR(4E"C(@:@+UZ M0#&ER`?JMI6U8SW*4YJ6MES+FUF7,QKCI]"!2(]94`.VL%YVOC!QRNBTB*-: M5PY`P8+09+-P(HI2KN[$TXHY5C`G41"#(UMY_#Z:\56&S,Z\R8I<*M6#L.IUYVM;DQT]N>[_PP`;I(7 M6@IE;F1S=')E86T-96YD;V)J#3DT(#`@;V)J#3P\(`TO5'EP92`O4&%G92`- M+U!A"!;(#`@,"`V,3(@ M-SDR(%T@#2]#'0@ M72`-+T9O;G0@/#P@+U14-B`Q.3,@,"!2("]45#@@,3DT(#`@4B`O5%0Q,"`Q M.38@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S,@,S@S(#`@4B`^/B`-/CX@ M#65N9&]B:@TY-B`P(&]B:@T\/"`O3&5N9W1H(#4W,#<@+T9I;'1EC0U#P?).AA@Q.ZNKJ[GJ:KO-V__ M9MMZ=@_V?=_VH[O8>72-&9VY>7=_\_;^OC21N3_>5-LJ-SO\\4=<5=LH-TFY M+4MS?[G9F=/-VX]?$W.:;G;;W2XW]PTV[Q]O@B0*[_^XV<3QMMP5LFK)/)OP7P.TVT>U+-I]*OCGY,--U&RS8+)N,[@.P[Z932CG6P] M-F>C9`=SL`^V[0>BV*;!!;M)8.5P-D,+NDV!@\GT])$'(RC!UO3SV8[FN,S+ M:`UXZ)5P4X'!%";X;^KCT3:SZTY&WG[P0@GQ$A(G"]:C"?]Q_PDF`.\X2[RZ MNU7=6-7M!SO6X2;#/>9K?PS$,R6>$SBQHH^N;>6KZR%0M"-9H/G2SF0,OW4. M210(KPS'UD&C@QU:.SO2(POZ<`?=.],?2?V29":=N\.T726&V:ITE3A=)8+DD=KSK5L'8Q^ M/(2;W;8,=.5:_=BWUAQAVZ,]V#%DG?6D-;-^_3`A[#3:H1]A4')Q$9S,L(P# M^[L,R*J=G36$U-I%,.I]]D+K:2?3Z/XX_L33CWYUF)YZ.(VB-:*K-:(C=7&8 M0=`CJ9LCA(9AE)T?\$46N`L6,>+=MN*0G^9-!-6BL(2G#.W%',5DA]9!L!P; M'2Y5@4&RT"^2!7'C$+>-GE](_D3O6:%N'#&+].X)1U&`\!%.\6Y740[EV#S` MR-A-@]%,,P2#;7\8LJALLMALVQP?)RRAEAHXQ_56V>DJ2 M5,4UPN7,"V7)#F-2]IJPD_]6Q>V:7^CLE"7\%6^-^;ME:6H10?0398P^1^@& MU9]'JS=^4JS&WQ5B?,XM\&,A@3$AA3M#+/AAJ^[X5W&6R>C!$O[:00$2@QT> M!4)(ZD9B@HBDB?'SPS2C/3B^K.?>>9%R>X`O8/AQ,K(^"L_56R5Y*Q`6\FHM MG%0FX67>Y-N=D7.AE5/*(^(A(A*`YNJ@RO,1!Q$Q'/3+R(WR-=,U6=(P49)-WS M81$P&J2L3H5?65G.PI2CBDN@$@^3@@$]3B,)G''47`*H`>X(U%+=C\1 M'Q@3V(LS"O)DIF7_!Z,[ZJ,70-G].O1>%Y;&C@+BE$14&CK3`AW91,Z?4-D! M&'#Q0GY-9H%>%.$=3%H&!ZO5032W+OCD5';(14&>S%=O/D M!=.VZ_Y/DJ?Y-4_56K]3[`*^/BWR84-&LZBJRELX@!J(LQR8#QPTCITIQ#5E M4Z&+1HJMG.M)RPNID7=-0]F"8!1Z8>[$N;)UDK#\*D>U;!XX;#B7W@D#16(J M]/*:',O_1=+E8+Y^X!"[^VH^R[6MB9+D=O59M!/;)&BYXCQ#3ZI.RZY.BU/? MK%!Q;1`;]#^B18]%A=<*+J/T'S'%VI>Z/IDCKX1R#"OLH=&1#R%\0-K(AY5C M%F[C1;J&NDCC0SU3W_EDIBB89EF-RT6:#L%_!+<>3$BZ@_2JYB^>A')9-T_R MXR@RH8(N$9MZ7P\>GI$]/[,OXXY:HFA77FW[)!]$!T$JPCE"F$)3(X+<5'7Q M/A6CE(.EE(@H.")NC9S+7:?Y0QIGNJ<$7"O20-B8^M!S<1P8&82K6L'T6A,_ MU=U2HXJ07TQT"T"%;_)@A\_1?L=W$2SR(-6U7*"2&*V5F1;J2F^!%PW\VMW% M:H<:K3GJ]U!KK^G07HZVZ4>JD*-[X#F$F&/$0C'SW3HI2^]$*#Q%GHNAO\&6 M^QHC2F/-=+:^2:T1`=-DR6,P*$\7K:OWKA4.2)LTJZZNHKZS67M1DM'-CMHQ M9G:Q-6,Y4@#H;=`Z'FLWFH>Z72Q\^I$SN:;*`EVZZRBS28![,;#Z"8S[=Q)Y MINU92LZR2><3BHF`6NKCR)A-/2G7OH::_JCD)"3D/K%9(HJBA._38'.V$$PZ M6HBWLL;T@EK'G7$_4:',"?BYD4\#)S=@*;:X+E#$]0MH!HR&ZD?IT7J>FC`G M,7MNORCN!ML=2&X9$\1MT)R'+("U6?!PKRQ>]P<"U8:`;G5>- M!#6U;^P)T3.M+ M9`?5J6/Y8T1_4J022&NM:=8"Q`I0VU]R!Q.!-X.`S' M$F4TL#B=::=9;W5L4+VK>Z,N*5\^R55/O7@2BI,,TU(DZUM9:[!Z75X,9VE\ MA;%8-(H)T!&D=[S9AQ2TQC%>7+@^#'4S,XP0\O"4)D14P6AH M8OV.'0K(I[XPA0:X10$.) M;O4JA_HDE5W%.X:[JZP#1[U.5[F^J(\(J^T:U4B'*EU'AO^Y%2'+_A^V(FGT M7UH17R4;7SC)1N^6R75PTJ;BBOX>$Q_0+]B[CIK[3H69;E_4X>IE&7X=P->) M3$(_A>P^]*^%*ZFN;M.J`.4H<9XK%[]6#D09WGVB6[DJ5PJKCSU"1_J1*GAT M*(G:LJ`)_BO]1A22&<]8O`LD^UTV.@X6/:6ZHQT,FOQ]:\T=HSK-))80F/:G M[Y^\+Q](ZG ML>O%_+69(-OS=E3`T[L_I&HUA7"SY'?)R1Q3$T-;DQ[Y8@O'%\"MEQ6%>7X+ M.'PH2?>0&Y;J9$*,*'B[5T&$?JB*\B=!]'JXN0811T4D9MJ:I'RM**3.LZ?Q M$%_[6XU)SE-&\$6ZV(QZ`*D%LK7L--\7JAQ4M2;G[Q%"%H'> MZ0@3X);WI"WWT"_96RY,7>,94=,E=X_"R;^Z<&<&!&W.\F6VO0U?YQM278O-J_>A(9,'P%>Z_9FVRC*BZ>=EG/ M.@D<\34TM(L#ZFM?$G%?4@0ZXJ);H-33%=)Q#_A1*8%"DVE8=D+\#564"^&0 MORK\7+@3LY=,.N$C5`ZBDXOC_*0 M!=5[+!QM%DK-_89T)85R`\PR.YFF,&F$^3IV_9OOJNEN&SF"?V5N`?-$A0"_ MQ-RTL9/GK#?[UI*3RUX@8$CB+0C0`"B;_AO)#TYU5P\`4I(O)#"8Z>GIZ:ZJ MYAB7VGDNSA@Z5=TV^"/?M_Q#4MCV+D4.JM2@'7[GPF!FO+/T5`JV3P4GI3SG M>)/:3(_4]TCKS=<#":S[6EMKQ_A*.R@\[WRUUQDV,9.DYA0.I-9CV&?-,'ZW M;K6D+J0Y]I/65OJ#193Y2@O6<>:%16:I\I#:F:;8];:GX.*MK7_!9\S21#M> ME^8<.DX2O?J%WI\>,74'2V"5U=(7[=00?QN]<<^7X+I[IH/^J\;=T?B6-W+1 M_"2;'Y3\KJYSA>VY:`0])OJ7J\['/=E[*^"V']H5";`J1&EXK;=1=I$&$UX+ MH0(X8NUR%(MVUG'6^=_\K>2]&Y+7-):O M-.IR)2M-NH4]GYES!66[XZ>*U\L97IN$'7-=GU/[('CY@8:1-/G8+)]KU<^< M<<.<6_4Y-V?.N6P\B^U-J:O9$>6:LVMSP]SD)GM=8MZXG:7\=*'4H\I=Y>%7 MPPS%?9HN+9VY:3X^]LI.H#7)TI73&P++M*=)TANB5\2]Q+SC&*WT_D[7RC-C MA^V-^SS[BU+H>64HA,2NLJARORVJPG!/"%2J[-3Z[:ET9?'L#6=:]S5,0N9J M4E9UU].P-*3DRJ8KOG/$$XA01Z?.-38-G*KV?*.&`3DJTF&G\VV'+$Q)DQUC M47I[;[OPI9+CX^]D66[#97G64BL.1QLIPA8'%`BRZR*_?R#0/_":WKJYY:LW M-[.;6^K-+?7F9J.;6U[=W.+BYA:CF]N&_%GW21)J1S?ACI:!S]Y,OYV763T^ MCY)T.`^+PEL%,,W=D]#\<*2#)AV_-:-DI&??<6/\]JS%AFYJ*"<8X:S&G>3D M(0Z26_0MG$5^GU4WV7ENC5665Q4>6W79J5]D>=^;*$YMMSX3=]:ZQ5*CR\:I M$0VU-&X#XD"5:I?%>:QDBH%!!LFZ[[Q34_V;(P6S&0 M+V./]-K#$#=$"6SMO7'_/(U]F39>Z/9A=+LZF('CIL# MCF];NGT-H@L#42ZT`U"@K"A0A*6-*![_3*D:#U(U9M@UQ!N$6*27FKE3@;*) M1+=&[JQM'8`M2AM^1?GO-,UD004MQ8?)3(5A'&E$-',:]PXC&UV=J9"Y0R'. M^2E>,CI@QMC]'G$)]*O.=J#4:+QUF)JXWN'1"NGK9)!;'+%%K#HY.O\^N7'^ M6^:/G/WZZA=8TXOYK%?X$JNJEFH#FJ620NOH`/S4;A#)\IU#]J7CG15UY6RD MTHK+P^M!\7`3C2PH8[UI!AW#LR%DH3T9N]M$%=!41&D+`XBREV-M MZR&3!FVFHNS+2-),@YN79)CTEQ&`'UEF)2<-C]2:Y(S6FU;;?SP2M83"PV=` M":@,_-#QGR4H8NHXD::U*T1Y<43LF8[3=Y2?8!<<7D M`BU.5.,KE2)X=[7MXNJCS6E(E;8)YQ6V2L3XG/)[*1V*S._/"W[9+'KBGP_$ M/[\@?O?K9*7J,9:0D;+)0$]>42.^N20Y1Z8:\W8ZIME,7M;VW;X8`=YGIEA/ M@:2G`^T'T:$,]6!ZA(-YVN3&@3]IM=^9BQB_H$C^&M'GKY/J@HG^WY?.F&)8 MC120.K,U/7"I:-Y0G?/U$.FU19J=WS$M^DY@%?V@+66;QVGNW;A'/0HTS4-S MR@BS7[WN#:4^/G*,MG?*/=./-"?R8RDANF_[\%$%K7@KB0W=_F_<\4K@1EWO MPK5]N[&*CKXQ,[FWIO?8>&MAN>C$`-I7-KNG7F"MM.O`>AZIH./!UM;"0LFX MLF.EIMCY)EF\-%LI!;F%YU4Y/&!`$D`128'FMI`X`XEWZ'-RE.N1-#/3RB-C ML..=QNJ8&$=:+F:KQ4`/<=]_Q&:]T;ZV8+T>)@+=2(H&BIUQZ00<\J(]:I)+ M'9J.E#('E-5;5]8V=X?!=325IL60'WBTF27)R`%K>U(A#68.3>FIA*!:OSM( M"LXU3;2#$PP"DD(BFI\5+L!@3=>29>:`B]G=ZBKYXW5_9$.9KF;=HN61@]52 M7NAOL%<QRKJN)Y_U+A` MVXA<0O(:KS`]5:NZ?4@=R2FCE.EZ&#).$:I0DJ#<98:%+27-!;*;7CI.+],! ME$;I*)W;1FDB5D81K1<(96.$@J1KBZX(R?81$0!^="9E6_Y&,M1D5`FG, M$!A()'U<.9;`UHEAM-N$*%X/"-?2:W"&*CQ!Z[W]QZ_N_PH%U M'$>_@>8_W_\+OX_#C'N]-SYS]-_OG4YZ)ZK@-_B#11\O%LRNY[^367Q[^-M' MT%/T\-GL?GK_X.Y_PF09__&9[V+-X,( MZ.]D;J=%`AZ,:X,B&_BV]5OJ-'N$!ZKSD#="6QLZ[*G:RP( M%H`S31ZL91ZY&%;M56WT6^I.:'S#9X!%YXY6LQ0`94$AN([.3ON%KM8LD1)! MEO@&B7QL"F36,2UO#`JI7T=XV$>"@9`H"#PS"OI$76QGAYY&AKG21B%!*64A M>[JS4[0T!U']!^^[D)%BJ@NV=J[R/BQ47;O4+:@'>1.+Z%MQD/[`"%.0T9T+ M7^8A]@".7R5FX3H6JN51K8?P7I'9<"-47`NM.ES#V;5'GQ7;HE_Y.JW/-CU5 M6*9DD-Q%Y[Z_:@JXY"AIP37JH3Z9&D39`=O/:?SLJN6P$ M.38`+*FD!FA;PP&058W06F<( M=08VHFWPXHQ=F)R_'8="FZ8./DD;,.C9I9S4VIE57ZX:SLYE*8&OM6#ME6+< MDPV7]H]::WFBC3(>IDA[VRKM]1DJF%DQ/CO-).WK]`3S"+V6%&%_*:*DI++M M3O?:LJ'RIR`+.]*!TK_UV:GIK]/N5T07`/S&[7QEVZ.DR[/[RN_%1+BQV[\A M85YZU4 M%>?N,RGX5A``U'`[D:Q\6:U3@[8K8/]'_6S7`31X@0O#S4@A%,B18U,84AP4 M\`R*&N)/$>XG`(GYV*8(;HWT!U=0BA+H(B M,`*/$7V2>H>L&J3;'KTVJ]`6E^\T\T?T0/N@F5:MRNZ_FD.C$K)>L$JS' M/6AC"(JDM<0D!4)D)>2DX&7N4HP\IT69(CFFD)/3-BT]-KE_#D`5KS;SD1[M M,32V2[E>'+;D9I(["%3C,Y%5&\1^%N4F&J5ZD6\X&SH$5'F9RGOF!X#"WHL7 M:='KT[D!5+L7:M(0`HZU%-U6$FT9V6#1&`\MM1[7!E("]086=E(`TO4&%R96YT(#,V-2`P(%(@#2]297-O=7)C97,@.3@@,"!2 M(`TO0V]N=&5N=',@.3D@,"!2(`TO5&AU;6(@,CDR(#`@4B`-+TUE9&EA0F]X M(%L@,"`P(#8Q,B`W.3(@72`-+T-R;W!";W@@6R`P(#`@-C$R(#$` M08)=!7GPYH&BFE)G*%+F9;3*U^?4I;F:V6PPP(AL5E=55YU35?W[ZMT'VU:3 M>[$_]FT_N(N=!E>;P9G5G_:K=_M]82*S;U;EILS-%G_\$)?E)LI-4FR*PNPO MJZTYK=[]\C$QIW&UW6RWN=G76-S?5D$2A_M_K]9QO"FVN]CDQ29*4WS_:;4F MR8@E\9"2]&^!_7UV4[B.XDT:W,VG(%QGFSRHPG6.G[J>+W.K+Y,]ANMT4P2F M]QO.=C#T&-3]Y3K8L\4+;>_""%]'O&TA[_CMQ9JV]TLCEN+@4RC6-N$ZP8\Q MOZ@IUX7_VO]E%2>;5'9[MI(\'B&ZRH+5RG-'6\^"FNYF&12\T0)6^UI/S.D?CU87K&#]0 M0;ZOO?-0'&<)G8`/4/H#Q)$<8+#7?D!L3=\9Q+6$BG.8;2(H&J^V=HVKU^Y( M9X'"H)MH`?@AZV70LZTHWT3;:"=QXB3'WDI4B)7.7$0%\GB6(/?'C3&_=I,= M["AGF7#Z'8>_[NDI#2[A%F&QQHUFL'[Q%%(*._=&7=K:F;XR^D3,QH*VO+R&`5`;ZY@CTBX'2?*&`/Z+(!%7'=9_)"(;$E$)AY7$P7S:.V%4LX)SYE'DI8B MJ`3[T)IFV_Q!%4/_-\3*7H"8:K@C)>-,"LJ@!;*C8!H14%-I$)/=)HJS0@`8 MEZQG88\X4Y\9NZE@%YFU9NJ-]8N=ZX1<)P5YRA3*P2\[$G4B^GAHW:C,!^>] MH.GLS=1,DHP"==#U$:-KTG>9X\QFR[6[*L;FJ1FF=)(L0$$JE%6A$D5<&RNO4!I'-W!ES3Y3&DB(\,:?EVX MS)CZ+#M%XB0DIJJYD)."D`4BMG!VJ1LEU0T*S?:AUDFU+A:\:1D:EEXR4KWK MY\$TU%10<0GA=[0_-*E:%\>S485M2%CL;Z-$ M^M;/'$+_0;9UO3`53%#KW(?8\&MW'._2;Z+"L`Y2BR6_'8B(B4_)(888%I!]U MNK'#@,&'06>T[A-Q,CA"A=\2&PIRA/(;*:%[7RT9<`<5LHV;3",Z!E/;8:J< MBGQ%("XE2[^CAL[3FH\*8S/EP23C@>?9WHVG[B6D^GIMM0S^&2JOI M7Z"_(6;?T?I'J=!^)E+5;V:B^$U;$I^(L@<>--'?W(FK`7HP MC''\X>D_"^5G[ MWLE,#JE>4P'!/OS2A)L@B@RV$_[S!!2C6)"D(R.H&RS8\393C0Q3(UM(BM++ M:S@>:G$HDSN%"V.=2HN*AOHHJM9/8C(QH!5287U2 M*VKZT7ET1EEE#UZKKXQ(W<,<9&3VB<"#`J:V/R79J!D#52NTB[8_O+)=4S_E MH]AO^_3(59VK*`NYL&2F'2E@-Y`-7*I8G=.N%LH`S<%J*L<2R#F68\D(*L.S M.#"%U!4[>T*B+#X\83QG1(>YG MPOU M"P]"&@TBR4>ILHSNTKM*K1%U1MQX#AD$?$MDV4'4&OG<>\;P]S75-7,3;7*8 M6N?G,\H_:C0?]-4Y7^FV(J#'J?3W.L@&L4SM9*:1)=((F^@'+OT/5O7#MWUD M`+Z2_=]M<9E;)-`\JLN$.(5TY70RK^L:70"3MW.X#*XTC?_:T<`="96HW$SB M!]T@S?E^U5M*O"EV6?G0%)>F%?GIB4H0S1IKUC6YNFJEP'1<5FAPXL8K(RN* M;P+4O+G?^;L$*;P.W,\QF%RL./XI2,$).G\,E? M51#<*$O>S'WQ8FBKAFZ(4/D%*?S62T^8VR,-_'E0:R6=0S+M*P!5R,\A*'3Q MM(JDIS*\P7_BBOD^2<#_D"*^-;*I$50S_VF$TPD.=('G"I;>SK;>;G69]F^D%?5P'S01_H$L,"*@=LHKD!?G^[ M>A<9P:]-JY\]S^3=N`2@D`#L_[A@\_4$N3]S,*WY^.T.$%"'J;*[3+< MQCJT]%X)_SR'!#?7G;0L=-"9<#!0@5%U$KFYH;TYW=$!B'P1XDL0"X-OU233 M(=WBBH!&5,ID776H?1.0YD=3<>\-5?*%*JGX.!-(T=L)C`4W+>[;"8.7;PX\ MF'!$2PH>K5,;C(,_D+.RSS0`0ZG;9_0HS-5"IU(EKK:6K[J!]1PE%!>.+5M] M9LVHTUR^Z8AYP+&/J"5PHH6_D*+QC0OTI%^8T64@7R<,]K4;F?N.Y)!?^2)K M-.DAO%31>5"558)]E''L253^S\Q^,)F]_1`6VDIP)>EQBF'ZNJQ+X\R6>T#F M>WDW55*(G.854!_GFKLPU5HJ1N:[AJA!%]^;2@-ULM2&=.'KI33KSW/X@*O1 M&\`](+`7R^>ADY#F:?P.Y5`,.]:$5@$=M)^G_(A=6(9"NM^D6?$`\B^]2L>3 MBV4>9WRU0*OB>T`6G(CPU!S^/CB=J%Y4$'7_(SW]E^\JV6T<2:+W_@K"EZ(` MNV&*HF@="X4>H($YS%0/T&>*3%DYHD@UES'T]_->1&2*DJOZ4F4E+FOB-PR?)$"+-@74@.@O2U@<$QP1U.DES"BS5>EGYT2:7> MD?N$4K38'DKQ)J\TO"=!L0PZY#45%&$I[NC[LE?I<`Q54OC;5&J+Y9`%_S*-JEN?N6&1/BD\)4\@B/^J7<,4[DJA M)-50B,8MTD:&+ZTR=AB5P;UK/<0M\*SJ&F(:"ZO'=]10,X:GL.@><7D7:\5B MK(*;)1PUZA43<.EY1`DK5B6CXM@V/?O6Y@](I61RF^X%=S,!*93L/+JP#9!5 MX;T,XH;Y+>0PN;N7:BIMP/!Y*_A,&\DBW0@LX^,BT`U$FIVA4\IK2:Y\_:+#:I39O&).Q%F9N#5LXVT-G_[U@49LLF7\:;DF/8]TKN MLUV[P&/0[+$WZTFAHV2=C='_'69Y<#&%HS1.A9_CO&A.I5*;G/<`7"(82X?OB2K2HIU%4GU#2K#?MF&Y` MC8-I,1-9[@!6-SB)$BHS"55YZG9H`K1`&=2[^E0.0QV+5MV(TZLK-&(PCW"Q MK]OU`@P>?-0F8@'KG3U+PS;;[Q;8"VXI0<(,/2]IK MA< MUQ3BBH"9//5@0"K"L31]"-W3$*N8M6]RQ5+4Q-J\7BG82G5Q_:),-,* M-F>'5JM[4T?-;)A?*R*CHD.HW(H.@/DI%/AS0]GXHXIY$?`.^GRB]6%::^_S7K7(X=II-Z.BH%1>G^2ZD7^K*M38> M1UE0]P_DX-[T8?LSRQN<6"]>34_T4]!%^6Z[`++<%%@P0[T\5C<^"U%@]W-0 MS2<'-83GZXW+C M>?=<>=/>:^/*NF];Z_Q]/]A?4WP:%NQ@0!6.;M2#<,(1<'^PC_74#\36?[7. M1@"K=Z`R]LB?2^)B!5^:0-+^6!LHSR+:*,2@V=`^@_V*B*F!Y!$QP^^(F-2! M*B0GUO3]K`8Q/WT/>PJRGI)_+"YAR#H^?0:\^ZX+/`F>^GURYR13EZ=OXDUL M?)?+&4Q?^F'Z]=ZBW-XF>I2U=CC7+H*FK3JJ6^Z[56KO*N+;W1LX1KY@TE?YV=*B[NPF(>$>$^4H'D+%H.3`+ MF($[4(BR)_!;9/):FD%T'6SL_2F!G,KUZ\+79+'9,I,6C`9Y8#39+5QIX3<& M2ZX`?L[6VE3:^)P(!JP%8]Y`-C)IN-AKFK`7]XK:QOPKMMNEBQH7M,`Q?L%K M$NI/B:U<^-Y`][YA^RU$99Y619FU:X*:6>L6]%2#72GW/RZ`H`= M^A518?@0PUH!H'6^#O<7+.-V1(R,VVJ;&)KKK M43XZ7*X,?X=(='92D7/DSSF$NR/:,8HL/:Q84S30XZF&9V>L""CB,4NV_R.'R`\A(CEL)&;4,L0SB M9JF1"L%4#8D],WSHWISL4'IW2'W#PZ@#\GQ1RF"9%DYB/RI`E>E?LO^L#(*' M#RRZ%1OXTHH(YC/)?R95@YU%;WJ\)V8,5Q@^&Z$O]@,(SHM[O=`H8?C`B>#4)364%0 M8B-RIE?`@)CQ)&CV/A,,%)5M`7BO15$N.?=3C;EAP$J\APH>$Z\C+).Z*5S= MA.MO__GEW[_\?P"%X&L0"F5N9'-T'0@72`-+T9O;G0@/#P@+U14-B`Q.3,@,"!2("]4 M5#@@,3DT(#`@4B`^/B`-+T5X=$=3=&%T92`\/"`O1U,S(#,X,R`P(%(@/CX@ M#3X^(`UE;F1O8FH-,3`R(#`@;V)J#3P\("],96YG=&@@,C@W,R`O1FEL=&5R M("]&;&%T941E8V]D92`^/B`-2^><>;P,%F,K`U6"QF\T!1+8E9BN3P8J]_8Y(/SJD+*6K&"0(!8E^KJNMR MJNK+S;M'5V9]\>S>UV7=%F?7MT5NVL+<_+B]>;?=)B8PV\--ZJ>Q6>+'@S!- M_2`V4>(GB=F>;Y;F>//N+T^1.78W2W^YC,TVQ^+VY<9&D;?])Q&*A=`B#/UD MN0E-G(!$LC';>[X2171G0<-E1#<_VP=OXT=VZ^&@_>EO)OG!6P2!GUKC+=:; MQ/[96_NA'OJ`<6#OO$6(SP=O$>/8>R_"CNSKSL_F2 M7YZ]GC^[VKO&X:_J/3R:A!GV15^#?F1;/M%YH?UJ'IT'6]AFOM,SKXOQA&LR MXSK9Y[/=GG`GL,[\6'ND@JS=&R*6V@,>)T]*;>'%MG5Y+SLM=D((L/83:[** M">S-D^[FWA+_OX-::$_>8H6);)0@LG=M=T5_U$O@A^MH%'`53&H)`I'S[A$/ M7=F'NWM^H_E(V(GEBF_L_ MS`V2KD;&JAJ,PHWP_<694P:/P^5G9W0T>`%D@$'@XO,3IOD8^9?[VN/-'F&E3>V\99$@]]720R_>B3W MOW_S3*9TY,)!0_P>^XE2RYV0V>&5T'EKHN#6A$NX76J7`7_$V4D%X5(W;B]K M5P*:UI7R*EF&<7,OB,!-))!+'2DVTJ520^VBE\M=D5ZFXZHJ2*1V0K`7('OS ML6^&6K`9/3Y0W*TYKAN/=(#44!/%$/*NF6X$NK>FZ\7/Y6Q.#$+[^TG<1!9+ M<1;$^U=#HI)2OWB)'0J]^\JJX\>:/.M./#2'4AF^=.8@E%KCLERW9>6@H-K+ MJC-*\L0PY*;"'\9$FNOAHZ>_#842[4 M0E![7POS!@8%T(H(%%B1_4I`%HR"R+'92Z?W'?GT-V_Q@DD[PM`WYN\,Y@/[ M=WMY!UF7`N?_?@WS$WO+>B>N^78,+(,)]5,Q;.^%S#`$+!OW1X/!!I[5=>2R M$3*(J1OV:;"O"G[7RM:5<,2WY]CD_$):X2C+*A19S$%R0L&OK3(Q?I4STB6VT(42[B/Z[2D;.J"4Z3C#L M.V#/J7D2N2;A$)YT'&\U>E#G>EIDZ#M?\5^D_R:'3H@2AE,.Q>OW0T[YDO@1 M2`RMI,V8L^F*LBE"5C14(5&L[+B/M-KN=5SESKP0@K#&3]^1&`D&SUKDP< M)^0W_2V*+U5?K.7-64*$D]\:Y8O/@++!N.9"IQ,X,/+M/>+*F6>-Y^`AO"S& M;-T7CY0P""V&!SHNY#*9R-$7<%US_H.NFI+/*U4S4C>-9!I0.H@LK0A[119% M$"I4)J`,>@*'2,4W\MEQ(*GT!.)KQ(^P:UTFCY"3LIKM1"8G3FSTB/Q3.0&A M5$XX1K:KA_%UD. M+HS(SQ!S/2*9D2`$KE%MZ>00$^P$*PBA#Y27:D[+G+U"X"6NMD3$@R7.1=<1 M6*PL?)6K/>!5@K;H4NVE4UQI5=534$O")\!B!+VKI%TA:_3P6Q(VLN6PAS^Z M/[)SH1?&[_'6(/@ST[NN'XLZY`(+%&@1G3/!3H5&*`; MFD:54;>]X"(@ZRA!'UJME>GB&:J!;P_L6CB#X->=BFN,O=F/][N<:@)233>T MI&QV@3$F#Q2!<",^O&9\)(^I\D)';"09]EQ5.4;.-8N`D*IZE8'A>6-]B0:I MI3=6\5XI#+Q)JAVI<^G>U:3J4F700Z[[+V[X1M=WY=@2C_.5@E2SUJ`X2G&G M\36%'V"2(V>04[HM(7EUL6DUGN=[N4R:*=[XA,+*H'+M+Z!P)9<0EBVAY7W7*TK;LCDZ!16F19MQ4K] M=H02,X?`4EX_[;GG3%:&;"YMI8I\NYA(ODU_Y*7U,[),61*49-R5K3F+D-Y' M%#E+HPA_A(50,50,)]@II%!(_&6\G'5_P52U!%JUU!4``,EVA]8#KDRU#[>/ M:%S[4]8;SKG#?FK?J!T)E_\38MA7*`!JBG&Q0\9875<`9_#*``&HU%NF+@`2 M!7Z20+Q+_3Q5S3E!"?)"1V2B ML5Q+D[%@FU!1VX%KE#F/.%,QU)'2J5Y":\76[= M8DQYO`9>M2:HN68 MAK:Y>_2HQ'JXNT<$K31&/_(%K31:JO0Y,ED/W"8B00[S6,HUPH3YK7E0./(O M4#.O*N9X,*\"=EVAU8>&OA92BC531%\_0227V$?[Q])*B:*-8,A/I`9ADH:2 M-?H^V;B]K%\70ZTR'LHWA"?K;/\T841^,S=&S0T.U0C*5QZUQF6Y[DH?\!US6>FCG4:R-:EVBE5L&MTKH M^RPI[CGI)E(D110A%.@IQR$Z1,() MDOLHMYH6"QS:*.KC-)P![(0[@09X7C1*J_165.%+]U!*XH_M*[%$X\`=`S_[ M4D1^JJ2\D;:!`+]CL\:D;@8H&$JGTU_A5@:[;JVASB5^%PSMR+$0@1T!L M999S83+(1/[)T/JF#O%GY"7%5YGI!ADDZ("<^]MYP@3U884E9V M+,/64H:-5+E.NI:`<^;;%<1JRL+:'4[]:]LOAF;J4:E103=5/*/O_<]2BQ'5 M)[#]#&IBXFQLZ@.=80CVJ:6&/K`,U'#U\=<$57.>(2&N"FH*(1!>J#.H(K74 M\'`%-]^!&[?"%-1EC_ MH1C*2,XH+8:U[4M*BK&'C(DEW"^P-H\7,,HM@(XL!?LFL:A2$QBTAA:@HAN8 M)2V!9;<1V"C7$*Y`+@`WI%YK"F5N9'-T'0@72`-+T9O;G0@/#P@+U14-B`Q.3,@,"!2 M("]45#@@,3DT(#`@4B`O5%0Q-"`Q.3D@,"!2("]45#$V(#(P,"`P(%(@+U14 M,3@@,C`Q(#`@4B`^/B`-+T5X=$=3=&%T92`\/"`O1U,R(#,X,B`P(%(@+T=3 M,R`S.#,@,"!2(#X^(`T^/B`-96YD;V)J#3$P-2`P(&]B:@T\/"`O3&5N9W1H M(#,X-S4@+T9I;'1EN%%3PXPGGY.CW>4R!,SH65'@!(B9Z:KNKG?=^N/D^]?]ZFJ[_-B_7*_6F^5-O]TL%VJS5"]?^O3U115KIT^KJ:N- M/E.__'CZ^J?3E^>_5E,3L#*O6OQ>O#R]G$U4YGU5>2R]K-7IJS,U^_6%<,S` MKR_.JBDNU(_.+#>'2#<_AY65$SBPM:_)YA!9<8C_=YE?0Y%]0+O&&5;)<#E<>\K!S%4+,?\7%^ MS@TSD0AF,S[;+=7!B@/DQ=NN;BULV`X>@'A^3]*4)3WK%Y4Q.+SGM5'?0.&H MWU8=;NXWE7'X4HXL7IO,,E'5U'>MU6H487`=_-VT\`\L%#O:1^Z"'-EU-)[< M>@'=#(Q]6S5:;)T(U6C5EX5/V:2+\CDLW^&HK1IV?;C: ME%-[AG&7PT@]=;ZN1@X]1EG6Q3&:\;&LDD MIU7Y;A!6/A9;G<^9!999X!M#S\06D6H5+%/#;$WMD]KT)^]*;IGTG&]-$VH7 M5?2)J0;?#IDEUG;=F%O(D=D,T9(M.*.QG]%+/"9Z^;IAL"RP4:G*!@]^$]LO M2!^;&EG>UC'M"^^A5!RI"*'_5S/GZ\X^T:PQ0PD`3\ZSA\VFO]VJJVH:ZU;? MW_?;^Q^>U3%$EW5,M6EMV#,1-`T[#^V)-J44WB6)9M]V@^=#&+/(%C$JT]0) M00-.J^\EA3X@A9)&\,GSFARX`\EF(>ASG'T5\/@#!D?\/2P_5K8AYRJOYV.V M2/R\"3EH&VN#_@Y',1H;XM`2ZPT*[N< M=ZWV"59O*:;3'5MGS`[1WNP(EH3LB*/5(W20UA\M'P/Y:?UXMFB$Z/@"M$`=\=U'-)NG:7=*7<7.9R0P==[7SU@?*N5]>9J);4Y4;RZ8YYIM(T!3W[[S\)-ER.YKN`[=SW->QTN'6 MA^4=08;5,#26C>2&DUSCU[6PJG?D,?JA8IH@R?";ZD M-?G12CI95I%)RDMV8(#T+"_'TDK`"]P=8BD6ZB"?<&>;?-`FYT7#5194'@V+ M(8=;(?C1E.U7\@(1\Z6\*.1O#2M"B_2DF<8!E#5=`667/;LH`V&*A!H>3!(Q M_D*"9B%?\%LU!<+7-^6Y&KBVY9!K=5W>[MAUB+O$0Q4Q]G#(,L MG`LK*>(G@K>!ZT:8W,!4CMPN__.E8UBX:6X;DWZC"]U`ETX"E]L(,0DI38=X M[AA6;ZH!=0+JTH4'._W!SL[XISOIW/E?"B@;*]&CXAPZ5B3:R=!.M`VKDVC< M0'S:L6>!_H.Z2E&*`R.LP2!$?8(4K5:W_59Z28L&8V2_K*?`,.Q\(Z%7%H-A MJT0M/QJ"C?\"L"O4;RS,ODVU?U*;_0Y%F5T3KH,4`($4G#7RTGNF:M3+MTB[ M2##AL9BAE4>)Z!BFZ^T(IKS.'"P*OH31/=X9VD%&!C_>DU<$#8'U=F_W=L0? MKL$)83).0?+P4E$H5IB4I38_;*XHQU&S9V-+1ZT[D+]JWM")>:,[`,L29FX' M!\J`PK+5[/5"_T?Q-XN3F`:W]D^JZ M0QZ^Y/OEQ>F+B\N+.;/6Z8OSF3I]=:9FY?MGC!!,ZK\S.W_,$^[/EUQK]=GY M:P1DA_F-&/>_ZOP?OP['_),9'V+7Y5+EDLO/+J1C(-Z.==^X87IAXW_@I2BJ MF*<$)VS5:@GL#N"P7*'+`M,N>\Y64YM:V^3,>.8^6QMX_0D(V!^X3G&^UXO% M&HF)/'NXE:S>%M#OF8=WXYCD\/EY'*_X]5;$7;&T>W9\WHH\Q(P0%0$C1Y,S MWK4X07#.?X-(/OJ.OAR)XS"#`WTJL,1,0L8T^`G2@+Y#[>@\4GXBO=L-G;T; MM.6(Z(#>]_7-4*<;_>\?C:K0#SEQM]YLE^M;^A>%;/T.%L!SM;Y]+_3IMM\0 M\1#`H>YC`YJI?+\5>CF%DB"[F6X\!Y6=]O3>Y>^=8Q`C37O`9IN&(V00QJ^, M>R;ZP76LM8L%)SUXCH-:X&Q+5R@ZE)Z]N635MFQ"!8L\6U M<$2IY/(RG`16^KFK6[UW5"P?[Y;Y$%8JEZT`E(R%5,9`JRIO9?R;1IL,Q]PR M.C;BO..3H1W!JG%A4)EW0N6'_KH2L]YMUOGM@0'<$LTP:+>2I%GV3.\K`LZ/ M_6I-YT49)JJV^*^36,=Q_:>[LIP7^GMQ6.K8^3@2=A"\E5_'FRC\@7H^"ED< M:D;MOTIS9JUWV*N=FDJA"SBZ*-U##:0LE^,$^+QLX5N^AS?FQ@5Y7@+1EB-V(VH+YL M\Q6/QD0@10NWEK+%-S&IM8V-TJZ]6,O*KSDT:0C(:9ATDNFQ\#ZR[*-NYMD, M,'3(J(>MARUEGVB_I:,XY,LS@!W=<`#L!3!=$N;JV_=30:$HV<1,](I@Q0TU M$Y@H)A,\SO6WM)?MD.AU;N7$61/VDZB3;\O"SG4A6`:">\S9YO)Q!.9DFZ"% M4IWG;3(2O\TF#4(S'H([?UE<8X?2FOR^7O]&OUH5RSY:L3%8B3EB*$)Z&)UE6 M`H>[WE1TM8\AA_9!NP9^B^:X]TPBQG_>>0/MFWQG._L,0$6^#[Y+V7Q4 M#P/+3MNXT#PGJ_0(0<)D`-2$DEI;P'R`;M`CG,Q;$VLC<:: M6/("LY^Q7[Q=7:1LQ^/D8KK))D7VJZH#NCD\:MR3JI[F_[+^!YY]'JC]1MT_ MR)OPYM!4S?N/UJ;K$5?9)%X4L3O>[,]3_XPF37)+JLX^FY=)N?(.B-KFWQ4B M%%>E#FY%JD&G:E3Z@W9W+;+1*/`AZ_Y%#LEA^Y*GJ@\M_QO=7EX+)@DZE(K! M[ZUD\P&,0K$6LL1-^L"1"Q/N*#'89P,7YEE@C1T2)XX:H`9JKLC< M!!-4>"YZV&5>@/-6_A[W\@GP4OET_BTBDA[H?T;=QJ^EWJUYW.EU47-?7B;V M9:SS@!OY$EB%8YS@3YE]_(0F3FQB,"--2/:Z/1$`N/&?PJMM='4\]V6V/2\* MU&P:)^;^22T[(*'$4_V>&572?YF/IY=Q-`_DZ[L>]#%;'MQSKN1E?T6:W=K" M&1L#<9B5._/W7%21$WFB=:-,JKL2)WS%1R4H@HP;?NMDS4/I&!B[7 M1(6O"ZW]%?7U[EZ[/)$:KOF;M<#)T&3\WJ&HP(#4!NG.7$E%3Y&DXC;#LPRE M^!U&Z>W[[HFKFBNDVB)FI>%P<_@SQ+$L\+JJBV)U,VWK*+9R^XW7`-G4D<-B M_H2@KP&T&*(.'Z(H68M)=4-6F;C%I#_*1!H?Z9P22/EZJ"K'?SH3[M/E0N#< MA9;;"X&K:91U&`JC=#MHU3$KW7;Y=I3,@&E=/D3ES1#7LEU<>1TTPT+B[2/N M;4.+)M4ZZM@2A-_EOJ8LK*[I`MH4RTT5YSM*43M0\O&,>R+.B%_9CHN/_((: MK.S&YEJ%=\H^)[`:`7L-Z%=2G/XX;T&-EL(H-+?,;:E%BH=5"UL_Y72?+1Q+ M:"`?ZN"XIX(R^$\P@)*D7JFZI1#NU-\/R-JFUW@?7;:+O"R-9[GE"W"!Q30? M87B3+_+0*197UJ=#?R)QB1NG(I#F8>LK[B'&;<)R;=@%U@>"Y_'U7G&PPB;C9A-4DYBMG,$6;$+0EUWR8R3E49&W;)2 M^[L6ZQ*^B;-]9DNQVYT!4G*G\U@HA&CHP8M:47NMFWLJ9W'DY#/UT57"H#;] M7=9:7-5=`Y=;]A^FU3K5L7AUC$DKTJ;U?()A+][`?0FZF3OL! M3TG3IIY=WC)M5!Q>W>@!3JN,T?0#U)GN,NW`YMRJ:&X46Q=%JWYU#XFB%0N9 M1ZW/9?$W5-%7H(JV;G_FB8U=X\7XM0_4EG-+Z!\SB1=4'6W]4+.T]=.N19AX MX1*U5DKN)(243'"!)T4:$:30H[G1:N%!.*$I)B>-`.T\$U&U3W!Q]QOW1BP/ M]#]NW%2UAOW*E_*/Q=>_!>Z-J&17"HR.W0%F^:B%9[S/1 M8^!P%$M&+<'#EED8""$B;%,B&J0IT,SFMX>^],=E_K1FRE\?_A\`S)%;"0IE M;F1S=')E86T-96YD;V)J#3$P-B`P(&]B:@T\/"`-+U1Y<&4@+U!A9V4@#2]0 M87)E;G0@,S8U(#`@4B`-+U)E"!;(#`@,"`V,3(@ M-SDR(%T@#2]#'1' M4W1A=&4@/#P@+T=3,B`S.#(@,"!2("]'4S,@,S@S(#`@4B`^/B`-/CX@#65N M9&]B:@TQ,#@@,"!O8FH-/#P@+TQE;F=T:"`T-C?Y[2_G%U>_54,3:&5<)?J]OCC_ M<#=0PGM3>5JZ&*GSFTMU]]M/S'%'_/KZLAK2@?I(9CGAZJ[ZS_A?9V;DD@MJ M:$:^)AWI8D/Z^'A#$OTHZH\?2'*DR?4E"31YE.A.;A3TE=`OJYH^ M5.$6TBM&%O!+-:SW^VYXW[CL4Q^)R=#"/V@YT>>OLL[,2=]B8(T\BZ4AZ.MN MSTT9[X2L6%%RAO'BC3P*EMW*$Y?2*'KRC!]!VX48(/C.`KD1$_R[9;&-GI1Q M0]HXO:4OJ]75\J%EO1K]H"ZK9F1UQS_M)HO/[=%6Y4SY'E3#3,/^IAUN7!R9 M[`S\DVIO>_\D6ZYGZB37NRZBEE6MU:Y\/*]><#]/MYDL'[KI@*E&J[8L?(4G MC)Z6SVYY3:)VJMOU/-D4J:TB86K=L77+AYP=33U,=KW93MS@ZI&SKB$_E'!P M"4JQ?K45K13^5<;KX\'6E:'=N@QDQAR")5_WA)I.;9*X?^ATL(2T2/`R"WQ*.;59T1Y_5ICU[+`G#Y+>@E>I18U7T`;`Z M3!6A5]0$4?2V8LBV5:#?+4>HS,GJ&*;/A"E20KZ$](78NOF2R2]M91J$W[U> M;V0ZX[@2,AQ,PXS4IS5R+WU,*LI-0<_G?^$&:7\"[Z8L2>DDE4,>8".RW!H" M(@<"KB^6H8 MO>P<>@("2"XXD(R<9T5(KH8V!&%T*;(,ZV(&HQU4)K`P9HVR\6#'.TX.$:F` M;'3DXGID%94&9R,R1&'R9*QXR.4HM^>.2I8]I'E*#"D>;/6'U%#;4=UO]>2O M>(*P-V'E#':=(,OTF=N6U/UQW6[(4X$,0]R[7VD3R M>](!TC,EKP0LX?+#"*48%@F@\`0))MO@F1P=)97,Y`RR)[+OR%!]_(,$KMM' M;C[6^&>^=:"+`OE-F6_XER/%ZGFG-^@<3'3W29DL)*@0KYT(F2,;P'57/0)7#2@`T$(ZKO)%$0A@:6&! M9V#_V4H`6@2015+V)66'J.^1HU'SS:"629"!S&9J^(4K0(P)O*:P#.(1+T5G MCCTK4-B+K8%7EB^#/V!]VR$ATT7MNP[IR.\XI"-_KT-B75K)0X=0V]`U^Z5E M^[@C\SG]S`U[NT')Q&RZ`LP6+2>+>]U^18$'KV5 M!$Y-%?ND+AG]O0S.Z/"B5P47BR4W#KM66NU-&;<[NA;2W8SD)$@%*D_6*";1<_`._AJKN%@"D7!D'H-!;T[,7R/;LP$T4(IFF*9 M"F45]"'H\_P< MJGWU!PDFV[W0@+O2I?Y2/%*!T&K9[M1\!2A1V&P5,-KH1\(,:=TNY9,A:V7S MM#R/MJ4SN:!,RRQU%*;'X&-[6KDF67`G1#'("<,&J;AQ`2E[E9 M)N][B-+>3Z85)_KIZ@7[$]^NT3/Y>"H1(V_/U"V7/:R"T^LY5;:A)6RYKOA3 M2SI(,@GEFZ.*S5<:!:1$X4[4CN8RD4%R9L>,Z+1^(/U+Z,0.44,C,]IWH>:) M^HTVH2._`[6._+U0\^G_-VT7W+2]5$C2C`PO+P#++X#4I>8O['JN2249%UAD MP*)KYQ+27LWZ`W#/+)O1D<5W4NP$&[F\TL2`TVF1\"*T@[./]L/WL#N)L"@2 MT]D:=VXH-IBYE$V/KONM%)J2R>1H)Z=&7QQV7`T/'AED33+9)WU3!9$N=H&. M>#[46NY-&5YHI:F:EVCH&7/0Q.(U),BTP)$55-:GS:L5/%I^ M'`D63Y$8BRSR6V%X%X'>?RO9=>3W$%C(WXM`:N9I>`N$G_2M%&O5JUY M>U-XVT=9/MB^.1#X@#,,&C=:8U"+Z.X.W9U^1^^3T2I`)4=YPE!/L5>)3)>B M/#WZIL)DDXH-Z(+>Q7AH!,9`@QV4VF/CR[9[C;8-_;UW*#`>236CB:`25W,5 M@\"AIZH7HU6$#A]]7TRDT+3"3Z>)$U.-C02`5&%HI`U4M>K.0HM=T!+,0Q_;WB[NB9UU=(4I2K M'@A5[69;8$)=S?_(+Y?E1HXCBN[]%5C,`JUP([K>55I;H=!.EA2AA5:<86L( M"P0F"'!"7Z+O];V95=T-D$W36WM#L+JRWIDW3P);-^H<9N*UM+C4#WR5Y`3^ M$.BFR!O^G0ZP3:'(/(AOT-QFGF7@!+R]7_Z%3OFZ6`-SXCM"++BP>6WIWZ;5 MNF'K%@MF9]49=JR"^M<7]'JH1><\[P?F9PB=27CQO$V\_8!%TIIHH7H#-*V* M5NU>$ZW:_4[1$?^/[YO.&59?J(?CHQ M>ECU,:V0^(G&1#;:,&`)IB/!FBXG&+,Y/TPS4P*!8-]REA8`-FE$#1J)N%GX M3\`M786@"V4=0US.K][GU(U29IU2VNC;ZYZZ=?3*:[31MZ\Q=>OH]SY6\#2Y MQ>F78/GC*,7CDU0E&TW:$.Y'!BZ>B6F%5]_QGA^D<:>V8RTZ13$^2DEZ)UG$ M;_<"GBRZOEW0PU+FM*;LEZKT`Q4B5JY/;W.]:1`NTI2V^I?2%%2:$J4)>TG4 M)C9%FN3#237S4R>>=-)S5H$*/"D7:;:J4DE4*JA*15$I>N>3VLX%1M("8UP< MVI0T'=J7^?:KN']ZEHL.`III*YB9-,.[AOA*[PTTB72*FJFA9M(*I%38C`J; MKM4A24DSS:0I<]0:86;-U%@S;J]K#)WM:@ZES51I,S7:S$J;KJUQ)>,XM[=V MDD,)2=5:T$@HJO/-@M?EFMCN(E;=9LV;H%!.9;-=D?);)(N9F>I M`AW7V;,/F@U>66"2;NA,F!?0>*R?)(G7N7=YR9Q]<+MB0GA1[;UTBQ?%AULM M/O*53[R[_"B+\L->N<1_7W[8=Q0?LSLT3!FN8T.N+.U*,A/V[`8^C*94[)BW M<_,NZD/Z.'U`F8':@/PSX!6GF6.[7A,6`!2%=IF[Y=2^UBN.%*1E2A3(-EFK MH+_4^*.(E#Q%;+U[E85/M,C6,$R0R!TEV#3OQ?&S5%O\U'&`D8(';E/-+=** M:>X(U=2TO:^\ZT8PN$ZT5A M,S2P%QCE"_PZ[C\+03Y/'\C\0*:TVSH.N,!ISK=FXOLT*11RR]*4=>HCNI'G0*;5OMK\(3V**O.%^&5[?$>'I(1+V;[>?.7?$+.,%ZWC-9YWT4N:X;I M$6WF4O8U3*PL8XLPHA5&C#,O1N'%OI1%H1$PO.7`=O<95=?1_='"7 M(W\L0O"*JR".T1L5?/)E&J:*S"4F-'?F@P:QUYPV3RJ<$19ZH)F#&NEJX&L$+S9RS3+! M%[=9[C+4(A0;\B5!1/#C4.2*+_LRPTN*]O\07GJ'TS(G*)F0T`WQ3H*N$^"> MN3_+B_^CHW%$C(V`2[&6=0,3B"D/L<(4A]XQZD@=KF(.6,KQQSBNZH5-4 M,XY)UO-P"B;\3\&$CR)@0A&18]@77&+4NGF7G'EI?(4E3+4[R3,J>O_=_1P(1.ZKWB+ MJ!M6()VTG;DK`7"]X$K$"LY7`Z\&/M?VH&VC`P*I1(K<%0^DVZ]SB2F% MKK/JH'7T"I>TT6O^6T>O<$D;_5[W1@B:*_?&$1+RSB)#@$X,Z$24-$#]^1N' M"=N&%WQK2HN.4+7]&W7D'Q#J>(4C')*)\`!=?::SWL.WCZ=C#PJ&LU(VX6%E M>WX0'\YHUQ%_=/0DL?NH)@BV&@;L/Y%X#"(@8;4O;)3M>#R+Z66/Y1`6XY\= M6;OUPOWP?Q MCGQ?&,A>XS%O'SJ"_*;V'*5UO[D?OXX'G!A'^=)1`A[U1!0-7-R%N^^#'*Y( MCA&*T-TG&V2S#N2MJNIYE497\!T#(/)04?.23U'MG#.W=A9G-M7,EBAF"?HO MY2C-XF3PN@]0/SY-HE+O`W?X_7B$'A[D_UKF=#RXIE^VH0LD`"[#3,4*2/Z> M+T],NVITD4]?1Z(4[N2+*MQ(%*Z%B$PPWHYG0XN2G\<17GR!+ZOP$C@[$!J4KWTSU.!XOYUW3K7_^ M[=\#`/C9WEH*96YD7!E M("]086=E(`TO4&%R96YT(#,V-2`P(%(@#2]297-O=7)C97,@,3$P(#`@4B`- M+T-O;G1E;G1S(#$Q,2`P(%(@#2]4:'5M8B`S,#`@,"!2(`TO365D:6%";W@@ M6R`P(#`@-C$R(#"!;(#`@,"`V,3(@-SDR(%T@#2]2 M;W1A=&4@,"`-/CX@#65N9&]B:@TQ,3`@,"!O8FH-/#P@#2]0'1'4W1A M=&4@/#P@+T=3,B`S.#(@,"!2("]'4S,@,S@S(#`@4B`^/B`-/CX@#65N9&]B M:@TQ,3$@,"!O8FH-/#P@+TQE;F=T:"`V-C0Y("]&:6QT97(@+T9L871E1&5C M;V1E(#X^(`US=')E86T-"DB)C%=)=QO'$;[S5_1!AYGW"&AZG>G<*)*6YOYUX\^OVK!DW#2W.:''Z^UGE4SW]%T394&1UX^C,B)\D*XV#<:T;MRQI M!';?,3]]M1Y"/E<7M^_JD4WCKKJ@]]A55^;CCQ>W/U]<7G^:TI8+M'59-[1S M\7Y")!U]G=>CMC*TV]'F!R*J+L>\=/'AJK;-V%9F\NG-!)+!?E6//+V47O6P MWCC.U?6D_N?T)]B7@V\-;=KO5A.C$W/Q#!S>7??[QY3Z:X=IRJZ]O)GZK?7/.I M4O4/&-96G]C.6$U_,6P8121E-JOS;C`KM6J6;9S8]<-Z4U,<0V5V),B2P$<1 MV+.IJ3*_]'?ZN=GR!WGL>G7?J_Y[<]7/>K8J5EZR^S^L` M?3;K?RX?Y\8U^MF4#Y90#%C5=(J65#)=HL_&#G0X=6,2)V:2Q.SB.`3C;1[' M?38AA\0',8L/)F0T5D3GN@1'7D%,)FN1=0\G1A-9VZ8#@YY$ M#NV/T-P>Q3*A7HE=6[5E+O:]2"HH`_0&AP:)B*1J-GL6B>FKY&:_^::L0[9,[$IV*Z+_(]91`U(C^E^3V0+)O4N9\$WE/LC^7 M_=UABBQ0#U&IC[)3LV:%O[;::D9IZJ]UV9AW*R&?K=%[PHP-_YP1_#$'NOI^!-)^;SCCJRC%G M1)FBWW6'K=Z8.G9P66X;>L9@R?3:AQ:OY**XWZ)\Z>5R!E$7&PS!.L0(UMB$ M2"_7)LR79%,0IM2U6B374T`J!TAE@2$<546#_*/&3N8&JF6R<].?/0"KG9Z" MFF9G6AKO`42LBS-DV#SM69!83L^^*]+;P!MCGNB(X'0K& M.[3H(Z^@PF<1R7N-B`['YJ:]XN1:$4J9ZX4A,RA]Q1Z!QB\,I:**:=!=O]30 M%)/24>HQ'5*<[#^P:Z\TA;U)>R%>W($4AJ`V[(,SA*SU05$68Y/$SGBJ79;M50U4^U)#5;\YTOD5((GC2\SHJ+,;3N+AQ<])G00I42N+J",#$E'+!SA(`P*#-]M9:+IZQDO&DVK&OV= MKB8<5$A>/\A844(:EQF$&R06$$[D>2G`Y(E(R.K;VEL3H4<=U=V)'Q`KH*OCET6A_/C M0H#SJUDP`1F7];!R`@Q;I\,6.O5@"UDE2^)P9#4M`JOA9F?NA`A+:NDM0#R? MQMGA."?Z(?Z[[IO5C=P#LG@/X%-Y^Z.^,MP"8CZHCJ>%7`-YQ$0H8:;0C&GZ MZCUL?W7X3-T;MYUS*U=0>G#3C`[7,!NQD-'^NP;@G#M_5V&9_K*D8+!:L\?= MK@EVB$$!H9.=-`]$'TV;>Y:MOHV^UCPLN;U56^DQ5#BZ7\B73]3=D$L,F;=" MK2+G\.N*(18M9<9!PG4J9;65\#POE%7DJ%1=V];-N#2E&.GV9>/)5:H]]'J7 M<#UU&:`8WUWQ^Z@P2WH>>"<-LT`3]%908"\%\_2\F0G`>)2F#[](\NDO&TQW MC5JR4*GUM:F1DST:>C4GO\RXWTK7]]66U[='XGAI5W?*.O_ZS"ME&].@6O2& M%XLN@T`F#/=O(B[18*)I+UZ/ M^RLO9Q6!Q>*V+XQB,$5I`*-F@@=T:=`@"`.7;<=XA5"@[F-36RB7AOU+_K;[ M_`UV"!&/>`5U]T/$\+=$YM!5B>('9Z*RYP)GUHKV>"A+-Y1_SE;.8[X#JJ"! M[`'57\C>]MPLE+60J%)55$#G5KOKI4I6PC<"C@$$EQ75'0[)(1A;TCC,3')]-P\QM1BW7` M6_31\7ITG1]CRW5!;DO\P0>V$^4(C>443C6^G_!<3*R$6IN7F MKD\5PVXZ:H!^@&)[).8'0'R,B,TGP)I`YT90-V781P#^Q7]HKYKF-HX<>M>O MF".GBF2FOWOV9L>NE"^[5;'WY+W($A6I)$HJ4?)NY=?O>P!Z9DC9B0_)AI&(.P MDPT?56]^$`%[D0STV>KC1M%0EKP):2@+M:;M?5P(17LR7UQ>H1_;C,$5Z5P$0424'A[!O*- M+'V=8IY?]XAV0ME^I^Z1L/T=`1X&"=PYL@VJCV+;T2]/$,S``[JW]C+H+]!^ MS!/\O/]T]M,O'WWWV^',9Y2=W!7R3_9AN)L-OI]V9U=G;S^!+%6T9MU&?H?. M5T1*A#1_/^UI)="*<-HZI8VWBO"6N8#"+Y1$6E<_".'Q@BR$_S4S`@=[IY_H M:CQIP+XG__N"NT\F^*26NJ"C4XM-W>GL:,/(&ZF`;%:P6`I)'OZ%XOC/>Q5; M#SI^TV35KZIK^!H'BVW&+4Q,$[XF(*_9/D2/.`EH*)HR"+F*@-X\J7XS-E' M'0&,4B%/WY9S:#$Q'"U$/]I"PG"\Q*%.:EM_O)P\DLV?1%I;PQ`GU;HMQ\MY MR+2FR^S3CE?!*^9]C]=^-+Q'2X9OA'>9^M-8DX;WAQ['&X$0T4O_(<-+'QGO M0$:TEZB(??!"1/"T8(FB<`5)]CBR`B(M%1,"9!Y]BM)MB2!*0FF44ZT_]VF0 M1DF4S,1M+_1MW2MNS-*RZU,?66-BTD];`M$T\*9T*DT:S6Z2UD*&NTG-_)/_ M-%NBY3N5?NA.9* M`.]!Y6[7ROU%U43,OLIU;0=A[-W-D4\;#9,TN<3_JB`=Y59Z2I2HHI4GNFJ7 M$)`$#N=N=%N+:(E61'U)C1KQ>1U!NR;Z6.:']7A8EN9!BIZ!U3CR73G'%V6M M&T6C1%51<<1!2AI#89"95\Q./E78$Y.79H*M",O3HS2:E]I9TMC.,GH]R_O_ ML=8(02)9O;@AB)(3.2<Z-K09!" M[,E]QY@U;D]9`T@#\TOK"1A155]&^X[VJ=99GM2D<8M`MN3:+'?*P!SG5&N= M=0PZY$E;;MWNW,GMO[IU?\(YOF.S3#:GC#JBV'GFV*-EU$&OU(87#F"V]\)I M+\A.JV74E31IG0E>X]4I^,1;55YAQE3@D:BIH5<8]X"?A(J?].;R_)GP_(Q M");+_\R_(Q`(#`L-2,)[>.L7H@HG!1Q!N[(%RZX+M/M\)!4524`DX7E>(HE> MQ40.AEST#!^?V5TX"21VBG(S<76[^:*8KQB-_F)W292.A&:1:`K[QQWCM2_%(N9"^<539+XC$A:W!6K%$YP'@G`:XY`N)_ M^D7?:$ZXX*R4!RWE(:^."W:9LBM,T&ZQ^:9GV[27WX>>'$KPF4?GF6_TXW=K M5Y[M6R6M;5DB?_L2*'BGWAQN9^*K, M9:<7?B=SIG,X_$."%-5?:O$?7T/Y@6NPA:"Q)8>7UYJ/;S33R*K6Q0GEPRG' MR+4%8@UZZG_N>J'Q\FYZ(A MUBR`E6XQ,8V2L>&DJ"6?"[7^J<(R-R?$'ER+`V.0_WJ^WCWU63BN9070R$M$ M9&&[#K_7.X`86D>D*I_^*RNLFZ/":R\EBBJGOQNDFSH\@#'JW[_^*D?W)U1I M$2B;F0_X828$<29$H57!3BKR//R;@$(N23>?E,;LA%B>WQ$J,G&,P^_,F6AK MEV2,T#>1!]XY@ M`,:/BQ=\Y&;!W'J^6KCE0GLX[W)"$"<:\`S8C968Q1MJ(FJ;$4BBE_)3>T%/^:!YG%WU90*\ M.B&>&Q2^1F0U`YRL4R"/,$W(X\17,H(P!W=4F*3.X:!M0[$;^]M@X>0>XH+V M:^H[.TRP<2VLO(JS;8Y=P+B=KNK]I[.??OGHN]\.9W'`>E=P;)?QQK%VN-WN M:7=V=?;V$T"C;I$1&_D=.G2EH&>0WF:DR9Y&`HW(-==D--1Y:^/>\JJ2E$W6 MTKOVYUY8[X60#<8I:DB`VR0EW3MC2C8["Q6L[HDK"?5)+<-`=BI,PYMV61LQ0H?:-FF[H2&$QXT(H`+.6HL% M7Y-;-16O'H_-E)R\9,;35KK%J'J`]4U8N.%4CW;%/2:*E$%NP(RQE$BV%ERN M9H9BUJ5ET#D!&<>[Y+4=.[P(GF`YY&%:.N=H&\RUM810Q1(ZLM MY]!";CA:B'ZTA83A>*D@0>NDMO7'R\FCV/B30&YK4(V3*D+A>#F#:<&:+@-] M3U;3N-CW>.U'L\<#OK^=/"&UY)%*Q.3YH)W;X45;!+:,I$!,B(&AKS643:D( M7O6;HK]$F<-SS_!_4+G;-=/)5$W$[*M-R>D M$AF].F7>BT?VWWUDN]#-^`>/?+B66&A**.Z$PT/W^/+TRI0]0F=O+G:Z-QH6 MO_;L-M6)-TQZMP+^UCE"9$60T+@\%JC:2DMH>TBET??)CWU9O$CXDFXJQNT/+/"W&Z^\!D9 M>8Z\?W>IQ*FS]2:^?]R1>%;&)EO+0],0HS<]2=[#/6MUPM0XZ9W:00>"Q\NK ME[O_\U[E2FX;03375R#8@*A:;LT%#.#,*L5V.5"F9`_(8HDB502E0%_O][I[ M0&!%L)18"8Z9[CGZ?$\4RRJVJHR-M3,JZE(V$I><@JG8F,G(P!QG_#3$]OSYH8GZ>+9_E63.2?H2R!X_ MUO[R-](EGH2BPRK'Y\]"![8J\D0]0#@30C)B\*661E!(HJ?1]5A?C7DHRF,( MF")=A"HT'4HG:1!87(UX$T'WOX"@(\%R<'I_0;[M0S8LK0VNH&F4*NT8"J1# MG]UCJ>Z6POP=_9!=WP_[B?1*3=4&HC8"]JDN]1P(%R>3!B!28I2"0RTU,AQ#F5 MFA2Z:PKS>&B*45Q)TY@L3?\^?QI.=5:;:(9((V9D<'1`F0N;3P.*&&M>I['A M+[&A8P>49[PF[:&6DJ(B6WJ-YOR]X7(U6+8+-'!!.[G0P=(Z?J9;[Z6M'\CJ MVLUIX$VSE`K8<[/?_1!&E#B*/C2$)+3UN*E]`OTU.P+'\VJ&]30<^M9NW<;N M@CQ"W[26`H"9G78<3X#5F0G+8K1APZ9K-@S%B*Y-4[4AZ>!U>^FHIYJD4(!*%?:6M0NYX@A%$'[W"L.-@`#QR(OO&W:V_N^ M9L7+LG)C8Y#I>^UYK\@@6A_(U"^2)!*X]CI),O:JR%#I^[+QZ$F MC'^6?MPR?NCJ^SH2V[^C*:;!BPR[WQ=U\1/K^KX)Q]ES'Q M+OM,)BOP#G2QV=S!@B%R88Q%F!M?T13"O>R,%5);ULWVD1.72+HLF],=L[9= MJ,\D/'')';&Z[%6.U$SG;54K;SK<*&0]&9S.R0^3O.,Y/,_]H:XH`+!B.TX[ MQ=!1MP^J"J'9ADX-U95MQ=ZIW$DGIYLA3K9Q<4./:CE3B,5`KI\=X75L(8VZ M*A*D!(NMA%?2\++9-I:P<_/Q%'H;;_!:S&2D4C1;%-03),B M@F$QVP*08"F=!3Q?3B)B+GLNIJZF#HK[`V#)ZM7##;.8ZL]V"5>MI>)7S156 MS&@J:W8,-VRLJM>-'-:L;TIKY@\W7*.J:[X)ZVXSQ:M^"VL.5:4UC]ZLDG#E M5IZHDDUB@80=9C72E5X1&^-JPU`=CN=AK,['BGCFF05-:!6AZ&$\[FN6[-W+ M(R<(Y0+A^XL(?]P=;!A0A&*FO1,=F]H+NZC&,]%)VBS7^3(_#<` MG)!=&0IE;F1S=')E86T-96YD;V)J#3$Q,B`P(&]B:@T\/"`-+U1Y<&4@+U!A M9V4@#2]087)E;G0@,S8U(#`@4B`-+U)E"!;(#`@ M,"`V,3(@-SDR(%T@#2]#'1'4W1A=&4@/#P@+T=3,B`S.#(@,"!2("]'4S,@,S@S(#`@4B`^/B`- M/CX@#65N9&]B:@TQ,30@,"!O8FH-/#P@+TQE;F=T:"`S-C(P("]&:6QT97(@ M+T9L871E1&5C;V1E(#X^(`US=')E86T-"DB)C%?;KKQ M^^3-C\/#;+?X,ERL']:;Q7+8;19SLUF8R5L^F08_^0A- MKAV&7.=L;I:3QGR:O'E_'P5<3>>X7>_[C597J8,^K::B=O30_?'W^X[?G%^]^JJ:NQ'_ZN+\F^LSH[3?51%+%[4Y_^[27/_TE5!<@]Y>75937&A/>)8;WEU7_[CY MZ\35L>D[,Y4QC8(%3\&F(IE7R2Z^KUIXQ./["E=Z>XD5W.$B MOF^J;-]QP5SS\V2Y'/JV@A!DR,7"U'P/@>U?*FIJ+LZOOR8'G7XS7@N"GZMI M;U5^V-A%-7*N6R_>DH^0<]UD&#S6-.Y2M6GC:/';9 M4DIKWJUNN9^P?FLNJQX2C/3S\6/Y<3@Y:H(K\[-JFC$8`Z%C"Y7V(H]Q$=HZ M-S[3_ET3/>TOT*N958;FJ&FMV97*_?MP6R\Y6M]NG!FGK+N<.!BE> M%:8>KBH\C6\J%VT#<5/;=;9,&U/YIH_1NI[SOJ8]P89$V*N M?82AG60'+DT&.L1L-L/D;A+R?L_%Q.%H4[/-Y9<4X_50AD!&@,X[!SGE]MCN<`$U%BB^5=QAT1]R\]PSHTO:5*?XW"71`<+VN[F. M)YN]K_/A;%<#"_Y/C^$D/18<$^^)T^C&T6FJ!F&KAR&BV`SQ!;-"+CM?TV.= M70[BC`_V8;T%`B18R_48/E1()^]2D^R?F`>-@[,^6(4'5SGZ`"%+B#GK=-KN M5PNUL.@;)QRB>X%#*!SR.)7!ZRH$SRF6J@=0%6/CC[)TB M,!`YA)L4NWX$AD-"C7!S#H?<2B'Y%1#3T4%(AN6PPAC*C.M&/]<(:B3/1NK` M@/LQS-=*/!R;'1U$%(]K9[WA5)YG7I??$^#GUSW`B>>438SNBJ+D/=" M9Q[)2*EO]_'FBV5@SC:%IX8)_<$RI4*O/P\;Q&PB&``4LA4VB6#`F9G-QW7& M4P0$,';+A!"PWQDDH*-]JQ)$IW!]D`!4KNG]:>I/`V2!T%.`@M^[E3G;.H," M[[/K1O'W.>?:I`PN!XC3VL\;&70R)WQ%NZ!"Q,\%',=$,S,=;ZD9;8M4L;-E MP5/E0+/C!-=:^^_9R70M`%IXX7!V?6<=,XJH60;D9`JQP9<[2[K4Z=`23H&N M5=_;,5TYYB;8,-(6+A+D6:AIC^;8CXHY?JS[<6^).UP-:8?-9K@U<\'\=34E M'"WA48<",*7KAM5VQC8*2;#`.@O&E%YPMG?Q.YISAK/T), M!+PH(WMK*H!4@E.R:M,7;8BX:"<]0S&1COFT4@_OUH?S/3N.[>,#J79R;K7; M"EE(B4)FRBMZ-;W8(-M8E9VGGHMH<.`P["1J=^JL$`Y)M^_1QE+Q7I3$_5&R MS9JU_&^)*%G7!5ZP<5?1M#LY<`^BP>AAU!G+0T77)>-&,M'9^=92OH5[-OC`T3^&D"?N$;$KGR0@-1TRC-O&6:N M14RZ9XYI70[',.B?I8]WHTM&(+E:?1E6N[4&](:IFNR_!!>-9$N"*9F9MZ;0 M[(#9R=[#K'-=>%2RS4;A!]S&D]OMH&L::ZBI5#3H9@#N1*291%RMH88AR7*9 MO)Q@K3+(0ADE!(7V.`CS`3'V;[.V1.'EXV`$,UK:-PC"3:GQ4C/7O!]63)DX M+BRD6YRK3%L&'H@NH*C&5A^;_(JH@6=:T54F%/5%:M]OY/*=D_@ M=NPU(3`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`UB M'&==4-).&[U>S3@&,W:P2CMTZ#'^2_/.-Z?T`B(B&RU4(U<>"ZRH+)[WTOWQ MN2"E][;B??I:,>7[9&/0RV@C MAY"N!;.4BS08\J%#UE=LK_:*:/_-I.PEX0_IH(E]S!G6I2X;/FNCG4\%O`(;IO20$"!=#(WO?SY<5ZH=WOO91HU`RT>G]L=;(! MT&LONV03[-6)TOJN)!2^#-N=3C])[V>$5^F"CSOE+POVA_(Y;-^*&1OMI3+1 M]AD"M2[U]E4+-NA?\JLF++NOV+#L_D\CJO5"EX\M*"CA#X_#$Y00-/C]<2%% M#-&JJ;Q8E\S>5H1P--I&7H+]B"6$2SY'D*::^+Z`P(S5+;!!5].SX"F307-H MSNJ!43DLJ@-^Z+<>+/>R\KG(].@*-+19H:$5@#U"!N1&<-JS<-^?]05N]O1. M./;]F!HI:.%T1^#DW`%R7@/<`]Z68/QA4[&W7,\'&?7_=BP62?"?W7HA$TM& M/FBX)>B1U&#IF!R=0W_@8Y8`'^^D^GHVTD*^D#:[;.CDA`\?2-*EESL%^6(Y M_!MOSN7`[C^$ES]SVS`,Q?=\"H[RG>,32=&DY@Q=^V]+E]16>^HE4FK)O#CI9#X^4S$0=UK"O? MK!E*1'@Q,.C1P+&0O,=_-N0%21?`L01/_#2NRY`^%.%D[XLPT[A3ZH^E81$9 M_I.LVTD=H*2T#H3JJ=-Y?6.VYYMY%@N]9ORPS+_P&D%8CK-[[<#80>+M+YHO M@$-/D/6$G?.=UW`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`G!RDS.TF@O?R?)QZU8$YSV:73JHET/4\;=5>BR]4*_-.T*&YM:QQ* M=BVXKCFF7<1U#['>2:H+O"_):]!*.S.JR7!E("]086=E(`TO M4&%R96YT(#,V-2`P(%(@#2]297-O=7)C97,@,3$V(#`@4B`-+T-O;G1E;G1S M(#$Q-R`P(%(@#2]4:'5M8B`S,#0@,"!2(`TO365D:6%";W@@6R`P(#`@-C$R M(#"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`- M/CX@#65N9&]B:@TQ,38@,"!O8FH-/#P@#2]04"0E[;H2NT0`,]T]W5\_Y\O9JX_= M:C8L'[J+[6K;+]?=T"_GJE^JL]?3LU?3::N,FB[.4IVBTOC/+S:EVD3EVKIM MU71]IM7MV:N_73EUNSO3M=913>=8G'X]*UQ;3O]#@J((JHRMC=5!Q:9.Q'W) M'%98\*8]\?VK./_XMHRU*\[+RM6FN%0??CC_^./YQ9N?R\H$K$S+!K]O+\[? M74V4T+XO/98N:G7^_E)=_?R:*:Y`7[R]+"L<6!S)S">\N2K_/?W[F:F]AFU5 M?F;%G"7%*M;,BF87/Y4!1P62K&M;T.>[D@RSD-_@]Q(K.,-XO$_+MGA#"^J* M7H^6,]./)90@@;28A:J?H'#QUY(L51?G5S^0!/E\-QX+@E_**A6B/S`V7D!N MZV#96_SBFK:.P-O5R:1$_F)S@A\A;Y,8]L\."AF@-,O/OG3`9T=J%NK-YH;V M(]9OU&69H,)(/Q]?UM?=$:MR)G]/]CJ.@>!`$*,EP*/G0&"UFJR508RP5F^S MA$VI"S7DC\^E!A+;^UV&<[:Y&5_5*1HVU3%I`SBR3_F(6#>A,7*$U:7QA8:N MC?9V_-3*)'I)B26^F5*,6XIQYW3=6$!J"%_3(K)@AZYA1M^=+7+JF/8Y;R1? M(Z:B#[">?'&8-_XQUK+Q%R5\1_YPM8][5<$<S M$_A@T1.J-8R'D2O9RXN;VTJ^!X(H%5U/R"9R1DO9<--=#^J:'+1GZ?O\\G4I MK)M;G%HU+MCB3]"DX5KG62>#+*JHI(6DR\K'0/1$U`8B02M2XI4FAI4[+,`1&$7$.T!1BX*`UA M80+,DEQEHEMAKH28N'O\K7.%NQ%P:/F:RTF6*1]98(2]^D$4LS1IC-"?RAW\XIR@+%$_0,10ZJ?KLF(Y`PW6\4)T$RD"B7 M.=T[657;A22H^HI"$+'39_H9N@UYA$)QV$W4IAM@A$DA4J0:(U/BL2EM-L6>F`)0=K.2`GW5O5JA$=A&4]4AG@9.(HKN M6BBRH%_Q$3B*#,2QF4B3[LO]4E[OUMUF8,VQG*UK$?BD$5R@ZMDH*?"W@F7U`M'CUB:@V/'C3*9R.- M5,Y8;ZAJ^Q%D:$[PS3F[MB)X-U"5L>AVKK#"9.21T8Z,:(;7$=K:(G``<2PF M#0#S^*,PRCI6K*0]S0>[+[GF_T+<_$^(^XPXK+^[[_?R::,MA"G#?L3Y!/6# M&'+QL4=GDW8#)\-V_FO6T1M,)\="GQ(I-Y>F@I[. M31XYSY1WU-R%?@>R?238MM:M#]0#M?'F:*#1HHUO>69ANGY87A-&#S##.#-2N.\3U7`:: MSS.90ZB-4>DCM[;T!.!=MT9:B()Z'C-\F\@LVFT0J-G M!C$?9#$1!'1'V->W?1:8G`7O.ZHE3JJ5U)I4[#[S513:;Q\H5DVQI!+(=1#S M#@7V-ZE3GXK[G2QC2+>&M5!<``V7$QZN2%:6+!\43,52*MJM"'K:`KEHX5(" MA4W=X@8B"F/\KY+(X"%L24%N:/)W,NS3U[C:[7(A\C4F!O=[AA*8G0,JGK]=I`5V$*4&'/3\)<,WGBX) M+]TSQNT7KAKC]A_=-N0JYQVH3V]R5&+F^[+S&!>1_=I0S>NYOWFYW,6Q\G_B M!N&*[G%_U]%LBKW,*7W0[1D_R^I,2H+0B!#%_XCUX/D=G^+BVAC;G%;1P"Y& M8/HFYEM4Q_'[I;0X_7[Y0%$+Y5:RO!%=!ZY'.\D"1\Z,7�"V1N0S&@V<(T M5/R0J9HVT90P:^"1?Z@W07PDO_+`;J).U!VM#/0MD5'5PML+@8%Z!I^_&!AY M^Z7`R-O?&1@ZGMQ"&4"_'R!,GD(O9+R?$0R>;S,>$T&B8,$(0,^;\:K`(410 M-\4]81B1H,3[4$:68&A(6PF9L`[`O,U"`1()O>811(CX"M5F*<(AO^,*,GU/ MA1*NOLFK<,]Z/I=*K4X./J/K$FT$T<2+230G>H#B):\#WT"8P.JQ#<5)YM%Y MAR];M3^J9$GO:T9(C[=6_SR.#>,H5Z?91EYNJ)0^1;)ABPTCV3R#)/,.C)O( MG92TKX[V1]E;\DQ`A^*3]X!9?8R8U98Z`5TW#:(8HT2"-2 MY^B-@8X'0#L:5N@21S0AV1'K>("UB-/'P#Z3(]K5(;Z<(WG[I1S)VR$PW]#G27:;_9!I M\Y"IU%77J[==81RP.78#ETL:<7C8`_5BR1>Z9MSE MKU:F9D]AJQ_W5B5]T%4(,9U.Y*V[S;"K5;X;``NQ"B^^1<2F!.0=F0ZK.+.\ M/6CHGY!@B%H>O:E*0PV>&BB(5Z4K[F_H,$MJ\Y,*=(ZP?YS]=P!5PD-Z"F5N M9'-T'0@ M72`-+T9O;G0@/#P@+T8S(#(P,B`P(%(@+U14-B`Q.3,@,"!2("]45#@@,3DT M(#`@4B`O5%0Q,"`Q.38@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S,@,S@S M(#`@4B`^/B`-/CX@#65N9&]B:@TQ,C`@,"!O8FH-/#P@+TQE;F=T:"`T-C,V M("]&:6QT97(@+T9L871E1&5C;V1E(#X^(`US=')E86T-"DB)?%?;N*Q-)N+-^\?(K,9+I;^$`@?: M5S+UA'BV]W'U3MOD9+HU!K( M#^WJH[G&2^RG]N,=CW_\@.\<)^.TH("ZH1]:WG;C+?%J?O'(&2ET"OW8WF%9 M9N\F(;?\^8$/8'&RGT=G41#_*_[]7.3>K50AMH9D)PC%(O2S+`@F3T?L:3:, MXD3F!#YLR(K$WI7CH8?30NN\!33LX)_0/O&(>>OE]N`M2/6A;MTPF+)=FX># M%Y`"NUTI.X^\Y_76AWK#GZULKV6XKLIV-%=516L#>VC'NI5UYI-L;^JJ=H/8 M`P@%2\'0DFR*XR2?0Q3%4XA2A<^=M\CAU=);)`CQ2-$/2?W`]@[*\>B31W+( M,LQ&,CO4'(#8MH[C.@S3Z?GYX44\^7,Y'QVJ.U=;9ZZ['2F0VSUKD-KV:""Y MP-O`T3.NW>C4QJVGN=:CH\T(">MZJ*!!Y&>V>W;]T4R">,G:K-VS:SK2/+/[ M'6+CX$Q6N7LRC[U3R[^.V[X37QPV6UFP@6Y'R4! MJ&H*4#8'*!*UN@.?'-B30\@3%(+`DC_87$;*ON_6AVH<+DVE+@W@A?4/D`Q2 MOU@&Q>E4\,B49H$>NW8>49!I@6TR*X3MS]WE=_B*_(C0M?PYO@"/3I=AS/&)3YD?S)("E33"II&0YLH!9M5C2G-[#Q$Z>``-AUH@1$D]J[6[TNSZ;GZA=.6)P)!:,>%/)\' M?=ER$+H!T145:XF*>WV4T?T=83^R3:,O+S5G"#-V@<=&N&`EZ5]37D+FCO*( MR*SM1O:TG.IZ/61_/&>*./A9W#_;DE@M!ZM!8R_BZD-:[5E^8+N^$XH>.&GJ M00+[IRFAS8OK%9I"B7NL*281R`K(V[(?)R&'C63Z]FS."0.'5A01)12T<92G M9^@+9_1I-[`!0<6VET*,3.G:&70^">RX<5-%0^VV%HNX6CSQ3$AK@QXG" M%E&*+N$5_EGZ'""EKOZP0<4!GPL^R$NI?44#J=``WF)PTK8DK8S[5]4=+*`S,NM<7[<2MXT97;75#UG=B#KRL3FB M6.G(J8998<:II*KP9^I$X.?^>'F.T;P(9Y#.#!#&$W\SO.;J*0J.W`:!@`WB MO>YU[K!!5=U*$+$*?>49[F,,T2/?[4F/]%^_*IK?&3.#SGYA,$E&3?7DI= MI,A0W)"LH[+$EB*L:8M,,*,N[#=NE+*"QUX'3YNHMWG1T2D.BRCPDR`/S@#Y MV;YL:^F%$B3MJ2&)J2'YZK1A.YJ-H^)=*[&*EL]=\RS]U3R862V>],F*'YFW MYM'?"2,)-QX)K`%LI#M3^W35P&T[>I'_W9Z&E*LWZU2_HI&^-4-@P3NNP"Z2Z0U'5WHGB*D%!NW98"S@5C]32]?`XU&NQ'\@%'NG>1KQ&"J>J,"YOB%&_5X+M M>@6?;B,WH;B5<+>=`1.*"5N`!A3P=RQYIK78&P4?@?=7*HV8$Y7FN/JNY( MN3;L7:5]U-Q?3LJ\KAGAW/XOM?V_>N_ALGK[Q8,O[]'[YG#B#54*6"ZKG^1>/ MZY-(HR)%DSN.Y9[17(J\X[>!['1EK_I4LL?H_'S52N2FE0@3G*D^_HBGGS21 MJ$^,BY1O5RG?A@38,=,-HD4],!5I)`]WPK*\U;%:G^2-(2`VS8+K^\R3B:`:,S6S2((*/)$O#8]" MJB#*EBJS2MOR3MW0<3?3<"IR@=:M(IXUS4XF9S!9I8P_N6.>[C"Q5F7R$#4$ MY"&BY5J?.CP21`*RD?L>+J3L+&XG=5BW $A@`"Z70ZR>YWEP5FO+*D-/*002W!;4\L!"\@%:`/I MZ1@OR&3^&J3*TPXN\4ZO!&NJ>P$AM"EE9>7,H!+<>`G/5"4UFZQ5-&L5(KFC M(#KO\HAV-$4.?3\5[ICKYMRB@]N>ZJIVFG8MYVM%SA#W$1R'F:&JKX+X+8OH MFK7K=>/PS;@_V/D'7IQR#4%!//IFJAJJXNNJ$16D[.(<4(AK1LT&<385#;Y7 MT,A1'$J8XHF#=$\R.?+E:I#R\B0+>C'B]?8-/\K_\ETMRW$3473/5VC!0J;L MU$CSDIQX6 MZ I^_9MD<*\ZXSFRSMH_V,[+:>-K_[35MD:PC#&^&5XD:L';Z.6;\2GW+L MR9;Q+=;IUQ>O-W_?5)=##;MOTY;#!!M;QUH#ETX?;8VZ MTWNX,IG?2FV:\2S<>*YTQ?R*(I$- M+)6$8/^'5FY,Q!G34YLFW]7AJ):4J-KD"WDSU7G=A7\ERI4PY.][\9Y@UY.% MCB&7)51L%DJ+LQ@^JL:"X>%)=I:XV-1'/:_SD_40/!?B9X4.,+5V(DYN3[W01)+^9'`W(D0`(>A`BXI)*BLRU;/; MW.NO&T-'FB.!B,?-=_AI(3$HF MP!0^,D#PLY;.*)D':0X,64O9)2=R-&GMELJZ1:F!R0$5'),L$/%Y!,'?2IT$'$^VMJ:UHG8?L%9_XNFN02TRFJW^D(/6W@WF!T^C^C%8.&V7G M@FDZ[&^GD<.>\"]_-(:'9-!:3^@XW%X[0P@6HXF9.%ER;\C.ZK','_WWK\[M M9.JS2:]-TX^XM"ZDGJ$+T2ELF0^IVQFR\G,X^%MLLZT_(OHOQ.73FRH=BZ:3 MC*V(U]Z(>`@$$`@S#1:E/3*$=C#ZL>ZHJ=?4$H?LZ.,B:A.@^:O=7(KYQS;Z MXU\W,T7-&7W^IBJKQ:7>BW*"RLJV!_E:D'K`[PP`3H[RI@[I37\0Z3@5I>EL M>8VZ4TF67I)4)RP1@N;)%(F5A26C%?@^J8BQA];$2[1"')"E MI+B8U;L=+$2MVT#T'FJ&EM8-+65R;*M<.>F$L5@LJZNM3ZA7>CFEK#V<#$I' M5`R4N)M6NRBG"FJ)%)%RN;C_6D1$-\Q'\P'_:5;ZK./'3-=J@I,;]^B@`FGY MGLO#R006[EAJ9J;@\S/A%.KT\"P@&_Q'Z\([E./$IS[4K(IPI$3%\MA/S'J. M]0A:R-98O[H*6:&\_C-?>GR?+(7XW.`MB:6Q-(V8\NP#AAT]J"H$M0:C8O;.1M5J9)BE=H854LEM=JXJF->BNG M%)G*[P9=?51>Z''X"J[?/07V^>("[.>^%24R5O**]&&,`\7+B=XS=TJE2)@; M"E"Y#![;DVE;ITP?3&3@4(BK_*AV)TU2I@^TGM>#"`F8&4@/8#)6!ME!D0BW M49D!'DP7\T^(KGSVF0BX(FV,OD^&R"A]A_.%8Z/QT-CG#@BX,XI&M[;WL5WW M^(IS>WD)4#WM.9IY6RK=]OIMLP_6$/CQ=T"<]!T(43)]2S.!/'E[L%KM0T,5 M_$FR>@S0PQ=>XV;FLP]U:0AQU@T`0 MO;=;E'PJ[34R\+F=FTUH5WH>$EF0AJ#&UAF\\6XA4Q77-?B#%<-EW*0?M84F^).3YOOOIMMKIAN]\*1E%\C2J+(2559R MA>3/#1.0X,\(RK/UNE?%T@9;\XCJO9Y%$Z3XH.<.M)4\/=W2T.5HS M#@QA^_GLK8/N"@FU&;6V`LLXV^<=KBF+201)DJ;-"J(9]2BS4TPC9K"@J!%K MM)X;XO,\!S]]T82^9/VW+*+[G-6/X7%,2HWF<^R0$XV(J5*-(,DZQ@+IVT^F M33IM?QI8.I9[T=4B==NKVKXD#3KJSJU1D&EX\$^[VC3.^H;FZM_S[LU'V>[X&B::A-_XEIM`"\$2T?%&V1;JD3S/(H MQ*^D[F]!P[Z*B87]U?W,#0S9/2=F9Z99):-M+.WQ9^Q>3_BM<_[WOVQKE\F@U02QZNVOML7G,AK89R?:+ MO/>3!SDQRO#;;"_25H(O\YV]W>WZ&M'>G`Y$ZB9I_-7J2JDEC%=P(!A4'`N) M(OU2ZG'E/@@M%[E6.X]]LU<',0NC*!`@SLDW@5!M#RB.0QTLU':4)R\[`:S# MN^_M:1T64\(7SI@@&W,?"@,MZ$F,(4K$Y=S/@*F/J97!8BNH>K#`SK&_P\F8 MVMY;Z_,(6J,YRFIZ1GV?G*CZQ52B[]Y_\]LW_P\`:B%U7@IE;F1S=')E86T- M96YD;V)J#3$R,2`P(&]B:@T\/"`-+U1Y<&4@+U!A9V4@#2]087)E;G0@,S8V M(#`@4B`-+U)E"!;(#`@,"`V,3(@-SDR(%T@#2]# M1QW&UWC".\A$>W*1]8)$J"FUN35/64 M/\/V!_OE0JJV&3MT$`$D@%Q?/GR]^?`WUU:+?W0?AW:8?.>6R==F\N;F=\>; M#\=C86)S?+@I=V5N(OSX(XV*78R_8E<4YMC=1.9T\^'SCZDYS3?1+HIR?QV8[,H./Z##HHC.2E,TMTAC@J3XXPB.ICCIYN0-B4'WK6+XD-!6W^R?ZJ" M,-L=[/0E".,<'VX)PGR76YV_#Y)=:EMG?G3U!2+)+K-3$$'`JZ!WF(XP/9O@ M[\<_/C,H,B'$RXRNI]NC3&^/DEQN/YZ=^3AT00@][1A`Q\)6?9!A]&3.U6QJ MG)W9%DK$MIIG_\"W9;O2-D&88M+X939=-7UQ2W4/-6>H.?D@A`_MXMW,*L$= M:9&F<*UJ$I>K)G$LFIB*[8<506+-OZO'RK=T8/@P!'OR3SA7K?N/@79[*-G< MFB!.;%77P]3X_B06M$^WIJZF"?>:^5*KN\Y\@#@G7%4)XUVR3S=]DDT?C8O8 M0188CD1AEX`.6T>GT^1.+U:<>="QG\RC?K87MS.&W-SXAP$/Z][4;V7FJ'7B*>094$?ES,\&#@]TMWT;Q#;>'2 M83F[R6!W>)#M=%U\V&5QFDG@PY<7IGKAY,YTPYYOB''#C$HU7@_O8<2!E$*` M<:PS=Y;LH9R,8=4PSW>!3,#/?ZBH)++5E?1)KCSK]TR>EYO@]T;\XBB/,[NX MJ?.]X\F]-??KEFU&-1!]-)E6\UXE4_XZN;\&$+07+N6!#I:@=@'58$6ZE[SKUE2+6RC"PK\R6`)(CM,//'T M&LJ.OY6<800+5S#;3LIQDOPOE'\)O$Q9""#:4XAG,;*:G,"#S*)0EH#*"2@' M^_:Z281UY3(KR/*67C+MQ!!D1.3,UZ+X161ZOCWTHM3M^ZN$MYD=+GI7%^3L MUXC-D+/Y/M&K(7'4<25G-F*.7%]-HA-LDIVR!9@@%[IJ4LGK]L8]NI:U$N&1 M*RZUJQHA,"JSJU=9P_R7(S*;@OH-4PY`&![B_ME[6W9+CZVENBK?P2;2T"93DK MDE+1<$.A_#W83H>UNRR^UD'+E6K6-6"#7U>,*$G)0E:9>SY[3_XB=$3"."JO MR727=A7U(QKCUGY8VY>(D>VWM(X5%Q"47M^"&8"(BVW6C0'.Z*; M,IY2[996JJ6T3ZS3+J";WD(?H][A5P+[5T(XM('1\;^,@*K0),=78W[_%5;` MD33R#/-C)[(BL?P/EG>E,NN%`V/#Z":Y9L\&.XW>5X3@XJE$$$DGJT!B/(`;G$MSXWZ):I@ M+YV.2CRU%E-L5D!\!N7KP`16P7UM4]7+26 M"$>0)"T(S16YEK/4"%,\VC7/#L!V9U,9FF4PL7Q&.O/D5'0"VX&KOZ>^D,)? M_&+`'V4)-^22,)+)!"%`B/!>_$1:]0VQ,UT9_:)?8%'03QB"'J`K,^ONS'#? M^I/.+:C`="440Q"OI&*F4U1FDE/P$EBV782F*R]=Q\]+](J$T6'+CE2R8Q'4 M=J8=)%3?8(BX4>:1=;-0U`/G!RH$[*^E0!XLV-]SV<[+M,CI0(DL/DSK*O2M ML9+41>\]%-FS5TOZ^I7PU&G78JZ%[@K@Y\M*?@Z`A\K32((/K8C8+U<1W_-' M[<:%E4FXK8A^I7TG930A53-)R&M&;MQZ!1NVAQ)&$PT*I56F-KST#;&=^/$]0;$>W2= MQ"EE^PINYWQ?OMLG27F]+RVN0*V>)K)3$35!YYT61BG/*/U/>GLPC7GD,1!M3/]?J4L7?K41N>RE6$+]>D#8JN/ MI,"!4$]F.T(`\B*1H%XGD=?F,X=]OZX,*NC)P."&0O7K MOO+[[:)BZ_*3$DX-,/>CY3RQ0H2T>#R>!*S.[U.;++X2#?71)R9KE-Z%DJ8< MI"E=*5-$TLD_OC"(>UO5@\K9?ZFF_HT/G*SPR7=V'_WF+GB_:25;7R!D M(-_[7EUU%HR19/_,9-H)@Z+6:0?U!A4-$$.;-E+16U"AJ9OU#.J^19YJ#7 M][.^VM!AE`V\KN-5GV(#T(VC)@KO/_0+%ZQ<3HDNE^L<5P]P?BLG7*QKTMG8 MO_70S\J\P$&)62U@!UXH7<<\45&!(1$)V#YM/7:\3/6Y8BPB6QIB`2R[`*+F MVQ=#4XUCJZ_%7(LXLWY@),B9.B5X2$#$]?,**SAC@RCJO`T>9>,P^W6[[-JI MM#':@Q0`7]&D#1&3\HJ(]3`O;^S9OS%GA3EABBMFDD(O;91O6"H.?&8OH:E7 M?H]*BJ/\&5?(-]4TU7H.3XJP\0%K]V]8W]EP?-;)^C(1707T/OA6%GR0(I\\Y=:HIRF//QA:;S>KNZJHZ7_'7H?FN'W'[ MG!R;=OY82"?5>VW_U6R4@[4R62O)M#I#%P_^CAH#+?8L/@^CR:%E=@\=C#<& MM15]Y$-V"FH-6CZ4HO^?&4+;I_"ZU\45=EOP07,):_9*2$2B08]P$HI&Z7UW M;%HG@'4^`0I*C$S+EIF_`8MGH;]N]I]4-N=(FUV-MEYQZZWVWH=7N\,J.QR" MCYTLQ+E#!J)M'!.OYOY?DS5W:)4<6CTX5"9K=VC3\VN_^,(<:GF#`I#Z*//< MJ*]BQB](B[)>R#%61VZI?J!O.<>N@=RV=&2!C5MO^+'*WK/.L>\$+=I$[*N/ M-^PHQI;8U:5F3^6@$Y]`#)S?Z8QBC->#?DSG,MS%8]VTC9T0"K=#*7E1)T/1 MLRNDJIPMK\IT/70*`Z79V#C:V,B#-GWH'1X@;,;/L7M2B!89D,7O;&<[3`1: M97ZI3+FY@:B>#4:CPL5V^\#76 M=,4J.^2"6MIDB\-);#.6)KUV`D:0%O+E1OO5"/N5^WFN:N'&FV!DVP_-"%^J MR?0)X8"[0?1\*6>Y!7B!,?W"FV$S-J6:_##E,7)_!H@O)X.A+DPQ]@1[W/-T MDC-2)I/@T*>51(N+;/44R$4%:],Y`OO*H1&[(64K8UG*\K-=*NYTL[G2#94< M@%)LDVK5:GT?K1W;RE\BOGN/=E^`]V]/FJ#MI4Q;C)HW34\\QT]\.;#%O7%< MFY1H.]H!2X*WIPO;D,S*A,.G3?2KKS+]%8FFTV@L^&8#,7SNWPG#*U\Z?::3 M?E*`AU9SXG)$=I\B!F89ZQ'O!A!*P.`5]_@PM\^A\_EO:-<#1WEZJ&C M]);PK"T9?`(ZNZ&E+,8M)8K?[R?"(>=^U>#OUJDUJ2?=ZG]"TDI(RHD_("E: MRX]!=-19+M19#N4U=99=O#71)>VUMS[2@M#KX\DVU>Z&>GE#GKL)P>K+J0M> M7*E1,\<$3$U*>:2\H=!KVU-<+[-V\CG^@0[:@&KO':.`.6T,RP$%!=9+J2!E M$W7?U`C15ZY6/R.XL&FZS=4Y]6BPV%_J=J/E2K.U!1E<7+"B&,9E8K9\GE3% MAYP%"35&-::<2B(-,+*N>Z,N+:%*]GPT73Y)I*\Y"ND==6U".)SH\\';YFM- M.=KSF]AD91*_ROP=``6%#;0$E()8>E.!W@-Z].UQS*X,%:.YO`5?U?L/[TIZ MP2FH`%;WZ2X.V_=MS,>9/H3BQ$/Q2FR'>!]CW5])Q6N#JC?[&^JP.VW5T,05YX8=W%%G=- MF^LW"T0[%<+@MQ?RT]*V1Q0"+->YQ;G2N>[8>KGFP$D8MVTTV]CY#C.]9EPT MQW/=="1ZKM'0,*^0D<(71V$"^P7%$0-SQUD@GN:[(N)'B5>;.'AYYHF+T,&. ML)^"!-*-SL;A(WV'$+A:)&#%M3'A$B'&!B*1)(-V/Z3FW%+3,!0%4>GY@2D5 MKNIY4BZG/RLMIQ>5_;O'+9FXYUGF=-T+G4EL5>;S+:6H%N'F/P]7$O+8FL;M MDG[4J:]I&*`@=Q13.=:C7^H7H1'FC_J+'V'B+N;?Y2L0M M>D"HLF:?[8ZDY5%6T8/NNAB/(K$TV#\EDWN#!`I<;.WGU2)T851C32>C$0OM M\HD<8<=D5-:\)%'M.VN/\7K/P%DU$&DZ/%HQ@U*4?_)*24*^M@9A=,C%"M'> MGJ,_Q7SB+59AVC0W.9(1XT&4D,?O:G2Q./C<,!#9;)A1KS4FWKRKE4!J6#N(GY\4\%U]W)!. MJ_?Q\[^-)U0C2D'D`B>!.J4IQ&J[G/PP*;P<]7C21,77)#?K^R;P2 M_)%/W=K%Y"R&V3]Y>$6I4W",UMDJ+K;Q)7:L/8HKA@SBJO9`UZ=UKC)86;\T MLG&QZ-+0+6>'8^ZQJHD`P_).JR(#[MA_:OQ*AZ>'CP.1`N!2L$CBQ"(2NZ.D MUC1R9A=B\@*'V:.%!V=$JTVE"?S6>CUV=6,U'NFL`8`, MGV62O>Q1@CCU+T];KVA3J.X2J309"YLQFU7B;^;RF56KF1E"9K;*'.36V8L( M:.`B1^WU+B0T7$WGBY%Q=U"M7>HO@IE.:-KCW0^SNQ_@O:$@T#T!..K*C"@L MP";WF/[ZCF[]+.?NM+UN+E[=SKZ*V#F2$I$_EW!L#MR`<38/L[#813RU42!, M7J=:<4+254-:"*N&F?X58W*?++GU4&^2HBWFBY&["6N;`>"XV7V#76Z)CRF5 M*!IR@%)`)(VM)R=7J_F([HL[K3D)4AA/F\;@Y+6YZ'`L_(64SNS\]Z]?_OSE MWP$`5A?MY`IE;F1S=')E86T-96YD;V)J#3$R-"`P(&]B:@T\/"`-+U1Y<&4@ M+U!A9V4@#2]087)E;G0@,S8V(#`@4B`-+U)E"!; M(#`@,"`V,3(@-SDR(%T@#2]#U!+M,V)+#FDU+T]?V/G!^\#0+D]GK5.WV-\VFJ52"'[_D2;U)\:@W=:UVIYM$'6[> M?+S/U<'?))LDJ=2NP^3NZ487:;3[]2;.\LTV36I586%1X/O?63#)61)OV9;$ M/^O[*"XWN391G&TR[1YM9[RZH\E"'Z)TTVAGS,F,LU=1G&;ZRFIEPJL'.PRF5].HPI3J)C\K9RP6)AB'K1ZB5"_.PU;,DXX1AC1Z M5@^K*NMOU5,4-W@_\C?;032']T<5_7OW#T0P3C=9F5^B55ZB54JT[-@-2X\( M]=:9;E:K`G':4T@2V`RQQ;E@!XRW(XP.\1EYJ[3:E%N<3T)[Q;Q9MFZ69[(9 M-K!D;J/A_).\V8B"-Q_AOS=P+-W2"75'"DZUJ309!$N08':VL#-,4RP*W;\, M@PU%4@4;/NOUXX`S*_!/T:W8LUQWX1N?>3C7@LSBPYOVJC-N#C+R;533*GS$ MP=.9A:&78,=YMFFVVXIC7J3I&G1ZDSBDS1KTJ(!/%%+$\N%9S4>>,.H=)Q,, MP;C4I[,$!)OS]V=U/:[@_E/K$;AN.D@6C/8W*,2<-TA\FBLTI?^3<4:=W?1H M>]-OV%I49II(:2)+L&>YW:X6EYPF\76>W$=;.OF(=CF%YZ(6$PG2;!S!%,:W<)IA&#B--2'EIQ%9G** M8C,?J@?5DNMACQ2=IW":HT%`.$0UBHO+FW)74]&1U60>\*5.\ZWD#A_6)7W3 M6HR2Y$WA%A_[@WW0"2W4>JG M27E[6%6R/#ZU\CJ'G%K-XCK.FM6X[%+(23@@9Q[A5`5=B_&L0NW=A&-HX#(= M!LY?HL%S/9459%'R(MURV`R+A/4BZ:)$!QF#5P'4:X$N2OB?B@$:HUQS6ENQ M1F4(X+6J+(D:G20(P*<@\1PQJN!CZX+FL[-A"<+++Z0GN55_XN935(IEYAKT MK@H0J+2F5P`BJ#^UTBTWW,8N7DT#D5"VS6\A!+V:/Z\/>35I>ZI`W.D MCJCA$@=S0M!SW79FF=EER_MV[W$NRU'YI>J@G0(3,G"?I9ILWH@V10C;#D M#+8$JH1G,=;^%5CES4N0`I[??T!P2GUWCYIFR-NH-,MOOW,;0F617;7(E]9` M^DG57==-RSB3F27ZQ($<1'CW4T2G[]1]^#1U7V-Y>TLGO:484"YQ#'@)PV>% M+V>9H,R4=M6NZ@G`MH#'5RY3,.HF>X'"Y&)F%CR^%61M15'?HT0\TIHR:V_' M,#UV-KP-*KS`.PI]I>&CT!V(1?1_6$5&+KI>H%E:;$Z1N`+$`MGRDKD_B*27 M]KV%P@P:>BF(,.?"T*L][8H@1,P6E9^GCFE.K;^BU4C/SV`0>C[>2%29;XN= MGV-9^!`T$(IJ-:Y%KE` MU6M.`L4C4&\6/9Y;&@!U=R0HY.S?0O1$#VJ?U)I:6O`L`'`$0S`#V%@`7J1] MKV0P,8]D/&)2R\,Q;&3'A?F@6<\BF"YX*Z2+X3K7:O%&S8)9L`K_AC""HL#5(V!$TB(B]F/BAQ;Q5-2XQ#Y&2"_BJ9)ULQ"M.SU4ME1 MM4^,R*WKO5I&-)-@YY%EP;]8@9-^,#UR9J,(O95>():.'@SA+\A[6I1_``MN M#86*?3NU3`NXE?Q\MJ,%!_XI5*8)Z-$QE1-W--,YO!B&X&$82HN^@[!J6";K>$)=1H*FZM:#2H?%P]J6&6 MP?0NHCO35R%.,N58IUK]CNO5-9Y'@7R+B"(LJR40H-VI$ME6'%AC0^&H..2Z;1^$;7S2G:Y*/;RS:E%2*'(2'D7 M7-Y;+N]]:]E]QVA6,IC1IB:$L-",:&2-J+Y>+GOTE(IK>A1$/-%IY(K(GE$J MT.FL1*.4\^?3;X-=/^#`>?T2T'"=>7^*J$L8=XB$#0B?938A4^J39ZKMB6LS M5=^U\O)5#/P@=,=UTA^,^J+_^_[3[@.O_OU+],*'FBI"H',=I_5MA///]7?L M"!6<-]OJFAXUEZ;>O*)'E9`"@LZ<8-ZI]T(?OC':+HQIA-,Q@6Q8\!S$/\EP M#)4?OKKE%)@2IS;MDI*X5SM1?93E;9!7=[AQ!%4>(>J#]O!Y$G*I?A:E83;H M0/:\4CJ^X!A'X16_22[@G0=F_EXJX41JJ!QCRJP!F856\BPC5`*'YJ[[)D8@ MF];^17(4/Y*[):9CN92I*Z=4'N^F\=KF*S5&:4L8)+ZGY:@;,5-!,\!&( M(2Y#5PT\N91#%@*!I%/MK`P.ANUB%)*V21&FM@DV0?/=)%>ET:,WN_4:9-=9 MI$-#>-,9^VBXU60KE,2K':_8R.50LH`GD[N*P%831U9V9;H%%YH+U%K\IK>1 M7&92*?]+1.V$N,'(VGHV%0V)/3FX,!SG3<3]4%$=I4*S"F:9(!G+()RHXHT+ MW"TZ%B*:7\!=8>;%Y;M<"Y$K817VYN/M)L\G@KBLZP\C1:P*!?2;K#,\Z%50 M(TI#^'9_DW#E%*[/NCO2+8!88*8/_V.\6G9;1X[HWE_1BRPH0';4;(J/+"*71J*7"MHW0B,C8+O;:\J]4>#N0"WWC9'<'6):*8*/ M_0BK@I3JNZ.<\C8_NG/L388%I8]BR/36;IX^`;0TE53KI/I?347H9&&$0&"& MCY<>8^[7R(_N-PSO-`AU%S^4/X^ILIEB9G/Y&_3]5*MHB'5W0@O=\_'2JP,F M70*NNJ`&(NT'>6"V@Y6X?H=U8H'3OZ8]OHZ*&V._)[J=A!)YR1XC_3L2(?<6 M]V@\T\@@-5YJSM9R8?5+="=K_PJ>QV>C2&(:*?Y6^5$&G:BOQR,SRO@_B2%N MO>?VM=+FFZ[^%?ENQP&JUQ?825W>Z&&YA@AQ>'&;L>/+6EYBW>PPS;T3B(3` M=H**/^\/B(2&&`"O2:8R,R2,<4N;:;N4!0]S`+A5U6C^A;4%A=Z.C,;9:,T2XLK["WF_LLCNV'_?(@.ERNQB8W$E?@A!$+. MB'\V\75P;P+,4KLC2E,"@\V%.Q6K:V4V.^3-(;VO&P`6L%,]$B M516Z3AXW>EMV])D4,LHE?ILH19!B]^%#[F07933)P?=%`>ZC)=&#Y`M^YX#O M0MO#VPY/CC62]$7"$5<[3N'J054+*+E8?[.1O2"[N_C**1V;\<`&KC\%V)[K MWH01#G,U#]B(GL3(`?]'%#!7>D@F;*TIRN6T#Q5^G(EV8>M.`Z@`3-(I^LH% M`F@$L4"S*"PP@M;U MD8/C!%3%91%?7F1B!6DJ#TYVV3(/U;(HT^7%,(U%6&8+U%&Y`N^82CBI8N.YT'U918)MS1]B?"E M.08S`&5K$PH_'ZVYXO+ZSD@:)"31(KPG*]RI:^ M++42LL3UQCQT@65_RHL,O,CW$`)Y;";$*Z<1Z>>_Z8,QR=S%T.:0+TI MS*M`F#N9%J[FX&3;S`=9N>NY%Z]IW'=5/AH&1=4@^QT.$X]]F_DMC'EQTWLO MEZ:02S!6CM^>FOUA;JU\VF=12B7)IKE?VR&>AKV=I)IG M`]?D]X@KS51F:F]*UQH;GH`O:1>,6(@Y,`K[`JZ&+-J4? M.W!H(;`H5FF2[:0;?WPN,T(?%-2*@3I&*1^U44!G0P?^I@\!J$DBY91(F=Q' MJ`KLYHLI]#DEIN"U1JMR'W35HZY:A1RKRBJ=D3B](+$)"=#:59G\'@4F`*R" MF8H]Z47F8#"B5Y62TD8F],5M6U"C#BQ.1W27YNY4SAP7:^)2F7"<9]4J$"G" M-HL5E1YX/5$;]Z'_A:D7^B.LRBQ)TR4(62*T"(]<=LD+B^$OWQ_^^H_?4O?2 M/V1%^52Z-,C-NR)U$H"L%!AXV#[\]/U!BB&7TEPY_"BDH',A>M732F#HJ%L$ MW>(^5$[1^T:D;+IXC"?USB=#?7`],1*R;MNU^B%-CJ[N^_$8*45RB$^==1:_ MI>2ZWB"U17CXC0'@"$2EU/*K**[8=;*/9!^^-.34/W3VRH=T#I3WRS)#^//E M&L_,:Z@J@,4]O7DE&3YY6IBGI&^G`5A?'VAH#X8SDW&^JO.<[NI^ID`DYU5B M&\%]$:)_QJ[98S-.BLB/68A%,FZRI?E0I$W M+9&FM[$/J,C_KTSGND"AAKN%6FGUZ;WP#BJ4:BF%NN$&!_P?X2-WX3BP\L-* M77@]L[<,QPM(7'55NY7M=&*WNE1P$"B:4S)DRPR:Q2?EJY7\&^ M"O+_MH+M2[EB]7XH;L%$"2%`\;;.2_',R].OY;+RZTIGW,-4ZIF)AV\G9Y@M M%SWVM?T\;?JOC"V*KTPJ[UE$Y/%9$,C^9`\+$H0AN\V(?VI+/RF4:#4?"0$1 M9"<9AF[_#)8BE^4)LWGRK'/*Y"`=K26P-%*=LERPR;8Y31U-.<*/'2KNL!%L MBHQ>( ME+I>,#K*O^V+O5]%JU,ZI9;%>/PT2:BEE.*P)\W!D)$H+UT^7Z4?Z?=\L3Y7 MBY(;6&\$R[__^R'S2@+*BQ_K;"83`NE96.LL[?KK/$^MZX=;IX6.^KEM:=(L M$&^F3B$^'(WM92N"T;W#_N"UYWF2BM02\N&3%#7[9<6*U_D7);M*GV3\WJ>J M^OSE7P__'0!S;Q;("F5N9'-T'0@72`-+T9O;G0@/#P@+U14-B`Q.3,@,"!2("]45#@@ M,3DT(#`@4B`O5%0Q,"`Q.38@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S,@ M,S@S(#`@4B`^/B`-/CX@#65N9&]B:@TQ,CD@,"!O8FH-/#P@+TQE;F=T:"`U M,SC19]Z?(#`(@D'"4A8),N?83O\O7ZY%$!1 MX[##1X\*=8A_A7KHC#;\\W&'&X^?+Z/S6&XV:PWF\QL:TQN7VYL M$@7;/Y.@<".25E&\SL--83+(*#:YV?[`9Z*<#^%K$]/)[_:NKKLI2->A;?EW M#%8A_C4R.IA/0;8N[3%8Q1A6.NLP&5H3_&G[Y4+]C5E%ZZ1,_&5Q2I>M^+94 M;ONI#?)U;,W=8]]`5&Q/_&O"LBQNS1@DZQ1WY>O$.G-WQD=HG>ZLJY87C,H8 M5%TZ(CN@>H[!)'/.=-@7V7T`#7)K/KG^3=@6VX=@56*W M**@JP#:;=0'U8306/HE.(K@*\/[45W/SI^BX97F MHE47K!+<+3+\@^4]JPS;Y(S:]Q?[]_N?X:3$RN%__!*(M^"COY/X7/$CR=?)CQ*+L0 M3:3H!A$U+-M-AY<6M'P_AZ"M5-[JCX\P-W*G&1L1(B=OKX(OA("H*!<5-Z$/ M]:B4YYF78U,?30_Q"3L=[HKMT]3T<,AXK,B.9%12S^CH=#+8'MFN/^A,V_Q5 M/M[L;S@TV$L%K-[ZXZ;N!GH/Y=2`G;#M@S/N+X^N'7"K;AN":.VMOHJP*R]B M=E02^NC_U%'^I/81L@O+R5/85QRA MQ^U8I82#)M,M%$TEK!)"W,[(2(0U`T()^G%(%1Q2"$NWW[M:MHDFS\Y\J=JI MZO66\!9Y'918*4NC"NQ,[VJYM:?P1M;!#`$L7/%.4\N557]@(9+%F>0"`OLW M<98@1"G/X&(Y4JEZU:^'.%#0!T(DAJNG\T1X3!F>V6=),ZN@8VJ[%%D(Y-OV9MB!/Z!#2*^0P_2]@/UM@/WL+^U\F^1"\?8?Z M6#`_PNT>HV5S)?Z104V#0M=U16L(Y^E;9+Z"2)FBP$(9\0@LD[NJWRE6?Q0! M5<\I3;GP!KWY5TH$X;CH>W=O_B#'UB:,X]MWOHT125%V@:!I,ELI2K040U2$ M%\;\&]*@PZ#$;1[:"3$%_0L='\R>1[*S1T8`1W]P\B$;GRG4^KKD-!=SNO"\YMM;]?<<`W[B?"Z=B19#<6\G`5"?>([_J5&^/*PC,9JS26*N[\V-%J0_WD;T3 MV[B!L;G?F1TXU[.NHO(&#$RP/1Y@1C9!!%4(&YUYT'TG+ZUV9C@Z-QJ=(-!( M[#P:W#@$7`Y-UYL3@1BE2"N/N]::F-_X-IPEH:S[[A7:@JR]JA599;R-EQJ<.RC(6@G/`-,-TXDI. MX&GV/5?ZV)Z1=QF5K8I!DM(TAC8'5CVD6(OY/(H#6!!4@C*S4)2:\2C:0D:@4U[O'+'HB3F*2J=%+-X MG::7(M_7R'9'SQ3NX[V>L='V"MJ3\U;0""^Q"I.MM#,;%4A8*N6,GW)X1 M*D@]6KF%*[PPWU!&0XS:?P=4!'HC)^BL>9HX'0J5PGS!`Z!L'R1/]ATG46]( M5*EKNT-`P5Q)]4#Z44X(Y(I\KB`1@59F+UF6I'O.Z5[:Y16='#6RJMH86C\2 MC_>:J4[RCU8K]I?<7#(.J0B9(.C@#\:/3-%C$P:416+^[6\7EEC/U)',+0RW M(#@FTF;:SC3:T9P#4'A=)@HD'@_9M1&[]E,G?.-,)_!<;G7T1!L0D7[]VX!: MM!(?A/0&20FLUXWN/)E'E3,TH[\R_> M-L-:HI#SN>N"0@A):5\:M'?*69`//PLE'BGTJ/7A6=<3HZ:)EH-%5^'R1"D, MVI^'DS-WBK14X?!)\\/ZFJW`1^7F`G?C='FLTBTCOLSGYR;B2P:)F#U..-[+ MT.VK3Z*"=5 MB8%Z.U;T=[)1[]2+7/\HR_VLJC!V0,AU#Q<5Z[R(PPO+EQG)?)3$AHVHC%TBHI$EJ%$$R22R1<.I]8 MH^/AU532?QB`X@%9SN!^=L+:,MOMS#_U=0F_#C39/$Y]?=1SX$EGMVP@*MSM M4++NQ6,_!L3*[J38Z9Q:V>OWED4E"V"$"AC(=?*R@`1($%_+78,LF,=>/IZ9 MJC:\81=LF-)+=W'@-)](Y>3-AHI2'^$.ML)\): M$3,J)UMM9GU4A@SV`?%'L&.,\ M>:/O4OE:KP^M[^4?@D*O-Q5BD*F8R)%U.>C%7-YLT$4QSCXTLJF2=UY>TJGH M]^T&Q5F^P'\^YUK.S>*O=(+,%UQ[Y!VZL::8EBTR(0PRT5'-`2;KVJB>%LXY MM[W:IY[5H!*N(D&;S5VCAJ%3-1LC55'2\`Z35W&MY]]5,@G2B)M=9=#Q0-!V='ZY)OLR-0R)E74,=EQ6J&F$TE1)`1LA MWA%91J*#=I'=[J7QMYV,3LIU=(,VC`9HADH`?X(B"V7>LP)U)W(!D4S/VR"A ML';MV(Q*LE\1Y/Z[,R^$7[:ICZP[[Y;4LN8T]NGDO(-D<(02" M-`#.>O09:W^PJS*K07"&(^_Z,D/TH[JZNBHSJ]%B22+'J8YORA5:NAE>M<"K M9GQ.K4G!R.]I6#)E/S?+WR?(9:Y8,M&**=%2)IK;S5?MT*6TV*TJ*E,9&"O1 MT@USDX=\QA;SQCU:GJ\RT`V$.M3@SX83P'J:;BV'>>A^?NW";H!"9+WJ[0UU M==EVD4R&Z!6Q+C'O.$8KD[^K$MPR=]B^>,Z3OX\^U_1/["F;;N\/3=<8UBEI M:FE=!G^XM*YMGKR!R^!^#HLD7Y&*W6FWE"3-]-OY^7N-+\/B#G>4&S2/%W+28QP5>\N>O,0!\TM^A;NHG^?H)7L/@_N98.;FM[A8KOU MJRR?6A'@U.'@=^I.B2-R1)=]4J^Z*3="$\01)8JFBNM8R1J!7+L?=%O*_,H2 MV_D2T+]BVZJ<-I\X9=O":F`@/^8>X=G#$`^4$CC8=^_^=)G[XM+UTB7K]4*U M5RPQ^L2R]\:M&;BUN#F!X^:`X]>!;K\$TDW1.`](G!GJ=">M.\&U6I.IC(Z" MI&@#)6V^<^JE0.TD2K`LUJV MA03QC*H8&PVI@FV!1]4UCA\'[9`2K5@6JXY9_\=U^U=3"9F5TQP>)V7'))QR MD+=F"[M1F+1?[F@_)!R-_6P7\(0\JP.[T4D.L>55X$<12F20AG*U5=?("`&=U!8DJ3KPO1N.L6=\8`E5'4L"1@T=2)Q0NY49LU)-DDG MN/'WJ/V-N2CC-]3)OR8`]O?)-D/:1_]^[8PIB6*FC.#,P73"K=)Y0XVFY372 MI46:;>"Y;J8.H8B^T:.RY^,R]W'>L)X5J-+0J3+";%Y?-HJ:B3]PC+;99JY^ MH#F5);F&Z/TPA8_JJ."K)#;T\!_3+!L-HP;N+[2*4+IA:D.*2)+2S.P]?P@$ M>^MGN>G"`-HL7;I,PJM`-R+[>:6&C@=;!PL+I61AUZI-R?-+LS@W6S6%NH7G M+KNO)[Y*C*]J20II=1N-L^#RHP#17LKP3-)1=`9B=>Q3%;'AF!J7M,S6138C MBT*M_T/S1GI;F)365HJ[U%3H1;\K:(Y:Z/MF4�EQ7#&OM$T:65DG?MJ6/4 M'E?:N>Q#:Z*\8!0SA+$.L205#?[Q&/J<#N@15JDN;*B'.XGN2H70X(*QTP*: MBM02+C5C>F#L)@0N3A@X:77T$DH<"FLH/WX<]!TV$=DE)XHBZ[6(=<'Q;-PL MU:[S8)F&]$+GN$]I)EA0BM&]9T@`A$$987[,JY2Z2S_Z]A].%!A&+@6D36:$H6V@4@93 M/BPPRB@FRE#-2]'2C(VQDA`46<(XX-+*.Z/T3V;P2A4%"::"_PHYPP-O\+M/ MG^*U$[_:&NI%GGAH#LVNADT,=,-D;C.W5LV@L;A" MHS4S'WP_XB&!CYQQA'2P\;UW-$0+`ENTS\]^DO0J/T59P^SAZK!9T9\*0!MSTH9Y%3=8 MHN&R_$?PCR/ZXCM(_]$J"!<8]6+!#_:\$$WIY&O/S2]6THC>W(/"%8AI$KKQ5!^HD=HYVH+^BQ_MYU8/R".YS>#%>&3]*%(B^2*^\D$`6N+CA9-8;`NB%0_U4VK`5H)3J^&6K5^MU^21>(';3HG M8_%T_=A*Q@E'+0P^]6;]OND>&8SV>>EV==^K;\-E!W31`LCT?@3T5`BB+),7 M1'A'M`S@38]N!/=6S)->\.-;?U[@F"90/: MEU5""^]AXB.+@.=YS>I"8I]JXYO&VO@NM(_DW]B@'?)0NX0PRY8FLB/:0`=Y9G<;.:>X?@OH%*[)=VI>6S_!0N\6I)79#C@-Y'A?T4. M51^6W1>1KU-H=\+F#D.#2N\W8ZVK[E35@Z;^\R>(:@_]W!5ZKJ.:)+`K:N*;M5X^8E\;$ M!:9,;'RCP&CR+.\CGG166K^QJFX*"OB;FO-OPM+=JLKB*>XJ937N/X-SR>R] M=^\R:0^5KRK!$@UV92!327C>91C(XB5G;,'2!6X]^]V<3)\\J9_JX0%G./?' MA78.VMP)W-`A``5;$77W+U@0,M.S\ M&-[5%K^X/E[S7;JTFZV#L7?\Y)F_YK[1DK>]VW6EU37]`T&.Y*B/R`CUIT0! M:,.W1>[,::",UK$@DB+]^]^Z<:VUHUL^(VG]2^J*$:)8VZ^I?(!Z5D#E5$#2 MN5KME*R=$AI=VU":X49NFJJ'E)+;I.,02B>-7GCVP5*=:VA?"VES6T@!9?[P MZ;N_????`0`T[`5B"F5N9'-T'0@72`-+T9O;G0@/#P@+U14-B`Q.3,@,"!2("]45#@@ M,3DT(#`@4B`O5%0Q,"`Q.38@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S,@ M,S@S(#`@4B`^/B`-/CX@#65N9&]B:@TQ,S(@,"!O8FH-/#P@+TQE;F=T:"`U M,C,V("]&:6QT97(@+T9L871E1&5C;V1E(#X^(`US=')E86T-"DB)?%?)CN/( M$;W75^2A#"0-2'=LVO+J3F[I[[MA^;@IJ&IS-"8A[^]/+Q[>.L!M M.YK/;G`&JW`3V<AB]S:-JVZ;UUMLEMMS'F@Y=L$CN`$+=T?QR-]^^7 M?SR$P2;*0E)%)0C#601(QR*I8#,H9)-`L3923,FJ51@PQN M9$&.KIJ\Q#98Y/;L@2:RKN75!?\+N_)\?)N2J,P/7@K='6]5[O#F!A,%*Q/Z M7H$=W]^(&+Y9AYNXB.E]>75Q2!3(^Q]*;TWL67OY[+QX$UH8@@Q5P,*Q'6$" M?Q/@-\`.[`(;Y4IHFN[L9H*)?S-[@&@@["9R,_9BF)W.X?"+F8;E)7&>+JNI M$;[$+=C$5BS/IQDY/"2ES>"._3#!9WUGICV`!-LUVZ9B'.5VW=1XES;TX@2A M85EB30@RB`'FG]B]1V;N:X!JMA?\%0?![##"3+7@B.SU_`W`$&.UTRAH+NQB M(N(+1*<1/+Z@4B.(^,;"UXQE2W;=FKL0(0-%EE6#!0.VH+@%@4/P%/[Q)HNR MZ,H_6%`?Y#/.#%L[)#F!MPGO3&YHRM;4)^$9V6['!KVX:PDP(1V^%6H.7`84.=2`NO$FFD`FCD23W)(Y([BD$*A M4<;Z_MUK%7(((1R$PD#D,J^P&9WIYJMW+Z/\"*V(=HO`V:YQLM@U2.;\1?PZ MY!M)7ZQKP_^_4$Z,+:$3ZYPL0&LYE!LCOF,2#FF.,I:LY;\#P&:*5P^2I6HP M(=W*SF-.V2Z@;Z2[5^L1NNUCLO(`EY3`*;,T`7.N`$$K3**;M94-E#_4SE?HIF38MBL5Q\=5Q M&N(1LO(Z*Q+[U$/PMBW?Z'>`XE2@21?S[$;$'G:J_2QM0$F/=$T8+B2=96+Y M;(G'\4"9]OU.V3F'M5R<1M;J6NA%T#PH_D_D_IVP"??]#-[P^]FILPY8QHCA MD"09R(+)"BZC(-KS#6>>Y(I0'CT2H11N%U8`[I,+J*LU!T1JY7R:LQ/=-WK) ME#N^-D`E9NEF8N)A/@N#6Q$$L#\*&U?M*?KBF?ZG. MT)%[&1)/\EG&!DC9=+E^#UQ3(UW)C49^R.>4W-0^B=@G4X9_4`*,$,I&UL+` M5#VIEEGY7PK1F[Y5JBRF%TYZ=>^M8X[)NN%;\GS%"4-NGMG9;I!NQ2Q9O'9G M)R_-FJ'4A%;%95M']E9J(W1;Z8%,/9Q$1]68<1+,NLB5P:-6T*GLW\ZD2^>C MA;P?)T?-(P2B'-\/O!BA!9HA[H5B[E`2SA8#NFC9F3PJB@#O&U_HR"2CTT.Y M[L:5D4.^[:BJ4UV5#A761GF^M@+1(IBVA(@A-1$W+$AWPU*K4^2&J%% MV?TGJ94KQQHQOZBQ5CWNL^5-TA-=*$<`Z@(8\G`"WSEN#GL&R-&+]&O@WE*^ M1VK!(^Z&"[U*4$\9Z(SQ0GFMF)>1Q9X/*`L=N/D@YJ50HY9H;F`V_%9YRTB$ MJ@E?Z2*'H7C/N>S\MVI9FI/@3X02`<_B=3/(_8:O"WW-E.>;`6"QA5)X: M$_J22OM5:7+<6^.^GDY.&W$Y/9DIMYPKP]D MT,:,W5F7>_`&R=(T)TLD4C]R.,(S/!->C.QLR>S4"T$T?QE0R5D=UY`5%6:Y`V:FIA,%O]KS+:.SP_;4<:ZK&WX6L2NEI9%M[('<\NR96@X!E.:+?JL M-8TBYH@Y14YJXJ\?-Z9-9].F;-J,3:N4=Y(D4EBHX)%R\V5QX[?[OS^E9S*6 MC&`ZK8*3SGHQA2!%3#E-I`P5 MCQ@Y%\20TX0IG#KQ<"NXI_J#\'W9HXJ])R,Q$8O`SV!\"[+;9XKE&4W:Z"6W MIT%*1$*E/]MHOXG^DBQ];JC]WO:2'HZE!%[$\&?B20,M0A<3Y_E7^2BZ#C6^ M:M9SIMM*3VL&65+.UB'N.I,UV@C?S'[4$B@'*@20.)4RH*E#CF0H/$KF7_+$ MFI(T%X>W\G9\JXW,3 MI8"JIYK4B69?8-F3''+^O=%'BVFJ-3'5&=7G3E'JG910^AYD7PB%M9KKFS@/ ME]PG#F'D4*FE*C.9\D".C3@]Y,@KH4`YA?&H(0KL'(I0]#&]RXFA%2:&,TPP MKZ!,(1FML%5[JO5S1Y&$+'%ED7`#PG>VLB*KK'/N2A,V3%GMM28R_,^"1D#> MH^A8E-!9EEALI6X"O\IBA!=NI:5B2!%ZDZ#GSO+EKXK=:!D-.2NXD4&16XE& MZ@TWB['1GQ7Q$@#Y-0!RN?_Q]#9R;7"?>,`X24E/N#66"4$Z]H0G*0PF9#R> ME:I>/CIMJ2EHJTG\U?"-GMJX5`G,9X]J2J-%@40B%/"_/9 MD)G4$?_/5ZD!([Y'Z4A+>?G""?DW4$96F)O$_XL126[UE&=@>B:2O47=^Y=8 ME`_>G*&N%E.=10YYHM)'GV0(I<[J[G'!Y*O]6513FN^40#]?TJ9.%/&KMS)E MVW)?A?ZDJYL:90>S1%<;#V+2$#%1H&`N[7HN(I2W*.7MI%(WH(;:IW9.OHT0 M=6RSG=D._<%<$W/`/8VD!1IGCCW-BNCJQ]O<;ZG=TC;/#7?Z)&&QZ+-D@%`A MR5U58L>QV76NUFZL!4I)G-K;8ST)UU7TLB;"[>F.K>S(Z$W28J&MI1I6I M(E(%Q#?5>NN3Z6!)>(AO!K.HZ@_QQ80@Q0DU46AOXIARZIM).GOT>.AXB-VZ MT?>4)K___=V'^_OOCF_/[LP+W3R\-0&HBYA^' M5A!=2*NGPZL/#5PJ?VTU(UI:&@76U9.;J$(V-0X4P!V]HN>S-;95'C+$,S\/ M9P2_5Q[Q2X/V=5^!L_A32KJX0J+ZQQ#(20J2L7"5?88%\:;G.Z>8A5'Z M(S*4X_@YCLJ!P_*8_]YBIFSW@+ZR\J?S556Y.UM]Y;[0+##:ZEHPGB#!&LN^7?U9/V9&O,ZT$3#-2<:@E<$X#@/1%<9"W\"6MOG$ M7?S7PS0QCBL:J+.PY9NN'R82^'=+2_%&6G[HB\XB6<7=YB`[I5=% M@YO\YWE]O7Y^01<(+A'?%>?S4?#'`QK$*:/;4#`)L'K46T<`ISJ2-NN=IT&K MS(9YUU`L!<.VTS`IR!0#RJ/43UV9*]/42N1U\"C4HJFU8`:U;5>J8I,RW.VF M-!`A^!1$[+0<]!4PL/HTC* MS1[("=\%HB;*2(7[-+1X!KN06Q1[Y:_BA?:XY17`&@UX%"W3;-`144#SW,X]4!CJ36U/5OUET MJZ8EB[[<6JE]Q-J_K'I[DT]#?9/%E(4[(S!RER1W&\K8?6?"/DT`!,UY4]P- MM2Y;?W"=RJVGDG]W;G>H@F#P@]+H)S$>>0M)"OX'@"CUK\.OJM[5_;,SA=&@ M`MV=G;!?MK5Z`06%C23S;;`=.4V3H)_^U=SDA3>L-.=SPE2N99;!PIE-=.ZW M!O/T?=-YQ.6>/VCT6MI8LW*T>FM]JR0:O**)0JW,L(T''_2;THA'T!-6P10J MF-ZJ#[72S"//37KJ%2WL^05W@*7$W"9WT'^6>*K$[GR>:)M?#*T<,#<_=^GIT94NWDAOS:E\M=W6UU2V*GL9X3\9+<*IE/D?DM^&&P(PHT>/'&>`/7[FL"AE:^%DL:J><<#@*]@K/-``. M8Z=IN/"R:%_3P-T!+R%]TE`2/Q.?%^'%],\>,!Y+QY4;OA-W"3ZQQ#*0Z)0Z M&SMV_"6"_Q2.>U\(K(0WR5"@.A&/#&+=E?9C&VO`H8+!IN M36^28B9%7)^&]5"46'Z`[`E44R`'B1HF)E+Z<4CD]!)!4GM=99=KU9*I129= MU!Y$*RBU)M'6??251^'(/4OIR92='?._*]MJ/QU5.X:M874'8Y#I'R4]G'\E,:L4U" M*7$4=MYH>H8M:VBV$*/2K]XIGR8T?#/18/_L`_%PEA-E2-!20O0X__;->.'; MS9\.S5\PT8HT6I)Q1+P1J!&@56CLT;J"BC!Z,K4/D-_WX#*9U2!C)063Q:DD M4[];A#P7S*"?K>M(U.B](Z0E(&TFU?)47ZQV57FL>_$$Y4I2K5AS$CA$"^01 MT5ER2^B=*9)_`QQ`TBD4?A0MA!*8VX&EN$WN`@3G/W&8K_FW.U5;16$TH^3& MK$L*A!-U?3@9.&TF>NSVQ;Q78U59X%O!1^UZ058%U=EBI'!#Q;3(LC]#Q<:P M96UM1R6J./;\/ZM$^7#?UKYS?W,!,X@AS:-O^WJ)*A<[(9&U?NW;5IZRZP_5 M'R/T(8H7=?.*6#6;"5Y;RY".N=+RY'OD]F8Z`S0JFNON)$9 M?=IB##";6!D68:[LR,-RY]%0<^>U!6J>Y+X"^_$G-.J;M94D`\;-C7<'Y2!; MT?UY%*(L+M3#$QG?PDLC_A2GT&D2M%^XAV=H;RU"B*-!E0W_M"M/9?NLH2Z< M=&_T$/TK6-H8-5O`I?W6U72RF\F-`)FX$2PR>RM>0TP&9:E:C3W[3,6C=*1W MY6-9[T1M@GK?QJ+92RPR029^K1:],Y0494YA)1=D3JB(9[?D1-M>K'M"U0-A MK^>#5,Y-E\G#KT[M91&"AID6R.@Y(6:&-RK=D6/21/S#%#=_0#4K$QDL=L[0 MDZM8M@O0BRHCS^'>H9X6$0]9@HAV]::TQ51:B1UB0/PV<@T-FJ0CL/>0)W5C MGQ:$E-X&;Z6SJCY24Q]9-'C2T:D&DTOUI4Z7*]MKAO+A_CZ^<1+)6J.2[DGT M/4V/)`/A9!;7K[Y]5.]70W4`LL!E3IR:#+=AU.]9NM1_FM%PV_S\LJQ8#`4U MX&5L>'G/KC3R&3#C".M7LGO%$.S`%5G$1"&6E)(3S9 M.R3+0&5QP)`^Q$`?9"!; M(#`@,"`V,3(@-SDR(%T@#2]#'1'4W1A=&4@/#P@+T=3,B`S.#(@ M,"!2("]'4S,@,S@S(#`@4B`^/B`-/CX@#65N9&]B:@TQ,S4@,"!O8FH-/#P@ M+TQE;F=T:"`T,S`T("]&:6QT97(@+T9L871E1&5C;V1E(#X^(`US=')E86T- M"DB)=%?+;N-($KS[*^K0`[``2\TWI=U3CQMHS!QV@&GO:;P'FBQ1W)5(-4G) MX_F,^>+-R"C24C]@P&*],K.R,B,CO]R]_]T=RJF]N(?^T`_MT4U#6YFA-7<_ M/]Z]?WSDJ7W\[]TJ3M9%%&Y,+@?35-8_ZD:_4[[B%-O_"*I^G$9C5U$< M]#MS&OI+6[=V)6J#SJ;K.&C,)*OAN@CV,HX"9P8WNG*H]J;L:E/6Q[;S!\9I MT*N9T?[G\=>[.%YOBVPCEYBU;Q?M$;6[X0+5ZSQH*[O*19T;S=1#Y7:]$8V9 MZ/OD.KLJ@E[4;X.C76UD6VN3H!K-@^LF-XB(-#`O;G"FVI=#XVK(6,Q48U:S M-:MH'6?);%(\6^0-*CN;![6IW<4=>IN)#2>1'AR=_$_D]IW,;0,Q+Y0?X_X\ M.G!85BXF)=YK7 MFHA6OHA**@).FFFOO^*,'C[=!//F52%:<:LX.+2UWF@;E).X:]=R3\F?JA6+ MQTF6CC(6#1T$%<$TKLWL3F\GW)E&T6QMH@&VFF,-YOZ[LT50NT$>%;+V%G[Z M+"_?JA:9 MH@\'^K]>3J\TGBS<[FRH,8[`6L$EE..-\C8]X-TC???9(+G(CHH'$X7A3X:# MG6R$ZM8'R)OM>`;LX(@K/N%N3DKNZ?AB(PT.#1<$FD0[U-,]2(U<5OQ=]#%" M!G6\76)F2;3(Q_6<#"(U#QB,.8-1OE*DDXPYR^\1(96+N3%NB@!53Z2B<\3; MR;/]TU"<1ED6O$C.#/?FV57E>;3R0`C!:?\6UVF61%=@\`T4/?3'4RE:"C4E M%5VOYJ47O'B50"KXF*#1:2M/,9?$KWB@T&+N%V1Y`>7H[6M33WH\F8" M!H_4YT7302(BEM711VXE M/BKD(<_=A.(@2;R1.-YQ+!^3QRZW6LTUUB7/7CY,N+-_#95WW3M7[X.U^9T'D9D M31J<2TYV$PJKVJZ)@X_/0,\$VO!,1`8K&2F*/Q!8&QLON"Y<`RD.U$:6](AG M";6))?L=0B['O[5=)4&*+W-L-7XE[/L.AQ4NPGCS%L;>51\U,EE!*L?"\6P35HC]]T-=U/*UTY$8,;HD`R`AV M2>#WJV6&"A2Y$H(06$2JI!-G%"LYS8MY-7J:D97Y.4)1$7S/@$\:ISS575^* MH@E'Z:SS#8Y2.@IOHY0,!\V'B[NVI05\)//9&SR*?MP<:-QE6K(E15$>G=#D M^A_F*8BX]&3U#=YQE/(G5*O7(4=$!`$#)0"S-%-YX>/>2DB"8#X%,9%,A";\ MNN=KA"&'Z@(4)[I*^T9J_?0B#V[B+6B:E M]CP>^/5JVG%D@3Y;Y5PU2%VS[Z\D[477S@T# MA$U]]3\^^U/PLE?J@EY@KWRK]?3Z>'1UZY-_4@P7).(2R,K4BJB%VT5Q?L6_ MOBDN3Q8>5I>E\+#2LGYHY$$[-\)M(EG$!.8=]T3\65=R5:JG9!"OA)L>W/D5MN_57E"ZLSGC'9!<5`=SG5+_W.B`>\8 MSN(YOV-B/[A!?DU*O*+@Q::LF\^O[%]S]*^8TFC(E4ADI"ET MT';/N\;KOB4&:;*@YMQP3DI(G(1B'E1[S7!%B$R`*F<#@*1J%%Q;HNIH]34' M_W%F.G`_Y2GM2Q6S ME`_4,?BX$3IB89*C`90JOOQ7[Q681+Q:S)V@C"OS)PH!9*WU\+F\B: M:)@YTPYG*LE+W5#R)%5\/[&C)9,BGTF-QCOBCT"]@MHCJJ5V=6!&SUK+,NWD MDJ#74$9QD#:)15^A#)!Z^N\4<@7N*KEN;D MP//<=U)5CA$NE70C,!#^N*.J&>'/VIN\ZG^M4)%G;9_TFRD7*?OKZ5F]]L.R MP#/*CG_!+FEOZY:3L'4['T/[)(AVS&:X3/%W^$V4^*E@PU]!UNB MOWK/ELSI#-6)0W/)T&+OZICX@8QHH@!ZK( MY`XP3"IXDMV+7ND!4%"!5.,7"]ITEBID=LX!E90U1*C[A_(9PZ%4%!DL,5PN MNLJ4G.K>G5!W,Y[*RMVCH3KFVNT:%=5\CJ",J578CC#K=Z-WIG?)U;QP@U"7^N0 M:(E2/?%8YY,+@T87>@N0U71N=5%KQO6A2;]?>-+Y&/%']MY@/WS1V@B1YJ0% MLD2OM0V&J;U2/&IZ+E'GM^*I4G]:*EH$+IPN,7UFR1>"14:K_:1FD]FUFH<7 M:?@T6QQ+32G]+/B7DCV`.X=CVW02F.?V='3*EF(M^R"WXM2#TVUH%&*E;"]X MQ%A=(UOV/R!DWS"@DKG6-(-K_/>D;R]OZ[K)3QV49YF3'[ZJ1:#0?*;)]T3" M?]YQ1\0?Y4G:46KG,?.D:8EEH`VIW(7=E^A4XHDV0KLQEKY<.X(<W&LRHV`4DI`N-/-+3=HGU6:#0)08U>.R2;5:L/)"(^(;6SP_B.N()IUXGN-',DYP$# MA71V(K389J,4F:.4.A"2A%HDHD^%)KH'38ZCKL_6OTC)#_O9S/WMB6'V,"0QB%F.^L]'!> MZ/\$:JZ5'_]W1JP?VX>5#MC*+HQW.SD[2`LX20E26XBC#6^'9&>'PU_0RVF: M8\,XXO0!2VIJ$];]CBV#Z@M(@6!$*1O!1'64=]%ZW#;#]E&"5-IMY+6`&I$* MD.>I!#E+:/9X^QF;_3J53#8C-YOQ(LA)=XXKW`*CH]G&<2W&H]TUIJ M^T]Q2DXR[J@D"V8I;UE*TI$E-$N$\I7(0[C/#'2G#-`+#0\;E@<-#7_SBV0[ MWK._*&Z].>@+F99&-G$Z\\0FY[E>F'O]GQ!@'&C#7L>6GZIF+O/8RG9FH)'Y3]V@%5B+S@"WV7Z MV02+N@&)&E?2S,9%D48UO^1Z`9C()!V, M.C3`9*2D2%5*`4^I_?:;U$XK`M?#KW(2(24D/'X7GTMA;=$/UDX!F^2Y,3;= M(5FMU_VQ4T=XT&7E$/ZR7FJRN'A.*#Z?5/>);A$PN?`M%4;%Z1XEA6L<-2A. M<,55';?;;YN#]#)GVB3C4.$$81L,CJ-2-?,Q--CR6-?Z%2T28V:B(DX(=/0% MK2<]R#7A3X!'V]%W)R/@Q8&QF$0<6FBT!*/:C_-=:4!3OV1=+;,JUUVMP M?4LO@?+5Y041(O1N457C^C*AP*R4C%.)GV?.PIP%Y'LY?NJ'F[-W5W_FR2:> M^1+N."P0;AK7YL&UWK0E?)Q[!W!9(.&U-:L6(/!\% M=[&VNSN1E+T]URDWP_4;Q(#5TH4G+N#B2>_K(B1X+#ES&N5H+0Q%)NJBS8*O M*["A>-9/.:`(G"0M9Z$(S`FD=N^\\$P(1772GXG;O7$[,E>97HM7_RC'E]^C M&=A*#*R'@16+BF][A`0FX\F]"F#2P9IN1X\IW!^C*IAJ0:XJ^[(&)_H+Q0FI MMJJKK)96%5WH`=8*U24!M@!93<-!DQLE#%(=T#3L<4?>Q9OKO#(`4BJ0$&:A MSD02_7]BSV%\>`MZ#@SY)BY="68O7\7ENYL;(!;;?/<2HDLT,F0"V"E_0*B; M[&'P6I./'9.7*GM_)#[DL+N-$X5].OMW``M@54\*96YD7!E("]086=E(`TO4&%R96YT(#,V-B`P(%(@ M#2]297-O=7)C97,@,3,W(#`@4B`-+T-O;G1E;G1S(#$S."`P(%(@#2]4:'5M M8B`S,3@@,"!2(`TO365D:6%";W@@6R`P(#`@-C$R(#"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TQ,S<@ M,"!O8FH-/#P@#2]0-X!L8N%EEDTT`>=O+0%[:MM5KJD=3V>C\CR0?G5!6E M;E\F&PP\+=Z*Q>*I4X??KC[^XIOU6#_ZFZ[I^OK@Q[[>JKY65Y]65Q]7JU(9 MM=I?57&5JP3_^,,E96SP4\9EJ5:'JT3=77V\_;M3=\-5$B=)KE9;=*Z>KG2: M1:O?R%`NAI;6Q85)2I63B;)0J\^\)#6\)BXJ^GJZ^E5GL?JIB_+8Z/8./U8O M5U&I?1^5^#ZHJ*@R_3G*M8^65F]&%?US]>.%QXE:VC@M344[+&F+)),MDL1E MLL5/T3*-,]U%)LZQRY*:3H]1$E>TT=)D:![43J9A(X^5DSE&?OXB(W,\0N!='J?.%6II8IMG4]C/-_6KMDE" M)I(JA]]H)),%8T-(8U,F8B%%WQ174TYQ34NQ]$.+T\)1J[O3L.:/=C>PN2\K M0HHEI+@*AE1>%(2BO(C35,$>;/3^:G^5%GF'.:Z?83O7%'-LL6ED)U7S;XO4`2(/741( MD]8HH+GGADP7$ZJ6"4,D^,-)]+IIR%NG_8O%,D6)V3V.A4VN39(LDLA0(TD0 M%C9]"E,O_1'3/B*'>W^YW2):LJV+TV=N/GUV/GU(9UI5\5$*W9,WN3Y%2_*7 M"*0,(^K'=>O"::A/6_O5V66?## MBV4X<.RB@GM8OTQM7&7(1Z*^*IU"A9P-"6H#3FY]ZWN`A)#;J"^-WS+M MWX2N8SW.@S>(`+%51Y%$7(_=M'!DVJS#`%+>]P?54HMF,Y-Z]6*NJJ05@[+Q MDTG+X!)2_>$[UWS.6%.=05X(Q*U`O`P0+QE298!XP:V*4,)E4G#Z4.-+'Z6.(TI"EE!_87^1Z2IL(_J*(6^YTU+^.^`"$*6G),FT794SO57 M;19IRBK`4(-:ZGQ)\21 M<57+4-7>$$FBV6OB,DM"B&F-U4_RQ%@^]VJ?Q[. M\LOAL#A[9^4\Q!3[/;O9.T;/8V'IR^$WQRZPC:UH@U?JPJ03WB&.&4BK^XC* M[P85)X/"<(03HDG1`2*,HHS9LB*VK$$02`]'HUOI;:BKB9Q>8^&ZJ?_P.[5Y M5F`KM1X&/PY0F*PMV=I-=SAB,T[X9_54DXR$Y?O(9$P$I"?N!P4Z_JF#KV1-"DAJ:YO)4LAWL8D'GO<(G+-(7V6>)\X+J6ZF=2 M=:JF6SB.S(X6[&RG>DD:!_D'[<<>+"WJ7>)>Z3@SOTLF(7-L_.[.J\.Z?_#C M>M-X-7CP)=\F^*;V7),M(P55X]0R4G90C[@P^A3(,<4_1*F^*,V&P882X1?! MB,),X_1N@9*HAM/V7OE'V<`Q*,KP^%CPO=7R,`D#T[S><^T81H6+\.JI.S5` M*6"S^RW4.A`,W.6UHQ23W?O@<6=5F[A)UZ4',9WLG;()\^^(Q,HL>;QENW+$J*MG*.^EJ3#`0I)N>5+;G#AL5BW M@]KZ?N27+L60LBB'GMQVC[XEF4="OD6*C7S9*2Z?Y$&8/\I[#)!CWR!9(YJ# M*#/']O[;-%"+0T6<6%#XS`)F5BDFJ!1:AG'B( MV$?(!>^U?W'("CVHF_O:[]67W\$6W)>Q\"YT_>C5S_M]C3A3FF][SQ:,'I#1 M+0D9\L:FL2G=!3_.4++%E(EBE?`)RFC],"Q4P\Q;Z$,]JBW;+>871($7Q'!D MKB<]O@M3VSL5AEM^*.S4,)GNM@^XM)T_'*<>>6%`0\\L*GZ^*CHSB]J)1?ON MOMY,ES^J7?U8[WR[4^(%T55?;R10N.#0B8M?B',E.V?A'$`DWA*/@>![J6'R M-"J94:$*CW,0+VO,&5TAAB\._HQ*J@+=LP,&,;9T,6?VEVY/)1D55RH!:@!* M3L_I2J%?UTBX8*`5')YCE;\J./2,"*$*.7C`:XBYN6:X'$Z<:4X?5(-BT'"( MG!:IL6[OZM!!P<6&#=TOLT?K1V1B/X;'PSTMN,90H@YUT]!%4DKA(I\Z"18B MD9E+R)V?JE,R/HCLJ(&9;2CY3%)DNI@MMRAC.]4(O*@".]0$(J)32(YZ-^FE M:?5G@)LP&?*EJ;[J^GS+IB8Y0TF4'L:E.QX!QRI1KR4LC M/[&H5"NM^5KH,0N(U2@K72-)W41XJF22>B2T^_`%.2H?(JI#&:*.FK.P5:$Y M*6VJG<+Q#*I[)@C_OI))STK&!"5S0QH"^?5?SJMEQW7L!N[O5VCAA178-Y9L M6=9RD'D@P46"!+V;V:C=Q[8`OUJ2NV_/UZ>J2#W-WQE-QX2FI\@(66'2SY``^RZ*@5U0Z1@E@8!D7V`:Z& MMH(DB47JH5:M4;6]D.TMK3BY)5IXJK3+:XO/1Z^EDE2QFL6(!@6=BQ]X=U]Y,,Y##F13BOQD"MG>9_T2PS M3OEF>\"H'.*2Y6HUHD`]^CK"H=6P*&W%.XP(Y4Z$4"B:R&?$B)3TF/6YL\$. M61`M/OBTC\E^4*W\3!,GADU&):A25&(DYV-`15E]']%I[W&G`TYS3D( MI3AM*BO[B$K?=;?L`UNYQ#5M+0V/[I:E@TD#0_;XV4KQ4O"&S\(J[ M6WNK?380S\=(?BT_:%DQM7.%Z#/*?E>8D))$=L',04O=QJA\YNI;C"D`]W,+ M]>#D)\L=B*&04O8LZ82OJ^BD&F@^$"VW+-S9J$8WL4AGV(JF!Z[)[E.M]TK/ M8;J0)=1:HE@=Q'M"IL0M58C3F)4(^_6/`-[818$,$R2BZ6'U6F0C*CXT!TDZ M*!)M@`*TIY"?(??^?@:$H\V2$!"1;)T,0M*^=)-[*4SE\X!&<,Y6HB&5?[GQ M550X]A1+#Z13ME<+?2UFNH=-%T6A_^@=:D>\89VDGS(DZR'?+S!)LTR`5G2` M5D#+)+6OQ6I8$V0BRN@I>LEVY&L_PQV\,Y/U&K:M(J/";S$E0^/_1\P7^1HG M/?W[Z]/3.L([[CS2\QX\>Q!*"C-TS>S-C#8P/>9YD4V_!9LM[:]A[JRGX6XT MD^'?*FLKM[Z(]DF]F@_%<8`43S[>'LZLS3QQV7]$+A\._U=KLP??6`.J3B<7 M[FLGVKCL1)]-M*\UW;V3Q?CBJVPSM*`]C"W]D7XNM]6Q:C^LUD??0JGF+_<^ MI_?E9BQRA!J],Q=%CQI*7.+LFO;R8:YJ'DI+=Y`-9HXG_XN1^]NV-;V-5:MJ M#`IV'-2EK48GNYTV`LHFBP5C!6'$9N%5<7LS8E@:>V$(STEDB0(2W4+(DLP# MT,,F,7(C0:@-&&JI;8A#4S0V^/D)9/V9&RR%-%DXI MSXK@"U\@]<']RE8#RRH-V*.56$:"RU6X_"]ZM)8_ZIX'7">2CZA]R;3.WLAZDBL$9N^4MD MXDM[99=A9K[KD-D?[4SN6YB;%#IPN-KX7A>G9+K=G4`7%;[;L+NL6V*L?(A>9PGE%1V.>/%W MH:]1W).*+>/1PI9\6P"SS`7GC:C.*YJ@8GI#W8YV(7#SIQ;`MCEO1W)RB^V( M?G@+1K@Y9TIM=_3;])^V1]JCU6_QP,W]8UCW1B%>J"G3"?DC==*OP.T&7/[J MRU'TGWC3'QW6F3)X'IF"EO`\DO_@@H_Y_7(UN-EI!][)X@=P!SKEH7V)[6W7 MTI%,>\C$[$Y,?U)D["I0U1=QP=(.;L1A"GZ4L-R)9=!*1&AI_RC!Z7J%UJ;` M8&%_Y$U,``5O+G)'D$,"^!G$_8^!;=JI MBR&(Q<=,`.\D9^TDQS?:/9A`N0@.]D4_WP0@W&1?M2"'[9TV6+];C9K7RG3; MPLW`S`9=3IQ-4FG:8$L7TVIO*-Q7'L+F*AW>Q9$*S%-0?E+$2UQ!KL+7-MRV M].B*CJ&V$F1C"9(8`N2Z9(&@4BWW0M77J,J$;"^N:&:QZODL'):2.V5>(X:Z M$WG=L?H'=ZXPJ@5I7F0(4QW:;8!VJ1;Y1'I+F#6:E/I1Y; M>6+C!UL?)\&FW. MK62G5RKGJQ,7DMF!#``3,X*-IO%ZG>;#0W+M7TW0=&`3-G6 MX:5"O?8%$<$*6W?UY12]^2SK<('_R\TI2A1>;]55+``$/HA)D'@21$9:*E_8 M8P$@1([,N#KUAB('8"+4=>9>XI50VZTA9\RGT(4X#:^$]AJ:;\MI9MK"Y@8[WROE/>T#*S8VC M&+K=CMU2I95]G/0/F*(:H/$:F`\[BFW?9="L?5D9!)P=*NKH2#=-&YJXO>RM MA3A7OPC!ZN3TPQW7O+G[GG57W:/?'V-H> M]0PTI=I5J"C=,$YE*?B9S[2?'MHC(._B#!\BB;OJ[`OG;>5?1USS>JDM`%"[ MS_N([YL:IF,NG];72Q,:?^DT!XD#CY5/?YT>2G8RP+HVU">^7@I=M2;/>[T: MHVRZ=Y1@5+<'>,LCSEZRF(JPLOQ;7S2GE/>JVW,PU3\]??GWE_\.`+'VFZP* M96YD7!E("]086=E(`TO M4&%R96YT(#,V-B`P(%(@#2]297-O=7)C97,@,30P(#`@4B`-+T-O;G1E;G1S M(#$T,2`P(%(@#2]4:'5M8B`S,C`@,"!2(`TO365D:6%";W@@6R`P(#`@-C$R M(#"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`- M/CX@#65N9&]B:@TQ-#`@,"!O8FH-/#P@#2]0'1'4W1A=&4@/#P@+T=3,R`S.#,@,"!2(#X^(`T^ M/B`-96YD;V)J#3$T,2`P(&]B:@T\/"`O3&5N9W1H(#0U.#0@+T9I;'1ESF\4$"1!DE=,B!YIL2D[-&_WZ\>3#Q`,1F9W5U=UO;_Z]O#I MWZZKEO;9?1ZZ86HO;IG:VDRM>?CKX>'3X5`8:P['AW)7YB;"/_Y(HF)G\:?8 M%84Y7!XB'D(TCP\_.]A&R>[O8T*D^-BFN+\ M9SJOF3HAPM^#YRK<9KLRF-KA.IO.Z7(.+7Z=F5SOPJU-L7@)XYT-]+SCA1DF M,UYQ'A&'^NPO.S.,2QMN\>Q@Z,/M?E<$L]'3!:R3P"QG9US?F.&(^Z6LV[Y= ML+*[-&B9.@\ZL[CILC/F@///.$RP.80)6%Q&7F:!DO;838.;:=K&],-BY.%^ M'VS`/]P6V%D&\^Y.^-_#WV&;K=W%6<)V(A.59*PM?4:EF*L/21<71OA]"7/\ M&O?MVH89OD92V`87;.>!$\HES`+3\;%<#'7LE'!$D95/TM M)+_?VSBUEHS\NYAI#U4IPDCF'C9I6-U]X,\0/S8@QE"![,$>CQ$!'9/)-3DP M]UN5[+FGJOYJ1,2$X,.!<'[#JQ8"D3R$VQ1Q<4]FJ@M663![DI.!]D=R"/14S^45%L+K%`1#K:S:L M,/PPFSD_NWD.)A)[3FMT$D.*Z.]J/H9R-;7X^M5ICA"*43J'L. M$RT4J!*7D.(1KJ""MC#/&&ZGXF7J@4(Q"WJY5[6]J\1GE8&:FT@"D3IQOHL+/#SRZD2K.K&JQ:P,!779+RG#RE)3.VFA91AMU^D=M-K+2YJRJD*GK@EH!EP=3NSG`WE?ZH.VGJ5WG8"ZI:JUU[T M>AFFKR04KSV9&B^G@!C;1;\ZHQ^D'X5?IW'0W3*C)/R3 MEHE2]JU>O%POYBA:VV"Y3MR;%XY/MEO!/3D.S*C+VT4:('4`BN5E-N)QO]$@ M::7K2H?FAEUP?_;]M]#^.QL.2[J=PVQTVWFP@-;NM+D7;&!N!&_"W9LQ6XM+ M+%:LQG$:P@(Z?(>=R#I[SDS$`J48I'38D'^7:1"4G1H+"@8\V MM#8H\TU$?S^@H^UD0]4('J%*C/!XY(J1!A_Q)?IT)ZH`E-E(4!FT0L!D^\*K M%:<^.B*MF?]HT3ES+MD"?G@A6TVXI9`P!UG6YQX8\'3S4HI[(66Z%HHU`JU& MX('\L.?P;4+)20E7[@"'+Q)O9TGT2IK<,^$P)H2GJ??J M8M#*XQAEI8%N4Y"LI>>EU;6\Q)-W/7/':^FSN).5O`^PN3[,U3S.Q$HPS*O!D7Y1D%[_F+#`_2>$G&R5D M(P]C81AY?-&K0>.ON.N/3=&WMX;%PHU1`J=1$(##`F`%HF'8Y((C? M+,G$50EF6UQ]IF.4BZ$3-0?NUBN(.ST?IDWXH.238[>;NSRSVK>`7)1TTQ7]OV!;Q7!EPTI^=PV3L+Z.$@@>3:^`(+-0A&U.@L;\P<5ZO?@Z'PE6RW] M"4POK?;.WG]H^\&'2HOA)47_W#"YW:*DPX9G-AP-+&?/>R)#Q6(Z-WF_P5RL M1XTLY$9"NT]A%,!@ND)O]FYNN;WU\X*N(.U`(^SF^2'AJ)W\[4ZI$S+ZI-_H MCX2P/LRC]+526TVD1QM_A+NL?-V?>=Q5,.I2%)CIC;LZ2X5Q^A%DO.-A/5XL MO=3_"XDI:E,F+WPBT!7&0KYQPECJ.A/OGOB64+P#GEZ>JR:^Z)E^C.FD4HO5 M&@(G`\L&MA<83CX&L`P6C^!1$%-NF@16`P\*\$HZKQ>"P<*"`#/QD!4`L_#A MRL/#W7IFI+/FW%D),;1RLUH(*U%S>(R3>$-S2!#1W)!+TZ,E^ND*G=F%.79! MRV?R1OI/XBL.V@\GB:1<0RA2+'B4X9!]GFRT`?OQ-16A<23K[&[`%0+)&3G- M98'H_B)4IFH:&7=I&FW52GL=S8K@[91:R:3&N)H&53_E"BU1TI"4GU0+5\B`#'SHW<9X7&D M3A__<*CX$U90*$T,+FW'53"8ET%&6-I&B2#XQ]^FF:XG"4(-WY3#5ZX1Q<)- M):2NN)]47R*AJ,S!_5$ MS!PTS91^ZD#.1@EJU:N48I6BN!+M94!=[!L=(@398BX:9H]B9P7\"1([CNU[ M(/&G04:'DWD>ZE:_98I`>K[X:68YKY..GYR.;2>C"R8KHQ=[;OL-A=?LZJN_ M(A@!@QQUJ]$+@<7\O5$;R8A6]N8-Z\WYQW"5,W/K9QA1+M/X^(7FD>_$`_KP M@W+B^JP[[(J4(QS09M3=?JYDUY,C*1'C6YL+V"(KFW\1YXY.E+AG9^:!^1#P M9OO]BJI7%_CZP2&GS\EV-"E`+EDEDN#@J8?Q%3#<;'0'510J2;QAJ"50BC@0 M!F/HT5W":<;3#$8/&C.A)-3IC=!T#`'UB]2\`4,+:OMUM8R^ MZ%V1C=8B&VL2W1RK#U`S*^A>7S8\:=1W[4F)%BU*B+!V1AFL/1:>&KQ8B69@ M-+BG`R1X\X@80]@/WJEH^18_**'"-%CL]5Q^ER=69@&'4D!S%BH9;,N$Q/ MGI"?G33!4YB3SV+.6@JV;A"_YX+4/2[\22<=*Z*$- M-UD5,OW!>M4TJ6T$T;M_Q1SV`"E,(9``'==KE\NI2NQD??2%!>%5\;41L!OR M,QS_X/1[KT=H6;`ON8`T,^KIZ>E^[_7"-BQHI'98&%`XV5YVOKFAKS9PU_J* MWA_]'KN3YZRYL-?-\VAR1$/NZ)W>X@S#@L\/YK_)W,9*MW&5CE+H[JBX7C0^ M5/RCH^+W?+[JY_FIXJ?RI4".RCY-3Y2_R:(QP_M6XH:">FH*8<0+1BMI!3:` MW'>CO>2H_31PW`;C25X[/`LJ0\>,>ZCU4(;>J_B MK[6I.7N!06NU*JGT=BLM@#"SZ&^U[BRCY>EE649"RR*AI2`T!.F!`I/T!>C4 M(F*5Y7,06V4M3>\*`%SI]*\A&;,TKJ`+D./[+0"8&)22RK*6SQQ($ZL3HT1H MR&1"1`6WC(R*5;&F%C1$8PX_E513T&N(-9!N>R13C*E+A8(<"9?[=?IC:#XO MC5`$EUP?Y63/,2AD6SD.?5^;:7HK6)G8YT>Y=A/KWD&K:LB8FGI(+VN$;<-."ZJE4?9=G#VQ&48 M>^JZT/29-+39_8-4)RG=[FWW%-7UV5+O98T&5:2%N[$C'L7CL)G"X^2DJ^MU M1WGJ"F?4#;=L3P>MJ;FVN-?STIBDC:S9?@OM49ZUWOVU+W>'\^689L=R'!_+ M<:P=/E6&"L"1GL$EVR(.5!R9A5O;!IF"V]I,%Q>*,*G5[TMI#ZJ^V:PD:U$E M*K>,A#]T$K?6-#DFM? M^99DJT53=]_T19-^>H;;>].3G44W,]H&^3*Z6_4_DPI*&U!+`+I^ MGA?$_BFS<]$)3B*SD'F!)98?,=> M9EF@OTQ(U>AR9*>J"(9HF?HDG%O_F(<&3!G@+?0BK&L#]D:=XVG%7U[L.Q+(-`P=/BF MZ]V&F#SA4UV0MRS(G`69MQ8F2A2_<-5/3:$F#2K(*+_8TL+)E%H;KS-V'G$R M_#H1/NQ-6AE*5(>0=0(E,J/*4%*C6EN)Z+FJN1>H&!^8S^C_W,P%9*I)LNCZ@%GEW*4$<; M_.!6AC!-Z@A/YJP1P0R53@=GX>X@;\1/^9)R(TUU'Z@1MC)2TZ^\[ MU]_+(O).WWDGB;R3M*+M.ZHF\0X65OPX=VZ@'N%>]7AS9^>(1!S11ZS1Y"R\ M4Q`5):*B1%3D9K8T$VYTL+CW_[#I=RTR:N*:TQ;6L_[,O7ZD#'2$_UV-BR#V MT:G!M!:45DYP&G>>L0^`ZD;+M?A!8&:904R*%&#YGSKB[RW7Q\C"#(+H!.3; M";JJ\U#?W!<'EG?$LOVNQ$69Z?5$3+'D1/!AM"F91;[^;L.&Q,0^ MDBJ%"3IY[S#SKXQ\<)S!A]89?)=,?V(^+=NL#=??^5IK9[;W_NQ[ M%##/\+W[_.J/5_\-`!I;O&,*96YD7!E("]086=E(`TO4&%R96YT(#,V-B`P(%(@#2]297-O=7)C97,@ M,30S(#`@4B`-+T-O;G1E;G1S(#$T-"`P(%(@#2]4:'5M8B`S,C(@,"!2(`TO M365D:6%";W@@6R`P(#`@-C$R(#"!;(#`@,"`V,3(@ M-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TQ-#,@,"!O8FH-/#P@#2]0 M1^:QO]GXF\W6[$H:W#W?V#CU=O^\68>1 MGP:;S&QI81S3]T\R,4IYYIH?-RG/_[N]=UWM)?[6NIY^8FONS-_DO?,"'MV[ MKG.5N1^\V,_LV4O]Q);T*;'?:5IJS8&&MK;PUB&MKDQA&ED.HS^\G.9<\%(5 M,(*W\TD6FJ<""R[TC?8SV&+OD9?DS6VP(E]7IM5)ZF2ABXNJ@K4KRV(!,]2X M*8[>EA:>+QC&=.-^7,8)R_/1(9(_F=9UXS[X?_'6*=F`)>/]8_>%@KX._#") MQ@`'N:2"GP+$MRC+S@TUG3;V(_%CG8H;_,J;QG9E>-*%HKSOSD?R9)W1;@?R M*Z)X5(7L%*23X]N8ZV#0+:L7YHG*GI93.M&\ZFI(%88AM*"-:<5_TY$QQB M>S+]:.)DS?#P9F[,T_?VF-[Y=2+.!EDO(^W843)>=?C@3G`,4=3(9S, M$$XTQ'0"RDE&!K=^;I_(G=RZKA=\,B1R;@44!IY\[Y$U`I<7D\HV>+X'WU4H:W-9_$ M'GPLG6[)6$_M@Q>)BR8*5B;(&E.&$+S'5M2+2V\,4PW M4]1&T]>Y_65%*[G24Q@C8K]1M3#4#/'NFEJCU+$U;<& MW0DY^<9\/9DO8I!J\J(/W8L)\!3C9P6^-B%>-Q2"+?W7EZLI7+O([K$=[6*S M%SK]5@`M+AS;Q@V4$UDPQS*>:S>?:S=',$=@9`!&I@T@IQ1MD)_0\E='$#I* M[HKZY#'3$RL_(M/1!*1,YBJ0,KLTQ0M@3K\)K+3M96A[TO3L%;1""QNED,H( M+8Q)>Z"E!?S`?[&`QP(&'`>(Y_/DGJDO%/1HJ`FE-+.:PORGC'5QO2 M&4/@^I7;15WI5!UY$`OCQ@-V>P=QV8RXL4EZB;`FX83;>B9X4`$3VI(_UV)8 M'-@RU*FF5F?YI6Q$-83(=LR\M_S,"&?R$^`3L^;`2GJU M*T8:68;%:HR!8\?-98P41J]Z*-'/1REM!X,#JP_U&V;WR)N^$6E+[RS^=QBD M,1;Z,G&[GXUCSFAL*P/]L[`FIWL'S!/7!LJU@D+BR*$WQ4!2^4$.2U)L*%BF M#/A,+E3.B;*285UUDK)Z\M!?!Q$V[=0Y>D9O3!&)!$@I$!P)@K]I+UQ+8,DT MS/*Q_7'Z2<[S)$@2]933$3,NBZQ`R,B#I MD%,BF^V;@`)-Y7G.OB9)'C])#W3B:ZDVJ*G/+9TZ>F;S7,4"W4."#2XBT`TA MT\R[LI,:`RI6?P@QK!=.S*#K1-3@?S@WYKYH7#]MD2UWR.>:#:8-@G#LN.#H MD(9(=1RT4=PAJM25\/UES"G&FTI#H*N+QY&'\'V/*C9%VW88^;I4X_'M$I9\@H<>:O0&?4RXJR7#JZ'U:_)K2W M)0*4.[;#R@%G"@\-B.JD4$V"@$EN6/`DHOQ#$;]\-_*@,))Y M?267CY2IML'G9RK2WS"'4;%15"3OJ3C6;N7-4O<*>.@R(JO:L1](T@A'$IF8 M(21Y26?TH+7BP%L$E4@W2](5Y)A(D8.LF7`QSRN7N^+_&5Q^DJ(4JN"[42E$ MEP`8_&4!#`PXK!O`.9)W+.1[F^:=!T3K4DYNZ:IFCA(]S7TBLI%M^;!E?HVY M331)X!3!^\@](;--PT*5Y9[H0N(E\N)GK=<\;Q*Y3$C,VEQ0$09\O4\F>%5! M"WR=N+QR$7,Q=SE,Z7A/:J`]962?O)22P5PY\("[JCR M4(-CZ)"_),)ME"5CW..I*03C70WE*ES_Y8('L+H)PQ7XD:3Z4ECD($IN$D?Z M3SGBV`:C^*'[&>E9M!(H#-@CX*N24'6"CWL.+"W!@KG9='+S@FHXJX-OA4@* MV"ZTDG2G9^FV-9K'+(B,B)51'-V[\J(-<6Y^3B7(I#8^_RQ5HF&$?=4`_9I. M)V0OTBYW&8(>[2)`3&Q?G\'C)]'!YG?+H/_C_O/=OW_WY.['[W7?\WTK2*5/ M\';T&*;;Q&QFI$T[1IK4TG$175H2,X;VI"B@&AC/(N$SZ:4SH+DZ!.I4'EP< M4AH1%\:9:YV6UR272CY)CJ:<2U-FR7R2YA-P0`C"*PH]=2*V4Y=2D($](%#K MT?5K'HV26:@D\/\9-PBH^!YD6;FR&2\6E7'[O6-=S:U51I^<>7C!50K#!P$V M)?GSG;!6)KQ$M?7Q@JO4!6&`>:RAJXP`WF?`Y\Q=1`B[T5*G=S!LN%SG)!#: MC;9Z^5&.[YC)'\KW<"\U6J`8.@ M3HS``M9CWP?5A!Q:CX"26NJM\OT@JY5-9@<%705,OT!IP3M,:\2K2KH2I2P/ MTU4:A+`L64HFU[$,FSF/FRG0SJ/87%(E(8#QO9ZOUOS&DFN90/B'AU+/<\4A@R/6#=$UA&,@:(>L="7+3%S&)Y2]>OIW^JJ_+`((P*-U![>:)\$FW]LT*?#=><=+^Q+V9)UX5?K>W_ M4!#&'AU=DQK]?-PB>":MCDR9LM7J?QN+8BT$259([/K(WAO[M*'J(U?-M-LO M0%-@229Y-!/R=1O1(0K2S##:4RCL<+6@GFBJ-.K$5DFK6W=*&22]($V4N3JO MU6DZ4XA)5S6]5K\9([I3>)98A#/9AH,QEU4)1U31.;!(*+Z2^RR)PHYZ/$5VU4+`.-A0;N%-ZX;/ M[/K!V5+)?*]")S,+H-^4@J'0_YP@:J<)]%#9":.A1LIHH!1(!A)#)77#KOYS M6?&Z"X-DT'^`Y_^5>_[_ZNV2!:(%WCG^!=50'0MPW^H`1("3:S.]XA`Y)_\M MF.XKW9L'U9:::EM!M0T4;H+TO!JX,0=.%GJ9`;^B!QXND+>\F4T$G`WT]3RQ MX^:,V$!WF@X*\U]3+G122K6`*P3B M<>3!(8C`^&F M=*3WV"S$A-^G;M0*T(&OUA1NV2NYAT^Q.>5HBD&C^C`%<1V52=;IJ\-IZ`>` MET2]5B8@H=M\A*N+U2HF8X2/H#(>0"ZVHF*]9DC'//DV0>O,H5JV0\]O][NR M_0`>T^_$]3&HIB\'XTVUXR]ML%GP/0/5,8(6=1,7YI?+71>*+*C*8Y222=E*69L M)IE26;9BD99B^S^`CWGR^V0J53N\ABF/!)V+2ANTPP$L%G`P5[=Z\)N[&-;N M`=>05Q:)S7'@B;@7"SJJ$&^]3GR9K>9CKWO?61+WI6P%SMK:/78GP7CINQ+P MM^GD\8]/P+JB6)WMCDZA3R0@$EY`)!([U\2F/\7T+%N,.R,!3[GS;N.U$;&) MY%@U*VD"&24;7 MSB9$:[TTM6<1HBTMLG-F$/M,9GVFAC@;NN;I-%@A-2JQ-):,&?)S[0ZM=_=Z MJNC-^2H]6DAU?$>/^-39MD5 M%,4A0B`%2P5)*73T:0>IW#F9RE=9JAH.C%,D!WTJ)CP`+T!"=8S&B[.>I5W^ MTKJ-;WVGI^VFS'/!HF5ZGJDCJ33%!W!;R9NV.'@^.A-?E&\H0>K=D_Y%=LJ? MRIC6WKO(,'3>6)4MX%22S#H_01D7EZ&S^X!6FAN>RN\:BFDZ/($-<^,5CJ/ MVXYJ9,ECWG1P:539MKKE@&Q(KX^?SPWU).4^M"LD)("TX'Q MG;T]NQWON4XL_TN\]P?KH8X_E,6FFDU+[63SH#7GJC4_PQ;HC2(YL.6U[)M" M"G1)I;B7)<]8*L*-^M.YQW#4%ZYC3S^_\J<&G=SLZ87S!'V&/[O=U#5VU89" M)+6K/:_HRAVZD?/\.C3##K#)\XB+((1^3_(/4[YI,[$;-OQJ#P*9=A$H/W+)8'\;L&*9Y]_I39[5I9J.A3630T[B_9Z)U+G]06',<148 M`4C_X300%OK)+.%4R3061DD91()U$A`B[=.K")>(ES<[WH8.TJLF8*$LH.)3L(32562'G76LJ,P-3:;J# M)*-C%Z0+9E;G>M\1Y&PNE?[VERZ!!0H3$%/5LS4?<&1)92N)IK7S2+($7IU_ MD=QY]_6"`YVSI44<#8/?'P?7Q*/W-E%[>:7Y-+SS&M&(]`+E*B_[$^$G;5.7 M`:!F(WE3B$+EO[G7AF^3(M(ODA0NK@$L2-X`FR1[UO:]Z=R+_=R=_$VL(=4! M'T/3+VPZ2"5M.F[[8>:J%X0!AP0.=">[79XSD\BQ4N-8%XF.`D*,E>ND`LU9 MPL^]JIJ!\56QVFKUUM1C3;O19>JZ3!VW(E)FBI3+Q$YLH1HU@;D^<+7SR[]> M;#]*KTG13N8``.P1PB]!^OM.VR&,E,P!.TTZQ"4)IE@&F` MT<:T)T7(@:+C'W!\7U:4&%'L8/EFLM#^1Y7$UU`3<7ZW(_3Z4:UR`K\XYX4D MC2)V2]W#J1H%ALB[4=RYHY#&6"L%HY%%M1>$V12-4<6@4VTG>-D8B!?1NM$< M.R-8JSQ(?]NI`@:-M395)7;+.Y7VPV(^=1-Q09"))PT]Y9Z0JM"ZQQT\GAXL M!7SI!,NA\X77%5R$QLR"J-BTTJ3+F71+33II'`^DJH`4L,UGZQ?R\D7R`@(K MT70Z_5L)+*!M;MG1!KP\%;:Z];M:>R,8PMLDI0&7;3B/?'T4 M<+GQ]3L8KABW4HQK:$R[;\D2@KVM;"9YQ]=WO?;9`@\F_0`X1: MROCIU#?FV];WO:NLGQWD+HGS4YS4N]600J.,W.;406/>TF,_/W[ZWZ=_!P`S MO-Q%"F5N9'-T'0@72`-+T9O;G0@/#P@+U14-B`Q.3,@,"!2("]45#@@,3DT(#`@4B`O M5%0Q,"`Q.38@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S,@,S@S(#`@4B`^ M/B`-/CX@#65N9&]B:@TQ-#<@,"!O8FH-/#P@+TQE;F=T:"`R-S(V("]&:6QT M97(@+T9L871E1&5C;V1E(#X^(`US=')E86T-"DB)?%?;26 MI(@4*9*/3K(UFZG:3=;6/HWW@28AF6.*5'BQX]_([`?OZ0LHR;%3KC(%H-'= M:'2?/O@V>W]MZWRH'NW'MFZ[ZF"'KBI,5YG9A^WL_7:;FL!L=[-LF6W,"G_\ M8[U*EP$^Z3)-S?8P6YG][/UO-VNS[V>KY6JU,=L"D]NGF1>E_O;/V2)<+Y-@ ME9H--D81UC^Q8!20Y()^!@')_^$-?K1,OT0]A*&^>823U?JCZC_XBFYPZ MB&2KSMV(2EDKL#WV'N;&YH48,==PW3F]Q_\$UG'^2&-FGF#"K=_X_X0[S!>N[M:K?E6\2M,Y*KNV[I$K`>ZVI_/_S`SV`9P-2"/K2*7Q'$&[@0>(MB[#K; M#,9^MUU1]>P+I4\2Q\@_YTQ(SOSA6;9-+I.!(W*7;))YG+T9#W?PK]VQ"SI; MD-W$^T:C&'E`WB!H7=7L#:VMY23+M7XS`W4Y)VE@=&1OPAAX;%J>+@7Y;DY M^!NWUCWPI!W@!=8>\WK$874D']5U,59V,[L:!3`>>#+F^4!](A&NN M?IFF$LJDA$)/]B/R2`HNI$3BNW9SQ_R9Y77VKF8=``5QQ_P^UB)@@FQNPA4; M6JV,*&ZE@D67'`P7+3]DK=;3=6H/SG:VD+6.[F?ME4:&DT7Y87VJ/C6K=I?F MYR*6Z`8N]=:!B[,UUY76,`J4*R+&L4,JSZ>JUJ4:EWJL`(-58P:I662[>;9< M)0DY28#7P_2O5985;BN@6N^J.ZZGT!N'JJ5T`U";JC>-I%Z+3(T]($@NP/5= MOW,9!_9*;>-RY>D51F5;\\^$=JM"&B+!QZO@61BG/"L?R5% M)72;*72;4^@^4/YLU*9:1"BHQ$I9PE4*3)M/"%\QM%@.J*:H,*B:95/-[:97 M3]RLZFB/@W7JAJ?6K1X0T8A!,.:#4AQ43)?T\$,OAPJ1ZTD4GH`TB-RA`CT4 M!?8,L6E_X-U#P94TVSVLH-*LY:L#A!!8E]2="3S@IOED"\O(&\1SI&7&61K- MS:U'8,])X?!1W1%\_`48_$5J,MQ99`AWI/^G4PE3>0]^S+6*"%WM`8_B(>7' M@?LB@USH-9/P_V[]N1SSSM*8JA[DP2I:$(2H:J16RX=`3LFJEKJ.2E%S0UIR M^F<-_X8+]#$?5.[AQ:YM-_;:?2'E;+"WQ!XR90^9AYZF1W.G7T@[.#\^W#V= MGQ;LZ:Q+#<4KL.`2NCAE.47\2G$H-]R0J%<*1`F@*13M!)D4Y12Q11Q-B(X2 M>W(-:\_A-D+%)(G79%+A6C;.+[69O!1;%))4S7,`UMX%'O(=_,(M$0!$KCB* MYVT@59F++G`E*[C$U\ZA8<@O3_7"HD:"`5I6+MR7O6+F14#S5]"_S&6W`OY% M9^%KW?[MK?HII5Y.V=;)!'5*<3#5`$K.R(Q4Q*G=3V7WLN+FE]6"8GU9IYM7 MJS06))D*E'/TE+7FW.MS]YCW(THUKTO=R(IF?H5.ENY6G*336RD\O97"%Q0I7+TS!WXV2$XW M9\2BTQY7G56OPE=UGLI`9NKB_`Z*77JKA+GZ#;>9>=O/;J80,!A+E3?]Q&IT M0JP_$3EPF2XF2G.G]F_$BM;03OTMS7]D0GD?OZ/0ER\/L*`(3N5G_I%WC_F; M6]FC5P)P!H9G]'P53R^=6`)]ZSW=5\+]T0OIG3.T>SOH_=$$O3.D53[Y.*X) MW]WZ8#+TV@N]?D171"HPO49QQ#0HVJ:QHA/AKOCY$',RQ9KK3]5P#R"H09N5 MV=#C`B@/3-Q3V9RFX4>FK`8Q*7$;=!'JP$8<0&,7B#P.E;Y"FXMV$&8GKI-- M7"<[/?:HZCB>:.7R?@KH'F(OE<\[$;CU97%.-(BJN"GJ43=7R@4;?M[ND;6+ MC#.#18DU],R7&(&)APBIBY',Q&>8U`7II(!('1_JD(L+C7[W$AU2TPQS86F) M*E&13FRJ8R>KQ-)T*Y&U?FZ<;C;IY`O;#;K`MRF1;OI16P'Q.5SLM!?+,5^1 M<.2?4T]*>^+GD?+S*TGUDKR;/O1Z"RAKY+P96PL\)KB\XE/)@^">7SDG2R="Q'(RS;=*T,"L%C_<6X_5]XYFQEF2G=', M"5()9^E8MIR;IW:L41A*_+E7%IW-D=_T1DV8V!.1.%!M<.ZP8,L8G.&`S\QX MD6`B+_!+>WJ94#VM/'S#X!T2]U^M"JOHB8JRRY?$*&;079'+7GKK+_WMGX31 MFW.,WF39A-$GB)93IGA,+)(L!C=L?:)LA1]Z#^:+3U=ZI([$M\A+#5?NI>!7 M']>9>:-(=@#A-:_<4Y"^UGG3O]'/HGAJ'.&44HX-7%VC'W^^^D3&D")?CI1( MSCHF6/&K_4B>0WS4$V4,-F?M*'-L.75LF="6$NH'W>+:(S#FYVH6@'XC.8G: M<^Y$/-0])3UF`UF@1D$!$[4%\\`'UHE(IH@CWATL4$F*BISH,9,^Q]'?T/25 M6T+M;[@CJ9>WJEA/YM-EF+\N1*$6`F)$=N%A88[2=IVE1Z;S%>\H&0.LVQ))^B'3,BKP_..N5#T*WUU[,A;#!;]Q'\X8G,P3F=^H9"40 M*0NB510QJU2:C_H]CEUQS\LY^1Q3(QR/YMPIX$D1Y$CCU6A$K5LJ9G2/YOV49@`ZE%Z M8:"W&N+=$:3)65"GJ`8*LKMV[!;/EA6'V'^T7=66..N%TS MV,:7!E M("]086=E(`TO4&%R96YT(#,V-R`P(%(@#2]297-O=7)C97,@,30Y(#`@4B`- M+T-O;G1E;G1S(#$U,"`P(%(@#2]4:'5M8B`S,C8@,"!2(`TO365D:6%";W@@ M6R`P(#`@-C$R(#"!;(#`@,"`V,3(@-SDR(%T@#2]2 M;W1A=&4@,"`-/CX@#65N9&]B:@TQ-#D@,"!O8FH-/#P@#2]0Z#2M7-*KUK3^4J[V5]LFR-4LCKP]X-W+3!+EK MEJ[3\KA`/#7+R-\W_5Z4A7?XZL4'++_'?QRAW73'>M?$+LO3U=^;@'/[1LNK M?5W78Z.N1]^(MUB0><%U_X#W)#\W%MLAU>I6Z-QH)7-N1:.--$K1IQ)LRHTP M_$6V\+BF-W&U[\55E46;JE[W5>_R];4L^$$T_UK]3/[0HT-'C[W>QPORHF8U#8;L=2="3ZQ7]AYM+WNV:W%QSO` MZ`DU&`V<'NOVU&&S$[Y3P=K!JO>-".&QXWKS.&Z)*N43BVB'& M_D$^/VQVCE:;WDBM9&?-L*+"6&KY87MRIQC[=^M*(`-!;"- ML0M.!&4E9':DAA@#1YVAHD^!LMOK=!,^*-HPXYH?_)!]CD>N$1-08K:P!-:! M!HGBVWO;-MI+JR@I*PZ8((EV]'W&T397"<@B>D(VQV3S3#8_DLU5LGEI3&@9 M$R]#I95_I)9X#TX1S6)-:(&+_=($%`JI6TXQ2-/<'YBJG?1=T"^G-'_$ MUQ9\I\+.,BX0XTBJ1B=4F:>-@JC>/]<_#N6 M\ZU!!,J^*(&B#!&6VB9\'17Q*1$EAR"(KM4E"+0ZHPOV3S')-KY".EM(9ROI M])1TA7*Z4"X5RKU`.,V$,T?"F3GAD!_T2#C7!EL&,\HMOR3#Z8,B[0)$*8/G M>.>BI<=?(QYZZ%FB*V8'F)WQ6ZQVW&YT7A8WB/[;S#'47^/S\WW?DE]R]/(M M[RL>&RWW\\3N:V+7U&=8ZC-*$F,JGV0S\J#U3EZ8`H`_#X#/QZX"IC(`XUSJ MW&SJ+#:(<-Q.YD6`:*(I<87:;XP]O:TIDM[88.[(=\@%(5)RU_J`[@N>HYN^BS:/8/;$"./-Q4&Q[ M,U=Y$%M.?-M?T\V64@4Y7M@RJ\NCI2L$5IGRJ3@9J),E/]0E]0+H#2/-+UKQ MO2<"2LI5:_%[LU'>[KX;#9JLQ7.:>2'^^7 M;O1:[;7>(:]=DW91XAK8P`.H,[CA(<&X4BT"0=IQB4Z"Z[?OS2[TD8$`S<(:DC=CI9?8+= M")L_@8T">$/>T.#Q4I5Z;:D7)@C)CKKH>#JN:`XE^&A)"2<]-84-$55!,JR8 MUY,(/1H7@PI3-#F)'?L>6G(.3_@DW)UB`YF;=EW.1 M,5*T,^/IH$_R>\,!TU_M&\^5D7J%3\U@ES=:SSRDT\C@.&<'-=EK*J)PUZ^$ M&O4=?(%$K&[1P5-:&/R8?7K9CX/1(WDB)X0EMU*/XJ>G_;[?'N[)1P$&A#'\ MD'507$_PF_#P)?]JROO5(93#AIC(B%/7&>/]S)U,F!H5)QQ]U;466,Y=J^(8 M:6D6NVZ(W3C$;I1U`L2CT36/[0A?M+D#`L'%_!Q6/\'AB!^AYT<5B>LV/0N1 M_P&X)55S,F59]:AF^C`RV%0*7W21Z!*E%\34)?_"?^,@DG;B]MC"IY*N!C1A M@DXB&6!'0)\O:H.-D_D5FAH2DZPIC MT>?7HU45%2:BM--%EHG/904QK_0I4U6V!H5'H&,##)/"K+VC(E]GW73*4#T: MI@*/3V?)(%-G8^Y.RCWB2FS$P@9PX]P:YU'^STVB7YA7,46:HQNF$^<-UM&S MNGH66%).B=)-/&N&03WQK$'IP;5/EYE<'H'X;&7KRV]]7EON\Z3M\W$V]E5O=IRDDE5[M';5N6)XZ@;SGAONRXP;'L7P?`*'>=GP M4)4Y@O9?#<^=FAMN8T6V&N["J/S,\'`*LIT:#L]3BT4ID=+KD!+=D16U$402 MH7SB).6Z;8L4*I\JQ$?Q\N'X^S) M,[:S'7U1;!288FN*Z(U,H=V.(+/S6F&$KJ!LL!6!:MYL[8NQ&#&NI6& MFJN'T/FS[6K)H1`&@7O/\18N?(F61VN/X?TO([_!2-[&!`;:*2$.?&Q89^&K MDSZO@\/A#24&P3@"^65*DV^G3/C*E=9KRA]16QS<:1;/.*73YO14*R+(Q-_E M=0^LH7WGG/XK4'F0EGX&/];X5HGQ7CPG[<^;4'(9+AY^A-/IR,BB52%'C9NN MEZY',L;[>NEJ$A@4`R@R97!E("]086=E(`TO4&%R M96YT(#,V-R`P(%(@#2]297-O=7)C97,@,34R(#`@4B`-+T-O;G1E;G1S(#$U M,R`P(%(@#2]4:'5M8B`S,C@@,"!2(`TO365D:6%";W@@6R`P(#`@-C$R(#"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@ M#65N9&]B:@TQ-3(@,"!O8FH-/#P@#2]0^ZX?VY*>A;=30JKMWV[LWVVVIC-H>[JJXRE6"__S@DC(V^"GC MLE3;TUVB'N[>_/F#4P_C71(G2:ZV#1:W3W=IB/ZU_>G.VM@EQL+W8#0I5JM.S,J.7(]M`UUP M5:O'NIN]0CJ.\JG?JZG'>SU&FPIFYL&K!KYX;$CQ_0SCJ1Z12OH.^;/ROUW\ MHCBRL85K[-!F\6AC8ILY6HC![6A3QEG0(*EE M4;QG6OG3I0OV^F?OQUB10;B!1:NW:_DS?H6CN)N@V)5M-(#N- M]Y+WA!.>&K-67[4DG-8HX4_'*-=/!4#_L1"542284T.SX,,D=I M,[?]8%=S23`WCNVAA8LUS@FIC7)8.\'K"VK$H;2Q`$OG2S]0I)>><@S5P.M5[/RC_)0)JZ+D-F7Y6-:5P M3P%V?!SC),[^9^\/?ACPTHCNTR6X"GGJ35FEM_^J8.7V*)>#7\0VU+D.)F6A M(UOMOB9KN[IC+QJO1M[L)YST+WPP9\X*4O=ZV5U384M)Q67H#_UPJL4CZ):' ML:72I=8ZAI5]P$!*A$5T]1*#@WN`P]`4U/(%U1A)'X)0.P#40F97:",U`FUL M!_A&$I8!*U]`CL12''Z&7O3G$2(9P2O7=]O+U[/`,VLY^PDM(U`*I#CYVT0( MX'%QEVN9!_C_I#O*-"'>IXA.F2SNE?P2TN)GX@YDC*+5IA<(.D7D4Y!15T4D M6_`I.@V=%]33>.2=U-A/(C5W^Y!G^2*P\^C5SGLQHP9_$=F!RA5N2,4=9+'K M@AM/X_<2+$:G265V.KB4YX![I+2B@2GAI]QVF]LV_R<*O2*(X((?E3\3XKSW MC3_MO"RJ"&XZ<[\:R<7(QJ)[3,5#)76N6*>*66=L&D#N+V>J=ZH4]/),Q\F/ MYSV293,:*Y^T_ZWQETF%\59JSIK`,^5M7X>7J?X4O8P7>`9/W!5@>*[A>.PR M;RW<0K[0%/281!M7`3Y,556LZT];8A.6V(1+D3250R5"LYC?QUH)F: M$3R$WBWURP9(H9D:X),629EW!"@,Q9A/^">9$BLN6#&Y6[`8&=[0(`)`Z@GT M;#=/_+P3_,?(H9J@%F;\!3LIX"+505*M3.M:;*'7T#C`QU-4D(?GJ*+:&B,: M,E-$DYD^(X(*P$QDZDC&*E[ML&`(F46<0C;(E/Z.XC4$"HB68,BZ>Q6=Y:EC?Y?2ZB><%A.`RSHC"*4F$YB"NGA`YP2FPLBXH*8I&@ M,%,2^\BZBSPAO^&P[=854,*W*NC]B#I^HY'!NC*A8;(OG%"R7?.JY5KP/= M_8;:/%W5?F7[A=[RNA\=D59+$<21+=-<%_3C="K]8?(X*\KTMD$H^B2UL@L9 M,0[V])6M9U7B7C94PD;T^[:;,0L`&_#E_PXU7M[/F`P4*,H3BH@P@F\W=/?) MZ6+1"X'*]>>CW-OZCF!"T:V!+@7S*)%BF,Y#<^1M8=@2;14]^QL$AB_9FO"K M,]7U>J2;9O`@=F>B?!L>FY/<+D+4A$YZX@5BYP@8_-#[DZS0,)=D_`[U;ZZ* M2_!GCOK1#U.["Y$N6X$L7[#%JE:!89?4]6D&YF`5P#&F*0V*S`#R#W5^!2@* M["VQI219`(64^(6J"JK_]MJ._,4.RDRZLNQPA1P61DQT&]F*DH5IA\;'U*NL M-)!9R7KF;N)><+T07'996H4NYSU'2)EMZV'QM MY^/-`+`T`%#M1/3765&R#V`U>++VODB#9+AP``)R5Q&_,EF>7;MB34::?MU[ MU=I[U>]Z+[OI/*;\,!7P<[D^55EV>WU:S!@;%S;4C[5\Z_AOT+:3-\_^R"YP?"62(Q5$&A3,$0U:(OD< MZ6&F'UED_DNO$G@P.(MYNK#>!OOKUTX`VE%LLB5>00?)I@,*V4ZOV0YUN\4- MD[75NYXS]B@7/+4GSPMV`5A[>0%P?G;K3"^ M(9(JEFZOG^F*/G661T` MXXGAEBZU)[\\1E1J,Q7E/+9,<0Q<?.! M@-HN[\>^\R-")"4="RV5'K`L":1DMWZCOW@S([+XL-4[NQ>)+-8C*S,R,O*J M496IPE%M.+G25-F,X=CAL4][0Z/V9@MC*;$,%")%"L2RY.MEI0SEFD!@>O:+ ME/GINO$^S.VIJO&<`DIKR&%&J6M%G*!`^.F+6W.L$08'@2)OH4K/S@VVC(M+[ ML(>="B&#OC'G$<`]331.YYT&,;>Q`_G+P)U'@/U,?#A34@JC&UMC;TQ+MVZ0 M0(O(U+`;;JD:$Z]"5%.ECYULF4<_W-77HH5MXU7P`$[U*\7-'$%1_,J4F5Y; M%:9[XZL2QGZ'!?/HJJ[5T49AADPEE"],52E#^RML7UB6;VB.PB$#K'3U4B]4 M1"^6_*-C18-]H9N?_G8;H$,0I#&#+LL0X>H&BA)`I\-)FB0?P)0:/"K)PC\( M`:*"2S:"[`X$530$O>7QC8R)@7P4A`X\[RQ*^,)=-MH-;/MTD:P2F5_KB=ZM M34J`1)EWWIVDT/^U&NF=``-MN>7R+WA@T?MY$5"L>YU$69TG2GX[14MJPPJ1(^7K'.&T-RLNV[PPSNQ7"[ M;`*"3H9AU9\@F=S:7,^YG.=]=M]M=RI'[ MI(J51>1;X_G`_=0KFD?TBUKYYGD?7N<>UW!!Z*8)E2Y55UZ4GV1\USH]_!,; M/#Y\=;_[B2J;`SLGOKBG+1\:_-;269TX<#GOEN@;"M@X$PQ.<:O'P_+>_>M\ M7+ZXOY_0M'[?RTW'&ORC'ISW.B5-.SU((`<9?;*DHO3ZJ68&(>N&>O:Y)417 M(,3=4!HW5\%Z#+.%:A]^GY31TV/LZM5'D#-MM.STQ81SEE"E+Y1_81DD"Y-# M*#,;9\?)A+&]6L%2'IA]L+L[RLSM2]OH%B&_<)0)T2&1O-YH"IIA-S"J,9I, M'P1\TIT=&HU`9S+W+Y6^[<5>N1G%=F:;NN&R)2_A3BQS>[C,%@O'/]@&7Z'P/4#) M/G(N?22$0.@DX1NEG9M:_E-IHBTG*$P>LF-WU_N%R3DW[[Q#V>\,9KC/EHC0 M`.B\$_N7DIU-\*$KBWB>E8YSN*0.2S['K`PQ6X28:::^'FF0[?)?8O0G2\C" M7(GFJ035=W[E:H^AE>.-;'O)J_F?$\>[7%]"1V6FRCO(RS4A\R MQWU.N"NWT34XP04^4L-_1K[TQVXE&?V.^6T"!9+QNQ-': MK)8P\[@E:K/WJ]:L6DL1=7>S%*;&TEK(7X)(*\-FN(F0=O?I_V"#H)]RZJ?% M!_VD2-%_X]LB0I94B&&E]U]S-OR?LQ2:6%+E$J)0(H^JJ.$D[DUOH/N)75E! M*5=15N9":E8IQ];E`-50W.6=N/M@EH4E[V8A+@N3QVKF=(&\P27KC2I:*D.O MC[5=PT)2(B0E0L(S.0H&2S4T18R&3W0??F/8\3G9_]W+_"PIK#=(Y]G_(IE9 M6%F$Z]"R]I,R;#3U7@\W&PBOT(U8,.KLJG4)W/"Y]X`@,Z,/]/"H-U" M31XOYU8=I"E=DY0.*VUIA,NF:N+F7K?_*QV,(V9YX.A%SC.^44^^LO5$+5>E M-=6V]JB\-Q.IA4'O1=YJFYF%#TNUXH7/[CLWNE#M-TLV75A9F=]M;_2BIG?>9GM/W1TEN2KX@'S6.OG>%]`M*Z#E7"`^';*5B/W%B-=M%] MW3?;9#\`LVY"=_3R6$OY3+RQ4%?D1A:"Y*5Q#R'6=N59%E0*&9"K4"L:&;F MU)**!M&2HAGE^@L(B9Q*\G)`&JPD\\Y;JK,P6XK37+N#FI,EF?\838:@;U56 M"ONJKIQ1_^BX2<1,ZEN6Y"[I@)UT9L]*,_MB;=ISJVFCQ'`X[^QIOT>\))*N M&W''M=N=6Z>TGP,\FG*G,/-X-;7F?>M>;=558+<5=IVJ]KMLMNX4/C2VRU$V MALW38/2XGB5=1F:6D>\[]9C&2021..#(QG2/E]7NP&\;>15GQJK9E]NZM8ZF MW3*IA#@U$84,6[W7>8N;%W]V;_7^XD6/!I^:>6,,WZ"*85H_HSI:RWHP;52@J@Z&=`Y=886(.>M# MDHXSS->6YP,":;R?#C(.];H(U9K5SD[D&B'QU#YS%>EA98G`$A.,FVKGY9MA MB57]CGP*O$AY*WP19<8624\R.@S50CYQ66E/%;1+&77U,D[F^*_B?C6GI"0U M6YCEU4CS)D4';9.\@LZ&@%P&,+Z:S#X(D4D6J9/2(0[?/7J40B7!3IA&)-#E M`*8PQ&Z!90]"B94ZM9?;O?G]]9[6?'OZ[1^__6<`;1OMG@IE;F1S=')E86T- M96YD;V)J#3$U-"`P(&]B:@T\/"`-+U1Y<&4@+U!A9V4@#2]087)E;G0@,S8W M(#`@4B`-+U)E"!;(#`@,"`V,3(@-SDR(%T@#2]# M'1'4W1A=&4@/#P@ M+T=3,B`S.#(@,"!2("]'4S,@,S@S(#`@4B`^/B`-/CX@#65N9&]B:@TQ-38@ M,"!O8FH-/#P@+TQE;F=T:"`T-C4Q("]&:6QT97(@+T9L871E1&5C;V1E(#X^ M(`US=')E86T-"DB)I%=)<^O&$;[K5\S!AT$5B8?9L.1F/R4NYQ!7Y;%RL7.@ MJ*$$%T@P`+3YU_OK[@%(191S2*E$S-+3W=/]]3+_N?GRS]AMI_8Y?NV[?F@/ M<1K:G1I:=?/#YN;+9E,KHS;[FR9O2E7@CP>NJ'.#3YW7M=H<;@KU&?5^YH%-5>3@\J6QN7 M.[V/?`?K\R88`R,GS8M*;%(4UHGB]W'8=FK:OJHAGOIA:H\/ZO0TG(B1[L-R>=!J>SH-LO(*B:5N#]FZA)SM%+LW]9TQ19X9 M`TJC#FS1MNO:7FB.?&Z5K>F@>GFDU:#;W2/6P9JNA)O$UU,[1+4C*4XS^UH+ MKR@<=FVVKL!"9@^9)W87:^`%OS:`CX?"0G6O]L)P4.,$91<+RR+NXC5LG3BR M@FRY@DWFS6PRXV>3(3K89.0<\0O[Y`AU@"&,P7=2XB(H5V,J>_"13'O6?*1) MP,>1XLD!_]/V:U*XE:,'\'&S!VH82AT6J\\669%"X;W5>:`N[>WUX1`9LB&= MVXFWDB19>U#OIAQ$%08V5Y=&.^,L90M"G!>C;1ZC^MH?B$VE3X@<8G1\4VG4 M999-`B!7;"8X\C'MP9.1@B11PHEC3)-A]SAS(%,3[7U\CEU_.A`Z@*WCI'9# MO&_Q84*K8>[^.0ZP]5ZEI1/=V6@..7P',C^"[;4])`*$G(X=:6OWF-J`95?TI<1\[QD%:4BCNN2?&!((4H[["ZLL<0E`/4'25'GO'=.@60I1?3"-*52H9=4R'F' M(U/DU+.83JA&'*G3KV":M^>TR&SIDH1R(4*5X5,6]-UO M7!KB+FDF'^&M=G&0^5:N?(E(NY2,PBV0K,3F77MHDZ$G6-!0/B^7"?FP!M/C MJ)Y(>RY:#O(`Q0601"ZYNTNSEWR1CY+57.01N^21>@X)R1P4B1ZP/YQ20NR/ MY`9/PB&QAD*>LT6I4Q78`^7[.,!N\/(N@>W`%,ASH$ZP1255+Q&6W(Z4#4E( MEU#YPD*OD7]1>T+SAG:4G3@ITC=ADG=P'H^ M"0][:Y9VHPB+AX-H;$PB'XA**_ M;J@'LM0#N0H)V*M0(0:\(F,4"&DDHYO]C:\HO*_OH>5ZWVA1HQ0"5*L2T<^CF-A.=K6U#&%QU616-F<]G"U_H[#'PH M2S16=6W/$>@+W'B!RU(5?"JE/P\/N%6MC^WO].'Q1,FXYOCCV#SR:D=1(@OC M-"J2ZVKO_MMIZ\JY2HL"ZQFU[V%B%Y@4RL#4IWY$(BO@-T8)XF[DKQU)>XN/)<` M-*-F=X82,?Y'G-AW#/.2:U4MM2I(2>0N=$T=^0,_#%3':T(^CAPR2[UJJ%[1 MQL!0R6V-+LD'."N'3!]K+](0>^ MZV5`8[PO=:APR>LV)\SX>F4=;W\2LMZ5.:YX-62O[GV:03R0Z?_/!`+[Y9\I ME[>(/0(2:;#_`F%R2X%"F!?M]QVX7.'?Y^Y)K3/SUP"9,9T,[/69E% M]95?@@'USB(N4"1H^4TJ8=SR:XN>GT)-_933%#'$GB/&Z=?MG0B-JN6O$.\2 MX_>KRC1-H^Z?8N)!J;'4ZJPOO6)$W\2^/?*J$LHTX<<+Y<0PDR45,JJ3B78O MZB[,UYXKWH^IQA1)J1I*8,MKT5>TW0ES]36^LX"PBL,J74KFZH4S0](DG;Q\ M.[HSR'-^/I*KMM(:WY&607>P2*^>)G2)O\M&5.GQ!C&J/_$KD67"(FMJ+1[H M_05)73^.*-6RBX*][X=T[B4CA>8=4J_2>#]!4.Q:.HVG8OH>,Y,>KBPCJO'I M;IS2-`F8]Z-*^/RR;?X#3T>T%&.U/>D<*6G)4<4O*+B%\9B4G/1CJ. M*V%R2$1X>W#R\[ES4+@XWZ-:[I%B^"&2%HT^I.]Q4G>$!`J*KDV+S^D[4D## M=14NZN#`M*Q$XP;U[&YF(S9/,[Y9PV9!CS&J1#[B+M0#IVUUF\AWLTXS-T83 MM6)RSLAGE:1+AS1?]B(&KC].+7425&I2DVK13QI=%.I>6B;WYC-@?G*[J'E):.[E()*>GIZJE?+C9X0: M'GPNAKE]VW6M?H=8BLA0A:G4)/L"E2\(C/!>]5M/$*_=<[$?=\RB(AS`1.\U M'5K[%]U7$L?AU(WBF*-DC_@JE8["#N5;@"RN!1'1 M##!VMFK"O<"[+A'D">^RD$;^@<,D;^@F>Q$33G&C"JOL!QG:[.JX9'*&IBNCW3*PDF,)*&)!')M1S_R!-,8TTT'FD:99&JML$ M5:01N"[]$!('7*%NQ/J0)IHDU!J@RS1',D5#I#*R)', M[>ETC>.DQ?3RF?3DBR11H,XGH#;8"EX"5LI%B9DIDCV5O\/>D#DA,J.?H[NS M2PBK^1M!96_&WTC817*A5_6&O^+$OAGG5B-RK>WO)2_L\1"C91D%@)#W;!9I M]&A:#I(KMF2VPN>\I7#.0CFGW'>US`JY?L#I:[WO:K/)]+YR7)S(./-S.[;W M,5V-NEW3>:;M^ES;=3)I2Z]GKFI%]G9'F@8^$".)]D?2SX+T\UI95:&L*B.K MRJPQ*Q>SA;V\9*1S!?`5ZZ4)E\0JU5F;;C`V@G9N;'(-N>/)']4(S]0F25Y- M6JN.XJ8W:*]4EZK2W7J&,W$U\$'E3RIGYU<,7F[;]G8)8\Y2=[-]HNZG$\S) M[%6-0J;FE]=0U<&I7T6Z53$AG<7TM^7MTMU8CT&R#*-OJQ$Q`6J>_(B\3I#` M^L4K2CQ@(!]TO8*,I9Y1T,R%J_VS?$]?/("NH:ZY?;=3UI[YN_(-0CL:;1[9&CY4` M2ST`+7-E;GGT^,_@6GN6"K3%3I+WCOU:AJ"V$NB0]AS$[MVL`DA4AW>WMP?_ M7A`FO+P72]I>C6#0"=A/;$EIB@5Y<,-H$]*A>K]P-TOW0]=4._>-LO?_P-)D MPM+,L/3E80EH*N#2C"/AKK$G6,?9S_[O+2QM3-)^[^HP9.#=V[9JI%,D>N;= MH"7&1]OBAD,7CAFH%E&$@$E['0A,9A*N&^B='JU_MZI<8/`]\X%VX?]N'-OW>OVD;^%^YU7RW=N^B3ZKI]]?JS/KV+EU,ERB4V](7B0YJPP7$Q1-P#BG'TK4X$KD,RU3<;4(:0:*:C)# M*2$#?JHP52-'L(5K/E;=J6YYW94@YA?HK14[S0CI)A2#V!A)0<`"*:4?]+^+ M$P(#AI\4Y&^!%PF*1((\3Y*IZW'&!=R-]P! ME%'=O1UJHCAG'#[CY5T,(7>V$.RK#B=KD_@ZP%>%I!N5'A2QF*X;+=4)IZH) MO,AYW2U2*HM>Q1CI7KN=4(/K/4C MSUY%^C8(4MR*0;"D-\,_HXC`1E3YM-%.P!;RA'D?4'=LK>94 MAI^>%ZNK12Q84T3R,=Z@@07J7)WS6?VF7+-FD\7H=T%^.5487=T:DQ:04!Y\ M3F;/MVVWJOF?)W2XU\_-!6,W2JX2[F+-!LJSOZQNRL=;F2ZLC_ MBTIF4R@3C62I$T#M[DKO6R:H?C$[/S&<85"`D9O(MWO>H#3OQU5!VJ2:M9DIN4H#>0Z7$0/ M-#:EI)H,8&L34EV>W\0,N%,0M;TJ8$=,ER)+5GG5J!KT5^_6SIX3-"!;(#`@,"`V,3(@-SDR(%T@#2]#'1'4W1A=&4@/#P@+T=3,B`S M.#(@,"!2("]'4S,@,S@S(#`@4B`^/B`-/CX@#65N9&]B:@TQ-3D@,"!O8FH- M/#P@+TQE;F=T:"`R.#8Y("]&:6QT97(@+T9L871E1&5C;V1E(#X^(`US=')E M86T-"DB)?%?;CMM&$GV?K^BWD(L1+5[$2]YB._#:6">+C(`%-MX'BFI)="A2 M)JD9S&\D^\%[JDZ3DL9>P_"(;-:MJZM.G?YR]^HWVY1C_6C?=$W7UT<[]G5E M^MKZN"(K4+/%/'^)E'H3XR8,\-^OCW=+L[UZ]>XC-?KA; M!LME:M85%M=/=]XJ\M>?[Q91'&3A,C[3^(DR"V&M'LSOWXV%Z[TT]F.&\^6RKT8Q87`:AU_E)D'H& M4N8-EF+(<0F:?ZK,RAO\I?3I+TCK5+8(D3XLKU6E+(4VT!EJ15PYF5];]O2FW]HN?23REOX@1 MS&A-V6Z-&EO$JP#.4[,(@V@53S;C0HPN-&4%S?:V'/Q5D&-S65!XK9][Y:;Q M4\_"A;QMD9%5$+GOQLH:5WH$%'K/?HIL&7[>^4O/Q2ERFAE^.?DQQ/H:EDNJ M6_/9S_'E[*^\[?X(,[EG_="[.*"E*\M;46>XE.?[(H4PEY&+R)/PC7S2&$;Y MGGL'/"-#%4W+UXXA&EZVUQ%N;W5F;,T96(QQ4$A39T[A:6F/PG#*?_R MY`[5I?]]B]W#XX_F=6.K`PH,.7ZPU;FOQ]H.YA\UBT6\1SCLO;\H\()M)JAM MU$ZKGGY>2^-$TCA99-(B#)+$A,E2V@O'G<+#W4Y:\;8!HS`2B;2(@BR5#KSN MOB2:BR5T;75OBL2\P691;H^!R5+8\'%$G[S?_`)K_WKXY-^;G1^&>.E]^2L) M2W!:&?K'/!WPN_)HH)*MI!Z7M,@R]X*.Z]!ENF).O7VL:>4\0#'V&BFYC"67 M.#=;V]OM5T;H]J29*UNGQ@9!XR\SM.>+!LDN#9)QSZ@Y*2PIKU2K#GW+%_ZU MP``IH)*OJ)^MW:$V,EDM^8NXO,"8]4'?4(6T(QO(4/_`JY[D*E MCB=GZQEN"M<:E)&:=PT`_Q7E6['4,_;-65ZF0-4ZA1!LHQ+\MI>RIS$N&TNC M54_Y)VTZ-$3U_T*GQ&U$&BIE.JG;F*(W+?(=A#KJL:G)4)LLU'`+[J[PRD9_ M9KART>5>OZ5`JSV[5YQJI%\GT+I7,X;?J6-HS%FFSTU]O<@('.II)632P)-/ M?R'#8XMBY`*-$X0*!T*1@/H&<8?9Q0L%*U2SB`RNDO%LZ3&8$Q8%27')V#?: M]%>="RT;ZV/IZCXL[O&_\'5RX?EELUPUZDE:,_%*FG#Z.[9MHW\MN\ZP(\_` MK:FM7=O6[;?Z^F-)!?[%SL.70.!ZW%)/TS:)FX?SR?;T6T&CG*O M35:Z2&C#??OH((@^2\M-L5+_C:F$=J7I=WC)W,X:)L=EY?ZZ@%=1,6/\S$7" MQ)&1`YS&7O`V,)^\O][V`:RN-%]"*E"1XN*HAPS;(OI?@=&1:J0?`&CL3P:, M`L%"3N3Y!Q4`(>AZ)T(KMC=OJ%S;G7FH:JL$!J"@BV.]DX2%"$!)"_(2%U>D MY>LI59E?=[NZLJ`=@[5_U"R/5NG0WM!ZXGW1.CG/$PL\PLHPE2`0HMF`:U0' MH4$'\"W"\.3\Y:!TJ;/'4Z,\#KM%M@#`=):J@3`5)@K0E6!67!)5 MS(D*)S8UV+)'6:5"5H`*8Z>@T1O^[H2>F"-ADTL8^X!1_);(4.W6_(3!A-[^ MV8`ROJZG5VP!!]S"P;UY+S]5,*72A7<[T9++1`O=1$,1OJX5ISNM[KV?H9\7 M2T5R<'$I/TZK7+'HX:S#P/7>I-4K4K'W(K=&07X9'0G3V;E8"1/7?J2,T"HC M(E:%CXI8PA&+&_-E_^P33(0I?J8N7RH_4H"0PUNLYA"X@XDY7JT(#MZB8.X5 M*$\?Y92[V,1:7S)HJM67O!2:*/-6)Q_#0R=3N.$&2N=KU],U5WD^Z[\A]6?' M)91%.#<+*3TU[=0U3AK8Z5S6Z>%-QT%:,V5KTOF!1F7\7S9-=3K:XAGGW#)C M;DHOR5C%Q_6N=\+LYY3V;G.J>9-3=R[FX'*5SIN;AGY.4H^_3YROUH&#VP.= M=[)EKDS?J2HN48J_.M:MJ3(?KLN`QL%D<:SN4(OBGH?Z\JS\PL5(K[=G]DTZ MLLSFBZ6[R>WJ!K5;=>=VM'W5E#5GS]%/%(K+_;32#B.3H#=(!;&4X"VS\EF` M5*^?*^\/Q(?,.K#:&R?B0`?(FD3Y]]!9T3\F"3;E4PG>T^[-MCR6>RO#0>U@ M/,11E%[9F;<6ZM:\:X"NNG;L<>_AC7+]62^467J#+B1I\60E=@G:E()4X)Z] M1*&;=_OL?)D22`$%6L%HR02ZYEM%\ICE#-C5&AHP:L2;%B`-$>:!7ILF"#RL= M.<)`%UIFPY36519>S83E?#R1.Q[SY":BT#]I6:,4@*&#D1[+5DM\(16>3/>3 M.(.)U8MR3"Y83ML":DK4H_1>;V(";05JOL#(4*K3:9'O";HM6?^.GQK]:Q47 M!(Z/RFNH,.I-M";]ZF8^F?%R@K"Y9FBIG6A]HATI!OM'Y\WR9K2ZOAEE[F:4 M.979S+6'PZ1>3<%<]N,DM6B>E'8<&`*%*NVH@Z'B9,C1QXL5`098X653X[BF M=/%W[B1[M=*K&]T),\:+5.J1_*\\?C$_Z3TI<:=P5MHD.4F(A6Q2QK>6YX?SEIOG9RI> MY\U\[/C`C73\YJ*[@69MAM]UNNA,--]'QD$B(!^=87H&0 M#!E?3'^^D33G4ZE&(BN:P\_RD3#\=6T4Y)][+12"\A*[V$ MZ&)+T5$K0,\YUB)*R"0N85.[5.!,72B7D%\H^KFR"=5VBI2<(OOV1>5KI)JF MFKLM-*40*Y@^#J[3ZJ9Q@[WCK>5)X)B/HB5MANDX=F;L:Z?=((6_W"Q@-/%I M!+$.!2P.;F'08\1H')5_6H.S47X^UL5VY['JIJM3K"0=RU;28CG+A.O_U&@6F"DCE!*1,$)#^H>\`305Q'AI2#.E3SL8XJ953\ M-L`UX(\Y0\\#!I'E8]TZ\8WP,`P".YG&7%U3Z%;XW[KG3\8:4.<%-W3ACX[.!:=QF MH&D%VQ:D8\G+XIHA,TQG>?D'_ACWA/??O%5>Y)Z^[\JJQB'01@&[KR$#@RF+6HJ$$A42]0&=*E4J M`_]7X[,3Q!C'L2_VV3KA63^J6[(3LV68]?DQJYXP35E&KI@4%$Z?)XV*),Y.^2^71MAII:P-( MZ*TA052$I$!QOXU_PUMM7;^?-V1@R\/"HZ(\N87J6?T!WV,V-0IE;F1S=')E M86T-96YD;V)J#3$V,"`P(&]B:@T\/"`-+U1Y<&4@+U!A9V4@#2]087)E;G0@ M,S8W(#`@4B`-+U)E"!;(#`@,"`V,3(@-SDR(%T@ M#2]#.)ZFRA/KTZ7.^ M_L[MK\&[![,IFO)HQM6FLN76-+:<"UN*P?5L\&XVRX02L^4@]_-$!/"?7L(@ M\Q4\,C_+Q&P[",1J\.[#8RA6]2#P@R`1LSE\G'T?R#CT9G^@HH05C92?!#H2 M"6K(4C&;#$:X)=2T!S=KW/A-WGNCU`_EE3?*_$@^S,3-C3=22MX([[^SV\%( M:U\%621&VH^TRE`3;M=AJRA(6=&-E\B9E_B9G'X2*OA%@,9(3O#SPW0,.@.W M_.7A45Q]QO.TG(CIOWD/2_S&(KCIJS<*P:*I^/(>9.5[+Z+/XREL_\*[\9N8 M?>0?4_$P_8`2CZSC`5Q2,6CXS+_9GS/6`;D4Q9U+*FI=`M#)I=G:B_U$&K$H MK9DWE:V'HEHNRSFIROPP"'.XK'9_C/N_26-K4>Q@9RH7`(+2\D]S$F:[WS#& MUG9KW3PU3/[L\]*4(!5S"/`=H%%Q7 M$JBG%NBDBY*8,?Y8V".PX=87U\:NC!V*3_Z$+M;W1CD:Y[_R#^Y8@PB2)X^5 MG\M8X7NH(W@?K\$YX$EIM\0((`S^1@$41=<3Y)I"#DG(:0CSM&.O[E0$3L4C.9W+!;NY MK,A+\`TQSA#C``@N'K<4GB6@,%()*'\5]3[XRH&O91PQ]+'\"JX*0C]OT4^E M,Z2-W0!X4S,J`<(1!?D9CO@IV^Z* M@RV-N/+%U69#B`[%M/[+R]!C+T`\M,Y_XCSX'79>1ZKU^I'T@7&4QL2NHVS#Q2!KB\%XS2H@=NZ+IA,:4YAJI_2PP^C3LC:;'@!][K=E][TM MF_^)<5&#J(M[JGN8Y48J>]W1YUZ?;SK6S[V.P+2*LA5Y'3[Q.FZ]3ENOTQ]X M?7VH2ZR$:"%*&%95NYKXA027O?QQ071J8X*NC0E=&W-;K7>\?^*+F\.F/,SG ME(ER60[%_=I5[#C-PE[%SKH4Y-3X$X`AHW3\4ZB2+@]G,O9&$7S(^='FY`RA M*RO;1RDCC"`B)O8`&1]D5ESEQ<0CG(Z M&/MB4FQ6A65;.+B&+F+ON7%DN^CFE58O!\S3K!"]!$>&<%PH/^&]UP1X.8?$ M5[CP7@@7%V9+SM+BX[QT:N;FQ51_;BPB]O=384\$9R[Y+V":4IKGDOAB:BQ9-^; MPD(,IQ@/$79P;[HLY9H.]"4)^BD<#RF]F(["LD6TN%H<2\K=[NL0AP]X[NDO MU">7OO'GUHT'9.-A!V3%AAJL1MV:^`UG%WS20M!DF<'<J/[?;>C0"8AN:W"E]Q^B61/D@QU M$)^@7IA#TT;SFK(R9A2NDQ&<)'GD3KDTJ1^'73$3@NH2FSR8F M+IMH9R+R^L6[?C8H@JTQ"TW(#Y/8N*:QQ)C5ZVD';JE3TYFPBK]UJB,;RT)+N#$I&A0RXIJ_%78QY'V8T:=_F_FA M*8_&]=GL*PZ*<=B%8GX.10?^%Z`)YGE*G.Q&2DGSGCY9*@G0[7,843[E(<>P M8$-54-2E2Y`I)6!%"9B[(D".UC:*Y^2IGA/S.RKNFRH M;I<$:-6.FB%675$T8@QC%0E4/%-44!AO=G/?-7>%^+VL&C-?[SB`JHT+F&IU M$E@8(II-<.MVCV4[H_J%1FGMYQ'0Y3Q@=M:Q<:>A*#'(T)X(S]X<%AQ%W;#&+6D#M%NXJ3+'3I3G2B9R:PI2.5*M/5''Y"X-Y@[D5-;4 M9/,[U904KYBHC4D1&92X91Q4/1Q:]WBTAKO"5MBP:,,]AMM0$BF._.`CRG:^ M0PV\QQ?B(_0>&Y;B%<$6$#E"MY6OB!?8%-ZR(*QBYF#K!*OFDUFE!4J@3_-B M8=AF7L782WJ^%HMVE2SM*^(#&FXR"GXZ'S$,(FRA]ON*/UT`TH+$>YP_3D.O M;K69IZ5.R#;NA%$W_LK]A$D@JYC@\UCDILFJ93;#](K57URS`*6^*IM2+F_OG/.S!I# M$O4%;._N[.S.S#EG4.LR^^@X"4,S04;.C=(P^=RB0W#'O>U<6I&-54-]7!W: MI"]SY4Z7!Q6'(INY-WNOSP?I6:9?9 M):';C(ZR"QFWY<4#^8>*_2.BZLU:9'U!<2N./$IKU;B;NL:A$EM3E-K/:,1- MK$:PXKY6BID"EZ4WESKV0<*I\)TH2&TBHBEK11:P]D1$% M;7)7K'1IS>OQJV.80P.(V6KV0688$1FRV+D-M)!J&<$$)&@-6'QZ`8;9(]$K M:6>V8YK"_!P4LY_0TZOJ'.N!WV,RI<*NW+C;DM@ MYH2`.:^V(?N9`G?VR@D+>I;#8-/'N24=-VT23IB#N3:8([:4V/\L#UJ!=,J# M)-,+>5;@'Z(6HMY7^WX7;R*R_I@?VZNC%7A9B3WUBRJ#`Z'&7_B`,B0 M2`DN`G4=M)6R.;::Y395;57@$P)[Q39GNUV94+$-G;EK%LS+4IG5%MO;)GBB M=*7NJ3NVS)TOGRDPV^(0YO-.)+6D/>UD&;>MA,'G=AAU*AQ`R[M6U/13+ M?>V;IM9+>_`;7]G(RCV2/,9$&A`-,V^'6Q(&:,(T\28QI!L3T("@?X51?_7- MO[E'>SWXC6[TN*UW).UWEH;OM/\7J/YDDIP.1_GP=V\J/(^EH]Y\6]D32A6@ M-43BR>MTK>\HG(2=Z[F(%_9+D_2D3.+L)&JM8`:NR\C>WN8J7.UMK\E?G9$[ ML)`L9B1KU%9W.5`9UKM?J4.+@/6=9:\"-)"Y)Q8.6R;$_^]&U1[JG<+`=H=0 M'/5L56@=1BVWG^__B\W;Y]6QE=83R+(3N9N$LBL[!]X.WUC"W1D-[.P?L)TW M(M]*2C9?*W%"G0FJ-\B@:*P-$(A0>Z M%M,#82"5C*%ID)4F4.A9TIM^-_!^J[7XW:"GI!X:.IK[7FN,282G(ZC-K M`Y7S:%E!6Y'-\87VH\)GP*D6];4!I&P"<59^=S_5I(4C*PX/"<&'-M"XS,-)NO MJ>[Q3QJ4Y/Y#$ADJ+9+?W4J7++3G5'LXR,0:SFN"*?\)$U*1A!Y\BYC!L=0B M6XQ<0D@O=$PG2AC%UH3]+A3G56*&H9\Y>4$<./)7@B4M9@^1BF*KD-C&!DYK MEUTH2C9CR;+W22D_\ZK0;3[&\>1TX9%=..I^V.=6D@W2(:$+F*Y)VB5IOI'Z M6_;1`+E=Y0_Z<0O%$@NMH\IJ8H0T/CH-]YKQ;(`!!2FWX=#><(]207I5C\AD M;/6^<`,5D?JM-G6B3ER%QZV:JH494B+CA9.W5:DK\4TMJ2]7W./Y*'?G*Q;H MM>WAIO_T(\A6]4]-OH(SX222+-/T5G/J_TYR?"**!;$1!8+0G`8E.&GZ"22G MIZQ/-0B!*U-P)<*J4D95G/"3TLI^UOVXH*M&`FM=JSRFUM#O\9"6U&/[KK:. MW=7?C085SD%ZE%E&7.=,"\%W9L\Z(.[/^DK8'Z9D,!6(.RG?M!>^12=6\V?" MX.!7QG*8N$/5Q($C-[99KEO/S-,5='32LZ\;RUI>TH):T,UM6],C2TYAA\II MYL?L?;V(8M?!X&O0'ERG=O)*W83J43XR=4V M07=X8]F8HY4'PV!4;T/##0!+J'M2RS?T.#-W,+RKO68C8;.UL(:*M=7U@W8/IZK(YALP=$7]( M@&C(4E(#_.KILH.JF^#S_'0@72`-+T9O;G0@/#P@+U14 M."`Q.30@,"!2("]45#$P(#$Y-B`P(%(@/CX@#2]%>'1'4W1A=&4@/#P@+T=3 M,R`S.#,@,"!2(#X^(`T^/B`-96YD;V)J#3$V-2`P(&]B:@T\/"`O3&5N9W1H M(#8Q-S@@+T9I;'1EB[/%^_5;5J:8H MVQG,(D!,]:6JNBZG3GT_>_>KZYJQ?727?=5L:: MV_59'=6%B>F??*1Q%5GZ4T5596ZW9[&Y/WOWZ28U]_NS.(KCPMRN:/'VZ2S( ML_#V=Q9D8TA:)FE4VK@R!JVZR/0X2KW9!B9C#\)7H24+G;ENAA6TF"2.$Q/2DR?]XL>ENF]IHR1/)Q_6 M1Q_6\"&+R6%63FXK2+_!'T?*LA"*Q&MS8#'RR]!;,5:S"A!UN/C>JDLX:6]=U2#ZS060D M3I;B)!GVV)($2THJ46$E(VHRAU>?Z?\D6,A)LQ[ZK81!1%,>BV@Y(?(-19=L M84GF?5B*6RSE!2Y]"U-VU0"OQ^+OS-K)X?G1X3D*0/L#7()25M*T@X.E[$B^T7TQ"_4H#[(DM-20(:4FA/GZW4# M@P=]^I35G^AOK:HA21W5>`''`.1)S0'X+;C4)-OM)89\(]>4C.3;F(]0)[\D M$=)`4FKQZ&6*_#2?'DX6YAM9(RO,<:KLIQCZQS9.X M;*I`OJ(QYN@MBZFP8"2"G'MDRG79X2;V)-R%ACN?ZI8M7T#(Q<&?%P5X+\S" MAAHB8>&P9[J+L'N3*.PU_=DJ8"SC%]I^4!9)YML#MQ>N"O(X5Z9D1],9281A M;YJ1^H3[DW9M1=EU-[2-^56*U%'<6;:E:S7%>^H3B1>MC8=ZR]B,SGSX+IET M:,>6_9+*&U.R=&%^WJVBA6G,0$*-PW$(IS91V^PH?&IK"82W.WIF1D[9CUN! M&<<+:3!2GBQK"U<9Q,:#?$8(%SK>> M/\)",H3VT?9PN-.2)9R;"O*G9A@@%'T*TK"K(JZN((1]V[GF;M[*()#!50U= M;;`!.1WG9:(_[LDJ0F3-1O1.;:1XG-$..FP7C.=R:2LIK;5<*:@+I!>B%:=. M$W2"[>H(VQ6E,%_`NX;F"1%47W!KYRINE>N46#<,I4U#+/3>;G5WA/ M(^YY$<%E^?^'L%:OP7[VI\^.?\P#>8QA_3*&\/W1N?Q^PC\O2-$/#K8_P?E?.#@G!U_#0TP=Q:3YDW;(`T;:P:TR#XJC#^20:C%?=[-0/1)3H,5!4-A'?8JB M2H.L-<,$$8Y+S1VN<_N% MV9"'KZ*KZ#IR=G1D;WDF#/_7O2!BV!!\4C&<&9?[)H,K0]01; MDB2*BUCY.P(](7.JZ/GO?O@#>?5U1U/+L&]'26)R#14'Q2J;,["N_*J%7)<'1FD2L MN>$MRPR=X7K3BYE$+SO34Y#(_U?L&LL%7@9/D?&SC!^4*#)D18W0B/JD].KS MTA<`-8"417"#>.3^8;D_WLQL@Z^ MOQBL2%":Y+/!JCC6HG;C2":K#'@%9$K`5A,E%<6,H29@J*DP[6QBJ)FD:19@ MCWEYIN0E\^0ETV4O$])PY"Z460B2F$UXQ,QDQL(AKNN,QBL(4W-Q&%M',E(P MQSU`@'\)G^CDJME#(/9YSN(F_/F`^SC)M"XF'$);5C>>\,TO$YDL900Y\N,# MAJ;]1`)+&8JX-VYF;/8O9@"5,,Q)_ES=6W3_;0)^J9UB,QLCH'&M(I6:*^V? M<6X5=7GR*&S-+5=*KJ-5SGSVP0O#!(+U;P#WU&"SUY9]F!-\Y=YE,+G^]93U MNEU[U]B7@]*I*@&?WXE04>A+^!FQRH9?=?L` MHH,U>2P-!D-D+IR..-XO,A'.M4O;GV*A:?!F?%X/=7\W0CK9,9Q8'C_.N>/D MPASRO,()Q M"S%ZR'QK^]%AC>D-%RBQ1"H]:HI=C]GC_MFL]'/[T/CW"FQ[<4]3PB?"!61U M8"Q/_2_N-7JX\7'&\$13`7;V#_W.+[;BQ&^=O[1&9^S#1'*LG4+""OT3.G]\ MA<9BB91"5V<>AO[AU+#QV6R]L\;CEL5PQN7MG_YP MUV+TNT<^/#28VR@=^2A^[&6Z`W[0;&FZ"6E(#KW0XS?+EAK"A:,Z+YX*^*/6 M)0?$#Y%;:1!4&U5NH!'K4E.+4!+37!,&H(L014'U%%H"WMRY0BF>'(623R]X M^3XYJI.J[G@#EMPQ!IQPS[-JH;^?"#!.9>![1+C4,ZKTY]WU)C% MVR1Y-FUJ!'50U3XOU4%52+3!DAV68:WSS(3+0A@9\\>4LG#[P%-OH)=WM%93 MA9@GHG]^VB4>$1=V1MF.!#+3&7/C@)E3E1!!?%3FUW>/G`@%^`KS3&:/CWIR M:/O#WDS%Q>%_<%,E[)E(B1$4MCJIY[RQGGBCNL&,J%:K`(ZRMUIH]+B1ZVFE MO_9[E*=%9=F@!X)LPP0I_^HR&GR:1@7/,L>Z@CD3<4N5N+&NP^"V3JJS$-]2 MC,G*05-JP^E8DD2IWAWTEW:0F+8L957XU`7QRNU!QS\H@DDK32\DAJ[WY6:RJZ0D" M,[H[LL,*3E?^J0Q;%S=RTIFND=!7Q/_7[;`-J7S[-;@CEY0.4\KP)[WI3 M3U,^D;DP/DZ$W,(2:8G":3=H?UNI(O:3=E+V#6I4IC\,?KG4FR"8N8ANY@." M2(84@1R>X,2!!%^I+6<.+"8'ZIPJ0Y[,:#HC9,3DN)@0&WKT=;O:X,2];,`S MB>1%)3C*FV1ANY\&%Y(RS2[J(#7E15]-IHCF6I(?^^&.\YMBT3`6$*`:&F5L M+:DH.<5U*6Q[WTJ]9=Q=9*9A!)=2U9DF!X3P$8PV_'$%\2K]*8*POS'DO*Z5 MCT,[_I?&7(&,BFK3L5"BQ%L62K[:O9A6BJC@K#A.*\FQKRFQH%`7,"]1;I^! M2&,^T%%%HM/H;B_=X4`!*71>80EMB&+EO4%N@FP73+;E_I?!00*6A6<3^N^0 M0QQ:EL/SR4P@C%B;BX._NRQEU"BF36RH<;\([UNOO6I%BL',5>/V2OJ.D[9: M_8_ULFEN&\G!\%_I([4EJT2*7ZH].?;63++))#7R5@XS%YIJ2\Q*I(J4G/&_ M'P`OFFQ*LI/:VHLM]G>C@1=;S<\XGLP1,KF/SS,%ZDKLWFEYV>.P-WH8.K%+E2.RX-GN MO#L=7+I")7HS5Z#/^\)._]\^%Z/V]ZH&"'#,/XD>UHV2CV2^K4RR;7&P)TQ5 M\W5X]O=85="#H:.G)KI?N44G&G=0Z4:93TCC!:5$J9YTT#.B>09KFY'+X:1, M?]G8H2(M!$,NH2;A0I#R@G[AR[UN+U(M/PJH&4G.;J^_:Q&`@6BDW]Q7+<`D M%'CB"&M%#&-1/1[\M6EW:S#B=TWJE7Y;I&RIO;B]JW1`;8E$[NVSU4IFI^V- MX,)A[]JA@%$VBU+'07\03>CQCF0Q\KX5RV4B#(,$+8?=_MLM6M7].:P%"":2 M'WB-_=0<=N74+6D.KD,`B?KULR1_J$K]V$DJ<I%,$<\[!_$5^L)?DB&,H;"YQG"&. MV?L3CD==*8I.A$E_,6H$@>1*]G!RORYE=_6S26P;KD9 MWU8LT9JBM[0.-SB_2#L%X801TCQAEU9/BJV?G/5;O>&C;?G6KU1/`RC-%7U7 MIUJEQ,8(4_`]065&(L@73BX[1WU]1_3M!IM(/Y,0K68#,`*P8(`^;!O?XWLH+% MQZ;54D"_]9]YTJ*&98D\=L\"E8BZAURFL8BQ'#ET2OS<[QM][@HP(E+O+='?1-:!U;;"X6"SXTV]H0I;\_[:I36593\V5+ MU#YY^.9AZG*VR,G"`Z8N!JQ:])C*>:W`8W9P`/RSPB&"J85VL,_'0JB)$FJF MV(*`C850$V6=1.2QM>H]6`,=HE\JCHFD[4STAZ8R<[AU3O"A#7P(/3@6T0@V M/#"3H7(,9PALMR!L[V^+7N93KA@_%/A6$H3`+WLR5>O]D$Q'(/?L@Y\(NT-# MT!,X;2IFSY0M38&^3HG"Y\[!_`G,GRHMM1Y/CE'R1Q0)J,-H/2$8$O:Z[RN` M5YDO/5]92D1PV6<1RU(SOD]*I(S2NA`[IT)-8Y3RMRXM%GR4!&U;GI-?BNH? M08^\/[+._!*T;^:@5W(=X.N9J493=5@IR`&[8!V?^-&K#_I_,:BL\>%4^PY# MMHC&IEO9@\*OF@T6$R.GY-+^34:UR7B9;Y-AV^*>.,G+L:>]1\S?8 MMT]\,:+&"9?/N:G/N9%0*%L^,[6QP803!=MIU31N*_9U(WERN;(6-6O MB?^;%\>\>K@?EG*NU!'%8^K-A7J3P=E!8FX(DU@\=@[G3]'LK#8:3\N2\VDR M*X^G(^FAW#4)DSYB_8!"2UE67A1I/8@Z=FW7NHM4JG0B66Q*@#Z%\\C34OU:0T ME+V_.J4SW]U)HWYWVI;3?NK)R!#[Y/[R]9?30E=+IKUB-AS(<8`7PK".73UQ MPN<,Y9Z7=[+F:]%B4]O>?"QZB;M\!9<5OBC7M,`#9YM,00"V<>KZ^R37A.LH M!;^+ML0R%)MH]]?`;UW6.L66[)9!G3.%(FZA&$B"A.%"_AQYS81%E'H6@=8_HXK:I4[A(]?H3 M4'7&SI`&*]:[S'VQ6B420JQ>:Z"H%A>=J6J6Y*4H<@S6Q"EO0E7DQ"DR#VI( MVUB*;E`5QEQ=/=C]05("891E$(^E#)`D]6P5P=G57F:OLG0?G(,VSE4;'ZI] M<]R^F"\S?AQS-V$Y6G"8E/_MR#H$\#4`VRVN@$UA$D9SG[#38?$4B\^4]<9A M]#\SGD\QZVMX]XN6MO,^=RLT/&B.4_1LBP-@U/0$Y:;Z/*0L@)#3T[@[^(`` M\"&H'I-*1(;HB=J9ZZ>0&FJ>*E*G$DH)@#46*\8B*:DB]1`:V%LY.M:/P<8Q M;)R(C>&&[#F207!#:F0$D7I01E)R_D73#]\AEBNG;IN'+;X&@XH42.#?2B[* M=*\.BTJ98?P-U&K]DF2U"7M#2S"]UWN38I;I,ZM#U%8(5QO8=V?C)O[1:LN#TCZ0*KABYP)D+[GW% MN>]@)=(6.0J"J='-OR.EGZ7<`V[2]7EGR<0I>H@>)N:,2%.-`4K2]/^D-8=? M>6";/ME>TXS+HLBZA([W4[UYK_'/T$JXZFWB9F%XS4*RT*X=\!8?>!)UEP$: M,H]91KCJN50*Y%R&UTF5W@@W=1YKK\<`:9)+=PD>:6L-1>N"3'I:5T*;?"P& M$O$`LR==S"DQ[&QYVA6M>92QDLO"H*LZ\]1(!FG-]B2F#"G3U68CPUJA+WJM M[YSRP@`;;:72I6Q!"_-+RO0]2A#*FUD2#7DF7+@#AUJ!-#4AR*DNCUIS5#1? MU#L3O9)L;0CQ(Q_!.Y%/S/,V\G9;]3IHM@22LIUNZY[O9 M+Y7Z!45&2G//R+BO`E5I*"C98"0@S2018%R0';B)'9"ANV)S+$DZ M6X<%P=X<=0RC0)C2+RS3LP"__8OA)9\XDLBJGP4D_F)VSH,G[FG7O3VP!2=[ M[M`C#;=D7UV*0>EIP3)+/25SCIYP=!-=DG]N_'/C:.[T5WTQS'N#JY'^4X.6 MW>UX9;D=7X7O1]O>%?O'MEIO+$6'\RX9T-)%.BNBB_A",Y9<0V=.I8A)%!PY M21[)O-9\^AV>1V$:IV\YWIV4,%2]-/1"S9/YU`CE[?@!%^03B`\RRTX<30PB M)G-N>6PXR\DO-D\DEDZ#QV8M%TE(&2347,6+$YT%<-0[UA+'LO6F4N"IK6VK M>@-*Y?==2$8]JL1MY=N2$S_;G80UY=*]K8]`"KK28:M3-S2JZ@X[_7PQ1]'$ MA;#M0M*M7(R#E_!$%]O\#)5>EHSWQ7.U)AAE->#:C%[YOMAMBG;"F:MN0*2S MFL(I%I3LR9C)CD*14;7;"I/O(&+U"H#N)`*)QE M;SE#1845O28=>XOW7PC")^@0>ZZHLN'%EK,XF7N>=5ERV+JD\J&39PSHM_FM M>>95B4:I]G-"0]H5QHNSM!L/D.]D2P""^)ZSOV!$+GDR5\`$BH'4D)11LKK$ MQ-G.I\Q MBW>DZAVN_/"+CW:\W#<*S00%DKM2[1.GCYJN9#'#N+&QX;L]AI<]F[.Q/_$2 M.>.%X-W?;5?+3L,P$+SG*WR-1%#:$QR1RKU5^P,0H%@B;I1'^_O,[,X*(O7D MS=J;6:^=F4WWG39N/L=`]=WZPP,3PC:@;6$I$.2A-]2-L=4EW>29DHPT=1G? M?C9R9)$VU(68G2F@V,61FLC*@\6@9\:O#4*X9E^W1GZ+B0K;._OK!).1SEE+ M:LXX1'9?)--P=\L4T&!L)^"2!BF!\K[,G[G@PR.]/T5.X]+-R[T&KU&_X255 M?_=!4/XD8:#N^3CVN;RYVE@%J(F`?R3]6A M^@6M#U*>"F5N9'-T'0@72`-+T9O;G0@/#P@+U14."`Q.30@,"!2("]45#$P(#$Y-B`P M(%(@/CX@#2]%>'1'4W1A=&4@/#P@+T=3,R`S.#,@,"!2(#X^(`T^/B`-96YD M;V)J#3$V."`P(&]B:@T\/"`O3&5N9W1H(#4W,S,@+T9I;'1E?/)[NIC M^V+O^EWOVKT]NK8QKC4W;UF?_,CB*DKHORJJ*K/: MW\1F<_/FW5-F-L--',5Q858-':Z^W01Y'J[^?3-/LZA,XLH4]'"QH/M[(4R% MD'XD3/PEN-N&16#WX2*J@C:<5\$09O3S2`=IX,)Y$ISEIWEV?3@OHB0`K0'% M-EP$UGSNR!PWM#C3!_VSH>=I\)$^D^"_84Q_G_LPCY:!6T?&O+?&V<;2R[79 MMD/XK]6'FS2/JC)GNTG=.:O)>D+A3#4V!U*D(@G#<1W.%U$6]*)RF\)QVMCGM](TS;R&D%6;]@9YEP?8\ MM`W]8D,'NB@#H_0=<5@&JI@1H^;>JGD2I7GF(S$:EL*NMRT[)PF(+UNQI8\T ML"R.5-JWP]'I[S.)6)#`H_FGT-0LC+6F.,@!N51).2;G"&I0:B4QCEY-1F85Z^:%VYW!>DCXUZY,&76?>18CH+Z[NU-?6L]:L+:.R)&:Q-S++ MF#$BF6G\*./(8<26="#OY6P,_K.4)$7@1/V$OM>FUON>WN3!B2RG>_/WEDZ+ MH+'FT5E0X&3-NN:![8Z2I#/A9SZ%%?WGF6Z(LE)6.WFEJN`-))'Q3&5NGY]K ML'97FK8<[05%FTUI*`-(J'FH]55*'HW")&7AYB[`$B+0Z^ M6J<)HU[D?%EP:.['T#27>+$O25`LE4B9&98L#CI0UI-XO@Z7I&`R([59\I:( M2)Y^6*`C7DK\W?Z)O#M.!"18"_8@`'N11?4)7EFB1;.;*N/MC347NG M9*241:Y9/3,_XVT3S4QMOH*&_>#YV`:<.M_(^&J'W,('LE7SRK/'%90\A"FJ MB9H1="V4/$+VCPF8C,+QTB3+JC`^Z_F<3I:I9$X-Q=?2]J^>++/K)RFG6!'$ M\R!Y1NNU/@^&>FTH(>)(, M5'M+#B+U2XK/DFR6-FST')\T6S;2Q)G-L7=GH[\IX_"C=8,_PY,UO1FLE]Q@ M(-%%L="!1,IQUWU'5G+QS%FGSAYE$G"W'2@424!!'UB3)<68^T)[/$G82OVV MG!:<$I4.U+-G#JVA5+\*',38T-E7X^-K+ITU`HNN]VCG!T*I%&7F_>] M7H0LW3RBT*1"48QK<2Q53(.*&,0R-/D[K=?#M`EH);4X@Y@9N-=F#?&,!(0/ M/I]1\/B`)FM(T"*2(ZUPL,=%4SMK&DC:']2F2V:32/.`6XCS1>%4\TF!:+VQ(PSV_ M3E748U)*[J,E,/>3DUMBN?^QK]J,/;Z0WLTS M6!J=]"'\UC9S>Z#L+F1D\U]I1#-I57BXE4Q`-,5F,02#]J%&6Q0DPP"`I5J= M687,K"*@$$Z?>N'2]`D-%!PQHG_ M?>_V9](MP0]"5+HO,[['&"DF8R3'&-$AM9O<;;B3I:)!J<-N]1=`S\L6H"VD MZ:G$F%X`,0_VLP!V"NT#'V?2W$KN[6ZDX\J:@GC"+V^CI\BL[<99:]K.OVTE M1QL7IHS;^Z_HW!3+?L-IFPFD+67'V%/8*:\SWBP$5'UF)Y0BK0ADS>`GI2PK M[(`S-\P'$-5PV##HCV9[&JSR.TI68X2GHT/B[T%6EE_::SYIKYCY"8<84)"F M"DV\VS\&US+8EM[9?N=:]?M69F0BG8Q&QE/][6Q#WD"<_)WA^'$;W7\'L*GD MXT4U`=@74.C91X95S=#22FEI"7!K(MTV&R&?7'"RI(*',P^MLPFT3@*B9`1JF`G&SX+0!3L:9X&2O`^/D-("\EY#;K16<[4?.5!S$X(4U M'^KN5'M:*OVEH&N2S%J^X,74#G#:R3E>J:;CX,G4%3IKU:W?C=KRXML2OAUT M]L<3X"Q*81(I]/PSK(QK)UP4)0,R7ST$YT9[!1Z_2.[";7[8_4^0MWG"*S!" M.]"I:E9.Q^>P]J/>`WSIB(H7@/6*`*@!S#]*[C?2?*8XGI<5"D0I+?AJ`X$) M<%%C]TI814(I8'2IIE]+>PT>9@(/OP0?3MC4SN-X^`Z%OK9+$97T]W)F=#I@ MG(TC8K)_\L`W.B;6YA:G^`L)35NK@'&=C!5Z^+VU=HKF%7'C%(I?87HH,#-/ MX.A.2!!*7F?G;W7EI=RZ']&;%X0-`CN!!FU4^M6Q^PI:O-,E<(]4&X0ES1&9 M0+QJ%!AK`(P5'$75_2M=V/D]T)+47!7@L6((\*T=&-<-KT9`@91`DHH4ND\Z M*!D^I/J>+:R\^RJ><9""IU>B6N"I7K'X$Q*L'_4F*ZI7ELW_VL-E2@I MQ*X[O,#A0693W;'=O*6]OJ94XYJ2PHN'+1DJ-K9D&^-4V448J)YG/&F28K)8 M/%$/:/L.S!/J!?GBTL*3Q3B-"S"_;[EI]-0I'BV6GX36G34/4TZV5**>$U^Z MIG."^9(^-&:#/>8=0PB115F74/.*?]^2QMQMK:*W?3L!.KC7>5GCA>:S= MKQ1Y"OJ`$8V>F6517BS*/V^:J%[@[Z54;V*N6L:/!)GT-$(?TU:)%D*S4K(# MQ%3G`D!T]5@;E."T@XZ@9-)Z&)X(B5;1G5]&."\S[4E3)M#7Z;TJ^EW#?.C] MKL0BKM:;-8I]Z3+$PA]HY^@MWA$;ZF6=`V8Q1"_HJS84IP> MI0@81O%9=#]%96CL;N.?M9<4R,846(B9L9HIL(Q,3X0AKTW"Y#-SR$5P"7#6 M>CK!9;>X=UBNVM\@L.]4LNYQOX>@DC\`.:MMOZ=.R:/3$`A[M(`\3O[#>1\R M2+V&3]01RF6.<@"_8MSFM/C,5K:?A!8=H!++@YZA(XGR5U0;I'A_2#2D/!V/.6NCJ MM.N6N+C$)-&8I/13@%G)P`S@1QP%B.8'/D#2(#4SK?N99H.':-BG2H:NF(/) M!'05/X*N1JOOX*N0Z<=ZHPU'AN_^Y`MOSC%IZFL\5.H"5ZF"YAI_=3C5?J4E MC>SN\*7:ML@!L&HH-+R<`I&40WWR M+R\ULT1\VA$W4)>P!ZN_!%_83D;CU]/5G-41*O,9%_]GO%J6VT:2X'V^HD\; MX(:D$/$B>)1D>]8.>\<3LKUG"`1)[(`$`R#EX7S&?O%695;C(=$S"J70%,N?6.KC&[4B\'>Y-?F`GJ8%+[2A/Y.9)IH54+G.?=?B!2,0?/*A MV-+6.\/E\V'#N`W(?1D>\C'^EP3^F]?JXWI*VI$A/L:>AA"1`(ZBH!;A\8GS MEM96B69.V,QBTQCP;\L::4B(%7*9S]Y2/'9N9T][^]QHB'JZG=2(.X`:M!VH MGM631J%:X4A42@UU0\E!%D4CL)U'/HXXLGG*`8X`7C*+'K>E.Y:UXH6N$JN$ M+UQWE--HPREV:3U@'?0D$+@BC,DIA$GEL/@V;$;8C0A$B?7AGK:/1+HK20%0 M7*,YK`S1M#\.0E_R@T#-Z>L%,[]GK'C%@6!$'O/(T',!O:_=N#&B> M7_"@P)F:M?U0NU]F.FRLUUPN1!./A>1X8VFV?,+8.3>HJ7/_2=ZI5^U-I MW2W#XWK<,F;&!YZ0/]L/UCP[S^R"JV*=LPG+2\!16!XZ\LL)]51;NH`Z$_,U M(VA_(!#2`&]P9+*Z92@Q_(H6F M=R8$;WO+G6Z3S-V=-MBB<20!-]"QZH*EO<2\_X)!4-,8!^,?]*)%5RVO'`_* M]T,OF1;QKMVW"G4HNO?SC&.)FI;\E;^M5!5:VA-[SQ4]OJ/%WJW M61P.0/@:3P&B2\5K<@MH1>;.GDDBR:G-FV^U;G6*"'3"D2XHNF&F5/&IR!\& MI6=?>_NT7`>^X`&^[M$G_="988[`D-9(:&O59=)=G_*NRXLM;$]=B0QI@T2H M->SJ9A&Z]^CN=L@TK<7O4035W0_81N;3/^FD#TT'K"SQ_[!U]RV^R8T6^0O6 MD5Z(XN60['#9E\1`.U;-T5#-_&"Y^ZDHL?"E[DXSM6W=&UF,I12TQ>2F$+/V MN-JT9HMD:8FC?BN]*ZWMT3OYT!*3>Q%=6V<%$V] M>XC!:# M0M6,7YXP[[CJ)SP%Z.Y(2._''2VEAV;\V(J`45/^MS&6W$4^2P/3`A_,#:E) M/4D:%HYNC'S?``?II2BY\0D53"#,_%BX(I%?#J0H;&%\T,G,NN$!/IFW7+,< MV:J\Z<7)_^X(2LA?VD&H"RB+].RQX_<7H=Y.0@W[4%,M$&.7>2\VN+F=NE)& M3^VA&D]>&`+#@*=R)YZ(7)+9JWE5WSU-CY3?*(U\F_DT;Y_R7L`Q=PF/GEO$ M#VV9C_<]EZ0.'\,GDLQX0"V+D_9/Y!_]>9'_+_\77$#YJA`$HTI M4>D4SJQ^J28[\&$#9)Y<[UNZM_<5UW0=\2D)N1/ MJ/AX_AL\\KI?ON4GD-%F2[IS;VZ42C)Q>>[P(5`SI1,)(@Q'=!*%@]>07J^` M^P1AG0GX!!80I=6]",MUZ5[+/C5K$7BW:V> MQ]XOG1W,(6[>VR;T"8G"DCC%,Z7CHJ=H3>2VS(F9]7%;V%=1>M`[2K/=J3[: MK%GM-^BF&(>)%#I5P45RA;G'727.LW:'+N"T(33T?7ONFKW[;H:=(KNXR;76 M)"G'K1:V(%KK!=7Y^OB]<>?2+.!(#$N\4BF[;G3+,CA+LS1K][:N>%T?J[H^ MNW_(-F4Q38B]XV(_1(NAM!;,R(%SGVI2R(="Q>@`<87-DY(B&AQZ&%%PO')K M'#!"*WL?7%;#I#M*:-Q(>GB]L!/'FP%6NA].`` M@.Z9]&$\S=*Y).UW:VX!Y0F,S_2=)2:63&#!(B];(^$UZ4"2WH^["ZOEA>%Z MS8MF4GY`KO&0>]/DA+`(^0J1'>:+Q!=Y!(Z#2&KL7R5R%2(VE"(D8ORIQ1_;!L8?![7] MO]:.Y$3I7L65I>XT=CS>BK`97\X5GLM2,(UY%.VDP`=I."A#$X9N9\)>J8;? M17X%=KL+1A=:=)ZU&%T6U/8?5*O,^3^]H1\F\ MRDX=)N]5Q)I#'M'LOJ,Q(*5"_\)O(BJ\""A_4/+\UF?ZPI2IC[WC,V6.1 ML36`=A"&W/XW4MG2EHD#[E'JO*4+C$=SW^@&&N_ID#L-6KB43^P;Q4J.0;U2 M-+@S%Z`8.UZO/W52>2['6GAGHXPF/`K&;[\F=CR9D]^\;E_T=J8]#75:\T&/ M5VBE=(#4NT,[AIVI!D^IP9.)!D_'&MRKSA]P`22Z(K#XZ?MQ(&0,#A,%D*.Z M+^B.!499N]`%%0"H&\"<^@TSE8.8O5(,I=@&N1IY)S#)Z;>RTKR.H85TUQ6$ MBI?+J>VBN0EFOX@N]G%L!L`&N6%Q1W)+;=E\W]';MFQI]7,_:HB`XEL+TR?N M/?>/E,F8@J^GHB0RB'JJFJ.<52MS`5&AP^#K.PG+V$'?%#,Z MM9#DV-DAGP38ZH91;/PQ%_Z8*C9A<^XWT]O*_7JJ]D<3>E5==J_1I,>0H@<6 M3=R7-M]W^_Q8-7LOZZ2*6B_3FE9_TK=*CU_!J40QGX>+06P/"I$NY=H.6Q%# M>D01QM>:2*:D=EW9/E>%GD_]2ZX:BTTA!!U]!LDHI.)ETMY9G(Q>9BI46@L# M$V:EJF.?W-\\:F''P0V!R*W*3:NCT=Y]WN9$'9Y+OA2HOK.)WU#*8;D(7U;: MO`\NMDI;]_(RTC;=B1(M=0("K*DNPPA4\3+4?V,[W+^;UJ]NW0.R+7X:*S&A M*UMR]KE'Z:PTHB7$XZ$N<=A0UI-L/DI*XD^IW_24TF_`4KG"E8";\,R6_>P> MZR:7=+3^@C=BV>8[EQ\5!%'82S4[*B6G'.M4TC7R(:6^=[47QA[$^9F'C[N,&YWO[Y:=??_K_`$;=H90*96YD7!E("]086=E(`TO4&%R96YT(#,V M-R`P(%(@#2]297-O=7)C97,@,3"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B M:@TQ-S`@,"!O8FH-/#P@#2]0'1'4W1A=&4@/#P@+T=3,R`S.#,@,"!2(#X^(`T^/B`-96YD;V)J M#3$W,2`P(&]B:@T\/"`O3&5N9W1H(#4W-3D@+T9I;'1E?7OMU\@*=F;VDK%(@F@7^C^^NL?=^_^,+NJ;\[FOMVU MMMF;WC:ULHVZ^["\>[=<%BI2R_5=&91:A?"/'I*P""+X*8*B4,O]7:@V=^_^ M^92H37<7!F&HU;*&C\N7.R_3_O(["HI"EC2/DR"/PD)ID)&FL'5!9Y(4#\WQ M,4SQZ#?O<[L]J`<_#THO\$-/+0P\Q]ZIK[[[$= M?(X\U?$RBZO]"):,>JALO:4O*BK+?*9XDQRI>+/ZA+^I?.U!9R:Z^/G$/T8] ML@'^/(K`1C'8\#'^*R:IBH\H_MF*BP_5=&_ESV,04V]/_&YXLS@G)E(LYQ+" M.3B5)4,6GJ+9]I_7D:%-Z.7.1-FPN\9%Z@U$=Z M0,?#P?$]_(THK+&XR=\IT'X)4F9*'/=#C/+1FG,S$<^7R[:R6M:G)!QTRI[- M2DG8U&*2`:-">^/3O9C)`OAJ>;^M6(^2.$E,:!^O[/RYAJ.L9T/F&+EN22PS MHVQT7ATEL&(Z75=(%Y5&D;NI.*+ZPXLJ^:*>3&U-7]F+CT%7[1IJ:6T.'4B' MI,Q`W4I]E0=C.]H-6TL/CDQVJ[\\L`[#^)XTQVF0A[G4&F5&E#K5J11Q_>/4 M=.@3I$9#OA40R`CB>U`5YEX!KL80SY4_SSA#?$A`^-KB;^GMVHV$Y$(A^,N' MC;`><`8I]6B;UJJ^A;281W&@(?]17M/-9,?6*%SQ7D1?)VGNS*<\C\O1B2%^ M:<1./-KVC.9`^H1@4@\Q0=DE5!P(?T"Q5&`:/G6=/-2@%(LQ@;539WKQHN\@ M'SKWUO2G7LP;9'*5S`MX;GU($M*\N3#0`7SJK$@F,0^'F"<2/CS=K]3W1* MU,6!2=)RU(LAZCF[`7@_QV0_5HQ1EE][++S$V\OJH1]MUE@4]UM9V4ME-EV/ M6(*+%R6R#F!N1CD'"8/6\1'UKVM=.[AOS$KY>MG1M0$4R+JZ;TF)]O;'WCT> M("7YKG00IM#JAEXTED0EL2 M.A*&)=0>Z46I!QM`L9YX2XU2`*&:3E4`9MS)2FH;B=,D=R*&7B-^&#MK8\W6 MWD,-UZT]SC",6(1JW1SD\5`W\K13G;%G*L;":VI#F(%E5[?[H]O-I7B!#(+R MT=Z3Y/XO!V,W%P+5A+`?L\<>6TOGH'KHWAKT(R<_(-7$&L1,Q"9E4`;NT'#? M=[5T=0"-.LKZG3J&D&`N_X'`0C\F'`>&&[M(+\SUA&MH$8LE_*L165.U@1O>W'@(H8V#M!PS+1U!U?7,S]4%T*4@#H@EHK[X M4(4^3C"&Q)V\G M8C=6>):/P(G!*'A6R#S>Q9-;3#.'YCE#RSX6CF,CYN?GBM]/R-`U#SDXS>`W M0K`;&5CNQ616T9@BZZED.355P\NRL*,75:W._)FEB-F#I7-](P.RA/>XYF-;J-U'O3ORFNA<`)CS#,[&>G87,,E0 MW(D4YOGF_$\BN">1R;R@VI`0PVU`J\!(A M,%*<9TA+*I4RD;5B)NA=IQ(!C)YLPL6)U MO)_BF7I\:D;TT$%S3E\+PASX6CL+Q"/*=.J0N5B@]B,0`8\XK2OQ[$3W",`B MMYV+)0R;N5C'NUC4CKV_$-;/)!3(^%Y5P160_+]E!_RDLES>[#GZB+%_&2[& M@82@PH*2B+?MV@&1W2[^R\OJ5W+$:?R;?)`D%?W_@%+?"7',AL\SND\V[_2\ M&[JOIF`CYZIK`8PIC%'"IMY8!33E"@XR>#!F"6F&(!%6B8%CO,AXHL4,KL2- M<^G$@^UOTVO'KH5_#@=.B1+>(,=*@OU&OF.75F),]` M@HWZ>N`4/1OT``?RLL>%'AJ)!X>^3B*YHN ML%Y2XJPD!F(=Z:(0#$*179)V`PW?PBF-W03L2=*$DFO/,U)9(. M=G`EQPG,']=2@:[))51B7$F2GXA]=/G2["3'7..>)#:7`%#/TV&:KJY;%S-I MQ-L1MX=R?S;2ZQSN2^>JAR(D1:[ADN"UO+DQX`8/WJ_7E?C@,,7!.Y-*%[R; M?JW'"&J.X(+X*3/DBA%WIIZH*)E\"$@GC@/S-PHN\/L'LV)&7#LZ[3`;Z3)E M?.PAQ5>+R23PM^](.=8:GL!:FQ)^/$+O'YP.*R9#;R_*V4CG M"@C)HS7_9;SJFMLVDN![?L6^W!581;$(@@2)>[-EQW:58_M.SCFI\@L$KDB4 M28`!0"G*K[^>GEF`E*C4O?!C/V9G9V=ZND\MK#4QO$[3N;!43I-H7JLQ7:^> MW@7^M[!A87^8)*7-K-6NV&K/0W01L?`T3W/Y#5%2>?]&D(UJ(7+W#:^6P`.&LG?6V%-ARS/^W8K;50270`]_3*>K_NZDPZVO<[^+6B M7\,2-5CI"F],9\Q!]T&7%),Q^O)M>7)DOUQ7U*?N;*3[S*2"Y,Q"G%O8E+IX M0/*")%2ZPLY2W166&,->*L-.K;9$ERP&7?)+/DR-8GFF#+FB<0IJY'++3OM& M9OE_4['FI9C7DF(S9-,>O1#)D^$!$T;1O2D%M6L4V9TF_9>F)L\3$$]0B";\ M8M1[FIYTCZ<<(9H\`,6 MJ#B2D*^/A9Z)!YC')RT]60U5;HVW8Y6W`FT,+RZ+II'*;9D3*R&U*4%3%NI4 MD8-7D'S%0J;P>E)L^GH@5H@S<(91CZ/`4J\2T.#I:O8DO:=9'XDHE,LQ]LRWM%O22S"B>9-/9?+B_D@4>9NUF MT]6JD"KY$J2M=SN_0:2OMTJ0P/0ZW^BR9?10"4VXDHPCHT+#>]S9+_"J\,N> M4IS-Q$+8,Y%$$G(1'-?0!$>?I&3O;6S>2D%('>U!L!1!E"P))!.?",F,CQ!$ M9I+NN).#`5.?_(/[G6MUO&&'60+@$U+BBW1K([K MBOD!#L=O9$+DOC9,J_K(H=N1>+=]PJU6DW@%>T.B+H9C%GK,V-5&=9[RJ>,% M%C7O(:$Q%O:$2^DSG5(I1NLS68$.G5JY19$%J9.VX2R M*E><,LA6^A2DX"GC.K.C0P,[HXLJ;VS(.Z.49U3/\L["KFG'O$..&9OP[K%G M1;EQ(1&L36EX*X%J!'WM-W]N)<]C8R2Z:4P\R0+!HHL/HT6X2F!3B->F/[`Z MV='DQO0H4A?G92R?Z,=!:H%D7FM:P4_U88+#"[E MA5N+\H(19(-/`R&[S2LAB6$#+RGN.@M7HUO,M)"\_'([GZYZ"#+@W]2HVDKA M1?N(J*=7BF5[/'`Z#]"R(<4LB#-C.C?P3%R6=ZN('.&&Q[9?0Y,:+T%5K M;!"(`&JR/MX*A$@06F?B\*R9O1$CX9Z`%,8G]F]3.Z><*U/OANHU#[7R,L M0RU>"<$I%%N4\LBE<=TOOFM*Z]YHWDLTJ>DYHP&/02%Y4X.MI,E"V`7SKBMK M!65),[N!&,9(Q'TN#;QYL>;UV[^O.L[YBL(I_#OQ!7#C/C`L] M-(B0:2]!@@126:):1F?&*HL^F!:SUUGVLLGDFPH>$SE&.`*A!X3BKEQ75J8# M^$B((QGC(==AE6?RD$UQU"Q4B]Y47?"BKU'R8L3R1,'927XMGNH^S$V:KJ/Y)#7S.JR;Y/;SR*(]BW29]^H5*U76KB5%H%.* M3ON&+K9:HAWU!6WJO5>B3P-D^YS7_[;O(@I>H*6O)J_)LFE;I!_8LC=).:.D M!#=]K?\>^+1K7">.=*049%ORGHD%8\9P)_;I:5&MZV\-91(4W)9_2BYNJ83< MQ\G'P:GYBT[]CBI--)>69Z>!WJBG[J90\_6I8Q/X'YHKJ'5ZPN#G:9;ULV.^[T8H1FD9%F>_0_^.5 M1%#:&F=:BH%M>7#_\0>UJA-`N(U&XEJ']P>F+BY0YE7AGX@"]1R*,3@^'QR? M#XZ3(97L/[71,_*:.-4[Z"`98BPD50Y6ZN-)ET@%C1&J>P*0,/"JT,7(R3_H M&KK8/$GB$ZA_1N:.8%"M(UPCY?EJC5L;K3(2UX(@Q"@]_Z@YB\ET"84Z_9OT%J&76LZ)X+HEZ?<$2*6T,V;-3`D]4$"_`&UR!)AAFJY. M;M)KS9EI35<_:)O!L[9""%5;",73II-DD]G21*M6(AV,9\'2W&+2;?-034*M M7*S_IOKU#Z6F.$':[U+U'/(#9Z^B_5Z^\;"54%V0.^&Z[#A"=CMFSX*4#9:1<;L&WD*R07#WS<:V\VI%,QYF-`U;]W]ELQ8[J MF[+;]NYM:=(_NU39MMR;22VQ%W-:3[I,9)+5D`@KC:X@@`(5@OBS_C,U8LHG M&;NY)DJ&1%D`9[]YZ-01FX9J*Q4QJJGNO2DY2>&J4CE:[4 MDNHM*?R%7;X)0O,R0^Y3.[;4ML(C;H3"DR3/1=)D+":J+H6,2EEMC$(2O-,* MQ?QB817Z0MJ?I\:0WR&EF;2HIJ?EP;!=J)'5LQHYKP[5JE81J`[K_?O#CNQN M:5GFUU9PR-&0H"'Y=SNK[7"_\^R;]G><&0IQ'TC%86?"989'O(JCG20&]9_@ M_D805)"110<0"3^JKD4V?JB"4-N;C1_]3D7B;NM;+T\O\42#*7:US*.Q'@EJ MC>B(!^^VN:JI>T&`78DT:R5"JLGF\&KWJ-+4(61%?;"'+3T!KCVJA$N0W"+J M!A2YE%;/$?/NV%0E2SK:XNBN=D>YWL5^G$@EO^G%;JAI2YT/HV7TE:7R]A<7 MQ_]"?%;SZ.UO.G3]J\[)JO\*2\"4J-LL^LPB^>7+VT\WKWB5>30L_:P:XA/7 MN(N]=K[HO8K[UA:;4U^WC#5>%AT5J2+FV'+1_+4%L[>2EM M>GA)[FWXW%DDO2^)U*S+-YO&;_+.NWPO_1,5+RDAYN(H&)%F+JVZ0!$>?=ZT M+Z#Q" M_#CXSOXTKB(GC:,_.Q,$RDLXW3+F-K$5N^@[G'@E_;+YD&)V=@R.HA'O[6GEL>4YP8TQ-]'$PW, MVZ\__?NG_PT`H%&/IPIE;F1S=')E86T-96YD;V)J#3$W,B`P(&]B:@T\/"`- M+U1Y<&4@+U!A9V4@#2]087)E;G0@,S8W(#`@4B`-+U)E"!;(#`@,"`V,3(@-SDR(%T@#2]#M:MGNKK[7K;KC9UUZ[F MK%VQJW?3J[?3J6."39=7OO"6E?"/?JC2%0(>KG".33=7);N_>OO[6\7N=U=E M49:63>?P<7K+!%+#$0T97@/7HBHGA@KJRI\(?55N'36@2DAX/&82".H&"17?H1D*?59PUA'7BOX&IH:A0X8?/WB"4XX27/OCLC1-] M2'W)KS,+AF[I+T3-%!5_K.%-\`:!2VPC,^ZX MB!_OLC[6F.L_'P8B&=BNGT,`)+^'3R%`GT-8'P/I(#UHQ?)!)XZ,4]\Q3J)Q M&J=_F`6GVJ?Z&:J6?2PP MQ?#C7=W>9]@+$_9#\;X(&L!^408'J*R%!W_C+-5#AXHH'*=CQ1]@WF.5K#"1 MAK<;&'Q0V`TJ\GP",U2J@6P%+8OUO&0?@-OPGY$,AOI\'^@[+&P@"\*>`E/D M&3><0"."9?V^$C".R+#/&;;S5U@<6CH,$AAVB2AZ:%; M%C@-:Z*4O.L#DQ(+?2-AWLE"4W\'$\:9E"5.*9AB(VN5UTC:'Y:'ARH<"H^' MWH=#4^C*>52$CS1=5)PI;W"3:*Z(Q4PRX4`JR0[<8JPW6J8LL9P2']FA%)V= MTD%BP=7!(JJ+$[3PA@7;^D>.Z0,AF$S+\R`+I'AU:"7FT@QX)2]S!"P'QJ6/ ML'.P#`]-H2Q`&,6%F!SE0I07W#P*AS07Z%SAG?ENAHA/D4WN3&[RX_I15)L3 M0CDP"NCM?)I&A/*`,-''ND`$V`II28*T1',6U@%.L6=$/"0LOIXW4Q@/VTVJ.ZAU/I.RF33]WA.`2 MZR(K>Z(FPZ7:X?3G+&(-DAL.%B>YB%,H'U7?]0-1)?%)])+=)&%=KRYJND[F M[YM=.EN_-'?TZ^>.>FGNZ'-SQQ[/'>"62""^WRG?ZZ@#A6<[2D-9'NBVD>P% M^W5UF:3OX5,2:-]*N']7F3HCZ4B9/6./QW%W/"IBR8P;V1MQIN/U:<>73EX> M#7)$Z)S_E4?#@3*:VKY?`C+VZ.]PYF-#PB#H"&W_$Y"`"%@36M!2(UKJ4%GR M-=RN"(XU`=%?F`J#1C&@D;CT;\-NKVG5Q_6]@A?'MRW[*N%M!!?77J$8;T?3,+@(S4'X93MQCJ9I&Z.?2RZ'LYWEX-];)"Z@6^ MTWV/9'63D;<'"$.K!'$J%R%.BQ"GXOO[>'=D[VNX+BJ\D-!['<[7\-$#^E!X MN:0#O&S2%*+S)L/&[5[J4?O:'C7*_((>1:S]FEU^I"5L,O/"+K_80L,N[W5? M7J^]6O7"+D];\(R489>G26;.[&DHCZHR4:$^WV7YB&AT,8G=Y,_H[E>[/P&# M9KRPQ;CAL:Z!ZLB4=(.QI$73G<'$(/3T)Q<'0$#CJX`3_\U]']JT[QA%'<,_ MU36[+MAM5]?KFF$<+VWO8+;N,;T?87IY"=/+'M.[B.GE@.GE14PO(Z:7"=/? MQ1%\ET6,?[XQ#['&]Y>G/M>8<(%Z]!*+WJK6&'WK8D,H7*^RK^8A]^!B^`*^"$:')D MZG#%^V3A$X9&)%)V?=&OLQ[=$,B.P4ZDX6R2(1AA,]8DECRVF1#R=*X*D2I! MFU`)7_>S-5I,J`HQ'Q'`&&XT6&8(.1J"D>&*A+A8F*LT07 M6@/@*8[KF^$DC<-?7RJ MVUWX`(T`+D"=PXSBQ,60?Q%.NSJC+2(P=53-`\D@]!MLHY&T10&D:3M?*#_E M^T&D1X.(2ZSIXR$D(=F$.>,0BM-`4(>-1Q#5D72$$)NS1!"9F]V!V!2.*H3#\_$',BG,B6AK$`QUC@N\5TT2FWLV3SJZ MECY](0$=_4Y'9.8.8-2C>TAVG55AM&C0L/L7Y=6VVS:21-_S%?V0`(A](?D]1\L(L'"R-<#D M3A041W.434[XW0D(U+)F>5`A.286#IEV3^C';RUWYH%,.M3L)5VYI%LLVEZZ M00^5TC;>MOO?VW8$(+3ZG'`-K6EJA6`?5TP.0E`SB8T#-^$AUMST3GX!(N=ZM@=<[V]P+$9)C23>;PB!2H/$-UX()@HKCX2W$/82N5.-PN-\\\J#0^UPRO?8R:MH'M!1R5 MR^-1"_.5Z!=2(!'_$.-A62I5X&J),Y:X>DQ,M8:_MY3-F;(2T/>JJG?=SJGD M!HZ#TI1.;Y?=/4_=W2*^ZTBZL&`0!?4RF]X6=*K6S.RV^)2XU26M91P5T7DT MWITZ0)X&RGK[0I"7J^Z)A_A M-Z`GEXKD?@_[.>%UW&_1SC&$5*++NJ?6?>!:773;'VQ-KUO2TZ4.37!N&_(Q M^&"B$PD_4OV8&44S&]ALW1HTSQZP7(X M'TQ4:6?V/UF?TK)3PTBG5,7%\$=*: M9:+>W:RTT-3'DJ.NN-Z#VV1BA8\>W2\QB.96@1-,B"BF$NL`IZ:P5H4).MV\ MAI.58*:CDFR)*;PJ!1I'B8>W,E.1X&5J+'X/$IW9L-:[M[D[DVDOSLS MJ;4)<,F,G1#&I<1=H*>0Q`0PA7#'RHFZUFX?%2WXKLZ3EBG,NG$BUH<,:5:0\'9J"V0!V(3#>QP63D^$_ MQSZ>=`T(?,MY`5.0 MYN\#13KIT>2FENZ?PO+;1F75IIFF*O+4%QX9*XG*S/$P!@0VKVHUQKE/Z[ON MJ;L[@,2PZDH'5T4?8^5"JM^X"#:_O'GUYN.U=_>[5VF5B@(!J1)Z'-Q:2[B_ M6KQZ>S,8D?ML9(4LS;"4_F!&9V+,S#+:76VD064+V%DW*L75Q1DL^K6-*QOI M_@BOMTKOEBPBHRY5W"[AD"9E-5Q$QE@T18@C;/HS:@F:HC1:W;9]/#0B,W89 M%UGED^C*)N:B%15I-)\6:9F($W^+*Q)DMAT@R-S6-7OW(V=VLA3_5&2S=S:W M7A^4/LIE'O,H]4.E.5(&?V:^D[_K!^U$&ZWC?9RQV>#'#K73\R#E+(MN-GN3 M6DK4H7/:(FMJQ-WZ*)N662U[_VJR^["9(QG/$,#S1W?5=W.;&9N=E/5`2/U0 M(M,SP__!U%W67W]I^;D3=$[,+MAR( MT8M95671C]Q_N^U;DVMP1*"Z''QV3#>$_&9]:O\0,E+T`WP5I_;C;IWLA)JY MC4EKU8,SA:7,U[CARQ696.I)-'<*6L)2">0BYHL\%^/@2>8TD2"0_`GF M2O3Z\S0=(Y@QG9^5K#'<"XMG'F@F/I/KXV=/'-8;_"J,BH-J)V6S0C+G0[#)D\M]A M$@L4BE?_I!:VS^ZG&$5MJ@7X;:ODO+\/+S%63=R7Z7MX:!"4@\HM14*6M%N: M)/I,$B:NW`.WS52=^`M?,IB"&^?V+;M(#%:1./@'>2T2-$^O73[59J=.J`4; M)-4;T-)2>"/5E+JO#4K2RRW7HO=UEJM`-=$]@GT))!`SK^M*1V8F4=F*I&]3;)@)RGZ>\O!OVWZWAV629S'@5A-Q)FZ\W/T[ MA@_)U<$Z!"O+9(*N;R:^B\E7$P?WI4#L3-7`7_!>$>6C@>`^V5K<5_@2""5' MTET*.@_"2?D&MRT;ZTRE>]@@G9=GB7#RW`0FM1E2,'ND,!7#E+<]9B-OY40,M;):_"'7B:O-(G,+ZHZHU06UQ93T(^D;'?+ZR!%3562#&E-`CC2H MSS6HLJ@J3`97B"+@)[9[D021RDQ^*:CR]`ATQHY^VCRL'4(K970(OGX2S`=? M0"N[[/0YYYC^:D&:N"ORL0?D)X:G@+`9J8*CF9Z1("[08WCSHC]ZT9]Z$?Y/ MY5!2.M1_60@J/P15'8+*1[9;I4ILP5W$;#0$0M`Y7!"P_$Q+6\DG M5-73)">8\@5X*KB>Y('&YL>*E!J.2A:B4*!E8/C%5C9JGT:_;,6FFL4>?>\& M70L8F1:#O:;TQMH'E3U@$EPJ1>S-B;8/6HL:56'+VU"-^!5$;)U.!D7"&M4H M4(Y3!1R;;[0-6L4>6;G1-D6-#0J"L?/'V`.ZIN/&*ZO)O,P9`&5V:W1&&9QQ MP^;E@5UA2T+"K7/[<(VHQRJUL`S]8XPH,LD)JJR(WAXA-S_=Y0Y!CR,KT]$] M>,C&Y.QA2E8LYK;6-5LZ2G][K24Z-T?T%"!S\(/T:EHC>'>#FC[VUO/!KOW) M(=7Y"W6(Y)$G$6MT&^MF*0,NH)-CJ]T+-MG4W`8[].>BNB2=/]=N)/FQ#:WB'U^=)#-.7/;,CSH*#/`-.]-=O#T MAH%62(`6PET28N;04(GK;O[UZJ+(IUF:Y>-@9+J61UR=:;J^E&4ZMAD2JQCG MCM[-TES(.UEKLNE]'5.._8B*,_S*:$^)3L?V*A$66[/DD^&#W4:FSH.(`%-V6V9P].EUP"WTS.!Y?9K)J,Y?L3UUC(HVZ2'^' M*=JN$-7IF-EE8&%*-W;DB7K#P*C1%>H;]>XD3@:8,JESN'H1C>H`GB:%[I"V M36U#!)"$&D/C/$2*OY1>@EBF5*M2$,L"B/UV!%]S?TKW(Y?7;!WT]Q![5/WF M/W17S4["0!"^\Q1[K`>([;:$GI6#!R,&7X!8@HW\)#5*?`V>V)GYOF%;P%,[ ML_/_M[-6Z1'EPY8^_("[X^YBG1*1-E9F.@0?&%9$4FVP6BBP@9`F[LT'POBT.`5&CRB(*)FK_#()U^]`^"JY+5TPJ%;I'>;^_Y#-90D MU5,+L@H_:G*3NPVO&FX!9;QZ%#)AY:V$/5+*1)\R5;)OP\#V4" M@70QV.8NA'EP@&Q]>2TOA1ZT3$M4;^5Q.X"P3W<<2`<08#%QF$'153:!=4-T M,Q"`($=TK(`%"N+>/V9&#LCT+VVY1%VSQR1Y"TC;T@)LQS!^`L"8+R-FR(<5 M_>.'IFQ1KJM4H?^D`;NLH5)&G]AEN@V;]^P('4F%I^&DIM79K320XIP`K;+K M*6&E5A6^>\YXD1QER12Y:YUQ==:MPZ;3D.@DWNN.64O\QE.;D_;R:P3*PC?/ M%+(P@%MV02WY#SV4*QR+`*75M?^%)7)4Z'W1D_2K2L2O]=?$0C9_&[V. M_@08`&S_'2P*96YD7!E M("]086=E(`TO4&%R96YT(#,V-R`P(%(@#2]297-O=7)C97,@,3"!;(#`@,"`V,3(@-SDR(%T@#2]2 M;W1A=&4@,"`-/CX@#65N9&]B:@TQ-S8@,"!O8FH-/#P@#2]0@ M*G[`I$CNX#(#S*,EK1RY9"MET:IR17F8)8>[C'A9#NN>;Y:9?K+I=OYBJ?J$&SR:#J\DD*J,F M\T$S;FI5XH\_7!G'!C]Q'*.:K`:ENAU$(F)/XTEUG_H;V^+>FST;3&JQHWN"W#H M3O;:73=3;PK:OR_*<=2[13$R%B<;/E_SIKK^W`G;=+'%>3FVNBM&1+95B[5Z MW6YWZB4S@+VD[6F[5+^`I=%=*ZRJ7<\4"=<'2K[H`NGH.I.>JY9T4N_:Y1[' MAM38%O^M:+5K;Y:=?-[WB?IA,8-+#+%LP>BT.N.<;_ITNL+: MP?'%J,'O(K$+E>JSC-NVGYT(J`Y79]5YU2$N')(X#MC;S&5[$V,[O4NTH"(+@FJ36E\-9ZG^4_0!'R/[R.:%3N`,/H M#C`L@WA]4P1(F,\7B&FMIUW/2()66'NM9ON\(03K6_P`>SO2W4*[P#;.%T(/ MU#"96/'(M%U1)LTIG'UAZ+Q;,^>L2Y!Z49!90CKM&$8>0:GQ_Z:P)*57S@R5 M!5[&2KTB=HAI9[/%#IZ)Y%0B%G/D=)B"P^=WQ',*&`<&Q$NOBX M[;-7TIW3S4/7PWTW%/3LZ[R26\Z"1'C)L9R>NB&;+IS9`:WX,(5G+^'**GQ& M$+%BE+.([+=L%O'(4=)!%)J"K](?1-43=]P+<"]&DIV?;&Y/`W?NR0P@47#: MK6ZRQS-LQ"1@3F5$2+0>4+=R("^FC2G=H5:YG#65W$V>4__FC/90EIPPDEW4 M!-CA=#=:23'9T+I*1-WC?[(5%3N@A&8["<$"E>H)^39A^5,2NIARG:Y@!*<; M;!`58$DN5QYEL-OF;Y&S.]2K$YC?BPYI='B7<<%G2DJCJ$H%V4.'^SYM>5=J7A;\>)XSG#2<,ZF+;/?B M&KFZT8K]"",+PVTTD/HLC&<+AWQ8U]GED7O5JU?:+\0""!X)W@\2"+'ODC6%4U];CV/#D2+DVN':X6/Y#WO6VB!**)EG]#Z4K] MXV;,XX*I]-N[`OW24'4.N(W:)I*EH%J*L)'=ZN>UD-"(PS14A-$)%OR#3FT: M*9:^L=59;2N/<;+'B:#ZDGZUKYW^.35$RSF-2ALU1ZEH//:3_&SY8)YT(E8&-^)TI\V,K(5@!/X<@4O&LFJ"O#T&[F"3JO1;< M_X6*O-7OBPQ[3]P_P6VH4LN3%/HUR6-4AC_AJ]^!J630C=#([=1P@HN';(T7 MDO47\>#3#*(FZ33RZ/Q9B&>03;43'U0['`$I_15)7^AKYBU=^8)#E=%'U:IXMUV4*/9>555>-%:Y1M/_8;&X(C9 M;S`?/)M<\"PP5M7D60AQ)(3<6G-W0JJ4P&HJ$X21VGG2(;C*TF\,/F@S]`3O MDOY9J*>ON#>24V+IH:DC35%Y:UVF(XCR32`KJFR%9).3"LX7AYHKU9/;*8"- MIU^#?GJ>BZYQ.1FK>("(31!YT3X4@9.%VO2,R@Z2Y+7\CODQII[1BNIMQ;VU MYJRL>>YE\#;$OR:BB&?DM?`*Q4?"%J#%CUP72P%87;.C!%^&812U'5(5BKJI M9>VO^#XCJS(1T?1E]3#(LLJ'[%6J!P0U\D9P5GN?CI-DW\C:B.3$;))(H8FR M2CHY65W`UUED&!SU$1Q?P`;*H#:PR6M[582DN=-4ULXA$;X("/=_`>*H]''P MM%%$O"QX*NZAP&)7T*OD5_4 M"'9MZRB&6%];AGB=ZFRM39!U)+1ZG5>$2*\339!5)6`90(PSAY<4>A_;!H$\/"*8U&[0D9NDJ[4\X2WD?+/>JAV!%I\R M9*E[RNV]/'S[*?%;FAF)OQ5IVTYM[])W+Z[8IDEX,Y>+-C+E9#$JR4G;JY6T MCKK\PF`3Y,/+C MA0JN89%M3T[AH1I.$=4V^YZV\#7=4.FP[`G'<2C8?]L=CP>;J338#S3BJCL> MN;N"P+,D:T!X@SVC'_E\D@C0NR,#F@AI[,-XW&,BQ6]Z2ZS8;$A)C#T-L?Q` M\?SNH'E5-!C27`K=,;T*!X649O%Y"LTG.(P>$_)28)JIC.VRI^``D2Y11&GQ MH7F:EL:?Y'3W&0\!F(`ZBRE[1//K#<-KV5&A"E172=3H3-8!%C8<8!$S+)S` MPAY@\8;C_U_"JZXY<20)OL^OZ(=]0!'@0PCQ\>@93VS<1NS,;:QCWP4T1F$$ MA"3LX6_<+[[*S)+`]L[>"T+=K>KJZJRLK.F@M(C/;;Q)+`XMX#U%!K!!.^FZ M!`!(`@(`[63@O:3=2KL\NT(+R,"MX?YD:OVHJ@ M#\H-NP8ZZGO5%_O>RF6X3V:#7^GR(^[,JA+RXVU#VZ?_..L./N7!^V-_YIT` M!7:*C2[H?`+ZA?:"O]L"6Y1UJ*2(N+X&",VQB,"9Q1)B):1?!C!'DOD.#&A"YXWRI+F`-^QKQ M:<8-&!;FX&SF*^S:]OKLV)3:YDFVPZE6CI9K@I7)&D33!=R>X"MX?F1\<(MB MMZG!XY^`/>GO)'5*7A\K,%U&P-R0W\2N%L>Q6#Q+?-A,NXOAV_V?#_=_P)F9 MXORM:`';S-)Y'WZ7U/`\J<&;2]S1E`XZG3Q$\?+:G]6*66NLD)$J4GT]%+&- M.39.^?AYKO6Z:=V+J:[D8(_AV$+H!\E&.KPNBO7*HD[^&20>07VS6T[ M>3@TUWZNB5G?[;"F9V?7A[A_B.FJT6O&FYETA7T*QI7UA'$T, M-+-T\9X(U?DYJ4ZDME/\^IW^Z_%Q%NQ8VT]6JV=VZ''@G_DDF!"[@\ZJ>C7A MQ#+S#K*LR5IQW1[U+WPY5J=X:(C-WOY"]JE4I@N`Q?E^T:>%E^ZOVZT9*U]B M*!HDWV0\EB!(AQ:UPRA6I_U1@;TD*)DQADU9TX$FV#/R6\,:Q+ME2G$XG"T_ MBM>BWL`@*OX(C%):742))P`/K/>H^YP[DF$#BWYA/)_F0SOTK?Z8ICWVQ_TA M,B\TE$.@=2OZ*/S:V5,S7'@>=1?H/OM5(G$VVH,@;:,\ M'X2GF@/&-(/VCD0>OA^H'0?`IJ/25@PY.<'?L7YR`+6;B#2SWO$>>\32,40T M[\GRIAUS)5"1OTY[TM7Q8O?*:^#Z;27 MJ1NC$WUTPMEH1#99OY?=Q[?F30V,H)#`JQ`$\_=;Q82B08B1^M6$KX4.I%79 MV[JPTIO;A1Z-&=?<6B1)&R5CHE$K'DW(@^UR9BE&O@$L[*O("':.4:H2$TX M[3M#"910<^=[6'\7W3>^UF4%=AQ MM>_6WU@#._LH]R3:K_ZU2HITX*.M+^[=ME3X#2N6[OO^$GIR=K/72[AB/.WO M(,TZ9AZG0^E\2Q5/$]"=5[*+(,\7\5UX-8XL]@V*"3XCQQFF"TO\.&JY%NPR M!4,CC>WNC`$70\N%?)`;H2'`Z/FV9HQ[7F)14_/<`B?M.ZU9GYE=!6A(G`#] M?%"_E(2IJ6+CLTA,@UKG2J+1G+(-;]:;:)*DS'],!,/30P(^EJ&:N,K<_%IJ M1LMK#FGW(?^;F`BW*RP,%0_*],P&/TJ]GN$(9!=>KINK)9,!.5E;P"])3D!A M@Z+6=N\<_J<(%#H\KN36-?UWO_97.K@:G>1#W@\'3RP)^DCV;R/K3MVB;++\ MJ#N-%\3SA,,Q`::-S*;H;%A(P6;3KKUE=V-IO;!8S+Q]9?7T&I;R+*C"%4B] M2G))+:3-C%'Q?;K%SWPUH@K6%]C)M'/$<1>@XY1-&8M5=C?-)Y.K^/J8*J;$ M,W'IG?'&V1S/V4V=.-RBA4HRJ;\92RJF&^7W:[RIEBM;RCK)#UG]!SMIXK`I M8"A"XT\&?4Z,.O?>IG-VK5EC%\!/B5!J>8F8X`)SHPWF=_B]O@M_5CW4-;GC M,HD8#KZP5LS`ZUY-%NRB@KX\LBI>C?OW6XW7.J\&9<^MZ1$3A7[$V)NL[IY&P,DY+I[\:=I4?UI[!/$4O),&N\2UO[>[#X*0V/T*?R!LG`C M^JS3>,;<;Q2CRTP9L)K? M>*6!DK\W2L;2[MQ(2+SJ74O6:NQ\R5KENNIL2K\;ADO]#;\5^G,N:KD8TN5R M8JIN,O"939`CD=1(2F<]?WE%P9>E]$31V@VN+B&2QPRM4B$6UU-1MY<[ M)5-X]&'#EN*A1*C M5[4DYA"TSW+@W:Y6;:1NHQ:J9QUR&3S'6+'G0KJO5>IV*UQ@YF8T4D?QG5<=B6V@(@:?S;J"2%'*'WNXDQ[7>+^?KXZ<_/OUO`%VHN/D* M96YD7!E("]086=E(`TO M4&%R96YT(#,V."`P(%(@#2]297-O=7)C97,@,3"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`- M/CX@#65N9&]B:@TQ-SD@,"!O8FH-/#P@#2]0'1'4W1A=&4@/#P@ M+T=3,R`S.#,@,"!2(#X^(`T^/B`-96YD;V)J#3$X,"`P(&]B:@T\/"`O3&5N M9W1H(#4W,3`@+T9I;'1E_<7,_ M.*<>5+L?N6B@+9%%JEAUZM3AT]WG?[BV'OVS^]JW??"=&X-O3/#F[LO]W>?[ M^ZU)S?W^KEI6:[/"'S_DJ^TRQ<]VN=V:^^YN90YWG__R/3>'X6ZU7*W6YK[! MX/WESI95J3N5W9!*??_F`_ M5S='\5T^*^[5P3S2>X4CC3@&?L5'G9;M="9=_?+&H^3?]W]%K!?I,BOS&%?- M`)ZR0L(Z'ITY4QQW_G0P5X<`E#8@"O:W`?&BM\$A4HMJF5E^;<7DNC0F62\+ M^RTLS1<7#BX8/QC7^H-_;)U)%FEF>3LL;(ZZ-9YI<_R8!/-C+SFD]-%L@9#[ M`<$:?7_2D7`UC[09UO2G"4\K#`Z?;@]8I&D\818/F,KY=FYTH4.HUM:?)+H[ MQ-6,.)$]RH`!MCCYP)8\(8AI04Y^\_!OE,%`'Z53S39\CNELU,"4G(7;2?F" M3W+\'PB:BS6&Q9$IR?"_;@F6"''=UAS47_?FXLR^]NV\;W#J^L6,T>?;_&;5 MG.!R3G`I`7#=N>V3Q08HN2:$[<[QX;;V-$K0M\`A@]ZY#A^"Z=:.G\PE66P9 MC`MR,YHB>RE_OW]$IG5P!")+"BSR>=:QJR%@)&ENOV")X!8[`3E`"HKC)#N6 M=K?SE&W*2$K([8'H@B('1ZA<:,U@&C[#VG9G=QIT95PA-FIPPO+2FGT?#&'[ M8Y2LMG.8,@E3<%WM3SN`N-_S0L`&VU/>NJ2PGTQMVJD[FT$0B%'9&B?;I@#; M*FZ=SCO+QN?ZRA'/U;?"CL8]34C[J%BF`U/!4H7%(UV`&!S)C)XJKT32!O-2 M:+\)E"@^M.7:BE,E@4EPI.?G28#)BQFFV>E%]/H-.\S%DRGI,EX91^3E/+=>HG3!BA#NG2RQ>'C>-_\,/V9:0/P].2)/4D5#-&> M8I+"Y1YN!"-54=FGA%R8;K[P"D(4J\5-L!0]_G"D!73.83FOR)9%5 M2(.M7O`IT!?BKP]Q0X89*"H!$"FM^DXA`NV/;B=@QX'*O/P([$JW1*W.EVVO%A-E;L*)"@EP?K'Q+33P$%(X'*H&!6QC6ZVBEI42K/D@E(8M\..X3)<=B8Q\2(5P#?VN9,'7SE.1"&$0K M?B"<5U13/=4>*$H<&:9'WF/@1,A^-14O&">N@-/NB35'W(U3(,97_D^XVC)+ MB5L<:$!JE6_^/V.ZX`;:!"R#/$\#MW]J.E<9K,V9L^S"`%#A<)R4@Q0-2Y=^ M$@LZRXLME7]*KI!Z0/X)`+%,%M&K-XWB/0A>RYU3/W*)0/>XAFLRM3)"?$)\ MF$3"@TIC1SO7/8I%&,CGC&0(8E<`%%2]BC&<3!R&3`"TOO0L]$BBQ+JN-IN; MOE.DLV1.M1C[9'TC"+_QF\=_`DPCPE%,@G:=`6\EJN?$1JJ%.QYT8%Z2W+78 MF*^B6&L/<45]**KON"%9&U`36WO"%I7>FCF%-Y?ONY<=-0]ZKC>Z)IU!DBIY M?B4A!!2ZO?GS3]=,=%@,E>9`DH(V4V0T?9K.;Q&=,B$ZD9,:\XNJ*B#LS;.LZH[N?:% M>#?5)G\'\1?)O(V:&1W7\RXYLR9IUXM@U;-H'8_0I,,9*#)*>%1Y5'H7E?V4)07U.M^N-031+4VX(S;HHO1SP>LC]'-P^HQ[ M1I1OS!GY+#J[@6:.7H52[+?\0@V7\<^M<,8AN_(1[][206RA+-1'/MZS\,J% M0\)P0_75P4'GB]D/(?_I/!KVLN(;A90AV7HQ&X0[9:Y]%CCF5C]%54T,]VKE M@XT?%W7&.ZVI@<Q;?"V*VP^ID=U"X3KP]*M)10^(!C$-D3E4"':B_) MMU5VTTORV8N-%N"#_8DOUJ>K$8WO3X+(0Y3*4GV(7W$K;=[?I*#D:[K9[J8` M`E#-57&3!Y&)&M9*0X;R;/-6XKPT.HV08O5%AD7%VB+P8/ZWPD[U1Z<"]J?O M)G6B,V?6N,/@'WF/C>X!U/4J?"%HRZ*AWHTIYNPT5SS4^L][GFV>G M(S%P&P3.Q]M:R8[E\?0/=E3K'PG=;&Y7R!/HZT/T9(66DZ2W:?KI1"I6"_,D M:N*QE[(6946DKO8#,0O=2-7^H.,0KB:5QY7\_)(L2*200`SN934=B2X9*+1Z MULW;6SSDZ[F_KK3VPY5+D='%L=PA`F_'3$T--.`3 M+H!K-:B9S<%MHMK$4G;0EXL0GF>#!IDMD(0C[RMC`[='P_I9O_#JLS/-\3%? MD"HGG,LHSV\2`_5TFO2IE7C1D_ZBE*(5E\2.V9K>?TI>4LMX)5AVR*4TE!-0 MSI?5-^4DPG\42*:DID,L^;*J_JA.B>CGSE,@(1E?ICBD@-)(,$75_9/O^GRELOQ=GBFG:L'4OGN1CN31FQ"FV^A7H4ST8(5J,_*K M9'G.PJ>6]Y;N`#ITA+0<1KK$BA@\DX#@'%(QIU1;`/R@E#F*PB-SW>N2K`1% M]!)$M^^D,H>$U:#.G8"<=9Q2)L3%;UUF?Q3A@6]4(")/N>=._S1YW/:"9QF. M+(Z#N,XTS[EOC>]HDMKLSH/+VZMYAM)'H>R@P)J^D(%75A6?$GD M.QMN;U>CC2QE&Q+3U-SY2U_HRWQ9TJ@5%"W%ISR*2V/@7QX>^3$ZS4.$ZO\Q M7BT[CB-'\%?JL`8H0]V0*$J4X-NLU\88&'AA+WSQ7"BR)!%+D0(?W:/?L/># MG1F11;+5/<9>))*55965E1D1N8_><\O36VF2K`.5:Z&E+&]`D@*F$DO@MAC< M%H/;:K/NA]8S#J&A2.Q$4@HW#UI-379W84YI1=H\KAL,4*K.WF2#O*G'25SK M#%EJ7:$9*GSI?ZY$O8\N]KD^>_=V,MJ%@_9=?6L>TN/J-UM)<0F4`KUV`->_ MB\'5AQWPX<'!]PF,K$TGRDQ#2ZHJX,0:E"*3-I0DMKB2_+V+/%,#OL<;&QITK# M&MN+&MP%1>RVWWA&=P:T8SF7_5A+3>0=IU.ZJW8(Z:[K:5>;:'8,5;$4]VZ^ M+I`?6\BV/:YU@*H$3T!O0:URK;.(UK,]]^CWQB'`_$Y4?R#LU3[9S/ADQ/'8 MRE'Y=(M5=F#O;LA-Q%XP(H!TM]9D%XR%_XX2UK)C%X&V0=1;U;S*#=V&UKX/ MF=F;P$C0JFZBB;OAW$/B)E/BFC!%JBJ8EZ;%=G!E-R:K*FS'SR?KQCCA`B-D MG`X6"!.E"$8*58I8QW_+2^O\]!HTM=*P2J9UOHF^:3GK,D,%2V5.Y555#3>. MS"<7(9&"MZER$H`&XR0E\)$PDT9MR&C&76USSG=3#-XLF!Q$_;P]^<<=XDAG MZ]CH;)%`[UEXMBS($Y]:85C1*+%1G@I MU*,\>WLNZR(87BE':5]BGU,IN:KF=]UAZ":0=[7'KA\+@ZG+3::^21<_63UZ MBMKVR=YM^)L[VE-7=L^T<>Z7BYD[^[^BG1`!?31`- M.&@,!4;^$0@)7I0R5Y,'^-VA40S+NCH8F^>B"F]AP9Y`6!H[:B4K==;N1F*3 M#R]E]SB(D/87V\#6<**OS6D+F?W9Q[PO7T)0"LKG06=*2$MS_#Q3'+_\\7L) M?F%MN=ZW5VC1O>X40VR94C:+[*RIY6N\(LYKME+Z+FDMBE-$4Q"1XK\NJ<(3 M1@K761_P-EGM=\1;TS]L+N.OA; MX)X_#U4YY*1!*9EG+5-K33[66MN)LJQ+$\3:$:],O^PTLQ;;R(3-+6BE!CC^ M`A*G#BG840*+P1:"D[?*9!J$LX0HLH51"-/JFB8I6$]2K!G4";ZP%$D_G)2; M;T<%9\GJS9K"*5ZM%BI9-]/^&KM/"VA.$WH\Q:3\Z#G](*4>-)8CV^TC1-7@ M5W_)$7E>VOV,DSZDKR0>(SSQ%P6>'A1:;2`Q\0M=!X M\7[I8AY45,9I8?U1.IY70RZJKU>QVFG^Z-[B..)NK_RE3J32B&V6 MH/]\*<<7*(M@8B\M0^)IX8JA#='5M<_P7N3;@W;^(4[BI=R?'LAN<"D?\3`? M^?T9'"[DASA.N9ZMNUJZUC,#;O,FXL7S'!K@)1%ZGA=YZTW6AZ^RWYH'\EEN M>7I?A*P6.#SBKK*05TQ89N6@,!._3?VMC4&<^EE?3(2;SF&NT>N*GU':R0A"$>).V$Q:O1^`\,*R?T44JJ16%L&FC24M= M+4%SWL9$;_EO/A^4"EFZ2II5>2Y)T4WU'OI& MKBSW)4GDQ3L;5PXZ->W57NO;+1&S/B"KKU1J_NPNMS(6"[..T M6L5CM['G\3\UZ%-VZEFLBESIZ,^E1K5I93]Y&VZS=N%)<]QM.&?%OS\LGA0[ MU/8B8;$%ZWJPIPI*2Y\Z3U86&-^L=K,N"!3Y;ZE"&&ZCRO[;^]*]7LK:JCVK]FQDKN&ZMVB MH15AZCK1"[Y#WRM((04F;ND6:Y&KNUGFO1=G_@G*3VN+B=2)JI'#;"AU-I`V MBE32>UU9#X,<;!OU0U9!X*,=["BQMA`R$C]G`U"\6TZ_96U?^D[B\-/IY'." M"W+4W'P@A60B!6MUOF0M@%K"NM[/]4(:Q=18^NF?[%0]^$`T@VN5?B@>4MP4 M+R\5\-^"-75%*9B,8]+L\E-),8[(4I03?PLU959O,R'L&DWO;!AW=IAFC& M8YYMK?0-<[3IN$`;;K6?*O3X:X"`AHTEWY$J[6/ MGM36GDMM)+>0XELIV6Z`[*'M>I-''7Q?W,7*5N&%"T#;O[5R-S:C`1M(%CF"UL\VED*(^="2JC5 MV$G`JK/6A6R\!7SNV%U@2?MG`FVI)$(F!T4Z!G@L2<&'%P6% M))KEO5)/.(>P.'I1)-]7L_JZ$$[E[."6RWEF\X]QXS$<+4],_=_+ZWE3]RT$ MK[!VM50\-#RZ+#;`_=.IS"6X"FXD]ZI2';:.H6">4%\"M&4OJF;%?E"_%:-V M>?%+.88YV24S?%5_Z%E($4WFO4H4P5=*SQ@8&1,16*H:T*<4]+:5 M5.$X9*+,O`.-@:!ZBH7&6(XBF?3$5-(/_:4D.&O]:]R4"`XK5V1WW&L'*Y>= M>HE'&H&7]>'"3`U:`>?9SF4D\WU$C$T0"UII"71Q;](?$3:5=)F M$'8Z`-[R@W0<`S.V+=IT"9=(?G5]D_]J3MUZ:&<5#!T_77Q56`KJ)2L[:-Y> ML(#-FK*VXNR*+L1RFL-J/R/V="1V\Z2\`E8/`JL%A+=6IJ_N[L5WO2(#*EB8 MB!R>B)V*_C8O.Y48?YI,I)!+*V(H70*$98PY\E"@H\R(3690NV<,@BIKK;%Z MK,`[1*`;1(*_!H31L/07>MX,/2.29T/G4=^74--:THC)^GFW6<]C\DY/R9U( MQB3:3DQZ11L>K7L1`$%34U:%NH?,S^VB*'Y$7]>42[WD;95)OHK\1B):7,R9 MF<)[R)36J[C7P$L1&";59^V(RJ8(UX\5S2Q@SZTJ<_MT9(=86?K;UQJ05X17 M.70S(!>2J._Z+"#789\:6R#O#J5!VH MFT-EI[C0W$PEG)J`$NQBD#H^CU"=`JJ3:((B./C]4L.1N_\M`Y:3J`"9^D)@E,+&!XE@/8I%K"%<@%P#_+5-$"F5N9'-T'0@72`-+T9O M;G0@/#P@+U14-B`Q.3,@,"!2("]45#@@,3DT(#`@4B`^/B`-+T5X=$=3=&%T M92`\/"`O1U,R(#,X,B`P(%(@+T=3,R`S.#,@,"!2(#X^(`T^/B`-96YD;V)J M#3$X,R`P(&]B:@T\/"`O3&5N9W1H(#4S,S8@+T9I;'1E>S<.X@ML M!8O`DP<.R9&8$4DM15D[W['^X)RZ-"6-'00#C-C=5=5UK]._W[SX5.^*L?E: MW_:[?FC:>AR:T@R-N7FUOGFQ7NOGV&P.-\$B"#*S+K&Y/MW8+'#K_Y"@3`3-HWBQ#(/<9"0B7YKU:V:) M<^*9TR<.P?G%WO8N6T2VW=?=`2K*JC-^NVW&L:Z-"R/[UBWIR($]LF,]\'(G M=.7CP11=9:YH#DVE5.9C(1\C"6K*9G]QE?OW^N\73@C,/%HD>;CR2B?AI'08 MBM*OP9K;HTL6*SLT+L5/M\%>:,V(56BWN&UE:_,@AP?\7]K2A>`J=KQEGIB^ M=@$6Q6#JSN6VJMT\#+%=&;E"CLNZA;REO7#_+2.=($O2/L.B\2::85U0A^Q'1"@/;=V:_PU496,PE8+H47(D M'KF;F$+VS4_)(G`A"5V9/8(@3-/5:%;\67V?X%]LE,Y29D9U@S%#LDAML\ZT M--=5)"MM1U,Q2C7V6LG"**4K!"5E<<2*AZHX?G]*$5>H+$UD>'[_8FJ7V66[ MS%:KD+N(62DU&\O-7-X]I%\%,J(Q3R\2W%,?,_A-I M;3_)]]NU!/Q?YL-O7#JY?<^TGYCM;V\_TH\$Z<,OYE;.UB^I$C$]J)+?R^DK M/A+F7RA\,%$(;M\*^3]8U(??+B\P+TF9]Z]%QCM9"?FO8J"(Y4:;VS5G\O\= M+_'J/!-7XJ_UED.'\4&1RNR..^*._!5;V3IQ6)J."3>^-"@!N*?']EZ8:LZ\ ME'LPA7^^U%*".2I]8`=0L2:YEL ML2WE6/T@_.;."NN=0V,LE145*;SG2_*K62/=[HOUW*(`?#:JVI:VN(U#( MZDE6?\JN-T_N.NZ_36ZMZH=+\1*CRESYZW.M9LEN3\,C\8=A?&>K.W=G8XX! M;'0Z8L_1.OL,ZJ6D(HY[^I"80<9/`C:1O@M]M M(=O=QM-1><(./1^_R?F=$YDSI7KL>@W/J3-T$<4I)#./A_/,/G&&$5B\5_&= M_CZ(N$80IUZF*U5IQ[WJ_/OD`FO:?O"*RJU;`8=J!2],*JN?B1!#N=?+##`$ M3W&M&@E8R\GI=U7"9W)"+![L5;M';[OW;]-XKQC52=7POA59T_57=3+!@F#I MXQ?%$C]2LVH&)'`_`)>@EAH:.8EMM!A-_0?2D=XE$/[0H&^8KA!C6\H3;G'" M`E1"U4SX!3:%&3+JR`:WK7(,3X9F!B`+G)#@O.7&D$S,!R4<522PTYK0`F7) M_:XVQP[/!4HO(GI#732SDW[?Y2P;FGB3Z3&D0"AE&)HR$`X9=4>,JJ``MXR" MYEW(6N0\BU/&IYG]1NTC0_W#45_AH6*W\^YCFD'X/=79=XJKB4:\Z`G]K]G@ M(Z1&%$PW'C'N5G:_,.9MI\VK+/6BBJ\H`?"U1<0,>.:"GC@,^%^;X;CS]NE5 M[*;U7W2<91-\5??LA[X]ZGC<.:JH32$H8*P%!E0,4^^?*-(*#&CVXN(W='([ MT\T#28$17'5;TXMR)Q=I;<;B,"+:-GO#:)G]3#.YW!WY'J4#+O30;BL(0Y4: M!)9(\$US^XTRO#P9M=:B[=GR#TZ(_=(-)>NS*#9 M#^":!5ITVVTM:.3***#Q@T=&R4;2[/&..ZZE^M MG\]Z[:@7(S$+3%4\Z0.3M>@?)E"R9%`B^`-?CK$=L,G55"UUAE>7FZ+T3,&$ MN3_JA)-345RW=L+77FKJW79IY^S'?2.<"L,_H!#H@8(+WHA""11$KB47;1V% MM2NH(^ZYCBDNW)_1P;;%X9IP:#;R$J2ER%.Q/9M10-@=J[]2V$L9&BO;Y&K*7Z/M=)2Y%$PJC M"Y<&TXLH4FB#$)(+J-ONI#>AYJ&&:3J^8M0BI[G$KO)5#Y4./3:_\JC+.*@T MTCII)!M6Q'>1CEL0"?TJHY`N:?UG-WJ?JK[/`%D03>U;F\6^/ZGBD3TUX@4D M&B'Q/<84X:5I$SFLJM_VK7BU[17=F,\C7,<]7%N7U:,33Z7.<`.6APJZQ3UG M[$KZ-68I8'/9*,E..NX%,[SH&9Y!Z1*DKOC?QZ!0M5A3DK#S@R;IW$9>)HEH3Y+.:FON3_H=QH+J47\F;+ MZ-E`W.1V!K2\.G+%#S_NF6DXN3L*Q=V`*SEUX18_&4TI@@"&1@)YBVHCYT<; M)]^C6](].=^CSXK,GHD+446$5-S+&UKD\)E_]!1"KF(>Q(\R>/AJ#!Y^@$4! MSYW<1@LQYL5ZG1EH_7"S7`1+H`:X)EE.F;0Z9Y+V!Q0(KL*3UD7VT7QPE)$G M_M\)B$-S(V!_('!#^4,3ZUW1%1O^K%M`D9EYS1R-"QC\$3VE%C0M5;P*06^N M3/HSZ_[*$2I5.E0:4X@(U-SNF2[!I(@8BAX4H>\%AC^B%9IC9I(H7V#.M6+B MU*ISK1KS_MC>U_HXHIZ-YY$+$XX(P[G*O"^DKT3V*`0UOT:84EH8XI)%G#)A M>,Z9LV,C';2O!!#4`F(Z6OV7\&I9;AM)@G=_15\<`3@D+KK1>!W7DCVV0X[P MKA4[%U\H$9*Y0XD:@)2M_?JMK*P&*=*:N1#L=SVSLNHTNEG*LX@8^\Y7_(K. M8``_]#<=&;#6V?OO+E_]X[>OP=V.KYK@HA1.#VFD+6L%'%_=O'I[>6B:,LJ^ M=E:T,(P<+G%8A6YV0AON2O2)=D7V-=="\9TB2#*)PT2D$2$AK/E0-Y#`O]-M M]90K4A[K*&1B<:A>%82)TTB3=**\'J3A;Z=_Y.!Z*&L7YD+.6.#X44]*Q93H^%QB^*V1G M//1)9_W+1W)9$0U0KJ4?(F4_;&"?A<':V?S!RN%2Q=QHNS*GS.ZSPN2JN MRA;LJ?B:U']?\&_]DY4PG1)BV:E11W%DJK8X`FP\YG[*-<+7&\UXC0GJFRY MO8;AH^%S)9WC%YZ;G>>"GS'3M&@A2JBPM$P,"U(?RB(*RSE)^9@^)'R3%,W+%@N_H'7> MW/@?95W*Q\1*M[P%FJO. MJL+&.T';8T$OW]"A\8B:T:%!90E`<:*<_#WOX2H!PHT*S'G07;72*4)N)_&XT M2$J0+Z&J1V'.FH."*67(?)U^_ M%`-A%P.-\5^Q%AG@E#J+7)O%FS5\/@T1"U\1J5&*)B8D\P$\3!X-@K(%>?4J MJV2)94U3<%P=R"YY]6(T5+L*:-FM]JU3L*X>C)JYKY;S.GJB^BIQ5)LB<%'L M[N:V10U:(YH`#8BG.F.H-.+KS#>,V=+V%?LQO"=\_7)!M(@QD3N*["%;J80# M[M;4Z2AH`R5:K6K8[BZ%\&)QO;W"LE<+=XK6G49S32))^W92W#CN#D3LLO)8 MQ'(F#`LT3/^44?)4FBD/SB9,3*2(A5+YPIBB1J0/Q43`CWB<;VO04SG]`LH` MZX2+K-Q"]9`.!SX1[WBT1[(H'>Z@'2)3``T)G)5QOX,;??93&R,>`OQY)#_. M+A_SAO/H5.2P$O#LFL;GX;WKY_O/[+DMB)&F:MX$J^:^L#2Y'5B)UTH+4%/P M+;.'1.3$Z,'F7)KL;<+.CN+E:KKA'EI@4M8JLL5@1;FK(F(/W"0"UZPCJ]KN M8,;'PF;,]Z*9DE!D@=&D82J5-.)PNF>4E2.!KW1F/.ZY:*$F4 M<"G0;/@*O>8>W>>J;X2WU<>K1ST+0J8[%Z4YH[/7QO!EW,-#-7L=>,>'Z<;^?I/3H+;_ M1KA1)K?U^Y=LT99LQHT]L0")TYMOW6COBL_EH=&JPW29($]Z:BWAVZ$!013; M)PGIQ@V7T^8_P`1W#$W<(W"58#UTR6"%Y=PW8"O>ULBHBUIPOE'!$392+_&8 MR*I?:6]I0/GC.-6#.85LM-/371*3UH`M7BJ%/1%OW<1!4PZD?.:CK M>JU[SI0>SG.-UP>I&966&QVN!(4]`5*LITPD9K=<$^((Z_1B5;2AE=;W"X42 M_LK%,K-:`U;%3G/NX;&%[J!.G'_-#KH."@T\&, M9YUNOE1BRDN7HUOR=51]CS]WK+1S&"E;FFQN:=+`]Y.$_4)U<:-:L)&^8-+?Z5]49M4T%#9;!/LSFY8A MR.FS,"O_"A,",<$G3$!N>I4X8^8BE,2"B$8M31A)^M/B3/VR.B&1*3@N"L!( M"`E'EHS73J'&,]-%^QP-I_AN^T`L,:AP?,E`Q_4_^P',WDMW-BH&^00_\L?$ M6E__88Q4P\LNY-H20=NEV\?9?H&ORBH9!T4G-1L^6:>D=0PWQ$2Q\ME'QNWU M:BMH)B$@B!Y3MD4U2:M$3`MGP;%81#>I620`!XWX='+)[P@]:[62;+G*$=E, M/+U[^Y`R3EJ<*1AMQT\RRIX77Y-$JNIP(6[OM9(CK2+32CD*UW"A+4AUD0J< MJ3WAZ8>-]";I)MM#,7ATPH_)++38@7$:VL$^'H\(>D8.`S\M9R=3-<\LI;8Q MS[7='1EXLM">6M=)%;,8[;6B>+O[#)Z%V#9'W,]/B5-%A@;*WBDJ MW9J?@7WVV M@L<-^"`ZQXV;<^N]-I0+UW)X(II(6YC#,X%3MH(TU%[1#B(9UZKWC6T@+=[7 MA++=D8+:W+VC5".".HI9U59R3^W1.;P(+[`]"HJ:OM((C+1\:?A>,A!K5`$X M1J11(H$-5]JE/?$&Y#)C0NYQO]OAE=W_7C]SQ(_T=N=^ M[^^5I?`=VPM0+QG-]02CIN)AN8Y)46](\78J30+?MSD8A/A\?J\$:\$*\F$^ M//9X3%3[-"-@NE\>/$%'HH!)_ZQ/B62F29GU?5J''5@B93!J/?3DTS`#]Q6A`]*V&7/?9.B0]A5V#$#4M*PS'/VH5:'-SCVF3)0RI+S_7EQ]!W M?%@_`V]/^9X].?*/E@R;T[M7=N&5>NA)Q3K2-?4E_WKU_P$`?Q]^7@IE;F1S M=')E86T-96YD;V)J#3$X-"`P(&]B:@T\/"`-+U1Y<&4@+U!A9V4@#2]087)E M;G0@,S8X(#`@4B`-+U)E"!;(#`@,"`V,3(@-SDR M(%T@#2]#'1' M4W1A=&4@/#P@+T=3,R`S.#,@,"!2(#X^(`T^/B`-96YD;V)J#3$X-B`P(&]B M:@T\/"`O3&5N9W1H(#,X.#D@+T9I;'1E'">;\5:._,;]XN_LU)/DSE<->=DI5(D$`W8V'UZ^!_QR]^=SVRTUWVYX,_3!V MU^UF[!HS=N;H[>+HS6)1&6<6ET=U7!=>ILM+G9C2U7&2R5P:[YU,H#>7\:S? M[";*XMJ.D8]+NYW0FJ(TSNW?S%54T-TFM^;6% MI8NHC`M['[%UMF71:WYK;09?5<"J$Y'-V:Z%^+?]#F49=/:]J.=[0=$SJ79$KAQSI[QH,6]Y60J`,L M[9*>Y$O=3PIT:&]XZ;%LB3FE?PH:*VGZ+/AS*5W8_RTB\R/?TSFFG32PAEP`97X0?=24>.P1[L%"F,.' M^Y+RODCJ>$Z=WRP(6LA",]F)$@3-0=`,R\W$0P&"E@^6^Z2+EBO!9?8&A!NV M4SL#S6'"54A*"522!I1 MA0M9Z2@)J4C$;$2C?2O=NCX9M*)_M;?$Y` MSS+X%(UWSV0.[U`:M"W)H6V_7,GN+DPZ7>L,C4TW%Q5]D5S.I77/9X`(;/%S*0BE% M*F&T&[!]AU_68SX$M,&`+CVR1RF#* MMFN"+020Q3K\5WD=(@Z^_\99Z=AX'=CHJ,:RHL!%?.BDAI/2PO0L8@D@R>9< MOY!_0=[9X+JVPHU*_8\2RTHZPQ=/W%V*YCF"*M=2+S;Y$4%Q#UNK$GJY1>KF2UD''<@#N4N97:9W0C42Z0#LS&"1T MJT"WSPY/2F\L7E7+6<$ZSFHXDC+6>KK8WPQKH;"B+:F$)@6ITS.^\C1[4 MXQ.8X_))>YM0.DTJSL+D`2>"2SU4H0\FM:MA3F7V&T=/Z`\W&U0.M3:$(P7[ MG[0`)B\7T+3M9(%+.CAVJ4B0JX,@IW&#SNJD%9"4@8Y^$EM5O@E7Z""OD ME+=J>HI?*%S/$:[X`<+Y##$F2KC,HUW]J0@7RD2]0S/<<;[8$C2K`IHGA&'% M!FGV6MXAP=U>B;4*:(GQ,^9-I82K^'`<2D<*:'.5MCK,5%L3KZ$@?&4+OD8! M78I%D*V5=!5(ERCI^4[FN*]1._@HP5!,^S@'#DP(Z$%`+U#SMQN171XD"`H1 M]VN-L:(7LC4K]C#Z`&/%,*(8["1^8IBN>1_`?Y6`F\M801XI4692IU7V%Z(B`[\'0#@(WPUN/2J%QTNB9^#N9G5&&%6 MNQI&/[??(&.`V,GQCU5*!R$>7<<2+47(`.L')Z>=:/C=%2QH1C$K1")J^2_X MHEK+%96O0WQ%Y6I;\V&[%`U@#>.+*I^T"WKG8R1QY03C,7VD*&D47UMI_^=" ME8_$<.IG)V?+L3DT-V/E)[$XHYON1YJB5L[@.=CDEF-T.%OVD^G\.-W@VC)L MIS966Z\>'Y_>4[Z$*X=#4E<'!&0^:%*7N[N'4,]C3J6WEE1O,>6KMY9=U1'> M<%)+U:GV5><@I>O]-6:7T`=''S$L";VK(*$622U]?!XZK$D/#T4N,&U7B3!B MG\J%I/*/E2.':N(/JM(NJ_W+5:E(_\=5B57Q_Z$J58SY@7RF.$4]*Y^UB%`F MN[E7SZ"[JIZYJF?R@GH>3/^.>E;/J6=QH)[9[EAUH)[\<:>>+(,=A#)H:*:L M?DY#BP<:ZI_74)GRC(B2;G"(!T`[7U0!Z%5BX=L=:@"UP#LT.82!Z(VR% MJPZ!#`]*U:/2E.1%^O(1ZTINFK@G4LFIN>149.6>G5*"+?M>KZ;<*7L+]H1) MS0;D'/!1[II+W%_%G+#/8_64^D(Y9[<;B;6#[5NH#%TS+O%!_30Z^=`T:SH] M],:[0I@8,&QO]'+Y9K$H#%6@RZ,ZK@N3T$]>2F_RA(`C'*X?U>JD!""G=)U= M",_?GQF7_I4H5V7VY/UG?#P^_60^O_]XC-8IG4KMSY_.?Z)!%(`T?SDWQY_> M'0QZSY4AL^_,XO/Q)PP\/SX)!F@^OGTZ#Z%7")TRA(2L=V!XL:P?Z\ M'.WZ93-\U[7IJ MJ9T*TSE,5X3C"&48A>*7B^[VW:15YB9\T%&!T5S+B[WD;@U.OK"#)NK=C1;[LTL/F("`\0)P?6V:Z=P M\)"@*A'L7"@.9F%:1@6+D9]/Y^Z%342D3.NY6JM[]8<66E79FQ7V[T3&4P'@+79M(V@S:I` M+E*['GKIY=W@L^;J/C;FC">*#DO/>A@[!.GLO9G"*RG!%?L+4X.A"SZ\48$< M)TH@+"6W'RC06C:_6XM.SIVX6,/"ZK#:\5E-CZY^EPX5L#L@`H/Q9)=+WF6) M_KE!$Q./#]0<4\S=82-J>G:M5!] MT_V7[VK9<=P&@O?Y"EX,V(#C6/)#&N24P)O#8!=(@@'VD)-BTY822YJAY-G, M;^2+TU7=E#23W5ST()M-LEE=73Q71U><7BK.NZ7[;!ZZI6(L%XR]Z:FQN_6)`:ERJ!FM]S>P&,7B3Q)%ZU=$<@DRY]F1FYKVAEFT_JM:_+ZJA=KI"`+8*/KS.>2V+FVK?4UTYSF@D"UF-#V MKJ%*$:A$W2:P.-D(\]TL$A8QR1PJ/ MZY$`Y1(>0/\1*T#YP%UF9:MT/PM([+N.:Q0LV9=U=:/#B7ETW>QK;.R-(OXZP9J(("!2DF.N`-O.OU_@AM<&N:#R'VR;1*&YG#BQ=';P9)+Q?$/-_O M1BK9I8,,2@U@Q?%9!!7()Z,LP3-XI[]/[')]*RH+DDC_]1EX?NT"]?5O0KVJ M*7X**!SABRM=O*H+[D4N2S.G(\Y:3'#\0X/B'3D,V@+EG%F- M"N%?W3#Q8>E^[0ZK"33&_KMAC/89Y,S2`8Z3XS.G1#J[`=W*%ZJD_M( M;YB>VU!!4?1 M=[NJW.#SQJOF\:A_2_=+R-U+IO]VJ M.FTGD%Q/L?@-I=:758BD\%2H9@P]))]2A$`PT]:-OF9O&&2CE9`HK57JI*0" MV>NHJ"1GA,^[WHK6=JZR2BRO-K<@[Y]12$E?@IA')9PG^7ZB2P8^-SC0U1(];PFEK60BA%5)%KE?7:E9JM^9F*QD@Y(=COK"Y MU"H47411S/6]Y^S=>\[N6SGQYQN#(L`/2J6U4ND>&I3104X`,_VKZX::H:6, M_9E$KU45?"69G:!UQ'FG2D9DZA6>JZC6E+OW*`$IX-+%L*;Y?3KAAW=W'="O MNXF2.R,$S:M;//YY)Z'=K'?_=RL1KN)M`^G`.V8'T/)$M2&>4R=X"ST$]*!+ MOMO(/I/[J<3[?3ZJ0<2FZ*M6@=@XHT5J;F[UBW=131J-H>8%?Q))CI;6%1?2 M6?!>W46;<51'\#KCN8H%%NTEOX#1!`I6YW7TJI7O23V;PU8XU0]*UHT>+%E: M-?_7KW[P#AFX*)"F5N9'-T'0@72`-+T9O;G0@/#P@+U14-B`Q M.3,@,"!2("]45#@@,3DT(#`@4B`^/B`-+T5X=$=3=&%T92`\/"`O1U,S(#,X M,R`P(%(@/CX@#3X^(`UE;F1O8FH-,3@Y(#`@;V)J#3P\("],96YG=&@@,CM+2F0V6Q7M`P0.161!@,;%BGXC7YR^#4A*BK=2 MJA(QM^Z>[M.G>[Y>O+YQ=3%4W]Q56[==M7=#5Y7057#Q9GWQ>KW.P,)Z>Y'/ M\P06^,F7\'LXA& MP7_7_[R8A>'<+K(89N$\#FWFQ41+$C-C.4N1\P&%1&8=H#YS_0EL_",$LSS+ MS/5_>.X?P1+_?PAF\3PU;WA*!W)F%:`X:U[!.]P8^;7/?.HR0/U6!U?!+,,5 MT:Q?XL!C9*-Y8N,E.S([.M)&/AXV%3_>FN(V MN#46KY>8VP!U)H948C#->N=@VP;Q?&GJFJX2F_:ADH\&IQ-S#U=\<5P(0MS6 M]+2:F+:N-L7@<"W"M0U=%L6^JYI"SI6\NRIJ0(6960VX>2_;4Q2]Q$-#_PH^ MDR$D#F=",V"`\11MPUT]##L.G>O<(!N@:'AF@]BB@YG1L3LX_2)+!^#C`>PPF)\49%OBGJ0K:43J=6.QX[-T@>]&>:%LOI8B>* M"$$YQK(]ERX("2*\#CF.\8?QBW!GCUC*C.YKMW1U/_H2T!4/_-]UR(TPVU=/S MY<3J$Z)5TPE&=BI8UIX1;1@PHR'3HJ^/5.OO0]4HP[Q=SBGAB),+\FRL@U(8 M2]9UI>8!K(:`+"_D!W,EQ34GQV0.5N6.AVXS4B3\4=<'1!9*0.D\#+/\&0LE M4T"4A5;DG"591%2^(W`0LX]J%$9EQZ"//14"!V.)A$?U@B%KB=4E%;A*D`#< M6^K!L7<,GQB_D>T=Z/P=\2XFOFO*DPW,P&7;J)Q)0:5ZFQY&+58-XB01A1C8 M#AYV54FL0A>9L'A>!Z9&QFHCP]4':\`C%)V#SGT-*!$[A%;+,>RD./!U1F9- M+%7@3YT=J(13&U[:ZO$]TI7GVJ66LEQOJ0M]0.62*PHNE?6X>2KLJ.\Y\S+; M:S>UI!=P MV:5*/==R2_4YCN)3HF+W3J:)9=2#7/^^XZZAXJ[AKI(D0&ZI];/7PLKXD22- MS(X;E^>G!^X.+"<8S6_<[QS";56CE!T:^5`-.U#1#4LA/])>!WMA#5R0TXB> MW@W8)G6G>I^80=NWA+Y\?FWQ?A;^4?+V0 M+X'!0V_GKR`DF!!_(D4W3/Z M7L3H.NH.S6$O.9BR+=CKOLQK+[RL*J4;JN+R/01+_2J([;D33W7F&U8/KC\% M[0+ZMY/F&'Y^LX)?BNYN[.ZQ6X3WR'@!W8L`V&+D!MK M:7"XSWH>88EK.I5N??-UKJ0;],.XD6=OA=7:6R^_"-1&"G-B'J#7Q*#2'4HO MB^U_/9-*NY=D(OZ/L/"78^U`!2/6">KC/9L6+N;Y`GGF)$FGLAJKIZ$L)`.H MCEO"?>4_"I\:LX4\`TE#CXF"?#:T,'0RHPM^-]RUC4[)W?8Z&G1'/WVP*&E@ M)\'>&FY:N`'._(/17T?(80+/Q#M6W=U30RWU`-LCRW[D]JOEIU_7T[N5:&DC M989RAQL&>N%0I$VTH>K.F$.>D8D1^L"^FRO:G2/8,#4QYX1&]%"U1/Q, MRBA17^YZM-?S6))B6@\DQ_(IQW*Y"V50S4C39Y25?A-K\Z%K^3,T5`!*76UTN=)?G1Y. M0&D9E*FB_5SX$>?V#.=6<6X]SKT0756)U-7DW#82VWA+VW[PFEMT/O,!?E+E MX9?B\3#)Y62W7C"B3S[(LR^B*XRG;B?QQ'1HN5_M@L4)2DF_HR1)F.0M9A%5 M#KVF5`LW"!-6M.L>1`S6"F32M3X$4!"*N=0#7546(@U6LANQJT(>8:MVP!OY MD)T.S0(]M8%/K,MUWA)LSWA'3^[`TE!TI=@^IV-_B?QRHHV7GEH MJ64_)8HC3R033TPW%#+()C)@!M.Y2G]UFLB`,/R@C]L8GZO8P0;D3[^*]Y"R M#%X6WI]ZT48<1;6,3@Z=#FM$&YU`X'QS72]NB[F\GV&'!7D2G3X[G@"-YEWO'D18$&:H0!.L&>8(HXA'TP9'D MH3W)H^GE:GT)V,*?\X#4(,#$F5B2#VZ?0W(PL(BJU(-**2A`#'0-X0KD`@#8 M&B)W"F5N9'-T'0@72`-+T9O;G0@/#P@+U14-B`Q.3,@,"!2("]45#@@,3DT(#`@4B`O M5%0Q-"`Q.3D@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S(@,S@R(#`@4B`O M1U,S(#,X,R`P(%(@/CX@#3X^(`UE;F1O8FH-,3DR(#`@;V)J#3P\("],96YG M=&@@,C,Y-"`O1FEL=&5R("]&;&%T941E8V]D92`^/B`-SY.3F_J33DTG^I9M^GZ9EL/?5.IOE&3\_GD=#[/ ME5'SY:0(BU1%\*,/%^6A@28/\US-MY-(K2:GW]\ZM7J81&$4I6I>P>#\\T2G M+IC_C@>EXT%Q+@?!A\VC,%>9R4-G(X-'37&_,WC`+_KVQV":A)G^'IM"O^?F M++#P/P^F*30_4>JN"W^=L#Q:?6AI%-G)K:,(M0W0M2T9**\&$L MZOF+OM[U01Q:_1#D>E>V@QHZ-:QKQ:-U$,'_QR`)G=X%<%:N&YG9UNT0&!O& MM%5URR"%874;@(UD7S4T73#-0=%6&:J,FBIP8*&!!8"BIG`Q3.3Z MQ-\S!UG&0;-J>.L01)HGRF#J0"VPR[J48T%K.)"L8?7F457ECF=JGH%CY1@& M93I>86I"&T?)>!&3>"PRODA?WP<9".W@(JGN"8N[6CW`8`*W,W#XJJT7JFM5 M,Q#T1O,D+%N7FR7+OWNDF^W:1=V/>\&_'&UFHX+S1,F!44W,GG>BP$A@K77= MU[L6Q"]V<,-R-ZPA2/ZH%R>J:?E6:*\LSPZ.\*XEG@6'L'\H,*Z>-<,C8I#@ MP*SF>)GIT]NDAF^CP(^BU#E]=D-1GT"<.\#U@BE`7?\`2F?P=79S M!5\XQ@MFE]!%A7\B2LBT;)^18\`Q[VY/Y`R9><_=62C#[`K`1'E*BL:%]TWG MC2Y@GC^^$4WU*?GH0X`!P]_JA[+_5#^JMZ$Z#XP!G6JTN-']JNXQLHP^00\T M8,'P(B2YEW.D3HO4Z2"04W`?@^!`F$1AJOIZLD0J?L:;6:22HD`2!LX\I%Y' MP30]])/WY190BW7]!E6P:.DDB_2H*P[&.B2B4N?@JOB!"I_(^##FT7M=0,*/>9 M=,PSAI3"W4PBZ9@ID-YD>R52\,J2!V@#F>42IF+]!>_E@`G*=B7Y!43FUAWD MEWV*E`@](R>OB!TXCW`6X?`GMJ4:SX_;+;P.:F72G,)F17M.(@DC-)$ZQ&]BL0+*E+($[QG$R>ARZR.42 M_GMVC/=D(_SX=TGQ&07F0%0JB=(PC54.O/0U$H2UKB@R%1<@[(@'GQ/W(=T9 MH#NF8>`[+,N$[BCM[>D.?=."+>'2N?%AX8,ZDJ">K:G<*)L`"](>R=;HLN4: M!-V(QM>4,&MUWI7]PL]=L%#96E>\MNL?3I0G39^;\.ZQ^^'>F-=JGJG@KG8LSB M:1AA&@>CIG8T3V+VYI&PA`*F(O9<@S@H&ZT=:QATT4R#UT@U!@\>`_2-+P]L M?>+S[)B(&YP^G*I;2B0.$LF2([WKN5VH"ZHV'#X,F'8PYP'R`W4=*/)2*,0) M^G\!SX57(B%&FHX=6/5)23!]FH<2X052TXJ:K*17$=\NVT8JQ(%2R/HK\>#R M/0=(#?`SQ51#[%]1+IA29,V`T_&B"%?)TQ`MZ"(0+80A10N.\Z(Q6L:Y"]F$ M;J-Y(80*?`-E9Y`+!%;9_014C'8/ZG@1+O8(5,P,F<2V,#?F@20V^ M%`>A-]T77%0!97M'..?7:<\5:0/V+NCU=Q;RA'HG0[]W37V$/"1O%4=0D:LL M>Z42I+6N2)[A#H7JW]*`O@3E.(0W3/8,Y>.R\L>6JDID+($XP?#/R+51)N"- MS9J6-8?+ENH[FN)!/J?D*>Y4Z)^IS,O,ACI,62BDXJ)6!",-X?PU_+M1CY8Z MU8$"]RQKPX_%[_#>2%#9GZFQWUF*_","9B_P=)`*'93\N(#L?E9QWI6FXP)S M)Z\6KG:'AF@`UJ_4!]ZYY,>*-$T0T57&#)X0/=,4$"#./27`)^C]3P@0RD87 M'1"@YQ2[=_N?A?]V*WJB01RW>^(CCW1:&/'Q`0JPER@/GHE(>19+@%>S/_A^ MXE[D/*]?+("@;AD^%%:D%*H3\BT[IF"X^57(]E<7]*2! MLG#`%Q1DF#])0^7JE]"YBYU/-&_@0TJBBQ*?2C/%)O>#3D4<_?5]R7 MQ3TOJK"07W.1>YQ?$%:;6X35O99?!%F;%B\@:_VC:\P*;\M'=1.J=R.90@U/ M7,-9H/[6X?)H'838#9%>H3?W1.E`>NJV!=!,BA5SS9."RY:H6C:\S'_PJ$7^ M,\#CK_-?`<3]?X3QK\1;M[5;>!H9]B:K8`.O4$Z'O*^%Q MS^??-I3&NVYBGF*)+Y/'+62G*;U6%^HV5'.?<6,P2;>[>YDK38%%6P%AF?Z5 MH#+Y\[J-5?-N%B=[[+!.1K7V^CC6QY`^_R\X3N=SJ`Y`UO(?(@,V_/?D/P,` M`//QF0IE;F1S=')E86T-96YD;V)J#3$Y,R`P(&]B:@T\/"`-+U1Y<&4@+T9O M;G0@#2]3=6)T>7!E("]47!E("]&;VYT(`TO4W5B='EP92`O5'EP93$@#2]&:7)S=$-H87(@,2`-+TQA M7!E("]47!E(`TO1FER7!E M("]&;VYT(`TO4W5B='EP92`O5'EP93$@#2]&:7)S=$-H87(@,2`-+TQA7!E("]4>7!E,2`-+T9I"!;(#`@,"`R-3<@,C(Y(%T@#2]& M;VYT3F%M92`O3T5'4$Q$*U140T(S;S`P(`TO271A;&EC06YG;&4@,"`-+U-T M96U6(#`@#2]#:&%R4V5T("@O9S$P-R]G,3@S+V6=70: MGX>>GMTA6^->8EWCG639)1QD'^,9XI<;4U2^SS[,QCWO_OGPT>S7Z9R M&:=QIWJD@IV#KX:_B@AR_&JD!Z"9CY61'Y:4D)>;&J![K&FV'ONZ]^4%_)+[ M*/DN!\:(LX&?'GZG>)ERC'R*=89N@W^D&/>5]P\%L@8.^C[YV_CD%2)H,T)$ M'D-#,V`FWB:=HYT@G*#;WQV=7MV>G"$<(QXBGF1 M>)ELG7:6?HQHBE!N.U,(^W+[,?=/^^.M3:9@GG89GW*@?*&#FH.MA\")?F88 M_'D&E[`%H9J0DI0?F964E8^9DIZ%J'6S^TCWX!C[/_R+!?L[!O=Z^3FXISAFF"B;`8]]+W!`6U!@X*96YD7!E("]&;VYT1&5S8W)I<'1OH]Y[3TL:\MJ49MJ2SF:V,L(JJ@:%Y"*)WEG5T M&G.#=GI^'GI[=(5OC7F)=XYUDV24<9!_C&>*7&U-4OL\^S,8][_[Y\-'LU^F M@F8^5D1^6E)"7FQJ@>ZQIMA[[NO?E!?R2 M^RCY+@?&B+.!GQY^IWB9],9LX]Y]SSV7??MP(!,`"KH5$YZ[K"RVMCX6W`R@1: M9]:U1%NO&O/P+.#F-P'IJEO>;N[]^/W/Z?L(\&YN;&UJ^>^D?<6`[R[`Q!%`BIM_9'-+^RV?_NF5 MU[@.`$GMBY;415_]_6[N;>L"C$DMT5M:$QZ5-F#%?L:;BZ,M#9-?7K47Z&AG M/TM;ERQK9]]\.N:X_M:VAM8%4]8,`-(WXRUXC78,-FY%DK:1[OS/.<"_ M?SO'G(,GOW;V&4_#ZJ\`M)?5.@$U'@-Q@<>YP'.A^/-W2AH[3KM@T!Q4P8>G M8&`QAT8A/%8A!4R$BNQ#H_IKYEA MAP28(1&U>$2NP!@.RV3G?N8=*BG.8\XA6JOP!"L_ M@Q?Q&O:*2"$S9*(:=6AA)]MP4N]$!B[!92C'3%32LX"^-MS+NNOQ4QQE5QI% MN`9A[EB)+>A3ESICG3>0VIN(@Y9V`6 MIY^+>JS"6KR)8S)$)NNU^B$GPOWLD[T,1P[[+$(3%A.'5:R\`;]CQG?Q'MYG M?+5:HCIUHP,GR8EP3R*1RL,$RC1V/(O=-N%6W(4'*5OB.]_`W[$?A_&%)$NZ ME,A"F3AHO>I5^ MR7.-I]S39Q0:4XU-QMZ3Q_KW.R.=,LH<9Y>SFZQ*Y"R7$#V3,HI5"W$%BE&* M(&>KP'1*%:[C>59SSD8L9!^+XYW\`"O8S2K*G8AQXH?P*#9QZB>(WI/X-;;# MINS`LW%Y$2_C+;R#S_`O'*,<%Q]1399!1"1#+A:3F.1)@%)$F2`39;*$Y'LR M7R)2+XMDJ=Q.N8^(;9&G9)OT2I]\(OW*4N/4->IU=4@=T0/U=-VH;]-;]4[] MMOZ'Q_0<,M*,)F^2-\.7<6)__XO]?W:&.:N==+ M#,HE!J.03PS&)YW]"7T\O[T$8E=Y.6[^`/>IWQ(SG^$C_$)/J5\ MAGUDW9>4(SS7XSB!DP)Q'R4&$1LH?B*62?RA3A*5()*4:EJL,HB MLI;*55=2KE8SU3QUO:I5#6J]^HG:JFSU@NI3'ZD#ZJ`ZJE-TFAZJ,W2F'J'' M\@QFZNOU#;I>+];+=*>^1_],;]1;],OZ5?T?W>]I]6SV_,KS@><#`A\U.HTU MQGKC<6^R-\];[KW>>ZO/Z\OSM?D.)5@)UY(=!7+^VW87^;J&M[%(=?1/Q@/R M6W)B'OQ(QR.80KR393G2L+6_4F;)FWB.&`VC;2AOR$(BJ=#6G],_'[=Y,CW5 MGGMEO?22W3-0;CR+3CQ.+F_'5X@Q;B=9/%H2L$B*\$/#K[[B33N*MVE]CFQ^ MA9J-3?HXUO`F+.";8,>U^WR70PWIALWR7"RK(=,J>+;Y:_DUA_)HKN!DHG% M$R<4C;OB\LO&%HXI".3GC1YU:6[.2&M$MCG\DF$79V5^)V-H^I"TP1<-\J<. M')"2G)28X/,:'JT$@9!5%C'MW(CMR;7*RPO6YD"2,;SXLL.159W+CBP%<9&=SAQG*:`Z:MD3,D%V^O#D6B@29KSLYJ=0J;4@J"*`[*9EJ,C6[ MS&KMEK*K):ZHLE!QMT+"`'9E5UC!D#W5"KHMV#HG%*VW*V>'0\&L[.R:@H`M MI756K0WK6CLU/QZ"TG@9VUMJ^^)ES!O=<;#6[`[TQKIZ_*B-Y*?46_71^6%; M1VO<&H/R[2E6T)ZR8F]&0:!'-L\)VXFE/8(YX>=1X:SNGKHZ&*QQJUU4&NX\ M.SQ+QT(9-YKN,A;K-.V-L\-G>[/=[YH:)BT(3*L*9[-K*]1ENF-4A>,3,*ED M%+))U^:.>6K@!BOD6B(+33O1NM9JCBV,\+`R8S:J.K*?SJPH>=[Y&RI"9FQ. MV,JV)V=9-='@Q=UIB%5U/#.UQ)QZKJ<@T.T?=`KI[H&IWR@I`\Y6&L[XXEH\ MW-78]6FHQ>W(FDJ*V&:=R4["EJUR)KA?#1,0JYO`,#XU0D1O)'Z1F+_8/0@C MQV^9L2,@$:R#!\ZU1+^Q>'/\1^"J+EW.4([^T[J=GV_GY;E,\97R:-G9U?'U M^(+`HW[6F$#)5A;JHI+B3DV=GN*:_M*4$M%_;JV>%3:Q.U64^CI#"_ MQE81U]-[VC-DKNM9?=IS9GO$(IUWP/WW>8B=D'OFD^I/'QQJ+K8E_5O<#:?\ MO#XAL]MCY,0JP[G1V-JLW$BLJX9'4\:K&(N56699+!*+_I_SJH^IZCSCSWG/ MN1^H5U#Q@E(\4/R<\P-1D(K"14`K"*)R"\PZI]09V82T:R;SCFI<;*HNFDZ- M-=89Z]:.&BOW4@6F-8Y9W!H7E_5C')JZQC5J:M753I=&N?L]S[F'$M)_-I+? M[_>>]_-YG_=YG_?2'MVZ-B,M(6-G:VGISL;B-.>:V,'%:N;*%^=>6.I9]^@=_&CH MZ;O=]T7<+K%]P)]ZU1VK4@YR:8N>0UN,'JHWB.9X4JG$W4([M+]2DVJA_<`D M_9=4@_8&1=%;^!Z"<6O4ZKY'Z)\#I`(3@)F&/-AD`O.`,F`:D"O]*?HYS^$` MAS8!=7LR5PF7VC]I"WS5Z\'Z+4AGO6_;>+?NHQJHVS^[@=%MQJ'J5C_BBK0-M6]GZ9SOIT[W!$K#_FI@ MCYO/'[$7DK.HHY48?QLZPOB,QL*690RL=9]CU/$5^P=U'"<5;*^7M.G0(`-S M93-X3=@P@_W.9Z\%^VYC[ALXHQ,,XUKT,^`"QN1+7+;0=AZ/>'G$:\A9Q)1A MQY^@D%7.B%$)NV+GY>";DA=*`CX'=P"K4OP=MYC[&/VD>E.-G$\<. MQZC.!53\8TRGP M`^*88[!?MU*VW%7>3[?X<;2C,?LJ^-["-P]8]55RUWF^28XZONG7J33;707? M-V#>9Q&O/EJN'X4V0;?1(L30#[0-AJG:9OX^P-Z67U(VQDHAZ&-V/?3CJ\&^;9TL+_Z_18[EV_1 M$LXSCL(O'#]=T&+H?3Y'Z#U;*9]S(;[OQ/)A)O::Y9Q%O\_W4+%QGYYP_#[8 M_P-B3OP^V-^#E7,IYS,G'K&6W]F_Y`/<:SC^_"VZ[:Z!7/E.@5 M_4CTBOL8D`3XHU?49?M><^XWME"YZS_D9U_Q&;,OV&:Y;[EV7#IYWU5&>7+O MCM-"OA^`EU MQC9J,C(I#NL'N5WOHFKNH]^D'.GW*3UAF'C3/J6)1C49TLY^Q)K&2XBU+OCU M".P\BON,.5T]^"[$OHYC#POP'EQ&+N.U./]"N4[R2Q&EHZ[<=5%RS*9O\DOT M@3<#;UIV%U-OK@F*F8@YZ=[A^$]GH/R1.X<'JQ+2;\V$N_YZ) MWN#W,,Z-<[M,M4YNC6DEZEZ1O'!9C3,N:YJK+7K;U::VVW#*`W4PM(MV&RMC M8-O_6O__0%EXG^NE_!%B&_D-L4*>S[690)JCV.=)(`1,]$[5#GKKM79/D!*, M>JJ!S]8;192'\\[#F>09PW$GI])8O,I$BB`K]:UK7[J#?/[Y_5R M_NVI%E`"H/1%87V2V:Z71-0D\VX@5>M&:X)>06G`3*``P$F`!]C;I\/9-FD:GGJ=^QJGO:.OD> MIZ>(IL;TL9B.C>D86U6FFB/??CTI/,)L/*\GP=)\/9'V`DKWA3?78L.M8]'HL<5MBXNE0R<5#6>9,P+QJA_RA/` MC_"?Q;^H_!YX?G"B=J;:=[':]_MJ7^![ M:H=JPK#GA0N8M5[A]X7?%;X@?%)X@_!ZX=7"0>%YPE.$1PN/8J8[PG\2;A,^ M(+Q15IQ&0?!HX6'".K.V7WBG<(5PF7"IL%DP,NA[/^C;'O2]$/15!7U'XBFN M76T(-U>8Y]13M&?J+M=L!,.*L+7/#"2H,K*&^+2EJ%E"EMI.*U%Z$J5L6H)2 M3L0*)_O;57;$>C,).C-B_6(D='K$"HV`3HE8SPR'9D2LJF'^P`251HW:4,38 M.$3C(>AC%,+DIDJA$)8UU1@*Q=\2`Y(IY/DW^OB5'WT>TNLH):*406M0BH^$ MWGK"WZY=">-6(H8O43//HUVDIN1:'J5UA7M_9@:2M7><+6GGG)(^4>O@U;4. M;(3U#-2D1>AS.F+=-#'OVQ&K)Q4:CEB_2H2>B%B[1T%_:V],.VYO3'M--)"N MO4K/C7HHRQRRMZ@=L+>F/8/_>GF1.NJ=IDF/M61-+I72&K(T+V6@M$H\%QBO MK8`GEFIG496+GQ)7:0=*V?T#YI#END#G4Y6J1D:L3K'P&*/'$6GYH)Y0\/FO=YV=2AL_LMJU[P%21G^N];= M-/\MZVF?_^/F!O-=ZP]C_1V-[:[9I\V3C9^8)T(=;%S8_V:H7:N,-/A?P[BA M9\QC;/RO0^A7D&`>0N3LPN#GK1_'^Y]M:GR3+2P9"_S&PB#;YX=T^/Z_F" M\2/C)$+NB=N'H>[]6]``;A\;YK>,O6DT5BN9)5@O5<_%<<3ZTV/%?,'8D3$R MQ%0S@EC,)[W-"%!1;T$[S0B#I*#K2!G.^$'G4C7S2.3`,!&)KX*#H M!P*WGH9=^EB*"G\4A]_'X4(<1@;\27S5&7P&87Q2].^G*@\A/ST_^-?(+XGM M!.!-23O'H;<#/0N]MY`?\XBJZ*C8T0:'&[^.?,PJ21V]J(/[K71N7@%=)$JZ M>CD>$VX5_7!7Q1M%_[?XZD2\_N'4Z^+!XV=F%+]J('!L$?R@F.:D.@';48<4 ME&T&YX(\*5\G^HW\&:R@/S_)WZ&)9U0G/V_C/_>!@D3^'R`NM:#AK_IK^8\" M[PC&WW2`2$%9(9_`'P^\5VM\PU?*]U-9"DJ^US_,]_A5,(=6#-#[)1E#[ M;/"G;/`U-KB/#3[/!K_#!MO9X`8VN)Z-3(\,).0M+`<4E,J\XG*!F1D5JO,* MRP4V;T'Y7"Z;LW"9W!PNG3-Q1BZ9TW-:+I'3<"J.XQ2CD('Q$$]# M#?:$1K8@SV9+Z%Z#-8)5JYI"S6]CK?6>;V>4(5$@\IX MD=(N4J"T!VB,TJ!./I!H/X[3#DDT-#Y#DUU!AR3:(=D5B38+R]*""M$,"]0,$=G@B^W=`HUF?5NP_4>3T1YN]TU"J-Q*[.>O,GQ?3___/^TU_W,! MS1['DRF/N1P#W?=/G'>W0RJL[G:PEM"!Y[:90MV;+9;PB?O480DQMI;-6[91 M;&T/W;>VUX5.6.LLX>[SL[C/4W>WM2Z,SKO7-(;/"^UU8K?0[;:VUGD'^F[L MWOO86B\]7&OWC5DFNT$GVTW7ZML[BWLO=??1M?;2M?;2M?J$/FDM[-Y.2\'* MQC"':KRU&^(X0-0J.-@MYBQOC5';42F=\B59IB[S&1G"QY#:X0UIK#6A!##J M6E"]H)JZX#6)NA+A5S(`+O;4@.7\1`"5@>ELLBN$=$"O8L[H&W$$S>'F08I%+((WC?*88A M3RE9&>UBM(P;^-+D6*&]XUI^U[5">\^U7'O7A:I$$F).3Y4Q?6UZM=K+DUDC]ZL['.-5_RL8G@TL^L: M?Y6L/1RKP^>H'1X_C/MC+=0.CX^/TRVJGSZKN"P7D0:EHSSD1&YT4JC(RG*>D8QTR82*H&?Q.SD!?DER-92P9;.I+%IZC1-NC:7R67GJ?,T>=HR=;UZK=I/ M$N%X&90ZI%=%<.'IQ-OR9?J7OBV=FN71OZ"J*JPK1[H2FA?,VE1X86DZ=J8F M8J+3ZHWDA9+>D;:VD=Z2IG6YN>MB[95[\%S<,CJ*6_#-HW$DW(;C6SC(+=,W/8C'<6=" MBD/_WT!`W89*K-=IBUL(TBGX(\6K0[UN:M=5"#5@ MMXDX[^A:&+=>5W':ZS5PUZO9K3=PKBX/^SP)]CS^^7X)E^/S_KS>[\_G6RJ> M=75BRWZSQR5^,6>3M.9P!SE'ZI`:Y5]6-7*R1HIB8+<-*#G$UFCP2O[YUZ1" MHL(,\OA7QXN%&6$F\>U`4K'/+&>`%PN?DS+4TM''NYUOO_)3W*'?V,XPAJ=; MY/#]]?/3^`QV(R6R#R%$;O7+E52$W!I4K%35]R8E`H5B(,T"BUFEB\LPJ@X& MJZLW![$[N*QZ\V8XPO\JQL5-Y'/PJ!:5!@2UBB<$(I-01."$010AWUYF-G*( M(GJ=,#YY$U7-5O3)LTF&_OS1/'/FAH_>O1T$=;[B_QY576 M>9:6Y[?6[2#GH/6>$YWB/\49\;8X>O((5N'?B-?$\?*\IW;A)?C@\-$_@:YI M\_^E>F7M*!>M&D(ZX@Z;3!H+I/:R`0OMHB)XW6#.1C=2&?]`YA`A_P;],_"S M_=:)U`BU])(R3[@3C\:%&,2O?SKNKXH!H)YXD=><7>HK2_SHDE'`R+*!TTQH M--$:S":S*1T;&>F#=HZ[:M&S:ADKIS4*O1A3LVH6M]U/4:O5Q\[/L=NI8U]B5Q9I=FW5'!8=XL6O*E(4O!+^AJ(E%MWS]ZA; MH'`6.A0HK"&KK%LM3=;]=+MYGZ7#>L3R,^NO+*>MJBPA2ULFE&EIZ+R-Q3;$ M\XB%]UM8+TL+V2)X.*!PCV0@E=6.8:SJ+ILF'1,N>XXP3#BD)H8P/XESLB%8 M9^/0,/_LK%0[R#`3CU;%0`6X2=04>5$0!\T@AZYTL=0RP"6CS%>)$YE)L+G$ M`:(8#6;)`.YQ\7A;T^H67NY>[V2_?VGWC9FPV"C_&M.O*CE..?I@F-L]=A_+ MVMN[ON?4O#%V:O43?[_0(]X5?P%J;<@OJ.0XJ7XO$'85ZB]!+?`TH2H&Z%0H MB"H?-&>'-"%MA.2%.<[C-$.Q`<$IHT<]:K4]FS%D3ADFP;2Z@?Q2.P@0@B<7 M2L5LZL9B#+=+:#$,D(HY2)YX!?0]4;!4IFD MPY,7'DO7A=KEC)T8#8S$=7:6]\GR-W?MZ3W^LG/5 MKNFKZ[^VM:MMWXJ_7;I=??`Q/7Y&=_*ETP<.'!?XI0WTBW7K=Q06ML@N'BOS MO-W=\-HROB:T:?J-+GO:"<@)A("%,>`[']ZP'P7TL'O(/83-D>5X?-Y63ZM7 MYHU0B\,T8Z`7P2%@A!-#,S3M)88041<,:D+%(]YAX@'X\:`)(8<"%.H)*^@L MB9',@,8QDF%7>;V(5FCU;[;"L5%?2K+L9K`?VJV+\?U,IO_$Z(8TCH- MH5/Q&Y3&X:]BV<+?&U(X^0J&@_%5RW)RA34=/TO>^:'X@_.41&`Z$'A!MA]Y MT2L!U4[/`0]QC-A-(P9M!*<$E!K"RS*RE-;Z@$BN5!197R"ZY3F\( M66C9:(':]B!MDIW*+: MEN?JM?R=*P.O*I6T)C*XOTVYHF75V)1X8;ZZH]R$2UGCL:UG>P[WN8O-#\Z. M_5JE4AJK/;:5/$.+@_F.B?`M\:K5VBV1N!0T^3.X,@5EHRT!M=%@0,AF--,& M)M-\!6T`HLF'69E/J9#-;DY4'TP/K,P M(Z!L8"$F/%(Z3*GDC$JN94QB+RL5=!"^3,*#9A>4G?1D=A:NW5O@W]0;/M1Q MO7M\SQ_QUO$-SJ7VAHFV-S=MV1M/]1]_V.LP3MNDU49 MW)%[7S?OG_C=SX^^N_X)J>.U\_=IA>Q%Y$!G`DODM%PAY\QTGB*/RY,V+74C M=8CZ)76>G*?.*ZZ0*]0-ZC/R%76/,K(4-H%&4,I>CS269JJFH_%@`I`HR+(GB(T$,7@E005M+.85HR+ M?=5KJ!?/Q)776=;^%B[`?EPE M8*QB3-EG%TPT'M5KIG;8(^AV!?EM0)BI"P4"6D3&R!K6!-V3FH3R<9ZG! M-82SNM/STT?ELOQ1O1JI4EV*"/&^G_J@<$HH<45P?3\UF0/9T0_M@LIBL[&' MP?M=[E8DUE+H\,,UG('IF@09?N6NQ$GJH>,4CQ_VO1#CC.:&>Q^^-[3AA9?+ M:\6[GUV)[L21JLK6;77-S>;:ZI//;>GR[2(#2_J>>^?+W_8^U;.B9'GPV(?B M-Y^\M:_O'T6MR[>W[5R_9J_XKT#/N@/G#N\(;*^5&*^8_YBZ#C5;8?:N#2A0 M"JV'1`J9)+YU";ZYE!2=8Y23Z=0)K-.P+L#Q.1E3O?_GN^QCFSCO./X\=[Y7 MG^WSR_GLQ,Z[[3B&.-AY69(+.0))@([!&CN&@6&PHD;0*J'C12TE@830\E+" M2SL*HY!!M99E'9`TP="UJV@7P:9"Z5!+52EL%+?3UFBE:A!TN\N>NR0,;=)D MR;Y[DG_N]_W^OM_/(9#2ZS2I/>(7"':U$AWEE=M3SD;/25(38`>BD2PH\)B! MTO=X)L2GEAOMLQ,[VU9<\Z.>-R'V^^>NM`ZIO[P5=]6XVC[<<#2&+-WT6$T$ M&]S@1)8>@<+V;ZXB/GKQ:Q(_$=1*D]3V,(+:_PM'E\]".#I[$DOQ8>T' M86E26?$`4#%0.WZ?S",Z$).%P<_EO'`11;I<3]&,@Z&9(IH)>3SK2,I!DA1C MHLD@%:136$#FBZ@<$S3-*"$90+D\@QDI[)[LG1X.+9G>.#U(%=$45F#C#`*LZ`H:"M5IMDM#/7R06(ANTV<0UR+V]KE3DM.S0JX MZB!\?W%PS_9P]Y/3;!EDX.E5!W8_BNW[T[+6]6MBA)FMZ_P2 M_\D_KUPKI&(4%2.L3GMK'X;]-)P4K**=16>&`F6<(-"N-8S?-]PB-B'715!` M],DS_':_H]Q>[FC);/&LK;H@7A8_%=G*('2[I$(&%$*ZL)>79*E-PB4)<"7) M<`K/0T9,&.,V#HM>+4.W_;X$3&&5<8FOO6:^FJBYROU M-!++RB=H'GW*LF&D8FJ+!8V.S#`_3Z-D^P.:-_W^+]__@TU+PH6OE!Z:F=K1WA.21>%=W[7;!&[!Y[P*3@XP9<()X:5OWZP6T;>[+*S==;\-Q//),YU-/T.H']?^Z:3EY M[/$N&6:@EZ;OM)Q?-)XF>M"&%X#&MX"`/08RL7M#)EP&N3C*JQ-#)(-#9Q^: MU`+9#!-6?U:[A:UE,=;OF]SM])C"7P>URO6,RQFU"J)%'^(7])PY!5@9#W(C MB%YT1B[&\_.`E1>=N9%RHM6=X5C_R1[U._5G[\'S@;C<=D7.Q!;?_-O^?1WJGV<>IJEHH>,,_/P:=#M8 M@N;C!/&\^M=+ZKBZYQBYWKP5YE^'XH%.5MFG;D3:+$0=?))8#^K!9[+)$NP) M'@_BC"4(Z6`*GI;9$N"##-`A%89DHS>1W1M)('(U.E(P*7.9"7>O*6%FXT:L M.@5GO%GY8?E@!0J1@9ES)F9BD@%=Y.OS^[U61Y_]`NP$5CQ_0*K\>&8*=LI" M=1^0>"E'*D%[14B-Y9E);R(R-3L6]YXK(60"(QH;=".,*AK6H@MDAS%]4\): M?J))2DHZK=2.2G>5M'Y\6TEKE)SD%>U[:LI\H!CJ,XYH?LE'-_IV4%K.:*$4 M)04Q7]-!.R8%7E\M=*HUB':VJVR:@\+SN[[:B042#92374B8`DU]L383MG;Y M;H^5(NEF@FBFC*00.5V!BGKXU!ZWV"0:EL8J3ASJ>(TJ=^4&MUMC'& MD)3QR<$##L9&J7\\1S&D:'OB5/0O70Z.,))E%>JM([AMV88S)UB#`>DT'Z75 M"I16#>`,TBG:$ST>13I%(1W5=#)7@?#I\._".`/"D`ZG8)%L]`\6]E8/5E4! M2V8*JY:]>8F<7FO"'! M@;P6?W4*N]-/F4$*]P[*J&GG-NH4B<)>NJT@%<9&'PB05B3=S_]G^!4H?AZ8 M7$\L78-`,:;/6GQ8!,>4"I0=<8DXT0?S.P0>YUB.-%HWGVY/_:%[Z:QJ5B!B M-"YT;$RL-&)0BA_.YBDCU8SCS;21M)<<[#(86,KL.-B[YUDJ!FU<]7OC;\.S MN1;2B*J!,!B$CE^OC8HNYE3#)\489>"$EL6)1PJ)D41YJKW8S2D`2,9T^ M7$&O49$TY.>@-$3Y:-!G[4?VGSC11HVJ`?]RJ&?[X6F%'#>LCO6H[>HC\!WX MBX/0_`SC-<<@)U_>B6+C*ISU]RTOT`7PBQ\:#++9OKHQ>FAN%.Z'M7`NW(4" ML^/M%?/FSU&%O[$1 MF.W^:;@I;@[R"5L@A)L1KU?B,`YJFA)5M8MP0-?Z4[B[/R\QYRV8@:(I!SFQ M-%1Y`<\`,[!O9'-Y[[BP^]OE7@2,9`D9@YI[MU2^.+EW?X#/]FNTJ`FSBO\/Y[K]:ZC]7* MEJS#D@]A2[8LRY(%WH`Q(N4PP:KL)!Z23@&7H]@$"`9L@PTQYBA)AM"0SB2M M&1I2F!R.W;I.H6%**4P(:3K$,#2E)0VF*7%I,\.D:<=+WZYL`FU'JU^KE7;F MW_>]]QT,WM9_>8"A`L]L:FL"_1(*8M=P'[**>E;+*C:'U=`YYB>?/;B4HM#< MU7&MF5:O\G2.]7M7^^3$2V5FKI$@X=;\V>VHG21GR__J;7(JUQ2D4G>_PB\# M4EYLD60R:].`B@YWH;0WDX^Q+J6^@[86NT('V?)*.K(E3$MT`_TFI+8"W[TJ MJU5-CBML`,MT$8V5A$*U4[72(88V&DS314GM*2`9$L_1VWHNKOW%B[M]%$?K MZ<*GU2=EW+4[4>L>1+_M8WFVD84CM_P)^??R%OE]IU;/9O=_]TOY8?P/L/]B M[*&?0SIP01KLM]%8FLA0"*=&B5Q,C_]CN,"1L>?!]O.&PP6H0-7DEHFQY`W# MY&1VTZ')&^5ACGJ+(2E=4PBA%SVUY:]B]U"N0',() MG#;L[W[B45>0HNRU#44EM`;G:!_E5C;-D2:#ZY2\2K[XS_*MOWUDIG:N77R( MKR]M_=$7!'DV8#=G,:!SU6GY4%H2<*%`I,I3Y6UV->>O+%\I;9RQL;0_TB?] MH/*0=,%]H?!"T=GRLY*I+!Q^RN6VA",NESN\7DI:I$A$^0`UE<))5\1-Y\4* MJ].+;>\03BR%Y0&"&J.*X`Q-NC$BX5@X[,(QDULHPHUID]^2L?D*"1.^.(;# M-"8>R30DJV$:_\^D@/47XLH;01G5D8+EVEGE2E]9L,P0["MCP?PK.1-KF1(` M>)DK`_>-C5)9(E*%U2*ULC%K=HST2)BB_1#R,MD;LHI\GQRDMNAY2D/S"/$: M6F?=/+3_M>]W%9(4TBU'VUIARM8N7+(\7F$&KH,8($A'26CH-#CS&-'$.QNK+%'Z&.H2\L6D9#*0/$.2IJY7E+4&>W MWZ^![S3#FJJ7/G>L_9S\O%Y#-^(4TWKCQ#X3@>>P*?G#718=S3&J7M2!6A\' M-(NPY1)GRDGK,T8M[A[%%V(NU#/HR.0I'LE7J'JD83\,V9@/=&'(/>(I@7'+ MA7_8IUV0EG`,4B7%60>I".^$(@+W/,_TH%7%3,;*PL"4PU$Y28=X!-$VTT=_>&"/5W*'0VRR&9#F M^\_;M%H>E+*1TW,Q\,-B_Q#C?*SKP"4=B2.%.6KOWF3>A>>68BL5XP6P3!+$;C\79! MA%-Q9E0@ZIRB:#;K\;JRLI(2C$W$N43<3$ABA!?07N&2<$L@!,%/12,=GK!? M\N/^^5+SS!%"DK2:82K#2$P#6+_Y*!2Q2M)M"4<,`/MO/#1-XOH1E;M[(_I=8!X/?8[*>85*\3>^"'KH?A1Z]'X ML'7,.F:[%.=7"BMCN%44UT?CEBB`%HVN%ZT64;1:HV(\K]DS2HB82$A#H=** M9A!ZIZ3#0N'0FZ$_ALA0*MD\>Q38*@Z_TRT<9E#8*B!QB$O-BXOX'*.G$#>D MC07FC-4;((SWK&ST@PH.J[V>]:)"\LZ4GF<)2G&MGTY.?*ID!PAA<`8@JT1% MGE%6ZLQ_$97"\/=XRH1LPO_.EJH.%@'X"4.!0J-%^)J;ZK98=0P,%L[36LO. MEQ<^B9'&4"Y:ORL?%#:-_U(T_:"H=6M1'SY0/RYE-H M">+NHKHWWI6/7#Q_NW_=S2L3/>=ST5:TX"]H[NNORI>O_%4^_LY:5(Q":-9/ M^N5/Y,MC\N5>Z)]%P(R_AAQ3@^V0C"L<8%BCPE.YNQP[(^$QF@6;7[]\ M^\[ME?4\2S"4SG;PK8XJT!,-K1?1FN/@G$UN0)`D:+)NS\K1?[-,@5>DZ+V= M>_MU\H6QE-QY6#`R*H2`H+R7?AD0#&)Q;+5DYTOYF1O@95=3$U M"46XSRJXJZJM2,ID\LZ$8>+ZA-(%D"4*H3@/]@)E$^!039"JU4J1(%-X:?1` MD^#&T)SO[I1/RMM.H0;$R=`HH_)I^;,%LQ&U<6Z)+S@_M6%IOC5OSFN_W+O* M'WP8><[_K7_=^)7/>\[)MTMCS0G4C>9--]*X_/J@7F-N"NC^PW6YP#9QWW'\ M_O?RV7>V[WR.?7[$]OD5QXX?Q'$20Q(;`EEI>94F=;/AT+%LM%G9DO!0RL;: MD@*%\.C:`%J[LK2(T`$3`IK&4`8M1=VHVC*IT(VIV[H.Z*25:=T6-'7S9;^[ M$&@;Q;[S7JEQ5KEQ6KFR\ M1;+4$6HM-@<[EO>L`YF$6U6L8.F5*K>'O0-$:`:"(A,G63')\W\4F-+%_=V'HR.71 M9*)NEC*_\(OW]'1$++ZR>&N@;&VI2S-YL<:"'"R2'$H*P@4GN&'MVL4ZXHVQY[:[?%R'"TQCS? MF[Q&/@$^K)$>1I1U5R[]4']G9'" MBJ@HICV$IJ*:ZWBF#I-K;5X$L1ZX9>D*JT?E4%5^3`:?P\+L>@`)*WZZ=,?/ M&[,_^_3`2!4H@_A\]]:]+=\?'YWUS6[EM/+)AG=666@&C0RG M[ZO;T[NRH<'N7S+2>QI1_BHI]YT-SXGR_$T/YY?'*QU2UT.''4C=QG\`,8 M!D..`8@Q23A/'(VB:`E_:=PF'K8^9,O4@30@2KGX:?E&N3A1GH[#FRJS0]QG M:C5($>LSO.HH$ZX+U%KW.L>3O5I*D#:+QZ67#328]I_86PK+06R90H0GKR=O:Q#8[3OO"!-:! M`C#5R2$"X14E=.CX#+WOM$83L[%JY#H>[PS!KCT>:Z&@#XZ;QOA3*D5#-=1W M-F9:FD$)B+@IB@;D@\93;F]9L$7?[>%/FT,(\("6=BU((+XXM_C5FU9@`&B) M8#@C3K%!]IWG5IQ8%C8R+$F3Q%WSNM>]>&@FC">T65K_Q*JNK=^:0;&(8GN5 M_[UQ0;G92U&XD9%A0(3!@J4V@FZM_@,.E,C'JW9ME' MRK6QQFUO_FA@_!@Z5_^'>0X3KVID`HTPT"B$GRB2%$( M]WD9O\_+DLCHMI?PO6,1KH[#N1)^Z%4?FA\^<%:*+>+_[70L+!=O9%5.QJ3< MEPG9M($_#T=).XDY)0V27\>^]#X%R45Q>A:LL-J1:(%8NPU9M`Z!`Q$.XIK. M[-M^<$V\';D^WA#[X7C+[(/?YJ5ERKM=D6>4?>MGN*NGA&0J[)47RXOP!*IK ML5MUZB6#27R_[/O](+$$^50U'!?B`4*>O,Z1YRLK9>)O@#-EC%&G&>5R@ M(C:6TEDV&3:Q@P)),E"U!HJEX*'7B#E8$(L0<_*IZNH0XLW!$`J%8+^F4%*N MJ<9H>R7XV5D`/YMYR4V%$!Z,5!,"%X`BN7`!2@1>5Z]J&)L%C#U_Z3R<-">+ MER[`44K>:)8N26I3]_45U1^LC[@CI0LA2T,:B?5W]%21E44!O:HIM$@"R:./ M;3[:$\_U(6S/[$XT\G)]=.!D;?/S2Y.VX*X7S@!83@X4=SEW]/!ARM?!,!VD M5.E7/BS?Q$74,/S?S_!5%Q;X*@CUCB[TM57ES\LEXE_EORB_>Q1?BRZU58)# MO9!EC=1.R++/\SU!+]+3))V@DT$OR5`4;1%%TF(1O;+7(POQ:#P1I;Q>.9Z( M1Q,>"+E((6PO5&`D-&Q8#G6$.4.*BB>\44&6^Z-Q:Q0>\'A6BZ05OB81ESVB M0.I2)L*@.$OHQWD?S!MX*AH-AS$&OE&[S7".NS-@7Q%!J3E:%7(@[RP+@UW/&Z_,P&&JUA8'CCS?KWZ;G3OOE\F'4%; M3(_6-=^SLFT6UWSE+?G')FW++"@?^6R!\*MOSH?V+@H7*5KIZ7E MZ`U4@2)>0;?TGIH59]Y$W=^H9YBE-&?N5+X[H/SZD9T2";NB93UZ1+F>N:SV M-@EKE*:V8G%L==YNDZ1^EK.R+,=R`N,.5E8RCB"#J1G+H&ZLFG#E>3\61$$A MF>!8![(*'982\N0Y*^'&JU%'32&J`LRH0';G??]A$-,AFW( M)).#%DO&9G9ZG4EGSKG82>G-3L0X2X0ES]M>].NP^\DN&ADR`RSK/(T\F`LB MMY;0YXUFTQ(3_G^VJSRVJ?N.O]_OY_>>KV<_V_$9.[$;'XD=QW'B(\[YKH5LW\LT8EG5)6AIW]WK,AG319UI/\_,_W\_U\/X>BC!Y2BZ%O!GZ+;8CF M%.X8YWS3>=YYS2ER1LI8C`OV(7SF?#/EK7F.+[`UR06>-WQ,3"YE%HE=+I7\L\XR,MPZ"&'2% MQ[(C%N\R",#)>G_7CM<:1"):E)OZ\L)(0Z"U(]J!$"7[\2EFW^[7J]IJ=@1; M&,6HREN8WV=0-^W9[M_W4NO>;%8-7G6N75[5N!:CY\?9[S!YDW!C]#9>.6H& M!4Z?/(X0)V%.JXG@+A/MBR/I%2N?< MFLMCA<'"@/4IKQH>3`7#9>^^=^9LD/?E(.92)>:2DUC&F90LI.1JN9;XAIJT MT?))K4RIAL`!.HDX4DRSCGP)AN.BP84C"7NW,IU:>1XDTZO7XW'!4B85NI<^ M,ULPP`>W],RY@$*:#EK*]"P;&;AR)-!E5^DT=8<;/_N7-6S+^NG:50V5VT(J M.^S=J387[3[U^T_5*EVQWV:;O]M^(&9A^\I,:K7Z+(%W.8AW&2=OXUV6$2]R MYGK[&COTA&&@R)03((KRB_Z93ZL[M;UZC92:@0Q!0\.4!`3B2#Z5(_/C6=ZW M"FTJ0N&M7C;<-A&07S,GE]Y67[0RQ0QDRB/L#6&[^LK$`I_6^82^D$Q3/TWX M].`XJ..`7@1<06%H]$0':!S'J*7GGK]ZJ=7O'&OR#(=^NEA\^=W"X:;<6_?SI,#1U26DRMH MTR0I(R"T`5L<*7'1?%LSH'+KUUOB\,%%<0%[)YE@[R82B2>$X/4@D5RH_#X\ M,8?^,1?"U5#@OA)0'B!0'F`HL+!BO!0`[;5XF]^.??8?1\[AZ=$S=]"9%4<_ M55XX%-F2DG1WMW:![FAHI?,#2[_7FTR\VA<=7/?^+6-I#OGK]VS@+;'8]_S6 M8#_/;6;Q(=*2L_C.#W`23F:3#KEGQ=XXZ)IVS2KM'Z!ZP@*.$58DYS1Z4`HZ M0[T!0IIOMN0CK\E4>A56X4SDQ5=/2PG^ZG7*6$@0CP; ML"SRA,`JB#40D\?I`:S^<8-AJJMP!($;:OM54@LHW7S"P76;*ZTJF:NPTQTN M8P8[NN2LM")P'!^5X6?'#QVB.DADK7_EPWF2#/C%I+)WZZ:-A_0%,MGVE\7N M`O_8=RQ;7D>F6ODVUNX1_" MRSG\>T:$8B`/LPM7'I>0U74VP6T(6]J+:C#:P4`-MB'^B3?`8XUQ)P7)2HNO M)F-)U>FKSA,UO*-(?7?!'"HRUCO`UHF^ZM3UU/R]+_/8WN95(9BWV,&6$3^9SK:&&-Z\+`IL7J%=5KK6#;%>-WA[ZWP> M1$@=`_;B4R4S\`'A1B1GE>3:0:3-_J;]FAW9FW1#1@E1"\36VN):6#M:/E`1 MA]]R$NEZ,:$8%S2B3EL\;V\O_%/7$K9!>))&5VR.CV6/OZC804= M+!'8;0&4%E'Z--7U.NW_"&.0=0D7K]7HGO#=]PP.1E(`*6C=4G6O)8=4(AJ" M_6YML.G4\J=),>GH?;Z_NX_)RLD?JNYWB("$E.F>&=MW!7-90LF-I\$6X)CO MR47-13F,AC:4I*YM/[DE3ZQ=N?)7J?$1HU(MPEJINGX5$%71\M9G4Q\/9>$: M)%P")&H6'\)Q\@PAPSK9]AM\&ZHIRFR,(\@QIM-FVLYTNGH=V=K'BE&R!A>/O^&44&3V3LN;PB29X1W7&W/P\X.4591 MS5]BK=O+LR&*JNNSKJ6.?U*8J\9^0,#%5/(>F!>F*21^D)G&:N:G82VGK30S MH!A@Y0/LGSQ*?J!I]-2LXRJ.?PQAQGHGDYS7@DB?%FB+O/Q,_.IO)(6AYA)L M(O%_IW()92&D5O%Q1W##3-QA:07\WF"+!EF^HC#/9R:AA#)N_W#O`(-3("D; MO-2I>SP?M^[?32U2TA4`$O#2]*V>+)F8C&KS+`K3/7Q\5^O.WGL17X,?7\,- M?`W5((O;5N&H<$8=46?,$7...&:RQ1+7?^FN]M@F[CM^OWOZXHO/K_@1OYWX M[-BQXSB.$Z>.?7F`(6E(FM"$TI[!IA02AY$L*`21`H$-MFXEB`'5QD@VBE@? M-$`H2[2IA:K=-$T;=)JZ_<'4:9/2=>JB3=O253";_>[L!#9I4IQ(/YVC^WV_ MGR?MH>O*+>6(:W&U<.V>]JK-KLUE4-69;?)@(Q/A$T! MBX?S.9W]MI3#0BH6P4N\AIW1(KXFD;V!YM03@6K(WL=8MK(L0DEL(^('K((L MMBQ`ZQ56!%'Y8*'S!3Z0?A-BHQL58/HLD%(MRACJED!7)RY$#O3%8J=`*5CK M=*NMCG,_ZC"U635-R$@"E]MW'O_!.HV,17$,17_]AV1C6^?>P-8[I[[P6\(C MJ8W)'3M.##"$-?M>2X+LPTM(1@=VOO?=E7FW!MU0ZK+)3+Z.O#[_:<.-'$'T MDNSZA5?SG[B,!&3BL9%O]WW_FR&=2F(@0**0@5^&F\T:U:,OS1H>]H%-0II;6^%8;U(AWU:,BJ5"]V$>(@OVJ M,/&.7/3DI6WE+(ZRCEV#F;;\1QTA"T8`4(++U42D2>-QZ?+GFOK+9I,3% MCM&'HXX]KP`=>/-](T/*Q3=M?GB?0J%KII$_\V6A)N`S^(SUME!C*$I80;?! MU"T7F<8Q,^K&[@FU`S51PH96/PX7O"Z(;D^EDFVA`(&46)L[ZR[4BS?R9/P_ MPBC$A9[AWKK8+0>&V\*&`"XL8-6](#TBZC@LD(M]'[L@\INNQW+(`?X11 MY;]AR%V2Z@O$G+X`.GT,/B>I>['+0#A)L@5U&XI6$4RPQEE`(*A<.ZP7C59*P?!8_,;:\\V[+;BL1!9O.3BW7D$I,/12>"A[R/%&[98+ M'1TH3I.6S(O"UC1CZMP63[$E%&8;.7;HPHL[G-JN]E"O60DP6"],VR>F0W!G M&F/M`IBRFP#:5>HV$T:-75%9>=#=]^P)=U?76WTO#4][]1H(/%+SVU_^XT#< M8_Y6_HN=?J,,GO1%/\Y-\@&O/LB9I\;?L&DE397PB=^&6V]%IF_HS>%2<<=F MQ4QXPJRFXE4B?5NJ4UY_`M*W4K`'+@1%\ZTJF*\=FJ]]UG[+CMG;->DF/4I# MV9+9X\$X&L]&Q27)\90L34+[)=O;BFM:RDGVJ_]__AM;7O/?@J44E7>U:985 MO%=,0&M[J0'26MRK>UDUW^@>J/P82A*ZXH?;G68I4J/?-323A]/2>G0\//=M8(I-A70$KK:?-^XX::6;CU-=B MW1?'V\K5#`WI0Y:^^[/\$T^N`\V20I(114/GQLA3[1#QJPA+N8+:#_B.&9C'` M2:&"[-W[U0?W/\G_ZR^?_AV4M=?!3&P1*^65 M!$-%/M/+K97]CI2M0A&%57*>;;$N8K*;9(8N1Q/B*EEONKH"R6ZO!M4]+:"% M5_Y4D#1;ZI*%6XCE`%X%;O!_NJ2FX)NP(!7OIP!4H42Z-;`O%2A42%N1^H*@ M%7I4D6KUU\:R"AR[6+?_]5_4K=_RBB7:X]]:C>/.[PX-AK+)+Z:PP:"M31ZI^=?V9*R^T'U`Y=+K\W2^Y>BFJ%Z/) M4L/-_"1X^:JQE*1SUZ--USZ8>344$O>X!4YO#D[/AS0BIWGM>194^]%@A%9$ M3$%#\#.+@8HLPJHE5\C=H-^;\B"*.C@VGK6K#JNF5;,J7!4U^9W(.Y@,H1$_ M3"%6E.!-[BQ]U0FBK!/T./"QF?[W M1($T+D@0#6Q;A;021PNB)68OBE2MB9-&)0F3E/\CZ`MUQHA2SF!X9_.&^M"5 M>S7-/QF.M3]YMJ.VP:A-U3[O66[>Q;RL_FNP5X[V4MA!O!.4_2U2Z_-Q2"VRV!;Q>#\ MZI&]/W345.K-E0H(N05V9GOE2"5:N8ANX#508FI`?UTJB)38[]ZV`NO&&HBY M&_JTMDI$G(I&%-0%'X\ MLI6)XX)R7FRGI"0>DE"(_*+*=K(,)4=Q$K.._GQ@EP+@=?%`>]3NH#&_OJ$Z MUL_(*)S5'QG);NK(P$Y*0>STGI[XD\]8AG=IS)Q&D1BO[6QTRI^_HG3;XA[K M7,YK+H&J`*<@NFO/PR4L+G72:WQ-E(NZGV8VE^),"2I3W7Z(AE%*48ATJ0Y4A42425H28,4)1F65&BED8:W M"9GN0$\F75$Q-C<8?^ZMDV<.*XAN4LYZFUHW"U[OS![O^HWY^S=CI_M9!@.) M*;8JWM,:=3B,7'1DTW,GGPH^]>:P!N;0SFB]S6[1JJQC6UY_VVQ2#?Q8G*;^ MX1)ZE5`B?F209\];`2'C$8=?F?9JT^I%,'"S1&`RCTB94:?MC$_=TSLOS M^<[OX_<^[_.*1XLOCQ5O'$P?2.>N]2N$7'Q[9&P4PDID$-1GG(_Z`VIO*3)3 M`/Y2RD89-@"-$DZ!JHK@`J#P@D`&(^PDF&:BZ?[9J4OZLG7:/+E/-+9V+LSJUCXX0ACI+W3LG6:MIK$B1:]SC][+DW/ M:&G.N?C6$X2J)0,P6XZ1E]!,]$Q,?Y`X2!(18YZ`SI$$LB-,V-\2*<:HL!*; M9_`W9+:&`GKZBDY)V8+6QPIQX:QP/%LH$0BA/6)6PC;G%7]O`R-:;30%E5'04&J;X4E65QI)J8]96"T0_S<=9T[VUX1JBJJ$ M#P!--N:KSZ^P4&9'U=R?"C> MLQ:0_CC^_MC%Y"ZT"[8=[85='(8_&R_8)W#6*'L-=)>$1:S,Q$#!Q*J#"=(# M)0QH`D=O_W'N:/9O6)'_=*5"X+GCY\H>Z;19?62R^IA32$YGO7\//$Z MSO^]WV:BU)`GT99H>1M77YT=LBL5IAW_.[V3_`A8:E.L:KMQ.T_L->[EB1"/ M0T;\,H]?-F(C%\D)A60,AP2M"555X,]!D9"98^AT&9)W-I*-&E&"Y#.G1$@C M'P0`!@94^7WKEJKP!B;R'XP/@I,=GSXS.S>'T<;A0/$>?B(W1LE7@'2C^:EJ MTH')K&E%.I!`/P2II$\H-:?]_GN[.TNGBI['?EN1MJ;\#TMG\RG=>^H:.FLM M1H-S377USY[\Z;'VHZ&3)AW+`QPT74]B"V]X/K$?GSDP^UPB@`T?>04]0ZNP MZ+76_,25C\>P$R])'$[\]1UBM=/,J%N2.'Z5'`8>ST6_B)7Y94RZ<89-E@_1 M86N8#MO"A$Q+&80H:QCH65HF1"1Z\PW=4#($RL_3!,,9M&P+,Y*-"]N"''L6 M[T8&'#_-,6FMHD#[E/^]A"ZFPPTYK1&D#QI0B:(!1L;@%2@Z6273)\L(<_U# M\6)NJ'^2L"=/I8[Z^Y7R07%U(I9@A:Q5F:4L-1(@FRPB$U:E0I+055X3JYWA MC>W[FR)%CLI5HCE<&IK_:&=G*%A8/&UJUL7V'7.+.K9*.7+F@;V+:]U^>J'6 MZMZ_Z_:"3!SSSN-SY2?WO/@FX$B+.5^^^GZ,*O%'I4#!W5^_J+(8-?8Y50_= MF(^>CJ4=9`](A$XG8:W$VK-SW"2+6#NR%V2>)30H0&AC'E0PU2WYTE)8O8_. MS@TCVI*F=%@JV:KA[5!D6:?#?:2]UV>"07;[6VUV?ZL-W1WF^K^9:T!?T'9* M9R4A@%+CHQ:ULP0UE*$4&6/`*80G(P#8J21O`.5`#<>6OA;W/-89?\K35-+F M]A[(E8QZKNOLFT7QKO+R:KM!+*HM:VB^OI7S0:&!S*3X5->]Q!=_Q+XI-C-D M3C'U)L:4FD@T)#9NAOF\HE57UG"9*,0Y/D'!QS=^C[Q$GD!^=":6HF,->HG0 M,JV:;&BX=XE@+W8?*D(QC@ M+O>/W.*NP4HVHB*G[&4CBL`:O14??)4X]^=3 M?RGDF"5F2M\:>>WK:&*P[;E+.TYOR[#S!F+OAI4SM`PS)]&<>`.[MTS;_G8* M2=+TG,U]F'^/IM)F*[A%\5;R0V(9,J+\T^PJO68523)]."^6HD>FRLIYVFNX M*J6IPQZJY49JQFHKVLJ'479QS5@>-ZQ\:QXF5*H[3QGD?G=&14HP_0RF/G_% MY/4<37SU-=[*-VYA&.N2330\J9!<1Q":`:1'CG=T.@:S!KJ/#/0B!"6(N6M# MUX#1%.86U#4';ER(;[B[VNJ*ZN2GI#YXY=.ITOC:I(62V-RF7S#O2U#EW'"$_)\X&WQWO'M\;O\9_]G M[&^3%DA]:`_MH?T_&'`G`6RL'%9$*AY.AY-&#SQ(!,)=BY"!1?E386A-FSZCJ#AY@_**.95SJ^;-KZZI MK5OP2/W"18L;&I">(PJ@4+?_G.^,W[S>XPO'ID4]_DL3Z7Q_D`[^3 M%JU,WH%$('22/@6^D/1I\"+*+TGI(!)!%4F?0"EH7=(G(;XMZ5/@'T_Z-/B? MU%54UE25A\JZN]M+N]:O[MFP/%S6W?'X=PNC.GAP):I!5:@1_6H#:V"6`=$UW['S_XWKYY`F#B,_K%/##8,60RL MP%`4`.83:P8&UAQ@W(/S"PL#XP2@#`<+D`7BP6B&-"8AH'8X0(]*>R!@<`"F MGFD<0&,9SG#H,&^"QBA3Y"SG:<=UX_EMOC)('#I#+"4M/`*.S0AX*96YD7!E("]&;VYT1&5S8W)I<'1O%35%?[/?6\F.PE+,)"(;WB$ M)9D8624A)"G)!`(4"`:D&)"09"* MU@5:VP\:7#[U0Z@+:&NU5`MY_=^P?&#K.]^;G'OON??\YYS_GA<(@`0T0<.4 MR;=D#ZDH][\)/)C&V4F5]:'&365[!@%+SP"RNW+^/./TJR<^Y]J[@+NCIK&V M_J/#6TX`4;L!_;7:V0MJ^ISJF0>8-P&!IKKJ4-6!A(Z)/&\V]XRHXT1B2_2K M0'P3Q_WJZN?=N]CZS5R.MP.Q\V8W5(86O[AV(+#8`EQY]:%[&Z,.R6K@I^=I M;\P)U5>OS/$=`YH/$D]N8\-/YA$WG^:MSGKCW.K&.Y+7W0][K^S%.6 MHX=K->*T9]'#_L8^<_F]<,(^Y:QWC@>T+K3;@O]]9O&MOZC:W_-$UM;\G[U7 MGDMV^ZGN_UZC`N0B"DOQ.'2,0I7[GP$O\:G MJM)^!9-Q*Q[$PUA/7)_8Q^C118_Q]%]+)*]PKATQ2"6R'Z`8/ONH?8K^X]$% M8U"*#?@]CMG3[!?L]Y&-20B@&;_@V?MDBKJ'7M/0GUYGX"GB.BF;M4+[+0CB M&.DD_(@>'B/BW7A;,F2*M-.SFXBS4<0]XU'.>/R4(!81X2K&_AQ^BSW8RVP< MP$LX@=/X`M](%\E7'=IV>P0SF(0,#"'V?!02W63NK<$#6(Y'N7L;GL`./,.8 MCN$=@63+"MD@.Z1=-6D/ZKKNUOMVOF2OLO<3H9L1I_&L41@-'[&&\&/FK9FR MD]X/XH^4D_2=([DR71;(,EDCN^20G%71*D?E:+VU&NUA;;VV5SNB[]3/V;%V MLKW>MNR/H3`(F3NJT(!YF(\EK%T+L3[+:%OQ`MI9SV., M]!-\B7/XC_2403)"9DBM+)'[Y!%913DO%]1]:IDZJMVM+7'M<7URX:0->DRU M,^QR>XG].2NFLV8I9$8J#$H&!A/![X!KF*G4UNS:XGG9_ M&=44M2.Z^_F\SHK.T[;7GFYWV&_;7S$&AQ]19&-<)!8/3`RD9#";(Y$3J54) M)F(*IE*F,9K;R+$[R/E:S*3,888;<#=C6X3%S/)2QKB,W%C.&']&64O90/9N M(2L=^25^A:?)%RL2]\L1>9W5>`-O\BZ^13G.''3@`_R-Z2?I,D!&21ZEA+F:+K?*[1*2.IDM5C^(L?E'3DE'\L_Q19;*:6K.&6H##5,C5#Y M:J(J5S-4E:I5TB9U_67M.[Z2FZH0_0<_0JO4;?H[?I[[MZNPI<1J%Y1,Z..LW\<^&YOTS.Q5X;KW3N3Y3Q6RGYYGO7QDT\]4>]: MRJZ3@![D7#=FO0OO0'>IDO?0K7,K$K&9W$O7SKL\Y.@1WO8AJ.=':A<.LXN^ MQ:XXC)UM`&UJ\3P9D(A_R#`YQQL?BUCYBN=_QJXS#ID20U:T=HL;2[[1B9V23R[W48R M90*_$O?PAM2QT_P!?T6N].&-*>27\U_RC(IC'$_RIOZ)YS_%^SN'NS:1@=FH M$1]"TH!WR*8^,I"].AGO1IMR$+/582E7B]1PWOPS\KH>+6$U1@;39U_QZLOT M[?I0?1+9^P`9O1`_QS85P_[0@,.%H_)&Y>:,O'G8T"&#;\J^,+C#\*74%1N6!`V? M-6Y^7=@7+.9YK7&Q1691=6R6%ZVQ<53CJ%DE9F.KE.1+1%$EOMQ6A>@$HK+& MF\4^J]0L=B!86KHO5&5-*?/[BE,]GD"6UY*B2K/"@CG&2LR,F*`HXL9R%UE1 M$3?&3"<95:';_986"C@^NF9:8\UB:^S"CU*RO&WR M9+G?BBEJ$Y3[VS'>;FHM;2HN#CC>NA7YEUUMGJJ%?2DS#6<8#B\SK*UE_JM7 M/!JT^?,!.\RK!AS MC%D7OBO(8O4.6YBZP+.K]_C"=OL#C/<9X7*_Z;$*4LU`J#BMM0?"4Q<\7UIH ME%Z[DN5M3>IZ,=.M71(O*?$)5RO55]8B6L329[FK#1=7KFR/6B2 MSKOA_,.=;/V7\^H/BNJZPN?=]V-WT05$6$6B"R(@)101$D5,9!M!@Z1%0IM0&W"7=K9.C+9.IG\Y:VHI8YR4 M:MHJ.J.9CDY,JKY^Y^P^2K73:>OX?=]Y]]UW[[GGGGONXLX?_Y^2ZIM:O6G1 MH.;[#Z]?B+_'\:G./F&8>=WUS?GKNGNR\MNZ][9@:VIP%+N[:W*S:[K;NM=% M[5?;<[-3<[M/K%C1O;VZS5E2U#[3DS58M;=EDX:@#I;%HS$X]9EF/4NUQ"V5 MI;?\]^.=Q'@U>UL&4]MD2#E<-0W-2[)RIF"4%<_GKEC9VKPPOO6)I^SJ[K9X M,O!%@?6ZUM]_A\C3]>#Z@^N>2HG`A'_JL)5H4@XJZ*BZ2X>,B[3)(*JPHO2! M58%?S?UT0/53+U"`>IZ/]R^C?S*>BZ`]>'X6_3^70"'P&*`#TX&E0#-0!E1R M?_Z6QW"@[Z.UYJ=4C;D*C`^IPCQ.#58I%<-^PMA!>58695K'J%B%Z2G5;X^9 M,:K`NS+7`2JQCE*Q54LEQG!4Z<;.FT'*`9*!8OA] MDGV&/AM?JWT;=K/XNI62X0_/W:H/4P7:I\&'1N,8^54CE6FC=C^>B'EZ"%:KMZDQXT+:-M-&=9Q2C-RL/X=-!ES%&',H'%1 M\=@9F+^)_11?L6Y>L[,FB4<\?H^`?63_)D+540E0J.KL.\#HN&\/@_V:"*)J MO8Q:H=]*[%V;<5&K,"UZ#3[G8V]F,US#''_:#R0;(:IT[2/#ZJY.=Q MD/V^\2;MT6_30KPKLKY/GT4[J5*@'_[U4YJ51Z]8J?04QE^"M2SEW)-\"-%* M?'\-.M/X"\V`+R$&]O`RYZ@3*XZ/ZQX%K1_&\\Y-VM.<7Y)C%93#8%_@0PG' MG?=>"SZXCK%'U5':PS!&R&=\`!#52E[R-_C>4T#'$[GXA*,,R;\PS072V)8] M8C3`K\1^.9"]Z*1:_.R<5)V4#:0!;JN.LA-P.^>&3S_\?=$I_V)DW/CBOG-$6IUSB/GF:/F:AFWG,^B^`_5&^*J+E`IYS'GX+A. MI1PYJVMH&9]3/BN.)ORKY7,K9P>J=]'CX@=RU%$G-N,Q^AC^G<:Y/X-QE]!R M?8B6Z5MHF?$#Z&8*(`>6\?I0P[:@MJW6']!1?2D5>[KPW3U:J7^'YB"WOH"Q MWGA(>QFN8:W#^"5U2;R'Z77U!]K%@!V&;L?^=3JQ^C>Q_9=X.8I]F<[[\H@> MDSCY'55A^Y9JM'LE[QJQSV'D=B.E))[+.;=0C[9)/41-,MI19Q)[,1[S>NB/ M:'HB[LL=?23NU^)Q'X_W4_':\'#\N99R/7/R$7/E.>N7>H`SS36!S[7JU]R( M3Z:U".>AG_YD;K!CKC+[O%Y@G[?VV^?->U"_?5[U4+I3^XU*U,$&C(U8\1YS M+-AG7C.OD\=RZKXY$W<&G[M.^(IS898B!L@;J?,C-)]KOG67,LT;B%4XX?-E M:M&7HUX=H&F8=X&Q&?4.;48O'IK[&!E4)_T:<.\5V3>- M<]`V2I?W7$LO4IZQG[;HK7AN1L[MH'0>TZS%NQ+[BI6!NZ>3EJD>^X;,Q=_P M>[1)?7%CO';*,_NP+]B+1(U)XWO.==:VW9NP_E3$!&LWH]C'77AV8L7`MY9A M_YG'H5&*U2^9*=X]0L?L2 M^G11CFLIYG@'X_31`D\RVIH10[Z#NFBC?D/.Z&P#:Y-Z<)62$+M,,XER&480 M>,6^;^[#//S,:\><7+_D_AI!K)!#R*?GY'[\&_KL(X_+C;LF#78/]NQ#S'$; M>)<66AO0M@!S\%GJ(3_/K??A[N/[%GYGIRE M/-2`V4X./ZQ.3EM<#ROH=;F';/8(T1[,6=04I%7G<@IAM,);28N3[8N,DD$R+K2*:@?MX'L[\ M2[B7O$`YD(=8K0HLQ`_##52O;Z+MJ,^O`D?TC632$95&`\!I(`:,`K<`&W!1 MJMX.K`="E`T[&W8V['FPY\&>![L*=A7L*MCUL.MAU^NA*D^*J4)^`P@DZ>OT M)LI$ZK0E=(W>%,GT>U*B>E-8<_M/HWD)L!;0U26M-5SJI\`,O0`S%/"/Y(35 M!J".D0&/_MGR76`0,/5"?6YXOC\E\)@^%S^R]X./``/`:2`&C`*W`!MPJ[^J M,4J'.S/U612"S@J[,OR!3'VZGB;/T_1DT1S=*SHEH:D)38FKR@V?#/E/Z:O4 M%5J`Q\OJ2GB!_U!4VQEV^0\%DK2=]C"BZ5/?U.Z0C@[0B*'[5D6UTDB)*5KE M@3$X4.L?'(AJIZHFU_I>&BCUQ"F0HL74]V@R^5FU^;!\ZC!:/!@+6I4SZIG0 MO6^@R!TGJJE!8J5-<5<%DM602J(6\FHGA#N$VX1SAUJ\;[5X`\^H;O4\$F>% ML(=9NR'\%>&MPAN%7Q!.9:;WA,\+_UHX*GQ8QOD&0N157Q*N$%XH7"3,@?=J MZX7;A9NJ)H6\YT+>WX2\[2%O8)5Z42M&QP[A5N$:X7+A`N%T9NV,\"GA;<+K MA)\4+A1.$4X6]@I/8J:/A*\*7Q;^O?`%X=\)'Y2YIE$07WTD?%/X->'/"]<* MSZI*"WI/![T_"7IW!;U?#'I_D4*>P%152%\SR[%K<[2?B>;0V*R]L'S*3S'/ ME[6W84V-Q$8_XXLJ=R3V[1E05R3V]>E0,Q)[T073U6()`0L)(0:"4$4H#P,`\!085% M2#A&8)M71ZH-QG:(J5)G;`,)5E('MP$#=FQ-AKBA=1TRF:D])BG2@K$DTX'. M)&.[[11/ZU]NZV8Z=CKN5.FTQ4[K6*5G5]1QG+AM5K/WN^=^W]US]YRS=U>< M=XE9PA*T(N*$51-H!9^=VT+?\X9P(YLR2?^37W-TJ)3Y\U`/\Z?)$/']!>:C ME27FU@IT+S`W^(7]!L2+''/=&Q*7LTG,+_A87>`=O.<%$<>\ZPT3FW$BFTB_ MX_W#'OJMH4+F=!C/X$6VGGD#C(F5FP7TV,IWM?01_GZ/WGZ&^26<83A?@//J M"AY>P5QL.W\8$(GF%FQ>7GZ>>$#!&EG"^)"1$; MXI#/^5(`#)Q/!Y#%^20`F9PO%T#'^?(!,N*@XGP=`$K.-PJ@B`/F1L]`FO\^ MY_UU#T1KEO,E@WF.\Z4#O,WYG@!XB_/U`'R/&[W!_`3[D3=Q7,CE-LZ7!>,> MSK>'J4_%;N03(O]UP./H#`@ZH2<7"J,=C0JETK)>(`F<3P%32FUNB/X50_PCPPU&(-AEQ%[1"?`TFS*8R;SN\S''(%CCL,Y7^7S-,_M'E^#F_\(J MH+H;$?P4G3J93N8/8<1JI?Y%J7]8ZM\G]3\O]?=)_<]*_3ND_BYI:&UY+BF_ MU`;(RF308`#$&*^UPA["6MT=T`56#.XPPKAEY35\#3;M@.2UDAYIV.,+PN`#SN,-SSBK--&*<<'I#=$&1XYO,R ML1;/\#+8U[2\#'(EZ(B%N.[\ND[A)A9X';&@<#^L0Q'B/.C0$`^\[C"*"&XC MBL."3H3CNDF8#[K;/(!./8TF!=VD>AITR!70\KJ@U^MT!'U>7A.L\((BZ*T0 MEE_U&3T:IWUQVB?0#\T>C-.5<;H2:+S/!0]0?>6NG8'%# MD49GG\G9X_COLMN3_X\L`IO=#%I7HL>5P^,.7%#0/]#?/S#0/_!5ISYR]-J_ MZHQ'%HOC$$9[L3TX?\G9"S=D^F+?.`23^\U.8+HDK/#';S$]CJXO>Q>IVFGPQ-& ML]@1')G^G,?QSSR.8,>7>73PEQSA/Y3U.\QZG>8^S[*S@$3N_ MR6\+6]U!"MD]#=OC.$NRT#_D0T,5=`_,%B` M^KO[N^-)Z4?]_?!M2&!HQ/"#[U(IVAH4BT)XG$,2Z44\#A_>&/_J/$FB!(DX MA,<62))HDDE!,3:/T2;JXS!^"6D*-BM7;2UW;)N5=VTMRCLV5&=3QFQW;-#= M4&),,:;D0H/A9NX;R.7[K!A]B@RB9?",3I+IQ&[Q*:1`#"I<1,EX`$F0'@^P M"IJ6D-J)5-D$N-#';H><,"'_E&`\GBY3S-D\5%1>J\?[$0AH5YHC0#;:E7 M$/DH#XG@+9N#Q(0.91)/(36Q%2432J3#?C9!KA3)13GR/'E1"!]9D"5/F9.F M+/#9QB::IZHT4VK#BFU*'<*KK(JAB^DZ>@LM4M!8!B=%7R2VHV*X^"=LJE*7 MR>:(%57#5?XJ4J:HPE15A&A&99@X+YMZQ/5P:&,1F-WHWQ8<8JJ6E5=C02`IAHKHTAYIPLK/Y(F M*R&9J6H]5J<4$1#J2DN91*K'#)9(398B;$G1$^EIR5@J49NLE6!;*W$RC*AI M=6HMZ&'D3='7CCP7'FN^_('8+<'[WFR2J.0U"NNV'=='V_I^?`J+/1+RR`^? MUXGQ@>]#YFQ%JO4;%9TGPJ6YB3$ M/M:SQWKW7WXQ\]7-K2^+LXO&SI+GY(Z#K0/5!73LB3372.O&G58M7^"_6UL4 M7Q=_@!*1!I)4@>RHDRUDM6:]T6C4EI'5$V6%$RR[K)B0T1.DH\&V7&)=SJ?, M6J.>E"\CU;*$1'71:]$Z6[&-1ZQ\_UKT6BSCMQFQ:U$^5L495ZY=R=A0@K,? M5*+$4FJM*#>;LJ62]#2:A)!8*^FR2HD4@@:CN8]3XD\.OKWP;=\[W,L;W9L; M-IK+6PNR#<2,09%/F\W:6*-.I5NI M8X/WGZVJ%5ML)1)L*[YWN:R(K/^BAJ_Z9]9N29+A2:Q#FU`[IMGFW64]%;NM MO>PKS>+FW!WF=NLK3:^XOJ,<-YW(G<@?+3G1>*));J>LS5/HR:[HC1!7BU)IR3=.(0[V;S:[H0$K7-_,:EZ7=NV7Z_7)I9. MV.T=G=5C\K]2_TAOZGQZ8MCBMQ#P/-R[L.66<5/']I/Q&H[=[8K"WM)RNW=[>__< M>MP/<+<')W` M\9&L+&6RET/A-,DO^1G?9(UQB<%/\H`K71`F5Y6U%&_M[Q"8-;_1U38V]]7X M:PU;"P+91ZZM__VZOB^>F?&+DE0A=Z,[I[2^2;G[LR^+@ZF<-7.[TM]7GC=] M-K2/OOWLO`O[MQ"WE](D!?4E1GI:YL*3WZF)A4)+\O3'EL_Y_-2!%VI7'5Z] ML#0KL%*PKUIT[:IR8[AB@UR9:Z59.']P7[1F\;+F)S__&.;-VE6_^QZV-[2? MM((]Z3MPA=E`?("-RR#HP MI0C4`_XAB\PF8?B3TK$$MB.L'\;/8L!$P,BR&",1B!WA$V>:M@Z^$MS072&_ MI+#YQR$;5E_^#'K`L#GRFO)/9?#&/>4MY8DZAH3',"?'",E>CN28;#*;64.N M83K(#F8GN9-A4TSP]<#7ATO'1B<';C1';"(>D05&*A+Q'%B0PL=[)T?>41E[ MB7HC?$RYI?SH\F?*9N5A1V0G\""__PG4@=H2D)_X@'A$=2$/VBBG&.TNDJ6T M-H@9B1NX&[R/<_H0TL(IW!6N(XZXAC=6W%YV'DP@%0.D2+X@;.XN[7.U;"0WP`6UZY/ M7PNZO__Q-J?ZC"#L([81N4B/@K_3M;!4"TDR>%LI)/351,,54YE.IY M%71K3:D6:DH>;XF6:'!FFCGQ@!S`RN11&NY@L:J4:JZ.6LRMU*SF:+\QRU%D M+'94$W%-G*KBJG15^A9JO::#>U7;;7S5(4P9)"GS(*NW#S%NPU`;7IY+N-TX M*JC):E3%0[4YLX"PHDU6`6%<)+]9L*MX%QD%234OG#4_W-'?,H%N_?!B;L;I M^GCGYNC\NME=FW83`]`%RUY1QB>4N'+@K9]L@GREY?#++^Z#K7#HX-;'*IHS M)QZ3;=1^E(XZSGH;W*@/FL]JP.5X&\Z!"V]?F\]FZ'B^C[@I.\Q6B]EL-?,Z MTFW5N)%.-H.9LMJTMC[BS[+9,41IM)=#5!NUC1J@ABB*RA"&&W'H5,50C"]Q MEXB:OD8\-8B$4A#&D\C;"R/E()F3"V*2_IT'F1$[PV&*XDACQ5^?G-=3B-,, M:6`S3T:G,GJ"@9+A-`W+I!:N7/JOU9N8&*F)/R2"8'<:A9I,T=BTO%W_0F)` MV;AWF9L@8XRZVBR\VH]PK?SHD.R)$3$RYHB)2YBU3`>SW:(5[P)A`2#`-X5P MI/']1!1I"6>OF4I35\C_2AP0A\1/Q;^)$R(M]L%2F?,U9""=Z"!(`:?Q@&QK MLX'-]YTV68>^4/#_#EW>W^L?/37 M2_J4XE3S;#J)AA,S]Q1&8QHZ*ON!)O09^@+]+'V=?J5NI;Y=[/!VY'12G72G MOI/?*6P7NT.FS'>@!E.%A2^0'T29#0RN2X?T=%,NZB?FH%SX::^&2NTC*F6C M<]"D][%$T!X<6L=T,@33#UY,IT"OH0AS;/2W;?8!.V$OQ-","\.)!`8EZ9^) M!'ZKH0+GXD?"^&03>(H!S81QW+5:)E4@15Q$P7]"FJ0ZT--FSM`&D(ODTZTG M+M9UR?'E37.AN/EHS]HYW1Z]U:XQC==4 MG^Y\YO4UCHP]SUU1+HCBIE[[_B6%YX[O.5K`OD@?[EC7$PT8Y4IUCT1B#EW" MBLE$0719UJ7Q05Z2IDF+>(J)L4G5(&C&('F)$'(B#[ADKU?4LA:;9,L1>=[H MDZ2['&_A.)Z3M+Q/T&0UV/I`/!NTX*A%&'I9I[8?1,02]3*7T>!%.@G_VH<% MZ4`BLA&YLL'(^(:,1RS.G#8.N)RIPO5+C<(]W*Y+\;9O))FT,+T>C(UA[=E+ M[X]$OV)8CW;+136=/4UDJ7B'(8PG>4>I`HP4E8&'D43`1FBG26,XHO+-GV&Q M34J0)$C5>*#L^<69M$[9\H;IS7?O%-8[&=B^G*;7M'L6M[S34VB]>VO]TOH] MS`R:2O44[I_&EH(3YL)\0T#7KOPE,:$+F?05[%@93<]@-.>4"\H&3;);IV(V M_IK:A]FX]]]L5W]0$]D=W_=V\V.SV22[)-D$(21A0X00@H&`*%ZVBB"HQ8+( MG8IZ_JCBH?CC0,1Z_D"Y'JA0VX[UJ*>>6JJEGJ(<%!6Q:L^[\49'J9T;YSQ/ MP;EKF^IT@/.N9NG;)5K^Z!!(]F6&-^_[/C\%8P$UGZJ@ME)UGCJO$AA4"8ET M8A1T^.FY<:6P7 M*#RON96%R$D$J8(2B/HM*19<\RQFW[<>N&/ M^XIV^CWHX@^=N-&E)4GMAO([ETE50?V\[L=BR^!K"Z8P-$B.]=::8L=?[3S2 M*>3H3@/=R:T:G4[CCXG.I)3*66+;)-^#]J_$,YQCDA-A,`?-ZI+B*&9&2C9/ ML.7K"]D"UR+]8G:1:ZVNDOUI;+FKEMGFVJZEE78-FHB@X3@#IK#W&FC8!1P? M\[?H\9)&$)8=1SHY*Y\:<"8E`569_SL69-)9#)<()M5(R8'0 M/'!+?KLH-C/K)RZ<=NJR^.SRQ7^U@J+,V;MMYN+MR"O0>\8I.0D#:O!MAT9) MZ$M1".@7*$9K9FD!]^>`P<4<89[_?VHL=S+DI5X8`BQ!2G0 MP"@K9*:`,EEZXM$1I9NV9YHP7!::#,!F^H!3H8.JEJ"*8G_U%5C5*:K/3(WU M9#(-(/_]952P0KRQ(Q[M?'?7VJ4E+*7+?K%93"%4T?=A,L`ODD!-&`,[4<=+ MDQ'_6\R*N3`_=E`H(C04%Z6)TB;Y)_GS\=SH7-<<;;%NKJ'$-=B!? MDN`OUZP`0O3+6J%4F5Z*<"#=%3$KA`@S)P,CHL-@1E5J\$E/V_7RYC]M$OMO MGO\:@B4E=965]>L3*I*#QW;4_^[7L$^=$YR[_GC?\:V+#[].EAZJOB@^O?/! MT.#$AOE5N[<.9/!LIBK2*5$:8QDC1.?% MC:]\1P=NYUP!\""W4E@^K?46@)_>>KKY>]OKMU_^.W\S07V>*.G$VBN M%V4FW/_S%X`6'XM_OR[>%&?Z"'#ZXH?'S]TL/(9.*:=DO`VE9`YS"5':/2RE MW(,I]2@LDZ9\2R0N9\\VA+-?9L0QF3GJ_^7G"9%WO.WEQW#\JT@-1[N#O*,9 MLPD:1BOM1^[!::E%L)SAK^%[DCC(36+L5F-:A2NR2TO,Q'[O?7ML1(]^@>^5[)*'Z))6%>[+HPOAI6JZO)ZJ@Z=1WY%+4U;, M_5&;5(UZJ=0ETH`-`8A:.SX' M_)#F3)Z]LWIMY[*`1F\+5X'G+\`71X_PG%%)!56J((#6".*!X#[E"&I:#'1*\A-/L=#L#SAG8=&+ZQ&)0 M#-_PO@G>A.O`.KC%NQ,V>ID\)(Q3$H/E4Z9(`].ZR_6)(#'1E^%KLDC3HF)+ M[>56F-%$(E6%CP5&J54GU_!\%IY5@^>Z@]W:;O@"N>^C<^R:W.F&S\50"`61 M!W*("Z,<$AH*(X4-A>10-Q`V2"I;)M-J5$:DR*\'`6EB`62K"1X02)/<)0C\ MG(0UQ2N&H1$SHP\IB(W1NWT+7?O3BAN_1AQ=X?X>*A=W+X<9)'%8T,*.J1 M"L5C]4+J?+@:+M'\#*XG=Y&[XE0DH2!(J);^NL@`.54QC9RJF6J>&D,ZB%B` M$)JEBNKA;_+5XX`5)/UMO0MF=Z:8J;>N2OSUC@PK!A2-*-TF8XN%:,R` M,39^)E]BF,NL-"QCMC/[>$U"D[:41/CIT&E@7!.JB-^U6TMC)`"1X]3Q-5$I M2=WCNF$_1B+@P#4IWE'@(-P@H1D:"`>OA09#$DHR,ZP@'1W0!P+F-%=F!H%0 M8\`<C[NX#Y4;68)?YB2T?J3[:"P+LK M@:7E@OBIV%?>K"UK`77`V;YCID6C#2H@`2>>'&D53XNYN$J;FFUL_@@4`A[X M34MJPQLZT)T'_LMVE0M:8_D0EN5+LB49&]M@ M8]F%;&(LH&G2QA`#YIH"+:&$&P(DS9!`@*&$FI!ZTL3XJH(S'2"=9B@T/08Z MH87A$(VG,2V'FNNXJ"T*E5P4L%%?;]$PO#-84*"MU/3RPV#+8$P+M,V5 MQ`AT$E;"1,XC7/#:26M7DV@Y!9*$`?56!GCYI!'2 M:@R_A145*M;?6RP6]G)%0(D^K*T(%%E[41X>BVA;+("S%%FN6DA+)3T,KPUX MB`2G,J!=1!7FP$(.<%V5%:@.\6Y4AE0(D3;>/9ZZ(O?BV/@8GKU2H7`2%2,U M40+T8+((.D-Z<-(CL)#I2K#<(0>X;'((0<)8\R_AOR]_/;ZC[J7#\2> M$KSM#3V;8;@]9BE2)X#;".TCK]/`N%@MXKR\W43P,OHI8-L"]\`@D>>B#$1B# MRR`-`_8?J_L#)9-"%Q]#Q!T/8;E+8:$+C253LE=@]BFHQZ*&K!8AAOS4XW+: M&86.-Z7GR`/)I%(4EQGI-SANL_3!_B^DMWY[`2P#EA6G#\[-Y*OY;$GJD3X[ M^.[^?E!V=$3!&N>O3BY=6`?^/$?L6%$2_@UH_-/?0.N'V06F11_5/*NS+SC< M*R6E_R3^7C]GP3JWFE5%5*IBC%P!RC$O(55H(4Y$=+DNT=-$B+.++6)&C5I4 MSL9NJN4\P-/H4698BP*D2;;3+%\)F0'9NK`<1H:TD5J40VJ+,-%RFQ+!<`G: M#?F"L>#[03(X3/K[6EDDF]<'7$0B#>4=>*U?G];5&N/_((4FZ(>6^.0.QQD< M9N25QWDFGI'B'X2^^9S6'J<=#")G*2ZOW;AFU6?5G1ZA8^8O=^_9YHWGTVP?T(^^IJ$*ZQOV;W_] M2%.S5^GLF+WCY^^\6M>43ZM?N2S]'GXHC39\?YLU&P>9>N"`\X"B'N^S'65_ MO&/+9"T(Y>M#)@-,3U`$>GI]D%1`JBO'CAK8)(-GDH%#"_[PM_A; MTWQE_P\7=.-K`*K"<;<]UMIS=.N2YGH723LZ:M:]>F);>3O8"+X']K;)9ZY; M+-V6CDOK6M`5.NVC46DI7(-.:R>:!CJSCV5!-(H<)FSP@SZ]`5-A0"?J.:A' M1^RWF!-*%'3Q@9DI M$-FA'`-,)&DL+8]%/,]-?[%G>$--:XXFRSNZ2"^MS,^:JW9TC9'SPGF&].#(I@2D;^.4Z`K0@ MG$S?%N7OP.A'T?0)'L#5\-UJO5#05AUM3K4X6:.2B\]Z>_VF-UMC=L2)H;;@ MERVU+N64MM5;0=:2AEGS2AN>&R"UJOP4-`7X>W M)&GKN"S=G;YT)_#,0-=E/;@&_D?CU!"J@8N(#3%PCVJ_5N11ACK)L=DX2@QD MBE8S9##55>M9CQ5QI<^1X'"N,B/:Z+L\;@3<&!;5*S=3$[21X]65:3ZW'`:P MR3`*IQN]>S7X#N6-.CTX]6S\U**9+:&H>4K[0=7OV"WT_"621 M\V@5:_S7R#&.50><,6"$'I`OOTW5U=3+TBW\!D6/;C$_1&]0`WR1*@UQ1G@@ MD(S@%OXBD!2@(4U2N6;*3&8,@3\H3E#&6@A#R&8I8++H-+<+DH)H\0J&&P(\)[ M24"N5PM`$`B&JP)5N+^(A+^P'&TB6L)O]T?\I+^6T``TR%PG&-#6G_Z\V:;# MC[WFKMKI`D.0+JIHKFUNON@077F%I!UJJLO)M+E!D1-U%56DEJ5()4+WFV$2 M?^.)QX1&R`O(Q?B;J50)8]"&??C8Q,<92C>R[#HPU/R-R)I=YSH M1D2%I--#@O\5WB>T.4T/]&GZQR7[5L#0T:/2I>.+<]V_E@YXE[EWBN%3T9I\ M6JND_$V!]PHJ.M<B#XM3)U?L?.E7?MK6G*H]U/[I&/2PV?0 MF)A\^)5TMQ%7U5.\ZR@L/5_CP.25[DFG4C?`.&#`@JD(EEWM@K(\BDK5BDI1J:^I MM3H6UVVUKJT/0&OQQ;:N,]99VYG:[N[LC"W.T-JM[,SNEJYV-Y<]YP;1=B=S MDMQS[S_W=[Z_W_?SM7U7BI\J!GS.&[_@KT?G7D#L#*M.)+]5`(G\_%&[F;'; MS>YT:.`HV9AFJC%[_*01TA*\(1'5B`6"7*$Y']H)]R4X3MC!8L*/3D+DSZ[, M/I--9H?I2^B4"+0M1LE!U1(.885C@6-VP"4G0G$`0\.`F^Y]TC0W[T7Y-1T' M$MC^0-+_E1/.E-,$M$"C12/`-]L'>/(SVC3@L#M`N9"V5(1;:N?]M71^*I5` M0D/05[#QJ=+JIM//@NKW%\]Y+O*;)=%]"Z-2H?QE#[-Z'>]8;.']Z((DFL*E M2 MX!L0FXE1UNH.-U(R2B72B@S%=*&L7%M%+Q$U\YKIE:(VJDVV5MM+;Y%ND@UH M7P7[I)\E:/@R/=!#%4]%Z47Z!*U,:ZCB55'-E%C?29**3J%0W(E3EDI4,6ES"QE9A"B^,!'J>%M ML!S4@7XVAWWK+^SU\SV[ILF3A^YMP7^'I2!O>P.]B8[S(;/@,7` M_P5D/C1;>`]L(V-S9`4[Q(U@!BT+ZRF+%I+O:W>_[SM>?\:2Z]%X'1X M7!?@#V&A9Y?#(HA$$Y>/0B`6^+J3,PD7$*(E<-$8 ME\A1I1AST["R!7,FRSDGEYFXU\2F/X6&XA27EV(3Z'N&.'_4=\@$%(^[+BN0 MH=6H&>RO/L"9+T?IE^F4%<5GF^LFZD(IR.)@H"GCQ;&V[?6^?[:V;/BZ-[^. MJ9V[_>B[)Y=3AMV_C?V!_91KF*1E_X*:CU_*"U%\7FWM_I8;ZU1/:X_OV7F8 M4P![F%.`%?'VR7`.SR9RBKR\=+U&92PSAVWESHBW5EUEK)I3:UZI7F%<:?ZU M<8VMQ[O)MLD^X-7R>#1?*E4HA?-%X'6"AM\2?/`F01`*!.E*^+>PF_!U&DA' M)\$(^?R@2:%@=`P!33IWMRF8W%VA`S[=:MV@CM2-!`.STL!-AFN%%ZH?T@F: M:O)8/.W@A65#:;0\W#]\&G<.-L[,K&R,[W$Q,9#F@\=2P@]`,J^]!Y#MCHHU M634[=]W_F3;0?++\+CLV\DAB7U_<%I,=!/#8P:^V[&5/#7[5FV@*K&*"><$$ M6V8UDUO8;A\&3W\!2CC!??1W]O6&8M(TS@XAN>F0W#RO;6-9I+:YB&S*J!W$ M/&(B'*)R]1(F-U62)ZG3K--LSA6@M"=F9&*9>!2;#4G\])I$-">S*)76K,02 M7392XHAN5Z#&CP4H2HV?W2'L?@.78..\B!9@0\!\9!5GE80%%E MVQL&_HS.Q#`]P=-R*?3+<*E+[E*Z/#F>B*A04J0H\91X([Z(?[%\L;+>A^:" M;ZM942(M<3K),*M`0@G3R`KCTGJ`SG=1KD@T7P*_"LN1.C5`FA:H$EQO:T\BKJ#L( M4D1`Y.I%R(*6#JDRC9?1I@$^(/1$`MI(PZ/D\\G;WZ&&F.R:TDU,QKL"VP]V M_MSX-X>I:-'R:*SM$W06;5$0C2?7-(#]FD&&8X)J!LU6NR/+$5`S&DRG&5R2 M1;:4&4P)9&C(,2,L=IUM//)>9..M6WMJV#/LO88/FY2@B+%E'ZB]?*MDP^_N M'ET*$A^NN$$5__*=RD4YH:,;*]L#*J9P[XH;[!V'O?M2QO*T1(=SJ+]R=994 M67JH_<,';E1W*YJ\UY%/NXG&LRF&B_`_A`:-G>_/6VJL25""T?(<9\JV*^C] M4^`/A!4^1(-D?`B.BJ\B@U:ARR14F"\)(YK)25X/*LL4F@:3Z#.%QRNVXOPI MG$[16/BIW.+NBPHA`\G900EZ"T#1%?8)/1D*8LEQ#9[M'S-Q9N^_: MFRKI@FVGYT>WOU,I'7PZA60#A*+L-/JI[^A3J%*.(E/PT\9U2`1.C5.>RDL M2:UF5L(F51/3G+H6K(7=9(>B0]7%=*7VPUY%KVHSTZ?6J!>H-0PS"DF&A*1Z M`20U&LSA2H>=L:-%0@&A<=@M3H$3;UO59L*/+(RP5%J@Q>W2,!*UW8$?4CL) MH<1H)6EN:";5((7-L9`"2,P2=/X8%]ZXY@'RVY]';T?'8KSG5[\YA3R]+U6[K)#=^@'&W5,5(Y.R)6`7<`RIRT]!HP%7V M]O_WQKT=N*[JZ6_H;ZE7B7R0&;:F$L[4_E0RH\:OJE&H#9K_L5WNL4U==QP_ MYQY?7[]B7\>/Z_AQ\ZA")M MNK*/=8[_N=_?]W=^GV^;*9&N:4OH56R;/AZ*M<7%W$RGJ$0^KS#B)C(A-_/$ M>PSO$&P.AR27S>GG>H4R'?%X9BO-PX';85,24PY?/"CT,!M4W3\;< M6?>0F[C?I]8A$3I^4%0)0AS'F^IV35A"2]F[W=:R)7FK)=^=AU]WN-JYZ\V2 MS;#PS'U+>Q)ATT#8!Z.6T,%G'UVTL!L*A:P6Q-[![,7_]WV#O2'5#AN2AFJS MC4H:I,GT*'T3*07YO&H*5F!P\C_UI9INID]ET^N_FK2*I. M((DD?0)%<%H4.K5`8JXV=Z^KU[W=?4B[WZU4:60"A4HT0D2KU4H%U)A<1J=9 MPYE<)I<+-B8C6F-$&RD>3L+9W+[XE'00T9I+.(WF/!:,V(D$#(]P7L,9.,47B/1_VHH;U\?"P>UU==G" MR(K"C5@\FIH?"20N41]^\V5;E,[&_)UCA3]3GGK;L<*7N_+_?#T`M:1V]!5: M5D%-X[@$ZJF%>OJAGD'T2W&^+%CEKPI4!9OL37R#OR'0$%SM6,WW!'J"N^S; M`H/!G_#/^?;Y]P7V!4TZN\ZAXW7E8Q."1E8B)+>9>0X=1KP@XRY"JC%P@220C-8B%`:/`MR94Y\N<%T@&\22!C+!GP]/G MXI#DPB'VX\^[I^_\!VA[NAAUI1H\&+#9O[!WBP32/2MH,F6H-H%H4G\\B+NT M)!X,6R\%\]5=D\Q"SH6'^EO=_NE3NPNON#5*N6/5]\[\H'"AKFH9-;7F.GZA;"3_V5KGH7-]M9Q"4<\P]8MPV8IU=W#7\K"]7F%A M]=;86\/%-/)P" M#-\LKI8[L-SM`N<)4C8!S22+:3&@"%Q!OA1=3"\8/#B!=:WQD$K3;-SY>&KJ MH_'"S9L=E M:M7=+7(MP[<,;LZD^[!243?04EB-\,S=&233S#R)"'("<*`O*(*;:=0DR^%% M[_Q*NH*OLS=0++-$`B?&:7)J9);[-T\^"0.U86::?$(N`;,ET83(J@1%G*I1 MC$"XXJBJ,%P?=T4S"F,49L-"^&+X2I@.AZN\_PCA4(Y4G`N,ZRA,Y8CGK/>T MG-'EB%M4E?886575;ILZF<.+WW/5<"0\I`=_I!=8EV8[/P`Y)+^).9AF28[Y[.=TM'W?W%BD@LU&]( M^:`"P+6EO)*RC>*\>;FK=G#/]=K M"&7T+QV(S%N+\6_MR?CPH743>!&5;/AQO+7"8<%_*-PZT=[0,E)/4>\L6%@? M%/;V-!;^6OCWO,<9IC,4?L6D']K8^V+C8T/991;+XOE',T]O:>YL77D-M-5" M#DG3OP-M,^B(6$$;:1-%&3MK-M9L,^TS/6>1ZQZ+DLJ4DZ]TC5>>YM6H'><( M)SH8E-IM8!*#2IT9*U@SOF+&YGKEN"X\Y1Y'.5(BFD67D_7@N&>?YXJ'"+`< M]1!/'?MY=_^`]=?6V]#&T^RU_@'0LDB/]_*0[8I-/J<:F#0II3(3R`+>G940 M`AK(QH"1O3[&5\1I:&^#<2Y%S,IHTG9TBXUJA8EF,-GM&VI\_4I3PO(G(;.R M9H-=DI$3HK2T<`C05%I/:UCG*=IM4F:.P;C&[C4 MXQA\0KE5.:0<5W[3NI9SF/_XYHHIM$5BHXI1PWY(A.U(QJ(00(6E%+M+62,\`57.;.C0<] M]M`7V>+]]M`:6)^0@D0R!2]/&#V\=OEL3R53\J(SOE/G@3"@"^0/TFZO:G_W MY'^9+O?8IJX[CI]SK^WK:\>YU^\\C!]Q;./8\2NV0VQ#;IX&$AX)CB$!$U/( M1M-!*&DH)#`;TC!H.A)-FH8&ZJ#0M5VZP0BE3D"%JNW4KFU`FZB0!MND!30J M4NW1P*)B9^?8H?"'+;_^\/F=[_?S_?YDR&2$B*D/#VR6[J!X;:^TU;PSO:'_ MX-9(U3ZNX>'UQ[>!DY"+NK]:&\97D_&,T\C*;'WI(7TW20INL/U+ZL MR=PPFXWYG?DY_('\GGY5O9KV+I632CW7=GLN3)LNAN>C8GE>SZE75#94XM MA,^[X!UL)*,%=TE?UC8E@D?\:R<;7ZV7ZM>=CWT^U^CX7]_OKQ.UH1<^>'3B MZ#EU1N7@RQ?V$112S:L<=><12Y0S\\1 M[R**.,'^\7V%T)2"[9Q4`Z2GRUD"_-VJL,6!%5I3I):C1?PH+8P+1/K+\!`H M0;&OOU`^9I]$+N&3TG$KF*!3I(%C1Z50^@\%P\!.IHU\20&0Y^T7I M:#1,A,5KNPN9L'XQQ8NL"DS"GX(E9/DX$=R#,E#'62-30,DJ M]%F7HGO!**M$Y0P%8/:BL&G1[Y"S^5F6Y\(0EF#I/O&Q%Z;G6J);XM>WV-V[L.[FWN#44. M+1=KU9ESR2WQOD0\_G+F7^&BB$S[QFC/V[&:"L[6]V0;=+;;:3_(K$ MVEU?[A\?;%GG]A27&\NLA:4-VLJ5O5V_=BU=[!(J;<[7#QS?OW/H%PGD0K_! MNV;'L=:1YIKG\BGD!-W\'.]U_I_1CCG*,8#O$S0*(@(>*++ZHY68CYH`*.KG M4199G"UEB+*HPF0E69'B,]6$L`,UD#]Q,HY.TN=HDJZE02D4HD."$53SAJ*\2\],G92U9SE9#CY*!`B5\8=#17MUSIEH@ M)(O+F[=L6K-:9NUN67>D2*9J6'^R<^NIZJ"63^73RQM.Q%I94L`GB5Z;OGWX MK`/`D)*7N*_0IR!8KUJ*;M(H[1> M/-*$:5J!J&+C)X`8V$$'1ZL7135%\0(1F(2_!0+X[GB>-8K6M_P+>11]!7U$ MPB&@)IE+DC'IA-&JP9.B.Y&070[H*&>G8G=B>%+3#V9G`!H*^W`FBQ`DU&RK MR`K2+T?"(Y3/S&=A%!B7:!3+(+0Y:FL=SMK:1`%:V6B>MJK^9WOW[(UZU*C_ M$CI_4W\O/U'G1#]P.NLR#4Q31^;V\*%-I1J*QF>E>8M:$W\[$=$5!64X;^=_ MD[X*-V?/:`7MG.SYHN>-^XKV&8\6'34*=-V+F.\/R^9%)?BP+$5/Y@[[GFQ, M/:'-RYZSQYPPCYA)FG9\SN`/)GCDCF+I3"!Y6SR)Q.B)VY#,JD MK-DXD_OG=1\/]VQ@"4*01VP>K&),.H5">C`S=SXS MGWDT_QIL%*B,Q^!_X")HK\3MR#A_G]>%C ML\/686\K7^]8[^PJ[W)T.?MM?1<*AZSZ\"$[R$5BV$S\TT;B/PCJJ%:K2((<99X`%# M9*E_U)%Y&%RE8>B&MLC)+I9/\"0;.4/?Z!]+C94[OKMB^Q0!RK!^>_#VZ6WP MF\1C+D#PJ4```B("FQ87!,OTBFWFS"N9'JK>K]GUDX"AYL9'EI1!R?#LED+7 M[=,;T#VYD=,,J/5I01TG%N9')>(X+2J.:O`0M4"()'8)C!$332GA,*J&";3NV[KP0K1)*("EF*UIO M[.?_(?.7F70F,V5%J82]0O$++#`$YZ\-NL5L2![,MNTY-+*/P&;P-5K/\GU, M([...:H_&A``(1%:%8VN1Q;A3!W'^26A?@F?XNUZCY MS2+-9]H]L@XD$%1&I4GI.2DIO4RJP!(@A%]S4@OCUKF=[E^YS[FONJ^[*3>B M[WM+)M!^:<<[=[=[MWO'?7_#<;O'Y^'!?0`'MX#(AX"@<"C*<+1^)&<; M!(Q5(D9QQ"AI==14G,:83&FMM9-6)\*A31M'FY9I:S.MIF,;D_PA9IQ*Q\Z( MD[:"??<.$:=_W.SM[NP?[_-[?L]'0S+?@I95+5A72ZP%:^D20ZT(U:-'[(-. M5O3*N;E.=AK]N_=HB60;PHA1Z#J[V!]A<,$74]>D@(O@\B_JMUK[7+3$\/?\ MS0MZAEZIBY)BMB`#<-^P,[.HL/=0\;[T@DAIQ[$:W%Y>5[`]*]*JRMSA^LZ*K/FIB4(=BE)R>4E&9.SBF5TK MHF79U_^ZR6LFDV90#=O^TV$,:EU68V803=R$_'0,Y:D(^)Z@!D2`7$&VD8>- M4F#.23JJ2K"&1\T#4C(+.2K'8+E1+9^SX*B*#E9T5%9T5$Q>(0<<\E,.=-/'2]ST^30,J=2)IJ%>@KE^\7$*]&<6 MDNJT,'[28J^LW/KVMOP;I?R/)DY[:4,*P,'SW4YC ML2+#)3%PR$5K4:,SH$ZB!%;0(A07,B5Z@6G4KV8VZ&/$M^@=Q(!2$<>@,2XA MU7&*4MUW`+@*?`&P".A"G]NT]UD2DG8;>_/SOADD@[U]R5XVDVJD:45BJ)#H MM&+QPM*T&G341>+5[OWJ^"T(SK[UR>_^^\MS9W:]M?;HNE6OV[/@[<-?['GR MYZ^/[8=*F']C_N^)*R?O;&JN6B^Z?M;<;EM#63.BCEBZ3947S1<)H5HV&D&$*-W1)8.R M&FMRQ(4=?H#I)KF\='1[@5O!WGF2+`[3+)\I4`0/]/!_6_ZW:6K+G[FJ\UCMGH:.L/> MEXH)/+>V9M)5-G^ZQ?S=V^MX5X@@0I4P@FU^MSW;4LYD&ZWQN>.UX7^.O7)Z74%; MIF6[B&,IPK$/S9T'`7!(X"EK@;?"6>%M=:[QQKQ[;#)]D0=?E@-RW,L&+)2: MBJIB+*V""3@DZ)%)D_D[!#N4`SN4L7:G';,'6622ESSM1?I)[#(<`31J:7+` M$F<(C`@%V9MW.J<>(/R2@(KU(`GJ_T&*$#6(VY$J:EZXL!M^(ME4N<6NIB>3 M%$JE_Z`?P[_Y$N<@*:XK[_2@]UI@??IW^JT%VO>G6YNT8^W;*O>SY:_6'#Q[ M84_E8`6.#U3I-U1L?##WZ?R-AF()1A37P+)_K%@I);Z^<>A*2+6^P#4:RO]X MXL-;0M.OH5/,*>E/_XUC2&7\(#8!6"!?_D,?X`)LRQ+`8&681".'I^91NL#>3 MRH&JI[@Q!KV8P%PICKPH%L\2)[>H%GH=W.WQAF+^H$T%&2S/$,DMW91!25BN M/GSJT(&A6*%%0J8IJUN[1TM5=-E7`.,\)B@JI;?8+.@D`6S M0@6#((%K!#J0?H-50T$-U8A:?_RTLV_FULPT(E;?S(Y9X\RT2*:%XCG3*:8R M\;J$9+UIR15-;B&*4?D8XA6"'.&-;E*\$G,6ELS$J'B*G//SHRKSR>8M0QRW M];=[A:L7WAR124LQM6&@>OVWD]X8\V!'X>6O[O6Z@YWKJC*DLJX`N\#%Y#C&9=LYU$D-2=P MZT5UARZ!.P2-D=5`5O.)!A,T79H>#:[AQ`K8%WXP??=)>'8N/`LBYBGS];GK MD=[P/70[S=Y$G!.S@;A(AN2:Y4-_4(V(%@AR/'I&X"B+DCP)^[5E7EO08NMV MAJWUF_/QQM71.DAN+S3+Y`.-S5361S@UO_-4M,!@A7N)G/2,X^< M76;7-LW?P25;($1GS4*.\PY2\%)P3K#3)"W#&,)*YI%ALH'<0,;)UT@9M.7Q M;-2C%O6:R=.2P6A)+`04M@$I!1+POB"7,SR4H1\*6NPEF#'IG0J*0NY@?`Z? MUX<[?8*OR]?C^[GO(]^7OJ<^F:],/V6:9,74I6!HV$7WT!@=%K%Y,'=7M/5[ M*,?/B,IT3W0OI$N1\"P*6@MNWBL-/H.F*`*+N.?Q2+<`7<#/+ME('8FI%VT? MKZ5+JX^\W#%4BN-I@75O]*]1DRI[K+KS!T8EI6A>M>5HLT*FEC",OJYDL+V" M_$!86=:P:__RCO?.<4&:U1&_2` M*#1IC%&3D'AZ4"CD6,;)T/0?/)S6X^$T+#O"N;4,4&G23`UFV*F_[%?K<%-7%?XWKW:A]XK:?58 M:5>2K8>1UM;:LF4A^8$Q?F!3&PC80+#`H6,;7-I@7@53QR3U5($`;B=`(6G# ME.DD:2@-(288TH#;<4(]PX1,Z@QIFZ%A6IA2QIT^PG2F,Q*]*]4AT,RD?_*G MPQ[M[KEW[^P]VG/O=[YO$_]=_A1_EV?X%OFYEQQ2._M):L#)MV5F[`EE+SKF M8>;*8L.--!F1#$/L9-H0<4@D=B2G`[`SD)WXO.M-]J9")F!,T:&*#E*J)D'[ M"!3,U]79?J4>N&".V@:+B%_W+5WS-8_=QG*U`SNZ^D;VEFMM<:G@V74;AHIK M>)/_X]=K#"IG)=JL`)^:MNV^E?W[#=@"XYMQ&4QB#JK7<*;UF:OPU.$DJ[68 M*:42F._^E1I";X&Y<'G=P29+$T>L%?8)1(V0+(W&VH6U5K+)"O=4PKWB,^[] M@?W!D5*RKW0'VL:-Z$<,9*/<4-IA[8BOMY-15P/?X&P4FD0R1`3D0&D%7^$D M=4BG(M2Y*R.<0Y*#5P7&*@Q`4RJ(8J&6I M#$$U?!/5`P"BJ+ZNXV@9+"L[%H9J8Q@RX9@#J(T\9!;SL(IOX)_G$6]4CZJ) MM>K'U=&L";)_'1Q$=*=4_(J8R_(]F)99A)8)AWZ/Q73EQ M4I6Q^0.SJ10<('%2_RNG2DK+;?;9S-Y[2"&\"H):2.#EH.Y=WE^G+R^('NM8 M=KRRUFX^\6'9O*@4>?=HL9X,2?7?[EGY2(FO=O_V^L=*>H;WK2AB80'LF"KP M*=DW:&QEF;?AA]]X87!3Y@Y\;F<-;[0+RI/F[%CV]N^&,&S59Z]>[L(KH/SN MQV@&_1S(\,FZXX]Z!L$VUZ#\M.>8BPJ#)&@%CX)^T%_2'^F7!TL&(YJ62(N\ MNF1U9+5,)DN2D:3<4MQ20I+(BIRN<'&X)!P)R\EBYA7V93-A<1MU7I/*!JD0 M'1`D7J9U"V7H71N`Q@`,Z'A@\]KJ;,A65OK@P#JY`$!:UZGNUM)4H+.PV^_5 MU-D*[+P6S)O&@)\'-'PJ#9R-Q&=/R$Y/IZ82TP.IJ:GJ[;)CZL$!BY:MK.L* M2P(9HBA691(EP4A==ALYM]'HOARBN!#N?Z"-A^*1*M%M#(2-2FK9R M[`:+@@C#1(XP*>@<)Q2W_.*\4/VS3Z6+G-8%E065M]*K:X..BJZ-Y3[;I34] M[>%"?VVY?\G6[>>_7FMRH;4I7F[]V\EW**H*B7+VVJ5O+K7JDU9OH%B`TI8# M3]!TC7G5DX>@M1OA=:'+7%"UH),@`?Y9%T^(WU+O$I'-8Y/#GD!%()90+XKN M+-U9-AC5%'4'+-TLY[)VL<$%H[)'=.D8FB7&X2MU5QNF\D#,YLQV1,IC,D* M-D^D&8S-"DA#4T*^\\7PC+5>O#Q7"RU!),//;E-,I\P6LP5O7OE>)\Z6LG]S MO+Y"MKLJA=K>_N*1U")?TYSU2VK_T!KT67KVC*P3&UJW=ZU8Z;.7&KU'PS\] MPA4--HLUF>L_\'IW0/-6V'SCU92R4YT6-I;]<_:7T`<-BTU>C5;I=#G*LS]+ M97NR+Q;6-YMQEB3,Y"_A2CD':Q[+*M4JLH??@_:JTHXC3MK*D=IQPH?I?+^Y M&W]5Z`0%YY$%.!$WYNHOZO;GF`?0..TD`H58*9K/^+FAPK`6>V>-)TIUNS&G M&(?9LX^#44QKPR&%FMY)86I_#5.)/"&]<2=S0\%%S"XRF3SA3]DQRS+'%8EC MA#Y,-..JW'(V0@K:HYCMSX/EE)WR!0ICFL=>O/[:OX97N+2&I)9@8/2%EXY7 M1'_XU>SUX?>.5!6:M54.V+@\>^CWM-Q_&=K^`AF27]C1W9)B**HR43NY*_LT M8:#\&ZK/]3(J`&$"OH&.J42@!=(YK`F'SE#ZYN96-$X,G5:WZ,[#"+2!7"5O MR[0W]C3/C>T>'L-?N1Z.H@M$!.A! M[*RN3T/V(42/0_2&!ACQ^YEQN/T,;#&L/G#_NZO;,M'\:K(4*7O:JVC!H,^[ M6._F#KX/[9/J`M.>V]DK<-30OH"FC:U-:D7'H@NH@WP?5R8KJ#A-DL0XT37& MZ%E6KS@6NXTVC\/)TU`'L-C*5$-V(H-M=H&)-/6:UUE(RTZ.XDY9!VV5MI_8(_;?.C[@ MWW)V._\Q:RX6VP5AC?".V"->=_=Z>KTZ[Q/>F8)?%%I]!M^K?MI_(C`_<#&X M.?BGHN_-:0HUAY=)0>GDEV"_^3*LV(AM>?$1;!,/[:$]M/\'`TI5@$`Y.*!P M1(`I!8`4^,(#`1+0C%JCU>F!D369+9S59G?P3I<@NG,#_(%@T9Q06"HNB*9ZABF,0PA6$JPS0% M805)!1D%606E__^!:D%J5!AT&!R!:A*!:B:CJ_G_&!DRJ#(H_O_$(/-@_H-Y M#V8`82HT)@@!9H(J.!C2H&8Q,P@!24:HCX08A*!L-B!+!13C+)Q`$14&,RB; MB8$/Z$<(FQDHG@%ELP#9/5`V&Y"]P=_5W=?;1=LI/S_;,:\DL[`TD1@1!G\& M5P9W!E\&;P87!FU@*L@'PFQ@B.4QE#!D,A0RE`)#+H@AE2$=R,H!LHN(TD$M M->"08IK+\(G!!BC."@P-`09]8*N"@642,(;!^0/8*)T`E`$V3EG`00JC&=*8 M@"'-"`?H46(/!`P.P#0RC0-H+,,9#B_F&FC,,$7.,CY[>$4\O\U7!FD.L.JE MGBM30/2F_*[F?Z_^-G-:@A%=WV(>$C7J7+"3FL=HJL9Q$L>H,7>Q531CI*8V<7Q-X[3J&&.B2=I, M-#J36&TR[NVYBS":COT#<@_?KY M![`PCEI0-3BN?.K_165M9>`A@)`&=/H7QZP?4P;@06WV%^=YV^L77'SVB0@ M4,_YK`O,7[38_-X*%2BV[(&%M8$EM.HTT'L3$%FNG.$HZY&H-")9.@&8_S&O MFU]V_K_W`=L.(S&DFZ:XP_HZ0/0W_XU'/.8CGD?Y_W0G7F'UE47T)-F(J7L=BG$4T9F`?0K03DUA.D;$$.>O$8C4)X,1VKI9L@I",/FQ&)"1QA"9[%*K1B M+_Z,<^8[*#:_,+^#C!3TXSB;\8U89A[DL_M@"(I99O..U9SI;AS'1[B%1#@Q M$,,X(Q]JL!X[T($S(MKP]_P=[)+:2;WE^,2L];!&68@BW/, MPWB./XWK^RT:&(L`5]2,%UC6,'K[.9\+N(RKN$H+:"4%J4-DB/%BDG13=BA5 M9D\SWUQK;C`[S)/FIUQG3\2&8S^.3(X^C+LSAK$KXLJM?"H9PYF,6@V>1B/F M,1*K&?/6<.?V\DG'\2FNX`;NX"[N432ETG`:25541[-IA8@5N6*V>%'L$):S9H@K%2P1?&G4L*1R M5MD8SCF-10'WKQCEX:RFP<.9S>(>U**>I0%S&(EY+`NPE/N[!B\R(S;@=W@) MOV=4-K%LP3:\C3UX!VTXC*/<_Y,LIYE)YQFO*_@,7W,-L11/2>2@/C2`)9N& M4B%+)4TE#\T,U[6&Y77:0EOI#=I%;72$SM,E\9A(%WEBG'A3[!+[Q$$I21HA MY4L3I">EZ=(,J4Y:+[TE[92.2L>D,](YZ89LDP_(5^4?E`/*L7M/A-RA\M#: MT('0UR;,+-/-:!P)WW;B^^%@OJ@8@!',K-',]/',%S=W9PHC,(,Y4,7=F8,F M/,^RDEFPBN_>JRQ;N=[M+&]QU6\S?_?@3\RL8_@+RW&E,!*#&(MAW-VQE,]22"Z:0"4TFD=JE#^DXR MF4L..5W.E66 M+=HVP';2/LH^-4*+F,PXO?$_[ZIJS)*:)2]T^6E,"<6+$]1!%^1_RGME-]E% M?^CT%=VFB^(B_EJJ]DNGVO\7_?JF)/=Q M/-8[*3$AOE=<;,^8'M%1D1%VFR)+@I#ITMP^U4CW&7*Z5ER<9M^XEG0Z5G0[4EQZAB,R,#JJ4"NL MCQR%%>%VY07Y]1?#61D3M2*74:(562D84IK+7V.4 ME7M<12E.ISB,T(NZ`P?(QA*S3LX6/4!JLDQ(@O;"96>0YAH-@=+ MFHN*O-9I\86>=0^ZITBZR]&@6E-=7Z<:V\L]#UJ=UJ?7RT&S,DLK/$[.6G.U MJE89%9YP!1R4'-FMS?-RL9-U`19.S+7EB MP2'S,TQTJ7JE1W,:^2F:UU_4-Y@(O:)I?TF!6O*P)2LS&->K$^E@S]C[2H^8 M!Y7:;EM8"[M;&F?=!359&6DE3!%#K58Y$X]FB+058CE+0X3=5O@XF@W;C^\(K__HHM+>XV+-6B2S?EV-ZE&QD9QJ!!%E/L MA=Q:SFQ<>#XB*W.I4:H%XE2CE"%#F8?.R&7*GT^IR2WL!JGAB-)=[.NG=?[%QO1-<]7D& M]?X_YMI..U\?EQJ4E32]S)/NUUM2TGUZJY=;X^:KJ.MN377K/MW?;C97:6J< MI@=+2_6`R]=54KN)EA1F9*NWGAA58U@G'$9"H4=*$=Y.3:1(K)5.T4K+IWMR M.KMV?Z:Z=%]G'\/?IK!7WWL?B#@;VA9:%?&,F,K?G0\\8JLM7`YK76,W@C(H M6;Z(>AD8;>\'TY:+^6(W);!MI]AM'I'ZX1#;EPB8IWAM(.];)F:9,OM[>:SF MT9>'RL/!0^+1P&,7CS)KA/UYKQ6C>X!2E!_@4CXTS\C7D/]?SJL].,JKBI_[ M/7:_O""$\)$0RD>19](02,(C$.PNED?#(Z8&=D*1,KH&"Z&+W2*E%`L4;"<8 M6!X9:$0%P=!)E-)O0]A`@%A;$#%VF)%6BH**"AG4Z3`44-M\_L[=_2"3Z3_Z MQ^_\[GQ>^W]7/TN^\=5+'.(P=`*9"SW/:9;$,NGX=/ZMS!WU= M:AV-4EMHH3J=O@);9^"LHY62[H\P?@7?AE*"M25.&>8-0+L"^HNQ5Q&^QV'. M=:R=BC5E0#[T;<+8E]@/V#L'W!\@N9;'+N/W8I-S"_L'^-P2.#>?V3T3VR]M M^CS`1K:O)^+V/81K6V](NWJ"<.8B6@RV`3[[&*`3J-&H^PSN9AC#()J&6)@- M]-."B(_7G#NPL4!OH8G\[0+G6*OM_^=8]3U%?O'**%F?1$5 M<.P9))K!YX$K.'L3T,&VP`8>)[Y[L;#[AVAS'"T'7M9*NL]JB[L;T9<'W2U8 MHW#\8J])B5B<[S(C'G\/D;BC39ZGH#1Q7R[D'33!CB;Z.?R5";X!/@7,0#L+ M^`RH`1S<0982CZ5G.78X1CE..$8X#]`>S_;S.6#'2(ZU1.Z.,Y?U M2JF7XVR:,@7WQGPRP8TR/TR.09?U/;29_<0QR'G*N>*R:Q_G+>P=SZQZXC[E M&'79]4V"/=H]:M3/4(7>@7T?I]G(P5EJ#&^R^&#-WKQ7H;WDEB.\V^4_KY$.Y4/Z%4&VC9X%6SU M/?!9;]_V\M<#O^%>8-/O>_$5KG%<9UR6<1:/H\]AYQ[70JY'7`_9)^KE>%U$ MWYD'OA]%AC97WH'T>V__]_)[56]_]^9$+8#'N6[H*VBEYSS5J!.HQC,5[61@.OGX3&[MU\9`_Q/.#9E[N&/V!=O,9^9S M8MXYM^[K4VF(K/FW2'#]U\[)_-C%MGFVTRNRYI^C-9@S.;'^@'H(=?)3O$U+ M:!+OJ]ZF:=RG&^3M?Y1 MVJ7EQ?.2[^)A?7%N>+<[%[WW8??[\DQ%^A+:J]_%-_OJ"LW%^@JY-N:L95W> M'AWM M\B[$G1S%F[R.QAFK2=?N.K^4[\^;>.?V@4[,>TA!Y57S(:=-_$]S7@?N=1)BU!7GP&^".0"]>A[`W5AA]:I#-$Z MA=!;G'_J+/!J$]W@< M8O@=O"GU0"Z0#E\][1]`?97?D`44`*IR7(GA=ZFE1)5FR@;;"7Y;:;:SK7)_ MJA*E'P$*YC=3.;`=<#"J)?5M1U.@4!Y5WCI6:&G*>"NF-/D&!0=:^S>+K8N& M6_L7B?U!T;%(=`1%8(&%X<-V[23KM)@B_D0J6;KY]IG]1;?WQQSFJ.%8']_IYD* ML>Z2J*0,K`.+JVB9XD/TI*$'+"I\N6D]UJ\^MV1X7`@2@I*$0@;-G(E;R>AG M^/SKE7WB'^(SK/X52R57*8<#!MKA,M``.UQN^?LK?42]5Q7SR%22:)'2@,#R4%"R M2D'Q.,W""$6#MR?BRKNCP0V/@/\5#2XUP?ND1M%@AR>#]MKA$!1?L*L'6?X, ML9VJ4S=`D4D=8ANN:EM"5T5# M%ZO`H6CHO4K3GR(F4%#].IW!DF(LWDE5:!4D;!D=#<[/,$^)4102M708([H= M7F:=$!J%E0:?9?TGN/-1\SYKOA'.M_X6/FR=#=U>9L:"@4SS2#`F=OJ2JLQF M5G*PNBU;UXM]R69#.-?J.-C1WA$3]=56UA&M,C>`[T9#YLOM;6FCL'.&^6T^WO+@<]GFLN#Y?//I]IC28%M5 MP9/*)VRH,M@.](/#Q&4]S#W\XTNHK679S\%]([N^T`,ECLL`/C0!$[P-?R/3M0"=I@UU9:I\0: MJM6NBG9,GFH'3'2,IX#(XEL68^UKA98_2>13+298XC&JE1>6:X>N6NUB#+:9 MA\\1\E9B8G@TU#C+/(W\"\A^P2;:UK]K8R+%MN[5MJF-8IXOQ;P92+?^`DO^ M&)+'OQ9J\^3!/>GFKMK=UFNAMG)S7>`EZZ5`3)GK&[C;?!Z]26^%1,E,FIDR M,WM!?E)^4N2T.$M>BHC54O;U6=[(=6_D)][("][(M[R1E=Y(C3?R36]DJ3>R MQ!OYJC?F=$33<@NG@'U)26CXU,177@H:PXUAQE!CB#'8&&1D&::1:608Z48? M(]5(-@S#8VB&8J"JB*/]U3G_9;Q:@)JZTO`Y]R:Y"6"XN0FY(0_"S>NB`0($ M$A!,PB.^`J."T(05145\C8\5JE;;VG''HCCM8EMVUZXZU8Z/Z6,FP#(&Q!EV MINYJ[3ILEW&W:[=TMNBNL\UN=SK:<82P_[UD7=OJ[B;<<\[_GX]SSO^=[S\Y MEP@U5.%0='0]"JW+CMYOL,9PRHKFJ-1:A:-,"(565NFBI$A2(290Z\8DG4$E.Q\\D?W+0N'EC]7 M"6$](KQ'A/>(\)[_P'6F MZ$]"#>'H.Z9(M$AHS)@BH6AI0_:J\!#N)4X$:X:($T(5`1OAWF"]X,>H)@*P MC2(,C7P'=@N-"#`T@F^)L'TBC#@U"SN9A!%NXI0``[];A!7,CM8&[IHA.)%. M";"^3]L`U-?VZ6,CH7;BI`#I$"IAI`AJ%R=L)R(`0WAG*(:_;@CW+^06!H_6 M1$(Q\B^"M5:T^CO:%P8W68.M-?\=UMSV_\"&(E$2BU1VKG[*IW_G@Q]H= M'1U/@WVO8T/5HR;ZWR.CI`,'-PM27A[NDZ.J2/6JV7J`2$T!8;8:N$B5EM[I M$U6:TN;G#`G#4$CA"U<: M"M7W224QO*4?R:A+>`M)`DX;U2&L.;^TE*<@EOAFL3PJI^@B!'"#M< M,RKQ)(+H[U?0TQ7W*NA[%HBR):/"W'J2 M)?XJ/8&4*`OY*N?`N/N0'!]!J5`3R``E`U8ZWC>@RS;/&8;3U(3K^C.D)$P1 MCV-Z_.:7TU^.PU-8@$F^V.,NTF9H*%)FM=A)1\GC-BXW$PYSEDUB)S/-.)@E M&%;2+LDTDQ[\8;D[G^>8O$2>TXP_M&46YN=8&"=8`C4S,Q=D6#H`-XM,-!=Y M434Z'K"93;S=WFTT:8Q&DZG;;M/8[#:;W6B26/06BR]/KU>FE%Z"I1`?8+N`*W]\*NZJ M\%>H&+8,VM.8OG$S_EF<_@P*%5/FFGW8,HIVPA^F1^E1($&(5XFM%@C>ATF- MUEW$E!0[K!89Z?%BCU?K]LHH+*-XR].11/W&U]:\U;RY>]7I/;Z"EDY?4>L. M+F0@54Y'KM$Q=]'4U'RC5T6^]'V4](>]6]:QZ\8.' M+5N=DCO!I5+"N_-AP:H2DKC\)!BHZERBFU1+;R`5<@;4RG9)0`4O%G*%FE$A M1L'):>377_5?A5T?OSI>ENG27=73TQ"S@W>4T&J/G951,B)#P[!X<+^OZ=R/ M<(9K?^C`R[611/?%,[>_P'ZLO?6U^]D=(XG&J2N)7UU`>.9RHIN8]Z09%7)& MQ:&GS:AEM1DT*9/R'J\'6"-X;-CO;SQ[,''7M2]TH*LN++UQ\?P7$XG1Q-_^ M>,_=N7T$OS]U!2\X"S-^E+B.6]!=E(*L_0J%+$8L',!IJ=)+1!C$?P:E(EK8 MZ@_&I\L6N`H+["Q!P6[YL->#%[)OG+=:Z14-YJ5W#8G?QN@TS;8KI]7`VUS\ M#O$"40`*M0<8C)44E:Z4KB/#U'X43EN7@EQW)JF=MX,?H$EJ6Z*#N(%(HW MR33Z9AS$65C`6AYEF.SC'/>B0KZHQN#-]ZTHR:VLA^R-S-PF/Y=VH73(;7.` M-DQ("?7$'`7]-M*-R+/-L)KXN#"2,)::]OJP,!1-BIKT"GH$;E6SBHRL7O[W M[M.C:Y;=.W3JE\=WK:J=O[YWZ^K6OEWXSSCCX1\NQZ<3=V;0[W]]_\SP6^5M MA`0;?G/BUO0_@%&4#:LX#*LH0<\&W`$C9THW%6O?M@=PHP/9\XJ+/8J1/*\G M8.*,1L:"4%KA7$;Y5=H$_?%B9@DCR\R,X<)!"R&;*%2(2P4"=[MV`YU,63() M%[AT^FMZ02)Q<#!EX_IIO0N:92YP0V2L+$,(QB,F%\4+Q/OP;*91L`^S84,F M4EF@79D$@N<]S46*P[MZKKW6%6Q6V&NURXZOW+ZVMJ-V;K6[\KG2WC/%S_0> MV5+Y>N+!SQM?66'%[7(_U]QQN[_KU4RJ/65EU]+(UNI-ALVM9G/O'M_>%1'; MDD,-+]P].J_D#>"#!#[&I-N0"W4&G%P@FV,T&H;)U]/YJ2-\80%"3A7GM`48 M3J6BE,IO;#8G:VS*;LJ*$41@#ML4T'.9F@P)->$4^1@=AR"!C4F!C+C(AGY, MKU/-LB,H+OZ!-J#OG05D],5(H=LF2"L MEO$RUY]F.168I)WT;KEN3"J8E!PLZ9C0A'.I!:NU;!9F,P2IE7@%CGF2@Q-$ MT"V<)IK#`./G1KGB#J]VE5>2^?>J9U9_V_J"[3 MX";..XSONZM86Y;MV);D"9$-@3&3:'%H#0/8#B2-.5P. MAR,$B#%V"@3'4!LFG":<*6U<6D+:F"$<[3!C#7$S"%YC)_'+AZW;C4JUM(:B:E!@*;"E MP=S=GY=ZU`PC/L/UF_`_7\^>ATT!;N;)[_&%Q`[$C420&N1"HI-@MYKWLIBN M%.BU'FU4N]3TLXI.T_J*/O.0^53@!'O>?#$P&E!6>R)L),6R;03)D`21HDG* M'^O(]W>H=$`7KR7("`;DQBI?-5?5[N%4OI`O[L,@TK)@^&:PG4;E:26G0-F[ M9>UV"4@7C^C:.&`-@C`I(?T94:P0*'CB;1)[/3?NFY!>U M)4.OC[[4=&[D_(SY`\,W78L75,\`6)W]PF=;M[.S0PG^-#905*R32F(1$GTN]N?[FLZ;2NCT?=+V'XQB.7SO4MH+Z\.&7QM'#F[=1 MDXB0<6]-?D.\#%N4$UF6:"#,F)6VVJUAZU)]I[[#O-+:H]MB'=3MMI[2'S+_ M43^JOVS5J(U]"LSI0`OZ"*FD(Y0?ST?S50FG`U%ITNKZL`JH"ET"'D@$\C%_ M8:;'FK/0\/`2O@F`W"0%D]J.J.E8N8/50_>Z/-%8$`AQK:,1"")&,$K9NNP@ M_Q7_AW_\`!:_-KK(JZK"L"5'5US\]R&@_.?R&^^,%[J;TZ`.N,'*;[\O*MJU MM]0R+Q%ZES]]BW_`WT[,AUY%DI/WB:M$+^)`6*0[L5#G`J'BB#ZIGZ?;@>W` M=Q7WX^_H^YW]['']L.YW[(WBJ^&KK#H2#K>1%$.F:*I`&I>B4E^'RA@WHL:R M4I(*1W"0%PRT,VA>FN:4J/-N8;M58N=`6M#,G8DIS8P]DLGGS=FQ9E$D?CHC MV`Q998C6HC%M+*>.J+BL2ED;T-&`=(BZ$!13"+\6B$!E4&B2]9J]R;RJ0NW& MO1N?6WTT\ MJT8.)A;WX(/X<>^)T(70GT*DPZ'V>/+S!5L)IH+]6A*-I%DUD];:U6$UJJZM M<7$>SMUCY_(YE2UDB]LP6X.-)(!]NUQ+ M8(`*UX(%8Z44.66W.93+[:A9Q(9V2,]M!9=>>\$DJR`U)O[>BXNBP6W+7C\@ M8[0[O]@UPWA\>.U"NT4F*:G6:N1SYD:7CF_8+XTHE$H`T$;`LFZ3K(HD)9O/ M_E9KPOGO^-L$+0^6*U!^[26U'&=,FE,KEZR1893@KY+)!_@6HAOFV5N)V3U$ M#SE(#)+'BHX5DTZG3U/$65,^7QLE8:@4+9%I=&E&`V?/^3A/CX.S<@4-!1(* MY%DX4SNC?J2X$I`.AG,)59VM%L3VJ9A0`L0G#!]G$XRFS+AQ.L%:S`(>$WP$ MT/440'@S%?HE5#)DT3"5SQ='MDD_60(^&]+EE1-YRX:JNVN"VSKWK95;\A:L MK1]/E>P_]/-.JI+`\XQ-@`/7`.[UYR`<6!)8&=@&YP*A[I&@D MH/)W[#(<-*`&&YN*1%ID4D::HF5*FS/M6&Y[PW802J\B%F%E4CR(D$@:XX@0 M[.TH`-Z@P]MGP<)*9;"/@=TC6QG*P"@2D#3GUN74KIP.S0B$X!+R"H@E0P=[ MEE!`=*0H*3&^-$)\P>>NF'=:?$'9"5&.[95\N&;UJXT>VDXUU;ZYN'$!?XW_ MZ"_W0?_:\67Y1D4!XN'[`TH'40K^!W55)7'4[VRR%JLIM4>O M`A7``M+W@,7MGK5J56I)67`??^AK_D?^;K3V8ZO:9X(,RO)?H*N[R]R8'\`-$?W&__T#RM/FDY;3_9,G) MFJ$Z4U)7Q]2E&$:T.4G`Y1FJ,56;JU-FF0%,5+`;246XF5Q\K MQ9!I=>71Y]1JGFYH#G$K&GZ'$&8BU!<"AC#RY%V4O. MD<^EJHY2HI0+E53S?4^<,[)6=;6G\CZ_%I?54GSES[*DT6;:<&?C*7JL`U MQ:`7_:\E("44%12\S]_+KY-(;HVD]0XM(3Y!U9YY?`O?E2UW&2GA"5;PXN_! M2SB>S18Q7H.T@LK-$1V'D66`OBCC^E<*CN$5'=CR`^U5($BCE@ MABDXG6ZE_JQ!U2OK;UU^>*/;4%`_1Z$Q=E$#/Q7.;0[6XTR%5TK*RRFJ'%?[ MCO,-O&.NWBE3B">:_):?B3Z`)_(@"Q+E!CF7]W+>ZKQN6[>3-!CLBI1RPJC%UY/G6.$SHBQIHU.^_^I MG$.=(;%@"6[4E@OKUG-[NPE,0 M+B(:A>G(M(&W>0/_?ZJK/+B)ZXSK[:ZTDI!DK5;2RI(E[TK6RBO9.M;6Y4L" M'S+8D)@B@2\<`O$XD`IB/"0<@7#%&#`$@H'2@)M`'.IZ6AH#,8$V+@1")\.4 MTH0)G?S3:1@RF;C3=IK,T$9+W\H6&(]VY7UO]T'/#P_`2MIC$IFK#.:`7GBV*LF]^%[2Z0Y4!%`C^XRIR=G,+J5:`ZM< M?>PZ5[^KO_R$ZICKI/]8^?O\I".?,!IS MOD.K``H/75/M*.@&1IJC(5 M]7F>3%C5S(1-5F6+[X,^;`;`K#K,ZH3L3(&L@(BW?KEVJE\Z;54Z*1@$H%?) MJ<4TPFA($@ZY9B@Q#RA`+C4@`)WN'?&I;&Z`-A:W57('\)_OV/;:`)-OKC\, M_F)1@C7%974)KOB&T(=@'/>LU]>V_)_"Q11FR!ML]]Q`1Z\TNH M.6(UYA`EP\(++X&[?EU('*8\^X2P+W.()Z55.`Y:P.K,-_EJ9HY<725.437, M$&Y8%T[2&Y\_@)U"3V$CTI'\$?/%_$NV&_F?V914PF1ZC#2T-(7)+AK0'C0!2SG[?*R_8B*EH3. MVI$\D'4CU7BDB,IOZ+*J^\]N>'4`;ZXE3;I4/;%_"YB3\%43A/+CUM$=J_?A M(8/*MA4<0FI3#B6F$/&0HH2Q+?.]\/P->>#/Z]*;`8;!6?OFT5U\!)Z[#CCC MUFLZ@!$Z@B;*B#JBAQ\E1J,?$1/1:\0UG4HGQE$%']0'"1T?Y,4GZ#ST!CZ@ M,^BRF\'<9K2;T.F):`4!PVHTHH]$(T]6@GPXPH3#=@6051$5B6A4_&63""L\ MK\)NR.8QAM8S-,UTV8&]H3ZHB\"=*,W8^8!"!6`34V(3&_)A$TY&&I+.")8(`0(+-M+>837(;,"KY(.&2!A80?Q^PF-[64,O[-V_3U M&Y>G%C>#QM=!WR=K0C7IM=`RX42-?^=[O7T'MKD-,CGM:!\2MI:7>(7+=\IM M^JUO+TKB,4/@%^`,N+J@T.=&8SC^OXXOD,U@"8['@$994C?\XW[^;Z:OO0L[D,%_7^96R^&O8,<;'_U=M@56/@CP>+I#NYQ;[D99 M3Z6R2;9:]J)A(SE`ON$Y3AXM/5]ROO2\5]U2TE+:XCV/8JUY'?H.0X<1:Y&T M@!:T58,92*M#TZTA]!SGT1!$-\?J68+D6$Y**N?Y_@V%KG\WSVM'F]M=7L!9J M70W;O7*#P.:_8G50&P\U>&51S)D!=1ZQ\R-"6#SQ48 M6;PVL/P/#Z)N*(>NOD-.*"4#ITA*%.8VCFO68 M<3VM[%)N4Z+*MPMMVL__`]/F%*2JV)3H6Z5V+PAJ)0RTJGH$`WH;**/)$%$^ M;561JU\\V`5&P1%``MM]X7#FV,K/]@'OT,"JJP=_^W#$LND?E\%:Q"E\+3P4 MA$5?(]$Q*(#H%&A^_],U9X5>V'=>F&UN2?=)>,G^^$I$K],[]4OR]V![I(-% M)[`3TE-%H]BH=*SH$G6)OL1\7#3N'O>,EUS5&ZS%L'-R!"RWK\\STL8N(_1O MA6DS+C-SQ3`^NNXX9[*C#O&"9"#E>]PE62;.BEH&:._"$S^AX)M9#@[F?,U, MO4-EO`T8]!IX[.R"V`G9P"/+3;@W'K.K;&?*=_VI-K[QY>#@4'+O7[=VMBZ- M'_UPZ&!%3VH^YQO^JB<-M0FU\*^@]WS%!7A8(94V''IA^\/=OIC]P:]W["6$ M.B'QPSS6I,KJD`7Z`RM$9Z[D9GP[,`"SWN`T5'H7NA9YD^9VUZ!K=W38=20Z MYAWCWXE>\5[A+X;_8/@T;+!:NCF.M5I8U,YQ;K<]'$Z$0CFT\J`Q\*^GJ'GV MVGE6"V/Y*LXQ)?,AJX;")3*@"MXI2Y.(J%]JA*D&R:)4/%7#VI^R!3`P3L,' MXZ+YICDS;0GN$A#.6;XJFQBK?54F\G:(8N64EV MLP;D<$8>.TI++,&HJ?;FX)Z[G0O6/\-/+%VZ:NSXV6,]5JJVK3H:;Q/^MC9> ML/RC%;OWS.^:V^&Q:OOE>[M6X94H:N8[$16XG'3;Y!5R&=;<_'KR@PT.X?LO MCY!YLDH<'P&_.VR4KQAN2V\FA?',;>''L'..3%DIUN+%1_>Q(CAOO.1@G.W0 M_H1,VE_2;M'NY(ZZWN+>Q7ZIND">LW_@O%!\V7_-/LG=\NL M&#.G;L&/+NJ=\G0"WX;/33!<=HI?HLOR=69\V1DERV0&"@ZFV)30,GB18#E, MD$9H]W*9T@#GEK)!""4..^L*G:Q&D+K^A:>NAR/[W]G>`&J^>W9CC%57`1#L M;AHZQZ\Y,+0V)KS[[;+3S0SX:7UMC"^Y,M@3"%CMBW:VWP0::]&.P::%$??8 MOJ9E530S;]/BJ\(-CWL`HO06[-A*J",NR7OQ=8T*T(@U2AME"7G"UE#82#^+U_LV#[[;%_LQ#:./["3 M8$,@60F$0A*'!#(^1BV&&!G0%@)EA:F#`AT4E0$-F@!I*U/7%:GK6"MC_/&%-0]"JY+CNZ<.[78]GK=WX/!U9$Z'G MJB",^B98`G7LTN$0.M_Q`+UZ9=`LK,PW:Q^O=;I%+E>/`=#YUQEPPNM:3*[6 MQG^5.D>=.G.>;,5QR;,$W`+;P1JLCG57UOVEL4221R:O+&HP/7QM<\2%&WR: M>'2'&(%(+4%^61IU9*1,-%/(;+4\GSF4/SIS,CK&7,F/9'S#7V&N9&YF? MM=W*WFKC0,$M$R19R1)G]/-U4IKR][N.]KGQ[\X:X- MSLQJ%5^3)TGMS[6'GQ2W'3CQ(BB#J2][`SP%3_.DW5O4KFA-VOUD`X<3,.M2 M1_==_,;FGI<2WP89\)/VB*0WKYE'?R=8HU4>^.FHXVH#ZK#9]-C1+GLYFT66 MO3:+S6&I!!4NJ`0=-J\L!94``+(4""H6AQ2.=*CV+^E?:_V M(_0#X.KTNQIP_91P>;1_:?NGM3S(8I/+)'CWYD?WJ(/XJT@+")32DDUJ[&#Z M&1-;46$J8WDUK%88EF/4*,-^T1G/LD;X#RE9CF>1JJA#/7\OBD8%$A,'U."`AF,W0$BZ/- MOR[VC>4[FBQ_^.2-O>'N&K!LCZ8K)U?VO<"LYI7?:S>VOGQ=2VH/OHH2C(EO M,MB<1T%31^V&-@)2X!G@_$A[_;.WT8T@N$_Q>3#CO1#1L,]NHTET;:U#:QOL M!.F_H?[NH$MG\Q6HNA>A-\60L5+=T>`K090765XTT/=#/?5[]:D]NE=::N;S M;(6D.(HB>1GW^MTR2=EQ.1"HX";.1/MQ@.-N>\*]R8VZF_F(Q^-&[?TV"XU% M0'^TK'ZNL;>G:T6]("4ATL,)75IC4[HF+(B'SO88/7[,KI-^'+(=SZ2R.;CQ M:&1.!Z#90ZEP9J'DZBBBY(+'@T.G8DQNQF MN[EN?J4PQ`WQ.[@=_`[A>?$B/Z;>4D5%4,102S@=SH2RX5RGT"F:&X92<'WS M6$3M8MEM&,IA&(IUT6@)D4^#2^`:P$!K(:]F8DZ6XR.X`Z`8;J*0V!Z%0(BZ M^Y:[U(`C,R#I7C]=K55A,M7Y.R?#1DNMGZDW3(ND#=O*`RC+TS7=^,$P$.=E M-P?MGH#NGDFS$>,_76&=$-JL'@5(/088(!L_AJ=80=R:]=%V^6GKSFV+%'?] MG*#O*/Q3\4^;-*AO:']^T*"Y;;$ M-^7=ON`Z>+OWGR][XP-GP=C`LNZ$T[F9H=WF_![M\E'%^^'7S^N8ER'F!_'W M$2\21PZ5VMI,>>()TPW*A+A%=Q?-#_E(4Q<=3_@V^5!?9.BP_9(=M;^03/B: MXU@LP(LNM\F)F$@GAEP'[X!G2W48$ANH(P(C3K-14XH/JO-V-;?Z#X:K1@R% M8-&@-OL]8RPSQ$,D,#*KS&9.U#2+F.%8D3!F`*FG?IVB!/HT]NX)R;XS-0"L M(ZV"\I;V\<$-^]*E98S'9NGM++?U'V$=J>U_W(6O;60ZA(*&_^/,U>#B/=/: MJ0\J7RH`!+2#5YZ2@F;3PQ-=O9DGP-#;@PW\I'8);FPOQ"0#>1A`-I9*5E$R M>P6I/FI."-'ZQ>:BT"UL$'8($S:;:\C"R.`Z4I+!&GE7H>A!F-XL3IE$&;W=)6>T!D"^1',SE]F;O"B7F%T:LPQ@\"H1:9@ MIJ\RNF/+ZF47]M'GQGOW']EZY?+*5 M/@.B8RO\O/\9.-L5\!XU.-LHTHJ\65JWV'1<^`T!N24V"(58&@DI,8'O"H6V MX02'=]$$U3"$I$$:H4""*E*;J,/4/0JGJ/:V4(1&"K%<,T7@)I,%4WA6-`6D MN8DS&-(\$B!L]^UW+0.Y`8G6C;9:K=7@\/]9G1_\O/1`#/2D-SU#42QFU\>`92&=Y`R2Y&:)$?[O[8$,0<\1'SXK]1TI MV&W-STD/U@D-7.8Y[;?+5W17E7^0_C91_;Q'W&\?OY7AP[9_OLN_.[8]_Y?+;O'!N( MG1@PL?-JX@"&T,8C(["4=-`V:\)+`X6AI*5M1BEE2\C$M#$J(!/MM+7:"&)E M,$ML2)25^8^H:K=I;%-!7;>J=&'=_IB=_>[,:+9JTO[PG4^Z/^SO[WD^S^?Q M\T._N_&!E'CBO3^S\<(?7J=67YQ-NH6IV'9A2M64R@INU"WNN@+RG;L^[=]9GE/7B^4*80+_ M52XLA5=QTPCNKV9**M\W'KNT\:FQH9=./-R^<6NYQ&SN3'RC,OOVE:7UF='` MTEOROL+A9R;`VLF.XL62\:\2-C0FB M@>1LHM7'R/4%T9@!7`/2Z^GU7021\VBOLQ>.P='S9J9``OB/BVFH">_?6ZZV M2[%:#]7M=:Y_#G)U3GF*JLA8KE4KIW@?'&F@#"HU!AM<%-2]"JUR5_2;@!ZH MT(6OJ14")9C?IM_9:A1U5,/!1S/)Q`:?Q^IMC176=L9["K4.Y."MVNS3N;V5$Y8:MN#!/B@/%LY M.Y(WM3^*IT*ICT%4DT40=.$W,+MY6!T1V(-=R)\RW_9:O7R]M9Y?0:;9E#W- MIYO7\/W\5_BAMJ?P$?.!YI&69\A#QD/F(\V'6B;-DRUGS&=:?E1[*3;;-)N: M;;D9*S856W[5Y8^@!I+2.5-=:(=;-^AV4UK@E3!4Z.BC$GU"EA)0H2^!IOML M]7WC*$"[!9(#3R7"(!"+:"!=,#G-=7)!9.APD6H<9HTKL:LFIU([- MJ4V[*F9?U+ZP=2'"U#*$[Y5C974D+J_>E7>H.;6!M1#A4)25BH3>`!^T_V[B M:B>K#XA"N<8F/%X=@6KU-@.@2+=2QTI[!]$[SQ-?>'$L$NB>YAOW?.>/%\Y? MOL[YORPP^XZ`VLL/C8@]`Y7?RCVIH73WCD+;P)K*]=,GCK]X=(;UY31E38Q= M>WZ7'(VX&U-[(^UK]_<\>63[T(U5O*N MSMGRZ_6G^K?LW;\^Y(^G%7^K@?W]'J1H(S!E'B,IS(=R'HKQ4=Q)WTGNI%\G M81(>T\7TDB&))?&D+JEO-.30');7Y?7YVCR9-WQUV5C#R\N.NXZ[I_GCTEGG M6==9]RPU&[\AU^E04]R02`QJ4$9C4*Y04!1#`1PP.\:6V-^S6C;9Q#J4&>P)RY%Z;$DB;C("W`)0#8[I#"2BNZ!7 M&&TBD24%"\'-\W<\!22H$OJ>.IV58ZPJS6<3^IW^G54V*T8#J'>I>P\41U8= MLCJOD7Y;T$)7Y[%*:W5RJP>M:`\\OC1XX#V*6ZJ8QO#7OL?. M>*^"<)^'KZ%7-WM-8O,JRT]3,N<6HD_:V)5/?_>5:-YI!B;-%.@7PSI<9E=: MR[XK?[TL\(+T2.76WY?YS5(P<-AKE0/2!3#;Z7%OWE?Y>>6F'G)YY<)MC1X_ MA]0B8>2U#++7`0G,HG5Q.I` MEF4$89!A&39+4$S,DK;D+5LMPY8Q2]%2LM189,G"L%;,;A(#`H^%O+J+8&7& M@J+DO.%.J&`BG/.N._:"5V'XWSZJ?A;YCWVNWUZ2B^KLTRH!C\9&/Z+>32JA MJM885UG.*+FAP>IW1;X76Z22)O3P[M41?ZA-]D?_R?QCG=T9'?4*!YEC_2+G M"B9V>'QXL&%=))Q<$RM_&/J)RYG^026[A>\+[HY;E]2W_`(\FQ<1S4*N?%5# MJBG5(Z]DK"E;RIZSY>W[[4?L1,;'>3V4(?P@FC",)A3Z+!HZ3>?IK?0P/487 MZ;MT#1V+PE]+8RY*#(;"6(17HZFM1A,I4`3D_NB/^5TNB)KR^_]O-'*I!#5; MARQ! M$R9OI]7/UQ8V-;A"G^7TY\#7&ERV9/E*Y>#$6QL;W#T)3KJ6JKVNVKHM0"ICEFM*A@66]5< MU:4&-2IG$52-71RI?7/2>K0;:&=ZLXQ`FR2VX5OC4YRUCN+6,S=%WK%\K%?R MNS(UE3;/GIRB3(/-M&M*PS]KU0V9(4C3'IZY$!\/R6SL.7S`P% MQC#,.R M@M_JJ/-A-*+3$AA&+EIOC/.F.V2!5KN[O,AP89RC<_;^TJ@,"_>7BI[,P7LU MN/O+#:K]W#Z8!A;576!>TT1IU+./>9PV&^6C[,$]*;];P(4FB>7=!AY?'ZYK MHLJ7!\H+VP6&V1-^O(4+!PS<&T#[LX'3Q2U!WJ149WSA-OX7:!L/@9(?_%=Y4'-W'>47VZM;IV5RNM=E?2ZK!NR[HE M;/E8PB$?V(;X$+8Q!BR.X$F=ID"+":9#,!EL:'"=EN(D-6>H,VF@!*MK^09/,E)(P*4TZ4#J=UMM^*YF$E&EG-9^D;_:/W?>]]WOOC6B' MW<.^&3&J5"N;Q68K$^U4=VG6+F^MZVG>JMZ8Z:WK7='7/(`.8`/X-MLV=EMX M1V87MVOQ,XTCV`@^9!MBA\+#Z4.+AC*'N$.+#VL/FXYDQKGQQ<>TQTRG,V]F MWJR]O/+RJJN9D*BI5JVJJ\LW-A&-*F%M:FQJRJ*-W`JP8EH\R5DQ0P6>R>1K M.*(&PW'AFZOAN"Q:PU6#:N&.+8S7&K5:LI%(WFHAK%G4(F)`F&EF>I@]S`1S MEIEE/F>43'M;620:DP:3C,7*2IUUF=H*M4&%*S%$MJ*Q:65U#;=8N$'3T`+C M]:V6W-)<,B?3F>6>N]Y;SEQ#55"0"=3)O+#>@>=:.-3_X8F*!5/L_D(Z5QZ( MYZ&]AYU2D(YW(:,3\@A>D,!D\7<8$K92TE2[>@^LS71EV$T\UBMMBWDPG4N\:?^'1Z*LA!3QZ_]UD:'^+>_?R[MMU(5_)*/ M?;@1,53[!NTF?TGD$[!^!V%H>^KX0?X<8M2!`Z"QF3+6[N2O\S]1$GK@_6QF MB86"+(S_^T\P)5T358CN"]%#K959@)75&BRH53$MGN&.5+IVE@Z&MH6'D8.E M!T.03"*11>,QW&;R""46XFC*HL8/<1"&?MV/2_#*C,OM\4KM`=QH,DOI M<)D:4M=VB\Y%[<59.2^TU__/`($`-]!'1N>- M@D75+7WXM!62:O%0P<2$3/9*(%-Z4H7BD2]`3:P(.DE(TYV[/53)V!=): MP]K::O"_K[(X'^LVXIDGCOPHDLZA=2D_IO>(;P:V1TP6B]'#OS+RAXU.UN)( M\A/\/TMMF8#O+:\K,P\VM!C)EF_R4_RL@L3N`>KW&:,1IJ,(]+$V>$8P"HEZ MN":I5*?&I$8EHW9*2]5):4:S7-J@:9/V@CP]!D9UX\91^B0XH9LTGJ#/@RG= MC/$?[FWQNUYX`4WPP&;^.LPK?X1]ZB)\;H\H*7J-VZ$*>A0>I5OE15)(>:S.WF5_,7;& M<*;TM=@EQR7GI=)+L>OJ7\8,P$XAWJ14Q:CRK)VP,\+*LG9[%F5%MK=M8ENH M:AX-=^4+S M@2RYWWUG[JM#@%P8`E]RHD`)H1&)=;#U>!^R3)?3(+AID1E0^@J3^7(VR9J8 MRI;3US)A.G#@!Q^UQ1N7TAV5NHU/!0QZ>UO7FM4CHR6>CH^ROJ#X$]^@D[)9 MW/S'^X]V!)9M/LE/?F<_Q<_\3HVKP:1X\"_P[.>#BW:!_6>J8A=/=7XH$G(R M1/0YB"@KBHE&N36(UB?V17VQ`B"6(&J93.1ZFA')RW)ZE:R( M6V4!M*\(JX`7=,Q9K!^;`\V@9W%%)C/JT34&JG,RE`2D\MAE[#N M!T0SP>3\AEXNM`B!:_?N+`PD;`&S.?I=NCB"RLL7L`/_Q3.%!"\F-3T0!HT. M%+TD50C'Z\G75\<<.($LF7BR.F%RF+0VQNT/-1TH4957-V$-730KON':6P;? MW97B?PUT?57JKD&%QYZ^/>+@_ZHQZWGPYPH?1"$$>]:O(`H)J,?MA`@%A)C1 MH0$B:`<>L3.84J>T*7]K<'UP0#.H'RLY57*A9-I]P?N^_F=!4B37,DZ_SY_7 MZN"%J7S^D%O5&7)W8B$L3H&[HL_C($Y9[C(]U!YJ@CI+S5(R*I7T^[0ZJ=SI M[#?)Y?T156'0?,&FN3OHW-?G[@B"#,^'A=1;$">JT,W/BN`O^"D,I;B"M,$& MD1(*K'`E$PNLB M^02I#0/CXHV;^D/.9U\HK>(_FTSW):W`N[;>ZWVF>PG+HA98R%8.96,4W7DP M9(WBJ4TMRUB28NQEZ_;=LS#?$-BT%^+X8YE#5")ZA5NM8%L5'6BKO=71A_9A MF]F=Z$YL&!W&CJK&T7'L5?15[*?**?N4XRIKU""(7J57PAQ9RK9N4+CA9VJM(%R0)`XR$ M+,1;CU=<"#7BI)F_WV7SE5:5U/?*-K28V57-))7=6A-5Z52]`T\3:/"VYX.P M/_8+0+P#@,,6V/XI'<3S_,\E6B025X+Y6^T,_1^^JP2XB?.,[JYNV5JM=K67 MI=4MZ[*U.BP9';9D.[Z$;7`@E>^F1B3A;LP``;_V^ MX[TGX-,`5(4.U%DU-)UN12'$!)G-T`GX4^A36#&L'<:&W<,>*8:DO.O8=67K M7#O8'65OND:A4?A$Z$3X1-59Z"Q\(7RA2@>'5,U*92X8TH>:@_P8\HMT+VFA MW3J\V>7*4;2>HNEFC+I)`J^'D3RY@%Q#;B-OD0JR*3:/I&A6:G2ZP+=E-L#F M05Y:$94K56JI1B+@&,T",:?)5FRTF>]9)HU9FX#J]`PV/25*BUFO4!R`1')@6?(E^5C+&7-?Y/? MV5=&MO\8;H%10HOFK^>G#]88Z7J?XS.7R[<`YK[7!(+B>& MW"I>XTM#5MBHT5`8UN.C=NZWG[0C]AV)N,"F,V(C,SSSN\]!%8*MT.LS*5"> MJ1EQVME3<"TLT*GHJ@K8%)75W"!$9A&)5HLV5>36QLI:QA1ERAN?<%0\ANU[ MKKOA)Y-^-VNC&OP6(M%VY:?KGUFZII'NG M.0+OCYR,()$=CW<*(`X]0%%HWN)-$5`14R!Y9U%-%2RK`&RT@"LH,T@GUIS@ M6(B"2YDMPF]#71P)LT48%3'G89N\I=)0D;89:MJC?$4YE?][NM+BB+T8-#Q6 MTX75!ZUML<9$SY9Y@3(KFPZXV%3;A?QT?R9'#*Y?N*ACQ;R@\[V>EFC4SB$? M]>TI594H=5S^;/[X]Y^D'>??SL*+44[SFZGWOC?07[40KMO7TH251>OD@P-' M\TNOK'TJL?KW*UM?>6G!^,+$!"I!K$)N"%"Q5T%NDG!5^G0JTA;I5O;;NZNZ M(RN4RZA5]A55*R*;JEYTO.8XJ#H8.A@95XV'/HK\MHILBG93N^6[(U('13J= M))D+*_7**H4RK`R''HE9Y;1!2CI=1%BIYF-6+^R4FXVIK9OW>2+D(9YM7J+"&W M9@UR[SW?I#3KRL9XT;E,S4P5>+#`=[,'&#*7BVKA+^_QV"A%7X MP%F'*P"!%BX"=\+]8-Z(E2&H+U&>"4U(T05+2XN"0Z[`"\53J`5`L8("`?T7 M#;A(A@VM'N'FQRP9CSM5:XF7]?1RSZV.EGM,1H,9#4;6;`S6AJG((F9[0Z77 M66>0VC:N#5IX+T\>D=>0N3M_/AT*Z9_HP[!MTR>?YTC\5\K`P(G\]9>-#?9- M;D/34>)EN!?W,E&V-I#!>_!NOCNPC%\6 MV,!L">PD7F?>XM]GWG>-ZHXSHZX_X*=P&5,""3_[ ML-Z;90:Q14M@N>@ORB,"+2N$3VJ1A]BAX#<"QCUM7KO)@9,TU;-_:W-O#17L M?"GTPP]WU7P02B=7?S]WLB MCOOGX!R.$VL!:\0_R/_C2'WW?#/M5UC*:9\ZI(7-P'^,P2\<4P_YKX;&D`.C&KG^^WNJIL>D5LIDE+S0$VQOM="5->D,.IS5EFO_4 MMM;(XK`1^;BOJ=(?;G6A'&I!Q@]UJ%5E;F,Y:C;]^UXY2:"H]VGITZ,EI29' MF8.7Q$T:-2J5^0&2W?`!R6TD`&D@=UI?.JB6#4I@I1:5="DV0UWJX7V,#^*! MFA.*)@9AD]@D^'=`M5#6@D*SVOHD-/$9K+OU%L+I_I:_>QH^J(TG%7)U8U0I M.,/SDBN2\[*+D`HBH-`1'->.(4U'2Y1*&;@>@TF]&AI#NHX`Y0/&STP2QB:N MS,1J>(87SV(L,":$II?-[6Y2*T>;M*WMY%(X1JXZUHB![1+)56[R!HNOFMA& M68QWKX'=Q]LI$/\&B']C+GXA[E&X\!['2D@]*A7BJZ'9^)78>%J#-"BSZ(!FQH(8B-67O(YL#;DXX.V47CU!^U)=H- MNWZI@\2?VKGUBK#@1G%MA7\MKML(BE2`M49<7R-?2S;][R5U2V_+%LK^*G]5 M856<4?Y'J"_8H;9#O::P6"8,K8:_\7]R(2;CIN;+'K+?NLJVW^5I*RE M?'[(P/_*_U7L51J`<.4H'(6C<#A`!E"=Q`@N0T48F$$L1BD@9F,@")@96!D8 M@%4:-P\#`[^`(+`Z81!CD$!2H**JIJZAJ:6MHZNG;V!H9,Q@:F8.;+\QV$#E M75S=W#T\O;Q]?/W\`P*#@D-"P\(C(J.B8V)QV+A]RU:&380=1BW`PK`#2&HP M*`!9'$!2B4&509-!C\&``>@58/\SG"&2H8IA$L,4AFD*P@J2"C(*LO__`W5` M5&HPZ$!5.C($`54F`E5.1E;Y_S%V"-2KR"#S8/Z#>0]F/)@!C1OB`+#1\/\C M7A4<#&E0$YD9)!D8H&P6(%L2RF8#LHQ`*8&%$RABQ.`-93,Q\#'40MG,0/%N M*)L%R-X+9;,!V>_]7=T#W-RTG?+SLQWS2C(+2Q-U/$L2.D`AS327X1,P)^0#,Q$3@P"#/H,U,$J6`-,/.`^R,#!.`,IPL`!9 M(!Z,9DAC$@)JAP/TZ+4'`@8'8`J[V"JA`\!U" MD!#919"JB&!V'4UV>2@J1`P,/M*F8&Q-5GQKJC9U?#5C[<.[&@W6^!@;,Z9& MTUI-$35U)E;;,289H^:A<'ONKCB:&7,/"^?_S_G_\YWO?+LL"$`,FB!1/&%2 MQM#R%>[W@5J%=\=7U/KJ$)_3&YC9`M#BBL8&[73'MA4-Z/V[&\L M/XS/*,TS:A9,[_AN3"2@G0'R%E97^2H/JQ],YOM*^R#)@]F/'LJ9M3WV#>Y`AFVZUXW&PX?=8!!4'L(M?7K338,R"@F/XDG?#:1'[UY`/'T_K0TQ`A6@T3R('S3B' M6AR@P>8)G,$5\LL[IH%$9&`4\E"`.3AEKD(DW)SU.OZ"_W&EX6QNKG$&1ZDG M4I`-)\;C#:S$,8K@.E%(QF@^78BUV,AH+E"B2$%OOG4"*K$#1W!#3#4W(0G/ MX#FN\5,4XWE&5L$U7L8)W,%=4LE.&6*UN<8TS(O,`'$7F4>'.&VN'_MS%$$97ALF8RM6J,9MM/GZ-?=S3!SB. M?^$RKN-KW*%D\E(+K:#-=(3:Q%`Q7NR0/N6:.K?S.".7"$<\NN$Q#$0:=_$, MN',Q^Q MW)?&ELPS&XATMB>9?Q=S-`XEF,83*,=T5HW5YTN8BWHT,KJ?XU7&]QHC7,KX MWF0&-^(M1KD96QGIVSS/GXJC[I1$ M@V@895(VY5`!S2(_;:"W:`O]CO;20?H;G1)QHIOH*Y+%8#%<-(AE8I/XD_A( M?"7NRE'2+>MEBUPO`_)[15>RE>>4.F658JA0SX85A1WON-V9WEG2NW!.SRU=YF#PSC*+!QC M.\T3;&-KYSE>9/N,IWF5%7.#-?,=[L(D!*FJ@1K8F:J;7:#&M MH_6TD5G^,P6HE=YC.T$?T]_I$VJG:_0U?2H*0HDY1JY55EB;)+>4\YISZONE6O.D-=IZY7MZJ[U??5JV&I MMNZV!%NS;5]X9'A4N([/*)H5\_!3QOK:R[PUX;1(QU&Y'2MP7CA9B1OY4V<' M*_B"DL2,'J)VN4IZQ2MB!#Z7T\VY2BD.TO*._11KYJ`_OCKSJ>'#A@X9G/%D>EKJH($#4I*3^NL_<6A//-ZO;V*? MW@F/]>K9HWNW>'M<;$QT5&1$N"U,5:0@I+GT?*]F)'L-)5DO*$BWUKJ/-WP/ M;'@-C;?R'\XQ-&\P37LX,Y4F7L_D^Q:-K+3TS27KADGG;K62E,F MNME?YM0]FG$]Z(\+^DIR#3VBNA&JG9I!7Z7;D`?;<2E!E.0%RQCA.49MF`9;:;5#I9J@;0C_I96 M.\J]J=&5>J5OJMN0/H]5(S[5&*,[C3$++R>DI[72VZ5N(R*OE5#JWH^Q9E.@ ML,GI]%C5NN6YESR8GBC]KH29FK7T^Y=HQN:)[@>C#NNWQ\.7IJ<5E;@=C%IW MM6A6&R7N8`=\*25D,$AKSVHSU'"5[K)VO+,T(T(?K5?[9WEY6'W\!DH6.';W M&9N[G_^!C'5I_E*W[C">3=0]/F??0`_X2Q;L*< MZ)@'G:K[L:`73+<\1MU%-5F(]$*6B*%5:(S$K1LB*=/Z594)?T4FI_'C(69T M)O/G]=NSK$&H279=\]\""T&__OG#.[Y[.V%)]ENP7$LN]R7'\2[?2$TU!@VR ME&++X]$RLIS@>D1Z6J-1I-?9-:.(*4.QFP]YLC*8*W*D*]*SS(HT=47N'_?J+.=W8'W][&F$)]__B;/WZNZJ MSC*HUX^$JT)Q?ONXM("B)OF+W>WHM^?KVOY?J_?UVHV ME>N:7?<'BHK\=2YO5TNMYI&EB49NBZ>:F%1C6(@-HWN>6R8*3\@3B9*]HDEZ MT<0I[LS0T.ZM-)??&QJC]2G'2&T5'8>`B/.=:SN-B#?$9/YV\\`C?AL6;(>] MKM=.S%9`\S-KG1*QUAW977;1LPO`-)5LO\(O@?\!3@)N`_8"AC` M",SO@;4K68<#Z+2PSRGMA/VJ%B!=JZ!GW3GV;;7%OJ4NLIO<.52%[T97NMT* M',:\?_*89YU]$/T?8FVE%K"O@:LP]J&ZB,:J+13`NE705^G%/PSH/X:^8?A6 M<8Z/U2;!?`O[KX.M-Y0]PH=UT]4I5`9[9G(;/%W9TW8&XQOP/1H^&(,UCZ$] M!>WMV&\@VIE`"=N)M>/ADVRLZP,N1?\H8!#F]8..JVBGP0>#L7:AVH0W=FX-Q\+N=,;+^TZ3^`;63[[D;4OCNX8]O7,*H#]KF&TG[8M@H8@.^9 M\$\Q>)ZZJ.TOVI2FDVUM\&)ZF7J"OL MF0AD>$G$<8PZOF+_>-91+GRT@.,,XU[PQ%H.ZI& MX[P8*%!;VMX`=F&\'W07(RX/8.\+.*>;]^"[<)@1B[]VR#MBS,2"V'TYB-W! M$\!W@8W`Y_'[B!=8._P7'+L<,QRG'",2+S8!%B"?;S.1#G M?Y.Q%LV=@TH+1[Z6Q_"XDS<.PS*>B-8H>_`;K87& MR/.BSV'>7YM!I4X^^[4:N,P[SO7$<_1<^ MS/5(UD/4)'4QC8[>A7V]W??+[0_4"AKJ^/VK_K\3%S&_9W3T=T?F6BKK62P> ME1EM9YSSUX=13YEV*W<3U7SUMM_`YV#;/DS2+ M:[Z':+5[`/GD6=GF']`TUSF:H09HJ*R16RB'^]3Y.,,DZ@)?/<;CKFTT@N>H M._'^\;P*?'>VCZH5]GMHIV)\N*REIOTN^C8AYB:K;U*QZP+ELDZME1Y5E]CE M6H-M:_^BDO:]>`V/HT_6^GC8.]%NE+6?[X)KRYCH.^<=9U_TYMH7X=.`/#O> M,G=_^YSTU6R\D^POK'4K=CGK\EZV3ZEOTS?=@^C[#%[C[F1?C/E+^M&=B+W@ MJ^A;`[W0Z2F3^7Y,CGU&1;YQ=J.OLWW.W8T"GDO8A_->C'@#7)=IK-9&_5U_HOM<)^PK[M%8^ZA]0>;27.3'9?E[ MA-_!/G?>/>0#WA/M.G(!.21MX/K/NGO;3TF^P3>CU_!ID_X M/?1^AEPZ37.=V@H$@+?0]Q+JPE+UM-)=/2V$5F=?U>J4YZ)PVG=S1XACT3%F MQMUC_VO__P/E/-[G,MD^1\3U#;X@3ZO(`GHXC'/N!98!_;P98HNW3(0]`4I4 MR^AAQ,]\=0+JQ"(Q]UE4%>\QUFXCWB\*0'@+>!;[*M#U"Q>IF:E%RG* M>Z:[IY'?21D@"BB-#+$]QIM%P<_3C/=+>QEAY4Q=),WP!K+PTJ\E=WY+A9Q MUH3D=KX1%D5F?^-&1!2ISYK]]9O\G6SRR53)$,22S%(2E_)GM*J1IRDI3=I%19 MBB^D?$W*:BE72OD=*;6\I&K_M6I_8[5_1[5_2;5_3K4_?[Q2+NJ@H$3*(BGS MI,QF*0Y+N5?*]5(^)*6<(SPLZ;J4?Y7R`RE_(>41*=^1\FDIB^6J++(@,Z0< M*"7E)5G^.LN_W_*OM/Q/6?XBRQ\6;C.!?&%EMEF;@FN?:M:F@Z:8M8:1GZ[D M4JTO2\3AG@>+%#$5]YPE4K1AX-X43#*5K1CI1<&X4Z(!K>X4A&='HI5J!:_V MT<-*HA7`L/WB9 M%7RHL]X@)HL4^@C:QYO!*FP^U`H^'(_A3*O^S[,1[4F.,X0_+RYXLZ_>RNHO M_2BL;#6-C^O#8KVU43]7V\`6TEE1(!I,XWW$;'V>;X'^!][JM]&YO\'J M]'<#NXS#AZ).)S"/':@/*YIY1-\;807UQIO!_=WTGP;ENIW!L.B>Y\O07^>- M?P(MBO6(_F)MV+/#^DC?@-'%U@A]?22BS<-2?2UON0I+_VZ6ZTNA3RV$@>41 MJ6L>ZS(S].:#.'2S*,CKIO@2`XFU2DYS:7.-\FK-OIHC-;^K42O52@VI];:P MZDJ-RB!2_;R804,0)=/,D`_A5&B&XD"3HY1OAOR@,68H'C32#"6`[C=#J:!^ M9FB`D9^BW(M_.&;0$8223B&71E5H)5-(%--HM!+02J(LM#0ST@?+7&8DRS@D MOJ1ZM4YZ_Z:\C[!XPPQUQC7MDIN([69H/*9MQ/+=,A[66:&K`S'M>3."^BBJ MS,@@E#E1$8O"I11)U.%Y73R#*%S(5HA)9B@9.L90R-V),T-D\Z*P>,",9(/^ MS7FU!C=Q7>%[=Z7=E>25UWI92);U\@-;4,L/)&QDM#:6C5$G<6W\$!ACP`1< MF\;$8!<"A#`\$C,)8NK0ALZ4)),XX3%%E@V2[)8R4SK4/]Q0,$T[:1J:0IM) MATD[%#K3V'+/7;L\,DVFT]7L/7?O^73/^>XY]^S==(DQUDETL"8Z8`,A1`?: M0:2,#'R4"]84T<2[,(4,Q5B!;"%,7XA]'C+\B00KUFZXGABTOI^0+$<-D_,Y M(O/54[*QH>'U@U&;X_KSF"$D8,<7Z8FQDA:$?Z/8-$*C*NC-QV-H+ MOG4E$IR".CEJ^+P5M\:IJS&;]>.FCXY3 M`L;WL2& MV]EP&QL.L?'9RR-\_K(RD&*9`CHBG5]4)JIR\LI$)319G(.S<9E\KF!$4;>V91CC5T,1ZJ4X1JM;XG@!>3YDCFA6 MM"3@M;#DT"MF(FK0@4KY4=!1DOD1+"A)7+&$HH4DJ"?CZ&I5"&"B!(,HC0,,=1`!,'P!K2K\J2[[^PCM<\$[>V=L&O_]OAB>OS96/^NB_ MV?O2,_K/(`YTDFU4US+,H1&$X MS\GA!^=/%M4/RV5QW!U%##N.N^$HBO&-"S2-E(P\CKNB-"L;QUU0Y!!NBE(4 M_1/\-E*@'^*U".@\\`DSOOL^X;X/^1]V"]WV-'M:-C087)^VT9>G13GZ`MED MEV&2V1/)T_@`7HA24$E4Q"A.[8MR=C9.K;C(RQ`K(ARG>D99.Z?FA:DIT\3T MA"E-4XJ$:=/$S(2IT$WG>C1^[/&FLVK,5N6LZF.C'K-C3=VOZE:4G+RY6/X@#;T M78;1K>N5@YW,V3NX'&92(9VHH/L52O0!PZ?`7'>1_VZAVUOB*2XRZ'6,TY&3 MV;AB>6U+9?G*K8T=J\2G-ZT$/Y.#R1GZC/PZ?"EDBQHN%0FIE(I6RG@Y#U&" M;R"_?\J7IDDO!?>N"%.%;N"/B6]>AL4,FYLFZ.5T>6PZ/5I)7`@K`,305P_KVSOX@>[#@: MZ5C]M\JRLKSE_OK:4D]N=6D=_B-^D3MZ#7U%W_8F]:;O6%:S$Q?A[6+:Y M?7%=\@_)+21&LP_H:GD?RD1;1WA>JXAC_:A.J],RT!$7DIY.5R.(&KO69H51 MK%"H->J4%*01M7:-W(0;++4>+Y.*8\F2?MXJ'&U3)D?+;RAJGZ3UJST<%RJ)MJ2]E%'=E94QK8HOR'35* MDM^W@,]A6.4S1(2(-@@D,'+\5SNI5+Z;`_)99+--G;3Q]W2KP@EGQZ_M,:?//?X=7]_?WYS7LU0_N]_FN MO+/CTW,W.E,HG)9J*6UU*2%Z.LBIUX!M$7I>3,\3!*5%S+!;:BW92*1@_Z]4 M7EH$Y[6`:,\N*1;Y.KZ=[^'W\V'^#9[%O#M#Z\CC)[6U6K=C`1"_X)"SDVY> M2CY@VU=@G"DE8=24;B>!O.LCG*?F8MQ7,"?+R4[U:M-)^(J+/!)Q-M?[L,\\ ML08X$X.0P3[4E57)>[L'?M#W;-53*IL]>_#4,ZUK=Y>4E7H\)]I/#U_=09WZ MT;'D]+NAXSZ\BEENVM?_Z9M']EM4G=S)/>LZ5G<:N_O=[M=?.)C(5J2]=6C? M)T=R8(15-:H,O?S]#'[AI%[^&&\B(-;`^L',96&>)G7<[.,X+020H<1REA35&!<)+"V6%K*C0T*Y`* MNK&U`[960-=,6S>)MIG02$6H>%DKNJ5#3$S:M(R]E'2K%%%U(I<]S]ED,$V. M?WK.^>L^S_?W_7U_#YR/Y]*-JZ#$`]9T?R4WUD_=S<'#JC+PF] MI*9PH&HTA2.TY?4D=)9X$D!SCMGLY@HH+4S3@7,V^EGSS(2GOZ_'5A2.Y\"$N:\Y9C'CM M4MTAD,7R8LY#8>C(L!;T/*\>BO3@G\ISU]*<$8J:N[YBSS,S\'^( M8]&AH4=#*_/[:@`4O52K-B]9;&')`^RU;:"^+@Q$CP$04/CHR2>2A(WEY1HS MS54.1SEWIIO=,0]&SKZ5.__;R]][45D\J3S1!GHW3+XZW+3YJ\V)P*FIAL>_ M-G#TQ,MA2)82ZB_A>E"UKIPV=FBU'0<>.7"QUO6=KS]U:4*'*WCOR;',HT%J M\5YW6<]/Q_;OQY5_HIRQ?_DOFG'8]UYL.*4_(A[QXAA&&:@S%:;W@)PR&S#C M74L6O2]1LLR?_N;I$>5?RJW?@U_ZN^2T.E7]LV=:VM[Z/WMUX[MM@WVE8)7$`+/Q/_K@]\<,3O"0S518[^Z.KB M'VYV/(HZ<`EVX%VHF#(LA&U(Q8-#)%PP0VHER2Z.8J0S-CD<"@I5)`5*:ZH. ME6:-.5/>@)N_8+>70;67_:P![9'+P MS::T\S&2,IK#N.C]](2XP97N6^Q9_=49[\(S5N<`QL`=]^_]3E MK%%Y5GD"S>POE^^6S,`W3D+'Z?;[>3$H>CQ#T&G(D%JUVBZ.I%/Q@PG'P4J> M3R0X>M(&;.TIC^@FM:`TP0?S@7SUE)CWY;T]7CY!R&YXKUM2K'L:P3'@9CR$ MGAEY&F3;+%/G&#$*AUPU0H)@%"ZB%Q4@,S+#(@(LU=1`E)8"B3IQ8U1]FW#KE5^JQ!VE2/, M)M>T+FO(<;@>#X-L)"^NAFF3W[#BZD6TB1[@9,P^7>[:OMY[__ M$NE4WNBM#SD;QL(Z97P7DTF!")@%;6LJ>$B2I`P7QY^OXJL89?!54*K?I-$H MG_]`K!$Z*>@Z+T+7^0*Z3@([/(U9H=&T6HQ&7SP^)/DL/DRMDM3%^7P!X0P] M&0"/!4"@L<$GB7&('--&+!%]-)B5""()6H-,J M\VHH*7KWW(*QD;N/",&3YV`\D>!@+@7(I^I,:'5P`Q(Y5>(AHTHBL:J>KI%( M^+,!UWB![_6G?Y)3;BI7;X`/_WSP=CO%^_5=.`$ZW][Z[C]693^9G=CF+Y?7 MCK#=P`F`3I`;&6/E!I*4/4[@!?27X"G`A"I+1R8W-G9V12.OG+CVV9V_A4X? MB+EU>Z#FUF*W4L>:L";0K&TFFZEFNDG7I&^V3I>] MFV'3-JM5%6`'JMT%'6ZA`"4[DFUM0Z&@)>1$M3L4#'9QH8TRD/O[VCIZTTZK MS4AI-<&0K`6Z9#Z=;Y]VY&WY;KZ'!SJC6R)TV[VV,P0P2SZW- MU36L(9!`B^'C@1"R1][S4`Q9B2)(G.2>HCBYZP\]K^20A+G(&?8_XDR0"4V! MO9@HB:F_D6@=('!X+78UDI#JW'4!OZCQDSA**E#&/K&:;1VH]F[U^V*C+)A( M7&%7=WIKQ5Z0F1$\K7M9T-PQ<8!UC=HX`R^M"\=VENG>>O/TMUAAI\41"0>7 MES&IK,%6N=')WDPQF>9/\'V?)86R#I+L:%3N?`P(?.;*L,1WT'2'@:T;^)-2 MH7S:Y#/1*-64>8$`+``'/U:FXAZ=*:/N6)^J.^-N3,+Z4F%ZR.6TN"BU.IU= MG&NR')3[?33E=)4`@\60->7,'%Q&LMZ<9\4'"KJV%SSVH8$$8P0./;+8Y"4Q M5:*(4K&I(24KV]98;3&Y:VJ:ZD;J66")@5Z=X_$@RU7L?&ICL;>B:Y['UO^A'L/7UNDO>O]WE^S^\#K+S#84-7-3D")\J#IZ.-CLH= MOH(J>Q/>(8M]G!Z-\#'3N,]+>7U>WSAMHGP<;:)C11\'/W&^8B)&^;R)1"R6 MX'B?S>3U29UT@C88BC(Y)5^$JDPNR\N5/*ET=N=BD83)1OL2#4$PG M&)KNK+.Q=9J"HT26:AN<$(!\)RB$2UVEYDAF`7[M[7/OJ5DO8C:B/M55<>19 M;HH\?QLYBNBL%RPDPWM`A/#=Z_5%BU/W'.^Q M`OF?`EV2<&NJ_2<;!#"Y(M#,:1K&%B<7+ROU'UEJ3C#%%"$\/J;.)0"!VX`E MZK8@;Q<7RL*;D3-KCPZR7A9^5RCLX='5_RS_^1%G3HFK=^R\_Y-5SPF_]#32 M2GEE9L@G?!_.S(>M3+>:16M@0179`S4[.MD(&OVAUN+=FA MZ'M+[D;4Y;.B*Y[%W\)&;[E>L47S($1;*/I9$825!5;()7A%PJ&`RQ5.#Y+O M0,Y0DTO5&UUM:PB@V_C8(4ULD*M1AXJ!@W=_F;&S[.)XS=>'A(_^I\YQ--@# M=CY\U6PWH?LS*5ZX7/Y*N*%JT&[;\,V#4CFZXQNWKBBFX1USV`?I_>Y.=R:* M14&T,YKIH1;7+PFKJ/%(B*)J(S1ZA^!_,1ZEHK6HQN/1^#B"9$*L,AD),=E< M9!P4$Q*KPT'F&3;*1")*G@5LOELNBR="S0Y&"3163<%4TI5J:0O$9J??(T$] MZRIEN":(3BH2554'M%F0SFWP\$S%-D-84/W"6#=T' MFW#K2RZ7)RN5#@M?EU>`"V?`3JDTVW&RK/AQR&5%E-AU4^(O?RE<^>MQ(`.- M^*!`"J<>Y6VVK`I-Z\JM+^0[X;0ZL&/I[TUH)W2XJ1CB*9.9UZ-W*,2'QM5* M2AT6JQ(F/+5:RYO&_1SE-XN5X_*D7\OK@B"82G)^DUD:=*M#RK"4U[H=V@); M@B!F7!(='N2Q."BTEQ)S)$K.S)-%A0)FAS$]-4^HH&(59X;+ MHJ<*->M1?H/V""475$H:U6)"$A.;?-9" M-+*U1&ZPEFX?M`7[[R(`"RY<_;7PX4=W;E4,)WMV%<8>&\KD^F&L&TX0PF<) M=8[Q@N_B=2^W^QJR MQ)+8S]*KC44O2WDAG1>-9LIL-)OM1J/7:V]M%5L1J0ISP2E[?3H%S]T>%AIL M!EZ,DRLBK3)0$RZ']I*EFD(M;(Q]$8">K:/4SC;<)I+7KD-?AA#?P<>,YNGI MJLAVMBKAPI](=(:`KYAE]FA;%?M4XJY$V=!9T_M8RX[Q,P\?R!H7>N[!];V=[&:K8-+AMP!/SCZ?MDBY^?WKZO;5UJ MM2U4B!'"L:PZYQX%$T`H^1WVK%R9V;?BB7=]UZX>C$&/U3[8^_?-+S#XX<-; M-I/"GO*Y7_&L7>PMEKKUJ92&>&_!'DJ3.I+0>YL"C9)1O`^>$:=Q]F0@']"; M&D_C]K2'U_?I=^HE>I-UU$*:'*;5)HG)U!HF=0:EMZF982X:),J+S?/98D[Y MXOSP3)F<&9[-&]14?$8#N ME-V0D8#@L35/'0P$G_U;)@.2GR]_MLNMR4F`:V)HSX^2L8'-%^)QX<5_;SJY M9-_+F]-M=QS8M=S/L:W]?7O>!8T^WXN[[TVTI"8?[EY/V8Q\3\_(.\+9,.I' M$6*M4[8="V#KT@;MJ,XE+[(,Q2I195B&S+.NT[>^2%M=M&743/-!5@Z4C/(W M^I*A#O>"@K_D^Y8!K8C_S'6R8\88JQ(OE*5H9$5!6YT>V72H0%#T98P#)DR4 MJ$3\5`O2;XF!3I?>E1_8\+MV?WW-78XZ`AP&5G#G4SK*INY51B9>:MYFX+KO M)JX^_D-USMS]/O@%^*^Q;D??JZ^KX-_&I]=N3,1MPL?EGK$@8Q/]#K8;\MT( M5)5#(BUHX/,)]/.HIZB M]`RJE+Z>(O/ZVC5ID,YEDQU8C`N$&6>CQ.ZIU5,2K3D6-L,,!"U2:YO$@F,% M24D&@Y;G-$@>UXI825TK?UMDJH.02$M3%2M:S5#D>:0RPZ[*1B&E@10(T1%I MA9(SGXKH6;47/;]^82G%9`0%'QW)WB0VG^A=KI5H:?73>X=&#I^KBV0][0,: M$"MDB.;_LUWML4W<=_Q^=W;\"G=^G7V.'_&=?;9C^^S8\8/#3G()20PDD`TJ55,SNHE.ZT;,?K^+`W2;;/_.]W/RQWU^G^_GXI)?%+AQL?@3/^0AWK@'Y/7OMU\=E/ MH]V;I;'J&^"5GR?M=F0];J%XK>@I?I'EO1#_4#AD`)3DVX?H89V MKELY#]JY!K<*,A>G[M?-^Q9>F+E2F!O"!^)3=4SI(WPX,NPDLF=:GCZKR0C? MZ=37;!N2%/8ZG%[@VDIZHRT'#Y_\06N,M]4*MC^_V&]CQ6[=XP_U/:[SAABJ MMFAX47L4]+V.K_%:$`8.KWBB^%3QKT^`L\#SX?QRBP6E59K:>F=W\2.(RJ:[ M_U#O51[`,MB_I/4\\.$^,T\KZ+&,:*;-F8PHCC&T64PR-"/VV)QF,6-SVIP] M8M+L="7%I',L'C/'76B-P4\/@"#2:`4`C\4381Q@&E%BV$H;@/J54=,9B.<% M/>:&_N],(&R%9+@V:W:X")I$_X*P]0L06XUH8X((WT`8XNND,\E$R3.F9E$N M9*?T_P?I_"S:M='AB@^8BBO_`WP(]:H'/]4QD%?BA,]_+SJIY).`V2EMJK%8 MT37U7P<"Z0QU`^HG@0-PW!IJ4RB:7T%C4%L?` M@2_`[RN.%J_,[,+C!S9]*V&VR?6BMOC0S/OO;'GXT,_PMJ(T7`+R.:H\ MB"6Q8])B2T#0"P;!*)A"OC*G.JC3&M2JGE#0'%++:S#@X8+Z7*C#``S".`?J M.<"E4P+<5WAB.JU:Y50"2C(*U"3^EC3/2G@X/`96)%;&[VGL5/T,C"]?RZ9# MA:MYJ!/,31AO2E(ARH$&Y*VE2`IQ@]`BW4BBBHK,QF*R&C'X$V1U&8[$^+[N M?ES>D:W6>;RYN\L5];2G?:H>]2WMW`*J_H4F[-+?IANAS4]IX1WOY MX1TGM3F[8T6ZX.T$Z4\65W$+>7>K6>R09%7K0$:7*3^A^ZGNNNYW"\HJO5EM[.5Y?<[+F@=J)#=;R;:S.%M7&TI%O+R?J&*UZDI687!$!MT.E82QX%)5 M;ZK70&@A:M/3"#%XG0.ME&GRZ%$1.UMJ1`E,";8BW0EE%KFR""DN"DL@B M_M4!!!W46`H@D:V)$[)=JV8%-PT55Z&FOQI@]=86XZ[HLH/-5CJ MWPX:5T4:]RRPV6IH4VA_L;*>\^!G+);\I:]V>SP&X9,O^Q"&@Q!#C?(W&`L3 M\KC4K%)PFC_:@7C*#NQ'.849WCF`>-(!'.A.P2GT.0I2+C@P2@$W)5$=5#^E MH.(QCA=4M,[NP&AL`DR"LC@8RD*>V5W:@.KXFC)*.2[/OGA^MKZOH:O.DGNB0:C/MCT59Z?)>96TV&#>YC\V,['ZRJ;KA MVU=?'Q\XLB"U+7T,_`0\5\W0_Y[HZDGFP)*GER]^OO@QO8`8-`VK M`WSDF_F".(,ZA![MQJJQ/&\EP2Q%YH9+CC-RE%/-D2-%Q*S7KB_?'!M8JE0QXDKFA=>OMLPUGETWV-`/9;=Y+-5;)QL<[IYWI\> M>?M`[\-=I8G9!T\[@;5@GTG'4E@*M&`M0*&F0'-T=6!UU0^I:]0'PF>D:@&9 MC":KD[$EU#)NF4=EHVQZ+^8%$2[BB7A52=*M&70#\6GW:3=><`-W'S36B&:0 MA%OD:1(OD(!$6]%(5)^+A.F!CBS(2B%6'^X+X^WAT3`^&@;A1;ED?9IT&UV1 M:"RLJ`D%)JH@=:1Y(2P]Z%+5]-;W&LMF!Q!2YW9I_.8J130_-(P&<'AZ+N/D M9_DC7TJ3F,\/(715]W(.Q+?L@7&$+TBM=*E4P-M2^(%SB3;*\-FQ1'.;5O#& M"XT1E\T345HMX;T7#JU,Y]JR7,WQ?..RFG;.X!/92/GDYW;.?XZQV(^TKEOI MB>^S&FE/MB4_;)W.[@_I=:F(W;Z]Z^6_'1\9V+8=<)MK^6T!I^7#+13#@*QB ME6G/A3OO#:QK!$400%HB@L:(HY9H(Z M7$:0!(3=>CBOA/?B*]9LOKXWLI%4D=[(W`$EXW/#R6DES%0O#GS*^*$\K=8"GM2 M:DCDE)I;2B`JCS(>,^.!KZ`AH11(26##05(RL/IZ$E22'>1+Y"OD9?(&64;. M3WL"3"*J-/66`RXY"3033N4=9A*_-A'M#5#HR6]GH1M./RA$!7DF"[(]SL8- MV$\1IV!Q16J40O2I`UZ9-%#!?;)RJV2"0.+X5816UGH__#,4GT$],/EKM'Q# M8]5_V*[VV";N.WYW?ISC1WRVSSZ?S_;9/L?OV/$S.'[$"4DNV`EV$DB"<9:L M(X1`RUI>U5`KTE9M)&04 M>3-7*"@*ZCY''R>W9"-ZJQ&!F"8:Z)[/]#AI0^B`H)WEE<$F,") M^NDE@4=&H:BM7B+@$QHJ&5H1SE?P=MW[J22Q#'G5`O@$#*\==P"KB\=JS(*7 M+3CH7!P..`;"LQD%==K`HE84)H#`0;`(P?JS:,WY=7AS3:E0R&[4'F>+<=9? M+*S+;GWZ9&]Z4P>W+GA5;DQ-F/0;9N;*2;4^]>)8][/?O_?IKZH;SL_M4TZF^EC=>?'Z^\PC3%O&009;&6IB=0]-O#[<;:7433LPJL$1R^"?C M$0=(50WMF\K.=AV9V'/L\=Y7VBBL8ZJ\X9WIROAO5T:#MNQ0Q>Q>YBA\1#/5+(8X:<0QLM>&LM4;XU)Y+2_X#M;L1 M):"[HA1LA@>6EJ`20"V$%$\TCD.P-^B;":=@"XTJ6).%6%A8)Y9HF"SLBD-D M*F)UE[2^?%Q>_O-6?3AZ\!3:/>7WR"51=R>E;J8'[%3U+Z,>#]%C(HQBO29: M>F:!G60TO_SK=]Y#?_8893.FI3&']N*ME9M_^Z,WZ(I0[Q^Y9=.9U'Y+^_5P MK*WG/Y7,04JFT??,5E^_@\.FD[W_.38O^1ZB`$WGY9R\H"RH,.1#*>F#(!LH MTN"%(-O@1%$\85@B436)LB1*1L)>GY]K!2QD-$T7T/[W1**-:`NWX$XHK&ZE0*44'>B;JP"?@"^U=P" M8,=C$#ST>"D;SA2SD4SULO%NUR8?X^RR%>;ZB,]"N[RV]1&*L&T4WQL8 MST3ZRIF5Y<3/[3YO"W_S\:^Z'5/QP[%F1319V/^/A82)\`!<[D^O7,9^6,?E M4$XQR`[:("Y*%P6!\?I(KP$"P\+)!VX/;]&%LB[4%0F[O#Y1B*,I@TC+-'!A M[3:(BYPYS$F5:NVND.`4G7?^54=D[=E1SVT(QY5'X`$H1@DL8AJ_'G<+_1EP M3($V@]L&_7$Q$TG#OY5+QB9P+@6\>MO$J)-J=JX?,*V<;*4MYF)O9N*GDV%6 M?&]P+!/ER]E_XT-#4F4FR*.7T5/G@TX=EVQ_/^]R1?97SU7O_OUW5R)0KP-` MKYN`7M/(C=Q^PD%PA-/E&.(D`3+@*,O+B@GNF/-X#/>)`I*`U"L'$:R6MO`< M-Y^(DPDND8C'$_ZD>#ZE(34B^$P!'J0(7N.WF=O,)?.466S.9N)MB18/QR52 M-IV6@A\0JU&Q2`H:HWQ!`?6KS:GMS8AM+]"OS^[W5-IJ\EU^2+ZU8O10K[XB MP(O63CI8J),X(0,:EBP)S0B!(M:U:UB^H'4-WUJW!9X8^;M6*[PUI,BN)530,-GP%8"063*C$/LGS7,`?R=G-M$B MUBA3*-5B"4DNZ(7VF3/:*01>@&Q%4E?T&J-LD!>63`%@H2#`AQ!HJS5))SB> M&X(+;%"!-JHD5K0N["J96`_W',MIM71O1].-JT;^**]6JBV%?R8.=EG6I<9? MQ8S/_N(IDFQ2I8T]ANH?5MZL7L_3!HT'HN"[_[ET/[A[9Y"57,SCR8OSDOQX M?HM$ADIXL7A^NXG<;IJV8-O!KS961K?PX^/S(RYRQ#7LP48(WN7DH;##$3+2 M!X6M`%,X$N&)<,AX$?L8<6(?Y]J*(90-%4-8:'9'*!R).UW2=4:3Q>F1(.3V MZ?$M(\-]O&Q2+(%90^::[6JH>?U@9;*BK`3L))Y+VS.+ZRI=FP6^UO,&_+\C M3`\21V!NS0N^O$VL<<>EAS+G_U^II5"MPD.8@3VXZWV^GD&K,PX/R)JOXC5G M!1M9LZA:,#5C&-[XDGI4P;!R;".-!D>;A9!)%:X#UC/!WC:'GG$HV6;O\Z]> MW&WWZ!+LU&>_Z>;<(9^>45,JLA!BSA1G&+M?MT>G51O,R>_N'I/VS!LIWN%B M2`W74=ZYL22M,,S@^KESI\L6*]$T'7V!#6E4#K,Y>2QP_D^'WO*Y/9L_VKMP M:WIGPPS3\<6.#U_V4<9@ M_]E#U4]*@"$AV#9`#]R`7+N`WIDYD MT1-I-"MXO8?TI"$E$G#R>GG"\PZ%WJ?0HQ1*`==W%?(NC]OF#"%U;0;;2^N8VG:.54EG!^7-B6\YI,UMD!I.WR`S_ M:G.JU1?(1+V4QI[CZ'/9D7B+\[]DEWUL$_<9Q^_%\=GGQ._V';;/=V>?WV([ MMF/'CE]P+G:),2%S("&0X@`!4P*!``DDP-9"E]*PE%9`62B@K5LIE=:N&V4O M9%VE(838H.T*4[2-=J52UVF;IDR;-C1-:MS][FQ'H9/LT^]T]\?I^WR?Y_MY MW(P7-QNTS7T3%]FC9E/4?RES&$9=5C7CC([F+"J*L7A'M\P\S6Z_Y#('_9G? M7SO;X]0Y;,FCC"^8:I_>>S9X@-7J^R;*/_@$%WAD$-1(`VJD!=.,YM76:W68 M<5B-ZTJ0N23G[$"6A;EY$;/![@$V5T!7`@(C52B(5<:)MD+`F'2P/P(G9T9? M6KD]TW=NU\%7+OZC.-#>G-FV94UNU)N"B5_]?.1F_OB>;Y3GLWT=H?,_?'*7 M/P6W7QX=*9V\!2C@_L(]21)\31.4AJ9_!M4!.^C=>KU$L$,,G-QZ5\"(NM4Y MO39:NFN%&6O0VFW=8I58^;9`*.[V0RZC7NN2.$""U:&0G%>P]2(@R:?C19,* M"PT[<$@)`1(0?+!0\X&V!I[5J3H_MZ3RWE`0%0JNJ]2[%OXJ1*PZ`8Z(LK)P M`4V$$[Q$$J'*6D.+G>G:9&(.F=^]V$1:I`'+]#.71II)WZ:]O]C3) MCSQ5_NW,DWY:N2G]*58=0YFE*5]@6.@2F;YRUL@8)IBJ&Z*92*MS(T M1T%2##9C]634V>P!B&GQ#)-8<[$>YV%64++"`/.I)>MJ%0*J(Q4\&)\;(.?5 MBYPER"UV4J6-=!7U0'-H8[7928".42!2`V'3-<&BL6K!I8W![^M\N"':VM5W M?W\VXH_WQ:C>U]9$\JF#\2V.QAW=6S&D;<+1X\]V6A.#%EVXL/.2:^&>PV9M M^\M#.#-Y-V'K+0[#BFX,=9$ZAOJ<14=!@/.WK>, MS34WL,?E*=5@@H<4"$%5`A#I_DNKP6VF`@W`H64+K>?4ZIP'7=&!_$HBT`F M?,YO`CZ1JTV`=,0-D0%+(DC'ZINX#B,X?XAEAPD,&PX!$18J2\K2?W55`4`# MA`!K"K@5!)E;?!&J'09"02!(F+""MA0S.``[74*BBCZ28G:7Z"`#V)MHV"BT MJQBY'"=/H]X7\L7-#-/5=]B777MC-C&>6J9**5(CB57]WL:)UITMD:]]?#*S M@YK^^F`DV[NBQ6Y7:Y=YTJ6)%9TXB##)R,'&]@;21G-*ISG%.D0@C@(,)8 M"I8KEKN`"YO\G,>H,RID$D,=X.^&(=LL+/^Q>4@S1,XB[_(X+\"AIV@0Z/!F M)=H^^VQAT4O54;9?4%#L/(T60#AX*GKINMA_B_01!9AHKS2?$%55U`;0"&Q4 M`\8KY,R!(^YP6M,9PA\HMYSDX.'3AK!WQ[XVF1)'-ZP?ML6\%H/5MPY6MHX4 M(H^EV0WPRM\E8H;@K1Y+A+QR528+VZRR`^7_OA!*3"+16"@S3=:Q)D$PD0WXHL2$\0[6 M^0Y;U!0CC2(;U.#@WX]DPA+4'K])+J4#P7J+(VV\R@:ZQ7"H,)Z@7!JMB(I\ M&?G:X!H4Q,".6>GH7G+J3HO-QB59(ZY3&]C(=P[&ZG:,:\*9@K7>M+Q9_]/. M+K/5;D\<>6>JS]>,R>Q45MU@16[%!W=SWLCDAU_=%R*,1H/MEP__V"YQZ"_^ MJ_QAEUUI\\0G0Q:OIWGRHS]<&$FVVVW^)XFX_F M8PA$*12$2E4J^&`?,0N?Y(T%!PQ^CGBK"H*%$,B9@C(T/(N\QZM04]&&@9S% M44P[YA%6E;;*8JA>T`")QN=(<#=0,>/"W,`"$&YYX,Z<()<9!CU*BW%)*!<' M?&6TN18I"I&((H%[J=TES#S_AD*ZT=YI(\::+1U3[9VI?'MQJLEEXPSNM2HC MD>MZ4'YP9.^ST8GOYU/[E_N:2.1'<(-2(I-0KM7__.NV;5M;"W#GB62"\E+K M"&SST)OES??/GNA_];4WM7#=ZK2@B1/L-B5T#NJ!;O"$A_30^4P^*PE0/5`# MJU1J3#Q)DT)/4[2>-@EN-8(31=$@0"F0J*R;A?,E#>L1%#(7HC`3[8XBT76] MI(FF.`L?8)MR/D67=(WP7"?U%<,8B`9+@Q3CQO1CR8Z*(]OF4O\GI!BLU=:> M!VQ68U2AL=5BML9A46'2=&?NMOJVZ,IJJE:57HQ2D"(5,OV2\C6:16KV%+EF ML0A>V`8R1FVU(SDJ'NQU4`?BU',OIOVY_J.)1.F0B4@G,^%D=ONS+5Z6(]N[ M&4.ZYY/7I\9Z]^B(Y4T;+[0/3,3'W\KN7!%+M"-7HYW]+?42&6IDSI__WJMOZ;`3$/S%WX&'<9!.2>AC_JDLE_/U<7TM$J>O@^@@S\EFY"\Y+[C. M1W\B?SN&MT1DW6M865VW:LZ]BZ\5@'.MG8QC8> MQ87!`+<9`4."1$!`)"&0\%Q,B/R!1@D)F(`A@-$EH@2)"?^IA)C@(VK0?TP[ MS[VWF\X82-3$:/A.>K_SG>^[M_>>\_M^YWQ.PEF7L%&LHKPVYIY:SLD4[F2` MJ[H<1F+6E/28GG7WL)2BI[(G%BZ$[MN'.3%A/9Q9%\W,;U)*PZM@&0M:)H)3 M`9Y:1NEXG701`@F];F0*C%5ME!3+;>'D(3+.+$+H"LE?*Z2Y`H=C!(.$U#-E MLK!N3NA0OY^?5]YN#\8KS8%V=^<&9]')`VF'UVX*J$+=+U67^:RA\";7&_4! M!SOJL5?M6S(WSG5NDW< M(*/Z>#SY_GR_L'^LN9OR#HQ',PPD#;SF!359K*X]E*BK2\3DS>9@0-@R#K/5 M6F9.\ERL)BHH-<-C9,Q,HR!#GR2S4QE]OAE"V, M1U8MB\1C&\XT11R^>(F1-3!Z5\9G4WV2GE/F]2O\*J.NLFW7?GG\S5)?1?^* MAJ'\[9VI_D#^<+O:J&YH3QX=__3+HZ^[;5U]?/>I^YXH9X[X>7JZ:[B5IX@+7?1L9MVK^7/Y]PY\]2#8(G).".N&*Y@-0[`]Z:LF,R1)IED[ M0Q!DLMRKXM1@5[.D@K`11-@6"9-6VB37X\'H9M*0M'-62D^QB%DLRJ&F3.9$ M^SM"8LN5\D$)@O5"J9X3@26B3\\'A=R&LW<$[IB@QJ0<5EI!"&>9@N<,(J[, MAD(ZT%9XA76M%O)*9F!TG[1L($Z!<$5%7D]C+I*-YC+A/5&^:CB ME6-V2L&Y!:_HB9VRZV06U(";#0A"0U,_FOQE'"CB6S^>_(W8:EF]5*HV]SRE`;/,? M*2-P%CZ$7XAFXBVRG#SWF\@LLK89\K/\K$*KV*-L5-ZC7J3[Z6OTM:(3Q9KB M^R4G2KY69559Q,H)C5%S1]NG2Z#&Q3?8[7:O3,P:CR2P.6(=D])1[*WRS*_T!J`[6A,(1P)IU'A^# M1.&F!4W-Z9;6A8L6+VG+M"]=]M33'<\L[^Q:T=W3^XA_/?_X%_NGFAPVX=4, M.OQ4);@@`C%HA798#EVP%8ZX#).3..^"`/#0`(M@&=H')/ODO9D"[.>G"U[^ MLX:NG/SAD>]"0[9POPP$]Q*%-W2@2+H2M9@007D16F+XEI).@@8.%709VD\7 M=#GJ=PNZ$F*$(=/4TMC6Z$\-#Z]OV#@RN'ET()`:'EK3.C(P-+CZKT]"!IJ@ M!1JA#7]^2,$PRGITV$9,RX.P&4;1:0'1/@1KT,$C.!["F=7HT+6P#N>'T++E M;SSGW[A3B`IY$GY$M`^#`J.@P_T5QY"M0M2(^TP.Q&LX0\M1$T93/61)!F^? M;G^$0CTV2"+NCM#X6/B(3LDN%A!!=AWK7KF[J$^;^`GLM+CZS**UEX3^_(;+ M6_.'^D4#DNFT/@K2);*/`IE;F1S=')E86T-96YD;V)J#3(Q-R`P(&]B M:@T\/"`-+U1Y<&4@+T9O;G1$97-C7!E+$)O;&0@#2])=&%L:6-!;F=L92`P(`TO4W1E M;58@,30P+C$U-C`Q(`TO6$AE:6=H="`T-3`@#2]&;VYT1FEL93(@,C$X(#`@ M4B`-/CX@#65N9&]B:@TR,3@@,"!O8FH-/#P@+T9I;'1E?9?[,_/#28X>5X`['UNW8%^6BYDU(T_6K>O::CPF&]8U/.#2WM*> M5H[<^;,VEM"DQGGHU8O;TFS%3K8EZ[!U71Y5 MF!6JK7=B`]4KZA6LM$Y)"^WY!FQR)94S7R8#4AIND0&;=+R/`8R0C>2G^!WV M4K[!D1Q@'T^%/>'?R?@MCC+0= M1^W[WC7`G';@!A`^O4CZ)A:)DUI>S' M=ZSG4&:]+]:3]N-->::<@C;>UW"6U5T&E74X?3>+SR%<%#[T;I/V2LUX6<0G M?\#H;TFE**6'#RNXSD8R+/NE5'ZBJ MFB/EHH#G)L_Z6.Z2BSE.5=-RIT[)R?[:XYD9Z:F*7"&9>0W^-:92E/6982+GFT[=:ZI% M_'.M"D?,TC:_X64,R:OH,]T M#X?8<'D8$RU3[EG&K/&19!/HEFA-B;7T7M,=-C&L'ZL8CXZ,9:$K5)X1<47" M&_RF$F8,QZ`4>7O6F3.:6X)4<682ZM%%Y3SV0]1!]_;H4?;%V!"?+H^HWU?T M_.$-B8I+(9>'MK0&_[/&N-/,H?2:V>5F(XEU\8)%0GTBTKZPR,[;IT>'-]D9CM@9<<=U;Y]'(!QY?M!![Z#?V^/R MLHS#L069+QM*T61?PS#SRX5C-.H5\84C##H6+PWW@A>GREDN,9X&T[W.%EAG MEYXKNL.>0%P5'Q`4;L(2\@0"AKVG4G.;OT'DXPI[G+$L)S2AN(8*;\(HHG4U M<093[];%R75Q:*UX;*I%M+O6KI41D.C5,N'E<_E"T:C/I?NBH6AXS-K3Y=*S M7-%CSH>4N@XMD M!Q+FEO]FCF;]@S7+X&OIU'TB4O%ZB5=.O"UT8Q;>)F]\`K>([ MP%$:L_&+8PWU?M*I?F2/Z]1.T'8%0]H3*.-\BTDUQU6R7T(,LE"L\RC0+U4@ MXIF,B"^!'>=#B.ED!-U M?@3$/B1C[T MH?D\+S=0+]"VH#XE%$.KH?PEZ4)]VGE*-^4)2A_E[VDO)`6LGSACE^A/>"[K M4U;'T,HH_60Q68KZU"ZL=RS'>FT**AU5S#V($OD5E,D7D6.W+R)=GH9YE+7L M5TGO47<0Q<+.+_4":;]U3;XA)`K42N3:?C'_J<)'ND0=_:47,87];-I2E*N< M,QAK4V8J^U&B7*=5A(?64QJ2`$1^K6DBS02MQBG'+=M]CCE<^0DQBE_ M8VWOC5M!%I%"(L9DD-3X?!OCXZKEYR7S&PR1XU85U58M[3C>)S]:=I_>"_WX*BJ.X[_SMU[[^X2\B@D MV2R[>#>(O`RRH%(NCW`7B88F-#&$&*T0.C6P$/(`"FE)(%%<1BEM(F$+X1$0 MJTRQ)7@7ITD1H3.V6NP4$>V,SG2@5%L?&0BM8+66[?><>S>$U`Z,4_K'Y_S. M^_[.[SQ^OUL-O]5+M2@WJ.LHC_M%:6(\Y/@$=^&_S^6QN<5Q)\UQO$OER*?8 M3+)9;^UI/!]R.^2ZA(]#_@/>IDR"C^BAD#LBWF$W[NQVG@!M*QP!\LEOTQ;I#_0P!WD3`!G`"++"(7P$?@--67KS[]1A;`[D$O(+ZM>#OR*^Y.NZ& MOKDK\',1?S@ MI,%V+&7PW&N>4SSU6;0:0[BSH M4XRZ"&*61S'?`A"C9>I:^(D\FJF\2\/5.OB+K?9W.8@9Y;R^N(S'8R1BGQC\ M?@#SW$>9ZA<`.KHVTF`W?Q_SJ53P5RJ3;T/,MO8J-Q7P+^J/^&CXX`<+B M!(Z5%.0H]U-.?S!''\HLL!1^)_XYK<)U$[`_<&AZ[::)\#?_QGX"^>'M(^9>%"IQ9 M8(R%\AKJH*QS#?C,PG4&?([Y!UFX/K$8U&*1M!JT@KTVFRRP'G)^A#$&SN>' M1/Q\RK`Q1PF!A\%RFS*+Q+^$/!C]"FW=UEBX8N#WX`X+YWJ0`GTG0BJ0W(:- M:'L'?!N,L>I$/>SGQ#?5]R'++5S0T?4L\%@X3UFXSULD!0!L.NCG-DLL<-Y( M_11]AE*>4H\[=(!:Y/=)E5^E$LB[ M&N4PE:B/(8]O_C_@:[D>8ITW$6X_W-7CEJ2G;,D9!U)LZ1$^^@#B+2'CJVSF MH1P"J7P.;O/K96_X$WNH8#C+,:Z$?/S M[]P`J@^^"'!]!L+U2\#UO"Y8PT#XFOK6=1C_/(=)`\G2X?AGD+EVO>>:==MK M_Q(F"%L,!#:Y#@4<^#!AN_YP.PY$V!4H6RS99^<;@.]#?_A^]$?L38*AT.$2 MUOTRS6>[Z$%E!#W$XSGNF_C_QLV2(NXCQ#-?47*?Q..&A!1G?Q7._E>1[3<@ M=?SC_IEN[Y/V';N>A`_-QG>\`Z4ZFQ[J9FXVR/3Y_=W,R5Q61F&JZ?,%0^D, M@3"01-K:E]O#5+H`'+PG_8XE&1W#SIS-]/C?>AM)0V.FKZ'1V]QXME$Z]28J MUM0CJ:Y#LKP6255-IF]"37%5:-*JFJIFGEL+V+.Y<>6GQL MJ?S=U>D9_B7+D"Q>BJ0RG.XS*MFQ\)GPA7`\+#>%6\)[*SO#DZT=9':NED/A:K9GAT;M9#:LV1VGH4!WS#==30QY632W@)'#0 M3*1%H*E?;1RH5,NRB;&LF$_3ZD*W,@^4]$#EF6P&.L_`+L[`\"*D+>`DN`#B M0!%]*NQ^B19^%F9P%;OCOV+,S,@0%F1FIA<6)#.>PRTXE0VA,ECN:[:L,K/* MM&Z6PI+-,NW"$98,:QBL/%92PE=<'LO/M^3L/$N&9EDR-]>2TZ;I3:&1K!PZ MED.3D$4`0J1,T%NTT2]17]1LBBGK'AS&^V:LW'F!\[Y*=>X,`" M_&9R*JPN,5DH[&`R-#T42D'Y..@%#FRS#+5E6%#F@V)[O'Z]B\M;;\/BQQG^ MB$[)%ZH(=5]-3V2(LZV,?;`AKON,T?P(!_&.[WGOF)_E[F,WP[ MC=C4J7KO+YD!Y0QC<&JZ1N?2SDF+=C,T[C/KU^JA9+:/=5`]]-K%RJ@!'*NU1[.UQYJ#6C/*Y]L"VM:V;&U+&VE/0;:A[=R?IFN7 M]AO:<^"?H(N-C^&N-+T$=5J`Q,J,"?L#VFFT;=N>H7T$GH@&M0^C/FT[^'$T M0RN.+HI*P:@1E29#FV"4=Q$\HM2!G[IAF9K?%3-]3VZ1F*CQNC%F#:"QHCH&D'7B'@` M(^+6/AI+2M&+C[(Y^/`;+!_:W6,VC<"6S&(A_&T3>([-BS]>$SO/CC^((0^'9(,HPH2PQ4F@/E&G26"<-V'DO9K!N MSSJ?]]QS[CWWG'L-6W"(0"PB9!#.(Q00U(I6UAQ"^!+A;D4;P:RPQDC,".SN,99]#*+\PJ(;R+(JZAP,`N>HHUU;*D%C[(G M#R;$@X?B07L1/)?Q.DWBZ3EPL(!80B#1G>,_DMQICLL>7^P/):"+>UGQ&M"8 MLI_#>H+%:EX/]F(#Z_@"[*C4BK4W-K-?W>AF"S?`L44+@[BK070UB-$<%>XN M#(H12CR%1WIJ6F`?W7>Q1V?J6,>#P`.2+G>4=Y1'R]/E:^6ORQJZS"J*\^5+ MJ%@I5V-#B@WW8NVQT_?@WCN-[,<%!YLL9`KDZ4*A0"8O0`D"8NV\EWV"<`%! M[N!YSB.WO-@WCQ?>WU;JV95C%O;D,8X]_@['OG>LB3V&]/!T@'U[FF.G9^SL MI9D`.XOP+L(["-/3*].D?Z9CYMH,U3$#X@R>ACA3HXV]@6U^3DGK.4SI.2R3 M_<71562W6*&#V&8X%#]/IP@7$A/(HTA/0$CBOEQV$\X ME,;RKT5:1[Y?F0+3I8/RXCJ[1X%A^J+'K)*C6;Q8;/HB>4X&>XS':<\5,8+K9C M]3$PBN4QBMHZU(X@E6LG7:%#%2L#RAF$0P@4YF@87X%A]"]+-*30=KKH-+GH] M6^=@:9JIUVIU==J:-;7:*DVUMHIRL@20VA),BG%J-XM-\`9NC#*PE$JMO4G! MU]0SBNR@SE,D34,'/4JOT-1:6*>S:NPZCZ2:Y-#``L#[*=1*Y!P^[_V2:JY$(M%W#@X-E,`F#\^L75!CKQ!2 M>V;FY,D4OT[:V[-K0#JT+B4),G-Z78K@O_?E)G*Y"9E49,G:DQRX0I#5Q-@5 M0JU@HX+K%6Q1<"WBU*K]@J>I2_)U9:57NC);_\OQJDO%=[X2*C_Q4MR\@H'G M\Q,3_/]\>7EZ'@TF*JN4)3ZW.A''*DYQ]6B"P[*8RU5&\R_\*ZL@F)U-/<\ MU[F7\K!0(Q]SLB_1(\7[>B0Z.23972A<1R&,@M:5(/#3$,*S"^I;ZL\((]X3 MS42(V$;T$T/@_3P46*/;.%AZ=E-\#9E0[=9:B+DU,#<`'EE M$)KMF^QDLV63A13ZAMQ\>$TTVJW:K+.%PZGZ[F['6"\PO=#;DG)455<3VOC& MC0DZ!:DA;WAWL@W:;$0+U+0$-VA%@=9!':6S;I=OX*X:6WC[+A-!,`3>0;7X MCA@HPFH3DR(.)/L:"@GP)SH2IQ)4XI`-&)O#)MJ2MC';:=N7-HW-EAX>35]* MD^EZ?W%T)#VR*EJ99106[;<7%X61-+.<7I2Y-$Y9 MDNGTF^DW>1Z,FBJ7TQUN"[F< M&E;FYB=_I_>_?O8. M?/QI(F0V;]N4W!GMW)-[LM1Y-12ZVMF=S6;/OKZ?_M4=`O]VMSXK5E6KKQ(! M(DQ$B"CI$`_'!?A6`)OP>X'\H0#5PD.!G!9@,G@T>#](U;;"MZW@:86_^*#? M!P]\__"1<][/O->]?_9^YU5_[H8';CAF@@<&.*J'ASKXB0[L=H-&HZVK8UI; MVP2M$`RVZ?6,01`,0JOA".EB`C4T!%_9$=D.J*JIR*HB\H%R#2Z MPC>C0$>AAHI&`TZN].RO8L%J#]=PT-C'?<#-<[>X;SBUBC-R[W(?<;_FU$XU M9^(XCMI>YB#,+7./.:J)^Q%'<@;G,G^??\Q3)_A?\N07/$SQX.&G^.L\==T' MW_F@T0>4Y(.B3T[+L@_.^C[QD;T^L/F@W0M.[S=>DO0FO&3-I!?^Z04M[_.J M`K3@%\A:E2`X`QL#8Z0SYGR-Q*+VRZ"/V?Q8VWI++(W5/CX^GD:4'A]%P%\: M:SR&"KD3$/&`Y6Z5[5]B1])$1WRI(][[V"+8'UF$>DL,6^F1@.GOF*UKX:O? M9A:16A5&4QVOCC,*AOJ@U5\?]+<&QN6PV\1]Q^_[NY?O'-MG9[9CQ\9VXB0XY\1)G-B)8VQ#7G9#PBODT=:&:1`6 MR@@)18,59CHF8#`*(6*CK%K()OR?5]2N4V&;8"K+BM8*)AX5J!UHW;(R85!7 M&D&9S7YG.T`J-I]U]OU^)\OZ?IY7(5VP#-:!3J_7SFYY/(7@\;H!Z\:M!Y+4 MN>M(DI%Q?ZU^]^<6LQ3%A_`RMY!GVN'[Z,#BUQ_: M.K@".5Q'!>E[)#GY8$:JO(^^HJ[0NPDG;DWMX'S'4>2L]CAQ7H>\90[/3!NT MM_6V3;61D>:!9J1K+&]$VZIAK1.V./_A_-))DD2I4&HMO5A*\42)4(+*Z/G8 M2=]V-7CF2TS:KS=X5GDAXAWRHBU.*'/`WQ!$T#6$U@%\MQ0BXH`X))*B6#\V M'``A4!,(!38%J$#`S+:,41275"1835&B.&EVC=F29M(=C,L_-4RJ3ZKAI'A6 M1,-B7$06T24&Q0GQ39$65550%2]3^3"=??$0$2:&D;I#_1)RA2$ZRQIC5PHC M?SD5K2IA)!5,S?B&5<]-4TP(7]CX,L.1_(R,X"K-\697C MULAC0ZS(@8D/K[J^0K(]?(FQQ%YGU>NT^"9\4""Y)J-59S<*!5L)J\9LD"ZH M*U]L_;V_XN[.=IY^CN$0J:#-JD&>'[BV;[A_`>C[JH<;FA9UPQN97TXO;J#T M;>\TV<3,'^>[*<=S/U[<`>\]W-<*-,.;"EP%FLTWX>&=L%E&,7PKQ]!4O*7O MM555.H-&`_Y/9$,#F=OHY9;TK\%)9FH[PVQ_#V[:1.S1%7H/?0Q7VX]"AQF3 MSN0QM9NHW<6)8B0KAOO%T&&`6P8X:H!K,N!H>$!#+PU3-/!F^,H,MWA8Q\,V M[CR'ME#``9R'!X!V<_!#"MS:%BW2:O0J*W#6>8?)0D(A*%"!0B%7:4#0A'A% M6*,?DU/&':ST3PH3(4(0!*0G!66)NQU>GU#,N62DB5EA!J(8L" MO:?Z4N9A>N;LP/4;\(,O_Z4HD7'-/"G;03]"(X`7'-` MH^\SWWT?29/`?T9#HA3^60(_$1,B8IIT36@3`@=J0J@(]2-$+K(#.F0'L-?: ME]E?M5-RT@$J$CF@D*H:,V,MV))8#J0BX1GCDJRF8@=1BS41PJ(@%DAL]V.V MSTY,Z)HVWDE)XYI.I8+3?Q?P=\!3S!(9,WE5-#NRK&7%I/GA%P@282O*RO\? MJW'P"[D!LHRZ4)05N="M!%2IP6\5&#],-T]W0(\7DA"I@";@" M!P,3`3H0,MO"@=9-WIU>1'@%K]5+A,#_3T$.RGNDEE54=< M22@AF/#[&Q*-2<$'9WT7?3>&>-C*3PFXT(J3]PO3MK">)^>`B@EW3=5-&#&=Z*CA=ETI+=4^R MK=24,'4.IYTP)4:#M358`X0(C)8M^Q\>5:9G&17*:B&+I5:K<^=N<^NEN,(R MJ<_!C-W*;96V@L@-:NJ`CD\[?M,Y%^6UEWZ'5'(%0[*\CP>5_`^1O@'YDMI= M+Q8(-!_@<2"U\-9E"]HB07HOV!?):9XKXA=D!.@^_*X48!+PA:-S@9<--Y1% MY?S>0J7`#IV^0`,H-5MX?E-T[5:.WRRR-)VYL.L5/<4JJ[?+,\\S/'81*=,J MZ5U$%W$S=$QKK6KRR.Q%=O2^_;X=N71!'4*;##L-B#!(A9HT".IQE<5B<5D. M6B8LM$7BA\514=%97].4<'N2]1I&/M[9GNB*)#O)VE!E5;A651D/=C1.!FV) M>?/T"6-RJ0D$TUD3(O#IHHDT$6PB=)PZ22%*1;CR@-,8\"48\&!W\"6T9,GP M$A1]"O:K(QAXX7)T9#0+NH!S*.V?$HG@3%T6Y!E_VI]MZ^?$:'KJ'.XXHSB9 M1D5XC)]-DJ)6K_LZ?'F99KM'MGT\4;:G82X9J$H%A8/$QR.E_A'AZ)>/N/<5 M7EF8^]1GA]4F6E%'O_5EW^$#/0KH^6!I7)^3Z&% M& MX[B6.!)ZH750A$_`BG>E M4I"5F]7;\.P]=?Z7F/7\M_YR-<;+LZ-V9^[^9VENWMR:BQ]%OX[`M1>XW,KZ MTV`/9Y?E_#Y[ZM?'RCU!?S8P_?^9RF/\\KKN7I=:1^2H=<&Y=;/4'3 M)YZUGKZ;7R6P(R][]!;Z`#MR%5&-!;#Z%.'"+ESGE"6`3I*::J-%BY]/)$-U MA>SE'I>KO+I:.:]JLES'3);'0TIE[<:XK$8RQGQ?N^?'8."A_Y?RJH%MXKKC M]W_O[(O/]IWC.]L7A\0.`>?#A'C!N6#GC"^!D,0Q65H"%%*3TC8C+1.0`-62 M#5'Z00I=AU!7*-50R41#A1K:K2H-*8BJ@E1+H2VL@ZJ;!-W:=*7`I@G0RIK+ MWMDF$)9N[&0]^]V].^O>___[(H+OIZ3H@NO$K)?9AG1TE$7_HQ#?L]DW-Q0R MT4G3PZ<_?MATQ][]_H$)NZF]E[35?C6-K42P40]983@PY<6R^4!^/Q1MC3R@A45%"3?'X9I81 MV7@#RRC$I+_IE,+ZMRK8[.&0S>,A@]M-!I@5]JL!Y!MQ,,7.` M&63H06:8084,-#&P@H%US),,.L&`@7$PR(PIY@T&91F;X@QN5F+S`_:](7:3 M6N3NS9NO9]QLFRB3;,/-IYJ!YYO!C9L7-Z]%>8OR)D!_>6)(#XF2+S$!&0*\9/$G%@&*=+ ML"<9Q<+NB\[N>>>7]1WFA?$EA#E73_[GC\/^U=<^+9`JDCR M2%D++%Q]_Y6[9Y!_'FQ^/OY4C8ZM.>QT^>R[X0[M.^V\W0QF*JW>SQ$$E5&M M:H6Q!$9*H*SPIATCQ)'DC1S"$QFZYT(!W5.1N$<%=3&'B1)L8$%61Y@6/$!5^*-!FOMI3C?P&?F#L8[66]80% M6Z8GO"MR+H)<$:BJJ5)KGN`%D:^IXX6J2%5U9+,DBE*D4A)I"&GZ3VK"LEU\(T_'" M^Q>N1J4MI9.I1(4YN_]67-A1<+Q]PN4),H[V:16^ M?VAK?W:4Q,F\T=AD:C4!D/%MVT97@@QC+8],KN-`W3=VWMA.^K&&.J-R^1PL MXMHXM*S\T7*4[+X-#JE.#N@#;^4W!V4Q&)1Y.6AU>OMRS-:LG'YKMATB)7U! M(@2!_NHR[+8"LL(\*\A6$(*P*-@6?"'X2O!:T&`.$@P3Y/)!L!JL0=FUE[_B MF^GI]47WRE=4ENK-J,U8C7SS?;<:8L'(D'OTBW0OA'3:[=!I-7G<[(BRZ/$1 M8A1LEW7/%NJ9Z>_9>)SRDVKK2?=F<6PNPK#4W967+)M($\;VE#&S6CO"VM71 MKN\M9>OBGJ70#B/IZ=JVS2M9@YPNC/:H%GW&)&1`"%&$ MK2)TB\,B"@GU`GK,!HS-94,57"W7PV':*EK1>NM5*WK%]);I#Z8O372;`;H, MWQK09_@B1B$$,Q"\AHZ@/Z%+B/:AQ0@Q%G@_$]JMT&:"1Q#D#A#'5^S>00L> M^PXSS>>^GGLL]Z-+ZH>@RZGG!XI)A6] M/!2]'`5='PE"237GQ/U*^M\[!O(>3"H5:"_:-O/G(3-L`0^ M/]S\]J"V!:;"(NW:U@/:!V\>AJP71H^.9\N#!!$*F`]3E<0]Y7CD2IT]+7:7 M'.*@B]O*(?/`V*>JBA!JZ%(_GHEQ3V8F3"&,L>?D?H!WVA8+^,W=/Z M2$CM]]@9U3M+9E3R:$:T;J*R>TGN4?7@0ZE3ILF4*CIEGHI2KU.8Q]0O1, M)`BY$IWM\.MF"$0Z?RH!A0X)N=R6KV?1NX'3-+U<]$'MJ]\H$9/;49S?UOVO MW&4F`A'3XV9VZS'B2#RR)IIU.\ MA3+,U3HISC5/1$WR[+-U%(6HY=IZ@I*7J&)BO9O5OJ=GPZ[94%NQI`(=*A\J M'RF_7DX_,PM>#<#N`&P+0'WITE*T90:X9A3,0'01/%4$KJ*"(E1;M*1H5]&Y M(GJ]#][RG?!]Z;OFH^OR[\M'&5-ABQT4#$?P27P)?X?I032,+J(;B'850E1UQ0PJ:;'370`/X`1A8`UF`(6+NS0 M6\C$9X:SO"9+F--=+2EB>&4)(4V8LC_+M<>0N9^S[/DWX54#V\1YAN^].Y]] M9R=W_DD<)^>?<_P3X\1)_!\GPP>$V/F!M&`2`C@)68M$VS4)",;0(%DK*"`D MFJYK![2,2*OYJ5`W4+-VFI2JHAF=-L90!NU6E8UUJ5HM6Z5!!I7B[/LN"3"Z M=3[K?/?=J[/TO<_SO,]C=*BC(RIC8,1+$P[0JQUE/,&7@94J*R.">UQ^Q+AZ M!`-7PO55QJ$&"Q?U=74*ZY+3H=#D[,?3PJV/IT&QNXLCUM[6V'V&U)I;5:G$_?ZC5)]K; M`JS65R@(LL\RTEB?:UQZ3J;6N@(YKQI0=O(9&.U+6O(@LL9"L27](@LY=HPE M-['P$0N'66`KT"K+0C/;Q9+?84'+MK73F0)96Y@NL/%%4#34W@(M+1G"+;A) MUGW2-A26&ZI&PS@)C6=^FR'Y3#+3GQG*T*;Y4!1>%_X/QS6(0+&@#-U9!)+L M=!;I@UXQ5XJAROKQL%V8M3,7%\1B`F>GNCH_3CRK%)>EN"NDX1@KVS"@\`OP MHEN-A$/).-2"@,2BT4A86;MOG+YV)D=#05Q5)*@PY!"4S*JCG-I^T!GJIYUW M^HL\6K.V+Q[JV-NP/1C@_F?@Z;NZN^WEUG./?LMMR%\.QH\=J#+[D,4"%5,2 MAQ-G[#8GV,7#F\_4BYJ^O\W>_G^!AV+L2QZK79'_8ENF8_JJE&V#!X9S#*\+$-#(G'$)IIL-C'1$&(&Q&&1)$6#&!0IUB2ZQ+!(F="I4,SZ/2D'Q=WB/O$-\7WQ-^+MT7U*?%3D6P6P62#B`T2-MAM.VLC;27F MTK1-=!=IL#!M*2A.:S0,H1-T#EVO;D#WCH[A=$4CC-$KHT=>KWN@$OA*>R6I MK0R-N&G19I$:$@01$V*.&!7#PRFV5V(+X/]!TM5Y9;P M%=459$&%!?]5.:K]D>4-R[B%LNR59:*7&$"CC@`3130BF6-7L$\]"&8[LM6D$0^':-/KZ!Y'D86]()&]JWO-OMUGKOY*)W)H8US9S5LGVKQ/1G;F;V>&#KT` M].?/JTM4VB1'J>VKUG3M7]V\-OI^46]]\/%0#"Z_MK<_&NPMWC[)<>;X)CE0 ML[H6;T..W\?4L0J MU7/(-9Q\F^#FWKS@\$0Y[/G]7G_47X/N_`YTA9P^LOEE!E6XP/?WI77GZBDF M1\F-J32%7_(6;)`+S:/"D">8DR-\'/@X7I+LHX0'"(_@D3W#GB\\J@K*DY0] M0R5VN5I.RN,RG5V4GU53MU"[2J>1_MS*7O-/$\FIX&S#9$-R!OT`&DMH*@'# MDXO[5_YUDH%W5SG0=BM:(TF.F*I*!R27U*H87=AT>C^Y(`8/Q#3JR`6;P+", M&I>12&/K83O\`#K6J_:TM)_BV.'B"A00_SE[Z;\J0OQ?=BW#"C61.,>]GE[% M<1Q!$5'DU&GDU)N(%)$F/GF;(-'./NJHB(Y5@47P"77"08%^7_A0(#_CX#4. M&.XE+L=1'=P6;H:C4C4P50FL%NYJ88Z'IWAXG8<-/.SF0OXMGKQ>^VDM MF<8>?'G@59VQ?"E0EIQCV4I*/+9].)">4L&4.(M^`'3JF M2Q;;]4'%L"ML\(/:N9"VL%?'S=(_E*2*%O(8=@,2G@*H:Q%AOK'WBMQZAN9V M\AJ:VG$\_^?\E]__KJ=DH66]DQ]L7%!T9R-HW^@+N#B6)#E-F?DQCNOYL.=`)_4`^T#E\4CIW.;]_W>D.7V;]FLP58'HW ME)FT[&+)W1D"=5&:.Z]:B;H8)6)$'+KD,@\%^P!R,`:DSX$\7BW,U0(?A$(F MC"S#A5)[&O_*?L&2J`Y7!\+/`&6"Y/>=N^XE^:\Q:.$ M%1JO6,%A?<0Z;'W>2A-6P2JCFP&KRHJEML!H3ENMB3HA`>,)Y/QP[_$,[\Y. M(;&] MP:SH*;8(SVD")M7*$[]X0LL8-+RE;Y'2?19>8WCU9$_`4:_E;JT,^]8=>;8^UV^PO\#- M'E=EKNX(#?7%V@C6MK3):*M1B"/6#_ MI93@OJQ'`9&@B4?FSE._H_Y-==G'-G'>Y[FSSV??F^T[)W8<'W9B.W:, M8SLYQXZ#KQX-3B@)%2]58"Y)@827HK0PPD*W@::$MU7-MK;0=5,G#3$V(3I: M!$JGO:`MN.T?'5O'UFE:12>AKAN-BJ:I6HOB['G.86WSQ_GM'$O/[_O]?3_? M3ZDD407N&&\8)3?KC^C5#/C4"9#A7.^$HA`0H(/AM5B[SFL.29]4CBFG%?0] MY:<*%'E@1TF^R$,Q&\@FLTB@PV0$7J5!ER5!TLGFU,+H01EDY>/R&1GEB$JZ M1-]'OB4?LOE\+H^U0T\9X;:R/>5+Q5/(F?JC(;H"+HB]+KDNN:ZY:`]RN8(. MG?SC<'-(/ZH#_5^.VRO/`^8B4KI%#UB!/*>#4BXG=G?'O.>Q&,BM!^WXY[$T M8-3O[Q`[02_5";C.&?&6"'XO`DTT1/B>"$1+P)+$0Q.M`6O2BIS(ZNJ8"1O) M'X5C,:-]I1XSO`&=BH$N,08&)V*S,3@4FX@=B=V(T6)L"#^9C=$"BO7$=D$Q M+XY]`4BQXI8;ZSS>1=)BH8#?G:\0JI06R&=8;/@&X,65=N'^@EK`]U2)[HH8 M`"B9B'(;N1>K$=\KYS*R^:TB%EOK>: MG"K">K$A&*JX28*K6*:M71;\+)-&,OJ#?>.^38,VVV\\&)TG#FW?"U9OS*P9 M3(3YC)4YMR'4?7UC+V*XUCZN]IUS!P[M=%OL#&,_]IQ,PV.3/WA@3>Z'^@JM M8G4(DX'$L^GY=@TI073,X;H.RMCB`@@*D?MAG*WO!-JN?6YNSGT^3R2 MUKU?]2X6YLW>T9@TN4TF';8!CSH3+WZ\4)Q?P(B'-U8&M]9MYH3Q']XQ^-MD MQ^!.$L*\WS/,^-&S'J@H]2DSG2:J6663Y^BIS:V%4>7+ M';WAY.1,)>%B`,UTV,L<]^MYE9_:F7;#6@FL^A"<[/Q55ZS3!I$]:W<7';53;^W9N?;:UEO/7@KYP[7HQ-@H M`:HM2S=1!;U)M5"OOT;12Q\87F^33OO=?B@>PT7QQW;$"B,KFA@6`,^-LY>8-$]%I19<)4%AVF`?D8#D?Z(AC:FQ9#= M>DOP-%+M*K"I3:=YR1D$L'G&0ED`CRBIX;RA2&'I(+2T6L9@('PC#/\_D9O8 M45*5S&5A&^Z%!*0Q5Q-(J[N(L$"%U#_B*F+D5G+6D'@)!WZF#L/W>3@4)"R' M3QA5VD],W_IP:V/?MT=WG!CF`&]'%J[`6=CVK]_<],A+(_W?V+X&4+=^M[./`H3;LC7U+[]*7L#*24>R9*?8D"UFA7Q_6(=_G[TOT(;TO?Z0T6X*E.\+M M3'W-!L^WOARA?/D7&B6ZY"ZUE)"CU+5J6A9E+'N?)72V:\9HZSR;Z$_L@G)9 M'H-:__K^N_V?&<`4_^WY@GG@INR+"QFB^?JJ([I_$NM^F9.)X,T9+)__H\0. M]]>:WK4L_.5AF$)?QJ^Z^K$[9'DY@T'7Y]H*\0!VP27NL:&U1VUTRY]4WNX]LO:/YID$LW@YB\V M-TC/#(W>V-&5B*X4QMHB)4%._!.U=DR:^1XG+7$+567?0$/!.> M(Q[:P[C(]/R-/OTI[5L:U#2\FJ94,*SN5N&4&Q1<`$GD6YS25$YS)0XO3A*R MFXZPLRP46<`^'PR%&IU/"$!PG':J;8'G&R4Q&HC":%1I:Z."[(PBBOZ`']K\ MTP:V;A%1<;S&*,50H(:4F#(&J?A('([$C\8A'DA]FRT_F+&$5UJZGE]DJE5L M(Q.ZJKB[%LDP*_%MII4JYBSQ1G-;R?@LH7K+]-1#2EI>6!(VDV)."N?1'+!/ M_S7R4M2R:7AV9+JA_;L7_O[)S-RYRX_MJ-W[R2OYY];U@BF8DH-""WIV9+SD MWUZIW0&>\6?&]UP$0NT_JLTF+.ZCRV0CK5_Z!#F8=W"/N6XX>QN:5^BB&E!A MDNF-XGI8((>LV@7=76@I0*H`6E`WEVZ77S!X[N?`H!!&BIC3K2.*D1B-P:3` MG.D#WM;S_N!%31$$RN?N;.EI.1OGW#-Q(XX)Y++-K9-'0VW6]`[\'GPO?C<. MX_'^\DC_T7YHGA$1N`D`BP7I_8)4D*KSA`((=Q87"0H0&JUZURW>K$K7R2(R M@1.8`[!ZK'5A*^8A6B-!ZV?@&?DB>=9#`+\V&^:R;^K600X:!CH&OB)8MZY^ M7/!PLP_Y!=;5_#C'#>SYVN5'<5OQN*%59>Q)3Y2S#7O]C-L>L$VM\L6R0S'F MS;T[G.GAQ/&G6?M^#H!7:_F`D[$BKI=#M)5<';;(-\&#KP*$NVM`6.F0\4IZ ML;LY;#_0XVN-XFXRN/@WNH+^A!FT2`W"G*'8-`>?5Z2F9MW3@"].UN/3F;FE MOQBK,58R#1Q&P3+8'!F+3$:N1JH1YF3X?XQ7#6P3YQF^[^Y\\?W8=W;N?/X) ML>/$3ASC.#XGE\0-SB6Q@Y.0I$/\E&2!4""%20TD+$AL12`V0UMM+5I!3""5 M"@NL5DJ*R@IADZ;1N;1JJQ;1EFV=M&JH0"66LDD(C:Z8?=]=$H*J;I4EO]_= M?7=GO^_[_+P@'5P=Q#\-`I.U0^YHWA'!'[1TI+H:+#WXJB1L->P5*`(_2S M%=7&V1F+H*921*CRUQZ-L64\'M=KXF_%]T1"=++6C+@CN2]Y*$DDO\1"0@AG M^!`(A5PKCA!E?,*;B":("B+QI>82/)6.0+-&,VIS-J`%-'^5&M!*'6H@X/#Y M.+"B>`C$1`Y9(6=3;=F'=J``V`^4$[X,$WS M5:J:)KM5[0"F89K#J?(8]/78X]B/<,>`8Q0?>!PL-C)SCM5PMJ@GW0)B@4\@ MW(<595B`"QCT46I^*X!'+;"3(5W`&]J0VX6#R,3')XU-AOL@.FW&$M; M7'_?O"3H\YK!(KI`&\>&30J;1*S"\+KPLRCJK()4`6JU;GJA8YH3`_T2:*CT M2T)<*44.JEH7"G2)'"Y>*/[[HW]5DZ,Q^?D:(NY<]N<[[Q>VM]ECFSB6/6RY MN76+7VWKKGW2>RQPK:F\N.75TU,GSZWPC?S>U_SW_./?.6@@%@GV*J5>^6EMM\C?%2TAJLXIO^>:S8O'^V:?+ M.(#CJ\>V[/PE8JVE#^Z1,]`-=&$SY]E6X.=+`8-:F.;%#%8)HB9(7.]J2VB+ MRM1(LIIV^/(N$R"63!$>:6E>BT[',.O,@WW:,LZJ6IO8HPD!DP79)Q.TG%.: MA&S0&\D%L2"H(\Q9+=EULCW3OA4/+@]""YL!VS,G,A]E/L^0PXMTO.!&Q1'N M7H(33>&&+N2*@FBJ[ZY[MJWUKJR@XWF6@C5:D.W&!H.NQ'F2>H2CD(-=+.#2 M_)@R-Z60,\S8BJX#C/W,^H;:$ER41UAFP]D%@BK!:T88YN);$L&O]_=4TAZBI9!$S@8$K^P,RTFTIR7DRMXM_:S[L M&>D_:KNR!@TN#&2HQ(,W\''3#,9B,4S!SFLLZ;0[,V;TA6IQ%D9\+LI0B<]' M8ZHY`J(*DN%(?=YB$?.V*5ZJR%=-!P7B&HUABJ#@^I=**$JMN]2?@I6/Y:IKX6SA]KKQ$.%V-VS-FN/N+7AX07GO7[I1F`NA^ZK95F$6R:\.(#1'B,8L"+/J*'TD];`PB\P3)=GF"F0"-P?;M,&AMN30 M\XM3S9LKN5[DDB2+48?B%Z8R;6A(ZQ@<_/K4HNP>>?&M*M&$$TPS:^NPG-M3 MO-AME.`%^/\2L+,_A)W=`S[0PFM-3YGP;>QN]CF6&/6`8UW@*+5!Z'1; MG7EIJE2JRFO5TR%,0>_)L!:50M.)29$4_$WE;04W*8`F%5'!"PJHI1(4?IP" MEREPC0(*U4'AQ"[J`(7S%!#(:%V:ZNE44D1=(H'$H+I6U:,S8$3!ID?-PUG4 M1**N)R#GRG5[3Q-"CJZMRY9K/6B?5511U'B:56'6:HF>%>6]Y;`C8$/HD\R\ ME2C$OS`0:M!J&-&OW`(MMM!JS#;CXY`WQ^%R(KP`W+L0M7+<%D?>PR:WP(T' MS75A:^_*)_9X?K).*!RTUCG#YCU"`3.(&`SKS+O`S.AQPQ,36KKWX0DF2&8$AR=':/H_C:]\)]\<(/&I\9\\K0XK)C[&=X/0%>/!/C>7L&8P7>+R4Y"&)G86'/2A",AM%$%@.)>;N*/CY""B, M?#*"3W)9[A3W)D?>XO[#X;ND`])IB=@1V13H4$UVZ=UKO$*@@0C^>#&6=_"38,+EW\O7)VY.D;_+R)#Z\:`;2X097KK?# MSAO(#_7=05"X<\DMW"]`\(WKS@B-5/#"-[`Q&*;@XO4E'8'7!ZDFQZ5WP+8DVZD=$-_[S6?FO/HXQ? M@I36(<_K;8FNT>@FZC:3./S3!JM`L_V=O9M)G*8D^P#+[7[FV!C+M#GM9@K@ M-FMU9/5E3;10)C/3"L^SCW&4B727_A!T[J@/NN36,G_B M+]KH-IO$`]CDU"*->;?\H<:<..3H7?^2_(ODOD9WL%[8CR2<7?!1L-_;L3]> MP"J,OM:-E!4:*;X)^"G=/S4A-^6!K:[E36"*(%P0VN5YSY1+"N>UNNEZW4NU M0R_UI!505H4]VE@O8)(@^22"EG**D/TOX54?W+1UP-][DK\D*Y:MR':L.%9" M;`).;$NVE3AV8N$D%^>2+EDAA`Y"LFL3")])**PM-\I1:`?\P=I="C1;V<;6 MM%MA.^CN^-C7'VE8V]V5V[&4;;?!K1Q_T&7+2H]KU^+L/8M1=H5-B9^DYRAW M>K_W^ZKVUQZO!M5&GDHM^WZF);,>5>>J<9YJ@5M;CK6\VW*EY4%YRHA3LUB) M\58!>*<8PCP[AXOAKHWBR'JHX01H@`-EB^ML6<<.#QSV[/`@\YX3?<<+5SIW.@TYJT@G?X.#CW#7N M(XX:YF"I';YAA[0=#N'15FU#T[9+-O2I#8[8(-5DA6;6!-.F3M.DZ5,339NJ M<3@QP6$$WT%_0H@Z@7Z!D-E'\EW2/4&[)=<$RU_U08?XV\T(HP_Z43.5-0(<#/98G0;*-:$$Y>;>HUR MTI5_?WSB^C]O;#L"L^O5P@>;1R]<.1@J_0V<+[S\]2;(?`S[QAO^O.'#3]XK M'"W$C_84#M%Y@$#T]E5Z+V9.$\XUMO8TL;-5ETXX%UX4&2&]N\O#O_<`:B M'>89\ZR9LIC7F1'K%Z9\[A->";6Z6JM:J=:VG+W]"',M,J68V34N4)NQM^T)1Z7BH>:^.>1^@0!=>^E`G*31= M/5WS7=2]51:O/G9C4F2(6F.I-OC7'R_*\5P<9Z9^$HA4''@&C)X)PX2"6)[# M=YHHUOA2DEO(#ZZ6SONV&Y)R#%O_W-@U@Y*F1%&LG20":?3>6CGAR>8>3:_N MZV/-(C_*,L^]OFL7PPPY&$33N#J:*4>5O8MA?C7MMK4,*\,??V5)86%;4V[G MEU=O/EY?CEIWCCZ<*HLF.Q?+A?T1A]5$6YEFQDIDE>)LC-"=Z9]$;_&7?!W_LJADJ\(.O]0*,^R:,^VGJ+1`%C>"SLT#`6EF#H1>\O$MC M$U(";4S`E*?#@S@!VA#C8E2&BM*Q&`::PSB=YEW%L[X=0QV+$;R57F6[LD^A MK9&BN$I3I5FJI.4?94 M+"G+IH`80'P@$++$N'V5X'@HN5?4'2)&.90)K4=B6AQ&Y!,.@V4<8\R8,4( M8G'%DW=:$T8>.@GI\%U4/[II36K9P6^O MK^.M)A-M>6=T6!+>]#3 MM]*]+O'4UF<+N;^L7,]9,5?0-?C;;8431[\Z@AU.7?B$DC!/X^#R6>#'B:X6 M6UP)'XUK6Y,_2:)`$F:3W$Z*X>&KIR=I(ENZF$6TF>2C-<'GS MRVHM3P&:QJXI`R2#&!@$HV`>F,A]#[[<#2Z"JWC":@<@Z4@.)%%)I,Y)G@^Y MQ+R3W2?K2\J.C\J[901D7H[)@_*OY8ORO&P)4')"-OH*XX)NVO9@?YO.#]:07+%Z MX1+53OT.)-&LWCRBP",*?%/]O8K^&O\PCJ@XK(]?B*._>3_S(M8+Z\7#(@)! MR#J"L`5_',%#P6-!RDD%@V&5)4O8Z/9I@^QN]B)+`9;'%Q3%LCS>XI.>\QX4 M]60]R.'!=%-A*>T1Q>=4!5=;1?3P`84$:XYKQ'UU7G^%7/`EO*:0X9(*@RHD MU36I#JFT7X6U*F35M-JI3JKT.16>5=]2_Z!2KZG0K+@5Y%=@K0)9):UT*I/* MCY7SBAF[F!)0NI4!9:MBDDVJ$N8G*'=X(L"+'D%2%1"Q3^EFFQ31;27:TY%# MD6,1*J('JO*1ZQ(OP:O2O(063^G5CJI`53<.[;2#J@(">6,[?@`(O"`+E+LX M$<9/#0CP7>&*\`^!$N;T00`=(`"R@/)3H!ZKN:1)PTBO[ZE'8_>P?!R+.:8K MB>5>_A*>F"U.\'-A8V8&WV+>I\@'6VP6&V[*J*[]AK<6W970'Y`_(7WWH3#I MNT4EP-\[<9#'IEO\VMC!AD08QY@2^REJ6;-*+S,[X0\0W).$^WV0J_/7(0\= MK<'A9@F.FZ?QV7]FX;)NN<#WF0A87/%#RHY)S)6^7T!OA3HBL$`H0O@]O0E1\Y3%\%!=M+#Q& MWG*L&";"AL?AXQ$(2XG>+=:R*$[T+:YJ=TA6E$`L?Q[,R45&XS`;=JJ&?MC0.[+EY]_=8&/-;(JEF>P37WJL-[3E56T% M;/S>FQG'FO@NEATMW;PRO[J"$Q?5M>Y[?M4:C:\[QS#YNIZNYN7E=G=EN`6S M+K+P/GK)5`T4\-Y90.-EK5BD261U`N4!;;L$*+L')L4VDG6.;VK#/8XFJ9'$A*2.MACNR1[*GLS7;(=(H3@[>\F&N(-*;K&5%KW*9"(4J#M[.^F>N3!.^)V#!H@&1LCB=P8?/Y]B@N<:W)X>KKN+GAHF->T'#I MB=,0=H"'V/K.IK;,ZSB_"`#5M3>*G"/>K'$+RD,^*\V'USTAVH2K%OJ17*.Q MBXL46I3%T9;\LL^^@+Q/MGK\SM&AE9Y8D[I]U1@K;A8J8\<"33DWA:@D)O>S MF-R[J1ZJEZJ80=.#724>(LDI#IH8V?34Z;8$3DV4#`HT3UR?YT4CB7]A]!)* M?BEIXLR4Y!./G03,&'(EWI)NM?M.%@*_-GJ"BMP;[)WH17QOK[.GIZONF#,4 MW>VD<$QKBZS8.A=9DLK'F() MO:N_:RUT]CDQZ?6##?U'^J_TW^A_*&H16>-,=7O*-W,+E_G2Y$:,W3-3RNTY M\J9*4T5B-[@Y_#-SUY[-X@Q6FKN5VINX'[V8*,Y>U?O!K^`;MG/?FPC-?=.1 MYB"!,(+EK'"@(?QJB.-RKSXZL.>PA9A1#>LPI2TH+>PL("CS>$\4?W_))5D9 MFV>1.'.1%FB:^_9`PP[OFWOMZ[,[IT(/3.G$#__P6J;8E#:1$(`E@JK!7@ M;1Z\#IO;D&LLK]S"'F"X:68MB7,B%) M0-&H2JF*"E7R6*.\M4_.!#,PA#(F7F=RF>>@FE6?A4HNE(,KU#B(!;`Q)#OL",8CJHIJ[,,%X MTN41S#'X#]I:R]566B;`PC`L8MAHO`'.*8%H`Y,+@]NETZT1E>0>[%N>%AYQ MVA+Y">'QTX7YPP/AN#LFBBM.'_J.*`ZD7GY4-8V5C0M%<7!X9+&`AD6+R/6] M4NGV3/SL.&!_]Y2-`Z(A("1TBM"F^BL7QU(']M])N"2\0[8I_)Z],Q];RO@] M%Z@.R@!?FF'9#90GU)7J#G6?:J&2KU%UDZ"!O>&O'3K(T;75X MB,;UC@Z.BH#/(R`22]R\D.[2'9%K1!FXW(RN:G_(H?^K^27"%8P)(K MD+-"L?`<]'?ZL>2*H2)<6=Q0_#_)*=>P[?J\ET#[ M@$%62<*_6(Y37^FQ-(-_,E65;/GKHL0SRQ6YHJT(B"BKFL1#3<]@KJ$!_+^` MQ2S-0B)0XC4XI!(-YD'\89U&JJ[NS#O:<]&Y78`L97Z^1S)V+?GY@B6+-P]T MVQV^W++AI8V5B_YTMR":YTX-"\)&00G_:.D/-@FBL7?AD%CY\!,TS,?=WZ_\ M[7IEXX6%_='>G?3`Y6?00'\4"$6BSZ+0Z/"U+*^\\A&FH?K:WG^MECZ22.=C MUIZ@EU!V*DI=,W>=<@(/&`4P"1=`_%D.X0H:/$^#;@8L9_Q6_I#8*W@F!->$L8A@Y:O.Z#-M9G)EOZ?'LY![E[#:]E1]`!>>38 M:U(Q:CODZKF7X=QM8^PD]XTYM$J=),O4FD-M'!F9FZD1H-0LWZ[O2;8DG*ZVH?T!&5ZKO/C. ME?<.@!7`<7C_HL='?SPS#?;\.G/HC7;NL1C MMSHMT,5G7EME963,MF#(96$10C9!K7];PCF/%W'FL[`"%TB#P?^\\*L%&:W4 MRG;T<`MWR9V;4N]7ME:^&]1H@1-(%?79?Z$I>HAJH:Z:N]@`X)MX<"H*>B)K M(ELB"%%6TPJMLA6$&3XDRH;,!WDH6EH:?V(B=HSVN.UVK"3=;H:CNOVP6<)]XSH4Z.6L=)8]I)I],T*;(JHB6F\%Z9B439]24V-,MN3%\V M8SM41K((0T_A41?KFAH?.GCDPPN.-U33.1$ M#E+?))GX(\Z55!5XAXD-_9?A]LEZ5"XHTBME4@W5TH0AXBSIBZ*'HJNA@%%\,_BZ(MJI[5$2[_6YTA!_F4;.E'FYO$XL4A"*H&J'Y M:#?Z$<(?PJ>`4,*;R$]@-B$KOE@6Q++JLJ9)#,TJ9:^XP(656!$4_4G[4D." MIFE(.UC*-$>A.]H?17Y9SBT\9H27$*7GCC&)W`DAKL7)Q,0%P@LI@A&C,P_P M@I52QQ/B^#63A-'8*"E\W60OF8VZR^9Y<[3(*,'JZWC/8O'![ MRG#YQ:6KGG^J]:4*R<>[DUR!P#Q_X6=='7]XLFT=7/EDZK/4>]O=@G/RM5T# M"QJ\F0L?&5BY[/'&O+EYK"/SG04-:Y6[DZ47+K(E8.WT'3SB7$H:^9<1? MH]ZAD,3#ISQ(Z#&T#6$?P`4`1A:D%@E)E"B*A#;%KXS\X/$0[;;LH-M30]97 MC!(VLZ;5O8&H+>78RQD?<%U@:04Z!Q' M^8\9@9SC"D49U!H*2]B*\/MV.=;FL1Z>*%$,KU`6E1=FB#"A#BE/`2J&2 MQL4.:K(]-633"@MS5`N:DO1H$,JVA\E;/4-?5I:P5-BLLVC=`HDR`6'$I!D* MB*"&"](>D`F'+8B(?(92$I[XVP]W-XME>E4=!T-5@4YF\M0*R>/+YN?R-)TY M\05$^GG'5U.KILY-7?LM[W3ZT#!ET_!"/^"T;MK[,\TZ6N+F%TY_@ M$>=J*D"XO!9]]XP6RBO4:ZT2SBM+ZKVU4%()=RJANQ*<<7!?+0.N#,3A'.#\ M<-W_;S]ZPWO8BQ@O7!6^$1`F9'60$/@T@RD'9#L#EON:%=$#5J9[5\O3/:'" M6?K%6G#6P%C-[1JTK`RVE@!7H!9$"S"C25I*PXV!U@"Z%@`Z%P1:A;I_JK!> MZ5/.*!<4AT\!6MF@;%7P805:%5@@@5\Z+)V5,"V!+K5*2"?NT*-X(AY\T0,O M"^#B`0M\C*_C._D!WOD^#T?X,1Y=XF$+.\"B,?8VB[(1.-!IA`2D@NY0K3_[ MD<=3X\H@*N90YZNGU?/J%^HW*LVM5Z%(_8Z*=-5B!2SFAG+1D#:A(3T)&Y,[ MDVBY&U)N&*R!>:5=I:B2W+Q;Q8WJ-15M(+<@AWL=:+ M(V]&0(H`$Y$BYR(XDXNH$4('D:8(BE3G1:BBI%LM=>15[Z>5O/W93)'AE9N* M_B&(FA@3L2)6?$@L(>Q.D:]I-6E/+Y#H2B63+"..=Q#W9_D-T^RE+.+H)=N]=\-L19Q< MG38?G::=>7KL\_8E'6::;7K3;&/9T=[.M&OI,,GY7K.7.%*P9<"BH:I*0C3V MM65U48^0U23.]GGEN^)F=?P>)]7<_`NWVKC]6I1Q<]\V:G5MOSF[%- ML=:ENT_UU*YH@;&UVV97/KQH;E[(Y9<63P[_X*%XF-_\T\[:W8.6&B^9"R=(M"+*JB[)9"&(T7(]HU@N1N?RX+$\8((K@NA6$%8&X4P`AE78 M*[TEC4CXJ!^*_3#B@U4"?.B&'0[XR''=@39B.("A%<$*!*_Z88Z0T<_;I&#I6_WQ8H-^75/PZ(7EZ^^_.@^ MW%@ZM9[YS9MJ0_S3Y6\^U*NKQ9I$J2C21AI="FQ]9 M4AC^5?.K4[\$!TA^,3_?G#KZ>)W5J?8[XT/DG25JE9$O*(1"@:5/4(+KA->>.?<>W:@C\:YX_2Y)%R4-2I*%QFG'V(B-`U)Y*N^XJ*B(G8+,3*E/S1%B M08G?7UJ]H>J:<-J&+5D_W$?Y-/OSSV@.!5=G M>5<]\7'TXEO1T]&CSWA"9@Z4*>;%9C$0*5Y$E*/0VPK-=K0[7G`HI0Y:J"W6 MQ*Z$4PG&]N@*`EZ>0"+H"3(L.R5 M3\M+4O5Q-2I/&Z(LM$(K+XHUN[%)LXLE@X'B9"0D>@2?&!;H_H02D<-![:U-:N+J&U*\ZH\NBH_LN7#X^5X0\CU(]51TB_XEM#1P@4*94 MT15U&!JV1T*D901UTCA7(RV0K*L^EKXD.L4QS1ER[G#N=\I&29+L?6[%83BY9">'_/P-T)7G1G:D;_>O/Z8^%3W[(*=A;K)WSQH#\*%!X#BAJ`.;_!N@<\DL'@;)?3.[9"Y2W`17UG'U\ M"U3M`:JW`[4Z\,`Q8.DLH([U'V2=%2W7637=QN:_0SW[]^IW@,8X8,TGDWF( MXV,3Q\-FS<;F#MC&7`5:#M\ M42"AP@$G.%]#'-Q\CX<'7OB0`#\"_-Y)2$:*I3_SAE?8C1P!R]C$*]@ MB/OV8A]>PWZ\CCC%HNQ&FO1A<>Q%4/!&>/CK!W$'$LKC%+6JL0B+&6M5CPRH242Z`R- MT3B=I!R^3HQ_85X\/E_4^^/YFW8^Y1\U-'18HRE(PX1;2Y;3+-G!4IGA_=+% M/66HMV3!?C9@R0KW#UNR9/D;2W:@C.*6URRIJZS,7=':W=K?M;FGCNG?VMN> M5]73W7:[OV$Y:K`$=6R_2N1B!=NOF^EG:V]&#_>;=3_;M!?M;/$J;G6C#2NY M]3`>BVEON>U1_NWG>"74,$[R5WT$KMBZI/,XN'7`/:AW<=$U$R3\'`-C$"FT*96YD7!E("]&;VYT1&5S8W)I<'1OC,GL&;5FV&+I;IP"K.'_!.ZVQCK;, M/V7`2#6@?-JVJWV/=9L61,JDO>T;C6TG=U?OXMI1 M0"O1/J2V0>M$&;9H3_`*1R]*>#V#?%LN0R=@7;).V=PF6Q"(S9R)1,1>\UF_);M>KR-O^%W.*7D80_.X#WTXA/ZK2(K.&*K M/"[(P"+.7:P\IACJLQSSXA?V<\K^WN:W%R&$,0^[^05>LJW?PVMX"F5JV.X= MQ#)KP)8Z93WD1Q6,3;<^4DS&VZ/,PC-<_S".X+O*!&4\?H08(UB%O9B/V8S\ M58[Z#CIP#;]4Z]"NOHIZM.`SG%8/8$C9SUEUU.!KV&Y=9OVKL1]3K&LHLOX. M5%94+UNZ9-'"1Q?,GS>W?,[L6;Z9,\H>>;C4JS]44CS5,V5RT:2)A07Y>;GN M+TT8/RXG.RLSPZ4Y':J"68HH\H<#S6*R/RJ"1I7AUD5PWC\5%65W8:[C/ M>X;M$;J(*?ZPU^L1:BE_:VCB[_&8'A?N$/5>3T*S1B`4EO1;ERNH=%=X(QZ! MNK`H8;??NLE^)'*7"-_B33`P*L9UBNGN"T[V5PD4]"%X6:!0#KI9`8'EHLS' M,-R4.%610+E0"FX))5\HA6L9\*CYI=='%6-W'X@W&X'X#F8Q'AW)X\U$%KVZ MJ9MUX=P%%.UH^W*R_8:_,7OV+/1EYU#,H42OMCXE^)AB"VHPL+1/1>9XYBI/ M1A>0-(O*[B@%HXI)HB5_Q-)O#?2DFT"WE)2?D!3A\HL,>UU]AZB,"73K?;,& MS)Y^-QJBOG%Q(Q[;$A:.&&/L@Z,TT+113*T)U5/%14BT29=5K;(OLD9ZH$DW MV9=CH[P:5;*VH_3QIL:H/`U*U*BB+AQDH MVJ'+KFD>TL6)VG"ZU2NO+'410S<#!E?C9('F+\MZE:?J8Y^Y-7%9B)@NNAJ: M$\%H^D'FBN MDDA''G!LHG=].-!D!)C+[L2"W#0%1^E87Z]73/9)1],,R/AB<4:>B)>&D>#E ML??X%,;C%Y4;[08;[?QSQ02,8-ENCPCV1(0[VJ0L9>7D(0K6R90' M]:98XAY?:7BY2&XD90[]+S-X='F`>:N8[AO,WC@^03QZ4,8LGP3RZ2!O+JZ^ M*-1(0E(]#BEE^_A\62XF^2BKI7+[?(29;D/_P!!NG]#\X0'/ M\HCNSN7S1Y9N@U%36Q^N2)8_T=,#YO"!2&B$ZD^,^8)V>.PH2V(^\,]4^\O@ M:;4W^_30P&!_]F[DPL'_\Y$WBKG:4%KOK/6VMADSM*=PR+4$,YP?DW;K7Y1? M=BVU+CN*H?!]8+]V%@IMZS,.6W]T+;&&7+TX1K^)=GL63F<[MM+>0;\?4_\" MWU".<.[/J&MG7[77>0`X_T&)C&8N'3N/H]DB\VKG]F2B3>7Y09!U2$?6(QV[-DF<)Q!@ M_(-:!+/9+^;:M[&,_>=DC)1-[FD.98,T M\@Q=I6^`>5Q,O\5LX]0O)$LX;B'GN$EYNI/O\/8Z#X#V"=9(9#QC28V1,=X/ M._ZQ<#\C>[HG\U)[MHG#D'NG[DZR/9]H49+,Q3":'_M&\G-/IDM<2]%HY\_& MND1Z[5R.I1@E,K^TWV1;DU[C"R-BE.6*\XE\G86==V-#C;AVYG M7L56[3J4[-,XEEF-CHQC"&7L0,C5RGI\;+DDFFZY,XZ3N.76.MC^DRRW7%EG M;)TKZRK;1]B>I#V3X^?89\JM%9,R,HEVDQRU\K2GV:ZP\NF72Q]WQ@M8[)J" MQ=I1M+MBB#/GF387$6/;H+Z'E]45:%'?)VO(3.NR^B'FT]ZFG$%,>0NJ^JXM M'W4NID_"KT5]$S/5,VR=V$R_!K:=M.VE[U[G`K8?8*=ZG>T/L,_Q/!H<%Q/S M,T]A4LOS9+$M)#DD+Z'#BV0)J9#C''[>Z\EQCBMPI,8YZC`M;=PRTD@*./:G MY,]D@/W5))\L9G](/8)OD1X2(DVD@C23KY-72)QL)2M('9E(YJA';-^Y9!YI M(#.)H;[$\4F407R?;*(\,P7[]<2C[,9.LIH^K:0CHQB'^(PY[ER)'M>>83K) M&Z0[V78FY6>3_>?3[%)^E_NZ]'^BCR%T%UTZ#Y%ISKAU1=9`^SDF.&[#K1VQ M[KB._I?W<@^*ZKKC^._.$CE$[4DW^J+7! MCK%&ZGCZ/7=W":%63:=V9S[[.^=WSCWGGG-_]_R^E]RHUVC]XGWF+TJ3^`RT M1=QEK*00J7(>'97/T28\HPM!*#O$`;`;#OVNP/]Q;GVKKR=7T/\;@::LI4VPV>@?!#OTPG8 MQ;#0!>89ERU-I9\(<*V8_J7:0KA53`/6W09$XOS#O>>TH):D#-%9@N453PN/*U52F]-).Z8_(&0#E M;MC96`=)/OY/S#F.+;[]GD*L&R0(*Z?3'%PK"2*(19E]@_M$9OE(L,X6!7UF M^57\'0EJ'.DP4["&]T$#V`;*0_5?HBV9Z'8/RC$H+X0='^I7@'&^@J\=3$3] M<(C=H?'.P[I"URK!?O13\!Z8`J[`EP:[>LBX_UJ!O#36LQQ MP"KF.,';U6OTB*4Z-&]02[ZL>'G_U_J+ORCTC^K!O?P):W\?FN<)@+DLY['> M1?SBH#9XD;;(5ZA">AW/+H2BT[/#\[[Z&>8.83G+;X>1Q_&_"OXM1RY`W@OS M!A!Q/Y.?4[_@YY1WD`O?&E^R_>G3OU5VMIM5K+ M+ZF7::DV!WOV"\1^-[^LG:1"^(Z"\=HI*M=.\4N6N51NV<,O18S!63.%7X_X M+LT!ZX#7.H?&@R+K6:+(6;0X\G%^&79VY'QJB7R(>QKUH__[NP ME@O\'Q%/TU.6-RD=S`8=H-4:01G62#"`=;U$3UE/TSCP-&@!K<$Q@GW4>8B- M(_RL:D,,>7"&OXEZ`VA"_.BT3\JF6>9[\"M\"[7R7RLM*#],"T5,J2-1WLQ[ ME4ST;P6=X"U*U;JI0M3%G/\/Q%KNA5CG@T3L MW[>'?P'+P,0A_L+[^'ZH,)^'`,_A?X5X9@\2Y)Q%FHSW=#'FPSD(3?)9$#-_ M(O>RR;!-J(OOJV:11V$O!BW+#_'CT/>7R,5"]PC-(5\=-,]]HKE$?"PH`V=`*F3$>"6%GY9_3^GR)6BA37X)N#\24QS_V@/LE?%XC[&8ZXOS#F?=X#I0%U#!6+OAF+NXW"PKP)\1YI6GDMI8I_O!_$AYT1N$IKD05F1FX4>^&^MR$E",X3M8.P_*!MZI[ZM MQ?W6PXX=;G%&?+^;$?/SW[H\\]3%Y$]O#I!$LA4U@^4QA&:R(D97) M%#=C9D.6ZPEP(76TL^X"<_7%QCM=?=$Q^+..<%[H2TQ*C^WM[)7:>IFKUPKW M)PF)^(LU^TF#.9J3$IU'A=-MCAG M8U/*QZ?1_=EU^%N]!G^NFKEU$M7$UF363*]1:NK@FE[+JFL3TVRUCMK,ZI)J MI:TV4"U5US8_DYKMR?1*-@]Y'9Y8K]+B;??V>.7IGAQOB7>-5R&/:"_S*&W> M3F^?]ZI':?$8GAY/P*-XO`GV])6K\)==F>F6;)7D=E3&NI46=[N[QRV3N\1= MYE[C5GK<`;?DJ,QV3W<;;J72C0M:JMHK>BIDJBJI*JM:4Z'T55RMD`RX`A5R M155"VHJJNJK.*A1]:U-3ZA.?+TS)>@ZX=K+?,(UIE$D.[+3FBLYT\/5C'+$# M)0,M`S*VYXV!I&2G::/MYG:-'X/CR>I;C^D=VQTOX!-WLR(VQV&6#T?$60\HYP.8=8EF')AV:<4ANV\_V[R*]`^P$.T#; M+K;K%=+W@3U[2=\+NQN4_(QMWZ3HV[8J^E:?HF_>H.CKUTOZ^F99?Z%9U9M] MLGX<_E8?Z9M@-_J8O@%VA:_.U^S#%9_Z_N*[Z9/W^X[Y3O@^\"E.WY.^4I\< M[4OSZ3[9]A@S`CV!JP$Y-N`*M`3D_M$L;8H].=]NGVR/>]ANR[-'Y=JMD^Q: MCEW.MM/W[!F.F$R'+:DP.6LD2``JL,6.C(J*CHFR1HZ(TBP149JMZ6,0V&:WY#5V1FJS^6%C5T2:S`D-.SLI@15TS%"PN,>`:[ MH,"0"I<8>7JQ\=A\(Q?&6K)L21=C+Y>F":^?M0]SE\)M2*U^1@L-I=4OP<05 M+EVVQ,]21+LOK4ME:#2*RWS;MY?JHXSRX@5+C)91I4:N*+2/*B4]]*OWU'L& MB_H=?QZ/IY[5X_?-]OK@&*;3$VKV#'81!0_3=>-??%=K;!37%;YWWN-9KW?V M-;M>>[TO>V=GL&>]CUGO^K%C&S`8C(EY&K(-,>^0("!0A32T1(:X*BIJ4T%4 M\0-2("$*M*:$-%254"44T8?52#R:5D'B1U!5M1:1@B)!ZZ7GSD+:_*F\<\Z] M<\^YML_W?>?>#4SK\!]"N`X1>VVS;Y]N>S*`++)2V_'K_9[\+2_K%\6,798! M8I9,-RQ?/]T8A\EUF)@P<<0'H#0ZQ&3&IEF8D"I>'UM[!7$,&KC(HX$KJ(Z, M)#00PA<1\KLN+D2[+J*%?=/6`C3=OV!:TJ?K(%&*#Z!R.:"[>O"WC:Y`I;); MYQS3'*SP\8%QN*G0"%7OLU7X#DDC'NW$)4LZLO[$>FK5\C5+K:5$FAZO:?OZ M!MM;0$1SZ=)^?FMETX9-Y(57=)B;/!LL78X+2=9R,$;I]/S4IWB M\2C]_5IO.)1(J)I93*>U>8JJ,EKOO'F\IO%PB]K%XP6+MKLL%R3^2G2;KD7C MUCC91/($S?'Q,4'0(R,.[=[C#L?ZRC@ MNN8N&CJ2W<6`(9-18\`U(I!@P3,0%C-W+GV7PMIKMLS)!G7 MLN2BZYJ.`\3`>M'>&R"R5V_.=*9Q!4?E*"U'9=Q6,`MFWA6/<3ZOXO=Y>4[Q M@HO'DFWY7,%,4O$8S=46XK%\SLR;M85\+MD&2;4X>&`7/V_O0=;@73;C\W(^ M2*4AE:T^HMCJND*V+9^CJ?7[A0S]W].$>ZG=8[>G9MQB+ MKPZOFYYY?NVA_;$I%E;ZCQX>Q;^ISA\]?+1?"<>:Q'S]\/Y#:Y^?F5ZW MJ)Q/4NSAML%>MI7"3<[UB[8)=:W)=O=@%R2O M($A1B9/:)"J1$:2\(&1?WREDA!TH(^3L4#HDOQ/PGO?3=.H=-.]\AQN5O^J9 MZ[&-K!0)8H:>K8[GX,/3`(^_A>)Y``YC@>=$L75EM%&MY.K#QK.\('[_@^%' M\'*/T^43ZELF0YJV#8+VWCJ#?U*=XX6,B"G:;_V-\N+V?K??0;."*?*\4!`8 MAG5[(J?GQ/=3D4:*A4B>O?GP'P@QZ)G'5QF5<:(DRJ(9$Z MR?02(V6P\M'C/UX*1DL.XL-/O#MH>VNHWEG*Y8+YO#.?%W.YCN:FL)J$FRH^ M'0LW:V(K*SG5F)96)5$5P['8E*AZ15$-JS'1%-4\7)?$@CBU3^@@$NP5);-C M4K9D*Z*;HS(^*6/9E+=@4\S!'K!7N*G9I1VW@JX3-*:M!MFD+J#W6L^Q_O1; M3C\JSY;G'LSJ%10H-X[,EFUER44`"@<,Z%9$7R.SM1DH+TN`"XP0Z%R\D\`' M"7:*VX91(8-B3;]/4"20ZT2?NEYI50"V>`RD9!8HYLF@C\YF_$I!J:$)\&*B M0HH,33>-&;>?N3S5'FF-Y,]5'ZSJ&.S*-@[]%D8^1`]Z=L1W?>G30&CV?"#6:@>Z3U9]_H"97 M4ZO:7ZNNW+KDWSB#-_[K(ASAR^'[XB'Z8]2.)B_3FJ^Y!(WP[J5`]/CTMYD[4K/0K&@Z1D@!+N\4'&H4&5WUIC-$B5`\3K34+"G=8+Z]-'`_VQ& M48#O?#SYM$F1^H`4S`*M*?3[GTTL.UA(E;M'-R\V5W=NV$LWZ+R4Y06\>F)H MK#`XMJC[Q]^[ISF^,['DT/"ZWQ\;+O493;Y.*7&Y2Q3-=M&W)+^M^O>7UNW, MKT2(`G[?8G:R?P9V#^#(%90"PF9#S26*C;$4Q0$TDK4_?"5,1UR>8"GBTX[6`[_S#"0GG.8O6J8%!`"PH2D>0@*FU&.I=7V=BV7RX=#1BC)#7$4 MYW!,A0QO*&1PAB,T&#+R*(1#\T-`[VZ2V07T[IY,6`E"[\1@8@L>#.7@=X0: M%/0N[$>SR#QNZ2X?8;;W@OQ>PSG%W_M6M,;LKV;U)\0NNXNS-9[:9/X_Q*X0 M9@L]0H_^-%Y_@1Q&:ZS:E*Y!JMRB%YFB*K]%7^9KDL,`A>^0F)%?L M8Z3-\Q2_;`8Z&_6AP-5]>C6XJ'E57QWK"^YU^.A?OYR,)]L\+7NJUS9VS[?6 ME&^\T-/U3,09ZG,OWCBR>'U7:VS;B2T>MD?4Q="@OWI]JKJ^^H>1I#NV"B?K M?]A=:NLZ-C+UU^KM%RNOP=6R](.D[T:E+12@YN;B^2^K#R:&EL_<>PXZ61G. M@0ITLC#T,A6ET-DKJ![HOM$7+=$11W.)(495G:D4FTK%5+7%%PN#!A2,8]^U MGI/QG^3[\F.9;I$C_Z?(VM MQYRNQJ=R`#7,?E,.]L`>90TBB&+Q?WL)U/R;ZG";"6@><"HSI/A$$&:AU21E MAAIC3/,*/?V7%8L/%E87G M*<>!2M^^_A?QV)DSXRNVG-T=7-P[,=22M.YV_'9E.G\!+[.[1!24X0=E].() M2UG('D]3#&XH&V6:2W"M5)$Y(E/L1X^_N!2.EQCB@?[$6Z/0[TO_8;S<8MNV M[C#.PZ.+)4L4=11W;GVN[;2Y M5)!,UF7%(\N*E9OE@(T%2E(>8KG4='L>G.>PL";]2%D2%A8Q.86T!?PDQ-N+=E=7EGJ' MM-0^E`B$B)X"3-Z(R9Q077VZP!)8DF28.5D^!M8]M"FH#8?G+UY['NSK[6;EWQT>?6E;?Z?5?9V\_N[>;I>_@P18A02B(WWK3Z9] M\&-B,ZE>(F+(_?Q,/HC+AX@&IJ"INZT*+6LMF\CAX'",=$P!9[*@NQ\BK+;H&/>.#(^MKY<(<9` M,EY,E0IR3A0P20(F2<`D,?B4P:<,/A7B(TS(&*B QRLAZ,$Z(0KC,!,:2 MJ52]4/04"L4P;C:0Z9:Q^[Z%!L-5$"Z7ZY6JIU*IBD8P;)PS7C3"P-A8'1@] M`!B3Q=DB2!7"U=DJ*%<"QC%0*Q1SM4HU5P/&7$5#BUEW.;"]F':,^V910JXY,3DU)DC^!6@Z7;EYF1#$N_-C'N]AV&&D3`&OQ^/=W#'&Q]_#KCN*+OOP6LW@7-5LOQ\8]/Z MR!94B0Y-*+'N'_[H_&.=Q=:L%?Z#-8U&!4BD+'D#PT'("QN`@3?((/\6IB MGK=9+;!]WN#SYGV8>1]FWH>9]S$%F<^P!D4@\P:OP5P0"9;@29;GZW(&>6=F MV#!GN&B`WGR^3AH\)&E@,[,9P,M>0YX:5Y*X5JZ>8.;F>W MGYM"P"C''UWE[XOV3X'Q_5]+9R-,(/$P`N7U4[DD.XPR1_&)795>TU,Q9@-X M!%"QR/U`L*?VE]VKY3>O_1&(VY3W+C\YZXG=AWAX>MUJ8?2_@*IT\4?.O7-U MR(J[J5VHFVI'&80F.((GPL3!G[7SE$O%\5$;M-E5"7YJ(*,FQ40Z^':[RO/& M<-@>#CMYGG&&7C;2GI,1D2(W0`O9"M2X$.KAMW` MR_6E3(%RG.2^'29(/5WTX3PQ1.IR)`'<53P##,=?^.F!GW]P]-#WU']N&2M, MWIO9O:[ZK1K8\1D(3`+FW?J%"R\UKKRP:^NIVJ$#I=<;>V;V/-Y8)'>A]$#> M^N3F^P897B-ZB-7$OR\1-O0#RY0K?XH#C'^:)#DVP@F@1X;$?+S-F!*MFIO- M6S7*D;=2\%DA#/ M.?I!/UH%5X^+=*UQ[36@B]-$25#:C/%4=N`L13]+`K#4LYA:,-+ZM,'L::89 MRA`^N.1/%IMQN7\%2;1XK:2\XGUFG).;E1UGM6;KIWL>T(%L.AXNZ*C]#*MCPVM9H,29N>N8?M5B6 MWYE-_6%VZ^JLOVB%@5]2W@?D8^W09;/UCE*`VK$]O:Y[N66W7R\I/(G_IN78=5>)5($A]ICY-T,";%X+0-M%O:H'4>>CTND4@` M/LRZO)X.E'(3)E$H6\);A_U0M(J7FAG$,32 MG3U,Y;[-1X*':KI1X"U!'V"YW*%B%,`-C+XI_L2*/:AJJ]IDF\T*:CB]9KU5 M0;MST'MOV1]ZV.$&;[P28SOIM92\;_<]4I`Q.SK\.3,Q8GT5S7O\(AY/MYX'WSLA.D ML-HM#EIU\NBCJQ5!)!Q!*(M=[4+EUDY[[';:CFM")T6K=EKJ,IC"4>[''.#P MLG)<%!*F$VAN_%3)8D/UQ12,GF9HU70ZZY.ZT@D[;74'^5=9UCJ3UM):3%+3 M6B>'/NPAE4N#]$!ZKZ&/?#6?3\RX-3?^$@E);1[17?BHV2TAE7:?=Y/N@ELW MF$ELP,U>,BO?R'[URO*Z_X_]:H]MZCKCWWWX^G7M>Z]]XYLXB>V\;,>/:Y.; MV,1QPHV3\`BT9$!;:'D%`H$E#8&E$DQDJJ`B%114J@I"UE%U%2NTL+6`M*W] MHQN+JFEB&AWTKVV:.FF=-*E3JW5,8N#L.]=.".RAT?6//7R\*$D8^"?86=8<-6J<#6Y-43Q&/6,P6A4]P=`*4H"Z M4"A(](+UCN)#'D!\"#DO5CZ#<2L3.O)0:EVLH:-GV^K.:./RLX]W3NR1!6O, M:H^/9Q9OW#BQ\8ELYN*AH=3H=M9625,AZ[KDDIJ^2'!AC:!4-*]/I;8NV5&M M;SYLL:R/);^D][1[7=&!7,_0D85BV%9[N9%H;V#F`V:9*00I^*W^S%#X2)BV M.05KN2(S@;*R`,6PC)6FK8V1&!.(4E&I,B`$.(X%S:II@7*FLL%J$QBG%.8$ M2L`LK%EE3;,*UH"6UJPM+VN_UFB4MD%::^98&=>R3JGPG=,IL:\!5)[0)2%. MLFOL0N.YAK,)#%PDIQ92*K(\$MEG4V3!1^;[QSTI5#2;,(21YS15/HV<3"H4 MGH6GJ[40O>I(24%^+>2IH(]@WD1=!.OJ.('FYFK/>PH4*ON^F>-7'Z-Y.;LO M[5`";8-[%]C1GGO7#DE*Q,^;*F579.DZITQ_=#R6:9/5AYE%MCK>G51Z=RUW MQ&2V8DL^;Q'5)IMYS=#TI!X4O%XIWD&%^+.+EV8:1MZG=@`PT((9-((95,>\ MDJ.>ULN:`LA]FDCF6">?JJ2%[D0WG40/N^124J37X^AD8\R1VL^23$[K-.5R M*M_9Z;'0H#/4JYGZAA`3?+5*J?!ZDJI'31H.4)MR8]/IAIY1)*EI5A=^C M*A$+;Q(RZ7;-6Z&$)ZLH;U75A.J15=4#%BQ<+5BXIC-R.IWQ>JI42X9/=ZF> MEJYTIB6!3M>M(J=*=Z7'H$MM[DHWW[NE<%+7(F&BZA`2*?_9B.<9AJ(OZ.?: M,7-YE0I1$6"6ZF\HEJKB#4Q5\QA^D27=SZS^/K&:_]7=:A7+UW&#Z&NS1,LP MC@0!B.^)[Q$KP9T-(E$(I231,<6Z-678#EH,71RGM;ND*\W!_)*6,U-4CT@? M?7MAIU*S1JCS//I(;B1GI3_C9]->@<'%H9W/.U_)N+JR.M3Z[Y\-2:7J[6-9VWK6A0RCQ"R#&U M,![*3D^^D_]QMBVT=H+*K8TX,U0W MC-/QCIA:[;/YU>KVCEC6P=O\68=VIJ6E/G@FI(>(:4ARBO3Z(J1BH9#??<;C M`?:,23<1;F8RV6(='<_:_++-YJ]6U8FL0\YF'1V.K%H=X_PV/UF$G:V]G>QA M+?.FH'VTG39&RQW.5+LC*[96J]X%L8Y(SF^KM80QYD7<91Y&ED66,UE,.N_$ M?R-:ZB-3M6*Y..454Q;P>M5#'):N6)1(%ESYI/T7KP'3$Q8]^FI@0)0M%Y0P$;L9+=YE2J M.916"@%#I8G&,?VB41!2I!!N1")+R*!!/GH>00^&G`QVHBA33;Q/J5MUPN.O M6>0+]LE\#3T@]BW9M*56?'ZPK[XZ7,='W66NU/"7_6JR(C[,*_1WAL)J;TWE M4UL7M05D18P]J]CQQK3INK=/)IH;6+?]=*)Q<'S\^HYZ\9'G+*VV_JFKKS1M MH!KX4VU+][_Y^KZ,8L;(/_-R_C1UE*H%'C*Z`#S%F5G^,G7)_!:KLT15O,.3 M8BF>-;/<18#$QPJYM\(EW/RXX$X+DDR(,+VT@O3/G&WH/&@^\'3-LL#F)S+Y MT[Z-U.H1)>D[VC'YU1QFFF_F;S&RZ0;(\)A>;A;12*PVGK&#[&98E\MN%PX6 M_O$E=WG*.("$MB*R%.O&@A>3AT\.D/A`CK%A3AN)5B.X&W52E`K2Z'P=M.&2 MM"2[%+.9^FS+&SW90Q^^Y`A25ZZM7<6$\[=V4Z$_'#_PJYN?CH<"?OY&_1<3RC&Q[^/IB1G\3PF"XW,!*I25F[)`EV.WMP5+@FT**@ M"[1@L_.2"SBW->#VS1UO`_(%(Z3,'4GTZY)!&3T"\>>ZNW;<(X MV`]__@83-MW8G+_QQ\D#O_PSGLOY+AVC-&KL=WBLV8:UZK\,YF()_Z\P'2J` M>P'`LA_`>OXN[#_Y6SCS`,CD0?H]@/MT`?)-`,]E@/(<@/?8751]NX022BBA MA`=%M>\!<`7`]W@))9100@DEE%!""2644,)_)X`&"DB3@2$2[0..MI&)PO2_ MT^@%]XZIOU"WC?Z3S[VE_0'7'T8\!T?AF#$Z/C=_`D["))Q"Z>OP$GP#3ANS MKWSN<_UO-A9&\>D!$6V#@P`T0@R603]L@QWXYBG8.S.#[P,0+LYOQ?DG80^9 MIR7J.C4]\9J(59\V11KBW*'$K=Q(I9*\YT MX_J"3(,37B_*#,Y_KRBS*-\NRAQT4_K*GMX577W1OO[A_K&=([M6(,;VC6Z+ MY78-#RP;ZQ_>N?6+6`$KH0=Z805T01]$$?TPC!B#G3`"NW"^T(_!/KSC;7BS M.1P-PP#>\)BQ=B?>\RI\,X@:(%_N^4)V_$_9P]"L*0G?0JL[#T1[#%3B"F!T M;G\A1K%`/0\FL+`HD=%L#]MI%WX^U^XWH4780$=[W6O!;>&J93NSNFA)B#B_ M,;I)R/[)4FDQ5E]H&GV!])<.3/TF_X,[YVV[+=MQ:)V-F'\=`/1`\:X*96YD M7!E("]&;VYT1&5S8W)I M<'1O"!;("TQ-S`@+3(Y,B`Q-#$Y(#$P M-3`@72`-+T9O;G1.86UE("]/14I,1D$K4&%L871I;F],:6YO='EP92`-+TET M86QI8T%N9VQE(#`@#2]3=&5M5B`Y,B`-+UA(96EG:'0@-#4P(`TO1F]N=$9I M;&4R(#(R,B`P(%(@#3X^(`UE;F1O8FH-,C(R(#`@;V)J#3P\("]&:6QT97(@ M+T9L871E1&5C;V1E("],96YG=&@@-#4Q,34@+TQE;F=T:#$@-CDR,#@@/CX@ M#7-TE3YA^=W<30ZK"Z<[^,_?^[__[_YO,0@#HB95043ZMY_T1A=W-3KDZP+S,>BOCXWVEAG_O/8 M$HB,\8"8WS1OX2+FS65&CI0W+:AK8K]F7\2_4,"UTW['OJ@$E;U=U;0#ZD;<;A_& M2?R4_NY".^KYM.@Y']M0CCW8CY]A*W90>3CVH@KWH1*EC/<0HIR"`+56(,YH MJU"-MWCMY.6EMA=CQ44\T278>5X?XX#2&T&\;D^\(M]%:!([\2%^@FY)Z,Y-FBAOX`/L5"U,$;Q._P*)ZF]SWT,$WIKX04OS*>MHOHLPHUR(.FY"@%6E1;2#P+:%V`R?@. MGN2U`+_'"<[;'-0+A9AX\*#]"&ZRSX@-E-6PDFJ,0#_[$_2QS]I+B=586L83 MWB=2%H`?-<1Z!C;2QSPL5_(<3=BHOL_ZSP;\+R_$]3I;L^C/$ MN%8<%NGLW0H!42#:6?^=J%(&*'F(H4R\0K^%1/EC3F6079Z`[V*_N(S/[!OQ M(TRP-?S<]J.%'1R!Y\1<3!3[U04XPKG>(5YBY@>48V*M\&*N:&/?2F!PYMYD MOS8+-VLZR&HW*?\FBB\ST^GT_CSJ6%T+9VL&'L`KG)\VSLC#/`U;B.DN[E?C M7FK4BY>%RFJ/<"(_57[`G,>+S9P[G[B-44NQEI5.I/WS]$QM3L0<3"-"=Y!W MS.ES]G:NLIO%C\4ZQQ?V+@1ME[I-/8P:>RN>T)JUC=Y* MK,HXW0<.9HF^TFQZ;T>N:_"[/LIS'#WBT.7RZRF-QJR; M*T*&QW7"W2D/AX24V*A/"2IS?YC M$9FN(B/LME`1L@9PVV9_SGU8NDMDX(\U>/RQV5;?XE@D8@4\/H]+MP*?CV1( MMV'HIFY6A#(+N906H$)3JPC<+A(+)>`?UZH@O2=3R\IG3GY)#9:W.<*%Q\>< M*.G]I:3-;F_I*@+-.E:]DRM]MN6-6FC66X>UFRUM+M1$\C-BGECT[I"E1IE# M*]1QB-SOP-$U/P)EM:$I,81W5K94U#LGO1%B*>P-LP75;@HD&$B7&'50JP M6*1!9MH0E=7Y&W2SN2Y184NB(G9<]S?X)$E#S@^J:%T=\L<]?L+8G`S(>KE0 M<[O;&H;5-U\:FJ9?YA>-,>EDOA1\F;R<*G>^8#[%EC>8>""8@)X1O5%?.,5* M*51+,RF)^,)A(]%34581*I;U>*(^=[+*3DXDQ2'#WR&4V7I*Z,'2:W4YN1ZJ M%LE;71',VJ($5D98T*J\TRK@"41,,^#1`V;$C+;9*VL\NLMCMI:5F4W^B)XX M%(+\5YO=5J`E;+DB<3&.39/S$ZB0D`?T>#1YA"9X#`;)#'>(R[].;+K.$;,, M'DNW'I"9RN,ECYP\+8Q9%>($UR:F+7'C9%?2EUO.N!K.]<^N3.7/.4KU7![^ MZ2DNG1B&G/[F-B]JN+%63@\E]SIJW'OA'9E/^"-2TMXAR:Z2DI4=DD[SB(>M M**O\II'L.HYFIB=+'SLRD8*1.LG%(=6MA),KQ:W*ME5ZRJ97AXI234SN=+_9 MV=8DQU**DSK_P^W4_5H/P:_P5]0I2ZU2?Q-C5GN0/?ASD96=%(#OUX[W+KVJ M[.XQ_/+VR]M[W"4Y5[PU%F@E_-_$CWSM=(Z%1_L(.8X]F.0H[+;/.HZCD++9'ZB=5*%%#=V)-G77M MM<_PF<7G/_A42(.3?+B[UMU1^U=06@*+[D1,OI%V8YJDM/]@LL2N*R5P[$[$ M-8%M7O+9@?.UD.Q#5TKUHRL-ZB!M,U8E\K^%]9["%/XPJM`:[<_4]2AGK4'U ME,0$HS@?D[2=N%X)(E]\8+=S?Q/7P])<&$Q^AG8O?-IQ#-668IHZ%&/4&$J5 M+1BAG81+6\.\]J"_9C#>0N[YNRP1YQK(Z<)P23*?[L3?6\&.'*]&B?R[TTZ[ ME;D[9$U*T/X[Z;^\EVMT5-45@/<]]]Z924()`1R!A`P)A!`%,C%@2`63&-XJ MH?)RE6?5A(&!!'D4%:P/#%A0L=CJ6O6Y6*Q:H2TXL%Q!4>(+_]2BM&C!*J)- M"DLD"%2"BK??N7,G3B-+L"W]\9V]S_N]_=\!K\#DYXY8W>GI_4>W8I M(C)G[R['/+E=2^=3UQ9)V*]CEX1]OIN!&M\3,MBU7S+8LCW:MNHX/!;'M?-Y MH,\A&?<\DHF?39PU4F&M8.WZ7&=P-Q9)C\!L*;>G27&:7P8&3LO00"<9[W]% MQOO"W)=WN2?O2Y$]6(K\TZ#&TW=`7RE*>18Y`?D!TH?\!>U_!3_`SOJ.TD#SU(CKUQFK)-:8Z1]7K<=V:+R&O7Z[Z2K+5'F0'Z:?",LAX M3GI39ZN7Q#8_0:ZFW0Z8)#[S+>Q=2%O&QTY7PNV0"WG0`7K!2)@!Y3!(MU/- MSK%$.W.?1_CW:A!`;G"7EG*S-ZRTBCV/F*LJ%PG:]!IJ;DRSJKDTST+6XCRY/927FM M=_3RF4GU6J]@3R_]EV2W8UF2GG.6^A(88HESQ-(>%RZ?E:W_SGWYL<04:5R/SQJ MOBGWZS+N\ZTP%GX+DV`I3*7-``U]%[GCQO/W&1MEF6J5.7I\:Y_10?U&:N!> MVM1XB&LCGUQK\I=K+\7_/^2N\6K0/F.(V5-*>$^"]A=Q_'OE.J.1-4Z2]=CC M1GS+.O6.K-"@QY`+V(>H!QE[G]'1F/SU-DN,7>CKM62]`Q+S!L1(<=NVY=$W MQ?/&I'B9J_^:9%,\XJ'_)H^+H"M^_0M/+P6B#6\WK?PLL\?IU@I[>G!U@*/R2?JN\.0]1]P:RCYXS M$0=9A]R8(\NJP+9Q4NWCSM'V,8[_;Y*5P'J/MP*P?7$RB1@F@?\2SF^O\W$O'&?9-W$7-+,J3:>79[[@O(P`89I_%5 M\MU\R9CLQ5['^%?*C,"+Z-<[+;YN/&9;Z'>[7./&D,2,5I^VN*Q5QUXZ]N%N MA6V'->5\/UOJ)=-:X_<8PIH?_,F)"L!YCCC?9Q]OH89EE_D.FLN\JZUK:/<]; M%68,[??C,]R?-9S-"M[!O\H8-V9_&)M=+V'U#.6[T`/$YVO=^#]LKY')NLZ] M,W^D?CGOW$'NRP?$E/IN5'$O/I<\WZ,R4H_?CD#[LD#AOQ%HEV_?WRVSJR7= M/BA!GQ_N9/_;/=[$?O?!,6Q:(*E^WB+_NQ(,\-4%=B#?@F8X0AY2/I5@:C?8 M*Y)Z1H)I&9`/`T0T_@7P`6T/Q"[H=C\#EYT&V@ MP+R->WB(-9V0"@AJ`L,9:QYK6L^X?T+VHGP7ZWV5=K^7"FU#'^6!+.J?I_Y> MZK1==?E;M-E*>0;C.?2#P'C&NX5V?Z"<=?C?0$)*G00UJ8WLZQ`R&SD668($ M?W_Z[Z%=FHRTL[D;F_#=+_/&].=^[9<'S*_YMK8YK;:!3YDMC=:#TMUZF;4, MD!>LNYPSUM6RW+J!^Q_EW2%N-=\C'GD'>0`?OE(R[6<8\W'\VBK]=LE@JXKO M.85_S8TRW)="O^S_#^Y>SH'>YX5$VP^Z>++>D]M@"G2`R5`,?BB`WFJVL^<; MB-%F.V?@8VWS(Y05?'>=JM='(A2[X MA9/&#MZMC9)&/A5YRI/X5T/[VGK/_^I89PMD00%,@Q&Z_S?(39#GJY$P;^YP M_K>R[5[N?\\:_/-#,!GP)%]O0"ZU5DMW[6>L3*FD?17Z4',J-BXB/L$7J'OD M!DC3/H.Z"=I/L`_]#4PF/U%+ZJZASX]<'_$X;_E-DD8[QG5.02OE7?4\YP/] M4C7N>MKSF.M'JMK6>0[UR;G`?$"*.T[9)Q[=@>[.K:]J.X;+/S>:#/(9GX>20C79.8:&U@WW,E M;*PD+K[1_?],O'-G$N6$OO\ M63JU2>\;.YX/Z2:RN9ZA! MS8K-TV)TK"X7,2HV#V'8L=HGL/W7ZZE&3^`I)Y=22A>49ZG1&M M#696U1J;:W?6JL+:IVIWUYIET;KH'5&S)>I$52A:&"V+SJ3$+HNNC>Z,'HA: MT=H[%O9H,#Z*1?0\!V/5"*=Q:_.X<:7(\HY-*(\T/]VL'FEZNDDUJ.%N0U49 MJ^F%N*I\T9S<4'/]I:$F^+(^)W2R)C^T>$G7B[)FSR4IG%,V1_6J"=>HFCED MJR-=,S='#D148:0LHM9&GHSLC)AED9:($S'+JTM*2J6ZJGIF]9/53U7;FZN- M]&IC`:JJCM3?W*/[HN!ME=US;H4&M62K>7FHL")?+98Z4'SBBZ7,TQ9)%2@W M-21$6@8SP:1V(3T6NNT64KY06L`!2V5OW7QYJ*ZB6"V0M;`9=H,EZ:2&E*M: M&0^S8`%PF4D[02\(NR7I:C[3SLR!TFW0(N;"Y&6P4R=4_.VFCFA](IT M%66R*.L)D99!';2`Q83C8P67E#:H:3&K;VB[TZCZQ_H6E,:5BS,]):5S:46J M<;,Q0RZ5D%%DA&6*A)Q&8TALS%C=Q!@<&SW&5<*QT:,]I;+24X8.+=UNC#9& MQ::$6BJZ&5>PSYG&*-D-Q\"4<@8TI!/IG;`%Z/8OJJLVJ*GL#-]S;H*K@C<) MQB0BG`!;=00U#0@-(+E!8;J"2ZK4@M@E;9W6SG9*IM6.,]4F2*^`K&NH2EL[ M+?G8ZK1,)Y=[ES18$7[@OW1(I_NCTQ\+,W9*F8Z5F9WQ1W_'$6,>P;RYH3^Z<`%N\K'^Z'P_=Q?]T8^4`C-?H?AJ]P_O!A\(Q/@-K/L':ME023Z<1B.L1M68*H;3T70L+0ZH@VI$O:.:5M4-E:ZF M-])433M96G%"M2GM:0#TRP(]T.9Y@/[\]_,=;/YI!Y,?DVM"D%R3+32X0#Q/ MY:R/N48CQG-^OW$I.8O5L,#N7*G39\G).>J!6,YMYDRV M<,!"&G'UC4(,$`4WI`>0@2`0(HVSYJD'Z0A!9O MI2$7@&5@!3#1'J(+'3#"=^&XI\%?![>`!TF34`\.:]OJTO?SFW^'' M"720KY*@L!?C;>284`MN(++A^*VD3C@./@`^7@[>#?XY!:_!6X`=X(K MP*=)O:%',_9%X)`FU]@D_-X@F]IQOZ_0.-L#7]C4%`09 M_;81:_22-EX'^E:!OJF#8/!U[>)%8\ZZAB`O-'I["PV]N]MG?'+Z]-;(R9-; M(_`U/J+#MX2`G:S#%.LPP3I\IQLR!+P$-@"<'3("Q,BZO$,41LGJZ,8H70U\ MCB3Q19([#N0"L`RL`'Q.$MZ7A+\GX9=)S$T*9JR;Q$Z%&0G,2&!&`FEV0!]N MA=EMY%](`B%#Y@WI@8P!<4`%3-2K(:[Y(7);N26W=9@<3RTK@5J2PSP_9`2@ MAMPT6HMD!"-3D&F`(H9O8O0F8O@FCCT%F08HU+H)M7CK?WWD8_),P\@WF]@DQO8Y(:Q MP0TL=F.6#GPP^`'B\-<:ZC`O#K*VK]JH$GX=C85YZH>:`M$$0JNTZQY<=F6! MW#HH/D\^A2D^A7HR>:5?^0$_^RLM"(>A99JR']])!7(4R*0-=X'L_-<3:J-6 M83\"O[@PN*-`;Q3(J@W#M[!:I(W-49GZM3=9*,"@4!B(`KPT^U$`_=A>@F1& MRT+FH-(<+#R'>YO#]7L@98"2.4WA)6)#&_XBZ)\%^FLF4L=^H[AX@I.E"_#" M_`7REXB7O3?&DW:U-E8+.J2-E8%J"E25&?.R6T"6'-3';7"7&F+#1C;8UP;% MTI`;`(4*#L."#BCF0"YTX"L'U''``Q?443N%0"5Q8C,GK.'$5DY,<&+3 M&&0XD_UUH;+T;)O7SY[EW3.JGNPM\JK/`LNR+!,K)I!$IDPC922P[ M"2-*D-U`$`@!/)`GL?6D8=;G*,S/!8IBE+QBE&,]M<7)K9=#:HN34('?[3=2 M:*RD2"@92H63X50T&4T5Q5-J:C&53YF$9#RI)A>3^:39\XG\"74G/`DY(;KC MGK@<%RT)-;&8$,.):"*6B"=,EK@:7XR+X7@T'HO'XZ9_*X?9WX;Y,^3O&II9 MZM&4O:"WY)W@=>!5A(_6RK?&JMAMY-)Q8`SXSM"UH=M##X:FA_XP5#04:637 M`3D2#/KDZ_!%.7*BW3<8B43HH2^._+#D?&1N1%31/&P$:SR MX^%&-JRT,EFY=,DG*[W]$#SC*FTG?&EE05E65I27BEE2F$('E$V%3BG$DJ4= MVK%*Z0EM%XX)E0CZ#BT0,**_@R=C.4O;Y?U=73XK'M!EC79G@]U^S&ZKMTMU M]F*O??OG[44>NWC4+ARQNQ_3/J2(/LV*D*&=FG4WZ)1NE5@L4$7?QI/V;>X] MD#(0!,(`?_QV(8B[C,+?A<+?9;RRNQ#477C5=N$1T"68H,\IS>DT%#NE[=EC M-#I?]W3*V]$E6UTNGS!/6U$86[E7T%;]0`T_0K,N63D?URLJ#-;XVX4&-/-! MQG^9;:`6S.'/')YCW,M_^`=/"`=*A&JJV1JJIWO5DM M5;!=;B9)%FMQ<FE)$HNYCKJ\KNZ70.NHI>N317JQS?Y2O?Y_]J+E^N@?S, MW\S!_>WJH?:OJ;7MH9/_/\60_Z6[:F"<.*ZPWZY_=]?V>NVUU^?S<>>?L[$! MG[W^N5N.V(?QG8GO(`FAY<^72PLT)*1@^TP:DA!H&NA%D5I5:96@-D307MH@ MU"OF7VJK2A1%H4U(2ZO\*>$$I:@J4M(F%)IPUS>VN8-(G=V=;]Z;?6]FY\U[ M;[92&:U49JC;"J#"ZLR[HZ/5VX0:!261C^+-/J)KM#K;&VZ2U7"]59V=V.C, MI"O5\!VETI!$(:*[#D1ME8Q5;8Y1#9.!Z\PO28=5M\:^-5O\MNIH-;N*Y*MX M[8$1$B#CAY,WEKC-J"Q?U1$[BH1+J&8=Q`PRB+&8U(`1N<&+X)/&1UWG MHVY,>(-X2$,7QD_*;U]\YO#S6U8^N4P904MXIT]K#9JW5%TJ&?^&$O0'F:`LV6R* M5@;6*,.*13)$)^7.98N6S,F7E9&B3@PY7GC\Q?:GF#RCF)IJ::&PBAY@Q M8"/*2Q*AKM=0+_9^7!-%A24H6!6FB883T_\DJ&^BKLG7-E'31"*76>AT*JS4 MVHJ5W:Y8R'SY1N5V*V9)$!03JN$$8`L$X/ML>=BE#8&S-P8Z&/=L54QFG\U"KHH2-HH9#=&+T>I:A0, M46>48H)^^*X/'O("X_V'E^(,GKD>2F`[((N/E6V'[-EV^+D9]I@@;`*#$1XW MCAE/&NG'C*`S`A,R0\@$(2,XOW(:-L2MX1[F MMG-[N=>X4YQN);N!_2'[,_8HJ]$S\#KS#D,]9@"M'BP&O5-/M1ETD%VMVZ2C MUFB!3XVDMJ;H1"3.>F.RQQ>5_;*8P044;;B4HN20%)%\O$!64EPN4OM$&!%! M%,WDUZ'F890U+Q[S1=G^G$EW7[@.?CXU8 MW6[:WM(R/T2/SU=-1B0A(G#L":J:"202U[P4'8/>%)K_8_X*7]R MIWQ.IEXAE2RGDA:AQQDIEH2>(M[%HBQ%+')$E>Y-I_EKO3=[^>:%KT6*5\-R MS"(X>B8BF(@R-E:G^[9?MOG],F%B M.(QZ<0`2)DBK29<(S>MZ>_%6\6_R;T:[H%@J#1?)A=U%A%*Y5$(>,A&*Y6)Q M>.8J%TOD-=+$1AG;"/\WA-^6*^H2Q?HX84<@D;J+2J4@F9+!T48['**NTZO5 M(3N)82A`=]`D)C78'NB@K?0\@V%IJ".V"?BAP3XXV./L<_HS>OW#*\?']?JM MW:8G;O[Z47?R48-^UX/?A%7PW\^[''I]7`_&P.9+U$-'CWYAV]VS6S("\@P: M-=:4V67W071:E6MW2H2MI^92:Z%PXS/,%ZW3U]5/:O9@-+I+5:`ALR-K@S7= M>[LIM0/4TFF)"K$LI`^RL)N!3@'ZA=W"98&V9_NSE[.T?0E<2H`ZX4O$$S27 M3)Q)4-KX>/Q8_$Q`L[YDI<;8EUAJFP/LCJ\X-CJV.=1QZQ+K$>MI MZWFKYE[A08'ZG?"V,"G01X1/!8H10@)E9"RPXI3E#YI5,ST\'&/.,!1&M',9DS^8WSH$]PR!>0BL MOKJ#;JGF?1V3<])]=^>CFW\EPR*+ZH&^=:W*.3)9B06`!R0L9>9TJ#^M'\J#*?YRG5/GV?%=^)*]F M\ODY&GJ.T)LN\']/0O+$](5:BUM)DL@M.0EB!G`@4ILR;K,1_P&-,-!N[#)2 M&2,8<[F5.6H@!_8N-9PD5#%F$665>DTQ@/BFAS7Z.4:*11&) MOW;5(CMAP`LY5*Y MT5VTHF?B$2%%S@'D4*!KHT6;B?9Z`NB?#;<5$I9`?`$=@.91@G1H12NA"-GA MT5E\>OW!HO=?R[Q[7AYYY>99=\7:]7!!;4.M[M!5^NN4W59]\X;ZA5V%3=WF-1>^J`CK#HQ\_Y!ZZB">A`:F MW]=4-/M57OCDI$J#MC%@GG"3C*$AEC)A:C?R@@V3-%9ZPF*PS]$&E]S@)C;E MK7F"F6&#*7^L%>36;.N*UDKK,ZV:]YS_8[O<8YNZ[CA^?^?V^=>G7/N MN?(]G_/]?@]8?7[?HJ]0E5_#:`P8`PL`Q&3T=O1BD(ER(P'8'(P2!8@DU!TAI\)TB"SJ90 M(<@:?(7@SVB]QUZG.=S=[NUN:G=+FE;HCAC&]>MSAM`],C=/XH7A"JZ%?#>N&81S>O]^(\_=B]-:J1UH-#7+ MX@?BS!T'ZRH+8$<5.1(27.WNEC9#U#1942+Q.`=5)%Z/6^2DYJ3'8Q_\I_J+ MZHH9V#][&,3-BN91LLQ2NO389/76L=]!^ITMXWN,R!'6?@P;)SOCEL[W M&3M96'FT.O?6V]4K)\)&BT"$17<_E_Z&'A(3EK7MS[42EN/.NK=.D-Z:OI7#FP8AW+&@F M/YLMJ)D=7#,[N&9V'##U@!D@>N"C`!$"@X'1`+71`$)YMJEY(-`9V%U#*<5! M&IDG*648./T+@'&Z:OF#AY\_?HQ,"-VWYT92W5>Q,+ADSN%WJ3Y=>E3"J"%R'21V\A42F"5<`UO<'4YA,==`5[UG$3O5#5??!N&M M1X9/O?_!$^6_]FM]#S&VW(629ZEKCMS'8.3AP_\`[!/\T.D9_W-UNOKN)DPOI;L7 MQ)_@7NIKPA9A*UQ]7?#@%.%[]4[-GQNXX;;AQAS)`0YS9$-_'A/C\8#`/\7'J/870.9(7?$(<0S1VB7-K MMF.W>`C[Q)W8(3Y%"J8ELWD"?$.93)^;/]>#9+F'I!FD;\WM53T]_3-]G5U< M7+)USH&N#N[Z'4-];DJW;BUOV5(L.ZSC3)*+B?%H<#P:;NGL6;E\?.5CF,7Y M/1%OXT#++XO@+.K%P2(M"MR%<8][$VG]=*",4T2-J;NS_$\;M3T$0F5PJ`P. ME6&T:_I"L\Z;@]BL\V:=-^L'S%`9A/)@>;1\O"S::'D!M_*V\I>X(6WS%MZ5 MS_*S9B!?R-G52F4Z59E&4S:([\[/^>< MG9U+80/O-5O+Y_/EA1%7/K_@Z=/.Z5I21S>O02BVA:+S$L83,U]5E%D&4:HA*6BLN;O[BQ\1Y*F/GTRI[92B\Y4E_)&]6+UYO9' M_@=JLEQ$CF59V?$GQE1EX[J`RWK\[$795A?-%AG;LW>&L:[5?H]->O#"E:_; M-.W77D5)7;^/?37N!S&B,;TS)+QUNX8O!I[(T8[8 M"S%JC6GM.5@00GXVHP@E<"B!0PD'3*<&@C:HC6H?:38NG3L0,2:QM.S^;PP[<8#7>)3O79M08 MK,RC6*FQ!]Y[F[4:0$6:R[F0LCA>HWWFD"X.9(Q_.'DN[STB%8_6X/V"23@# M8*E?MHNQZN)0E;'A%=XZ``)JK0Y^T__/?S.G1699A2B2]5MGU^^U'LAL?+*Q M#L=O8PH554,1J3VT=^2;Y,3%\WOZO0Y1-A@>ABS:/%V[KL&E\R,]#781$R/> M8QQX@C%E=2X3L96K5TZ1.MOBSF5,?2\VL#[-V$8C8[=QKDS,AN]B-NPB%G-I M2R/FOHB)D.A%,(NC13):!$?Q0/'5XH=%T3H8V1$ALKO!O;R-JD(J;IT-V2'F7>]=Z:4,"CB1`M<._[&!UK'60.P[8$H1M]MWVI^QT MD^MA%RD%=P:_%WPV*!Z*GXF3'R;^GB#/1F$B`331ENA-/)YX+2$U)B#6"K$Z MB"5@+`'N!'CL9^S$WW*NA?A=S[G.N6B#MRE,R417^T2N:R8WXRAD"T0M%.K3 MJH5:DA`C27QPTE3IPONUUS5]/0 M+:-)=DMA)6D+:QMMD4H3V(!6I47;-#$5FB(ZE4J@1'391S6MZE2VEA^KM!+$ MX-<6"FT%C6E55E`A0C`V(#;G7-N)2PO$)^\Y][WVM?6>YSS/\P9K3NI>G^1R M.CT`;I"ZVBB#9EM)]MLXZ!]EP&S[\"4)D`0R^]^))%E*2H:T0]HK34N2D]D8 M,*]'X:$HN*+O1G&=,QJ(?BTJU$>Y1XQRCQCE'C%ZP#@B@^"1F3^4[Y=7_.%H M4=.W65[/\H?6DF-]3F:H3;6EY/D.RRS>GBA9Q=+*WV%U3C=OL23P MK"E:D?M1?LD[H3A87<\VRT+&@3%2-?.'?DFLK6O`7-1IV3NVBA7>L:>[B[<] M_"SX>:]DNR*V$[O3;<__*7_MM_D3[\%E.`#Z-8GHC$1M@M1P[(4M;^9O'CD! M]&WSM5ZG-OBTTWG_]Q]+[\&UX:J0NVK\4Y_9[7K\97CH.FR%X]O=V4N2XXE. M$NH+'<__YLQ;^7?.U(;IY[\XV"1C9\*);7:&X53A(_M3C!MWP7'CJ\88H+'D M&*9CTV/X@0U94BW7!V:#TF.S*)F9[7EXRZQ)@[FPB'(XU9/K&C1SPS*W@_)( M,@MR=IHQU4)67,@"R@)E!(91EF:3%H]-64RVF'6ZLED\W$6&25C`0DTO)\)> MAHDW&0_V3ANU'9PK5[%D!^?*CIF8?5.9/3?QS*;I_IV;^8D9'&=&"6<&OUW/P&(<-#RQUV-8$6)CL3U8'@//6-O8]K&WQ\37QZ"ZOT2= M?#::V5/Z.77V<^KL9WK.70Z@D:&10R,+S.XP]AS9/;+"GLMBON(./-PW;[X65NKBLT3+8":ASJA/CCF"[X&B=1=[:V;`-Y00]G`L*0I!T='C:VYOL_C*4_!Q* M_AE/,L*A%&%8.LK2J7 MW7;JD\UW%1XZJVW/,N=UKR)SAW1W-8FX.];4MI8N>>&FM557>;R%.R5"JJV8U7-T]G4T]EK/H*KL/7GR\ M7^KG)>T]?.Q!KQ>#H*9ZV_M6VXN8EZ2ENOI_V;Y>+N52QP]^=LJT-3<'VE=% M&_M>7BOLJH!UD4EM%[C+%']LR$A7E`S2PV$6_'ZK`S(2_D"&,"W(^*FJ9WP\ M>'G0@BRP3H35BRIJ!LLL<&_XAE_/R-9]J-S3;7S7P4)!=%,P8A?/T78I?I>R@L_$JN4($ M>94,9DB&UV3HEN%C8(H/=K*;8`7K(;K1!>`'/4@WV@%2+N91]BDG%/R$LD]Y M7CFO7%'^H=C/*A!3X"7X*?P*!)MZ3,6-ZI,J?E&%@S*$4_3F]2@4WC=-Q*MB(ES22#>1%8OL6@0\(M)!7"':2%O(XN45$ MI\8+R`"GEF92FC4.Q)H:GK=F8EE\ME!H#"IL"XAA,#>'00R?#,^'!;4[M"6$HRSL#OTH="ED0R$:,D)[ M0V(-TL"4M2$-(\W0IK1%30P@%6)8!?,1=5+%6%VO?D']CGI&?4_]BRKM)Q#B MY8!SK!"XA:1915XAXE.DN,&R"=0TS!VF@,RDN=><-D^;-J`,;LQF^MO M2LW&DKG6&M)*'$*_H(4B1#2Q0MUO%2Z\P4K)9X,?!-D-;!CNTVZ,W$FWX=[K MGF87S`29#[:4N;J%,TG+-%W?SJFDG>^3BV7:9]+#"-$2G]`RGU#.)Y3S"3UH MH/10^E!Z(;V89L*=?B2]+-S+(KU6OA&/EYJ;.:[*S,$IZ33QIRVMEHNMCA4N MW68+A=TY?=^`^5G#AS#^O4(T12%$(XKVC5!$"X4BSU6WQAT'Y(MLUN,B6SP* M$Y/;1G5N.B>45!M24HRJ^#>Q%[.0H_RNY4TM$SE16DQ8MI6_XG?_(7Z?OV72 M=.EM+\^R?N]6Q8AWN*],CUB/5"`#Y?V4%$ MH\L=W;VDJJ=2T^#>?66/A(_![CZDYTV8B++="WN07D[H5NO-@-M-&1F@5;#G*"X%-7US?_K3&G MCM03&O$%.'#UV'T;`R?;N%31($X&AX*G@T(PFK!SP"H,HG8.6/NT!W&\HI+T MH3N]1=-_>@N9B^I0XE!B.K&06$S8JX1$5V+%:);DCX&5`U;^Q;SE'COF>/_R MX6WYHI+^-]O5&MS$=87WW"MI[PK9VM7JM4):2:M=(>/X(5M(2&ZP;+"1)=L\ MS*-IXT*)H9DA0'";9BCC8$@&TT="'L!TIL,,E(PS:!,-:MS=,]>Z:[N/=]WSM=.!0M-TZ^8/2,K M@G+FS@[#[?.9FB.=R;3Z;#9ZGE%CYORJ1=$@G]RQX]:WKN]8.*<.A"1/)/+K M\N_+?QZZGY!%CIIJD_?(K&ZN>[SSN,.GO%Q+2.+#I>8Y1.V1VNN_@..54V#[ M'I_^@-]@W<.MP#6GZ"%<>6INEN!B"=S&'PRD&TN,QPPL&(J!A*)2_%,1"V\9<*\*&U4H$EG.]3!3 M8"9*Z&)%D1)X#S,%!S5%S>/+]3!38*:7/8K+G>NK^%Y6+.CZ?17?SWPHE-/8 M?5\H%ZMXUM_DWZ6_U]V_IG]3/][#3".P+P]KPM\(HHZY5T9`*IP?`.;!L M`'$#L'[@R0%4,E1<2$9/:*SEE;-F5=)5*0IN79;"WHLZ\1U0068X[:%!D.2X>%1JJ+-W``@U'C,4I]IT4 MVQ"%1E)'"UJTWZ(:HVTJDV$D M6/-.Q+4M;QMMN])F<>"VE6VGP,)5`?$E7(A3DB]KDCA#1_4#55I*$^>O$#F[ MIL2IVY3>M/T..I_;7^I?7MH35=W14C&J&J5":;=FN+52KV:,D<;Z,K] M)KG?8X*,D>[@%TR\W>1>1NB#PY1NZTUR'_Q_',O1>(6!OV#=&1DGN54T6ZU) M@/A8?!Y4[]S!NE(*Q>/57M;K`W"Q3_P]`MFZP(LM-KGE(2(7G M]GQSWD*]K%G=[$[^OJ61\X1L3?DP;=M8I.NAK2MIVNZ$-3]L7C^XRKJ')'DL M&@]\5FX=^KQ.QGR2"`)I)C2V]2;ZZZW&\G\^WMV')V]U;9A.N!%I%K"54(O$ M^/W3<.[K8*TSHU;K;P]_?@.]"=%=5LH!R>F+-L8!W:CFE6S$,')9E@::/T#[ M8FK\?FJ4(.VN?`PP?F:4(#59Q@]S0\Q?ROOD0.YG6;B8A>>SD-$BT71:"\;3 M:<:QP5#.]'1NIN(7GIR^P'R:99XGP.*F7\CN5\;Y=90D,NR!%C+3XX,>#]@\ M<4_:@X5,72:;>3YC$<0"<`5P9!5/U_S(^+S8I%$[[I$FY3P>7\Q-IO)*J)#J M2M.&U,`R3GNR8:V)`HYA0F-_TTDQH5U5Q$0D@4XG(%&M&0D&G\2UI-@9Z42= M+.JAT4X6[;R:%2<`9E05^PT6#$,3K937LOY(-)EJ(V3%H>\O$DAGP<7S5+>V[%SZSJVO\79QP0`AJ>\< MY(5&`H[@HO>:<*(U60.DB:9L><.MES>OQS;]7^W>.4`::8A-JU%S[S67C?+4 MV#Y)6046O.P6-'[4(HOT6X3G+%SS]!E;P'J>$[D(%^4T=)`>)*L^O$@-%JF: M0,PXV1&_2$/C3GA6A#,NV(0A3:D7/<<#O=;Z@>I0&SJ$D)AV=CN1)>*.K(K@ M(3M8W1[W1C=V\3YP6WG(;>3!X#?R:(A_EO^`QT,VV&R'+;4CM8AJN0T(OLT_ MRC_#XU?M\*)P54"2?84=_=$/'O]J/UKBAE7NQ]PH*8,D;Y=WRR_(EFX9>H(0 M#-X;_%$0([F%JHJ5LD6PL3\@L\?NHQ]L%LC],PRV\*$PLM>%(1[:&T(-(;"' M`B'DLM%'L\E>&?DT1]3J%0-&SNX%EU?SMGCQL'>/]VDO]CY5<(!#9K4@?Q>= M8%4AOD4=41]7<8T:4AM4/$]]BK?"?*M%TZ1H5'($8."C``089&G-"+!LIT4D MP++]H-N7ZPJ`-?!*X/4`UFP!;^"[`1P+C.0Y`D,B`8Z,D@L$MV"BDVWH01TX M?4)'G"[J1W0L.W48:-(_UE&[?D)'3GV;OE_'#DSU[M\D*$I@IV+WG(0U05*D M'1*.21'Z`)*?KBX1NK(TDG=R,!3FP,GMY][GZ#)K%L^)9$TQF#V^6$:80.'-0 MK4CT-6P.A^^89Q:GX2H`Y90KK;=&.,F-+#%-CZ.,V^6E"$N[%J20'M,XD)O7 MG`?])*R&`V?+^S\\5O[W;]9>6';X[4=_!\@5XZ>9_*>NWTH[[F'4OUP[[ M\CL%MG6$M;\D3YG]L@,.^N"R#Q8+SPAH+P_'E=>4MQ7\FC*E(*79/[=`'*"0 M4P2Y"3Q(3W*"X(D."'>LZT`N6?*(QETYS^&(<]2)G,[ZT-S$_);"W`.VN\+-XW4-D_4NA&7)Q3K)6@9`%]!+<+GLB6H+,\/!1R+MC8QJ&\WFA$8: MCZ8=?L@[_3"PV@_=?O!7VA<_FQ&CF>`?R4_8X8@=G/:P?9T="]C>8=^&Q`[8 MU7&B`\W2J,:7-:KX/[[+/;:IZX[C]W>N?7-]8]^'7S=Q;,?73K@XM_'[,=L8 MF[8A&;0\FBPK[4+Y`Z("ZL`9RT8W:,N@=--:'BNIAK1!,Y%MM*A4Y5&Z2>L? M`:E3-_@C9`U;Q9`8TJ:AHJD@JD*RW[&=J*5LMN\Y)R?GVM>^Y_OY?G\98#(K M,L]C]7$C@V5JIISY2NR?HW-]IG9GYW*./1>E.^=L$LE_WS=RL'?A(XIE:?1'AX[\^LEG++,UW4P@>.>>BLZ\BS>;\@>? M>>(WPTFQ*"C'=K\T&GQT>FHZ/E>]\?J+HB#GP!C`U>VK30A@W873T&M7[LJXM>PH'%#DLY"_1^9(%U-F@VP\_- M<,L#,RQ\IL.(."9>$]D#Q2/%?Q197VX@1WQ%N!8#>RP1(\YT7YJTJVFU2UVG MFK;8=MK(/`L89ACG)CAR*@67..C@GN7(23L\J#RF[%#8AQU]CJL.UFD'UG`8 M(8/MBG\C3N+T8I8ISAZ(+8JMC%5B+\3>CG&6QMS2'+&MRD%&Z]=(_SQ8M0#R M^27Y)_+L$O-/S,3&=7*$V*`1PW+;`O"W:FS(YTV$(!J"$-UE*";L+Y27X@[? M%H*-.'V;\<0\FSVLO<\#C$?V$`\!ANUL#<.F,'!A=Y@XPK=-R2JCDV!/!I.) M)#N4W)'N%N@13VJ8W0:#*Y0BSC MEQCTO!A39C8SSS,WF`8+P_#6+)3QZ,W6J9VMW[(LI?8(I786S-F3V;-9I';6 MG1W.LJ$L4EM":DO`H*0O2(A3J20AM4O`E(Z7"%.22X=+2.T24KOT28F42F^5 MB%3:5-I30FI'H(Q'[Y((")'W(G^,(+8CS9&M$384H=B.T(T2H=B.(+;1'5IY MD/@]_.6J.RSD_P>V:RC]O]RF?56*\CA6(TQIZ'IMN5&JLGO!7:K?/ZNY"7 M;WTX.;K!8LUV1>T-0:%1COMD+?Q-E]?+WKS'%ACTA(Z9V^9EZ`G+V?UG&!]N M#*^W5A-6<*#(V#@"3;Z\G38*;63:2+01:<.%H<7D@+7C3AAWT`RUU@YG%3`K MX!7LT"W8C]J)NH':-VB"C!/R49FH@H0CZ:B$(Q&ZGQ5AS4I826UA-69WLQUN MVN'S,)@#8/C`\,-4`*8T*/"PRO]//S'S+OX(S^Z2X(AT42)AY8SR@<(^KCRM M$+<"J^3U,AF78)<#SN*+^@M86D%HE$!T406LZ,VXZ[U:[ZOSD41M'GNUWMOH M#_$R1BV3"(Z`"@$W!%S0Y@2+%7I-[8#3)IO31FSSH:4Y"):VYC9B"36'2+?; M,F@A@SSL$O%U0#PKWA1-G!T.H,O:3MK(L(:Q#6R35ABQP2T;;&F$Q4%8WX9O M`AZ31K]D1[!NZ*5/2WY/1I(^+M(6DG; MHUW63)+6JD4UUJ*)&NM^H(-Z<,>K#&6!G65] MVLIH4,O..F^6.F_V,`8>ZKPE_.:G<*+T>K?^[LR_RNYF7WZ!#E8=RNTZN'6X MI8.^3:!7HWL\>:''P].+&1F%ZFLC>> MFN6",4&=&8,5BO]Z%0T58\Z3E:12*Y6H(6,SY\ET&J)5HN!YQ]?1DLGJ$,47 M-)]3$VV:;S;_^2MJ;)X24[]CX\9'U M`])L=#"_T3V_=>;>\+"]@6\@[V[O&_V.3U_S^X'S+1R6:1S7=_[&GUK9L9_M MW.US3Q_Z0I3@R'VR!#*G//-7$VO^%5,@@^718EFT9Y@B:&\502I"/EH\7R2M MQ>=H$RW^H7BY:+KDA4L^F$J#NQ.V=L`6`4X)YP0RV72MZ583>\8+PV9X,0<[ M97C1"8OC8&Z&23N,M(^UDZWM,&6'K0X8=,"\<":\.,SVYP9SP[F1W&3.[)V/ M7VQQ#(;C>%I_G"R6^V6R482UG8@1F&BZVO1I$XL1\Z/R#JN<:>],=Y)P.I(3`*$%8G9`)E)@6)-J8;)PS=IX3S/^]MZ!-[#DQW\?GZ49T-\DG^( M9_E]68=.71O7Z-2UVW&=67?II-VF^_1.G2U^J/]-_[?.ZOL\)E/(&2*?TC0" M#:=G`A"0_>"G*FKR!WO\9:N26>X_[R?^5"/;PI+/66!QX2DFK][!8K">$:SU M?&VEGU9$H[9N/Y2"&RF04['4WM3?4Z:409WYP:>DX>'Z@H2=1A55)5Z=7MN5(=5*>&:B57I2HZ:M24!U20CFR2*B>10;%$ MB!XQI5-M*"I513<.Z1',W1SG&8Y'^?-RI.O/;KAMZL[5S[] M7[JK/[:)ZX[?][WX?!M$LV$ MJJ&5CDEE%&U)]M[EPJ#5+N?/Y^Z]DV/[?;Z?S_?MV3TZLBX--7_YTA^^X%0< M8DY`PBL#6YY;WUS9>>BGDSOG3M]^\\=\+?0)PEBA:_F&%[:OWE4,>:5@^^8# MW;_X1].*NFWG!.>W5FY;\X/UQ:UM0;_>^Z.'_S1W[<'Z+I;"";HSFW8\R76` M4N[PD!WD*,$&V4CI))DB5PD?(2UDA)PGT^0*N4F<'"G3VVEZZ1`=9GZLKKY^ M19(M73A.DLS10S2:N:24C"0Q27X_S[7-Y+$2T2-5E@%L\U3V4I?7F.=KDU*8 M6;Z5^EXZ$)Z,._E3&)HSI[(YL(4`;-9#5WP'`-R1-N4@=T>R'9QQ.40=7&)J MD)B#2P>/QF$D/AU'T_$K<13/4-^S_/I:OW2-+J[T]HVL]:(VS5Y7K2Z98M&UY;WYA)L%3TH:OGB MTDC-ST51R`@N00SL6W-)L#QLR.FG6;:+PSXHHI&:'?Y][-7<_AJGI11=6VBVVHW=?C^Z(/7[!VNW\N][K<:P=;8;`` M+C)$'B-/DQJ1JXQ5)BJXKC??@Q/1J&-%)"((:QQKJC3N8QAC.:`91'[Q6![R M_MY>3T]/T)-<7/PD6_SDI-G(%K_1SOO&B2"_^`#/'N`G/!Q[@&/KGZ4#W&0I M.%;>8<*P>=6<-[''/&E.F=B+S8JY#[$/A%R9"G@J&RL'*]AC2X1Q.4$EXF$2 M\3")>`Z6I1)PI4VEL=)$Z?W2S1)?ATMK2T.+S?^H'?',/1:'OD['%C5CO3Z@ M,4\;?F^!-BZC-YJZNB1+2'?_+DN7+0W9^6T?]\8KU9$;RTYO@#G$2M3FS2': MJE-9W9UTTDDWCC8VX[:%/(WAL/!)O)'JJ'M=HPO5-_6=VKOOE[L-A[]UOR`\ M]]#Z"5'<7E!=""_9^>25D>^^\WB[9(G`50IH!`UHH;(4-DS_T0^&;48V@\T<$^DE>E&CQ>($,T`,@`'' MX%CZ3!I%S!9SS)PPSYN.3>:(.6[BC+G1/&KB@10D@_!N$,Y@J#9!-X)N#KHQ MO)!Z.84&=!C$,*C`4/#I()(,.&B<-*8,;!BZX8$1S[@'>3QR)G$U@1*)82<(K-3/%YP2/775KUG^MH_`%8 M$=;=M;0(K$K`4O.166YN_AFJ>77^AO,]Q[-<&3_RLV*$;LY"3%M^C2@V%]E. M@VJMR+2DZ(QOEGO\,GFF"&,AZ-3\(5)BL))!%X,R`Y-!ED$K@QR#-@;M#/(, M"'M+&JT%FSML)DR6LLK&+>ZPFS50*RME`"E,%FSF:5M6BBST<:ZBCDK(+TD0C[TGEZH92@T`F/%F&@ M"'JQ4'RHB+L)-!2@FYX=<+T#CN6@KQ7>;@6.1.Q%DO>,N^LOB"!PPH+`$ M^AO@L09XJJ':@.[H,*"!KAW04$&%/AFZ`W`;01^RBHB>`-^A)\<*REC=M7KC M:IQ.Z3I)IV@&IE,T$-,I^M;I=)9GP4AG+&YH8#Q=UD,AK%NPXR?33FJ-UW,5"YYY: MIDC+\9Z"3N6SV<-&*&`8H6*Y2,J'%3V@*'I'L7@H&`H$BYW!$(?0(;\2\/N5 MNX4NT$I?K'B!L=L>6"C])JOHFQ:(U;EUU]1$3<#:?([VWW]L_96:W2P(X\.;3XK" M<'JY=.+VSNWE35O^?BZX/OM-03@7C9P7A$)\29#L48K#`WO77/OMT`H][X=) MG-^EU@HI:A9B2JAQ!^6K/;/KT)Z/P?7O#V?WHRW;(:LUU&,Z28^T$WFC6UZ? MFZIUYD/1L__X:CA?9L!8YP1?AVV2U*X65$E`(:.2.R M;=#'%\)+B[32*OM`SF;VVQNMSG_*;]@_E%^A%Z< M]<.Y`*@"3+%6J*6$OD*[H?_27?ZQ45Q''-]Y[]WN[9[M6]_O/=^MU^OS8M^N M[\?>^2YW&/FB@&L,"%0G-)B8N&J4'Z8MM:%(29K2-)"JC6BH2%"AJ4*:0B") M1-ND%)JH00H_2I0$JP'4$#60%*J4")5*I4U5U73>VJ[4/RJ?Y[V=W9W;VS=O MOI^97D3;JB`G,"/+TF)ID[158@NM>E5(N'*5,4O@^T'83QMRZQ!E+:%6M:F% MMMO[S>Z/K-#"A<5Z76-5*'8\IR'>->T-04AC;`MR>U&6M3D@XV,CCD"F<2#3 M.)!I6URU"--%*.;'IOH]],(D3Z@GQVIY]?S8.^IE]3+F?6T>M[A2#9SO+Y74 MLW^PK]D\QT.UGV5XEC?+LE)UJX\R.<*8S-/X._Y'CJ\1$AZ.C7&E\9+O?S,, M#\.8.%TZ"<6KU?!L`HFDA:#FS0*_N<":1_YJM<_B_4`7#,7^X.G/Q^7^XYLY=7U@2;>'<+Y(Y\*_>\=)O*N\\N?B7 MMP8.=9`J-WH[&=7E[ MA>V9/MMFI;'<^1M8ZHHJSHH&)Z($7D[]X0@O])^]@FL/O`RWX$1*M*708*WW M;I9Q]D--0"%(8^="%"T48Q5QPX5D-GG7Y9%J#V[5[M$T:'76@R7W9 M?=U]VV7-AXL@YR$>Z(7!];T0Z%W6^UKOI[VL"0./5!S0G*7.^PYN2,UYP#GM ML.:%SC+G">91\Y\FE;7S6TF[3/!9^XS3YB-XA7SANF+!,PV?JZ&*T[Z\G<@ZZ._I0/4W=3+@V4%] MM4XJ^J!.=".@5I:UK6TC?]9`2D*SMETC3(MH&>U5C2ER$K)2HMY?D1(YMZ)( M,#(A@2(-2WLDFF82C.-_@/DC_J?\/_6S=L4/(U?]H/JAAP(UPMK0(KJ"DCI] MB)(L':83%(4M2;.4IA0-DYXIYN[$&ES!HA;.,8B%D0 M>V#D<7:8$;$+VL0\+,,E3.PR`=]D&K$8GS.'/4/]NVD0)4NJ2(/2>>E/DJBL M$7>+Q"?"$G&;>$.D.QE0]AA[DU$-X]YVB4&PDJ\01:C`B%%95?E6A0H5HS)> MV5MA\H0!5PV(&I`S?.54R=4*-`N$"AS6HA[0'VO4<4=L$."B`$&A72!-0B.9 M'A(:X=B0X%-?"(?C'T4#-MRUW(8/;6BV0;3WVX?MDS:S;+XQEMMVW6?#B&2# M9)^RB6G_Y4`G0"=D2">,#'?"5.?'G62\$SH[?7(!XB<+0`JA`M$+:BI=+_CC M\7IA5RH:E5.03?%%=]"3BDD6Y`0+[ARW$(3Q4['("@NZK5LLTF2E+*);,=Q3 M%M^U6I*/UQL6QK.>\:GELE(J&;(23[C!$#2.A:9#))3`XA#BNSET!$@CKV0W MD"WD$*%!TDY(0"`-0CIV$!`(W(5=XS2Y1(A`"NA>19B)Q>'8KUI:AXBA=7K[ M'%^9R[_R%JP1[C9!@<:X`C@$@PJL#"IY94!Y4GE#\=U$EP)-2C@'XSFXE`,M M!W(.W!Q*6.,6W:CG(OC0N4BRK9Y3D='G!4GP MSDQQ4)H[R?_P>AX>)_C;;._Q^-WV?*0I[VG^^Y-G#R?G0WN?R+?:TQO>;W+QWHOSW(+E1O7;5QT1'8LW5#_>Z6/)R>^>1[ M/]KV[1>C9+^B?&/KZD=7GYXYOR@I4Y_<[1?%EN=>C-?O']ZYK_[4@V;T:\_G MOSSYS!XR\Z^W!7+SZLV/6=)E<:)8N`6:E*Q\@02 M:!1N9&Z0N?_^2M@K3Y]PDD)R^ELC@N- MQW!2X`04,%!;%6[R!@IKWC`ZT&`MR1MX25D&JQ6L(/2ZT%.!GA*(_E!ZZ!0# MN:R5>\KT_2;X(``?*/"6?$$FFWMA@YPJP.W8P1G9'#T;)'ZOP MI=:-K61-&-:Z#[OD2@(0_ZX?3K4/759`X1SU`YRO41]0R:HF=:LJRD\SZ&)+V#9V@K%(`G]$ ME>NZ7L87HCM8R4L&ROHB'28B<&\9UI9@:1Z&=?AK$,3@YN#C02H&K2!I;=1` MJ,'`JMJ.VMX:O52#&J^FW6ECZ&(-@K5\;65M2XTUIYF>;$\GN^5QYST&:M,T_WO?>]UZ??7Z?S_/]/EOSN_/?R=/\JRZE MC>TC)I`VYHAQ&]NL+0NR_H&Y%%-)V_,'5!A2#Z@W5.I6[ZJB(?E'G1G70,1%5K%RC3"M3RFU,+\IE9EJ#+:Q06L"_8B4I3#5(;X8E'#;? M,X=G[I39XMIB49GJJ":-S$**8*52^5&&(%5\V40%ZR),%%6.K>F-WK$-3YT0>M';^G/. MO5],S`=WI!.CO]BY_7Q776Y[>V-Z3'6Z)=F4\F=Y[9 MM!]#8NW\IW2$OD\::(>IN!*X;0DE'L=8Q*9^P56&6(]GF/LTFW%"BB#H,FOL MK"$1U=OI9ARZ)50ZMX)+ZEE8"PLA8O6X$/L9\SCBG7*`PPVI`#P=`W\"@L)) M@0OR)WGN,`]'!!A/P&&`DS`)%X!.RK#?#F_98:(>;H?A[P)LE.%^#+RQD1@W M$ML7XP)U,.V_YN?\89@+PXP+IES`R>OE)^7WY=_+`B=GY8K\-YE_4X:]$IR1 M8*,$_Y!@K0#3`NP2OBU\+E",M3^\6U/;[V`^YL:#;T($3_[+COX#;%X%KL=FPN1B=B MYZT#_B]QR,X9G.HV$%DC;O087S'V&#<,L<4`-FXQ+N)HWA"!DM$&:-#=FL<,APL> M,QK'IC98\+#4X$.!/^>YY.'<'O#\4KNL<7,::`S9UEP_Z\U&3&G:B9IG=)!U M&-+WZ`=TJGLQ->O,*^D_I/X:9P@]1>ZB ME2&CY"BY1*Z2FT0D)('#@^0T$>PDPOZJ=LQX$0VO%V&V(\(JT0BS'9X(O!R! M8@0BM\PKX@T1O9$(<5%,BD]S&=!:AK8-#@V&OG2GC#K,'LQGE"M+LEGE6OE. MID)Z&-.52IG9AL'*5!5:M<@J6;6(6#^2:$MY4><9Y*QG"P>KS)(,0[M2G2]; M;J92'JP^+=FNX/7_%^!))L9*5;2\/=XS$N\HO2O*& MSM**U[^Q]9V]?9$$(1S9,/\9_R/4W%9BTK8+)(\X8706K-H0#](*-F%6;J*, MA%A?I?6F68=EP-($JP68JBY-H`==DO!KG9T:#KM84\>68Z^SY3(>9+5`I!!D MA:3'4P@Q8N?QP!\%7P0\(?"$P1,$V@WVI4!3(&3!X\C"P#2%WPA`T\^EN?MI M\%,0*1RG$Y3[?O''1O5/]:Y@`[!*(2"$,S"\CJ8J0-_-Q@ZV/7K^JS^0.=E77.K M_;=3L#R](3V2IK?2,)6<27(S21"3_J21?"8YEKR=G$O:G,XF<*;`U0Y\%M)A MH(V]C0.-U#.9@$VL$G27P$=*,&"6`%^D=*[$U;RM*-Y/55];T#2ZTKFFU5WP M7A=\T`5=K1B_70F,WZ[C'R+/?B-7R/7E:([5`W@JQPCQH37)G6I2!/Y0*[2^ M?84#-P<(0ZXY(%R7JEH:DNQ+U4GGW')S):>4$B6S-%P:+1TL M72K9"`Y'2T=+IW%PKV23Y0[(=C`(.QB$'0S"#@9AQRW3C643ONMI_;+Z"UPO M>03?-@9?U>8SA<3)S%#5\5;8*2:_4TN*RK7+Z.\'481)SQR35K5H<=F#C&80 M*51:%-H>9MS/Z8\/?/5\2`DJW4H:;[,#'YO_$U1+;0<'2;4P*&>JV%:J$%8L M)`IF\!@(+%AI5=K$EP54CW8VH!E"#ZSV6]B*\_O9L M-Y?GWK!$V*:FAF5Y]Y+"B(/"XL7K@HLVCO]Z_<;7+VPYL)?G)&=TUYO=)]9L M.&;^=&Q5>9536/-(C!^6MY^(J))DR#:;X\E&06]JZU<#+WR\I_R[X1T]-_9M MJ94>OM2W>LN[7W]GIK=2>940GK3/3]%C])\D3IK)8V0176/ZJAY90Q$**]B$ M6,.QZ/`B^4XFN,09B';FFV&\&40&+4/9$0O'.([5M;]2??TI4B2K"%T1A\X, M&+%"K"]&D_%\?$6QXCC>0>?%ATPW.?8Y)AVT'&`\3B,A2'2 M!->;9INX\2;HM(W;N)VV9VT?V:[;>)0NNPAIUNX4GQ4_$F?%!Z(H[PM97]P0 MHLZ8E>CPED'#FT0!O6H.X,%F@'^%P`C!6`B:1!"=(#A@LP"3&?AM!B9JSM=P M4BW84S#AAM%6(*V)5K/U:BOO4<^WRQ+W'C'V?[<.PDCH.-36Y-&H[\:$@32@I+!@)6 MH&7%'AM5V084!:JU(TC\Z!@;4+6BHYL&&N-'MS_()D!CZAJD14P(3;"6\D>U M:#_*'Z4L9,][]N@FV<_[WOGUJ]?GY_E^/X]72QH;_3#MO^VG_#]F/`_B$"BP<-ZQQ=SP"U2O"Z!JM5W4W8FKHM@H@'/RO[,V34UPMB9IDXA6!-$[Y> M)MX1&5X495+O,JEWF=2[3.I=%II;#9L,#3$9.-DK4R%Y-\=!G-/3F4PGMX,H MS&FB-8TSXXQ:V+4G$0:O0]N5B:VMMFY#' MJD_69I.63G,M?F,,%6%VC,R(1^-W9DO"U:)&.!P-_4/A0]0!S2QI8KIEQC:K MG+AT&XM5` MA@Y"X"@"0--;`QO>UE_^\]YT]K4?CKY\H9=V=-\+/[I$?7"P9Y&9MH^)PVJ:LWNJC;[X'X8@N.82HZ8+Z;%Z%]%H2X:BE)T%/@&<-D5Z*M7H%I) M*)235H(*M>F``K3B4H85VL)1["MW;HP!>UN_QG_3?\].8UX%J/_2] M[H>E/CCB@^T2_$9"EQ8;C&@`SQ(B+:.W/IJS9^NS\2Q])`K'HK`O>BSZBRA- M"%E_5O08W_?#7A\L*X"ED"I,%6B'L]!9>*DP76`DCYO67'7M7JVEO;G]32W? M%`B&=(]L6$)"*!"BQ1!";Y<_`M7`FZ.(CZ*INLYG M[(1E[/C!.;QE?]M-EC3BU(TTDSOC!K>8NIJ\D:2$)`22<")Y)DDE+T*=7I4) M!>>;X*6FXTU4TT40=474,MX,:30SI-',3`1$6"UN$?>+)[!138Z1W,X+>>'^ M6/%**XFEL2LD>[6[FH;F1YPO/Y?OG"/U<14S/$L\\"KVIGEAYHHH$1@M]Y:D M@RP1[#1QLY*WE6S^,HW'S,_^#S?1P9I4T\/:.Q8S[;5D[*C@I\U6=B\W9K%Y MH0;1]6A*Y[C&9Y\>?G&"X];4BS9^%V_;+;:\\M7NYL@"D!;VIOO]+PSW\B+? MP+\ZP',NK8V+\PS#\7&.95WJK87PJHV3[5WY=<^OF%BN.-_A6[4U6Z99QZ@= MX-'FP"=1D4/16C+W.V8%_5M+N^5)RS-,LRY4+\`'R2S`YJ.'9*J[PJA6HE0* MWN@,@;4%V%YH'($S(_\80=3=.;)_A+:/D!5U;J^QP.OR&K,:\)JL/:?1CA#Y M9W67Q[@5A+5U<*@.KM1]4D?MZ8<-/7!X`.0X/)6'5ZI_5/U>-8W&5L5R$8ZJ MM3`@#Q"?3)&@F&)J=K;FV$-P%T^ZA#CG4IP<#@$O@Y4#R@94'E@>;%/UG,K%L(&U-PKQEN*K!'@9L-L$>&H_)#F=+D1?)1^637WDA@!YJ*[A0-C$?4/^3ZV/79R[ZC`NF7-===UQT!!O%1U-=L+H++%V!+HKOZO-&$@;=!\-W M^X#K@T`?AT^J[Y#/'Z_Z.`=\3LY182X'^F@.VG*0XWQ*+G=(EYT.N.V`98[5 MCOV.*0=C<:1P2CL<2+?W]1K=`.^%4,QPZK!$)_99A7MLTT'1 MQW1*OT@-Z7M;A:IX[+H3G!-)M5,=5.DM*EC4@)I2=ZH,KZJ!T�P`#AP2N# MU&"JX0GCU"`,/DQ*D])I:5IB`A)8)$%*2;JT6MHIG9"F)*Y&ZC56&IL,^C,# MC(<7`K`C,!DX'J`#B313P+P&`5)P`A@GL`5/(5*@"R1Q\.@%'A_+HJ9DA1D"V*49XGNS MZ&]%$ZYKB9V6BG.E[,P?+9VS)C>;S*[A0MQQ5BN9FY7RA,S+SDU,NS2+8F0* MCI:5D[B55_A+68HT=.JKN+68'1]K28U7^-Q4,/-5-"4*U M;[76F;9=L>NF&LK$]@RY$6$&N9C]U_ZO;#TPWKRH:6C'G4W%GLE'_SJRXL@W M>SR-YU8DY+?VK>WYP6GCN\5SV_7M%U=MA_!;+2NS/WUCXR^7+RG2 M6\5.5T=^R9[QA1Z7WLXDMX:/C@Z=&"T;>AN MX0UCZ_8-)[?]^V]<_GF]N&_T8'?W&K<%'=\^_SESP'K-TD^?U$,HQ?&!9F8VQUUCFF@V^50WG@[`TN#%(\4$0;ZAP6+VA4MTJ,/VA_G3_ MNOYW^JVNNWBI_H?O:H]MJ[SB]WSW$3^N[>O[]-O7KSCI39S$<1QB6F+G48=T M=9#23+0C39G:J9LFK4T?ZHJJ5FL#@@F5/Z@T:9I@A!*)?^@H[2*85IC:C/$0 M12J5!MJ4H!&5:AG9M'::MC8[W[4#3+#Y<<[Y'O?Z^ON=[_?]#@3^B#=P0]29 M#69)+)P"=PH&T7UD1_Y(\J$D*7B`\Q0\0YY7/%ST(Q'PXQ;?%I$`1$TD)4W, MB(2(>7%`9%VC33`JP)NH.AWXY/:C"=1RKG:B1&CU_XL'(")?1Y@*!R%)(Z[IWKG#/4E$;F7MO"_BV M@'?+/$!989@,(E%LS8`O`P&2@9;,_-J'93\BD?F)X((-+DFG.D6G@AX[]=>` M820L\F[8<[KI6/=S5A^%KJ\A8/IF1RF((H:CM']TMA*GET?MZF>U_!#R1GQ& MXBP&+"I5+"I5K)E*62JW=Q9]$HR/2<>E9Z27)&X*#<$>+RO5I+V$P3^ZJP8= MM;$:.5U[IG:IQOIJ_;4I#-ZK\;*O`A7ZSP/M^2)3@?%R!9B*6>FL/%!9K?`I ME@[^$E>ELK6RAU@0Z+"F;+5BV02%U$#[INHL886DK7VF_UWT:[4E=1M_%*?SG]=C65S;`K#(FQ3W-M&M.:)]F^."8T_EP4&ERTW&) M_YUXX.X+_Q@>4F3UOHF#$^?\-Z;2#LOA<+A_]/[)PWLG.C(/WKOM9?VS%ID7 M4*DYOA!J1+CV@V]*V';J#)Y.BAUU]:+4@+SC9P/T)P/S$HYFMLYVNO&CMQLC+9C M]L/1HF>VV?D)VTA[ECX#)CE+LS/=/51D)9KX$DU\:::,A4*::88\V]Q@Y>?Y?6I4R_G6C2[16Y3[H]N6+7GE/US*%Y MP#32(4_/(2P;\112#.%K<+=3(DN!5[#`&!CHR`T.GE3<7\78P8>RVQ#B'OX( M3AJH='0,W*UX3K[U\=>!>:7E"=,'"+SQ[WZ&(6NOW_D-?-M&LPUV7I`H.%ZZ M0`T4S_\7?BWKD/KFU][\?Y#NQ^#^!/0EP*G_4"<3^A[]D'Y+YWZFPZT$"*9N M$I]I(@$?QAD)\.L!KW\DG@-?#L;CN>,YTI\;0WBK`K M%':%PJ[,Q-/0GQY+D]-I>#8-Z0XJ+#Z'^OH52C/2E84\EF04WNO3*_UWK+Z^ M!_QUS/^6&QC( M(>3O.']]2G:SQ5\]TN1U.75/HEP(.)N$<&;"R1^I=-9GW?F+PRAX3OYY_NX; M9^_>^"WT>4BF=N!6*]G<\GC2"PZJ%I)K-[@=J!:&^5/EM-$6B99T:C1JC#9Z MA)B&4=*H4:E)TL7",;/A$PT?:?AHP\<:/O[%^.+Y>C5D^UC#QQO>;/A$P^/O M+)8#&,@4,X4:MPIN&=Q8*H3L;:LHJ#K0I.A/X,RP7?#)M-!:Q!244;!0(]9K M+SP/HW2*[7G;&R6.WF@-[RT,@P.`"X,&!O`!X(/@CH([!JXXN$QP)<"5!&\* M7"J,X]>I@%.`33+\05Z1"9L"+01\6`L3A1@@ZT!TD`W`>'?>&##(0``&L/;2 MX*=)X)4]"O$Z-:B>'8:>X3/#'PRS?`JD:`H\*7`F8;-4/K\K@DD-R21Z5=\A'Y;?D#V6'_K+PL4`X0S7^9+`1 MDP>&[^2O\FR6XV%P-P\%_B#_-/\\SUWC_\X3GM?X87Z"/\.7`[Q/X&#P(H&C&KBT)[2;&KO#I4&:5>$0 M?O-%%02UJ)*-R^IME:A-Z2;RJ0"?-OVSB92K)ZI$JIK5SNHN#)^J/EM=K3I, M#,Y5KU87J_Q4%;QE7.,Q+[!>Q4OV>6&?]X3W*>_KWJM>?M4+WB"EI1Q."09P M`4\$X5QP,4B"04-5'TM%U)0JIR*&RK&N2-GJ*D;$)<>2BUXB-;<673Z45G.^ M(1@;@B%*B&EF0V&NO6NI`TL&-65,12Y%/HNP6!&D4FD&TH-TOPTB[!>1)P=G MZYQI4/*DIRG3)K415]MSZ3R=EJ=C<>S.SZ8I7Z8I7Z9GRDQIM412;&ES:0_A MGFP6ESLLV>A[S)&SO,>D MRY`/=$Q.6]8"+>HFK:Y.N[J;G*[KKOI[^C^$EW]L$^<9Q^]YW[NSSW>.SV>? M8SN.28Q_Q+ED@80DQ`5B0[(&QYA,(1!:$EA+7;*U@/&@K%(%VHBZKII`&R#H M/S!"ZS)-*],84/''_F%345?!M(T_6FDE@Z'2"0EU:\>VKMGSGL\AHPQ.\7/O M^[ROG=?GY_D\W\?2999H,XRBI9@H]U MFQ5OQ6.]V,(.)D>+E4\>&ZNTI?>N\;'_^7BX;WZ_%G0O(PSZW5CS:XC-YN-0 M#^JB+=Y&XHG$PU3@WKG2"=;`_%7ML2RHXF^W_T M2!7XA>']\66)4BDA4>_V)U!@&+C&LBL*-=NPJ++( M]'(.;]GIGG9A9'+`1UB(1:Q(C$P%E:JN4U@D*E.\61\TYFU&AS;%LQCD60SR MD^EM07`%\9\%]P9),PT&$ZC7XL&Y>FU.1%9Z!?7J>_>B$#L%K0=+^/B8N9EC M91Q'YJ_TD!]BUX/$V'V/^C\_>*2B!BX^F9]`QM:&Q,\(Z(BD\A_*!WD$BY M0(YT.V#""4X5==8Z[5F-G#)`8:*+-[Q&U*`%"0HJ%#00W+J;"`[=0>0&31\` M)NA%]BZ'$!2:!:KP(;X%D4.#M)E2/N?-17-4DQT0#SA`/33^I/U_>SJ+8#YRJ)&$PJ=;5=263X$J"GR2A*J)_M+IAE&T8/3&TE6W86FU]MDZ-L_DXFWMP/CY5T%G. MZ"QG],DHUDZFAJ-,33&2GX?#:6<;V]'&=K1-]EMZN=_2R_UL1VJ(#G$PQ+8- ML6U#6``*Z<*5`AU4"P<*)%T8PAOE"FIA0>$X^N\4Q``M["A@,E9RD;&UTCV] MQ_HCP\`AVMN5U+0ZJ>IK?(S9T_L&AT=_'HF^I/YF/>?OO6T4L3J,C^'`Q#(; M=GQVVTSFJE%ONSO<5DX7[Q4!JWPP>5ZL3G!DP7SVVF%5&)/NB&O3.6;@N#@& MZ.)F@6^V=,@)6_( M9&-3<%/GYL/1EUN?6KAZ7]XIDO@6NWU/:V"WTQG>FNL:'T3">`(FCKXY:>%H M7F'5DJ=[7;,+7VH:Z=O.Y1O6Q?30T^OVANK[MN[=/N'^:&,4&T2[7?[.[W8? MV_,U8V3E4R^U?-+DOA]C.XHOKFGK7[+YX(,6[S6:2#AEYBY_$`F7H\?224$- M(;:C:"@S-ON\YI3(C*"BX9FAS.3.SWR&-M<&<(2!GV-AJ]>R^T=II^9-,:JE1"Q%":939Q@&!9`2X$/( M.)M@L$GU^`8""@00M':DX!NX*@2$I'!)X"^)L%.!LQ%8&9F($%3OVM4X'$Y< M39"^!`BY6*XS]TSN]9S@N9$`/@'^/\E@'@L&7UT'R7[**RA MF^E)>H;RJ00$TP8/N@!R`AQ-$$JT)(@HQ(4N@6JN/`SCJ^9`_GB>7,E?RY,\ MTY?^0&B`1KWEVMJZZ8"^\+'RHL737?I`>="LYLC!J,G`*&"5]Y,H-"%9WC?Y M%#UBDZ!94GV,4SZS)<-^\P)PG(OKL!C6P=8Z3A@][*?KJ3*L9RK+YEE+%V2G M,F$+2JQ'2:]'`(4G7=3@P&!$,AB1C,E,VI5N7=#EUS'76RY^(QJ" MGAKJRKNV$`Z_XZ8\M.57Y\G^_+'\K_+H[\UOQ,'EO*!EV!?VMK9WI3,HJ!LR M"S)#F3L983YE"^?P061692I`8S*!`:C(E.$T M2%_637-XM.+YY7T>S;MLY%LCI^>RZ+N[MHRTZ9F>A4,_>Y"HF@,$."6!VYYX2]!**OG5"+:0;*S2,PC.@KJ+I7<5&&S`@<5^+6" MQ)A4#BE44%Y72(U(('V6P%H"9X/P!^<-)_FK\F^%Z,J(0M:B-A(_$\FD",^( M.T4BLM.\JOL'/A;_)9(G@O"I'4;LH(;3X>UA>B5\+7PG3#\/P-$`K*M]MI9\ MBH?R_--#NE0H.T&2`S(Y*IV2R)MV>%,$7O`*9"5=3RV0P^=G*,6=?I/`(?.>[L!% MT?^&GS38,$=)5/&'_.1S/RA^^(K_$(^(KZFKJXGI0#E=U8__E^]J@8WB.,/[ MS]SN/=:WN_=>^QX^^\XO#GL/WWGM6U_/:]=8Y]#8"$-*4DQH1*#!:<&&.A6B M#2JQ11(B:)70YJ506>#25B(5:IY$6"H@0:J$-H!2:%1H296H02"5TI8(W'_V MSJ814>5]SNS-KF?^[Q6@:3[`9CN"%N2-V<\.5X79^?IAM9*=;YKCF'8#.TQ[ MS/X(X6+;8^2K\5@:_^,]L9D8S\7BL5?QO[8I<@S9*388VQT[%'L_QL_&0(Y5 MQX[&J.N4!/T2')3>E(BDXELD/[Y"JL#Q)0''EG:8'*=P<<[D-G'[.*&>?2<,LKYR!S[RX+`GI^'&=5V9>P8[T(0@L#"L*N\I[UEV@SF* MT=)N'4?'.`8^-O;8F-50`BMS(*D2C$=+47(.D;ZLKF=:N8"?2]36U[?[$8*M M>EL6D2<`[7WH']-_`,?MWY_;]:='WBF^M';\A>F7?_ACT&0X]=A'/[O]K],? MW_[P)^>/[_IH\NTC9T$Y`AV?_XXC7-.M&=LV>IPS4(-_^R:G,-?I]:)6XB'/ M%@;/:OGL937-D#"NP+@'O@?PJ?H?E528$9-$NF"O!_8JP*&#-,.8%';U`SC\ MT2)M1$ER*2C5#B44,CP6MD)&+ZN>8-`HLJI60U48:_#.C#[=W6^U+OD5[;B6ZP MF9#,9_.7\_2>/.3R$#1@W#AG$%6)U12_K8);C:KD*^J]ZK!*U;2OLFCS@,VS MW$,J7`KF!V6Q0M24#*(E2Y( M]*0$-@DJ>/=B]PKWPVY;0'`%722.Z.JYSPFGG.>=).N$Y`=8YQ M!W$ZH-)QTO%'![4Y_([ECK6.+0[>56_7[7UV>L)^SG[#3H,V>-KV2]O;-MJO MXCSBS.[*PZ<\&I(;#G+0A)MF,P\O]-[L)>.+X28:$/ZOO8D@1P_OO2:EA_M`_Z?BHH M[4R?V\OZC"&E9BZ4U#!!KYGJ;&`/-%A+CPT-4QI'H5/H@5;R1[24V:% MGC(K]+`2P"_M8:RP`I';\T2U>$A\7Z2*&!?3XHQX4>0YD=UL%VU.450[F?AW M,O'OG#!E#3*>^]PF65*RH^-C"$8*>!VMS0#&ZU,*G=T6K=4VB\1NV"7D!\:[M9ES[PN M^RP>T"G2,[EDV.];0L:>[K*J1JES9_:_V<-F]FVKRF"K79*80: MF38_U;)SV3>?6];__'UM:[]>3^CQBK&5VY8VKW]Q7?'9'S0UU2^L]GK;SMZE MS0O^DB.WLT\&)4N<;[5IBQ]Z9_/POE5UQ>Y4%8?<-(C<-([I`+F5ALW*DUEX M2X-?%CWX6IVGK%R`K"@-D$M"U0+8FH1?12':J(:+>41(4>\` MH;V^G6@*UC!G\5K`2##$.;':"1N=LSX2@!N?.)L@1N)\ M@K@3<"5Q*T$2Z4AU\5@'M*6>2Y'*'"B6-=W4O:][IEN8[8:-W7_N)@<7P(&F MUYI(H@EHHZ]Q1R-=US+>,ME"^>3^)/DX"5P2Q.1(\D+R[\G/D[PSV=+;0NH7 M]2TB0D.P@?`:N#1P\W40B>;3U$`T-&:0)VR`$./"X";++PB7!6H3Q!TU'Y=9]^L,S^@,PYD;89^V93KH(G6 MF77KB.V9+_J`U#%MW@T1U8-F`.WW<3`/XZ))&` MYVZ(6]@G;=EVG?UE6D-V!G$A8#F'=D0\O5@7E1&.ODK+=(],.!R6Z3ZG.O7: MU\]JR:7J\VLV/KYSL';7P,2!H=W+)T#^C$)_`PM%]' MMX%&XTD7/.T%GCVPN%\&P;;71FIX"@O.\L#S`9YT M[>=_PQ.>AW_RJ+,OVLC?='A*@J,2R!*(DB*Z'%0)UTW':B_%`ZW3;4P&JW'< MW0K(Z!*<"@Q5*%"C?(+&?\BAN"+@CS`(BXJ_&`ED6?5:["-A]7)9R$XE6%." M-;E94P*&$E,I:;>;6:>5"W*ZVRV:6-)I$3@4LQGQM&CSR"*LZA)?0`2UU,D2J::D_=4;>2LED1 M]-A\-:=:M=05Y3*SFI=Q5TY@O7(L@9:%:#Z!>C)8Q)D9<@07B18+0K_/S)N]PET25WN:XT+&^P*:6Z\O["J M&LNU^G&G<^)'7Y81C6BX%)TQ+[ M?=Y[[_+Z==[O^WT^S_[HO93'X?S_]2!P&Q8_IPGZ:ZZ/?GLQ'4?SM:L:M-U` M(QTDV#9%L)-7<#3/.+;`&IV16*$%+<.&4@'__VG&MZVL"EK$3KX%-[G@PEY! MQL)28SN49\WETL>EFR7Z1P&0#)T:W-!!UH$ORD7B<_@@Z\C"L)`%Y5T)BS;H M$EL@E``Q`<,_UG^JDYE6>%^&8^UPK`+!,@1S73FRK02E`":!P9:G6TA0@$'A M:8%D--BK09/NTR_JLSJ?TM[79K0O--Y7@%]F8&OA6.%D@0[DM^2/YD_DO\PW MK7X@>R6+*FT@2.K9">SU,VGN]-KTU06TK#;H4-;JP>(#IZ-B6<2 M)!#PQ"O'RW?+Y&L!B%R2B9>784U]<%(^*1/3`TLH3(^Y&*_B@3LJGY#?D>E% M>58F'VOPUS1^B:XRX4MR*56BS7)8SLETH09<;:PV5:-"C1VD#F11)-2^_35X MK_;[&G'7]-K+-=9M$HV&_QNV)V`>OVZ`:'A5/N6LD_AMM?1^=T"4$ET59SU;J#@?="M1Q@#X M$2S6>Y8MJT;CN+7[HQ"+[L"*\S36G$WO1>%$%+BHA"4I;8FFXCBE(P6[GTW! M$ZE/4B3%Y(23IM@JV,2I!XKDB$&:QF#X3S&(W9OJ@([S(1!#X'.'8'A3"-RA M6(AX0L8^`CH!H*8<(,(8,T&VJ^7J^JJ$JF9HRW+N#26*QK.)4:B">J;O5OZM?JHLHG116> M/:2">C?F!-4J5;PZH]*1KQY7II_;%C!NNT4NYRGK M\U^-CT@WMH\L>/W0ZB\N]'^TNDEL(@!I MX:D^?<7$IEQ_5T<@7!_I/?;S3D^;^BM!6&F8F=1@=[JOT]61*.VQ7IOK\+2N MB?7O0BK"T]")^U/'(=(04-5P*-+LUV*EK.S3BUG2M7SNM\6YL2&LL&HDG MQ`@,1^J^#BL2=LL>J957^&:2;U>Z\LJ;S7W"=0_6[B"O<$HI4 MPRY4Z.8PA-D9>2Y;L,(G$TI*]2N\XN`D7"17EX,6I[:[/1*[?$>"6>E3B4B1 M'5$X$@5V]@C&J.K"^D]A7JNPE*@91BK/E$J;`7!_FR#EIA@D7M:J/3(R,SXV;_0^0^_JDJ](L MZG3.3I7MIJ=4>'-6EWE6N_W':TKJFO,0."9[LIM'KH* M5>H)B"[%][XGI%,>88#GPWU>MKA-(\&*"W.\*?H M-]Q:;H!;1_R7$FNZJ\+NLIG;(4E"K28-$6AV+I3!PO8:7TM>KLH"S).N*==WBUW4/8*GG\IT+(&!=#(>D M^KDU#+5:$+4ZSZFW\[>S/A?+M:EPN**X8,$%#US@2J,7N]X*(EC;@6P\,.^POZZ!>\J9]M6L8%5;,"-`ZO.FJ%PM%7/TT); M(Z&TL7N[4#YM1^N+47!'H8U&K>CSQ&WI%I$L.(_+OF71(]9Y=EFW=EICUI35 MQ%E#UH)%FSG@F0)YID#^:+UWRH1;)G"F9!;-,^85\[JY8#J#U$2Q?U`H6>9Z MD.DMH=5EJPRJ/=U#VFSF'E MP8J&7/\=)+;RTALK#^F:=`T%.MYP0JPN&EYI"W/IQ68:R2&D^99*A!KIZ7D, M8SWV.!I@N?P0URH]J%CFANGE__5@IQ>V>9LS.U*(; M.@37&\650X*#]C\9^^&&L;SZ>&QUY\Q&K=.'S> M?6=+I]NE"BZG:W2]L3F677]X>M-O'CWSTK>?H$]&%__);Z._X`PZ=9D3%O]Q M`9T%96-'9R,Z&K&I$?E&I(U(&A$:D7L<;]4SP6!5D=%__*PI!'!<8XW.FB)K M#-:$&SJR"]+WUQHEZLAC'4O=HHN+Q(E:S36A-E]7]"^ MSV*P$3F;28-L678DC4C91WR&G>D@;#5&C4F#"@8(.@A%$#0(\H@%NXP)@^PJ M3A3)?`'D`MR/@!"!0QW'.\C;8=@8!CD,=\+P=@C\_HS_53\=9:<&7]/*384* MH[Y)'VGV@=@D0_\!&;Z4X=\RA"F(%/90>(&^2XE`I^E-2@63P(\(_(?L\H]M MXCSC^/N\9_ON;).[Q#[?G9T?YR-GQ[EV`.@E<0C#8BTK3$ MI&"G;1Q`-BAE&\C@+MHP8\_99^RS]JI]P_;5:)E6SMH>F_X>Q.389!_MBOKH M;>SKLWA-BA1XD=QIGJ[[B:/[%@\\S\3IM(/L=.-'XG@F#BA^(X[]C7)R@S@9 MCT<%ZO\>"H`$4="$LE`3%H4SPEGABK`JW!`"@D#ID2"?(PB2$F%BEA?U:UI[ MNY>%#'O.G]RXL:W-?]-`07"#5+^)5#8H#"/ZE9>SY'B@F!C#$<0,QRS?Q1C\ M4`%;(3@(*UA`"KA(653^J3"B4FLD'D6Q,T2C:KK52LW79;MN(B7MN$22SIHC MTNLSDM*D7[&BO#EG4ZII#S25>4 MYA*TVX0N5.+$HM%QGB94]G1.[!8U38_:N8;':R)B7\-1U9OUYNQHXTF*1^N/ MS=?3KNJIAS>99`8QA43CYTYBJ:N20W*.>"EBO)Y8:,,LZV-@O;3]:KA'&^+X M;^P\ML!QA_6^DS.S4T.=`],<_Y72IE=Y;C1I[)E1OMOQUD_AS^EN'^9,GF6Y M`8Z1.[H/K*_>NO7[A>?%4+NG4>=-SJM,O'MUT_I;Y"!V/;SG>XWY&1KSC%]" M+E%VF*CTC@M^%0)Z3,?!@`H;-E(9]_8V^\`02XC["_#[?+],N:+$"S"W>*# M(@Z6X&[I00D'7;CK/G!QO@0'=9BK@E!UJ]B?&H,Q,=J9O5"$"R5@*W(E66'8 MLES&"1=2[@D7?\F%$B?'LEQ)*1TN,=M+,%J"-TN0(OU9$4X6OU[$(\7)(M[M M`)N7\SB?@[4V%"WZ7CA`83&GQ>@Y]W@Z\STHE'.B$I0Q(#PR$% MX2"J0AB3,"560:O6JG/5*]75ZHVJ3ZQJ9:4Z0PJ+=(JJ0ZW)V:JO2@4N2\ID MSS"L#,/;PS"LT<9P^+<$"Q3<`ID1/EPP03.'3&S26F=$+CQK@F!>,_]J_L/T MF*8A:*2&!.`%^H966)X4!`@2$J@Z([E&EF513W=P:.#FH)U*M9!`:!`DMGBP M02)"@T'A$1O*9@,.3G$,%=%Q"?9*)Z4/).:(!(($2!(EO"C!F`2;))`,:KS( M&30HSQ?)]VPH)'S9@&,&]!KO&'C<>-VX93"V`5N,W<9/C.O&QX:W9@`R9HPY MXXSA,9Y3X2/U$Q6+ZJ**59W>@'WD^]5!U&%!!Y\.2*_I,SI#_APR"TI$IA5966 MO(,F8=02856#8CK=&;KJ)HYN]K=T-L#4M#`7: MO%FO4Z+5,^19/_J8:_LIJ?;7G^@4ZXUNLIF;3<;-FY1P\TW7=?3H_*-KOM7K M/OU`362;7F;0\Q3:(G(V%\KF;`JYIQDG,#[27C("AHM+B:URM'L+RT]^_^V= M//MBJJL>T6/#W]EL#>]]:7I'97)@AN>//3N[A^.RR>',`6MK7-@W]+>9(\^' MX,JK?QR-^CDN10F7XH"TJ;/KEW?,5EZ$;0LO?[+^EP]_??XC30LS7#]'V)CB M.W3?R'"PMZ'_V7N,I>1BU?+'8$"3"W(X)6!]UJ2A:48 ME0I/G(FCD0.9^\7##RB.)(I$GIQ7*4&J*C4C9$NT-;*MT4=WO4\27@&>@ZG$ M`%R3X#1W(,9\'Q'!R%;07X8A[R2E"8/)9_(X\OC0#Y.S@" M/[;@)>MU"^^UP!+)ZH$!J`_`DH/A2%:17&9?#)L%N&E`QJ)!^9CC!!)129?#,`:B`5 MR`?.!SP\#Y?8/[%8J)!NI4(ZE0J@BE;!-"Q6&+Y"M;V9P*&C(R!H9(]6TY8U M1M0TJ]#OXY1`9)27&/%QA8*3'\D%:="HF[7Q:;H@JNBG8?8_4VY1LDT/F8SW/4W?S?\(D%9E( MCK8RR4&&-BU)TLH0A=#XA-=@63G209J>5FM#=.IC2#+`\49Z?->/=H5>KB7# MO$!4=NB5B:7M[K8WTIW1`8Z+=]?&G8[VDJ'^ZIEX@N.V]P6/[9PZ],+%ZH8P MR_=Q((T??N^USG>FPL#V^8/1_/L+M?V7B0K[.*;M<\]-2I%:OG?]/],"ER+: M?&'Q!POK_V81@\3/KGBV,Y^B";0%;<6_*P\Z854K%&DHT>#24*:ATEC@.D*% M$@WN_^@N_]@FSC..W_/>[[.=NYSMW#G.G2_F2)R?#K:QFXS$'@HA;C>%$88( MJD-6QD9`6W"@=+"U"2S\"(B!MA8IK!K5)L:0.D&IQ(!.&^JR#&A1^(-E*Q1! MNI6I8UGIU+*-*F;O>S&B_6/6^7GN?=_+*;Y[/\_W^Y`0<1H,M:6ZF%EB8K!E MX(JYDF0\SSO9GF/4P"<91=-;ODA"*PEM)*1)$$D'%#!:I&)V%;.[F#W%+!+J M\?42L3LXNXK97

8G\^(#?$I>#W/`3"$*B$@`6[0X=#B#%AQ(2@!X(A$&I@ M+P][,Z1G4+*'LLC*+LMNRI[*WLZRBI/N99EHMBN+WBJY47*WA*YQ04TU\2%C M(ARIA.T"''%#3[H?2YH`[V1`RI1G:C,;,HRXM,,_G()4JG42>X0%$4JW]`LZ MK>M62`55Q>Y#ID-TE*9+:5;7L!=@H7N8A7X6V/="[=`>7-JQM,.F41\%,CEL M.])JN5E%:(X>3\:F$^7*<#,Z9<"V.>P.LLH/X M($*[R`D.[N6.<&9:6_=&;%\D8KL%88]M^6R!MRW,]F.T';(#RC5,C#YUI30> MCT:I=&Z6(%8WT9M3FX%HZ6>_E#(1Q6#B/Z!R\%@\G4;!`9$(YF#N_PKEHP_1 M0XQ>,E6%NP'Z=L/OBSPKG6!-B/=%EY8D>BV1"M5RPLK-O>G!6%^?61]XIF_F3T[ M.M-PZ^[L](J.A0<^VK@&]K7^1?.)&$:'2.`#2ND;G2\?R3Z;V7EM>40L4S@. M]Q).0P%JXQ\'_S3[UXY7EG)/?/JVHYG_H<_2QZ@%J/Y7JUF@*\#M`(7-/5?, M)L$!*Z0#(,:#(:#I>,'0L3,SG:#@+2;I^**JN44,#0F6AA=#]220*VAR!\WI M'_Z9Z<4,&RJ>-51,<0599RV0>.C^`P._,.&$=' MXQ?B-!57XGW.Z=7X[3@O!GD-64W8*;NP4[Z,_8&W1=8"_FFB_-@%-W3R+U$: MI#6R[=UXVVLR5:/4(+&&3`1EM;/&:J2FFRHM!5]KO=3D/Q.9B$Q%Z,A9H#/* M4`,\Q%J_J0[J@N<\X"&3"1^E9)1E"NU2R@,\W13,!-%D$.3@FN!0\&AP,LBZ M@T!9Q%%URRB*T!`"%'5$('Z%=*Y:;*HW-S&35Z8&)_*#,WDJ/5OG.-0)Q[;V MYF:(?([C$PPW@M8>Q/N0%48\P6@/^_QXCP.#`V2=(U2YP7S^D;W, M?5:)/F<6L1Y5.Z9P7ICC9#2O&F_TZA3C['*.!XZ/I]J8%+:,6)/L>>&D*.[8 M>G/]ZG]47"[S6_+#P8$NTX^*W#PEX0A*8OG2^\_J/%-"@N<4M,$$_W"2)%(:KMX9_I M,^PPI5`F=2ZS?XD,'3J4F?!-#I[E81T/&TM@HPP?E,!7^5T\>I__A$>,`!\+ M,(&F$.(DZ)`@*4&5-^E%VTI@I?P-^8Q,MWOAJ2!LX?#;^T(0^$J\*K)BZ>@`=9!"'U+010U00Q1]B#I%H4.8+Z?>#@8_;_)DJ4?^/5\4?5*'O`DUF8S'RE2_@FM$(TKY5%)CU(5DR+79WSVW M=?=;/9^\\ZWC&^M>;=[U=,]SJ9V'O[\;K3T-QJV!?87W[AE MXU-7U&;\R_)U5,Y+S(F=TI"_U&?2VIP788E]H=6%I0H>X#W!C:F2]'6(+2Y7 M.+>1V,'S-U:W%_[-"X?KM!*15IB2^6O;F`W<`"X+?!*?><.9A\^\;Z+[##Q!`ZN3OL+%PE,(LEJ/AMQ\!5^/2[ND0_<9`Y!BVIT?,\2@5X;6 MF`,F,H]43U/3M;HJ=LG0):^1C\HGY5LR*[\LOBHB\8B?-X';IP3@7@`R`0@$ MH"H\;+]B7["OV@Q1U`^QA'K4Y0J<5$#!MP#4!0,P!`?AM\`"Y"-P\;NZ2*6=;EOE]>`R5&'+2%_)5F&RFT0U=D]M??.$KWZFI%FLD3>S] M6<^&-[TB^LS#5]+7"64EJA+4W[JW?_M-8VT%!W#/R='S9 MZUM7O79L<^%-CQ!.Q0P7P['X3)-^C1VADK`SDTU60:(61F,P%H-M0>@O M@?.UEVNOU]+;+D+](9JK+:N=JJ4ER04>*0HM+=$GHVA?%,Y'+T>O1^F= M33`2A2AI_W*BIW-))8SP,`+0J/F\&2V0]"K^3S70QA3\9)5$5<0RL)61[37V M@#UD,W8&BX@=H9AA!E',,J:/V<2<8BXP').@Q,2[!OS=@%\:<-,`XRS,/QWA MQ;-@9XQ$X']LEVMP$]<5Q_?<74FKU6-7K]7#DJR'+4L6LKVR'@B4>$F"QSQM MWB%&P=2&U#9@RV#Q2H(SV$[-8_"TJ1.3MD,*,6T",7D,<=H9DJ'DS>#K8 M;7$GA3:A"8D&\@%_H8C>E>UDIM.=._=JKZYF-/><___\CN>V[V`Q%".#B35" MK1&,1@&5L;9"&[*-@%?DAH-0%:P-HN`]#?P[7QL\8ADG5`BH2S@IC`MW!4H4 M&H0N@1P6K@IW!%*0$0T(<%FH16WH.")1/NKIL3[E;D6!1<#3#CQ MN-F)L!'-YH2B1.*9N9=\AL2E_,#IH9"2A/!Z?#_6"[)BK;=N8,/.%ZJ/'"A] M;+&*7U70V7>\>?$!OZZ8"=')YR9/7N='N<_,DM^KL9]]+.LEYA$",2$> MJ]9"0(!`.>RMP.,G%>BP%MHT!S4HJ%FFJ=>0L0J(:B'#0B<+Q6R475E&G5_"*IP':?K M_.!WU\)F0$#;+3:3N\Q]I):&-OH@?8,1J5N3P^2XDA33%IX+#RO MUV1THEEO!;=!3L`2FGXI;M-,?=BM>PM>/F95D8>7*3$X,%L65:IMM5N4]/D] MEW(?P)O*AMS?:3I(4XSKV>JE\AA4HY:$^HW[N5M70<;X=&Z74OYX^].X?\&' M:/@6_;$OYR&P*ET/I\ASLC9B(?&=F+#%K\?1=!2F*Z$QLBORKPC9+H=M\EXY M4K%3+%K&UK.H,@[>0G<@%.19$["F0A,RE>NP1D0G%^X/GPR3X7"B+MB`%7#" M+2>4DK"Z*)+*ZT>5L)K,5IM=QH?*1\`G/LH7^1M\X(LY.1Z&^:O\/WB21YJ^ MS3$8CEV-(2Y6$4-=L9.Q\=C=&'4W!C'9;1;5(G0'/41(PB>I!&,=9+EKJ8XQ M/.'H/!C#W096R"CN%*JR:4DW#Q)CJ72"PU^.Y3DG%T2;H_OD&49\JK7!'ZZ:NLOEB\[L7%^_2.E`14E(S6#HS\? MIQ0DT_%1[GXI*U_=O6+'QXVYMW/WJ^NU*]_3&,F7`_$GS^YH?;7.65ZF_LLC MC[Y3MR2D9M1J1B@U"7(:97*3R6#3Q9V?YMZT2*JHQA'ZO>PP48!U<5_BF#&Z40L9SRX-V.:'3=-F$6CC8QF4X=$L'&W7-.K1"`;>Q0U&PT@(_4T.W MYB7-:0UYP/>-#VWT-?O0>N,38I5I12WT51*\C0 M_>L+F2N?IRY"R?$'7R:>7[?DV47B_E7)O8OTLF?4YK.YSS^S>((N2_W;F3,W MMT#HNY-0LF5PW8*E:R2M/(W]:5JVE_`1E\3E^Q2POQ`" M;&%5CJ-'DPXX!D!OR@`=YMW&=H-R`!7G=#@['*..TF74W0V.-N=E-/)0B'N M&#`<('SG_?C:<:_RKE)=`^5!B=ZD6TWAZI#,XL87)L&^`;,^/P/["CFAD$SH15-1^OVS`Q5V)O=)YP67 MAM8K2Y4RF3$.JQ*?WJ7[#^7.KV`2CC+:%'L'BL`*:&V$H5E^T3'L,?KR'S%R MK9:./+S]X."?:!E!D(2(&>`]V7["3OB)*$+BT-^,,*Í,EL"$'R8<,,'" M%$!K`'IH^!*3?`0^L`%M!M8"1RS060J[';`UU!E"UPEXBF@A]A/D>F&;D!'( MM<8FXV[CJ)&Z0L.`8\B!CD9A011:HG"O`+IHZ*7@SQ0T1>!:!+9RL([;REWF M)C@*<="!!PN7V0D6=?I[_)?]$_Y[?MFD$DC:@,U_Y.%?QM:(CB'S* M#\4%$'%9';&H-`6DR2Y-A#1I,WZ\_IQ/:6?)^(S\_`9D>VW`AYM5JBUMEF151)J1S:(316K-9@-2O::[=#- M&&M5%J_?]XVSK0_.*0+_*$^_W/5UZ_+NMI:C M]56932>?7W]T\>OH\L+!'8-3B_O6/OG:&N7\E3T;]DQUC)[J_C#:_/B+*W?U M[FE=M>>;ZM>V'3]5=V1UIAL[;03WFV_)GB-XP@L+1>,^$I8:8-H*TT880$/H M`H8S*1IJ1E9Q&OA`'ED/*"DMSG MA?K"UL(#A>1:59-J5$66.A8X4)_^O^Q7_V\3YQE_GO>]\WWQM[.=V+'!<4Q" M'&/'3IS$D2$D!^0+9(@P*%^:D>!VD-&M'7'HF@%E247I5LI&IJJ=@*FD4\6T MH))T*Q/\4EJ6C4YJ!D@("A,"533K$)2TTC95:IP]=\DZMO]@TNQ[O^CN['OO M\SS/Y_U\\,4"W$/2Q?^QGVWT]_C90C>J0<*N MK9;C%F:Q>&UAO!?^,LS"!@]WV"6O7_`5>YV(5E0W%&/QP2%M6&.@E6A56E;K MU8:TVYID=VKHT33?BZ!B\T[UL#JJ*0&$E%"KJA M%DEW:N/=7 M/+,&UCZ@PW/#/WDV?Y79(^.3Z`X M^MVQ9ZZC)3^9_\?WKGUT_CF7(&WZY3>.O_;&Y3'BDLR,F[\C7B/EL@+:<9U^ M<'L4WVC'$W:\7H5_;\5T#,MM>""&*^W8%L,/HY]$V85J?-6&/2[L=."1&'XS MCKEESRUCG:OVK#JXBOOB]?&V^*:X\#Z0,I[` M_&!Y@U!:X2VMJ(BG5E8<20::`EL#/)#*-"\!2>!J>HHC5PV^V$8WJ$Q9D6E6U3:][&YX-'@QR(*ZS;TRF!#O4IQ:VC#=AKUMV'9H,(%Z8FUB*'$I M,940G8E08C3!$XOU=IWMT5$_]$###FVK=ECC1HS'-*Z9JC37=W-VZ-.N7"4E M%,M=O6_8A8F&!A*L#0U4LK'QK@FC>F<#.#XW=_DRODS.*."'MERS+,U:K:<2 MK/%Y?10W5X(;%4EZJ<9'=L!'Y6AL&>7T=15STT&2@C4\97D$'&I.58[ZE.DL[2S?M7O/JO5"V6%'D/D^3/51? MO4.1'U_1S:>G7)&O]Z_N__VNT)%*10F_+JP6;DBU`]T#676Z@H\-;OM^D;&' M_VCF4^R'FV"%I6=!((YU!].R4=4AFK`2ZE2CLT`[C%D4WLY';RD("BK)/D(. MDO>)\`S:6V@ZHUFF0JAJ:ZU.M;;>;*ZM;FU)I5KI23.?YR_@CV$:[#"@=UZU MT;9-++[;BF<9JI((-M$.YC_;%:=]IYVY[(IJLSLA!$G@C<8X"N?@(H@=@(?- MV2T0X->W553?NB7B5G%&9,=%%).F2YPT+5Z&@@I4NG3D*,(F-<<@QQLYQ9)\ M!I,D1V,Z:K>)-:UK_`.G-N1O?VO'KL;'F,T5G)^__D'$T)LF0GR8$/)!_UG0 M9C$J,#!RT,1AP.,U.N',0_"E_AL^RQ@XW;9VVYC[810+G>W.T5N%"(58:"+Z M%:Q-_T+6^.!#Z'K^`^GJ5@/IMNHYQ/EP:\HX5=L\O?0K\!%VYR,L*QX#%V3T MLA[$C1;\BXC7[.C2G&3H%)5+@E-3A]1AXD';\YRDZ31))R`+E_35F!:!MB;F MJG6[Z\F0@4MS^R2))2[?&?QXLS64?_^E-W%A/O(6?H;S)K$'XTT8L>;'IC_* M7\EONF0+&YG63FNHIC5HT*G7]FCX5R=.VO&">$UDC]I0U1`9YZ`J,K<*+*0< M5T85KEB>W^K`*@=J#B1%\.[;=D_:08LS%-[TE8<6B%TYHV9SGDBD+NUV:5A7 M7^^E9;)G;>5OOI1_/V0]BJ4W\Q$,VR[A",98,:ZU1C"7=^9/YN_EG;2^2KX? M3XFO@`I/G0650KF^.ZT:(6UJ,<8I?;'+FSY&8;/I-B:+*@J'Z5>_D01)5@'? MTV3LE0=E=EM&^=VLV"LR42]9D!;U@J*TF(S%NNY32DZ:&4E;AYF,1C;&8IY( M(YM-QJ\5UZAG;"@Q1+5@(CWO!;'>-1)N^#YID!'8)28 M67-**)WOL*'-&0U%62C:$1V('H[.1,7H&1S1*S7!XHAY2T0U%E,=CJ`*95C6 ML0@7+:*I!W=ZT)-UHM,99'H0@_2+T\/J%`GX9->=KC\0F_9-].4,KNV:,`9_ MTI5)$JM"4=.=KMS5KOLY$DYSG7F9+"D!,EN81+HY#S%J.EV_<$&$J+/&YZDW MJ95,3MH@7JD\XC4&"WTC7.HM]:@%(RWY+YE%*$P575RB+==%W^;R=9E!NX=[ M"PZ<3/KJ%!ZH+G'Z8S=XTY;0?+&E9!_S+NC\$(-6KZ,@\O(:J]7OJ%FKA0L> MK=CB"]B*/;*"B0\,Q&%&94/B99!@K6ZS$$-QAJ(@@G"&;=3G(12@0,801!3( MWC+!0AT*QGW)B4S&:)!L:&H@VOFAG(C)^[1QI#=UF6];B/1R*)6R^>HVR_0= MZ^/W+*=E]8O5BO'<2CS%K-M.\`PRF&#$`'YH9SXD5*1WZ+/6",88AW\`'.G1P+ M*4ET:E4,P>'0BUS>K<.FL<8#M%.]O/P+PY`+X)[ME$Q)%&,;QWSN[;K-J^56I+(0'D?QHLVY%4![T M8)82D9F5>7##$%UJA;0(\A!A69JUF9I91D4F8AJ%]*5TB`@Z=.E00MTZ]`D5 ME+4]NSOV(4)N)43."[]Y_O/PG]G9]_V_PU`I?8_DHEJ\M?MAST>HDSSMD_/Z MG=`@NFD`FM^#]S&TV:`S%KHD>^?E\^1BI(G)_T%W!ER*AA[9'[VCT.>&?LGZ M0#M<&8%KNV$PS62ZW*B#FSF31/RWMDW,;7UJ&*K]3=Y.S/!E@THYP$$:.,1A&FGB",TCM/""5IIHYV3='"*3DYS MAJX0_Z-F5&?(T_/O#RL7Y)A,DBBK')-))8T,%N!D(4M82B%%U,JL>I/BDA)] M/G'[7?-_<&6**TM0UM%]QK: M)OI)?G9N7DY6>D%I1:FGO+(J3_#4N,M":Y,O/YQ+'CDR7>D4R(15"![*J:1* M^L'JH08W9:P1ME(=\&P/\=JI=`=G."R3`=FAY[`'YMC!2K"OCMD5?,=848VR MJW5_J`A$*UAQ:;%R^;>%\%&`"V&GF."F5N9'-T-%$B5DDU-&!2)5A9/FAU751? M"G,Q3TXG5$!F9UQ-,D!-+RI;=45D."@L:F(N55QG-EI*8TIN+&U:.6-'4R\J M.V\R3%91(DLC,&5M(C@V:&575RHY"E(O/2@D4SM)/#(L:C=:0FL\:C%I*"== M.5EJ8$!O=2-#)F!M6"LW+&A#(41R25E182LZ"BE?7S$^ M541,0FU(:3IE2E],=64\7S)'85Y!7CHC14MQ*TY4(W-*1FMJ9D)#,GX^#65N M9'-T)PI>-3UD/G%-6SUQ M:D5A:B)G6FY'<2Y3?CX-96YD63HM35,I7DI`5%Y`(E1R(30Q6CEP M=6-D,_/V`Y0E!/=#!*9B,H2FMJ3FE) M/TYS.UHA;50A2`I94"M)4552)D9?.&XW/%TN<5!@:V-%(VLC;4)L/R]74'`] M4$]R*$%U;VPI;E=C(D`D;D=873=^/@UE;F1S=')E86T-96YD;V)J#3(S-R`P M(&]B:@TS,C`@#65N9&]B:@TR,S@@,"!O8FH-/#P@+T9I;'1E3FE!94`F)4@V2U$K+6EO2%DM32AM M(6UQ9U1T M2%MD<2E'-VMB8EI*4%PG.65()G-7(6(V,FM-9&-E46E2)W!&/#DO)3Q6*SPZ M<#%"0"IL*4(P;PIQ*"9-7R=@2W$K+5LB5%TK;%8\4#MM5BIK+&X^*%H]0F`J M6#A7:TM()&EG528V/3E^/@UE;F1S=')E86T-96YD;V)J#3(T,2`P(&]B:@TS M,30@#65N9&]B:@TR-#(@,"!O8FH-/#P@+T9I;'1E,3EN-"A?/UXF5C%J M54]>8&-8:"I!.#]16&=N3`HW9%I!;3TN8S]B,6YA,B8F.&]/1U)+ M=5E".#5@-V0V97)8(CH_<$H])'!==&%*1V1M/T=?6TI.;B9)=5]03#PC<@HH M6#Q>4D]+6&114T=E9R@^(38\/2%G8W4D76TA(VLX0"U8-&\H4RU!*G(D73Y, M*E@H8$HP7&9D(2E<7W!69CD^6`I6<28[7UHL4U\U7D-085-!9#E+-UIA65@K M0'-O;'4R8CHX1E]=0E8S/#`L M545>-%8V1C9=(RXH70I&+BI),VPK6G%)0"]41"-O;CQ0 M.U)+;"I.)6-#.TY@.RY*8EY-,61`1S9J8&%!759G*759=`HP9S19=40F3'(B M,VI>-4QQ:&0[5#,E8U5B*5LL)7%B4B(G95-E+S53,VP_/3!#22U,6DAM(RM: M5B,F(RPH;"PN0@HE;E=4<%]Q+D5-47-L9$TX=6`^1BPI1D0C*TXY-TPO,SU* M-%-6:59#*SY6)3I$6SU>1T9P8C9-;5LB/&--:3=E30I% M9RXZ<5%H)`HW+ULN95EN/5!/170R2VD_,C$D3D@^9C$L.R)N34Q&4B558UTA M3%=<9UU<4UAK0B15-$9&9$:61:,5XA,4-$6F0O?CX-96YD;C4D M0RE!(2Y03$9P-3E>2$%,,&PT/&-F:2Y#5$TI6PIB9#)6(C]E-DPD)C1:1DAG M22-/9&-P4EE:(E-"45\G9SM>(B-S)DMF?CX-96YD M0"$L0")I-&HU73I*44)B)2TB93,J-UQ&2&(V*C-J*C!%<3$U26E=03XO(0IS M*21O.$-M7#XM86Y':%M&+T`I=#(W=5!S8EE4)&\Q5G1:4$=1(D%L9E%(VY59#A=9S5M4$];0D1L24I#(C(I3W(K.5AJ M2U!E+6-*=&-F56TI65!E7CP^=2U$74=P4'%75&T**&4C4RDK1D$A3F](35QN M33A)/49J6U=G34-J."XO76XB5$=/,2DO+CI58V4A52DN;"UM.U)!;RET/#-# M7"%(:G`*32)-15U27%AN:V-?6&YE(F!T8%`A8W4**&UG-'):535":%M63ULT)U9P(D)644,B:%$B.F,C2&,W.T5+ M-&E")2Q#/4Y#)4]2."Q*0#M:4DEA5CA,*TUQ M13IO;RYU.FTF5D):=&Y30$(_,@IM0R9:4613.$`[0"3#0W;SXQ5U1093Y$/%YQ-71$ M0#,O;$%)*TXK.D\[;D]O/CA;858G)CMG=%%`:DM820I5)3E;42A<2&0_04@K M1&I6/"L_<2UU3G1.;E5O12)I9BPD6C4C1TI@3#)&03Y@4#8[1F8D*T!50D)) M/RUO*&].60IK/6A;2VA`/$\^3EEL+$M?:TTY-7%756@X1%57=45#8$AF-54X M:&,B73!L+$0W:TYD464\:G$E:BQ.8$M98&=610I`0W!,8TAP:5UT;UI$5&)< M3E,I,S1(6"IJ*EE*8R9+1F=(52M?-#QM(3P_8"1%`]+W1!93HR/S@E16AC-DUH7VHQ(U4K:U]$ M7U]B)51S+R--?CX-96YD:V+$U)67,O,VHR95I>849M46]81'): M/C=R*&]O7D!E+S(C:UM9)V4N5&14-0IO;%QT*$XT/&`S2ETN M54I()%%&22$J)W1<6W-,0D2&\]0C-*:ETY-6I!6SU*+FE/;S=#-BIG551#3%DU)VI98T!P2CXB M/&@B*7)O-CAG.PHH1C%*0B@T:&=<2B5F/T)H=3!:.2PL-2P\(2$A(CXO2%HB M*EE!0$U^/@UE;F1S=')E86T-96YD;V)J#3(W.2`P(&]B:@TQ,#<@#65N9&]B M:@TR.#`@,"!O8FH-/#P@+T9I;'1E-2)`;#PB;B91 M/"%6<#M'6D-F4V!*)2=%)D)F72$D8&1,/')^/@UE;F1S=')E86T-96YD;V)J M#3(X,2`P(&]B:@TS,S,@#65N9&]B:@TR.#(@,"!O8FH-/#P@+T9I;'1E5'(P1R5+)T4R+D)Q-2YN(D1N6C\D1T9+)'-<1"M, M.&HM=2,_6$%8;CEK-R-O0R8K(U]%;$)*)U%("C9';#,M94Y3:490+#ID3CU( M92EP<"8V-&Q64%5884)W%M;5([/RM:/&,I+DHE1T!E7"P[6@IE M339;*4$N6%9L7D4C8G4J.68R*4QP75A:74E;7"PA4C=S46\X7G)B-4--544J M9F)>=#A7<%%F)$1::VDR;$9A-0IP5%-@=5XR;S=&/S5M,6@P5SY9:&E7,V8B M/6-B9EA6=6MN7"5%8SDZ.V])8"U'3&ER)VM993P]+$M=)#,K.T`W-@HT<"AC M8E9(37-^/@UE;F1S=')E86T-96YD;V)J#3(X-2`P(&]B:@TR-S4@#65N9&]B M:@TR.#8@,"!O8FH-/#P@+T9I;'1E2B\A5BY;6C!E42HQ.V-:0V!/7C="7&585&`N"E,N,7!/3#U- M2#XL,ULM3RXE44TC83UJ*"UP:51I,S.C9S36]J)C5K:7(S,SPA2S!*/2D_0&)C,$).?CX-96YD5FXA9&A$85!G45,W9W!5339?75<\ M13XJ:4]73#4^1RHV1TE?76YJ/4!.;#%>*F(P)2PX*V\C86(H80I454Y!.3U= M+2IS4B1*.6U$.E]28#,N<")2*F9J2B1<.6TI5#5C.$,S;T`J6TXH1$,W*CMQ M*DM*,#`Q3&`B7VLD.0IR7$H^-F5>9V5P6DLR7'0E62,J2U%/<$@]0B$J0FLC/VE^/@UE;F1S=')E86T- M96YD;V)J#3(Y,R`P(&]B:@TS,#@@#65N9&]B:@TR.30@,"!O8FH-/#P@+T9I M;'1E-'%)+&)R*V@^6T-K+RD^<&TQ,BU37TQ# M"B1U4C,^;B5&;F9N6EU?4#I1:"@_1%0H+T=+*3LM*E%%8$=:-D-F\X,5TP)B,F,&UA938P(E;W%B5$0A(W!O2DAL)D%82TI+*F\W,W4I M:FI836!6;&=`254I1C]07$1B6E]#(D%#=5-Q/6U5*`HU035M)3HI/S]A:69. M.$Y")#MI)S=7(6\G2BXS5W,C=3(H(S,W8"9+0SAB-6`T.R0\2B0R,"A)3F]/ M0RTT5$T^4"\F5GX^#65N9'-T83PS M47)):'1B)D!1)7,W3TA@344H/W1%*6E'338F=&-@=4U5:7$I8V-%0$I3,2E1 M*4%J;&LF6B)624PW3TTT M3$%H9W!N3C0]4S!!3EXN6@IP+R0CM4 M565J*FI?6UTI8'%18E%S.#\R9E!29E0C*"%Q)U=6.VTM82IN5#!<;$EK;U0S M6UMA(BYQ2%)*(3Q-)@I/,754<3AR+6))2RIT1VTW65AK0EPK-F!G;G5*2F4O M24=4:RPV;%]U2T@Y5R1#"F1>:#-I73]J M9"YR(EI16%HP-DHA82EC+2PP(RY`-D0L)G4W00IK3#`[ M6S4W1#<\)&!;03!'3%-"-$\J6C54*6U$-F465I.3\C52MJ-`HV,W,B(3(C<3U"0SE2?CX-96YD;7%"959&-2TL(F)G3C1',&9Q8SQ65#IH2RIC8U(P2U5"5#DI4V$Z M,S1<449?4%(L4&,V9%E!5%!T2$=R M2',V.BE,<6\X+C@Y-PIG1F,E:UA$-E-@9#H^74$A0%8L.4\W3"I-85]2;21" M36U$7R@K0B5M27-$+R0U=3]4(2$R+TPD9$I^/@UE;F1S=')E86T-96YD;V)J M#3,S-2`P(&]B:@TS,C,@#65N9&]B:@TS,S8@,"!O8FH-/#P@+T9I;'1E2$`J0"]J,B4]<'!98V]:*CPR:3%/-4U;.%0L46YK8C]C/BMQ;463\Y/E54/"5*1V-(3&]<.S)J;ETR2#XD(G%3 M/2UR+"M#9C.2I-8D1,1F5F<&A@9'(Y6PIE M<"5I2D=;;V8R;"%A/")+07!96E1!;3`L-T-T)3]A<4M,/&(N5DHK36EO,2-% M.D=,5C%Q8$A6.#EK<%17<&I)<0I5*TM/)#9'8R,T;6]?2`HE.2A` M4E\_1SYC-3AA1SAB3F-*=6DP/$E*9UHE5"]&429,/#!?/W!52RQ8=2YR2EUE+S(H3'$L-CYS M3"1"2RQ69U136#M383Y?)7)G:S5,/U)19%U/ M64)U-D1S:#`N7T=F9EHK8CE49EXE;%XC2C-C7"(S:28I22A*;3]13B4Z22H\ M42-C,#0U;F=K,C(]+%=9(0IO;B-'65)U)D=A5#@E3&=3.E%@4G$A*DEU0CAE M45A(2U5Q4$908%`S,58D9CTK*D\I*SY!8EA2:B)Q*G541U=4)`HM33A*:"U? M=&)<8"Y),D)K3S9>2F-=5E)B)U5E8CY;1TLF620K)5EL52$^,S4I93`Z:T]S M1VXJ0BEJ4SHT=%%^/@UE;F1S=')E86T-96YD;V)J#3,T-R`P(&]B:@TS,CD@ M#65N9&]B:@TS-#@@,"!O8FH-/#P@+T9I;'1E2RE$"CDF:")664(]5&4P M3REH-V1H/48_7$<[<#PG8$E11S8Y+E1B2E-14U]%/$]P/C4J5EQ5/&9S8BTV M54$W:%M:+D\\"BD^/W);/SEO3CA`74EG739,25@W.48^1$U,8#Y&4TEC;"]$ M(3XC9#QE4RM+3%9E4R)U;R0%M05T!$ M"D1<74(J<6U&)7!'3BL_2#LZ7V93(T5'1&%-5F5?+"-5*VHT-C-N8C98.2]) M7W)$.4)^/@UE;F1S=')E86T-96YD;V)J#3,U,2`P(&]B:@TR-#D@#65N9&]B M:@TS-3(@,"!O8FH-/#P@+T9I;'1E=64^"F=&+R@K1V%+;R1Q M;F5,5T1R42,[-5Q3*%PD<27!E("]086=E7!E("]086=E(`TO4&%R96YT(#,V,2`P(%(@#2]297-O=7)C M97,@,S"!;(#`@,"`V M,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TS-S0@,"!O8FH-/#P@ M#2]07!E("]&;VYT(`TO4W5B='EP92`O5')U951Y<&4@#2]&:7)S=$-H87(@,S(@ M#2],87-T0VAA_+J[=*JV_U)%H5)JC+\ M;:Q6WT\^ZX\7\]7L7"U7T]4LF!1AK)=!%!9:!5]6?S^9I&&6%PEI-PG$G0:*+0Z$]!CO_/9/U=8,-,#YO>#GO4 MV>7[]_/EZA*=>; M`';K)DA"IW?\?-NW\G"JS@.'+6%@PA0F'9Z5C1)7B-9G44UMF.8JM5GH\D'K M412L!.'-91!#WN(]?#+DDXDFO_'22\YD5J7&A5E*`EE,EI'$.(PSZR6J*PUA MEL)70JC3G0_7'_#&0FP3"!+HC MIM2@6[@Q/)'NSY^^**6F%P2(T1! MNGP32&A7[V;*D[0(L]AXDHZ"XX/@^!E%9Y_.WDT#>`+3`OK_+11F>D8.0/;T M;*4HIA9&O"%G`*`I8N?U1:'-#]I$1S)&+_%<"`"R;H,)95.G"!+=;VIU$TPR MK#2B:K\NM^I'77:JWE7`+=.5.J_7_'07P`"CKVDG@YH!?80W-J?@*MC'UN1A M6ARYSF:0!?IR$:R^GDQ`X#A^:JT9K34>:R!-:*\6TXOEG..^F'T0UQGD6"]6 MXH1?!;I#JF292X\@/:3%()UH0/$%#1C=%X`5,`1>/0`+19&#[,?(Y@?YOO@0 M%P9T81WA:)$.A#/D:F!]\1:%(=6S$5IP7S.5,H:62I_5[L6:@SQ)56(CGRVD M.$X.-@QXMYWJ-R@Y5M>J[\H=/^[!*PNP"<&^:651W*Q%S%*ICWRXK@M)&,2 M&N>3L&\5VQ&).5'R@@790;T-W2^U6UN0]@B5W3[5'F>'6&:B_:SE6G<7)!*2 M9G^(8Z:YDE/0FFVMY/D!^S.$F'=?\U+=*17%\21+*;+.N)]4]BBF"NS2E'HN MP3ND!KV2,=/%?'JN/FS*CDA,%B5@4DE9Z?1:UNJ`"MY#WR"=]Z9(W4Y$J_.,2E]]]"50:2[^M?!,B`: M>.[0ACU8?I+QP_\KKS^38S'SH)[^&IHXRVA,/,+F"!9K)[&),$(2\MFO(8GC MA`;-)Y`<^DLQ0#(/%^$R5#)`4*9:`WOOM^0Q\?!'0+6)TG9>U00(*-O<(*&` MC]\BJ^JB#9_[9V@N9/_XR20%,P79'=N1>X?Q=\@K9-KOY:[:5RWUG>\R/^T" MRU5\&?!4A0B#.C7W\[H_56>!H0)3WEUWO(;0.[Q7MS4R'U+>(\,*KOV@#HB] MWCS(0MT'F>[WO`DQBHN)HT<[#!:'&-.(X)*,N6>*=&A])G\V=Z,\9T5D$>!I M5<%(0^/&?@\BH?%AUJ!N`S-U@WK$WWCP0.!+>=TJ?^;/P'`9>*"#N+[03TTI M4>B;)J`,7==[:IB6YDJZ($R2(DZ@^-\!IE@(OE=G;54_+PLT\Z%ATA!AJ-6< MC\P8P/`D6=2WS3[@T;67\8C:*!I!_S\)6D\@Y'I;WV]:_D"3+A6IW0.]W5W7 MG4!`WO).@B;6#U7#VV_E:E-V(J>4US6LYO?7F+93$W!5S>"'*^3932(G3U$D MSN%\U'(3V?D:C+BF`(9I>U[/)2:MF$""1')GN9LE.(3,@[%D=O M'>$Q2!2G?7HA"+^N[AE(7_CY+:=H^O'WJ%GPA!K1P,/&552Q:W7-%A14U7DR MP>#`_I&_='DMO`-6&D&!7#3<]HC5QY^_$^RQWHSA(>.)U9N:YVU>YGFGX'#3 MISW?'F5;QV.2%N-D"5EN0"XY2WIE/\^3E2JW6XB[;[O>+W?UMP<13G$$B$3* M:[K(\464#UWSAA]B]U*F>QDL>`6&&ID=#Q<<&"?WYW:&RFZXBRW M)8XBH?G`*UW3-[5?(9O1(C$L%I(DO"HGR]VM2)!AD<,[I?"Z<6.O1G5RW\66 M:M"RXU^1H<"@7`\6W7>XLE;#!HP8"JC*,,+MM)`N.ASP1EYI!,6K\UL[)=\> M7C!?[>47R`S>=@%/N_=TD^)OE8@98E7VAZ@)17A0RKT%?>!D)&8P5G\5"`Y% M//*IS!SDD1]:,SZ$4'OYPJQW^HA/*;`_5>6.URN$P'HF.F(B MZ.:%7]>U[%&R(/*NO]*=@KHTU]+C3VMOG-9>3GF#O$#&*05._JNH`P-*V=>S#E5$JBI_\#=9#Y7R;:5`C<1\^(3X-ALG M1A_T?\V62GU6G]0717\N6DDE+#$K%=:E((M$JLA19ITTJJ.B1"/C45$Z&C7E M-N-\48+_?\A\>2A+ED>$F`M3C(-^`U&(JZQA,55#MZ-4#V*VK;P_\.ZN]O<* MVEEO&['HFS=%]M3@H-\#]@S:1`IU4I:SEU^QR`_(0/Y_FY M%%S"R"MKY``M-VBU")KU!"'R3E!6PKW:EAVZ/C`$5FPX/URS/T:4U/`9:*&V MA0KRJ0K")(-7P-ZD%R3(AQN_I]]:>KB M>AKN[[[WL3HP$F-5'PI+?:R=;BWF8%-DZ([_+^!:`I3.2>0]1Z)ZM$1[$@!; M;5]*8Z/#T%)_,3&X-+EI(_N*=;QD39ZZ75OH\UZ_Z5"^( MD@V+_?FLVJ`BG3!]9PJRUYY&F63534QTYXJ^5G9)TF;&.73+[)JRX20";D6M6Y-$D. MP-/(-/NVZ82M-RN6?JJM9%+#B@R4V05ZLRZ)`+5ZRHFS+EQY77YF6++Q:9W& M?2D8IHQ9P%DKR\'L^'XWL5O'G]Z[&O"3PCR[5-@WD2T++^,Y;MD6,7OBA&0S M8%34'KR6'6@;V8R12"E.KB6+IBP_7!E("]&;VYT1&5S8W)I<'1O(6:NB%6[LU+@FBJ60A&*Z6IBVF,1[5T MQJN=SK#DI%[!M/6:TC9>-8R%16BF0U%FUNB4RCWSWQOC,?M?YZQ_[_V__V__ M(`"!>!,2.6->3NY=,,*Q`U@=PZ>C"\M=%?^Y5I0%K%@+T)'"697:_1]JDOGN M$F!94%(QI?R?(3]7`M8\0,V:,KVJI,LBZPD@9B=0L*FTV%5T\+6D[6R/9="O ME`^"&OSR@8`MO(\I+:^'P/\!TU_M="%[VVC@1H'[VWEKCD5?@>I MA/45EM=FN,J+J_+F"V#E?(ZGIN+5URLY;EXK\[SW%3.+*\8-^^H^$,KR@=O5 MWZ"K.M+W1,QG,8@A780,/,&UB(,U2&K:S]"=G0'2,IR[R"L<@Q][`/8"#>PP<4A*Y\ MXT^Z>9DMO(X:[,,YF)B(M>H&MI*#<9AA[D$>3M-$FF1&83AF8`'68B,^0S.] M0P<4U72B+PHPDZP40O&RVOP$J>KY-KO,(^8I!+/\1K9Z2R0HF>:/L.&Z0F8I M5S0$?9AF8!-VXQ*%45^9CB"DL*_)F(\Z&<\Q9F$)Y[:/YE&=##*W<#;]48@W MT$1SZ("(5L^K=\VYZ,#YI7"D;FS!01S&3;:62>-EN2?-'`V"'Q)@9T^+\#:V M<^4.,1VA=A1-P]GR0;I,5^4,^3U;_@-NXR?\3/%41@M$FJA6>[S!8+Q!MRM[RDQ"MWS%3S,"Q(9MEJ_(GS.H$S^!OW M*Y-&T3FQ0.Y0WS;G<;S)*.4L%N$C[,4]4JD-!5!'TJ@/]>?,YM$!NBHZ"UTX M9(&L4Y>95>9R1#-6)J.8-:?B+2S&'IS$-=S$;8I@S6363*,<6D[OTA%Q4DZ0 M>7*-8E/6*%N50\I#M;UZR'/:T\15]]KIA5%,DU&"N5SK!J;#N$"2(JD+6QI, MV6PIGTIH/M72:MI,']-N.DJGZ`;=H?LB3"P3J\1^\1=Q4IR2G65/F2%_+QN5 M:.6"\HO5U=+9\X7GCMG63##[F+7F>O.B>=O7A2A&?!K2&5W3>!8L0BU6XT.N M^4X,N]^`7LC":PCFB;J13=TKD[":0@V:3FU;2%OJ2KE(S/100 M`:(;4T_13V2+/%$M;HF'TE_J=V9>Q:&'DA?";2\%0QEPV=[D(KS'-Q"S,YAK-Y8JO9^34X5/L MQS$TW)ET1HN3BKFWK32/JFD) MK65:1[^CC5S?T_0MG:$K]!W=XYP@DL00,8PSRA&3Q&2F?%$H%HJE8B?3"7%. M7!37Q`,9+-O+KK*[M,LI\AWIEH;<*?\JSRIQRA`E2YFF'%5.<^99ZG`U7RU4 MEZH;U#>8HUXL]H5,\HG=3K."HB\"//PU72)3X7[XLPZB<'*HN51IXZ51SG9G%% M6$4=2]SD;N3C5Q2.?RFOX`[7_Z3JYIIFBLNT57PILAG)Y[%%[,?[V(!BZL_1 M%6$7'F`%[94:[6;]@K M4S!1:>*>)[=\Y([T7? MQ''JQE4\8[F`#_`N]LE.B)4?B3>%*8\I&GZ+)CF2O?Z:YU,4I;"E#&U?]^4/KU?Z)7\?%)B0L\>\=WC8F/T;M%:URZ=HR(CPL-"G^O4 M,:1#^^!V08$!;?W;^%DMJB(%(=&N9SHU(\YI*'%Z5E:2=Z^[^,#UU('3T/@H M\UD90W/ZQ+1G)6TL6?)_DK962=MC20K6!F%04J)FUS7C>(:N-=#$L0[FEV?H MN9IQV\>/\O&U/CZ0^>AH5M#L8:49FD%.S6YDSBIUVYT9;*Z^K7^ZGE[LGY2( M>O^VS+9ES@C5*^HI]"7R,2+4/J!>P"^0@S(B]`R[$:YG>",P9*S=563DC'78 M,R*CHW.3$@U*+]0+#.A#C78)/A&D^]P8EG3#ZG.CE7FSP5*M/O&`>UE#,`J< M"0%%>I$KSV%(5Z[71_L$]IMAA,YM#GNR9>,=TATU3]]&2K<]K$SS;MWN&LW8 M,-;Q]&VT]Y^;RS985\1F.MV9['H9%W'$RQI[$XMS'08M9I>:-Q-O5JWY%>MV M[XESJF:TT8?JI>ZI3FY-A-O`N*KH3R,B;'O-)D38-?=XAQYMI$7JN:Z,J/J. M<(^KVA%NT\*?O4E*K`]NWUK8^J!VCYB`P*>9XL=W/LXG[N5&C'M<6?)&I`]G M0!A:H<:1.'3.*=7[*TZ%NS"5Q7CE$FL91=R1,J--NM,=/,![[M4WU-A@77/? M`R-`OWWKV1/7HQ-+;/`]>%DO3AY#C>__QQL)"4;/GEZ(6-/_RWG5QS9U7?'S M[GU^MG&"'5/2T<#B8.?3"0D.-(TCR',A@22$)'S#F.*R%#$0(RRBTXJZN%HE MVM"6=-T'22L15?N0@E0L@[JTFC9/U=;M#Q3^"030"%(W:?2#9%(U:97@[7>N MGTU"T;0-\CN_>^[GN?>>>\XS[A0VKE?ZVIKJYR;$N6"_+P#"\5$WSO:9O=%: M''])"5_PZ0F3#D!))GKV9/0`'2A*D5D;WIL4<6Y)9UN6[N261+8E-SP>A"=? M(OXN7IITE>7^O+[")2V'HDFM\#\T/YMI[]@>[.C9MR?0,A2WS[9CQP(MT_Y4 MKLTN)9=LV".+A%T215*UPBGWYSJSLBC%#T89IN9C(87ZDT+]`7FY0U)&*R7B8X=^X:&%BUH:T4$ M&AIJ#09:A^)#STQ8B0/!@"\X]#ZR9/E0?TL\>Z,3U@>GBY*MK^[%)@YIT1H^ M;&?)_1;:[1;W3]U_V?6>.OYY_\09HU%;KDI9C-,%_3@E\4.@`NAR$;UNC-,V MT4BO"N9Q6H;Z[^IGJ`+]GX8>`>]#NT!].W`*B``E0#W0`FRQ>3/0S&L`9S%' M)<^CF.@%YW':[_B(?(Y=%`;W`$4H5^H?TRJCD;8#8;E"]2U$>17:RIRO427Z MK8#>C7YKF*&7Z0-T&.WM*-?QG-B''[P8\*.^!.M?99O!&_1?TILZ69^C7(:Y M]V-L6+Y&6\%=X"[4/XWZ3NBM&%,EQJV/4-Z(]Y&&MJCCB^IB>$B MZQ[V]5>@4.\C+_0[L+/'<8G6L@XL5N#OD;=ATQ>T%6UAXZ>T"O5KQ&KXV$%: M)7Y.3QFEY,;^]J'O1F!`^1[[0A_MP'U8X'S];_0$VD)`&>[P@GU./CX;Z'R_ MV)\U"SL^0Y\>8#O[EO*O/O)A?3YSOOL";==]]LVE:/LFT(M]-0%/HNX[\.&] M:@S&8]XFVP\KL\9J,<^!!X"7@#Z`<.\!;8']FWV&>RS/ZM_/Z\]FO>)]_Y/"YRW*+M;(/:.WQK'I>QGS'+-%4I MKJ(*]EGVMRRK-YFQOXS?1)9S]N!]\AMAUL-4RF^5?3''>*=\%CE^G"HQ9Z?Q M#FS_'NW6RZE='J&8OH_:9!+QYSZO9WVN3]&[XD\4=J:5SV"/-/(0\SV?=4YI MAQUI>@]G6:I?IA%P4)\2*_4IS>$X;]UQG!<_R"!;GL\/0TMGVI@9\]O^U_K_ M!^*JXSP=1/D3QQ3>SA3]"'LEYZ=:'1#(,NI30`*HI04\C)BPE$^=4BOJ=QD_@H''/?$R;]$>5IQ+X&27B?6$M<1;P` M>'YPYSP_6N!SC_`EQ5E_?02';5]2S/Z,N';#YILVWP57PR?+.3=P?.;\P#$: MV)SSUZQ?EE,UN"/KGP_[J>V?6VW__*I?/N!Z\`8[MW#L]O,[Q5I.^\WNY_C( M,8YC),= M<+9:)_0:ZX31:+UL?`H^9#TG3EI'=1RA`3NF M<=Y=XVA";LKD494_C76PXY#*;]70"_D=JC=XFOSB),ZUG!;I#710_I:DW(J\ MB7J]!C&9VXY32-ZEY?HKB'5O6I_)-VB=RIN;Z5D9IT8>*U/D=;Q()8[KR&4G MK3DU'^Q_<9!BG$LP'8^K^>Y=!N6Y="I7?2XC-LV0G_>BSJ"= M5JISX+$OXGH6*]49U#@*'&_)/R^#SXC!:<128WMZLY9U0\6ZSFGL&: M?Z9=#*.8VITW$3-YK:,4=PN.B];?[9S=AGS:)M_!=U`>D?+_RY0G&Z@(N;+5 MQB;]!9SY`/J^;7]7,"/NJWQ_%[$*/N)XA;:I[PEN^R&^>WY/FQCZ.(6,9L3' M)L3^$[3<6($SVD%!Y==;,FNCODU]GW">XN\$?B_K*,^(8SS>A;*!\PW/7:G. MM@T^&G,M0FXY@!P/G^;8\KZ5EN&4:W$D4R@L4H6JBX\]'BF.^6047YM>?%/@ MFQ,[#`!U0`(U.KI%+OK\D>Y8GXR@@PD9!\:`)*`C<4?0/4+=P&U5XY5/TB!@ M`9+Z(><`@?K5U`R<`7X'W`85D`SP"P@:5+S0?-!\YFGY.3ZF?6SZ^5DYTSG M;*>K-5JS5J7IO?*8W)0GI%Z ML:R5S;)+ZG%/OR?AD74>T]/MD3Y/P".&/6.>I"?MN>)Q)(VT<<6X;ML]EI&OI<;(.XB4,=@TP"@A*0PZKD4RUIR"M*'U9Z'+)? MZ29DMRH%(>NX!`0QUPWT2T`.`]R/]2!D'>M`$%^2UU'7#SD,"''=7+ZR+F2& MA"\4"`D*:7,A[4KH=D@D0^F02,>B8EI9.0TKIY65TQ@YK=:>QKPH`4%8>TWU MNX9^UU2_:^C'I4?5Q2'[5H>6*+BY[(M(;\XI13#N* M:4?51*.8:!130[/28B2UD?N.I-9E*%H_$VL4(\J<$?P0&X&Y79#G5*D6LEF5 M+J@^WIR>A+RM2OV08[EQO:K$_8J!['A=C.+_"$I>\3QJGS<]@@H+$37\!2[_ MA/@@]6U_\82XE*KP@2YF*,446R(D[B!?NZODNTJ>4_+'2NY6TFMZ@OG_"N;_ M(9C_JV!^;)%HIQ"JYY2\H^3A?Q-?M;%-76?XG&L[]]K)3>S83DP8_KN;?JN9_5,U/XS\A/Q`^I<+/?^'G_^#G+_CY,W[^ MB)_O]?/=?OY9/S451%[$,Q[:XBUZ6ZF4>_G[7OZ/7OXW7OZJEW_3RZ>]_#>\ M(,?_1&&0?%]OC^MMY$*8%\*\)\Q?8F!O\&92@LS3#(,W(]Y@(5)4T`QF'1@? M49<"5!*U'X`NS`-'I"T` M)B(U"QI>(%(`X![)>`"^(IDJ@+LD$P:X0^$RO@6?'F`&WR294V`>?XF"U"S^ M,Z1)9P$UHK:!^D+>.SZ'HG@I#!/(!JGL'2)!7B+2`+` MFR13"W"*9(X`_(!D;@"<),&=U-[KD$E2.R?@JX?B&%'=0(\2E5K81=0Z@!>) M&@'80:+7`+:1Z`TZ=2O.8;BZ<09>7#32`9*1@'Y^<2%]**C3O?`M2BT_352Z M)9W42#N/$XL+B>,.3.D8SNE6%"+5@RQ*)!&@-;]S+20C`ZPD0=ACW$2"IV#G M&A<=+*/_SV5<#6%00P$BG0610#++`*I()@'@IC,A*/NBUU(4U8.R$8FJK$3R M"A_B0I31+5J0B$^>%QZ`W7M1#6\@PE>*QF$B_"L(<%[XFSHH_%75C##R)=S& M9\\+GX/T>A2Z2J'P>^F&\+N,7_BU!`K%+7PBU0I7Q)<%+3@M3*E50@X"RV8& MA?#&H-A]AN99X43DBP<%S4:PV$0[Z,^P-!>Z67A57&/,`&7 MPKAZ0!B3/,*NX!9A>Y`Z*A>V23W","QD*\P9RFP5!J0C0G]$CWB+=$U8%]'7 MD,SH*UH=U8EG,CU")T0`1!LE(()5<%TVP-3:R#3=(Q3"'5/7A.>:+C/P-L:O M0'U)J64_8'>S@^QZ-@;OG1IV*>MCJU@'5\I9N6*NB+-P'%?`&3F&0QQB'-K# M.45&\`1S%%@I%!AI:]3[5H:VT-#0$E![W9N^L"&K9T;\J:`C&<+4VBY/J8"\199K^&T?J4 MAA_2&7O=V=*.U$6$\5-[#[DI=NX]E$ZCLLDV5UMIU-;<&7]"T[_8)N+RH^*2 MY:^=>;+'DNM2V3.>=+:!=AYZTLGLLG7>WM1%9B>S/1&_R.R@D$Y=Q,/,SD0/ M'"X:S8O6X!P5P4VS1A=M MRHLZ'A<9#N(.7=1A.*B+3N4=2A`'.%0H@,RT$TFZ0\FT4Y>YJ"PGBF`I(U)) MKD$$04YLT.GN1W0P3[^;I]^EM(;Q(SXBYJ,-(E'W(#)!T,C_QS(4^Q\FX:G6 MR9%48BB0Z`\DAJ#V9P].#KNRKPQZO;F124IXLP:Q?_"%88H#0]G)P%`\.Q*( M>W.MJ2?0*4JW!N(YE$JL3^52RE":B4"K6'VBD%MS2EBF&X9)%R M[5[EN_+$N)S0>1",0V]< M+Z"$/JUC^N@B/XXF'A59SFO1F-R1RJEJPK4M[H9D?HKFWW)Z#,ERWJ$L(_`) MJ]83_C(]X2\L*%OQF?J%>DG[T^=]TP$YH-S84,38L14%=I#!$^.B;DL0DZ#,]">-1!8X(#C+,H M=H[!5PI8S<`I=F0R7C$@"VN\@M$2KL!TA3%9_/9ED(##U9TWVN8N:^8T#WD-3AI^81I%(JI% M$?R4%!=7<&:-N4HLE>X/<06J0'603;#(CD^< M8S^U\.(TG'I0#3XQY:DP^C1\E'B]PC0HX3,2'SU77,Q_6JXQM]^7%9LC+'_` MW$)NR%AOHP;XTV"D06-N*1Z.8]FZND@$(5'T>"K-%HO=[G#4UM;45%14:KA7 ML;J][GIWOWN7V^AN:KQSTR7;2IO[ZN9;K/_]N"O/0WUPN\4Z;Z4-[.:\=;[M M!C2PI_`K;:YK`3-UM-(3#)UF6I&MM+QY7W&M7/P=ZR]+H"RO1WVXK+S,Z2A@ MG8&(*-;85E0QY391C(0;FR(KG&7EM@",BC4U!6R!TU%6;F]LC(3%&J;Q'['4 M[,6-VW^\77)L^.[`S1]>O;KQS#LUGFYE^=J-JY_J;/_VQ@UKGW[>T'%<'3YT M\C/KQ`@C+,,=(_L3'/[[\?>_]>JOEM35%?4M?#ZX.^0K,Q3X(\G:+=WWSSD& M5K>-=-*W:L]"ACELVH%*T5HEN*_X0@G39#S!?,]\FOF)V80_0H:BCW@[7U0$ MVGI'"4N_)`VLQAQ5S(H56S?87SQ&+[J^^3ZX\NB^H;;YMGE]P7W8":MA"VS6 MTO*R(;%;$'!Y>'A?K-R;#?3<7!YB6P*QI?78>A1_HW&?:7^)5F(\QKQN?IOYF=D(T=DA.KA#K*QW,2K; M&AJ5`][B145\O;WG`$1W>_$/A2`?B\X>:6R"PV9E8-__S735!D=UE>'SGGOO MWKO?=^]^?R2[>WN]]CE43/0TN6;MB[[>!?V`Y:89#NI$M0P1'=0:\1$A$@S+-_=J\\ M+7],6OKPK)!L3]*=LQ?H"AB<9+/6W?X$3D(;L1-UE/1:[%P9O+H]89UOI=:P M8W`_FWVKV,>VBK/-#54W!V3Y^E)/S_KUT&9V/3TEK%1DY>UI;DS81`)$@Y5Z MV!JUQ"T9:V-0#$7]"7\FU&@5)=@AU6`8.ZL(]=B=LSB58)FSZ1FBI^O:B*YE ML^"@MY02P;.#C(:CZ.-WN)):W"[912WI5"9%+7:'S6%U2`[>X@_X`M02#D5"T1!G MH<`!#YRE26O4J*76HY9(G8A-S!LL08.`3=)54X*4H[Y$0@%\T@"?S!3!FJ:Y MOSUD"(;`)[HH`H_L1/`7+63<"`8$F?UFA$%=!0.!7"N2F!O+JUM_\$#I^;N: MD]J2W#O;'G]K?K=QE;?5A3NT<";BY)2)(H@-?QH$"LPK9Y>IW M#[I_Y^9D%$0XY/H]9GJ)_I&$:!#^:OK6-+I6L=C9)\\6F7,5E/R-RBVXH4%1 M0QIZ?'C6G#_9GFM%S7C:ZA@&]1EZ-+"\+SZ[,/W@RHBR()'K5>#?PJ;__69W M3W,FT[#\VW3BX99D(CUMJ@5/]#,\48S\0T\_37]+3W%,P1VUVFQV($%6. M!T8#-!"CN">;74+G&!A76H)G@C18!O4L*!*CB]W9)I6Y]*A+``=*9T:/$D$6 MJ#"EO.>.P40,8I%:-\`$`(1K+L(:.$1,/1:'L`(-]S/QCP%<^RTQ[0=9C]%3U[) MXT_Y,BLOI)A,MA,%C81A91((Q2Q:((D8+LIQ_;?^!H,__\[#1U9G%DX=^NJO M!U8^8IR"S*-=36HZ`&.0/;3YP!'G:^6!D[U[]U\PQA2MA^&8O/UW;AAQU,BD M'A?=0?VU[\W<-1[./`KY43@HM<^+U:(49\$:.BZE1"9?<(E[5U6&,!/ MOB2]BF'_;0P#$A['Z6DS<54P:)3IV^.Z2X@XB:],O:,)`,%V$0X3.T3&:ZLP M8S$X[WF/-,J-M)$5!H\[",'(/'N>*67N_FCXV?.KO[3]">,MPSAU7WZIEJR1WUB]\FNOT9=2R?SVSOMW_,AY M\J536^\YT)X_^D2 M9\6%11C00RU\@:=N/LY3/N(F#"(2=E4KZ#0S[F+?3*>IN`+ZY,U.)`\CDI+? ME]7X:GRI8N.%G"?G3V&,3"Y*>G+TN[N>?-*H&/[U,`RWNS+@M8;6%;`VG@>)_-'_7'N`Y+K^6\P-D%B$1M,;Y&QK:& MAPC/<=53JGA*%:L_$%4V#<`ZJA`>^#)<'U<2W`1'<:!Z#L-LI`Q'=)O;&_=2 M[Y3#23%KGH-W)7*)6HA*:N"&'M&E?NFXQ$F1M/SN0154AH$:3E4QF$$7F4:2 M5-`P9U"8E6(%4S,3G^[C=)08IZ/>.*90CFG55)PQ9(J31];B"'Y.E/R<2,T> MA[+^K,]A3M'65HILDEZKLD55MJC*%E79HJJ.PU1=L5?':FOW"5D-P3>#)+`& M(\M0$;84AR#))47>C))\Z@XKT1>"55ZFDZH('?2)1V;_E8.U%T>^;QA'3JQ= MTJ75]Z^_JSE>_X6MQG%C)KI06&48^YS'GGIC]_4]2YH[M*6)94VRXQM?/#,% M2)Q5>'^OF[6_'C5N]7&P,?!X@-K*M_^K^Q5?6Q.7]O_)SQ4D00V%XH*USO\J M?1,CUV'\:+'"D;&Z.ID(<33Z4=FI3CG*\-$Y$FD,E>GE,73<[+WMVM]38( MFV+9YR9':JV^#R:^]^&N_2`=G8;]_YQ];%@?-HRVS-=_";[-R^;4,(EJL)$? MZW9B#0O4(J&T;65X7G=7!6T#PEE%D$3F)PXE02 MT6W6B..0".)-^XT+\!SSS8^+##-F*9UH&E7B4L8QRCA&&R+&-2>;'8EP3F\$N?S+N(V M6@,6;8)&]>GT5LPK"[7U=_*$LN)MPB""#:4E.,M=UTRR_`-2?2&,,P`!O4<$\B@ MGD,*,F^CU0#I/SEE%S5?B7`E'X%ZY;5=OZ`[RPZCH>QQ"J6" MH`>&&!M_C*E)^$-4!3D5+N-&J@PJPM,C^W`'*`):4L"RB`C;RKK1 M#WK^W+/UYH\_*'2!!)OTUP:JTJ'X?+LU'@I9A_[^\W#@T]\/??;RWD+AV%\+ M+^7QO;W?.WMD94*QYQPO_`L2%>)W$CJC_Q(3T!FI6/H\%GAP.1OP>!NH5HSF M6CTN-]'*5%^2@1SP?W*]"`9\DO=QW_1TT2QU=BXL^R=BHK/D MGSJG-C_NI$0,(T_!^D6P&*C+'HR*+D_+>K%?W&KL$8>,$_PYD?X%?YK'0,-QBV,`B8@2/&'BD1A)]DB0: MN!'!JP2W3Q#<>+\`!':;!"*2Z'8H1D02(,*JX8[&JN!4`N`+,2NZ"2AZ6)9Q MNA6@7``[,0.DLD:8#=19O=:@]9;UH?4/BS)%*VQEK>7PR7[KE$4//P\!ZA-S MDX%@VU0^!S57LPB_+:$,PF>?G3)7;&1K&UJ\F-B M'HB72S'W>$*+S*:Z+RI7FU96*'P4->?/@0[=\^WFS31:9JN=:\[9M\? M>R-129JF(E9XO,S\;\!?"C5PJK<_^)Q<27;#2D7.8\J#P=,,VQ`:+YU4^>3A MFMN"0\K/@L+8OY.R6NCT#TH!GG_0V-<8?4_^H7M-82L&L!

\?^5CAY[AI8-3'\9D<@7$N3W87D M^)4#_:^=/UOXZ)>]^U[4T:48YZJ74"'=:Q:-09UH6H$4JY!3PZ M0],PIZ%X(J8)5JXU8;Y1%^= MC_#-A)!"D,]:;74^4,SRJZ"O%:&^A.:C!.QJ!.Q2PQ:#'J_DQ:FJ>"*>C!/4 MHPRG%%F5_7)`=E`QTQ8M$R11,((PQ+TA%&SXS#;EJ(G98O/T'$6?TB!%:68& M@GCF#*D!%L*8$8&8PW$*E1!E$)*OJ!X;9THBFJQ:S9P6-Z,L:*K!UWQSZ,S% MC@.7?CIWU[.B5\N\_/@H6`/+RMNA*R)(%ACF]A/>K!D]F\X@@P>#A3E^G-[,^,J1_[/E9O MJ_=49H#=(F]/[2,.^,A][`@QPAZ4QX@QE@K[%LG9S/+,`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`7 MO+*7>@,8#7JF?W3!(THC35JXS1%1+=5QQ?D-\8:UJ('5/\SKK>\>:0CA&1<*=:A8L2T/Y7R?O.)TL\1 MJ`_STT^L['GG>.TQ1L2IQ.O^YXU?F&YYKQAY3S/F^8-1_C88A=E\*C6@B#>B6` M=[X3`M]U*:3IW>OL2R/[NMXT8S*(,A\*A[6FG&GC7?.\-831^]`(?0X[ID.$ M.B<2)L=U#WS6&*XM_?3'O]\]^L<7[SF8#U;OT>F/MA=%US.U3TZ_L_IN[U9` MRSOPX*9K_FA7``U1N_K>V=K[/WNW]M&IU@"TCV03AM$DQUONJ]TH%`^?/7+J M+&R&,R*W/=6/B8Z8A#@"R-=A*%?\PQJF0T54)$[3PA6_IQQF=?;V1LLD+(;G MPC:FJ@OT+Q>US8J4UK0">]R"ZPH57",4Y,*Y@FU(D0JXYFW-R79PWMK!*3KG MG#90)"?;0?4G#J7LNFHTKBF\E6]6Y'Z-5U3D\.$4;>,+:GDR%QB`X-;A:Z`5_[47=/D.JC55JICE3GJO-5>U410`8* M@SXB`KY&1!!/;!DXUO#KR89ACTW<7)N0M6C*/OW]J-`K)>MLF(W/=4-+B$6F MQ7`W`K>RUH0!K/[/G8W?H%T;F4VOL;'@@8^#6_HWT:N;2CK.V'BE5!_3[]9& M-U*]/JY-P_3MV?+)VV-XC=2]F'Z&V,OD5*5390"X%8EJ6KLB^34MHDB@Z1Y% M\FFZWT+)MQ MAPI8_[GN2HX1_*=%>.P2&5B]P`+]J7N`O%N<'EHE_#IT@$\H489#?E=U=?!P.9CCB+18%02AF,ME. M`:V(YRP?"FI:IR(E1K7>8I_4ZP#,'4BIUE%=5B1#TX4\Y+,Y*?_;+&0SUXJ0 M20K%`.X"A&"_1TFGE\=6C"=%;!:N7,`B%]D/[6.#+&90'@@W(-X:!GOS"8,& M6YT.SM%>&8"!3D&412H.RG,QB+65!B[3W9:/M=6U<6(M@MS`JI=*[+W6=IDF M-W-_QASS8M=EG\&NRQJ--?HM/.SK6JW&9$SD2ES)*7H;881)';`VJ]OJN;#) M`J>%VAU`;6`*]5:LKH*VA^!O![;EBBN#PQVCM=]M#F_9OK)['=JO5A'L9OC7 M83.XA_KN??"'MNK*V:<[%<-PQ(+I;\%,NO:]QWLVG(2`5VT[6-L'IQ_J3@0] M-I3#U#$\$PGL#'@\$P;Y?B7_-9B"X_IXAWU6GXV?B=MN$V&'5J<`*KJX2O$V5MD171Z5CKL,VL)>= M_$8&7%I:P4R!"K-26AHKH1?Y6/W-1NMJ^W\4"%G1#JV![_YRQ[K:?%BTF!#6 MVQZ=.#I[.`M_K<7OP(BY0_U>UX[7YNK\=Q[""N1A9V4R)GK\94\,7+'C,=K5 M5\V/]+U.KI,F(YJ'*3(5G9*>(S/1&>DEZ0WI']*_I>;QOL4^*OOE%CD@QD6C M2?`++4*`Q(GARCO6"TFF("6T1A7E`J-`5I%R&F:,YRO#1(HJ>/*3T4@@&HV0 M?)Z03BD6D*08@;P4M9V6! M:*S'^D%]+*&X6H,]?3$YFC;/L`QFER4RG>=EOBV7CEB_#*YTW\GK%:E[?S M@:2'XD.3IN%]V].(JAH^L/S,.@?X]$O3_MYR]>NAS67#`+DGZWG$MN]@=X?! M-%]:_7O3:<1.\E0E;G*V9+C@BBT$LFE7%U6IE6?T!F MA5EE5GV+O*7R=L6NINT='JTEW>X0%U8?.=^2P\L9S"(Y.Z:$`(CB+,Q%Y\7Y M*$>8JJ&T/3P\NO>7(A>(E''I8L7E#Y<)YVTIDX75SQLS(5`6%E8_N8!K\/K1 M>6^H#-;Q(*;Y,`!KPIS(9B]M];%C4#\9*)2^#DQ^.:C15_2N";CRE:*J+1\Y M4E5J\OA>R1P:;-JQ?)'>^VVS0`W#\Q^VRS^VB?.,X_>^]OE'?/:=G=AW/MNY MN_?L<_.NFJ+=>\]OESR MQ_M]G^_S^>I]@SP'I1;H$&Z#/ M-^[>QMU%V^I!F@3H6X@N@0ET"!]Q''$=XB:\)_`)[BWV+?J_ MJJRU0']N@:+\"HKR/:A52,2,%L.=8(VP+,G8P7L#"=BG2`(%75")#JC\G"^! MO%$,*VIN"B48V0Y+)M,#'TO(M*7F$PBZO`3'X:S+$2BRY9GKIB=0Q%*@R,&% MRS.?G?$7(3Q=@QM+OWF+;OCVJK?(9!H_:]%L!4<+Q2';.+&F)@V_P+#@''X! M?!X<(]`I8,,FHD7H9Q.7:B_4?G+I)704S3^_OF_WJB.;%M^[X<&C[#JN-EQ[ MMU:[6+OYKXO(BW+HA:6_?['VU]KQ$X_.,U'X8WCF&0;88SH8QGXN17(#)1:.. MY@`&X!`TI'TX&-H;^GG(%GHF;R`C4D?MK)?A!`[W\[MT6'MZN$@2"7W^L&T[K2Z_.'Z!2/AP]1P^>'CB.;J# ME!K^`CNH,UGTF+EPE;Q#/ARTN71)OUM>$EU"UD_)5T(WQ#9O,NKHS?/VOML570;8;"+-*MAF%H-4!6 M)RVZ3L;T9W6L,^FH%ME+KI+KQ":0?G*9V"X31,1TE.A&(A9248$GDR]NS)U-6EG33)M<"P]7#'C MXHI1J3G8B^HF6H(W_H_4\T*@-4Q<2I]B4$,V/Z4D2W,5M*[>U=!\=/KJ@:V+ MOX?N,".IKMJJVMUKB\\^TW?P9;RY-OY-]1>]_OBA#;U*K7-M2+$E\&9\I'JZ M_:DM1W]*Y^CFF8_L&CAM$2&S*!76I'9I-H#&3Y3-"RI\G:B8^ MIRO=E=F4VI_:GS[944Z?[V@NQI@!'$.HC.XT@\P`WZ5TX:Z3/LJ/IH[RQSVO>2[RCDR*]]AUMG.N M3>\,NOO0.K0-C:'G$8O6,(9@8*.,!-,7D!>8'F_'`MZE`*C"H[/*W%RXNXR* MKS8\]VH%?#4S#0UYM62Y)R!I:81J6RPRPK72]4H)"97KE7IME1171X!7FW60 M@#B"@#7U3[#%KA,C21\Z=7][J-%^1C*'.SNZVN>)UI-;;&]Z4K%/QC?N"L;, M_*G/[UE9^^?;YH[5!47N#B02SVG?WCDT],-37\KQEK849JY\LGM%86#%;??M?6G=L:L"=YMZ*U7J M+NA8#CI697XUR1"(5)+<02@7+A`"'2HQH8W>(/8"%!A]X'3>!%TD-280XE9C M/!#K![)\LS6F..4V1L4"[V*V(RIG:UV9RWZW["_=XUHL$MK!\>V:8$;?_\: M"^VA[A6'T#:Z(X69C]A78$=RR&:^+/%A@J6F)$GKC^L_\OU8_[7^)WU&=\-[ MF+$)"+*D;3M@Z5AH3)ST76J[TO99FX_5@SZ!J)JAS]4&B/--[4L=G_"=\^%V MEU.-(4(@ZDJ$I-5J8PI:I\PH6-E3*)B%_L+V MPB\*;,'%.Q4G=O:F4OUIE-Z3;_`A'1:S$V.DSH>5NAEE9DV&:&UNOLDP$KZ$ M)^'*,\DVKR[`O-#<22[/\`06NL4]F?K?4*,9V8'@:J:H[FB`>L-0DD8]<]4! MWN'0"?"9Y33.`KZ@]RT(W_+]P>&CRXQ8=B5Z/UIS][9H8NBS)Q'.49$/S`#*F?"LT$.<6&B;]6>?^3K MP)21P\NJ56GYXH<6_2UC'>2>'DA'",P";&/?LER&3@"6AB0H2AN@%;@**0(3*H*"#.KF.*!37DU00@B]"EJ%3<=@S_R:\[&.;..\X M_CR/S[X[VSD_=NS76`E>4&5]"3WE0IH=7?&_%+;4ZW3'Y[S_R?Z%OD MMT_#V_K9?>R_%#0L;!!?%V:%=\6/Q8\5.B=`NI4',N@$8YDUF7%M$W'X&:SI MVK@VJ>W0]FO'M#,:^S9\/_-G@I,01;@`"[N`)`519IE[:(H^/V,`P3(COL+16I+S*`;N7E/T!U. MD+0%R"YTNH(XY"BC:832@N9U,(['78*)_PB2]@0;"O) MME-:%'(M\$[BX!WI<(A84N2P,S2K&7CTV>$E(J8*Z@4Z$;OCLW:28H/B%BE]E/9CI98QXV`M+1"F(N2B5RV"*>&Z?;8&R1=!L1@N#]:1+&=N?/#6NZ^MK MU&7I6[$.KRU7_6:\>J;ZO%Q=.M"IH]'EJ32T7^]NR_05T0O+))^0_/RC*.X> M(P1:FF7GOCNO6#9^=8AZX.2@3991/!A[O+(9H?U;QXC5@'8ZXN.W5IY$RQY< MVJBDD$$E1_K5!4)E$;Z@_\HS7#>$AZ61T![XQ1*;TJ5TC\"'X;JV;>%MD<=2 MAUI?#Y]'%\*7(Q?;+K9?+'[2Y_9BKR2V6UR0C;M2(1B@0BE;>PJFI5"82TNN M,%?$(`6+V,;109LH^8/B_CB,IQ+!>*[8$\Q9(16T`@$*F`\*L3!)3-WIKF!W M>\@%**MYC(E%C!-2VBM):9C:R\%4()HI[KCL>0*-BLC-XW"Z\O4--"J%E$!!J^9&ZN,C=70\=M M$D-0X0@K)8((\9J"2L;%)_^/BMH1WG//13XU,(!A/'5O"(NN(F<>$EQ]$88] M0A'6,AML,,QEUB`B'HM;:KID6E'2FKL@).*T(%D&.GQ]EVE[3)H,V"P/P:VE ML<[*IK$VFNM^Y_U2>\K75_E\M=;_&*RKGESI#'2TH5>:>MKH9:_MVQSJ60)O MYX<4_WI+H')])D\`LC7[/9ST=2A7MBC!C(/SH#;7Y"6$`6MAM]YH/J#%I/J,)@XR5T!K@!1"\"#SJ@A]S,Q0[T1!-[ ML0,_$4408>!A6,,KUMS-+/JG[@+D%1!`#"?@)*3@S^"KP`U_#/>"6G&!>O=B;^5-$_,!/)!D$U]S4 M3-;87YV!U\TUKM2]]Z[*0R2(90S7QI*5U63.6!E'T@LT`HSA>6L+\X`WX'.U M`&,XK;M7Y39,E-GA29FBT2R\7MV\N![KZ!>%F+_SNU;G!!>-)H@6?VO^MN7W MEJL@#7I17O?9,,Y189S+Z+T#'3_,OD@?R5H*QI(>6I$]EX-/TB>2/^T]GWPG M^6'DM\D/LW]-LEEZ&3U2/\(/9U?QZYB#X$CV.#P'SS%.C88["B]1/TJ^G*9` M8;SPG8:)PA1_R'<:'N^Y#/]8L#,-XX5'\Y8A!OD\/I0W_LLO^=P_\C"C,42H MU=:$VBJKK4JO=DI[2[-0VA+M/FV[]IQV5'M#NZ3]1OM(NZDY)C6HY;U,A%G+ M?)^A$)-G1IEMS+/,4>8$\R[S.X9U,`%FDK%X/8Q%J(N%5/)&95TJ/X0RAT$I ME4*"KJ@=+B$DK!$>$8X*IX7+`OT'X>_"5\3I"CJ'.P1$[)K#U1IJ3;466ZG6 M`:7?)8=D)/\-@!1;9*?9RRP5)@,"+#9H@F_I6"_L*""],%%`A==\T!=[,\ M5U9_42*6>JY4FC+BZF=&=BEZ8R#.V=&UAS^ M-8-[N=Y>4%+AE&DB,]T]C5$[ME`NHGP1V1'+Q3C)+0%GF)5@4[3'TB4!W%@G M07L3.713>0D05TFR:\U4FK[RJ:<@Z2YFARFKH$SNR<0_QDCND4TM,,V,$9$6 M[I(X9"2FFOWLX@VS&8N[;;596@8-GWIF?.,LS/)ZHJ_%WQ@;SA=73KVW>?<1 MGK-[Z_P!*;-I8/Q!^P_R\8B8S,PH`-EW/(C#^W679Y`!/.81%$1W M#FW*YL(,'`#?!)IWV>Q12O3=79(U![\XOZ1A7KBFH M7=&5<652.::<4:XHM,*1?2J&1"2VN#TZANU8Q^/X"KZ&K5A,?*UR\8 M5N*L&"GB62.HAQFR=SU^(81 M9%4+ATDS*=5*[)>I.JO<'`OX&_W(QI(F)U--<1ATBA*HXT)V+07R=) M(,)(\7M*W&*4N'^5'MUNG60GP]/-AYB3UA/,>8IYFMG-HFEJVCX=FI8/60\W MVTB;*9=60[=18:/>9F5)D88^D8SY_?Y_KZ_)_B6(!E;>/?^L[LC?4M[3][X\U@O5OK1!_/4!E"M"'%' MWWJ/1E$;6F=[+S1'SD6NH9OHKR33:$49,BVL$3?;OB-NMVUOG`X=X4_R)X4* M>5XX&SH?F0M=CD&%\/`$Y6BI$C<@1ZKH!B(M2$`DDGCH0ORW7Z"(HQZTN320YAET&MYH/A6[!9K@;!%;R)9VIOX3BE9E M$&,H.^O0F$"T^Y!15)2R`H"71XV6#R[GIW'/5ZM-=O:._X?[$3-GUYXX]1/U_<\-KJI&`ATC!Q[Y4Z?DB-@'U8"*T/` M2HC(HA?UR%OV]^WG[)]X+6YWEY4(<2'2)V9M5O]Q,307,7M9X.<,.DZ+#*12I"T(R;S\021 MML,0^'F?,9QTO.`RX2GV)YG4&W:M*MUNE6ZW3CU=<191,>:&T+^,`3 MCW34K.P%WCCQAT?>17U&6[/=][<]/K%D=OS)\8_'%X_WV=A\Z;5E6V+^F*IE M?G-G[VR.W7M06H>8MWM:6],*^0X+X]CN__B#. M'S2S@"H#8QXBC`KZ6MJ]7"@+$\*XY]O^G0(3:SQ!?DI>IR:'AJ/N=Q6( M9E4NRAOD6[)%#J>P0R)1.UC>R4)[' M#"H*3A8%NRF@\.Y"/RZNY7G$79HR,@2J9&O,[POX2+K%+8:(9L$;0B%7,(1\ M'AC,O$@K>Z`)PX<\A2231K/@X0-TP_DQVD-8/51YX8%M_=`W^S=VRRLJ.ZM; M5B]\<.C*OR(Q3T23^M"]\]];M7B-]^B>F3T7;B+//XZ_\X+H[EAW-`);42(( MJM2P!0A5]*=U%=&\&"6=-,&(-,=8T@IXV92+L[.L&P1?X9QL5&3F9!05:6`V M*`:+0>H46)'V^%X/RCI>SL`C4(X;5=WG*$)3I5Y7*17Z&N3'VY8/!#5_*"7K M$.7#*?7SZUF4O4H0J?JFI]FJ$SFO5D$AK]KM[A2+]QP6PE%74^U:F*VR)#@, M-L^^Q!YF9UB:8#GV6>.RRMYF&3805O,JF5/_()U'FQ`-WE:9&@66I[$L0HV; MFI\"ZV-<_8W[4KG[.S@]W"^5%:,(]O>/+`#?-2RC'-@=`)O!L3YBQ`$H$ZDN MZ&0&R8(K4N@H)+3_B2A65+-,T1Z?I\.#K@OAU0M_*1:$_?O1G\[LVK%L0!N@ M+2RTC0GR(#6TL.,9?XR*1E$POX(\L'%(/7SQZ>YLJ5.RM;BL^W/OIGZV'+.]E'J;.YV]-YCC8T= MM@+=0_>%1QNL@&W*EA*[Q6'QQ]97TT=M)[(G%C?IP]&29$_Y.8+J9:+"8,JN MLH9#;X9D']3=/8-Z/*$-ZB$1!H]?RP\B_.M9MU\;K%`6W2,(&%&AM>L(R[:J M)*6K;1I5H5IT%C*X[8C*#,5;G<,&:NXBCGHC?-OP,!H>]O=6'E0-Z;7WHMYV M_S1#HFF102JN;A2MIS(E'5Z"P5E42\A9$DMD:5CB\"1G3'+(R8D3&D9;)"=F8G,3S+46*::(3,[1L`>&TX* MN)WOQ^?-U.=L9\IMW((,HLQ?6[ M./D+U#?;QOLG+BRCI[,#78._^FSEU/A3>][_477]T#-[O_O]?2_<.%U>UCNV MLK-_+!O>MEGJV?[+UX\Y@UNIMY]O2W;V;7IS54-?*IHC<_JK3[TNM;6MR>>6 M!O3IH;WYMIGG#EP:W%;Y^<3SQV87Y;^ZXQ(+':N6+0ZX0E[LE)80A*4;:GD& M73]'T`]N?]34DS.H7%[0&I:0Y%BNFB.9A@;:2\=IB]-.R$1&M',REZ'=IQP7 M'&00$7Q4=%3(+W27G(B*GKA)M\&0R()@Y*%08["`%G+ MZYQ+N\PC)X_"_&6>Y'C$XY;*?3&'Q-SI'*GF)O%.#!;P/S(+2QD15C,B+&A$ M6,F(F9P1=0\UPYW(*(./>"$(<@5'=@?2$+QX?KKL*RA\C3D MK`(IZ^HT33AT63Z0N$Y0,Y?1C-$,EKW_FP-C_ON1EX;6_C"5'+@?;P^XW4HP MN2+CY/ON_Y?PP)8,<))N71)T=M"LP08,QMHA7^MUP%Y?XL5IZNX5%>G6=A@0 M8T/3=!O0`#6&Y(.W?3""H5N4G4O)<1X#)@CW7%Z*5^`]YW_.[V0'U6!N`W#X M)Y_==.#L;.O5PQ71-,5T["#ZP?.#Z>IG6M(!->,V32'5=9B[])6RNQM8(0_8 M:/!'&(E),'^QN[3I8&0(!QF92>A!(I.$$#%UF4)BQF_J03HQHJ:>^"7Z.R"\ M`&\;+*\KGQ>08#/(EQ#DH-=#SR`!JXR'>%B/S?7Z?-BO^UE_/AJQ8?L(/8PG M*]3,IXRR8T,1Q]HEJZ\\%T$S$>0T>9%3MC:FL;JV3YO5YC1721O29F#2U&YH M0G*T"0D%''=[PDDJ;;>1E>5.91E:=O*%<]0%M%8KUH4>/&F)1-9#(9HYIXVG_`?]S_0G#:_]WX]_SG\#GRT]@% M_T5\G=PD"HLYXHG%Y!Z99TRF2$Q2[#-X:&&3R82F!1!B8=2]`4GW=B4B>E>O MJ9L@8A;T&2:*'M9-W3",O*D7#8/CWV:AH#?AJ6$MH,"#!.,O)A,*[(7]6C)! M<(!%[CZ=*3)>CQ`XA@';+B3W:H!Q=M0TC:ZP]^.^?_2Q4WVH#_@AO-F+_NQ9 M0)/SO5[D74#G+P2.D5^@`(.19G^?$W?- M73OKC([S8=\)$%F5]K+@[718$$0QU-46EI/I.3'\<$B\_=&F]&,V^F%M_*5# M?_T6`&TKF4KFWZKU;&@E.TK[SYD/ZD_&XZ:[NYM[8OI`ZS?O1#,0)]%`9`/" M@S]Q]'>?V"!J"J`V$Z*&,"`1F6IMGXSF9(1Y1F"(SA.!$$$"U',4!\S'.XH# M!"0PL;L,>%+@O\DJEH..K&A:?$!7CJ16Y03KZ!$1S:^)9_N_ MOWY/,MQ[7Z*2@;??SC#"UX"FAME16Q]AD2SKME>KNG&(J3'#>@C2[;"`UE55 M4U<6V`\O9BQ3[X&)K63JIEXS,MC40X9AYU#&U',+[/4W#7L054U]$.9VWMAH MZL.&(6:L=6D1N;3:XX=GA+P-&PC%0:.GM4R9:DYKW&BP@L_TE7UVXYK$[^1WND<].Z5F@U_/ M[A1V^CX57)32CQ[;XQ3'!H145](YZ'D2'A(6[OYK'LJC8Z%H0G?QSWLVZ&^O M@W6NL=2^QIW[I/,<6'K]G"61KCT4P._O M>&ET_&1Z[-6QYXY;.=#Y0%Q6"LG",U8P4F\E=*D"]S0G!W`_/K5K MTZ[=XV-[OGVN=?I(&:HKGXL_AUYY<7-Z:*CE/1CKIBHP^C^'7IFRS;"^K>7= M/R0X:>$(2YRTT":]*NBBP+HHZ=U\0QKP",BBL;1^6V7,0CQ07K?`?<1>XSZ( M<6&A`OS'74,?QUD9!R"Y%O0`29/">7P9NU$\H9@Z;E-?%DC/R'B!`AWJ2U'J M"QO`@@7#2*=2&`>\ZB&>%`Q\(F5H<'K0[_61TNM#IQBELMV@##;`<)L&P3-W#;S>^OX1!P:[U?UH M]G@M?:HE?7F]^$`8PF%NO;O$O0EQZ&?2:)<=?3>&\@7*DIJ!/:8OYBKKC]+,V7;>CN6) M4;)*[;?!53N6F;:#:LM..MR,TJ2;[=:UE,8*2B@<8@4A&T_$$FJ"$[!?SL%; M)C74Y9$U)BHF/+#/RW=NOK$EDA`:A0M M+>=7LMTQ[LHW;W[GW9=?1SU7WD>%D1V?_/[PQ,A6-?/4LRC]LZEDF'HPU]KJ M@A]"*UA"S]NJ7')C@1&9H"X0D02%4,D`2C=UD<*$1/E"^*W1X7H[;EAG(F)0 M!H87NK.Z)(@!THMZ[7A,[F_[EYKYP?^273ZP;5QU''_O_OG/.?;Y?/;93GQW M]IWMV.?X3W)MXC;!E_7?RFB2`@N-AMN.MEM9^9.T;*+M2F#M*(C1EHF6E0HA MC6E5)Z%",CIO()%*4Q$2TB(QB0'2J%`8:&WXUZQ:5:7A]^[<4H2CO-][Y]\] MO[OW^WU_GS=D$6M7(0O':O,UJEJS:V.UR1I3$]M8TB':`5P-V(&QP%Q@/L`& M$M41V#D`OBDG60(P32)-U'QN-JXY=D9623I,..5/:))==5QKKFNM[5J[S_4F M1`"!DD67]4E"!@52+]OE4,N5XDHB:^92N7RV%"_D<4Z!IICLR>/NKFP>H?;6 MFFZ16VO8C4V63IKI^+0RG9LN,5^2IA.3J:?UR?RT^:STG'Y&^E[\K'(V<\YX M6;J0><6X)/W"$-=',8*];<)\$UE(T%C?_1F:CD+7*4L2!QN?S^6=_0;H)/F, M+\K5C1+A^J?O/[OB;7/$\9Z""'Z"Q`!!9RW_7R. MK_-20'!3"@09[%]G.U7+;#,?V*_.J*N<84IQ+X<$Q]IY*68))C[#GS(I/M$1 MMD(II*""FA(4H<#A:$R64>9%57%05;ZBIAQ4U0VU0*(II?M[0[8R"(K7U=\( M/4Z*#"IP2LH?:B+_&W@'8O".UTYYYCU7/33$XQLVCPHA684S7U'/N/&6<:J! M93FV4W.L+8DQ:RZ#)S,8980,E?E#<>1A)[9<5H4`@B/%XJ*PX)X!00U,DP2' MQPD.$AO(Q&VN!<0R[\JM>SK,NVC`1:,RR4Q':\E&YG,.(#2?&QY8-UQ>->+Q M=Z22A:B&/8'*P!W/D.GUYZKT^;>_LV-#8]U'US-<+--X],G?#=2%S@0-4%`_ M1+%CL:XD2^K]UI4%ZFW8HU[JN/UIOAH5&HS049"$5('AI)AT)7LE]WOA?>&6 MX"D(V>*`L+IXG#^MGS8N\#_26_RK.L\&V`YO(1K8Q#\4X&S>#E!BKXK.42K& MI.Y@FQ<;/R3%'&^P(^B<6($+5N6&&5<3YSK59)((*[B<2N)D"^^S]<2YV`U1 M9'.F1U1R(M_.8UN,6O@1$:6%-)4FKY[G0Y8[R@3)N`QBK09Q,!FR<,4:M798 M7[2FK8L69XDAK^JEO#;G>@CFDXD?#,8">PW1V'-]@5AD;HA"8H0],1 MGZPL3HTN/=LSP.GO_VQ39UA,1:G+]^Y?&)OO]&9*/SJ6^,C9\:* M?"\>.W9L;;&Z<=,3`Q_?];F+V5`(BA/*K=R@SC#+*(%>L(,G^9,!RFGX`$JT M\"78'D:2Z.A1"G,:7^5MGN;W^_8$>8INX:"=8OE+@60G9A@48E668HN16/2@ M)$5L>/D1$D\"G,TJD;G(?(2.)))$.2#VX/4"""XYK`=P-R)`:8$A:BPO-!MP M,"/(MS2(A5_#R7<*3>%P7U1W=+ZW7W9%8U58!YWHQZUWWPWEA.$URM9+$X?# M_D-?^>D#S/*=5W8M_W)K);4K-K=K*',&W](GWCQ(M+JQLL#4Z/,H@Y]_'1FP MNI>!]HUY@_(%.@/%P.8`4P]\O^M"5ZN+^8?G[UXJ8_,=5IHT(19%5%:(,'_R MX!4/AD+.ZGK(4".ZKAAJ1M=9CO4G]OAX/X\R&7@!'.**[>JL<`3>.:!Y#@"> M(P#/$7;G"+9S!-LY0O$<87>.L/M;'`YQ6./>XBC$"1S%$9#W&^1,8`##&VV& M-]KL;K39G=B9HOLUS&RT$9Y8.P'P,&=@U?B)056,28,R)#6*H\40T959F#C8 M)OA@F^"#[F2.[$0`Y/\9Q)7@7'`^2`<3>AOIVZ(^N(4@_5TR))^EYOTC4B(6 M'::'/X<8'9YO3I':`$#@Y,1^$[=1FZ1"+M>NY>U=7]WO#.G?=`_=.;KNZY\8 M/5S,?P0?B10ZC53W`.'N96,?`/>1L_EKN]0H7FJ?^L(K M"^P,['Z)^M2K(@KC$AQR[?.B9"$:,7R,EP4DT`+CJ4B56$5N2(U80QZ51F.C M\C9VFSBN?)Y]S+^;WRONB^V3=RN/J4\)A\0CL:?E`\I![XOZ'W M@N^7/D0?^#_@;P9OEW*^00?Y6.\JD^.:+"R2$R5%J1P6(#X0]3&L`A]46!HBO&5E(B($1?F M-7Q-NZU1FIE734V%JV&!P?Y2/A>7_3ZN1%.(+Q-:*:TJ.[$Q8#E62SO6CB>2 M5MGF@Q:"9Z(NEG%9EI/Y)S6UA7LNV3O#DV$J_'/<@S3D`^\HJ4.^:=^*CZ[Z M;-^8C_8E>LHM:GPV??GA>`N7GH5S!@FH9`*B*1E?3B:6XR,;]JQ_K^D&$CEJ MD."!CRC7<5BLUYM3T`O+]>-;RJ;WB/`F>[P<-Z>"_]\C'=-,QI&PB(4YIS5= M,]?\'^.VQP7OH'>02$^S"<'I5!5EY>HLU"ZA=<]^"'6C'O-*=1G^7:R=8#&M MTT2W`4(=;8]$'(Y)1SEWY,BZ,_1@>F$%W;9N#>03??B=JJ%]\YA?Z:G\A_UJ MBXFC"L/?F;T-LK,7]CX++-2]P=)==KDN4-AN8;DL%$KI15ILJU"@A=(`!FUJ MT@<5C=4V:+2I-C8\-,3$ICZTZ4-],<:HZ8/U0=^TL3Z8)L3:T)=&%O_9V=IB M@JC1/NV9?#/?.><_9\_\_[?SG\-^J"TL>.EYT5O#+,'J0.I^/G=QN9>[\%ZH M2.?QY.<9=Z3>8N/V9`GO\2@<-FN2JCUMHL^M]'C45<>7'=)WSIA**!9)Z2'V M[&6]X!(XK92V+IHLC4IF9AWH$-K$I\1^Y^[@(?&002SOS),NM);0A;.9CZTE)*RZAK:7G@)THN:0$%)M,;4^GCTV58;%I<-$JR MR9,T9(OF16?Y8""MD%E=1BJ0.Z./ZF6U0C2\05:())`!%5LSQIQT])23N-5F MMR/G!^O#S>R:+"N.75O*-PRLGVXM3*RB3&>U]N=_FHO M=_E<&\6=VV#W'DW-,>>[]9XRSN-1;?IX.9GZK:%OWY:ZSM@6;VYN0>D[4N3/ M<#QY1)>QC[@; M99$/^@PYO,:XMS$^^/+TJ>_QH(RM#6YD-11*POQ#*-V$?L*',M0G`$TOP)\% MD1%X$]A8"P1I7.A;($QV%3\#U8V/X$<9-9.K44?O MT^`'-M$\32>!S:5`G.9HH3E:KP)M=V0DO4`G_6XWK67;9\!VLM_QJHQ=94!_ M&["'WG<@(F-_OHQGK%D\%LQGD446662111;_!\#1CE8J9B@DQD2"&NL6!4%# MR-4">H,1)K/%:J/SJC._0#9PP^OSEY0&RA`,E8WHP6[LP0!&<13/808O8*[(L;)"]I*='V4H)[LM2*(W;7<`AS'YT&[EUE]? M<-\\EXG*WRF*=2UX',S,IP`=7C-<2=R1X6IB$4D!RAQJB=#*9XDO@G&:XF_DMW2VLRWAWH&QT?FMHZ--,[,7[@2%E\8FSPGW>@&RUHI27$ MB0701VX>QQ"FL)7N,^32":H?P!%R24RJ/7CB()='P_\H?PYO$Q7Z3Q5A MCI>FN9.0/]&8>\^?<,]WL&GK>=O526DYZ4G-RZD9I=/\E?X*JI* M<4_/_/L`1K?A5PIE;F1S=')E86T-96YD;V)J#3,X,2`P(&]B:@T\/"`O1FEL M=&5R("]&;&%T941E8V]D92`O3&5N9W1H(#(Y,3$Y("],96YG=&@Q(#0U-C`T M(#X^(`US=')E86T-"DB)7%4+=(U7%O[V.?]_+XGW*RDJ-[EYD41$XQ5**KD1 MXA%OT9;<(`D2+D(QZE'U6.+1&L]9*&-EHM7A1H>B9AH6G:JJ]W/48TH]IHQ1 M[9B%>^9+.JNKG?NM_ZY]SMGGG&_OL\]W(`!J8RXTLOL-3&R;ES6L!*C8P-Z^ MHXJ]OCXCGL\`=F0#!I*5`X>S",=[1GP?]G>X5W_&O?2$[&K:L7P;4:<1V9&%QR?1_KT[: MR79'H%%*T<117GD2LP;X72VVTXN]TWW!)?);SI]%?]<$;_&8R$,#U@+^>/+) M]DV<4D+>_/EK58W[)H_QGPQ$,(:ZH?9RLNJ-,'[-]2HT`\P-?C?YW0GT M,L_L\7`'QIGKNB%G__%_'Q"%-7@/D7@H23B$2O3"'_`*LK$*/7`".U$',^08 M++B1CFV(DC`H9"!$;*S');R&R;B%ZXA%%JY*`Z[C@0]-T,G=5YA*A"#6'#<7V=J(6Q)I*I!)ZUO41PSFX%TTP#A\ M89Y591!Y*)=9/1&;MQ3K)H]<$,^V+-W2CBK*T2(I7FFKF- MOUB",5SI+2PFXUVH5*UUFKT9+D3C9?2%EZ._P25I*$DZU<28[F8]>\OQ2,6I MS[23/.+0$R.Q#%N8C?.XB1\D6-K)1ME.G)(']D5RR\)4S&1=;63VRO$A]DF2 M)*D0%<)LA:`E!G-L!@]D&N7 M\I1V82]QGE'6%Q>CZ"A]98`4R`I9(WOEDEQ2#A6N)JE[VJ^/Z2M6>]LV*5RI M"5IP7S>&HI`G,)O97LEXM^$(CDICB98$1G2>\W]4G54ZL56=4%?U`KW">F8O M#%P/_"/PU"R!DU76@WF8B@^8A7]*$W)H*>-DBGQ#YN^H/^DZNIYVZW;Z%3U( MY^C%>I7^7']E3;:V6Y?MGK;7WN[T!B8$3IDL\S9S(7"05PSBD8P.K)]\5M-X M\O,1DS$+\[`$RUDO*[$9VQGWISB*<_@:W_$$(.'D/):[%[/J%LAR8KU\*`?E MB!R5&_)C%50$$:O:JVXJ366H`K6`6*5.JO/JCFZN1^DY>BZQ2>_1ERQ8EF7L MMD2F76J7.XXY8YV9SKP:7SZ[_[S5\YSG5P,(-`V\&E@3.!BX;8:8&>0?A02T M)M-%9+F>-5A&?,!*W(//\"4N5'-])$IL5GRHN%D-\3RU;M)#>A)]I#\QF!@J MPPFOY$DA,4?FRELR7]Z69;*Z&NL86YF\+WN(CV4_<4ZNR;=R3QXI%K'2K.8H M%:,252=&FJ9ZJ'YJ`%&@)A(^-5E-XPF5JX_4/G5>-]11.D%[]22]7N_0A_19 M_1]+6?%6HM7%&F(56/.M$]8IZZ+UU`ZS/7:AOJ(GRA#UJ43H,#M%YV,IC&Q7-]1C==MJ M+(/478FUWI6/U42=IAQ5F]AGK,;6?/L.H"X@1;TIE>J(GJ_GFS\CQ=XDU^Q- MZA1W[>G,]]=U6)II<]:FW!+N]7W M\E#64#6.2R\K4HU0G60[%?>YM,!]F02?K$:J?")?RUZ(;-/ETEO5XFGY56WI MP&?LN`Z7LSH(.54<)5HUEFSU4`W6!QPG=3L1JL1IS!0M;3#KYWP%,($W8)6* MH:9YJ"9GI"U"L99Z_SAPH$JQ[8MV*>MLBX['`+3!Z^H84G@W;A'#L!!ML9\U MN!AMU#K,,G-E-'6_#_538:^,0Z($4RU#R&T.WXLF*H):.)*[/J'^?T'5SY(' M>$-J M-]_$HQAKUB*-9S?`S#>E&&FVF-=0@(%F&_5WFMF%]EADYZ@A=IR53(T]*H?Y M'OU-2JG;F;A,/8J24-PC=I!15_L3++$N4#N[F:7F'!HS'Q',4!Y?T9LHQ@/F M+5-7XJ5`7U5A,K2/+]0U]#?E)DR"4&B*J+P'4.:TJ3UST<(N2TU-[=;UY2Z= M4SIU[-"^7?)+;9/:)+9.B(]KU3(V)CHJTAT1[@IK\6+S9DU?"`UITJAA@_KU MZM:I72LXJ&8-I\.VM!+$>]P9N2Y_=*[?BG9G9B94M=U>=GA_T9'K=[$KX]<^ M?E=NM9OKUYZI],S_/\_4GSQ3?_:4>JXNZ)(0[_*X7?[CZ6[77AG>?QCM9>GN M')?_?K7=I]I^I]JN33L\G!-?\:TPB6>W'0N5Q$JXHO>]>?MV0VR\-G_; MD%TO:^0?YE,;UA38Q-Z-P33$'\RNZ[1K,!'&34+%)Z6-@E%B2![0AK2-""(( MH39%N`W/0%K32LBH0BBM@%:50?FT34EH2YM`A*`21/7KN?/V+>N%%EK5\MD[ M,W<^=^Z<.W>>7,;4:TVW7,;7Q;NA[;[^\D%CQX"75B3*LCH#G1WM,5-TQ'F- MW#*L6V=.^.;'$V]7,7E>;6Q;NK9`&)&)73ZN&L8VG[F_,9:N]?-O/(XY3#48 M31A1++P#+FQH]F$MM3<>,Y5>+.CC??">[-VM"D2X);'&9SX0>"2PVEB3P,'D M&R8U;?(?R<\/'[<^I/R(SVB)!?SFPH)`O*.NL'\L&4V;CDX*^R:-U%24]WMS M;;?VC\Y)%K*RTPNK4CI9DMVYU-"4\JO"%@46@0ZF;Z4/EL0"V--<_EDUEXR5 M<]$-?W$%H\Q.G$>7^4!MPO#6H-W+XTU7T!OP&3<(YQ_X]).1+1W)%CWHO4%< M9):DB`:]4S;+RLS24B:(NQ8G"AL7R'I51?G&`=4,K/7Z(.`^>AR^[8C75,+Y M?C\?[_:!,*U`Q>QIC-EU'ZTH.$+ARK*XJ298,^AHQBUC38^C20U/!,#C8\1? M%N-,3W'J/\<[?DQD=8VIC/\/ZE6VOJ$YT-#8%O-%C$32MPTM(VJV?FY*ERPI MM@(.-[4@/+4H`.HUM<6X`?^N8#00Z4K4(]1@HSFF-B8*U+A=4@N$G`K\;4_- MS)58%L^E!77)_\X!MP<$EBV*+VIZ$_7V;WR4WW^?@P:LSWB4%+>')?=DUI2- MK,\;41]A7I8A8+!6K#:TM!G&J!&Z*"XKPX@&?%$C870,6#TK`CYOP#@N8B)F MK(TDG.,?L'Z^O<",[HAC$ZN5F@I^(Y+;/QRAY5[Z?/UPD[=&'E;:GRM;#RF% M7%(=X'4JZJA7P_<3\#7]$-7K(62XKU,C="W`=+3OTEZ@(/H_C7HSY"XU1`+M MBX'/@'*@&?`!*X`8L`1X#FA$7Q/X-L_A0.RD=O=7J,-UFKRN5BH"%J,C[VGK$NO1KTCV:\6X==0#_0+4'P3RW#NI M`#('&(/V?,QSD&V&;!`G>:_6590WPHY%*'\.&86M=9!+T+X4Y?E`-L9\40U9 M*U'.17D^?).+Y+];-ABS@OIBS1%Q0"I0]>(]< MH'ZMA<9"/UH"^^8].WMB^]FF?X,HVY<.VSX)ME6];=L=4#.P2LR69[4EN=>] MZAE:*_9;UU`.Z&,IPG!?H"G8WR=`2.ND2>[)UE]AXR+7,:I"W0-,E.`Y]])6 M<9W"T)7IKX$WG;1`G0E%E75+_19-UH/T*/8+?],TV!YG[H$+4]&O68[OI"G: M)]\&\X]%_"NQXGCG#W&1^,#^4J[Y,YE28# MKG*YMHQ!YE::+&'NLQ1AN8<2=9"JF;.VKQTI;8AP/'),.-*QA^-3Q@BDZ*8Q M[#L^=TU;Y/'ZN]I+H' MJ1QGR;'[>H;E'%*+M"'%Y>JS+KOZU.=M..5TF0EE MT-:Q9*3K_MOV_P7J>5<&;Z\`S6AC??F&:HPW20FV'7)OB42;G[N22E`Y?[R(Y!K(=*6,J9/U!QE7(^J., MR9`U;$L*<6[@^UGF!Y)W/G/(SS9O(R38YFF<_IDR-?X0#:B'K/?E/7R&VIRX!F8"0>A_ MF;Q'<`_CO#EG[K3:]6>M=K'8:L<^?ZIO@[QF'56G6?VIG!JD6PG MUQDJ3.71("U-WF=!SJ?:0>1P.X^.D?GS+S31=4W>;;.DO1R''(.5N/>F(8__ MP[JEY='3XF4B@;CD=G"DD76:A\:)/^'.74SKQ3[K=V*7O(,B8ICBH@PQC+'P MV4272H6N.FK`&)+S<1](;F/[=0W\Y+N@'G6F^2*9FQ?PG'J3 MY&R.'#/;NN7)HQ##]2958_V@7*N>:CPA*G:U6E?DNR*/'A.G:8:HIX=0SI>\ MWX8<58)\68_\"(B/@&%PTVO79:Z6TKHI\_UFF<^S7)6T7+XG6*?3%+V$IC.T M`'0)JA!O8IYGP*M;*+]E6?)]\'O*Y;71'DV^3_B=H,IX^2W&O4,5'&-L@\PW M;,\>\.T@96S'F`\BW:+[X%76)0;P/+O(;@?S:!L@G M@#JJ57Y,W>I-ZM:KD9/G66_(^1GKK2]+'$#>O)@#*R0X9V>T9]8SS_5>=?4HWKII<'B0XL.K]")#6XC^0&;=\PZ]R-!/ M07?JSKKVHWN@#6^4/=(FDAS+J.M+Z2F&.A6VYLLQ.QBI^CE\:P#<5X[/IIT, M&;N`>HRZ&"E]%6UGI/FUFOV*-:7>.1_G7#+/!_:%M;-`&]ZS9VD&9#/DPXY, M\3MY7XS@?*/-]U2=[Y)+&7UNQ\3MV/@7]U4;&\5QAF=VSGMW'.L['$,`8^;L M]8&-C]@<3J?G M>6;>]YUW9F=G=V?PK-POY_\3\.R\#[P+O/._[HOB_2#>$1Y`[E'7DJCZ,/:> MFPF.JS<_(&0R&_H`O@MX\B;'4?X=RDU`,A"*-).W8)_"=P1+Z=8I MVT+LWPDY""#'K;94VYLW@&=3.6Z>)^1??TAC3ZK]Y(O`>OBP"B?/`%B]DS\' M(F@SG><'J.^"_@KU#:E<>Q?IQ MIOZ$C$R-LFN):#1@)*'%#TFU"HL"TF$M7!3X!;NF#)"EA,-PU9J7(SU7K/+R M=.&+JU*%Q++E@:OA6>P*^2N@L"OL*BE,M4H4/A28"&LP4/8MXJ:4<-*+G:P) M*,1@?TP4+`GT7&0?P/\^>X]LEL[0Y`21\E[U)LK#C/EO@Y="'T-]L705U$7VI.NGX0*_XFT M_674YT&/I_48[#G0HZ@+_5&ZOA$%\/O!4H!AM(1E(Y@ MZHZ(KS68LF^S';*G86@`NC.EF*X.*T^7]Z@C\>""0"^FM`-3WX&9Z\#,=1`; M7.W3,>VIF.6L'3'MB&E'3#MFI93M1G^[Q?(!>P`OP##ONS'OPFZ"1X$Q:?\. MN!OH%37V+.:Q"*,ZQ+9;A1R+;%MBM1$(G6=/8:H-]E1B06Z@ZT[-.4LL1&AF M6MTBMD5Z6Q+.V<+:DEB8FU)$/1/.9,WDFX!"LL$%P!>`"&!CS59!"7^+/49V M.HB1R3N53M9IZ\RPE49HUD46(#5XMW*2Q9:3(`**>#Q(RQJ<;IVE M3L-9X\QH99VLBS'.2EB(5;,XRTA.C5KV-2LAQ@9US!.*X&W%,Q9-B#PHFJ'F`,93'H1FHN1'G M1IP;5C>L;E@)6'AJ@`:@+>U5;WNFVXCX">$!Q'8E$]9,S.TX>$*4@$K4--0T MU#1$C2F3&*$'[`5J`"9MXP!6#7C:5YKV-P"J]$_(F&F?(=HJDT;CTM$B:A;1 MWB+:742-8"@<,/)!65E9<3WNBQ?&^VRM>JNOM;"USU:M5_NJ"ZO[;"$]Y`L5 MAOIL)7J)KZ2PI,_&=>[CA;S/UE4U5'6QZE*5+5[56M59QCR&]20$Q($V((-<8EO(50#9P1QH`X8`&ZO' M?PO;H@SB/Z`,,+^AK9C+R;QYV-)DS7%XPAYE-M:"AFVPX..2#TD.22XP,BNU M&Y7:+RNUYRNUI2@HA20,QQ')>88KK)T):]5AK2BL(=N#)(]HRES)JF#Z%\F/ M2?8;V7G:)WG:QWG:AWG:*WG:KCSMD3S1;A&>84W)ENP23(]*KI2\Q'!Q[1VN M;>%:&=?"&CU%T3LIE[Q8!A?H%^0N6GC=ZP"J[S\%SZ-UIA$_6/T_HAK2#]T`GH-NAI M$J0^Z.M6<+^(_PG:GT#]-9+O$/&ODAK9KH=62/LKZ78_MOQ-Z/6DY?\&>CU! M_++78Y;_.JR'+?\AR`\M_PY(E^43`]QN!9?Q\!RZC10H(K:9^!0QDJITCU]" MYAW0#:G&492W298A'1Y:!SB$]J M)G7+P6LD7ZK#TO7#CY.W5;I_B?+^#Z-J/Z)UIA]?/?CHCI MLO@E?Y+ZSO'?Z.?YKPN2=+/%1_U)!QP7_4F%GN7#F&03L0H]QX?\V_B@+KU] M.KRXU3W!Y?RD7L]?]J%N\?W^"V(89">N>#/<=?Y'>56PGZ_W)2G<1A"=&;/X M&OUK?#7,JY*T(M'/5Q0DQ5!*D:/_'%^&'I?H9C8Z=<-OWV/O_@IU*'AVS`=83(EM+*=F5HS$-I6;9<6QI'WJ"7-5<A9BH'DY1LJL4"%:8#.6;6NMH10FG)@9=RA+8?>*FNCL;,T682 M:_*:-S;B.F8]7F]FZ.7SR;R]H?FAK$?GK%X?F8$:TEQ\YS>_^.[?_%SS:&QC MK?E&;IT9$(6IW+J8N6&C]ZNU(\HNI34:&5':A-35CM#GE%W1)X2=/A>INQU& M\I4VA&%/WI8*2Y!\$4;R:4*&5UKG.& M9)TBV3K1U^G8#.Z8<)\6?<7^37:Q!3=Q7>^]^Y!7DO66=E=^H(YLF\@'H4GEC>2-=@MU)EPS`-LXN22_.N;G_P2B4220BH5`IQ,23E>$C:MNZ-U8L&R[LZ)^$2\94+M:^["-!RIV6=^ MIVJZ$K\1)UOBN^+#\='X>)Q+I;J`;;GBN>$AO9XMGEV>8<^H9]S#TX65G1?5 M^*CG'QXF!=F$D_"T-.=DIH#"CTZ3J01]$`A(`,R("Z5"\SL;/>@YZ'HQ=.CE MR`K@!:@!Z`#@T*\`?PKP%X!_`;#H^X!?!W@+X#SE,.5,>8NTOIE*[`K1HB,Q MU>?#2G5M&NCJ=3.THWN&MK3/T'ACM03T7$.-MM$(#3A&DX`_`O@CP.<`7P-P M3#53G?MX:B9KNQ(H$<*@/H))DJ)$*(E#,,#4W8]P M(H7`%1`0(/!2CIN@?TM1^N0]."<1>(#VS$B#VLX2_"ZY#,VJAEPYAS@V32Y? M8)!60P?O8"3G\=P56">(P:5(P!OP*B2%3/?CT_%VT[UXVW0<-<#8-`6H*NPV MN\T^0%#ZT92+>6]*Y=`CY&+?`UD;'Z]ACG*7D0^5(04/G"V,I?%!M%E^IW!/FZB.MD=[(NK+MXC8Y5;8MO%W9PQTJ.L.?T8S;QNWOU_Q:>]VE?.*GZ98['589?T`<,5?`#9B8R,R(!'40`_ M=\%HU'/XEQA:1N@3W/CH!8]G3CY^%[\*#K'C5\^/V[`MC?>KCNK/Q@IQH1/% ML"NFQOIBMV-LS.!*,P%5R$?N/O?S;L:=)I9SP<^$-/YYE[/3E/]0S>[VF#2<:4`7^9[F0R@*=A=L=LJ;/4U9E%BC&= MB'12%9Z_70U65,TM+2K6ZL)5E56$KRBN[L=S=<%^5%54WH^*YU24EVH#P`KH M],@4-\5#.01Y$=P-#QKLP3TA:XW#(9K]`;\2B<:4&KM#A*G7[P^8'0Z[C=?8 MO0I,L)GG[3:'-1J+1I6(/["Q3'?HX)];E4N_4)?7%KT5R-^W;VKXDTEUU<_Z M/%3FX#TJ-E:H'6,%0\$-5) M026BKP64UEW7_4%W5\?J41JON,0S!E%T"BC-**I6KQ$U/IY8=^!["VJ MPXKL8K*3^Q&RHGK5>\A\TDQ>TN\Q$^T1P8R.8"OL%*WPML&SE,?\D&W%*BJP M)S,=!S>CADQ#IBJ,P,?8#NXEB@G%[#Q/[#:QF)"=A]?N'\'5]W<<:W<[%W\W MN\6W9-T!O/=W.(H?;PXV?Y$]=.WWXWM/_@1TJ``=OIG3H4XM*66#>0LY!H2; M00DK]#>"%A1P\6%>Y1E^R-YY_/^5P#U6!>)JL9N01HE&+4HD4$$JCJP='LG> M>+!CM,TMM^[DU@1;U[V6_<[-[$=9O-G7\G>\X=K-B;TGJ`:;LZ?@AU;;[3/L0_9&7L:!Z'9-/8:B5&6 M1H[/YOMT#Z1WYHZ%9C)-8G#.H%6A.17P>ST:WNMY$A=^\\"@H-'H?!9;57UK MM&E@.'NJS#.\U)HOV(3ZFJH%B=Z!LS1&'7B(=,+5B4$-JHMP0T5KHKLX3!O* M"89!Q(27XCZ\'X_ACS&/TSCR#AIB5W13+TWW4!]59@!354)6M]W=0;CI1T0\ M3+]\X/$=O`5=13H44@N1RNL855#K%4%M4'H%/"J,"T3X@?[;+]!O#4):4=NJ MPKZ<]C.68%2I-E94-#9>S>&*2A4Z7+3X\5WF$O#=K[D=S>&<_ MMAE@Y-##J`2[^G%!'B"+R=Z/9"V@7.]$43`'P>!N:\02@UB)#K.-@+T!?\PD M.FJJH4:8(9PS`26+7TEV]XWL?./E3_NO[M[T04O=8#197!$NJ2NM;U861LBQ MN_B9Y8VCU[+C7V0O'OSK^P^R=\\>7+WU-*Z[^T8B['ZJ(SL"D?@2#B,>/.9` MAU6;*O5)8])MB462*I%MZ"5$#(U6O![NL`(>0QXXB>@X#\9>".._D1&O1P[@ M(/Q/%6YG1B(0S`EY>L*@2?P`7E^D6@P&HVI6PL9=QOW&,2-KE,5)4H+OS#HW M%&^#4DPW5+PA;J;I6X>^RDSAKT*AW!X?[+'Z:LPV**5VM_(T4:@#J/U?XL5N M:WQEEO35.K0:G]/7Q/[FIX]^N+6VF/A\I*CJ!?*G'P==Q7-HMI6!C:?`QF*\ M0/V>1M+5B5+A4Q%)!2139"QV.$HU<U;LEC;D)F6>$NZ[7K(/A3M<%-E9:[`+CMDL4C2"*).TA5%Y&_( M>\1AET:2"1&=LE[F\YG_4%WNP4U<5QB_Y^ZN5BOM6BO)MBQAV5H+21;"LD&2 MP<2#KYT$0NQ@,C0PI'5MG,08XP3L#`_SJ(5#ZO"*/6E"T]+:H@D$0AD>!B,; M)J0=8)HV4_HF:2?%I6X2TG';/^AD:&+3LRO3T#^T>V>ET[YS?^3XW%4QY M+IV)3EY)0RN3))8M5R4ED-)<#->8X.ESPZ#[I)NZ1[D8%F[_$%"Y(`W[F4), M-^N=C<[USFXG[TR#R)P,7\I#?,R7]'%-OI2/^MP7X`[.J0*,93?2];2;]M%+ M]!J]0?])S=1=.`HO?]7/XY43TWOQWEJ\\>>'@P&W-<.'OZH[-$C=Q9"<_O*11X0IKX(0`V\?FSGD8T=(U=_U[]FS8_. M3?UKOCI'MXW+<897H%ISH6Z$6.Z.G9$KI/3==UFE7%$M/6Q99*TMXJ])$`[/ M#[-X4_Q:?"S^N44D<:B6NOU;HV_/')DY>O>L-_(_"GZ&=%MP+R$G,X#?N& MBHM5DJ;C0[\J@[(T%S_'"6HNY*9A\)R714KCWC0\.*0JX>(+T$JRB43_RJS+ ML,*TWZ@PZC1T2@99MRG6927)$MI?DBJA)?C\7*/8C>^>IG]C%A:'5/S=.(WC M]EQXGCDO.:G3'=-Q\NG_RF_4?J*AX[9^&4F_K[[J5+-[;%O<05FM7S7[RF,'%CJJQ]\9&?3P5;^T=VOM=4_^>K` MG.%MIW8>?2CDG6T6JDS6@?;ZVOG>XNH"RS=WU:_I/J(3VH>S.(+J6HA"KK/B M7`5LY&&%V3AF@UDRY(B(4^`DP02\;%4(+RN\259P9O*90S1GBZ+9S/&B2383 M-)#*!?@!^F'#DS^E&Y\[/#43;K\\ M]7UH27(]7^ZCAR8;=3HU8[]W"75HBTWLP3=Y<*PJ6%O0+72;NKW[^/U>,4$3 MVA/<$[Z5VKK\34)7?B_=X]F3_P9W5$KYQ_PVX@>;:GHNTOWV+:-BXPT(<;5!KX[1 MVN.ZTT:R5$T8#8U,U['2:XY&!"P7F78H'<@3#)O,NHY?[WBZ8(.PP2LTK$+C M(FHBKW>JR72?;YEN4NS1$'!=2Z=:5X%T\,65NQY_OFOK^JC?$RJM?6SCZ8&] MSUX$7JA[>S@T\%)ZW7`R-&_YW/R(JL5/=V_[_8(2D=KTFM?='><.8\VMY,0( MX>^.#3EG+!32=\=8!`]N,PC<+*F&,*5)22D_A_?H!_`!'5.L'@)6(`I3.(H! M*`W?81Z.9G, M\85ZH+_>8>_,B/:9-7SY7;LJCTX9VX2)#'8RD97 MH:&-%<9FA=;'MA8EK4DYZ4G.Z`DD@WMBQ_(.>]X*#,EG/>>#%T)7+%>LUY5< MD5C`I%"/%,I57)Z`$LBJA7WP@O)BUC&2]0!9`+6D%I84-\+70]^(M9$V6$O7 M!-M"K;%ML#VT:?;V6!_?)R3%I+G'WN/HR^[+?9T_8'[5?L!Q,/=(\$3H1"S- M#YMO63^3;V7="MV:&Q85*;2`5,#\N<)#9B)[0KQQ45V&AS,))?K-J7BK)22& M!,SXE.%9Q2E728(E*$LT)5*)L02?\%_$+SCLZEEH[2QE+N;J=W$N=WP4_C'= MLKJMNVVTZ\3X[8RST]L2I@/@W$AI09$]ES?G!#3!CS9.]#;#[&Q,@%$'LK:( M1_@6Z#8NDHN!L-2.EZ]\7$0GK][>';IJP:^,MYCKRCA8(Q0&C,2'*Q3SG\MI MQ,!I#L/N0PWO'WOS9^W'3U74_?'T3]I7=,&<+6Q32TLR,:=\^;+]S[;W!!?3 MX[M2*W9=.M-9-[#NI:4M'7V_Z%K]_).G_]"^HW[MYDWU\=;2J4\6'6[:>7#K MRD<)$0R"RV+?2A<+WHPQ#?RG<).\Q;I0)7$.")*(S"4R0/V-G0,F0F[DLFE0;6!]!QD0)=GBP! M8\"^LRX74?)TIGC`=IXX5(?/P3G2\`QSD#`+)\,<"S>%4^&Q,!^&4511PY\Q MRR4+M;B+_V]33F16Y62&)U4Z3!HF.M7;*)5!%,.E&'K-FC'3;)>#:B`_Z`\6 M*EHS\=ITNVW&D\]:@)[;CI>W>9E6#-O>DU29`_H`F44 M,O#3WC/VZ_`/N_O>;]EV]:W-K_SYZJ%W:,Q1T_78JF^OJFZ,?BL_0#?"S)// M?'3^S-YC>XY_<7.J:V<;'>E9NOHO6U(#O]V\8K:>G3#[]'.GD#TN4G.:/KA)`8DN6P%'%I MX,+&$VW6QQNJQ]%D]3BD5(\#]O&XSU[,%X6Z',O7P#_OX)?S MCPB/*CU:/_^$T.==HSS%;Q(V*]N%4<<8MYY3GU2/\$>&P>$29XJ>$ M-T-3RCO\.>$/D7/*7_B+PG5^1IA1[O#_%NY$[BA-#+]"QBK0J:I@(J(H889S MRXP_')#]-*9DVB=Z9=\.A1>B@A(.QT3!*PZ*2!1XCBOAMTT1*UZ,%35RG"`& MT2C"T,D39BTM\*3/[Z=IA@Z7T.-X&C2SGQ[BJ$(X5N!9)'P.#K4N$,(N$ M,U]]C@F[?I^G\O!C*Z9^_PN!U=`HFSH@&$$RG(^RJ)J2+%I)U6#RE?*_UL86 M?KO2UQ?,+D9_C:.+'855Y6N/=:2_>_4&.GNA)Z5FJ$2"EXP#CK5W#SW_F#.1 M<+1H3>L0B^O+ERR=7'[O;TX>>J.>N&LN890,RN`,F5$/\H>58_PQSR3_AJ>& M5I`_@':1([X=_I^0>_T_(P^&BN0IDJDE.0>.+"/[26>&%L1Z&231.8%EA*:) M$KEB,OJ2,QTF40E?GA#U$P(22F37Q#[VYRQF2V3&;/`RN$@@A%J%XJLB4L5. M$8LA,XF23#XJ(5Y2)2P]FMBPODH6PRNM4//I\!#P^A"4O`SV^O;5SMD;MZ&, M%M6_;1-%U">[:B$O)FN2_H1+9IJ)6A\\Z*"S&;D#;+-%#^A!*J"ZN,T" MV.?U6#0P/^!RQ*,6AWOJ+;+(MD+Y'>^IZN*KOQS[\Z[MLX=^>&ZG^IW*S5.5 M5Z?V3J+.-P_L:_3(WE"-''0-4KOIW$2>"8QTTHQ!"50/11);6\I-NEJM(K>W MB:".$%$T"Q'8H2)J?#:5:+R^"8M MZ)$2B7G1Y\BMU7WEPKK^M,5`69"H'8""2HR8!S0RZ%[Z29I<1Y^AS],D/1`=U$:U M*QII:+W:DQIY1CNOX8%+4"RH$A#)$-1JI17YH%`6#JF00[JX;B2_=RMI_\8*]M^X6`^6]"'=;BDWSXQ'N+0YO M)=!N8AL>X;8;.]N>:S_MGF;IIPGD<72WP*7;<1_>B$?Q'G,_/FR>9%_GIK/3 M2__$?MC*>FH0R6$7=K;^B!AK/4H4T2^X]UKI&N!/`CMK549A&XD$RC"=3`_S M8^)L[B/B5HYG:H(U!FK#67.)V=O]*W0,'S(\^@#?(&\3EQ' M-]$G[INUMUC)G_7GUD\RJ(3+&)+^,X;&3ZF*DEO>T$BT(N:7CEHS# M.B?BNOZ`?L^]@'@/%X:(H>&E:\`S9YN[,DN:ESH*_05]Z=HUIKM=\K.=[JBW MHQ5"Z*3080I16A1 MIE]Z!FV6GL[LE%Y$+V7^PW>YQS9UW7'\_,YU8CN.[>MK)[[V]>L^;%_;\?6- M7^4F@.^T+VK$2_S_G^/K]W M^6O\7^$CWNWF2<]NU?MTILI7]24\TZFG^93.M/(M>C#(Y%"&/)%9-6CPE5!% MKQ4'BAO1=K2%WQ8:TR?0'OX%_36T3S^&CNB'BZ>*OPW^FI\J_C%XE9\N-H*W M^%NA#XK_1)\$_Z4GE\*R8%]A#0P%!PM/![>&+O.7]/?Y]_6;_$W=0SAWBE(B M+H1%2;/N`(X+#E%FK707+?Z#/"\A""`^A"#$\Q3^Q7HAH/-!O<`3KR)_>S`< M"@6QT^%`2-?3JD/_"LF^4$&3$@GQL'A*I$'U@=@J'C2+4`1,?N(LZSW8;457 M,^>7TQY,#PM]1F&6)-@\O4W_I/.2,>Z8=T\'898>^"9*=)8@T3=*&!VF2`H% M-M!>@^;"&CSO,WB6,Y"#-X*3<]-G@D90#QC4E%#S-01DD!(M\A[F+D4(`_A, M7G[F8V#Z[M\5DBOT654?5#H#GO['B7M_#'^&78552F_X=M M\\R6G?%L,EE.U)DM:]1H.GGONLUZG)GX](.)>R^19)V[.7>KY2>$J31,F/T3 M''![`;`Y4-F+@8MB2..\?X%_JW\_OH'GL-TO21RI59LHD5H)HL30>LH!6D^9 MXWR`L<1)`8Z3I$EXW?2F3T";TPE8"#LX)T/K8'JXQWV^!*NS)LNP!S-TV&%K M%3,#B0S001=G_`'K>Z*H2S`E@112GWR]*:ZCI&Q6Z4;K.5H]]B^T^=2:16LT MQIOU0J1'&U:M[.Q"*DPT250G%^(R4$,&-X"^Q*U#:[A-Z&EN._<#.`9OPQGN M7?@$N-L8J%\-(=+(1TEMSR,\=_2M&%?#=%0CP<.1I#E+Z#`C!CV>GM\$:SL; M,DA#I<84,/WGOM,L@/S/=W/Y])F!@T_<@GAZ(M(4'&F8( M'>6'FJ?\W[A84B?`"+.(EAZN4"B4F>>%U``AA!+1NZ@WVMORZ(R=\3RH^;T] MMB_,_/13`DY^LS5B MW\:?4RZHUX7KD6M*:RC-:FK*2!KI7E77UJ2?2H]HNS37903A2";2'_E#Z+K0 M4J^DKZD=*:\24HZK#0R^\!''!+LHD#CI$&4437=FH6I,'9")- M]HZLVMG9@1UV!X?";%@/F^&1<$MXF499"=<++\\Z2.*2;_H6!MC:&FV#5(ARH,-SC#H#Z7LT:>B)() M1OBDFLH$4R50(F1)A[(E2`IRZ<&T\]QS:-G*;28;(U=`[K5)L40O$A-Q!#0X M2/VL46BT#G5*4NY_W'):U2+Y#P.MLI1*=](QB707,C79X8U(:GGY_MNEP61` M2"\OP=_/_OZ5Z[_JKG^N\N7HQGU+=Z\LK<`[9C?OBGV)\_#L>3YU+OY.>4CM;$;GA9 MV9T^H+P);^`CRLG\Q?P5_79^+N_F4">$,:>2.G7W:#WZ!N6I0EO6@2,1Z(@+ M7E%"255`1$(]HMP9%R*B;.*NI*)(&`)$0)43.('MV)`!8DG13Q`(A^+9]@JF-61 MZG25J98=4F?'P3>;E0@NX8632IJX1D14\42X!R M!`>P@($Z0:)N=8OS*$DDI9U*RIW3`4.E$A.P(H(<[YQA#9WUDE"`9A:03B&* M8''R_SBR4Z6!XCQ)!*26C;/?GZV4$NX8&TD]6K&(ZHA0HOYVY7=[?W0<^"YX<74[_AX[&.2UJ2C3DAN``>ST]4Q"GSE=75`-,X)M';\N MM"Z\3FAM<;=X4':JQS;F&G./>;9X1V(C\9'"B+['\:)KW#WNV>T=SQVU'2VQ MG+OD+KLKT5*T'*V0EH_SMD0L$<]D\J7%L!C7;'I(C^EQ75Q47E19ZEZ:7>D: M=*]B!S.#N6@ MWHS>4^?J_CW*?OO^PFOZT<*4^O/LY=Q4SYV>P&..!0+:A(63\!Y@>!8`+J!) MIM]T5PYT1X3HIK@0BUV(TG?*H0.!;"ZWL-T3:&_WY-JS'EO*:6VM,MPGQJ9V M,[(:<.(38,:D,D`\!:E)D$VVX+OHPS=\D/"=]-WP,;Y)/'XN?B*68\G-I%^( M']+@HG9;FR,A9RZIF-I[Y(%!6D+32?39M'>@#QG0!WP3\N'AW&A]>:-^MW&? M:GK=*.0:J-:H-:RLHTHS[^&>IH!_?)?PW+C;L$[#P(Z2LY6"546W^]64J\M9 M0ADO#4(_6>PZ>6S+MY>0J[TKEV9)+'H]F6R2(]'H*+12X'-6!%I+LY\1]`GX MP]3DU[LVN+_*KL]1DP>2RV@46?;4[N*]ADWW&B7=:W7#(?#)&I:EU@YJYC%L MY21U(ZG5+OM*,=RD/)U24JE*N5HJ!BGWCS#'D]SPB;4;OYU;_.'/7NJ__1_& MJSZVB?.,WW.?/MN)S^?$GXE]9^=\)HY]!XF37##Q>4#Y2)J$CVV084C;%$9# M1?A85[JQNFH@2JDFVJ&.HDED92"R=>)S-)!*9*.=RG]L$].V/SHF(;1_IC&) M5>U8W#VO/3K4OW;6>\_=:\MZWN?C]_L][R_MB-T(AYH%30MO^L6N@V]T]>B5 MG_R@_\[/=QWH#H15)S=624].;WUY76][W\'MSQ];=^+/(E>(&O";-]\8F1A> MLKTM>F/_ZQO?_%TN%#/(#-J++'F^RI(W[9YA&*:'FX>C8S!&CS6/11V&6E`' MU>/<#R-GN3,1@8;F*,*=I,9%@H()(9B@8K3D<:BS]+SM$R%-V8'Z@NS!OQNB MSE$L#GFI]QQB/."/I:,$WNK)UU14BFZ+3D?9Z#4Z1?GI^4O*:"F8ECYY4"(X M%D4T=.7(SR^Z/!T8N_1=*;^0?U"-.&6[[=^KTMY"'FE,NBG=)"H6&08HIY=[[%0 M.%M2T4[;1:9(CORG6*+C!>I%[TOQ\?1+F1/QMQ-GX(PTH\[$9Q)G,C/&7&). MFTM>Z[Y2^$CZ,/*A\I$U7[PMWU8^<]TO-LF&I,AQI26=RAK&,LF4366IVJF; MZ544DE11*9K%6T7VUQG8G_FN<2@]9;#+TYO=FU5&3(02_MY"L2^\7.?EABRT M9)]53ZNGL<,4`S*J8DAQKQ27"Q1DY`(O"1$^K$0B83V3BNA6H2=B<G&,5H4!0CJWHIMGJ#N-7=K>M)&L<9 MGN<QN"YB8$I(3GBA3MYTQ8!%<:.7P=8FA;=3'4WO-D:*I-73@*V>)HWNV:[O M[*9;@ZBB$U(=T`1_SY8J\+`/4VBG&R&_#Y:K^J[9!&859`XL"WAA>N M]30U1D3!O%>YFY$[^RNQ=JUW?#78E7\^?_P9>M_04O/6/UI];D]V-?S%:ND< M7D__O3)P>1NG:>`2-5\@X%T%6RK'>O1&I971-$X*;_H&'(/)D\_@&Y-MTE95 M;L+BSE1CH]3H!=SR!`9VDF[S8;?-8+=EX:W+'`6R2=KI+,Y5YM;@UM"0R;8% MOA,XD#R@'PE,Z7R("_$T938*C2G%'#(YCL-3I!II5J44:!%2>DM*RYKF$V"; MZV"3,!S=E!HR]_'[A'VI?:WC9AG*_(0PD2JWELV3K:?@%#UM?M!\N_F.J1SB M)X7)%`,"'8$:_,622B1&I;(1J@:$T6!S)-J2#`8"".H-6/R"PT&:8Y&>PK=4 M,!DP4H+I2`EZ,LC%)*"H6"Q*@#/@C]L.\5U%)T>3ZW**;NJV/J2/ZV7]J"[H ML_3Q2P;I@Q!283J\D`\'R73X>!>@XK?(FF1K)(@V6'U`@???=D@_5O"U9P*4 MI3U["%_!7DA7-1Q'\`L+&5*RJT"16Y"4H-L2:H84Y`5WE^)5SU7)5&#`6HE##A'V:>% M$=]^=J\P[CO,OBJ4?3/4C/-TW75J%JX[9^L:/!)6#\<='9((I. M47(X@<)=(F88VVYW.%T)KY="S9_`E(L.A3=YFS_)LWS8\!5\@S[&YUVB2"!] MWQ&2?0?4L5)UDGOR0>GN@%2Z5Y)(,E''8SY1G]^3:WH&TSF9)1J=PKQ6=QXC MM_1>S-9E2L),U.2V<_;S3R\T6+6<@(JR(<"H.5#C-;([\>]#=%MY*J?:#\\S MVRL#NYYJ;TPV\D`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`ZO:MVXOT MK.-YH.#.6,[M%9/P-'N)O8@^CF%UR?.%=BWY=7H/\RWZ(/,J?99#?0AV&8<7Z9Y&O`BK_$M^.T22`%7$#/N%^K#,Z?/H"QT`I3IC^6*HI`^+D?(/\5@>E^CQSC8%R_@$>.>6T!_,GA[(!]<#BT11V-%T-%=4^HK!Z2GO=7?)70 MJ_`T=2Y^'KX%+Z/+X;]QB^K'V@H,L52_M%4Z'#NLC<>7X\BGP9_=7@`:7C'< M\:`:$(UHP<@5]7&=`KJH:_J07M3'](I^4I_6Y_1Y?4%?UGE]=_5U+_1>5A). M5$TB;L`D)9>5S.I6VJU?C7G@H.>(A_*D1=`"E4Y,[[NO(P`@<&0@F4[*>V+1_AVG3M_*-^_%;`*]MQ<9!V93 M##3!YEF0OCUWOJ\ODR:(WVTT9XKI)YDG'8>8\?2Y]%P:Y=+C:0JDE91L;'%L MX38;1Q':B*"6[G#UN89=+S(_3)U,H[GTLD%I&M#T-S!X;JQ*]W1K@]J#VF[7 MP]H^;0I,:6?0+'HWY4YR_CK/>BGJ[Y6KZY3U:K2Z-X:_YF8:99#`Z,4:86-C MC';'@%OW:$3A);FHC"OG%#JF5!1*N=$PQ.)G/5_?G"'U];XV-M^SW3O3(_=LGWYX^T,;UMUZYQW8-_#C$Q8S;_WA5)_J MBY?>@]=ZQ\S!KUQY_W<$M7LQ0S?1TR``JJE\+BR-A@KA(B@&?DL[PIJ*U5\U ME9QJQ@B,KGQ_AHL1XL:LDZK/6+>WIYHS$3;L'/$_J(P&[P]MKT*0=K+(R7D< M\A?82>I9]J#GD#A1_0/J;.BB_S?4A]Z/Q!7J'[1?PI[+B4CDBJC(C6&;G72^ MA:YXEY&'@8A_AJ*=!'86PYYO=VZ@^IR#LQ(D/4\A'\W)@=42T?M2`9]<]D[I[7+"4Y3%L-F6/.9/%Y61_^/^6_SLT'B M'QW!.V(C$;%)Z%AH<%>S'\%=NP[>/]$4D]]_\94;GUPZ_N[J0?@CAQC>V;[I M`-5U]?''=SX1F/PCA!_>@.B#,YTCM=G<4]A'!@&@]SF>!0:LSMUU6#LF'TO2 MO72O9V-X@I[P.(XS,-VT7Z^P%33%33E?%E_V33B:(;FFQ:VVK57.*JF_SWPMN.!-_YOKJL^MHVS#M][YX_X M?/&]_DA\YZ\[Q^>/^.*SG=B)+W'K2^)DG=,D;I,V;4W:K!V@C8\XD5JF2H"[ M,"/M5FI`J);J*J)2;`&_N"?"6V(4FW:(B)1*@1+RON> MW1:P<_>[]^.D^/G]WN?W/-D>I+9TN:4S?H/PD4>A_U]P'B<>(P^5?M64=[^97(^5Z*2,`*>2I^:HHDXB;% MM/][HJ'0-UF9[SL9J5:6#$O&Y]S?XI:RW]W]W,C2V+S;P[ME[9J'Q8V:IX/6);#\RZ>H6*\2H,E+\$/.^R0M;4R M5MIB<3I=EA8DY!UAG`(74\!1LSJLA>7P&^&WPU1X#;RFV0[)M2!P+`??"+X= MI(+-K7I$.X-XBZ->`B4-S98T-%4JNX!K#;1<:\F:S@^#X34JK3%\B4[RH,S7 M>)*_3OZ!,!$6:IS(HR7:9.;W@7U=7>SX6U0*"8(`NJO$.)72.)@"\ZFEU'** M2F55A:I-@^FP$`,Q_'_ZW9[,4@Q,QJJQ]=A&S!`[*592%:VR@D`P5O1BLC*9 MBFWIY5$PFA;;`=M>;;^%B&B-O*XYSQ=`(9VBRA19I@!!08JD\"_B_1D.5'X)GD$RC+[R`C*0]V0L,75CLKEX&\H+]Q#=+"*9<1O5Y";<;#+/]AW, M0P6XN0COH@N]A+@(T=#56\$/@N3LX<6[FZAYX7'X@S`>XQJV.]RZOT$7P/&! MU3D]-M,_(F5]?C<'C)%P=[HGG4E3IL'(9$0)QR,'P],^X!L(^(BQ[+A(#(&" M2.PR%GQ$.3'N(_;+TR(H]9\+".KH*WT9#%3WGM\I&?GG\E4_Y/7K_ZL)W/ASV"B\Z7#W[FI M&4T6MXY?./'#F>Y>C@L/64X(:2%TE#Q[ZO1K M,T.+IY>/#'UVIN=0."7M_N:>3'N[`345HA6Q[]^1LNLE_J4EGR^(PMIK`WXC/R/F!N\9C]F%:;=@DL+"*EC4Z' M#.R81QNN%66WR;%]B&1UP68RZW(-S2(A_6`2J3@P/O_LX$35Z[31*6UG=YO6 M35-",95^NM2FCN[T[PJY.%;PM"5MP&%\<.4KL:B@[IBSR2<&:4&2O10;RO\74)S$E5J2ZM2%N2 M493*$JGAFX3YH+L[H\=IH[0PX4)ZB_*`8"!89 MGG'63<"D$D0'8W8ZZ+H%6%1,+:O#61PTMI"EOL0PK7RKQ&FRRN$Y3V]_ILZ! M,@?FN"I7YU:X+<[(K896?Z3G!XN439P4I*TW&_T.,0[B"]C,#I(V^LE$V&.S MVG0L^`PY'P*MXQQ]`'1G?&`@'L\/?(-/#^X,#RM>BSG@\<5LP&5\$2_DX_&! MG>"V>%!%R'KR!\`3Y[I$GI40CO=/[(R")>,2PK&3^.C:JQY@XH&,?X;:EVV5 M5U&Q:W)9KLNOVU[WK\@F$0UJ,@71S(9,>5IB47$P&H@5>:?'$N>]8B=C;E\# M-LT!F\`Q9N][D%UV`B=V'EWQ!H3:8UE*D=UN#\).$H2Z"%@1S(DKXI9(B:MQ M^?=!C)8\@;5>?AQNYR?@R.>+=\;O(L@0,R..+A3P4R&OVG6R10SUR(E`7\#& M^L,^5O"!@,V+:1`\T`I('")8_Q?4YA/6"NT]_X=M3,[G901A[3V/$%[2E^-R?D?\[`N?W!X*A;I;S3/AF1^0WW]%#NHH`\).$`8&56L? M.:#=9U5!)1TF"-#?2Y9S=-U:9RZR%^P7'1>$9?5-FE9YU7,,'K,?$[X,Y^WS MPD72\DE@4R!KEC.V=ZAWV(_)C]E-^]\<+05[@2L(.;&@CK*+]$FV)4G&H1@6 M(TDU!W+0W`8/@/UP6C2$X`R88>_`?T#CX_8]P@W+#?HOM-%M:8>"7Q!&R"'6 M9+6SSE8/XV<#-L$T11TP3!D/PVG[M-/$LWY_0)@B#9`%I-WA=$)>\`1X!3%; MM(,F+0$:$ULTU!M-#F8#O44B25B=$$JBX!(!*0HL1`J`=`%``N1G!8UU`D.4 M9&D(.;J/(-QKX%-M+\?\UFJE30AWGN=H:XJI,>06`S:8#QFRRJPS))-TNYQW%? MGX"+]_#CW5E$D0]Y,8^7"GD>E5`2MVRWBO@O?]:F<++MZ_#FV9;F`X$V<,T3 M"C^[./L<^V^>7 M\_DE/M_Y_7QVXK>SXS@E%Q(2$L?$0$EB7HJ+HK(5*IP@H+R46*RPMNNHM3_* M)"I@6MFF3BUIA5:8MBYKMVG5-I%->Q'[8W\A50BB5A/2A*!FSYT32*=-6F2? MSX\M2WF^S^_[_7QA^D+&5?)4RH8C$D]KM01A4_-6<82<$J1`\0>F;<3YM4X\ M<7N,U/%A<';+"P-W[NSQ)X.N=:W!L"?:^LS556YU#0=H@]G$N>F8!5":LP_K M?QFRDJ3=BW(<1LY_V&06F2\8C%'[P7!6>95["\4L8#XPSN0J#)"9"E-CZDR3 MN02_2)`"2XSY@#0P([#"\D=<% MMD7*`T^SVX9T0KXL%X2H#B%"(Y-31%]<$XJ3>@.AQ37$R'`JZ63T56B>E"7( M)SE0YQ8XE+L&)-F<%[K$8$\R#^KYA3R:5]8Q8*1QW2QRA?^(&DVA@+A(,EW`I/9;PJMY0N(%R*`7@R/JHH7_P4R M5HZQVMP(@GDBW.-E8@U]?,6X,Z`R8TU\+3-Y@MY[MC0ZRSN,^MQ3K3Y;D6?T MN"T;1U&Z=[B5&B\8-'Q\(B=M3;A2I5:Q/^U6[3UB!G81O3MC#L=F=K]8 M*FWK/=$Z/,DY((PP5,!2`:_5NV1IHT%LE51"@0.Q!:ZE9&\\WZ*WYSS!H*>X M#3QS+MZ.`7AV2,B3_X)G)P-T5(G*:74.@36WT5(0V."87R>PIK&`5V`#;;1,16(#238UU(D$ MTAG"'4>)8"!@-IOTC"-(-'5@00?,NKKNHNZ&#M"G^_WAI=;HP+1YR84PGT&B=&O>J^%#[7;/P M`?$2CBKXGVP)=5R[^&16,Z#TO>^4]G,.DR&UOE6TR1D]/E`^P MZU`=,^(%T_(&:X,&/W3\Q/%K\&G'K[PW.[36S_1@8\<&QQ1]&KS>\:KYIH?P MR6D)]PU"#2_ZP&_H3]VH[`.C.BJ$$$Q(9[#BR@Z*T/XGH*XX6%*N%;R&U_$F MOH!K\;ND##^4R8LPX`;9P9)3W$3=FQ/+RPK'BZ6%Z-;20F7S]O=)=O1]'SZZ M9?OTSQ'RT2*"PZ?OT6)/3T]U-6_A@%856%I6%J((HLG=QW^,;\C6-[7_K]5FG?^HNGGCWY]1'L MRH5O7CG^L''Y6^^>O']DH/_"B=^V_G'IDWNOUZ!NC^ZWQK"?0MTB2`'@\DE] M4=&C0(U2.ZA7+?B9."C&^XNE^([X\Y;GXP=U1RU'XR_K+A.W=?<[C,GB=*:: MW9_%Y2+HUF%1P6J#WNTZX[=!!X\$D`@_$6&1(=0J1C&\B\J!7%5+H$17R&1P M.4WIE$_?U*,U?4-_18_I[W"HBKD>CJOP=1YM\`#A*7Z!7^27>`U?Z_VXM!)1 M?90Z1'/+2DRI,&MA'C<`S$0I)JMJQG5+A%$7RH;)<#(D$6D.=!OA)=.1XT#* MT,5!MET51^UL$#QVB5@H0^=4GJ7MA+K3D567S#C6E#1->[[2>77O%3=%@3L\ M\L;$:SMG7ZF_,Y:+IIE"J<6Y\A$;30589PAD.TPO;)U9MWFG/)WL#F*%N;\> M?7;_RW]>/C]/FQ.MV\]DV%`(.`RI&6Q/->DTS;?>.1#HG=[TW/4_S6YR6I4I M&VJ-X0A4RZM0N?R>V^QF)RD,)-3XY)R12@*5$XW$V]%+"3SI3O+]L1YQ@I+= M,C\1VRA.FRON*EOAM\=VBP>H/>X]_('8"6K6/<_.\O/B:?>WQ;?,;[K?8M_D MOQN[(/[(\0/WCSO?%:\[/A+_(/Y=O"L^$&-)'9`4_/$XSZ\,";@$(5:LA$/(Z"4)K\G@0G\^DJ!M`?*`)T!IH@"L``W?" M*8JNT.@OZ!OTYS1&#\8'Y]4QGITK+T.)H4TJ=*GRR'+_EXK0UL**1SJ#41L3 M9,(<$K7!2\@1X$#$+G!M4960A*,$5>T1D2?:TL*1TFI M,-@^9V:LE;;U>.W.':^,GOXCL']2J(5[I6]$9OKKE[Y_L+@3N_+@N>ET9RA$ M&0HPMO9/_/-WMT&(XSJ#7W:#]Z!K?O3+ZXL9F%E&*-J'4*\H\K9\`(*&.8VF MS3(JFT_AA!P#NV/`IXR*2C9G`A%8",-L9`C1&V(6.T5=EC9U%!#J">3-*9E"*X'2KG,'C^8W9H.!*=I*)Y(V MX_IU+7'8[])KC/_FN^ICXS;+N%_[/OR1B[_NP_9]^<[VV=.Z8'Z3!MT<4]Y?%RM1QBRW6DNI-0[UXG6HIDALSV$4\@[*H`SQ9';4M8!=+=:2X_`8I(U],9I2L@CA%57#%6Y0O MQKW%O"#H6H0)L*8?@AGT1ZS4L6$CA@6-#6'EN^#;ZL16-QKOR!@"@[\K("1< MSWV0^T>.R-6)J,N,LV@/.\[.L@1;1SVN;"IR*4LBTJZ9:(\Y;E9-0C4[3=Q\ M$WQB%U)??^+1]Q]J3*SXFF-U=//NA?4<&AUQ.H!A%M813`%#&\NP#C3GJ9%E MKO%0DB88:*1"`.VSC=S(Q+&W5MI@%?C&BN-YMR?^CV9LHI9E>-# MX2P/LC54)%-0EID4%K:"*?2H,3T-`S>G'H3O<_?Y!U9@=`0$+90?7)1KJ(;7 MB!IS/#(;FU5FD[.IN?Q/M%I["S`C2%X,R!.V,1U:A_ZJ/:_/V\'1$8\O>4N5 M'32#@XCZ=E!VE$\$2'33@DNV?Z@G!8N(_2WJMX!R'4AZ?A!=O3Z^IT% MT=&:`?S2G471L26Q>2^A>2\6K*@KP",$QU8%[S\?NRP+VUB'X"+PG(AW@X]= M(0+/B<`>&!+O#ZSM__T@-R/0@KSV$(O`GB::O>C3B\:7/;KQ+*SNL[]'49[> MPV=SA0-?W?J4FAW[\=6++W_IZ[E8(I++I7[Q_,#3SZW]O;U]_CL]0V6>$UJ( M,VM7CKZTH_TQJU@:W'ORT%R&5M#@:S_\@C/P[&R?\_3^GR;85LG3VM'U?^*? M";R%);&;%[#(^AUW4XLSAL9PO#\]Q\_)EV*7XG7YCARNI=&T@H9;AB-C+6.1 M?TF@56.2*1'QF"0K!/(.T>0)1,0Z`W64=%.(Z,1Q%&JID#;+Q*_'/O!1_\5H M\EV,J:-[KJT"U)4ZTF?3>!I#*!`(ZM%=(JJ*"!,Y\:QX67Q/_%`,B7M2OYE^ MI`96?1G-C:Z,@F*#D@=AO;KL`1W7@*5E!&"'^;RQL1/XW:?YB3;$EV,:[^-] M;]EG@T*%URH]@'*]:,?-FV4K]SAO:M4MI=T;?M3[K?9$,?#6VI^WKOYVY/&B M]?S>\MA>_&NY^+YMA1S(N'E1WV8(WO_2\!``!` MIB!1GNUH-*V'U^S_<1Y^_W+)%,NG6"6%<7R22ZK=AC:-]+=]XPGG&>+8 MZHW:8(K7]K]=_=S(:U4TMZDKB8S5^>JNGIUX^/.]N`'YY"&?#YE/!% M>K?T%9F0Z^OO+S"5O->#S\4J43FJ:%2>SO&JH$NJK"I]E$/W"8Y4D?N4'>1V M:@L](`W(VY5]Y,_(.>KGRO%D+?]K[#3Y2^JD?%(YG?P]^0:U2"]*Y^4WE:7D MY?P-Z3Y]7WJ@M->;C^V;6S&3+$9!P>;T32;4=.:D>?]Z+IRJIO- M'P35,8&/!P^JAX/?YV?R5!_937=+3O(/H5)93$5(R"]V6% M;LI[;SGMQX6NBA?.MU0PZC*%4W5T:9'+HVJ^F0W8Y<5%5NS.>A25J7;,A2;M*(TO#@A-9IBPR\RKP,GF^PQ&2Q)_J0-:*2!N,O_?001,@K6 M[1$>^C77AB8`W=^@U7BDGP1`/@^1TD$>U-<_!(RF(;BTZ)`J@#0,7\UC/I2* MN5@31D715^@%K9*+A4#3(`T5"IZJ1V=29C%VXV:"9/+=J*T[JJ76EHIK%^)6 MEN\BCAD%5>M<"^&1Q]*M%,L81H#/;/WT(R+8T\%1I(>2D?7EX.^@3FTB_[I0 M\CY]JK\2-T&(\8:IEL9*^ZCQTEWCKO6)\8G5XFU8$"O^OBO);'>N5"J^T).6 MY6Q2XTH!NI`NV`6G\.7$J<0IZ52!9(Q>O=<M2Z8IQQ;IEW++>*V6Q8"`X`'X!* M@RP9!HW"4&M<@L]PJI;+J%C1SF`LW9IALW(FDX52/4=:IEI?/^2ZDJ&K9)BD MPGK1BA:+%F39,#M)*DJ2%/""'--I(TK3AJ;KG9(/_6+3^Z M(`@&9#_^6`RO$#(LJD52BT@UN$PKJ`I$@ M#E[DC6#PV8-Q8L1/Q9DX2M,%ZT0B:_DMDL>"0L9CT4%.)9>33!*7OH-+DV?, MC>JUJI%3&@%-TL*:H9W5+FF7-;-VJ.<+O;JQDJJ-*8$;JTN8.8VM,0:G`CB! MA_U+`10Q"DHA2J``53(L?]"4UWY-_T8S64-.-;GE0&Y9[I#,4&#<<(+9[&:5I22U$&QB6/4*')SBQ:-V5?AR[?8SS4+)^7=94:;V-T MSMLD)&V4CVU-.B8H^YIDO$//M3&)LDUVVLDI5)7%WQ?\"5^97-@2\E@NO^M) MZ"2R5ZO_4?N@_IE:O]8Q4$:6BMOS%#JQ=99BAOQ\T3!&`_0M8.L(>-VZZ-/)FV3SNFG5/QJ<(5VQ7Y M6N):WBIFXKQJBPGC_`G;ASES^V!&/%#B,A531:HX!^*5I%[H'1RRC4@CSDVA MH?CVY+:",;A'V:-6!T^8)VV3TJ1STCD6:*%4'N3AR`2NM1*%0Y&V"D/?S5K-9B1>*A7Q1=4W[LD[B M+`IVNT_HF%"J(1+*JL]$)Z-,=#I*HHJ:R>CYGD\U+9&OXA^<*)*BR616%;,Y M5E0]Q:(J^!*)WKS@R><%?-=^JR#G$ZIB&\@:W7$_SPH%EL-N.6 MF`$4(J>3JDN&ZR$]/:%0!R]@CO+.,S[BRZCSQ#$;5HA"(YD@%0WEK/)795GA MZ`15%66!*4$>S.2I\\5,`ADX"WF27V#>!1T&F1VSD?>0#*F;-:P:I-54+35V M`W.WYFZOW5$-S%4:G52NT5*UD<31S8YER)1CHKFUJ4/\+GTBZ_]$6JKA:=DE MVB%JV1K.2(VA]-U/T#-;I+*C/.60RA.+B]0L6A;-:"PXBUM^O%:CBC,&8[C; M?P,VW,2\;IN__<^+5EVFI0+Z'\^B]:(UK.W.BMT(2A4_G<4!M89;=E1,ALM6 M,?NQ*U%OD"HJ6BTITJLMSXFZ&A:I;ET]+^IFRAQ1SZ&9L^,!>V.&EACQ,(43 MYYQT'68^#:W#(J1AG$WE"]IU"?^_$R%C/2))HNY$I`VO[F[2T-/5DKT?7$$Z+3[^2^?[VGV4- MN>\`)?Z=#_5ZR!Y6XM$;;[UV[9T MQ4FI+]:W>V)IUQ:]7NU1W,:+/]S0TU/_Q*Q@- MY"QO=DZ7NF%]H8J]7DLBB6@#7E"<2M,55(X$G@J/IYRPG^9/*LX%O!Y]+O\R_K)R&T]:?!'Z<6H#+A0_: MHBBHJ52ZNYLGC>1-H1E?.K>6\<4M8240Z.WF/7A".I5JY'JI;ES2';!RO"6- M5D&9M$37LKX$Y9X#GS:1C>H=8D&6`PJ5NN`T3Z[SRSQSB#_._YUG^8F*=<1Z MT,I:)[#(]/;T1*Z_YS1;NE*D6TWZK4K]E=+;.Q_:WM\;T9-\ M:'-L??VB&%$D.8_;(=&1V%C/D<^UI,MJLV/^YH\X*K>>?N&E#>GNO$]W,1`5)P'V@H2H-`9>%\W,SW(Q]QO$&-\^99V1BET_8^TI5V"=6 MO6R0DQUN\1O<(^)U[K)HAIN2M-X;HB5LS,B93!?XD(USB&*,Y3PLR[$VAA.) MX)#MK,@XN*J)F'KM0IMT4"1B+V%X<8%9!P[@F'5&FB69&7R:3-5.>NV&_;B= MM0>RD5E9R-B*P!!&\,NZOY@SJ5S?B]U/Y[SHBLVW'/B_4$# M(\)^PD:*)-)%OW6T/^(ED1QE//NX[=95YE#]_6^6W4$NV<;"ZD_)\-%MLF0C M2OVC&-NM1'-;Z^JM]Z/I\%/P1?O.@\&\>!,`C^(S[S(` M]EX#V(_OY@!>JX9K#LT!/(GG'/D#P.CS+;300@LMM-!""RVTT$(++;300@LM MM/#_`6"``&T>8*E'`H@V^,K&(LP`O$T`$"4GN#U>G^R'0+"]HWE"#.*0U`#2 MD('>/LA#L=2/TP^5'UX'!CH;-F[:O&5HZ[;M.X9'JCL?>737[CU[]^T_\-CC MM:^^^?^B[W MO[S\X=Z[;/`DVZAB#S[V<8``31RAC5.<8:@4U5JUSA-O82=7U7/5(54MG%`5 M*:6F18_)H[A$H4*B8Z8)Y@O#-GG9<(E4ULG;\]PIHV;8@HL+PX+[?<,V>6RX M1)Z$]4;@AY5V-XFS9CQHI4G4FW4/(1UJT"&?5*&3722(D='7&`-ZEK*/T"/% MN,0-KMCU9_[JOW5TS/'P3H]2.'3(PR93AO/"[`5[FC-WQS=27QCDU^9G1<=: MHOF_]3>F71;_B34,I1[S+%V1F;2L^_'KT^CX?+'V(5=DKGZ8KD[T^AB\+7Q> M?]UZ5>FRU?GED[\!E-B)I`IE;F1S=')E86T-96YD;V)J#3,X,B`P(&]B:@T\ M/"`-+U1Y<&4@+T5X=$=3=&%T92`-+U-!(&9A;'-E(`TO4TT@,"XP,B`-+T]0 M(&9A;'-E(`TO;W`@9F%L7!E("]&;VYT(`TO3F%M92`O6F%$8B`-+T)A"`O071I;&1E("]!9&EE"`O561I97)E"`O961I97)E"`-+W5D:65R97-I6%C=71E("]T:&]R;B`O>61I M97)E7!E("]834P@+TQE;F=T:"`Q M,S4V(#X^(`US=')E86T-"CP_>'!A8VME="!B96=I;CTG)R!I9#TG5S5-,$UP M0V5H:4AZDY48WIK8SED)R!B>71E&UL;G,Z6YT87@M;G,C)PH@>&UL;G,Z:5@])VAT='`Z+R]N&UL;G,] M)VAT='`Z+R]N&%P+S$N,"\G"B`@>&UL;G,Z>&%P/2=H M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O)SX*("`\>&%P.D-R96%T941A M=&4^,C`P,BTP,RTR,E0Q.3HS-SHS.%H\+WAA<#I#&%P.D%U=&AO&%P.D%U=&AO M&%P.DUE=&%D871A1&%T93XR,#`R+3`S+3(R5#$T.C0Q.C(V+3`U M.C`P/"]X87`Z365T861A=&%$871E/@H@(#QX87`Z5&ET;&4^"B`@(#QR9&8Z M06QT/@H@("`@/')D9CIL:2!X;6PZ;&%N9STG>"UD969A=6QT)SY"-#$V-C9? M07)I861?,3`M2U\V-5!G&UL;G,Z9&,])VAT='`Z+R]P=7)L+F]R9R]D M8R]E;&5M96YT EX-10.49 4 b41666arex10-49.txt EX-10.49 AMENDMENT TO LOAN & SECURITY AGREEMENT EXHIBIT 10.49 EXECUTION COPY DECEMBER 2001 AMENDMENT TO LOAN AND SECURITY AGREEMENT ------------------------------------------------------ This December 2001 Amendment to Loan and Security Agreement (the "AMENDMENT AGREEMENT") is made as of December 26, 2001 by and among ARIAD PHARMACEUTICALS, INC., a Delaware corporation (the "BORROWER"), ARIAD CORPORATION, a Delaware corporation and a wholly-owned subsidiary of the Borrower (the "LESSEE Subsidiary"), ARIAD GENE THERAPEUTICS, INC., a Delaware corporation which is controlled by the Borrower ("AGT" and, together with the Lessee Subsidiary, the "SUBSIDIARIES", the Borrower and the Subsidiaries being referred to collectively herein as the "COMPANIES"); and FLEET NATIONAL BANK (f/k/a BankBoston, N.A.), a national banking association with an office at 100 Federal Street, Boston, Massachusetts (the "BANK"). RECITALS A. The Companies and the Bank are parties to a Loan and Security Agreement dated as of September 23, 1992, as amended (as so amended and as hereafter amended, replaced, restated, supplemented, renewed or otherwise modified from time to time, the "LOAN AGREEMENT"). Capitalized terms used herein without definition have the meanings assigned to them in the Loan Agreement. B. The Borrower has requested (i) that the Bank increase the New Term Loan by $1,500,000 and re-advance $2,300,000 of the New Term Loan, and (ii) that the Bank amend certain other provisions of the Loan Agreement as hereinafter set forth. C. Subject to certain terms and conditions, the Bank is willing to provide such financing and amendments, as hereinafter set forth. NOW THEREFORE, for good and valuable consideration paid, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as to the following: I. LOAN AGREEMENT AND NEW TERM LOAN (a) The Bank has previously made the New Term Loan to the Borrower which, as of the date hereof, has an outstanding principal balance of $3,700,000. The Borrower has requested, and the Bank has agreed, subject to the terms and conditions of this Amendment Agreement, that the Bank will re-advance to the Borrower $2,300,000 of principal of the New Term Loan which the Borrower has previously repaid to the Bank. The Borrower has also requested and the Bank has agreed, subject to the terms and conditions of this Amendment Agreement, that the Bank will make a $1,500,000 increase to the aggregate principal amount of the New Term Loan. The New Term Loan (after giving effect to this Amendment Agreement, including the aforementioned re-advance and increase) shall be in the principal amount of $7,500,000 and is evidenced by the Second Amended and Restated Secured Term Note (the "NOTE"), executed as of the date hereof and a copy of which is attached hereto as EXHIBIT A. The Maturity and amortization of the New Term Loan shall be as set forth in Section 3.4 of the Loan Agreement, as amended hereby. The New Term Loan shall continue to bear interest at the rate provided in Section 3.8, shall be jointly and severally payable by the Borrower and the Subsidiaries, and shall otherwise be governed by all of the terms and conditions and covenants of the Loan Agreement applicable to Advances. (b) The definition of "Note" in Section 1.24 of the Loan Agreement is hereby amended to read as follows: "1.24 `Note' means the Second Amended and Restated Secured Term Note in the principal amount of Seven Million Five Hundred Thousand Dollars ($7,500,000) jointly and severally executed by the Companies and delivered to the Bank pursuant to Section 3.1A of this Agreement, as amended and restated from time to time, together with any and all substitutions therefor." (c) Article 2, Section (a) of the Loan Agreement is hereby amended in its entirety to read as follows: "(a) Accounts and Accounts Receivable, including without limitation, electronic chattel paper and commercial tort claims;" (d) Article 2, Section (c) of the Loan Agreement is hereby amended in its entirety to read as follows: "(c) General Intangibles, including without limitation, payment intangibles." (e) Article 2, Section (i) of the Loan Agreement is hereby amended in its entirety to read as follows: "(i) Instruments, Investment Property, Documents of Title, rights to proceeds of letters of credit, letter of credit rights, supporting obligations of every kind and description, policies and certificates of insurance, Securities, security entitlements, deposits, deposit accounts, money, cash, or other property." (f) Article 2 of the Loan Agreement is hereby amended so that immediately following the phrase "together with all products and proceeds of the foregoing (the "COLLATERAL"), the following provision is added: "If any of the Companies shall at any time acquire a commercial tort claim, as defined in Revised Article 9 of the Uniform Commercial Code, such Company shall immediately notify the Bank in writing signed of the brief details thereof and shall grant to the Bank in writing a security interest therein and in the proceeds thereof, all on the terms of this Agreement, and in writing in form and substance satisfactory to the Bank. Each of the Companies hereby authorizes the Bank, at any time and from time to time, without such Company's further signature or authorization, to file financing statements, continuation statements and amendments thereto that describe or indicate the Collateral and which contain any other information required by Part 5 of Article 9 of the Uniform Commercial Code for the sufficiency or filing office acceptance of any financing statement, continuation statement or amendment, including whether such Company is an organization, the type of organization and any organization identification number issued to such Company. The Companies agree to furnish any such information to the Bank promptly upon request. Each of the Companies shall at any time and from time to time take such steps as the Bank may reasonably request for the Bank (i) to obtain an acknowledgement, in form and substance satisfactory to the Bank, of any bailee having possession of any of the Collateral that the bailee holds such Collateral for the Bank, (ii) to obtain "control" of any investment property, deposit accounts, letter-of-credit rights or electronic chattel paper (as such terms are defined in Article 9 of the Uniform Commercial Code) with any agreements establishing control to be in form and substance satisfactory in the Bank, and (iii) otherwise to insure the continued perfection and priority of the Bank's security interest in the Collateral and of the preservation of its rights therein." (g) Section 3.4 of the Loan Agreement is hereby amended to read in its entirety as follows: 2 "3.4 TERM LOAN REPAYMENT. New Term Loan shall be repaid, without set-off, deduction or counterclaim, in thirty-seven (37) monthly installments of $100,000, beginning January 1, 2002 and ending January 1, 2005, on which date the outstanding principal balance under the Note, together with all accrued and unpaid interest and other charges under the Note and this Agreement, shall be due and payable in full." (h) The following provision is hereby added to the end of Section 7.2 of the Loan Agreement: "No Company shall change its corporate name, identity, structure or state of incorporation without the Bank's prior written consent." (i) The following subsection (f) is hereby added to Section 7.19 of the Loan Agreement: "(f) Notwithstanding the aforementioned exceptions, the Bank consents to the indebtedness incurred pursuant to the Companies' $1,2000,000 equipment loan with General Electric Capital Corporation (the "GE LOAN") evidenced by those certain [Agreements] dated as of December 27, 2001 between General Electric Capital Corporation and the Borrower. The Bank agrees to release all liens on equipment to be financed by the GE Loan." (j) Section 7.21(c)(ii) of the Loan Agreement is hereby amended and restated to read in its entirety as follows: "(e) MAINTENANCE OF LIQUID ASSETS. (i) The Borrower shall not permit its unrestricted cash and marketable securities to decrease to an amount below the sum of twelve (12) months of its projected cash requirements (as reflected in its projections and forecasts delivered to the Bank) plus the principal amount of the Loan then outstanding, plus the outstanding balance of the GE Loan, unless the Borrower invests, utilizing the services of the Bank's Money Desk or Trust Department, an amount of cash and/or marketable securities equal to the outstanding principal amount of the Loan, until such time as the Borrower either (A) shall have restored its unrestricted cash and marketable securities to such sum of projected 12-month cash requirements plus the principal amount of the Loan outstanding, including, without limitation, by raising cash through sale of equity securities (`equity securities' meaning common and preferred stock not having provisions for required payments or distributions by the Borrower during the period ending thirty (30) days after the Termination Date), or (B) shall have pledged to the Bank Portfolio securities under the Pledge Agreement in an amount sufficient (as determined by the Bank's credit policy generally in effect from time to time) to secure the entire principal amount of the Loan outstanding. (ii) The Borrower shall not permit its unrestricted cash and marketable securities to decrease to an amount below the greater of the sum of six (6) months of its projected cash requirements (as reflected in its projections and forecasts delivered to the Bank) plus the then outstanding principal amount of the Loan, plus the outstanding balance of the GE Loan, or $15,000,000, unless the Borrower pledges to the Bank Portfolio Securities under the Pledge Agreement in an amount sufficient (as determined by the Bank's credit policy generally in effect from time to time) to secure the entire principal amount of the Loan outstanding." II. NO FURTHER AMENDMENTS. Except as specifically amended hereby, the Loan Agreement, the Pledge Agreement, the Patent Mortgage and the Leasehold Mortgage shall 3 remain unmodified and in full force and effect and are hereby ratified and affirmed in all respects, and the indebtedness of the Companies to the Bank evidenced thereby and by the Note is hereby reaffirmed in all respects. III. CONFIRMATION OF SECURITY. Each of the Borrower, the Lessee Subsidiary and AGT hereby confirms that (1) the terms "Liability" and "Liabilities", as defined in the Loan Agreement and the Pledge Agreement and the term "Obligations", as defined in the Patent Mortgage, include the obligations of the Companies under the Note, as amended and restated herewith, and (2) the term "Note", as used in each of the Loan Documents, including the Leasehold Mortgage and the Patent Mortgage, includes the Note, as amended and restated herewith. IV. CERTAIN REPRESENTATIONS. As a material inducement to the Bank to enter into this Amendment Agreement, each of the Borrower, the Lessee Subsidiary and AGT hereby represents and warrants to the Bank (which representations and warranties shall survive the delivery hereof), after giving effect hereto, as follows: A. The execution and delivery of this Amendment Agreement and the amendment and restatement of the Note have been duly authorized by all requisite corporate action on the part of each of the Companies. B. The representations and warranties contained in Article 6 of the Loan Agreement and in the other Loan Documents are true and correct in all material respects on and as of the date of this Amendment Agreement as though made at and as of such date. No material adverse change has occurred in the assets, liabilities, financial condition, business or prospects of any Company from that disclosed in the financial statements most recently furnished to the Bank. No Event of Default has occurred and is continuing. C. None of the Companies is required to obtain any consent, approval or authorization from, or to file any declaration or statement with, any governmental instrumentality or other agency or any other person or entity in connection with or as a condition to the execution, delivery or performance of this Amendment Agreement or the Note. D. Each of this Amendment Agreement and the Note, as amended and restated herewith, constitutes the legal, valid and binding obligation of the Companies, enforceable against each of them in accordance with their respective terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the rights and remedies of creditors generally or the application of principles of equity, whether in any action at law or proceeding in equity, and subject to the availability of the remedy of specific performance or of any other equitable remedy or relief to enforce any right thereunder. V. CONDITIONS. The willingness of the Bank to agree to the foregoing is subject to the satisfaction of the following conditions precedent and subsequent: A. On or before the date hereof, the Companies shall have executed and delivered to the Bank (or shall have caused to be executed and delivered to the Bank by the appropriate persons) the following: 1. The Amendment Agreement; 2. The Second Amended and Restated Secured Term Note; 3. True and complete copies of any required stockholders' and directors' consents and/or resolutions, authorizing the execution and delivery of such documents, certified by the Secretary of the appropriate company; 4 4. The letter executed as of the date hereof by Forest City Cambridge, Inc. with respect to the lessor's consent signed in connection with the Mortgage. B. On or before the date of this Amendment, the Borrower shall have paid the Bank a non-refundable fee in the mount of $30,000. VI. MISCELLANEOUS. A. As provided in Section 10.8 of the Loan Agreement, the Borrower and the Subsidiaries agree to reimburse the Bank upon demand for all reasonable fees and disbursements of counsel to the Bank incurred in connection with the preparation hereof and the Note. B. This Amendment Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. C. This Amendment Agreement may be executed by the parties hereto in several counterparts hereof and by the different parties hereto on separate counterparts hereof, all of which counterparts shall together constitute one and the same agreement. D. The obligations of the Borrower and the Subsidiaries under this Amendment Agreement and the Note shall be joint and several in nature. Executed as a sealed instrument as of the date first set forth above. ("Borrower") ARIAD PHARMACEUTICALS, INC. By: /s/ Harvey Berger ------------------------------------ Name: Harvey Berger Title: Chairman & CEO ARIAD CORPORATION By: /s/ Harvey Berger ------------------------------------ Name: Harvey Berger Title: CEO & President ARIAD GENE THERAPEUTICS, INC. By: /s/ Harvey Berger ------------------------------------ Name: Harvey Berger Title: Chairman & CEO 5 ("Bank") FLEET NATIONAL BANK By: /s/ Karen M. Kinsella --------------------------------- Name: Karen M. Kinsella Title: Vice President 6 EXHIBIT A SECOND AMENDED AND RESTATED SECURED TERM NOTE 7 SECOND AMENDED AND RESTATED SECURED TERM NOTE $7,500,000.00 Boston, Massachusetts December 26, 2001 FOR VALUE RECEIVED, the undersigned, ARIAD PHARMACEUTICALS, INC., a Delaware corporation (the "Pharmaceuticals"), ARIAD CORPORATION, a Delaware corporation (the "Lessee Subsidiary") and ARIAD GENE THERAPEUTICS, INC., a Delaware corporation ("AGT" and , collectively with Pharmaceuticals and the Lessee Subsidiary, the "Makers"), hereby jointly and severally promise to pay to the order of FLEET NATIONAL BANK (f/k/a BankBoston, N.A.), having an address at 100 Federal Street, Boston, Massachusetts 02110 (the "Bank"), the principal sum of Seven Million Five Hundred Thousand and 00/100 Dollars ($7,500,00.00) or, if less, the aggregate unpaid principal amount of advances made hereunder by the Bank to Pharmaceuticals or any other Maker pursuant to that certain Loan and Security Agreement dated as of September 23, 1992, as amended (as so amended and as hereafter amended, replaced, restated, supplemented, renewed or otherwise modified from time to time, the "Loan Agreement"), between the Makers and the Bank, together with interest on any and all principal remaining unpaid hereunder from the date hereof until payment in full, payable on the dates and at the interest rate or rates specified in the Loan Agreement. Capitalized terms used in this Note without definition have the meanings assigned to them in the Loan Agreement. The aggregate principal amount outstanding hereunder shall be payable as provided in the Loan Agreement. This Note may be prepaid in accordance with the terms and provisions of the Loan Agreement without penalty or premium (other than certain makewhole payments under Section 3.6 of the Loan Agreement). All principal and interest hereunder are payable in lawful money of the United States of America to the Bank at its address specified above in immediately available funds as provided in the Loan Agreement on the date on which such payment shall become due. Payments of principal and interest hereunder which are not made by such date may be made by debiting any deposit account(s), if any, in the name of the Makers, or any of them, with the Bank. The Makers hereby irrevocably authorize the Bank to so debit such deposit account(s). The Makers, for themselves and their legal representatives, successors and assigns, to the extent they may lawfully do so, hereby expressly waive presentment, demand, protest, notice of protest, presentment for the purpose of accelerating maturity, diligence in collection, and the benefit of any exemption or insolvency laws, and consent that the Bank may release or surrender, exchange or substitute any personal property or other collateral security now held or which may hereafter be held as security for the payment of this Note, and may extend the time for payment or otherwise modify the terms of payment of any party or the whole of the debt evidenced hereby to the extent provided in the Loan Agreement without in any way affecting the liability of the Makers; provided that such modifications do not increase the obligations hereunder. This Note is the "Note" referred to in and is entitled to the benefits of the Loan Agreement (including Schedules thereto) and all other instruments and agreements evidencing and/or securing the indebtedness hereunder, which Loan Agreement and other instruments and agreements are hereby made part of this Note and are deemed incorporated herein in full. The occurrence or existence of an Event of Default shall constitute a default under this Note and shall, subject to the provisions of the Loan Agreement, entitle the Bank to accelerate the entire indebtedness hereunder and to take such other action as may be provided for in the Loan Agreement or any other instrument or agreement evidencing and/or securing this Note, all in accordance with the terms of the Loan Agreement. This Note (a) supersedes and replaces the Amended and Restated Secured Term Notes, each dated April 6, 1998, made by the Makers and payable to the order of the Lender and USTrust, respectively, in the principle amounts of $2,601,000 and $2,499,000 under the Loan Agreement, as combined and amended by the First Amendment to Amended and Restated Secured Term Note, dated as of December 28, 2000 (b) represents the Bank's Commitment and outstanding Advances under the Loan Agreement as of the date hereof and (c) represents a continuation (not a refinancing or reborrowing) of the outstanding obligations of the Borrower with respect to the New Term Loan. All agreements between or among the Makers and the Bank are hereby expressly limited so that in no contingency or event whatsoever, whether by reason of acceleration of maturity of the indebtedness or otherwise, shall the amount paid or agreed to be paid for the use or forbearance of the indebtedness evidenced hereby exceed the maximum amount which the Bank is permitted to receive under applicable law. If, from any circumstances whatsoever, fulfillment of any provision hereof or of the Loan Agreement, at the time performance of such provision shall be due, shall involve exceeding such amount, then the obligation to be fulfilled shall automatically be reduced to the limit of such validity and if, from any circumstances, the Bank should ever receive as interest an amount which would exceed such maximum amount, such amount which would be excessive interest shall be applied to the reduction of the principal balance evidenced hereby and not to the payment of interest. As used herein, the term "applicable law" shall mean the law in effect as of the date hereof, PROVIDED, HOWEVER, that in the event there is a change in the law which results in a higher permissible rate of interest, then this Note shall be governed by such new law as of its effective date. This provision shall control every other provision of all agreements between or among the Makers, or any of them, and the Bank. This Note and all transactions hereunder and/or evidenced herein shall be governed by, and construed and enforced in accordance with, the laws of The Commonwealth of Massachusetts. If this Note shall not be paid when due and shall be placed by the holder hereof in the hands of any attorney for collection, through legal proceedings or otherwise, the Makers will pay reasonable attorneys' fees to the holder hereof together with reasonable costs and expenses of collection, including, without limitation, any such attorneys' fees, costs and expenses relating to dissolution or liquidation of any of the Makers or any party (other than the Bank) to any instrument or agreement securing this Note. This Note shall be binding, jointly and severally, upon the Makers and upon their heirs, successors, assigns and legal representatives and shall inure to the benefit of the Bank and its successors, endorsees and assigns. IN WITNESS WHEREOF, the Makers have caused this Note to be executed under seal by their duly authorized representative as of the date first above written. ARIAD PHARMACEUTICALS, INC. By: /s/ Harvey Berger ------------------------------------ Name: Harvey Berger Title: Chairman & CEO ARIAD CORPORATION By: /s/ Harvey Berger ------------------------------------ Name: Harvey Berger Title: President & CEO 2 ARIAD GENE THERAPEUTICS, INC. By: /s/ Harvey Berger ------------------------------------ Name: Harvey Berger Title: Chairman & CEO 3 EX-10.50 5 b41666arex10-50.txt EX-10.50 MASTER SECURITY AGREEMENT DEC-27-2001 EXHIBIT 10.50 MASTER SECURITY AGREEMENT dated as of December 27, 2001 ("Agreement") THIS AGREEMENT is between General Electric Capital Corporation (together with its successors and assigns, if any, "Secured Party") and Ariad Pharmaceuticals, Inc. ("Debtor"). Secured Party has an office at 401 Merritt 7, Suite 23, Norwalk, CT 06856. Debtor is a corporation organized and existing under the laws of the state of Delaware. Debtor's mailing address and chief place of business is 26 Landsdowne St., Cambridge, MA 02139. 1. CREATION OF SECURITY INTEREST. Debtor grants to Secured Party, its successors and assigns, a security interest in and against all property listed on any collateral schedule now or in the future annexed to or made a part of this Agreement ("Collateral Schedule"), and in and against all additions, attachments, accessories and accessions to such property, all substitutions, replacements or exchanges therefor, and all insurance and/or other proceeds thereof (all such property is individually and collectively called the "Collateral"). This security interest is given to secure the payment and performance of all debts, obligations and liabilities of any kind whatsoever of Debtor to Secured Party, now existing or arising in the future, including but not limited to the payment and performance of certain Promissory Notes from time to time identified on any Collateral Schedule (collectively "Notes" and each a "Note"), and any renewals, extensions and modifications of such debts, obligations and liabilities (such Notes, debts, obligations and liabilities are called the "Indebtedness"). Unless otherwise provided by applicable law, notwithstanding anything to the contrary contained in this Agreement, to the extent that Secured Party asserts a purchase money security interest in any items of Collateral ("PMSI Collateral"); (i) the PMSI Collateral shall secure only that portion of the Indebtedness which has been advanced by Secured Party to enable Debtor to purchase, or acquire rights in or the use of such PMSI Collateral (the "PMSI Indebtedness"), and (ii) no other Collateral shall secure the PMSI Indebtedness. 2. REPRESENTATIONS, WARRANTIES AND COVENANTS OF DEBTOR. Debtor represents, warrants and covenants as of the date of this Agreement and as of the date of each Collateral Schedule that: (a) Debtor's exact legal name is as set forth in the preamble of this Agreement and Debtor is, and will remain, duly organized, existing and in good standing under the laws of the State set forth in the preamble of this Agreement, has its chief executive offices at the location specified in the preamble, and is, and will remain, duly qualified and licensed in every jurisdiction wherever necessary to carry on it business and operations; (b) Debtor has adequate power and capacity to enter into, and to perform its obligations under this Agreement, each Note and any other documents evidencing, or given to connection with, any of the Indebtedness (all of the foregoing are called the "Debt Documents"); (c) This Agreement and the other Debt Documents have been duly authorized, executed and delivered by Debtor and constitute legal, valid and binding agreements enforceable in accordance with their terms, except to the extent that the enforcement of remedies may be limited under applicable bankruptcy and insolvency laws; (d) No approval, consent or withholding of objections is required from any governmental authority or instrumentality with respect to the entry into, or performance by Debtor of any of the Debt Documents, except any already obtained; (e) The entry into and performance by, Debtor of the Debt Documents will not (i) violate any of the organizational documents of Debtor or any judgment order, law or regulation applicable to Debtor, or (ii) result in any breach of or constitute a default under any contract to which Debtor is a party, or result in the creation of any lien, claim or encumbrance on any of Debtor's property (except for liens in favor of Secured Party) pursuant to any indenture, mortgage, deed of trust, bank loan, credit agreement, or other agreement or instrument to which Debtor is a party; (f) There are no suits or proceedings pending in court or before any commission, board or other administrative agency against or affecting Debtor which could, in the aggregate, have a material adverse effect on Debtor, its business or operations, or its ability to perform its obligations under the Debt Documents, nor does Debtor have reason to believe that any such suits or proceedings are threatened. (g) All financial statements delivered to Secured Party in connection with the indebtedness have been prepaid in accordance with generally accepted accounting principles and since the date of the most recent financial statement, there has been no material adverse change in Debtor's financial condition; (h) The Collateral is not, and will not be, used by Debtor for personal, family or household purposes; (i) The Collateral is, and will remain, in good condition and repair and Debtor will not be negligent in its care and use; (j) Debtor is, and will remain, the sole and lawful owner, and in possession of, the Collateral, and has the sole right and lawful authority to grant the security interest described in this Agreement; and (k) The Collateral is, and will remain, free and clear of all liens, claims and encumbrances of any kind whatsoever, except for (i) liens in favor of Secured Party, (ii) liens for taxes not yet due or for taxes being contested in good faith and which do not involve, in the judgment of Secured Party, any risk of the sale, forfeiture or loss of any of the Collateral, and (iii) inchoate materialmen's, mechanic's, repairman's and similar liens arising by operation of law in the normal course of business for amounts which are not delinquent (all off such liens are called "Permitted Liens"). 3. COLLATERAL (a) Until the declaration of any default, Debtor shall remain in possession of the Collateral; except that Secured Party shall have the right to possess (i) any chattel paper or instrument that constitutes a part of the Collateral, and (ii) any other Collateral in which Secured Party's security interest may be perfected only by possession. Secured Party may inspect any of the Collateral during normal business hours after giving Debtor reasonable prior notice. If Secured Party asks, Debtor will promptly notify Secured Party in writing of the location of any Collateral. (b) Debtor shall (i) use the Collateral only in its trade or business, (ii) maintain all of the Collateral in good operating order and repair, normal wear and tear excepted, (iii) use and maintain the Collateral only in compliance with manufacturers recommendations and all applicable laws, and (iv) keep all of the Collateral free and clear of all liens, claims and encumbrances (except for Permitted Liens). (c) Secured Party does not authorize and Debtor agrees it shall not (i) part with possession of any of the Collateral (except to Secured Party or for maintenance and repair), (ii) remove any of the Collateral from the continental United States, or (iii) sell, rent, lease, mortgage, license, grant a security interest in or otherwise transfer or encumber (except for Permitted Liens) any of the Collateral. (d) Debtor shall promptly when due all taxes, license fees, assessments and public and private charges levied or assessed on any of the Collateral, on its use, or on this Agreement or any of the other Debt Documents. At its option, Secured Party may discharge taxes, liens, security interests or other encumbrances at any time levied or placed on the Collateral and may pay for the maintenance, insurance and preservation of the Collateral and effect compliance with the terms of this Agreement or any of the other Debt Documents. Debtor agrees to reimburse Secured Party, on demand, all costs and expenses incurred by Secured Party in connection with such payment or performance and agrees that such reimbursement obligation shall constitute Indebtedness. (e) Debtor shall, at all times, keep accurate and complete records of the Collateral, and Secured Party shall have the right to inspect and make copies of all of Debtor's books and records relating to the Collateral during normal business hours, after giving Debtor reasonable prior notice. (f) Debtor agrees and acknowledges that any third person who may at any time possess all or any portion of the Collateral shall be deemed to hold, and shall hold, the Collateral as the agent of, and as pledge holder for Security Party. Secured Party may at any time give notice to any third person described in the preceding sentence that such third person is holding the Collateral as the agent of, and as pledge holder for, the Secured Party. 4. INSURANCE (a) Debtor shall at all times bear the entire risk of any loss, theft, damage to, or destruction of, any of the Collateral from any cause whatsoever. (b) Debtor agrees to keep the Collateral insured against loss or damage by fire and extended coverage perils, theft, burglary, and for any or all Collateral which are vehicles for risk of loss by collision, and if requested by Secured Party, against such other risks as Secured Party may reasonably require. The insurance coverage shall be in an amount no less than the full replacement value of the Collateral, and deductible amounts, insurers and policies shall be acceptable to Secured Party. Debtor shall deliver to Secured Party policies or certificates of insurance evidencing such coverage. Each policy shall name Secured Party as a loss payee, shall provide for coverage to Secured Party regardless of the breach by Debtor of any warranty or representation made therein, shall not be subject to co-insurance, and shall provide that coverage may not be canceled or altered by the insurer except upon thirty (30) days prior written notice to Secured Party. Debtor appoints Secured Party as its attorney-in-fact to make proof of loss, claim for insurance and adjustments with insurers, and to receive payment of and execute or endorse all documents, checks or drafts in connection with insurance payments. Secured Party shall not act as Debtor's attorney-in-fact unless Debtor is in default. Proceeds of insurance shall be applied, at the option of Debtor, to repair or replace the Collateral or to reduce any of the Indebtedness, except that in the event of a loss of all or substantially all of the collateral, the option will revert to the Secured Party. 5. REPORTS (a) Debtor shall promptly notify Secured Party of (i) any change in the name of Debtor, (ii) any change in the state of its incorporation or registration, (iii) any relocation of its chief executive offices, (iv) any relocation of any of the Collateral, (v) any of the Collateral being lost, stolen, missing, destroyed, materially damaged or worn out, or (vi) any lien, claim or encumbrance other than Permitted Liens attaching to or being made against any of the Collateral. (b) Debtor will deliver to Secured Party Debtor's complete financial statements, certified by a recognized firm of certified public accountants, within ninety (90) days of the close of each fiscal year of Debtor. Debtor will make available to Secured Party copies of Debtor's quarterly financial reports certified by Debtor's chief financial officer, within ninety (90) days after the close of each of Debtor's fiscal quarter. Debtor will make available to Secured Party copies of all Forms 10-K and 10-Q, if any, within 30 days after the dates on which they are filled with the Securities and Exchange Commission. Availability will include Internet availability and will not require other by the Debtor. 6. FURTHER ASSURANCES (a) Debtor shall, upon request of Secured Party, furnish to Secured Party such further information, execute and deliver to Secured Party such documents and instruments (including, without limitation, Uniform Commercial Code financing statements) and shall do such other acts and things as Secured Party may at any time reasonably request relating to the perfection or protection of the security interest created by this Agreement or for the purpose of carrying out the intent of this Agreement. Without limiting the foregoing, Debtor shall cooperate and do all acts deemed necessary or advisable by Secured Party to continue in Secured Party a perfected first security interest in the Collateral, and shall obtain and furnish to Secured Party and subordinations, releases, landlord waivers, lessor waivers, mortgagee waivers, or control agreements, and similar documents as may be from time to time requested by, and in form and substance satisfactory to, Secured Party. (b) Debtor authorizes Secured Party to file a financing statements and amendments thereto describing the Collateral and containing any other information required by the applicable Uniform Commercial Code. Debtor irrevocably grants to Secured Party the power to sign Debtor's name and generally to act on behalf of Debtor to execute and file applications for title, transfers of title, financing statements, notices of lien and other documents pertaining to any or all of the Collateral; this power is coupled with Secured Party's interest in the Collateral. Debtor shall, if any certificate of title be required or permitted by law for any of the Collateral, obtain and promptly deliver to Secured Party such certificate showing the lien of this Agreement with respect to the Collateral. Debtor ratifies its prior authorization for Secured Party to file financing statements and amendments thereto describing the Collateral and containing any other information required by the Uniform Commercial Code if filed prior to the date hereof. (c) Debtor shall indemnify and defend the Secured Party, its successors and assigns, and their respective directors, officers and employees, from and against all claims, actions and suits (including, without limitation, related attorneys' fees) of any kind whatsoever arising, directly or indirectly, in connection with any of the Collateral. 7. DEFAULT AND REMEDIES. (a) Debtor shall be in default under this Agreement and each of the other Debt Documents if: (i) Debtor breaches its obligation to pay when due any installment or other amount due or coming due under any of the Debt Documents; (ii) Debtor, without the prior written consent of Secured Party, attempts to or does sell, rent, lease, license, mortgage, grant a security interest in, or otherwise transfer or encumber (except for Permitted Liens) any of the Collateral; (iii) Debtor breaches any of its insurance obligations under Section 4; (iv) Debtor breaches any of its other obligations under any of the Debt Documents and fails to cure that breach within thirty (30) days after written notice from Secured Party: (v) Any warranty, representation or statement made by Debtor in any of the Debt Documents or otherwise in connection with any of the indebtedness shall be false or misleading in any material respect; (vi) Any of the Collateral is subjected to attachment, execution, levy, seizure or confiscation in any legal proceeding or otherwise, or if any legal or administrative proceeding is commenced against Debtor or any of the Collateral, which in the good faith judgment of Secured Party subjects any of the Collateral to a material risk of attachment, execution, levy, seizure or confiscation and no bond is posted or protective order obtained to negate such risk; (vii) Debtor breaches or is in default under any other agreement between Debtor and Secured Party; (viii) Debtor or any guarantor or other obligor for any of the Indebtedness (collectively, "Guarantor") dissolves, terminates its existence, becomes insolvent or ceases to do business as a going concern; (ix) If Debtor or any Guarantor is a natural person, Debtor or any such Guarantor dies or becomes incompetent; (x) A receiver is appointed for all or any part of the property of Debtor or any Guarantor, or Debtor or any Guarantor makes any assignment for the benefit of creditors; (xi) Debtor or any Guarantor files a petition under any bankruptcy, insolvency or similar law, or any such petition is filed against Debtor or any Guarantor and is not dismissed within forty-five (45) days; or (xii) Debtor's improper filing of an amendment or termination statement relating to a filed financing statement describing the Collateral. (b) If Debtor is in default, the Secured Party, at its option, may declare any or all of the Indebtedness to be immediately due and payable, without demand or notice to Debtor or any Guarantor. The accelerated obligations and liabilities shall bear interest (both before and after any judgment) until paid in full at the lower of eighteen percent (18%) per annum or the maximum rate not prohibited by applicable law. (c) After default, Secured Party shall have all of the rights and remedies of a Secured Party under the Uniform Commercial Code, and under any other applicable law. Without limiting the foregoing, Secured Party shall have the right to (i) notify any account debtor of Debtor or any obligor on any instrument which constitutes part of the Collateral to make payment to the Secured Party, (ii) with or without legal process, enter any premises where the Collateral may be and take possession of and remove the Collateral from the premises or store it on the premises, (iii) sell the Collateral at public or private sale, in whole or in part, and have the right to bid and purchase at said sale, or (iv) lease or otherwise dispose of all or part of the Collateral, applying proceeds from such disposition to the obligations then in default. If requested by Secured Party, Debtor shall promptly assemble the Collateral and make it available to Secured Party at a place to be designated by Secured Party which is reasonably convenient to both parties. Secured Party may also render any or all of the Collateral unusable at the Debtor's premises and may dispose of such Collateral on such premises without liability for rent or costs. Any notice that Secured Party is required to give to Debtor under the Uniform Commercial Code of the time and place of any public sale or the time after which any private sale or other intended disposition of the Collateral is to be made shall be deemed to constitute reasonable notice if such notice is given to the last known address of Debtor at least five (5) days prior to such action. (d) Proceeds from any sale or lease or other disposition shall be applied: first, to all costs of repossession, storage, and disposition including without limitation attorneys', appraisers', and auctioneers' fees; second, to discharge the obligations then in default; third, to discharge any other Indebtedness of Debtor to Secured Party, whether as obligor, endorser, guarantor, surety or indemnitor; fourth, to expenses incurred in paying or settling liens and claims against the Collateral; and lastly, to Debtor, if there exists any surplus. Debtor shall remain fully liable for any deficiency. (e) Debtor agrees to pay all reasonable attorneys' fees and other costs incurred by Secured Party in connection with the enforcement, assertion, defense or preservation of Secured Party's rights and remedies under this Agreement, or if prohibited by law, such lesser sum as may be permitted. Debtor further agrees that such fees and costs shall constitute Indebtedness. (f) Secured Party's rights and remedies under this Agreement or otherwise arising are cumulative and may be exercised singularly or concurrently. Neither the failure nor any delay on the part of the Secured Party to exercise any right, power or privilege under this Agreement shall operate as a waiver, nor shall any single or partial exercise of any right, power or privilege preclude any other or further exercise of that or any other right, power or privilege. SECURED PARTY SHALL NOT BE DEEMED TO HAVE WAIVED ANY OF ITS RIGHTS UNDER THIS AGREEMENT OR UNDER ANY OTHER AGREEMENT, INSTRUMENT OR PAPER SIGNED BY DEBTOR UNLESS SUCH WAIVER IS EXPRESSED IN WRITING AND SIGNED BY SECURED PARTY. A waiver on any one occasion shall not be construed as a bar to or waiver of any right or remedy on any future occasion. (g) DEBTOR AND SECURED PARTY UNCONDITIONALLY WAIVE THEIR RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, ANY OF THE OTHER DEBT DOCUMENTS, ANY OF THE INDEBTEDNESS SECURED HEREBY, ANY DEALINGS BETWEEN DEBTOR AND SECURED PARTY RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS, AND/OR THE RELATIONSHIP THAT IS BEING ESTABLISHED BETWEEN DEBTOR AND SECURED PARTY. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT. THIS WAIVER IS IRREVOCABLE. THIS WAIVER MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING. THE WAIVER ALSO SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT, ANY OTHER DEBT DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR ANY RELATED TRANSACTION. THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT. 8. MISCELLANEOUS. (a) This Agreement, any Note and/or any of the other Debt Documents may be assigned, in whole or in part, by Secured Party without notice to Debtor, and Debtor agrees not to assert against any such assignee, or assignee's assigns, any defense set-off, recoupment claim or counterclaim which Debtor has or may at any time have against Secured Party for any reason whatsoever. Debtor agrees that if Debtor receives written notice of an assignment from Secured Party, Debtor will pay all amounts payable under any assigned Debt Document to such assignee or as instructed by Secured Party. Debtor also agrees to confirm in writing receipt of the notice of assignment as may be reasonably requested by Secured Party or assignee. (b) All notices to be given in connection with this Agreement shall be in writing, shall be addressed to the parties at their respective addresses set forth in this Agreement (unless and until a different address may be specified in a written notice to the other party), and shall be deemed given (i) on the date of receipt if delivered in hand or by facsimile transmission, (ii) on the next business day after being sent by express mail, and (iii) on the fourth business day after being sent by regular, registered or certified mail. As used herein, the term "business day" shall mean and include any day other than Saturdays, Sundays, or other days on which commercial banks in New York, New York are required or authorized to be closed. (c) Secured Party may correct patent errors and fill in all blanks in this Agreement or in any Collateral Schedule consistent with the agreement of the parties. (d) Time is of the essence of this Agreement. This Agreement shall be binding, jointly and severally, upon all parties described as the "Debtor" and their respective heirs, executors, representatives, successors and assigns, and shall inure to the benefit of Secured Party, its successors and assigns. (e) This Agreement and its Collateral Schedules constitute the entire agreement between the parties with respect to the subject matter of this Agreement and supersede all prior understandings (whether written, verbal or implied) with respect to such subject matter. THIS AGREEMENT AND ITS COLLATERAL SCHEDULES SHALL NOT BE CHANGED OR TERMINATED ORALLY OR BY COURSE OF CONDUCT, BUT ONLY BY A WRITING SIGNED BY BOTH PARTIES. Section headings contained in this Agreement have been included for convenience only, and shall not affect the construction or interpretation of this Agreement. (f) This Agreement shall continue in full force and effect until all of the Indebtedness has been indefeasibly paid in full to Secured Party or its assignee. The surrender, upon payment or otherwise, of any Note or any of the other documents evidencing any of the Indebtedness shall not affect the right of Secured Party to retain the Collateral for such other Indebtedness as may then exist or as it may be reasonably contemplated will exist in the future. This Agreement shall automatically be reinstated if Secured Party is ever required to return or restore the payment of all or any portion of the Indebtedness (all as though such payment had never been made). (g) THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF CONNECTICUT (WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES OF SUCH STATE), INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, REGARDLESS OF THE LOCATION OF THE EQUIPMENT. IN WITNESS WHEREOF, Debtor and Secured Party, intending to be legally bound hereby, have duly executed this Agreement in one or more counterparts, each of which shall be deemed to be an original, as of the day and year first aforesaid. SECURED PARTY: DEBTOR: General Electric Capital Corporation ARIAD Pharmaceuticals, Inc. By: /s/ John Edel By: /s/ Brian A. Lajoie ------------------------------- -------------------------------------- Name: John Edel Name: Brian A. Lajoie Title: SVP Title: Interim Chief Financial Officer EX-10.51 6 b41666arex10-51.txt EX-10.51 ADDENDUM TO MASTER LEASE AGREEMENT EXHIBIT 10.51 FINANCIAL COVENANTS ADDENDUM NO. 001 TO MASTER LEASE AGREEMENT DATED AS OF DECEMBER 27, 2001 THIS ADDENDUM (this "Addendum") amends and supplements the above referenced agreement (the "Agreement"), between General Electric Capital Corporation (together with its successors and assigns, if any, "Lender") and Ariad Pharmaceuticals, Inc. (each of the aforementioned parties shall hereinafter be collectively referred to as "Borrower") and is hereby incorporated into the Agreement as though fully set forth therein. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Lease. The Agreement is hereby amended by adding the following: FINANCIAL COVENANTS. (a) Borrower shall, at all times during the term of the Agreement, comply with the following: Maintain minimum Unrestricted Cash (as defined below) in the amount of $10,000,000.00. If this covenant is violated, Borrower will provide Lender within ten (10) days of such occurrence, an irrevocable letter of credit as described in section (c) below. Unrestricted Cash shall be defined as cash on hand, including investments in marketable securities with maturities of less than twenty four (24) months, less cash pledged to other parties and any contingent liability associated with similar cash covenants under leases, loans or other financial arrangements. (b) COMPLIANCE REPORTS. Borrower's Authorized Representative shall certify that Borrower is in compliance with the requirements of subsection (a) above. Such notification and certification shall be provided within ninety (90) days after the end of each fiscal year, the "Compliance Date"), reflecting such information as of the end of such fiscal year. If Borrower fails timely to provide such notification and compliance certificates, within fifteen (15) days after the Compliance Date, such failure shall automatically be deemed a default under the Agreement without notice or other act by Lender. The reports required under this section are in addition to and not a substitute for the reports required under the REPORTS Section of the Agreement. (c) The irrevocable letter of credit provided pursuant to this addendum under a default of Financial Covenant shall be (i) in an amount equal to the total of all Borrower's then outstanding Indebtedness to Lender under this Agreement, (ii) issued by a bank which is acceptable to Lender in its sole discretion, (iii) in the form attached as Exhibit A or as may be acceptable to Lender in its sole discretion, and (iv) for an initial term of at least one (1) year with automatic renewals thereafter (without amendment except for extension of the then current expiration date by an additional year) until Borrower has received written notice from Lender to the effect that the letter of credit is being released in its entirety. Borrower shall also execute a Letter of Credit Agreement in the form attached as Exhibit B. Except as expressly modified hereby, all terms and provisions of the Lease shall remain in full force and effect. This Addendum is not binding nor effective with respect to the Lease until executed on behalf of Lender and Borrower by authorized representatives of Lender and Borrower. IN WITNESS WHEREOF, Borrower and Lender have caused this Addendum to be executed by their duly authorized representatives as of the date first above written. LENDER: BORROWER: GENERAL ELECTRIC CAPITAL CORPORATION ARIAD PHARMACEUTICALS, INC. By: /s/ John Edel By: /s/ Brian A. Lajoie --------------------------- -------------------------------------- Name: JOHN EDEL Name: BRIAN A. LAJOIE Title: SVP Title: Interim Chief Financial Officer ATTEST By: /s/ Joseph Bratica -------------------------------------- Name: Joseph Bratica EX-10.52 7 b41666arex10-52.txt EX-10.52 PROMISSORY NOTE DEC-28-2001 EXHIBIT 10.52 PROMISSORY NOTE DEC. 28, 2001 (Date) FOR VALUE RECEIVED, Ariad Pharmaceuticals, Inc. a corporation located at the address stated below ("Maker") promises, jointly and severally if more than one, to pay to the order of General Electric Capital Corporation or any subsequent holder hereof (each, a "Payee") at its office located at 401 Merritt 7 Suite 23, Norwalk, CT 06856 or at such other place as Payee or the holder hereof may designate, the principal sum of Seven Hundred Eighty-Nine Thousand Eight Hundred Two - 93/100 Dollars ($789,802.93) with interest on the unpaid principal balance, from the date hereof through and including the dates of payment, at a fixed interest rate of Nine and 51/100 percent (9.51%) per annum, to be paid in lawful money of the United States, in Thirty-six (36) consecutive monthly installments of principal and interest as follows: Periodic Installment Amount ----------- ------ 35 x $25.104.46 each ("Periodic Installment") and a final installment which shall be in the amount of the total outstanding principal and interest. The first Periodic Installment shall be due and payable on JAN. 1, 2002 and the following Periodic Installments and the final installment shall be due and payable on the same day of each succeeding month (each , a "Payment Date"). Such installments have been calculated on the basis of a 360 day year of twelve 30-day months. Each payment may, at the option of the Payee, be calculated and applied on an assumption that such payment would be made on its due date. The acceptance by Payee of any payment which is less than payment in full of all amounts due and owing at such time shall not constitute a waiver of Payee's right to receive payment in full at such time or at any prior or subsequent time. The Maker hereby expressly authorizes the Payee to insert the date value is actually given in the blank space on the face hereof and on all related documents pertaining hereto. This Note may be secured by a security agreement, chattel mortgage, pledge agreement or like instrument (each of which is hereinafter called a "Security Agreement"). Time is of the essence hereof. If any installment or any other sum due under this Note or any Security Agreement is not received within fifteen (15) days after its due date, the Maker agrees to pay, in addition to the amount of each such installment or other sum, a late payment charge of five percent (5%) of the amount of said installment or other sum, but not exceeding any lawful maximum. If (i) Maker fails to make payment of any amount due hereunder within fifteen (15) days after the same becomes due and payable; or (ii) Maker is in default under, or fails to perform under any term or condition contained in any Security Agreement, then the entire principal sum remaining unpaid, together with all accrued interest thereon and any other sum payable under this Note or any Security Agreement, at the election of Payee, shall immediately become due and payable, with interest thereon at the lesser of eighteen percent (18%) per annum or the highest rate not prohibited by applicable law from the date of such accelerated maturity until paid (both before and after any judgment). The Maker may prepay in full, but not in part, its entire indebtedness hereunder upon payment of the entire indebtedness plus an additional sum as a premium equal to the following percentages of the original principal balance for the indicated period: Prior to the first annual anniversary date of this Note: Five percent (5%) Thereafter and prior to the second annual anniversary date of this Note: Two percent (2%) Thereafter and prior to the third annual anniversary date of this Note: One percent (1%) and zero percent (0%) thereafter, plus all other sums due hereunder or under any Security Agreement. It is the intention of the parties hereto to comply with the applicable usury laws; accordingly, it is agreed that, notwithstanding any provision to the contrary in this Note or any Security Agreement, in no event shall this Note or any Security Agreement require the payment or permit the collection of interest in excess of the maximum amount permitted by applicable law. If any such excess interest is contracted for, charged or received under this Note or any Security Agreement, or if all of the principal balance shall be prepaid, so that under any of such circumstances the amount of interest contracted for, charged or received under this Note or any Security Agreement on the principal balance shall exceed the maximum amount of interest permitted by applicable law, then in such event (a) the provisions of this paragraph shall govern and control, (b) neither Maker nor any other person or entity now or hereafter liable for the payment hereof shall be obligated to pay the amount of such interest to the extent that it is in excess of the maximum amount of interest permitted by applicable law, (c) any such excess which may have been collected shall be either applied as a credit against the then unpaid principal balance or refunded to Maker, at the option of the Payee, and (d) the effective rate of interest shall be automatically reduced to the maximum lawful contract rate allowed under applicable law as now or hereafter construed by the courts having jurisdiction thereof. It is further agreed that without limitation of the foregoing, all calculations of the rate of interest contracted for, charged or received under this Note or any Security Agreement which are made for the purpose of determining whether such rate exceeds the maximum lawful contract rate, shall be made, to the extent permitted by applicable law, by amortizing, prorating, allocating and spreading in equal parts during the period of the full stated term of the indebtedness evidenced hereby, all interest at any time contracted for, charged or received from Maker or otherwise by Payee in connection with such indebtedness; provided, however, that if any applicable state law is amended or the law of the United States of America preempts any applicable state law, so that it becomes lawful for the Payee to receive a greater interest per annum rate than is presently allowed, the Maker agrees that, on the effective date of such amendment or preemption, as the case may be, the lawful maximum hereunder shall be increased to the maximum interest per annum rate allowed by the amended state law or the law of the United State of America. The Maker and all sureties, endorsers, guarantors or any others (each such person, other than the Maker, an "Obligor") who may at any time become liable for the payment hereof jointly and severally consent hereby to any and all extensions of time, renewals, waivers or modifications of, and all substitutions or releases of, security or of any party primarily or secondarily liable on this Note or any Security Agreement or any term and provision of either, which may be made, granted or consented to by Payee, and agree that suit may be brought and maintained against any one or more of them, at the election of Payee without joinder of any other as a party thereto, and that Payee shall not be required first to foreclose, proceed against, or exhaust any security hereof in order to enforce payment of this Note. The Maker and each Obligor hereby waives presentment, demand for payment, notice of nonpayment, protest, notice of protest, notice of dishonor, and all other notices in connection herewith, as well as filing of suit (if permitted by law) and diligence in collecting this Note or enforcing any of the security hereof, and agrees to pay (if permitted by law) all expenses incurred in collection, including Payee's actual attorneys' fees. Maker and each Obligor agrees that fees not in excess of twenty percent (20%) of the amount then due shall be deemed reasonable. THE MAKER HEREBY UNCONDITIONALLY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF, DIRECTLY OR INDIRECTLY, THIS NOTE, ANY OF THE RELATED DOCUMENTS, ANY DEALINGS BETWEEN MAKER AND PAYEE RELATING TO THE SUBJECT MATER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS, AND/OR THE RELATIONSHIP THAT IS BEING ESTABLISHED BETWEEN MAKER AND PAYEE. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT (INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS.) THIS WAIVER IS IRREVOCABLE MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS NOTE, ANY RELATED DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR ANY RELATED TRANSACTION. IN THE EVENT OF LITIGATION, THIS NOTE MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT. This Note and any Security Agreement constitute the entire agreement of the Maker and Payee with respect to the subject matter hereof and supercedes all prior understandings, agreements and representations, express or implied. No variation or modification of this Note, or any waiver of any of its provisions or conditions, shall be valid unless in writing and signed by an authorized representative of Maker and Payee. Any such waiver, consent, modification or change shall be effective only in the specific instance and for the specific purpose given. Any provision in this Note or any Security Agreement which is in conflict with any statute, law or applicable rule shall be deemed omitted, modified or altered to conform thereto. ARIAD PHARMACEUTICALS, INC. /S/ JOSEPH BRATICA By: /s/ Brian A. Lajoie - -------------------------------------- --------------------------------- (Witness) Name: Brian A. Lajoie Title: Interim Chief Financial Joseph Bratica Officer - -------------------------------------- (Print name) Federal Tax ID#: 26 Landsdowne St., Cambridge, Ma 02139 Address: 26 Landsdowne St. Cambridge, - -------------------------------------- Middlesex County, MA 02139 (Address) EX-10.53 8 b41666arex10-53.txt EX-10.53 RESEARCH & DEVELOPMENT AGREEMENT EXHIBIT 10.53 REVISED AND RESTATED RESEARCH AND DEVELOPMENT AGREEMENT This Revised and Restated Research and Development Agreement (the "Agreement"), dated as of March 15, 2002 ("Execution Date"), between ARIAD Pharmaceuticals, Inc., a Delaware corporation ("Pharmaceuticals") and ARIAD Corporation, a Delaware corporation ("Corporation") supersedes and supplants in its entirety the Research and License Agreement between Pharmaceuticals and Corporation dated June 23, 1992 ("Original Agreement"). WHEREAS, Pharmaceuticals has certain patent rights and technology and has acquired licenses to certain other patent rights and technology, for the purpose of allowing Pharmaceuticals to develop and commercialize certain Products; WHEREAS, Corporation has personnel experienced in the research and development of human health care products and has, or is expected to acquire, the facilities, equipment and employees that will permit it to carry out research and development activities for Pharmaceuticals, with respect to such rights and technology; and WHEREAS, Pharmaceuticals desires to engage Corporation to perform such services and Corporation desires to provide such services. NOW, THEREFORE, in consideration of the foregoing premises and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Corporation and Pharmaceuticals hereby agree as follows: 1. Definitions. Definitions. As used herein, capitalized terms shall have the respective meanings set forth below: (a) "Pharmaceuticals Technology" shall mean all information, developments, discoveries, inventions, improvements, know-how, processes, formulas, methods, trade secrets and other intellectual property, whether or not patentable, whether or not copyrightable, now owned or hereafter developed, acquired, reduced to practice or conceived by Pharmaceuticals, either alone or jointly with others, or licensed or sublicensed to Pharmaceuticals. (b) "Confidential Information" has the meaning set forth in Section 8.1 below. (c) "Improvements" shall mean all information, developments, discoveries, inventions, improvements (including improvements to Pharmaceuticals Technology), know-how, processes, formulas, methods, trade secrets and other intellectual property, other than the Pharmaceuticals Technology, whether or not patentable, whether or not copyrightable, which are developed, acquired, reduced to practice or conceived by Corporation, either alone or jointly with others, in carrying out Research and Development under this Agreement. (d) "Legal Order" has the meaning set forth in Section 8.3 below. (e) "Product" shall mean any article, composition, apparatus, substance, chemical, material, method, process or service. (f) "Programs" shall mean research and development programs set forth by Pharmaceuticals for Research and Development to be performed by Corporation. (g) "Research and Development" shall mean research, development, pre-clinical and clinical testing, and related services and activities. 1.1. Singular and Plural. Singular and plural forms, as the case may be, of terms defined herein shall have correlative meanings. 2. Research and Development 2.1. Research and Development Services. Pharmaceuticals hereby engages Corporation, and Corporation hereby agrees, to undertake Research and Development of the Pharmaceuticals Technology in accordance with each Program for the purpose of allowing Pharmaceuticals to develop, manufacture, use, sell and market one or more Products. During the term of this Agreement, Corporation shall use its best efforts to conduct the Research and Development for Pharmaceuticals with respect to each Program in a prudent and skillful manner in accordance with applicable laws, ordinances, rules, regulations, orders, licenses and other requirements now or hereafter in effect. Corporation shall obtain all labor, supervision, services, materials, supplies, tools, machinery and replacement parts thereof necessary to perform the Research and Development in accordance with each Program then in effect, which expenses shall be paid by Pharmaceuticals as described below. All such materials, supplies, tools, machinery and replacement parts thereof shall be used exclusively by Corporation to perform the Research and Development for Pharmaceuticals under each Program. 2.2. Reports and Records. Within sixty (60) days after the end of each calendar quarter during the term of this Agreement, Corporation shall provide to Pharmaceuticals a report setting forth the total Research and Development costs incurred during such quarter. All Research and Development and any other work performed under each Program should be duly recorded and evidenced in laboratory notebooks maintained by the persons working on the Program, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. Upon the request of Pharmaceuticals, Corporation will provide to Pharmaceuticals a report setting forth (a) a summary of the work performed hereunder by Corporation and its employees and agents, and (b) a description of any material development with respect to the Programs. Pharmaceuticals shall also have the right, during normal business hours, to inspect and copy the records pertaining to the Programs kept by Corporation. 2.3. Rights to Property. As between Pharmaceuticals and Corporation, all right, title and interest in and to any Improvements acquired or developed pursuant to this Agreement, including all intellectual property rights therein, shall be the exclusive property of and are hereby assigned to Pharmaceuticals. This Section 2.3 shall survive the expiration or termination of this Agreement for any reason. 2.4. Exclusion from Assignment. Pharmaceuticals and Corporation acknowledge and agree the assignments set forth in Sections 2.3, 5.3 and 7 shall not extend to, and do not include, any Improvements owned or controlled by third parties (alone or jointly) that Corporation does not have the right to assign; and to the extent any Improvements are owned or controlled by a third party and licensed to Corporation, Corporation hereby grants Pharmaceuticals a sublicense to such Improvements that is of the same scope and duration and includes all rights Corporation received under the license granted to Corporation by the third party, provided that Corporation has the right to sublicense its rights to Pharmaceuticals. This Section 2.4 shall survive the expiration or termination of this Agreement for any reason. 2 3. Payment for Services; Timing of Payments. 3.1. Payments. In consideration of the Research and Development activities to be carried out by Corporation during the term of this Agreement, Pharmaceuticals shall reimburse Corporation for all of its Research and Development costs, and Pharmaceuticals shall additionally pay Corporation a fee equal to ten (10%) percent of all such Research and Development costs (a "Cost-Plus Fee"). 3.2. Timing of Payments. If requested by Corporation, Pharmaceuticals shall advance funds for all Research and Development costs in reasonable amounts. Within sixty (60) days after the end of each calendar quarter, Corporation shall deliver a statement to Pharmaceuticals of the Research and Development costs actually incurred in such calendar quarter and the Cost-Plus Fee thereon, and Pharmaceuticals shall pay to Corporation any additional amounts shown to be due therefor and not yet paid. 3.3. Calculation of Costs. Directs costs shall be allocated on a reasonable and consistent basis, and charged to Pharmaceuticals for Research, Development and other services performed by Corporation for Pharmaceuticals hereunder. Corporation's expenditures and estimated expenditures of conducting the Research and Development hereunder shall be determined using Corporation's internal financial and accounting systems. Allocation of all indirect costs, including general and administrative costs, will be made by Corporation on a reasonable basis consistent with Corporation's regular internal cost accounting system. 3.4. Competitive Costs. All costs to be paid by Pharmaceuticals hereunder shall be no greater than the cost to Pharmaceuticals would be if Pharmaceuticals obtained similar services, materials or other resources from a third party similarly situated to Corporation. 4. Representatives, Warranties and Covenants. 4.1. Representations, Warranties and Covenants of the Corporation. Corporation represents, warrants and covenants to Pharmaceuticals as follows: (a) Corporation is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware; has all corporate power required to own its property and to carry on its business as now conducted and proposed to be conducted; and is qualified to do business in all jurisdictions in which such qualification is necessary; (b) The execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Corporation; (c) This Agreement has been duly executed and delivered by Corporation and is a legal, valid and binding obligation of Corporation, enforceable against Corporation in accordance with its terms; (d) The execution, delivery and performance of this Agreement does not and will not conflict with or contravene any provisions of the certificate of incorporation or by-laws of Corporation or any agreement, document, instrument, indenture, lien, judgment, order or other obligation of Corporation; and (e) Corporation shall not knowingly misappropriate or otherwise misuse, nor shall it knowingly permit of its employees, consultants or agents to misappropriate or 3 otherwise misuse, any intellectual property of any third party in performance of the Research and Development for a Program. 4.2. Representation, Warranties and Covenants of Pharmaceuticals. Pharmaceuticals represents, warrants and covenants to Corporation as follows: (a) Pharmaceuticals is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware; has all corporate power required to own its property and to carry on its business as now conducted and proposed to be conducted; and is qualified to do business in all jurisdictions in which such qualification is necessary; (b) The execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Pharmaceuticals; (c) This Agreement has been duly executed and delivered by Pharmaceuticals and is a legal, valid and binding obligation of Pharmaceuticals, enforceable against Pharmaceuticals in accordance with its terms; and (d) The execution, delivery and performance of this Agreement does not and will not conflict with or contravene any provision of the certificate of incorporation or by-laws of Pharmaceuticals or any agreement, document, instrument, indenture, lien, judgment, order or other obligation of Pharmaceuticals. 5. Term and Termination. 5.1. Term. This Agreement shall be effective as of the Execution Date set forth on the first page of the Agreement and shall continue in full force and effect through December 31, 2010, unless earlier terminated in accordance with the terms and conditions set forth herein. The Agreement may be renewed upon the mutual agreement of the parties in their sole discretion. 5.2. Termination. Either party hereto may terminate this Agreement for any reason on sixty (60) days' written notice to the other party. 5.3. Prior Research and Development. Pharmaceuticals and Corporation acknowledge that certain research, development and other services were provided between the parties following the expiration of the Original Agreement on June 23, 1997. Therefore, the parties expressly agree that the terms and conditions of this Agreement shall apply to any such research, development or other services that were provided between the parties after June 23, 1992 and prior to the Execution Date of this Agreement (as well as to any Research and Development performed by the parties under this Agreement during its term). To the extent necessary to affect this intention of the parties, Corporation hereby assigns to Pharmaceuticals all of its right, title and interest in and to the Improvements existing prior to the Execution Date of this Agreement, and all intellectual property rights therein. Corporation shall cause any of its employees, consultants and agents to also assign any rights in the Improvements to Pharmaceuticals. 5.4. Effects of Expiration and Termination. Following expiration or termination of this Agreement, Corporation shall deliver to Pharmaceuticals all Confidential Information of Pharmaceuticals, including, without limitation, the laboratory notebooks and records of the 4 Research and Development kept by Corporation, and all copies thereof in Corporation's possession. 5.5. Survival. The following provisions shall survive any expiration or termination of this Agreement: 1, 2.2 (during period set forth therein only), 2.3, 2.4, 4, 5.3, 5.4, 5.5, 6, 7, 8, 9, 10, 11, 12, 13 and any payment obligations due as of the effective date of such expiration or termination. 6. Relationship of the Parties. Nothing contained in this Agreement is intended, or is to be construed, to constitute Corporation and Pharmaceuticals partners or joint venturers or Corporation as an employee of Pharmaceuticals. Neither party hereto shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any contract, agreement o undertaking with any third party. 7. Further Assurance. Corporation and Pharmaceuticals each agree to duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including, without limitation, the execution and filing of additional assignments, agreements, instruments and other documents that may be necessary, or as the other party hereto may at any time and from time to time reasonably request, in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure and confirm unto such other party its rights under this Agreement. Without limiting the foregoing, Corporation expressly agrees that each of its employees, consultants and agents performing work under a Program has entered, or promptly will enter, into a written agreement assigning all right, title and interest to Pharmaceuticals in any Improvements conceived or reduced to practice by such individual pursuant to any Program as necessary for Pharmaceuticals to exercise its rights hereunder. 8. Confidential Information. 8.1. Confidential Information. As used herein, "Confidential Information" means all information that Pharmaceuticals discloses to Corporation under this Agreement, all Pharmaceuticals Technology and all other Information deemed "Confidential Information" under this Agreement, provided that Confidential Information shall not include any information excluded under Section 8.2. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Corporation agrees that it shall keep confidential and shall not publish or otherwise disclose any Confidential Information to any third party, and shall not use such Information for any purpose other than as provided for in this Agreement. 8.2. Exceptions. Notwithstanding Section 8.1 above, "Confidential Information" shall not include any information that Corporation can demonstrate by competent written evidence in existence at the time of disclosure or development (as applicable): (a) Was already known to Corporation other than under an obligation of confidentiality, at the time of disclosure by Pharmaceuticals or, in the case of Pharmaceuticals Technology, prior to its creation or discovery hereunder; (b) Was generally available to the pubic or otherwise part of the public domain at the time of its disclosure to Corporation by Pharmaceuticals; 5 (c) Became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of Corporation in breach of this Agreement; (d) Was disclosed to Corporation, other than under an obligation of confidentiality to a third party, without breach of any party's confidentiality obligation to Pharmaceuticals; or (e) Is independently developed by Corporation without using any Confidential Information. 8.3. Permitted Disclosure. Notwithstanding the limitations in this Article 8, in the event that Corporation is required to disclose Confidential Information by any court of competent jurisdiction under any legal or regulatory statute, rule, order or regulation ("Legal Order"), Corporation shall provide Pharmaceuticals with immediate written notice of same so that Pharmaceuticals may have the opportunity to seek an appropriate protective order. If Pharmaceuticals does not obtain a protective order, Corporation shall disclose only such part of the Confidential Information as is specifically required by the Legal Order. 9. Publicity. Neither Party shall use the name of the other Party in connection with any product, promotional literature, or advertising material without the prior written permission of the other party, which permission shall not be unreasonably withheld. This restriction shall not apply to materials used by Pharmaceuticals solely for financing or corporate partnering purposes or to documents available to the public that identify the existence of the Agreement. 10. Successors and Assigns. The terms and provisions of this Agreement shall insure to the benefit of, and be binding upon, Corporation, Pharmaceuticals, and their respective successors and assigns. 11. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to conflict of laws principles. 12. Execution in Counterparts. This Agreement may be executed in any number of counterparts, each of which counterparts, when so executed and delivered, shall be deemed to be original, and all of which counterparts, taken together, shall constitute one and the same instrument. 6 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed under seal and delivered as of the date first above written. ARIAD PHARMACEUTICALS, INC., A DELAWARE CORPORATION By:/s/ Harvey J. Berger -------------------- Harvey J. Berger Chairman and Chief Executive Officer ARIAD CORPORATION, A DELAWARE CORPORATION By:/s/ Laurie A. Allen ------------------- Laurie A. Allen Senior Vice President Chief Legal Officer 7 EX-10.54 9 b41666arex10-54.txt EX-10.54 RESEARCH & DEVELOPMENT AGREEMENT EXHIBIT 10.54 REVISED AND RESTATED RESEARCH AND DEVELOPMENT AGREEMENT This Revised and Restated Research and Development Agreement (the "Agreement"), dated as of March 15, 2002 ("Execution Date"), between ARIAD Gene Therapeutics, Inc., a Delaware corporation ("AGTI") and ARIAD Corporation, a Delaware corporation ("Corporation") supersedes and supplants in its entirety the Research and License Agreement between AGTI and Corporation dated July 1, 1994 ("Original Agreement"). WHEREAS, AGTI has certain patent rights and technology and has acquired licenses to certain other patent rights and technology, for the purpose of allowing AGTI to develop and commercialize certain Products; WHEREAS, Corporation has personnel experienced in the research and development of human health care products and has, or is expected to acquire, the facilities, equipment and employees that will permit it to carry out research and development activities for AGTI, with respect to such rights and technology; and WHEREAS, AGTI desires to engage Corporation to perform such services and Corporation desires to provide such services. NOW, THEREFORE, in consideration of the foregoing premises and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Corporation and AGTI hereby agree as follows: 1. Definitions. 1.1 Definitions. As used herein, capitalized terms shall have the respective meanings set forth below: (a) "AGTI Technology" shall mean all information, developments, discoveries, inventions, improvements, know-how, processes, formulas, methods, trade secrets and other intellectual property, whether or not patentable, whether or not copyrightable, now owned or hereafter developed, acquired, reduced to practice or conceived by AGTI, either alone or jointly with others, or licensed or sublicensed to AGTI. (b) "Confidential Information" has the meaning set forth in Section 8.1 below. (c) "Improvements" shall mean all information, developments, discoveries, inventions, improvements (including improvements to AGTI Technology), know-how, processes, formulas, methods, trade secrets and other intellectual property, other than the AGTI Technology, whether or not patentable, whether or not copyrightable, which are developed, acquired, reduced to practice or conceived by Corporation, either alone or jointly with others, in carrying out Research and Development under this Agreement. (d) "Legal Order" has the meaning set forth in Section 8.3 below. (e) "Product" shall mean any article, composition, apparatus, substance, chemical, material, method, process or service. (f) "Programs" shall mean research and development programs set forth by AGTI for Research and Development to be performed by Corporation. (g) "Research and Development" shall mean research, development, clinical testing and related services and activities. 1.1. Singular and Plural. Singular and plural forms, as the case may be, of terms defined herein shall have correlative meanings. 2. Research and Development. 2.1. Research and Development Services. AGTI hereby engages Corporation, and Corporation hereby agrees, to undertake Research and Development of the AGTI Technology in accordance with each Program for the purpose of allowing AGTI to develop, manufacture, use, sell and market one or more Products. During the term of this Agreement, Corporation shall use its best efforts to conduct the Research and Development for AGTI with respect to each Program in a prudent and skillful manner in accordance with applicable laws, ordinances, rules, regulations, orders, licenses and other requirements now or hereafter in effect. Corporation shall obtain all labor, supervision, services, materials, supplies, tools, machinery and replacement parts thereof necessary to perform the Research and Development in accordance with each Program then in effect, which expenses shall be paid by AGTI as described below. All such materials, supplies, tools, machinery and replacement parts thereof shall be used exclusively by Corporation to perform the Research and Development for AGTI under each Program. 2.2. Reports and Records. Within sixty (60) days after the end of each calendar quarter during the term of this Agreement, Corporation shall provide to AGTI a report setting forth the total Research and Development costs incurred during such quarter. All Research and Development and any other work performed under each Program should be duly recorded and evidenced in laboratory notebooks maintained by the persons working on the Program, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. Upon the request of AGTI, Corporation will provide to AGTI a report setting forth (a) a summary of the work performed hereunder by Corporation and its employees and agents, and (b) a description of any material development with respect to the Programs. AGTI shall also have the right, during normal business hours, to inspect and copy the records pertaining to the Programs kept by Corporation. 2.3. Rights to Property. As between AGTI and Corporation, all right, title and interest in and to any Improvements acquired or developed pursuant to this Agreement, including all intellectual property rights therein, shall be the exclusive property of and are hereby assigned to AGTI. This Section 2.3 shall survive the expiration or termination of this Agreement for any reason. 2.4. Exclusion from Assignment. AGTI and Corporation acknowledge and agree the assignments set forth in Sections 2.3, 5.3 and 7 shall not extend to, and do not include, any Improvements owned or controlled by third parties (alone or jointly) that Corporation does not have the right to assign; and to the extent any Improvements are owned or controlled by a third party and licensed to Corporation, Corporation hereby grants AGTI a sublicense to such Improvements that is of the same scope and duration and includes all rights Corporation received under the license granted to Corporation by the third party, provided that Corporation has the right to sublicense its rights to AGTI. This Section 2.4 shall survive the expiration or termination of this Agreement for any reason. 2 3. Payment for Services; Timing of Payments. 3.1. Payments. In consideration of the Research and Development activities to be carried out by Corporation during the term of this Agreement, AGTI shall reimburse Corporation for all of its Research and Development costs, and AGTI shall additionally pay Corporation a fee equal to ten (10%) percent of all such Research and Development costs (a "Cost-Plus Fee"). 3.2. Timing of Payments. If requested by Corporation, AGTI shall advance funds for all Research and Development costs in reasonable amounts. Within sixty (60) days after the end of each calendar quarter, Corporation shall deliver a statement to AGTI of the Research and Development costs actually incurred in such calendar quarter and the Cost-Plus Fee thereon, and AGTI shall pay to Corporation any additional amounts shown to be due therefor and not yet paid. 3.3. Calculation of Costs. Directs costs shall be allocated on a reasonable and consistent basis, and charged to AGTI for Research, Development and other services performed by Corporation for AGTI hereunder. Corporation's expenditures and estimated expenditures of conducting the Research and Development hereunder shall be determined using Corporation's internal financial and accounting systems. Allocation of all indirect costs, including general and administrative costs, will be made by Corporation on a reasonable basis consistent with Corporation's regular internal cost accounting system. 3.4. Competitive Costs. All costs to be paid by AGTI hereunder shall be no greater than the cost to AGTI would be if AGTI obtained similar services, materials or other resources from a third party similarly situated to Corporation. 4. Representatives, Warranties and Covenants. 4.1. Representations, Warranties and Covenants of the Corporation. Corporation represents, warrants and covenants to AGTI as follows: (a) Corporation is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware; has all corporate power required to own its property and to carry on its business as now conducted and proposed to be conducted; and is qualified to do business in all jurisdictions in which such qualification is necessary; (b) The execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Corporation; (c) This Agreement has been duly executed and delivered by Corporation and is a legal, valid and binding obligation of Corporation, enforceable against Corporation in accordance with its terms; (d) The execution, delivery and performance of this Agreement does not and will not conflict with or contravene any provisions of the certificate of incorporation or by-laws of Corporation or any agreement, document, instrument, indenture, lien, judgment, order or other obligation of Corporation; and (e) Corporation shall not knowingly misappropriate or otherwise misuse, nor shall it knowingly permit of its employees, consultants or agents to misappropriate or 3 otherwise misuse, any intellectual property of any third party in performance of the Research and Development for a Program. 4.2. Representation, Warranties and Covenants of AGTI. AGTI represents, warrants and covenants to Corporation as follows: (a) AGTI is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware; has all corporate power required to own its property and to carry on its business as now conducted and proposed to be conducted; and is qualified to do business in all jurisdictions in which such qualification is necessary; (b) The execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of AGTI; (c) This Agreement has been duly executed and delivered by AGTI and is a legal, valid and binding obligation of AGTI, enforceable against AGTI in accordance with its terms; and (d) The execution, delivery and performance of this Agreement does not and will not conflict with or contravene any provision of the certificate of incorporation or by-laws of AGTI or any agreement, document, instrument, indenture, lien, judgment, order or other obligation of AGTI. 5. Term and Termination. 5.1. Term. This Agreement shall be effective as of the Execution Date set forth on the first page of the Agreement and shall continue in full force and effect through December 31, 2010, unless earlier terminated in accordance with the terms and conditions set forth herein. The Agreement may be renewed upon the mutual agreement of the parties in their sole discretion. 5.2. Termination. Either party hereto may terminate this Agreement for any reason on sixty (60) days' written notice to the other party. 5.3. Prior Research and Development. AGTI and Corporation acknowledge that certain research, development and other services were provided between the parties following the expiration of the Original Agreement on July 1, 1999. Therefore, the parties expressly agree that the terms and conditions of this Agreement shall apply to any such research, development or other services that were provided between the parties after July 1, 1994 and prior to the Execution Date of this Agreement (as well as to any Research and Development performed by the parties under this Agreement during its term). To the extent necessary to affect this intention of the parties, Corporation hereby assigns to AGTI all of its right, title and interest in and to the Improvements existing prior to the Execution Date of this Agreement, and all intellectual property rights therein. Corporation shall cause any of its employees, consultants and agents to also assign any rights in the Improvements to AGTI. 5.4. Effects of Expiration and Termination. Following expiration or termination of this Agreement, Corporation shall deliver to AGTI all Confidential Information of AGTI, including, without limitation, the laboratory notebooks and records of the Research and Development kept by Corporation, and all copies thereof in Corporation's possession. 4 5.5. Survival. The following provisions shall survive any expiration or termination of this Agreement: 1, 2.2 (during period set forth therein only), 2.3, 2.4, 4, 5.3, 5.4, 5.5, 6, 7, 8, 9, 10, 11, 12, 13 and any payment obligations due as of the effective date of such expiration or termination. 6. Relationship of the Parties. Nothing contained in this Agreement is intended, or is to be construed, to constitute Corporation and AGTI partners or joint venturers or Corporation as an employee of AGTI. Neither party hereto shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any contract, agreement or undertaking with any third party. 7. Further Assurance. Corporation and AGTI each agree to duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including, without limitation, the execution and filing of additional assignments, agreements, instruments and other documents that may be necessary, or as the other party hereto may at any time and from time to time reasonably request, in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure and confirm unto such other party its rights under this Agreement. Without limiting the foregoing, Corporation expressly agrees that each of its employees, consultants and agents performing work under a Program has entered, or promptly will enter, into a written agreement assigning all right, title and interest to AGTI in any Improvements conceived or reduced to practice by such individual pursuant to any Program as necessary for AGTI to exercise its rights hereunder. 8. Confidential Information. 8.1. Confidential Information. As used herein, "Confidential Information" means all information that AGTI discloses to Corporation under this Agreement, all AGTI Technology and all other Information deemed "Confidential Information" under this Agreement, provided that Confidential Information shall not include any information excluded under Section 8.2. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Corporation agrees that it shall keep confidential and shall not publish or otherwise disclose any Confidential Information to any third party, and shall not use such Information for any purpose other than as provided for in this Agreement. 8.2. Exceptions. Notwithstanding Section 8.1 above, "Confidential Information" shall not include any information that Corporation can demonstrate by competent written evidence in existence at the time of disclosure or development (as applicable): (a) Was already known to Corporation other than under an obligation of confidentiality, at the time of disclosure by AGTI or, in the case of AGTI Technology, prior to its creation or discovery hereunder; (b) Was generally available to the public or otherwise part of the public domain at the time of its disclosure to Corporation by AGTI; (c) Became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of Corporation in breach of this Agreement; 5 (d) Was disclosed to Corporation, other than under an obligation of confidentiality to a third party, without breach of any party's confidentiality obligation to AGTI; or (e) Is independently developed by Corporation without using any Confidential Information. 8.3. Permitted Disclosure. Notwithstanding the limitations in this Article 8, in the event that Corporation is required to disclose Confidential Information by any court of competent jurisdiction under any legal or regulatory statute, rule, order or regulation ("Legal Order"), Corporation shall provide AGTI with immediate written notice of same so that AGTI may have the opportunity to seek an appropriate protective order. If AGTI does not obtain a protective order, Corporation shall disclose only such part of the Confidential Information as is specifically required by the Legal Order. 9. Publicity. Neither Party shall use the name of the other Party in connection with any product, promotional literature, or advertising material without the prior written permission of the other party, which permission shall not be unreasonably withheld. This restriction shall not apply to materials used by AGTI solely for financing or corporate partnering purposes or to documents available to the public that identify the existence of the Agreement. 10. Successors and Assigns. The terms and provisions of this Agreement shall insure to the benefit of, and be binding upon, Corporation, AGTI, and their respective successors and assigns. 11. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to conflicts of laws principles. 12. Execution in Counterparts. This Agreement may be executed in any number of counterparts, each of which counterparts, when so executed and delivered, shall be deemed to be original, and all of which counterparts, taken together, shall constitute one and the same instrument. 6 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed under seal and delivered as of the date first above written. ARIAD GENE THERAPEUTICS, INC., A DELAWARE CORPORTION By: /s/ Harvey J. Berger ------------------------ Harvey J. Berger Chairman and Chief Executive Officer ARIAD CORPORATION, A DELAWARE CORPORTION By: /s/ Laurie A. Allen ----------------------- Laurie A. Allen Senior Vice President Chief Legal Officer 7 EX-10.55 10 b41666arex10-55.txt EX-10.55 CONSULTING AGREEMENT WITH BRIAN LAJOIE EXHIBIT 10.55 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the "Agreement") is made as of October 5, 2001 (the "Effective Date") by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and Brian A. Lajoie (the "Consultant"). WITNESSETH THAT: WHEREAS, the Company is engaged in the business of discovering, developing and commercializing pharmaceutical products; WHEREAS, the Consultant previously served as a financial executive officer of a company in the biotechnology industry and is familiar with the business in which the Company is engaged and otherwise has experience and expertise which is useful to the Company; and WHEREAS, the Company wishes to retain the Consultant, and the Consultant is willing to be retained by the Company to provide the Company with consulting services in the financial operation of its business, subject to the terms and conditions and for the consideration hereinafter set forth. NOW THEREFORE, the Company and the Consultant hereby agree as follows: 1. Consulting Term; Termination 1.1 The term of this Agreement shall commence on the Effective Date and shall end on April 30, 2002 (the "Initial Term"); provided, that the Term (as defined below) shall be automatically renewed for successive 30-day terms (the Initial Term and, if the consulting period is so renewed, such additional consulting period(s) are collectively referred to herein as the "Term"), unless either the Company or the Consultant terminates this Agreement earlier pursuant to the terms of Section 1.2 hereof or either the Company or the Consultant commits a material breach of the terms of this Agreement. 1.2 Notwithstanding the provisions of Section 1.1 hereof, the Company or the Consultant may terminate this Agreement, with or without cause in its sole discretion, prior to the end of the Initial Term or any subsequent applicable Term by providing not less than fifteen (15) days prior written notice to the other party. 2. Consulting Services 2.1 The Company hereby engages the Consultant to provide consulting services related to financial matters of the Company generally as directed by the Chief Executive Officer of the Company, unless otherwise agreed to by the Company and the Consultant. The specific services to be performed by the Consultant, number of hours required to perform such services, and schedule of performance shall be agreed from time to time by the Company and the Consultant based on the needs of the Company and the reasonable availability of the Consultant. 2.2 In addition to the services described in Section 2.1 hereof, the Consultant agrees to be elected as the Interim Chief Financial Officer of the Company and to assist the Chief Executive Officer, the Controller and other members of Company's management in managing the financial affairs of the Company. 2.3 The Consultant hereby accepts such engagement as a consultant to the Company and agrees to use his best efforts to render the services described above. 2.4 The Consultant shall perform the services for the Company contemplated by this Agreement principally at the Company's corporate offices located at 26 Landsdowne Street, Cambridge, Massachusetts. 3. Compensation. In consideration for the performance of the services to be rendered by the Consultant to the Company pursuant to Section 2.1 hereof, the Company shall compensate the Consultant at a rate of One Thousand Six Hundred Dollars ($1,600.00) per day, payable on a bi-weekly basis promptly after receipt of an invoice detailing such days, or portions thereof, served; provided, however, that the aggregate compensation paid to the Consultant by the Company in any one (1) month period shall not exceed the total sum of Twenty Four Thousand Dollars ($24,000.00). The Company and the Consultant agree that the Company shall not withhold any amounts on account of any withholding or employment taxes from any payments to the Consultant under this section and that it shall be the sole responsibility of the Consultant to report and pay all applicable income or other taxes on all such payments made to him. 4. Expenses The Company shall pay or reimburse the Consultant for all reasonable travel and other expenses (excluding commuting expenses) incurred by the Consultant in the course of performing the consulting services requested by the Company and performed by the Consultant hereunder, upon presentation of appropriate documentation substantiating such expenses in accordance with the usual policies and procedures of the Company. The Company will provide the consultant with parking at no expense. 5. No Employment Relationship Nothing in this Agreement shall create or shall be deemed to create any contract or relationship of employment between the Company and the Consultant or render or be construed to render the Consultant an employee of the Company or to provide the Consultant with any rights or benefits, including, but not limited to health insurance, dental care insurance, life insurance, long-term disability insurance, accidental death and dismemberment insurance, deferred compensation awards, performance bonuses or 401(k) plan participation benefits, to which any employee of the Company or any of its Affiliates may be entitled. 6. Confidentiality 6.1 The Consultant acknowledges and agrees that during the course of performing services for the Company, the Company will furnish, disclose or make available to the Consultant confidential and proprietary information relating to the Company's business, including, but not limited to, inventions, projects and business plans (collectively, "Confidential Information"). The Consultant further acknowledges and agrees that such Confidential Information has been developed and will be developed by the Company through the expenditure by the Company of substantial time, effort and money, that the Company's business is extremely competitive, that the Company's business is dependent in part upon the maintenance of secrecy, and that any disclosure of the Confidential Information would result in serious harm to the Company. 6.2 The Consultant agrees that the Confidential Information shall only be used by the Consultant in connection with his activities hereunder as a consultant to the Company and shall not be used in any way that is detrimental to the Company. 2 6.3 The Consultant agrees not to disclose, directly or indirectly, the Confidential Information to any third person or entity, other than representatives or agents of the Company. The Consultant shall treat all such information as confidential and proprietary property of the Company. 6.4 The term "Confidential Information" does not include information that (a) is or becomes generally available to the public other than by disclosure in violation of this Agreement, (b) was within the Consultant's possession prior to being furnished to such Consultant, (c) becomes available to the Consultant on a non-confidential basis or (d) was independently developed by the Consultant without reference to the information provided by the Company. 6.5 The Consultant may disclose any Confidential Information that is required to be disclosed by law, government regulation or court order. If disclosure is required, the Consultant shall give the Company advance notice so that the Company may seek a protective order or take other action reasonable in light of the circumstances. 6.6. Upon termination of this Agreement, the Consultant shall promptly return to the Company all materials containing Confidential Information, as well as data, records, reports and other property furnished by the Company to the Consultant or produced by the Consultant in connection with services rendered hereunder. Notwithstanding such return or any of the provisions of this Agreement, the Consultant shall continue to be bound by the terms of the confidentiality provisions contained in this Section 6 for a period of five (5) years after the termination of this Agreement. 6.7 The Consultant acknowledges receipt of a copy of the Company's policies regarding trading in the Company's securities and agrees to comply with such policies, as well as other SEC regulations regarding insider trading and disclosure of material non-public information. 7. Non-Competition and Non-Solicitation. During the Term and for a period of six (6) months following the expiration or termination of this Agreement: (a) the Consultant shall not in the United States or in any country in which the Company shall then be doing business, directly or indirectly, enter the employ of, or render any services to, any person, firm or corporation engaged in any business competitive with the business of the Company or of any of its subsidiaries or affiliates; he shall not engage in such business on his own account; and he shall not become interested in any such business, directly or indirectly, as an individual, partner, shareholder, director, officer, principal, agent, employee, trustee, consultant, or any other relationship or capacity; provided, however, that nothing contained in this Section 7 shall be deemed to prohibit the Consultant from acquiring, solely as an investment, shares of capital stock of any public corporation; (b) neither the Consultant nor any Affiliate of the Consultant shall solicit or utilize, or assist any person in any way to solicit or utilize, the services, directly or indirectly, of any of the Company's directors, consultants, members of the Board of Scientific and Medical Advisors, officers or employees (collectively, "Associates of the Company"). This non-solicitation and non-utilization provision shall not apply to Associates of the Company who have previously terminated their relationship with the Company. 7.1 If the Consultant commits a breach, or threatens to commit a breach, of any of the provisions of this Section 7, the Company shall have the following rights and remedies: 7.1.1 The right and remedy to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach shall cause irreparable injury to the Company and that money damages shall not provide an adequate remedy to the Company. 3 7.1.2 The right and remedy to require the Consultant to account for and pay over to the Company all compensation, profits, monies, accruals, increments or other benefits (collectively "Benefits") derived or received by the Consultant as the result of any transactions constituting a breach of any of the provisions of the preceding paragraph, and the Consultant hereby agrees to account for and pay over such Benefits to the Company. Each of the rights and remedies enumerated above shall be independent of the other, and shall be severally enforceable, and all of such rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity. 7.2. If any of the covenants contained in Section 6 or 7, or any part thereof, is hereafter construed to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants, which shall be given full effect without regard to the invalid portions. 7.3 If any of the covenants contained in Section 6 or 7, or any part thereof, is held to be unenforceable because of the duration of such provision or the area covered thereby, the parties agree that the court making such determination shall have the power to reduce the duration and/or area of such provision and, in its reduced form, such provision shall then be enforceable. 7.4 The parties hereto intend to and hereby confer jurisdiction to enforce the covenants contained in Sections 6 and 7 upon the courts of any state within the geographical scope of such covenants. In the event that the courts of any one or more of such states shall hold any such covenant wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the Company's right to the relief provided above in the courts of any other states within the geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, the above covenants as they relate to each state being, for this purpose, severable into diverse and independent covenants. 7.5 The Company and the Consultant hereby acknowledge and agree that the Company may waive, on a case-by-case basis, the terms and covenants of this Section 7 upon the request of the Consultant in accordance with the provisions of Section 10.4 hereof, which such waiver shall not be unreasonably withheld. 8. Indemnification The Company shall indemnify the Consultant, to the maximum extent permitted by applicable law, against all costs, charges and expenses incurred or sustained by him in connection with, and to hold him harmless from, any action, suit or proceeding by a third party to which he may be made a party by reason of his being a consultant of the Company or of any Subsidiary or Affiliate of the Company, or arising from his performance of services under this Agreement. 9. Notices All notices, requests, consents and other communications required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given if sent by private overnight mail service (delivery confirmed by such service), registered or certified mail (return receipt requested), or delivered personally, as follows (or to such other address as either party shall designate by notice in writing to the other in accordance herewith): 4 If to the Company: ARIAD Pharmaceuticals, Inc. 26 Landsdowne Street Cambridge, Massachusetts 02139 Attention: Harvey J. Berger, M.D. Chief Executive Officer Telephone: (617) 494-0400 Fax: (617) 494-1828 If to the Consultant: Brian A. Lajoie 6 Crestview Drive Millis, MA 02054 (508) 376-5948 10. General 10.1 This Agreement shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Massachusetts applicable to agreements made and to be performed entirely in Massachusetts. 10.2 The Section headings contained herein are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement. 10.3 This Agreement and the Consultant's rights and obligations hereunder may not be assigned by the Consultant or the Company; provided, however, the Company may assign this Agreement and its rights and obligations hereunder to a successor-in-interest. 10.4 This Agreement may be amended, modified, superseded, canceled, renewed or extended, and the terms or covenants hereof may be waived, only by a written instrument executed by the parties hereto, or in the case of a waiver, by the party waiving compliance. The failure of a party at any time or times to require performance of any provision hereof shall in no manner affect the right at a later time to enforce the same. No waiver by a party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant contained in this Agreement. 10.5 This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 11. Definitions As used herein the following terms have the following meaning: (a) "Affiliate" means and includes any corporation or other business entity controlling, controlled by or under common control with the corporation in question. 5 (b) "person" means any natural person, corporation, partnership, firm, joint venture, association, joint stock company, trust, unincorporated organization, governmental body or other entity. (c) "Subsidiary" means any corporation or other business entity directly or indirectly controlled by the corporation in question. [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 6 IN WITNESS WHEREOF, the Company and the Consultant have executed this Agreement as of the date first above written. ARIAD PHARMACEUTICALS, INC. By: /s/ Harvey J. Berger -------------------- Name: Harvey J. Berger, M.D. Title: Chairman and Chief Executive Officer CONSULTANT /s/ Brian A. Lajoie - ------------------- Brian A. Lajoie 7 EX-10.56 11 b41666arex10-56.txt EX-10.56 EXECUTIVE EMPLOYMENT AGREEMENT W/L. ALLEN EXHIBIT 10.56 2002 EXECUTIVE EMPLOYMENT AGREEMENT 2002 EMPLOYMENT AGREEMENT (the "Agreement") made as of March 4, 2002 by and between ARIAD Pharmaceuticals, Inc. (the "Company") a Delaware corporation, and Laurie A. Allen, Esq. (the "Employee"). 1. EMPLOYMENT, DUTIES AND ACCEPTANCE. 1.1 The Company hereby employs the Employee, for the Term (as hereinafter defined), to render full-time services to the Company, and to perform such duties as she shall reasonably be directed by the Chief Executive Officer of the Company to perform. The Employee's title shall be designated by the Chief Executive Officer and initially shall be Senior Vice President, Chief Legal Officer, and Secretary. 1.2 The Employee hereby accepts such employment and agrees to render the services described above. 1.3 The principal place of employment of the Employee hereunder shall be in the greater Boston, Massachusetts area, or other locations reasonably acceptable to the Employee. The Employee acknowledges that for limited periods of time she may be 1.4 Notwithstanding anything to the contrary herein, although the Employee shall provide services as a full-time employee, it is understood that the Employee may (a) have an academic appointment, (b) participate in professional activities, and c) provide limited consulting services from time to time to Alexandria Real Estate Equities, Inc. ("Alexandria"), including attendance at its Board of Director meetings (collectively, "Permitted Activities'),; PROVIDED, HOWEVER, that such Permitted Activities do not interfere with the Employee's duties to the Company and that the consulting services to Alexandria be agreed upon by the Company in advance. 2. TERM OF EMPLOYMENT. The term of the Employee's employment under this Agreement (the "Term") shall commence on March 4, 2002 or such other date as agreed upon by the parties (the "Effective Date") and shall end on December 31, 2004 unless sooner terminated pursuant to Section 4 or 5 of this Agreement; PROVIDED, HOWEVER, that this Agreement shall automatically be renewed for successive one-year terms (the Term and, if the period of employment is so renewed, such additional period(s) of employment are collectively referred to herein as the "Term"), unless terminated by written notice given by either party to the other at least 90 days prior to the end of the applicable Term. 3. COMPENSATION. 3.1 As full compensation for all services to be rendered pursuant to this Agreement, the Company agrees to pay the Employee, during the Term, a base salary at the fixed rate of $225,000 per annum during the first year of the Term and increased each year thereafter, by amounts, if any, to be determined by the Board of Directors of the Company (the "Board"), in its sole discretion, payable in equal biweekly installments, less such deductions or amounts to be withheld as shall be required by applicable law and regulations. 3.2 Each year, the Employee shall be eligible for a discretionary bonus of up to 30% of base salary, which bonus shall be determined annually by the Board. The bonus, if any, may be paid in the form of stock options, stock awards, cash, or deferred compensation, as determined by the Board. 3.3 The Company shall pay or reimburse the Employee for all reasonable expenses actually incurred or paid by her during the Term in the performance of her services under this Agreement, upon presentation of expense statements or vouchers or such other supporting information as it may require. 3.4 The Employee shall be eligible under any incentive plan, stock award plan, bonus, deferred or extra compensation plan, pension, group health, disability and life insurance or other so-called "fringe" benefits which the Company provides for its senior executives at a comparable level to the Employee. All stock options and stock awards granted to the Employee shall be subject to a vesting schedule which shall be determined by the Compensation Committee of the Board. Stock options and stock awards, if any, to be granted to the Employee shall also be subject to the terms of a stock option plan and certificate or stock award plan and certificate, as the case may be. 3.5 The Company shall grant the Employee an option to purchase 100,000 shares of the Company's Common Stock at the fair market value on the date of the Board's approval of such grant (the "2002 Stock Options"), in accordance with the Company's 2001 Stock Plan. The Employee agrees that all such options shall be subject to a four-year vesting schedule, vesting in equal increments of 25% on each anniversary of their issuance. 3.6 All options to purchase shares of the Company's Common Stock held by the Employee prior to the date hereof pursuant to that certain consulting agreement, dated January 2, 2000, by and between the Company and the Employee (the "Consulting Agreement"), (that is, options to purchase 135,000 shares of the Company's Common Stock) (the "Prior Stock Options") shall continue to vest and be exercisable subject to the Company's 1991 Stock Option Plan for Employees, as amended, and the relevant certificates. As of the Effective Date of this Agreement, the Consulting Agreement shall terminate, except as provided in Section 8.8 herein. 3.7 Except as specified in Section 6.1, any unvested options shall be forfeited to the Company in the event (a) this Agreement is terminated by the Company for Cause pursuant to Section 4 herein, or (b) either party elects not to renew this Agreement pursuant to Section 2 herein. 4. TERMINATION BY THE COMPANY. The Company may terminate this Agreement, if any one or more of the following shall occur: (a) The Employee shall die during the Term; PROVIDED, HOWEVER, the Employee's legal representatives shall be entitled to receive the compensation provided for in Section 3 to the last day of the month in which her death occurs. (b) The Employee shall become physically or mentally disabled, whether totally or partially, so that she is unable substantially to perform her services hereunder for (i) a period of 180 consecutive days, or (ii) for shorter periods aggregating 180 days during any twelve month period. (c) The Employee acts, or fails to act, in a manner that provides Cause for termination. For purposes of this Agreement, the term "Cause" means (i) the conviction of the Employee of any felony involving moral turpitude, (ii) any acts of fraud or embezzlement by the Employee involving the Company or any of its Affiliates, (iii) the failure by the Employee to perform any of her material duties hereunder, (iv) violation of any federal, state or local law, or administrative regulation, (v) conduct that results in negative publicity, (vi) failure to comply 2 with the policies of the Company, or (vii) a material breach of the terms of this Agreement by the Employee (including, without limitation, actions taken by Employee which create a conflict of interest for Employee between the Company and a competitor). As the term "Cause" applies to clauses (iii) through (vii), such acts, conduct, or failure, as the case may be, must materially adversely affect the Company's business. The Company shall provide the Employee written notice of termination pursuant to this Section 4, and Employee shall have 30 days to cure or remedy such failure or breach, in which case this Agreement shall not be terminated. 5. TERMINATION BY THE EMPLOYEE. 5.1 The Employee may terminate this Agreement, if any one or more of the following shall occur: (a) a material breach of the terms of this Agreement by the Company and such breach continues for 30 days after the Employee gives the Company written notice of such breach; (b) the Company shall make a general assignment for benefit of creditors; or any proceeding shall be instituted by the Company seeking to adjudicate it as bankrupt or insolvent, or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief, or composition of it or its debts under law relating to bankruptcy, insolvency or reorganization or relief of debtors, or seeking entry of an order for relief of the appointment of a receiver, trustee, or other similar official for it or for any substantial part of its property or the Company shall take any corporate action to authorize any of the actions set forth above in this Section 5.1(b); (c) an involuntary petition shall be filed or an action or proceeding otherwise commenced against the Company seeking reorganization, arrangement or readjustment of the Company's debts or for any other relief under the Federal Bankruptcy Code, as amended, or under any other bankruptcy or insolvency act or law, state or federal, now or hereafter existing and remain undismissed or unstayed for a period of 30 days; (d) a receiver, assignee, liquidator, trustee or similar officer for the Company or for all or any part of its property shall be appointed involuntarily, or (e) a Change in Control, as such term is defined in Section 14. 6. SEVERANCE. 6.1 If (i) the Company terminates this Agreement without Cause or (ii) the Employee terminates this Agreement pursuant to Section 5.1(a), then: (1) except in the case of death or disability, the Company shall continue to pay the Employee her then-current base salary for the remaining period of the applicable Term; (2) all stock options granted pursuant to this Agreement that would have vested during the Term shall vest immediately prior to such termination; and (3) the Company shall continue to provide all benefits subject to COBRA at its expense for up to one year. Notwithstanding the foregoing, if the Company elects not to renew this Agreement pursuant to Section 2 herein or this Agreement is terminated according to this Section 6.1, prior to March 4, 2006, all 2002 Stock Options, shall vest immediately. 6.2 In the event of a consummation of a Change in Control of the Company, and if the Employee gives notice of termination within 90 days after such occurrence, then (i) all stock options, stock awards, similar equity rights, and deferred compensation awards granted to the Employee shall immediately vest and remain fully exercisable through their original term 3 with all rights; (ii) the relocation loan provided pursuant to Section 7 (f) shall be considered fully paid, and all loan obligations shall be forgiven; and (iii) the Company shall continue to pay Employee her then-current base salary for the shorter of (a) six months, or (b) the remaining period of the applicable Term. 7. OTHER BENEFITS. In addition to all other benefits contained herein, the Employee shall be entitled to: (a) Relocation expenses for the Employee and her family, consisting of (i) all reasonable direct out-of-pocket costs of transporting the Employee, the Employee's family and household items from the Employee's current residence to a new residence in the greater Boston, Massachusetts area; (ii) reasonable travel and lodging to visit the greater Boston, Massachusetts area to search for a new residence; (iii) the cost of storing household items in the greater Boston, Massachusetts area (and transporting them to and from storage) for up to six months from the Employee's date of employment; and (iv) except as described in the next succeeding sentence and subject to prior approval, the reasonable closing costs associated with the Employee's purchase of a new residence in the greater Boston, Massachusetts area within one year of the Employee's date of employment. The following closing (settlement) costs will NOT be paid by the Company: (1) real --- estate and other taxes, (2) insurance premiums other than title insurance, and (3) commitment fees and prepaid interest (i.e., "points") in excess of 2%. If any payments made to or in respect of the Employee pursuant to this Section 7(a) become subject to any tax (taking into account relevant deductions), the Company shall make a special payment to her sufficient, on an after-tax basis (taking into account federal, state, and local taxes), to put her in the same position as would have been the case had no such taxes been applicable to any payments of benefits provided in this subsection. This special payment will be made to the Employee at the time such taxes actually are paid. (b) Vacation time of four weeks per year taken in accordance with the vacation policy of the Company during each year of the Term. (c) After six years of employment, one three-month period of fully paid leave of absence in accordance with Company policies in place at that time; it being understood that such policies may restrict the Employee from taking such leave of absence until a time that is acceptable to the Company and may include other such limitations. (d) Group health, disability and life insurance. (e) The Company shall provide the Employee with an automobile allowance of $750 per month and standard tax preparation and planning services. (f) To facilitate the Employee's relocation, the Company will provide the Employee with a one-time relocation loan (the "Loan") in the amount of $75,000 to be used towards the purchase of the Employee's new principal residence (the "Residence"), payable at the time of closing on such residence. The Loan will be secured by a second mortgage on the Residence (the "Secured Note"). The principal of the Loan shall be repaid within thirty days of the occurrence of the following events: (a) the Employee terminates this Agreement prior to the third anniversary of execution of the Secured Note, except as provided pursuant to Section 5.1 herein, or (b) the Company terminates this Agreement for Cause pursuant to Section 4 herein. Upon the third anniversary of the execution of the Secured Note, the Loan obligation shall be fully forgiven. 4 8. CONFIDENTIALITY. 8.1 The Employee acknowledges that, during the course of performing her services hereunder, the Company shall be disclosing information to the Employee related to the Company's Field of Interest, Inventions, projects and business plans, as well as other information (collectively, "Confidential Information"). The Employee acknowledges that the Company's business is extremely competitive, dependent in part upon the maintenance of secrecy, and that any disclosure of the Confidential Information would result in serious harm to the Company. 8.2 The Employee agrees that the Confidential Information only shall be used by the Employee in connection with her activities hereunder as an employee of the Company, and shall not be used in any way that is detrimental to the Company. 8.3 The Employee agrees not to disclose, directly or indirectly, the Confidential Information to any third person or entity, other than representatives or agents of the Company. The Employee shall treat all such information as confidential and proprietary property of the Company. 8.4 The term "Confidential Information" does not include information that (a) is or becomes generally available to the public other than by disclosure in violation of this Agreement, (b) was within the Employee's possession prior to being furnished to such Employee, (c) becomes available to the Employee on a nonconfidential basis or (d) was independently developed by the Employee without reference to the information provided by the Company. 8.5 The Employee may disclose any Confidential Information that is required to be disclosed by law, government regulation or court order. If disclosure is required, the Employee shall give the Company advance notice so that the Company may seek a protective order or take other action reasonable in light of the circumstances. 8.6 Upon termination of this Agreement, the Employee shall promptly return to the Company all materials containing Confidential Information, as well as data, records, reports and other property, furnished by the Company to the Employee or produced by the Employee in connection with services rendered hereunder. Notwithstanding such return or any of the provisions of this Agreement, the Employee shall continue to be bound by the terms of the confidentiality provisions contained in this Section 8 for a period of three years after the termination of this Agreement. 8.7 In connection with her employment by the Company, the Employee hereby acknowledges that she may enter into more than one agreement with regard to (a) the confidentiality of certain books, records, documents and business, (b) rights to certain inventions, proprietary information, and writings, (c) publication of certain materials, and (d) other related matters (the "Confidential Matters") of the Company (the "Confidentiality Agreements"). In order to clarify any potential conflicts between certain respective provisions of such Confidentiality Agreements, the Employee and the Company hereby agree that, as among such Confidentiality Agreements, the provision (or part thereof) in any such Confidentiality Agreement which affords the greatest protection to the Company with respect to the Confidential Matters shall control. 8.8 The Employee hereby acknowledges that she has previously entered into one or more Confidentiality Agreements (as such term is defined in Section 8.7 hereof) with the Company. Notwithstanding any of the provisions of this Agreement, the Employee acknowledges and agrees that Section 8.7 of the Executive Employment Agreement by and between the Company and the Employee, dated as of November 25, 1998, as amended (the "Executive 5 Employment Agreement"), Section 6.7 of the Consulting Agreement, defined above, and her obligations under such Confidentiality Agreements shall continue to survive any termination of the Executive Employment Agreement, the Consulting Agreement or this Agreement. 9. INVENTIONS DISCOVERED BY THE EMPLOYEE WHILE PERFORMING SERVICES HEREUNDER. During the Term, the Employee shall promptly disclose to the Company any invention, improvement, discovery, process, formula, or method or other intellectual property, whether or not patentable, whether or not copyrightable (collectively, "Inventions") made, conceived or first reduced to practice by the Employee, either alone or jointly with others, while performing service hereunder. The Employee hereby assigns to the Company all of her right, title and interest in and to any such Inventions. During and after the Term, the Employee shall execute any documents necessary to perfect the assignment of such Inventions to the Company and to enable the Company to apply for, obtain, and enforce patents and copyrights in any and all countries on such Inventions. The Employee hereby irrevocably designates the Chief Patent Counsel to the Company as her agent and attorney-in-fact to execute and file any such document and to do all lawful acts necessary to apply for and obtain patents and copyrights and to enforce the Company's rights under this paragraph. This Section 9 shall survive the termination of this Agreement. 10. NON-COMPETITION AND NON-SOLICITATION. During the Term and, in the event of an earlier termination of this Agreement by Employee during the Term (other than any termination by Employee pursuant to Section 5.1(a)), for a period of one year following the date of such termination by Employee (the "Section 10 Period"): (a) Employee shall not compete with the Company or any subsidiary or affiliate of the Company for whom she is an employee or officer during the Term (each, an "Interested Entity") by (i) entering the employ of, or rendering services to, any biopharmaceutical entity which is engaged in a business competitive with the Company's Field of Interest in such a capacity as to create, on the date of such employment, a potential conflict of interest for Employee between such biopharmaceutical entity and an Interested Entity, (ii) engaging, during the Section 10 Period, in any business for her own account which would be competitive with the Company's Field of Interest, or (iii) acquiring, during the Section 10 Period, an equity or financial interest in any business which is competitive with the Company's Field of Interest, directly or indirectly, as an individual, partner, shareholder, director, officer, principal, agent, employee, trustee, consultant, or any other relationship or capacity as to create, on the date of acquisition of such interest, a potential conflict of interest for Employee between such business and an Interested Entity; PROVIDED, HOWEVER, that nothing contained in this Section 10 shall be deemed to prohibit Employee during the Section 10 Period from providing approved consulting services to Alexandria, accepting a position with a law firm, investment bank, venture capital or investment fund or other professional or financial services firm or from acquiring, solely as an investment, shares of capital stock of any public corporation; (b) neither the Employee nor any Affiliate of the Employee shall solicit or utilize, or assist any person in any way to solicit or utilize, the services, directly or indirectly, of any of the Company's directors, consultants, members of the Board of Scientific and Medical Advisors, officers or employees (collectively, "Associates of the Company") in any manner which is directly or indirectly competitive with the Company's business . This non-solicitation and non-utilization provision shall not apply to Associates of the Company who have previously terminated their relationship with the Company. 10.1 If the Employee commits a breach, or threatens to commit a breach, of any of the provisions of this Section 10, the Company shall have the following rights and remedies: 10.1.1 The right and remedy to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed that any 6 such breach or threatened breach shall cause irreparable injury to the Company and that money damages shall not provide an adequate remedy to the Company; and 10.1.2 The right and remedy to require the Employee to account for and pay over to the Company all compensation, profits, monies, accruals, increments or other benefits (collectively "Benefits") derived or received by the Employee as the result of any transactions constituting a breach of any of the provisions of the preceding paragraph, and the Employee hereby agrees to account for and pay over such Benefits to the Company. Each of the rights and remedies enumerated above shall be independent of the other, and shall be severally enforceable, and all of such rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity. 10.2 If any of the covenants contained in Section 8, 9 or 10, or any part thereof, is hereafter construed to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants, which shall be given full effect without regard to the invalid portions. 10.3 If any of the covenants contained in Section 8, 9 or 10, or any part thereof, is held to be unenforceable because of the duration of such provision or the area covered thereby, the parties agree that the court making such determination shall have the power to reduce the duration and/or area of such provision and, in its reduced form, such provision shall then be enforceable. 10.4 The parties hereto intend to and hereby confer jurisdiction to enforce the covenants contained in Sections 8, 9 and 10 upon the courts of any state within the geographical scope of such covenants. In the event that the courts of any one or more of such states shall hold any such covenant wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the Company's right to the relief provided above in the courts of any other states within the geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, the above covenants as they relate to each state being, for this purpose, severable into diverse and independent covenants. 11. INDEMNIFICATION. The Company shall indemnify the Employee, to the maximum extent permitted by applicable law, against all costs, charges and expenses incurred or sustained by her in connection with any action, suit or proceeding to which she may be made a party by reason of her being an officer, director or employee of the Company or of any subsidiary or affiliate of the Company. The Company shall provide, subject to its availability upon reasonable terms (which determination shall be made by the Board) at its expense, directors and officers insurance for the Employee in reasonable amounts. Determination with respect to (a) the availability of insurance upon reasonable terms and (b) the amount of such insurance coverage shall be made by the Board in its sole discretion. 12. NOTICES. All notices, requests, consents and other communications required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given if sent by prepaid telegram (confirmed delivery by the telegram service), private overnight mail service (delivery confirmed by such service), registered or certified mail (return receipt requested), or delivered 7 personally, as follows (or to such other address as either party shall designate by notice in writing to the other in accordance herewith): If to the Company: ARIAD Pharmaceuticals, Inc. 26 Landsdowne Street Cambridge, Massachusetts 02139 Attention: Chief Executive Officer Telephone: (617) 494-0400 Fax: (617) 494-1828 If to the Employee: Laurie A. Allen, Esq. 11181 Cashmere Street Los Angeles, California 90049 13. GENERAL. 13.1 This Agreement shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Massachusetts applicable to agreements made and to be performed entirely in Massachusetts. 13.2 The Section headings contained herein are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement. 13.3 Except as set forth in Section 8.8 of this Agreement with respect to Confidentiality Agreements, this Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter hereof, and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter hereof. No representation, promise or inducement has been made by either party that is not embodied in this Agreement, and neither party shall be bound by or liable for any alleged representation, promise or inducement not so set forth. 13.4 This Agreement and the Employee's rights and obligations hereunder may not be assigned by the Employee or the Company; PROVIDED, HOWEVER, the Company may assign this Agreement to a successor-in-interest. 13.5 This Agreement may be amended, modified, superseded, canceled, renewed or extended, and the terms or covenants hereof may be waived, only by a written instrument executed by the parties hereto, or in the case of a waiver, by the party waiving compliance. The failure of a party at any time or times to require performance of any provision hereof shall in no manner affect the right at a later time to enforce the same. No waiver by a party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant contained in this Agreement. 14. DEFINITIONS. As used herein the following terms have the following meaning: (a) "Affiliate" means and includes any corporation or other business entity controlling, controlled by or under common control with the corporation in question. 8 (b) The "Company's Field of Interest" is the discovery, development and commercialization of pharmaceutical products based on (a) intervention in signal transduction pathways and (b) gene and cell therapy. The Company's Field of Interest may be changed at any time at the sole discretion of the Company and upon written notice to Employee. (c) "person" means any natural person, corporation, partnership, firm, joint venture, association, joint stock company, trust, unincorporated organization, governmental body or other entity. (d) "Subsidiary" means any corporation or other business entity directly or indirectly controlled by the corporation in question. (e) "Change in Control" means the occurrence of any of the following events (without the consent of the Employee): (i) Any corporation, person or other entity makes a tender or exchange offer for shares of the Company's Common Stock pursuant to which such corporation, person or other entity acquires more than 50% of the issued and outstanding shares of the Company's Common Stock; (ii) The stockholders of the Company approve a definitive agreement to merge or consolidate the Company with or into another corporation or to sell or otherwise dispose of all or substantially all of the Company's assets; or (iii) Any person within the meaning of Section 3 (a) (9) or Section 13 (d) of the Securities Exchange Act of 1934 acquires more than 50% of the combined voting power of Company's issued and outstanding voting securities entitled to vote in the election of the Board. IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written. ARIAD PHARMACEUTICALS, INC. By: /s/ Harvey J. Berger, M.D. ------------------------------------------------ Harvey J. Berger, M.D. Chairman and Chief Executive Officer EMPLOYEE /s/ Laurie A. Allen, Esq. ------------------------------------------------- Laurie A. Allen, Esq. Date: --------------------------- 9 EX-10.57 12 b41666arex10-57.txt EX-10.57 STOCK TRANSFER AGREEMENT EXHIBIT 10.57 ARIAD GENE THERAPEUTICS, INC. STOCK TRANSFER AGREEMENT In consideration of the covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the parties hereto covenant and agree as follows: The undersigned stockholder (the "Stockholder") of ARIAD Gene Therapeutics, Inc. (the "Company") agrees that, in the event he or she desires to sell, assign, transfer or otherwise dispose of any of the shares of capital stock of the Company now held or at anytime hereafter acquired by him or her (the "Shares") to any person, he or she will notify (the "Notification") the Company in writing addressed to its principal executive offices of his or her intention to do so, specifying the amount of Shares proposed to be transferred (the "Offered Shares"), the name of the person or persons (the "Third Party Purchaser") to whom he or she proposes to transfer the Offered Shares, and a price per share which shall be the minimum price per share at which he or she proposes to effect the transfer (the "Minimum Price"). The Notification shall contain an affirmation by the Stockholder that such Offered Shares are proposed to be transferred pursuant to a bona fide written purchase contract and that the Stockholder has a reasonable expectation of being able to effect the transfer at the Minimum Price to the Third Party Purchaser, and shall recite the basis for such expectation. The Notification shall offer to sell to the Company and/or its designees the Offered Shares, free and clear of any liens or encumbrances in favor of third persons, at the Minimum Price and on such other terms and conditions, if any, not less favorable to the Company and its designees as those proposed to be offered to such Third Party Purchaser. In the event all or any part of the consideration shall consist of consideration other than cash, the Minimum Price shall include the fair value of such other consideration as determined in good faith by the Company's Board of Directors. The Company and its designees shall have the right to purchase the Offered Shares in accordance with the terms contained herein. The Company shall respond to the offer of the Stockholder within 30 days after receipt of the Notification. If the Company does not accept the offer of the Offered Shares in its entirety, the Stockholder shall be free to proceed to sell all, but not less than all, of the Offered Shares to the Third Party Purchaser specified in the Notification at not less than the Minimum Price. At least two business days prior to the closing of the purchase of the Offered Shares by the Third Party Purchaser (the "Third Party Closing"), the Stockholder shall deliver to the Company a certificate executed by the Third Party Purchaser stating that (i) the terms and conditions set forth in the Notification have been approved by the Third Party Purchaser's board of directors (or the equivalent governing body if the Third Party Purchaser is not a corporation), if applicable, (ii) the Third Party Purchaser is aware of the rights of the Company contained in this Agreement, and (iii) upon consummation of the Third Party Closing, the Third Party Purchaser shall become a party to this Agreement and agree to be bound by the terms and conditions hereof. If the Stockholder fails to complete his or her proposed sale within a period of 60 days after the earlier to occur of (i) the date of rejection by the Company of the offer contained in the Notification or (ii) the date that is 30 days after the date of receipt by the Company of the Notification (the "Offer Expiration Date"), then the Offered Shares shall once again be subject to the requirements of a prior offer to the Company pursuant to the provisions of this Agreement. In the event the Company and it designees shall elect to purchase or acquire all of the Offered Shares, written notice (the "Acceptance") to the Stockholder of such election to purchase or so acquire all of the Offered Shares shall, when taken in conjunction with the Notification, be deemed to constitute a valid and legally binding purchase and sale agreement. The closing of a purchase and sale of Offered Shares pursuant hereto shall take place at the principal executive offices of the Company on the 30th day following the Offer Expiration Date (unless another time is specified in the Acceptance or is otherwise mutually agreed upon), at which time the Stockholder shall deliver the stock certificate or certificates representing the Offered Shares so sold (duly endorsed or accompanied by a duly executed stock power or assignment to effect transfer of ownership to the purchaser or purchasers on the records of the Company) against the Stockholder's receipt of payment of the Minimum Price by certified check, bank cashiers check or wire transfer. The Stockholder acknowledges that the Company shall be authorized to (i) affix a legend referencing this Agreement on each certificate representing Shares issued to the Stockholder, and (ii) impose stop transfer orders with the Company's transfer agent. The provisions of this Agreement shall not apply to the transfer of Offered Shares by the Stockholder to (i) the heirs, executors or legal representatives of the Stockholder, (ii) the members of the immediate family of the Stockholder, or (iii) the trustees of an inter vivos or testamentary trust for the benefit of members of immediate family of the Stockholder, provided that, in each such case, such transferee shall become a party to this Agreement and agree to be bound by the terms and conditions hereof. IN WITNESS WHEREOF, this Agreement has been executed on behalf of each of the Stockholder and the Company on this ____ day of March 2001. STOCKHOLDER /s/ See Exhibit A -------------------------------- Name: ARIAD GENE THERAPEUTICS, INC. By: /s/ Harvey Berger ---------------------- Title: Chairman and CEO EXHIBIT A

STOCKHOLDER EXECUTION DATE - ----------- -------------- Harvey J. Berger March 12, 2001 David L. Berstein March 13, 2001 Gerald Crabtree January 31, 2001 John D. Iuliucci March 13, 2001 Jay R. LaMarche March 13, 2001 Stuart Schreiber January 31, 2001 Manfred Weigele March 13, 2001

EX-10.58 13 b41666arex10-58.txt EX-10.58 NOTICE OF EXTENSION OF LEASE EXHIBIT 10.58 CERTIFIED MAIL - RETURN RECEIPT October 2, 2001 Mr. Michael Farley Vice President, Asset Management Forest City Commercial Group 38 Sidney Street Cambridge, MA 02139 Re: Notice of Extension of Lease Dear Mike: Please be advised that pursuant to Section 2.6 of the lease dated January 8, 1992 by and between Forest City and ARIAD Corporation for certain lease space in the building at 26 Landsdowne Street, Cambridge, Massachusetts, as amended (the "Lease"), ARIAD hereby extends the lease for the first lease extension period commencing on August 1, 2002 and terminating on July 31, 2007. Moreover, the Annual Fixed Rent (as defined in the Lease) to be paid by ARIAD during the first extension term shall be determined pursuant to the formula described in Section 2.6 of the Lease. To that end, attached please find a spreadsheet containing ARIAD's proposed formula in Section 2.6 of the Lease. For illustrative purposes, the attached calculations hypothetically assume an extension start date of September 1, 2001, since bi-monthly inflation indices are presently available only through July, 2001. Once you have had an opportunity to review the attachment, please feel free to call me with any questions or comments you may have. Also, I would be happy to send you an electronic copy of the Excel spreadsheet that produced the attachment, if it will assist your review. Please confirm receipt of this letter by signing and dating below and returning to my attention by facsimile at 617-494-1828. Sincerely yours, /s/Harvey J. Berger Harvey J. Berger, M.D. HJB:bdm Received: /s/Michael Farley ----------------- Name Vice President October 3, 2001 EX-23.1 14 b41666arex23-1.htm EX-23.1 CONSENT OF DELOITTE & TOUCHE LLP

INDEPENDENT AUDITORS CONSENT

We consent to the incorporation by reference in Registration Statements Nos. 33-90854, 333-36597 and 333-63706 of ARIAD Pharmaceuticals, Inc. on Form S-8 and Registration Statements Nos. 33-85166, 333-51687, 333-63708, and 333-76486 of ARIAD Pharmaceuticals, Inc. on Form S-3 of our report dated January 18, 2002 (which report expresses an unqualified opinion and includes an explanatory paragraph referring to a change in accounting principle in 1999 relating to accounting for start-up activities), appearing in this Annual Report on Form 10-K of ARIAD Pharmaceuticals, Inc. for the year ended December 31, 2001.

/s/ DELOITTE & TOUCHE LLP

Boston, Massachusetts

March 21, 2002

GRAPHIC 15 b41666arxbox.gif GRAPHIC begin 644 b41666arxbox.gif M1TE&.#EA#``,`/?^``````$!`0("`@,#`P0$!`4%!08&!@<'!P@("`D)"0H* M"@L+"PP,#`T-#0X.#@\/#Q`0$!$1$1(2$A,3$Q04%!45%186%A<7%Q@8&!D9 M&1H:&AL;&QP<'!T='1X>'A\?'R`@("$A(2(B(B,C(R0D)"4E)28F)B7IZ>GM[>WQ\?'U]?7Y^?G]_?X"`@(&!@8*" M@H.#@X2$A(6%A8:&AH>'AXB(B(F)B8J*BHN+BXR,C(V-C8Z.CH^/CY"0D)&1 MD9*2DI.3DY24E)65E9:6EI>7EYB8F)F9F9J:FIN;FYRGI^?GZ"@ MH*&AH:*BHJ.CHZ2DI*6EI::FIJ>GIZBHJ*FIJ:JJJJNKJZRLK*VMK:ZNKJ^O MK["PL+&QL;*RLK.SL[2TM+6UM;:VMK>WM[BXN+FYN;JZNKN[N[R\O+V]O;Z^ MOK^_O\#`P,'!P<+"PL/#P\3$Q,7%Q<;&QL?'Q\C(R,G)RWM_?W^#@X.'AX>+BXN/CX^3DY.7EY>;FYN?GY^CHZ.GIZ>KJZNOK MZ^SL[.WM[>[N[N_O[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ M^OO[^_S\_/W]_?[^_O___R'Y!`$``/X`+``````,``P`!PA>`/]%8T:PH,%_ M&0`H7,@0(3UF_R)&C*8N`T)P"O1(1"4@F$6+UB@0^H=*P2V$*/]94\!$P$F4 J%B/^`1!%XL>('#-EC'BSY,F0(S]& GRAPHIC 16 b41666arbox.gif GRAPHIC begin 644 b41666arbox.gif M1TE&.#EA#``,`/?^``````$!`0("`@,#`P0$!`4%!08&!@<'!P@("`D)"0H* M"@L+"PP,#`T-#0X.#@\/#Q`0$!$1$1(2$A,3$Q04%!45%186%A<7%Q@8&!D9 M&1H:&AL;&QP<'!T='1X>'A\?'R`@("$A(2(B(B,C(R0D)"4E)28F)B7IZ>GM[>WQ\?'U]?7Y^?G]_?X"`@(&!@8*" M@H.#@X2$A(6%A8:&AH>'AXB(B(F)B8J*BHN+BXR,C(V-C8Z.CH^/CY"0D)&1 MD9*2DI.3DY24E)65E9:6EI>7EYB8F)F9F9J:FIN;FYRGI^?GZ"@ MH*&AH:*BHJ.CHZ2DI*6EI::FIJ>GIZBHJ*FIJ:JJJJNKJZRLK*VMK:ZNKJ^O MK["PL+&QL;*RLK.SL[2TM+6UM;:VMK>WM[BXN+FYN;JZNKN[N[R\O+V]O;Z^ MOK^_O\#`P,'!P<+"PL/#P\3$Q,7%Q<;&QL?'Q\C(R,G)RWM_?W^#@X.'AX>+BXN/CX^3DY.7EY>;FYN?GY^CHZ.GIZ>KJZNOK MZ^SL[.WM[>[N[N_O[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ M^OO[^_S\_/W]_?[^_O___R'Y!`$``/X`+``````,``P`!P@Z`/\)'$APX)L? M"!,J_/<#F;B'$!\:8"BNX,`#%"T*Q/BCHD:.'BV"U/AOY,>,)SN2Y&C@@,N7 &+@$$!``[ ` end -----END PRIVACY-ENHANCED MESSAGE-----

EX-10.49

                                                                   EXHIBIT 10.49

                                 EXECUTION COPY


             DECEMBER 2001 AMENDMENT TO LOAN AND SECURITY AGREEMENT
             ------------------------------------------------------

This December 2001 Amendment to Loan and Security Agreement (the "AMENDMENT
AGREEMENT") is made as of December 26, 2001 by and among ARIAD PHARMACEUTICALS,
INC., a Delaware corporation (the "BORROWER"), ARIAD CORPORATION, a Delaware
corporation and a wholly-owned subsidiary of the Borrower (the "LESSEE
Subsidiary"), ARIAD GENE THERAPEUTICS, INC., a Delaware corporation which is
controlled by the Borrower ("AGT" and, together with the Lessee Subsidiary, the
"SUBSIDIARIES", the Borrower and the Subsidiaries being referred to collectively
herein as the "COMPANIES"); and FLEET NATIONAL BANK (f/k/a BankBoston, N.A.), a
national banking association with an office at 100 Federal Street, Boston,
Massachusetts (the "BANK").

                                    RECITALS

A.   The Companies and the Bank are parties to a Loan and Security Agreement
     dated as of September 23, 1992, as amended (as so amended and as hereafter
     amended, replaced, restated, supplemented, renewed or otherwise modified
     from time to time, the "LOAN AGREEMENT"). Capitalized terms used herein
     without definition have the meanings assigned to them in the Loan
     Agreement.

B.   The Borrower has requested (i) that the Bank increase the New Term Loan by
     $1,500,000 and re-advance $2,300,000 of the New Term Loan, and (ii) that
     the Bank amend certain other provisions of the Loan Agreement as
     hereinafter set forth.

C.   Subject to certain terms and conditions, the Bank is willing to provide
     such financing and amendments, as hereinafter set forth.

NOW THEREFORE, for good and valuable consideration paid, the receipt and
sufficiency of which is hereby acknowledged, the parties hereby agree as to the
following:

I.   LOAN AGREEMENT AND NEW TERM LOAN

     (a)  The Bank has previously made the New Term Loan to the Borrower which,
          as of the date hereof, has an outstanding principal balance of
          $3,700,000. The Borrower has requested, and the Bank has agreed,
          subject to the terms and conditions of this Amendment Agreement, that
          the Bank will re-advance to the Borrower $2,300,000 of principal of
          the New Term Loan which the Borrower has previously repaid to the
          Bank. The Borrower has also requested and the Bank has agreed, subject
          to the terms and conditions of this Amendment Agreement, that the Bank
          will make a $1,500,000 increase to the aggregate principal amount of
          the New Term Loan. The New Term Loan (after giving effect to this
          Amendment Agreement, including the aforementioned re-advance and
          increase) shall be in the principal amount of $7,500,000 and is
          evidenced by the Second Amended and Restated Secured Term Note (the
          "NOTE"), executed as of the date hereof and a copy of which is
          attached hereto as EXHIBIT A. The Maturity and amortization of the New
          Term Loan shall be as set forth in Section 3.4 of the Loan Agreement,
          as amended hereby. The New Term Loan shall continue to bear interest
          at the rate provided in Section 3.8, shall be jointly and severally
          payable by the Borrower and the Subsidiaries, and shall otherwise be
          governed by all of the terms and conditions and covenants of the Loan
          Agreement applicable to Advances.

     (b)  The definition of "Note" in Section 1.24 of the Loan Agreement is
          hereby amended to read as follows:



          "1.24 `Note' means the Second Amended and Restated Secured Term Note
          in the principal amount of Seven Million Five Hundred Thousand Dollars
          ($7,500,000) jointly and severally executed by the Companies and
          delivered to the Bank pursuant to Section 3.1A of this Agreement, as
          amended and restated from time to time, together with any and all
          substitutions therefor."

     (c)  Article 2, Section (a) of the Loan Agreement is hereby amended in its
          entirety to read as follows:

          "(a) Accounts and Accounts Receivable, including without limitation,
          electronic chattel paper and commercial tort claims;"

     (d)  Article 2, Section (c) of the Loan Agreement is hereby amended in its
          entirety to read as follows:

          "(c) General Intangibles, including without limitation, payment
          intangibles."

     (e)  Article 2, Section (i) of the Loan Agreement is hereby amended in its
          entirety to read as follows:

          "(i) Instruments, Investment Property, Documents of Title, rights to
          proceeds of letters of credit, letter of credit rights, supporting
          obligations of every kind and description, policies and certificates
          of insurance, Securities, security entitlements, deposits, deposit
          accounts, money, cash, or other property."

     (f)  Article 2 of the Loan Agreement is hereby amended so that immediately
          following the phrase "together with all products and proceeds of the
          foregoing (the "COLLATERAL"), the following provision is added:

          "If any of the Companies shall at any time acquire a commercial tort
          claim, as defined in Revised Article 9 of the Uniform Commercial Code,
          such Company shall immediately notify the Bank in writing signed of
          the brief details thereof and shall grant to the Bank in writing a
          security interest therein and in the proceeds thereof, all on the
          terms of this Agreement, and in writing in form and substance
          satisfactory to the Bank.

          Each of the Companies hereby authorizes the Bank, at any time and from
          time to time, without such Company's further signature or
          authorization, to file financing statements, continuation statements
          and amendments thereto that describe or indicate the Collateral and
          which contain any other information required by Part 5 of Article 9 of
          the Uniform Commercial Code for the sufficiency or filing office
          acceptance of any financing statement, continuation statement or
          amendment, including whether such Company is an organization, the type
          of organization and any organization identification number issued to
          such Company. The Companies agree to furnish any such information to
          the Bank promptly upon request.

          Each of the Companies shall at any time and from time to time take
          such steps as the Bank may reasonably request for the Bank (i) to
          obtain an acknowledgement, in form and substance satisfactory to the
          Bank, of any bailee having possession of any of the Collateral that
          the bailee holds such Collateral for the Bank, (ii) to obtain
          "control" of any investment property, deposit accounts,
          letter-of-credit rights or electronic chattel paper (as such terms are
          defined in Article 9 of the Uniform Commercial Code) with any
          agreements establishing control to be in form and substance
          satisfactory in the Bank, and (iii) otherwise to insure the continued
          perfection and priority of the Bank's security interest in the
          Collateral and of the preservation of its rights therein."

     (g)  Section 3.4 of the Loan Agreement is hereby amended to read in its
          entirety as follows:


                                       2


          "3.4 TERM LOAN REPAYMENT. New Term Loan shall be repaid, without
          set-off, deduction or counterclaim, in thirty-seven (37) monthly
          installments of $100,000, beginning January 1, 2002 and ending January
          1, 2005, on which date the outstanding principal balance under the
          Note, together with all accrued and unpaid interest and other charges
          under the Note and this Agreement, shall be due and payable in full."

     (h)  The following provision is hereby added to the end of Section 7.2 of
          the Loan Agreement:

          "No Company shall change its corporate name, identity, structure or
          state of incorporation without the Bank's prior written consent."

     (i)  The following subsection (f) is hereby added to Section 7.19 of the
          Loan Agreement:

          "(f) Notwithstanding the aforementioned exceptions, the Bank consents
          to the indebtedness incurred pursuant to the Companies' $1,2000,000
          equipment loan with General Electric Capital Corporation (the "GE
          LOAN") evidenced by those certain [Agreements] dated as of December
          27, 2001 between General Electric Capital Corporation and the
          Borrower. The Bank agrees to release all liens on equipment to be
          financed by the GE Loan."

     (j)  Section 7.21(c)(ii) of the Loan Agreement is hereby amended and
          restated to read in its entirety as follows:

          "(e) MAINTENANCE OF LIQUID ASSETS.

               (i)  The Borrower shall not permit its unrestricted cash and
                    marketable securities to decrease to an amount below the sum
                    of twelve (12) months of its projected cash requirements (as
                    reflected in its projections and forecasts delivered to the
                    Bank) plus the principal amount of the Loan then
                    outstanding, plus the outstanding balance of the GE Loan,
                    unless the Borrower invests, utilizing the services of the
                    Bank's Money Desk or Trust Department, an amount of cash
                    and/or marketable securities equal to the outstanding
                    principal amount of the Loan, until such time as the
                    Borrower either (A) shall have restored its unrestricted
                    cash and marketable securities to such sum of projected
                    12-month cash requirements plus the principal amount of the
                    Loan outstanding, including, without limitation, by raising
                    cash through sale of equity securities (`equity securities'
                    meaning common and preferred stock not having provisions for
                    required payments or distributions by the Borrower during
                    the period ending thirty (30) days after the Termination
                    Date), or (B) shall have pledged to the Bank Portfolio
                    securities under the Pledge Agreement in an amount
                    sufficient (as determined by the Bank's credit policy
                    generally in effect from time to time) to secure the entire
                    principal amount of the Loan outstanding.

               (ii) The Borrower shall not permit its unrestricted cash and
                    marketable securities to decrease to an amount below the
                    greater of the sum of six (6) months of its projected cash
                    requirements (as reflected in its projections and forecasts
                    delivered to the Bank) plus the then outstanding principal
                    amount of the Loan, plus the outstanding balance of the GE
                    Loan, or $15,000,000, unless the Borrower pledges to the
                    Bank Portfolio Securities under the Pledge Agreement in an
                    amount sufficient (as determined by the Bank's credit policy
                    generally in effect from time to time) to secure the entire
                    principal amount of the Loan outstanding."

II.  NO FURTHER AMENDMENTS. Except as specifically amended hereby, the Loan
     Agreement, the Pledge Agreement, the Patent Mortgage and the Leasehold
     Mortgage shall


                                       3


     remain unmodified and in full force and effect and are hereby ratified and
     affirmed in all respects, and the indebtedness of the Companies to the Bank
     evidenced thereby and by the Note is hereby reaffirmed in all respects.

III. CONFIRMATION OF SECURITY. Each of the Borrower, the Lessee Subsidiary and
     AGT hereby confirms that (1) the terms "Liability" and "Liabilities", as
     defined in the Loan Agreement and the Pledge Agreement and the term
     "Obligations", as defined in the Patent Mortgage, include the obligations
     of the Companies under the Note, as amended and restated herewith, and (2)
     the term "Note", as used in each of the Loan Documents, including the
     Leasehold Mortgage and the Patent Mortgage, includes the Note, as amended
     and restated herewith.

IV.  CERTAIN REPRESENTATIONS. As a material inducement to the Bank to enter into
     this Amendment Agreement, each of the Borrower, the Lessee Subsidiary and
     AGT hereby represents and warrants to the Bank (which representations and
     warranties shall survive the delivery hereof), after giving effect hereto,
     as follows:

     A.   The execution and delivery of this Amendment Agreement and the
          amendment and restatement of the Note have been duly authorized by all
          requisite corporate action on the part of each of the Companies.

     B.   The representations and warranties contained in Article 6 of the Loan
          Agreement and in the other Loan Documents are true and correct in all
          material respects on and as of the date of this Amendment Agreement as
          though made at and as of such date. No material adverse change has
          occurred in the assets, liabilities, financial condition, business or
          prospects of any Company from that disclosed in the financial
          statements most recently furnished to the Bank. No Event of Default
          has occurred and is continuing.

     C.   None of the Companies is required to obtain any consent, approval or
          authorization from, or to file any declaration or statement with, any
          governmental instrumentality or other agency or any other person or
          entity in connection with or as a condition to the execution, delivery
          or performance of this Amendment Agreement or the Note.

     D.   Each of this Amendment Agreement and the Note, as amended and restated
          herewith, constitutes the legal, valid and binding obligation of the
          Companies, enforceable against each of them in accordance with their
          respective terms, subject to bankruptcy, insolvency, reorganization,
          moratorium and similar laws affecting the rights and remedies of
          creditors generally or the application of principles of equity,
          whether in any action at law or proceeding in equity, and subject to
          the availability of the remedy of specific performance or of any other
          equitable remedy or relief to enforce any right thereunder.

V.   CONDITIONS. The willingness of the Bank to agree to the foregoing is
     subject to the satisfaction of the following conditions precedent and
     subsequent:

     A.   On or before the date hereof, the Companies shall have executed and
          delivered to the Bank (or shall have caused to be executed and
          delivered to the Bank by the appropriate persons) the following:

          1.   The Amendment Agreement;

          2.   The Second Amended and Restated Secured Term Note;

          3.   True and complete copies of any required stockholders' and
               directors' consents and/or resolutions, authorizing the execution
               and delivery of such documents, certified by the Secretary of the
               appropriate company;


                                       4


          4.   The letter executed as of the date hereof by Forest City
               Cambridge, Inc. with respect to the lessor's consent signed in
               connection with the Mortgage.

     B.   On or before the date of this Amendment, the Borrower shall have paid
          the Bank a non-refundable fee in the mount of $30,000.

VI.  MISCELLANEOUS.

     A.   As provided in Section 10.8 of the Loan Agreement, the Borrower and
          the Subsidiaries agree to reimburse the Bank upon demand for all
          reasonable fees and disbursements of counsel to the Bank incurred in
          connection with the preparation hereof and the Note.

     B.   This Amendment Agreement shall be governed by and construed in
          accordance with the laws of the Commonwealth of Massachusetts.

     C.   This Amendment Agreement may be executed by the parties hereto in
          several counterparts hereof and by the different parties hereto on
          separate counterparts hereof, all of which counterparts shall together
          constitute one and the same agreement.

     D.   The obligations of the Borrower and the Subsidiaries under this
          Amendment Agreement and the Note shall be joint and several in nature.

Executed as a sealed instrument as of the date first set forth above.


                                                ("Borrower")
                                        ARIAD PHARMACEUTICALS, INC.

                                        By: /s/ Harvey Berger
                                            ------------------------------------
                                            Name: Harvey Berger
                                            Title: Chairman & CEO




                                        ARIAD CORPORATION

                                        By: /s/ Harvey Berger
                                            ------------------------------------
                                            Name: Harvey Berger
                                            Title: CEO & President




                                        ARIAD GENE THERAPEUTICS, INC.

                                        By: /s/ Harvey Berger
                                            ------------------------------------
                                            Name: Harvey Berger
                                            Title: Chairman & CEO






                                       5



("Bank")
FLEET NATIONAL BANK

By: /s/ Karen M. Kinsella
    ---------------------------------
    Name: Karen M. Kinsella
    Title: Vice President










                                       6



EXHIBIT A

SECOND AMENDED AND RESTATED SECURED TERM NOTE













                                       7




                  SECOND AMENDED AND RESTATED SECURED TERM NOTE

$7,500,000.00                                              Boston, Massachusetts
                                                               December 26, 2001


     FOR VALUE RECEIVED, the undersigned, ARIAD PHARMACEUTICALS, INC., a
Delaware corporation (the "Pharmaceuticals"), ARIAD CORPORATION, a Delaware
corporation (the "Lessee Subsidiary") and ARIAD GENE THERAPEUTICS, INC., a
Delaware corporation ("AGT" and , collectively with Pharmaceuticals and the
Lessee Subsidiary, the "Makers"), hereby jointly and severally promise to pay to
the order of FLEET NATIONAL BANK (f/k/a BankBoston, N.A.), having an address at
100 Federal Street, Boston, Massachusetts 02110 (the "Bank"), the principal sum
of Seven Million Five Hundred Thousand and 00/100 Dollars ($7,500,00.00) or, if
less, the aggregate unpaid principal amount of advances made hereunder by the
Bank to Pharmaceuticals or any other Maker pursuant to that certain Loan and
Security Agreement dated as of September 23, 1992, as amended (as so amended and
as hereafter amended, replaced, restated, supplemented, renewed or otherwise
modified from time to time, the "Loan Agreement"), between the Makers and the
Bank, together with interest on any and all principal remaining unpaid hereunder
from the date hereof until payment in full, payable on the dates and at the
interest rate or rates specified in the Loan Agreement. Capitalized terms used
in this Note without definition have the meanings assigned to them in the Loan
Agreement.

     The aggregate principal amount outstanding hereunder shall be payable as
provided in the Loan Agreement. This Note may be prepaid in accordance with the
terms and provisions of the Loan Agreement without penalty or premium (other
than certain makewhole payments under Section 3.6 of the Loan Agreement).

     All principal and interest hereunder are payable in lawful money of the
United States of America to the Bank at its address specified above in
immediately available funds as provided in the Loan Agreement on the date on
which such payment shall become due. Payments of principal and interest
hereunder which are not made by such date may be made by debiting any deposit
account(s), if any, in the name of the Makers, or any of them, with the Bank.
The Makers hereby irrevocably authorize the Bank to so debit such deposit
account(s).

     The Makers, for themselves and their legal representatives, successors and
assigns, to the extent they may lawfully do so, hereby expressly waive
presentment, demand, protest, notice of protest, presentment for the purpose of
accelerating maturity, diligence in collection, and the benefit of any exemption
or insolvency laws, and consent that the Bank may release or surrender, exchange
or substitute any personal property or other collateral security now held or
which may hereafter be held as security for the payment of this Note, and may
extend the time for payment or otherwise modify the terms of payment of any
party or the whole of the debt evidenced hereby to the extent provided in the
Loan Agreement without in any way affecting the liability of the Makers;
provided that such modifications do not increase the obligations hereunder.

     This Note is the "Note" referred to in and is entitled to the benefits of
the Loan Agreement (including Schedules thereto) and all other instruments and
agreements evidencing and/or securing the indebtedness hereunder, which Loan
Agreement and other instruments and agreements are hereby made part of this Note
and are deemed incorporated herein in full. The occurrence or existence of an
Event of Default shall constitute a default under this Note and shall, subject
to the provisions of the Loan Agreement, entitle the Bank to accelerate the
entire indebtedness hereunder and to take such other action as may be provided
for in the Loan Agreement or any other instrument or agreement evidencing and/or
securing this Note, all in accordance with the terms of the Loan Agreement.

     This Note (a) supersedes and replaces the Amended and Restated Secured Term
Notes, each dated April 6, 1998, made by the Makers and payable to the order of
the Lender and USTrust, respectively, in the principle amounts of $2,601,000 and
$2,499,000 under the Loan Agreement, as





combined and amended by the First Amendment to Amended and Restated Secured Term
Note, dated as of December 28, 2000 (b) represents the Bank's Commitment and
outstanding Advances under the Loan Agreement as of the date hereof and (c)
represents a continuation (not a refinancing or reborrowing) of the outstanding
obligations of the Borrower with respect to the New Term Loan.

     All agreements between or among the Makers and the Bank are hereby
expressly limited so that in no contingency or event whatsoever, whether by
reason of acceleration of maturity of the indebtedness or otherwise, shall the
amount paid or agreed to be paid for the use or forbearance of the indebtedness
evidenced hereby exceed the maximum amount which the Bank is permitted to
receive under applicable law. If, from any circumstances whatsoever, fulfillment
of any provision hereof or of the Loan Agreement, at the time performance of
such provision shall be due, shall involve exceeding such amount, then the
obligation to be fulfilled shall automatically be reduced to the limit of such
validity and if, from any circumstances, the Bank should ever receive as
interest an amount which would exceed such maximum amount, such amount which
would be excessive interest shall be applied to the reduction of the principal
balance evidenced hereby and not to the payment of interest. As used herein, the
term "applicable law" shall mean the law in effect as of the date hereof,
PROVIDED, HOWEVER, that in the event there is a change in the law which results
in a higher permissible rate of interest, then this Note shall be governed by
such new law as of its effective date. This provision shall control every other
provision of all agreements between or among the Makers, or any of them, and the
Bank.

     This Note and all transactions hereunder and/or evidenced herein shall be
governed by, and construed and enforced in accordance with, the laws of The
Commonwealth of Massachusetts.

     If this Note shall not be paid when due and shall be placed by the holder
hereof in the hands of any attorney for collection, through legal proceedings or
otherwise, the Makers will pay reasonable attorneys' fees to the holder hereof
together with reasonable costs and expenses of collection, including, without
limitation, any such attorneys' fees, costs and expenses relating to dissolution
or liquidation of any of the Makers or any party (other than the Bank) to any
instrument or agreement securing this Note.

     This Note shall be binding, jointly and severally, upon the Makers and upon
their heirs, successors, assigns and legal representatives and shall inure to
the benefit of the Bank and its successors, endorsees and assigns.

     IN WITNESS WHEREOF, the Makers have caused this Note to be executed under
seal by their duly authorized representative as of the date first above written.



                                        ARIAD PHARMACEUTICALS, INC.

                                        By: /s/ Harvey Berger
                                            ------------------------------------
                                            Name: Harvey Berger
                                            Title: Chairman & CEO




                                        ARIAD CORPORATION

                                        By: /s/ Harvey Berger
                                            ------------------------------------
                                            Name: Harvey Berger
                                            Title: President & CEO









                                       2


                                        ARIAD GENE THERAPEUTICS, INC.

                                        By: /s/ Harvey Berger
                                            ------------------------------------
                                            Name: Harvey Berger
                                            Title: Chairman & CEO













                                        3

EX-10.50

                                                                   EXHIBIT 10.50

                            MASTER SECURITY AGREEMENT
                   dated as of December 27, 2001 ("Agreement")

THIS AGREEMENT is between General Electric Capital Corporation (together with
its successors and assigns, if any, "Secured Party") and Ariad Pharmaceuticals,
Inc. ("Debtor"). Secured Party has an office at 401 Merritt 7, Suite 23,
Norwalk, CT 06856. Debtor is a corporation organized and existing under the laws
of the state of Delaware. Debtor's mailing address and chief place of business
is 26 Landsdowne St., Cambridge, MA 02139.

1.     CREATION OF SECURITY INTEREST.

       Debtor grants to Secured Party, its successors and assigns, a security
       interest in and against all property listed on any collateral schedule
       now or in the future annexed to or made a part of this Agreement
       ("Collateral Schedule"), and in and against all additions, attachments,
       accessories and accessions to such property, all substitutions,
       replacements or exchanges therefor, and all insurance and/or other
       proceeds thereof (all such property is individually and collectively
       called the "Collateral"). This security interest is given to secure the
       payment and performance of all debts, obligations and liabilities of any
       kind whatsoever of Debtor to Secured Party, now existing or arising in
       the future, including but not limited to the payment and performance of
       certain Promissory Notes from time to time identified on any Collateral
       Schedule (collectively "Notes" and each a "Note"), and any renewals,
       extensions and modifications of such debts, obligations and liabilities
       (such Notes, debts, obligations and liabilities are called the
       "Indebtedness"). Unless otherwise provided by applicable law,
       notwithstanding anything to the contrary contained in this Agreement, to
       the extent that Secured Party asserts a purchase money security interest
       in any items of Collateral ("PMSI Collateral"); (i) the PMSI Collateral
       shall secure only that portion of the Indebtedness which has been
       advanced by Secured Party to enable Debtor to purchase, or acquire rights
       in or the use of such PMSI Collateral (the "PMSI Indebtedness"), and (ii)
       no other Collateral shall secure the PMSI Indebtedness.

2.     REPRESENTATIONS, WARRANTIES AND COVENANTS OF DEBTOR.

       Debtor represents, warrants and covenants as of the date of this
       Agreement and as of the date of each Collateral Schedule that:

       (a)    Debtor's exact legal name is as set forth in the preamble of this
              Agreement and Debtor is, and will remain, duly organized, existing
              and in good standing under the laws of the State set forth in the
              preamble of this Agreement, has its chief executive offices at the
              location specified in the preamble, and is, and will remain, duly
              qualified and licensed in every jurisdiction wherever necessary to
              carry on it business and operations;

       (b)    Debtor has adequate power and capacity to enter into, and to
              perform its obligations under this Agreement, each Note and any
              other documents evidencing, or given to connection with, any of
              the Indebtedness (all of the foregoing are called the "Debt
              Documents");

       (c)    This Agreement and the other Debt Documents have been duly
              authorized, executed and delivered by Debtor and constitute legal,
              valid and binding agreements enforceable in accordance with their
              terms, except to the extent that the enforcement of remedies may
              be limited under applicable bankruptcy and insolvency laws;

       (d)    No approval, consent or withholding of objections is required from
              any governmental authority or instrumentality with respect to the
              entry into, or performance by Debtor of any of the Debt Documents,
              except any already obtained;





       (e)    The entry into and performance by, Debtor of the Debt Documents
              will not (i) violate any of the organizational documents of Debtor
              or any judgment order, law or regulation applicable to Debtor, or
              (ii) result in any breach of or constitute a default under any
              contract to which Debtor is a party, or result in the creation of
              any lien, claim or encumbrance on any of Debtor's property (except
              for liens in favor of Secured Party) pursuant to any indenture,
              mortgage, deed of trust, bank loan, credit agreement, or other
              agreement or instrument to which Debtor is a party;

       (f)    There are no suits or proceedings pending in court or before any
              commission, board or other administrative agency against or
              affecting Debtor which could, in the aggregate, have a material
              adverse effect on Debtor, its business or operations, or its
              ability to perform its obligations under the Debt Documents, nor
              does Debtor have reason to believe that any such suits or
              proceedings are threatened.

       (g)    All financial statements delivered to Secured Party in connection
              with the indebtedness have been prepaid in accordance with
              generally accepted accounting principles and since the date of the
              most recent financial statement, there has been no material
              adverse change in Debtor's financial condition;

       (h)    The Collateral is not, and will not be, used by Debtor for
              personal, family or household purposes;

       (i)    The Collateral is, and will remain, in good condition and repair
              and Debtor will not be negligent in its care and use;

       (j)    Debtor is, and will remain, the sole and lawful owner, and in
              possession of, the Collateral, and has the sole right and lawful
              authority to grant the security interest described in this
              Agreement; and

       (k)    The Collateral is, and will remain, free and clear of all liens,
              claims and encumbrances of any kind whatsoever, except for (i)
              liens in favor of Secured Party, (ii) liens for taxes not yet due
              or for taxes being contested in good faith and which do not
              involve, in the judgment of Secured Party, any risk of the sale,
              forfeiture or loss of any of the Collateral, and (iii) inchoate
              materialmen's, mechanic's, repairman's and similar liens arising
              by operation of law in the normal course of business for amounts
              which are not delinquent (all off such liens are called "Permitted
              Liens").

3.     COLLATERAL

       (a)    Until the declaration of any default, Debtor shall remain in
              possession of the Collateral; except that Secured Party shall have
              the right to possess (i) any chattel paper or instrument that
              constitutes a part of the Collateral, and (ii) any other
              Collateral in which Secured Party's security interest may be
              perfected only by possession. Secured Party may inspect any of the
              Collateral during normal business hours after giving Debtor
              reasonable prior notice. If Secured Party asks, Debtor will
              promptly notify Secured Party in writing of the location of any
              Collateral.

       (b)    Debtor shall (i) use the Collateral only in its trade or business,
              (ii) maintain all of the Collateral in good operating order and
              repair, normal wear and tear excepted, (iii) use and maintain the
              Collateral only in compliance with manufacturers recommendations
              and all applicable laws, and (iv) keep all of the Collateral free
              and clear of all liens, claims and encumbrances (except for
              Permitted Liens).


       (c)    Secured Party does not authorize and Debtor agrees it shall not
              (i) part with possession of any of the Collateral (except to
              Secured Party or for maintenance and repair), (ii) remove any of
              the Collateral from the continental United States, or (iii) sell,
              rent, lease, mortgage, license, grant a security interest in or
              otherwise transfer or encumber (except for Permitted Liens) any of
              the Collateral.

       (d)    Debtor shall promptly when due all taxes, license fees,
              assessments and public and private charges levied or assessed on
              any of the Collateral, on its use, or on this Agreement or any of
              the other Debt Documents. At its option, Secured Party may
              discharge taxes, liens, security interests or other encumbrances
              at any time levied or placed on the Collateral and may pay for the
              maintenance, insurance and preservation of the Collateral and
              effect compliance with the terms of this Agreement or any of the
              other Debt Documents. Debtor agrees to reimburse Secured Party, on
              demand, all costs and expenses incurred by Secured Party in
              connection with such payment or performance and agrees that such
              reimbursement obligation shall constitute Indebtedness.

       (e)    Debtor shall, at all times, keep accurate and complete records of
              the Collateral, and Secured Party shall have the right to inspect
              and make copies of all of Debtor's books and records relating to
              the Collateral during normal business hours, after giving Debtor
              reasonable prior notice.

       (f)    Debtor agrees and acknowledges that any third person who may at
              any time possess all or any portion of the Collateral shall be
              deemed to hold, and shall hold, the Collateral as the agent of,
              and as pledge holder for Security Party. Secured Party may at any
              time give notice to any third person described in the preceding
              sentence that such third person is holding the Collateral as the
              agent of, and as pledge holder for, the Secured Party.

4.     INSURANCE

       (a)    Debtor shall at all times bear the entire risk of any loss, theft,
              damage to, or destruction of, any of the Collateral from any cause
              whatsoever.

       (b)    Debtor agrees to keep the Collateral insured against loss or
              damage by fire and extended coverage perils, theft, burglary, and
              for any or all Collateral which are vehicles for risk of loss by
              collision, and if requested by Secured Party, against such other
              risks as Secured Party may reasonably require. The insurance
              coverage shall be in an amount no less than the full replacement
              value of the Collateral, and deductible amounts, insurers and
              policies shall be acceptable to Secured Party. Debtor shall
              deliver to Secured Party policies or certificates of insurance
              evidencing such coverage. Each policy shall name Secured Party as
              a loss payee, shall provide for coverage to Secured Party
              regardless of the breach by Debtor of any warranty or
              representation made therein, shall not be subject to co-insurance,
              and shall provide that coverage may not be canceled or altered by
              the insurer except upon thirty (30) days prior written notice to
              Secured Party. Debtor appoints Secured Party as its
              attorney-in-fact to make proof of loss, claim for insurance and
              adjustments with insurers, and to receive payment of and execute
              or endorse all documents, checks or drafts in connection with
              insurance payments. Secured Party shall not act as Debtor's
              attorney-in-fact unless Debtor is in default. Proceeds of
              insurance shall be applied, at the option of Debtor, to repair or
              replace the Collateral or to reduce any of the Indebtedness,
              except that in the event of a loss of all or substantially all of
              the collateral, the option will revert to the Secured Party.

5.     REPORTS



       (a)    Debtor shall promptly notify Secured Party of (i) any change in
              the name of Debtor, (ii) any change in the state of its
              incorporation or registration, (iii) any relocation of its chief
              executive offices, (iv) any relocation of any of the Collateral,
              (v) any of the Collateral being lost, stolen, missing, destroyed,
              materially damaged or worn out, or (vi) any lien, claim or
              encumbrance other than Permitted Liens attaching to or being made
              against any of the Collateral.

       (b)    Debtor will deliver to Secured Party Debtor's complete financial
              statements, certified by a recognized firm of certified public
              accountants, within ninety (90) days of the close of each fiscal
              year of Debtor. Debtor will make available to Secured Party copies
              of Debtor's quarterly financial reports certified by Debtor's
              chief financial officer, within ninety (90) days after the close
              of each of Debtor's fiscal quarter. Debtor will make available to
              Secured Party copies of all Forms 10-K and 10-Q, if any, within 30
              days after the dates on which they are filled with the Securities
              and Exchange Commission. Availability will include Internet
              availability and will not require other by the Debtor.

6.     FURTHER ASSURANCES

       (a)    Debtor shall, upon request of Secured Party, furnish to Secured
              Party such further information, execute and deliver to Secured
              Party such documents and instruments (including, without
              limitation, Uniform Commercial Code financing statements) and
              shall do such other acts and things as Secured Party may at any
              time reasonably request relating to the perfection or protection
              of the security interest created by this Agreement or for the
              purpose of carrying out the intent of this Agreement. Without
              limiting the foregoing, Debtor shall cooperate and do all acts
              deemed necessary or advisable by Secured Party to continue in
              Secured Party a perfected first security interest in the
              Collateral, and shall obtain and furnish to Secured Party and
              subordinations, releases, landlord waivers, lessor waivers,
              mortgagee waivers, or control agreements, and similar documents as
              may be from time to time requested by, and in form and substance
              satisfactory to, Secured Party.

       (b)    Debtor authorizes Secured Party to file a financing statements and
              amendments thereto describing the Collateral and containing any
              other information required by the applicable Uniform Commercial
              Code. Debtor irrevocably grants to Secured Party the power to sign
              Debtor's name and generally to act on behalf of Debtor to execute
              and file applications for title, transfers of title, financing
              statements, notices of lien and other documents pertaining to any
              or all of the Collateral; this power is coupled with Secured
              Party's interest in the Collateral. Debtor shall, if any
              certificate of title be required or permitted by law for any of
              the Collateral, obtain and promptly deliver to Secured Party such
              certificate showing the lien of this Agreement with respect to the
              Collateral. Debtor ratifies its prior authorization for Secured
              Party to file financing statements and amendments thereto
              describing the Collateral and containing any other information
              required by the Uniform Commercial Code if filed prior to the date
              hereof.

       (c)    Debtor shall indemnify and defend the Secured Party, its
              successors and assigns, and their respective directors, officers
              and employees, from and against all claims, actions and suits
              (including, without limitation, related attorneys' fees) of any
              kind whatsoever arising, directly or indirectly, in connection
              with any of the Collateral.

7.     DEFAULT AND REMEDIES.



       (a)    Debtor shall be in default under this Agreement and each of the
              other Debt Documents if:

              (i)    Debtor breaches its obligation to pay when due any
                     installment or other amount due or coming due under any of
                     the Debt Documents;

              (ii)   Debtor, without the prior written consent of Secured Party,
                     attempts to or does sell, rent, lease, license, mortgage,
                     grant a security interest in, or otherwise transfer or
                     encumber (except for Permitted Liens) any of the
                     Collateral;

              (iii)  Debtor breaches any of its insurance obligations under
                     Section 4;

              (iv)   Debtor breaches any of its other obligations under any of
                     the Debt Documents and fails to cure that breach within
                     thirty (30) days after written notice from Secured Party:

              (v)    Any warranty, representation or statement made by Debtor in
                     any of the Debt Documents or otherwise in connection with
                     any of the indebtedness shall be false or misleading in any
                     material respect;

              (vi)   Any of the Collateral is subjected to attachment,
                     execution, levy, seizure or confiscation in any legal
                     proceeding or otherwise, or if any legal or administrative
                     proceeding is commenced against Debtor or any of the
                     Collateral, which in the good faith judgment of Secured
                     Party subjects any of the Collateral to a material risk of
                     attachment, execution, levy, seizure or confiscation and no
                     bond is posted or protective order obtained to negate such
                     risk;

              (vii)  Debtor breaches or is in default under any other agreement
                     between Debtor and Secured Party;

              (viii) Debtor or any guarantor or other obligor for any of the
                     Indebtedness (collectively, "Guarantor") dissolves,
                     terminates its existence, becomes insolvent or ceases to do
                     business as a going concern;

              (ix)   If Debtor or any Guarantor is a natural person, Debtor or
                     any such Guarantor dies or becomes incompetent;

              (x)    A receiver is appointed for all or any part of the property
                     of Debtor or any Guarantor, or Debtor or any Guarantor
                     makes any assignment for the benefit of creditors;

              (xi)   Debtor or any Guarantor files a petition under any
                     bankruptcy, insolvency or similar law, or any such petition
                     is filed against Debtor or any Guarantor and is not
                     dismissed within forty-five (45) days; or

              (xii)  Debtor's improper filing of an amendment or termination
                     statement relating to a filed financing statement
                     describing the Collateral.

       (b)    If Debtor is in default, the Secured Party, at its option, may
              declare any or all of the Indebtedness to be immediately due and
              payable, without demand or notice to Debtor or any Guarantor. The
              accelerated obligations and liabilities shall bear interest (both
              before and after any judgment) until paid in full at the lower of
              eighteen percent (18%) per annum or the maximum rate not
              prohibited by applicable law.



       (c)    After default, Secured Party shall have all of the rights and
              remedies of a Secured Party under the Uniform Commercial Code, and
              under any other applicable law. Without limiting the foregoing,
              Secured Party shall have the right to (i) notify any account
              debtor of Debtor or any obligor on any instrument which
              constitutes part of the Collateral to make payment to the Secured
              Party, (ii) with or without legal process, enter any premises
              where the Collateral may be and take possession of and remove the
              Collateral from the premises or store it on the premises, (iii)
              sell the Collateral at public or private sale, in whole or in
              part, and have the right to bid and purchase at said sale, or (iv)
              lease or otherwise dispose of all or part of the Collateral,
              applying proceeds from such disposition to the obligations then in
              default. If requested by Secured Party, Debtor shall promptly
              assemble the Collateral and make it available to Secured Party at
              a place to be designated by Secured Party which is reasonably
              convenient to both parties. Secured Party may also render any or
              all of the Collateral unusable at the Debtor's premises and may
              dispose of such Collateral on such premises without liability for
              rent or costs. Any notice that Secured Party is required to give
              to Debtor under the Uniform Commercial Code of the time and place
              of any public sale or the time after which any private sale or
              other intended disposition of the Collateral is to be made shall
              be deemed to constitute reasonable notice if such notice is given
              to the last known address of Debtor at least five (5) days prior
              to such action.

       (d)    Proceeds from any sale or lease or other disposition shall be
              applied: first, to all costs of repossession, storage, and
              disposition including without limitation attorneys', appraisers',
              and auctioneers' fees; second, to discharge the obligations then
              in default; third, to discharge any other Indebtedness of Debtor
              to Secured Party, whether as obligor, endorser, guarantor, surety
              or indemnitor; fourth, to expenses incurred in paying or settling
              liens and claims against the Collateral; and lastly, to Debtor, if
              there exists any surplus. Debtor shall remain fully liable for any
              deficiency.

       (e)    Debtor agrees to pay all reasonable attorneys' fees and other
              costs incurred by Secured Party in connection with the
              enforcement, assertion, defense or preservation of Secured Party's
              rights and remedies under this Agreement, or if prohibited by law,
              such lesser sum as may be permitted. Debtor further agrees that
              such fees and costs shall constitute Indebtedness.

       (f)    Secured Party's rights and remedies under this Agreement or
              otherwise arising are cumulative and may be exercised singularly
              or concurrently. Neither the failure nor any delay on the part of
              the Secured Party to exercise any right, power or privilege under
              this Agreement shall operate as a waiver, nor shall any single or
              partial exercise of any right, power or privilege preclude any
              other or further exercise of that or any other right, power or
              privilege. SECURED PARTY SHALL NOT BE DEEMED TO HAVE WAIVED ANY OF
              ITS RIGHTS UNDER THIS AGREEMENT OR UNDER ANY OTHER AGREEMENT,
              INSTRUMENT OR PAPER SIGNED BY DEBTOR UNLESS SUCH WAIVER IS
              EXPRESSED IN WRITING AND SIGNED BY SECURED PARTY. A waiver on any
              one occasion shall not be construed as a bar to or waiver of any
              right or remedy on any future occasion.

       (g)    DEBTOR AND SECURED PARTY UNCONDITIONALLY WAIVE THEIR RIGHTS TO A
              JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING
              OUT OF THIS AGREEMENT, ANY OF THE OTHER DEBT DOCUMENTS, ANY OF THE
              INDEBTEDNESS SECURED HEREBY, ANY DEALINGS BETWEEN DEBTOR AND
              SECURED PARTY RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION
              OR ANY RELATED TRANSACTIONS, AND/OR THE RELATIONSHIP THAT IS BEING
              ESTABLISHED BETWEEN DEBTOR AND SECURED PARTY. THE SCOPE OF THIS
              WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES
              THAT MAY BE FILED IN ANY COURT. THIS WAIVER IS IRREVOCABLE. THIS
              WAIVER




              MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING. THE WAIVER ALSO
              SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR
              MODIFICATIONS TO THIS AGREEMENT, ANY OTHER DEBT DOCUMENTS, OR TO
              ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR
              ANY RELATED TRANSACTION. THIS AGREEMENT MAY BE FILED AS A WRITTEN
              CONSENT TO A TRIAL BY THE COURT.

8.     MISCELLANEOUS.

       (a)    This Agreement, any Note and/or any of the other Debt Documents
              may be assigned, in whole or in part, by Secured Party without
              notice to Debtor, and Debtor agrees not to assert against any such
              assignee, or assignee's assigns, any defense set-off, recoupment
              claim or counterclaim which Debtor has or may at any time have
              against Secured Party for any reason whatsoever. Debtor agrees
              that if Debtor receives written notice of an assignment from
              Secured Party, Debtor will pay all amounts payable under any
              assigned Debt Document to such assignee or as instructed by
              Secured Party. Debtor also agrees to confirm in writing receipt of
              the notice of assignment as may be reasonably requested by Secured
              Party or assignee.

       (b)    All notices to be given in connection with this Agreement shall be
              in writing, shall be addressed to the parties at their respective
              addresses set forth in this Agreement (unless and until a
              different address may be specified in a written notice to the
              other party), and shall be deemed given (i) on the date of receipt
              if delivered in hand or by facsimile transmission, (ii) on the
              next business day after being sent by express mail, and (iii) on
              the fourth business day after being sent by regular, registered or
              certified mail. As used herein, the term "business day" shall mean
              and include any day other than Saturdays, Sundays, or other days
              on which commercial banks in New York, New York are required or
              authorized to be closed.

       (c)    Secured Party may correct patent errors and fill in all blanks in
              this Agreement or in any Collateral Schedule consistent with the
              agreement of the parties.

       (d)    Time is of the essence of this Agreement. This Agreement shall be
              binding, jointly and severally, upon all parties described as the
              "Debtor" and their respective heirs, executors, representatives,
              successors and assigns, and shall inure to the benefit of Secured
              Party, its successors and assigns.

       (e)    This Agreement and its Collateral Schedules constitute the entire
              agreement between the parties with respect to the subject matter
              of this Agreement and supersede all prior understandings (whether
              written, verbal or implied) with respect to such subject matter.
              THIS AGREEMENT AND ITS COLLATERAL SCHEDULES SHALL NOT BE CHANGED
              OR TERMINATED ORALLY OR BY COURSE OF CONDUCT, BUT ONLY BY A
              WRITING SIGNED BY BOTH PARTIES. Section headings contained in this
              Agreement have been included for convenience only, and shall not
              affect the construction or interpretation of this Agreement.

       (f)    This Agreement shall continue in full force and effect until all
              of the Indebtedness has been indefeasibly paid in full to Secured
              Party or its assignee. The surrender, upon payment or otherwise,
              of any Note or any of the other documents evidencing any of the
              Indebtedness shall not affect the right of Secured Party to retain
              the Collateral for such other Indebtedness as may then exist or as
              it may be reasonably contemplated will exist in the future. This
              Agreement shall automatically be reinstated if Secured Party is
              ever required to return or



              restore the payment of all or any portion of the Indebtedness (all
              as though such payment had never been made).

       (g)    THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES
              HEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN
              ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF CONNECTICUT
              (WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES OF SUCH STATE),
              INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE,
              REGARDLESS OF THE LOCATION OF THE EQUIPMENT.

IN WITNESS WHEREOF, Debtor and Secured Party, intending to be legally bound
hereby, have duly executed this Agreement in one or more counterparts, each of
which shall be deemed to be an original, as of the day and year first aforesaid.



SECURED PARTY:                         DEBTOR:

General Electric Capital Corporation   ARIAD Pharmaceuticals, Inc.

                                    
By: /s/ John Edel                      By: /s/ Brian A. Lajoie
    -------------------------------        --------------------------------------
    Name: John Edel                        Name: Brian A. Lajoie
    Title: SVP                             Title: Interim Chief Financial Officer

EX-10.51

                                                                   EXHIBIT 10.51


                               FINANCIAL COVENANTS
                                ADDENDUM NO. 001
                            TO MASTER LEASE AGREEMENT

                          DATED AS OF DECEMBER 27, 2001


THIS ADDENDUM (this "Addendum") amends and supplements the above referenced
agreement (the "Agreement"), between General Electric Capital Corporation
(together with its successors and assigns, if any, "Lender") and Ariad
Pharmaceuticals, Inc. (each of the aforementioned parties shall hereinafter be
collectively referred to as "Borrower") and is hereby incorporated into the
Agreement as though fully set forth therein. Capitalized terms not otherwise
defined herein shall have the meanings set forth in the Lease.

The Agreement is hereby amended by adding the following:

FINANCIAL COVENANTS.

(a)    Borrower shall, at all times during the term of the Agreement, comply
       with the following:

       Maintain minimum Unrestricted Cash (as defined below) in the amount of
       $10,000,000.00. If this covenant is violated, Borrower will provide
       Lender within ten (10) days of such occurrence, an irrevocable letter of
       credit as described in section (c) below.

       Unrestricted Cash shall be defined as cash on hand, including investments
       in marketable securities with maturities of less than twenty four (24)
       months, less cash pledged to other parties and any contingent liability
       associated with similar cash covenants under leases, loans or other
       financial arrangements.

(b)    COMPLIANCE REPORTS. Borrower's Authorized Representative shall certify
       that Borrower is in compliance with the requirements of subsection (a)
       above. Such notification and certification shall be provided within
       ninety (90) days after the end of each fiscal year, the "Compliance
       Date"), reflecting such information as of the end of such fiscal year. If
       Borrower fails timely to provide such notification and compliance
       certificates, within fifteen (15) days after the Compliance Date, such
       failure shall automatically be deemed a default under the Agreement
       without notice or other act by Lender. The reports required under this
       section are in addition to and not a substitute for the reports required
       under the REPORTS Section of the Agreement.

(c)    The irrevocable letter of credit provided pursuant to this addendum under
       a default of Financial Covenant shall be (i) in an amount equal to the
       total of all Borrower's then outstanding Indebtedness to Lender under
       this Agreement, (ii) issued by a bank which is acceptable to Lender in
       its sole discretion, (iii) in the form attached as Exhibit A or as may be
       acceptable to Lender in its sole discretion, and (iv) for an initial term
       of at least one (1) year with automatic renewals thereafter (without
       amendment except for extension of the then current expiration date by an
       additional year) until Borrower has received written notice from Lender
       to the effect that the letter of credit is being released in its
       entirety. Borrower shall also execute a Letter of Credit Agreement in the
       form attached as Exhibit B.

Except as expressly modified hereby, all terms and provisions of the Lease shall
remain in full force and effect. This Addendum is not binding nor effective with
respect to the Lease until executed on behalf of Lender and Borrower by
authorized representatives of Lender and Borrower.


IN WITNESS WHEREOF, Borrower and Lender have caused this Addendum to be executed
by their duly authorized representatives as of the date first above written.


LENDER:                               BORROWER:


GENERAL ELECTRIC CAPITAL CORPORATION  ARIAD PHARMACEUTICALS, INC.


By: /s/ John Edel                     By: /s/ Brian A. Lajoie
    ---------------------------           --------------------------------------
    Name: JOHN EDEL                       Name:  BRIAN A. LAJOIE
    Title: SVP                            Title: Interim Chief Financial Officer



                                      ATTEST

                                      By: /s/ Joseph Bratica
                                          --------------------------------------
                                          Name: Joseph Bratica

EX-10.52

                                                                   EXHIBIT 10.52


                                 PROMISSORY NOTE

                                  DEC. 28, 2001
                                     (Date)

FOR VALUE RECEIVED, Ariad Pharmaceuticals, Inc. a corporation located at the
address stated below ("Maker") promises, jointly and severally if more than one,
to pay to the order of General Electric Capital Corporation or any subsequent
holder hereof (each, a "Payee") at its office located at 401 Merritt 7 Suite 23,
Norwalk, CT 06856 or at such other place as Payee or the holder hereof may
designate, the principal sum of Seven Hundred Eighty-Nine Thousand Eight Hundred
Two - 93/100 Dollars ($789,802.93) with interest on the unpaid principal
balance, from the date hereof through and including the dates of payment, at a
fixed interest rate of Nine and 51/100 percent (9.51%) per annum, to be paid in
lawful money of the United States, in Thirty-six (36) consecutive monthly
installments of principal and interest as follows:

         Periodic
         Installment                                 Amount
         -----------                                 ------

         35 x $25.104.46

each ("Periodic Installment") and a final installment which shall be in the
amount of the total outstanding principal and interest. The first Periodic
Installment shall be due and payable on JAN. 1, 2002 and the following Periodic
Installments and the final installment shall be due and payable on the same day
of each succeeding month (each , a "Payment Date"). Such installments have been
calculated on the basis of a 360 day year of twelve 30-day months. Each payment
may, at the option of the Payee, be calculated and applied on an assumption that
such payment would be made on its due date.

The acceptance by Payee of any payment which is less than payment in full of all
amounts due and owing at such time shall not constitute a waiver of Payee's
right to receive payment in full at such time or at any prior or subsequent
time.

The Maker hereby expressly authorizes the Payee to insert the date value is
actually given in the blank space on the face hereof and on all related
documents pertaining hereto.

This Note may be secured by a security agreement, chattel mortgage, pledge
agreement or like instrument (each of which is hereinafter called a "Security
Agreement").

Time is of the essence hereof. If any installment or any other sum due under
this Note or any Security Agreement is not received within fifteen (15) days
after its due date, the Maker agrees to pay, in addition to the amount of each
such installment or other sum, a late payment charge of five percent (5%) of the
amount of said installment or other sum, but not exceeding any lawful maximum.
If (i) Maker fails to make payment of any amount due hereunder within fifteen
(15) days after the same becomes due and payable; or (ii) Maker is in default
under, or fails to perform under any term or condition contained in any Security
Agreement, then the entire principal sum remaining unpaid, together with all
accrued interest thereon and any other sum payable under this Note or any
Security Agreement, at the election of Payee, shall immediately become due and
payable, with interest thereon at the lesser of eighteen percent (18%) per annum
or the highest rate not prohibited by applicable law from the date of such
accelerated maturity until paid (both before and after any judgment).

The Maker may prepay in full, but not in part, its entire indebtedness hereunder
upon payment of the entire indebtedness plus an additional sum as a premium
equal to the following percentages of the original principal balance for the
indicated period:


Prior to the first annual anniversary date of this Note: Five percent (5%)
Thereafter and prior to the second annual anniversary date of this Note: Two
percent (2%)
Thereafter and prior to the third annual anniversary date of this Note: One
percent (1%) and zero percent (0%) thereafter, plus all other sums due
hereunder or under any Security Agreement.

It is the intention of the parties hereto to comply with the applicable usury
laws; accordingly, it is agreed that, notwithstanding any provision to the
contrary in this Note or any Security Agreement, in no event shall this Note or
any Security Agreement require the payment or permit the collection of interest
in excess of the maximum amount permitted by applicable law. If any such excess
interest is contracted for, charged or received under this Note or any Security
Agreement, or if all of the principal balance shall be prepaid, so that under
any of such circumstances the amount of interest contracted for, charged or
received under this Note or any Security Agreement on the principal balance
shall exceed the maximum amount of interest permitted by applicable law, then in
such event (a) the provisions of this paragraph shall govern and control, (b)
neither Maker nor any other person or entity now or hereafter liable for the
payment hereof shall be obligated to pay the amount of such interest to the
extent that it is in excess of the maximum amount of interest permitted by
applicable law, (c) any such excess which may have been collected shall be
either applied as a credit against the then unpaid principal balance or refunded
to Maker, at the option of the Payee, and (d) the effective rate of interest
shall be automatically reduced to the maximum lawful contract rate allowed under
applicable law as now or hereafter construed by the courts having jurisdiction
thereof. It is further agreed that without limitation of the foregoing, all
calculations of the rate of interest contracted for, charged or received under
this Note or any Security Agreement which are made for the purpose of
determining whether such rate exceeds the maximum lawful contract rate, shall be
made, to the extent permitted by applicable law, by amortizing, prorating,
allocating and spreading in equal parts during the period of the full stated
term of the indebtedness evidenced hereby, all interest at any time contracted
for, charged or received from Maker or otherwise by Payee in connection with
such indebtedness; provided, however, that if any applicable state law is
amended or the law of the United States of America preempts any applicable state
law, so that it becomes lawful for the Payee to receive a greater interest per
annum rate than is presently allowed, the Maker agrees that, on the effective
date of such amendment or preemption, as the case may be, the lawful maximum
hereunder shall be increased to the maximum interest per annum rate allowed by
the amended state law or the law of the United State of America.

The Maker and all sureties, endorsers, guarantors or any others (each such
person, other than the Maker, an "Obligor") who may at any time become liable
for the payment hereof jointly and severally consent hereby to any and all
extensions of time, renewals, waivers or modifications of, and all substitutions
or releases of, security or of any party primarily or secondarily liable on this
Note or any Security Agreement or any term and provision of either, which may be
made, granted or consented to by Payee, and agree that suit may be brought and
maintained against any one or more of them, at the election of Payee without
joinder of any other as a party thereto, and that Payee shall not be required
first to foreclose, proceed against, or exhaust any security hereof in order to
enforce payment of this Note. The Maker and each Obligor hereby waives
presentment, demand for payment, notice of nonpayment, protest, notice of
protest, notice of dishonor, and all other notices in connection herewith, as
well as filing of suit (if permitted by law) and diligence in collecting this
Note or enforcing any of the security hereof, and agrees to pay (if permitted by
law) all expenses incurred in collection, including Payee's actual attorneys'
fees. Maker and each Obligor agrees that fees not in excess of twenty percent
(20%) of the amount then due shall be deemed reasonable.

THE MAKER HEREBY UNCONDITIONALLY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM
OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF, DIRECTLY OR INDIRECTLY, THIS
NOTE, ANY OF THE RELATED DOCUMENTS, ANY DEALINGS BETWEEN MAKER AND PAYEE
RELATING TO THE SUBJECT MATER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS,
AND/OR THE RELATIONSHIP THAT IS BEING ESTABLISHED BETWEEN


MAKER AND PAYEE. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF
ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT (INCLUDING, WITHOUT
LIMITATION, CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER
COMMON LAW AND STATUTORY CLAIMS.) THIS WAIVER IS IRREVOCABLE MEANING THAT IT MAY
NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY
SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS NOTE, ANY
RELATED DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS
TRANSACTION OR ANY RELATED TRANSACTION. IN THE EVENT OF LITIGATION, THIS NOTE
MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

This Note and any Security Agreement constitute the entire agreement of the
Maker and Payee with respect to the subject matter hereof and supercedes all
prior understandings, agreements and representations, express or implied.

No variation or modification of this Note, or any waiver of any of its
provisions or conditions, shall be valid unless in writing and signed by an
authorized representative of Maker and Payee. Any such waiver, consent,
modification or change shall be effective only in the specific instance and for
the specific purpose given.

Any provision in this Note or any Security Agreement which is in conflict with
any statute, law or applicable rule shall be deemed omitted, modified or altered
to conform thereto.



                                           ARIAD PHARMACEUTICALS, INC.

/S/ JOSEPH BRATICA                         By: /s/ Brian A. Lajoie
- --------------------------------------         ---------------------------------
(Witness)                                      Name: Brian A. Lajoie
                                               Title: Interim Chief Financial
Joseph Bratica                                        Officer
- --------------------------------------
(Print name)
                                           Federal Tax ID#:
26 Landsdowne St., Cambridge, Ma 02139     Address: 26 Landsdowne St. Cambridge,
- --------------------------------------               Middlesex County, MA 02139
(Address)

EX-10.53

                                                                   EXHIBIT 10.53

                              REVISED AND RESTATED
                       RESEARCH AND DEVELOPMENT AGREEMENT

This Revised and Restated Research and Development Agreement (the "Agreement"),
dated as of March 15, 2002 ("Execution Date"), between ARIAD Pharmaceuticals,
Inc., a Delaware corporation ("Pharmaceuticals") and ARIAD Corporation, a
Delaware corporation ("Corporation") supersedes and supplants in its entirety
the Research and License Agreement between Pharmaceuticals and Corporation dated
June 23, 1992 ("Original Agreement").

WHEREAS, Pharmaceuticals has certain patent rights and technology and has
acquired licenses to certain other patent rights and technology, for the purpose
of allowing Pharmaceuticals to develop and commercialize certain Products;

WHEREAS, Corporation has personnel experienced in the research and development
of human health care products and has, or is expected to acquire, the
facilities, equipment and employees that will permit it to carry out research
and development activities for Pharmaceuticals, with respect to such rights and
technology; and

WHEREAS, Pharmaceuticals desires to engage Corporation to perform such services
and Corporation desires to provide such services.

NOW, THEREFORE, in consideration of the foregoing premises and for other good
and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, Corporation and Pharmaceuticals hereby agree as follows:

1.     Definitions.

       Definitions. As used herein, capitalized terms shall have the respective
       meanings set forth below:

       (a)    "Pharmaceuticals Technology" shall mean all information,
              developments, discoveries, inventions, improvements, know-how,
              processes, formulas, methods, trade secrets and other intellectual
              property, whether or not patentable, whether or not copyrightable,
              now owned or hereafter developed, acquired, reduced to practice or
              conceived by Pharmaceuticals, either alone or jointly with others,
              or licensed or sublicensed to Pharmaceuticals.

       (b)    "Confidential Information" has the meaning set forth in Section
              8.1 below.

       (c)    "Improvements" shall mean all information, developments,
              discoveries, inventions, improvements (including improvements to
              Pharmaceuticals Technology), know-how, processes, formulas,
              methods, trade secrets and other intellectual property, other than
              the Pharmaceuticals Technology, whether or not patentable, whether
              or not copyrightable, which are developed, acquired, reduced to
              practice or conceived by Corporation, either alone or jointly with
              others, in carrying out Research and Development under this
              Agreement.

       (d)    "Legal Order" has the meaning set forth in Section 8.3 below.

       (e)    "Product" shall mean any article, composition, apparatus,
              substance, chemical, material, method, process or service.

       (f)    "Programs" shall mean research and development programs set forth
              by Pharmaceuticals for Research and Development to be performed by
              Corporation.

       (g)    "Research and Development" shall mean research, development,
              pre-clinical and clinical testing, and related services and
              activities.

       1.1.   Singular and Plural. Singular and plural forms, as the case may
              be, of terms defined herein shall have correlative meanings.

2.     Research and Development

       2.1.   Research and Development Services. Pharmaceuticals hereby engages
              Corporation, and Corporation hereby agrees, to undertake Research
              and Development of the Pharmaceuticals Technology in accordance
              with each Program for the purpose of allowing Pharmaceuticals to
              develop, manufacture, use, sell and market one or more Products.
              During the term of this Agreement, Corporation shall use its best
              efforts to conduct the Research and Development for
              Pharmaceuticals with respect to each Program in a prudent and
              skillful manner in accordance with applicable laws, ordinances,
              rules, regulations, orders, licenses and other requirements now or
              hereafter in effect. Corporation shall obtain all labor,
              supervision, services, materials, supplies, tools, machinery and
              replacement parts thereof necessary to perform the Research and
              Development in accordance with each Program then in effect, which
              expenses shall be paid by Pharmaceuticals as described below. All
              such materials, supplies, tools, machinery and replacement parts
              thereof shall be used exclusively by Corporation to perform the
              Research and Development for Pharmaceuticals under each Program.

       2.2.   Reports and Records. Within sixty (60) days after the end of each
              calendar quarter during the term of this Agreement, Corporation
              shall provide to Pharmaceuticals a report setting forth the total
              Research and Development costs incurred during such quarter. All
              Research and Development and any other work performed under each
              Program should be duly recorded and evidenced in laboratory
              notebooks maintained by the persons working on the Program, in
              sufficient detail and in good scientific manner appropriate for
              patent and regulatory purposes. Upon the request of
              Pharmaceuticals, Corporation will provide to Pharmaceuticals a
              report setting forth (a) a summary of the work performed hereunder
              by Corporation and its employees and agents, and (b) a description
              of any material development with respect to the Programs.
              Pharmaceuticals shall also have the right, during normal business
              hours, to inspect and copy the records pertaining to the Programs
              kept by Corporation.

       2.3.   Rights to Property. As between Pharmaceuticals and Corporation,
              all right, title and interest in and to any Improvements acquired
              or developed pursuant to this Agreement, including all
              intellectual property rights therein, shall be the exclusive
              property of and are hereby assigned to Pharmaceuticals. This
              Section 2.3 shall survive the expiration or termination of this
              Agreement for any reason.

       2.4.   Exclusion from Assignment. Pharmaceuticals and Corporation
              acknowledge and agree the assignments set forth in Sections 2.3,
              5.3 and 7 shall not extend to, and do not include, any
              Improvements owned or controlled by third parties (alone or
              jointly) that Corporation does not have the right to assign; and
              to the extent any Improvements are owned or controlled by a third
              party and licensed to Corporation, Corporation hereby grants
              Pharmaceuticals a sublicense to such Improvements that is of the
              same scope and duration and includes all rights Corporation
              received under the license granted to Corporation by the third
              party, provided that Corporation has the right to sublicense its
              rights to Pharmaceuticals. This Section 2.4 shall survive the
              expiration or termination of this Agreement for any reason.


                                       2

3.     Payment for Services; Timing of Payments.

       3.1.   Payments. In consideration of the Research and Development
              activities to be carried out by Corporation during the term of
              this Agreement, Pharmaceuticals shall reimburse Corporation for
              all of its Research and Development costs, and Pharmaceuticals
              shall additionally pay Corporation a fee equal to ten (10%)
              percent of all such Research and Development costs (a "Cost-Plus
              Fee").

       3.2.   Timing of Payments. If requested by Corporation, Pharmaceuticals
              shall advance funds for all Research and Development costs in
              reasonable amounts. Within sixty (60) days after the end of each
              calendar quarter, Corporation shall deliver a statement to
              Pharmaceuticals of the Research and Development costs actually
              incurred in such calendar quarter and the Cost-Plus Fee thereon,
              and Pharmaceuticals shall pay to Corporation any additional
              amounts shown to be due therefor and not yet paid.

       3.3.   Calculation of Costs. Directs costs shall be allocated on a
              reasonable and consistent basis, and charged to Pharmaceuticals
              for Research, Development and other services performed by
              Corporation for Pharmaceuticals hereunder. Corporation's
              expenditures and estimated expenditures of conducting the Research
              and Development hereunder shall be determined using Corporation's
              internal financial and accounting systems. Allocation of all
              indirect costs, including general and administrative costs, will
              be made by Corporation on a reasonable basis consistent with
              Corporation's regular internal cost accounting system.

       3.4.   Competitive Costs. All costs to be paid by Pharmaceuticals
              hereunder shall be no greater than the cost to Pharmaceuticals
              would be if Pharmaceuticals obtained similar services, materials
              or other resources from a third party similarly situated to
              Corporation.

4.     Representatives, Warranties and Covenants.

       4.1.   Representations, Warranties and Covenants of the Corporation.
              Corporation represents, warrants and covenants to Pharmaceuticals
              as follows:

              (a)    Corporation is a corporation duly organized, validly
                     existing and in good standing under the laws of the State
                     of Delaware; has all corporate power required to own its
                     property and to carry on its business as now conducted and
                     proposed to be conducted; and is qualified to do business
                     in all jurisdictions in which such qualification is
                     necessary;

              (b)    The execution, delivery and performance of this Agreement
                     have been duly authorized by all necessary corporate action
                     on the part of Corporation;

              (c)    This Agreement has been duly executed and delivered by
                     Corporation and is a legal, valid and binding obligation of
                     Corporation, enforceable against Corporation in accordance
                     with its terms;

              (d)    The execution, delivery and performance of this Agreement
                     does not and will not conflict with or contravene any
                     provisions of the certificate of incorporation or by-laws
                     of Corporation or any agreement, document, instrument,
                     indenture, lien, judgment, order or other obligation of
                     Corporation; and

              (e)    Corporation shall not knowingly misappropriate or otherwise
                     misuse, nor shall it knowingly permit of its employees,
                     consultants or agents to misappropriate or

                                       3

                     otherwise misuse, any intellectual property of any third
                     party in performance of the Research and Development for a
                     Program.

       4.2.   Representation, Warranties and Covenants of Pharmaceuticals.
              Pharmaceuticals represents, warrants and covenants to Corporation
              as follows:

              (a)    Pharmaceuticals is a corporation duly organized, validly
                     existing and in good standing under the laws of the State
                     of Delaware; has all corporate power required to own its
                     property and to carry on its business as now conducted and
                     proposed to be conducted; and is qualified to do business
                     in all jurisdictions in which such qualification is
                     necessary;

              (b)    The execution, delivery and performance of this Agreement
                     have been duly authorized by all necessary corporate action
                     on the part of Pharmaceuticals;

              (c)    This Agreement has been duly executed and delivered by
                     Pharmaceuticals and is a legal, valid and binding
                     obligation of Pharmaceuticals, enforceable against
                     Pharmaceuticals in accordance with its terms; and

              (d)    The execution, delivery and performance of this Agreement
                     does not and will not conflict with or contravene any
                     provision of the certificate of incorporation or by-laws of
                     Pharmaceuticals or any agreement, document, instrument,
                     indenture, lien, judgment, order or other obligation of
                     Pharmaceuticals.

5.     Term and Termination.

       5.1.   Term. This Agreement shall be effective as of the Execution Date
              set forth on the first page of the Agreement and shall continue in
              full force and effect through December 31, 2010, unless earlier
              terminated in accordance with the terms and conditions set forth
              herein. The Agreement may be renewed upon the mutual agreement of
              the parties in their sole discretion.

       5.2.   Termination. Either party hereto may terminate this Agreement for
              any reason on sixty (60) days' written notice to the other party.

       5.3.   Prior Research and Development. Pharmaceuticals and Corporation
              acknowledge that certain research, development and other services
              were provided between the parties following the expiration of the
              Original Agreement on June 23, 1997. Therefore, the parties
              expressly agree that the terms and conditions of this Agreement
              shall apply to any such research, development or other services
              that were provided between the parties after June 23, 1992 and
              prior to the Execution Date of this Agreement (as well as to any
              Research and Development performed by the parties under this
              Agreement during its term). To the extent necessary to affect this
              intention of the parties, Corporation hereby assigns to
              Pharmaceuticals all of its right, title and interest in and to the
              Improvements existing prior to the Execution Date of this
              Agreement, and all intellectual property rights therein.
              Corporation shall cause any of its employees, consultants and
              agents to also assign any rights in the Improvements to
              Pharmaceuticals.

       5.4.   Effects of Expiration and Termination. Following expiration or
              termination of this Agreement, Corporation shall deliver to
              Pharmaceuticals all Confidential Information of Pharmaceuticals,
              including, without limitation, the laboratory notebooks and
              records of the


                                       4

              Research and Development kept by Corporation, and all copies
              thereof in Corporation's possession.

       5.5.   Survival. The following provisions shall survive any expiration or
              termination of this Agreement: 1, 2.2 (during period set forth
              therein only), 2.3, 2.4, 4, 5.3, 5.4, 5.5, 6, 7, 8, 9, 10, 11, 12,
              13 and any payment obligations due as of the effective date of
              such expiration or termination.

6.     Relationship of the Parties.

       Nothing contained in this Agreement is intended, or is to be construed,
       to constitute Corporation and Pharmaceuticals partners or joint venturers
       or Corporation as an employee of Pharmaceuticals. Neither party hereto
       shall have any express or implied right or authority to assume or create
       any obligations on behalf of or in the name of the other party or to bind
       the other party to any contract, agreement o undertaking with any third
       party.

7.     Further Assurance.

       Corporation and Pharmaceuticals each agree to duly execute and deliver,
       or cause to be duly executed and delivered, such further instruments and
       do and cause to be done such further acts and things, including, without
       limitation, the execution and filing of additional assignments,
       agreements, instruments and other documents that may be necessary, or as
       the other party hereto may at any time and from time to time reasonably
       request, in connection with this Agreement or to carry out more
       effectively the provisions and purposes of, or to better assure and
       confirm unto such other party its rights under this Agreement. Without
       limiting the foregoing, Corporation expressly agrees that each of its
       employees, consultants and agents performing work under a Program has
       entered, or promptly will enter, into a written agreement assigning all
       right, title and interest to Pharmaceuticals in any Improvements
       conceived or reduced to practice by such individual pursuant to any
       Program as necessary for Pharmaceuticals to exercise its rights
       hereunder.

8.     Confidential Information.

       8.1.   Confidential Information. As used herein, "Confidential
              Information" means all information that Pharmaceuticals discloses
              to Corporation under this Agreement, all Pharmaceuticals
              Technology and all other Information deemed "Confidential
              Information" under this Agreement, provided that Confidential
              Information shall not include any information excluded under
              Section 8.2. Except to the extent expressly authorized by this
              Agreement or otherwise agreed in writing by the Parties, the
              Corporation agrees that it shall keep confidential and shall not
              publish or otherwise disclose any Confidential Information to any
              third party, and shall not use such Information for any purpose
              other than as provided for in this Agreement.

       8.2.   Exceptions. Notwithstanding Section 8.1 above, "Confidential
              Information" shall not include any information that Corporation
              can demonstrate by competent written evidence in existence at the
              time of disclosure or development (as applicable):

              (a)    Was already known to Corporation other than under an
                     obligation of confidentiality, at the time of disclosure by
                     Pharmaceuticals or, in the case of Pharmaceuticals
                     Technology, prior to its creation or discovery hereunder;

              (b)    Was generally available to the pubic or otherwise part of
                     the public domain at the time of its disclosure to
                     Corporation by Pharmaceuticals;


                                       5

              (c)    Became generally available to the public or otherwise part
                     of the public domain after its disclosure and other than
                     through any act or omission of Corporation in breach of
                     this Agreement;

              (d)    Was disclosed to Corporation, other than under an
                     obligation of confidentiality to a third party, without
                     breach of any party's confidentiality obligation to
                     Pharmaceuticals; or

              (e)    Is independently developed by Corporation without using any
                     Confidential Information.

       8.3.   Permitted Disclosure. Notwithstanding the limitations in this
              Article 8, in the event that Corporation is required to disclose
              Confidential Information by any court of competent jurisdiction
              under any legal or regulatory statute, rule, order or regulation
              ("Legal Order"), Corporation shall provide Pharmaceuticals with
              immediate written notice of same so that Pharmaceuticals may have
              the opportunity to seek an appropriate protective order. If
              Pharmaceuticals does not obtain a protective order, Corporation
              shall disclose only such part of the Confidential Information as
              is specifically required by the Legal Order.

9.     Publicity.

       Neither Party shall use the name of the other Party in connection with
       any product, promotional literature, or advertising material without the
       prior written permission of the other party, which permission shall not
       be unreasonably withheld. This restriction shall not apply to materials
       used by Pharmaceuticals solely for financing or corporate partnering
       purposes or to documents available to the public that identify the
       existence of the Agreement.

10.    Successors and Assigns.

       The terms and provisions of this Agreement shall insure to the benefit
       of, and be binding upon, Corporation, Pharmaceuticals, and their
       respective successors and assigns.

11.    Governing Law.

       This Agreement shall be governed by and construed in accordance with the
       laws of the Commonwealth of Massachusetts, without regard to conflict of
       laws principles.

12.    Execution in Counterparts.

       This Agreement may be executed in any number of counterparts, each of
       which counterparts, when so executed and delivered, shall be deemed to be
       original, and all of which counterparts, taken together, shall constitute
       one and the same instrument.


                                       6

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed under seal and delivered as of the date first above written.

                                       ARIAD PHARMACEUTICALS, INC.,
                                       A DELAWARE CORPORATION


                                       By:/s/ Harvey J. Berger
                                          --------------------
                                          Harvey J. Berger
                                          Chairman and Chief Executive Officer



                                       ARIAD CORPORATION, A DELAWARE CORPORATION

                                       By:/s/ Laurie A. Allen
                                          -------------------
                                          Laurie A. Allen
                                          Senior Vice President
                                          Chief Legal Officer


                                       7

EX-10.54

                                                                   EXHIBIT 10.54


                              REVISED AND RESTATED
                       RESEARCH AND DEVELOPMENT AGREEMENT


This Revised and Restated Research and Development Agreement (the "Agreement"),
dated as of March 15, 2002 ("Execution Date"), between ARIAD Gene Therapeutics,
Inc., a Delaware corporation ("AGTI") and ARIAD Corporation, a Delaware
corporation ("Corporation") supersedes and supplants in its entirety the
Research and License Agreement between AGTI and Corporation dated July 1, 1994
("Original Agreement").

WHEREAS, AGTI has certain patent rights and technology and has acquired licenses
to certain other patent rights and technology, for the purpose of allowing AGTI
to develop and commercialize certain Products;

WHEREAS, Corporation has personnel experienced in the research and development
of human health care products and has, or is expected to acquire, the
facilities, equipment and employees that will permit it to carry out research
and development activities for AGTI, with respect to such rights and technology;
and

WHEREAS, AGTI desires to engage Corporation to perform such services and
Corporation desires to provide such services.

NOW, THEREFORE, in consideration of the foregoing premises and for other good
and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, Corporation and AGTI hereby agree as follows:

1.     Definitions.

       1.1    Definitions. As used herein, capitalized terms shall have the
              respective meanings set forth below:

              (a)    "AGTI Technology" shall mean all information, developments,
                     discoveries, inventions, improvements, know-how, processes,
                     formulas, methods, trade secrets and other intellectual
                     property, whether or not patentable, whether or not
                     copyrightable, now owned or hereafter developed, acquired,
                     reduced to practice or conceived by AGTI, either alone or
                     jointly with others, or licensed or sublicensed to AGTI.

              (b)    "Confidential Information" has the meaning set forth in
                     Section 8.1 below.

              (c)    "Improvements" shall mean all information, developments,
                     discoveries, inventions, improvements (including
                     improvements to AGTI Technology), know-how, processes,
                     formulas, methods, trade secrets and other intellectual
                     property, other than the AGTI Technology, whether or not
                     patentable, whether or not copyrightable, which are
                     developed, acquired, reduced to practice or conceived by
                     Corporation, either alone or jointly with others, in
                     carrying out Research and Development under this Agreement.

              (d)    "Legal Order" has the meaning set forth in Section 8.3
                     below.

              (e)    "Product" shall mean any article, composition, apparatus,
                     substance, chemical, material, method, process or service.

              (f)    "Programs" shall mean research and development programs set
                     forth by AGTI for Research and Development to be performed
                     by Corporation.

              (g)    "Research and Development" shall mean research,
                     development, clinical testing and related services and
                     activities.

       1.1.   Singular and Plural. Singular and plural forms, as the case may
              be, of terms defined herein shall have correlative meanings.

2.     Research and Development.

       2.1.   Research and Development Services. AGTI hereby engages
              Corporation, and Corporation hereby agrees, to undertake Research
              and Development of the AGTI Technology in accordance with each
              Program for the purpose of allowing AGTI to develop, manufacture,
              use, sell and market one or more Products. During the term of this
              Agreement, Corporation shall use its best efforts to conduct the
              Research and Development for AGTI with respect to each Program in
              a prudent and skillful manner in accordance with applicable laws,
              ordinances, rules, regulations, orders, licenses and other
              requirements now or hereafter in effect. Corporation shall obtain
              all labor, supervision, services, materials, supplies, tools,
              machinery and replacement parts thereof necessary to perform the
              Research and Development in accordance with each Program then in
              effect, which expenses shall be paid by AGTI as described below.
              All such materials, supplies, tools, machinery and replacement
              parts thereof shall be used exclusively by Corporation to perform
              the Research and Development for AGTI under each Program.

       2.2.   Reports and Records. Within sixty (60) days after the end of each
              calendar quarter during the term of this Agreement, Corporation
              shall provide to AGTI a report setting forth the total Research
              and Development costs incurred during such quarter. All Research
              and Development and any other work performed under each Program
              should be duly recorded and evidenced in laboratory notebooks
              maintained by the persons working on the Program, in sufficient
              detail and in good scientific manner appropriate for patent and
              regulatory purposes. Upon the request of AGTI, Corporation will
              provide to AGTI a report setting forth (a) a summary of the work
              performed hereunder by Corporation and its employees and agents,
              and (b) a description of any material development with respect to
              the Programs. AGTI shall also have the right, during normal
              business hours, to inspect and copy the records pertaining to the
              Programs kept by Corporation.

       2.3.   Rights to Property. As between AGTI and Corporation, all right,
              title and interest in and to any Improvements acquired or
              developed pursuant to this Agreement, including all intellectual
              property rights therein, shall be the exclusive property of and
              are hereby assigned to AGTI. This Section 2.3 shall survive the
              expiration or termination of this Agreement for any reason.

       2.4.   Exclusion from Assignment. AGTI and Corporation acknowledge and
              agree the assignments set forth in Sections 2.3, 5.3 and 7 shall
              not extend to, and do not include, any Improvements owned or
              controlled by third parties (alone or jointly) that Corporation
              does not have the right to assign; and to the extent any
              Improvements are owned or controlled by a third party and licensed
              to Corporation, Corporation hereby grants AGTI a sublicense to
              such Improvements that is of the same scope and duration and
              includes all rights Corporation received under the license granted
              to Corporation by the third party, provided that Corporation has
              the right to sublicense its rights to AGTI. This Section 2.4 shall
              survive the expiration or termination of this Agreement for any
              reason.


                                       2

3.     Payment for Services; Timing of Payments.

       3.1.   Payments. In consideration of the Research and Development
              activities to be carried out by Corporation during the term of
              this Agreement, AGTI shall reimburse Corporation for all of its
              Research and Development costs, and AGTI shall additionally pay
              Corporation a fee equal to ten (10%) percent of all such Research
              and Development costs (a "Cost-Plus Fee").

       3.2.   Timing of Payments. If requested by Corporation, AGTI shall
              advance funds for all Research and Development costs in reasonable
              amounts. Within sixty (60) days after the end of each calendar
              quarter, Corporation shall deliver a statement to AGTI of the
              Research and Development costs actually incurred in such calendar
              quarter and the Cost-Plus Fee thereon, and AGTI shall pay to
              Corporation any additional amounts shown to be due therefor and
              not yet paid.

       3.3.   Calculation of Costs. Directs costs shall be allocated on a
              reasonable and consistent basis, and charged to AGTI for Research,
              Development and other services performed by Corporation for AGTI
              hereunder. Corporation's expenditures and estimated expenditures
              of conducting the Research and Development hereunder shall be
              determined using Corporation's internal financial and accounting
              systems. Allocation of all indirect costs, including general and
              administrative costs, will be made by Corporation on a reasonable
              basis consistent with Corporation's regular internal cost
              accounting system.

       3.4.   Competitive Costs. All costs to be paid by AGTI hereunder shall be
              no greater than the cost to AGTI would be if AGTI obtained similar
              services, materials or other resources from a third party
              similarly situated to Corporation.

4.     Representatives, Warranties and Covenants.

       4.1.   Representations, Warranties and Covenants of the Corporation.
              Corporation represents, warrants and covenants to AGTI as follows:

              (a)    Corporation is a corporation duly organized, validly
                     existing and in good standing under the laws of the State
                     of Delaware; has all corporate power required to own its
                     property and to carry on its business as now conducted and
                     proposed to be conducted; and is qualified to do business
                     in all jurisdictions in which such qualification is
                     necessary;

              (b)    The execution, delivery and performance of this Agreement
                     have been duly authorized by all necessary corporate action
                     on the part of Corporation;

              (c)    This Agreement has been duly executed and delivered by
                     Corporation and is a legal, valid and binding obligation of
                     Corporation, enforceable against Corporation in accordance
                     with its terms;

              (d)    The execution, delivery and performance of this Agreement
                     does not and will not conflict with or contravene any
                     provisions of the certificate of incorporation or by-laws
                     of Corporation or any agreement, document, instrument,
                     indenture, lien, judgment, order or other obligation of
                     Corporation; and

              (e)    Corporation shall not knowingly misappropriate or otherwise
                     misuse, nor shall it knowingly permit of its employees,
                     consultants or agents to misappropriate or



                                       3

                     otherwise misuse, any intellectual property of any third
                     party in performance of the Research and Development for a
                     Program.

       4.2.   Representation, Warranties and Covenants of AGTI. AGTI represents,
              warrants and covenants to Corporation as follows:

              (a)    AGTI is a corporation duly organized, validly existing and
                     in good standing under the laws of the State of Delaware;
                     has all corporate power required to own its property and to
                     carry on its business as now conducted and proposed to be
                     conducted; and is qualified to do business in all
                     jurisdictions in which such qualification is necessary;

              (b)    The execution, delivery and performance of this Agreement
                     have been duly authorized by all necessary corporate action
                     on the part of AGTI;

              (c)    This Agreement has been duly executed and delivered by AGTI
                     and is a legal, valid and binding obligation of AGTI,
                     enforceable against AGTI in accordance with its terms; and

              (d)    The execution, delivery and performance of this Agreement
                     does not and will not conflict with or contravene any
                     provision of the certificate of incorporation or by-laws of
                     AGTI or any agreement, document, instrument, indenture,
                     lien, judgment, order or other obligation of AGTI.

5.     Term and Termination.

       5.1.   Term. This Agreement shall be effective as of the Execution Date
              set forth on the first page of the Agreement and shall continue in
              full force and effect through December 31, 2010, unless earlier
              terminated in accordance with the terms and conditions set forth
              herein. The Agreement may be renewed upon the mutual agreement of
              the parties in their sole discretion.

       5.2.   Termination. Either party hereto may terminate this Agreement for
              any reason on sixty (60) days' written notice to the other party.

       5.3.   Prior Research and Development. AGTI and Corporation acknowledge
              that certain research, development and other services were
              provided between the parties following the expiration of the
              Original Agreement on July 1, 1999. Therefore, the parties
              expressly agree that the terms and conditions of this Agreement
              shall apply to any such research, development or other services
              that were provided between the parties after July 1, 1994 and
              prior to the Execution Date of this Agreement (as well as to any
              Research and Development performed by the parties under this
              Agreement during its term). To the extent necessary to affect this
              intention of the parties, Corporation hereby assigns to AGTI all
              of its right, title and interest in and to the Improvements
              existing prior to the Execution Date of this Agreement, and all
              intellectual property rights therein. Corporation shall cause any
              of its employees, consultants and agents to also assign any rights
              in the Improvements to AGTI.

       5.4.   Effects of Expiration and Termination. Following expiration or
              termination of this Agreement, Corporation shall deliver to AGTI
              all Confidential Information of AGTI, including, without
              limitation, the laboratory notebooks and records of the Research
              and Development kept by Corporation, and all copies thereof in
              Corporation's possession.


                                       4

       5.5.   Survival. The following provisions shall survive any expiration or
              termination of this Agreement: 1, 2.2 (during period set
              forth therein only), 2.3, 2.4, 4, 5.3, 5.4, 5.5, 6, 7, 8, 9, 10,
              11, 12, 13 and any payment obligations due as of the effective
              date of such expiration or termination.

6.     Relationship of the Parties.

       Nothing contained in this Agreement is intended, or is to be construed,
       to constitute Corporation and AGTI partners or joint venturers or
       Corporation as an employee of AGTI. Neither party hereto shall have any
       express or implied right or authority to assume or create any obligations
       on behalf of or in the name of the other party or to bind the other party
       to any contract, agreement or undertaking with any third party.

7.     Further Assurance.

       Corporation and AGTI each agree to duly execute and deliver, or cause to
       be duly executed and delivered, such further instruments and do and cause
       to be done such further acts and things, including, without limitation,
       the execution and filing of additional assignments, agreements,
       instruments and other documents that may be necessary, or as the other
       party hereto may at any time and from time to time reasonably request, in
       connection with this Agreement or to carry out more effectively the
       provisions and purposes of, or to better assure and confirm unto such
       other party its rights under this Agreement. Without limiting the
       foregoing, Corporation expressly agrees that each of its employees,
       consultants and agents performing work under a Program has entered, or
       promptly will enter, into a written agreement assigning all right, title
       and interest to AGTI in any Improvements conceived or reduced to practice
       by such individual pursuant to any Program as necessary for AGTI to
       exercise its rights hereunder.

8.     Confidential Information.

       8.1.   Confidential Information. As used herein, "Confidential
              Information" means all information that AGTI discloses to
              Corporation under this Agreement, all AGTI Technology and all
              other Information deemed "Confidential Information" under this
              Agreement, provided that Confidential Information shall not
              include any information excluded under Section 8.2. Except to the
              extent expressly authorized by this Agreement or otherwise agreed
              in writing by the Parties, the Corporation agrees that it shall
              keep confidential and shall not publish or otherwise disclose any
              Confidential Information to any third party, and shall not use
              such Information for any purpose other than as provided for in
              this Agreement.

       8.2.   Exceptions. Notwithstanding Section 8.1 above, "Confidential
              Information" shall not include any information that Corporation
              can demonstrate by competent written evidence in existence at the
              time of disclosure or development (as applicable):

              (a)    Was already known to Corporation other than under an
                     obligation of confidentiality, at the time of disclosure by
                     AGTI or, in the case of AGTI Technology, prior to its
                     creation or discovery hereunder;

              (b)    Was generally available to the public or otherwise part of
                     the public domain at the time of its disclosure to
                     Corporation by AGTI;

              (c)    Became generally available to the public or otherwise part
                     of the public domain after its disclosure and other than
                     through any act or omission of Corporation in breach of
                     this Agreement;


                                       5

              (d)    Was disclosed to Corporation, other than under an
                     obligation of confidentiality to a third party, without
                     breach of any party's confidentiality obligation to AGTI;
                     or

              (e)    Is independently developed by Corporation without using any
                     Confidential Information.

       8.3.   Permitted Disclosure. Notwithstanding the limitations in this
              Article 8, in the event that Corporation is required to disclose
              Confidential Information by any court of competent jurisdiction
              under any legal or regulatory statute, rule, order or regulation
              ("Legal Order"), Corporation shall provide AGTI with immediate
              written notice of same so that AGTI may have the opportunity to
              seek an appropriate protective order. If AGTI does not obtain a
              protective order, Corporation shall disclose only such part of the
              Confidential Information as is specifically required by the Legal
              Order.

9.     Publicity.

       Neither Party shall use the name of the other Party in connection with
       any product, promotional literature, or advertising material without the
       prior written permission of the other party, which permission shall not
       be unreasonably withheld. This restriction shall not apply to materials
       used by AGTI solely for financing or corporate partnering purposes or to
       documents available to the public that identify the existence of the
       Agreement.

10.    Successors and Assigns.

       The terms and provisions of this Agreement shall insure to the benefit
       of, and be binding upon, Corporation, AGTI, and their respective
       successors and assigns.

11.    Governing Law.

       This Agreement shall be governed by and construed in accordance with the
       laws of the Commonwealth of Massachusetts, without regard to conflicts of
       laws principles.

12.    Execution in Counterparts.

       This Agreement may be executed in any number of counterparts, each of
       which counterparts, when so executed and delivered, shall be deemed to be
       original, and all of which counterparts, taken together, shall constitute
       one and the same instrument.


                                       6

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed under seal and delivered as of the date first above written.



                                       ARIAD GENE THERAPEUTICS, INC.,
                                       A DELAWARE CORPORTION

                                       By: /s/ Harvey J. Berger
                                       ------------------------
                                           Harvey J. Berger
                                           Chairman and Chief Executive Officer



                                       ARIAD CORPORATION, A DELAWARE CORPORTION

                                       By: /s/ Laurie A. Allen
                                       -----------------------
                                           Laurie A. Allen
                                           Senior Vice President
                                           Chief Legal Officer


                                       7

EX-10.55

                                                                   EXHIBIT 10.55
                              CONSULTING AGREEMENT

THIS CONSULTING AGREEMENT (the "Agreement") is made as of October 5, 2001 (the
"Effective Date") by and between ARIAD Pharmaceuticals, Inc., a Delaware
corporation (the "Company"), and Brian A. Lajoie (the "Consultant").

                                WITNESSETH THAT:

WHEREAS, the Company is engaged in the business of discovering, developing and
commercializing pharmaceutical products;

WHEREAS, the Consultant previously served as a financial executive officer of a
company in the biotechnology industry and is familiar with the business in which
the Company is engaged and otherwise has experience and expertise which is
useful to the Company; and

WHEREAS, the Company wishes to retain the Consultant, and the Consultant is
willing to be retained by the Company to provide the Company with consulting
services in the financial operation of its business, subject to the terms and
conditions and for the consideration hereinafter set forth.

NOW THEREFORE, the Company and the Consultant hereby agree as follows:

1.     Consulting Term; Termination

       1.1    The term of this Agreement shall commence on the Effective Date
              and shall end on April 30, 2002 (the "Initial Term"); provided,
              that the Term (as defined below) shall be automatically renewed
              for successive 30-day terms (the Initial Term and, if the
              consulting period is so renewed, such additional consulting
              period(s) are collectively referred to herein as the "Term"),
              unless either the Company or the Consultant terminates this
              Agreement earlier pursuant to the terms of Section 1.2 hereof or
              either the Company or the Consultant commits a material breach of
              the terms of this Agreement.

       1.2    Notwithstanding the provisions of Section 1.1 hereof, the Company
              or the Consultant may terminate this Agreement, with or without
              cause in its sole discretion, prior to the end of the Initial Term
              or any subsequent applicable Term by providing not less than
              fifteen (15) days prior written notice to the other party.

2.     Consulting Services

       2.1    The Company hereby engages the Consultant to provide consulting
              services related to financial matters of the Company generally as
              directed by the Chief Executive Officer of the Company, unless
              otherwise agreed to by the Company and the Consultant. The
              specific services to be performed by the Consultant, number of
              hours required to perform such services, and schedule of
              performance shall be agreed from time to time by the Company and
              the Consultant based on the needs of the Company and the
              reasonable availability of the Consultant.

       2.2    In addition to the services described in Section 2.1 hereof, the
              Consultant agrees to be elected as the Interim Chief Financial
              Officer of the Company and to assist the Chief Executive Officer,
              the Controller and other members of Company's management in
              managing the financial affairs of the Company.

       2.3    The Consultant hereby accepts such engagement as a consultant to
              the Company and agrees to use his best efforts to render the
              services described above.

       2.4    The Consultant shall perform the services for the Company
              contemplated by this Agreement principally at the Company's
              corporate offices located at 26 Landsdowne Street, Cambridge,
              Massachusetts.

3.     Compensation. In consideration for the performance of the services to be
       rendered by the Consultant to the Company pursuant to Section 2.1 hereof,
       the Company shall compensate the Consultant at a rate of One Thousand Six
       Hundred Dollars ($1,600.00) per day, payable on a bi-weekly basis
       promptly after receipt of an invoice detailing such days, or portions
       thereof, served; provided, however, that the aggregate compensation paid
       to the Consultant by the Company in any one (1) month period shall not
       exceed the total sum of Twenty Four Thousand Dollars ($24,000.00). The
       Company and the Consultant agree that the Company shall not withhold any
       amounts on account of any withholding or employment taxes from any
       payments to the Consultant under this section and that it shall be the
       sole responsibility of the Consultant to report and pay all applicable
       income or other taxes on all such payments made to him.

4.     Expenses

       The Company shall pay or reimburse the Consultant for all reasonable
       travel and other expenses (excluding commuting expenses) incurred by the
       Consultant in the course of performing the consulting services requested
       by the Company and performed by the Consultant hereunder, upon
       presentation of appropriate documentation substantiating such expenses in
       accordance with the usual policies and procedures of the Company. The
       Company will provide the consultant with parking at no expense.

5.     No Employment Relationship

       Nothing in this Agreement shall create or shall be deemed to create any
       contract or relationship of employment between the Company and the
       Consultant or render or be construed to render the Consultant an employee
       of the Company or to provide the Consultant with any rights or benefits,
       including, but not limited to health insurance, dental care insurance,
       life insurance, long-term disability insurance, accidental death and
       dismemberment insurance, deferred compensation awards, performance
       bonuses or 401(k) plan participation benefits, to which any employee of
       the Company or any of its Affiliates may be entitled.

6.     Confidentiality

       6.1    The Consultant acknowledges and agrees that during the course of
              performing services for the Company, the Company will furnish,
              disclose or make available to the Consultant confidential and
              proprietary information relating to the Company's business,
              including, but not limited to, inventions, projects and business
              plans (collectively, "Confidential Information"). The Consultant
              further acknowledges and agrees that such Confidential Information
              has been developed and will be developed by the Company through
              the expenditure by the Company of substantial time, effort and
              money, that the Company's business is extremely competitive, that
              the Company's business is dependent in part upon the maintenance
              of secrecy, and that any disclosure of the Confidential
              Information would result in serious harm to the Company.

       6.2    The Consultant agrees that the Confidential Information shall only
              be used by the Consultant in connection with his activities
              hereunder as a consultant to the Company and shall not be used in
              any way that is detrimental to the Company.


                                       2

       6.3    The Consultant agrees not to disclose, directly or indirectly, the
              Confidential Information to any third person or entity, other than
              representatives or agents of the Company. The Consultant shall
              treat all such information as confidential and proprietary
              property of the Company.

       6.4    The term "Confidential Information" does not include information
              that (a) is or becomes generally available to the public other
              than by disclosure in violation of this Agreement, (b) was within
              the Consultant's possession prior to being furnished to such
              Consultant, (c) becomes available to the Consultant on a
              non-confidential basis or (d) was independently developed by the
              Consultant without reference to the information provided by the
              Company.

       6.5    The Consultant may disclose any Confidential Information that is
              required to be disclosed by law, government regulation or court
              order. If disclosure is required, the Consultant shall give the
              Company advance notice so that the Company may seek a protective
              order or take other action reasonable in light of the
              circumstances.

       6.6.   Upon termination of this Agreement, the Consultant shall promptly
              return to the Company all materials containing Confidential
              Information, as well as data, records, reports and other property
              furnished by the Company to the Consultant or produced by the
              Consultant in connection with services rendered hereunder.
              Notwithstanding such return or any of the provisions of this
              Agreement, the Consultant shall continue to be bound by the terms
              of the confidentiality provisions contained in this Section 6 for
              a period of five (5) years after the termination of this
              Agreement.

       6.7    The Consultant acknowledges receipt of a copy of the Company's
              policies regarding trading in the Company's securities and agrees
              to comply with such policies, as well as other SEC regulations
              regarding insider trading and disclosure of material non-public
              information.

7.     Non-Competition and Non-Solicitation. During the Term and for a period of
       six (6) months following the expiration or termination of this Agreement:
       (a) the Consultant shall not in the United States or in any country in
       which the Company shall then be doing business, directly or indirectly,
       enter the employ of, or render any services to, any person, firm or
       corporation engaged in any business competitive with the business of the
       Company or of any of its subsidiaries or affiliates; he shall not engage
       in such business on his own account; and he shall not become interested
       in any such business, directly or indirectly, as an individual, partner,
       shareholder, director, officer, principal, agent, employee, trustee,
       consultant, or any other relationship or capacity; provided, however,
       that nothing contained in this Section 7 shall be deemed to prohibit the
       Consultant from acquiring, solely as an investment, shares of capital
       stock of any public corporation; (b) neither the Consultant nor any
       Affiliate of the Consultant shall solicit or utilize, or assist any
       person in any way to solicit or utilize, the services, directly or
       indirectly, of any of the Company's directors, consultants, members of
       the Board of Scientific and Medical Advisors, officers or employees
       (collectively, "Associates of the Company"). This non-solicitation and
       non-utilization provision shall not apply to Associates of the Company
       who have previously terminated their relationship with the Company.

       7.1    If the Consultant commits a breach, or threatens to commit a
              breach, of any of the provisions of this Section 7, the Company
              shall have the following rights and remedies:

              7.1.1  The right and remedy to have the provisions of this
                     Agreement specifically enforced by any court having equity
                     jurisdiction, it being acknowledged and agreed that any
                     such breach or threatened breach shall cause irreparable
                     injury to the Company and that money damages shall not
                     provide an adequate remedy to the Company.

                                       3

              7.1.2  The right and remedy to require the Consultant to account
                     for and pay over to the Company all compensation, profits,
                     monies, accruals, increments or other benefits
                     (collectively "Benefits") derived or received by the
                     Consultant as the result of any transactions constituting a
                     breach of any of the provisions of the preceding paragraph,
                     and the Consultant hereby agrees to account for and pay
                     over such Benefits to the Company. Each of the rights and
                     remedies enumerated above shall be independent of the
                     other, and shall be severally enforceable, and all of such
                     rights and remedies shall be in addition to, and not in
                     lieu of, any other rights and remedies available to the
                     Company under law or in equity.

       7.2.   If any of the covenants contained in Section 6 or 7, or any part
              thereof, is hereafter construed to be invalid or unenforceable,
              the same shall not affect the remainder of the covenant or
              covenants, which shall be given full effect without regard to the
              invalid portions.

       7.3    If any of the covenants contained in Section 6 or 7, or any part
              thereof, is held to be unenforceable because of the duration of
              such provision or the area covered thereby, the parties agree that
              the court making such determination shall have the power to reduce
              the duration and/or area of such provision and, in its reduced
              form, such provision shall then be enforceable.

       7.4    The parties hereto intend to and hereby confer jurisdiction to
              enforce the covenants contained in Sections 6 and 7 upon the
              courts of any state within the geographical scope of such
              covenants. In the event that the courts of any one or more of such
              states shall hold any such covenant wholly unenforceable by reason
              of the breadth of such scope or otherwise, it is the intention of
              the parties hereto that such determination not bar or in any way
              affect the Company's right to the relief provided above in the
              courts of any other states within the geographical scope of such
              covenants, as to breaches of such covenants in such other
              respective jurisdictions, the above covenants as they relate to
              each state being, for this purpose, severable into diverse and
              independent covenants.

       7.5    The Company and the Consultant hereby acknowledge and agree that
              the Company may waive, on a case-by-case basis, the terms and
              covenants of this Section 7 upon the request of the Consultant in
              accordance with the provisions of Section 10.4 hereof, which such
              waiver shall not be unreasonably withheld.

8.     Indemnification

              The Company shall indemnify the Consultant, to the maximum extent
       permitted by applicable law, against all costs, charges and expenses
       incurred or sustained by him in connection with, and to hold him harmless
       from, any action, suit or proceeding by a third party to which he may be
       made a party by reason of his being a consultant of the Company or of any
       Subsidiary or Affiliate of the Company, or arising from his performance
       of services under this Agreement.

9.     Notices

       All notices, requests, consents and other communications required or
       permitted to be given hereunder shall be in writing and shall be deemed
       to have been duly given if sent by private overnight mail service
       (delivery confirmed by such service), registered or certified mail
       (return receipt requested), or delivered personally, as follows (or to
       such other address as either party shall designate by notice in writing
       to the other in accordance herewith):


                                       4

If to the Company:

       ARIAD Pharmaceuticals, Inc.
       26 Landsdowne Street
       Cambridge, Massachusetts 02139
       Attention: Harvey J. Berger, M.D.
       Chief Executive Officer
       Telephone:          (617) 494-0400
       Fax:                (617) 494-1828


If to the Consultant:

       Brian A. Lajoie
       6 Crestview Drive
       Millis, MA  02054
       (508) 376-5948

10.    General

       10.1   This Agreement shall be governed by and construed and enforced in
              accordance with the laws of the Commonwealth of Massachusetts
              applicable to agreements made and to be performed entirely in
              Massachusetts.

       10.2   The Section headings contained herein are for reference purposes
              only and shall not in any way affect the meaning or interpretation
              of this Agreement.

       10.3   This Agreement and the Consultant's rights and obligations
              hereunder may not be assigned by the Consultant or the Company;
              provided, however, the Company may assign this Agreement and its
              rights and obligations hereunder to a successor-in-interest.

       10.4   This Agreement may be amended, modified, superseded, canceled,
              renewed or extended, and the terms or covenants hereof may be
              waived, only by a written instrument executed by the parties
              hereto, or in the case of a waiver, by the party waiving
              compliance. The failure of a party at any time or times to require
              performance of any provision hereof shall in no manner affect the
              right at a later time to enforce the same. No waiver by a party of
              the breach of any term or covenant contained in this Agreement,
              whether by conduct or otherwise, in any one or more instances,
              shall be deemed to be, or construed as, a further or continuing
              waiver of any such breach, or a waiver of the breach of any other
              term or covenant contained in this Agreement.

       10.5   This Agreement may be executed in one or more counterparts, and by
              different parties hereto on separate counterparts, each of which
              shall be deemed an original, but all of which together shall
              constitute one and the same instrument.

11.    Definitions

       As used herein the following terms have the following meaning:

       (a)    "Affiliate" means and includes any corporation or other business
              entity controlling, controlled by or under common control with the
              corporation in question.


                                       5

       (b)    "person" means any natural person, corporation, partnership, firm,
              joint venture, association, joint stock company, trust,
              unincorporated organization, governmental body or other entity.

       (c)    "Subsidiary" means any corporation or other business entity
              directly or indirectly controlled by the corporation in question.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]



                                       6

IN WITNESS WHEREOF, the Company and the Consultant have executed this Agreement
as of the date first above written.

ARIAD PHARMACEUTICALS, INC.

By: /s/ Harvey J. Berger
    --------------------
Name: Harvey J. Berger, M.D.
Title: Chairman and Chief Executive Officer


CONSULTANT


/s/ Brian A. Lajoie
- -------------------
Brian A. Lajoie


                                       7

EX-10.56

                                                                   EXHIBIT 10.56

                       2002 EXECUTIVE EMPLOYMENT AGREEMENT

2002 EMPLOYMENT AGREEMENT (the "Agreement") made as of March 4, 2002 by and
between ARIAD Pharmaceuticals, Inc. (the "Company") a Delaware corporation, and
Laurie A. Allen, Esq. (the "Employee").

1.     EMPLOYMENT, DUTIES AND ACCEPTANCE.

       1.1    The Company hereby employs the Employee, for the Term (as
              hereinafter defined), to render full-time services to the Company,
              and to perform such duties as she shall reasonably be directed by
              the Chief Executive Officer of the Company to perform. The
              Employee's title shall be designated by the Chief Executive
              Officer and initially shall be Senior Vice President, Chief Legal
              Officer, and Secretary.

       1.2    The Employee hereby accepts such employment and agrees to render
              the services described above.

       1.3    The principal place of employment of the Employee hereunder shall
              be in the greater Boston, Massachusetts area, or other locations
              reasonably acceptable to the Employee. The Employee acknowledges
              that for limited periods of time she may be

       1.4    Notwithstanding anything to the contrary herein, although the
              Employee shall provide services as a full-time employee, it is
              understood that the Employee may (a) have an academic appointment,
              (b) participate in professional activities, and c) provide limited
              consulting services from time to time to Alexandria Real Estate
              Equities, Inc. ("Alexandria"), including attendance at its Board
              of Director meetings (collectively, "Permitted Activities'),;
              PROVIDED, HOWEVER, that such Permitted Activities do not interfere
              with the Employee's duties to the Company and that the consulting
              services to Alexandria be agreed upon by the Company in advance.

2.     TERM OF EMPLOYMENT.

       The term of the Employee's employment under this Agreement (the "Term")
       shall commence on March 4, 2002 or such other date as agreed upon by the
       parties (the "Effective Date") and shall end on December 31, 2004 unless
       sooner terminated pursuant to Section 4 or 5 of this Agreement; PROVIDED,
       HOWEVER, that this Agreement shall automatically be renewed for
       successive one-year terms (the Term and, if the period of employment is
       so renewed, such additional period(s) of employment are collectively
       referred to herein as the "Term"), unless terminated by written notice
       given by either party to the other at least 90 days prior to the end of
       the applicable Term.

3.     COMPENSATION.

       3.1    As full compensation for all services to be rendered pursuant to
              this Agreement, the Company agrees to pay the Employee, during the
              Term, a base salary at the fixed rate of $225,000 per annum during
              the first year of the Term and increased each year thereafter, by
              amounts, if any, to be determined by the Board of Directors of the
              Company (the "Board"), in its sole discretion, payable in equal
              biweekly installments, less such deductions or amounts to be
              withheld as shall be required by applicable law and regulations.

       3.2    Each year, the Employee shall be eligible for a discretionary
              bonus of up to 30% of base salary, which bonus shall be determined
              annually by the Board. The bonus, if any, may be paid in the form
              of stock options, stock awards, cash, or deferred compensation, as
              determined by the Board.



       3.3    The Company shall pay or reimburse the Employee for all reasonable
              expenses actually incurred or paid by her during the Term in the
              performance of her services under this Agreement, upon
              presentation of expense statements or vouchers or such other
              supporting information as it may require.

       3.4    The Employee shall be eligible under any incentive plan, stock
              award plan, bonus, deferred or extra compensation plan, pension,
              group health, disability and life insurance or other so-called
              "fringe" benefits which the Company provides for its senior
              executives at a comparable level to the Employee. All stock
              options and stock awards granted to the Employee shall be subject
              to a vesting schedule which shall be determined by the
              Compensation Committee of the Board. Stock options and stock
              awards, if any, to be granted to the Employee shall also be
              subject to the terms of a stock option plan and certificate or
              stock award plan and certificate, as the case may be.

       3.5    The Company shall grant the Employee an option to purchase 100,000
              shares of the Company's Common Stock at the fair market value on
              the date of the Board's approval of such grant (the "2002 Stock
              Options"), in accordance with the Company's 2001 Stock Plan. The
              Employee agrees that all such options shall be subject to a
              four-year vesting schedule, vesting in equal increments of 25% on
              each anniversary of their issuance.

       3.6    All options to purchase shares of the Company's Common Stock held
              by the Employee prior to the date hereof pursuant to that certain
              consulting agreement, dated January 2, 2000, by and between the
              Company and the Employee (the "Consulting Agreement"), (that is,
              options to purchase 135,000 shares of the Company's Common Stock)
              (the "Prior Stock Options") shall continue to vest and be
              exercisable subject to the Company's 1991 Stock Option Plan for
              Employees, as amended, and the relevant certificates. As of the
              Effective Date of this Agreement, the Consulting Agreement shall
              terminate, except as provided in Section 8.8 herein.

       3.7    Except as specified in Section 6.1, any unvested options shall be
              forfeited to the Company in the event (a) this Agreement is
              terminated by the Company for Cause pursuant to Section 4 herein,
              or (b) either party elects not to renew this Agreement pursuant to
              Section 2 herein.

4.     TERMINATION BY THE COMPANY.

       The Company may terminate this Agreement, if any one or more of the
       following shall occur:

       (a)    The Employee shall die during the Term; PROVIDED, HOWEVER, the
              Employee's legal representatives shall be entitled to receive the
              compensation provided for in Section 3 to the last day of the
              month in which her death occurs.

       (b)    The Employee shall become physically or mentally disabled, whether
              totally or partially, so that she is unable substantially to
              perform her services hereunder for (i) a period of 180 consecutive
              days, or (ii) for shorter periods aggregating 180 days during any
              twelve month period.

       (c)    The Employee acts, or fails to act, in a manner that provides
              Cause for termination. For purposes of this Agreement, the term
              "Cause" means (i) the conviction of the Employee of any felony
              involving moral turpitude, (ii) any acts of fraud or embezzlement
              by the Employee involving the Company or any of its Affiliates,
              (iii) the failure by the Employee to perform any of her material
              duties hereunder, (iv) violation of any federal, state or local
              law, or administrative regulation, (v) conduct that results in
              negative publicity, (vi) failure to comply



                                       2


              with the policies of the Company, or (vii) a material breach of
              the terms of this Agreement by the Employee (including, without
              limitation, actions taken by Employee which create a conflict of
              interest for Employee between the Company and a competitor). As
              the term "Cause" applies to clauses (iii) through (vii), such
              acts, conduct, or failure, as the case may be, must materially
              adversely affect the Company's business. The Company shall provide
              the Employee written notice of termination pursuant to this
              Section 4, and Employee shall have 30 days to cure or remedy such
              failure or breach, in which case this Agreement shall not be
              terminated.

5.     TERMINATION BY THE EMPLOYEE.

       5.1    The Employee may terminate this Agreement, if any one or more of
              the following shall occur:

              (a)    a material breach of the terms of this Agreement by the
                     Company and such breach continues for 30 days after the
                     Employee gives the Company written notice of such breach;

              (b)    the Company shall make a general assignment for benefit of
                     creditors; or any proceeding shall be instituted by the
                     Company seeking to adjudicate it as bankrupt or insolvent,
                     or seeking liquidation, winding up, reorganization,
                     arrangement, adjustment, protection, relief, or composition
                     of it or its debts under law relating to bankruptcy,
                     insolvency or reorganization or relief of debtors, or
                     seeking entry of an order for relief of the appointment of
                     a receiver, trustee, or other similar official for it or
                     for any substantial part of its property or the Company
                     shall take any corporate action to authorize any of the
                     actions set forth above in this Section 5.1(b);

              (c)    an involuntary petition shall be filed or an action or
                     proceeding otherwise commenced against the Company seeking
                     reorganization, arrangement or readjustment of the
                     Company's debts or for any other relief under the Federal
                     Bankruptcy Code, as amended, or under any other bankruptcy
                     or insolvency act or law, state or federal, now or
                     hereafter existing and remain undismissed or unstayed for a
                     period of 30 days;

              (d)    a receiver, assignee, liquidator, trustee or similar
                     officer for the Company or for all or any part of its
                     property shall be appointed involuntarily, or

              (e)    a Change in Control, as such term is defined in Section 14.

6.     SEVERANCE.

       6.1    If (i) the Company terminates this Agreement without Cause or (ii)
              the Employee terminates this Agreement pursuant to Section 5.1(a),
              then: (1) except in the case of death or disability, the Company
              shall continue to pay the Employee her then-current base salary
              for the remaining period of the applicable Term; (2) all stock
              options granted pursuant to this Agreement that would have vested
              during the Term shall vest immediately prior to such termination;
              and (3) the Company shall continue to provide all benefits subject
              to COBRA at its expense for up to one year. Notwithstanding the
              foregoing, if the Company elects not to renew this Agreement
              pursuant to Section 2 herein or this Agreement is terminated
              according to this Section 6.1, prior to March 4, 2006, all 2002
              Stock Options, shall vest immediately.

       6.2    In the event of a consummation of a Change in Control of the
              Company, and if the Employee gives notice of termination within 90
              days after such occurrence, then (i) all stock options, stock
              awards, similar equity rights, and deferred compensation awards
              granted to the Employee shall immediately vest and remain fully
              exercisable through their original term




                                       3


              with all rights; (ii) the relocation loan provided pursuant to
              Section 7 (f) shall be considered fully paid, and all loan
              obligations shall be forgiven; and (iii) the Company shall
              continue to pay Employee her then-current base salary for the
              shorter of (a) six months, or (b) the remaining period of the
              applicable Term.

7.     OTHER BENEFITS.

       In addition to all other benefits contained herein, the Employee shall be
       entitled to:

       (a)    Relocation expenses for the Employee and her family, consisting of
              (i) all reasonable direct out-of-pocket costs of transporting the
              Employee, the Employee's family and household items from the
              Employee's current residence to a new residence in the greater
              Boston, Massachusetts area; (ii) reasonable travel and lodging to
              visit the greater Boston, Massachusetts area to search for a new
              residence; (iii) the cost of storing household items in the
              greater Boston, Massachusetts area (and transporting them to and
              from storage) for up to six months from the Employee's date of
              employment; and (iv) except as described in the next succeeding
              sentence and subject to prior approval, the reasonable closing
              costs associated with the Employee's purchase of a new residence
              in the greater Boston, Massachusetts area within one year of the
              Employee's date of employment. The following closing (settlement)
              costs will NOT be paid by the Company: (1) real --- estate and
              other taxes, (2) insurance premiums other than title insurance,
              and (3) commitment fees and prepaid interest (i.e., "points") in
              excess of 2%. If any payments made to or in respect of the
              Employee pursuant to this Section 7(a) become subject to any tax
              (taking into account relevant deductions), the Company shall make
              a special payment to her sufficient, on an after-tax basis (taking
              into account federal, state, and local taxes), to put her in the
              same position as would have been the case had no such taxes been
              applicable to any payments of benefits provided in this
              subsection. This special payment will be made to the Employee at
              the time such taxes actually are paid.

       (b)    Vacation time of four weeks per year taken in accordance with the
              vacation policy of the Company during each year of the Term.

       (c)    After six years of employment, one three-month period of fully
              paid leave of absence in accordance with Company policies in place
              at that time; it being understood that such policies may restrict
              the Employee from taking such leave of absence until a time that
              is acceptable to the Company and may include other such
              limitations.

       (d)    Group health, disability and life insurance.

       (e)    The Company shall provide the Employee with an automobile
              allowance of $750 per month and standard tax preparation and
              planning services.

       (f)    To facilitate the Employee's relocation, the Company will provide
              the Employee with a one-time relocation loan (the "Loan") in the
              amount of $75,000 to be used towards the purchase of the
              Employee's new principal residence (the "Residence"), payable at
              the time of closing on such residence. The Loan will be secured by
              a second mortgage on the Residence (the "Secured Note"). The
              principal of the Loan shall be repaid within thirty days of the
              occurrence of the following events: (a) the Employee terminates
              this Agreement prior to the third anniversary of execution of the
              Secured Note, except as provided pursuant to Section 5.1 herein,
              or (b) the Company terminates this Agreement for Cause pursuant to
              Section 4 herein. Upon the third anniversary of the execution of
              the Secured Note, the Loan obligation shall be fully forgiven.


                                       4


8.     CONFIDENTIALITY.

       8.1    The Employee acknowledges that, during the course of performing
              her services hereunder, the Company shall be disclosing
              information to the Employee related to the Company's Field of
              Interest, Inventions, projects and business plans, as well as
              other information (collectively, "Confidential Information"). The
              Employee acknowledges that the Company's business is extremely
              competitive, dependent in part upon the maintenance of secrecy,
              and that any disclosure of the Confidential Information would
              result in serious harm to the Company.

       8.2    The Employee agrees that the Confidential Information only shall
              be used by the Employee in connection with her activities
              hereunder as an employee of the Company, and shall not be used in
              any way that is detrimental to the Company.

       8.3    The Employee agrees not to disclose, directly or indirectly, the
              Confidential Information to any third person or entity, other than
              representatives or agents of the Company. The Employee shall treat
              all such information as confidential and proprietary property of
              the Company.

       8.4    The term "Confidential Information" does not include information
              that (a) is or becomes generally available to the public other
              than by disclosure in violation of this Agreement, (b) was within
              the Employee's possession prior to being furnished to such
              Employee, (c) becomes available to the Employee on a
              nonconfidential basis or (d) was independently developed by the
              Employee without reference to the information provided by the
              Company.

       8.5    The Employee may disclose any Confidential Information that is
              required to be disclosed by law, government regulation or court
              order. If disclosure is required, the Employee shall give the
              Company advance notice so that the Company may seek a protective
              order or take other action reasonable in light of the
              circumstances.

       8.6    Upon termination of this Agreement, the Employee shall promptly
              return to the Company all materials containing Confidential
              Information, as well as data, records, reports and other property,
              furnished by the Company to the Employee or produced by the
              Employee in connection with services rendered hereunder.
              Notwithstanding such return or any of the provisions of this
              Agreement, the Employee shall continue to be bound by the terms of
              the confidentiality provisions contained in this Section 8 for a
              period of three years after the termination of this Agreement.

       8.7    In connection with her employment by the Company, the Employee
              hereby acknowledges that she may enter into more than one
              agreement with regard to (a) the confidentiality of certain books,
              records, documents and business, (b) rights to certain inventions,
              proprietary information, and writings, (c) publication of certain
              materials, and (d) other related matters (the "Confidential
              Matters") of the Company (the "Confidentiality Agreements"). In
              order to clarify any potential conflicts between certain
              respective provisions of such Confidentiality Agreements, the
              Employee and the Company hereby agree that, as among such
              Confidentiality Agreements, the provision (or part thereof) in any
              such Confidentiality Agreement which affords the greatest
              protection to the Company with respect to the Confidential Matters
              shall control.

       8.8    The Employee hereby acknowledges that she has previously entered
              into one or more Confidentiality Agreements (as such term is
              defined in Section 8.7 hereof) with the Company. Notwithstanding
              any of the provisions of this Agreement, the Employee acknowledges
              and agrees that Section 8.7 of the Executive Employment Agreement
              by and between the Company and the Employee, dated as of November
              25, 1998, as amended (the "Executive



                                       5


              Employment Agreement"), Section 6.7 of the Consulting Agreement,
              defined above, and her obligations under such Confidentiality
              Agreements shall continue to survive any termination of the
              Executive Employment Agreement, the Consulting Agreement or this
              Agreement.

9.     INVENTIONS DISCOVERED BY THE EMPLOYEE WHILE PERFORMING SERVICES
       HEREUNDER.

       During the Term, the Employee shall promptly disclose to the Company any
       invention, improvement, discovery, process, formula, or method or other
       intellectual property, whether or not patentable, whether or not
       copyrightable (collectively, "Inventions") made, conceived or first
       reduced to practice by the Employee, either alone or jointly with others,
       while performing service hereunder. The Employee hereby assigns to the
       Company all of her right, title and interest in and to any such
       Inventions. During and after the Term, the Employee shall execute any
       documents necessary to perfect the assignment of such Inventions to the
       Company and to enable the Company to apply for, obtain, and enforce
       patents and copyrights in any and all countries on such Inventions. The
       Employee hereby irrevocably designates the Chief Patent Counsel to the
       Company as her agent and attorney-in-fact to execute and file any such
       document and to do all lawful acts necessary to apply for and obtain
       patents and copyrights and to enforce the Company's rights under this
       paragraph. This Section 9 shall survive the termination of this
       Agreement.

10.    NON-COMPETITION AND NON-SOLICITATION.

       During the Term and, in the event of an earlier termination of this
       Agreement by Employee during the Term (other than any termination by
       Employee pursuant to Section 5.1(a)), for a period of one year following
       the date of such termination by Employee (the "Section 10 Period"): (a)
       Employee shall not compete with the Company or any subsidiary or
       affiliate of the Company for whom she is an employee or officer during
       the Term (each, an "Interested Entity") by (i) entering the employ of, or
       rendering services to, any biopharmaceutical entity which is engaged in a
       business competitive with the Company's Field of Interest in such a
       capacity as to create, on the date of such employment, a potential
       conflict of interest for Employee between such biopharmaceutical entity
       and an Interested Entity, (ii) engaging, during the Section 10 Period, in
       any business for her own account which would be competitive with the
       Company's Field of Interest, or (iii) acquiring, during the Section 10
       Period, an equity or financial interest in any business which is
       competitive with the Company's Field of Interest, directly or indirectly,
       as an individual, partner, shareholder, director, officer, principal,
       agent, employee, trustee, consultant, or any other relationship or
       capacity as to create, on the date of acquisition of such interest, a
       potential conflict of interest for Employee between such business and an
       Interested Entity; PROVIDED, HOWEVER, that nothing contained in this
       Section 10 shall be deemed to prohibit Employee during the Section 10
       Period from providing approved consulting services to Alexandria,
       accepting a position with a law firm, investment bank, venture capital or
       investment fund or other professional or financial services firm or from
       acquiring, solely as an investment, shares of capital stock of any public
       corporation; (b) neither the Employee nor any Affiliate of the Employee
       shall solicit or utilize, or assist any person in any way to solicit or
       utilize, the services, directly or indirectly, of any of the Company's
       directors, consultants, members of the Board of Scientific and Medical
       Advisors, officers or employees (collectively, "Associates of the
       Company") in any manner which is directly or indirectly competitive with
       the Company's business . This non-solicitation and non-utilization
       provision shall not apply to Associates of the Company who have
       previously terminated their relationship with the Company.

       10.1   If the Employee commits a breach, or threatens to commit a breach,
              of any of the provisions of this Section 10, the Company shall
              have the following rights and remedies:

              10.1.1  The right and remedy to have the provisions of this
                      Agreement specifically enforced by any court having equity
                      jurisdiction, it being acknowledged and agreed that any



                                       6


                      such breach or threatened breach shall cause irreparable
                      injury to the Company and that money damages shall not
                      provide an adequate remedy to the Company; and

              10.1.2  The right and remedy to require the Employee to account
                      for and pay over to the Company all compensation, profits,
                      monies, accruals, increments or other benefits
                      (collectively "Benefits") derived or received by the
                      Employee as the result of any transactions constituting a
                      breach of any of the provisions of the preceding
                      paragraph, and the Employee hereby agrees to account for
                      and pay over such Benefits to the Company.

                      Each of the rights and remedies enumerated above shall be
                      independent of the other, and shall be severally
                      enforceable, and all of such rights and remedies shall be
                      in addition to, and not in lieu of, any other rights and
                      remedies available to the Company under law or in equity.

       10.2   If any of the covenants contained in Section 8, 9 or 10, or any
              part thereof, is hereafter construed to be invalid or
              unenforceable, the same shall not affect the remainder of the
              covenant or covenants, which shall be given full effect without
              regard to the invalid portions.

       10.3   If any of the covenants contained in Section 8, 9 or 10, or any
              part thereof, is held to be unenforceable because of the duration
              of such provision or the area covered thereby, the parties agree
              that the court making such determination shall have the power to
              reduce the duration and/or area of such provision and, in its
              reduced form, such provision shall then be enforceable.

       10.4   The parties hereto intend to and hereby confer jurisdiction to
              enforce the covenants contained in Sections 8, 9 and 10 upon the
              courts of any state within the geographical scope of such
              covenants. In the event that the courts of any one or more of such
              states shall hold any such covenant wholly unenforceable by reason
              of the breadth of such scope or otherwise, it is the intention of
              the parties hereto that such determination not bar or in any way
              affect the Company's right to the relief provided above in the
              courts of any other states within the geographical scope of such
              covenants, as to breaches of such covenants in such other
              respective jurisdictions, the above covenants as they relate to
              each state being, for this purpose, severable into diverse and
              independent covenants.

11.    INDEMNIFICATION.

       The Company shall indemnify the Employee, to the maximum extent permitted
       by applicable law, against all costs, charges and expenses incurred or
       sustained by her in connection with any action, suit or proceeding to
       which she may be made a party by reason of her being an officer, director
       or employee of the Company or of any subsidiary or affiliate of the
       Company. The Company shall provide, subject to its availability upon
       reasonable terms (which determination shall be made by the Board) at its
       expense, directors and officers insurance for the Employee in reasonable
       amounts. Determination with respect to (a) the availability of insurance
       upon reasonable terms and (b) the amount of such insurance coverage shall
       be made by the Board in its sole discretion.

12.    NOTICES.

       All notices, requests, consents and other communications required or
       permitted to be given hereunder shall be in writing and shall be deemed
       to have been duly given if sent by prepaid telegram (confirmed delivery
       by the telegram service), private overnight mail service (delivery
       confirmed by such service), registered or certified mail (return receipt
       requested), or delivered


                                       7


       personally, as follows (or to such other address as either party shall
       designate by notice in writing to the other in accordance herewith):

If to the Company:
ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, Massachusetts 02139
Attention: Chief Executive Officer
Telephone: (617) 494-0400
Fax:       (617) 494-1828


If to the Employee:
Laurie A. Allen, Esq.
11181 Cashmere Street
Los Angeles, California  90049


13.    GENERAL.

       13.1   This Agreement shall be governed by and construed and enforced in
              accordance with the laws of the Commonwealth of Massachusetts
              applicable to agreements made and to be performed entirely in
              Massachusetts.

       13.2   The Section headings contained herein are for reference purposes
              only and shall not in any way affect the meaning or interpretation
              of this Agreement.

       13.3   Except as set forth in Section 8.8 of this Agreement with respect
              to Confidentiality Agreements, this Agreement sets forth the
              entire agreement and understanding of the parties relating to the
              subject matter hereof, and supersedes all prior agreements,
              arrangements and understandings, written or oral, relating to the
              subject matter hereof. No representation, promise or inducement
              has been made by either party that is not embodied in this
              Agreement, and neither party shall be bound by or liable for any
              alleged representation, promise or inducement not so set forth.

       13.4   This Agreement and the Employee's rights and obligations hereunder
              may not be assigned by the Employee or the Company; PROVIDED,
              HOWEVER, the Company may assign this Agreement to a
              successor-in-interest.

       13.5   This Agreement may be amended, modified, superseded, canceled,
              renewed or extended, and the terms or covenants hereof may be
              waived, only by a written instrument executed by the parties
              hereto, or in the case of a waiver, by the party waiving
              compliance. The failure of a party at any time or times to require
              performance of any provision hereof shall in no manner affect the
              right at a later time to enforce the same. No waiver by a party of
              the breach of any term or covenant contained in this Agreement,
              whether by conduct or otherwise, in any one or more instances,
              shall be deemed to be, or construed as, a further or continuing
              waiver of any such breach, or a waiver of the breach of any other
              term or covenant contained in this Agreement.

14.    DEFINITIONS. As used herein the following terms have the following
       meaning:

       (a)    "Affiliate" means and includes any corporation or other business
              entity controlling, controlled by or under common control with the
              corporation in question.


                                       8


       (b)    The "Company's Field of Interest" is the discovery, development
              and commercialization of pharmaceutical products based on (a)
              intervention in signal transduction pathways and (b) gene and cell
              therapy. The Company's Field of Interest may be changed at any
              time at the sole discretion of the Company and upon written notice
              to Employee.

       (c)    "person" means any natural person, corporation, partnership, firm,
              joint venture, association, joint stock company, trust,
              unincorporated organization, governmental body or other entity.

       (d)    "Subsidiary" means any corporation or other business entity
              directly or indirectly controlled by the corporation in question.

       (e)    "Change in Control" means the occurrence of any of the following
              events (without the consent of the Employee):

              (i)   Any corporation, person or other entity makes a tender or
                    exchange offer for shares of the Company's Common Stock
                    pursuant to which such corporation, person or other entity
                    acquires more than 50% of the issued and outstanding shares
                    of the Company's Common Stock;

              (ii)  The stockholders of the Company approve a definitive
                    agreement to merge or consolidate the Company with or into
                    another corporation or to sell or otherwise dispose of all
                    or substantially all of the Company's assets; or

              (iii) Any person within the meaning of Section 3 (a) (9) or
                    Section 13 (d) of the Securities Exchange Act of 1934
                    acquires more than 50% of the combined voting power of
                    Company's issued and outstanding voting securities entitled
                    to vote in the election of the Board.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first above written.


ARIAD PHARMACEUTICALS, INC.
                               By: /s/ Harvey J. Berger, M.D.
                               ------------------------------------------------
                               Harvey J. Berger, M.D.
                               Chairman and Chief Executive Officer


                               EMPLOYEE

                                   /s/ Laurie A. Allen, Esq.
                              -------------------------------------------------
                               Laurie A. Allen, Esq.



                              Date:
                                   ---------------------------



                                       9

EX-10.57

                                                                   EXHIBIT 10.57
                          ARIAD GENE THERAPEUTICS, INC.

                            STOCK TRANSFER AGREEMENT

In consideration of the covenants and agreements set forth herein and for other
good and valuable consideration, the receipt and sufficiency of which are hereby
mutually acknowledged, the parties hereto covenant and agree as follows:

The undersigned stockholder (the "Stockholder") of ARIAD Gene Therapeutics, Inc.
(the "Company") agrees that, in the event he or she desires to sell, assign,
transfer or otherwise dispose of any of the shares of capital stock of the
Company now held or at anytime hereafter acquired by him or her (the "Shares")
to any person, he or she will notify (the "Notification") the Company in writing
addressed to its principal executive offices of his or her intention to do so,
specifying the amount of Shares proposed to be transferred (the "Offered
Shares"), the name of the person or persons (the "Third Party Purchaser") to
whom he or she proposes to transfer the Offered Shares, and a price per share
which shall be the minimum price per share at which he or she proposes to effect
the transfer (the "Minimum Price"). The Notification shall contain an
affirmation by the Stockholder that such Offered Shares are proposed to be
transferred pursuant to a bona fide written purchase contract and that the
Stockholder has a reasonable expectation of being able to effect the transfer at
the Minimum Price to the Third Party Purchaser, and shall recite the basis for
such expectation. The Notification shall offer to sell to the Company and/or its
designees the Offered Shares, free and clear of any liens or encumbrances in
favor of third persons, at the Minimum Price and on such other terms and
conditions, if any, not less favorable to the Company and its designees as those
proposed to be offered to such Third Party Purchaser. In the event all or any
part of the consideration shall consist of consideration other than cash, the
Minimum Price shall include the fair value of such other consideration as
determined in good faith by the Company's Board of Directors.

The Company and its designees shall have the right to purchase the Offered
Shares in accordance with the terms contained herein. The Company shall respond
to the offer of the Stockholder within 30 days after receipt of the
Notification. If the Company does not accept the offer of the Offered Shares in
its entirety, the Stockholder shall be free to proceed to sell all, but not less
than all, of the Offered Shares to the Third Party Purchaser specified in the
Notification at not less than the Minimum Price. At least two business days
prior to the closing of the purchase of the Offered Shares by the Third Party
Purchaser (the "Third Party Closing"), the Stockholder shall deliver to the
Company a certificate executed by the Third Party Purchaser stating that (i) the
terms and conditions set forth in the Notification have been approved by the
Third Party Purchaser's board of directors (or the equivalent governing body if
the Third Party Purchaser is not a corporation), if applicable, (ii) the Third
Party Purchaser is aware of the rights of the Company contained in this
Agreement, and (iii) upon consummation of the Third Party Closing, the Third
Party Purchaser shall become a party to this Agreement and agree to be bound by
the terms and conditions hereof.

If the Stockholder fails to complete his or her proposed sale within a period of
60 days after the earlier to occur of (i) the date of rejection by the Company
of the offer contained in the Notification or (ii) the date that is 30 days
after the date of receipt by the Company of the Notification (the "Offer
Expiration Date"), then the Offered Shares shall once again be subject to the
requirements of a prior offer to the Company pursuant to the provisions of this
Agreement.

In the event the Company and it designees shall elect to purchase or acquire all
of the Offered Shares, written notice (the "Acceptance") to the Stockholder of
such election to purchase or so acquire all of the Offered Shares shall, when
taken in conjunction with the Notification, be deemed to constitute a valid and
legally binding purchase and sale agreement.

The closing of a purchase and sale of Offered Shares pursuant hereto shall take
place at the principal executive offices of the Company on the 30th day
following the Offer Expiration Date (unless another time is specified in the
Acceptance or is otherwise mutually agreed upon), at which time the Stockholder
shall deliver the stock certificate or certificates representing the Offered
Shares so sold (duly endorsed or accompanied by a duly executed stock power or
assignment to effect transfer of ownership to the purchaser or purchasers on the
records of the Company) against the Stockholder's receipt of payment of the
Minimum Price by certified check, bank cashiers check or wire transfer.

The Stockholder acknowledges that the Company shall be authorized to (i) affix a
legend referencing this Agreement on each certificate representing Shares issued
to the Stockholder, and (ii) impose stop transfer orders with the Company's
transfer agent.

The provisions of this Agreement shall not apply to the transfer of Offered
Shares by the Stockholder to (i) the heirs, executors or legal representatives
of the Stockholder, (ii) the members of the immediate family of the Stockholder,
or (iii) the trustees of an inter vivos or testamentary trust for the benefit of
members of immediate family of the Stockholder, provided that, in each such
case, such transferee shall become a party to this Agreement and agree to be
bound by the terms and conditions hereof.

IN WITNESS WHEREOF, this Agreement has been executed on behalf of each of the
Stockholder and the Company on this ____ day of March 2001.


                                       STOCKHOLDER


                                       /s/ See Exhibit A
                                       --------------------------------
                                       Name:


                                       ARIAD GENE THERAPEUTICS, INC.

                                       By:  /s/ Harvey Berger
                                       ----------------------
                                       Title:  Chairman and CEO

                                    EXHIBIT A


STOCKHOLDER                                                  EXECUTION DATE
- -----------                                                  --------------
                                                          
Harvey J. Berger                                             March 12, 2001
David L. Berstein                                            March 13, 2001
Gerald Crabtree                                              January 31, 2001
John D. Iuliucci                                             March 13, 2001
Jay R. LaMarche                                              March 13, 2001
Stuart Schreiber                                             January 31, 2001
Manfred Weigele                                              March 13, 2001

EX-10.58

                                                                   EXHIBIT 10.58


CERTIFIED MAIL - RETURN RECEIPT


October 2, 2001


Mr. Michael Farley
Vice President, Asset Management
Forest City Commercial Group
38 Sidney Street
Cambridge, MA  02139

       Re:    Notice of Extension of Lease

Dear Mike:

Please be advised that pursuant to Section 2.6 of the lease dated January 8,
1992 by and between Forest City and ARIAD Corporation for certain lease space in
the building at 26 Landsdowne Street, Cambridge, Massachusetts, as amended (the
"Lease"), ARIAD hereby extends the lease for the first lease extension period
commencing on August 1, 2002 and terminating on July 31, 2007.

Moreover, the Annual Fixed Rent (as defined in the Lease) to be paid by ARIAD
during the first extension term shall be determined pursuant to the formula
described in Section 2.6 of the Lease. To that end, attached please find a
spreadsheet containing ARIAD's proposed formula in Section 2.6 of the Lease. For
illustrative purposes, the attached calculations hypothetically assume an
extension start date of September 1, 2001, since bi-monthly inflation indices
are presently available only through July, 2001.

Once you have had an opportunity to review the attachment, please feel free to
call me with any questions or comments you may have. Also, I would be happy to
send you an electronic copy of the Excel spreadsheet that produced the
attachment, if it will assist your review. Please confirm receipt of this letter
by signing and dating below and returning to my attention by facsimile at
617-494-1828.

Sincerely yours,

/s/Harvey J. Berger

Harvey J. Berger, M.D.

HJB:bdm



Received:         /s/Michael Farley
                  -----------------
                  Name

                  Vice President

                  October 3, 2001

EX-23.1

INDEPENDENT AUDITORS CONSENT

We consent to the incorporation by reference in Registration Statements Nos. 33-90854, 333-36597 and 333-63706 of ARIAD Pharmaceuticals, Inc. on Form S-8 and Registration Statements Nos. 33-85166, 333-51687, 333-63708, and 333-76486 of ARIAD Pharmaceuticals, Inc. on Form S-3 of our report dated January 18, 2002 (which report expresses an unqualified opinion and includes an explanatory paragraph referring to a change in accounting principle in 1999 relating to accounting for start-up activities), appearing in this Annual Report on Form 10-K of ARIAD Pharmaceuticals, Inc. for the year ended December 31, 2001.

/s/ DELOITTE & TOUCHE LLP

Boston, Massachusetts

March 21, 2002